# Lahart_2018_Physical activity for women with breast cancer after adjuvant therapy.

Cochrane
Library

Cochrane Database of Systematic Reviews

Physical activity for women with breast cancer after adjuvant
therapy (Review)

Lahart IM, Metsios GS, Nevill AM, Carmichael AR

Lahart IM, Metsios GS, Nevill AM, Carmichael AR. 
Physical activity for women with breast cancer after adjuvant therapy. 
Cochrane Database of Systematic Reviews 2018, Issue 1. Art. No.: CD011292. 
DOI: 10.1002/14651858.CD011292.pub2.

www.cochranelibrary.com

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

T A B L E   O F   C O N T E N T S

ABSTRACT.....................................................................................................................................................................................................
PLAIN LANGUAGE SUMMARY.......................................................................................................................................................................
SUMMARY OF FINDINGS..............................................................................................................................................................................
BACKGROUND..............................................................................................................................................................................................
OBJECTIVES..................................................................................................................................................................................................
METHODS.....................................................................................................................................................................................................
RESULTS........................................................................................................................................................................................................
Figure 1..................................................................................................................................................................................................
Figure 2..................................................................................................................................................................................................
Figure 3..................................................................................................................................................................................................
Figure 4..................................................................................................................................................................................................
Figure 5..................................................................................................................................................................................................
DISCUSSION..................................................................................................................................................................................................
Figure 6..................................................................................................................................................................................................
AUTHORS' CONCLUSIONS...........................................................................................................................................................................
ACKNOWLEDGEMENTS................................................................................................................................................................................
REFERENCES................................................................................................................................................................................................
CHARACTERISTICS OF STUDIES..................................................................................................................................................................
DATA AND ANALYSES....................................................................................................................................................................................
Analysis 1.1. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 1 Overall HRQoL (follow-
up values)..............................................................................................................................................................................................
Analysis 1.2. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 2 Overall HRQoL (change
values)....................................................................................................................................................................................................
Analysis  1.3.  Comparison  1  Comparison:  HRQoL  outcomes,  all  physical  activity  vs  control,  Outcome  3  FACT-G  (follow-up
values)....................................................................................................................................................................................................
Analysis 1.4. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 4 FACT-G (change values)....
Analysis  1.5.  Comparison  1  Comparison:  HRQoL  outcomes,  all  physical  activity  vs  control,  Outcome  5  FACT-B  (follow-up
values)....................................................................................................................................................................................................
Analysis 1.6. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 6 FACT-B (change values).....
Analysis  1.7.  Comparison  1  Comparison:  HRQoL  outcomes,  all  physical  activity  vs  control,  Outcome  7  FACT  Breast  Cancer
Subscale (follow-up values).................................................................................................................................................................
Analysis  1.8.  Comparison  1  Comparison:  HRQoL  outcomes,  all  physical  activity  vs  control,  Outcome  8  FACT  Breast  Cancer
Subscale (change values).....................................................................................................................................................................
Analysis 1.9. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 9 FACT Trial Outcome Index
(follow-up values)..................................................................................................................................................................................
Analysis 1.10. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 10 EORTC QLQ-C30 Global
Health (follow-up values).....................................................................................................................................................................
Analysis 1.11. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 11 EORTC QLQ-C30 Global
Health (change values).........................................................................................................................................................................
Analysis  1.12.  Comparison  1  Comparison:  HRQoL  outcomes,  all  physical  activity  vs  control,  Outcome  12  Overall  emotional
function/mental health (follow-up values).........................................................................................................................................
Analysis  1.13.  Comparison  1  Comparison:  HRQoL  outcomes,  all  physical  activity  vs  control,  Outcome  13  Overall  emotional
function/mental health (change values).............................................................................................................................................
Analysis 1.14. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 14 FACT Emotional well-
being (follow-up values).......................................................................................................................................................................
Analysis 1.15. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 15 FACT Emotional well-
being (change values)...........................................................................................................................................................................
Analysis  1.16.  Comparison  1  Comparison:  HRQoL  outcomes,  all  physical  activity  vs  control,  Outcome  16  MOS  SF  Mental
composite (follow-up values)...............................................................................................................................................................
Analysis  1.17.  Comparison  1  Comparison:  HRQoL  outcomes,  all  physical  activity  vs  control,  Outcome  17  MOS  SF  Mental
composite (change values)...................................................................................................................................................................
Analysis 1.18. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 18 MOS SF Mental health
(follow-up values)..................................................................................................................................................................................

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1
2
4
9
10
10
13
14
22
24
26
27
35
39
41
43
44
59
219
230

231

231

232
233

233
234

234

235

235

236

236

237

238

239

239

240

240

i

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.19. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 19 MOS SF Mental health
(change values).....................................................................................................................................................................................
Analysis 1.20. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 20 MOS SF Emotional role
(follow-up values)..................................................................................................................................................................................
Analysis 1.21. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 21 MOS SF Emotional role
(change values).....................................................................................................................................................................................
Analysis  1.22.  Comparison  1  Comparison:  HRQoL  outcomes,  all  physical  activity  vs  control,  Outcome  22  EORTC  QLQ-C30
Emotional function (follow-up values)................................................................................................................................................
Analysis  1.23.  Comparison  1  Comparison:  HRQoL  outcomes,  all  physical  activity  vs  control,  Outcome  23  EORTC  QLQ-C30
Emotional function (change values)....................................................................................................................................................
Analysis  1.24.  Comparison  1  Comparison:  HRQoL  outcomes,  all  physical  activity  vs  control,  Outcome  24  POMS  total  mood
disturbance (follow-up values).............................................................................................................................................................
Analysis  1.25.  Comparison  1  Comparison:  HRQoL  outcomes,  all  physical  activity  vs  control,  Outcome  25  POMS  total  mood
disturbance (change values)................................................................................................................................................................
Analysis 1.26. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 26 POMS anger subscale
(follow-up values)..................................................................................................................................................................................
Analysis 1.27. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 27 Happiness/satisfaction
with life (follow-up values)...................................................................................................................................................................
Analysis 1.28. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 28 Happiness/satisfaction
with life (change values).......................................................................................................................................................................
Analysis  1.29.  Comparison  1  Comparison:  HRQoL  outcomes,  all  physical  activity  vs  control,  Outcome  29  Overall  physical
function (follow-up values)..................................................................................................................................................................
Analysis  1.30.  Comparison  1  Comparison:  HRQoL  outcomes,  all  physical  activity  vs  control,  Outcome  30  Overall  physical
function (change values)......................................................................................................................................................................
Analysis 1.31. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 31 FACT Physical well-
being (follow-up values).......................................................................................................................................................................
Analysis 1.32. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 32 FACT Physical well-
being (change values)...........................................................................................................................................................................
Analysis  1.33.  Comparison  1  Comparison:  HRQoL  outcomes,  all  physical  activity  vs  control,  Outcome  33  MOS  SF  Physical
composite (follow-up values)...............................................................................................................................................................
Analysis  1.34.  Comparison  1  Comparison:  HRQoL  outcomes,  all  physical  activity  vs  control,  Outcome  34  MOS  SF  Physical
composite (change values)...................................................................................................................................................................
Analysis  1.35.  Comparison  1  Comparison:  HRQoL  outcomes,  all  physical  activity  vs  control,  Outcome  35  MOS  SF  Physical
function (follow-up values)..................................................................................................................................................................
Analysis  1.36.  Comparison  1  Comparison:  HRQoL  outcomes,  all  physical  activity  vs  control,  Outcome  36  MOS  SF  Physical
function (change values)......................................................................................................................................................................
Analysis  1.37.  Comparison  1  Comparison:  HRQoL  outcomes,  all  physical  activity  vs  control,  Outcome  37  EORTC  QLQ-C30
Physical function (follow-up values)...................................................................................................................................................
Analysis  1.38.  Comparison  1  Comparison:  HRQoL  outcomes,  all  physical  activity  vs  control,  Outcome  38  EORTC  QLQ-C30
Physical function (change values).......................................................................................................................................................
Analysis 1.39. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 39 Body Esteem Scale -
Physical condition (follow-up values)..................................................................................................................................................
Analysis 1.40. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 40 Overall role function
(follow-up values)..................................................................................................................................................................................
Analysis 1.41. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 41 Overall role function
(change values).....................................................................................................................................................................................
Analysis 1.42. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 42 FACT Functional well-
being (follow-up values).......................................................................................................................................................................
Analysis 1.43. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 43 FACT Functional well-
being (change values)...........................................................................................................................................................................
Analysis 1.44. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 44 MOS SF Physical role
(follow-up values)..................................................................................................................................................................................
Analysis 1.45. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 45 MOS SF Physical role
(change values).....................................................................................................................................................................................
Analysis 1.46. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 46 EORTC QLQ-C30 Role
function (follow-up values)..................................................................................................................................................................

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

240

241

241

242

242

243

243

243

244

244

245

246

246

247

247

248

248

249

249

250

250

251

251

252

253

253

253

254

ii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.47. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 47 EORTC QLQ-C30 Role
function (change values)......................................................................................................................................................................
Analysis 1.48. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 48 Overall social well-
being/function (follow-up values).......................................................................................................................................................
Analysis 1.49. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 49 Overall social well-
being/function (change values)...........................................................................................................................................................
Analysis 1.50. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 50 FACT Social well-being
(follow-up values)..................................................................................................................................................................................
Analysis 1.51. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 51 FACT Social well-being
(change values).....................................................................................................................................................................................
Analysis  1.52.  Comparison  1  Comparison:  HRQoL  outcomes,  all  physical  activity  vs  control,  Outcome  52  MOS  SF  Social
functioning (follow-up values).............................................................................................................................................................
Analysis  1.53.  Comparison  1  Comparison:  HRQoL  outcomes,  all  physical  activity  vs  control,  Outcome  53  MOS  SF  Social
functioning (change values).................................................................................................................................................................
Analysis 1.54. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 54 EORTC QLQ-C30 Social
function (follow-up values)..................................................................................................................................................................
Analysis 1.55. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 55 EORTC QLQ-C30 Social
function (change values)......................................................................................................................................................................
Analysis  1.56.  Comparison  1  Comparison:  HRQoL  outcomes,  all  physical  activity  vs  control,  Outcome  56  Overall  cognitive
function (follow-up values)..................................................................................................................................................................
Analysis  1.57.  Comparison  1  Comparison:  HRQoL  outcomes,  all  physical  activity  vs  control,  Outcome  57  Overall  cognitive
function (change values)......................................................................................................................................................................
Analysis  1.58.  Comparison  1  Comparison:  HRQoL  outcomes,  all  physical  activity  vs  control,  Outcome  58  EORTC  QLQ-C30
Cognitive function (follow-up values).................................................................................................................................................
Analysis  1.59.  Comparison  1  Comparison:  HRQoL  outcomes,  all  physical  activity  vs  control,  Outcome  59  EORTC  QLQ-C30
Cognitive function (change values).....................................................................................................................................................
Analysis  1.60.  Comparison  1  Comparison:  HRQoL  outcomes,  all  physical  activity  vs  control,  Outcome  60  POMS  confusion
subscale (follow-up values)..................................................................................................................................................................
Analysis 1.61. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 61 Overall general health
(follow-up values)..................................................................................................................................................................................
Analysis 1.62. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 62 Overall general health
(change values).....................................................................................................................................................................................
Analysis 1.63. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 63 MOS SF General health
(follow-up values)..................................................................................................................................................................................
Analysis 1.64. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 64 MOS SF General health
(change values).....................................................................................................................................................................................
Analysis 1.65. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 65 Overall sexual function
(follow-up values)..................................................................................................................................................................................
Analysis 1.66. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 66 Overall sexual function
(change values).....................................................................................................................................................................................
Analysis 1.67. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 67 Body Esteem Scale -
sexual attractiveness (follow-up values).............................................................................................................................................
Analysis 1.68. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 68 Overall sleep (follow-
up values)..............................................................................................................................................................................................
Analysis 1.69. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 69 Overall sleep (change
values)....................................................................................................................................................................................................
Analysis 1.70. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 70 PSQI Global sleep score
(follow-up values)..................................................................................................................................................................................
Analysis 1.71. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 71 PSQI Global sleep score
(change values).....................................................................................................................................................................................
Analysis 1.72. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 72 PSQI sleep quality
(follow-up values)..................................................................................................................................................................................
Analysis 1.73. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 73 PSQI sleep efficiency
(follow-up values)..................................................................................................................................................................................
Analysis 1.74. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 74 PSQI sleep latency
(follow-up values)..................................................................................................................................................................................

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

254

255

255

256

257

257

258

258

258

259

259

260

260

261

261

262

262

263

263

263

264

264

265

265

266

266

266

267

iii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.75. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 75 PSQI sleep duration
(follow-up values)..................................................................................................................................................................................
Analysis  1.76.  Comparison  1  Comparison:  HRQoL  outcomes,  all  physical  activity  vs  control,  Outcome  76  PSQI  daytime
dysfunction (follow-up values).............................................................................................................................................................
Analysis 1.77. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 77 PSQI medication use
(follow-up values)..................................................................................................................................................................................
Analysis 1.78. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 78 Accelerator-derived
sleep efficiency (follow-up values)......................................................................................................................................................
Analysis 1.79. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 79 Accelerator-derived
sleep latency (follow-up values)..........................................................................................................................................................
Analysis 2.1. Comparison 2 Comparison: anxiety, all physical activity vs control, Outcome 1 Overall anxiety (follow-up values).....
Analysis 2.2. Comparison 2 Comparison: anxiety, all physical activity vs control, Outcome 2 Overall anxiety (change values).......
Analysis 2.3. Comparison 2 Comparison: anxiety, all physical activity vs control, Outcome 3 POMS tension - anxiety (follow-up
values)....................................................................................................................................................................................................
Analysis 2.4. Comparison 2 Comparison: anxiety, all physical activity vs control, Outcome 4 State Trait Anxiety Inventory (follow-
up values)..............................................................................................................................................................................................
Analysis 2.5. Comparison 2 Comparison: anxiety, all physical activity vs control, Outcome 5 Cohen's Perceived Stress Scale.......
Analysis 3.1. Comparison 3 Comparison: depression, all physical activity vs control, Outcome 1 Overall depression (follow-up
values)....................................................................................................................................................................................................
Analysis 3.2. Comparison 3 Comparison: depression, all physical activity vs control, Outcome 2 Overall depression (change
values)....................................................................................................................................................................................................
Analysis 3.3. Comparison 3 Comparison: depression, all physical activity vs control, Outcome 3 Beck Depression Inventory-II
(follow-up values)..................................................................................................................................................................................
Analysis 3.4. Comparison 3 Comparison: depression, all physical activity vs control, Outcome 4 Beck Depression Inventory-II
(change values).....................................................................................................................................................................................
Analysis 3.5. Comparison 3 Comparison: depression, all physical activity vs control, Outcome 5 CES-Depression scale (follow-
up values)..............................................................................................................................................................................................
Analysis 3.6. Comparison 3 Comparison: depression, all physical activity vs control, Outcome 6 POMS depression subscale
(follow-up values)..................................................................................................................................................................................
Analysis 3.7. Comparison 3 Comparison: depression, all physical activity vs control, Outcome 7 POMS tension subscale (follow-
up values)..............................................................................................................................................................................................
Analysis 4.1. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 1 Overall fatigue (follow-
up values)..............................................................................................................................................................................................
Analysis 4.2. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 2 Overall fatigue (change
values)....................................................................................................................................................................................................
Analysis 4.3. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 3 FACT-Fatigue (follow-
up values)..............................................................................................................................................................................................
Analysis 4.4. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 4 FACT-Fatigue (change
values)....................................................................................................................................................................................................
Analysis 4.5. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 5 EORTC QLQ-C30 Fatigue
scale (follow-up values)........................................................................................................................................................................
Analysis 4.6. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 6 EORTC QLQ-C30 Fatigue
scale (change values)............................................................................................................................................................................
Analysis 4.7. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 7 Multidimensional Fatigue
Symptom Inventory (follow-up values)...............................................................................................................................................
Analysis 4.8. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 8 Multidimensional Fatigue
Symptom Inventory - interference (follow-up values)........................................................................................................................
Analysis 4.9. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 9 Revised Piper Fatigue
Scale total fatigue (follow-up values)..................................................................................................................................................
Analysis 4.10. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 10 Revised Piper Fatigue
Scale total fatigue (change values)......................................................................................................................................................
Analysis 4.11. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 11 Revised Piper Fatigue
Scale behavioural/severity (follow-up values)....................................................................................................................................
Analysis 4.12. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 12 Revised Piper Fatigue
Scale affective/meaning (follow-up values)........................................................................................................................................

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

267

268

268

268

269

270
271
271

271

272
273

274

275

275

275

276

276

281

282

282

283

283

284

284

284

285

285

286

286

iv

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.13. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 13 Revised Piper Fatigue
Scale sensory (follow-up values).........................................................................................................................................................
Analysis 4.14. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 14 Revised Piper Fatigue
Scale cognitive/mood (follow-up values)............................................................................................................................................
Analysis  4.15.  Comparison  4  Comparison:  fatigue  and  vigour,  all  physical  activity  vs  control,  Outcome  15  Schwartz  Cancer
Fatigue Scale (follow-up values)..........................................................................................................................................................
Analysis 4.16. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 16 POMS fatigue scale
(follow-up values)..................................................................................................................................................................................
Analysis 4.17. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 17 Visual analogue scale
fatigue (follow-up and change values)................................................................................................................................................
Analysis 4.18. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 18 Overall vigour/vitality
(follow-up values)..................................................................................................................................................................................
Analysis 4.19. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 19 Overall vigour/vitality
(change values).....................................................................................................................................................................................
Analysis 4.20. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 20 MOS SF vitality (follow-
up values)..............................................................................................................................................................................................
Analysis 4.21. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 21 MOS SF vitality (change
values)....................................................................................................................................................................................................
Analysis 4.22. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 22 POMS vigour scale
(follow-up values)..................................................................................................................................................................................
Analysis 4.23. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 23 POMS vigour scale
(change values).....................................................................................................................................................................................
Analysis  5.1.  Comparison  5  Comparison:  pain/disability,  all  physical  activity  vs  control,  Outcome  1  Overall  pain/disability
(follow-up values)..................................................................................................................................................................................
Analysis  5.2.  Comparison  5  Comparison:  pain/disability,  all  physical  activity  vs  control,  Outcome  2  Overall  pain/disability
(change values).....................................................................................................................................................................................
Analysis 5.3. Comparison 5 Comparison: pain/disability, all physical activity vs control, Outcome 3 Brief Pain Inventory severity
score (change values)...........................................................................................................................................................................
Analysis  5.4.  Comparison  5  Comparison:  pain/disability,  all  physical  activity  vs  control,  Outcome  4  Brief  Pain  Inventory
interference score (change values)......................................................................................................................................................
Analysis 5.5. Comparison 5 Comparison: pain/disability, all physical activity vs control, Outcome 5 DASH (follow-up and change
values)....................................................................................................................................................................................................
Analysis 5.6. Comparison 5 Comparison: pain/disability, all physical activity vs control, Outcome 6 EORTC QLQ-C30 Pain scale
(follow-up and change values).............................................................................................................................................................
Analysis 5.7. Comparison 5 Comparison: pain/disability, all physical activity vs control, Outcome 7 MOS SF Pain (follow-up
values)....................................................................................................................................................................................................
Analysis  5.8.  Comparison  5  Comparison:  pain/disability,  all  physical  activity  vs  control,  Outcome  8  MOS  SF  Pain  (change
values)....................................................................................................................................................................................................
Analysis 5.9. Comparison 5 Comparison: pain/disability, all physical activity vs control, Outcome 9 WOMAC joint pain (follow-
up and change values).........................................................................................................................................................................
Analysis  5.10.  Comparison  5  Comparison:  pain/disability,  all  physical  activity  vs  control,  Outcome  10  WOMAC  physical
dysfunction (follow-up and change values)........................................................................................................................................
Analysis 5.11. Comparison 5 Comparison: pain/disability, all physical activity vs control, Outcome 11 WOMAC total score (follow-
up and change values).........................................................................................................................................................................
Analysis 6.1. Comparison 6 Comparison: self-esteem, all physical activity vs control, Outcome 1 Overall self-esteem/body image
(follow-up values)..................................................................................................................................................................................
Analysis 6.2. Comparison 6 Comparison: self-esteem, all physical activity vs control, Outcome 2 Overall self-esteem/body image
(change values).....................................................................................................................................................................................
Analysis 6.3. Comparison 6 Comparison: self-esteem, all physical activity vs control, Outcome 3 Body Esteem Scale - weight
concern (follow-up values)...................................................................................................................................................................
Analysis 6.4. Comparison 6 Comparison: self-esteem, all physical activity vs control, Outcome 4 Physical self-perception profile
- attractiveness of body (follow-up values).........................................................................................................................................
Analysis 6.5. Comparison 6 Comparison: self-esteem, all physical activity vs control, Outcome 5 Physical self-perception profile
- attractiveness of body (change values).............................................................................................................................................
Analysis 6.6. Comparison 6 Comparison: self-esteem, all physical activity vs control, Outcome 6 Rosenberg Self-Esteem Scale
(follow-up values)..................................................................................................................................................................................

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

287

287

287

288

288

289

289

290

290

291

291

293

294

294

295

295

296

296

296

297

297

298

299

300

300

301

301

302

v

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 6.7. Comparison 6 Comparison: self-esteem, all physical activity vs control, Outcome 7 Rosenberg Self-Esteem Scale
(change values).....................................................................................................................................................................................
Analysis 6.8. Comparison 6 Comparison: self-esteem, all physical activity vs control, Outcome 8 EORTC QLQ-C30 Body image
(follow-up and change values).............................................................................................................................................................
Analysis  7.1.  Comparison  7  Comparison:  cardiorespiratory  fitness,  all  physical  activity  vs  control,  Outcome  1  Overall
cardiorespiratory fitness (follow-up values).......................................................................................................................................
Analysis  7.2.  Comparison  7  Comparison:  cardiorespiratory  fitness,  all  physical  activity  vs  control,  Outcome  2  Overall
cardiorespiratory fitness (change values)...........................................................................................................................................
Analysis 7.3. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control, Outcome 3 Directly assessed
VO2max/peak (follow-up values)..........................................................................................................................................................
Analysis 7.4. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control, Outcome 4 Directly assessed
VO2max/peak (change values).............................................................................................................................................................
Analysis 7.5. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control, Outcome 5 Directly assessed
VO2max/peak - treadmill (follow-up and change values)...................................................................................................................
Analysis 7.6. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control, Outcome 6 Directly assessed
VO2max/peak - cycle ergometer (follow-up values)...........................................................................................................................
Analysis 7.7. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control, Outcome 7 Peak Power Output
- cycle ergometer test (follow-up values)............................................................................................................................................
Analysis 7.8. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control, Outcome 8 Peak Respiratory
Exchange Ratio - cycle ergometer test (follow-up values).................................................................................................................
Analysis 7.9. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control, Outcome 9 Peak Heart Rate
- cycle ergometer test (follow-up values)............................................................................................................................................
Analysis 7.10. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control, Outcome 10 Ebbeling single-
stage treadmill test (follow-up and change values)...........................................................................................................................
Analysis 7.11. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control, Outcome 11 Modified Bruce
treadmill test (follow-up and change values).....................................................................................................................................
Analysis  7.12.  Comparison  7  Comparison:  cardiorespiratory  fitness,  all  physical  activity  vs  control,  Outcome  12  Naughton
submaximal treadmill test (follow-up and change values)................................................................................................................
Analysis  7.13.  Comparison  7  Comparison:  cardiorespiratory  fitness,  all  physical  activity  vs  control,  Outcome  13
Cardiorespiratory fitness walk tests (follow-up values).....................................................................................................................
Analysis  7.14.  Comparison  7  Comparison:  cardiorespiratory  fitness,  all  physical  activity  vs  control,  Outcome  14
Cardiorespiratory fitness walk tests (change values).........................................................................................................................
Analysis 7.15. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control, Outcome 15 6-Minute walk
test (follow-up and change values).....................................................................................................................................................
Analysis 7.16. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control, Outcome 16 12-Minute walk
test (follow-up values)..........................................................................................................................................................................
Analysis 7.17. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control, Outcome 17 2-Kilometer
walk test (follow-up and change values).............................................................................................................................................
Analysis 7.18. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control, Outcome 18 Resting Heart
Rate (follow-up values).........................................................................................................................................................................
Analysis 7.19. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control, Outcome 19 Resting Heart
Rate (change values).............................................................................................................................................................................
Analysis 7.20. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control, Outcome 20 Resting Systolic
Blood Pressure (follow-up values).......................................................................................................................................................
Analysis 7.21. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control, Outcome 21 Resting Systolic
Blood Pressure (change values)...........................................................................................................................................................
Analysis 7.22. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control, Outcome 22 Resting Diastolic
Blood Pressure (follow-up values).......................................................................................................................................................
Analysis 7.23. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control, Outcome 23 Resting Diastolic
Blood Pressure (change values)...........................................................................................................................................................
Analysis  8.1.  Comparison  8  Comparison:  physical  activity,  all  physical  activity  vs  control,  Outcome  1  Overall  self-reported
physical activity (follow-up values).....................................................................................................................................................
Analysis  8.2.  Comparison  8  Comparison:  physical  activity,  all  physical  activity  vs  control,  Outcome  2  Overall  self-reported
physical activity (change values).........................................................................................................................................................
Analysis 8.3. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 3 Self-reported total physical
activity (follow-up values)....................................................................................................................................................................

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

302

302

307

308

308

309

309

309

310

310

311

311

311

312

312

313

313

314

314

314

315

315

316

316

316

322

322

323

vi

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 8.4. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 4 Self-reported total physical
activity (change values)........................................................................................................................................................................
Analysis 8.5. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 5 Self-reported moderate
physical activity (follow-up values).....................................................................................................................................................
Analysis 8.6. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 6 Self-reported moderate
physical activity (change values).........................................................................................................................................................
Analysis 8.7. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 7 Self-reported moderate-
vigorous physical activity (follow-up values)......................................................................................................................................
Analysis 8.8. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 8 Self-reported moderate-
vigorous physical activity (change values)..........................................................................................................................................
Analysis 8.9. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 9 Self-reported vigorous
physical activity (follow-up values).....................................................................................................................................................
Analysis 8.10. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 10 Self-reported vigorous
physical activity (change values).........................................................................................................................................................
Analysis 8.11. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 11 Self-reported walking
(follow-up values)..................................................................................................................................................................................
Analysis 8.12. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 12 Self-reported walking
(change values).....................................................................................................................................................................................
Analysis 8.13. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 13 7-Day PAR self-reported
moderate physical activity (follow-up values)....................................................................................................................................
Analysis 8.14. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 14 7-day PAR self-reported
moderate-vigorous physical activity (follow-up values)....................................................................................................................
Analysis 8.15. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 15 Godin LSI self-reported
moderate-vigorous physical activity (follow-up values)....................................................................................................................
Analysis 8.16. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 16 Meeting recommended
physical activity guidelines (follow-up values)...................................................................................................................................
Analysis 8.17. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 17 Overall objective physical
activity (follow-up values)....................................................................................................................................................................
Analysis 8.18. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 18 Overall objective physical
activity (change values)........................................................................................................................................................................
Analysis 8.19. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 19 Objective moderate-
vigorous physical activity (follow-up values)......................................................................................................................................
Analysis 8.20. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 20 Objective moderate-
vigorous physical activity (change values)..........................................................................................................................................
Analysis  8.21.  Comparison  8  Comparison:  physical  activity,  all  physical  activity  vs  control,  Outcome  21  Objective  vigorous
physical activity (follow-up values).....................................................................................................................................................
Analysis 8.22. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 22 Accelerometer counts
(follow-up values)..................................................................................................................................................................................
Analysis  8.23.  Comparison  8  Comparison:  physical  activity,  all  physical  activity  vs  control,  Outcome  23  Pedometer/
accelerometer steps/d (follow-up values)...........................................................................................................................................
Analysis  8.24.  Comparison  8  Comparison:  physical  activity,  all  physical  activity  vs  control,  Outcome  24  Pedometer/
accelerometer steps/d (change values)...............................................................................................................................................
Analysis  8.25.  Comparison  8  Comparison:  physical  activity,  all  physical  activity  vs  control,  Outcome  25  Overall  sedentary
behaviour (follow-up values)...............................................................................................................................................................
Analysis 8.26. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 26 Objective sedentary
behaviour (follow-up values)...............................................................................................................................................................
Analysis 8.27. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 27 Objective sedentary
behaviour (change values)...................................................................................................................................................................
Analysis 9.1. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control, Outcome 1 Mass (follow-
up values)..............................................................................................................................................................................................
Analysis 9.2. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control, Outcome 2 Mass (change
values)....................................................................................................................................................................................................
Analysis 9.3. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control, Outcome 3 BMI (follow-up
values)....................................................................................................................................................................................................
Analysis 9.4. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control, Outcome 4 BMI (change
values)....................................................................................................................................................................................................

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

324

324

325

325

326

326

326

327

327

328

328

329

329

330

330

331

331

332

332

332

333

333

334

334

338

339

339

340

vii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 9.5. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control, Outcome 5 Overall body fat
(follow-up values)..................................................................................................................................................................................
Analysis 9.6. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control, Outcome 6 Overall body fat
(change values).....................................................................................................................................................................................
Analysis 9.7. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control, Outcome 7 Percentage body
fat - DEXA (follow-up values)................................................................................................................................................................
Analysis 9.8. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control, Outcome 8 Percentage body
fat - DEXA (change values)....................................................................................................................................................................
Analysis 9.9. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control, Outcome 9 Percentage body
fat - BIA (follow-up values)...................................................................................................................................................................
Analysis 9.10. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control, Outcome 10 Percentage
body fat - BIA (change values).............................................................................................................................................................
Analysis 9.11. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control, Outcome 11 Percentage
body fat - SKF (follow-up values).........................................................................................................................................................
Analysis  9.12.  Comparison  9  Comparison:  anthropometric  outcomes,  all  physical  activity  vs  control,  Outcome  12  Fat  mass
(follow-up values)..................................................................................................................................................................................
Analysis  9.13.  Comparison  9  Comparison:  anthropometric  outcomes,  all  physical  activity  vs  control,  Outcome  13  Fat  mass
(change values).....................................................................................................................................................................................
Analysis 9.14. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control, Outcome 14 Fat mass -
DEXA (follow-up values)........................................................................................................................................................................
Analysis 9.15. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control, Outcome 15 Fat mass -
DEXA (change values)...........................................................................................................................................................................
Analysis 9.16. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control, Outcome 16 Lean mass
(follow-up values)..................................................................................................................................................................................
Analysis 9.17. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control, Outcome 17 Lean mass
(change values).....................................................................................................................................................................................
Analysis 9.18. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control, Outcome 18 Lean mass -
DEXA (follow-up values)........................................................................................................................................................................
Analysis 9.19. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control, Outcome 19 Lean mass -
DEXA (change values)...........................................................................................................................................................................
Analysis 9.20. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control, Outcome 20 Waist-to-hip
ratio (follow-up values).........................................................................................................................................................................
Analysis 9.21. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control, Outcome 21 Waist-to-hip
ratio (change values)............................................................................................................................................................................
Analysis  9.22.  Comparison  9  Comparison:  anthropometric  outcomes,  all  physical  activity  vs  control,  Outcome  22  Waist
circumference (follow-up values).........................................................................................................................................................
Analysis  9.23.  Comparison  9  Comparison:  anthropometric  outcomes,  all  physical  activity  vs  control,  Outcome  23  Waist
circumference (change values)............................................................................................................................................................
Analysis  9.24.  Comparison  9  Comparison:  anthropometric  outcomes,  all  physical  activity  vs  control,  Outcome  24  Hip
circumference (follow-up values).........................................................................................................................................................
Analysis  9.25.  Comparison  9  Comparison:  anthropometric  outcomes,  all  physical  activity  vs  control,  Outcome  25  Hip
circumference (change values)............................................................................................................................................................
Analysis 10.1. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 1 Lower body strength
(follow-up values)..................................................................................................................................................................................
Analysis 10.2. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 2 Lower body strength
(change values).....................................................................................................................................................................................
Analysis 10.3. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 3 Leg press (follow-up
values)....................................................................................................................................................................................................
Analysis 10.4. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 4 Leg press (change
values)....................................................................................................................................................................................................
Analysis 10.5. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 5 Back & leg strength
(follow-up values)..................................................................................................................................................................................
Analysis 10.6. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 6 Leg extension (follow-
up values)..............................................................................................................................................................................................
Analysis 10.7. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 7 Leg extension (change
values)....................................................................................................................................................................................................

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

341

341

342

342

343

343

344

344

344

345

345

346

346

347

347

347

348

348

349

349

350

353

353

354

354

355

355

356

viii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 10.8. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 8 Hip extension (follow-
up values)..............................................................................................................................................................................................
Analysis 10.9. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 9 Hip flexion (follow-
up values)..............................................................................................................................................................................................
Analysis 10.10. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 10 Leg flexion (follow-
up values)..............................................................................................................................................................................................
Analysis 10.11. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 11 Upper body strength
(follow-up values)..................................................................................................................................................................................
Analysis 10.12. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 12 Upper body strength
(change values).....................................................................................................................................................................................
Analysis 10.13. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 13 Chest press (follow-
up values)..............................................................................................................................................................................................
Analysis 10.14. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 14 Chest press (change
values)....................................................................................................................................................................................................
Analysis  10.15.  Comparison  10  Comparison:  muscular  strength,  all  physical  activity  vs  control,  Outcome  15  Grip  strength
(follow-up).............................................................................................................................................................................................
Analysis  10.16.  Comparison  10  Comparison:  muscular  strength,  all  physical  activity  vs  control,  Outcome  16  Grip  strength
(change values).....................................................................................................................................................................................
Analysis 10.17. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 17 Grip strength right
hand (follow-up)....................................................................................................................................................................................
Analysis 10.18. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 18 Grip strength left
hand (follow-up)....................................................................................................................................................................................
Analysis  10.19.  Comparison  10  Comparison:  muscular  strength,  all  physical  activity  vs  control,  Outcome  19  Elbow  flexion
(follow-up values)..................................................................................................................................................................................
Analysis  11.1.  Comparison  11  Comparison:  bone  health,  all  physical  activity  vs  control,  Outcome  1  Bone  mineral  content
(follow-up and change values).............................................................................................................................................................
Analysis  11.2.  Comparison  11  Comparison:  bone  health,  all  physical  activity  vs  control,  Outcome  2  Bone  mineral  density  -
femoral neck (follow-up and change values)......................................................................................................................................
Analysis  11.3.  Comparison  11  Comparison:  bone  health,  all  physical  activity  vs  control,  Outcome  3  Bone  mineral  density  -
lumbar spine (follow-up and change values)......................................................................................................................................
Analysis 11.4. Comparison 11 Comparison: bone health, all physical activity vs control, Outcome 4 Bone mineral density - total
hip (follow-up and change values)......................................................................................................................................................
Analysis 11.5. Comparison 11 Comparison: bone health, all physical activity vs control, Outcome 5 Bone formation - alkaline
phosphatase (follow-up and change values)......................................................................................................................................
Analysis 11.6. Comparison 11 Comparison: bone health, all physical activity vs control, Outcome 6 Bone resorption - serum NTx
(follow-up and change values).............................................................................................................................................................
Analysis 12.1. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 1 Overall HRQoL (follow-up values)........
Analysis 12.2. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 2 Overall HRQoL (change values)...........
Analysis 12.3. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 3 Overall emotional function/mental
health (follow-up values)......................................................................................................................................................................
Analysis 12.4. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 4 Overall emotional function/mental
health (change values)..........................................................................................................................................................................
Analysis 12.5. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 5 Overall physical function (follow-up
values)....................................................................................................................................................................................................
Analysis  12.6.  Comparison  12  Subanalysis:  outcomes  by  menopausal  status,  Outcome  6  Overall  physical  function  (change
values)....................................................................................................................................................................................................
Analysis  12.7.  Comparison  12  Subanalysis:  outcomes  by  menopausal  status,  Outcome  7  Overall  role  function  (follow-up
values)....................................................................................................................................................................................................
Analysis 12.8. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 8 Overall role function (change values)....
Analysis  12.9.  Comparison  12  Subanalysis:  outcomes  by  menopausal  status,  Outcome  9  Overall  social  well-being/function
(follow-up values)..................................................................................................................................................................................
Analysis 12.10. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 10 Overall social well-being/function
(change values).....................................................................................................................................................................................
Analysis 12.11. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 11 Overall cognitive function (follow-
up values)..............................................................................................................................................................................................

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

356

356

357

357

358

358

359

359

360

360

360

361

362

363

363

364

364

365

373
373
374

374

375

375

376

376
377

377

378

ix

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 12.12. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 12 Overall cognitive function (change
values)....................................................................................................................................................................................................
Analysis 12.13. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 13 Overall general health (follow-up
values)....................................................................................................................................................................................................
Analysis  12.14.  Comparison  12  Subanalysis:  outcomes  by  menopausal  status,  Outcome  14  Overall  general  health  (change
values)....................................................................................................................................................................................................
Analysis 12.15. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 15 Overall sexual function (follow-up
values)....................................................................................................................................................................................................
Analysis  12.16.  Comparison  12  Subanalysis:  outcomes  by  menopausal  status,  Outcome  16  Overall  sexual  function  (change
values)....................................................................................................................................................................................................
Analysis 12.17. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 17 Overall sleep (follow-up values).......
Analysis 12.18. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 18 Overall sleep (change values).........
Analysis 12.19. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 19 Overall anxiety (follow-up values).....
Analysis 12.20. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 20 Overall anxiety (change values).......
Analysis  12.21.  Comparison  12  Subanalysis:  outcomes  by  menopausal  status,  Outcome  21  Overall  self-esteem/body  image
(follow-up values)..................................................................................................................................................................................
Analysis  12.22.  Comparison  12  Subanalysis:  outcomes  by  menopausal  status,  Outcome  22  Overall  self-esteem/body  image
(change values).....................................................................................................................................................................................
Analysis  12.23.  Comparison  12  Subanalysis:  outcomes  by  menopausal  status,  Outcome  23  Overall  depression  (follow-up
values)....................................................................................................................................................................................................
Analysis 12.24. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 24 Overall depression (change values)....
Analysis 12.25. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 25 Overall fatigue (follow-up values).....
Analysis 12.26. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 26 Overall fatigue (change values)........
Analysis 12.27. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 27 Overall pain/disability (follow-up
values)....................................................................................................................................................................................................
Analysis  12.28.  Comparison  12  Subanalysis:  outcomes  by  menopausal  status,  Outcome  28  Overall  pain/disability  (change
values)....................................................................................................................................................................................................
Analysis 12.29. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 29 Overall cardiorespiratory fitness
(follow-up values)..................................................................................................................................................................................
Analysis 12.30. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 30 Overall cardiorespiratory fitness
(change values).....................................................................................................................................................................................
Analysis 12.31. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 31 Overall self-reported physical activity
(follow-up values)..................................................................................................................................................................................
Analysis 12.32. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 32 Overall self-reported physical activity
(change values).....................................................................................................................................................................................
Analysis 12.33. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 33 Overall objective physical activity
(follow-up values)..................................................................................................................................................................................
Analysis 12.34. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 34 Overall objective physical activity
(change values).....................................................................................................................................................................................
Analysis 12.35. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 35 Mass (follow-up values)...................
Analysis 12.36. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 36 Mass (change values)......................
Analysis 12.37. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 37 BMI (follow-up values).....................
Analysis 12.38. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 38 BMI (change values)........................
Analysis 12.39. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 39 Overall body fat (follow-up values)....
Analysis 12.40. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 40 Overall body fat (change values)......
Analysis  12.41.  Comparison  12  Subanalysis:  outcomes  by  menopausal  status,  Outcome  41  Lower  body  strength  (follow-up
values)....................................................................................................................................................................................................
Analysis  12.42.  Comparison  12  Subanalysis:  outcomes  by  menopausal  status,  Outcome  42  Lower  body  strength  (change
values)....................................................................................................................................................................................................
Analysis  12.43.  Comparison  12  Subanalysis:  outcomes  by  menopausal  status,  Outcome  43  Upper  body  strength  (follow-up
values)....................................................................................................................................................................................................
Analysis  12.44.  Comparison  12  Subanalysis:  outcomes  by  menopausal  status,  Outcome  44  Upper  body  strength  (change
values)....................................................................................................................................................................................................
Analysis 12.45. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 45 Bone mineral density - femoral neck
(follow-up and change values).............................................................................................................................................................

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

378

378

379

379

380

380
380
381
381
382

382

382

383
383
384
385

385

385

386

386

387

387

388

388
389
389
390
390
391
391

392

392

393

393

x

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 12.46. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 46 Bone mineral density - lumbar spine
(follow-up and change values).............................................................................................................................................................
Analysis  13.1.  Comparison  13  Subanalysis:  outcomes  by  mode  of  physical  activity  intervention,  Outcome  1  Overall  HRQoL
(follow-up values)..................................................................................................................................................................................
Analysis  13.2.  Comparison  13  Subanalysis:  outcomes  by  mode  of  physical  activity  intervention,  Outcome  2  Overall  HRQoL
(change values).....................................................................................................................................................................................
Analysis 13.3. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 3 Overall emotional
function/mental health (follow-up values).........................................................................................................................................
Analysis 13.4. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 4 Overall emotional
function/mental health (change values).............................................................................................................................................
Analysis 13.5. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 5 Overall physical
function (follow-up values)..................................................................................................................................................................
Analysis 13.6. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 6 Overall physical
function (change values)......................................................................................................................................................................
Analysis 13.7. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 7 Overall role function
(follow-up values)..................................................................................................................................................................................
Analysis 13.8. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 8 Overall role function
(change values).....................................................................................................................................................................................
Analysis 13.9. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 9 Overall social well-
being/function (follow-up values).......................................................................................................................................................
Analysis 13.10. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 10 Overall social
well-being/function (change values)...................................................................................................................................................
Analysis 13.11. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 11 Overall cognitive
function (follow-up values)..................................................................................................................................................................
Analysis 13.12. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 12 Overall cognitive
function (change values)......................................................................................................................................................................
Analysis 13.13. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 13 Overall general
health (follow-up values)......................................................................................................................................................................
Analysis 13.14. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 14 Overall general
health (change values)..........................................................................................................................................................................
Analysis 13.15. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 15 Overall sexual
function (follow-up values)..................................................................................................................................................................
Analysis 13.16. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 16 Overall sexual
function (change values)......................................................................................................................................................................
Analysis 13.17. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 17 Overall sleep
(follow-up values)..................................................................................................................................................................................
Analysis 13.18. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 18 Overall sleep
(change values).....................................................................................................................................................................................
Analysis 13.19. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 19 Overall anxiety
(follow-up values)..................................................................................................................................................................................
Analysis 13.20. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 20 Overall anxiety
(change values).....................................................................................................................................................................................
Analysis  13.21.  Comparison  13  Subanalysis:  outcomes  by  mode  of  physical  activity  intervention,  Outcome  21  Overall
depression (follow-up values)..............................................................................................................................................................
Analysis  13.22.  Comparison  13  Subanalysis:  outcomes  by  mode  of  physical  activity  intervention,  Outcome  22  Overall
depression (change values)..................................................................................................................................................................
Analysis 13.23. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 23 Overall fatigue
(follow-up values)..................................................................................................................................................................................
Analysis 13.24. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 24 Overall fatigue
(change values).....................................................................................................................................................................................
Analysis 13.25. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 25 Overall pain/
disability (follow-up values).................................................................................................................................................................
Analysis 13.26. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 26 Overall pain/
disability (change values).....................................................................................................................................................................
Analysis  13.27.  Comparison  13  Subanalysis:  outcomes  by  mode  of  physical  activity  intervention,  Outcome  27  Overall  self-
esteem/body image (follow-up values)...............................................................................................................................................

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

394

407

408

409

410

411

412

413

413

414

415

416

417

417

418

419

419

420

421

421

422

422

423

424

425

426

427

427

xi

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis  13.28.  Comparison  13  Subanalysis:  outcomes  by  mode  of  physical  activity  intervention,  Outcome  28  Overall  self-
esteem/body image (change values)...................................................................................................................................................
Analysis  13.29.  Comparison  13  Subanalysis:  outcomes  by  mode  of  physical  activity  intervention,  Outcome  29  Overall
cardiorespiratory fitness (follow-up values).......................................................................................................................................
Analysis  13.30.  Comparison  13  Subanalysis:  outcomes  by  mode  of  physical  activity  intervention,  Outcome  30  Overall
cardiorespiratory fitness (change values)...........................................................................................................................................
Analysis  13.31.  Comparison  13  Subanalysis:  outcomes  by  mode  of  physical  activity  intervention,  Outcome  31  Overall  self-
reported physical activity (follow-up values)......................................................................................................................................
Analysis  13.32.  Comparison  13  Subanalysis:  outcomes  by  mode  of  physical  activity  intervention,  Outcome  32  Overall  self-
reported physical activity (change values)..........................................................................................................................................
Analysis 13.33. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 33 Overall objective
physical activity (follow-up values).....................................................................................................................................................
Analysis 13.34. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 34 Overall objective
physical activity (change values).........................................................................................................................................................
Analysis 13.35. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 35 Mass (follow-up
values)....................................................................................................................................................................................................
Analysis 13.36. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 36 Mass (change
values)....................................................................................................................................................................................................
Analysis 13.37. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 37 BMI (follow-up
values)....................................................................................................................................................................................................
Analysis  13.38.  Comparison  13  Subanalysis:  outcomes  by  mode  of  physical  activity  intervention,  Outcome  38  BMI  (change
values)....................................................................................................................................................................................................
Analysis 13.39. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 39 Overall body fat
(follow-up values)..................................................................................................................................................................................
Analysis 13.40. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 40 Overall body fat
(change values).....................................................................................................................................................................................
Analysis  13.41.  Comparison  13  Subanalysis:  outcomes  by  mode  of  physical  activity  intervention,  Outcome  41  Lower  body
strength (follow-up values)..................................................................................................................................................................
Analysis  13.42.  Comparison  13  Subanalysis:  outcomes  by  mode  of  physical  activity  intervention,  Outcome  42  Lower  body
strength (change values)......................................................................................................................................................................
Analysis  13.43.  Comparison  13  Subanalysis:  outcomes  by  mode  of  physical  activity  intervention,  Outcome  43  Upper  body
strength (follow-up values)..................................................................................................................................................................
Analysis  13.44.  Comparison  13  Subanalysis:  outcomes  by  mode  of  physical  activity  intervention,  Outcome  44  Upper  body
strength (change values)......................................................................................................................................................................
Analysis 13.45. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 45 Bone mineral
density - femoral neck (follow-up and change values)......................................................................................................................
Analysis 13.46. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 46 Bone mineral
density - lumbar spine (follow-up and change values)......................................................................................................................
Analysis 13.47. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome 47 Bone mineral
density - total hip (follow-up and change values)..............................................................................................................................
Analysis 14.1. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 1 Overall HRQoL
(follow-up values)..................................................................................................................................................................................
Analysis 14.2. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 2 Overall HRQoL
(change values).....................................................................................................................................................................................
Analysis 14.3. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 3 Overall emotional
function/mental health (follow-up values).........................................................................................................................................
Analysis 14.4. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 4 Overall emotional
function/mental health (change values).............................................................................................................................................
Analysis 14.5. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 5 Overall physical
function (follow-up values)..................................................................................................................................................................
Analysis 14.6. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 6 Overall physical
function (change values)......................................................................................................................................................................
Analysis  14.7.  Comparison  14  Subanalysis:  outcomes  by  intensity  of  physical  activity  intervention,  Outcome  7  Overall  role
function (follow-up values)..................................................................................................................................................................
Analysis  14.8.  Comparison  14  Subanalysis:  outcomes  by  intensity  of  physical  activity  intervention,  Outcome  8  Overall  role
function (change values)......................................................................................................................................................................

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

428

429

430

431

432

432

433

434

435

435

436

437

438

439

439

440

441

442

442

443

451

452

452

453

454

455

455

456

xii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 14.9. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 9 Overall social
well-being/function (follow-up values)...............................................................................................................................................
Analysis 14.10. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 10 Overall social
well-being/function (change values)...................................................................................................................................................
Analysis  14.11.  Comparison  14  Subanalysis:  outcomes  by  intensity  of  physical  activity  intervention,  Outcome  11  Overall
cognitive function (follow-up values)..................................................................................................................................................
Analysis  14.12.  Comparison  14  Subanalysis:  outcomes  by  intensity  of  physical  activity  intervention,  Outcome  12  Overall
cognitive function (change values)......................................................................................................................................................
Analysis 14.13. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 13 Overall general
health (follow-up values)......................................................................................................................................................................
Analysis 14.14. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 14 Overall general
health (change values)..........................................................................................................................................................................
Analysis 14.15. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 15 Overall sexual
function (follow-up values)..................................................................................................................................................................
Analysis 14.16. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 16 Overall sexual
function (change values)......................................................................................................................................................................
Analysis 14.17. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 17 Overall anxiety
(follow-up values)..................................................................................................................................................................................
Analysis 14.18. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 18 Overall anxiety
(change values).....................................................................................................................................................................................
Analysis  14.19.  Comparison  14  Subanalysis:  outcomes  by  intensity  of  physical  activity  intervention,  Outcome  19  Overall
depression (follow-up values)..............................................................................................................................................................
Analysis  14.20.  Comparison  14  Subanalysis:  outcomes  by  intensity  of  physical  activity  intervention,  Outcome  20  Overall
depression (change values)..................................................................................................................................................................
Analysis 14.21. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 21 Overall fatigue
(follow-up values)..................................................................................................................................................................................
Analysis 14.22. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 22 Overall fatigue
(change values).....................................................................................................................................................................................
Analysis 14.23. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 23 Overall pain/
disability (follow-up values).................................................................................................................................................................
Analysis 14.24. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 24 Overall pain/
disability (change values).....................................................................................................................................................................
Analysis 14.25. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 25 Overall self-
esteem/body image (follow-up values)...............................................................................................................................................
Analysis 14.26. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 26 Overall self-
esteem/body image (change values)...................................................................................................................................................
Analysis  14.27.  Comparison  14  Subanalysis:  outcomes  by  intensity  of  physical  activity  intervention,  Outcome  27  Overall
cardiorespiratory fitness (follow-up values).......................................................................................................................................
Analysis  14.28.  Comparison  14  Subanalysis:  outcomes  by  intensity  of  physical  activity  intervention,  Outcome  28  Overall
cardiorespiratory fitness (change values)...........................................................................................................................................
Analysis 14.29. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 29 Overall self-
reported physical activity (follow-up values)......................................................................................................................................
Analysis 14.30. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 30 Overall self-
reported physical activity (change values)..........................................................................................................................................
Analysis  14.31.  Comparison  14  Subanalysis:  outcomes  by  intensity  of  physical  activity  intervention,  Outcome  31  Overall
objective physical activity (follow-up values).....................................................................................................................................
Analysis  14.32.  Comparison  14  Subanalysis:  outcomes  by  intensity  of  physical  activity  intervention,  Outcome  32  Overall
objective physical activity (change values).........................................................................................................................................
Analysis 14.33. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 33 Mass (follow-
up values)..............................................................................................................................................................................................
Analysis 14.34. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 34 Mass (change
values)....................................................................................................................................................................................................
Analysis 14.35. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 35 BMI (follow-
up values)..............................................................................................................................................................................................
Analysis 14.36. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 36 BMI (change
values)....................................................................................................................................................................................................

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

457

457

458

458

459

459

460

460

461

461

462

462

463

463

464

465

465

466

466

467

467

468

469

469

470

471

471

472

xiii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 14.37. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 37 Overall body
fat (follow-up values)............................................................................................................................................................................
Analysis 14.38. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 38 Overall body
fat (change values)................................................................................................................................................................................
Analysis 14.39. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 39 Lower body
strength (follow-up values)..................................................................................................................................................................
Analysis 14.40. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 40 Lower body
strength (change values)......................................................................................................................................................................
Analysis 14.41. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 41 Upper body
strength (follow-up values)..................................................................................................................................................................
Analysis 14.42. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 42 Upper body
strength (change values)......................................................................................................................................................................
Analysis 14.43. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 43 Bone mineral
density - femoral neck (follow-up and change values)......................................................................................................................
Analysis 14.44. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 44 Bone mineral
density - lumbar spine (follow-up and change values)......................................................................................................................
Analysis 14.45. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome 45 Bone mineral
density - total hip (follow-up and change values)..............................................................................................................................
Analysis 15.1. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 1 Overall HRQoL
(follow-up values)..................................................................................................................................................................................
Analysis 15.2. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 2 Overall HRQoL
(change values).....................................................................................................................................................................................
Analysis 15.3. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 3 Overall emotional
function/mental health (follow-up values).........................................................................................................................................
Analysis 15.4. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 4 Overall emotional
function/mental health (change values).............................................................................................................................................
Analysis 15.5. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 5 Overall physical
function (follow-up values)..................................................................................................................................................................
Analysis 15.6. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 6 Overall physical
function (change values)......................................................................................................................................................................
Analysis  15.7.  Comparison  15  Subanalysis:  outcomes  by  duration  of  physical  activity  intervention,  Outcome  7  Overall  role
function (follow-up values)..................................................................................................................................................................
Analysis  15.8.  Comparison  15  Subanalysis:  outcomes  by  duration  of  physical  activity  intervention,  Outcome  8  Overall  role
function (change values)......................................................................................................................................................................
Analysis 15.9. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 9 Overall social
well-being/function (follow-up values)...............................................................................................................................................
Analysis 15.10. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 10 Overall social
well-being/function (change values)...................................................................................................................................................
Analysis  15.11.  Comparison  15  Subanalysis:  outcomes  by  duration  of  physical  activity  intervention,  Outcome  11  Overall
cognitive function (follow-up values)..................................................................................................................................................
Analysis  15.12.  Comparison  15  Subanalysis:  outcomes  by  duration  of  physical  activity  intervention,  Outcome  12  Overall
cognitive function (change values)......................................................................................................................................................
Analysis 15.13. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 13 Overall general
health (follow-up values)......................................................................................................................................................................
Analysis 15.14. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 14 Overall general
health (change values)..........................................................................................................................................................................
Analysis 15.15. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 15 Overall sexual
function (follow-up values)..................................................................................................................................................................
Analysis 15.16. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 16 Overall sexual
function (change values)......................................................................................................................................................................
Analysis 15.17. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 17 Overall sleep
(follow-up values)..................................................................................................................................................................................
Analysis 15.18. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 18 Overall sleep
(change values).....................................................................................................................................................................................
Analysis 15.19. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 19 Overall anxiety
(follow-up values)..................................................................................................................................................................................

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

472

473

474

474

475

475

476

476

476

484

485

485

486

487

488

488

489

490

490

491

491

492

492

493

493

494

494

494

xiv

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 15.20. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 20 Overall anxiety
(change values).....................................................................................................................................................................................
Analysis  15.21.  Comparison  15  Subanalysis:  outcomes  by  duration  of  physical  activity  intervention,  Outcome  21  Overall
depression (follow-up values)..............................................................................................................................................................
Analysis  15.22.  Comparison  15  Subanalysis:  outcomes  by  duration  of  physical  activity  intervention,  Outcome  22  Overall
depression (change values)..................................................................................................................................................................
Analysis 15.23. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 23 Overall fatigue
(follow-up values)..................................................................................................................................................................................
Analysis 15.24. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 24 Overall fatigue
(change values).....................................................................................................................................................................................
Analysis 15.25. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 25 Overall pain/
disability (follow-up values).................................................................................................................................................................
Analysis 15.26. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 26 Overall pain/
disability (change values).....................................................................................................................................................................
Analysis 15.27. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 27 Overall self-
esteem/body image (follow-up values)...............................................................................................................................................
Analysis 15.28. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 28 Overall self-
esteem/body image (change values)...................................................................................................................................................
Analysis  15.29.  Comparison  15  Subanalysis:  outcomes  by  duration  of  physical  activity  intervention,  Outcome  29  Overall
cardiorespiratory fitness (follow-up values).......................................................................................................................................
Analysis  15.30.  Comparison  15  Subanalysis:  outcomes  by  duration  of  physical  activity  intervention,  Outcome  30  Overall
cardiorespiratory fitness (change values)...........................................................................................................................................
Analysis 15.31. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 31 Overall self-
reported physical activity (follow-up values)......................................................................................................................................
Analysis 15.32. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 32 Overall self-
reported physical activity (change values)..........................................................................................................................................
Analysis  15.33.  Comparison  15  Subanalysis:  outcomes  by  duration  of  physical  activity  intervention,  Outcome  33  Overall
objective physical activity (follow-up values).....................................................................................................................................
Analysis  15.34.  Comparison  15  Subanalysis:  outcomes  by  duration  of  physical  activity  intervention,  Outcome  34  Overall
objective physical activity (change values).........................................................................................................................................
Analysis 15.35. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 35 Mass (follow-
up values)..............................................................................................................................................................................................
Analysis 15.36. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 36 Mass (change
values)....................................................................................................................................................................................................
Analysis 15.37. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 37 BMI (follow-
up values)..............................................................................................................................................................................................
Analysis 15.38. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 38 BMI (change
values)....................................................................................................................................................................................................
Analysis 15.39. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 39 Overall body
fat (follow-up values)............................................................................................................................................................................
Analysis 15.40. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 40 Overall body
fat (change values)................................................................................................................................................................................
Analysis 15.41. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 41 Lower body
strength (follow-up values)..................................................................................................................................................................
Analysis 15.42. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 42 Lower body
strength (change values)......................................................................................................................................................................
Analysis 15.43. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 43 Upper body
strength (follow-up values)..................................................................................................................................................................
Analysis 15.44. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome 44 Upper body
strength (change values)......................................................................................................................................................................
Analysis 16.1. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 1 Overall HRQoL (follow-up values).....
Analysis 16.2. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 2 Overall HRQoL (change values).......
Analysis 16.3. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 3 Overall emotional function/mental
health (follow-up values)......................................................................................................................................................................
Analysis 16.4. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 4 Overall emotional function/mental
health (change values)..........................................................................................................................................................................

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

495

495

496

496

497

498

498

499

499

500

501

501

502

503

503

504

504

505

506

506

507

507

508

508

509

519
520
521

522

xv

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 16.5. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 5 Overall physical function (follow-
up values)..............................................................................................................................................................................................
Analysis 16.6. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 6 Overall physical function (change
values)....................................................................................................................................................................................................
Analysis 16.7. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 7 Overall role function (follow-up
values)....................................................................................................................................................................................................
Analysis  16.8.  Comparison  16  Subanalysis:  outcomes  by  format  of  intervention,  Outcome  8  Overall  role  function  (change
values)....................................................................................................................................................................................................
Analysis 16.9. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 9 Overall social well-being/function
(follow-up values)..................................................................................................................................................................................
Analysis 16.10. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 10 Overall social well-being/function
(change values).....................................................................................................................................................................................
Analysis 16.11. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 11 Overall cognitive function (follow-
up values)..............................................................................................................................................................................................
Analysis  16.12.  Comparison  16  Subanalysis:  outcomes  by  format  of  intervention,  Outcome  12  Overall  cognitive  function
(change values).....................................................................................................................................................................................
Analysis 16.13. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 13 Overall general health (follow-
up values)..............................................................................................................................................................................................
Analysis 16.14. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 14 Overall general health (change
values)....................................................................................................................................................................................................
Analysis 16.15. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 15 Overall sexual function (follow-
up values)..............................................................................................................................................................................................
Analysis 16.16. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 16 Overall sleep (follow-up values)....
Analysis  16.17.  Comparison  16  Subanalysis:  outcomes  by  format  of  intervention,  Outcome  17  Overall  anxiety  (follow-up
values)....................................................................................................................................................................................................
Analysis 16.18. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 18 Overall anxiety (change values)....
Analysis  16.19.  Comparison  16  Subanalysis:  outcomes  by  format  of  intervention,  Outcome  19  Overall  depression  (change
values)....................................................................................................................................................................................................
Analysis 16.20. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 20 Overall depression (follow-up
values)....................................................................................................................................................................................................
Analysis  16.21.  Comparison  16  Subanalysis:  outcomes  by  format  of  intervention,  Outcome  21  Overall  fatigue  (follow-up
values)....................................................................................................................................................................................................
Analysis 16.22. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 22 Overall fatigue (change values).....
Analysis 16.23. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 23 Overall pain/disability (follow-
up values)..............................................................................................................................................................................................
Analysis 16.24. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 24 Overall pain/disability (change
values)....................................................................................................................................................................................................
Analysis 16.25. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 25 Overall self-esteem/body image
(follow-up values)..................................................................................................................................................................................
Analysis 16.26. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 26 Overall self-esteem/body image
(change values).....................................................................................................................................................................................
Analysis 16.27. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 27 Overall cardiorespiratory fitness
(follow-up values)..................................................................................................................................................................................
Analysis 16.28. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 28 Overall cardiorespiratory fitness
(change values).....................................................................................................................................................................................
Analysis 16.29. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 29 Overall self-reported physical
activity (follow-up values)....................................................................................................................................................................
Analysis 16.30. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 30 Overall self-reported physical
activity (change values)........................................................................................................................................................................
Analysis 16.31. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 31 Overall objective physical activity
(follow-up values)..................................................................................................................................................................................
Analysis 16.32. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 32 Overall objective physical activity
(change values).....................................................................................................................................................................................
Analysis 16.33. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 33 Mass (follow-up values).............
Analysis 16.34. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 34 Mass (change values).................
Analysis 16.35. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 35 BMI (follow-up values)...............

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

523

523

524

525

526

526

527

528

528

529

529

530
530

531
532

532

533

534
534

535

536

536

537

538

538

539

540

541

541
542
542

xvi

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 16.36. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 36 BMI (change values)...................
Analysis  16.37.  Comparison  16  Subanalysis:  outcomes  by  format  of  intervention,  Outcome  37  Overall  body  fat  (follow-up
values)....................................................................................................................................................................................................
Analysis  16.38.  Comparison  16  Subanalysis:  outcomes  by  format  of  intervention,  Outcome  38  Overall  body  fat  (change
values)....................................................................................................................................................................................................
Analysis 16.39. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 39 Lower body strength (follow-up
values)....................................................................................................................................................................................................
Analysis 16.40. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 40 Lower body strength (change
values)....................................................................................................................................................................................................
Analysis 16.41. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 41 Upper body strength (follow-up
values)....................................................................................................................................................................................................
Analysis 16.42. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 42 Upper body strength (change
values)....................................................................................................................................................................................................
Analysis 16.43. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 43 Bone mineral density - femoral
neck (follow-up and change values)....................................................................................................................................................
Analysis 16.44. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 44 Bone mineral density - lumbar
spine (follow-up and change values)...................................................................................................................................................
Analysis 16.45. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 45 Bone mineral density - total hip
(follow-up and change values).............................................................................................................................................................
Analysis 17.1. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 1 Overall HRQoL (follow-up values).....
Analysis 17.2. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 2 Overall HRQoL (change values).......
Analysis 17.3. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 3 Overall emotional function/mental
health (follow-up values)......................................................................................................................................................................
Analysis 17.4. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 4 Overall emotional function/mental
health (change values)..........................................................................................................................................................................
Analysis 17.5. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 5 Overall physical function (follow-
up values)..............................................................................................................................................................................................
Analysis 17.6. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 6 Overall physical function (change
values)....................................................................................................................................................................................................
Analysis 17.7. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 7 Overall role function (follow-up
values)....................................................................................................................................................................................................
Analysis  17.8.  Comparison  17  Subanalysis:  outcomes  by  setting  of  intervention,  Outcome  8  Overall  role  function  (change
values)....................................................................................................................................................................................................
Analysis 17.9. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 9 Overall social well-being/function
(follow-up values)..................................................................................................................................................................................
Analysis 17.10. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 10 Overall social well-being/function
(change values).....................................................................................................................................................................................
Analysis 17.11. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 11 Overall cognitive function (follow-
up values)..............................................................................................................................................................................................
Analysis  17.12.  Comparison  17  Subanalysis:  outcomes  by  setting  of  intervention,  Outcome  12  Overall  cognitive  function
(change values).....................................................................................................................................................................................
Analysis 17.13. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 13 Overall general health (follow-
up values)..............................................................................................................................................................................................
Analysis 17.14. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 14 Overall general health (change
values)....................................................................................................................................................................................................
Analysis 17.15. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 15 Overall sexual function (follow-
up values)..............................................................................................................................................................................................
Analysis 17.16. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 16 Overall sexual function (change
values)....................................................................................................................................................................................................
Analysis 17.17. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 17 Overall sleep (follow-up values)....
Analysis 17.18. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 18 Overall sleep (change values)......
Analysis  17.19.  Comparison  17  Subanalysis:  outcomes  by  setting  of  intervention,  Outcome  19  Overall  anxiety  (follow-up
values)....................................................................................................................................................................................................
Analysis 17.20. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 20 Overall anxiety (change values)....
Analysis 17.21. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 21 Overall depression (follow-up
values)....................................................................................................................................................................................................

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

543
544

545

545

546

546

547

548

548

549

559
560
561

562

563

564

564

565

566

567

567

568

568

569

570

570

571
571
572

572
573

xvii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis  17.22.  Comparison  17  Subanalysis:  outcomes  by  setting  of  intervention,  Outcome  22  Overall  depression  (change
values)....................................................................................................................................................................................................
Analysis  17.23.  Comparison  17  Subanalysis:  outcomes  by  setting  of  intervention,  Outcome  23  Overall  fatigue  (follow-up
values)....................................................................................................................................................................................................
Analysis 17.24. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 24 Overall fatigue (change values)....
Analysis 17.25. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 25 Overall pain/disability (follow-
up values)..............................................................................................................................................................................................
Analysis 17.26. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 26 Overall pain/disability (change
values)....................................................................................................................................................................................................
Analysis 17.27. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 27 Overall self-esteem/body image
(follow-up values)..................................................................................................................................................................................
Analysis 17.28. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 28 Overall self-esteem/body image
(change values).....................................................................................................................................................................................
Analysis 17.29. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 29 Overall cardiorespiratory fitness
(follow-up values)..................................................................................................................................................................................
Analysis 17.30. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 30 Overall cardiorespiratory fitness
(change values).....................................................................................................................................................................................
Analysis 17.31. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 31 Overall self-reported physical
activity (follow-up values)....................................................................................................................................................................
Analysis 17.32. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 32 Overall self-reported physical
activity (change values)........................................................................................................................................................................
Analysis 17.33. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 33 Overall objective physical activity
(follow-up values)..................................................................................................................................................................................
Analysis 17.34. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 34 Overall objective physical activity
(change values).....................................................................................................................................................................................
Analysis 17.35. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 35 Mass (follow-up values).............
Analysis 17.36. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 36 Mass (change values).................
Analysis 17.37. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 37 BMI (follow-up values)...............
Analysis 17.38. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 38 BMI (change values)...................
Analysis  17.39.  Comparison  17  Subanalysis:  outcomes  by  setting  of  intervention,  Outcome  39  Overall  body  fat  (follow-up
values)....................................................................................................................................................................................................
Analysis  17.40.  Comparison  17  Subanalysis:  outcomes  by  setting  of  intervention,  Outcome  40  Overall  body  fat  (change
values)....................................................................................................................................................................................................
Analysis 17.41. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 41 Lower body strength (follow-up
values)....................................................................................................................................................................................................
Analysis 17.42. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 42 Lower body strength (change
values)....................................................................................................................................................................................................
Analysis 17.43. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 43 Upper body strength (follow-up
values)....................................................................................................................................................................................................
Analysis 17.44. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 44 Upper body strength (change
values)....................................................................................................................................................................................................
Analysis 17.45. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 45 Bone mineral density - femoral
neck (follow-up and change values)....................................................................................................................................................
Analysis 17.46. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 46 Bone mineral density - lumbar
spine (follow-up and change values)...................................................................................................................................................
Analysis 17.47. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 47 Bone mineral density - total hip
(follow-up and change values).............................................................................................................................................................
Analysis 18.1. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 1 Overall HRQoL (follow-up values).........
Analysis 18.2. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 2 Overall HRQoL (change values).............
Analysis  18.3.  Comparison  18  Sensitivity  analysis:  outcomes  by  risk  of  bias,  Outcome  3  Overall  emotional  function/mental
health (follow-up values)......................................................................................................................................................................
Analysis  18.4.  Comparison  18  Sensitivity  analysis:  outcomes  by  risk  of  bias,  Outcome  4  Overall  emotional  function/mental
health (change values)..........................................................................................................................................................................
Analysis 18.5. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 5 Overall physical function (follow-up
values)....................................................................................................................................................................................................

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

573

574

575
576

576

577

577

578

579

580

580

581

582

582
583
584
585
585

586

587

587

588

589

589

590

590

598
599
600

600

601

xviii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis  18.6.  Comparison  18  Sensitivity  analysis:  outcomes  by  risk  of  bias,  Outcome  6  Overall  physical  function  (change
values)....................................................................................................................................................................................................
Analysis 18.7. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 7 Overall role function (follow-up values)....
Analysis 18.8. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 8 Overall role function (change values)......
Analysis  18.9.  Comparison  18  Sensitivity  analysis:  outcomes  by  risk  of  bias,  Outcome  9  Overall  social  well-being/function
(follow-up values)..................................................................................................................................................................................
Analysis 18.10. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 10 Overall social well-being/function
(change values).....................................................................................................................................................................................
Analysis 18.11. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 11 Overall cognitive function (follow-
up values)..............................................................................................................................................................................................
Analysis 18.12. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 12 Overall cognitive function (change
values)....................................................................................................................................................................................................
Analysis 18.13. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 13 Overall general health (follow-up
values)....................................................................................................................................................................................................
Analysis  18.14.  Comparison  18  Sensitivity  analysis:  outcomes  by  risk  of  bias,  Outcome  14  Overall  general  health  (change
values)....................................................................................................................................................................................................
Analysis 18.15. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 15 Overall sexual function (follow-up
values)....................................................................................................................................................................................................
Analysis  18.16.  Comparison  18  Sensitivity  analysis:  outcomes  by  risk  of  bias,  Outcome  16  Overall  sexual  function  (change
values)....................................................................................................................................................................................................
Analysis 18.17. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 17 Overall sleep (follow-up values)........
Analysis 18.18. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 18 Overall sleep (change values)...........
Analysis 18.19. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 19 Overall anxiety (follow-up values)......
Analysis 18.20. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 20 Overall anxiety (change values)........
Analysis  18.21.  Comparison  18  Sensitivity  analysis:  outcomes  by  risk  of  bias,  Outcome  21  Overall  self-esteem/body  image
(follow-up values)..................................................................................................................................................................................
Analysis  18.22.  Comparison  18  Sensitivity  analysis:  outcomes  by  risk  of  bias,  Outcome  22  Overall  self-esteem/body  image
(change values).....................................................................................................................................................................................
Analysis  18.23.  Comparison  18  Sensitivity  analysis:  outcomes  by  risk  of  bias,  Outcome  23  Overall  depression  (follow-up
values)....................................................................................................................................................................................................
Analysis 18.24. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 24 Overall depression (change values).....
Analysis 18.25. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 25 Overall fatigue (follow-up values).......
Analysis 18.26. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 26 Overall fatigue (change values).........
Analysis 18.27. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 27 Overall pain/disability (follow-up
values)....................................................................................................................................................................................................
Analysis  18.28.  Comparison  18  Sensitivity  analysis:  outcomes  by  risk  of  bias,  Outcome  28  Overall  pain/disability  (change
values)....................................................................................................................................................................................................
Analysis  18.29.  Comparison  18  Sensitivity  analysis:  outcomes  by  risk  of  bias,  Outcome  29  Overall  cardiorespiratory  fitness
(follow-up values)..................................................................................................................................................................................
Analysis  18.30.  Comparison  18  Sensitivity  analysis:  outcomes  by  risk  of  bias,  Outcome  30  Overall  cardiorespiratory  fitness
(change values).....................................................................................................................................................................................
Analysis 18.31. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 31 Overall self-reported physical activity
(follow-up values)..................................................................................................................................................................................
Analysis 18.32. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 32 Overall self-reported physical activity
(change values).....................................................................................................................................................................................
Analysis 18.33. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 33 Overall objective physical activity
(follow-up values)..................................................................................................................................................................................
Analysis 18.34. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 34 Overall objective physical activity
(change values).....................................................................................................................................................................................
Analysis 18.35. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 35 Mass (follow-up values).....................
Analysis 18.36. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 36 Mass (change values)........................
Analysis 18.37. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 37 BMI (follow-up values)......................
Analysis 18.38. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 38 BMI (change values)..........................
Analysis 18.39. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 39 Overall body fat (follow-up values)......
Analysis 18.40. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 40 Overall body fat (change values)........

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

602

603
603
604

605

605

606

606

607

607

608

608
608
609
609
610

610

611

611
612
613
613

614

614

615

616

617

617

618

618
619
619
620
621
621

xix

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis  18.41.  Comparison  18  Sensitivity  analysis:  outcomes  by  risk  of  bias,  Outcome  41  Lower  body  strength  (follow-up
values)....................................................................................................................................................................................................
Analysis  18.42.  Comparison  18  Sensitivity  analysis:  outcomes  by  risk  of  bias,  Outcome  42  Lower  body  strength  (change
values)....................................................................................................................................................................................................
Analysis  18.43.  Comparison  18  Sensitivity  analysis:  outcomes  by  risk  of  bias,  Outcome  43  Upper  body  strength  (follow-up
values)....................................................................................................................................................................................................
Analysis  18.44.  Comparison  18  Sensitivity  analysis:  outcomes  by  risk  of  bias,  Outcome  44  Upper  body  strength  (change
values)....................................................................................................................................................................................................
Analysis 18.45. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 45 Bone mineral density - femoral neck
(follow-up and change values).............................................................................................................................................................
Analysis 18.46. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 46 Bone mineral density - lumbar spine
(follow-up and change values).............................................................................................................................................................
ADDITIONAL TABLES....................................................................................................................................................................................
APPENDICES.................................................................................................................................................................................................
CONTRIBUTIONS OF AUTHORS...................................................................................................................................................................
DECLARATIONS OF INTEREST.....................................................................................................................................................................
SOURCES OF SUPPORT...............................................................................................................................................................................
DIFFERENCES BETWEEN PROTOCOL AND REVIEW....................................................................................................................................
INDEX TERMS...............................................................................................................................................................................................

622

622

623

623

624

624

625
640
647
647
647
647
647

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

xx

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

[Intervention Review]

Cochrane Database of Systematic Reviews

Physical activity for women with breast cancer after adjuvant therapy

Ian M Lahart1, George S Metsios1, Alan M Nevill1, Amtul R Carmichael2

1Faculty of Education, Health and Wellbeing, University of Wolverhampton, Walsall, UK. 2Department of Surgery, Queen's Hospital,
Burton on Trent, UK

Contact: Ian M Lahart, Faculty of Education, Health and Wellbeing, University of Wolverhampton, Gorway Road, Walsall, West Midlands,
WS1 3BD, UK. i.lahart@wlv.ac.uk.

Editorial group: Cochrane Breast Cancer Group.
Publication status and date: New, published in Issue 1, 2018.

Citation:  Lahart IM, Metsios GS, Nevill AM, Carmichael AR. Physical activity for women with breast cancer after adjuvant therapy.
Cochrane Database of Systematic Reviews 2018, Issue 1. Art. No.: CD011292. DOI: 10.1002/14651858.CD011292.pub2.

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Background

A B S T R A C T

Women with a diagnosis of breast cancer may experience short- and long-term disease and treatment-related adverse physiological and
psychosocial outcomes. These outcomes can negatively impact prognosis, health-related quality of life (HRQoL), and psychosocial and
physical function. Physical activity may help to improve prognosis and may alleviate the adverse effects of adjuvant therapy.

Objectives

To assess effects of physical activity interventions after adjuvant therapy for women with breast cancer.

Search methods

We searched the Cochrane Breast Cancer Group (CBCG) Specialised Registry, the Cochrane Central Register of Controlled Trials (CENTRAL),
MEDLINE, Embase, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), the Physiotherapy Evidence Database (PEDro),
SPORTDiscus, PsycINFO, ClinicalTrials.gov, and the World Health Organization (WHO) International Clinical Trials Registry Platform, on 18
September 2015. We also searched OpenGrey and Healthcare Management Information Consortium databases.

Selection criteria

We searched for randomised and quasi-randomised trials comparing physical activity interventions versus control (e.g. usual or standard
care, no physical activity, no exercise, attention control, placebo) after adjuvant therapy (i.e. after completion of chemotherapy and/or
radiation therapy, but not hormone therapy) in women with breast cancer.

Data collection and analysis

Two  review  authors  independently  selected  studies,  assessed  risk  of  bias,  and  extracted  data.  We  contacted  trial  authors  to  ask  for
additional information when needed. We calculated an overall effect size with 95% confidence intervals (CIs) for each outcome and used
GRADE to assess the quality of evidence for the most important outcomes.

Main results

We included 63 trials that randomised 5761 women to a physical activity intervention (n = 3239) or to a control (n = 2524). The duration
of interventions ranged from 4 to 24 months, with most lasting 8 or 12 weeks (37 studies). Twenty-eight studies included aerobic exercise
only, 21 involved aerobic exercise and resistance training, and seven used resistance training only. Thirty studies described the comparison
group as usual or standard care, no intervention, or control. One-fifth of studies reported at least 20% intervention attrition and the average
physical activity adherence was approximately 77%.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

No data were available on effects of physical activity on breast cancer-related and all-cause mortality, or on breast cancer recurrence.
Analysis of immediately postintervention follow-up values and change from baseline to end of intervention scores revealed that physical
activity interventions resulted in significant small-to-moderate improvements in HRQoL (standardised mean difference (SMD) 0.39, 95% CI
0.21 to 0.57, 22 studies, 1996 women; SMD 0.78, 95% CI 0.39 to 1.17, 14 studies, 1459 women, respectively; low-quality evidence), emotional
function (SMD 0.21, 95% CI 0.10 to 0.32, 26 studies, 2102 women, moderate-quality evidence; SMD 0.31, 95% CI 0.09 to 0.53, 15 studies,
1579 women, respectively; low-quality evidence), perceived physical function (SMD 0.33, 95% CI 0.18 to 0.49, 25 studies, 2129 women; SMD
0.60, 95% CI 0.23 to 0.97, 13 studies, 1433 women, respectively; moderate-quality evidence), anxiety (SMD -0.57, 95% CI -0.95 to -0.19, 7
studies, 326 women; SMD -0.37, 95% CI -0.63 to -0.12, 4 studies, 235 women, respectively; low-quality evidence), and cardiorespiratory
fitness (SMD 0.44, 95% CI 0.30 to 0.58, 23 studies, 1265 women, moderate-quality evidence; SMD 0.83, 95% CI 0.40 to 1.27, 9 studies, 863
women, respectively; very low-quality evidence).

Investigators reported few minor adverse events.

Small improvements in physical activity interventions were sustained for three months or longer postintervention in fatigue (SMD -0.43,
95% CI -0.60 to -0.26; SMD -0.47, 95% CI -0.84 to -0.11, respectively), cardiorespiratory fitness (SMD 0.36, 95% CI 0.03 to 0.69; SMD 0.42, 95%
CI 0.05 to 0.79, respectively), and self-reported physical activity (SMD 0.44, 95% CI 0.17 to 0.72; SMD 0.51, 95% CI 0.08 to 0.93, respectively)
for both follow-up values and change from baseline scores.

However, evidence of heterogeneity across trials was due to variation in intervention components (i.e. mode, frequency, intensity, duration
of intervention and sessions) and measures used to assess outcomes. All trials reviewed were at high risk of performance bias, and most
were also at high risk of detection, attrition, and selection bias. In light of the aforementioned issues, we determined that the evidence
was of very low, low, or moderate quality.

Authors' conclusions

No  conclusions  regarding  breast  cancer-related  and  all-cause  mortality  or  breast  cancer  recurrence  were  possible.  However,  physical
activity  interventions  may  have  small-to-moderate  beneficial  effects  on  HRQoL,  and  on  emotional  or  perceived  physical  and  social
function, anxiety, cardiorespiratory fitness, and self-reported and objectively measured physical activity. The positive results reported
in the current review must be interpreted cautiously owing to very low-to-moderate quality of evidence, heterogeneity of interventions
and outcome measures, imprecision of some estimates, and risk of bias in many trials. Future studies with low risk of bias are required
to  determine  the  optimal  combination  of  physical  activity  modes,  frequencies,  intensities,  and  durations  needed  to  improve  specific
outcomes among women who have undergone adjuvant therapy.

P L A I N   L A N G U A G E   S U M M A R Y

Physical activity for women with breast cancer who have completed active cancer treatment

Review question

What effects do physical activity (PA) interventions have on women with breast cancer who have completed cancer treatment?

Background

After  receiving  breast  cancer  treatment,  women  may  experience  adverse  mental  and  physical  events  caused  by  the  cancer  and  by  its
treatment. These adverse events can result in a shorter life after treatment and can have a negative impact on quality of life (QoL) and on
physical and mental health. Some studies suggest that being regularly physically active after treatment might lower the chance that breast
cancer may come back, or that women may die of breast cancer. Regular PA may lead to a wide range of other beneficial effects, including
improved QoL, mental health, and physical function. We wanted to determine whether PA has an effect on risk of recurrence and dying
from breast cancer, QoL, and other aspects of well-being in women who had breast cancer after treatment.

Study characteristics

We included only studies consisting of women with breast cancer who had completed active cancer treatment. These studies compared
outcomes of women involved in PA interventions versus outcomes of those who were offered usual care or no PA. Participants must have
been assigned to a group in random or somewhat random fashion. The evidence is current to September 2015.

Key results

This  review  includes  63  trials  involving  5761  participants.  Most  trials  (28)  consisted  of  aerobic  exercise  (e.g.  walking,  cycling,  dance),
whereas seven trials included a resistance training-only group, and 21 trials included a combined aerobic exercise and resistance training
group. One in five participants placed in a PA intervention group dropped out before the end of the study, and on average one-quarter of
target PA sessions were missed by participants. We found no studies that looked at effects of PA after cancer treatment on risk of recurrence
or  dying  from  breast  cancer  or  any  other  cause.  We  found  that  participants  performing  PA  had  more  favourable  values  by  the  end  of
the intervention and experienced greater positive changes over the intervention period in terms of QoL, views on their emotional health
and physical ability, social function, feelings of worry, stamina, PA levels, body fat, and strength of muscles, compared with usual care

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

2

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

participants. Researchers found no effects on perceived health, ability to sleep, feelings of pain, sexual function, body mass index, waist-to-
hip girth ratio, and bone health of the upper and lower spine or hip. At least three months after completion of the intervention, actual values
and changes from the start of the intervention in feelings of tiredness, stamina, and self-reported PA levels remained more favourable in
participants given PA intervention than in those given usual care. Both aerobic exercise only and combined aerobic and resistance training
interventions improved QoL and stamina. Aerobic exercise improved views on perceived emotional health and physical ability, as well as
social function and self-reported PA levels, whereas resistance training resulted in greater improvement in muscle strength. Combined
aerobic and resistance training interventions led to reduced feelings of tiredness. Trialists reported few minor adverse events among those
given PA interventions.

Quality of the evidence

We rated the quality of evidence related to various aspects of health as very low, low, or moderate. We noted wide variation among the
interventions that we looked at in terms of types of PA, frequency of sessions per week, levels of effort among participants, and session and
intervention duration. Also, researchers measured aspects of health in many different ways. Other problems with eligible studies included
lack of information on how study authors placed participants in groups at random, whether researchers who were carrying out the tests
knew which group the person being tested belonged to, and how researchers dealt with data missing from their studies. In many aspects,
we could not rule out the chance that positive effects observed were small enough that they were not important. It is also possible that
smaller studies that have not found favourable effects of PA in women with breast cancer after treatment have not been published, because
study authors often find it difficult to publish studies that have not found beneficial effects.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

3

 
 
S U M M A R Y   O F   F I N D I N G S

Summary of findings for the main comparison.   Physical activity versus control for women with breast cancer after adjuvant therapy (immediate
postintervention values)

Physical activity versus control for women with breast cancer after adjuvant therapy

Patient or population: women with breast cancer after adjuvant therapy
Settings: home-based, facility-based, and combined home and facility-based
Intervention: physical activity
Comparison: control

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

Control

Physical activity

HRQoL at end of
intervention fol-
low-up
Follow-up: median
12 weeks

Mean HRQoL at end of inter-
vention follow-up ranged
across control groups from
-2.70 to 2.72 standard de-
viation units

Mean HRQoL at end of inter-
vention follow-up in the inter-
vention groups was
0.39 standard deviations
higher
(0.21 to 0.57 higher)a

Emotional func-
tion/mental
health at end of
intervention fol-
low-up
Follow-up: median
12 weeks

Mean emotional func-
tion/mental health at end
of intervention follow-up
ranged across control
groups from
-4.80 to 0.21 standard de-
viation units

Mean emotional func-
tion/mental health at end of
intervention follow-up in the
intervention groups was
0.21 standard deviations
higher
(0.10 to 0.32 higher)a

Perceived physi-
cal function at end
of intervention
follow-up
Follow-up: median
12 weeks

Mean physical function
at end of intervention fol-
low-up ranged across con-
trol groups from
-2.64 to 1.64 standard de-
viation units

Mean physical function at end
of intervention follow-up in
the intervention groups was
0.33 standard deviations
higher
(0.18 to 0.49 higher)a

No. of partici-
pants
(studies)

Quality of the evi-
dence
(GRADE)

Comments

1996
(22 studies)

⊕⊕⊝⊝
lowb,c

2102
(26 studies)

⊕⊕⊕⊝
moderated

2129
(25 studies)

⊕⊕⊕⊝
moderatec,e

SMD 0.39 (0.21 to 0.57) re-expressed
using FACT-G (0 to 104 scale); the inter-
vention mean HRQoL was 5.9 (3.2 to
8.6) points higher than control (MID 5
to 6 points).

SMD 0.21 (0.10 to 0.32) re-expressed
using FACT-EBW (0 to 24 scale); the
intervention mean emotion function
was 0.7 (0.3 to 1.0) points higher than
control (MID 2 points).

SMD 0.33 (0.18 to 0.49) re-expressed
using FACT-PBW (0 to 28 scale); the in-
tervention mean physical function was
1.7 (0.9 to 2.5) points higher than con-
trol (MID 2 points).

Anxiety at end of
intervention fol-
low-up

Mean anxiety at end of in-
tervention follow-up ranged
across control groups from

Mean anxiety at end of inter-
vention follow-up in the inter-
vention groups was

326
(7 studies)

⊕⊝⊝⊝
very lowc,f

SMD -0.57 (-0.95 to -0.19) re-expressed
using PROMIS (0 to 9 scale); the inter-
vention mean anxiety was 1.9 (3.2 to

C
o
p
y
r
i
g
h
t

©
2
0
1
8
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
h
y
s
i
c
a
l
a
c
t
i
v
i
t
y
f
o
r
w
o
m
e
n
w

i
t
h
b
r
e
a
s
t
c
a
n
c
e
r
a
ft
e
r
a
d
u
v
a
n
t

j

t
h
e
r
a
p
y
(
R
e
v
i
e
w

)

4

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Follow-up: median
12 weeks

-1.33 to 1.19 standard de-
viation units

0.57 standard deviations
lower
(0.95 to 0.19 lower)a

Depression at end
of intervention
follow-up
Follow-up: median
12 weeks

Mean depression at end
of intervention follow-up
ranged across control
groups from
-0.79 to 2.84 standard de-
viation units

Mean depression at end of in-
tervention follow-up in the in-
tervention groups was
0.34 standard deviations
lower
(0.62 to 0.05 lower)a

Fatigue at end of
intervention fol-
low-up
Follow-up: median
12 weeks

Mean fatigue at end of inter-
vention follow-up ranged
across control groups from
-1.83 to 1.69 standard de-
viation units

Cardiorespirato-
ry fitness at end of
intervention fol-
low-up
Follow-up: median
12 weeks

Mean cardiorespiratory fit-
ness at end of intervention
follow-up ranged across
control groups from
-0.51 to 3.59 standard de-
viation units

Mean fatigue at end of inter-
vention follow-up in the inter-
vention groups was
0.32 standard deviations
lower
(0.47 to 0.18 lower)a

Mean cardiorespiratory fit-
ness at end of intervention
follow-up in the intervention
groups was
0.44 standard deviations
higher
(0.30 to 0.58 higher)1

657
(12 studies)

⊕⊕⊝⊝
lowg

2020
(26 studies)

⊕⊕⊕⊝
moderatec,h

1265
(23 studies)

⊕⊕⊕⊝
moderatei

0.6) points lower than control (MID 3 to
4.5 points).

SMD -0.34 (-0.62 to -0.05) re-expressed
using BDI-II (0 to 63 scale); the inter-
vention mean depression was 3.8
(7.0 to 0.6) % lower than control (MID
18%).

SMD -0.32 (-0.47 to -0.18) re-expressed
using FACT-F (0 to 52 scale); the inter-
vention mean fatigue was 2.8 (4.1 to
1.6) points lower than control (MID 3
points).

SMD 0.44 (0.30 to 0.58) re-expressed
as VO2max (mL/kg/min); the interven-
tion mean was 2.1 (1.4 to 2.7) mL/kg/
min higher than control (MID 3.5 mL/
kg/min).

*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based
on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
BDI: Beck Depression Inventory; CI: confidence interval; FACT-EBW: Functional Assessment of Cancer Therapy Emotional Wellbeing; FACT-F: Functional Assessment of Can-
cer Therapy - Fatigue; FACT-G: Functional Assessment of Cancer Therapy-General; FACT-PBW: Functional Assessment of Cancer Therapy Physical Wellbeing; HRQoL: health-
related quality of life; MID: minimal important difference; PROMIS: Patient Reported Outcomes Measurement Information System; SMD: standardised mean difference;
VO2max: maximal oxygen uptake.

GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

aAs a rule of thumb, 0.2 SD represents a small effect, 0.5 SD a moderate effect, and 0.8 SD a large effect.
bWe downgraded by two levels due to evidence of inconsistency supported by presence of substantial heterogeneity (I2 = 50% to 90%) and point estimates widely differed and
95% confidence intervals that did not overlap (P value Chi2 < 0.01), and suspected publication bias (Egger's test, P < 0.05).
cAll trials lacked blinding of participants (performance bias), and most trials lacked blinding of outcome assessors (detection bias) and had incomplete outcome reporting and/
or high attrition (attrition bias), but most were at a low risk of selection bias, reporting bias, and other bias, and therefore, we did not downgraded based on risk of bias.

C
o
p
y
r
i
g
h
t

©
2
0
1
8
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
h
y
s
i
c
a
l
a
c
t
i
v
i
t
y
f
o
r
w
o
m
e
n
w

i
t
h
b
r
e
a
s
t
c
a
n
c
e
r
a
ft
e
r
a
d
u
v
a
n
t

j

t
h
e
r
a
p
y
(
R
e
v
i
e
w

)

5

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
8
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
h
y
s
i
c
a
l
a
c
t
i
v
i
t
y
f
o
r
w
o
m
e
n
w

i
t
h
b
r
e
a
s
t
c
a
n
c
e
r
a
ft
e
r
a
d
u
v
a
n
t

j

t
h
e
r
a
p
y
(
R
e
v
i
e
w

)

dWe downgraded by one level because all trials lacked blinding of participants (performance bias) and most trials lacked blinding of outcome assessors (detection bias), had
incomplete outcome reporting and/or high attrition (attrition bias), and half of them had unclear or inadequate randomisation and/or allocation concealment procedures..
eWe downgraded by one level due to evidence of inconsistency supported by presence of substantial heterogeneity (I2 = 50% to 90%) and point estimates widely differed and
95% confidence intervals that did not overlap (P value Chi2 < 0.01).
fWe downgraded by three levels due to evidence of inconsistency supported by presence of substantial heterogeneity (I2 = 50% to 90%) and point estimates widely differed and
95% confidence intervals that did not overlap (P value Chi2 < 0.01), suspected publication bias (Egger's test, P < 0.05), and imprecision because the 95% confidence intervals
included negligible effects as well as an appreciable benefit (>0.5) and sample size did not meet the ‘‘rule of thumb’’ of approximately 400 (200 per group) participants.
gWe downgraded by two levels due to evidence of inconsistency supported by presence of substantial heterogeneity (I2 = 50% to 90%) and point estimates widely differed and
95% confidence intervals that did not overlap (P value Chi2 < 0.01), and imprecision because the 95% confidence intervals included negligible effects as well as an appreciable
benefit (>0.5). All trials lacked blinding of participants (performance bias), had incomplete outcome reporting and/or high attrition (attrition bias), and unclear or inadequate
randomisation and/or allocation concealment procedures (selection bias), but because most were at a low risk of detection, reporting, and other bias, we did not downgraded
based on risk of bias.
hWe downgraded by one level due to evidence of inconsistency supported by presence of substantial heterogeneity (I2 = 50% to 90%) and point estimates widely differed and
95% confidence intervals that did not overlap (P value Chi2 < 0.01).
iWe downgraded by one level because all trials lacked blinding of participants (performance bias) and most trials lacked blinding of outcome assessors (detection bias), had
incomplete outcome reporting and/or high attrition (attrition bias), and had allocation concealment procedures that were inadequate or unclear (selection bias).

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

Summary of findings 2.   Physical activity versus control for women with breast cancer after adjuvant therapy (change from baseline to end of
intervention values)

Physical activity versus control for women with breast cancer after adjuvant therapy

Patient or population: women with breast cancer after adjuvant therapy
Settings: home-based, facility-based, and combined home and facility-based
Intervention: physical activity
Comparison: control

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

Control

Physical activity

No. of partici-
pants
(studies)

Quality of the evi-
dence
(GRADE)

Comments

HRQoL change from
baseline to end of
intervention
Follow-up: median
12 weeks

Mean HRQoL change from
baseline to end of interven-
tion ranged across control
groups from
-2.40 to 1.25 standard de-
viation units

Mean HRQoL change from base-
line to end of intervention in the
intervention groups was
0.78 standard deviations high-
er
(0.39 to 1.17 higher)a

1459
(14 studies)

⊕⊕⊝⊝
lowb,c

Emotional func-
tion/mental health
change from base-

Mean emotional func-
tion/mental health change
from baseline to end of in-

Mean emotional function/men-
tal health change from baseline
to end of intervention in the in-
tervention groups was

1579
(15 studies)

⊕⊕⊕⊝
lowc,d

6

SMD 0.78 (0.39 to 1.17) re-ex-
pressed using FACT-G (0 to 104
scale); the intervention mean
change was 5.0 (2.5 to 7.5) points
higher than control (MID 5 to 6
points)

SMD 0.31 (0.09 to 0.53) re-ex-
pressed using FACT-EBW (0
to 24 scale); the intervention
mean change was 0.8 (0.2 to 1.3)

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
8
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
h
y
s
i
c
a
l
a
c
t
i
v
i
t
y
f
o
r
w
o
m
e
n
w

i
t
h
b
r
e
a
s
t
c
a
n
c
e
r
a
ft
e
r
a
d
u
v
a
n
t

j

t
h
e
r
a
p
y
(
R
e
v
i
e
w

)

line to end of inter-
vention
Follow-up: median
12 weeks

tervention ranged across
control groups from
-0.39 to 3.47 standard de-
viation units

0.31 standard deviations high-
er
(0.09 to 0.53 higher)a

Perceived physi-
cal function change
from baseline to
end of intervention
Follow-up: median
12 weeks

Mean physical function
change from baseline to
end of intervention ranged
across control groups from
-1.34 to 1.66 standard de-
viation units

Anxiety change
from baseline to
end of intervention
Follow-up: median
11 weeks

Depression change
from baseline to
end of intervention
Follow-up: median
12 weeks

Fatigue change
from baseline to
end of intervention
Follow-up: median
12 weeks

Mean anxiety change from
baseline to end of interven-
tion ranged across control
groups from
-1.47 to 0.73 standard de-
viation units

Mean depression change
from baseline to end of in-
tervention ranged across
control groups from
-1.51 to 1.83 standard de-
viation units

Mean fatigue change from
baseline to end of interven-
tion ranged across control
groups from
-1.81 to 1.83 standard de-
viation units

Mean physical function change
from baseline to end of interven-
tion in the intervention groups
was
0.60 standard deviations high-
er
(0.23 to 0.97 higher)a

Mean anxiety change from base-
line to end of intervention in the
intervention groups was
0.37 standard deviations lower
(0.63 to 0.12 lower)a

Mean depression change from
baseline to end of intervention in
the intervention groups was
0.34 standard deviations lower
(0.63 to 0.05 lower)a

Mean fatigue change from base-
line to end of intervention in the
intervention groups was
0.3 standard deviations lower
(0.61 lower to 0 higher)a

Cardiorespiratory
fitness change from
baseline to end of
intervention
Follow-up: median
12 weeks

Mean cardiorespiratory fit-
ness change from base-
line to end of interven-
tion ranged across control
groups from
-1.45 to 2.38 standard de-
viation units

Mean cardiorespiratory fitness
change from baseline to end of
intervention in the intervention
groups was
0.83 standard deviations high-
er
(0.4 to 1.27 higher)a

1433
(13 studies)

⊕⊕⊕⊝
moderatec,e

235
(4 studies)

⊕⊕⊝⊝
lowf

816
(7 studies)

⊕⊝⊝⊝

very lowc,g

1289
(13 studies)

⊕⊕⊝⊝
lowc,h

863
(9 studies)

⊕⊝⊝⊝
very lowi

points higher than control (MID 2
points).

SMD 0.60 (0.23 to 0.97) re-ex-
pressed using FACT-PBW (0
to 28 scale); the intervention
mean change was 1.3 (0.5 to 2.1)
points higher than control (MID 2
points).

SMD -0.37 (-0.63 to -0.12) re-ex-
pressed using PROMIS (0 to 9
scale); the intervention mean
change was 4.6 (7.6 to 1.5) points
lower than control (MID 3 to 4.5
points).

SMD -0.34 (-0.63 to -0.05) re-
expressed using BDI-II (0 to 63
scale); the intervention mean
change was 2.5 (4.6 to 0.4) % low-
er than control (MID 18%).

SMD -0.3 (-0.61 to 0) re-expressed
using FACT-F (0 to 52 scale); the
intervention mean change was
2.6 (5.2 to 0) points lower than
control (MID 3 units).

SMD 0.83 (0.4 to 1.27) re-ex-
pressed using VO2max (mL/kg/
min); the intervention mean
change was 2.3 (1.1 to 3.4) mL/
kg/min higher than control (MID
3.5 mL/kg/min).

*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based
on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
BDI: Beck Depression Inventory; CI: confidence interval; FACT-EBW: FACT-EBW: Functional Assessment of Cancer Therapy Emotional Wellbeing; FACT-F: Functional Assess-
ment of Cancer Therapy - Fatigue; FACT-G: Functional Assessment of Cancer Therapy - General; FACT-PBW: Functional Assessment of Cancer Therapy Physical Wellbeing;

7

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
HRQoL: health-related quality of life; MID: minimal important difference; PROMIS: Patient Reported Outcomes Measurement Information System; SMD: standardised mean
difference; VO2max: maximal oxygen uptake.

GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

aAs a rule of thumb, 0.2 SD represents a small effect, 0.5 SD a moderate effect, and 0.8 SD a large effect.
bWe downgraded by two levels due to evidence of inconsistency supported by presence of considerable heterogeneity (I2 = 75% to 100%) and point estimates widely differed
and 95% confidence intervals that did not overlap (P value Chi2 < 0.01), and suspected publication bias (Egger's test, P < 0.05).
cAll trials lacked blinding of participants (performance bias), and most trials lacked blinding of outcome assessors (detection bias) and had incomplete outcome reporting and/
or high attrition (attrition bias), but most were at a low risk of selection bias, reporting bias, and other bias, and therefore, we did not downgraded based on risk of bias.
dWe downgraded by two levels due to evidence of inconsistency supported by presence of substantial heterogeneity (I2 = 50% to 90%) and point estimates widely differed and
95% confidence intervals that did not overlap (P value Chi2 < 0.01), and imprecision because the 95% confidence intervals included negligible effects as well as an appreciable
benefit (>0.5).
eWe downgraded by one level due to evidence of inconsistency supported by presence of considerable heterogeneity (I2 = 75% to 100%) and point estimates widely differed and
95% confidence intervals that did not overlap (P value Chi2 < 0.01).
fWe downgraded by two levels due to suspected publication bias (Egger's test, P < 0.05), and imprecision because the 95% confidence intervals included negligible effects as well
as an appreciable benefit (>0.5) and the sample size does not meet the ‘‘rule of thumb’’ of approximately 400 (200 per group) participants. The majority of trials were at a low risk
of selection bias, attrition bias, reporting bias, and other bias, and therefore, we did not downgraded based on risk of bias.
gWe downgraded by three levels due to evidence of inconsistency supported by presence of substantial heterogeneity (I2 = 50% to 90%) and point estimates widely differed and
95% confidence intervals that did not overlap (P value Chi2 < 0.01), suspected publication bias (Egger's test, P < 0.05), and imprecision because the 95% confidence intervals
included negligible effects as well as an appreciable benefit (>0.5).
hWe downgraded by two levels due to evidence of inconsistency supported by presence of considerable heterogeneity (I2 = 75% to 100%) and point estimates widely differed
and 95% confidence intervals that did not overlap (P value Chi2 < 0.01), and imprecision because the 95% confidence intervals included null effects as well as an appreciable
benefit (>0.5).
iWe downgraded by three levels due to evidence of inconsistency supported of considerable heterogeneity (I2 = 75% to 100%) and point estimates widely differed and 95%
confidence intervals that did not overlap (P value Chi2 < 0.01), suspected publication bias (included studies were small and the funnel plot shows asymmetry), and all trials
lacked blinding of participants (performance bias) and most trials lacked blinding of outcome assessors (detection bias), had incomplete outcome reporting and/or high attrition
(attrition bias), and had unclear or inadequate randomisation and/or allocation concealment procedures.

C
o
p
y
r
i
g
h
t

©
2
0
1
8
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
h
y
s
i
c
a
l
a
c
t
i
v
i
t
y
f
o
r
w
o
m
e
n
w

i
t
h
b
r
e
a
s
t
c
a
n
c
e
r
a
ft
e
r
a
d
u
v
a
n
t

j

t
h
e
r
a
p
y
(
R
e
v
i
e
w

)

8

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

B A C K G R O U N D

Description of the condition

Worldwide, breast cancer is the most frequently diagnosed cancer
among women, accounting for one in four of all new female cancer
cases  (1.7  million  total  cases)  in  2012  (Ferlay  2013).  Although
incidence rates vary markedly across world regions, breast cancer
is the most common cancer among women in both more developed
and  less  developed  regions,  with  slightly  more  cases  reported  in
less developed (883,000 cases) than in more developed (794,000)
regions (Ferlay 2013). Breast cancer is the most common cause of
cancer  death  among  women  in  less  developed  regions  (324,000
deaths)  and  is  the  second  most  common  cause  of  cancer  death
among  women  in  more  developed  regions  (198,000  deaths).
Globally, researchers reported a 20% increase and a 14% increase
in  breast  cancer  incidence  and  mortality,  respectively,  from  2008
to 2012 (Ferlay 2013; Jemal 2011). Although incidence rates remain
highest  in  more  developed  regions,  mortality  rates  are  relatively
much  higher  in  less  developed  countries  -  a  fact  that  can  be
attributed to lack of both early detection and access to treatment
facilities (IARC 2012).

In  2012,  breast  cancer  was  the  most  prevalent  cancer  worldwide
with  approximately  6.3  million  women  alive  who  had  received  a
diagnosis of breast cancer in the previous five years, representing a
17% increase from 2008 figures (Bray 2013; Ferlay 2013). Owing in
particular to this rising prevalence, attention to tertiary prevention
among  women  with  breast  cancer  has  increased.  In  addition
to  risk  of  cancer  recurrence,  women  with  breast  cancer  often
experience numerous short- and long-term disease- or treatment-
related adverse physiological and psychosocial outcomes, such as
cardiotoxicity, neurotoxicity, secondary leukaemia, lymphoedema,
premature menopause, sexual dysfunction, infertility, weight gain,
difficulty sleeping, and fatigue (Azim 2011; Beisecker 1997; Bovelli
2010; de Jong 2002). These adverse effects would be expected to
have  a  negative  impact  on  health-related  quality  of  life  (HRQoL)
and physical function. In addition, these unwanted effects can be
prolonged after completion of active treatment and may hinder the
woman's return to normal life (Fong 2012).

Description of the intervention

important  for 

Encouraging  women  with  breast  cancer  after  adjuvant  therapy
to  adopt  a  healthy  lifestyle,  such  as  low  alcohol  consumption,
greater  fruit  and  vegetable  consumption,  and  higher  physical
activity  levels,  may  be 
improving  quality  of
life  and  the  health  of  survivors  and,  in  turn,  may  reduce
the  healthcare  burden  (Demark-Wahnefried  2005).  In  particular,
higher  levels  of  physical  activity  represent  a  modifiable  health
behaviour  that  could  alleviate  the  sequelae  related  to  breast
cancer  and  assist  women  in  returning  to  the  health  status  they
had  before  receiving  the  diagnosis  and  treatment  (Fong  2012).
Physical activity is defined as any bodily movement produced by
contraction  of  skeletal  muscle  that  increases  energy  expenditure
above  a  basal  level,  performed  as  part  of  occupation,  active
transportation, household and gardening chores, and recreational
activities.  Exercise,  a  subcategory  of  physical  activity,  is  defined
as  planned,  structured,  and  repetitive  physical  activity  that  is
aimed  at  improving  or  maintaining  one  or  more  components  of
physical fitness (Caspersen 1985; Physical Activity Guidelines 2008).
Current recommendations for breast cancer survivors are to avoid
inactivity,  return  to  normal  daily  activities  as  quickly  as  possible

Cochrane Database of Systematic Reviews

after surgery, continue these activities during and after non-surgical
treatments,  and  engage  in  150  minutes  per  week  of  moderate-
intensity  aerobic  activity  (e.g.  any  activity,  such  as  brisk  walking,
that requires a moderate amount of effort and noticeably increases
heart rate) (Schmitz 2010).

How the intervention might work

Evidence  from  observational  data  suggests  that  higher  levels
of  physical  activity  in  breast  cancer  survivors  or  post  diagnosis
are  associated  with  reduced  risk  of  dying  from  breast  cancer  or
from  all  causes  (Beasley  2012;  Ibrahim  2011).  Increased  physical
activity is also associated with reduced exposure to oestrogen and
androgens and increased concentrations of sex hormone-binding
globulin,  as  well  as  improved  insulin  sensitivity  and  decreased
concentrations  of  insulin  growth  factor-1  and  of  adipokines  and
inflammatory markers, with the exception of a beneficial elevation
in  adiponectin  concentrations  (Lynch  2011).  These  effects  of
increased  physical  activity  may  serve  as  the  mechanisms  that
can explain associated reductions in all-cause and breast cancer-
related mortality. Furthermore, lack of physical activity has been
shown to be related to weight gain post breast cancer diagnosis,
which, in turn, has been linked to poorer survival in some studies
(Camoriano  1990;  Kroenke  2005).  More  active  women  have  been
found  to  possess  a  lower  body  mass  index  (BMI)  and  to  be  less
likely to gain weight after diagnosis, thus improving their survival
chances (Holmes 2005; Lahmann 2005).

Evidence  suggests  that  physical  activity  can  promote  positive
physiological  and  psychological  benefits  among  cancer  survivors
after treatment (Brown 2012; Fong 2012; Galvao 2005; Ingram 2007;
Knols  2005;  Speck  2010).  A  recent  meta-analysis  revealed  that
physical  activity  was  associated  with  important  positive  effects
on  physical  function,  body  weight  and  BMI,  and  quality  of  life,
which  included  physical  and  social  functioning  domains,  among
patients who had completed cancer treatment (Fong 2012). Results
reported in a Cochrane review indicate that physical activity may
have  beneficial  effects  on  overall  HRQoL  and  on  certain  HRQoL
domains,  including  cancer-specific  concerns  (e.g.  breast  cancer),
body image and self-esteem, emotional well-being, sexuality, sleep
disturbance, social functioning, anxiety, fatigue, and pain at varying
follow-up periods (Mishra 2012a).

Why it is important to do this review

Despite benefits derived through physical activity, consensus has
not  been  reached  regarding  the  magnitude  of  benefit,  the  most
effective  delivery  mode,  and  prescription  of  physical  activity  in
breast  cancer  survivors.  Physical  activity  interventions  in  this
population  typically  are  delivered  under  supervised  -  Courneya
2003; Milne 2008 - or self-directed, home-based conditions (Pinto
2005; Vallance 2008). They consist of, or serve as a way to compare,
aerobic  exercise  training  (Cadmus  2009;  Herrero  2006),  walking
(Matthews  2007;  Payne  2008),  and  resistance  training  (Schmitz
2009; Winters-Stone 2011). Their duration can vary from less than
10 weeks - Daley 2007; Fillion 2008 - to six months or longer (Schmitz
2009; Winters-Stone 2011). Previous systematic reviews and meta-
analyses have included studies involving patients with all types of
cancer  (Brown  2012;  Cramp  2010;  Fong  2012;  Knols  2010;  Mishra
2012a; Mishra 2012b; Speck 2010), rather than focusing on patients
with  breast  cancer;  studies  of  patients  with  cancer  who  received
adjuvant therapy (Carayol 2013; Markes 2009; McNeely 2006; Mishra
2012b); studies that focused on a particular physical activity mode,

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

9

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

such  as  walking  (Knols  2010),  yoga  (Cramer  2013),  dance  (Bradt
2011), or resistance training (Cheema 2014; Cheema 2008; Cramp
2010);  or  studies  that  investigated  a  particular  outcome,  such  as
quality of life - Cramp 2010; Mishra 2012a; Mishra 2012b - and upper
limb  dysfunction  (McNeely  2010).  Therefore,  a  systematic  review
and  meta-analysis  is  needed  to  investigate  effects  of  physical
activity on the large range of outcomes reported in trials including
women who have completed adjuvant therapy for breast cancer.

O B J E C T I V E S

To  assess  effects  of  physical  activity  interventions  after  adjuvant
therapy for women with breast cancer.

M E T H O D S

Criteria for considering studies for this review

Types of studies

We considered for inclusion in this review all randomised controlled
trials  (RCTs),  as  well  as  quasi-randomised  controlled  trials,
investigating  effects  of  physical  activity  interventions  for  women
with breast cancer after adjuvant therapy.

Types of participants

We sought trials that included women with a diagnosis of breast
cancer  who  had  completed  adjuvant  therapy  (radiotherapy  or
chemotherapy).

We  excluded  studies  including  cancers  other  than  breast  cancer
unless separate data were available for the breast cancer subgroup.
We  also  excluded  studies  including  only  patients  with  metastatic
breast cancer (stage IV and above).

We  excluded  studies  including  women  who  were  undergoing
adjuvant  therapy  (radiotherapy  and  chemotherapy  but  not
endocrine  therapy)  for  breast  cancer  during  the  physical  activity
intervention.

Types of interventions

We  included  all  trials  that  reported  and  evaluated  effects  of
interventions such as physical activity (including exercise), as well
as  studies  comparing  a  physical  activity  group  versus  a  group
described  as  receiving  no  physical  activity  and  no  exercise,  and
given control, attention control, usual or standard care, or placebo.

We excluded studies that:

• included an additional treatment arm or combined intervention
arm  (e.g.  physical  activity  with  diet  modification)  for  which
effects of physical activity could not be isolated;

• provided single exercise sessions that measured acute effects;
• investigated effects of physiotherapy; and
• were restricted to stretching or local muscular endurance (e.g.
training of shoulders, back, or legs only) or therapeutic exercise
regimens  that  addressed  only  specific  impairments  related  to
the shoulder, the arm, or both.

Types of outcome measures

For selected outcomes, we extracted:

• immediately postintervention follow-up values;

Cochrane Database of Systematic Reviews

• three-month or longer postintervention follow-up values;
• change from baseline to end of intervention scores; and
• change from baseline to three-month or longer postintervention

scores.

Primary outcomes  Breast cancer-related mortality, defined
as time from date randomised to date of death due to primary
breast cancerHRQoL domains, via a validated questionnaire,
including but not limited to physical function (e.g. performance
of self-care and everyday physical activities), psychological
function (e.g. emotional well-being, anxiety, depression, self-
esteem), social and economic role function (e.g. performance of
work or household responsibilities, social interactions), pain,
and fatigue or vitality (e.g. energy)

Primary outcomes

• Breast  cancer-related  mortality,  defined  as  time  from  date

randomised to date of death due to primary breast cancer

• HRQoL  domains,  via  a  validated  questionnaire,  including  but
not  limited  to  physical  function  (e.g.  performance  of  self-
care  and  everyday  physical  activities),  psychological  function
(e.g.  emotional  well-being,  anxiety,  depression,  self-esteem),
social  and  economic  role  function  (e.g.  performance  of  work
or  household  responsibilities,  social  interactions),  pain,  and
fatigue or vitality (e.g. energy)

Secondary outcomes

• All-cause  mortality,  defined  as  time  from  date  randomised  to

date of death (any cause)

• Breast  cancer  recurrence,  defined  as  time  from  date  of
randomisation  to  emergence  of  local,  regional,  or  distant
recurrence or metastasis

• Cardiorespiratory fitness, defined as ability to engage in physical
activities that rely on oxygen consumption as the primary source
of  energy,  and  measured  directly  or  indirectly  to  obtain  an
individual's maximal oxygen uptake (VO2max)

• Physical  activity  assessed  as  an  outcome  measure,  defined
as  any  bodily  movement  produced  by  contraction  of  skeletal
muscle that increases energy expenditure above a basal level,
and  measured  by  self-report  via  questionnaires  or  objectively
via accelerometers

• Body  mass,  BMI,  body  composition  (e.g.  measures  such  as
body  fat  percentage,  fat-free  or  lean  mass,  and  fat  mass)
and  other  anthropometric  measurements  (e.g.  waist  and  hip
circumferences)

• Muscular  strength,  defined  as  maximal  force  (expressed  in
Newtons,  kilograms,  or  pounds)  that  can  be  generated  by  a
specific muscle or muscle group

• Bone health-related outcomes such as bone mineral density and

bone mineral content

• Adverse events such as musculoskeletal injuries, lymphoedema,

and illness (such as bronchitis and influenza)

Search methods for identification of studies

Electronic searches

We searched the following databases.

• Cochrane  Breast  Cancer  Group  (CBCG)  Specialised  Register.
Details of search strategies used by the CBCG for identification of

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

10

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

studies and procedures for coding of references are outlined in
the  CBCG  module  (http://onlinelibrary.wiley.com/o/cochrane/
clabout/articles/BREASTCA/frame.html).  We  considered  for
inclusion  in  the  review  retrieved  trials  using  the  following
terms:  'breast  cancer',  'physical  activity',  'physical  activity
intervention',  'exercise',  'walking',  'resistance  training',  'weight
training', 'weight lifting' or 'fitness'.
• MEDLINE (via PubMed); see Appendix 1.
• Embase (via Embase.com); see Appendix 2.
• Cochrane Central Register of Controlled Trials (CENTRAL; 2015,

Issue 8) in the Cochrane Library; see Appendix 3.

• World  Health  Organization  (WHO)  International  Clinical  Trials
Registry  Platform  (ICTRP)  search  portal  (http://apps.who.int/
trialsearch/Default.aspx)  for  all  prospectively  registered  and
ongoing trials; see Appendix 4.

• Clinicaltrials.gov (http://clinicaltrials.gov/); see Appendix 5.
• Cumulative  Index  to  Nursing  and  Allied  Health  Literature

(CINAHL) (via EBSCOhost.com); see Appendix 6.

• Physiotherapy  Evidence  Database  (PEDro)  (via  PEDro.org.au);

see Appendix 7.

• SPORTDiscus (via EBSCOhost.com); see Appendix 8.
• PsycINFO (via OvidSP); see Appendix 9.

Searching other resources

Bibliographic searching

We attempted to identify further studies by reviewing reference lists
of identified relevant trials or reviews. We obtained a copy of the
full article for each reference reporting a potentially eligible trial.
When this was not possible, we attempted to contact trial authors
to request additional information.

We conducted a search for relevant grey literature using OpenGrey
and  Healthcare  Management  Information  Consortium  (HMIC)
databases.

Data collection and analysis

Selection of studies

We merged results of the searches described above and removed
duplicate  records  on  the  same  study.  We  examined  titles  and
abstracts  to  remove  obviously  irrelevant  reports.  Two  review
authors  (IML  and  GSM)  independently  screened  and  assessed
records  for  eligibility.  We  resolved  disagreements  on  study
eligibility  through  consensus,  and,  when  necessary,  we  met  with
a  third  review  author  not  involved  in  the  particular  assessment
(AMN)  for  discussion.  We  retrieved  full-text  articles  of  potentially
relevant reports and linked together multiple reports of the same
study.  We  examined  full-text  reports  for  compliance  of  studies
with  the  eligibility  criteria.  We  corresponded  with  investigators,
when  appropriate,  to  clarify  study  eligibility  or  to  seek  further
information, such as missing data.

We recorded in the Characteristics of excluded studies table a list
of studies that were close to inclusion but did not meet the criteria
after further inspection.

We  included  non-English  language  trials  and  translated  them,
when  necessary,  so  that  we  could  assess  eligibility  and
subsequently extract study data.

Cochrane Database of Systematic Reviews

Data extraction and management

We  devised  a  checklist  of  items  to  be  considered  during  data
collection.  This  checklist  included  the  source  of  the  report;
confirmation  of  eligibility  or  reason  for  exclusion;  methods  such
as  study  design,  total  duration,  sequence  generation,  allocation
sequence  concealment,  blinding,  and  other  sources  of  bias;
participant information such as total numbers, diagnostic criteria,
and  demographic  information;  dates  of  the  study;  intervention
details;  for  each  outcome  of  interest,  the  definition,  unit  of
measurement  and  scales,  time  points  of  assessment,  results
including  numbers  of  participants  allocated  to  groups,  sample
size,  missing  data,  summary  of  data  for  each  group,  and
effect  estimates  with  confidence  intervals;  and  miscellaneous
information such as funding sources, key conclusions, and details
of any correspondence.

IML  and  GSM  independently  extracted  trial  data,  and  AMN
arbitrated  any  conflicts  not  due  to  extractor  error.  We  collated
multiple  publications  for  the  same  trial  and  used  the  most
complete report (i.e. the one with outcomes most relevant to the
review or with the most recent outcomes) as the primary reference.

Assessment of risk of bias in included studies

We  summarised  in  the  Characteristics  of  included  studies  table
data  collected  from  these  reports.  We  used  the  Cochrane  ‘risk
of  bias’  tool  to  assess  possible  sources  of  bias  in  the  included
reports  (Higgins  2011).  Assessment  of  risk  of  bias  was  a  two-
part  process  addressing  specific  domains  such  as  sequence
generation, allocation concealment, blinding, incomplete outcome
data,  selective  reporting  bias,  and  ‘other  issues’.  The  first  part  of
the  process  describes  what  was  reported  to  have  happened  in  a
study, and the second part includes judgement related to the risk
of  bias  for  each  domain  in  that  study.  Two  review  authors  (IML
and  GSM)  assessed  risk  of  bias,  and  a  third  review  author  (AMN)
arbitrated conflicts not due to assessor error. If we found evidence
of heterogeneity, large risk of bias, or low quality of evidence, we
interpreted trial findings cautiously.

We have displayed our assessment of risk of bias in a ‘risk of bias’
table.

Measures of treatment effect

We performed a meta-analysis on an outcome only if at least two
studies assessed that outcome; we did not perform meta-analysis
if outcomes were too diverse, studies were at risk of serious bias, or
evidence suggested serious publication or reporting bias.

We  combined  continuous  outcomes  (such  as  cardiorespiratory
fitness,  physical  activity,  anthropometric  measures,  muscular
strength,  and  bone  health-related  outcomes)  using  mean
difference  (MD)  when  trials  measured  an  outcome  by  using  the
same measurement method or scale to generate continuous data.
We  used  standardised  mean  difference  (SMD)  when  trials  used
different instruments to measure the same outcome.

For  dichotomous  outcomes  (such  as  meeting  physical  activity
guidelines), we used risk ratios (RRs) with 95% confidence intervals
(CIs).  We  transformed  data  presented  as  odds  ratios  (ORs)  using
the method outlined in Chapter 12 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011).

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

11

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

For  this  review  version,  no  outcomes  were  reported  as  time-
to-event.  In  future  review  versions,  for  time-to-event  outcomes
such as mortality and recurrence, we will use hazard ratios (HRs)
with  95%  CIs.  We  will  report  the  ratios  of  treatment  effects  for
responses, so that HRs less than 1.0 will favour the physical activity
intervention  and  HRs  greater  than  1.0  will  favour  usual  care  or
control. To perform meta-analysis of time-to-event outcomes, we
will  obtain  the  log  HR  (intervention  relative  to  control)  and  its
standard  error  (SE).  As  outlined  in  Chapter  7  of  the  Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011),
the  log  hazard  ratio  is  estimated  by  (O  -  E)/V,  which  has  an  SE
1/√V,  where  O  represents  the  observed  number  of  events  in  the
intervention  group,  E  the  log-rank  expected  number  of  events  in
the  intervention  group,  O-E  the  log-rank  statistic,  and  V  variance
of  the  log-rank  statistic.  Alternatively,  when  trial  authors  analyse
data using a Cox proportional hazards model, they directly report
estimates of the log hazard ratio and its SE.

Unit of analysis issues

For trials that included more than one applicable physical activity
group (Cormie 2014; Dolan 2016; Ergun 2013; Loh 2014; Martin 2013;
Musanti 2012; Portela 2008; Short 2014; Vallance 2007) and more
than  one  relevant  control  group  (Daley  2007),  we  created,  when
possible,  a  single  pair-wise  comparison  by  combining  outcome
data  as  recommended  in  the  Cochrane  Handbook  for  Systematic
Reviews of Interventions (Higgins 2011).

Dealing with missing data

We  requested  missing  data  from  trial  authors.  If  variability
was  presented  by  measures  other  than  standard  deviation,  we
obtained an estimate of the standard deviation (SD) using standard
approaches  for  transforming  data.  We  transformed  CIs,  t  values,
and  P  values  to  estimate  SD  using  methods  described  in  the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011); if F-statistics were reported for comparisons of two groups,
we  transformed  F-statistics  into  T-statistics  using  the  following
formula: T = √F, then estimated SD from the T-statistic.

Assessment of heterogeneity

For  each  outcome,  we  first  assessed  study  heterogeneity  using
Cochran’s  χ2  (Chi2)  test  (Cochran  1954),  with  P  <  0.10  indicating
evidence of heterogeneity.

We  evaluated  inconsistency  of  results  across  studies  by  using
the  I2  statistic.  I2  describes  the  percentage  of  variability  in  point
estimates that is due to heterogeneity rather than to sampling error
(Higgins  2003).  In  accordance  with  Higgins  2011,  we  interpreted
I2  values  of  0%  to  40%  as  'might  not  be  important',  30%  to
60%  as  'may  represent  moderate  heterogeneity',  50%  to  90%  as
'may  represent  substantial  heterogeneity',  and  75%  to  100%  as
showing 'considerable heterogeneity'. However, the importance of
the observed value of I2 depends on the magnitude and direction of
effects and the strength of evidence of heterogeneity (e.g. P value
from the Chi2 test, CI for I2).

We used a random-effects model to determine the average effect
of  physical  activity  because,  in  addition  to  the  presence  of
random  error  (i.e.  chance),  differences  between  physical  studies
after  adjuvant  breast  cancer  treatment  can  result  from  real
differences  between  study  populations,  types  of  adjuvant  breast
cancer treatment received, and the training stimulus. The random-

Cochrane Database of Systematic Reviews

effects model considers these additional sources of between-study
variability, as well as within-study variability. We presented pooled
intervention effect estimates and their 95% CIs for each outcome.

Assessment of reporting biases

in  the  Cochrane  Handbook 

To  investigate  publication  bias,  we  prepared  funnel  plots  and
visually  examined  them  for  signs  of  asymmetry.  We  followed
recommendations  provided 
for
Systematic  Reviews  of  Interventions  (Higgins  2011)  regarding
statistical  testing  for  funnel  plot  asymmetry.  For  example,  if  a
sufficient number of trials were available in a particular analysis, we
examined publication bias using Egger’s linear regression method,
with  P  <  0.10  taken  as  an  indication  of  publication  bias  (Egger
1997). If we noted evidence of statistically significant asymmetry,
we considered interpretations other than publication bias.

Data synthesis

We have presented pooled intervention effect estimates and their
95% CIs.

For  continuous  outcomes,  we  combined  data  using  the  inverse
variance random-effects method (DerSimonian 1986).

For dichotomous outcomes, we applied the random-effects model
(DerSimonian  1986),  along  with  the  Mantel-Haenszel  method
(Mantel 1959; Greenland 1985), to combine data.

For time-to-event outcomes, we combined study results using the
generic inverse variance method. We carried out all analyses using
Review Manager 5 (version 5.3) (RevMan).

IML  and  GSM  assessed  the  quality  of  the  evidence  by  using  the
GRADE system (Guyatt 2008); we have presented these results in the
'Summary of findings' tables.

Subgroup analysis and investigation of heterogeneity

We  considered  the  following  important  methodological  factors,
physical activity programme design components, and participant
characteristics as potential sources of heterogeneity: removal of the
most extreme values; study quality based on risk of bias (low risk
of bias vs moderate unclear/high risk of bias); menopausal status
of  participants  (premenopausal  vs  postmenopausal);  duration  of
intervention (shorter duration, i.e. ≤ 12 weeks, vs longer duration,
i.e.  >  12  weeks);  measurement  type  (instrument/method  used,
e.g. direct vs indirect, subjective vs objective measurement); and
mode  of  physical  activity  (aerobic  exercise  vs  resistance  training
vs combination of aerobic and resistance exercise vs yoga, tai chi,
qigong, and pilates interventions). When it was possible to inform
physical activity prescription for patients with breast cancer post
adjuvant  therapy,  we  conducted  subgroup  analyses  of  treatment
effect based on intervention mode (aerobic exercise vs resistance
training  vs  combination  of  aerobic  and  resistance  exercise  vs
yoga,  tai  chi,  qigong,  and  pilates  interventions),  intensity  (light
and  light-moderate  vs  moderate-high  and  high),  duration  of
intervention  (≤  12  weeks  vs  >  12  weeks),  format  (individual  vs
group vs combined individual and group), setting (home-based vs
facility-based vs home and facility-based combined), participants'
menopausal  status  (premenopausal  vs  postmenopausal),  and
treatment regimen (chemotherapy vs no chemotherapy).

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

12

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Sensitivity analysis

We  conducted  sensitivity  analyses  to  assess  the  robustness  of
review results by removing studies with high or unclear risk of bias.

R E S U L T S

Description of studies

Results of the search

Through a comprehensive literature search, we identified 8454
potentially relevant references and screened them for retrieval.
After removing duplicates, we excluded a total of 5955 references
upon title and abstract review and retrieved 211 references for

Cochrane Database of Systematic Reviews

more detailed evaluation. From these, we excluded 86 trials as
they did not meet the inclusion criteria, and identified 63 trials
as appropriate for inclusion in the current review (Figure 1). In
addition, we identified 10 ongoing trials (Deli-Conwright 2014;
Galiano-Castillo 2013; IRCT2014042117379N1; KIlbreath 2011;
NCT02057536; NCT02235051; NCT02332876; NCT02420249;
NCT02433067; NCT02527889), as well as three trials that were
awaiting classification (Lahart 2016; Lohrisch 2011; Luu 2014).
We did not include these latter trials in the analysis presented
below but will consider them in future updates of this review. See
Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification; and
Characteristics of ongoing studies.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

13

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 1.   Study flow diagram.

Cochrane Database of Systematic Reviews

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

14

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Included studies

Final  selection  resulted  in  inclusion  of  63  trials  in  this  review
(Banasik  2011;  Baruth  2013;  Basen-Enquist  2006;  Blank  2005;
Bower  2011;  Cadmus  2009;  Cantarero-Villanueva  2013;  Carson
2009;  Cerulli  2014;  Cormie  2014;  Courneya  2003;  Cuesta-Vargas
2014; Daley 2007; DeNysschen 2011; Do 2015; Dolan 2016; Duijits
2012; Ergun 2013; Fillion 2008; Guinan 2013; Hatchett 2013; Heim
2007;  Herrero  2006;  Irwin  2015;  Kaltsatou  2011;  Kiecolt-Glaser
2014;  Kim  2015;  Ligibel  2008;  Littman  2012;  Loh  2014;  Loudon
2014;  Malicka  2011;  Martin  2013;  Matthews  2007;  McKenzie  2003;
Mehnert 2011; Milne 2008; Murtezani 2014; Musanti 2012; Mustian
2004;  Naumann  2012;  Nieman  1995;  Nikander  2007;  Payne  2008;
Peppone  2015;  Pinto  2003;  Pinto  2005;  Pinto  2015;  Portela  2008;
Rahnama  2010;  Rogers  2009;  Rogers  2013;  Rogers  2014;  Rogers
2015; Saarto 2012; Schmitz 2005; Schmitz 2009; Segar 1998; Short
2014; Taleghani 2012; Vallance 2007; Waltman 2010; Winters-Stone
2011)  (we  used  the  earliest  main  publication  of  each  trial  as  the
trial  reference).  We  reviewed  and  included  information  on  trial
characteristics  and  outcome-related  data  from  an  additional  125
publications  that  were  secondary  publications  of  these  63  trials.
We corresponded with, and requested additional data from, nine
trial  authors  (Baruth  2013;  Carson  2009;  Daley  2007;  Heim  2007;
Loh  2014;  McKenzie  2003;  Payne  2008;  Peppone  2015;  Vallance
2007),  and  four  of  these  trial  authors  replied  to  requests  for
additional data (Daley 2007; Loh 2014; Payne 2008; Vallance 2007).
Full  descriptions  of  the  included  studies  can  be  found  under
Characteristics of included studies.

Study design

Of the 63 included trials, 60 (95%) were RCTs, and three studies used
a quasi-randomised design to allocate participants to treatment(s)
(Cuesta-Vargas 2014; Heim 2007; Segar 1998). Twelve trials (19%)
consisted  of  more  than  one  exercise  intervention  group  (Cormie
2014; DeNysschen 2011; Dolan 2016; Duijits 2012; Ergun 2013; Loh
2014;  Martin  2013;  Musanti  2012;  Naumann  2012;  Portela  2008;
Short 2014; Vallance 2007). One study consisted of two comparison
arms  (usual  care  and  exercise-placebo  control  in  the  form  of
stretching) (Daley 2007), and Duijits 2012 included a non-exercise
cognitive-behaviour therapy group, while Naumann 2012 included
a  non-exercise  counselling  group.  In  all,  investigators  allocated
5761 participants (mean 91, range 14 to 573) to a physical activity
intervention group (n of participants = 3239, mean 51, range 7 to
302) or a control group (n = 2524, mean 40, range 8 to 271).

Study participants

Forty trials (63%) reported numbers of participants at each cancer
stage (Baruth 2013; Basen-Enquist 2006; Cadmus 2009; Cantarero-
Villanueva 2013; Carson 2009; Cerulli 2014; Cormie 2014; Courneya
2003; DeNysschen 2011; Do 2015; Dolan 2016; Fillion 2008; Guinan
2013; Hatchett 2013; Herrero 2006; Irwin 2015; Kiecolt-Glaser 2014;
Ligibel  2008;  Littman  2012;  Loh  2014;  Loudon  2014;  Matthews
2007;  Mehnert  2011;  Milne  2008;  Murtezani  2014;  Musanti  2012;
Peppone  2015;  Pinto  2003;  Pinto  2005;  Pinto  2015;  Portela  2008;
Rogers 2009; Rogers 2013; Rogers 2014; Rogers 2015; Schmitz 2005;
Schmitz  2009;  Short  2014;  Vallance  2007;  Winters-Stone  2011).
Of  these  40,  18  reported  numbers  of  participants  with  stage  0
breast  cancer  (total  n  =  173,  mean  6,  range  1  to  28)  (Baruth
2013; Basen-Enquist 2006; Cadmus 2009; Dolan 2016; Fillion 2008;
Irwin 2015; Kiecolt-Glaser 2014; Littman 2012; Loudon 2014; Pinto
2003;  Pinto  2005;  Pinto  2015;  Rogers  2014;  Rogers  2015;  Schmitz
2005; Schmitz 2009; Short 2014; Winters-Stone 2011), all 40 trials

Cochrane Database of Systematic Reviews

reported numbers of participants with stage I-II breast cancer (n =
1334,  mean  33,  range  5  to  194,  and  n  =  753,  mean  32,  range  3  to
161, respectively), and 34 trials reported numbers of patients with
stage  III  breast  cancer  (n  =  413,  mean  12,  range  1  to  69)  (Baruth
2013;  Basen-Enquist  2006;  Cadmus  2009;  Cantarero-Villanueva
2013; Cerulli 2014; Cormie 2014; Courneya 2003; DeNysschen 2011;
Do  2015;  Dolan  2016;  Fillion  2008;  Guinan  2013;  Hatchett  2013;
Irwin 2015; Kiecolt-Glaser 2014; Ligibel 2008; Littman 2012; Loudon
2014;  Matthews  2007;  Mehnert  2011;  Milne  2008;  Murtezani  2014;
Musanti  2012;  Peppone  2015;  Pinto  2015;  Portela  2008;  Rogers
2009; Rogers 2013; Rogers 2015; Schmitz 2005; Schmitz 2009; Short
2014;  Vallance  2007;  Winters-Stone  2011).  Kim  2015  reported  the
numbers of participants with stage 0-I (n = 19) and stage II-III (n =
28) breast cancer. Five trials included a small number of patients
with metastatic breast cancer (Banasik 2011; Basen-Enquist 2006;
Hatchett 2013; Portela 2008; Short 2014).

Twenty-four (38%) trials reported participants’ average time since
cancer diagnosis (range 3.5 to 62.5 months) (Basen-Enquist 2006;
Cadmus 2009; Carson 2009; Dolan 2016; Ergun 2013; Fillion 2008;
Guinan  2013;  Irwin  2015;  Kiecolt-Glaser  2014;  Kim  2015;  Ligibel
2008; Littman 2012; Matthews 2007; Pinto 2003; Pinto 2005; Pinto
2015;  Rogers  2013;  Rogers  2015;  Schmitz  2005;  Schmitz  2009;
Segar  1998;  Vallance  2007;  Waltman  2010;  Winters-Stone  2011).
In Hatchett 2013, 60% and 40% of participants were less than 30
months and 30 to 70 months post diagnosis, respectively, and Loh
2014 reported that 14 and 71 participants were within one year and
two to five years post diagnosis, respectively. Eighteen (29%) trials
reported  average  time  beyond  active  treatment  (range  3  months
to 7.1 years) (Baruth 2013; Bower 2011; Cerulli 2014; Cormie 2014;
Courneya 2003; Guinan 2013; Herrero 2006; Kaltsatou 2011; Kiecolt-
Glaser  2014;  Milne  2008;  Naumann  2012;  Nieman  1995;  Peppone
2015; Pinto 2003; Rogers 2009; Schmitz 2005; Short 2014; Waltman
2010).  Other  studies  reported  that  all  participants  were  between
two  weeks  and  30  months  (Mustian  2004),  two  months  and  five
years (Portela 2008), six months and four years (Irwin 2015), and 12
and 36 months (Daley 2007) post treatment; within four weeks (post
surgery, Rogers 2015), six months (Cuesta-Vargas 2014; Martin 2013;
Nikander 2007), one year (Cadmus 2009; Matthews 2007; Mehnert
2011), 1.5 years (Heim 2007), and two years post treatment (Musanti
2012);  or  at  least  four  weeks  (Saarto  2012),  eight  weeks  (Banasik
2011;  Blank  2005;  Rogers  2015),  three  months  (Kim  2015;  Ligibel
2008; Littman 2012), six months (McKenzie 2003), one year (Winters-
Stone 2011), and two years post treatment (Fillion 2008). Cantarero-
Villanueva 2013 and Duijits 2012 reported that 48.3% and 80% of
participants were 12 months and less post treatment, respectively.

Forty-eight (76%) trials reported the numbers of participants who
had  received  chemotherapy  (mean  68%,  range  20%  to  100%)
(Baruth  2013;  Basen-Enquist  2006;  Bower  2011;  Cadmus  2009;
Cantarero-Villanueva 2013; Carson 2009; Cerulli 2014; Cormie 2014;
Courneya  2003;  Daley  2007;  DeNysschen  2011;  Do  2015;  Dolan
2016; Duijits 2012; Ergun 2013; Fillion 2008; Guinan 2013; Hatchett
2013;  Heim  2007;  Herrero  2006;  Irwin  2015;  Kiecolt-Glaser  2014;
Kim  2015;  Ligibel  2008;  Loh  2014;  Loudon  2014;  Malicka  2011;
Matthews 2007; Milne 2008; Murtezani 2014; Musanti 2012; Mustian
2004;  Naumann  2012;  Nikander  2007;  Peppone  2015;  Pinto  2003;
Pinto 2005; Pinto 2015; Rahnama 2010; Rogers 2009; Rogers 2015;
Saarto  2012;  Schmitz  2005;  Schmitz  2009;  Short  2014;  Vallance
2007;  Waltman  2010;  Winters-Stone  2011).  Five  trials  consisted
entirely  of  participants  who  had  received  chemotherapy  (Cerulli
2014; Ergun 2013; Guinan 2013; Herrero 2006; Rahnama 2010).

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

15

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Forty-six  (73%)  of  the  63  trials  reported  participants’  hormone
therapy  details  (Baruth  2013;  Blank  2005;  Bower  2011;  Cadmus
2009; Cantarero-Villanueva 2013; Carson 2009; Cerulli 2014; Cormie
2014;  Courneya  2003;  Daley  2007;  Do  2015;  Dolan  2016;  Duijits
2012;  Fillion  2008;  Guinan  2013;  Hatchett  2013;  Heim  2007;  Irwin
2015;  Kiecolt-Glaser  2014;  Kim  2015;  Ligibel  2008;  Malicka  2011;
Matthews 2007; Milne 2008; Murtezani 2014; Musanti 2012; Mustian
2004; Naumann 2012; Nikander 2007; Payne 2008; Peppone 2015;
Pinto  2003;  Pinto  2005;  Pinto  2015;  Rahnama  2010;  Rogers  2009;
Rogers  2013;  Rogers  2014;  Rogers  2015;  Saarto  2012;  Schmitz
2005;  Schmitz  2009;  Short  2014;  Vallance  2007;  Waltman  2010;
Winters-Stone  2011).  The  total  number  of  participants  who  had
received hormone therapy in these 46 trials was 3161 (mean n per
study  69,  range  9  to  442).  Seventeen  trials  reported  use  of  both
selective oestrogen receptor modulators (SORMs) and aromatase
inhibitors  (AIs)  (Cadmus  2009;  Cantarero-Villanueva  2013;  Carson
2009; Dolan 2016; Guinan 2013; Kim 2015; Ligibel 2008; Naumann
2012; Rogers 2009; Rogers 2013; Rogers 2014; Rogers 2015; Schmitz
2005;  Schmitz  2009;  Vallance  2007;  Waltman  2010;  Winters-Stone
2011). One study specifically investigated only women receiving AIs
(Irwin 2015), and another reported only the number of participants
receiving SORMs (Matthews 2007). A total of 690 participants (mean
38, range 5 to 182) had taken SORMs, and a total of 456 had taken
AIs (mean 25, range 2 to 121).

The  mean  average  age  of  participants  in  the  58  (92%)  trials  that
reported this characteristic was 54 (mean age range 46 to 63) years.
Heim 2007 reported the number of participants 30 to 50 years (n
= 32) and 51 to 70 years (n = 31), and Blank 2005 reported the age
range of participants (range 48 to 69 years). Two studies reported
no  age  data  (Hatchett  2013;  Taleghani  2012).  Twenty-seven  trials
(43%)  reported  the  percentage  of  postmenopausal  participants
(Cadmus 2009; Cantarero-Villanueva 2013; Carson 2009; Courneya
2003;  DeNysschen  2011;  Dolan  2016;  Ergun  2013;  Fillion  2008;
Guinan  2013;  Irwin  2015;  Kiecolt-Glaser  2014;  Kim  2015;  Ligibel
2008;  Loh  2014;  Matthews  2007;  Milne  2008;  Payne  2008;  Pinto
2003; Rogers 2009; Rogers 2013; Rogers 2014; Rogers 2015; Saarto
2012;  Schmitz  2005;  Vallance  2007;  Waltman  2010;  Winters-Stone
2011).  The  mean  percentage  of  postmenopausal  participants  in
these trials was 78% (range 0 to 100%). Eleven (18%) trials included
exclusively postmenopausal participants (Cadmus 2009; Courneya
2003; Dolan 2016; Ergun 2013; Irwin 2015; Kim 2015; Matthews 2007;
Payne  2008;  Rogers  2014;  Waltman  2010;  Winters-Stone  2011);
Bower 2011 consisted of only premenopausal and perimenopausal
participants, and Heim 2007 stated the percentage of participants
who  reported  symptoms  of  menopause  (n  =  64%),  rather  than
menopausal status.

Thirty trials (48%) reported the ethnicity of participants (Banasik
2011; Baruth 2013; Basen-Enquist 2006; Bower 2011; Cadmus 2009;
Carson  2009;  Daley  2007;  DeNysschen  2011;  Dolan  2016;  Guinan
2013; Hatchett 2013; Irwin 2015; Kiecolt-Glaser 2014; Littman 2012;
Loh 2014; Matthews 2007; Musanti 2012; Mustian 2004; Payne 2008;
Peppone 2015; Pinto 2005; Pinto 2015; Rogers 2009; Rogers 2013;
Rogers 2014; Rogers 2015; Schmitz 2005; Schmitz 2009; Segar 1998;
Waltman 2010). Most participants were white (mean % participants
=  83%).  Black  participants  were  the  next  largest  ethnic  group  (n
studies  =  18;  mean  %  participants  =  11%).  Loh  2014  consisted  of
Chinese (64%), Malay (25%), and Indian (11%) participants.

Thirty-two (51%) trials reported the education level of participants
(Baruth  2013;  Basen-Enquist  2006;  Bower  2011;  Cadmus  2009;

Cochrane Database of Systematic Reviews

Cantarero-Villanueva  2013;  Carson  2009;  Courneya  2003;  Cuesta-
Vargas 2014; Daley 2007; DeNysschen 2011; Do 2015; Duijits 2012;
Ergun 2013; Fillion 2008; Hatchett 2013; Irwin 2015; Kiecolt-Glaser
2014; Kim 2015; Littman 2012; Loh 2014; Mehnert 2011; Murtezani
2014;  Mustian  2004;  Payne  2008;  Pinto  2003;  Pinto  2005;  Pinto
2015; Schmitz 2005; Schmitz 2009; Segar 1998; Short 2014; Vallance
2007), with an average of 47% (range 22% to 70%) of participants
reporting educational attainment of a university degree or higher.
In  addition,  six  trials  reported  the  number  of  years  in  education
(mean 15 years, mean range 14 to 16 years) (Matthews 2007; Rogers
2009; Rogers 2013; Rogers 2014; Rogers 2015; Saarto 2012). Twenty
trials  (37%)  reported  the  sociodemographic  status  (i.e.  earnings
per  week,  month,  or  year)  of  participants  (Banasik  2011;  Bower
2011;  Courneya  2003;  DeNysschen  2011;  Do  2015;  Fillion  2008;
Kiecolt-Glaser  2014;  Kim  2015;  Littman  2012;  Loh  2014;  Mustian
2004;  Payne  2008;  Pinto  2003;  Pinto  2005;  Rogers  2009;  Rogers
2013; Rogers 2014; Rogers 2015; Short 2014; Vallance 2007). Three
studies  reported  the  percentage  of  participants  earning  >  USD
40K  (mean  61%,  range  50%  to  70%)  (Mustian  2004;  Payne  2008;
Pinto 2005), eight studies reported the percentage earning > USD
50K (mean 61%, range 39% to 76%) (Banasik 2011; Kiecolt-Glaser
2014;  Pinto  2003;  Pinto  2005;  Rogers  2009;  Rogers  2013;  Rogers
2014; Rogers 2015), three studies reported the percentage earning
> USD 60K (mean 46%, range 30% to 65%) (Courneya 2003; Littman
2012;  Payne  2008),  one  study  reported  that  56%  of  participants
earned > USD 70K (DeNysschen 2011), three studies reported the
percentage  earning  >  USD  75K  (mean  42%,  range  17%  to  55%)
(Banasik 2011; Bower 2011; Kiecolt-Glaser 2014), and two studies
reported participants earning > USD 80K (mean 28%, range 26% to
29%) (Littman 2012; Vallance 2007). Short 2014 reported that 39%
of participants earned > USD 1K per week, and Kim 2015 noted that
42% of participants earned ≥ USD 2K per month. One study reported
the percentage of participants at low (8%), medium (81%), and high
(11%) income status (no definition of income categories were given)
(Do 2015).

Fourteen  (22%)  trials  reported  comorbidity  data  for  participants
(Cadmus 2009; Daley 2007; Do 2015; Irwin 2015; Kim 2015; Peppone
2015;  Rogers  2013;  Rogers  2014;  Rogers  2015;  Saarto  2012;  Short
2014;  Vallance  2007;  Waltman  2010;  Winters-Stone  2011).  Five  of
these  14  studies  reported  a  comorbidity  index  score  (mean  2.2,
range  1.8  to  2.7)  (Rogers  2009;  Rogers  2013;  Rogers  2014;  Rogers
2015;  Winters-Stone  2011).  In  three  studies  all  participants  had
lymphoedema  (Cormie  2014;  Loudon  2014;  McKenzie  2003),  and
another study included an arm of participants with lymphoedema
and  an  arm  at  risk  of  lymphoedema  (Schmitz  2009).  Kim  2015
consisted  entirely  of  participants  with  a  diagnosis  of  osteopenia,
and Irwin 2015 included participants reporting arthralgia.

Twenty (32%) studies included physical activity-specific eligibility
criteria  to  recruit  only  ‘sedentary’,  ‘inactive’,  or  those  performing
‘no  activity’  or  ‘not  meeting  recommended  physical  activity
guidelines’  (i.e.  >  75  minutes  of  vigorous  physical  activity  and
>  150  minutes  of  moderate  physical  activity  per  week)  (Baruth
2013;  Basen-Enquist  2006;  Cadmus  2009;  Cerulli  2014;  Ergun
2013;  Herrero  2006;  Ligibel  2008;  Matthews  2007;  Milne  2008;
Mustian 2004; Naumann 2012; Pinto 2003; Pinto 2005; Pinto 2015;
Rahnama  2010;  Rogers  2009;  Rogers  2013;  Schmitz  2005;  Segar
1998; Taleghani 2012). Twelve studies reported the mean baseline
minutes  of  total,  walking,  moderate,  or  moderate-to-vigorous
physical activity per week (mean ± SD min/week 108 ± 109 minutes,
range  13  to  378  minutes)  (Cadmus  2009;  Cantarero-Villanueva

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

16

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

2013; Courneya 2003; Guinan 2013; Irwin 2015; Kiecolt-Glaser 2014;
Pinto  2005;  Pinto  2015;  Rogers  2009;  Rogers  2014;  Rogers  2015;
Vallance  2007).  Six  studies  expressed  baseline  physical  activity
in  Met-h/week-1  (mean  ±  SD  19.5  ±  14.1  metabolic  equivalent
(MET)-h/week-1, range 4 to 40 MET-h/week-1) (Baruth 2013; Littman
2012;  Matthews  2007;  Musanti  2012;  Saarto  2012;  Schmitz  2009).
Eleven studies categorised baseline physical activity to report the
proportion  of  participants  engaged  in  given  amounts  of  physical
activity  (Daley  2007;  Do  2015;  Dolan  2016;  Duijits  2012;  Fillion
2008;  Hatchett  2013;  Heim  2007;  Loh  2014;  Mehnert  2011;  Saarto
2012; Waltman 2010). A single study noted each of the following:
participants’  baseline  walking  steps/d  (Nikander  20077),  energy
expenditure (Winters-Stone 2011), leisure score and sport physical
activity  score  (Schmitz  2005),  and  self-selected  levels  of  fitness
(Loudon  2014).  Four  trials  excluded  participants  who  engaged  in
any/regular prior resistance exercise at the time of enrolment (Kim
2015; Schmitz 2005; Schmitz 2009; Winters-Stone 2011), two studies
excluded  participants  performing  regular  yoga  practice  (Carson
2009;  Peppone  2015),  and  one  study  recruited  only  participants
with  no  prior  practice  or  experience  in  traditional  Greek  dances
(Kaltsatou 2011).

Twenty-eight  trials  (44%)  reported  the  mean  body  mass  of
participants  (Cadmus  2009;  Cerulli  2014;  Cormie  2014;  Courneya
2003; Daley 2007; DeNysschen 2011; Dolan 2016; Duijits 2012; Heim
2007; Herrero 2006; Irwin 2015; Ligibel 2008; Littman 2012; Malicka
2011;  Martin  2013;  Matthews  2007;  McKenzie  2003;  Murtezani
2014; Musanti 2012; Naumann 2012; Nieman 1995; Nikander 2007;
Pinto  2003;  Rahnama  2010;  Saarto  2012;  Schmitz  2009;  Vallance
2007; Winters-Stone 2011), and 38 (60%) trials reported mean BMI
scores  of  participants  (Baruth  2013;  Basen-Enquist  2006;  Bower
2011;  Cadmus  2009;  Cerulli  2014;  Cormie  2014;  Courneya  2003;
Daley  2007;  Dolan  2016;  Duijits  2012;  Ergun  2013;  Herrero  2006;
Irwin  2015;  Kiecolt-Glaser  2014;  Kim  2015;  Ligibel  2008;  Littman
2012;  Loudon  2014;  Matthews  2007;  McKenzie  2003;  Milne  2008;
Murtezani  2014;  Mustian  2004;  Naumann  2012;  Nikander  2007;
Pinto 2003; Pinto 2005; Portela 2008; Rahnama 2010; Rogers 2009;
Rogers 2013; Rogers 2014; Saarto 2012; Schmitz 2009; Short 2014;
Vallance 2007; Waltman 2010; Winters-Stone 2011). Average mean
body mass in these trials was 74 kg (SD 4.4 kg, range 65.5 to 84.7
kg),  and  average  mean  BMI  was  28  kg/m2  (SD  2.1  kg/m2,  range
23.4  to  32.1  kg/m2).  Two  additional  trials  reported  the  numbers
of participants who fell into particular BMI ranges (Do 2015; Heim
2007).

Intervention characteristics

Intervention  length  ranged  from  four  weeks  to  24  months.  Most
studies provided interventions lasting eight (Banasik 2011; Blank
2005; Cantarero-Villanueva 2013; Carson 2009; Cuesta-Vargas 2014;
Daley  2007;  Guinan  2013;  Herrero  2006;  Loh  2014;  Loudon  2014;
Malicka 2011; Martin 2013; McKenzie 2003; Naumann 2012; Nieman
1995;  Taleghani  2012)  or  12  weeks  (three  months)  (Baruth  2013;
Bower  2011;  Cormie  2014;  Duijits  2012;  Ergun  2013;  Hatchett
2013;  Kiecolt-Glaser  2014;  Matthews  2007;  Milne  2008;  Musanti
2012; Mustian 2004; Nikander 2007; Pinto 2003; Pinto 2005; Pinto
2015; Rogers 2009; Rogers 2013; Rogers 2014; Rogers 2015; Short
2014;  Vallance  2007).  Four  (6%)  studies  conducted  year-long
interventions  (Irwin  2015;  Saarto  2012;  Schmitz  2009;  Winters-
Stone  2011).  Seventeen  (27%)  trials  had  a  follow-up  period  that
extended  beyond  completion  of  the  intervention  (Bower  2011;
Cantarero-Villanueva 2013; Carson 2009; Daley 2007; Duijits 2012;

Cochrane Database of Systematic Reviews

Fillion 2008; Guinan 2013; Kiecolt-Glaser 2014; Loudon 2014; Pinto
2005; Pinto 2015; Rogers 2009; Rogers 2015; Segar 1998; Short 2014;
Vallance 2007; Waltman 2010). Follow-up duration ranged from two
weeks  in  Carson  2009  and  Segar  1998  to  12  months  in  Waltman
2010; the most common follow-up duration was three months (n
=  8;  Bower  2011;  Duijits  2012;  Fillion  2008;  Guinan  2013;  Kiecolt-
Glaser  2014;  Pinto  2015;  Rogers  2009;  Rogers  2015).  Two  trials
provided  follow-up  only  to  intervention  groups  (Do  2015;  Dolan
2016).

Physical  activity  modes  differed  across  trials.  Only  seven  (11%)
trials  included  a  separate  resistance  training  condition  with  no
form  of  aerobic  activity  (i.e.  any  activity  that  uses  large  muscle
groups,  can  be  maintained  continuously,  and  is  rhythmical  in
nature)  (Cormie  2014;  Martin  2013;  Musanti  2012;  Schmitz  2005;
Schmitz  2009;  Waltman  2010;  Winters-Stone  2011).  Twenty-one
(33%)  trials  involved  an  intervention  arm  that  combined  aerobic
activity and resistance training (Cantarero-Villanueva 2013; Cuesta-
Vargas  2014;  Do  2015;  Ergun  2013;  Heim  2007;  Herrero  2006;
Irwin  2015;  Kaltsatou  2011;  Ligibel  2008;  McKenzie  2003;  Milne
2008;  Musanti  2012;  Naumann  2012;  Nieman  1995;  Pinto  2003;
Portela 2008; Rahnama 2010; Rogers 2013; Rogers 2014; Short 2014;
Taleghani 2012). Twenty-eight (44%) trials consisted of an aerobic
activity-only condition (Baruth 2013; Basen-Enquist 2006; Cadmus
2009; Cerulli 2014; Courneya 2003; Daley 2007; DeNysschen 2011;
Dolan  2016;  Duijits  2012;  Ergun  2013;  Fillion  2008;  Guinan  2013;
Hatchett  2013;  Loh  2014;  Malicka  2011;  Matthews  2007;  Mehnert
2011;  Murtezani  2014;  Musanti  2012;  Nikander  2007;  Payne  2008;
Pinto  2005;  Pinto  2015;  Rogers  2009;  Rogers  2015;  Saarto  2012;
Segar  1998;  Vallance  2007).  Eight  studies  (13%)  included  a  yoga-
only  arm  (Banasik  2011;  Blank  2005;  Bower  2011;  Carson  2009;
Kiecolt-Glaser  2014;  Littman  2012;  Loudon  2014;  Peppone  2015),
and  one  study  provided  each  of  the  following  intervention  arms:
pilates only (Martin 2013), tai chi only (Mustian 2004), and qigong
(similar to tai chi) only (Loh 2014).

Frequency (number of days per week) of physical activity ranged
from two days to seven days per week, with most studies providing
physical  activity  at  least  three  days  per  week  (n  =  44;  Baruth
2013; Blank 2005; Cadmus 2009; Cantarero-Villanueva 2013; Carson
2009; Courneya 2003; Cuesta-Vargas 2014; Daley 2007; DeNysschen
2011; Do 2015; Dolan 2016; Ergun 2013; Fillion 2008; Guinan 2013;
Heim 2007; Herrero 2006; Kaltsatou 2011; Littman 2012; Loh 2014;
Loudon 2014; Martin 2013; Matthews 2007; McKenzie 2003; Milne
2008; Murtezani 2014; Musanti 2012; Mustian 2004; Naumann 2012;
Nieman 1995; Nikander 2007; Payne 2008; Pinto 2003; Pinto 2005;
Pinto 2015; Portela 2008; Rahnama 2010; Rogers 2014; Rogers 2015;
Saarto 2012; Segar 1998; Short 2014; Taleghani 2012; Vallance 2007;
Winters-Stone 2011). Duration of sessions ranged from 15 minutes
to longer than 95 minutes, with a modal duration of 60 minutes (n
= 16; Cantarero-Villanueva 2013; Cerulli 2014; Cormie 2014; Cuesta-
Vargas  2014;  Fillion  2008;  Kaltsatou  2011;  Malicka  2011;  Milne
2008; Mustian 2004; Naumann 2012; Nieman 1995; Nikander 2007;
Saarto  2012;  Schmitz  2005;  Taleghani  2012;  Winters-Stone  2011).
Five  studies  gave  participants  a  goal  total  number  of  minutes  of
physical  activity  to  achieve  each  week  (90  minutes/week,  Ligibel
2008; 150 minutes/week, Irwin 2015; Rogers 2009; Rogers 2015; 150
to 180 minutes/week, Duijits 2012). The total number of sessions for
physical activity interventions ranged between 12 and 260.

Among  48  (76%)  trials  that  consisted  of  aerobic  physical  activity,
13  provided  walking  only  (Baruth  2013;  Ergun  2013;  Fillion  2008;

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

17

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Heim  2007;  Matthews  2007;  Musanti  2012;  Nieman  1995;  Payne
2008;  Portela  2008;  Rahnama  2010;  Rogers  2009;  Rogers  2014;
Rogers 2015), four involved primarily walking (Basen-Enquist 2006;
Cadmus  2009;  Irwin  2015;  Vallance  2007),  one  involved  Nordic
walking (Malicka 2011), and one provided walking with gymnastics
(Mehnert  2011).  Other  aerobic  intervention  modes  involved  arm
ergometer exercise (McKenzie 2003), cycling only (Courneya 2003;
Herrero  2006),  deep  water  running  (Cuesta-Vargas  2014),  deep
water  aquatic  exercise  (Cantarero-Villanueva  2013),  Greek  dance
(Kaltsatou  2011),  horse  riding  (Cerulli  2014),  line  dancing  and
qigong (Loh 2014), and step aerobics and circuit training (involving
steps, hops, and jumps) (Nikander 2007; Saarto 2012). In all other
trials, participants performed the prescribed physical activity using
a range of modes (e.g. treadmill, rowing ergometer, stair climbing).

Of  the  45  studies  providing  an  aerobic  activity  intervention,  39
reported frequency of aerobic activity ranging from two to seven
days per week. In 33 (53%) studies, the number of aerobic activity
sessions  per  week  ranged  between  three  and  five  (Baruth  2013;
Cadmus  2009;  Cantarero-Villanueva  2013;  Cerulli  2014;  Courneya
2003; Cuesta-Vargas 2014; Daley 2007; DeNysschen 2011; Do 2015;
Dolan 2016; Ergun 2013; Fillion 2008; Herrero 2006; Kaltsatou 2011;
Kim 2015; Littman 2012; Loh 2014; Matthews 2007; McKenzie 2003;
Milne 2008; Murtezani 2014; Musanti 2012; Nieman 1995; Nikander
2007;  Payne  2008;  Pinto  2003;  Pinto  2015;  Portela  2008;  Rogers
2014;  Saarto  2012;  Segar  1998;  Taleghani  2012;  Vallance  2007).
Duration  of  aerobic  activity  ranged  between  10  and  90  minutes.
Twenty-four  (38%)  trials  included  aerobic  activity  sessions  with
duration  of  30  minutes  or  greater  (Baruth  2013;  Cadmus  2009;
Cantarero-Villanueva  2013;  Cerulli  2014;  Daley  2007;  DeNysschen
2011; Do 2015; Ergun 2013; Fillion 2008; Heim 2007; Herrero 2006;
Ligibel 2008; Loh 2014; Malicka 2011; Mehnert 2011; Nieman 1995;
Nikander 2007; Pinto 2003; Pinto 2015; Portela 2008; Rogers 2014;
Saarto 2012; Segar 1998; Vallance 2007).

Intensity of aerobic activity varied substantially between trials, as
did  methods  used  to  measure  and  monitor  intensity.  Seventeen
(27%) trials set intensity according to percentage of maximum heart
rate  (%HRmax  range  40%  to  80%)  (Cadmus  2009;  Cerulli  2014;
Daley 2007; Herrero 2006; Irwin 2015; Kaltsatou 2011; Ligibel 2008;
Malicka 2011; Milne 2008; Musanti 2012; Nieman 1995; Pinto 2003;
Pinto  2005;  Portela  2008;  Rahnama  2010;  Segar  1998;  Taleghani
2012),  four  (6%)  set  percentage  of  target  heart  rate  using  the
Karvonen method (Karvonen target heart rate range 35% to 80%)
(Duijits 2012; Guinan 2013; Murtezani 2014; Rogers 2014), one (2%)
study  set  intensity  as  heart  rate  at  the  intensity  of  activity  that
elicits  a  blood  lactate  concentration  of  2  to  3  mmol,  three  (5%)
studies  used  percentage  of  directly  measured  maximal  oxygen
uptake  (%  VO2max  range  45%  to  75%)  (Courneya  2003;  Do  2015;
Mehnert 2011), seven (11%) studies used rate of perceived exertion
(RPE; range 10 to 16) (Baruth 2013; Daley 2007; DeNysschen 2011;
Kim  2015;  Matthews  2007;  Nikander  2007;  Saarto  2012),  and  12
(19%) trials reported subjective intensity of the intervention (low
to moderate, moderate, or moderate-to-vigorous intensity) (Basen-
Enquist 2006; Cantarero-Villanueva 2013; Dolan 2016; Ergun 2013;
Naumann 2012; Payne 2008; Pinto 2015; Rogers 2009; Rogers 2013;
Rogers  2015;  Short  2014;  Vallance  2007).  Two  (3%)  trials  did  not
provide  the  intensity  at  which  aerobic  activity  was  performed
(Fillion 2008; Heim 2007).

Frequency  of 
interventions  with  resistance  training  ranged
between two and five days, with a modal frequency of three days

Cochrane Database of Systematic Reviews

(n  =  14;  Ergun  2013;  Heim  2007;  Herrero  2006;  Kaltsatou  2011;
Kim 2015; Martin 2013; McKenzie 2003; Milne 2008; Musanti 2012;
Naumann 2012; Nieman 1995; Pinto 2003; Taleghani 2012; Winters-
Stone 2011). Cuesta-Vargas 2014 did not report resistance training
frequency. Duration of resistance training sessions ranged between
15  and  90  minutes,  with  11  studies  reporting  duration  of  30  to
60 minutes (Cormie 2014; Ergun 2013; Herrero 2006; Ligibel 2008;
Martin  2013;  Milne  2008;  Nieman  1995;  Rahnama  2010;  Schmitz
2005;  Waltman  2010;  Winters-Stone  2011).  Eleven  (17%)  studies
did  not  report  the  duration  of  sessions  (Heim  2007;  Irwin  2015;
Kim 2015; McKenzie 2003; Musanti 2012; Pinto 2003; Portela 2008;
Rogers 2013; Rogers 2014; Short 2014; Taleghani 2012). The number
of resistance exercises ranged between four and 12, with a modal
exercise  number  of  nine  (n  =  6;  Do  2015;  Heim  2007;  Kim  2015;
Rahnama  2010;  Schmitz  2005;  Schmitz  2009).  Seventeen  (27%)
trials  provided  resistance  training  exercises  for  both  upper  and
lower body (Cormie 2014; Do 2015; Ergun 2013; Herrero 2006; Irwin
2015;  Kim  2015;  Martin  2013;  Milne  2008;  Musanti  2012;  Portela
2008;  Rahnama  2010;  Rogers  2013;  Rogers  2014;  Schmitz  2005;
Schmitz  2009;  Waltman  2010;  Winters-Stone  2011),  one  targeted
the  lower  body  and  abdominals  (Ligibel  2008),  one  targeted  the
upper  body  and  abdominals  (Pinto  2003),  one  described  the
programme  as  general  strengthening  (Cuesta-Vargas  2014),  and
four targeted the upper body only (Kaltsatou 2011; McKenzie 2003;
Naumann 2012; Taleghani 2012). Remaining studies did not report
areas of the body targeted by exercise (Heim 2007; Nieman 1995;
Short  2014).  One  study  combined  resistance  training  with  jump
exercises with added resistance up to 10% of body weight (Winters-
Stone 2011).

Ten  (16%)  trials  used  resistance  machines  (Irwin  2015;  Kaltsatou
2011;  Ligibel  2008;  Portela  2008;  Rahnama  2010;  Schmitz  2005;
Schmitz  2009;  Segar  1998;  Taleghani  2012;  Waltman  2010),  eight
(13%) used free weights (i.e. dumbbells and barbells) (Cormie 2014;
Pinto  2003;  Portela  2008;  Rahnama  2010;  Schmitz  2005;  Schmitz
2009;  Waltman  2010;  Winters-Stone  2011),  and  seven  (11%)  used
resistance  (Thera)  bands  (Ergun  2013;  Kim  2015;  Musanti  2012;
Portela 2008; Rogers 2013; Rogers 2014; Winters-Stone 2011). The
number  of  sets  per  resistance  exercise  ranged  from  one  to  four
(mode 2 sets; Cuesta-Vargas 2014; Kim 2015; Milne 2008; Nieman
1995;  Portela  2008;  Rogers  2014;  Taleghani  2012;  Waltman  2010),
and  the  number  of  repetitions  per  set  ranged  from  6  to  20,  with
the modal repetition range of 8 to 12 (n = 4; Irwin 2015; Taleghani
2012;  Waltman  2010;  Winters-Stone  2011).  Intensity  of  resistance
exercises was set according to the percentage of maximum weight a
participant could lift in one repetition (%1RM range 65% to 85%) in
four (6%) trials (Cormie 2014; Do 2015; Ligibel 2008; Winters-Stone
2011), with 12 to 15 repetition maximum in one trial (Herrero 2006),
and with RPE in three (5%) trials (Martin 2013; Musanti 2012; Portela
2008); participants lifted “as much as they could” in Rahnama 2010,
and as much as they could achieve “with good form” in Milne 2008.

Most of the eight yoga studies employed a form of Hatha yoga (n = 6;
Hatha: Kiecolt-Glaser 2014; Peppone 2015; Iyengar: Banasik 2011;
Blank  2005;  Bower  2011;  Viniyoga:  Littman  2012);  Loudon  2014
included a Satyananda yoga intervention arm, and Carson 2009 a
Yoga of Awareness intervention arm. Yoga studies ranged between
4 and 24 weeks in duration, with four studies lasting eight weeks
(Banasik 2011; Blank 2005; Carson 2009; Loudon 2014). Frequency
of yoga practice ranged between two and seven sessions per week
(mode 2 sessions/week; Banasik 2011; Bower 2011; Kiecolt-Glaser
2014; Peppone 2015), and yoga session duration ranged between

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

18

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

20 and 90 minutes (mode 90 minutes; Banasik 2011; Bower 2011;
Kiecolt-Glaser  2014;  Loudon  2014).  Investigators  in  these  studies
described the intensity of all yoga interventions as moderate, apart
from Carson 2009, which referred to gentle intensity, and Peppone
2015, which described light intensity. Light-to-moderate-intensity
qigong  and  tai  chi  interventions  in  Loh  2014  and  Mustian  2004,
respectively, had a duration of 8 weeks and 12 weeks, a frequency
of  three  sessions  per  week,  and  session  duration  of  30  minutes
(twice  a  week  at  home)  or  90  minutes  (once  a  week  supervised)
and 60 minutes, respectively. Martin 2013 provided the only pilates
intervention, which consisted of three 50-minute sessions per week
performed within an RPE intensity range of 9 to 14 for eight weeks.

the 

trials, 

(38%) 

intervention  arm 

In  24 
involved  a
psychobehavioural  component  designed  to  promote  physical
activity  behaviour  change  (Baruth  2013;  Basen-Enquist  2006;
Carson  2009;  Courneya  2003;  Cuesta-Vargas  2014;  Daley  2007;
DeNysschen 2011; Duijits 2012; Ergun 2013; Fillion 2008; Hatchett
2013; Matthews 2007; Musanti 2012; Pinto 2005; Pinto 2015; Portela
2008; Rogers 2009; Rogers 2013; Rogers 2014; Rogers 2015; Segar
1998;  Short  2014;  Vallance  2007;  Waltman  2010).  Seven  studies
delivered the psychobehavioural component via group discussions
(Basen-Enquist  2006;  Carson  2009;  Fillion  2008;  Rogers  2009;
Rogers  2013;  Rogers  2014;  Rogers  2015);  some  trials  employed
face-to-face  counselling  in  a  single  session  at  the  beginning  of
the intervention (Baruth 2013; Matthews 2007); others scheduled
multiple  sessions  during  the  intervention  period  (Rogers  2009;
Rogers  2013;  Rogers  2015),  mailed  or  emailed  support  (Hatchett
2013;  Pinto  2005;  Short  2014),  or  provided  information  booklets
promoting physical activity behaviour change (Musanti 2012; Short
2014;  Vallance  2007).  Two  studies  applied  cognitive-behavioural
theories (Cuesta-Vargas 2014; Daley 2007), and one study utilised
self-efficacy  theory  during  supervised  exercise  sessions  with
participants (Waltman 2010). Segar 1998 included a study arm that
applied self-awarded rewards to serve as reinforcements to induce
physical  activity  behaviour  change.  Courneya  2003  incorporated
into the intervention individual or small group meetings designed
to  outline  goals  and  provide  feedback  on  participants’  progress.
Eleven studies (17%) implemented weekly or fortnightly telephone
counselling  or  monitoring  throughout  the  intervention  period
(Baruth  2013;  DeNysschen  2011;  Duijits  2012;  Ergun  2013;  Fillion
2008;  Matthews  2007;  Musanti  2012;  Pinto  2005;  Pinto  2015;
Portela 2008; Waltman 2010). The number of telephone counselling
sessions  ranged  between  4  and  26,  and  their  duration  ranged
from  5  to  15  minutes.  Topics  covered  in  the  psychobehavioural
component  included  goal  setting,  barriers  to  and  benefits  of
physical  activity,  physical  activity  adherence  monitoring  and
safety,  behaviour  reinforcement,  and  symptom  management.
Several  studies  included  an  educational  component  at  baseline
that  was  deemed  not  to  promote  physical  activity  behaviour
change  (Heim  2007;  Irwin  2015;  Mehnert  2011;  Schmitz  2009).
Two of these studies provided participants with education related
to  lymphoedema  and  other  cancer-related  topics  (Irwin  2015;
Schmitz 2009), one study provided education on how to perform
specific  exercises  (Mehnert  2011),  and  another  trial  provided  an
educational  programme,  physical  therapy,  group  exercise,  and
psycho-oncological interventions for both intervention and control
groups (Heim 2007).

Interventions in 32 (51%) trials involved a supervised component
(Banasik  2011;  Bower  2011;  Cantarero-Villanueva  2013;  Cerulli
2014;  Cormie  2014;  Courneya  2003;  Cuesta-Vargas  2014;  Daley

Cochrane Database of Systematic Reviews

2007;  Do  2015;  Dolan  2016;  Ergun  2013;  Herrero  2006;  Kaltsatou
2011;  Kiecolt-Glaser  2014;  Littman  2012;  Loudon  2014;  Malicka
2011;  Martin  2013;  McKenzie  2003;  Mehnert  2011;  Milne  2008;
Murtezani  2014;  Mustian  2004;  Naumann  2012;  Nieman  1995;
Peppone 2015; Portela 2008; Rahnama 2010; Schmitz 2005; Schmitz
2009;  Segar  1998;  Taleghani  2012);  16  (25%)  trials  included  a
home-based  physical  activity  component  (Baruth  2013;  Basen-
Enquist 2006; DeNysschen 2011; Duijits 2012; Ergun 2013; Hatchett
2013; Heim 2007; Kim 2015; Matthews 2007; Musanti 2012; Payne
2008;  Pinto  2005;  Pinto  2015;  Portela  2008;  Short  2014;  Vallance
2007), and 17 (27%) studies provided an intervention that included
both  supervised  and  home-based  physical  activity  (Blank  2005;
Cadmus 2009; Carson 2009; Fillion 2008; Guinan 2013; Irwin 2015;
Ligibel  2008;  Loh  2014;  Nikander  2007;  Pinto  2003;  Rogers  2009;
Rogers  2013;  Rogers  2014;  Rogers  2015;  Saarto  2012;  Waltman
2010; Winters-Stone 2011). With regards to the format of physical
activity interventions, 27 (43%) studies consisted of an individual
physical activity format (Baruth 2013; Basen-Enquist 2006; Cerulli
2014; Courneya 2003; Daley 2007; DeNysschen 2011; Duijits 2012;
Ergun 2013; Hatchett 2013; Heim 2007; Kim 2015; Matthews 2007;
McKenzie  2003;  Musanti  2012;  Naumann  2012;  Payne  2008;  Pinto
2003;  Pinto  2005;  Pinto  2015;  Portela  2008;  Rogers  2013;  Rogers
2014;  Schmitz  2005;  Short  2014;  Taleghani  2012;  Vallance  2007;
Waltman  2010),  15  (24%)  studies  incorporated  a  group  physical
activity  format  (Banasik  2011;  Bower  2011;  Cantarero-Villanueva
2013;  Cormie  2014;  Cuesta-Vargas  2014;  Fillion  2008;  Herrero
2006;  Kaltsatou  2011;  Malicka  2011;  Mehnert  2011;  Milne  2008;
Murtezani 2014; Mustian 2004; Peppone 2015; Schmitz 2009), and
14  (25%)  studies  used  a  combination  of  group  and  individual
physical activity interventions (Blank 2005; Cadmus 2009; Carson
2009;  Guinan  2013;  Irwin  2015;  Kiecolt-Glaser  2014;  Ligibel  2008;
Littman 2012; Loh 2014; Loudon 2014; Nikander 2007; Rogers 2009;
Saarto  2012;  Winters-Stone  2011).  The  format  employed  in  the
intervention  was  unclear  in  seven  studies  (Do  2015;  Dolan  2016;
Martin  2013;  Nieman  1995;  Rahnama  2010;  Rogers  2015;  Segar
1998).

Most  trials  enlisted  the  services  of  doctorate  students,  exercise
physiologists,  exercise/sports  trainers/specialists,  fitness/exercise
instructors, health counsellors, kinesiologists, physical and sports
therapists,  physiotherapists,  nurses,  yoga  instructors,  or  other
professionals to lead the exercise programme (n = 46, 73%; Banasik
2011; Blank 2005; Bower 2011; Cadmus 2009; Cantarero-Villanueva
2013;  Carson  2009;  Cerulli  2014;  Cormie  2014;  Courneya  2003;
Cuesta-Vargas 2014; Daley 2007; DeNysschen 2011; Do 2015; Duijits
2012; Ergun 2013; Fillion 2008; Hatchett 2013; Heim 2007; Herrero
2006;  Irwin  2015;  Kaltsatou  2011;  Kiecolt-Glaser  2014;  Kim  2015;
Ligibel 2008; Littman 2012; Loh 2014; Loudon 2014; Matthews 2007;
Mehnert 2011; Milne 2008; Mustian 2004; Naumann 2012; Peppone
2015; Pinto 2003; Portela 2008; Rogers 2009; Rogers 2013; Rogers
2014; Rogers 2015; Saarto 2012; Schmitz 2005; Schmitz 2009; Short
2014;  Taleghani  2012;  Waltman  2010;  Winters-Stone  2011).  Pinto
2015 trained breast cancer survivors to deliver the physical activity
intervention; Baruth 2013 utilised doctorate students, Martin 2013
used sport and exercise science students, and Musanti 2012, Payne
2008, and Segar 1998 used research staff.

Most trials (n = 30; 48%) described the comparison arm as “usual”
or  “standard”  care,  “no  intervention”,  “sedentary  control”,  or
“control”, and 24 (38%) studies included a comparison arm that was
a "waiting list" or “delayed exercise” control, wherein participants
were  offered  a  portion  of  or  the  full  exercise  programme  at

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

19

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

completion  of  the  trial  (Blank  2005;  Cadmus  2009;  Carson  2009;
Cormie 2014; Courneya 2003; Cuesta-Vargas 2014; Do 2015; Dolan
2016;  Duijits  2012;  Hatchett  2013;  Kiecolt-Glaser  2014;  Ligibel
2008;  Littman  2012;  Loh  2014;  Loudon  2014;  Matthews  2007;
Milne  2008;  Peppone  2015;  Pinto  2003;  Pinto  2005;  Rogers  2009;
Rogers  2013;  Schmitz  2005;  Schmitz  2009).  Baruth  2013  offered
counselling to the usual care group at the end of the intervention
period.  In  eight  (13%)  trials,  the  comparison  group  received  an
intervention that included health education (Bower 2011); phone
calls  (DeNysschen  2011);  an  educational  programme,  physical
therapy,  group  discussion  exercises,  and  psycho-oncological
interventions (Heim 2007); psychosocial support therapy (Mustian
2004);  light-intensity  body  conditioning/stretching  exercises  (e.g.
flexibility, passive stretching) (Daley 2007; Musanti 2012; Winters-
Stone 2011); and an attention control (Milne 2008; Pinto 2005).

Trial attrition and adherence

Fifty-five (87%) of the included trials reported attrition data. Nine
trials (16%) reported no dropouts at postintervention follow-up in
both intervention and control groups (Cerulli 2014; Cuesta-Vargas
2014;  DeNysschen  2011;  Ergun  2013;  Malicka  2011;  Martin  2013;
Milne 2008; Nikander 2007; Segar 1998), and four additional trials
(7%) reported no dropouts in the control group only (Baruth 2013;
Mehnert  2011;  Pinto  2005;  Portela  2008).  Twelve  trials  (22%)  -
Basen-Enquist  2006;  Carson  2009;  Do  2015;  Herrero  2006;  Ligibel
2008;  Loh  2014;  Loudon  2014;  Mustian  2004;  Nieman  1995;  Pinto
2003;  Portela  2008;  Rogers  2013  -  and  eight  trials  (15%)  -  Do
2015; Guinan 2013; Herrero 2006; Loh 2014; Mustian 2004; Nieman
1995; Pinto 2003; Rogers 2013 - reported attrition of at least 20%
in  the  intervention  and  control  groups,  respectively.  Most  trials
that included a postintervention follow-up period reported greater
attrition at least three months post intervention than immediately
post intervention.

Fifty-two trials (83%) reported adherence data in several different
ways,  including  average,  median,  range,  number,  or  percentage
of  participants  completing  all  or  a  certain  percentage  or  number
of  sessions,  numbers  meeting  physical  activity  guidelines,  and
minutes of physical activity achieved per week. Furthermore, some
trials  provided  adherence  data  for  completers  only.  Among  trials
that  reported  the  percentage  of  completed  aerobic  exercise  and
resistance  training  sessions,  average  adherence  was  79%  (range
36%  to  163%  of  targeted  session)  and  75%  (range  26%  to  98%),
respectively.  Most  trials  that  included  postintervention  follow-up
adherence  data  showed  considerable  reductions,  for  example,
one trial reported that only 50% of intervention participants met
the  recommended  physical  activity  guideline  of  150  minutes  of
moderate-to-vigorous  physical  activity  per  week  (Vallance  2007),
and  another  trial  observed  a  decrease  in  moderate-to-vigorous
physical  activity  from  130  minutes  per  week  at  the  end  of
intervention to 98 minutes three months later (Pinto 2015).

Outcome measures

Health-related quality of life outcomes

Investigators  performed  HRQoL  assessment  using  the  Cancer
Rehabilitation Evaluation System Short Form (CARES-SF) (Schmitz
2005),  the  European  Organization  for  Research  and  Treatment
of  Cancer  (EORTC)  Quality  of  Life  Questionnaire-C30  (QLQ-C30)
(Do  2015;  Duijits  2012;  Ergun  2013;  Herrero  2006;  Mehnert  2011;
Saarto  2012),  Functional  Assessment  of  Cancer  Therapy  (FACT)  -
Fatigue (FACT-F) (Mustian 2004), EuroQol-five dimensions (EQ-5D)

Cochrane Database of Systematic Reviews

and  EQ  Visual  Analogue  Scale  (Cuesta-Vargas  2014),  Functional
Assessment  of  Cancer  Therapy  -  General  (FACT-G)  (Cadmus  2009;
Cerulli 2014; Courneya 2003; Daley 2007; Heim 2007; Littman 2012;
Loh  2014;  Milne  2008;  Murtezani  2014;  Rogers  2009;  Rogers  2015;
Vallance  2007),  Functional  Assessment  of  Cancer  Therapy-Breast
(FACT-B)  (Courneya  2003;  Daley  2007;  Heim  2007;  Littman  2012;
Loh 2014; Milne 2008; Murtezani 2014; Naumann 2012; Pinto 2015;
Portela 2008; Rogers 2009; Rogers 2015; Short 2014; Vallance 2007),
International  Breast  Cancer  Study  Group  (IBCSG)  Quality  of  Life
Core  Questionnaire  (Baruth  2013),  Lymphoedema  Quality  of  Life
Tool  (LYMQOL)  (Loudon  2014),  Medical  Outcomes  Study  Short
Form-12  (MOS  SF-12)  (Cuesta-Vargas  2014;  Fillion  2008),  Medical
Outcomes Study Short Form-36 (MOS SF-36) (Baruth 2013; Basen-
Enquist  2006;  Cadmus  2009;  Cormie  2014;  Duijits  2012;  Kiecolt-
Glaser  2014;  McKenzie  2003;  Mehnert  2011;  Mustian  2004;  Pinto
2015; Schmitz 2009; Winters-Stone 2011), National Medical Center
and  Beckman  Research  Institute  Standard  Instrument  of  Quality
of  Life  Breast  Cancer  Survivors  (Taleghani  2012),  and  Perceived
General Health (Rogers 2009). We have provided in Table 1 details
of HRQoL subscales (cognitive function, emotional function/metal
health,  general  health  perspective,  perceived  physical  function,
role  function,  sexual  function,  sleep,  social  function)  and  other
psychological outcomes (anxiety, depression, fatigue and vitality,
pain/disability, and self-esteem/body image) as provided in eligible
studies.

Cardiorespiratory fitness outcomes

Investigators assessed cardiorespiratory fitness using maximal or
submaximal  tests  for  direct  or  indirect  measurement  of  VO2max/
peak or by assessing the distance walked for a given time period.
Six  (10%)  trials  directly  measured  VO2max/peak  using  a  maximal
exercise  test  (Courneya  2003;  DeNysschen  2011;  Dolan  2016;
Herrero  2006;  Irwin  2015;  Mehnert  2011).  Twelve  (19%)  studies
assessed  VO2max  indirectly  either  maximally  or  submaximally
(Cerulli  2014;  Daley  2007;  Do  2015;  Fillion  2008;  Milne  2008;
Musanti 2012; Naumann 2012; Rahnama 2010; Rogers 2009; Rogers
2013;  Rogers  2014;  Rogers  2015).  Eleven  (17%)  studies  assessed
cardiorespiratory  fitness  using  a  field  test  (Basen-Enquist  2006;
Heim  2007;  Kaltsatou  2011;  Kim  2015;  Murtezani  2014;  Mustian
2004; Nieman 1995; Nikander 2007; Pinto 2005; Portela 2008; Saarto
2012).  Details  of  these  cardiorespiratory  outcomes  are  provided
in  Table  2.  One  trial  assessed  only  the  intervention  group  via  a
peak graded exercise stress test on a cycle ergometer (Pinto 2003).
Other cardiovascular measures assessed in studies included resting
heart  rate  (Courneya  2003;  Dolan  2016;  Rahnama  2010),  resting
systolic  blood  pressure  (Cadmus  2009;  Courneya  2003;  Guinan
2013;  Kaltsatou  2011;  Rahnama  2010),  resting  diastolic  blood
pressure  (Cadmus  2009;  Courneya  2003;  Guinan  2013;  Rahnama
2010), and heart rate reserve (Courneya 2003).

Physical activity outcomes

In  all,  23  (37%)  studies  measured  physical  activity  via  self-report
and 12 (19%) studies performed objective measurements. Twenty
(32%) studies reported both preintervention and postintervention
physical activity (Baruth 2013; Basen-Enquist 2006; Cadmus 2009;
Courneya  2003;  Guinan  2013;  Hatchett  2013;  Irwin  2015;  Kiecolt-
Glaser 2014; Kim 2015; Littman 2012; Matthews 2007; Pinto 2005;
Pinto 2015; Rogers 2009; Rogers 2015; Saarto 2012; Schmitz 2009;
Short 2014; Vallance 2007; Winters-Stone 2011). Ten (16%) studies
assessed  preintervention  to  postintervention  physical  activity
objectively via accelerometers (Guinan 2013; Matthews 2007; Pinto

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

20

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

2005; Pinto 2015; Rogers 2009; Rogers 2014; Rogers 2015); Cadmus
2009,  Short  2014,  and  Vallance  2007  used  pedometers.  We  have
provided details of these physical activity outcomes in Table 2.

Anthropometric outcomes

Anthropometric outcomes included in eligible studies consisted of
body  mass  (n  =  22;  35%),  BMI  (n  =  19;  30%),  hip  circumference
(n  =  7;  11%),  waist  circumference  (n  =  9;  14%),  and  waist-to-hip
ratio  (n  =  5;  8%).  Nineteen  (30%)  studies  included  some  body
composition measure (Cadmus 2009; Cerulli 2014; Courneya 2003;
Daley 2007; DeNysschen 2011; Guinan 2013; Herrero 2006; Ligibel
2008; Matthews 2007; Musanti 2012; Mustian 2004; Naumann 2012;
Rogers 2009; Rogers 2013; Rogers 2014; Saarto 2012; Schmitz 2005;
Schmitz  2009;  Winters-Stone  2011).  We  have  provided  details  of
anthropometric and body composition outcomes in Table 2.

Muscular strength outcomes

Seventeen  (27%)  studies  assessed  lower  body  muscular  strength
(Cerulli 2014; Cormie 2014; Do 2015; Dolan 2016; Heim 2007; Milne
2008; Musanti 2012; Naumann 2012; Nieman 1995; Nikander 2007;
Rogers  2009;  Rogers  2013;  Saarto  2012;  Schmitz  2005;  Schmitz
2009;  Waltman  2010;  Winters-Stone  2011),  whereas  20  (32%)
studies  included  a  measure  of  upper  body  muscular  strength
(Cerulli  2014;  Cormie  2014;  Do  2015;  Heim  2007;  Irwin  2015;
Kaltsatou  2011;  Kim  2015;  Malicka  2011;  Milne  2008;  Musanti
2012; Mustian 2004; Naumann 2012; Nikander 2007; Portela 2008;
Rogers  2009;  Saarto  2012;  Schmitz  2005;  Schmitz  2009;  Waltman
2010; Winters-Stone 2011). We have provided details of muscular
strength  outcomes  in  Table  2.  One  study  reported  the  “maximal
weight  lifted  for  each  exercise  during  strength  training  sessions”
only for the intervention group (Ligibel 2008).

Bone-related outcomes

Two (3%) studies measured total bone mineral content (BMC) using
dual-energy  X-ray  absorptiometry  (DEXA)  (Cadmus  2009;  Saarto
2012); Saarto 2012 assessed BMC of the distal tibia, tibial midshaft,
and femoral neck. Six trials assessed bone mineral density (BMD)
via  DEXA  (Cadmus  2009;  Kim  2015;  Rogers  2009;  Saarto  2012;
Waltman  2010;  Winters-Stone  2011).  Saarto  2012  assessed  BMC,
total  cross-sectional  area,  cortical  density,  and  density-weighted
polar  section  modulus  via  peripheral  quantitative  computed
tomography (pQCT) scans of the left distal tibia and tibial midshaft.
Four (6%) studies provided data for biomarkers of bone turnover
(Kim 2015; Mustian 2004; Waltman 2010; Winters-Stone 2011). We
have provided details of bone-related outcomes in Table 2.

Cochrane Database of Systematic Reviews

Excluded studies

We retrieved a total of 86 studies, then excluded them after review
as they did not meet the inclusion criteria. We excluded 13 (15%)
studies  as  they  used  a  non-randomised  controlled  trial  design
and  included  no  comparison  group  (Fernandez-Lao  2013;  Fong
2014;  Galantino  2013;  Hojan  2013;  Hunt-Shanks  2006;  Hutnick
2005;  Johnsson  2013;  Lee  2010;  Naumann  2012a;  Sherman  2010;
Speed-Andrews  2010;  Sprod  2010;  Ulger  2010).  We  excluded  13
(15%)  studies  as  they  did  not  analyse  populations  with  breast
cancer separately (Buffart 2012; Burnham 2002; Culos-Reed 2006;
Demark  2006;  Ibfelt  2011;  LaStayo  2011;  Ligibel  2012;  May  2008;
Oh  2010;  Stevinson  2007;  Tang  2010;  Thorsen  2005;  Van  Weert
2005). We excluded two (2%) studies as they involved only patients
with  stage  IV  breast  disease  (Cunningham  1998;  Headley  2004).
We  excluded  one  (1%)  study  as  it  involved  only  pretreatment
patients  with  breast  cancer  (Cohen  2010),  and  13  (15%)  as  they
included  patients  receiving  concurrent  adjuvant  chemotherapy
and  radiotherapy  (Anderson  2012;  Danhauer  2009;  Hsiao-Fang
2013;  Hsieh  2008;  Husebo  2014;  Isabell  2010;  Kilbreath  2012;
Moadel 2007; Naraphong 2015; Sandel 2005; Segal 2001; Taso 2014;
Yuen 2007). We excluded 29 (34%) studies as they did not compare
a physical activity intervention versus no physical activity, another
intervention,  or  usual  care  (Benton  2014;  Cadmus-Bertram  2011;
Carter 2012; Cheema 2006; D'Atillio 2007; Damush 2006; De Backer
2007;  Dimeo  2008;  Eyigor  2010;  Hanna  2008;  Johansson  2005;
Kovacic 2011; Noble 2012; Oldervoll 2011; Pinto 2008; Pinto 2013;
Rabin 2006; Rabin 2009; Schmidt 2012; Schneider 2007; Schwartz
1999;  Sprod  2005;  Stan  2012;  Stan  2013;  Szczwpanska-Gieracha
2010;  Turner  2004;  Van  Puymbroeck  2011;  Wong  2012;  Wu  2008).
We  excluded  10  (12%)  studies  in  which  the  effect  of  physical
activity  could  not  be  isolated  because  the  intervention  included
dietary  modification  (Casla  2015;  Djuric  2002;  Kim  Soo  2011;
Mefferd  2007),  lifestyle  interventions  and/or  patient  education
(Bloom 2008; Cho 2006), or manual therapy (Cantarero-Villanueva
2012a;  Cantarero-Villanueva  2012;  Cantarero-Villanueva  2013a;
Fernandez-Lao  2012).  We  excluded  seven  (8%)  studies  as  the
physical  activity  intervention  was  limited  to  shoulder  and  arm
training  (Gordon  2005;  Hayes  2013;  Jeff  2012;  Kilbreath  2006;
Kilgour 2008; McClure 2010; Tidhar 2010). For detailed information
on reasons for exclusion of retrieved studies, see the Characteristics
of excluded studies table.

Risk of bias in included studies

For  each  trial,  we  have  detailed  risk  of  bias  in  the  ’Risk  of  bias’
tables included under Characteristics of included studies and in the
’Risk of bias’ summary provided in Figure 2. In addition, we have
presented an overall assessment of risk of bias in Figure 3.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

21

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 2.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

22

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 2.   (Continued)

Cochrane Database of Systematic Reviews

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

23

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 2.   (Continued)

Cochrane Database of Systematic Reviews

Figure 3.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.

Allocation

Thirty-two  (51%)  trials  were  at  a  low  risk  of  selection  bias  owing
to  adequate  generation  of  the  randomised  sequence  because
these trials used a random component to generate the sequence
(Cadmus  2009;  Cantarero-Villanueva  2013;  Carson  2009;  Cormie
2014; Courneya 2003; Daley 2007; Do 2015; Duijits 2012; Ergun 2013;
Fillion  2008;  Guinan  2013;  Irwin  2015;  Kiecolt-Glaser  2014;  Kim
2015; Loh 2014; Loudon 2014; Martin 2013; Milne 2008; Murtezani

2014;  Musanti  2012;  Mustian  2004;  Peppone  2015;  Portela  2008;
Rogers 2009; Rogers 2013; Rogers 2014; Rogers 2015; Saarto 2012;
Schmitz 2005; Schmitz 2009; Short 2014; Vallance 2007). Four (6%)
trials  had  high  risk  of  selection  bias  as  they  used  a  non-random
component  to  generate  sequences  (Cuesta-Vargas  2014;  Heim
2007; Naumann 2012; Segar 1998). We considered 26 (41%) trials to
have unclear risk of selection bias, mainly because study authors
did not describe generation of the random sequence (Banasik 2011;

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

24

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Baruth  2013;  Blank  2005;  Bower  2011;  Cerulli  2014;  DeNysschen
2011;  Dolan  2016;  Hatchett  2013;  Herrero  2006;  Kaltsatou  2011;
Ligibel 2008; Littman 2012; Malicka 2011; Matthews 2007; McKenzie
2003;  Mehnert  2011;  Nieman  1995;  Nikander  2007;  Payne  2008;
Pinto 2003; Pinto 2005; Pinto 2015; Rahnama 2010; Taleghani 2012;
Waltman 2010; Winters-Stone 2011).

Twenty-one (33%) studies were at low risk of selection bias owing
to adequate concealment of allocation to the intervention because
participants  and  investigators  could  not  foresee  assignment  to
study  groups  (Cadmus  2009;  Cantarero-Villanueva  2013;  Cormie
2014;  Courneya  2003;  Daley  2007;  Herrero  2006;  Kiecolt-Glaser
2014; Loh 2014; Loudon 2014; Mehnert 2011; Milne 2008; Murtezani
2014; Musanti 2012; Rogers 2009; Rogers 2014; Rogers 2015; Saarto
2012;  Schmitz  2005;  Schmitz  2009;  Short  2014;  Vallance  2007).
Six  (10%)  trials  were  at  high  risk  of  selection  bias  because  it
was  possible  that  participants  and/or  investigators  could  foresee
assignment  to  study  groups  (Carson  2009;  Cuesta-Vargas  2014;
Heim  2007;  Mustian  2004;  Naumann  2012;  Winters-Stone  2011).
Although participant allocation was placed in sealed, sequentially
numbered envelopes, trial authors in Winters-Stone 2011 did not
report  whether  the  envelopes  were  opaque.  We  determined  that
36  (57%)  studies  had  unclear  risk  of  selection  bias  owing  to
allocation concealment, predominantly because investigators did
not describe allocation concealment or did not describe allocation
concealment in adequate detail for a decision to be made (Banasik
2011;  Baruth  2013;  Basen-Enquist  2006;  Blank  2005;  Bower  2011;
Cerulli 2014; DeNysschen 2011; Do 2015; Dolan 2016; Duijits 2012;
Ergun 2013; Fillion 2008; Guinan 2013; Hatchett 2013; Irwin 2015;
Kaltsatou  2011;  Kim  2015;  Ligibel  2008;  Littman  2012;  Malicka
2011; Martin 2013; Matthews 2007; McKenzie 2003; Nieman 1995;
Nikander 2007; Payne 2008; Peppone 2015; Pinto 2003; Pinto 2005;
Pinto 2015; Portela 2008; Rahnama 2010; Rogers 2013; Segar 1998;
Taleghani 2012; Waltman 2010).

Blinding

All trials included in this review were at high risk for performance
bias because the nature of the intervention (i.e. physical activity)
made  it  impossible  to  blind  trial  personnel  and  participants.
We  considered  24  (38%)  studies  to  be  at  low  risk  of  detection
bias  because  outcome  assessors  were  blinded  to  allocation  of
participants  to  study  groups  (Basen-Enquist  2006;  Bower  2011;
Cadmus  2009;  Cantarero-Villanueva  2013;  Carson  2009;  Cuesta-
Vargas 2014; DeNysschen 2011; Ergun 2013; Guinan 2013; Herrero
2006;  Kiecolt-Glaser  2014;  Loudon  2014;  Murtezani  2014;  Musanti
2012;  Pinto  2015;  Portela  2008;  Rahnama  2010;  Rogers  2014;
Rogers 2015; Saarto 2012; Schmitz 2005; Schmitz 2009; Short 2014;
Winters-Stone 2011). However, this was typically done for outcome
assessors  measuring  physical  fitness  outcomes  rather  than  in
cases  of  self-report  outcomes,  such  as  HRQoL  and  psychological
outcomes.  Eleven  (17%)  studies  were  at  high  risk  of  detection
bias  owing  to  lack  of  blinding  of  outcome  assessment  (Daley
2007; Fillion 2008; Heim 2007; Littman 2012; Mehnert 2011; Milne
2008;  Mustian  2004;  Payne  2008;  Pinto  2003;  Pinto  2005;  Segar
1998).  Twenty-eight  (44%)  studies  had  unclear  risk  of  detection
bias (Banasik 2011; Baruth 2013; Bower 2011; Cerulli 2014; Cormie
2014; Courneya 2003; Do 2015; Dolan 2016; Duijits 2012; Hatchett
2013;  Irwin  2015;  Kaltsatou  2011;  Kim  2015;  Ligibel  2008;  Loh
2014;  Malicka  2011;  Martin  2013;  Matthews  2007;  McKenzie  2003;
Naumann  2012;  Nieman  1995;  Nikander  2007;  Peppone  2015;
Rogers 2009; Rogers 2013; Taleghani 2012; Vallance 2007; Waltman
2010).

Cochrane Database of Systematic Reviews

Incomplete outcome data

Eighteen  (29%)  studies  were  at  low  risk  of  attrition  bias  owing
to  the  quantity,  nature,  or  handling  of  incomplete  outcome  data
(i.e.  no  missing  data  or  used  an  acceptable  method  for  handling
missing  data,  such  as  multiple  imputation)  (Basen-Enquist  2006;
Bower  2011;  Cerulli  2014;  Courneya  2003;  Cuesta-Vargas  2014;
DeNysschen 2011; Irwin 2015; Malicka 2011; Martin 2013; McKenzie
2003;  Milne  2008;  Musanti  2012;  Naumann  2012;  Peppone  2015;
Pinto 2015; Rogers 2009; Rogers 2015; Waltman 2010). Thirty-five
(56%)  trials  had  high  risk  of  attrition  bias  owing  to  exclusion  of
participants with missing data, lack of description of how missing
data were handled, or inappropriate methods of handling missing
data,  such  as  use  of  the  last  observation  carried  forward  (LOCF)
method  (Banasik  2011;  Baruth  2013;  Cadmus  2009;  Cantarero-
Villanueva 2013; Carson 2009; Cormie 2014; Do 2015; Dolan 2016;
Duijits 2012; Fillion 2008; Guinan 2013; Hatchett 2013; Heim 2007;
Kiecolt-Glaser  2014;  Kim  2015;  Littman  2012;  Loh  2014;  Loudon
2014; Matthews 2007; Murtezani 2014; Mustian 2004; Nieman 1995;
Pinto 2003; Pinto 2005; Portela 2008; Rahnama 2010; Rogers 2013;
Rogers 2014; Saarto 2012; Schmitz 2005; Schmitz 2009; Segar 1998;
Short 2014; Vallance 2007; Winters-Stone 2011). Ten (16%) studies
had  unclear  risk  of  bias  (Blank  2005;  Daley  2007;  Ergun  2013;
Herrero 2006; Kaltsatou 2011; Ligibel 2008; Mehnert 2011; Nikander
2007; Payne 2008; Taleghani 2012).

Selective reporting

Most  trials  (n  =  55;  87%)  were  at  low  risk  of  reporting  bias,
and,  based  on  information  provided  by  trial  authors,  we  had  no
reason to believe that selective reporting of primary and secondary
outcomes  occurred.  Owing  to  incomplete  reporting  of  outcome
variables,  we  considered  six  (10%)  studies  to  be  at  high  risk
for  reporting  bias  (Banasik  2011;  Baruth  2013;  DeNysschen  2011;
Guinan 2013; Martin 2013; Musanti 2012), and only two (3%) studies
to have unclear risk (Basen-Enquist 2006; Littman 2012).

Other potential sources of bias

Forty-five  (71%)  studies  were  at  low  risk  of  other  biases,  and  we
considered 16 (25%) trials to be at high risk of other biases (Basen-
Enquist 2006; Blank 2005; DeNysschen 2011; Do 2015; Heim 2007;
Irwin  2015;  Ligibel  2008;  Loh  2014;  Mehnert  2011;  Milne  2008;
Murtezani 2014; Musanti 2012; Nieman 1995; Peppone 2015; Pinto
2003; Pinto 2005) owing to potential contamination (i.e. increased
physical  activity  in  usual  care  groups),  possible  occurrence  of
‘null  bias’  due  to  insufficiently  delivered  interventions  (e.g.  low
adherence  to  intervention,  high  dropout  rates),  and  imbalance
between groups at baseline. Two (3%) studies were at unclear risk
of other biases (Matthews 2007; Payne 2008).

Effects of interventions

See:  Summary  of  findings  for  the  main  comparison  Physical
activity  versus  control  for  women  with  breast  cancer  after
adjuvant therapy (immediate postintervention values); Summary
of findings 2 Physical activity versus control for women with breast
cancer  after  adjuvant  therapy  (change  from  baseline  to  end  of
intervention values)

See Summary of findings for the main comparison and Summary
of findings 2. For detailed information on each of the outcomes, as
well as on numbers of trials reporting the outcomes, numbers of

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

25

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

participants for whom outcomes were reported, statistical methods
used for analysis, and effect estimates, see Data and analyses.

Breast cancer-related mortality

No  randomised  or  quasi-randomised  controlled  trials  reported
breast cancer-related mortality.

Quality of life

Health-related quality of life

Immediately after physical activity interventions, follow-up values
showed significant small improvement in overall HRQoL compared

Cochrane Database of Systematic Reviews

with  control  interventions  (standardised  mean  difference  (SMD)
0.39, 95% confidence interval (CI) 0.21 to 0.57, I2 = 68%, 22 studies,
1996  participants;  low-quality  evidence;  Analysis  1.1;  Summary
of  findings  for  the  main  comparison).  This  improvement  did  not
persist  at  three  months  or  longer  post  intervention  (Analysis  1.1;
Figure  4).  For  analysis  of  immediately  postintervention  values,
exclusion of the two most extreme trials lowered heterogeneity to a
level where it might not be important (I2 = 18%) while maintaining
the significant effect of physical activity (Cerulli 2014; Milne 2008).

Figure 4.   Forest plot of comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control, outcome: 1.1
Overall HRQoL (follow-up values).

Change  in  overall  HRQoL  from  baseline  to  end  of  intervention
revealed significant moderate improvement with physical activity
compared  with  control  (SMD  0.78,  95%  CI  0.39  to  1.17,  I2  =  90%,
14  studies,  1459  participants;  low-quality  evidence;  Analysis  1.2;
Figure  5;  Summary  of  findings  2).  This  change  in  overall  HRQoL

persisted from baseline to three months or longer post intervention
(SMD 0.52, 95% CI 0.15 to 0.88, I2 = 0%, 2 studies, 132 participants;
Analysis 1.2; Figure 5). Exclusion of extreme values did not reduce
heterogeneity to acceptable levels for the change from baseline to
end of intervention analysis.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

26

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 5.   Forest plot of comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control, outcome: 1.2
Overall HRQoL (change values).

Low versus unclear/high risk of bias studies

Data  show  significant  small  effects  of  physical  activity  on  HRQoL
compared  with  control  for  postintervention  follow-up  values  in
trials with both low and unclear/high risk of bias (SMD 0.43, 95%
CI  0.19  to  0.66,  I2  =  76%,  15  studies,  1521  participants;  and  SMD
0.30,  95%  CI  0.06  to  0.55,  I2  =  32%,  7  studies,  475  participants,
respectively; Analysis 18.1). A significant moderate effect on change
from baseline to end of intervention scores (SMD 0.70, 95% CI 0.28
to 1.12, I2 = 91%, 11 studies, 1360 participants; Analysis 18.2) with
physical activity was observed compared among controls only in
trials with low risk of bias.

Postmenopausal only versus not postmenopausal only (i.e.
premenopausal or varied menopausal statuses)

A  significant  small  effect  of  physical  activity  versus  control  on
immediately  postintervention  HRQoL  values  was  observed  only
when  ‘not  postmenopausal  only’  studies  were  analysed  (SMD
0.42,  95%  CI  0.22  to  0.63,  I2  =  73%,  19  studies,  1810  participants,
Analysis  12.1).  Significant  small  changes  from  baseline  to  end  of
intervention were found in postmenopausal only studies (SMD 0.49,
95%  CI  0.19  to  0.79,  I2  =  0%,  3  studies,  186  participants;  Analysis
12.2).

Measurement type

Analysis  was  possible  only  for  EORTC  QLQ-C30  and  FACT-G  and
-B  questionnaires,  as  only  these  questionnaires  were  included
in  at  least  two  trials.  Significant  improvement  in  immediately

postintervention  values  was  noted  in  physical  activity  groups
compared  with  control  groups  for  FACT-G  (mean  difference  (MD)
7.06, 95% CI 2.82 to 11.30, I2 = 86%, 10 studies, 1094 participants)
and  FACT-B  (MD  6.31,  95%  CI  1.15  to  11.47,  I2  =  87%,  11
studies,  1395  participants)  and  for  QLQ-C30  global  health  (MD
7.85,  95%  CI  2.16  to  13.55,  I2  =  21%,  4  studies,  195  participants;
Analysis 1.3; Analysis 1.5; Analysis 1.10). Between-group differences
immediately post intervention represented a meaningful clinically
important difference (MCID) for FACT-G (MCID 5 to 6 points) but not
for FACT-B (MCID 7 to 8 points) (Eton 2004).

Significant  changes  from  baseline  to  end  of  intervention  scores
in  physical  activity  groups  compared  with  control  groups  were
found  for  FACT-G  (MD  5.04,  95%  CI  1.32  to  8.75,  I2  =  91%,  6
studies,  663  participants)  and  FACT-B  (MD  8.16,  95%  CI  2.56  to
13.76,  I2  =  89%,  6  studies,  605  participants),  but  changes  in
QLQ-C30  were  not  significant  (Analysis  1.4;  Analysis  1.6;  Analysis
1.11).  These  changes  from  baseline  scores  represented  an  MCID
in FACT-G and FACT-B. The FACT-breast cancer subscale indicated
significant improvement in breast cancer symptoms in immediately
postintervention  follow-up  values  only  (MD  1.98,  95%  CI  0.92
to  3.04,  I2  =  48%,  11  studies,  1043  participants),  but  these
improvements were below the MCID for this subscale (MCID 2 to 3
points) (Eton 2004). FACT-trial outcome index subscale analysis was
possible only for immediately postintervention values and revealed
no significant effect of physical activity compared with control.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

27

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Intervention mode

Compared with control, data show improvement in overall HRQoL
immediately post intervention for aerobic exercise (SMD 0.41, 95%
CI 0.19 to 0.63, I2 = 55%, 12 studies, 971 participants) and combined
aerobic and resistance exercise (SMD 0.63, 95% CI 0.08 to 1.19, I2
=  87%,  7  studies,  589  participants;  Analysis  13.1).  No  differences
were found for yoga, tai chi, qigong, and pilates interventions when
compared with control. Trials on resistance training were too few
for subgroup analysis of immediately postintervention values. We
found a significant change from baseline to end of intervention in
HRQoL for aerobic exercise interventions (SMD 0.68, 95% CI 0.22 to
1.15, I2 = 92%, 12 studies, 971 participants; Analysis 13.2) compared
with controls, but not for combined aerobic and resistance exercise
interventions. Subgroup analyses of change from baseline scores
were not possible for yoga, tai chi, qigong, and pilates or resistance
training interventions.

Intervention intensity

light-to-moderate  physical  activity
Compared  with  control, 
improved HRQoL (SMD 0.51, 95% CI 0.25 to 0.77, I2 = 72%, 16 studies,
983  participants;  Analysis  14.1).  A  similar  result  was  observed  at
change from baseline to end of intervention (SMD 0.99, 95% CI 0.39
to 1.60, I2 = 90%, 10 studies, 534 participants; Analysis 14.2).

Intervention duration ≤ 12 weeks versus > 12 weeks

Immediately  post  intervention,  interventions  of  duration  ≤  12
weeks  and  >  12  weeks  led  to  significant  small  improvement
compared with controls (≤ 12 weeks: SMD 0.45, 95% CI 0.19 to 0.70,
I2 = 77%, 16 studies, 1404 participants; and > 12 weeks: SMD 0.38,
95% CI 0.10 to 0.65, I2 = 35%, 6 studies, 399 participants; Analysis
15.1). However, interventions of ≤ 12 weeks but not > 12 weeks in
duration  led  to  significant  large  changes  from  baseline  to  end  of
intervention in HRQoL compared with controls (SMD 0.99, 95% CI
0.49 to 1.52, I2 = 90%, 11 studies, 828 participants; Analysis 15.2).

Intervention format

improvement 

led  to  significant 

intervention  settings 

in
All 
immediate  postintervention  follow-up  values  compared  with
controls, with large effects evident for group format interventions
(SMD 0.99, 95% CI 0.22 to 1.75, I2 = 84%, 5 studies, 214 participants)
compared  with  small  effects  for  both  individual  and  combined
individual and group format interventions (SMD 0.21, 95% CI 0.03
to 0.38, I2 = 39%, 10 studies, 1137 participants; and SMD 0.33, 95%
CI 0.04 to 0.62, I2 = 36%, 6 studies, 390 participants, respectively;
Analysis  16.1).  Both  group  and  individual  format  interventions
significantly improved change from baseline to end of intervention
HRQoL scores (SMD 1.88, 95% CI 0.19 to 3.56, I2 = 95%, 5 studies, 198
participants; and SMD 0.43, 95% CI 0.25 to 0.61, I2 = 6%, 6 studies,
649 participants, respectively) compared with controls; combined
group and individual format interventions led to no improvement
(Analysis 16.2).

Intervention setting

Facility-based interventions resulted in moderate improvement in
immediately postintervention follow-up values (SMD 0.55, 95% CI
0.27 to 0.83, I2 = 71%, 15 studies, 833 participants) and large effects
on  change  from  baseline  to  end  of  intervention  scores  of  HRQoL
(SMD 1.18, 95% CI 0.53 to 1.82, I2 = 90%, 10 studies, 492 participants;
Analysis  17.1).  Compared  with  controls,  significant  small  effects
on  immediately  postintervention  HRQoL  values  were  found  for

Cochrane Database of Systematic Reviews

combined home and facility-based interventions (SMD 0.48, 95% CI
0.04 to 0.92, I2 = 55%, 4 studies, 227 participants), and small effects
were  observed  on  change  from  baseline  to  end  of  intervention
HRQoL scores for home-based interventions (SMD 0.27, 95% CI 0.04
to 0.50, I2 = 0%, 2 studies, 375 participants; Analysis 17.2).

Studies from which data could not be extracted

Data could not be extracted from five trials that reported on HRQoL
(Baruth  2013;  Duijits  2012;  Heim  2007;  Herrero  2006;  McKenzie
2003).  Baruth  2013  reported  their  findings  in  Cohen  d  units  (d
<  2  indicates  a  trivial  effect,  0.2  a  small  effect,  0.5  a  medium
effect, and ≥ 0.8 a large effect), and found that participants given
a walking intervention showed improvement in indicators of QoL,
such as current health (d = 0.27), as measured by the IBCSG QoL
Core Questionnaire, and general health perspective (d = 0.66), as
measured via MOS SF-36, compared with those in the control group.
Duijits 2012 found no significant overall group differences over time
in general health perspective measured via MOS SF-36. Heim 2007
reported  that  physical  activity  resulted  in  a  significant  group-by-
time increase in HRQoL (P = 0.0015), measured via FACT-G, in favour
of the intervention group. Herrero 2006 reported a significant mean
change on the global scale (P = 0.002) after a training programme,
as  measured  by  the  EORTC  QLQ-C30,  compared  with  a  control.
McKenzie  2003  found  no  significant  group-by-time  increases  in
general health (P > 0.05) measured via MOS SF-36 in the exercise
group compared with the control group.

Quality of life subscales

Emotional function

For emotional function, immediately postintervention (moderate-
quality  evidence)  and  three  months  or  longer  postintervention
follow-up values and change from baseline to end of intervention
scores (low-quality evidence) showed small but significant effects
of  physical  activity  compared  with  controls,  but  not  for  change
from  baseline  to  three  months  or  longer  postintervention  values
(Summary  of  findings  for  the  main  comparison;  Summary  of
findings 2; Table 3). Heterogeneity (I2 = 72%) observed in the change
from baseline to end of intervention analysis was reduced to a level
that  might  not  be  important  (I2  =  23%)  by  removal  of  the  most
extreme trial value (Murtezani 2014); this could be further explained
by the wide range of measurement instruments used, participants'
menopausal status, and variations in study duration.

Sensitivity analysis revealed that significant effects on immediately
postintervention  follow-up  values  and  on  changes  from  baseline
to end of intervention scores for emotional function were retained
when  only  trials  with  low  risk  of  bias  were  analysed  (Analysis
18.3; Analysis 18.4). Significant improvement in emotional function
was  noted  in  immediately  postintervention  follow-up  values  for
QLQ-C30 emotional function (Analysis 1.10), Profile of Mood States
(POMS)  total  mood  disturbance  (Analysis  1.24),  and  POMS  anger
(Analysis 1.26), but not among postmenopausal only women; these
effects  were  also  observed  for  aerobic  exercise  and  combined
aerobic  and  resistance  exercise  interventions  (interventions  of
low-to-moderate  intensity,  ≤  12  weeks'  duration,  facility-based,
group  and  individual  format  physical  activity  interventions)
compared  with  controls.  Significant  changes  from  baseline  to
end  of  intervention  were  found  for  the  FACT  emotional  well-
being  subscale  (Analysis  1.15)  and  the  MOS  SF  mental  health
scale  (Analysis  1.19)  among  postmenopausal  women  (aerobic
exercise  only,  light-to-moderate  intensity,  ≤  12  weeks'  duration,

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

28

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

facility-based,  individual  format  interventions)  compared  with
controls. Improvement in FACT emotional well-being was below the
minimum important difference of two points (Cella 2002a).

Perceived physical function

Analysis  of  immediately  (moderate-quality  evidence)  and  three
months or longer postintervention follow-up values and changes
from  baseline  to  end  of  intervention  scores  (moderate-quality
evidence) was possible for perceived physical function; all analyses
revealed  significant  effects  for  physical  activity  compared  with
controls  (Analysis  1.29;  Analysis  1.30;  Summary  of  findings  for
the  main  comparison;  Summary  of  findings  2;  Table  3).  Removal
of  the  most  extreme  immediately  postintervention  follow-up
value  -  from  Milne  2008  -  reduced  heterogeneity  to  a  level  that
might  not  be  considered  important  (I2  from  61%  to  18%),  but
removal  of  the  most  extreme  change  from  baseline  to  end  of
intervention  score  -  from  Murtezani  2014  -,  did  not  substantially
lower heterogeneity. However, heterogeneity could be explained by
the wide range of measurement instruments used, physical activity
modes,  participants'  menopausal  status,  and  variations  in  study
duration.

in  a  sensitivity  analysis  of  studies  with 

Effects  on  immediately  postintervention  follow-up  values  and
changes  from  baseline  to  end  of  intervention  scores  were
maintained 
low
risk  of  bias  (Analysis  18.5;  Analysis  18.6).  Subgroup  analyses
showed  significant  effects  of  physical  activity  on  immediately
postintervention  follow-up  physical  function  values  for  FACT
physical  well-being  and  for  MOS  SF  physical  function  composite
and  subscale  instruments  (Analysis  1.31;  Analysis  1.33;  Analysis
1.35),  but  not  for  postmenopausal  women  only;  these  effects
were also observed for interventions consisting of aerobic exercise
only  (low-to-moderate  intensity,  ≤  12  and  >  12  weeks'  duration,
combined home and facility-based settings, group and individual
formats)  compared  with  controls.  Improvement  in  FACT  physical
well-being  was  below  the  minimum  important  difference  of  two
points (Cella 2002a). Change from baseline to end of intervention
scores was significantly improved for the MOS SF physical function
instrument  (Analysis  1.36)  and  for  interventions  consisting  of
aerobic  exercise  only  (low-to-moderate  intensity,  ≤  12  weeks'
duration, facility-based, group format) compared with controls.

Role function

Low-quality evidence suggests that immediately postintervention
follow-up values, but not three months or longer postintervention
follow-up  values,  or  change  from  baseline  to  end  of  intervention
scores (analysis of change from baseline to three months or longer
postintervention scores was not possible), for role function showed
a small statistically significant improvement with physical activity
compared  with  control  (Analysis  1.40;  Analysis  1.41;  Table  3).
Heterogeneity was reduced to a level that might not be considered
important (I2 = 10%) by removal of the most extreme immediately
postintervention  follow-up  values  -  from  Milne  2008  -  and  could
be  explained  by  the  wide  range  of  measurement  instruments
used,  intervention  mode  intensity,  duration,  setting,  format,  and
menopausal status.

revealed 

Sensitivity  analyses 
in
immediately  postintervention  role  function  values,  but  not  in
change  from  baseline  to  end  of  intervention  scores,  for  physical
activity interventions with low risk of bias compared with controls
(Analysis 18.7; Analysis 18.8). Subgroup analyses revealed that the

improvement 

significant 

Cochrane Database of Systematic Reviews

significant  effect  on  immediately  postintervention  follow-up  role
function values was maintained for the FACT functional well-being
measurement  instrument  (Analysis  1.42)  and  for  interventions
consisting  of  aerobic  exercise  only  (light-to-moderate  intensity,  ≤
12  and  >  12  weeks'  duration,  individual  format)  compared  with
controls. Significant improvement in change from baseline to end
of intervention role function scores was found in analysis of FACT
functional well-being measurement data (Analysis 1.43), but not in
other subgroup analyses.

Social function

For social function, analysis of both immediately postintervention
follow-up values and change from baseline to end of intervention
scores  (both  moderate-quality  evidence)  showed  significant
improvement  with  physical  activity  compared  with  control
(Analysis  1.48;  Analysis  1.49;  Table  3).  Data  were  insufficient  for
analyses  of  three  months  or  longer  postintervention  follow-up
values  or  change  scores.  Heterogeneity  observed  in  the  change
from  baseline  to  end  of  intervention  scores  analysis  (I2  =  87%)
was  accounted  for  by  removal  of  the  three  most  extreme  values
(Murtezani  2014;  Saarto  2012;  Vallance  2007),  without  altering
the  significant  improvement  in  social  function.  Heterogeneity  in
the  change  from  baseline  to  end  of  intervention  analyses  was
also  explained  by  the  wide  range  of  instruments  used  and  by
menopausal status and intervention mode.

revealed 

significant 

improvement 

Sensitivity  analysis 
in
postintervention  follow-up  values  and  in  change  from  baseline
to  end  of  intervention  scores  of  social  function  for  physical
activity  trials  with  low  risk  of  bias  compared  with  controls
(Analysis  18.9;  Analysis  18.10).  Significant  effects  on  immediately
postintervention social function values were maintained in analysis
of  the  FACT  social  well-being  subscale  measurement  instrument
(Analysis  1.50),  and  with  interventions  consisting  of  aerobic
exercise (light-to-moderate intensity, ≤ 12 weeks' duration, facility-
based and combined home and facility-based settings, combined
group and individual format) compared with controls. Significant
improvement  in  change  from  baseline  to  end  of  intervention
social  function  scores  was  found  for  the  FACT  social  well-being
subscale  (Analysis  1.51),  among  postmenopausal  women  only,
and for interventions consisting of aerobic exercise and combined
aerobic  and  resistance  exercise  (light-to-moderate  intensity,  ≤  12
weeks' duration, facility-based, individual format) compared with
controls.

Cognitive function

We  observed  a  significant  but  small  effect,  with  no  evidence
of  heterogeneity,  of  physical  activity  on  cognitive  function  at
immediately  postintervention  follow-up  (low-quality  evidence),
but  not  at  three  months  or  longer  postintervention  follow-up,
or  change  from  baseline  to  end  of  intervention  or  change  from
baseline  to  three  months  or  longer  postintervention  scores,
compared with control (Analysis 1.56; Analysis 1.57; Table 3).

A  sensitivity  analysis  revealed  small  significant  improvement  in
postintervention follow-up cognitive function values with physical
activity  interventions  at  low  risk  of  bias  compared  with  controls
(Analysis  18.11;  Analysis  18.12).  Subgroup  analysis  revealed
significant  improvement  in  postintervention  follow-up  cognitive
function values with the POMS confusion subscale (Analysis 1.60),
not  among  postmenopausal  women  only,  and  for  interventions
consisting  of  combined  aerobic  and  resistance  exercise  (light-to-

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

29

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

moderate intensity, all studies ≤ 12 weeks' duration). We observed
no significant effect on change from baseline to end of intervention
score for physical activity in any of the subgroup analyses.

General health perspective

Data  show  no  significant  effect  of  physical  activity  compared
with control on overall general health perspective, or in analyses
involving  individual  instruments,  studies  with  low  risk  of  bias,  or
any other subgroup analysis of follow-up values and change scores
(very  low-quality  evidence  for  both)  (Analysis  1.61;  Analysis  1.62;
Table 3).

Sexual function

Trialists  noted  no  significant  effects  of  physical  activity
interventions compared with controls on sexual function for follow-
up values or change scores in main or subgroup analyses, or for any
reported  measure  (very  low-quality  evidence  for  both)  (Analysis
1.65; Analysis 1.66; Table 3).

Sleep

We  observed  no  significant  effects  of  physical  activity  on
postintervention  follow-up  values  and  on  change  from  baseline
scores for overall sleep, any measure of sleep, sensitivity analysis
by risk of bias, or subgroup analyses (low-quality evidence for both)
compared with control (Analysis 1.68; Analysis 1.69; Table 3).

Studies from which HRQoL subscale data could not be extracted

Data could not be extracted from four trials that reported emotional
function (Baruth 2013; Carson 2009; Duijits 2012; McKenzie 2003),
five trials that reported perceived physical function (Baruth 2013;
Duijits  2012;  Heim  2007;  Herrero  2006;  McKenzie  2003),  four
trials  reporting  role  function  (Baruth  2013;  Duijits  2012;  Heim
2007; McKenzie 2003), three trials that reported social functioning
(Baruth  2013;  Duijits  2012;  McKenzie  2003),  and  two  trials  that
reported general health perspective (Duijits 2012; McKenzie 2003).
Baruth 2013 observed significant effects on mood (d = 0.30), role-
emotional (d = 0.14), mental health (d = 0.28), physical well-being
(d = 0.38), physical functioning (d = 0.69), and role-physical function
(d = 0.60), but not on social functioning (d = 0.04), as measured via
MOS SF-36, with a walking intervention compared with a control.
Duijits  2012  observed  a  significant  effect  on  physical  functioning
(d = 0.41) but not on mental health, role-physical function, social
functioning,  or  general  health  perspective,  as  measured  via  MOS
SF-36, with physical exercise compared with cognitive-behavioural
therapy  (CBT),  CBT  and  physical  exercise  combined,  and  control.
McKenzie  2003  found  no  significant  changes  in  role-emotional
and  mental  health,  physical  functioning,  role-physical  function,
social  functioning,  or  general  health  perspective  (via  MOS  SF-36)
in  an  exercise  group  compared  with  a  control  group.  Carson
2009 found no significant postintervention differences in negative
mood between yoga and control groups. Heim 2007 reported that
increases in physical and functional well-being (measured via FACT-
G)  from  baseline  to  post  intervention  in  both  physical  activity
and  control  groups  were  sustained  in  the  only  exercise  group  at
three  months  or  longer  postintervention  follow-up.  Herrero  2006
reported a significant mean change in physical function scale, as
assessed via EORTC QLQ-C30 (P = .04), after an exercise programme
compared with a control.

In one trial from which data could not be extracted, Kiecolt-Glaser
2014  found  that  cognitive  complaints  did  not  differ  significantly

Cochrane Database of Systematic Reviews

between a yoga group and a wait-list group immediately following
the  intervention  (P  =  0.25),  but  participants  in  the  yoga  group
reported 23% fewer cognitive problems than wait-list participants
at  three-month  postintervention  follow-up  (P  =  0.003).  Mehnert
2011 did not report findings from analysis of sexual attractiveness,
and  Do  2015  did  not  report  sexual  functioning  and  sexual
enjoyment outcomes.

Sleep  data  could  not  be  extracted  from  two  trials  (Carson
2009;  Payne  2008).  Carson  2009  found  a  significant  reduction
in  sleep  disturbance  (measured  on  a  0  to  9  scale)  after  a  yoga
intervention  compared  with  control  (P  =  0.007),  but  this  effect
was  not  sustained  after  three  months'  follow-up  (P  =  0.17).
Payne  2008  found  a  significant  improvement  in  sleep  quality
assessed via the Pittsburgh Sleep Quality Index (PSQI) with a 12-
week  exercise  intervention  compared  with  a  control  (P  =0.007).
Payne  2008  also  assessed  sleep  using  Actigraph,  and  observed
significant reductions in actual wake time (P = 0.02), actual sleep
time  (P  =  0.05),  and  movement  during  sleep  (P  =  0.002),  but
no  statistically  significant  improvement  in  sleep  efficiency,  with
exercise compared with control.

HRQoL-related outcomes

Anxiety

Data show a significant reduction in anxiety with physical activity
interventions,  compared  with  controls,  for  both  immediately
postintervention follow-up values (very low-quality evidence) and
change  from  baseline  to  end  of  intervention  scores  (low-quality
evidence) (Analysis 2.1; Analysis 2.2; Summary of findings for the
main comparison; Summary of findings 2; Table 3). Available data
were insufficient for analysis of three months or longer follow-up
values or change scores.

Heterogeneity  observed  in  immediately  postintervention  follow-
up  anxiety  analysis  was  lowered  to  a  level  that  might  not  be
considered important (I2 from 60% to 38%) by removal of the most
extreme  value  (Segar  1998),  with  maintenance  of  the  significant
effect of physical activity. Heterogeneity was explained by the range
of assessment instruments used, participants’ menopausal status,
physical activity mode, and intervention setting and format.

Sensitivity  analysis,  which  was  possible  only  for  immediately
postintervention  follow-up  values,  revealed  a  significant  but
small  effect  in  physical  activity  trials  with  low  risk  of  bias.
Subgroup  analysis  revealed  significantly  improved  immediately
postintervention  anxiety  follow-up  values  for  the  POMS  anxiety-
tension  subscale  (Analysis  2.3),  not  for  postmenopausal  women
only,  with  aerobic  exercise  only  (light-to-moderate  intensity,  ≤
12  weeks'  duration,  facility-based,  group  format  interventions).
Significant  changes  from  baseline  to  end  of  intervention  anxiety
scores  were  noted  for  interventions  including  combined  aerobic
and  resistance  exercise  (light-to-moderate  intensity,  ≤  12  weeks'
duration,  facility-based,  group  format  interventions).  When  the
overall  effect  of  physical  activity  on  anxiety  was  expressed  via
the  0  to  9  PROMIS  (Patient  Reported  Outcomes  Measurement
Information System) scale, effects on change from baseline to end
of  intervention  scores,  but  not  on  immediately  postintervention
follow-up  values,  for  anxiety  revealed  a  minimum  important
difference improvement above the minimum important difference
of  3  to  4.5  units  (Summary  of  findings  for  the  main  comparison;
Summary of findings 2) (Yost 2011).

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

30

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Depression (i.e. depressive symptoms)

Immediate  and  three  months  or  longer  post-physical  activity
intervention  follow-up  values  (very  low-quality  evidence)  and
change from baseline to end of intervention (low-quality evidence)
showed  small  significant  improvement  in  depressive  symptoms
compared  with  controls  (Analysis  3.1;  Analysis  3.2;  Summary  of
findings for the main comparison; Summary of findings 2; Table 3).
Available data were insufficient for change from baseline to three
months or longer postintervention analysis.

analysis 

observed 

Heterogeneity 
immediately
in 
postintervention follow-up values and change from baseline to end
of  intervention  scores  could  be  explained  by  the  wide  range  of
measurement instruments used, participants’ menopausal status,
physical activity mode and intensity, and variations in intervention
duration, setting, and format.

of 

Sensitivity  analyses  of  trials  with  low  risk  of  bias  did  not  reveal
significant  effects  of  physical  activity  on  depression,  compared
with controls, for immediately postintervention values or change
from  baseline  to  end  of  intervention  scores  (Analysis  18.23;
Analysis  18.24).  Subgroup  analyses  revealed  significant  effects
on immediately postintervention follow-up depression values for
Beck  Depression  Inventory  and  Profile  of  Mood  States  (POMS)
depression  and  tension  measurement  instruments  (Analysis  3.3;
Analysis  3.6;  Analysis  3.7),  not  for  postmenopausal  women
only,  with  physical  activity  interventions  (≤  12  weeks'  duration,
facility-based,  group  format)  compared  with  controls.  However,
improvement  on  the  Beck  Depression  Inventory  was  below  the
minimum important difference of 18% (Button 2015). For change
from baseline to end of intervention depression scores, significant
effects  were  found  for  interventions  that  consisted  of  combined
aerobic  and  resistance  exercise  (light-to-moderate  intensity,  ≤
12  weeks'  duration,  facility-based,  group  format)  compared  with
controls.

Fatigue

Both immediate (moderate-quality evidence) and three months or
longer post-physical activity intervention follow-up values revealed
significant  but  small  beneficial  effects  on  fatigue  compared
with  controls  (Analysis  4.1;  Summary  of  findings  for  the  main
comparison;  Table  3).  Change  from  baseline  to  three  months  or
longer  postintervention  values,  but  not  change  from  baseline  to
end  of  intervention  scores,  demonstrated  significant  but  small
improvement  in  fatigue  with  physical  activity  compared  with
control (Analysis 4.2; Summary of findings 2; Table 3).

the  most  extreme  studies 

Removal  of 
immediately
postintervention  follow-up  fatigue  values  -  Cantarero-Villanueva
2013;  Milne  2008  -  resulted  in  heterogeneity  that  might  not  have
been important (I2 = 9%). Heterogeneity was further explained by
participants’ menopausal status, physical activity mode, intensity,
duration, setting, and format.

for 

For immediately postintervention values only, sensitivity analysis
revealed  significant  effects  of  physical  activity  on  overall  fatigue
compared  with  control  for  studies  with  low  risk  of  bias  (Analysis
18.25;  Analysis  18.26).  Subgroup  analyses  of  fatigue  revealed
significant  improvement  in  immediately  postintervention  follow-
up values as maintained for EORTC QLQ-30 fatigue scale, MOS SF
vitality, POMS fatigue and vigour scales, and revised Piper Fatigue
Scale (PFS) affective/meaning measurement instruments (Analysis

Cochrane Database of Systematic Reviews

4.5;  Analysis  4.12;  Analysis  4.16;  Analysis  4.20;  Analysis  4.22),  not
for  postmenopausal  women  only,  with  interventions  consisting
of  aerobic  exercise  only,  combined  aerobic  and  resistance
training,  yoga,  tai  chi,  qigong,  and  pilates  (light-to-moderate
intensity, ≤ 12 weeks' duration, facility-based, group or individual
format).  For  change  from  baseline  to  end  of  intervention  fatigue
scores, significant effects of physical activity were maintained for
combined  aerobic  and  resistance  training  and  for  interventions
≤  12  weeks'  duration  compared  with  control.  Significant  effects
for  revised  PFS  total  fatigue  scores  were  maintained  at  three
months or longer postintervention follow-up, whereas significant
changes from baseline to three months or longer postintervention
values were observed with revised PFS total fatigue scores (Analysis
4.9;  Analysis  4.10).  When  we  expressed  the  overall  effect  of
physical  activity  on  fatigue  using  the  FACT-F  instrument,  effects
on  fatigue  immediately  post  intervention  follow-up  values  and
changes from baseline to end of intervention scores were below the
minimum important difference of three units (Cella 2002; Summary
of  findings  for  the  main  comparison;  Summary  of  findings  2).
Pooled  analysis  of  only  vigour/vitality  measures  revealed  small
but  significant  improvement  with  physical  activity  interventions
compared  with  controls,  for  immediately  postintervention  and
three months or longer postintervention follow-up values, but not
for change from baseline scores (Analysis 4.18; Analysis 4.19; Table
3).

Pain/disability

Low-quality  evidence  suggests  no  significant  effect  of  physical
activity  compared  with  control  on  pain/disability  (immediately
postintervention  follow-up  and  change  from  baseline  to  end  of
intervention  analyses)  both  overall  and  in  sensitivity  analyses
involving  studies  with  low  risk  of  bias  (Analysis  5.1;  Analysis  5.2;
Analysis 18.27; Analysis 18.28; Table 3). No pain/disability data were
available for three months or longer postintervention analysis.

Compared with controls, physical activity led to significant effects
only  for  change  from  baseline  to  end  of  intervention  scores  for
brief  pain  inventory  severity  score  and  disabilities  of  the  arm,
shoulder,  and  hand  (DASH)  (combined  follow-up  and  change
data) measurement instruments. Subgroup analyses did not reveal
significant differences between groups in effects of physical activity
on pain/disability for any of the analyses conducted.

Self-esteem

A  small  significant  effect  of  physical  activity  versus  control  was
observed on self-esteem scores for immediately postintervention
follow-up values (moderate-quality evidence) but not for changes
from baseline to end of intervention scores (low-quality evidence)
or  sensitivity  analyses  of  trials  with  low  risk  of  bias  (Analysis
6.1;  Analysis  6.2;  Analysis  18.21;  Analysis  18.22;  Table  3).  Owing
to  insufficient  data,  three  months  or  longer  follow-up  or  change
analyses could not be performed.

Heterogeneity was reduced to 13% by removal of the most extreme
immediately postintervention follow-up value (Musanti 2012); this
was  explained  by  the  wide  range  of  measurement  instruments
used,  participants’  menopausal  status,  physical  activity  modes
and intensity, and variations in intervention duration, setting, and
format.

For  immediately  postintervention  values,  significant  effects  of
physical  activity  on  self-esteem,  compared  with  control,  were

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

31

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

maintained  in  analyses  by  the  Physical  Self-Perception  Profile-
attractiveness  of  body  subscale  (Analysis  6.4)  (with  interventions
of light-to-moderate intensity, ≤ 12 weeks' duration, facility-based).
A  significant  effect  of  physical  activity  versus  control  was  found
for  change  from  baseline  to  end  of  intervention  scores  on  the
Rosenberg Self-Esteem (RSE) scale (Analysis 6.7).

Studies from which HRQoL-related outcomes data could not be
extracted

Five  trials  assessed  both  anxiety  and  depression  (Duijits  2012;
Fillion  2008;  Heim  2007;  Loh  2014;  Musanti  2012),  whereas  one
additional  study  measured  only  depression  (Schmitz  2005).  No
significant  differences  were  found  between  physical  activity  and
control  groups  for  anxiety  assessed  via  the  Depression,  Anxiety
and Stress Scale (DASS)-21 (Loh 2014) or the Hospital Anxiety and
Depression  Scale  (HADS)  (Heim  2007),  for  depression  assessed
via  HADS  (Duijits  2012;  Heim  2007;  Loh  2014)  or  the  Center  for
Epidemiologic  Studies  (CES)  Depression  Scale,  or  for  frequency
of  depression  (Schmitz  2005),  psychological  distress  (assessed
via  HADS)  (Duijits  2012),  and  combined  anxiety  and  depression
assessed by POM subscale scores (Fillion 2008). Musanti 2012 used
combined anxiety and depression scores from HADS and observed
a  significant  decrease  over  time  only  among  participants  who
scored  above  the  threshold  of  clinical  significance  on  the  HADS
(score ≥ 11) at baseline (P = .001).

Data  could  not  be  extracted  from  six  trials  that  assessed  fatigue
(Baruth 2013; Carson 2009; Heim 2007; Musanti 2012; Payne 2008;
Peppone  2015).  Baruth  2013  found  significant  small-to-moderate
improvement  in  fatigue  (d  =  –0.36)  and  moderate  increases
in  vigour  (d  =  0.57)  when  comparing  the  walking  intervention
versus  control.  Musanti  2012  observed  a  significant  reduction  in
clinically  significant  fatigue  post  physical  activity  versus  control
(both P < 0.000), whereas Heim 2007 found that at three months
postintervention follow-up, but not immediately post intervention,
fatigue was significantly reduced with physical activity compared
with  control  (P  =  0.003).  However,  Payne  2008  reported  no
group-by-time differences in fatigue. Of two trials that compared
yoga  interventions  versus  control,  Carson  2009  found  significant
improvement in fatigue and vigour assessed via 0 to 9 scales (both
P < 0.01) with yoga, whereas Peppone 2015 reported significantly
greater improvement in fatigue and significantly greater reduction
in levels of ‘needing help finishing activities’, time spent in bed, and
feelings of heaviness in the body post yoga (all P < 0.05).

We could not extract pain/disability data from three trials (Baruth
2013;  Peppone  2015;  Carson  2009).  Baruth  2013  found  no  effect
on  pain  (d  =  –0.04)  with  a  walking  intervention  compared  with
control.  Compared  with  control,  yoga  was  found  to  significantly
reduce  musculoskeletal  symptoms,  such  as  general  pain,  muscle
aches, and total physical discomfort (all P < 0.05) in Peppone 2015,
and  joint  pain  in  Carson  2009.  In  the  only  study  from  which  self-
esteem  data  could  not  be  extracted  (Mustian  2004),  a  significant
improvement in self-esteem was observed from baseline to post tai
chi intervention compared with control (P = 0.04).

All-cause mortality

No randomised or quasi-randomised controlled trials reported all-
cause mortality.

Cochrane Database of Systematic Reviews

Breast cancer recurrences

No  randomised  or  quasi-randomised  controlled  trials  reported
breast  cancer  recurrence  as  an  outcome.  Seven  studies  reported
breast  cancer  recurrence  data  as  a  reason  for  dropout  or  as  an
adverse  event,  with  similar  numbers  in  intervention  and  control
groups  (n  =  15  and  14,  respectively)  (Basen-Enquist  2006;  Fillion
2008;  Ligibel  2008;  Loudon  2014;  Nieman  1995;  Saarto  2012;
Schmitz 2005).

Cardiorespiratory fitness

interventions  compared  with  controls 

Data show significant small and large increases in cardiorespiratory
fitness  when  all  measurement  methods  were  considered  with
physical  activity 
for
immediately  postintervention  follow-up  values  and  for  change
from  baseline  to  end  of  intervention  scores,  respectively  (SMD
0.44,  95%  CI  0.30  to  0.58,  I2  =  30%,  23  studies,  1265  participants;
moderate-quality  evidence;  and  SMD  0.83,  95%  CI  0.40  to  1.27,
I2  =  82%,  9  studies,  863  participants;  very  low-quality  evidence,
respectively)  (Analysis  7.1;  Analysis  7.2;  Summary  of  findings  for
the main comparison; Summary of findings 2). This effect was still
evident three months or longer post intervention for both follow-
up values and change from baseline scores (Table 3).

Removal of the most extreme value did not reduce heterogeneity
in  the  change  from  baseline  to  end  of  intervention  analysis
(Nieman  1995).  Heterogeneity  in  change  from  baseline  to  end  of
intervention  scores  was  explained  by  risk  of  bias,  menopausal
status, intervention mode, and duration.

Sensitivity  analysis  revealed  that  a  significant  effect  of  physical
activity  versus  control  was  evident  across  trials  with  low  risk  of
bias  for  immediately  postintervention  follow-up  values,  but  not
for  change  from  baseline  to  end  of  intervention  scores  (Analysis
18.29; Analysis 18.30). When separate measurement methods were
considered, significant effects for physical activity, compared with
control,  were  evident  for  directly  assessed  VO2max/peak  (mL/
kg/min)  for  both  immediate  postintervention  values  and  change
from  baseline  to  end  of  intervention  scores,  estimated  VO2max
via  a  modified  Bruce  treadmill  test  (combined  follow-up  and
change from baseline data), and 6-minute walk test performance
(combined  follow-up  and  change  from  baseline  data)  (Table  3).
The mean difference for directly measured VO2max/peak (1.89 mL/
kg/min) was below the improvement of 3.5 mL/kg/min associated
with  a  13%  decrease  in  risk  of  all-cause  mortality  in  the  general
population (Kodama 2009). However, average improvement in walk
distance (MD 54.74 m) exceeded the MCID of 32 to 34 m reported for
this test in various clinical populations (Shoemaker 2013).

improvement 

postintervention 

in  subgroup  analysis 

Significant 
follow-up
in 
cardiorespiratory  fitness  values  was  maintained  for  physical
for
activity  compared  with  control 
postmenopausal  women  only,  for  both  aerobic  exercise  and
combined aerobic and resistance exercise interventions, regardless
of  intervention  intensity,  duration,  setting,  or  format.  Significant
changes from baseline to end of intervention for cardiorespiratory
fitness with physical activity interventions compared with controls
were  maintained  for  postmenopausal  women  only,  with  both
aerobic  exercise  and  combined  aerobic  and  resistance  exercise
(physical  activity  modes, 
light-to-moderate
intensity, facility-based, individual format, regardless of duration).

interventions  of 

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

32

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Studies from which data could not be extracted

Two trials from which we were unable to extract data also reported
on  cardiorespiratory  fitness  (DeNysschen  2011;  Heim  2007).
DeNysschen  2011  (via  maximal  exercise  testing)  and  Heim  2007
(via  the  Harvard  Step  Test)  reported  no  significant  improvement
in  cardiorespiratory  fitness  with  physical  activity  compared  with
control.

Other outcomes-related to cardiorespiratory fitness

In  a  pooled  analysis  of  just  two  studies,  a  significant  increase  in
immediately postintervention follow-up peak power output during
cycle ergometer testing was found for physical activity compared
with  control  (Analysis  7.7).  Furthermore,  significant  reductions
were found in immediately postintervention follow-up values, but
not  in  change  from  baseline  to  end  of  intervention  scores,  for
resting  heart  rate  observed  with  physical  activity  interventions
compared  with  controls  (Analysis  7.18;  Analysis  7.19).  Data  show
no significant effects for physical activity compared with control on
peak heart rate and respiratory exchange ratio or resting systolic
and  diastolic  blood  pressure  (Analysis  7.8;  Analysis  7.9;  Analysis
7.20; Analysis 7.21; Analysis 7.22; Analysis 7.23).

Physical activity assessed as an outcome measure

For  overall 
immediately
self-reported  physical  activity, 
postintervention follow-up values and change from baseline to end
of intervention scores showed significant moderate improvement
in  intervention  groups  (SMD  0.52,  95%  CI  0.33  to  0.71,  I2  =  72%,
17  studies,  2012  participants;  low-quality  evidence;  and  SMD
0.57,  95%  CI  0.25  to  0.90,  I2  =  82%,  8  studies,  1274  participants;
low-quality evidence, respectively) compared with control groups
(Analysis  8.1;  Analysis  8.2;  Table  3).  These  significant  effects
persisted for both three months or longer postintervention follow-
up  values  and  change  from  baseline  to  three  months  or  longer
postintervention scores (Table 3).

Heterogeneity  in  self-reported  physical  activity  analysis  was
explained  by  the  intervention  mode  and  setting  for  follow-up
values,  participants’  menopausal  status,  and  intervention  setting
and format for change scores.

For  objectively  measured  physical  activity,  we  found  significant
small  and  moderate  effects  of  physical  activity  interventions
compared  with  controls  on  both  immediately  postintervention
follow-up values and change from baseline to end of intervention
scores,  respectively  (SMD  0.43,  95%  CI  0.19  to  0.66,  I2  =  67%,  10
studies,  1248  participants;  moderate-quality  evidence;  and  SMD
0.71, 95% CI 0.14 to 1.29, I2 = 83%, 5 studies, 508 participants; low-
quality evidence, respectively) (Analysis 8.17; Analysis 8.18; Table
3). No significant effect was observed for three months or longer
postintervention follow-up values or change from baseline to three
months or longer postintervention scores for objectively measured
physical activity (Table 3).

For  analysis  of  change  from  baseline  to  end  of  intervention
objective  physical  activity  scores,  removal  of  the  most  extreme
value reduced heterogeneity to levels that might not be important
(I2  =  0%)  (Vallance  2007),  while  maintaining  a  significant  effect.
Heterogeneity  was  explained  in  analysis  of  both  immediately
postintervention  follow-up  and  change  from  baseline  to  end
intervention  by  participants’  menopausal  status  and  by
of 
intervention intensity, setting, and format.

Cochrane Database of Systematic Reviews

Sensitivity  analyses  of  trials  with  low  risk  of  bias  maintained
significant  improvement  in  both  self-reported  and  objective
physical  activity  for 
immediately  postintervention  follow-up
values,  but  not  for  change  from  baseline  to  end  of  intervention
scores,  compared  with  controls  (Analysis  18.31;  Analysis  18.32;
Analysis 18.33; Analysis 18.34).

Analysis  of  trials  that  assessed  moderate  and  moderate-to-
vigorous  physical  activity  immediately  postintervention  follow-
up  values  via  the  self-report,  a  seven-day  physical  activity  recall
instrument  revealed  significant  effects  of  interventions  versus
controls (Analysis 8.14). Analysis of immediately postintervention
follow-up accelerometer-derived counts per minute also revealed
significant increases with physical activity compared with control
interventions (Analysis 8.22).

In  subgroup  analyses,  we  found  significant  effects  of  physical
activity compared with controls on immediately postintervention
follow-up  self-reported  physical  activity  values  with  aerobic
exercise and yoga, tai chi, qigong, and pilates intervention modes,
with individual and group and individual intervention formats, in
addition  to  any  intervention  intensity,  duration,  or  setting.  For
change from baseline to end of intervention, self-reported physical
activity  scores  maintained  significance  regardless  of  intensity  for
interventions  consisting  of  aerobic  exercise  only  and  combined
aerobic and resistance exercise (≤ 12 weeks' duration, home-based
and combined home and facility-based, individual and combined
group and individual formats).

improvement 

For  objective  physical  activity,  significant 
in
immediately  postintervention  follow-up  values  was  found  for
physical  activity  interventions  consisting  of  aerobic  exercise  only
(light-to-moderate  intensity,  ≤  12  weeks'  duration,  home-based
and  combined  home  and  facility-based  settings,  individual  and
combined group and individual formats) compared with controls.
Compared  with  controls, 
light-to-moderate
intensity  with  combined  home  and  facility-based  setting  and
combined  group  and  individual  format  maintained  a  significant
effect  on  objectively  measured  physical  activity  change  from
baseline to end of intervention scores.

interventions  of 

With regards to other physical activity outcomes, significant effects
of  interventions  versus  controls  were  found  in  change  from
baseline  to  end  of  intervention  self-reported  walking  scores,  and
in both immediate postintervention follow-up values and change
from  baseline  to  end  of  intervention  scores  for  self-reported
total and moderate-intensity physical activity, and for objectively
measured  moderate-to-vigorous  physical  activity  (Table  3).  The
odds of participants given physical activity interventions meeting
recommended  physical  activity  guidelines  were  significantly
greater than for control participants immediately post intervention
and  at  three  months  or  longer  post  intervention  (Table  3).  No
significant reductions in overall or objectively measured sedentary
behaviour were found for physical activity interventions compared
with controls (Analysis 8.25; Analysis 8.26; Analysis 8.27).

Studies from which data could not be extracted

Among  trials  from  which  no  data  on  physical  activity  could  be
extracted, one trial measured the number of walking steps during
one  week  before  and  in  the  middle  of  the  12-week  intervention
with  a  pedometer,  but  not  post  intervention  (Nikander  2007),

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

33

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

and  another  reported  accelerometry  data  from  baseline  to  post
intervention in the intervention group only (Rogers 2013).

(Analysis 9.20; Analysis 9.21; Analysis 9.22; Analysis 9.23; Analysis
9.24; Analysis 9.25; Table 3).

Body mass, BMI, body composition, and other anthropometric
measurements

Body  mass  change  from  baseline  to  end  of  intervention,  but
not  immediately  postintervention  follow-up  body  mass  values,
showed  a  significant  effect  of  physical  activity  compared  with
control  (MD  -0.05  kg,  95%  CI  -0.98  to  -0.01,  I2  =  59%,  11  studies,
1047 participants; low-quality evidence; Analysis 9.1; Analysis 9.2).
However,  no  significant  effect  of  physical  activity  was  found  for
either follow-up or change from baseline BMI when compared with
control (Analysis 9.3; Analysis 9.4).

Physical activity also resulted in a small but statistically significant
reduction in postintervention follow-up values and in change from
baseline to end of intervention body fat levels (SMD -0.18, 95% CI
-0.34  to  -0.03,  I2  =  35%,  18  studies,  1162  participants;  moderate-
quality  evidence;  and  SMD  -0.62,  95%  CI  -1.19  to  -0.06,  I2  =  88%,
9  studies,  499  participants;  low-quality  evidence,  respectively)
compared  with  controls  (Analysis  9.5;  Analysis  9.6).  Owing  to
insufficient data, three months or longer data analysis could not be
performed for follow-up values nor for change scores in body mass,
BMI, or body fat.

Removal  of  the  most  extreme  values  reduced  heterogeneity  to
0%  in  both  body  mass  -  Irwin  2015;  Murtezani  2014  -  and  body
fat  -  Schmitz  2005  -  analyses.  Heterogeneity  in  analysis  of  body
mass  was  explained  by  participants’  menopausal  status  and
intervention mode and format, whereas heterogeneity observed in
body fat analyses was explained by diversity in measurement type,
participants’ menopausal status, and intervention mode, intensity,
duration, setting, and format.

Sensitivity  analysis  of  physical  activity  trials  at  low  risk  of  bias
revealed  no  significant  effects  on  follow-up  nor  change  in  body
mass,  BMI,  and  body  fat  when  compared  with  controls  (Analysis
18.35; Analysis 18.36; Analysis 18.37; Analysis 18.38; Analysis 18.39;
Analysis 18.40). Analysis by body composition measurement type
revealed  significant  reductions  only  in  change  in  body  fat  %,  fat
mass,  and  lean  mass  from  baseline  to  end  of  intervention  as
assessed via DEXA and immediately at postintervention follow-up,
as  well  as  change  from  baseline  to  end  of  intervention  body  fat
as  measured  by  bioelectrical  impedance  analysis  (BIA)  (Analysis
9.7;  Analysis  9.8;  Analysis  9.9;  Analysis  9.10).  Subgroup  analyses
revealed  no  significant  effects  of  physical  activity  on  body  mass
but significant changes in BMI from baseline to end of intervention
with  aerobic  exercise  compared  with  control.  Subgroup  analyses
also showed significant reduction in immediately postintervention
follow-up body fat values with interventions consisting of aerobic
exercise  (light-to-moderate  intensity,  facility-based,  individual
format)  and  significant  reduction  in  changes  in  body  fat  from
baseline to end of intervention for aerobic exercise interventions
(moderate-to-high intensity, ≤ 12 weeks' duration) compared with
control.

Among other anthropometric measurements, significant effects of
physical activity versus control were found for change in both waist
and hip circumferences from baseline to end of intervention (MD
-1.71 cm, 95% CI -2.56 to -0.86, I2 = 48%, 5 studies, 285 participants;
and  MD  -2.37  cm,  95%  CI  -3.31  to  -1.44,  I2  =  5%,  2  studies,  115
participants,  respectively)  but  not  for  waist-to-hip  ratio  (WHR)

Studies from which data could not be extracted

Of four trials from which data could not be extracted, one found no
changes in body mass (P = 0.53), BMI (P = 0.43), percentage body fat
(P = 0.25), or muscle mass (P = 0.46) (Guinan 2013); one observed
no significant differences in BMI and body fat percentage at post
intervention  between  supervised  exercise  and  usual  care  and
between  supervised  exercise  and  exercise-placebo  (Daley  2007).
One trial reported no significant differences between intervention
and  control  conditions  at  post  intervention  in  BMI  and  in  hip  or
waist  circumference  (Basen-Enquist  2006).  Another  trial  reported
postintervention body mass values for the intervention group only
(Pinto 2003).

Muscular strength

For immediate postintervention follow-up values and change from
baseline  to  end  of  intervention  scores,  physical  activity  showed
significant increases in lower body (SMD 0.44, 95% CI 0.09 to 0.78,
I2  =  74%,  10  studies,  637  participants;  low  quality-evidence;  and
SMD 0.72, 95% CI 0.38 to 1.07, I2 = 73%, 8 studies, 720 participants;
low quality-evidence, respectively) and upper body (SMD 0.42, 95%
CI  0.08  to  0.76,  I2  =  79%,  13  studies,  768  participants;  very  low
quality-evidence;  and  SMD  0.72,  95%  CI  0.30  to  1.14,  I2  =  86%,  8
studies, 832 participants; moderate-quality evidence, respectively)
muscular strength compared with controls (Analysis 10.1; Analysis
10.2;  Analysis  10.11;  Analysis  10.12).  We  found  insufficient  three
months or longer data for analysis.

Removal of the most extreme values did not reduce heterogeneity
in any analyses. Heterogeneity was explained by intervention mode
(follow-up  values  and  change  scores),  intensity  (follow-up  values
and change scores), setting (follow-up values), and format (change
scores) in lower body strength analysis, rather than by participants’
menopausal status (follow-up values), intervention mode (follow-
up  values),  setting  (follow-up  values  and  change  scores),  and
format (follow-up values).

Sensitivity  analyses  of  studies  with  low  risk  of  bias  revealed
significant  effects  for  immediately  postintervention  follow-up
values  and  change  from  baseline  to  end  of  intervention  scores
on lower body and upper body strength (Analysis 18.41; Analysis
18.42;  Analysis  18.43;  Analysis  18.44).  In  subgroup  analyses,  we
found  that  physical  activity  significantly  increased  immediately
postintervention  follow-up  lower  body  strength  when  measured
via leg press (Analysis 10.3) for interventions involving resistance
exercise (light-to-moderate intensity, > 12 weeks' duration, facility-
based,  group  and  individual  formats).  Changes  in  lower  body
strength  from  baseline  to  end  of 
intervention  significantly
improved when assessed via leg press and leg extension (Analysis
10.4; Analysis 10.7), and for interventions that included a resistance
exercise  mode  (facility-based,  group  and  individual  formats),
regardless of intervention intensity and duration.

For immediately postintervention follow-up upper body strength,
subgroup analyses revealed significant effects of physical activity
on  grip  strength  values  (Analysis  10.15),  with  interventions
involving  aerobic  exercise  or  resistance  exercise  (>  12  weeks'
duration,  home-based  and  home  and  facility-based  combined
settings, combined group and individual format). Significant effects
of physical activity on change from baseline to end of intervention

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

34

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

values were found via chest press (Analysis 10.14) for interventions
consisting of resistance exercise (light-to-moderate intensity, > 12
weeks'  duration,  facility-based  and  combined  home  and  facility-
based settings, group format).

Studies from which data could not be extracted

Data  could  not  be  extracted  from  three  trials  (Heim  2007;  Ligibel
2008;  Musanti  2012).  Ligibel  2008  reported  only  postintervention
strength  outcomes  (measured  by  recording  the  maximal  weight
lifted  for  each  exercise  during  strength  training  sessions)  for  the
intervention  group  only.  Heim  2007  reported  no  time-by-group
interaction effects for leg extensor and arm flexor strength values,
and Musanti 2012 did not report results of analysis of leg press data.

Bone health-related outcomes

No  significant  effect  of  physical  activity,  compared  with  control,
was found for immediately postintervention follow-up values and
change  from  baseline  to  end  of  intervention  scores  for  BMC,
femoral neck, lumbar spine, and total hip BMD values, and alkaline
phosphate  and  serum  N-telopeptides  of  type  I  collagen  (NTx)
concentrations, in the main analysis or in sensitivity analysis of low
risk of bias trials (Analysis 11.1; Analysis 11.2; Analysis 11.3; Analysis
11.4; Analysis 11.5; Analysis 11.6).

No  significant  effects  on  total  or  hip  BMD  were  found  in  any
subgroup  analyses,  whereas  analysis  of  combined  follow-up
and  change  from  baseline  to  end  of  intervention  lumbar  spine
BMD  values  revealed  significant  improvement  only  for  resistance
exercise interventions.

One trial from which data could be extracted found no difference
for femoral neck and lumbar (L2–L4) bone mineral density (i.e. -0.01
change for each measure in both intervention and control groups)
(Rogers 2009).

Adverse events

Of  the  34  trials  that  provided  data  on  adverse  events,  10  trials
reported  no  adverse  events  during  the  trial  (Basen-Enquist  2006;
Dolan  2016;  Ergun  2013;  Herrero  2006;  Kim  2015;  Loudon  2014;
Naumann 2012; Rogers 2009; Waltman 2010; Winters-Stone 2011).
Adverse  events  reported  in  intervention  groups  of  the  remaining
studies included two instances of plantar fasciitis (Cadmus 2009),
three reports of discomfort and low-intensity stiffness (Cantarero-
Villanueva  2013),  two  recurrences  of  chronic  back  and  shoulder
problems (Irwin 2015), low back pain in one participant (Murtezani
2014),  two  instances  of  tendonitis  in  the  shoulder  and  foot
(Musanti  2012),  one  pelvis  stress  fracture  and  14  further  reports
of  back  or  lower  extremity  pain  or  injury  (Rogers  2015),  one
instance  each  of  chest  pain  and  high  blood  pressure  during  a
treadmill  stress  test  (Rogers  2014),  one  report  of  intervention
discontinuation due to chest pain developed during exercise (Pinto
2005), one report each of an asthma episode and a hypoglycaemia
episode (Portela 2008), and an unspecified number of self-resolving
musculoskeletal issues (Schmitz 2005). One trial reported a broken
hip  in  one  participant,  which  was  not  attributed  to  the  yoga  or
control  intervention  (Loudon  2014).  Ten  participants  in  another
trial  developed  musculoskeletal  injuries,  but  it  was  not  clear
how  many  occurred  in  each  group  (Schmitz  2009).  Of  four  trials
that  reported  an  impact  on  lymphoedema  as  an  adverse  event,
one  trial  reported  that  three  participants  in  the  intervention
group developed lymphoedema (Murtezani 2014), and three trials

Cochrane Database of Systematic Reviews

reported  no  lymphoedema  exacerbations  (Cormie  2014;  Schmitz
2005;  Schmitz  2009).  Indeed  in  Schmitz  2009,  the  intervention
group experienced reduced risk.

With  regards  to  medical  complications  and  poor  health,  one
study reported medical complications as an adverse event in two
control participants (Daley 2007). Payne 2008 reported worsening
health condition as a reason for dropping out of the trial in both
intervention  and  control  groups  (no  numbers  per  group  were
provided);  one  participant  each  in  the  intervention  and  control
groups reported health issues during Pinto 2015, four participants
in the intervention group developed poor health leading to missing
data in Short 2014, one participant in the intervention group and
four in the control group discontinued the study because of poor
health in Winters-Stone 2011, and in another study (Waltman 2010),
continuation  of  health  problems  was  a  cause  of  missing  data  for
two  participants  in  the  control  group.  Finally,  one  trial  reported
cognitive deficit leading to study discontinuation for 10 participants
(Mustian 2004).

D I S C U S S I O N

Summary of main results

We  included  63  trials  with  a  total  of  5761  women  with  breast
cancer  post  adjuvant  therapy  randomised  to  physical  activity
intervention  (n  =  3239)  or  comparison  (n  =  2524)  groups.
Modes  of  physical  activity  interventions  differed  across  trials
and  included  aerobic  exercise  such  as  walking,  cycling,  and
water-based  exercise;  resistance  training;  and  yoga,  pilates,
qigong,  or  tai  chi.  Investigators  examined  a  wide  and  diverse
range  of  outcomes  and  measures  across  trials,  including  health-
related  quality  of  life  (HRQoL),  HRQoL-related  and  psychological
outcomes,  cardiorespiratory  fitness,  physical  activity  as  an
outcome, anthropometric outcomes, muscular strength, and bone
health outcomes. Attrition was a problem across trials, with one-
fifth  of  trials  reporting  that  at  least  20%  of  participants  dropped
out  of  the  intervention  group.  Similarly,  few  trials  reported  that
participants  had  complied  with  the  amount  of  physical  activity
prescribed, and approximately one-quarter of the targeted number
of  sessions  were  missed  on  average  across  trials  reporting  such
data.

Physical activity interventions of a median of 12 weeks' duration
resulted in significant small-to-moderate improvements in HRQoL,
emotional  function,  perceived  physical  function,  social  function,
anxiety,  cardiorespiratory  fitness,  physical  activity  (both  self-
reported and objectively measured), body fat, and lower and upper
body  strength  in  analysis  of  both  immediately  postintervention
follow-up values and change from baseline to end of intervention
scores.  Role  function,  cognitive  function,  depression,  fatigue,
vigour,  and  self-esteem  improved  only  with  physical  activity
interventions  in  analysis  of  immediately  postintervention  follow-
up values, and only body mass and waist and hip circumferences
were  significantly  reduced  in  the  change  from  baseline  to  end
of intervention scores analysis only. No significant improvements
were  noted  in  immediately  postintervention  follow-up  values  or
change  from  baseline  to  end  of  intervention  scores  for  general
health, sexual function, sleep, pain, body mass index (BMI), waist-
to-hip ratio (WHR), bone mineral content (BMC), BMD of the femoral
neck,  lumbar  spine,  or  hip,  and  measures  of  bone  formation
(alkaline phosphatase) and bone resorption (serum biomarker N-
terminal telopeptide (NTx)). Unfortunately, we could not find any

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

35

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

evidence  on  effects  of  physical  activity  on  breast  cancer-related
mortality,  breast  cancer  recurrence,  or  all-cause  mortality.  Also,
relatively  few  adverse  events  were  reported  across  the  included
trials,  suggesting  that  physical  activity  is  safe  for  patients  with
breast  cancer  after  they  have  received  adjuvant  therapy.  Only
HRQoL,  perceived  physical  function,  anxiety,  cardiorespiratory
fitness, and both self-reported and objective physical activity were
considered precise effect estimates (i.e. 95% confidence intervals
(CIs) do not include a harmful effect, or show no effect or negligible
effects, and effects exceed a minimal important difference) for both
immediately  postintervention  follow-up  values  and  change  from
baseline to end of intervention score analyses, although effects on
cognitive function, fatigue, and vigour were precise for immediately
postintervention  values  alone,  and  social  function  and  lower
and  upper  body  strength  effects  were  precise  for  change  from
baseline to end of intervention scores only. When effects were re-
expressed using the most commonly employed measure, physical
activity  interventions  led  to  meaningful  important  differences
(using  change  from  baseline  scores)  in  only  HRQoL  and  anxiety
(Summary of findings 2).

Available  evidence  regarding  sustainability  of  the  benefits  of
physical  activity  was  limited  because  only  14  studies  included  a
follow-up  period  of  three  months  or  longer  beyond  the  end  of
the  intervention  for  all  conditions.  Physical  activity  intervention
improvements  were  sustained  three  months  or  longer  post
intervention for fatigue, cardiorespiratory fitness, and self-reported
physical  activity  for  both  follow-up  values  and  change  from
baseline  scores.  Beneficial  effects  on  emotional  health,  physical
function, depression, and vigour were still apparent in analysis of
immediately postintervention follow-up values, and improvements
in  HRQoL  remained  significant  in  analysis  of  change  from
baseline  to  three  months  or  longer  post  intervention.  However,
no  significant  improvements  were  found  for  physical  activity
interventions  after  three  months  or  longer  post  intervention  in
analysis  of  follow-up  values  or  change  from  baseline  scores  for
cognitive  function  and  objectively  measured  physical  activity;
or  of  follow-up  values  for  HRQoL,  role  function,  sit-to-stand
performance,  or  change  from  baseline  scores  for  emotional
function  values.  No  analysis  was  possible  for  general  health
perspective,  sexual  function,  sleep,  anxiety,  pain,  self-esteem,
body mass, BMI, body fat %, WHR, waist and hip circumferences,
upper and lower body strength, or bone health outcomes of three
months or longer postintervention follow-up values or change from
baseline to three months or longer postintervention scores.

We performed subgroup analysis by intervention mode, intensity,
duration,  setting,  and  format,  wherever  possible.  Caution  is
required when interpreting these analyses owing to small sample
sizes and high heterogeneity. Regarding mode of physical activity,
both  aerobic  exercise  and  combined  aerobic  and  resistance
exercise  interventions  improved  HRQoL  and  cardiorespiratory
fitness,  and  aerobic  exercise  interventions  resulted  in  greater
increases 
in  HRQoL-related  outcomes,  such  as  emotional,
perceived  physical,  and  social  function,  and  in  self-reported
physical  activity.  Resistance  exercise  interventions  were  superior
for  improving  upper  and  lower  body  strength,  and  combined
aerobic  and  resistance  exercise  interventions  led  to  reduced
fatigue.  Interventions  of  light  or  light-to-moderate  intensity
appeared to be more effective than those described as moderate
or  moderate-to-high  intensity  for  improving  HRQoL,  emotional
function,  perceived  physical  function,  social  function,  anxiety,

Cochrane Database of Systematic Reviews

cardiorespiratory  fitness,  objectively  measured  physical  activity
levels,  and  lower  body  muscular  strength.  Physical  activity
interventions longer than 12 weeks in duration were more effective
than  interventions  of  12  weeks  or  less  for  improving  only  upper
and lower body muscular strength, but interventions of 12 weeks
or  less  were  superior  in  improving  HRQoL,  emotional  function,
perceived  physical  function,  social  function,  anxiety,  depression,
and  fatigue.  It  appears  that  interventions  that  were  facility-
based  were  more  effective  than  home-based  interventions  and
those utilising combined home and facility-based physical activity
in  improving  HRQoL,  emotional  function,  perceived  physical
function,  social  function,  anxiety,  depression,  and  lower  body
strength.  However,  both  home-based  and  combined  home  and
facility-based  interventions  were  superior  in  improving  self-
reported physical activity, although greater increases in objectively
measured  physical  activity  and  upper  body  strength  were
observed  in  combined  home  and  facility-based  interventions.
Group-based  and  individual-based  interventions  appear  to  be
effective  in  improving  HRQoL  and  lower  body  strength  among
breast  cancer  survivors  compared  with  combined  (both  group-
and  individual-based)  interventions,  whereas  individual-based
and  combined  interventions  were  more  effective  than  group-
based  interventions  for  improving  self-reported  physical  activity.
Group-based  interventions  were  more  effective  in  improving
emotional  function,  perceived  physical  function,  anxiety,  and
depression, whereas individual-based interventions were superior
for  cardiorespiratory  fitness,  and  combined  interventions  were
better for improving objective physical activity.

Overall completeness and applicability of evidence

The  current  review  draws  upon  trials  from  across  the  world,
although  most  trials  were  based  in  North  America.  This  review
includes  63  trials,  of  which  60  were  randomised  controlled  trials
(RCTs)  and  three  were  quasi-RCTs  (we  excluded  non-randomised
controlled trials) consisting of a total of 5761 participants. All trials
included  only  participants  with  a  diagnosis  of  breast  cancer  who
had  completed  adjuvant  cancer  treatment  (except  for  endocrine
therapy). We excluded trials in which all participants had received
a diagnosis of metastatic breast cancer (two trials), but five of the
eligible trials included a small number of patients with metastatic
breast  cancer.  Eligible  trials  used  a  wide  range  of  intervention
modes; however, most trials provided aerobic-based activity (e.g.
walking,  cycling,  Nordic  walking,  dance,  water-based  exercise,
horse-riding), and only seven trials included a resistance training-
only  study  arm.  Similarly,  only  one  trial  was  available  for  each
of  pilates,  qigong,  and  tai  chi.  We  included  trials  only  when  it
was  possible  to  isolate  effects  of  physical  activity;  therefore,  we
excluded interventions that combined physical activity with calorie
restriction,  manual  therapy,  or  cognitive-behavioural  therapy
components if studies included a no physical activity control group
that did not receive the additional component. The Characteristics
of  included  studies  table  provides  detailed  information  on  trial
attributes.

We  obtained 
information  from  several  electronic  databases
through  a  comprehensive  search  strategy  (Cochrane  Breast
Cancer  Group  Specialised  Register,  MEDLINE  PubMed,  Embase,
Central  Register  of  Controlled  Trials  (CENTRAL)  in  the  Cochrane
Library,  Cumulative 
to  Nursing  and  Allied  Health
Literature  (CINAHL),  Physiotherapy  Evidence  Database  (PEDro),
SPORTDiscus,  PsycINFO,  OpenGrey,  and  Health  Management

Index 

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

36

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Information  Consortium  (HMIC))  and  via  review  of  reference  lists
of  other  reviews  on  the  topic  (i.e.  physical  activity/exercise  and
cancer)  and  reference  lists  of  all  included  trials.  We  identified
future potentially eligible trials via the World Health Organization
(WHO)  International  Clinical  Trials  Registry  Platform  (ICTRP)  and
clinicaltrials.gov. We applied no language or date restrictions in our
search strategy. We included all outcomes apart from those related
to  specific  impairments  in  the  shoulder,  the  arm,  or  both  (e.g.
range of motion, arm volume, arm circumference), as well as blood
biomarkers,  which  we  excluded  because  they  were  beyond  the
scope of the current review. See Search methods for identification
of studies for details.

Regarding  applicability  of  evidence,  owing  to  underreporting  of
sociodemographic  characteristics  of  participants  (cancer  stage,
cancer  treatment  received,  race/ethnicity,  menopausal  status,
education  level,  annual  income,  and  baseline  physical  activity
levels and body mass/BMI), a thorough comparison between trials
with assessment of the generalisability of findings was not possible.
However, based on the characteristics reported, most patients with
breast  cancer  who  were  enrolled  in  eligible  trials  had  stage  I-III
cancer,  received  chemotherapy,  and  were  undergoing  endocrine
therapy.  Most  participants  were  postmenopausal  and  Caucasian,
earned over USD 40,000, received at least a high school education
(47% attained at least a University degree), and were overweight
(BMI ≥ 25 kg/m2). These characteristics would potentially limit the
applicability of evidence to a broader population of patients with
breast cancer.

Interventions  tested  in  eligible  trials  were  diverse  in  terms  of
mode,  frequency,  intensity,  and  duration,  as  well  as  sessions,
setting,  and  format.  As  evidenced  in  our  subgroup  analysis,  a
paucity  of  data  is  available  regarding  the  efficacy  of  activity
modes,  such  as  yoga  (n  =  8),  resistance  training  (n  =  7),  pilates
(n  =  1),  qigong  (n  =  1),  and  tai  chi  (n  =  1);  settings  (facility-
based vs home-based vs facility and home-based combined); and
formats (individual-based vs group-based vs combined individual
and group-based) across many of the outcomes examined in the
current review. Variation in these important elements required to
make  physical  activity  recommendations  limits  the  precision  of
evidence-informed  decision  making  and  applicability  of  findings.
Furthermore,  most  trials  were  short-term  (≤  12  weeks'  duration),
and  only  a  minority  of  trials  included  postintervention  follow-up
to  assess  the  sustainability  of  intervention  effects.  Only  one  trial
included  a  follow-up  assessment  12  months  post  intervention.
Most  of  the  remaining  studies  included  follow-up  only  at  three
months or less post intervention. Thus it is unclear how sustainable
the beneficial effects of physical activity interventions would be.

Unfortunately,  we  could  not  provide  an  analysis  of  effects
of  physical  activity 
interventions  on  one  of  our  primary
outcomes - breast cancer-related mortality - because currently no
randomised  or  quasi-randomised  controlled  trials  have  reported
this  outcome.  Similarly,  physical  activity  interventions  for  breast
cancer recurrence and all-cause mortality could not be investigated
owing  to  lack  of  available  data.  We  assessed  outcomes  for
which  sufficient  data  were  available  using  a  wide  range  of
instruments  with  varying  psychometric  properties  (i.e.  level  of
measurement,  reliability,  validity,  responsiveness)  (see  analysis).
Although analysis of outcomes by different instrument types used
revealed  varying  intervention  effects,  sample  size  was  small  in
many  analyses.  Furthermore,  HRQoL  and  subscales  and  HRQoL-

Cochrane Database of Systematic Reviews

related  psychological  outcomes  were  reliant  on  self-report  and
therefore were at risk of biases such as recall and social desirability.
We  included  analyses  of  both  follow-up  values  and  change
from  baseline  values;  however,  owing  to  underreporting,  change
from  baseline  analyses  included  smaller  sample  sizes  than  were
included in analyses of follow-up values. Similarly, small samples
for analyses of sleep, anxiety, waist-to-hip ratio, and waist and hip
circumferences precluded firm conclusions.

Quality of the evidence

The  GRADE  system  revealed  moderate-quality  evidence  by  end
of  intervention  follow-up  for  change  from  baseline  to  end  of
intervention  values  analyses  of  HRQoL,  physical  function,  and
social  function;  for  follow-up  values  analyses  of  BMI,  body  fat
%,  cardiorespiratory  fitness,  emotional  function,  fatigue,  self-
esteem,  and  objective  physical  activity;  and  for  change  from
baseline  values  analysis  of  upper  body  strength  (Guyatt  2008).
Low-quality  evidence  was  provided  by  the  end  of  intervention
follow-up  for  change  from  baseline  to  end  of  intervention  values
analyses  of  cognition,  sleep,  pain,  role  function,  self-reported
physical  activity,  and  lower  body  strength;  for  follow-up  values
analyses  of  depression  and  mass;  and  for  change  from  baseline
values  analyses  of  anxiety,  BMI,  body  fat  %,  emotional  function,
fatigue,  objective  physical  activity,  and  self-esteem.  Although
very  low-quality  evidence  was  provided  by  end  of  intervention
follow-up  for  change  from  baseline  to  end  of  intervention  values
analyses  of  femoral  neck,  lumbar  spine,  and  hip  BMD,  general
health,  and  sexual  function,  follow-up  values  analyses  included
anxiety and upper body strength and change from baseline values
analyses of depression, cardiorespiratory fitness, and upper body
strength.  Specifically,  all  trials  were  at  risk  of  performance  bias
owing to inability to blind study participants to administration of
physical  activity.  Most  trials  were  at  risk  of  selection  bias  owing
to  inadequate  or  unclear  allocation  concealment,  detection  bias,
lack  of  blinding  of  outcome  assessors,  and  attrition  bias  due  to
incomplete outcome data reporting (most often as a result of high
attrition  and  inadequate  handling  of  missing  data).  However,  a
large number of trials were at unclear risk of selection and detection
bias, which may reflect poor quality of reporting rather than poor
methodological practices. When we performed sensitivity analyses
of  both  immediately  postintervention  values  and  change  from
baseline  to  end  of  intervention  by  including  only  trials  at  lower
risk of bias, we found that effects of physical activity interventions
on HRQoL, emotional function, physical function, social function,
anxiety,  and  lower  body  and  upper  body  muscular  strength
remained significant and were of similar or higher magnitude than
when all studies were included.

When considering both end of intervention follow-up and change
from  baseline  to  end  of  intervention  values,  we  found  precise
estimates  of  effects  of  physical  activity  interventions  on  HRQoL,
self-reported physical function, cardiorespiratory fitness, and both
self-reported  and  objective  physical  activity.  In  addition,  precise
effect  estimates  were  provided  from  change  values  analyses  of
social  function,  lower  and  upper  body  strength,  and  end  of
intervention  follow-up  fatigue.  Heterogeneity  was  evident  in  all
outcomes,  except  for  sleep,  cognition,  pain,  and  self-esteem,
for  both  end  of  intervention  follow-up  and  baseline  to  end  of
intervention change values analyses; for BMI, body fat %, emotional
function,  mass,  sexual  function,  and  social  function  immediately

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

37

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

postintervention  values  analyses;  and  for  anxiety  change  from
baseline to end of intervention change values analyses.

Evidence  of  heterogeneity  might  be  explained  by  several  factors
including  variation  in  participant  characteristics  (e.g.  disease
severity,  treatment  regimen,  menopausal  status,  baseline  levels
of  outcomes),  components  of  the  physical  activity  intervention
(e.g.  frequency,  intensity,  duration,  mode  of  activity),  and  types
of  comparison  groups  used  (e.g.  attention  control,  usual  care,
delayed intervention), including potential variations in usual care.
Both our exploration of heterogeneity and subgroup analyses were
limited  owing  to  the  large  number  of  potential  heterogeneity
factors, small sample sizes, and underreporting of key components
(e.g. ˜ 50% of trials reported an assessment of activity intensity).
For  instance,  variation  in  intervention  components  within  each
mode  of  intervention  (i.e.  aerobic,  resistance,  combined  aerobic
and  resistance  exercise,  and  interventions  such  as  yoga,  tai  chi,
qigong, and pilates) impacts consistency and limits confidence in
our analyses by intervention mode.

Potential biases in the review process

Strengths of this review include the comprehensive search strategy,
which  comprised  a  search  of  12  databases,  review  of  reference
lists  of  relevant  reviews  in  the  field  and  reference  lists  of  all
included  trials,  systematic  appraisal  of  study  quality  through
GRADE  and  risk  of  bias  through  the  Cochrane  'Risk  of  bias'  tool,
and  systematic  and  well-defined  data  synthesis.  In  addition,  we
applied  a  broad  definition  of  physical  activity,  which  included
lower intensity interventions such as tai chi, qigong, pilates, yoga,
horse-riding, and line-dancing, as well as higher-intensity activities
such  as  resistance  exercise  and  interval  training.  Inclusion  of
lighter-intensity  activities  might  be  contentious,  but  application
of  the  World  Health  Organization  (WHO)  definition  of  physical
activity  (i.e.  any  bodily  movement  produced  by  contraction  of
skeletal  muscle  that  increases  energy  expenditure  above  a  basal
level) meant that interventions including these types of activities
were  eligible  (Caspersen  1985).  It  is  important  to  note  that  we
attempted  to  isolate  effects  of  physical  activity  as  much  as
possible;  therefore,  we  excluded  trials  that  combined  physical
activity  with  another  component  (e.g.  dietary  modification),  in
which  a  potential  synergistic  or  additive  effect  could  not  be
ruled  out.  In  particular,  this  criterion  led  to  exclusion  of  several
studies that would potentially have been eligible, including trials
that  combined  physical  activity  with  dietary  modification  (Casla
2015;  Djuric  2002;  Kim  Soo  2011;  Mefferd  2007),  educational
counselling (Bloom 2008; Cho 2006), or manual therapy (Cantarero-
Villanueva 2012; Cantarero-Villanueva 2012a; Cantarero-Villanueva
2013a; Fernandez-Lao 2012). Although the contributions of these
additional  components  to  the  overall  effect  of  physical  activity

Cochrane Database of Systematic Reviews

may  be  small,  an  effect  could  not  be  isolated  and  accounted
for;  therefore,  the  review  authors  believe  that  a  more  robust
approach would be to exclude them from the review. We analysed
effects  of  physical  activity  interventions  on  a  broad  range  of
outcomes,  including  both  patient-important  outcomes,  such  as
HRQoL, and objective outcomes related to future health, such as
cardiorespiratory fitness.

The  search  strategy  was  designed  and  applied  to  ensure  that
review  authors  identified  and  retrieved  the  maximal  number  of
eligible published and grey literature trials. We applied no language
restrictions,  so  that  all  trials  published  in  non-English  language
were  translated  and  screened  for  eligibility.  However,  although
we  screened  several  non-English  language  trials  for  eligibility,
we  found  none  to  be  eligible.  Similarly,  we  found  no  additional
eligible trials through our searches of grey literature. In spite of our
comprehensive search strategy, it is still possible that this review
may  have  a  publication  bias.  We  have  presented  funnel  plots  for
end of intervention follow-up (Figure 6) and change from baseline
to  end  of  intervention  values  (no  shown)  from  analyses  of  our
primary outcome of overall HRQoL. Visual inspection of both figures
revealed  asymmetry,  indicating  that  some  publication  bias  for
HRQoL may characterise this field of research; this was supported
by Egger's test for these analyses (P = 0.06 and 0.07, respectively).
To  investigate  publication  bias  in  the  remaining  outcomes  for
which  we  identified  a  sufficient  number  of  studies  (n  >  10),  we
also  performed  Egger's  test  (Egger  1997)  analyses  of  body  mass
(both end of intervention follow-up and change from baseline to
end of intervention values) and BMI (immediately postintervention
values), which suggested publication bias (P < 0.10). Whereas we
included fewer than 10 studies in analyses of both follow-up and
change  values  for  anxiety,  BMD  of  femoral  neck,  lumbar  spine,
and hip, cognitive function, general health, pain, sexual function,
and  sleep,  and  in  analyses  of  change  values  for  depression,
self-esteem, and self-reported and objectively measured physical
activity, inspection of funnel plots revealed asymmetry, suggesting
the presence of publication bias. In all cases, observed asymmetry
was  evident  particularly  because  trials  were  lacking  on  the  side
of  the  plot  that  would  suggest  a  negative  effect  of  physical
activity. A potential rationale for apparent publication bias in the
change from baseline to postintervention values analysis may be
underreporting of change values in the included trials, rather than
lack  of  unpublished  trials  with  negative  findings.  Across  most
analyses,  fewer  trials  were  available  for  analysis  of  these  change
values than were available for analysis of follow-up values. We may
have missed potentially eligible trials in our grey literature search,
although  it  is  unclear  whether  additional  trials  found  only  in  the
grey literature would meaningfully impact the results of this review,
given that these types of trials typically include small samples and
produce inclusive results (McAuley 2000).

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

38

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 6.   Funnel plot of comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control, outcome: 1.1
Overall HRQoL (follow-up values).

Deviations  from  our  proposed  protocol  were  few.  However,  we
did  not  perform  planned  analysis  of  effects  of  physical  activity
on  blood  biomarkers  because  we  considered  these  outcomes
to  be  beyond  the  scope  of  the  current  review,  and  because
uncertainty  persists  regarding  the  prognostic  value  of  blood
biomarkers  in  breast  cancer  populations  (Ballard-Barbash  2012).
Therefore,  future  reviews  are  required  to  explore  both  the
prognostic  value  and  effects  of  physical  activity  on  biomarkers
that  might  be  relevant  to  patients  with  a  diagnosis  of  breast
cancer,  such  as  glucose,  insulin,  inflammatory  cytokines,  and
growth  factors.  We  originally  planned  to  conduct  subgroup
analyses  by  participants'  menopausal  status  (premenopausal  vs
postmenopausal)  and  treatment  regimen  (chemotherapy  vs  no
chemotherapy).  However,  we  identified  insufficient  numbers  of
trials that included premenopausal patients with breast cancer and
those  who  had  not  undergone  chemotherapy  to  perform  these
analyses.

We  corresponded  with  and  requested  additional  data  from  nine
trial  authors  (Baruth  2013;  Carson  2009;  Daley  2007;  Heim  2007;
Loh  2014;  McKenzie  2003;  Payne  2008;  Peppone  2015;  Vallance
2007), four of whom (Daley 2007; Loh 2014; Payne 2008; Vallance
2007) replied to our requests. Of these four trial authors, only the
authors of Vallance 2007 were able to provide data on all outcomes
requested. The addition of data obtained from these trial authors
allowed us to increase sample sizes in quantitative meta-analyses

and  to  perform  more  complete  analyses,  leading  to  more  robust
conclusions. Conversely, our inability to obtain complete data may
have contributed to observed publication bias.

Agreements and disagreements with other studies or
reviews

Several  relatively  recent  systematic  reviews  have  investigated
effects  of  physical  activity/exercise  on  health  outcomes  among
patients  with  cancer;  however,  some  included  all  cancer  types
(Bourke 2013; Bourke 2014; Bradt 2011; Brown 2011; Brown 2012;
Buffart 2012a; Chiu 2015; Craft 2012; Cramp 2012; Ferrer 2011; Fong
2012; Knols 2010; Mishra 2012a; Speck 2010; Winters-Stone 2010;
Zimmer 2016), instead of focusing on breast cancer only (Battaglini
2014;  Bluethmann  2015;  Bluethmann  2016;  Bourke  2013;  Bourke
2014;  Cheema  2014;  Chung  2013;  Duijts  2011;  Keilani  2016;
Meneses-Echavez  2015;  Nelson  2016;  Pan  2015;  Paramanandam
2014;  Yang  2016;  Zeng  2014;  Zhu  2016).  Most  of  these  systematic
reviews included a meta-analysis (Bluethmann 2015; Bluethmann
2016; Bourke 2013; Bourke 2014; Bradt 2011; Brown 2011; Brown
2012;  Buffart  2012a;  Candy  2016;  Cheema  2014;  Chiu  2015;  Craft
2012;  Cramp  2012;  Duijts  2011;  Ferrer  2011;  Fong  2012;  Knols
2010; Lee 2010a; Meneses-Echavez 2015; Mishra 2012a; Pan 2015;
Paramanandam  2014;  Speck  2010;  Yang  2016;  Zeng  2014;  Zhu
2016).  Some  of  the  listed  systematic  reviews  focused  on  specific
outcomes,  such  as  aromatase  inhibitor-associated  arthralgia

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

39

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

(Yang  2016),  breast  cancer-related  lymphoedema  (Keilani  2016;
Nelson  2016;  Paramanandam  2014),  bone  health  (Winters-Stone
2010), cancer-related fatigue (Brown 2011; Cramp 2010; Meneses-
Echavez 2015), cognitive impairments (Chan 2015; Zimmer 2016),
depressive symptoms (Brown 2012; Craft 2012), physical activity/
exercise  behaviour  (Bluethmann  2015;  Bluethmann  2016;  Bourke
2013;  Bourke  2014;  Knols  2010),  outcome  maintenance  (Spark
2013), sexual function (Candy 2016), sleep (Chiu 2015), and quality
of  life  (Ferrer  2011;  Mishra  2012a;  Zeng  2014).  Some  investigated
effects  of  particular  types  of  physical  activity  such  as  dance/
movement  therapy  (Bradt  2011),  physical  activity  interventions
based on behaviour change theory (Bluethmann 2015; Bluethmann
2016), physical activity and/or dietary interventions (Spark 2013),
resistance  exercise  (Cheema  2014;  Keilani  2016;  Nelson  2016;
Paramanandam  2014),  supervised  exercise  (Meneses-Echavez
2015),  tai  chi  (Lee  2010a;  Pan  2015),  walking  (Chiu  2015;  Knols
2010),  and  yoga  (Buffart  2012a),  and  others  included  trials  in
which participants were still undergoing breast cancer treatment
(Battaglini  2014;  Bradt  2011;  Brown  2011;  Brown  2012;  Buffart
2012a; Cheema 2014; Chung 2013; Cramp 2012; Duijts 2011; Fong
2012; Lee 2010a; Meneses-Echavez 2015; Mishra 2012a; Spark 2013;
Zeng 2014; Zhu 2016; Zimmer 2016).

Similar to meta-analyses included in the current review, previous
meta-analyses  investigating  effects  of  physical  activity  found
improvements  in  HRQoL  in  analyses  that  included  only  trials
involving  solely  breast  cancer  survivors  (Duijts  2011;  Fong  2012;
Mishra  2012a;  Zeng  2014;  Zhu  2016),  trials  including  mostly
(83%)  breast  cancer  survivors  (Speck  2010),  and  trials  with
female  cancer  survivors  (Ferrer  2011).  Similarly,  two  previous
systematic  reviews  concluded  that  physical  activity  improves
HRQoL  among  breast  cancer  survivors  (Battaglini  2014;  Chung
2013).  Likewise,  our  findings  of  improvement  in  breast  cancer-
specific  HRQoL  were  similar  to  those  of  previous  meta-analyses
(Mishra  2012a;  Speck  2010).  Although  previous  meta-analyses  of
resistance  exercise  interventions  found  improvements  in  HRQoL
among breast cancer survivors in Cheema 2014 and among patients
with breast cancer-related lymphoedema in Paramanandam 2014,
owing  to  differences  in  review  methods  (both  reviews  included
trials comprising patients with breast cancer who were undergoing
adjuvant  therapy,  and  Cheema  2014  combined  overall  HRQoL
and  physical  function  values  in  analysis),  we  did  not  identify
a  sufficient  number  of  trials  for  investigation  of  this  particular
analysis.  Similarly,  in  conflict  with  Buffart  2012a,  we  found  no
effects of yoga interventions on HRQoL among patients with breast
cancer. However, Buffart 2012a included trials in which participants
were  undergoing  breast  cancer  treatment.  Unlike  previous  meta-
analyses  (Lee  2010a;  Pan  2015),  we  could  not  perform  a  meta-
analysis  of  only  tai  chi  interventions  owing  to  lack  of  available
eligible  trials.  However,  we  found  evidence  of  double-counting
of  trials  within  these  analyses,  for  instance,  the  six  publications
produced  from  the  single  trial  of  Mustian  2004,  were  included
separately in analyses of Pan 2015.

Among  HRQoL-related  outcomes,  we  observed  improvement  in
emotional  function  similar  to  those  reported  in  three  meta-
analyses (Mishra 2012a; Zeng 2014; Zhu 2016), perceived physical
function  increases  similar  to  those  reported  by  Speck  2010,  and
enhanced  social  function  similar  to  that  described  by  Zhu  2016.
However,  Mishra  2012a  found  no  improvements  in  perceived
physical  or  social  function,  and  Speck  2010  reported  no  increase
in  mental  health  or  social,  emotional,  and  role  function  with

Cochrane Database of Systematic Reviews

physical activity interventions. Unlike one previous meta-analysis
(Paramanandam  2014),  we  found  no  improvements  in  perceived
physical function, specifically with resistance exercise. Similarly, we
found no change in emotional, social, or role function with yoga,
unlike  Buffart  2012a,  although,  similar  to  this  meta-analysis,  we
found no effect on physical function among breast cancer survivors.
Consistent with findings of the Mishra 2012a meta-analysis and the
Zimmer 2016 systematic review, we did not find an effect of physical
activity  on  cognitive  function  among  breast  cancer  survivors.
One  previous  systematic  review  -  Chan  2015  -  concluded,  based
on  two  trials,  that  physical  activity  interventions  were  effective
in  improving  executive  function  and  self-reported  concentration
among patients with breast cancer after chemotherapy. However,
our  findings  of  no  effect  of  physical  activity  on  sexual  function
of  breast  cancer  survivors  differed  from  those  of  Mishra  2012a,
which reported a small effect at six months, but was in agreement
with the findings of three other meta-analyses (Candy 2016; Speck
2010;  Zhu  2016).  Our  finding  of  no  effect  of  physical  activity  on
the  general  health  perspectives  of  breast  cancer  survivors  was
consistent  with  that  of  Mishra  2012a.  In  agreement  with  two
meta-analyses  (Buffart  2012a;  Zhu  2016),  we  found  no  effects  of
physical  activity  interventions  on  sleep  outcomes.  However,  one
previous  meta-analysis  found  improvement  in  sleep  disturbance
with physical activity when comparing follow-up values with those
of the comparison group at 12 weeks' follow-up (Mishra 2012a), and
another  meta-analysis  revealed  that  moderate-intensity  walking
exercise improved sleep among patients with breast cancer (Chiu
2015).

Regarding  other  psychological  outcomes,  we  found  significant
reductions in anxiety with physical activity interventions; this was
consistent with the findings of two previous meta-analyses among
breast  cancer  survivors  (Mishra  2012a;  Zhu  2016),  as  well  as  one
examining effects of yoga among cancer survivors (Buffart 2012a),
but not with the findings of two other meta-analyses (Duijts 2011;
Speck  2010).  Although  we  found  a  small  decrease  in  depression
with physical activity interventions, we failed to find a significant
reduction in the change from baseline to end of intervention values
analysis. Two previous meta-analyses found no effect of physical
activity  on  depression  (Mishra  2012a;  Speck  2010),  and  another
six found a significant reduction in depression among cancer and
breast  cancer  survivors  (Brown  2012;  Buffart  2012a;  Craft  2012;
Duijts 2011; Fong 2012; Zhu 2016). We found a significant but small
decrease in fatigue in favour of physical activity interventions when
we  analysed  immediately  postintervention  values;  however  we
noted a significant reduction in fatigue in the change from baseline
to  at  least  three  months  follow-up  analysis,  and  we  found  that
the  change  from  baseline  to  end  of  intervention  values  analysis
was not significant (P = 0.05). Several other meta-analyses showed
significant reduction in fatigue with physical activity among cancer
survivors (Brown 2011; Buffart 2012a; Cramp 2012; Speck 2010), as
well as breast cancer survivors (Duijts 2011; Fong 2012; Meneses-
Echavez  2015;  Mishra  2012a);  however,  similar  to  the  current
review, one review did not find significant reductions in fatigue (Zhu
2016).

Our finding of no effect of physical activity on pain among breast
cancer survivors is consistent with that of previous meta-analyses
(Mishra 2012a; Pan 2015; Speck 2010; Yang 2016), although Mishra
2012a observed significant effects when using follow-up values at
12 weeks only. Similar to Mishra 2012a and Duijts 2011, we found
improvements  in  self-esteem/body  image  among  breast  cancer

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

40

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

survivors,  although  two  previous  meta-analyses  could  analyse
only body image and reported improvement with physical activity
interventions (Speck 2010; Zeng 2014).

We  found  improved  cardiorespiratory  fitness  when  comparing
physical activity versus control groups, which was consistent with
the findings of previous meta-analyses in mixed cancer population
trials  (Bourke  2013;  Bourke  2014;  Fong  2012;  Speck  2010),  as
well  as  one  systematic  review  involving  only  trials  of  physical
activity among breast cancer survivors over the previous 25 years
(Battaglini  2014).  However,  Fong  2012  did  not  report  significant
improvement  in  a  separate  subanalysis  involving  only  trials
consisting solely of breast cancer survivors. Previous meta-analyses
of  Bluethmann  2015,  Bluethmann  2016,  and  Speck  2010  were
consistent with our finding of increased physical activity (both self-
reported and objectively measured physical activity) among breast
cancer survivors given physical activity interventions. Furthermore,
we  found  that  increases  in  self-reported,  but  not  objectively
measured, physical activity were maintained at least three months
post  intervention,  which  is  somewhat  supported  by  a  previous
meta-analysis (Spark 2013). Spark 2013 investigated the number of
trials consisting of breast cancer survivors that achieved successful
postintervention  maintenance  of  physical  activity  and/or  dietary
outcomes.  The  authors  of  Spark  2013  found  that  four  out  of
nine  studies  that  targeted  physical  activity  improvement  among
primarily breast cancer survivors achieved successful maintenance
of  physical  activity  at  least  three  months  post  intervention,
although another four trials involving only breast cancer survivors
did not achieve successful maintenance.

Our finding of significant but small decreases in body mass (change
from  baseline  to  end  of  intervention  values  only)  was  consistent
with the findings of two previous meta-analyses (Fong 2012; Speck
2010);  however,  Fong  2012  found  no  decreases  in  a  separate
analysis  of  breast  cancer  survivors  only.  In  agreement  with  the
findings  of  Fong  2012,  we  found  no  significant  reduction  in  BMI
among  breast  cancer  survivors.  However,  Speck  2010  did  note
reductions  in  BMI  in  physical  activity  trials  consisting  mostly  of
breast cancer survivors. We also found significant small reductions
in  body  fat  (both  follow-up  and  change  values)  similar  to  those
reported by Speck 2010 but in disagreement with the findings of
Fong 2012.

In agreement with previous meta-analyses of mostly breast cancer
survivors in Speck 2010 and only breast cancer survivors in Fong
2012,  we  found  that  physical  activity  interventions  improved
both  upper  and  lower  body  strength  and  lower  body  strength.
This  finding  was  also  supported  by  a  previous  systematic  review
(Battaglini  2014).  Similarly,  in  subgroup  analyses  by  intervention
mode,  we  observed  the  greatest  effect  with  resistance  exercise.
Previous  meta-analyses  -  Cheema  2014;  Paramanandam  2014  -
and  systematic  reviews  -  Chung  2013;  Keilani  2016;  Nelson  2016
-  have  concluded  that  resistance  exercise  interventions  improve
upper  and  lower  body  strength  among  breast  cancer  survivors,
while adding that these strength gains are achieved safely without
triggering changes in lymphoedema status, worsening symptoms,
or increasing arm volume. Our findings of a lack of effect of physical
activity  on  BMD  is  consistent  with  a  previous  systematic  review
of  exercise  interventions  to  improve  bone  health  in  adult  cancer
survivors (Winters-Stone 2010). Winters-Stone 2010 found that only
two of eight included trials reported significant effects of aerobic

Cochrane Database of Systematic Reviews

exercise on preservation of BMD at the spine or in the whole body,
and none reported exercise benefits at the hip.

Differences between the current review and previous reviews are
likely  due  to  variations  in  time  and  design  of  search  strategies,
as  well  as  in  eligibility  criteria  and  their  application.  Specifically,
previous  reviews  focused  on  certain  types  of  interventions  or
outcomes  and/or  included  mixed  cancer  populations  at  various
stages of treatment.

A U T H O R S '   C O N C L U S I O N S

Implications for practice

Physical activity may have small to moderate beneficial effects on
overall health-related quality of life (HRQoL), some HRQoL domains
(such  as  emotional,  perceived  physical,  and  social  function),
anxiety,  cardiorespiratory  fitness,  self-reported  and  objectively
measured  physical  activity,  body  fat,  and  lower  and  upper  body
muscular strength among women with breast cancer after adjuvant
therapy. Furthermore, at the end of the study period, participants
in physical activity interventions achieved more favourable values
for  role  and  cognitive  function,  depressive  symptoms,  fatigue,
vigour, and self-esteem compared with survivors in control groups.
In  addition,  physical  activity  may  lead  to  greater  albeit  modest
decreases  in  body  mass  and  waist  and  hip  circumferences  from
the  beginning  to  the  end  of  the  intervention.  We  found  a  small
number  of  minor  adverse  events  and  no  evidence  of  negative/
harmful  effects  of  physical  activity  interventions.  Therefore,
physical activity could be considered relatively safe and effective
in  improving  HRQoL  along  with  psychological,  behavioural,  and
physical outcomes in breast cancer survivors.

Positive  results  must  be  interpreted  cautiously  owing  to  the
heterogeneity  and  imprecision  of  observed  effects,  the  risk  of
bias  in  many  trials  (primarily  performance,  attrition,  detection,
and selection bias), and very low-to-moderate quality of evidence.
Variations in design of physical activity interventions (i.e. modes of
physical  activity,  frequency  and  intensity  of  sessions,  duration  of
both sessions and intervention, and level of behavioural support
given),  risks  of  bias,  and  diversity  among  instruments  used  to
assess outcomes likely explain most of the heterogeneity observed.
In  addition,  most  statistically  significant  effects  were  small  to
moderate  and  lacked  precision  (i.e.  95%  confidence  intervals
(CIs)  included  a  harmful  effect,  no  effect,  or  a  negligible  effect).
When effects were re-expressed via the most commonly employed
measurement  tool  or  test,  physical  activity  interventions  led  to
meaningful  clinically  important  differences  in  overall  HRQoL  and
anxiety  only.  Furthermore,  intervention  adherence  and  attrition
varied greatly across trials. All of these factors limit the degree to
which results are attributable to physical activity interventions, and
as a result the practical application of findings.

We  found  limited  evidence  related  to  maintenance  of  outcomes
beyond  the  period  of  active  intervention.  Only  a  minority  of
trials  included  data  regarding  outcome  maintenance  at  least
three months post intervention. Therefore, although we observed
sustained  favourable  effects  of  physical  activity  interventions
on  fatigue,  cardiorespiratory  fitness,  and  self-reported  physical
activity  at  least  three  months  post  intervention,  these  analyses
were  based  on  small  sample  sizes.  Furthermore,  assessments
of  follow-up  beyond  intervention  completion  were  affected  by
in
poorer  adherence  and  greater  attrition  than  were  seen 

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

41

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

assessments performed immediately post intervention. Owing to
these limitations, it is difficult to draw firm conclusions regarding
how  sustainable  effects  of  physical  activity  interventions  are
beyond  the  intervention  period.  Owing  to  insufficient  available
data,  we  could  make  no  conclusions  regarding  maintenance  of
general  health  perspective,  sexual  function,  sleep,  anxiety,  pain,
self-esteem,  mass,  body  mass  index  (BMI),  body  fat,  waist-to-hip
ratio (WHR), waist and hip circumferences, upper and lower body
strength, or bone health outcomes.

in  HRQoL,  fatigue,  cardiorespiratory
postintervention  values 
fitness, and self-reported physical activity, compared with control
groups. Therefore, additional trials that include long-term follow-
up assessments beyond completion of interventions are required
to establish whether effects of a physical activity intervention are
maintained  beyond  the  active  intervention  period.  In  addition,
future research is needed to determine the optimal duration after
intervention  completion  at  which  breast  cancer  survivors  should
receive follow-up assessments.

From  a  practice  perspective,  we  need  a  greater  understanding
of  which  components  of  physical  activity  interventions  can  lead
to  more  optimal  effects  on  outcomes  important  to  breast  cancer
survivors.  Our  findings  appear  to  suggest  that  effects  of  physical
activity are not transferable across all modes, and that the mode of
physical activity chosen may influence potential benefits received.
Therefore,  practitioners  would  benefit  from  knowledge  of  which
mode or combination of modes of physical activity (e.g. continuous
aerobic  exercise,  high-intensity  intermittent  exercise,  resistance
training,  yoga,  tai  chi,  pilates)  coupled  with  physical  activity
prescription  components  (frequency,  intensity  and  duration  of
sessions  and  programme)  is  optimal  for  improving  a  particular
outcome.  In  addition,  understanding  which  behavioural  change
techniques facilitate the greatest physical activity adherence would
promote the sustainability of physical activity-induced benefits.

Implications for research

This systematic review and meta-analysis of 63 trials investigated
effects  of  physical  activity  interventions  among  women  with
breast cancer after adjuvant therapy and found that after physical
activity interventions, breast cancer survivors had more favourable
postintervention  values  and  experienced  greater  changes  during
the  intervention  period  in  overall  health-related  quality  of  life
(HRQoL); in emotional, perceived physical, and social function; and
in anxiety, cardiorespiratory fitness, self-reported and objectively
measured  physical  activity,  body  fat,  and  lower  and  upper  body
strength.  Furthermore,  despite  a  non-significant  change  from
baseline  to  end  of  intervention,  breast  cancer  survivors  given
physical  activity  interventions  had  more  favourable  values  post
intervention  for  role  and  cognitive  function,  depression,  fatigue,
vigour,  and  self-esteem  compared  with  survivors  given  control
interventions. Conversely, although end of intervention values in
the intervention group were not different from those in the control
group,  breast  cancer  survivors  experienced  greater  decreases
in  body  mass  and  in  waist  and  hip  circumferences  during  the
intervention period. We found no data on effects of physical activity
on  breast  cancer-related  mortality,  breast  cancer  recurrence,  or
all-cause  mortality.  Therefore,  future  research  is  required  to
investigate  effects  of  physical  activity  interventions  on  these  as
primary outcomes. Similarly, limited data are available regarding
the cost-effectiveness of physical activity interventions for women
with  breast  cancer  after  adjuvant  therapy.  Further  research  is
needed to determine whether physical activity interventions offer
equivalent  or  superior  health  outcomes  for  a  similar  level  of
expenditure compared with other available interventions.

Although  available  data  were  scarce,  three  months  or  longer
postintervention  follow-up  values  for  emotional  and  perceived
physical  function,  depression,  fatigue,  vigour,  cardiorespiratory
fitness,  and  self-reported  physical  activity  were  more  favourable
among  intervention  groups,  and  intervention  groups  maintained
longer
greater  change  from  baseline  to  three  months  or 

Future  trials  could  help  to  enhance  precision  around  effect
estimates  for  presented  outcomes  by  adopting  more  rigorous
methods.  A  large  proportion  of  trials  included  relatively  small
sample  sizes,  with  28  of  the  63  trials  consisting  of  intervention
and  control  groups  including  fewer  than  30  breast  cancer
survivors.  More  adequately  powered  trials  are  required  for  each
particular  outcome.  Most  of  the  outcomes  included  in  this
current  meta-analysis  were  secondary  outcomes  in  the  included
trials.  For  some  outcomes,  such  as  fatigue,  we  found  little
evidence  from  trials  that  specifically  targeted  improvement  for
this outcome. Trials could ensure that appropriate randomisation
and  allocation  concealment  are  performed  by  using  computer
sequence  generation  coupled  with  either  telephone-  or  Internet-
based central randomisation, or at least sealed opaque envelopes.
Although  blinding  of  participants  to  the  allocation  of  physical
activity  is  not  possible  (even  though  physical  activity  placebo
interventions  may  be  an  option),  when  possible,  such  as  in
non-patient-reported outcomes, assessments could be conducted
by  an  independent  clinician  blinded  to  allocation.  In  addition,
trials  could  limit  loss  to  follow-up  rates  by  better  monitoring
participants during the intervention period and by using attention
and  delayed  intervention  control  groups.  However,  when  loss
to  follow-up  occurs,  incomplete  missing  data  could  be  analysed
appropriately  via  intention-to-treat  analysis  based  on  a  multiple
imputation method. Establishing risk of bias across trials was made
difficult by inadequate reporting; adherence to CONSORT reporting
guidelines for randomised controlled trials (RCTs) would increase
transparency in future trials and would aid their critical appraisal
and interpretation (Moher 2010).

Further  research  is  necessary  to  establish  the  optimal  physical
activity  prescription  needed  to  improve  a  particular  desired
frequencies,
outcome.  Trials  manipulate  different  modes, 
intensities,  and  durations  of  both  sessions  and  interventions  to
determine their effects on specific outcomes important to women
with  breast  cancer  post  adjuvant  therapy,  and  to  provide  more
refined physical activity guidelines for breast cancer survivors. In
addition, because compliance with physical activity interventions
during  and  after  the  intervention  period  is  an  issue,  future
research  is  required  to  gain  a  better  understanding  of  the  most
effective  physical  activity  behaviour  change  techniques  among
breast  cancer  survivors.  Comparisons  of  findings  between  trials
were challenging owing to the heterogeneous range of measures
used to assess outcomes included in the current review. Consensus
on  the  most  valid  and  reliable  measures  for  assessment  of  each
outcome  would  help  researchers  to  address  this  issue.  Similarly,
when possible, researchers could utilise more objective measures
to  assess  outcomes  of  interest  (e.g.  use  of  accelerometers  to
measure  physical  activity,  use  of  functional  tests  to  measure
physical function).

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

42

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

A C K N O W L E D G E M E N T S

The review authors would like to thank Melina Willson and Fergus
Tai for their assistance in completing this current protocol.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

43

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

R E F E R E N C E S

References to studies included in this review

Banasik 2011 {published data only}

*  Banasik J, Williams H, Haberman M, Blank SE, Bendel R.
Effect of Iyengar yoga practice on fatigue and diurnal salivary
cortisol concentration in breast cancer survivors. Journal of the
American Academy of Nurse Practitioners 2011;23(3):135-42.

Baruth 2013 {published data only}

*  Baruth M, Wilcox S, Der AC, Heiney S. Effects of home-based
walking on quality of life and fatigue outcomes in early stage
breast cancer survivors: a 12-week pilot study. Journal of
Physical Activity and Health 2015;12 Suppl 1:S110-S8.

Basen-Enquist 2006 {published data only}

*  Basen-Engquist K, Taylor CL, Rosenblum C, Smith MA,
Shinn EH, Greisinger A, et al. Randomized pilot test of a lifestyle
physical activity intervention for breast cancer survivors.
Patient Education & Counseling 2006;64(1-3):225-34.

Blank 2005 {published data only}

*  Blank SE, Kittel J, Haberman MR. Active practice of
Iyengar yoga as an intervention for breast cancer survivors.
International Journal of Yoga Therapy 2003;13(1):51-9.

Bower 2011 {published data only}

*  Bower JE, Garet D, Sternlieb B, Ganz PA, Irwin MR,
Olmstead R, et al. Yoga for persistent fatigue in breast
cancer survivors: a randomized controlled trial. Cancer
2012;118(15):3766-75.

Bower JE, Greendale G, Crosswell AD, Garet D, Sternlieb B,
Ganz PA, et al. Yoga reduces inflammatory signalling in
fatigued breast cancer survivors: a randomized controlled trial.
Psychoneuroendocrinology 2014;43:20-9.

Cadmus 2009 {published data only}

*  Cadmus LA, Salovey P, Yu H, Chung G, Kasl S, Irwin ML.
Exercise and quality of life during and after treatment for breast
cancer: results of two randomized controlled trials. Psycho-
Oncology 2009;18(4):343-52.

Cadmus-Bertram L, Littman AJ, Ulrich CM, Stovall R,
Ceballos RM, McGregor BA, et al. Predictors of adherence to a
26-week Viniyoga intervention among post-treatment breast
cancer survivors. Journal of Alternative and Complementary
Medicine 2013;19(9):751-8.

Irwin ML, Cadmus L, Alvarez-Reeves M, O'Neil M, Mierzejewski E,
Latka R, et al. Recruiting and retaining breast cancer survivors
into a randomized controlled exercise trial: the Yale Exercise and
Survivorship Study. Cancer 2008;112(11 Suppl):2593-606.

Irwin ML, Varma K, Alvarez-Reeves M, Cadmus L, Wiley A,
Chung GG, et al. Randomized controlled trial of aerobic exercise
on insulin and insulin-like growth factors in breast cancer
survivors: the Yale Exercise and Survivorship Study. Cancer
Epidemiology Biomarkers and Prevention 2009;18(1):306-13.

Irwin ML, varez-Reeves M, Cadmus L, Mierzejewski E, Mayne ST,
Yu H, et al. Exercise improves body fat, lean mass, and bone
mass in breast cancer survivors. Obesity 2009;17(8):1534-41.

Jones SB, Thomas GA, Hesselsweet SD, Alvarez-Reeves M, Yu H,
Irwin ML. Effect of exercise on markers of inflammation in breast
cancer survivors: the Yale Exercise and Survivorship Study.
Cancer Prevention Research 2013;6(2):109-18.

Latka RN, varez-Reeves M, Cadmus L, Irwin ML. Adherence to a
randomized controlled trial of aerobic exercise in breast cancer
survivors: the Yale Exercise and Survivorship Study. Journal of
Cancer Survivorship 2009;3(3):148-57.

Cantarero-Villanueva 2013 {published data only}

*  Cantarero-Villanueva I, Fernandez-Lao C, Cuesta-Vargas AI,
Del Moral-Avila R, Fernandez-De-Las-Penas C, Arroyo-Morales M.
The effectiveness of a deep water aquatic exercise program in
cancer-related fatigue in breast cancer survivors: a randomized
controlled trial. Archives of Physical Medicine and Rehabilitation
2013;94(2):221-30.

Carson 2009 {published data only}

*  Carson JW, Carson KM, Porter LS, Keefe FJ, Seewaldt VL. Yoga
of Awareness program for menopausal symptoms in breast
cancer survivors: results from a randomized trial. Supportive
Care in Cancer 2009;17(10):1301-9.

Cerulli 2014 {published data only}

*  Cerulli C, Minganti C, De Santis C, Tranchita E, Quaranta F,
Parisi A. Therapeutic horseback riding in breast cancer
survivors: a pilot study. Journal of Alternative & Complementary
Medicine 2014;20(8):623-9.

Cormie 2014 {published data only}

*  Cormie P, Pumpa K, Galvao DA, Turner E, Spry N, Saunders C,
et al. Is it safe and efficacious for women with lymphedema
secondary to breast cancer to lift heavy weights during exercise:
a randomised controlled trial. Journal of Cancer Survivorship
2013;7(3):413-24.

Courneya 2003 {published data only}

Courneya KS, Jones LW, Mackey JR, Fairey AS. Exercise beliefs
of breast cancer survivors before and after participation in a
randomized controlled trial. International Journal of Behavioral
Medicine 2006;13(3):259-64.

*  Courneya KS, Mackey JR, Bell GJ, Jones LW, Field CJ,
Fairey AS. Randomized controlled trial of exercise training in
postmenopausal breast cancer survivors: cardiopulmonary
and quality of life outcomes. Journal of Clinical Oncology
2003;21(9):1660-8.

Fairey AS, Courneya KS, Field CJ, Bell GJ, Jones LW, Mackey JR.
Effects of exercise training on fasting insulin, insulin resistance,
insulin-like growth factors, and insulin-like growth factor
binding proteins in postmenopausal breast cancer survivors: a
randomized controlled trial. Cancer Epidemiology, Biomarkers &
Prevention 2003;12(8):721-7.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

44

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Fairey AS, Courneya KS, Field CJ, Bell GJ, Jones LW, Mackey JR.
Randomized controlled trial of exercise and blood immune
function in postmenopausal breast cancer survivors. Journal of
Applied Physiology 2005;98(4):1534-40.

Fairey AS, Courneya KS, Field CJ, Bell GJ, Jones LW, Martin BS,
et al. Effect of exercise training on C-reactive protein in
postmenopausal breast cancer survivors: a randomized
controlled trial. Brain, Behavior, & Immunity 2005;19(5):381-8.

Cuesta-Vargas 2014 {published data only}

*  Cuesta-Vargas AI, Buchan J, Arroyo-Morales M. A multimodal
physiotherapy programme plus deep water running for
improving cancer-related fatigue and quality of life in
breast cancer survivors. European Journal of Cancer Care
2014;23(1):15-21.

Daley 2007 {published data only}

Daley AJ, Crank H, Mutrie N, Saxton JM, Coleman R.
Determinants of adherence to exercise in women treated
for breast cancer. European Journal of Oncology Nursing
2007;11(5):392-9.

Daley AJ, Crank H, Mutrie N, Saxton JM, Coleman R. Patient
recruitment into a randomised controlled trial of supervised
exercise therapy in sedentary women treated for breast cancer.
Contemporary Clinical Trials 2007;28(5):603-13.

*  Daley AJ, Crank H, Saxton JM, Mutrie N, Coleman R, Roalfe A.
Randomized trial of exercise therapy in women treated for
breast cancer. Journal of Clinical Oncology 2007;25(13):1713-21.

Daley AJ, Mutrie N, Crank H, Coleman R, Saxton J. Exercise
therapy in women who have had breast cancer: design of the
Sheffield women's exercise and well-being project. Health
Education Research 2004;19(6):686-97.

Cochrane Database of Systematic Reviews

*  Duijts SFA, Van Beurden M, Oldenburg HSA, Hunter MS,
Kieffer JM, Stuiver MM, et al. Efficacy of cognitive behavioral
therapy and physical exercise in alleviating treatment-induced
menopausal symptoms in patients with breast cancer: results
of a randomized, controlled, multicenter trial. Journal of Clinical
Oncology 2012;30(33):4124-33.

Mewes JC, Steuten LM, Duijts SF, Oldenburg HS, van Beurden M,
Stuiver MM, et al. Cost-effectiveness of cognitive behavioral
therapy and physical exercise for alleviating treatment-induced
menopausal symptoms in breast cancer patients. Journal of
Cancer Survivorship 2015;9(1):126-35.

Ergun 2013 {published data only}

*  Ergun M, Eyigor S, Karaca B, Kisim A, Uslu R. Effects of exercise
on angiogenesis and apoptosis-related molecules, quality of
life, fatigue and depression in breast cancer patients. European
Journal of Cancer Care 2013;22(5):626-37.

Fillion 2008 {published data only}

*  Fillion L, Gagnon P, Leblond F, Gelinas C, Savard J, Dupuis R,
et al. A brief intervention for fatigue management in breast
cancer survivors. Cancer Nursing 2008;31(2):145-59.

Guinan 2013 {published data only}

*  Guinan EM, Hussey JM, Walsh JM, Kennedy MJ, Connolly EM.
The effect of aerobic exercise on the metabolic risk profile of
breast cancer survivors 2-6 months post chemotherapy. Journal
of Clinical Oncology 2011;29(27):1983–92.

Hatchett 2013 {published data only}

*  Hatchett A, Hallam JS, Ford MA. Evaluation of a social
cognitive theory-based email intervention designed to
influence the physical activity of survivors of breast cancer.
Psycho-Oncology 2013;22:829–36.

DeNysschen 2011 {published data only}

Heim 2007 {published data only}

*  DeNysschen CA, Brown JK, Cho MH, Dodd MJ. Nutritional
symptom and body composition outcomes of aerobic exercise
in women with breast cancer. Clinical Nursing Research
2011;20(1):29-46.

Do 2015 {published data only}

*  Do J, Cho Y, Jeon J. Effects of a 4-week multimodal
rehabilitation program on quality of life, cardiopulmonary
function, and fatigue in breast cancer patients. Journal of Breast
Cancer 2015;18:87-96.

Dolan 2016 {published data only}

*  Dolan LB, Campbell K, Gelmon K, Neil-Sztramko S, Holmes D,
McKenzie DC. Interval versus continuous aerobic exercise
training in breast cancer survivors - a pilot RCT. Supportive Care
in Cancer 2016;24(1):119-27.

Duijits 2012 {published data only}

Duijts SF, Oldenburg HS, van Beurden M, Aaronson NK.
Cognitive behavioral therapy and physical exercise for
climacteric symptoms in breast cancer patients experiencing
treatment-induced menopause: design of a multicenter trial.
BMC Women's Health 2009;9:15.

*  Heim ME, Malsburg ML, Niklas A. Randomized controlled trial
of a structured training program in breast cancer patients with
tumor-related chronic fatigue. Onkologie 2007;30(8-9):429-34.

Herrero 2006 {published data only}

Gómez AM, Martinez C, Fiuza-Luces C, Herrero F, Pérez M,
Madero L, et al. Exercise training and cytokines in breast
cancer survivors. International Journal of Sports Medicine
2011;32:461-7.

*  Herrero F, San Juan AF, Fleck SJ, Balmer J, Pérez M, Cañete S,
et al. Combined aerobic and resistance training in breast cancer
survivors: a randomized, controlled pilot trial. International
Journal of Sports Medicine 2006;27(7):573-80.

Irwin 2015 {published data only}

*  Irwin ML, Cartmel B, Gross CP, Ercolano E, Li F, Yao X, et al.
Randomized exercise trial of aromatase inhibitor-induced
arthralgia in breast cancer survivors. Journal of Clinical
Oncology 2015;33(10):1104-11.

Kaltsatou 2011 {published data only}

*  Kaltsatou A, Mameletzi D, Douka S. Physical and
psychological benefits of a 24-week traditional dance program

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

45

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

in breast cancer survivors. Journal of Bodywork and Movement
Therapies 2011;15(2):162-7.

Kiecolt-Glaser 2014 {published data only}

Derry HM, Jaremka LM, Bennett JM, Peng J, Andridge R,
Shapiro C, et al. Yoga and self-reported cognitive problems in
breast cancer survivors: a randomized controlled trial. Psycho-
Oncology 2015;24(8):958-66.

*  Kiecolt-Glaser JK, Bennett JM, Andridge R, Peng J, Shapiro CL,
Malarkey WB, et al. Yoga's impact on inflammation, mood, and
fatigue in breast cancer survivors: a randomized controlled trial.
Journal of Clinical Oncology 2014;32(10):1040-9.

Kim 2015 {published data only}

*  Kim SH, Cho YU, Kim SJ, Hong S, Han MS, Choi E. The
effect on bone outcomes of adding exercise to supplements
for osteopenic breast cancer survivors: a pilot randomized
controlled trial. Cancer Nursing 2016;39(2):144-52.

Ligibel 2008 {published data only}

*  Ligibel JA, Campbell N, Partridge A, Chen WY, Salinardi T,
Chen H, et al. Impact of a mixed strength and endurance
exercise intervention on insulin levels in breast cancer
survivors. Journal of Clinical Oncology 2008;26(6):907-12.

Ligibel JA, Giobbie-Hurder A, Olenczuk D, Campbell N,
Salinardi T, Winer EP, et al. Impact of a mixed strength and
endurance exercise intervention on levels of adiponectin,
high molecular weight adiponectin and leptin in breast cancer
survivors. Cancer Causes & Control 2009;20(8):1523-8.

Littman 2012 {published data only}

*  Littman AJ, Bertram LC, Ceballos R, Ulrich CM, Ramaprasad J,
McGregor B, et al. Randomized controlled pilot trial of yoga
in overweight and obese breast cancer survivors: effects on
quality of life and anthropometric measures. Supportive Care in
Cancer 2012;20(2):267-77.

Loh 2014 {published data only}

*  Loh SY, Lee SY, Murray L. The Kuala Lumpur Qigong trial for
women in the cancer survivorship phase-efficacy of a three-arm
RCT to improve QOL. Asian Pacific Journal of Cancer Prevention
2014;15(19):8127-34.

Loudon 2014 {published data only}

*  Loudon A, Barnett T, Piller N, Immink MA, Visentin D,
Williams AD. The effect of yoga on women with secondary
arm lymphoedema from breast cancer treatment. BMC
Complementary and Alternative Medicine 2012;12:66.

Loudon A, Barnett T, Piller N, Immink MA, Visentin D,
Williams AD. Yoga management of breast cancer-related
lymphoedema: a randomised controlled pilot-trial. BMC
Complementary and Alternative Medicine 2014;14:214.

Malicka 2011 {published data only}

*  Malicka I, Stefanska M, Rudziak M, Jarmoluk P, Pawlowska K,
Szczepanska-Gieracha J, et al. The influence of Nordic walking
exercise on upper extremity strength and the volume of
lymphoedema in women following breast cancer treatment.
Isokinetics and Exercise Science 2011;19(4):295-304.

Cochrane Database of Systematic Reviews

Martin 2013 {published data only}

*  Martin E, Battaglini C, Groff D, Naumann F. Improving
muscular endurance with the MVe Fitness Chair™ in breast
cancer survivors: a feasibility and efficacy study. Journal of
Science & Medicine in Sport 2013;16(4):372-6.

Matthews 2007 {published data only}

*  Matthews CE, Wilcox S, Hanby CL, Der Ananian C, Heiney SP,
Gebretsadik T, et al. Evaluation of a 12-week home-based
walking intervention for breast cancer survivors. Supportive
Care in Cancer 2007;15(2):203-11.

McKenzie 2003 {published data only}

*  McKenzie DC, Kalda AL. Effect of upper extremity exercise on
secondary lymphedema in breast cancer patients: a pilot study.
Journal of Clinical Oncology 2003;21(3):463-6.

Mehnert 2011 {published data only}

*  Mehnert A, Veers S, Howaldt D, Braumann KM, Koch U,
Schulz KH. Effects of a physical exercise rehabilitation group
program on anxiety, depression, body image, and health-
related quality of life among breast cancer patients. Onkologie
2011;34(5):248-53.

Milne 2008 {published data only}

*  Milne HM, Wallman KE, Gordon S, Courneya KS. Effects of a
combined aerobic and resistance exercise program in breast
cancer survivors: a randomized controlled trial. Breast Cancer
Research and Treatment 2008;108(2):279-88.

Milne HM, Wallman KE, Gordon S, Courneya KS. Impact
of a combined resistance and aerobic exercise program
on motivational variables in breast cancer survivors: a
randomized controlled trial. Annals of Behavioral Medicine
2008;36(2):158-66.

Murtezani 2014 {published data only}

*  Murtezani A, Ibraimi Z, Bakalli A, Krasniqi S, Disha ED,
Kurtishi I. The effect of aerobic exercise on quality of life among
breast cancer survivors: a randomized controlled trial. Journal
of Cancer Research and Therapeutics 2014;10(3):658-64.

Musanti 2012 {published data only}

*  Musanti R. A study of exercise modality and physical self-
esteem in breast cancer survivors. Medicine & Science in Sports &
Exercise 2012;44(2):352-61.

Mustian 2004 {published data only}

Janelsins MC, Davis PG, Wideman L, Katula JA, Sprod LK,
Peppone LJ, et al. Effects of Tai Chi Chuan on insulin and
cytokine levels in a randomized controlled pilot study on breast
cancer survivors. Clinical Breast Cancer 2011;11(3):161-70.

*  Mustian KM, Katula JA, Gill DL, Roscoe JA, Lang D, Murphy K.
Tai Chi Chuan, health-related quality of life and self-esteem: a
randomized trial with breast cancer survivors. Supportive Care
in Cancer 2004;12(12):871-6.

Mustian KM, Katula JA, Zhao H. A pilot study to assess the
influence of tai chi chuan on functional capacity among
breast cancer survivors. Journal of Supportive Oncology
2006;4(3):139-45.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

46

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Peppone LJ, Mustian K, Rosier RN, Piazza KM, Hicks DG,
Palesh OG, et al. The effect of tai chi chuan on bone remodeling
and cytokines among breast cancer survivors: a feasibility trial.
Journal of Clinical Oncology 2009;27(15):9610.

Pinto BM, Rabin C, Papandonatos GD, Frierson GM, Trunzo JJ,
Marcus BH. Maintenance of effects of a home-based physical
activity program among breast cancer survivors. Supportive
Care in Cancer 2008;16(11):1279-89.

Peppone LJ, Mustian KM, Janelsins MC, Palesh OG, Rosier RN,
Piazza KM, et al. Effects of a structured weight-bearing exercise
program on bone metabolism among breast cancer survivors: a
feasibility trial. Clinical Breast Cancer 2010;10:224-9.

Pinto BM, Trunzo JJ, Rabin C, Cady B, Fenton MA, Herman A, et
al. Recruitment strategies for a home-based physical activity
intervention for breast cancer patients. Journal of Clinical
Psychology in Medical Settings 2004;11(3):171-8.

Sprod LK, Janelsins MC, Palesh OG, Carroll JK, Heckler CE,
Peppone LJ, et al. Health-related quality of life and biomarkers
in breast cancer survivors participating in tai chi chuan. Journal
of Cancer Survivorship 2012;6(2):146-54.

Naumann 2012 {published data only}

*  Naumann F, Martin E, Philpott M, Smith C, Groff D,
Battaglini C. Can counselling add value to an exercise
intervention for improving quality of life in breast cancer
survivors? A feasibility study. Journal of Supportive Oncology
2012;10(5):188-94.

Nieman 1995 {published data only}

*  Nieman DC, Cook VD, Henson DA, Suttles J, Rejeski WJ,
Ribisl PM, et al. Moderate exercise training and natural killer cell
cytotoxic activity in breast cancer patients. International Journal
of Sports Medicine 1995;16(5):334-7.

Rabin C, Pinto BM, Frierson G. Mediators of a randomized
controlled physical activity intervention for breast cancer
survivors. Journal Sport Exercise Psychology 2006;28:269-84.

Pinto 2015 {published data only}

Pinto B, Stein K, Dunsiger S. Peer mentorship to promote
physical activity among cancer survivors: effects on quality of
life. Psycho-Oncology 2015;24:1295-302.

*  Pinto BM, Stein K, Dunsiger S. Peers promoting physical
activity among breast cancer survivors: a randomized
controlled trial. Health Psychology 2015;34(5):463-72.

Portela 2008 {published data only}

*  Portela A, Santaella C, Gómez C, Burch A. Feasibility of an
exercise program for Puerto Rican women who are breast
cancer survivors. Rehabilitation Oncology 2008;2(26):20-31.

Nikander 2007 {published data only}

Rahnama 2010 {published data only}

*  Nikander R, Sievänen H, Ojala K, Oivanen T, Kellokumpu-
Lehtinen P, Saarto T. Effect of a vigorous aerobic regimen on
physical performance in breast cancer patients - a randomized
controlled pilot trial. Acta Oncologica 2007;46(2):181-6.

Payne 2008 {published data only}

*  Payne JK, Held J, Thorpe J, Shaw H. Effect of exercise on
biomarkers, fatigue, sleep disturbances, and depressive
symptoms in older women with breast cancer receiving
hormonal therapy. Oncology Nursing Forum 2008;35(4):635-42.

Peppone 2015 {published data only}

*  Peppone LJ, Janelsins MC, Kamen C, Mohile SG, Sprod LK,
Gewandter JS, et al. The effect of YOCAS© yoga for
musculoskeletal symptoms among breast cancer survivors
on hormonal therapy. Breast Cancer Research and Treatment
2015;150(3):597-604.

Pinto 2003 {published data only}

*  Pinto BM, Clark MM, Maruyama NC, Feder SI. Psychological
and fitness changes associated with exercise participation
among women with breast cancer. Psycho-Oncology
2003;12(2):118-26.

Pinto 2005 {published data only}

*  Pinto BM, Frierson GM, Rabin C, Trunzo JJ, Marcus BH. Home-
based physical activity intervention for breast cancer patients.
Journal of Clinical Oncology 2005;23(15):3577-87.

Pinto BM, Rabin C, Dunsiger S. Home-based exercise among
cancer survivors: adherence and its predictors. Psycho-Oncology
2009;18(4):369-76.

Nuri R, Kordi MR, Moghaddasi M, Rahnama N, Damirchi A,
Rahmani-Nia F, et al. Effect of combination exercise training on
metabolic syndrome parameters in postmenopausal women
with breast cancer. Journal of Cancer Research and Therapeutics
2012;8(2):238-42.

*  Rahnama N, Nouri R, Rahmaninia F, Damirchi A, Emami H.
The effects of exercise training on maximum aerobic capacity,
resting heart rate, blood pressure and anthropometric variables
of postmenopausal women with breast cancer. Journal of
Research in Medical Sciences 2010;15(2):78-83.

Rogers 2009 {published data only}

Rogers LQ, Hopkins-Price P, Vicari S, Markwell S, Pamenter R,
Courneya KS, et al. Physical activity and health outcomes
three months after completing a physical activity behavior
change intervention: persistent and delayed effects. Cancer
Epidemiology Biomarkers and Prevention 2009;8(5):1410-8.

*  Rogers LQ, Hopkins-Price P, Vicari S, Pamenter R,
Courneya KS, Markwell S, et al. A randomized trial to increase
physical activity in breast cancer survivors. Medicine and
Science in Sports and Exercise 2009;41(4):935-46.

Rogers LQ, Markwell S, Hopkins-Price P, Vicari S, Courneya KS,
Hoelzer K, et al. Reduced barriers mediated physical activity
maintenance among breast cancer survivors. Journal of Sport &
Exercise Psychology 2011;33(2):235-54.

Rogers LQ, McAuley E, Anton PM, Courneya KS, Vicari S,
Hopkins-Price P, et al. Better exercise adherence after treatment
for cancer (BEAT Cancer) study: rationale, design, and methods.
Contemporary Clinical Trials 2012;33.(1):124-37.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

47

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Rogers 2013 {published data only}

*  Rogers LQ, Fogleman A, Trammell R, Hopkins-Price P, Vicari S,
Rao K, et al. Effects of a physical activity behavior change
intervention on inflammation and related health outcomes
in breast cancer survivors: pilot randomized trial. Integrative
Cancer Therapies 2013;12(4):323-35.

Rogers 2014 {published data only}

Rogers LQ, Fogleman A, Trammell R, Hopkins-Price P,
Spenner A, Vicari S, et al. Inflammation and psychosocial factors
mediate exercise effects on sleep quality in breast cancer
survivors: pilot randomized controlled trial. Psycho-Oncology
2015;24(3):302-10.

*  Rogers LQ, Vicari S, Trammell R, Hopkins-Price P, Fogleman A,
Spenner A, et al. Biobehavioral factors mediate exercise effects
on fatigue in breast cancer survivors. Medicine & Science in
Sports & Exercise 2014;46(6):1077-88.

Rogers 2015 {published data only}

*  Rogers LQ, Courneya KS, Anton PM, Hopkins-Price P,
Verhulst S, Vicari SK, et al. Effects of the BEAT Cancer physical
activity behavior change intervention on physical activity,
aerobic fitness, and quality of life in breast cancer survivors: a
multicenter randomized controlled trial. Breast Cancer Research
and Treatment 2015;149(1):109-19.

Saarto 2012 {published data only}

Luoma ML, Hakamies-Blomqvist L, Blomqvist C, Nikander R,
Gustavsson-Lilius M, Saarto T. Experiences of breast cancer
survivors participating in a tailored exercise intervention - a
qualitative study. Anticancer Research 2014;34(3):1193-9.

Nikander R, Sievanen H, Ojala K, Kellokumpu-Lehtinen PL,
Palva T, Blomqvist C, et al. Effect of exercise on bone structural
traits, physical performance and body composition in breast
cancer patients - a 12-month RCT. Journal of Musculoskeletal
Neuronal Interactions 2012;12(3):127-35.

Saarto T, Penttinen HM, Sievanen H, Kellokumpu-Lehtinen PL,
Hakamies-Blomqvist L, Nikander R, et al. Effectiveness of a
12-month exercise program on physical performance and
quality of life of breast cancer survivors. Anticancer Research
2012;32(9):3875-84.

*  Saarto T, Sievanen H, Kellokumpu-Lehtinen P, Nikander R,
Vehmanen L, Huovinen R, et al. Effect of supervised and home
exercise training on bone mineral density among breast cancer
patients. A 12-month randomised controlled trial. Osteoporosis
International 2012;23:1601–12.

Schmitz 2005 {published data only}

Ahmed RL, Thomas W, Yee D, Schmitz KH. Randomized
controlled trial of weight training and lymphedema in
breast cancer survivors. Journal of Clinical Oncology
2006;24(18):2765-72.

Ohira T, Schmitz KH, Ahmed RL, Yee D. Effects of weight training
on quality of life in recent breast cancer survivors: the Weight
Training for Breast Cancer Survivors (WTBS) study. Cancer
2006;106(9):2076-83.

Cochrane Database of Systematic Reviews

*  Schmitz KH, Ahmed RL, Hannan PJ, Yee D. Safety and efficacy
of weight training in recent breast cancer survivors to alter
body composition, insulin, and insulin-like growth factor
axis proteins. Cancer Epidemiology Biomarkers & Prevention
2005;14(7):1672-80.

Schmitz 2009 {published data only}

Brown JC, Schmitz KH. Weight lifting and physical function
among survivors of breast cancer: a post hoc analysis of a
randomized controlled trial. Journal of Clinical Oncology
2015;33(19):2184-9.

Brown JC, Troxel AB, Schmitz KH. Safety of weightlifting among
women with or at risk for breast cancer-related lymphedema:
musculoskeletal injuries and health care use in a weightlifting
rehabilitation trial. Oncologist 2012;17(8):1120-8.

Hayes SC, Speck RM, Reimet E, Stark A, Schmitz KH. Does
the effect of weight lifting on lymphedema following breast
cancer differ by diagnostic method: results from a randomized
controlled trial. Breast Cancer Research and Treatment
2011;130(1):227-34.

*  Schmitz KH, Ahmed RL, Troxel A, Cheville A, Smith R, Lewis-
Grant L, et al. Weight lifting in women with breast-cancer-
related lymphedema. New England Journal of Medicine
2009;361(7):664-73.

Schmitz KH, Ahmed RL, Troxel AB, Cheville A, Lewis-Grant L,
Smith R, et al. Weight lifting for women at risk for breast
cancer-related lymphedema: a randomized trial. JAMA
2010;304(24):2699-705.

Schmitz KH, Troxel AB, Cheville A, Grant LL, Bryan CJ, Gross CR,
et al. Physical Activity and Lymphedema (the PAL trial):
assessing the safety of progressive strength training in breast
cancer survivors. Contemporary Clinical Trials 2009;30(3):233-45.

Speck RM, Gross CR, Hormes JM, Ahmed RL, Lytle LA,
Hwang WT, et al. Changes in the Body Image and Relationship
Scale following a one-year strength training trial for breast
cancer survivors with or at risk for lymphedema. Breast Cancer
Research and Treatment 2010;121:421-30.

Winters-Stone KM, Laudermilk M, Woo K, Brown JC, Schmitz KH.
Influence of weight training on skeletal health of breast
cancer survivors with or at risk for breast cancer-related
lymphedema. Journal of Cancer Survivorship: Research and
Practice 2014;8(2):260-8.

Segar 1998 {published data only}

*  Segar ML, Katch VL, Roth RS, Garcia AW, Portner TI,
Glickman SG, et al. The effect of aerobic exercise on self-esteem
and depressive and anxiety symptoms among breast cancer
survivors. Oncology Nursing Forum 1998;25(1):107-13.

Short 2014 {published data only}

*  Short CE, James EL, Girgis A, D’Souza MI, Plotnikoff RC.
Main outcomes of the Move More for Life Trial: a randomised
controlled trial examining the effects of tailored-print and
targeted-print materials for promoting physical activity among
post-treatment breast cancer survivors. Psycho-Oncology
2014;24(7):771-8.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

48

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Short CE, James EL, Girgis A, McElduff P, Plotnikoff RC. Move
more for life: the protocol for a randomised efficacy trial of a
tailored-print physical activity intervention for post-treatment
breast cancer survivors. BMC Cancer 2012;12:172.

Short CE, James EL, Plotnikoff RC. Theory- and evidence-based
development and process evaluation of the Move More for Life
program: a tailored-print intervention designed to promote
physical activity among post-treatment breast cancer survivors.
International Journal of Behavioral Nutrition and Physical
Activity 2013;10:124.

Taleghani 2012 {published data only}

*  Taleghani F, Karimain J, Babazadeh S, Mokarian F,
Tabatabaiyan M, Samimi MA, et al. The effect of combined
aerobic and resistance exercises on quality of life of women
surviving breast cancer. Iranian Journal of Nursing and Midwifery
Research 2012;17(1):47-51.

Vallance 2007 {published data only}

Vallance J, Plotnikoff RC, Karvinen KH, Mackey JR, Courneya KS.
Understanding physical activity maintenance in breast
cancer survivors. American Journal of Health Behavior
2010;34(2):225-36.

Vallance JK, Courneya KS, Plotnikoff RC, Dinu I, MacKey JR.
Maintenance of physical activity in breast cancer survivors after
a randomized trial. Medicine and Science in Sports and Exercise
2008;40(1):173-80.

Vallance JK, Courneya KS, Plotnikoff RC, Mackey JR. Analyzing
theoretical mechanisms of physical activity behavior change
in breast cancer survivors: results from the Activity Promotion
(ACTION) trial. Annals of Behavioral Medicine 2008;35(2):150-8.

*  Vallance JK, Courneya KS, Plotnikoff RC, Yasui Y, Mackey JR.
Randomized controlled trial of the effects of print materials
and step pedometers on physical activity and quality of
life in breast cancer survivors. Journal of Clinical Oncology
2007;25(17):2352-9.

Vallance JKH. Promoting physical activity in breast cancer
survivors: a randomized controlled trial. Dissertation Abstracts
International Section A: Humanities and Social Sciences [Internet]
2008;68(7):2877.

Waltman 2010 {published data only}

McGuire R, Waltman N, Zimmerman L. Intervention components
promoting adherence to strength training exercise in breast
cancer survivors with bone loss. Western Journal of Nursing
Research 2011;33(5):671-89.

Ott C, Waltman N, Twiss J, Gross G, Lindsey A, Moore T.
Predictors of adherence to strength training at six months
in breast cancer survivors at risk for osteoporosis. Oncology
Nursing Forum 2007;34(1):200-1.

Ott CD, Twiss JJ, Waltman NL, Gross GJ, Lindsey AM. Challenges
of recruitment of breast cancer survivors to a randomized
clinical trial for osteoporosis prevention. Cancer Nursing
2006;29(1):21-33.

Cochrane Database of Systematic Reviews

Twiss JJ, Waltman NL, Berg K, Ott CD, Gross GJ, Lindsey AM. An
exercise intervention for breast cancer survivors with bone loss.
Journal of Nursing Scholarship 2009;41(1):20-7.

*  Waltman NL, Twiss JJ, Ott CD, Gross GJ, Lindsey AM,
Moore TE, et al. The effect of weight training on bone mineral
density and bone turnover in postmenopausal breast cancer
survivors with bone loss: a 24-month randomized controlled
trial. Osteoporosis International 2010;21(8):1361-9.

Winters-Stone 2011 {published data only}

Dobek J, Winters-Stone KM, Bennett JA, Nail L. Musculoskeletal
changes after 1 year of exercise in older breast cancer
survivors. Journal of Cancer Survivorship: Research and Practice
2014;8(2):304-11.

Winters-Stone KM, Dobek J, Bennett JA, Nail LM, Leo MC,
Schwartz A. The effect of resistance training on muscle strength
and physical function in older, postmenopausal breast cancer
survivors: a randomized controlled trial. Journal of Cancer
Survivorship 2012;6(2):189-99.

*  Winters-Stone KM, Dobek J, Nail L, Bennett JA, Leo MC, Naik A,
et al. Strength training stops bone loss and builds muscle
in postmenopausal breast cancer survivors: a randomized,
controlled trial. Breast Cancer Research and Treatment
2011;127(2):447-56.

Winters-Stone KM, Dobek J, Nail LM, Bennett JA, Leo MC,
Torgrimson-Ojerio B, et al. Impact + resistance training
improves bone health and body composition in prematurely
menopausal breast cancer survivors: a randomized controlled
trial. Osteoporosis International 2013;24(5):1637-46.

Winters-Stone KM, Leo MC, Schwartz A. Exercise effects on
hip bone mineral density in older, post-menopausal breast
cancer survivors are age dependent. Archives of Osteoporosis
2012;7(1-2):301-6.

References to studies excluded from this review

Anderson 2012 {published data only}

Anderson RT, Kimmick GG, McCoy TP, Hopkins J, Levine E,
Miller G, et al. A randomized trial of exercise on well-being and
function following breast cancer surgery: the RESTORE trial.
Journal of Cancer Survivorship 2012;6(2):172-81.

Benton 2014 {published data only}

Benton MJ, Schlairet MC, Gibson DR. Change in quality of life
among breast cancer survivors after resistance training: is
there an effect of age?. Journal of Aging and Physical Activity
2014;22(2):178-85.

Bloom 2008 {published data only}

Bloom JR, Stewart SL, D'Onofrio CN, Luce J, Banks PJ.
Addressing the needs of young breast cancer survivors at the
5 year milestone: can a short-term, low intensity intervention
produce change?. Journal of Cancer Survivorship: Research and
Practice 2008;2(3):190-204.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

49

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Buffart 2012 {published data only}

Cheema 2006 {published data only}

Buffart L, Ross W, Chinapaw M, Brug J, Knol D, Korstjens I, et al.
How does exercise improve cancer survivors' quality of life?.
Journal of Science and Medicine in Sport 2012;15:S333-S4.

Cheema BSB, Gaul CA. Full-body exercise training improves
fitness and quality of life in survivors of breast cancer. Journal of
Strength & Conditioning Research 2006;20(1):14-21.

Burnham 2002 {published data only}

Cho 2006 {published data only}

Burnham TR, Wilcox A. Effects of exercise on physiological and
psychological variables in cancer survivors. Medicine & Science
in Sports & Exercise 2002;34(12):1863-7.

Cho OH, Yoo YS, Kim NC. Efficacy of comprehensive group
rehabilitation for women with early breast cancer in South
Korea. Nursing & Health Sciences 2006;8(3):140-6.

Cadmus-Bertram 2011 {published data only}

Cohen 2010 {published data only}

Cadmus Bertram LA, Pierce JP, Patterson RE, Ojeda-Fournier H,
Newman VA, Parker BA. Training overweight/obese older
women at high risk for breast cancer to use web-based weight
loss tools: the HELP pilot study. Journal of Clinical Oncology
2011;29(27):233.

Cantarero-Villanueva 2012 {published data only}

Cantarero-Villanueva I, Fernandez-Lao C, Fernandez-de-las-
Penas C, Lopez-Barajas IB, Del-Moral-Avila R, de la-Llave-
Rincon AI, et al. Effectiveness of water physical therapy on pain,
pressure pain sensitivity, and myofascial trigger points in breast
cancer survivors: a randomized, controlled clinical trial. Pain
Medicine (United States) 2012;13(11):1509-19.

Cantarero-Villanueva 2012a {published data only}

Cantarero-Villanueva I, Fernandez-Lao C, Del Moral-Avila R,
Fernandez-de-Las-Penas C, Feriche-Fernandez-Castanys MB,
Arroyo-Morales M. Effectiveness of core stability exercises and
recovery myofascial release massage on fatigue in breast cancer
survivors: a randomized controlled clinical trial. Evidence-Based
Complementary and Alternative Medicine 2012;2012:1-9. [DOI:
10.1155/2012/620619]

Cantarero-Villanueva I, Fernandez-Lao C, Diaz-Rodriguez L,
Fernandez-de-las-Penas C, Del Moral-Avila R, Arroyo-Morales M.
A multimodal exercise program and multimedia support reduce
cancer-related fatigue in breast cancer survivors: a randomised
controlled clinical trial. European Journal of Integrative Medicine
2011;3(3):e189-e200.

Cantarero-Villanueva 2013a {published data only}

Cantarero-Villanueva I, Fernández-Lao C, Caro-Morán E,
Morillas-Ruiz J, Galiano-Castillo N, Díaz-Rodríguez L, et al.
Aquatic exercise in a chest-high pool for hormone therapy-
induced arthralgia in breast cancer survivors: a pragmatic
controlled trial. Clinical Rehabilitation 2013;27(2):123-32.

Carter 2012 {published data only}

Carter CL, Onicescu G, Cartmell KB, Sterba KR, Tomsic J,
Alberg AJ. The comparative effectiveness of a team-based
versus group-based physical activity intervention for cancer
survivors. Supportive Care in Cancer 2012;20(8):1699-707.

Casla 2015 {published data only}

Casla S, Lopez-Tarruella S, Jerez Y, Marquez-Rodas I, Galvao DA,
Newton RU, et al. Supervised physical exercise improves
VO2max, quality of life, and health in early stage breast cancer
patients: a randomized controlled trial. Breast Cancer Research
and Treatment 2015;153(2):371-82.

Cohen L, Chen Z, Arun B, Shao Z, Dryden M, Xu L, et al. External
Qigong therapy for women with breast cancer prior to surgery.
Integrative Cancer Therapies 2010;9(4):348-53.

Culos-Reed 2006 {published data only}

Culos-Reed S, Carlson LE, Daroux LM, Hately-Aldous S. A
pilot study of yoga for breast cancer survivors: physical and
psychological benefits. Psycho-Oncology 2006;15(10):891-7.

Cunningham 1998 {published data only}

Cunningham AJ, Edmonds CV, Jenkins GP, Pollack H,
Lockwood GA, Warr D. A randomized controlled trial of
the effects of group psychological therapy on survival in
women with metastatic breast cancer. Psycho-Oncology
1998;7(6):508-17.

D'Atillio 2007 {published data only}

D'Attilio MG, Angelillo A, Fochitto M, Sorrentino P, Capelli G,
Federico B, et al. Adapted physical activity for breast cancer
patients. Can the quality of life be enhanced?. Igiene Moderna
2007;128(5):167-78.

Damush 2006 {published data only}

Damush TM, Perkins A, Miller K. The implementation
of an oncologist referred, exercise self-management
program for older breast cancer survivors. Psycho-Oncology
2006;15(10):884-90.

Danhauer 2009 {published data only}

Danhauer SC, Mihalko SL, Russell GB, Campbell CR, Felder L,
Daley K, et al. Restorative yoga for women with breast cancer:
finding from a randomized pilot study. Psycho-Oncology
2009;18(4):360-8.

De Backer 2007 {published data only}

De Backer IC, Van Breda E, Vreugdenhil A, Nijziel MR, Kester AD,
Schep G. High-intensity strength training improves quality of life
in cancer survivors. Acta Oncologica 2007;46(8):1143-51.

Demark 2006 {published data only}

Demark WW, Clipp EC, Morey MC, Pieper CF, Sloane R,
Snyder DC, et al. Lifestyle intervention development study
to improve physical function in older adults with cancer:
outcomes from project LEAD. Journal of Clinical Oncology
2006;24:3465-73.

Dimeo 2008 {published data only}

Dimeo F, Schwartz S, Wesel N, Voigt, Thiel E. Effects of an
endurance and resistance exercise program on persistent

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

50

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

cancer-related fatigue after treatment. Annals of Oncology
2008;19(8):1495-9.

following breast cancer. Breast Cancer Research and Treatment
2013;137(1):175-86.

Djuric 2002 {published data only}

Headley 2004 {published data only}

Djuric Z, DiLaura NM, Jenkins I, Darga L, Jen CK, Mood D, et al.
Combining weight-loss counseling with the weight watchers
plan for obese breast cancer survivors. Obesity Research
2002;10(7):657-65.

Eyigor 2010 {published data only}

Eyigor S, Karapolat H, Yesil H, Uslu R, Durmaz B. Effects of
pilates exercises on functional capacity, flexibility, fatigue,
depression and quality of life in female breast cancer patients:
a randomized controlled study. European Journal of Physical &
Rehabilitation Medicine 2010;46(4):481-7.

Fernandez-Lao 2012 {published data only}

Fernandez-Lao C, Cantarero-Villanueva I, Fernandez-De-
Las-Penas C, Del Moral-Avila R, Castro-Sanchez AM, Arroyo-
Morales M. Effectiveness of a multidimensional physical therapy
program on pain, pressure hypersensitivity, and trigger points
in breast cancer survivors: a randomized controlled clinical trial.
Clinical Journal of Pain 2012;28(2):113-21.

Fernandez-Lao 2013 {published data only}

Fernandez-Lao C, Cantarero-Villanueva I, Ariza-Garcia A,
Courtney C, Fernandez-De-Las-Penas C, Arroyo-Morales M.
Water- versus land-based multimodal exercise program effects
on body composition in breast cancer survivors: a controlled
clinical trial. Supportive Care in Cancer 2013;21(2):521-30.

Fong 2014 {published data only}

Fong SSM, Ng SSM, Luk WS, Chung JWY, Ho JSC, Ying M, et
al. Effects of qigong exercise on upper limb lymphedema
and blood flow in survivors of breast cancer: a pilot study.
Integrative Cancer Therapies 2014;13(1):54-61.

Galantino 2013 {published data only}

Galantino ML, Callens ML, Cardena GJ, Piela NL, Mao JJ. Tai
chi for well-being of breast cancer survivors with aromatase
inhibitor-associated arthralgias: a feasibility study. Alternative
Therapies in Health and Medicine 2013;19(6):38-44.

Gordon 2005 {published data only}

Gordon LG, Battistutta D, Scuffham P, Tweeddale M, Newman B.
The impact of rehabilitation support services on health-related
quality of life for women with breast cancer. Breast Cancer
Research & Treatment 2005;93(3):217-26.

Hanna 2008 {published data only}

Hanna LR, Avila PF, Meteer JD, Nicholas DR, Kaminsky LA.
The effects of a comprehensive exercise program on physical
function, fatigue, and mood in patients with various types of
cancer. Oncology Nursing Forum 2008;35(3):461-9.

Hayes 2013 {published data only}

Hayes SC, Rye S, Disipio T, Yates P, Bashford J, Pyke C, et al.
Exercise for health: a randomized, controlled trial evaluating the
impact of a pragmatic, translational exercise intervention on
the quality of life, function and treatment-related side effects

Headley JA, Ownby KK, John LD. The effect of seated exercise
on fatigue and quality of life in women with advanced breast
cancer. Oncology Nursing Forum 2004;31(5):977-83.

Hojan 2013 {published data only}

Hojan K, Molinska-Glura M, Milecki P. Physical activity and
body composition, body physique, and quality of life in
premenopausal breast cancer patients during endocrine
therapy - a feasibility study. Acta Oncologica (Stockholm,
Sweden) 2013;52(2):319-26.

Hsiao-Fang 2013 {published data only}

Hsiao-Fang H, Tsai-Chung L, Liang-Chih L, Chien-Teng W, Ya-
Jung W. Effects of a walking program on fatigue and exercise
capacity in post-surgery breast cancer women [Chinese].
Journal of Nursing 2013;60(5):53-63.

Hsieh 2008 {published data only}

Hsieh CC, Sprod LK, Hydock DS, Carter SD, Hayward R,
Schneider CM. Effects of a supervised exercise intervention on
recovery from treatment regimens in breast cancer survivors.
Oncology Nursing Forum 2008;35(6):909-15.

Hunt-Shanks 2006 {published data only}

Hunt-Shanks TT, Blanchard CM, Baker F, Hann D, Roberts CS,
McDonald J, et al. Exercise use as complementary therapy
among breast and prostate cancer survivors receiving active
treatment: examination of exercise intention. Integrative Cancer
Therapies 2006;5(2):109-16.

Husebo 2014 {published data only}

Husebo AM, Dyrstad SM, Mjaaland I, Soreide JA, Bru E. Effects
of scheduled exercise on cancer-related fatigue in women with
early breast cancer. ScientificWorldJournal 2014;2014:271828.

Hutnick 2005 {published data only}

Hutnick NA, Williams NI, Kraemer WJ, Orsega-Smith E, Dixon RH,
Bleznak AD, et al. Exercise and lymphocyte activation following
chemotherapy for breast cancer. Medicine and Science in Sports
and Exercise 2005;37(11):1827-35.

Ibfelt 2011 {published data only}

Ibfelt E, Rottmann N, Kjaer T, Hoybye MT, Ross L, Frederiksen K.
No change in health behavior, BMI or self-rated health after a
psychosocial cancer rehabilitation: results of a randomized trial.
Acta Oncologica 2011;50(2):289-98.

Isabell 2010 {published data only}

Isabell UB, Maja R. Yoga supports physical and mental well-
being after breast cancer surgery. Journal of Psychosomatic
Obstetrics and Gynecology 2010;31:125.

Jeff 2012 {published data only}

Jeffs E, Wiseman T. Randomised controlled trial to determine
the benefit of daily home-based exercise in addition to self-care
in the management of breast cancer-related lymphoedema: a
feasibility study. Supportive Care in Cancer 2012;21(4):1013-23.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

51

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Johansson 2005 {published data only}

May 2008 {published data only}

Johansson K, Tibe K, Weibull A, Newton RU. Low intensity
resistance exercise for breast cancer patients with arm
lymphedema with or without compression sleeve. Lymphology
2005;38(4):167-80.

Johnsson 2013 {published data only}

Johnsson A, Johnsson A, Johansson K. Physical activity during
and after adjuvant chemotherapy in patients with breast cancer.
Physiotherapy 2013;99(3):221-7.

Kilbreath 2006 {published data only}

Kilbreath S, Refshauge K, Beith J, Lee M. Resistance and
stretching shoulder exercises early following axillary surgery for
breast cancer. Rehabilitation Oncology 2006;24(2):9-14.

Kilbreath 2012 {published data only}

Kilbreath SL, Refshauge KM, Beith JM, Ward LC, Lee M,
Simpson JM, et al. Upper limb progressive resistance training
and stretching exercises following surgery for early breast
cancer: a randomized controlled trial. Breast Cancer Research
and Treatment 2012;133(2):667-76.

Kilgour 2008 {published data only}

Kilgour RD, Jones DH, Keyserlingk JR. Effectiveness of a self-
administered, home-based exercise rehabilitation program for
women following a modified radical mastectomy and axillary
node dissection: a preliminary study. Breast Cancer Research
and Treatment 2008;109(2):285-95.

Kim Soo 2011 {published data only}

Kim SH, Shin MS, Lee HS, Lee ES, Ro JS, Kang HS, et al.
Randomized pilot test of a simultaneous stage-matched
exercise and diet intervention for breast cancer survivors.
Oncology Nursing Forum 2011;38(2):E97-E106.

Kovacic 2011 {published data only}

Kovacic T, Kovacic M. Impact of relaxation training according to
Yoga in Daily Life system on perceived stress after breast cancer
surgery. Integrative Cancer Therapies 2011;10(1):16-26.

LaStayo 2011 {published data only}

LaStayo PC, Marcus RL, Dibble LE, Smith SB, Beck SL. Eccentric
exercise versus usual-care with older cancer survivors: the
impact on muscle and mobility - an exploratory pilot study. BMC
Geriatrics 2011;11:5.

Lee 2010 {published data only}

Lee SA, Kang J, Kim YD, An AR, Kim S, Kim Y, et al. Effects of a
scapula-oriented shoulder exercise programme on upper limb
dysfunction in breast cancer survivors: a randomized controlled
pilot trial. Clinical Rehabilitation 2010;24(7):600-13.

Ligibel 2012 {published data only}

Ligibel JA, Meyerhardt J, Pierce JP, Najita J, Shockro L,
Campbell N, et al. Impact of a telephone-based physical activity
intervention upon exercise behaviors and fitness in cancer
survivors enrolled in a cooperative group setting. Breast Cancer
Research and Treatment 2012;132(1):205-13.

May AM, Van Weert E, Korstjens I, Hoekstra-Weebers JEHM, Van
Der Schans CP, Zonderland ML, et al. Improved physical fitness
of cancer survivors: a randomised controlled trial comparing
physical training with physical and cognitive-behavioural
training. Acta Oncologica 2008;47(5):825-34.

McClure 2010 {published data only}

McClure MK, McClure RJ, Day R, Brufsky AM. Randomized
controlled trial of the Breast Cancer Recovery Program for
women with breast cancer-related lymphedema. American
Journal of Occupational Therapy 2010;64(1):59-72.

Mefferd 2007 {published data only}

Mefferd K, Nichols JF, Pakiz B, Rock CL. A cognitive behavioral
therapy intervention to promote weight loss improves body
composition and blood lipid profiles among overweight
breast cancer survivors. Breast Cancer Research and Treatment
2007;104(2):145-52.

Moadel 2007 {published data only}

Moadel AB, Shah C, Wylie-Rosett J, Harris MS, Patel SR, Hall CB,
et al. Randomized controlled trial of yoga among a multiethnic
sample of breast cancer patients: effects on quality of life.
Journal of Clinical Oncology 2007;25(28):4387-95.

Naraphong 2015 {published data only}

Naraphong W, Lane A, Schafer J, Whitmer K, Wilson BR. Exercise
intervention for fatigue-related symptoms in Thai women
with breast cancer: a pilot study. Nursing Health Science
2015;17(1):33–41.

Naumann 2012a {published data only}

Naumann F, Munro A, Martin E, Magrani P, Buchan J, Smith C,
et al. An individual-based versus group-based exercise and
counselling intervention for improving quality of life in breast
cancer survivors: a feasibility and efficacy study. Psycho-
Oncology 2012;21(10):1136-9.

Noble 2012 {published data only}

Noble M, Russell C, Kraemer L, Sharratt M. UW WELL-FIT: the
impact of supervised exercise programs on physical capacity
and quality of life in individuals receiving treatment for cancer.
Supportive Care in Cancer 2012;20(4):865-73.

Oh 2010 {published data only}

Oh B, Butow P, Mullan B, Clarke S, Beale P, Pavlakis N, et al.
Impact of Medical Qigong on quality of life, fatigue, mood and
inflammation in cancer patients: a randomized controlled trial.
Annals of Oncology 2010;21(3):608-14.

Oldervoll 2011 {published data only}

Oldervoll LM, Loge JH, Lydersen S, Paltiel H, Asp MB,
Nygaard UV, et al. Physical exercise for cancer patients with
advanced disease: a randomized controlled trial. Oncologist
2011;16(11):1649-57.

Pinto 2008 {published data only}

Pinto BM, Rabin C, Abdow S, Papandonatos GD. A pilot study
on disseminating physical activity promotion among cancer
survivors: a brief report. Psycho-Oncology 2008;17(5):517-21.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

52

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Pinto 2013 {published data only}

Sprod 2005 {published data only}

Pinto BM, Dunsiger S, Waldemore M. Physical activity and
psychosocial benefits among breast cancer patients. Psycho-
Oncology 2013;22(10):2193-9.

Sprod LK, Drum SN, Bentz AT, Carter SD, Schneider CM. The
effects of walking poles on shoulder function in breast cancer
survivors. Integrative Cancer Therapies 2005;4(4):287-93.

Pinto BM, Papandonatos GD, Goldstein MG. A randomized trial
to promote physical activity among breast cancer patients.
Health Psychology 2013;32(6):616-26.

Rabin 2006 {published data only}

Rabin CS, Pinto BM, Trunzo JJ, Frierson GM, Bucknam LM.
Physical activity among breast cancer survivors: regular
exercisers vs participants in a physical activity intervention.
Psycho-Oncology 2006;15(4):344-54.

Rabin 2009 {published data only}

Rabin C, Pinto B, Dunsiger S, Nash J, Trask P. Exercise and
relaxation intervention for breast cancer survivors: feasibility,
acceptability and effects. Psycho-oncology 2009;18(3):258-66.

Sandel 2005 {published data only}

Sandel SL, Judge JO, Landry N, Faria L, Ouellette R, Majczak M.
Dance and movement program improves quality-of-
life measures in breast cancer survivors. Cancer Nursing
2005;28(4):301-9.

Schmidt 2012 {published data only}

Schmidt T, Weisser B, Jonat W, Baumann FT, Mundhenke C.
Gentle strength training in rehabilitation of breast cancer
patients compared to conventional therapy. Anticancer
Research 2012;32(8):3229-33.

Schneider 2007 {published data only}

Schneider CM, Hsieh CC, Sprod LK, Carter SD, Hayward R.
Effects of supervised exercise training on cardiopulmonary
function and fatigue in breast cancer survivors during and after
treatment. Cancer 2007;110(4):918-25.

Schwartz 1999 {published data only}

Schwartz AL. Fatigue mediates the effects of exercise on quality
of life. Quality of Life Research 1999;8(6):529-38.

Segal 2001 {published data only}

Segal R, Evans W, Johnson D, Smith J, Colletta S, Gayton J, et al.
Structured exercises improves physical functioning in women
with stages I and II breast cancer: results of a randomized
controlled trial. Journal of Clinical Oncology 2001;19(3):657-65.

Sherman 2010 {published data only}

Sherman KA, Heard G, Cavanagh KL. Psychological effects
and mediators of a group multi-component program for
breast cancer survivors. Journal of Behavioral Medicine
2010;33(5):378-91.

Speed-Andrews 2010 {published data only}

Speed-Andrews AE, Stevinson C, Belanger LJ, Mirus JJ,
Courneya KS. Pilot evaluation of an Iyengar yoga program for
breast cancer survivors. Cancer Nursing 2010;33(5):369-81.

Sprod 2010 {published data only}

Sprod LK, Palesh OG, Janelsins MC, Peppone LJ, Heckler CE,
Jacob Adams M, et al. Exercise, sleep quality, and mediators of
sleep in breast and prostate cancer patients receiving radiation
therapy. Community Oncology 2010;7(10):463-71.

Stan 2012 {published data only}

Stan DL, Rausch SM, Sundt K, Cheville AL, Youdas JW,
Krause DA, et al. Pilates for breast cancer survivors: Impact
on physical parameters and quality of life after mastectomy.
Clinical Journal of Oncology Nursing 2012;16(2):131-41.

Stan 2013 {published data only}

Stan D, Cheville A, Croghan I, Pruthi S. Randomized controlled
study of yoga versus strengthening exercises in breast cancer
survivors with persistent fatigue. Supportive Care in Cancer
2013;21:S261-S2.

Stevinson 2007 {published data only}

Stevinson C. Exercise programme improves functional
outcomes during breast cancer therapy. Focus on Alternative &
Complementary Therapies 2007;12(3):202-3.

Szczwpanska-Gieracha 2010 {published data only}

Szczepanska-Gieracha J, Malicka I, Figula M, Rymaszewska J,
Wozniewski M. The influence of eight-week Nordic walking
exercise on life quality of women after mastectomy. Onkologia
Polska 2010;13(2):90-5.

Tang 2010 {published data only}

Tang M, Liou T, Lin C. Improving sleep quality for cancer
patients: benefits of a home-based exercise intervention.
Supportive Care in Cancer 2010;18(10):1329-39.

Taso 2014 {published data only}

Taso CJ, Lin HS, Lin WL, Chen SM, Huang WT, Chen SW. The
effect of yoga exercise on improving depression, anxiety, and
fatigue in women with breast cancer: a randomized controlled
trial. Journal of Nursing Research 2014;22(3):155-64.

Thorsen 2005 {published data only}

Thorsen L, Skovlund E, Stromme SB, Hornslien K, Dahl AA,
Fossa SD. Effectiveness of physical activity on cardiorespiratory
fitness and health-related quality of life in young and middle-
aged cancer patients shortly after chemotherapy. Journal of
Clinical Oncology 2005;23(10):2378-88.

Tidhar 2010 {published data only}

Tidhar D, Katz-Leurer M. Aqua lymphatic therapy in women
who suffer from breast cancer treatment-related lymphedema:
a randomized controlled study. Supportive Care in Cancer
2010;18(3):383-92.

Turner 2004 {published data only}

Turner J, Hayes S, Reul-Hirche H. Improving the physical status
and quality of life of women treated for breast cancer: a pilot

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

53

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

study of a structured exercise intervention. Journal of Surgical
Oncology 2004;86(3):141-6.

References to ongoing studies

Deli-Conwright 2014 {published data only}

Ulger 2010 {published data only}

Ulger O, Yagli NV. Effects of yoga on the quality of life in
cancer patients. Complementary Therapies in Clinical Practice
2010;16(2):60-3.

Van Puymbroeck 2011 {published data only}

Van Puymbroeck M, Schmid A, Shinew KJ, Hsieh PC. Influence
of Hatha yoga on physical activity constraints, physical fitness,
and body image of breast cancer survivors: a pilot study.
International Journal of Yoga Therapy 2011;21:49-60.

Van Weert 2005 {published data only}

van Weert E, Hoekstra-Weebers J, Grol B, Otter R, Arendzen H,
Postema K, et al. A multidimensional cancer rehabilitation
program for cancer survivors - effectiveness on health-
related quality of life. Journal of Psychosomatic Research
2005;58(6):485-96.

Wong 2012 {published data only}

Wong P, Muanza T, Hijal T, Masse L, Pillay S, Chasen M, et al.
Effect of exercise in reducing breast and chest-wall pain in
patients with breast cancer: a pilot study. Current Oncology
2012;19(3):e129-e35.

Wu 2008 {published data only}

Wu H, Dodd MJ, Cho MH. Patterns of fatigue and effect of
exercise in patients receiving chemotherapy for breast cancer.
Oncology Nursing Forum 2008;35(5):E90-E9.

Yuen 2007 {published data only}

Yuen HK, Sword D. Home-based exercise to alleviate fatigue and
improve functional capacity among breast cancer survivors.
Journal of Allied Health 2007;36:e257-e75.

References to studies awaiting assessment

Lahart 2016 {published data only}

Lahart IM, Metsios GS, Nevill AM, Kitas GD, Carmichael AR.
Randomised controlled trial of a home-based physical
activity intervention in breast cancer survivors. BMC Cancer
2016;16:234. [DOI: 10.1186/s12885-016-2258-5]

Lohrisch 2011 {published data only}

Lohrisch CA, McKenzie D, Truong P, Jesperson D, Gelmon KA,
Premji S. Randomized trial of exercise versus control for
musculoskeletal symptoms from adjuvant anastrozole for
postmenopausal early breast cancer. Journal of Clinical
Oncology 2011;29(S15):636.

Luu 2014 {published data only}

Luu X, Rifkind K, Dhage S, Castaneda M, Zeng X, Joseph KAP. The
effects of yoga on urban underserved breast cancer patients.
Journal of Clinical Oncology 2014;32:e17557.

Dieli-Conwright CM, Mortimer JE, Schroeder ET, Courneya K,
Demark-Wahnefried W, Buchanan TA. Randomized controlled
trial to evaluate the effects of combined progressive exercise
on metabolic syndrome in breast cancer survivors: rationale,
design, and methods. BMC Cancer 2014;14(1):238.

Galiano-Castillo 2013 {published data only}

Galiano-Castillo N, Ariza-Garcia A, Cantarero-Villanueva I,
Fernandez-Lao C, Diaz-Rodriguez L, Legeren-Alvarez M.
Telehealth system (e-CUIDATE) to improve quality of life in
breast cancer survivors: rationale and study protocol for a
randomized clinical trial. Trials 2013;14(1):187. [NCT01801527]

IRCT2014042117379N1 {published data only}

IRCT2014042117379N1. Comparing self-efficacy, outcome
expectations for promoting the physical activity of the women
with breast cancer in two groups with and without educational
program. http://apps.who.int/trialsearch/Trial2.aspx?
TrialID=IRCT2014042117379N1 (accessed 16 July 2016).

KIlbreath 2011 {published data only}

Kilbreath S, Refshauge KM, Beith J, Ward L, Sawkins K,
Paterson R, et al. Prevention of osteoporosis as a consequence
of aromatase inhibitor therapy in postmenopausal women
with early breast cancer: rationale and design of a randomized
controlled trial. Contemporary Clinical Trials 2011;32(5):704-9.
[ACTRN12608000220369]

NCT02057536 {published data only}

NCT02057536. The Effect of an Exercise Program in Breast
Cancer Patients With Joint Pain While Taking Aromatase
Inhibitors. https://clinicaltrials.gov/show/NCT02057536
(accessed 16 July 2016).

NCT02235051 {published data only}

NCT02235051. Exercise Intervention in Preventing Breast Cancer
Recurrence in Postmenopausal Breast Cancer Survivors. https://
clinicaltrials.gov/show/NCT02235051 (accessed 16 July 2016).

NCT02332876 {published data only}

NCT02332876. Physical Activity and Neuropsychological
Outcomes in a Cancer Population. https://ClinicalTrials.gov/
show/NCT02332876 (accessed 16 July 2016).

NCT02420249 {published data only}

NCT02420249. Qigong for Breast Cancer Survivors. https://
ClinicalTrials.gov/show/NCT02420249 (accessed 16 July 2016).

NCT02433067 {published data only}

NCT02433067. Physical Activity Intervention on Myocardial
Function in Patients With HER2 + Breast Cancer (CARDAPAC).
https://clinicaltrials.gov/show/NCT02433067 (accessed 16 July
2016).

NCT02527889 {published data only}

NCT02527889. The Effect of Resistive Exercise on Forearm Blood
Flow and Tissue Oxygenation Among Breast Cancer Survivors
With or at Risk for Breast Cancer-related Lymphoedema (BCRL).

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

54

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

https://clinicaltrials.gov/show/NCT02527889 (accessed 16 July
2016).

Additional references

Azim 2011

Azim HA Jr, de Azambuja E, Colozza M, Bines J, Piccart MJ. Long-
term toxic effects of adjuvant chemotherapy in breast cancer.
Annals of Oncology 2011;22(9):1939-47.

Ballard-Barbash 2012

Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM,
McTiernan A, Alfano CM. Physical activity, biomarkers, and
disease outcomes in cancer survivors: a systematic review.
Journal of the National Cancer Institute 2012;104(11):815-40.

Battaglini 2014

Battaglini CL, Mills RC, Phillips BL, Lee JT, Story CE,
Nascimento MG, et al. Twenty-five years of research on
the effects of exercise training in breast cancer survivors: a
systematic review of the literature. World Journal of Clinical
Oncology 2014;5(2):177-90.

Beasley 2012

Beasley JM, Kwan ML, Chen WY, Weltzien EK, Kroenke CH,
Lu W, et al. Meeting the physical activity guidelines and
survival after breast cancer: findings from the after breast
cancer pooling project. Breast Cancer Research and Treatment
2012;131(2):637-43.

Bovelli 2010

Bovelli D, Plataniotis G, Roila F, ESMO Guidelines Working
Group. Cardiotoxicity of chemotherapeutic agents and
radiotherapy-related heart disease: ESMO Clinical Practice
Guidelines. Annals of Oncology 2010;21(Suppl 5):277-82.

Bradt 2011

Bradt J, Goodill SW, Dileo C. Dance/movement therapy for
improving psychological and physical outcomes in cancer
patients. Cochrane Database of Systematic Reviews 2011, Issue
10. [DOI: 10.1002/14651858.CD007103.pub2]

Bray 2013

Bray F, Ren J-S, Masuyer E, Ferlay J. Global estimates of
cancer prevalence for 27 sites in the adult population in 2008.
International Journal of Cancer 2013;132:1133-45.

Brown 2011

Brown JC, Huedo-Medina TB, Pescatello LS, Pescatello SM,
Ferrer RA, Johnson BT. Efficacy of exercise interventions
in modulating cancer-related fatigue among adult cancer
survivors: a meta-analysis. Cancer Epidemiology Biomarkers and
Prevention 2011;20(1):123-33.

Brown 2012

Brown JC, Huedo-Medina TB, Pescatello LS, Ryan SM,
Pescatello SM, Moker E, et al. The efficacy of exercise in
reducing depressive symptoms among cancer survivors: a
meta-analysis. PLoS ONE 2012;7(1):e30955.

Beisecker 1997

Buffart 2012a

Beisecker A, Cook MR, Ashworth J, Hayes J, Brecheisen M,
Helmig L, et al. Side effects of adjuvant chemotherapy:
perceptions of node-negative breast cancer patients. Psycho-
Oncology 1997;6(2):85-93.

Bluethmann 2015

Bluethmann SM, Vernon SW, Gabriel KP, Murphy CC,
Bartholomew LK. Taking the next step: a systematic review
and meta-analysis of physical activity and behavior change
interventions in recent post-treatment breast cancer survivors.
Breast Cancer Research and Treatment 2015;149(2):331-42.

Buffart LM, van Uffelen JG, Riphagen II, Brug J, van Mechelen W,
Brown WJ, et al. Physical and psychosocial benefits of yoga
in cancer patients and survivors: a systematic review and
meta-analysis of randomized controlled trials. BMC Cancer
2012;12:559.

Button 2015

Button KS, Kounali D, Thomas L, Wiles NJ, Peters TJ, Welton NJ,
et al. Minimal clinically important difference on the Beck
Depression Inventory-II according to the patient's perspective.
Psychological Medicine 2015;45(15):3269-79.

Bluethmann 2016

Camoriano 1990

Bluethmann SM, Bartholomew LK, Murphy CC, Vernon SW.
Use of theory in behavior change interventions: an analysis of
programs to increase physical activity in posttreatment breast
cancer survivors. Health Education & Behavior 2016;May 25:
[Epub ahead of print]. [DOI: 10.1177/1090198116647712]

Bourke 2013

Bourke L, Homer KE, Thaha MA, Steed L, Rosario DJ, Robb KA,
et al. Interventions for promoting habitual exercise in people
living with and beyond cancer. Cochrane Database of Systematic
Reviews 2013, Issue 9. [DOI: 10.1002/14651858.CD010192.pub2]

Bourke 2014

Bourke L, Homer KE, Thaha MA, Steed L, Rosario DJ, Robb KA,
et al. Interventions to improve exercise behaviour in sedentary
people living with and beyond cancer: a systematic review.
British Journal of Cancer 2014;110(4):831-41.

Camoriano JK, Loprinzi CL, Ingle JN, Therneau TM, Krook JE,
Veeder MH. Weight change in women treated with adjuvant
therapy or observed following mastectomy for node-positive
breast cancer. Journal of Clinical Oncology 1990;8(8):1327-34.

Candy 2016

Candy B, Jones L, Vickerstaff V, Tookman A, King M.
Interventions for sexual dysfunction following treatments for
cancer in women. Cochrane Database of Systematic Reviews
2016;2:Cd005540.

Carayol 2013

Carayol M, Bernard P, Boiché J, Riou F, Mercier B, Cousson-
Gélie F, et al. Psychological effect of exercise in women with
breast cancer receiving adjuvant therapy: what is the optimal
dose needed?. Annals of Oncology 2013;24:291-300.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

55

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Caspersen 1985

Caspersen CJ, Powell KE, Christenson GM. Physical activity,
exercise, and physical fitness: definitions and distinctions for
health-related research. Public Health Reports 1985;100(2):126–
31.

Cella 2002

Database of Systematic Reviews 2013, Issue 10. [DOI:
10.1002/14651858.CD010802]

Cramp 2010

Cramp F, James A, Lambert J. The effects of resistance training
on quality of life in cancer: a systematic literature review and
meta-analysis. Supportive Care in Cancer 2010;18(11):1367-76.

Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE. Combining
anchor and distribution-based methods to derive minimal
clinically important differences on the Functional Assessment
of Cancer Therapy (FACT) anemia and fatigue scales. Journal of
Pain and Symptom Management 2002;24(6):547-61.

Cramp 2012

Cramp F, Byron-Daniel J. Exercise for the management
of cancer-related fatigue in adults. Cochrane Database of
Systematic Reviews 2012;11:Cd006145.

Cella 2002a

de Jong 2002

Cella D, Hahn EA, Dineen K. Meaningful change in cancer-
specific quality of life scores: differences between improvement
and worsening. Quality of Life Research 2002;11(3):207-21.

de Jong N, Courtens AM, Abu-Saad HH, Schouten HC. Fatigue in
patients with breast cancer receiving adjuvant chemotherapy: a
review of the literature. Cancer Nursing 2002;25(4):283-97.

Chan 2015

Demark-Wahnefried 2005

Chan RJ, McCarthy AL, Devenish J, Sullivan KA, Chan A.
Systematic review of pharmacologic and non-pharmacologic
interventions to manage cognitive alterations after
chemotherapy for breast cancer. European Journal of Cancer
2015;51(4):437-50.

Cheema 2008

Cheema B, Gaul CA, Lane K, Fiatarone Singh MA. Progressive
resistance training in breast cancer: a systematic review
of clinical trials. Breast Cancer Research and Treatment
2008;109(1):9-26.

Cheema 2014

Cheema BS, Kilbreath SL, Fahey PP, Delaney GP, Atlantis E.
Safety and efficacy of progressive resistance training in breast
cancer: a systematic review and meta-analysis. Breast Cancer
Research and Treatment 2014;148(2):249-68.

Chiu 2015

Chiu HY, Huang HC, Chen PY, Hou WH, Tsai PS. Walking improves
sleep in individuals with cancer: a meta-analysis of randomized,
controlled trials. Oncology Nursing Forum 2015;42(2):E54-E62.

Chung 2013

Chung C, Lee S, Hwang S, Park E. Systematic review of exercise
effects on health outcomes in women with breast cancer. Asian
Nursing Research 2013;7(3):149-59.

Cochran 1954

Cochran WG. The combination of estimates from different
experiments. Biometrics 1954;10(1):101-29.

Craft 2012

Craft LL, Vaniterson EH, Helenowski IB, Rademaker AW,
Courneya KS. Exercise effects on depressive symptoms in
cancer survivors: a systematic review and meta-analysis. Cancer
Epidemiology Biomarkers and Prevention 2012;21(1):3-19.

Cramer 2013

Cramer H, Lauche R, Klose P, Lange S, Langhorst J, Dobos GJ.
Yoga for women diagnosed with breast cancer. Cochrane

Demark-Wahnefried W, Aziz NM, Rowland JH, Pinto BM. Riding
the crest of the teachable moment: promoting long-term
health after the diagnosis of cancer. Journal of Clinical Oncology
2005;23(24):5814-30.

DerSimonian 1986

DerSimonian R, Laird N. Meta-analysis in clinical trials.
Controlled Clinical Trials 1986;7:177-88.

Duijts 2011

Duijts SF, Faber MM, Oldenburg HS, van Beurden M,
Aaronson NK. Effectiveness of behavioral techniques and
physical exercise on psychosocial functioning and health-
related quality of life in breast cancer patients and survivors - a
meta-analysis. Psycho-Oncology 2011;20(2):115-26.

Eastell 1993

Eastell R, Robins SP, Colwell T. Evaluation of bone turnover in
type I osteoporosis using biochemical markers specific for both
bone formation and bone resorption. Osteoporosis International
1993;3:255-260.

Egger 1997

Egger M, Davey Smith G, Schneider M, Minder C. Bias in
meta-analysis detected by a simple, graphical test. BMJ
1997;315(7109):629-34.

Eton 2004

Eton DT, Cella D, Yost KJ, Yount SE, Peterman AH, Neuberg DS, et
al. A combination of distribution- and anchor-based approaches
determined minimally important differences (MIDs) for
four endpoints in a breast cancer scale. Journal of Clinical
Epidemiology 2004;57(9):898-910.

Ferlay 2013

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C,
et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality
Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France:
International Agency for Research on Cancer; 2013. Available
from http://globocan.iarc.fr (accessed April 2014).

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

56

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Ferrer 2011

Jemal 2011

Ferrer RA, Huedo-Medina TB, Johnson BT, Ryan S, Pescatello LS.
Exercise interventions for cancer survivors: a meta-analysis
of quality of life outcomes. Annals of Behavioral Medicine
2011;41(1):32-47.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D.
Global cancer statistics. CA: A Cancer Journal for Statistics
2011;61(2):69-90.

Keilani 2016

Fong 2012

Fong DY, Ho JW, Hui BP, Lee AM, Macfarlane DJ, Leung SS,
et al. Physical activity for cancer survivors: meta-analysis of
randomised controlled trials. BMJ 2012;344:e70.

Keilani M, Hasenoehrl T, Neubauer M, Crevenna R. Resistance
exercise and secondary lymphedema in breast cancer
survivors - a systematic review. Supportive Care in Cancer
2016;24(4):1907-16.

Galvao 2005

Knols 2005

Galvao DA, Newton RU. Review of exercise intervention
studies in cancer patients. Journal of Clinical Oncology
2005;23(4):899-909.

Greenland 1985

Greenland S, Robins JM. Estimation of common effect
parameter from sparse follow up data. Biometrics
1985;41:55-68.

Guyatt 2008

Knols R, Aaronson NK, Uebelhart D, Fransen J, Aufdemkampe G.
Physical exercise in cancer patients during and after medical
treatment: a systematic review of randomized and controlled
clinical trials. Journal of Clinical Oncology 2005;23(16):3830-42.

Knols 2010

Knols RH, de Bruin ED, Shirato K, Uebelhart D, Aaronson NK.
Physical activity interventions to improve daily walking activity
in cancer survivors. BMC Cancer 2010;10:406.

Guyatt GH, Oxman AD, Vist G, Kunz R, Falck-Ytter Y, Alonso-
Coello P, et al. Rating quality of evidence and strength of
recommendations. GRADE: an emerging consensus on rating
quality of evidence and strength of recommendations. BMJ
2008;336:924-6.

Kodama 2009

Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Asumi M, et al.
Cardiorespiratory fitness as a quantitative predictor of all-
cause mortality and cardiovascular events in healthy men and
women: a meta-analysis. JAMA 2009;301(19):2024-35.

Higgins 2003

Kriska 1990

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring
inconsistency in meta-analyses. BMJ 2003;327:557-60.

Higgins 2011

Kriska AM, Knowler WC, LaPorte RE. Development of a
questionnaire to examine relationship of physical activity and
diabetes in Pima Indians. Diabetes Care 1990;13:401-11.

Higgins JPT, Green S (editors). Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1.0 (updated
March 2011). The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.

Kroenke 2005

Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight
gain, and survival after breast cancer diagnosis. Journal of
Clinical Oncology 2005;23(7):1370-8.

Holmes 2005

Lahmann 2005

Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA.
Physical activity and survival after breast cancer diagnosis.
JAMA 2005;293(20):2479-86.

IARC 2012

International Agency for Research on Cancer. Latest World
Cancer Statistics. Lyon, France: International Agency for
Research on Cancer; 2013; Vol. Press release no. 223.

Ibrahim 2011

Ibrahim EM, Al-Homaidh A. Physical activity and survival after
breast cancer diagnosis: meta-analysis of published studies.
Medical Oncology 2011;28(3):753-65.

Ingram 2007

Ingram C, Visovsky C. Exercise intervention to modify
physiologic risk factors in cancer survivors. Seminars in
Oncology Nursing 2007;23(4):275-84.

Lahmann PH, Schulz M, Hoffmann K, Boeing H, Tjonneland A,
Olsen A, et al. Long-term weight change and breast cancer
risk: the European prospective investigation into cancer and
nutrition (EPIC). British Journal of Cancer 2005;93:582-9.

Lee 2010a

Lee MS, Choi TY, Ernst E. Tai chi for breast cancer patients:
a systematic review. Breast Cancer Research and Treatment
2010;120(2):309-16.

Lynch 2011

Lynch BM, Neilson HK, Friedenreich CM. Physical activity and
breast cancer prevention. Recent Results in Cancer Research
2011;186:13-42.

Mantel 1959

Mantel N, Haenszel W. Statistical aspects of the analysis of
data from retrospective studies. Journal of the National Cancer
Institute 1959;22:719-48.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

57

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Markes 2009

Paramanandam 2014

Markes M, Brockow T, Resch KL. Exercise for women
receiving adjuvant therapy for breast cancer. Cochrane
Database of Systematic Reviews 2006, Issue 4. [DOI:
10.1002/14651858.CD005001.pub2]

McAuley 2000

McAuley L, Pham B, Tugwell P, Moher D. Does the inclusion of
grey literature influence estimates of intervention effectiveness
reported in meta-analyses?. Lancet 2000;356:1228–31.

McNeely 2006

Paramanandam VS, Roberts D. Weight training is not harmful for
women with breast cancer-related lymphoedema: a systematic
review. Journal of Physiotherapy 2014;60(3):136-43.

Physical Activity Guidelines 2008

Physical Activity Guidelines Advisory Committee. Physical
Activity Guidelines Advisory Committee Report, 2008.
Washington: US Department of Health and Human Services.
Available at http://www.health.gov/paguidelines/Report/pdf/
CommitteeReport.pdf (accessed 09 January 2018) 2008.

McNeely ML, Campbell KL, Rowe BH, Klassen TP, Mackey JR,
Courneya KS. Effects of exercise on breast cancer patients and
survivors: a systematic review and meta-analysis. Canadian
Medical Association Journal 2006;175(1):34-41.

RevMan [Computer program]

Nordic Cochrane Centre, The Cochrane Collaboration. Review
Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic
Cochrane Centre, The Cochrane Collaboration, 2014.

McNeely 2010

Schmitz 2010

McNeely ML, Campbell K, Ospina M, Rowe BH, Dabbs K,
Klassen TP, et al. Exercise interventions for upper-limb
dysfunction due to breast cancer treatment. Cochrane
Database of Systematic Reviews 2010, Issue 6. [DOI:
10.1002/14651858.CD005211.pub2]

Meneses-Echavez 2015

Meneses-Echavez JF, Gonzalez-Jimenez E, Ramirez-Velez R.
Effects of supervised exercise on cancer-related fatigue in breast
cancer survivors: a systematic review and meta-analysis. BMC
Cancer 2015;15:77.

Mishra 2012a

Mishra SI, Scherer RW, Geigle PM, Berlanstein DR, Topaloglu O,
Gotay CC, et al. Exercise interventions on health-related quality
of life for cancer survivors. Cochrane Database of Systematic
Reviews 2012, Issue 8. [DOI: 10.1002/14651858.CD007566.pub2]

Mishra 2012b

Mishra SI, Scherer RW, Snyder C, Geigle PM, Berlanstein DR,
Topaloglu O. Exercise interventions on health-related quality
of life for people with cancer during active treatment.
Cochrane Database of Systematic Reviews 2012, Issue 8. [DOI:
10.1002/14651858.CD008465.pub2]

Moher 2010

Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC,
Devereaux PJ, et al. CONSORT 2010 explanation and
elaboration: updated guidelines for reporting parallel group
randomised trials. BMJ 2010;340:c869.

Nelson 2016

Nelson NL. Breast cancer-related lymphedema and resistance
exercise: a systematic review. Journal of Strength & Conditioning
Research 2016;Jan 29:[Epub ahead of print]. [DOI: 10.1519/
JSC.0000000000001355]

Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W,
Galvão D, Pinto BM, et al. American College of Sports Medicine
roundtable on exercise guidelines for cancer survivors. Medicine
and Science in Sport and Exercise Science 2010;42(7):1409-26.

Shoemaker 2013

Shoemaker MJ, Curtis AB, Vangsnes E, Dickinson MG. Clinically
meaningful change estimates for the six-minute walk test
and daily activity in individuals with chronic heart failure.
Cardiopulmonary Physical Therapy Journal 2013;24(3):21-9.

Spark 2013

Spark LC, Reeves MM, Fjeldsoe BS, Eakin EG. Physical activity
and/or dietary interventions in breast cancer survivors: a
systematic review of the maintenance of outcomes. Journal of
Cancer Survivorship: Research and Practice 2013;7(1):74-82.

Speck 2010

Speck RM, Courneya KS, Masse LC, Duval S, Schmitz KH. An
update of controlled physical activity trials in cancer survivors:
a systematic review and meta-analysis. Journal of Cancer
Survivorship: Research and Practice 2010;4(2):87-100.

Vallance 2008

Vallance JK, Courneya KS, Plotnikoff RC, Yasui Y, Mackey JR.
Randomized controlled trial of the effects of print materials
and step pedometers on physical activity and quality of
life in breast cancer survivors. Journal of Clinical Oncology
2007;25(17):2352-9.

Winters-Stone 2010

Winters-Stone KM, Schwartz A, Nail LM. A review of exercise
interventions to improve bone health in adult cancer survivors.
Journal of Cancer Survivorship: Research and Practice
2010;4(3):187-201.

Yang 2016

Pan 2015

Pan Y, Yang K, Shi X, Liang H, Zhang F, Lv Q. Tai chi chuan
exercise for patients with breast cancer: a systematic review
and meta-analysis. Evidence-Based Complementary and
Alternative Medicine 2015;2015:535237.

Yang GS, Kim HJ, Griffith KA, Zhu S, Dorsey SG, Renn CL.
Interventions for the treatment of aromatase inhibitor-
associated arthralgia in breast cancer survivors: a systematic
review and meta-analysis. Cancer Nursing 2016;Jun 21:[Epub
ahead of print]. [DOI: 10.1097/NCC.0000000000000409]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

58

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Yost 2011

Zimmer 2016

Yost KJ, Eton DT, Garcia SF, Cella D. Minimally important
differences were estimated for six Patient-Reported Outcomes
Measurement Information System-Cancer scales in advanced-
stage cancer patients. Journal of Clinical Epidemiology
2011;64(5):507-16.

Zimmer P, Baumann FT, Oberste M, Wright P, Garthe A,
Schenk A, et al. Effects of exercise interventions and physical
activity behavior on cancer related cognitive impairments:
a systematic review. BioMed Research International
2016;2016:1820954.

Zeng 2014

Zeng Y, Huang M, Cheng AS, Zhou Y, So WK. Meta-analysis of the
effects of exercise intervention on quality of life in breast cancer
survivors. Breast Cancer (Tokyo, Japan) 2014;21(3):262-74.

Zhu 2016

Zhu G, Zhang X, Wang Y, Xiong H, Zhao Y, Sun F. Effects of
exercise intervention in breast cancer survivors: a meta-analysis
of 33 randomized controlled trials. OncoTargets and Therapy
2016;9:2153-68.

C H A R A C T E R I S T I C S   O F   S T U D I E S

Characteristics of included studies [ordered by study ID]

Banasik 2011 

Methods

Study design: single-centre RCT

References to other published versions of this review

Lahart 2014

Lahart IM, Metsios GS, Nevill AM, Carmichael AR. Physical
activity for women with breast cancer after adjuvant therapy.
Cochrane Database of Systematic Reviews 2014, Issue 9. [DOI:
10.1002/14651858.CD011292]

* Indicates the major publication for the study

Number randomised: 18; 9 to yoga intervention, 9 to wait-list control

Study start: not reported; stop date: not reported

Length of intervention: 8 weeks

Length of follow-up: to end of intervention

Country: USA

Participants

Age, years (mean SD):

• Intervention: 63.3 (6.9)
• Control: 62.4 (7.3)

Stage, n (%):

• All women had a diagnosis of stage II-IV breast cancer.

Inclusion criteria:

• Women with stage II-IV breast cancer who were at least 2 months post treatment

Exclusion criteria:

• Receiving Herceptin therapy (an immune modifier).

• Pregnant or lactating

• Past or current history of another neoplasm

• Active serious infection, or immune deficiency

• History of psychiatric disorders requiring use of psychoactive medications or of documented alcohol
or drug abuse
• Taking current steroid therapy or other known immunomodulating medications

• Physical condition preventing participation in yoga

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

59

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Banasik 2011  (Continued)

Interventions

9 participants assigned to exercise intervention:

• Active yoga practice used in this study was primarily physical in nature and included poses traditional-
ly found in beginning Iyengar classes. Sessions were more physically demanding than those of restora-
tive or gentle yoga, with progressing difficulty of poses, including increased duration of weight-bear-
ing on the arms as individual abilities improved. Two 90-minute group yoga sessions per week were
performed over 8 weeks.

Adherence:

Seven participants in the yoga group who completed the study attended an average of 14 of 16 possi-
ble yoga sessions (87.5%) with a range of 12 to 15 sessions.

9 participants assigned to control:

• Control group participants were instructed to continue their regular routines and were offered an op-

portunity for yoga programme participation at the end of the study period.

Contamination of control group: not reported

Outcomes

Outcomes:

• Quality of life via Functional Assessment of Cancer Therapy Form B (FACT-B)
• Fatigue by a fatigue score determined by averaging Likert scale responses to fatigue-related items

using the same scoring range

• Salivary cortisol via collected salivary samples using salivette collection vials (Starsedt Inc., Newton,
NC) 4 times during the day for 2 consecutive days at baseline and again 8 weeks later. The supernatant
was assayed for cortisol via enzyme-linked immunoassay kits (R&D Systems, Minneapolis, MN).

Numbers of participants assessed:

• Intervention: baseline, 9; at 8 weeks, 7
• Control: baseline, 9; at 8 weeks, 7

Adverse events: not reported

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: no

Funding: in part by University of Washington Center for Women’s Health and Gender Research, Wash-
ington State University Cancer Prevention and Research Center, and in part by Washington State Uni-
versity College of Nursing

Authors' judgement

Support for judgement

Unclear risk

“Randomly assigned”; method of randomisation was not reported.

Unclear risk

Whether allocation was concealed was not reported.

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

60

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Banasik 2011  (Continued)

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Unclear risk

Blinding of outcome assessments was not described.

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

Analyses included only 14 participants - 7 in each group - who completed the
study.

Selective reporting (re-
porting bias)

High risk

Summary outcomes of FACT-B were not provided (FACT-B, FACT-G, and TOI).

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Baruth 2013 

Methods

Study design: single-centre RCT

Number randomised: 32; 20 to intervention, 12 to control

Study start: not reported; stop date: not reported

Length of intervention: 12 weeks

Length of follow-up: to end of intervention

Country: USA

Participants

Age, years (mean SD):

• Intervention: 57.4 (6.1)
• Control: 54.9 (6.5)

Stage, n (%):

• Intervention: stage 0, 1 (7.1%); stage I, 5 (35.7%); stage II, 7 (50.0%); stage III, 1 (7.1%); missing, 6
• Control: stage 0, 0 (0.0%); stage I, 5 (41.7%); stage II, 5 (41.7%); stage III, 0 (0.0%); missing, 2

Inclusion criteria:

• Given a diagnosis of stage I-III cancer, had completed adjuvant treatment within the previous 12
months, and were postmenopausal

• Free of cardiovascular disease and major orthopaedic limitations

• Not regularly active (< 5 days/week)

Interventions

20 participants assigned to exercise intervention:

• 12-Week home-based walking programme (3 to 5 days per week of 20 to 30 to 40 minutes at RPE 10
to 11 to 12 to 15 by week 8) using the Active Choices model developed and refined by King and col-
leagues. Primary purpose of the intervention was to increase walking. Participants received a brief
(˜30 minutes) in-person counselling session, followed by 5 short (10 to 15 minutes each) telephone
counselling calls during weeks 1, 2, 4, 7, and 10.

• Initial one-on-one counselling session focussed on goal setting and exercise safety. Subsequent coun-
selling calls applied key constructs of the social cognitive theory, whereby the counsellor and partic-
ipants discussed a specific behaviour change principle (e.g. social support, rewards) that participants
could use to increase their walking.

Adherence:

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

61

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Baruth 2013  (Continued)

Cochrane Database of Systematic Reviews

• On average, participants completed 86.2 ± 11.9% (range 62.1% to 100%) of prescribed walking ses-
sions each week (missing logs were assigned zeros for the number of walking sessions completed dur-
ing those particular weeks; data not shown).

12 participants assigned to control:

• Usual  care  control  group  asked  to  maintain  usual  physical  activity  levels  throughout  the  12-week
study period. Study staff had contact with this group only at follow-up appointments. Upon comple-
tion of the study, women in the usual care control group received baseline intervention counselling
session, materials, and pedometer.

Contamination of control group: not reported

Outcomes

Outcomes:

• QoL assessed via 2 measures:

◦ Medical Outcomes 36-Item Short Form Health Survey (MOS SF-36)
◦ International Breast Cancer Study Group (IBCSG) QoL Core Questionnaire, breast cancer-specific
questionnaire, developed to measure the impact of adjuvant therapy on QoL. Questionnaire con-
sists of 10 single-item visual analogue scales, anchored at both ends with words describing highest
and lowest extremes of item content.

• 13-Item subscale of the Functional Assessment of Cancer Therapy: Fatigue (FACT-Fatigue) question-

naire used to assess fatigue

• Completed  41-item  validated  Community  Health  Activities  Model  Program  for  Seniors  (CHAMPS)

questionnaire

Numbers of participants assessed:

• Intervention: baseline, 20; at 12 weeks, 18
• Control: baseline, 12; at 12 weeks, 12

Adverse events: none reported

Notes

Trial registration link: none available

Trial authors contacted: yes, for additional data (means and SDs for outcomes), but trial authors did
not reply

Intention-to-treat analysis: no

Funding: supported by the US Army, Grant # DAMD17-01-1-0628

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

"Participants were randomized 2:1 (intervention: control)".

It is unclear how the allocation sequence was generated.

Allocation concealment
(selection bias)

Unclear risk

Whether treatment assignment was concealed from study personnel and par-
ticipants was not described.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Unclear risk

Blinding of outcome assessments was not described.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

62

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Baruth 2013  (Continued)

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

High risk

Post-test data at 12 weeks were collected on 94% of participants; only com-
pleters were analysed.

High risk

Physical activity data post intervention were not reported.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Basen-Enquist 2006 

Methods

Study design: single-centre RCT

Number randomised: 60; 30 to intervention, 25 to standard care

Study start: April 2003; stop date: April 2004

Length of intervention: 6 months

Length of follow-up: to end of intervention

Country: USA

Participants

Age, years (mean SD):

• Intervention: 55.7 (11.1)
• Control: 54.4 (11.7)

Stage, n (%):

• Intervention: DCIS, 9 (27); stage I, 9 (27); stage II, 7 (21); stage III, 8 (24); stage IV, 1 (3); missing, 1
• Control: DCIS, 4 (17); stage I, 8 (33); stage II, 8 (33); stage III, 3 (13); stage IV, 1 (4); missing, 1

Inclusion criteria:

• Within 7 years of a breast cancer diagnosis

• No longer receiving treatment for breast cancer (except hormone therapy)

• Not engaging in focussed moderate physical activity for 30 minutes or longer a day most days of the
week

Exclusion criteria:

• Clearance received from physician to ensure that they had no medical conditions contraindicating
moderately intensive exercise

Interventions

35 participants assigned to exercise intervention:

• Participants in the lifestyle programme attended 90-minute group meetings each week for 16 weeks,
and every other week for 8 weeks (21 sessions total). Behaviour change methods were based on the
transtheoretical model. Participants were taught to assess their motivational readiness for physical
activity, which they did every 4 to 5 weeks, and received booklets about increasing physical activity
matched to their stage of readiness.

• Intervention sessions emphasised information and skills such as benefits of physical activity, mak-
ing small changes, overcoming barriers, goal setting, rewarding yourself, and self-monitoring. Several
methods of self-monitoring were used, including recording minutes of activity and recording steps us-
ing a pedometer. Information and skills were sequenced so that cognitive methods (e.g. recognising
benefits of physical activity) were presented in earlier sessions and behavioural methods (e.g. moni-
toring steps, rewarding yourself) were presented in later sessions.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

63

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Basen-Enquist 2006  (Continued)

Adherence:

Cochrane Database of Systematic Reviews

Among those who started the intervention, the mean number of sessions attended was 14.6 out of 21
(SD 5.1), with a range of 2 to 21 sessions.

25 participants assigned to control:

• During 6-month intervention period, standard care participants received 2 mailings of the same writ-
ten material as the intervention group, which included topics related to breast cancer survivorship
but did not address physical activity, and standard care participants did not meet as a group.

Outcomes

Outcomes:

• Physical activity during the past week assessed via a 7-day physical activity recall questionnaire (7-

DPAR), an interviewer-administered measure

• Physical performance assessed via a 6-minute endurance walk test; a 50-foot walk test; a timed sit-to-

stand test; a timed reach-up test; and a forward-reach test

• Anthropometric measures such as BMI, hip and waist circumferences
• Quality of life assessed via Medical Outcomes 36-Item Short Form Health Survey
• Patient satisfaction measured via a brief questionnaire administered to participants in the lifestyle

programme during the last session of the programme

• Lymphoedema assessed by a physical therapist who measured arm girth circumferentially at prede-
termined bilateral points. Jobst measuring tapes were used to take circumferential measurements
every inch and a half, starting at the elbow and moving toward the shoulder and toward the wrist.

Numbers of participants assessed:

• Intervention: baseline, 35; at 6 months, 28
• Control: baseline, 25; at 6 months, 23

Adverse events: The intervention group did not show a significantly larger number of increases in arm
circumference compared with the standard care group.

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: yes

Funding: grants R21 CA89519 and R25 CA57730 from the National Cancer Institute

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

“Participants were assigned to study arms using a form of adaptive random-
ization called minimization”.

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Unclear risk

Whether the allocation was concealed is unclear.

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Low risk

Staff conducting assessments were blind to participants’ study condition.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

64

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Basen-Enquist 2006  (Continued)

Incomplete outcome data
(attrition bias) 
All outcomes

Low risk

Cochrane Database of Systematic Reviews

All participants who were randomised were included in the analysis, regard-
less of their attendance at intervention sessions. Data for participants who
did not complete the 6-month assessment were imputed based on regression
models predicting outcomes in the remaining sample, using covariates and
design variables.

Selective reporting (re-
porting bias)

Unclear risk

No selective reporting of outcomes is apparent.

Other bias

High risk

Imbalance between numbers allocated to intervention and control groups
could potentially lead to additional bias.

Blank 2005 

Methods

Study design: single-centre RCT

Number randomised: 18; 9 to intervention, 9 to control

Study start, not reported; stop date, not reported

Length of intervention: 8 weeks

Length of follow-up: to end of intervention

Country: USA

Participants

Age:

• Ages 48 to 69 years

Stage:

• Stage I-III breast cancer

Inclusion criteria:

• Minimum of 8 weeks post chemotherapy

• Oestrogen receptor positive status

• Surgery for lumpectomy, modified mastectomy, or full mastectomy (with/without reconstruction)

• Life expectancy greater than 6 months

• Adequate blood cell counts and kidney, liver, and cardiac function

• Physical and mental ability to attend all yoga training sessions

Exclusion criteria:

• Receiving Herceptin therapy, current steroid therapy, or other known immunomodulating medica-
tions

• Pregnancy or current lactation

• Past or current history of another neoplasm, active serious infection, or immune deficiency
• Documented alcohol or drug abuse

• History of psychiatric disorders requiring use of psychotropic medications

Interventions

9 participants assigned to exercise intervention:

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

65

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Blank 2005  (Continued)

Cochrane Database of Systematic Reviews

• Beginning level Iyengar yoga class 3 times per week (2 supervised and 1 home-based). Attention to
alignment and symmetry, use of props, and careful sequencing all improve stamina, strength, flexi-
bility, and confidence, while decreasing stress and side effects.

Adherence: not reported

9 participants assigned to control:

• Wait-list control

Outcomes

Outcomes:

• 31-Question self-report survey about reasons for participation, feelings of stress, level of physical and
mental effort during class sessions, and perceptions about how yoga practice influenced awareness

Numbers of participants assessed:

• Intervention: at 6 weeks, 9
• Control: at 6 weeks, 9

Adverse events: not reported

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: unclear

Funding: not reported

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

"Women were randomized", but it was unclear how the allocation sequence
was generated.

Allocation concealment
(selection bias)

Unclear risk

Whether treatment assignment was concealed from study personnel and par-
ticipants was not described.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Unclear risk

Blinding of outcome assessments was not described.

Unclear risk

It is unclear how many participants were included in each outcome assess-
ment.

Selective reporting (re-
porting bias)

High risk

Outcome measures were poorly described and reported. Scores for each ques-
tion were not reported.

Other bias

High risk

Outcomes were not assessed at baseline, so it was not possible to assess
whether outcomes changed as a result of intervention.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

66

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Bower 2011 

Methods

Study design: single-centre RCT
Number randomised: 31; 16 to intervention, 15 to control
Study start: March 2007; stop date: July 2010
Length of intervention: 12 weeks
Length of follow-up: to end of intervention, at 3 months post intervention

Country: USA

Participants

Age, years (mean SD):

• Intervention: 54.4 (5.7)
• Control: 53.3 (4.9)

Stage, n (%):

• Stage 0-II

Inclusion criteria:

• Original diagnosis of stage 0-II breast cancer

• Completed local and/or adjuvant cancer therapy (with the exception of hormone therapy) at least 6
months previously

• Ages 40 to 65 years

• Postmenopausal

• No other cancer in the past 5 years

• Experiencing persistent cancer-related fatigue

Exclusion criteria:

• Chronic medical conditions or regular use of medications associated with fatigue (e.g. untreated hy-
pothyroidism, diabetes, autoimmune disease, anaemia (defined as haematocrit < 24), chronic fatigue
syndrome)

• Evidence that fatigue was driven primarily by a medical or psychiatric disorder other than cancer (e.g.
current major depression, insomnia, sleep apnoea)

• Evidence that fatigue was driven primarily by other non-cancer-related factors (e.g. shift work, recent
change in activity or schedule)
• Physical problems or conditions that could make yoga unsafe (e.g. serious neck injury, unstable
joints)

• Body mass index (BMI) > 31 kg/m2

Interventions

16 participants assigned to exercise intervention:
• Iyengar yoga, a traditional form of Hatha yoga, performed in groups of 4 to 6 women for 90 minutes
twice a week for 12 weeks

Adherence:

Over 80% of participants attending at least 20 of the 24 yoga classes offered. Mean number of classes
attended was 18.9 of 24 classes (78%), and median number was 22 of 24 classes (92%). At 3-month fol-
low-up, 9 of 14 women who attended the yoga classes (64%) were continuing to use techniques learned
in class.

Control group: 15 assigned to control:
• Health education classes conducted for 120 minutes once a week for 12 weeks (24 hours) in groups of
4 to 7 women. Classes were led by a PhD-level psychologist with clinical experience.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

67

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bower 2011  (Continued)

Adherence:

Cochrane Database of Systematic Reviews

In the education group, the mean number of classes attended was 9.2 of 12 classes (77%), and the me-
dian number was 11 of 12 classes (92%).

Outcomes

Primary outcome:

• Subjective fatigue severity assessed with the Fatigue Symptom Inventory (FSI)

Secondary outcomes:

• Vigour assessed by the vigour subscale of the Multi-dimensional Fatigue Symptom Inventory (MFSI)
• Depressive symptoms assessed via the Beck Depression Inventory-II (BDI-II)
• Subjective sleep quality assessed by the Pittsburgh Sleep Quality Index (PSQI)
• Feelings of stress assessed on the Perceived Stress Scale
• Timed chair-stands used to assess lower extremity strength and endurance
• Functional reach test used to assess strength, flexibility, and balance
• Self-efficacy for managing fatigue assessed via the fatigue subscale of the Human Immunodeficiency

Virus Self-Efficacy Questionnaire adapted for breast cancer

• Fatigue interference with activities, mood, and enjoyment of life assessed with the interference sub-

scale of the FSI

Numbers of participants assessed:

• Intervention: n = 16 at baseline, n = 14 post intervention, n = 13 months after intervention
• Control: n = 15 at baseline, n = 13 post intervention, n = 13 months after intervention

.Adverse events: none reported

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: yes

Funding: National Center for Complementary and Alternative Medicine/National Institutes of Health
(NCCAM/NIH U01-AT003682; Iyengar Yoga for Breast Cancer Survivors with Persistent Fatigue)

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

"Allocation sequence was generated independently by the study statistician",
but it is unclear how the allocation sequence was generated.

Allocation concealment
(selection bias)

Unclear risk

"Allocation was concealed in opaque envelopes" but whether "sequential" is
not mentioned.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

High risk

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Low risk

Incomplete outcome data
(attrition bias) 
All outcomes

Low risk

Owing to the nature of the intervention, it was not possible to blind partici-
pants; however, it is unclear whether the outcome was influenced by lack of
masking.

"Outcomes assessors for the performance tasks were blinded to group assign-
ment, and all were trained in standardized testing procedures".

"All statistical analyses were performed on an intent-to-treat basis". Mixed
model analysis was used to account for missing data.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

68

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Bower 2011  (Continued)

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Cadmus 2009 

Methods

Study design: single-centre RCT

Number randomised for 6-month study: 75; to intervention; 37, to control, 38

Number randomised for 12-month study: 50; to intervention, 25; to control, 25

Study start: March 2004; stop date: July 2006

Length of intervention: 6 months; subsample study: 12 months

Length of follow-up: to end of intervention

Country: USA

Participants

Age, years (mean SD):

• Intervention: 56.5 (9.5)
• Control: 55.1 (7.7)

Stage, n (%):

• Intervention: in situ, 4 (11); stage I, 20 (54); stage II, 10 (27), stage IIIA, 3 (8)
• Control: in situ, 4 (11); stage I, 10 (27); stage II, 18 (46), stage IIIA, 6 (16)

Inclusion criteria:

• Postmenopausal women

• Ages 40 to 75 years

• Stage 0-IIIA breast cancer

• 1 to 10 years post diagnosis

• ≥ 12 months post completion of adjuvant treatment

• Physically able to exercise and physician consent to begin an exercise programme

• Sedentary activity pattern (< 60 minutes/week)

Exclusion criteria:

• Diagnosis of recurrent or other primary cancer event

• Current smoker

• Diabetes mellitus

• Current or planned enrolment in a structured weight loss programme

Interventions

37 participants assigned to exercise intervention:

• Exercise intervention consisted of a combined supervised training programme at a local health club
and a home aerobic training programme. Participants exercised at the health club during designated

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

69

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cadmus 2009  (Continued)

Cochrane Database of Systematic Reviews

sessions 3 times per week and were instructed to exercise 2 days/week on their own, either at the
health club or at home.

• Intervention consisted primarily of walking, although participants could choose to meet the exercise
goal through other forms of aerobic activity. Participants were asked to perform three 15-minute ses-
sions during week 1, building to five 30-minute moderate-intensity sessions by week 5. Exercise start-
ed at 50% of predicted maximal heart rate (220-age) and was gradually increased to approximately
60% to 80% of predicted maximal heart rate.

Adherence:

• Exercise group participants averaged 123 minutes/week (SD 52) of moderate-to-vigorous-intensity

sports/recreational activity (range 0 to 637)

• 34% of exercisers met the study goal of 150 minutes/week
• 56% completed at least 120 minutes/week (80% of the study goal)
• 67% attended supervised exercise sessions
• 96% reported exercising at least twice per week at home

38 participants assigned to control:

• Control groups were told that they could exercise on their own if they chose, but that the study’s physi-
cal activity programme would not be available to them. They received all exercise programme materi-
als at 6-month follow-up. Participants in both groups were also asked not to make significant changes
in their dietary habits.

Outcomes

Outcomes:

• Happiness assessed by the 2-item Fordyce Happiness Measure
• Self-esteem assessed on the Rosenberg Self-Esteem (RSE) Scale
• Depression assessed via the Centers for Epidemiological Studies—Depression Scale (CES-D)
• Anxiety assessed by the State-Trait Anxiety Index (STAI)
• Stress assessed on Cohen’s 10-Item Perceived Stress Scale
• Quality of life (QoL) assessed by FACT-B and Medical Outcomes 36-Item Short Form Health Survey

(MOS SF-36)

• Physical activity assessed via a 7-day physical activity log (PAL) and daily steps recorded on a 7-day

pedometer log

• Anthropometric measurements including body weight, body mass index (BMI), total percent body fat,

and lean mass obtained with whole-body dual-energy X-ray absorptiometry (DEXA)

• Bone mineral density and bone mineral content via DEXA
• Waist and hip circumferences
• Insulin and plasma concentrations of total insulin-like growth factor-1 (IGF-1) and insulin-like growth
factor binding protein-3 (IGFBP-3) measured in serum with an enzyme-linked immunosorbent assay
(ELISA) kit

• Systolic and diastolic blood pressure (available for 65 participants)
• Metabolic variable assays, fasting high-density lipoprotein (HDL-C), triglycerides, blood glucose (all
enzymatically measured via Alfa Wassermann ACE Alera Chemistry Analyzer with reagents supplied
by the company), and metabolic syndrome z-score (all outcomes available for 65 participants)

Numbers of participants assessed:

• Intervention: baseline, 37 (35 for metabolic variable assays); at 6 months, 37 (35 for metabolic variable

assays)

• Control: baseline, 38 (30 for metabolic variable assays); at 6 months, 37 (30 for metabolic variable

assays)

Adverse events: none reported

Notes

Trial registration link: none available

Trial authors contacted: no

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

70

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Cadmus 2009  (Continued)

Intention-to-treat analysis: yes but last observation carried forward (LOCF)

Funding: Lance Armstrong Foundation, American Cancer Society, Susan G. Komen. In part by the Na-
tional Center of Research Resources (NIH)

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Random number generator was used.

Allocation concealment
(selection bias)

Low risk

“The randomization code for each participant was obtained by the principal
investigator (who was not involved in recruitment or data collection) only after
baseline measures for that individual had been completed and staff conduct-
ing clinic visits did not have access to the randomization program”.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Low risk

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

Study personnel and outcome assessors were not masked or blinded to study
interventions.

Last observation carried forward (LOCF) approach was used; “baseline QoL
values were carried forward”.

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Cantarero-Villanueva 2013 

Methods

Study design: single-centre RCT

Numbers allocated, 68; 34 to exercise intervention; 34 to usual care

Study start: March 2009; stop date: June 2010

Length of intervention: 8 weeks

Length of follow-up: at 6 months after discharge

Country: Spain

Participants

Age, years (mean SD):

• Intervention: 48.4 (10.8)
• Control: 46.2 (7.4)

Stage, n (%):

• Intervention: stage I, 4 (12.4); stage II, 23 (72.0); stage IIIA, 5 (15.5)
• Control: stage I, 10 (34.4); stage II, 14 (48.3); stage IIIA, 5 (17.3)

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

71

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cantarero-Villanueva 2013  (Continued)

Inclusion criteria:

Cochrane Database of Systematic Reviews

• Between 25 and 65 years old with a diagnosis of breast cancer (stage I-IIIA)

• Finished oncology treatment except hormone therapy in the previous 18 months

• Exhibit clinically significant fatigue (> 3 in total score on the Piper Fatigue Scale)

Exclusion criteria:

• Receiving oncology treatment at the time of the study

• Physical limitations associated with orthopaedic conditions

Interventions

34 participants assigned to exercise intervention:

• 8-Week water-based intervention was carried out 3 times per week for a duration of 60 minutes (10
minutes of warm-up, 40 minutes of aerobic and endurance exercises, and 10 minutes of cool-down
exercises) in an indoor heated swimming pool sized 25 × 12.5 m, with 140 to 200 cm water depth, 28°C
of water temperature, and 30°C of room temperature.

• Aerobic exercises consisted of different horizontal movements: forward and backward jogging with
arms  moving,  pulling,  and  pressing;  leaps,  leg  cross-overs,  and  hopping  movements  focussing  on
movement in multiple directions. Endurance exercises were considered moderate as the parameters
set for each exercise included 2 to 3 sets of 8 to 12 repetitions.

Adherence:

• 34 participants finished the aquatic exercise programme and completed 84% of the 24 physical ther-

apy sessions (mean ± SD, 20 ± 4 sessions).

34 participants assigned to control:

• Participants allocated to the usual care group followed oncologist recommendations for maintaining
a healthy lifestyle based on adequate nutrition, energy balance, and maintaining usual activities.

Outcomes

Primary outcomes:

• Piper Fatigue Scale (PFS) score

Secondary outcomes:

• Mood state assessed via the Spanish version of the Profile of Mood States (POMS) containing 63 ad-

jectives rated by participants on a 5-point scale

• Lower body muscular strength assessed via the “multiple sit-to-stand test” involves counting the time
in seconds needed by participants to rise until they reach full knee extension and sit back, 10 times,
as fast as possible

• Muscular endurance of abdominal muscles tested via the trunk curl static endurance test

Numbers of participants assessed:

• Intervention: baseline, 34; at 8 weeks, 34; at 6 months, 32
• Control: baseline, 34; at 8 weeks, not stated; at 6 months, 29

Adverse events: Adverse effects reported during the study included discomfort or low-intensity pain/
stiffness after an exercise session in 3 participants; nevertheless, they continued the programme.

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: no

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

72

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cantarero-Villanueva 2013  (Continued)

Cochrane Database of Systematic Reviews

Funding: Health Institute Carlos III and PN I+D+I 2008-2011, Madrid, Spanish government (grant no. FIS
PI10/02749); Research Office of the University of Granada, Spain

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Computer-generated numbers produced a sequence that was entered into
opaque envelopes.

Allocation concealment
(selection bias)

Low risk

“Computer-generated number sequence was entered into opaque envelopes.
These envelopes were opened by a blinded researcher after the first outcome
measurement”.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Low risk

Assessors were blinded to treatment allocation.

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

Only those who completed postintervention and 6-month assessments were
included in analysis.

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Carson 2009 

Methods

Study design: single-centre RCT

Number randomised: 37; 17 to intervention, 20 to control

Study start: June 2005; stop date: October 2006

Length of intervention: 8 weeks

Length of follow-up: at 8 weeks, at 3 months

Country: USA

Participants

Age, years (mean SD):

• Intervention: 53.9 (9.0)
• Control: 54.9 (6.2)

Stage, n (%):

• Intervention: stage IA, 7 (41.2); stage IIA, 5 (29.4); stage IIB, 5 (29.4)
• Control: stage IA, 8 (40.0); stage IIA, 6 (30.0); stage IIB, 6 (30.0)

Inclusion criteria:

• At least 1 hot flash per day on 4 or more days per week

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

73

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Carson 2009  (Continued)

• No signs of active breast cancer

• No current cytotoxic chemotherapy

• Diagnosis of breast cancer at stage IA-IIB ≥ 2 years before

• No hormone replacement therapy currently or within prior 3 months

• Stabilised on a constant regimen of menopausal symptom medications and supplements for at least 3
weeks

• Taking antidepressants, stabilised at a fixed dose for at least 3 months

Exclusion criteria:

• Resided > 70 miles from the research site and thus were less likely to attend intervention sessions

• Unavailable to attend the intervention on the day and at the time offered (most yoga groups were
scheduled so as to be accessible to women holding full-time day jobs)

• Currently engaged in intensive yoga practice (> 3 days/week)

• Received treatment for serious psychiatric disorders (e.g. schizophrenia) in the previous 6 months

• Not English speaking

Interventions

17 participants assigned to exercise intervention:

• Yoga of Awareness including yoga postures, breathing techniques, meditation, study of pertinent top-
ics, group discussion. Once per week (participants were encouraged to spend time practicing yoga
strategies daily at home, but actual adherence to this was not reported) for a duration of 40 minutes
over 8 weeks

Adherence:

On average, participants attended 6 of the 8 classes (range 0 to 8). Only 3 women attended < 4 classes.
Adherence to daily yoga practice, average 30 minutes/d at post and 16 minutes at 3 months

Control group: 20 assigned to control:

• Wait-list

Outcomes

Treatment outcomes. assessed via a brief daily diary measurement strategy

• Daily menopausal symptoms on 0 to 9 scales in which higher scores reflected greater amounts, com-
mon menopausal symptoms across the preceding 24 hours: hot flash frequency, hot flash severity,
joint pain, fatigue, negative mood, sleep disturbance, night sweats, and bother (menopausal symp-
tom-related distress). Primary outcome of hot flash total scores was computed as frequency × severity.
• With 0 to 9 scales in which higher scores reflected greater amounts, 3 therapeutic processes targeted
by the Yoga of Awareness programme—relaxation, vigour, and acceptance—were assessed by tele-
phone voice system diaries.

• Minutes spent in daily yoga practice (post and follow-up assessments only)

Numbers of participants assessed:

• Intervention: n = 17 at baseline, n = 13 at 8 weeks, n = 13 at 3 months
• Control: n = 20 at baseline, n = 17 at 8 weeks, n = 17 at 3 months

Adverse events: not reported

Notes

Trial registration link: none available

Trial authors contacted: yes, for means and SDs for outcomes. However, trial authors did not provide
these data.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

74

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Carson 2009  (Continued)

Risk of bias

Bias

Intention-to-treat analysis: no

Funding: Susan G. Komen Breast Cancer Foundation

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Random number table was used.

Allocation concealment
(selection bias)

High risk

"Concealed in envelopes"; sequential sequencing or opaque envelopes were
not mentioned.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

High risk

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Low risk

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to blind partici-
pants; however, it is unclear whether the outcome was influenced by lack of
masking.

Research assistant collecting assessment data was kept blind with regard to
participant condition assignments.

No ITT, and no mention of how missing data were handled. 8 participants did
not complete the intervention.

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Cerulli 2014 

Methods

Study design: single-centre RCT
Number randomised: 20; 10 to exercise, 10 to control
Study start and stop dates: not reported
Length of intervention: 16 weeks
Length of follow-up: to end of intervention

Country: Italy

Participants

Age, years (mean SD):

• Intervention: 45.3 (4.3)
• Control: 46.0 (2.8)

Stage, n (%):

• Intervention: stage I, 3 (30); stage II, 5 (50); stage III, 2 (20)
• Control: stage I, 1 (10); stage II, 5 (50); stage III, 4 (40)

Inclusion criteria:

• Age 40 to 50 years

• Conclusion of all cancer-related treatments at least 6 months previously

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

75

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cerulli 2014  (Continued)

• Mastectomy

Cochrane Database of Systematic Reviews

• No external physical activity for at least the preceding 12 months

• Medical eligibility for non-competitive athletic activity

Interventions

10 participants assigned to exercise intervention:

• All intervention group participants received two 1-hour therapeutic horse-riding treatments at an in-
tensity of 65% to 70% of HR maximum (220-age) per week, for 16 weeks. Each riding session consisted
of 3 phases: (1) warm-up, horse-caring, and grooming; (2) riding; and (3) unsaddling and grooming
activities.

Adherence: not reported

10 assigned to control:

• Participants randomly assigned to control group were instructed not to begin any new formal physical

exercise programme

Outcomes

Outcomes:

• Maximal oxygen consumption (VO2max) obtained via the Astrand–Rhyming cycle ergometer test
• Maximal strength of principal muscle groups assessed by an inertial measurement system (Free-Pow-
er; Sensorize, Rome, Italy). Maximal strength evaluated for each of 5 weight lifting machines (Techn-
ogym SpA, Cesena, Italy): leg press, leg extension, leg curl, shoulder press, and vertical traction. Par-
ticipants were asked to perform at least 2 repetitions at 30%, 50%, and 70% of presumed 1RM.

• Body composition (fat mass % and total body water %) assessed via a portable multi-frequency digital

bioelectrical impedance device (Handy 3000; DS Medica, Milano, Italy)

• Quality of life assessed via FACT-G
• Fatigue assessed by FACT-F

Numbers of participants assessed:

• Intervention: baseline, 10; at 16 weeks, 10
• Control: baseline, 10; at 16 weeks, 10

Adverse events: none reported

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: no dropouts reported

Funding: not reported

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

"Patients were randomly divided into two groups". It is unclear how the alloca-
tion sequence was generated.

Allocation concealment
(selection bias)

Unclear risk

Whether treatment assignment was concealed from study personnel and par-
ticipants was not described.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to blind partici-
pants.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

76

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Cerulli 2014  (Continued)

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

Whether study personnel and outcome assessors were masked or blinded to
study interventions was not reported.

Low risk

No dropouts were reported.

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Cormie 2014 

Methods

Study design: RCT

Number randomised: 62; 22 to high-load resistance exercise, 21 to low-load resistance exercise, 19 to
control

Study start: June 2010; stop date: not stated

Length of intervention: 3 months

Length of follow-up: to end of intervention

Country: Australia

Participants

Age, years (mean SD):

• High-load resistance exercise (HLRE): 56.1 (8.1)
• Low-load resistance exercise (LLRE): 57.0 (10.0)
• Control: 58.6 (6.7)

Stage, n (%):

• HLRE: stage I, 2 (9.1); stage II, 18 (81.8); stage III, 2 (9.1)
• LLRE: stage I, 5 (23.8); stage II, 10 (47.6); stage III, 6 (28.6)
• Control: stage I, 6 (31.6); stage II, 9 (47.3); stage III, 4 (21.1)

Time since cancer diagnosis, mean (SD) years:

• HLRE: 5.9 (6.1)
• LLRE: 6.1 (5.2)
• Control: 9.5 (9.8)

Inclusion criteria:

• Histological diagnosis of breast cancer at least 1 year before the study

• Clinical diagnosis of breast cancer-related lymphoedema and medical clearance from general practi-
tioner

• Clinical diagnosis of lymphoedema defined as having at least a 5% inter-limb discrepancy in volume
or circumference at the point of greatest visible difference

Exclusion criteria:

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

77

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cormie 2014  (Continued)

Cochrane Database of Systematic Reviews

• Unstable lymphoedema defined as receiving intensive therapy (i.e. decongestive therapy or antibi-
otics for infection) within the previous 3 months

• Musculoskeletal, cardiovascular, and/or neurological disorder that could inhibit exercise

Interventions

43 participants assigned to 1 of 2 resistance exercise interventions

• Two 60-minute exercise sessions were performed per week for 3 months. Intensity varied across con-
ditions (moderate-high (12 to 16 RPE); high-load, 75% to 85% of 1RM using 10-6 RM, 1 to 4 sets per
exercise; low-load, 55% to 65% of 1RM using 20-15 RM, 1 to 4 sets per exercise)

• Exercise sessions were conducted in groups of up to 8 to 10 participants. The resistance exercise regi-
men included 6 exercises that targeted major upper body muscle groups including chest, back, shoul-
ders, upper arms, and forearms (chest press, seated row/lat pulldown, shoulder press/lateral raise,
biceps curl, triceps extension, and wrist curl). Additionally, 2 exercises targeting major muscle groups
of the lower body were performed (leg press/leg extension, squat/lunge).

Adherence:

Exercise attendance was high for both resistance training groups, with an average of 23.2 ± 1.9 out of a
possible 24 sessions attended (HLRE 23.4 ± 1.1; LLRE 22.9 ± 2.4).

19 participants assigned to control:

• Participants randomised to the control group were offered the exercise programme after completion
of the intervention period. All participants were instructed to maintain their usual lymphoedema self-
care management regimen, physical activity levels, and diet throughout the intervention period.

Outcomes

Primary outcome:

• Severity of swelling associated with breast cancer-related lymphoedema assessed via standard ob-

jective measures:
◦ Bioimpedance spectroscopy (BIS) impedance ratio
◦ DEXA
◦ Arm circumference measurements

Secondary outcomes:

• Severity of symptoms assessed via:

◦ Disability of the Arm, Shoulder, and Hand questionnaire (DASH)
◦ Brief pain inventory questionnaire (BPI)
◦ Arm  morbidity  subscale  of  the  Functional  Assessment  of  Chronic  Illness  Therapy  breast  cancer

questionnaire for patients with lymphoedema (FACT-B+4)

◦ Arm  symptoms  subscale  of  the  European  Organization  for  Research  and  Treatment  of  Cancer

breast cancer module (QLQ-BR23)

• Maximal grip strength tested with an isometric hand dynamometer (Model 78011; Lafayette Instru-
ments, Lafayette, IN, USA). Affected and non-affected limbs were assessed individually, and the best
of 3 trials was reported.

• Maximal strength of major muscle groups assessed by the 1RM method in chest press, seated row, and

leg press exercises

• Muscle endurance assessed by a repetition maximum test, which involved participants performing
the maximal number of repetitions possible with 70% of current 1RM in the chest press, seated row,
and leg press

• Range of motion about the wrist, elbow, and shoulder assessed by standard goniometric techniques
• Health-related QoL assessed with MOS SF-36

Numbers of participants assessed:

• HLRE: baseline, 22; at 3 months, 22
• LLRE: baseline, 21; at 3 months, 21
• Control: baseline, 19; at 3 months, 19

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

78

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Cormie 2014  (Continued)

Adverse events: No lymphoedema exacerbations or any other adverse events were reported.

Notes

Trial registration link: ACTRN12610000788077 (http://www.anzctr.org.au/ACTRN12610000788077.aspx)

Trial authors contacted: no

Intention-to-treat analysis: yes, but using LOCF

Funding: Edith Cowan University and University of Canberra

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Participants were randomised in an allocation ratio of 1:1:1 by a random as-
signment computer programme.

Allocation concealment
(selection bias)

Low risk

Exercise physiologists involved in assigning participants to groups were blind-
ed to the allocation sequence.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Unclear risk

Blinding of outcome assessments was not described.

High risk

Missing data were addressed by imputing change across time as zero.

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Courneya 2003 

Methods

Study design: single-centre RCT

Number randomised: 53; intervention, 25; control, 28

Study start: May 2001; stop date: June 2001

Length of intervention: 15 weeks

Length of follow-up: to end of intervention

Country: Canada

Participants

Age, years (mean SD):

• Intervention: 59 (5)
• Control: 58 (6)

Stage, n (%):

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

79

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Courneya 2003  (Continued)

Cochrane Database of Systematic Reviews

• Intervention: stage I, 10 (42); stage IIA, 6 (25); stage IIB, 6 (25); stage IIIA, 2 (8)
• Control: stage I, 11 (39); stage II A, 11 (39); stage IIB, 5 (18); stage IIIA, 1 (4)

Inclusion criteria:

• Histologically confirmed stage I-IIIB breast cancer

• Diagnosis between January 1999 and June 2000

• Completed surgery, radiotherapy, and/or chemotherapy (≥ 6 months before randomisation) with or
without current tamoxifen or arimidex therapy

• Postmenopausal (not experiencing menstrual periods for previous 12 months)

• Non-smokers (not smoking for previous 12 months)

• Between 50 and 69 years of age

• English-speaking

• Willing to travel to the exercise facility

Exclusion criteria:

• Known cardiac disease

• Uncontrolled hypertension

• Uncontrolled thyroid disease

• Diabetes

• Mental illness

• Infection

• Immune or endocrine abnormality

• Body weight reduction ≥ 10% in the past 6 months

• Positive exercise stress test

Interventions

25 participants assigned to exercise intervention:

• Participants trained 3 times per week for 15 weeks on recumbent or upright cycle ergometers. Exer-
cise intensity was set at the power output that elicited the ventilatory equivalent for carbon dioxide
to ensure optimal training adaptations. This training intensity corresponds to approximately 70% to
75% of VO2max in untrained participants. Exercise duration began at 15 minutes for weeks 1 through
3, then systematically increased by 5 minutes every 3 weeks thereafter to 35 minutes for weeks 13
through 15.

Adherence:

Exercise group completed 98.4% (44.3 of 45) of prescribed exercise sessions.

28 participants assigned to control:

• Control group did not train and were asked not to begin a structured exercise programme. To reduce

attrition, control group was offered the intervention after the trial ended.

Outcomes

Primary outcomes:

• VO2peak
• Overall QoL assessed by FACT-B scale and FACT-General (FACT-G) scale
• Natural killer (NK) cell cytotoxic activity in isolated peripheral blood mononuclear cells

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

80

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Courneya 2003  (Continued)

• C-reactive protein (CRP) assessed in serum by enzyme-linked immunosorbent assay kit

Other outcomes:

• Peak power output, oxygen consumption, and power output at the ventilatory equivalent for oxygen,

and oxygen consumption and power output at the ventilatory equivalent for carbon dioxide

• QoL outcomes such as happiness assessed by the Happiness Measure, self-esteem assessed on the

RSE scale, and fatigue assessed via FACT-F

• Body composition outcomes were body weight, BMI, and sum of skinfolds (biceps, triceps, subscapu-

lar, suprailiac, and medial calf)

• Exercise outside of the exercise intervention monitored via the Leisure Score Index (LSI) of the Godin

Leisure-Time Exercise Questionnaire

• Fasting insulin, glucose, insulin resistance, IGF-I, IGF-II, IGFBP-1, IGFBP-3, and IGF-I:IGFBP-3 molar ra-

tio

• Whole blood neutrophil function, phenotypes of isolated mononuclear cells, estimations of unstim-
ulated and phytohemagglutinin (PHA)-stimulated mononuclear cell function {rate of [3H] thymidine
uptake, production of proinflammatory [interleukin (IL)-1alpha, tumour necrosis factor, TNF-alpha,
IL-6] and anti-inflammatory cytokines (IL-4, IL-10, transforming growth factor-beta 1)}

• Blood  pressure  measurements  obtained  by  trained,  certified  individuals  who  used  a  random  zero

sphygmomanometer

• Total cholesterol, high-density lipoprotein cholesterol (HDL-C), triglycerides (TGs), and low-density
lipoprotein cholesterol (LDL-C) calculated via the Friedewald formula. TC:HDL-C ratio calculated as
total cholesterol divided by HDL-C

Numbers of participants assessed:

• Intervention: baseline, 25; at 15 weeks, 24
• Control: baseline, 28; at 15 weeks, 26

Adverse events:

• Intervention: lymphoedema (n = 3), gynaecological complication (n = 1), influenza (n = 1)
• Control: foot fracture (n = 1), bronchitis (n = 1)

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: no

Funding: NCIC, CCS, Canadian Institutes of Health Research, Izaak Walton Killiam Memorial Scholar-
ship, Alberta Heritage Foundation for Medical Research studentship

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Low risk

Random numbers table. Block permutation procedure was used.

Allocation concealment
(selection bias)

Low risk

“The allocation sequence and group assignments were generated by a re-
search assistant and then enclosed in sequentially numbered and sealed en-
velopes”.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

81

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Courneya 2003  (Continued)

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Unclear risk

Cochrane Database of Systematic Reviews

Participants were not blinded for self-report measures. Participants were
blinded to their exercise test results until after the trial. Exercise physiologists
were blinded for physical outcome measures. Laboratory staff and those who
assessed study endpoints were blinded to treatment assignment.

Incomplete outcome data
(attrition bias) 
All outcomes

Low risk

One study participant withdrew from the intervention group. Two participants
withdrew from the control group and were not included in cardiopulmonary
outcome analyses. Only 1 participant who had withdrawn from the exercise
group was missing from QoL analyses.

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Cuesta-Vargas 2014 

Methods

Study design: single-centre quasi-RCT

Number randomised: 42; 22 to intervention, 20 to control

Study start: September 2010; stop date: July 2012

Length of intervention: 8 weeks

Length of follow-up: to end of intervention

Country: Spain

Participants

Age, years (mean SD):

• Intervention: 47.3 (6.6)
• Control: 48.7 (9.7)

Stage, n (%):

• Not reported

Inclusion criteria:

• History of primary breast cancer

• Within 1 year of cancer diagnosis

• Aged 25 to 65 years

• Post cancer treatment in the past 6 months (eligible if receiving hormone therapy)

• Cancer-free at the time of study enrolment

Exclusion criteria:

• Fear of aquatic exercise that would prevent participation in deep water running programme

Interventions

22 participants assigned to 8-week exercise intervention:

• Land-based exercise and deep water running (DWR) combined with education based on cognitive-be-

havioural principles

• Each  session  was  performed  in  groups  of  8  to  10  participants  and  comprised  30  minutes  of  land-
based exercise followed by 20 minutes of DWR, with an additional 10 minutes of warm-up and cool-

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

82

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cuesta-Vargas 2014  (Continued)

Cochrane Database of Systematic Reviews

down time. Land-based exercise included 15 minutes of full-body mobility and 15 minutes of general
strengthening exercises. Deep water running (cross-country style) simulates running by using a flota-
tion device in water levels over head height.

• From weeks 1 to 4, DWR workload corresponded to heart rate at 2 mmol of lactic acid. For weeks 5 to

8, workload was set at 3 mmol of lactic acid, based on pretest lactic acid values.

Adherence:

42 participants attended more than 80% of the 24 treatment sessions. Although 2 intervention partic-
ipants reported ‘wake up tired in the morning’ after 1 session, this event did not impact programme
completion and was not repeated.

22 participants assigned to control:

• Wait-list control group

Outcomes

Primary outcome:

• Fatigue assessed by the PFS-R

Other outcomes:

• Physical and mental general health via MOS SF-12
• QoL via European Quality of Life 5 dimensions (EuroQoL-5D) and European Visual Analogue Scale (Eu-

roQoL-VAS)

Numbers of participants assessed:

• Intervention: baseline, 22; post intervention, 22
• Control: baseline, 20; post intervention, 20

Adverse events: No further adverse events were associated with participation in the intervention.

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: No missing data were reported.

Funding: not reported

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 

Authors' judgement

Support for judgement

High risk

Participants were allocated in order of arrival to complete each group.

High risk

Allocation was not concealed from researchers.

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Low risk

“Assessor, who was blinded to participant group allocation”

Low risk

No missing data were reported.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

83

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Cuesta-Vargas 2014  (Continued)

All outcomes

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Daley 2007 

Methods

Study design: single-centre RCT

Number randomised: 108; 34 to exercise therapy, 36 to exercise placebo, 38 to control

Study start: January 2003; stop date: July 2005

Length of intervention: 8 weeks

Length of follow-up: at 24 weeks

Country: UK

Participants

Age, years (mean SD):

• Exercise therapy group: 51.6 (8.8)
• Exercise placebo group: 50.6 (8.7)
• Control: 51.1 (8.6)

Stage:

• Exercise therapy: not reported
• Exercise placebo: not reported
• Control: not reported

Inclusion criteria:

• Women who were not regularly active

• Treated for localised breast cancer 12 to 36 months

• Aged 18 to 65 years

• Willing to attend supervised exercise sessions 3 times per week for 8 weeks

• Exercise pre-contemplator, contemplator, or preparer as defined by the TTM

Exclusion criteria:

• Women with metastases

• Inoperable or active locoregional disease determined ineligible by clinician

• Physical or psychiatric impairment that would seriously influence physical mobility

• Nausea, anorexia, or other diseases affecting health

• High activity level

• Contraindication to exercise, assessed by Physical Activity Readiness

Interventions

34 participants assigned to 8-week exercise intervention:

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

84

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Daley 2007  (Continued)

Cochrane Database of Systematic Reviews

• Supervised one-to-one aerobic exercise performed 3 times per week for 50 minutes at moderate in-

tensity (65% to 85% of age-adjusted HR maximum and RPE of 12 to 13)

• In addition to exercise therapy, a variety of cognitive-behavioural techniques for promoting exercise

behaviour change were explored with participants during sessions.

36 participants assigned to exercise placebo:

• Exercise placebo group also attended 24 one-to-one 50-minute sessions during 8 weeks; performed
light-intensity body conditioning/stretching (e.g. flexibility, passive stretching) exercises during which
HR was maintained below 40% heart rate reserve (HR typically was kept below 100 beats per minute).
No exercise counselling or behavioural change advice was provided; instead, conversations were cen-
tred on topics of everyday life (i.e. weather, news items, and families). Participants assigned to exer-
cise placebo were otherwise asked to continue with their lifestyle as normal.

Adherence:

Attended at least 70% (at least 17 of 24 sessions) of sessions; exercise therapy group, 77%; exercise
placebo group, 88.9%

38 participants assigned to control:

• No activity or education. Usual care group was asked to continue with their lives as usual.

Outcomes

Primary outcomes:

• FACT-G
• FACT-B

Secondary outcomes:

• Fatigue assessed with Revised PFS
• Satisfaction with life
• Depression assessed by BDI-II
• Physical Self-Perception Profile, including five 6-item subscales: perceived sports competence, attrac-
tiveness of body, physical conditioning competence, physical strength competence, and physical self-
worth

• Physical activity and exercise behaviour assessed by asking participants how often they had partic-
ipated in 1 or more physical activities for 20 to 30 minutes per session in the past 5 months and by
completing the stage of change for exercise ladder (SOC)

• Aerobic fitness assessed via submaximal 8-minute single-stage walking test performed on a treadmill
• Weight and BMI
• Body fat assessed by bioelectrical impedance analysis
• Muscle function assessed by a Bioidex isokinetic machine

Numbers of participants assessed:

• Intervention: baseline, 34; at week 8, 33; at week 24, 31
• Exercise placebo: baseline, 36; at week 8, 36; at week 24, 34
• Control: baseline, 38; at week 8, 33; at week 24, 31

Adverse events: not reported

Notes

Trial registration link: none available

Trial authors contacted: yes, trial authors provided additional outcome data

Intention-to-treat analysis: unclear

Funding: Cancer Research UK (grant number: CE8304)

Risk of bias

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

85

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Daley 2007  (Continued)

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Low risk

“performed using stratified random permuted blocks”

Low risk

Telephone randomisations service was provided by an independent trials unit.

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

High risk

“Outcome assessors were not blinded to participants’ group allocation”.

Unclear risk

“Data were analysed on an ITT basis”

It is unclear how this was done.

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

DeNysschen 2011 

Methods

Study design: single-centre RCT
Number randomised: 100; 36 to exercise begun during treatment (EE), 30 to exercise begun after treat-
ment (CE), 34 to control
Study start and stop dates: 1999 to 2006
Length of intervention: 4 to 6 months
Length of follow-up: at 1 year from baseline

Country: USA

Participants

Age, years (mean SD):

• Intervention (EE): 48.7 (8.4)
• Intervention (CE): 49.5 (9.5)
• Control: 51.6 (10.9)

Stage, n (%):

• Intervention (EE): stage I, 13 (39.4); stage II, 14 (42.4); stage III, 6 (48.2)
• Intervention (CE): stage I, 11 (39.3); stage II, 15 (53.6); stage III, 2 (7.1)
• Control: stage I, 14 (42.4); stage II, 13 (39.4); stage III, 6 (18.2)

Inclusion criteria:

• Women aged 18 years or older

• Confirmed diagnosis of breast cancer

• Beginning second cycle of chemotherapy

• Ability to read, write, and understand English

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

86

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

DeNysschen 2011  (Continued)

• Mentally able to understand and able to provide written informed consent

• Karnofsky Performance Scale (KPS) score > 60

Exclusion criteria:

• Receiving concurrent radiotherapy for another disease

• Had bone marrow transplantation

• Uncontrolled hypertension or diabetes mellitus

• Pain intensity rating ≥ 3 on a 0 to 10 numerical scale

• Lytic bone lesion or other orthopaedic limitations

• History of major depression or sleep disorders

• Chemotherapy in the past year

• Diagnosis of AIDS-related malignancies or leukaemia

• Absolute contradictions to exercise testing as established by American College of Sports Medicine
(1995)

Interventions

66 participants assigned to exercise intervention (36 to EE, 30 to CE):

• Individualised programme adjusted to participant’s fitness level and adjusted weekly to maintain the
exercise prescription. Programme consisted of cardiovascular/aerobic exercise of participants' choice
(e.g. walking, jogging, cycling) performed 3 to 5 times per week for 30 minutes at 2- to 14-point inten-
sity level (Borg scale, moderate exertion) over 4 to 6 months

30 participants assigned to control:

• Usual care; telephoned weekly by research nurse to enquire about their health

Adherence:

EE group reported adherence rate of 74% by end of intervention and 78% by end of follow-up; CE group
reported 86% adherence at end of intervention

Outcomes

No primary outcome stated:

• Physical activity questionnaire recorded self-reported exercise activities, frequency, intensity, and du-

ration

• Physical performance measured on Karnofsky Performance Status (KPS) scale
• Symptom checklist: list of 25 symptoms commonly experienced by individuals receiving chemother-
apy. Format is a Likert-type rating scale with descriptive anchors from 0 = none to 10 = terrible/awful

• Body composition via DEXA (fat mass, percent fat, lean body mass)
• Cardiorespiratory fitness assessed by maximal exercise testing

Outcomes measured:
• EE group: n = 36 at baseline, n = 36 at 4 to 6 months (end of intervention)
• CE group: n = 30 at baseline, n = 30 at 4 to 6 months (end of intervention)
• Control group: n = 34 at baseline, n = 34 at 4 to 6 months (end of intervention)

Adverse events: none reported

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: no missing data evident in this study

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

87

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

DeNysschen 2011  (Continued)

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Funding: National Cancer Institute; Clinical & Translational Science Institute, Clinical Research Center

Authors' judgement

Support for judgement

Unclear risk

Generation of random sequence was not described.

Allocation concealment
(selection bias)

Unclear risk

Whether treatment assignment was concealed from study personnel and par-
ticipants was not described.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Low risk

"Measurements of study variables were taken by research nurses who were
blinded to the participants' group assignment".

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Low risk

No missing data were reported.

High risk

Data on cardiorespiratory fitness and on physical activity were not reported.

Other bias

High risk

Control group and intervention groups were reported as having similar activity
levels as intervention groups post intervention, possible contamination. Low
adherence rate of 74% by end of intervention and 78% at end of follow-up in
the intervention group

Do 2015 

Methods

Study design: single-centre RCT

Number randomised: 212; 106 to early exercise group (EEG), 106 to delayed exercise group (DEG)

Study start: not reported; stop date, not reported

Length of intervention: 4 weeks.

Length of follow-up: at 6 to 8 weeks only in early exercise group

Country: South Korea

Participants

Baseline demographic and medical history variables for 32 in EEG and for 30 in DEG

Age, years (mean SD):

• EEG: 47.1 (8.5)
• DEG: 48.3 (8.2)

Stage, n (%):

• EEG: stage I, 3 (9.3); stage IIA, 13 (40.6); stage IIB, 12 (37.5); stage III, 4 (12.5)
• DEG: stage I, 2 (6.6); stage IIA, 15 (50.0); stage IIB, 10 (33.3); stage III, 3 (10.0)

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

88

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Do 2015  (Continued)

Inclusion criteria:

• Not reported

Exclusion criteria:

Cochrane Database of Systematic Reviews

• Evidence of recurrent disease or other musculoskeletal involvement such as low back pain, disc prob-
lems, osteoarthritis, rheumatoid arthritis, shoulder problems

Interventions

106 participants assigned to early exercise intervention:

• 40 minutes of aerobic exercise (40% to 75% of VO2max) and 20 minutes of resistance exercise (9 dif-
ferent exercises of 2 sets of 8 to 12 repetitions at 60% to 80% of 1 repetition maximum for exercises of
the extremities, or 5 to 10 repetitions for exercises of the axial muscles) 5 times a week over 4 weeks

Adherence: not reported

106 participants assigned to control:

• Delayed exercise group (DEG; n = 30) completed exercise programme from 4 to 8 weeks.

Outcomes

Outcomes:

• QoL evaluated based on European Organization for Research and Treatment of Cancer Core Quality

of Life Questionnaire (EORTC QLQ-C30) (version 3) and EORTC QLQ-BR23

• Cardiorespiratory function measured on the cycle test. Patients commenced cycling at 20 W and work-
load was increased by 25 W every minute. Test was completed when patients reached 85% of estimat-
ed maximal heart rate. Cardiorespiratory test score was assessed as power output that coincided with
85% maximal heart rate.

• Fatigue Severity Scale (FSS) consists of 9 questions responded to via a Likert scale ranging from 1 to
7, with lower scores meaning “disagreement” (greater disagreement with lower scores) and higher
scores meaning “agreement” in the same fashion.

• Maximal isometric strength was assessed in 4 muscle groups bilaterally with a hand-held digital dy-
namometer. Muscles assessed included elbow flexors, hip flexors, hip abductors, hip extensors, knee
extensors, and knee flexors. Muscular groups were tested in the middle of the joint range.

Numbers of participants assessed:

• EEG: baseline, 32; at 2 weeks, 32; at 4 weeks, 32; at 6 weeks, 32; at 8 weeks, 32
• DEG: baseline, 30; at 2 weeks, 30; at 4 weeks, 30; at 6 weeks, 30; at 8 weeks, 30

Adverse events: not reported

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: no

Funding: not reported

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Authors' judgement

Support for judgement

Low risk

"1:1 ratio using a computer-generated allocation sequence”

Unclear risk

Whether allocation was concealed was not reported.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

89

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Do 2015  (Continued)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Unclear risk

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

Not mentioned whether study personnel and outcome assessors were masked
or blinded to study interventions

Analysis performed only on “completers”; withdrawals not included in analy-
sis.

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

High risk

Dropout rate was high (71%).

Dolan 2016 

Methods

Study design: single-centre RCT

Number randomised: 36, 12 to aerobic interval training (AIT), 12 to continuous moderate training
(CMT), 12 to control

Study start: February 2013; stop date: December 2014

Length of intervention: 6 weeks

Length of follow-up: at 3 months for physical activity

Country: Canada

Participants

Age, years (mean SD):

• AIT: 56.2 (9)
• CMT: 56.3 (9)
• Control: 59.4 (9)

Stage, n (%):

• AIT: stage 0, 0 (0); stage I, 1 (3); stage II, 5 (15); stage III, 3 (9); other, 1 (3)
• CMT: stage 0, 1 (3); stage I, 2 (6); stage II, 2 (6); stage III, 5 (15); other, 1 (3)
• Control: stage 0, 1 (3); stage I, 4 (12); stage II, 2 (6); stage III, 3 (9); other, 0 (0)

Time since cancer diagnosis, mean years:

• AIT: 6
• CMT: 4
• Control: 7

Inclusion criteria:

• Completed different combinations of surgery, chemotherapy, radiation, and hormonal therapy for
early-stage breast cancer (stage I-IIIA)

• Postmenopausal status was a set condition to minimise possible confounding factors associated with
oestrogen status, treatment, and exercise response.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

90

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Dolan 2016  (Continued)

Exclusion criteria:

Cochrane Database of Systematic Reviews

• Received diagnosis of metastatic disease, uncontrolled hypertension, history of cardiac disease, or
pulmonary disease

• Did not receive approval from physician to participate

• Age > 75 years

• BMI> 40 kg/m2

• Could not commit to 18 exercise sessions in 6 weeks

• Any other contraindications to exercise

Interventions

23 participants assigned to 1 of 2 exercise interventions:

• AIT group was prescribed an interval programme that started with 2 weeks of introductory intervals
at a maximal intensity of 80% VO2peak, followed by progressively higher intensity interval bouts of 3
supervised sessions per week for 4 weeks, eventually requiring 2-minute efforts that would elicit close
to maximal effort.

• CMT was prescribed a continuous, moderate-intensity aerobic protocol. Depending on baseline fit-
ness  and  experience,  individuals  completed  3.22  km  (2  miles)  at  initial  intensity  of  55%  to  60%
VO2peak for 3 supervised sessions per week. By end of week 5, individuals progressed to 4.02 km (2.5
miles) at 70% VO2peak (6-week intervention).

• Exercise sessions were matched by ensuring a set distance was covered at each session, starting with

a minimum of 3.22 km and progressing to 4.02 km by week 5 (2 to 2.5 miles).

Adherence:

CMT group (n = 11) completed 17.8 sessions that took an average of 40 minutes to complete and cov-
ered a total distance of 65.34 km. AIT group (n = 12) completed 17.8 high-intensity interval sessions in
average time of 36 minutes and covered a total distance of 64.86 km. At 3 months, 92% of women in
the AIT group reported achieving or superseding the recommended weekly exercise dose according to
guidelines. Only 42% of individuals in the CMT group reported meeting the recommended dose.

10 participants assigned to control:

• Control group was offered a delayed exercise intervention. Exercise volume in the control group was
not officially tracked. All participants were asked to maintain their current normal dietary habits and
daily activities for the 6-week duration. If individuals deviated from their current habits, they were
asked to report changes at endpoint.

Outcomes

Primary outcomes:

• VO2max via maximal incremental cardiopulmonary exercise protocol and expired gases analysed via

the TrueOne 2400 metabolic cart (Parvo Medics Inc., Sandy, UT)

Secondary outcomes:

• Weight (kg)
• Hip circumference (cm)
• Resting heart rate (RHR) noted after 5 minutes of seated silence
• Muscle strength 1RM assessed on the leg press. Maximum weight and number of repetitions used to

estimate 1 repetition

• Insulin measured by the Siemens Immulite 2500 (Siemens Healthcare Diagnostics, Newark, DE, USA)
• Glucose measured via Siemens ADIVA 1800 (Siemens Healthcare Diagnostics, Newark, DE, USA)
• CRP measured on Siemens BNII (Siemens Healthcare Diagnostics, Newark, DE, USA)
• Homeostatic Model Assessment (HOMA)-insulin resistance

Numbers of participants assessed:

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

91

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Dolan 2016  (Continued)

• AIT: baseline, 12, at 6 weeks, 12
• CMT: baseline, 12; at 6 weeks, 11
• Control: baseline, 12; at 6 weeks, 10

Cochrane Database of Systematic Reviews

Adverse events: No adverse events occurred during supervised exercise sessions or were self-reported
by participants.

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: no

Funding: BC Sports Medicine Research Foundation

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Authors' judgement

Support for judgement

Unclear risk

“Randomly assigned”; method of randomisation not reported

Unclear risk

Whether allocation was concealed was not reported.

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Unclear risk

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

Not mentioned whether study personnel and outcome assessors were masked
or blinded to study interventions

Analysis performed only on “completers”; withdrawals not included in analy-
sis

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Duijits 2012 

Methods

Study design: multi-centre RCT

Number randomised: 422; 109 to cognitive-behavioural therapy (CBT); 104 to physical exercise; 106 to
CBT and physical exercise combined; 103 to control group

Study start: January 2008; recruitment stop date: December 2009

Length of intervention: 12 weeks

Length of follow-up: at 6 months (at 3 months post intervention)

Country: Netherlands

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

92

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Duijits 2012  (Continued)

Participants

Age, years (mean SD):

Cochrane Database of Systematic Reviews

• CBT: 48.2 (5.7)
• Exercise: 47.7 (5.6)
• CBT + Exercise: 49.0 (4.9)
• Control: 47.8 (6.0)

Stage:

• Stages: T1-4, N0-1, and M0 (i.e. stage I-IIIC)

Inclusion criteria:

• Primary breast cancer (stages T1-4, N0-1, and M0)

• Younger than 50 years and premenopausal at diagnosis

• Had received adjuvant chemotherapy and/or hormonal therapy

• Disease-free at study entry

• Reported at least a minimal level of menopausal symptoms

• Chemotherapy had to be completed at least 4 months before but not more than 5 years before study
entry (hormonal therapy could still be ongoing)

Exclusion criteria:

• Lack of basic proficiency in Dutch

• Serious cognitive or psychiatric problems

• Serious physical comorbidity

• Obesity (body mass index > 35), because exercise may be contraindicated as a treatment for hot flash-
es in obese women

• Participating in concurrent studies targeted at menopausal symptoms or involving similar interven-
tions

Interventions

109, 104, and 106 participants were assigned to CBT, exercise and CBT, and exercise 12-week interven-
tion, respectively:

• CBT consisted of 6 weekly group sessions of 90 minutes each and 1 booster session 6 weeks post com-
pletion, including relaxation exercises. The primary focus of CBT was on hot flashes and night sweats,
but other symptoms (e.g. vaginal dryness) and problem areas (such as body image, sexuality, and
mood disturbance) were also addressed.

• The  aerobic  exercise  programme  was  an  individually  tailored,  home-based,  self-directed  exercise
programme of 2.5 to 3 hours per week. During the intake session, the physiotherapist assisted each
woman in selecting an appropriate form of exercise (e.g. swimming, running, cycling). Each woman
was provided with a heart rate monitor and was instructed in its use to achieve a target heart rate (60%
to 80% Karvonen). During weeks 4 and 8, women had telephone interviews with the physiotherapist
to discuss their experiences and possible need to adjust the programme. During the last week, women
visited the clinic for a final session, during which they received advice on how best to maintain their
desired level of physical activity.

• Women in the combined intervention group underwent CBT and exercise programmes concurrently.

Adherence:

• Fifty-eight per cent of the CBT group, 64% of the PE group, and 70% of the CBT and exercise group did
not meet criteria for compliance (i.e. at least 4 of 6 CBT sessions and/or minimum of 24 PE training
sessions, with an average of 3 kCals/kg or 6.45 METs per session).

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

93

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Duijits 2012  (Continued)

103 participants assigned to control:

• Wait-list control: On completion of the study, control group participants could choose to undergo the

CBT or PE programme.

Outcomes

Primary outcomes:

• Endocrine symptoms assessed by the 18-item endocrine subscale of the Functional Assessment of

Cancer Therapy questionnaire (FACT-ES)

• Hot flashes and night sweats (HF/NS) assessed by the Hot Flush Rating Scale. The Hot Flush Rating
Scale comprised 2 items measuring frequency of hot flashes and night sweats (HF/NS frequency rat-
ing) and 3 items measuring the extent to which these symptoms were perceived to be problematic
and interfered with daily life (HF/NS–problem rating).

Secondary outcomes:

• Sexual functioning assessed by the Sexual Activity Questionnaire (SAQ)
• Urinary symptoms assessed by the 5-item incontinence scale of the Bristol Female Lower Urinary Tract

Symptoms Questionnaire (BFLUTS)

• Body image assessed by the 4-item QLQ-BR23 subscale
• Psychological distress assessed by the 14-item Hospital Anxiety and Depression Scale (HADS)
• Generic HRQoL assessed by the MOS SF-36, which includes 8 subscales as well as physical and mental

component scores

• Program compliance assessed via session attendance records for CBT participants and number and
intensity of training sessions, as recorded by the heart rate monitor, for PE participants. Participants
were considered to be compliant if they attended at least 4 of 6 CBT sessions and/or had a minimum
of 24 PE training sessions, with an average of 3 kCals/kg per session (or 6.45 METs).

Numbers of participants assessed:

• CBT: baseline, 109; at 12 weeks, 86; at 6 months, 88
• Exercise: baseline, 104; at 12 weeks, 87; at 6 months, 79
• CBT + Exercise: baseline, 106; at 12 weeks, 90; at 6 months, 89
• Control: baseline, 103; at 12 weeks, 89; at 6 months, 84

Adverse events: not reported

Notes

Trial registration link: https://clinicaltrials.gov/ct2/show/NCT00582244

Trial authors contacted: no

Intention-to-treat analysis: no

Funding: supported by grant No. NKI 2006-3470 from the Dutch Cancer Society; the Integral Cancer
Center, Amsterdam; the Pink Ribbon Foundation; and Polar Electro Nederland

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

“Computerized block randomization”

Allocation concealment
(selection bias)

Unclear risk

Whether treatment assignment was concealed from study personnel and par-
ticipants was not described. Centralised randomisation was not mentioned.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

94

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Duijits 2012  (Continued)

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Unclear risk

No mention of whether study personnel and outcome assessors were masked
or blinded to study interventions

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

“Missing values were replaced by the average score of the completed items in
the same scale for each individual, provided that at least 50% of the items in
that scale had been completed”.

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Ergun 2013 

Methods

Study design: single-centre RCT

Number randomised: 60; 20 to supervised exercise, 20 to home exercise, 20 to control

Study start: not reported; stop date: not reported

Length of intervention: 12 weeks

Length of follow-up: to end of intervention

Country: Turkey

Participants

Age, years (mean SD):

• Supervised exercise: 49.7 (8.3)
• Home exercise: 55.1 (6.9)
• Control: 50.3 (10.4)

Stage, n (%):

• Not stated but recurrent or progressing breast cancer excluded

Inclusion criteria:

• Completion of surgical therapy, radiation therapy, and chemotherapy

• Postmenopausal

• Not smoking in the past year

• Agreeing to participate in the study

• Absence of any physical condition that would prevent exercising

• Having the cognitive capacity to answer the questions

Exclusion criteria:

• Recurrent or progressing breast cancer, lymphoedema, serious cardiac disease or unregulated hyper-
tension, acute or chronic respiratory disease, mental disease, any infection, any immune or endocrino-
logical disorder that would alter immune indicators, rheumatic disease, serious musculoskeletal dis-
ease (that would hinder exercising)

• Loss of more than 10% of body weight in the past 6 months

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

95

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Ergun 2013  (Continued)

• Attended a regular exercise programme in the past 6 months

Interventions

40 participants assigned to two 12-week exercise interventions:

• Supervised exercise group performed aerobic exercise + resistive exercise for 45 minutes/d for 3 days/
week and brisk walking for 30 minutes/d for 3 days/week. Exercise programme comprised 10 minutes
of warming, breathing exercise, upper and lower limb resistive exercises with Theraband set at mod-
erate resistance, and semi-squatting periods. Warming exercise comprised brisk walking, rhythmical
range-of-motion exercises, repeated 10 times, for upper and lower limb joints; cool-down exercises
comprised breathing, stretching (shoulder and pectoral muscles, gastrocnemius-soleus, flexors and
rotators of the hip, back muscles) and relaxation exercises.

• Home  exercise  group  performed  brisk  walking  for  30  minutes/d  for  3  days/week.  Participants  in
groups 1 and 2 were taught how to measure their heart rate and maximal heart rate for age calculated
to establish pace of walking.

• All participants were given a 30-minute education regarding adverse effects of breast cancer, preven-
tion of lymphoedema, and related activities, and were given a patient information booklet that in-
cluded lymphoedema-specific exercises.

Adherence: No data on adherence were reported.

20 participants assigned to control:

• Participants received only the education programme mentioned above.

Outcomes

Primary outcomes:

• Angiogenesis and apoptosis-related molecules including interleukin-6, interleukin-8, tumour necro-
sis factor alpha, epithelial neutrophil activating protein-78, platelet-derived growth factor, vascular
endothelial growth factor, growth-related oncogene alpha, regulated upon activation, normal T cell,
thrombopoietin, angiogenin, oncostatin M, and monocyte chemotactic proteins 1, 2, and 3

Secondary outcomes:

• HRQoL via EORTC QLQ-C30
• Fatigue assessed via the Brief Fatigue Inventory (BFI)
• Depression via the BDI

Numbers of participants assessed:

• Supervised exercise: baseline, 20; at 12 weeks, 20
• Home exercise: baseline, 20; at 12 weeks, 18
• Control: baseline, 20; at 12 weeks, 20

Adverse events: No participants experienced any side effects or developed lymphoedema (although 1
participant developed metastasis).

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: unclear

Funding: supported by Ege University Medical Faculty BAP project (Project Number: 2010-TIP-069)

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Using random numbers table

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

96

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Ergun 2013  (Continued)

Cochrane Database of Systematic Reviews

Allocation concealment
(selection bias)

Unclear risk

Whether treatment assignment was concealed from study personnel and par-
ticipants was not described.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Low risk

“Molecular biologists that performed the measurements and the oncology
specialist who made the assessment were blind to the exercise groups of the
patients”.

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

Missing data handling methods were not reported.

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Fillion 2008 

Methods

Study design: single-centre RCT

Number randomised: 94; 48 to intervention group, 46 to control group

Study start: not reported; stop date: not reported

Length of intervention: 4 weeks

Length of follow-up: at 3 months

Country: Canada

Participants

Age, years (mean SD):

• Intervention: 53.09 (9.65)
• Control: 51.84 (10.25)

Stage, n (%):

• Intervention: stage 0, 2 (4.5); stage I, 21 (47.7); stage II, 18 (40.9); stage III, 3 (6.8)
• Control: stage 0, 4 (9.3); stage I, 17 (39.5); stage II, 12 (27.9); stage III, 10 (23.3)

Inclusion criteria:

• Diagnosis of initial non-metastatic breast cancer

• Completion of initial breast cancer treatment no longer than 2 years before enrolment

• Receipt of 1 series of adjuvant treatments of radiation therapy, or had received radiation therapy in
combination with other adjuvant treatments (e.g. chemotherapy, hormonal therapy)

• Ability to understand and speak French

• Residence near the cancer centre

• Availability to take part in a series of 4 weekly sessions

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

97

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Fillion 2008  (Continued)

Cochrane Database of Systematic Reviews

• Acceptance of randomisation procedure pass revised Physical Activity Readiness Medical Examination

• Authorisation of supervising physician before performing fitness assessment

Exclusion criteria:

• Clinical levels of depression symptoms, as measured by HADS (score > 10)

• Insomnia, as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition

• Any symptom of cancer recurrence

• Known severe health problems other than cancer

Interventions

48 participants assigned to exercise intervention:

• 4 weekly group meetings of 2.5 hours and 1 short telephone booster session (5 to 15 minutes)
• 1 hour devoted to supervision of walking training by a kinesiologist or a trained research nurse
• 1.5 hours devoted to psychoeducational fatigue management sessions

Adherence:

• 45 of 48 participants completed the full treatment

Co-intervention: psychoeducational fatigue management

46 participants assigned to control:

• Normal activity

Outcomes

Primary outcome:

• Fatigue measured by General/Physical Fatigue subscale of the MFSI

Other outcomes:

• Cardiorespiratory fitness measured as submaximal oxygen consumption, estimated from single-stage

treadmill walking test

• QoL measured with MOS SF-12
• Energy level measured via the vigour subscale of the shortened POMS
• Anxiety and depression measured on the POMS

Numbers of participants assessed:

• Intervention: baseline, 48; at 4 weeks, 45; at 3 months, 45
• Control: baseline, 46; at 4 weeks, 43; at 3 months, 43

Adverse events: cancer recurrence: 2 in exercise group, 1 in control group

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: no

Funding: Fonds de Recherche en Sante du Quebec, Investigator Award

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Low risk

Sequence of randomisation was “computer generated”.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

98

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Fillion 2008  (Continued)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Unclear risk

High risk

“Sealed envelopes, which were concealed to both kinesiologist and patient”;
no mention of whether they were sequential or opaque

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Blinding of outcome as-
sessment (detection bias) 
All outcomes

High risk

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

Study personnel and outcome assessors were not masked or blinded to study
interventions.

Four participants from the exercise group were not included in the analyses
(withdrew, n = 1; cancer recurrence, n = 2; metastatic breast cancer diagnosis,
n = 1); 3 participants from the control group were not included in the analyses
(withdrew, n = 2; cancer recurrence, n = 1).

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Guinan 2013 

Methods

Study design: RCT

Number randomised: 26 total; 16 to an exercise intervention, 10 to a control

Study start: March 2010; stop date: January 2011

Length of intervention: 8 weeks

Length of follow-up: at 3 months post intervention

Country: Ireland

Participants

Age, years (mean SD):

• Intervention: 50.05 (8.27)
• Control: 45.05 (9.04)

Stage, n (%):

• Intervention: stage I, 3 (18.8); stage II, 10 (62.6); stage III, 3 (18.8)
• Control: stage I, 4 (40.0); stage II, 3 (30); stage III, 3 (30)

Inclusion criteria:

• Breast cancer survivors who had consented to the PEACH trial

• Completion of adjuvant chemotherapy or radiotherapy with curative intent within the preceding 2 to
6 months

• Receipt of neoadjuvant chemotherapy or chemoradiotherapy followed by surgery

• Continuing onto adjuvant hormone therapy and anti-Her2 directed therapy

• Ability to understand English

• Willingness to be randomised

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

99

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Guinan 2013  (Continued)

• Medical clearance to exercise

• Aged 21 to 69

Exclusion criteria:

• Evidence of active cancer

Cochrane Database of Systematic Reviews

• Chronic medical and orthopaedic conditions that would preclude exercise (e.g. uncontrolled conges-
tive heart failure or angina, recent MI, breathing difficulties requiring oxygen use, hospitalisation)

• Taking beta-blocker medication

• Prior history of another cancer in previous 5 years (exceptions: non-melanoma skin cancer, non-inva-
sive cancer of the cervix)

• Confirmed pregnancy

• Dementia or psychiatric illness that would preclude ability to participate in study

• Incomplete haematological recovery after chemotherapy (WCC < 3, Hb < 10, or platelets < 100)

• BMI > 35

• LVEF post chemotherapy < 50% or > 20% deterioration of baseline compared with LVEF before sys-
temic treatment

Interventions

16 participants assigned to exercise intervention:

• Twice-weekly supervised aerobic intervention and a home exercise programme for 8 weeks. Partici-
pants rotated between 3 aerobic exercise stations during the class (stationary bike, treadmill, rowing
ergometer). Participants with “poor” fitness started the intervention at an intensity range of 35% to
55% heart rate reserve (HRR), participants with “fair” fitness started at 40% to 60% HRR, and those
classified as “average” commenced at 45% to 65%HRR. Aerobic intensity zones were progressed by
5% HRR every 2 weeks. Duration of individual sessions was 21 minutes in week 1, progressed to 42
minutes in week 8 (3-minute increase every 2 weeks alternate with intensity increase).

Adherence: 6/16 (37.5%) adhered to < 90% of the exercise class but completed follow-up assessments.

10 participants assigned to control:

• Did not engage in a structured exercise programme but were offered an exercise advice session fol-

lowing final assessment

Outcomes

Outcomes:

• Body composition including body weight estimated by a bioimpedance analyser (Tanita MC 180 MA

Multi-Frequency Body Composition Analyzer; Tanita Corp., Tokyo, Japan)

• Waist circumference measured at midpoint between top of the iliac crest and last rib
• Resting blood pressure measured by the auscultatory method following a 5-minute rest period. Blood
pressure measurements were taken on the non-surgical side, in duplicate, and averaged for data en-
try.

• Venous blood samples taken to measure glucose, insulin, lipid profile (TC), HDL-C, LDL-C and triglyc-
erides,  glycosylated  haemoglobin  levels  (HBA1c),  and  CRP.  Insulin  resistance  was  calculated  via
HOMA: [(fasting glucose (mmol/L) × fasting insulin (mU/L))/22.5]

• Metabolic syndrome diagnosed in the presence of any 3 of the following: elevated waist circumference
(≥ 80 cm); elevated triglycerides (≥ 1.7 mmol/L) or drug therapy for lipid abnormalities; reduced HDL-C
(< 1.3 mmol/L) or drug therapy for lipid abnormalities; elevated blood pressure (systolic ≥ 130 mmHg
and/or diastolic ≥ 85 mmHg) or antihypertensive medication; elevated fasting glucose (≥ 100 mg/dL)
or glucose-lowering medication

• Physical activity measured objectively with the triaxial RT3 activity monitor (Stayhealthy Inc., Montro-
via, CA, USA). Participants wore the monitor for 7 days, during waking hours, following each assess-
ment.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

100

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Guinan 2013  (Continued)

Cochrane Database of Systematic Reviews

• Physical activity measured subjectively with the Godin Leisure Time Exercise Questionnaire, which
records the frequency of strenuous, moderate, and mild exercise bouts of at least 15 minutes' duration
• Estimated  dietary  record  (Medical  Research  Council,  UK)  prepared  by  participants.  Diaries  were

analysed via WISP (Tinuveil Software, Llanfechell, Anglesey, UK) nutrition analysis programme.

Numbers of participants assessed:

• Intervention: baseline, 8 weeks, and 3 months post intervention, 16 (except total and HDL-C, TC:HDL

ratio, triglycerides, glucose, and HBA1c); 15 (LDL-C, insulin); HOMA, 14

• Control: baseline, 8 weeks, and 3 months post intervention, 10 (except LDL-C, insulin, HOMA, HBA1c,

sedentary activity, light-, moderate-, and vigorous-intensity activity); 9

Adverse events: not reported

Notes

Trial registration link: https://clinicaltrials.gov/ct2/show/NCT01030887

Trial authors contacted: no

Intention-to-treat analysis: yes, but LOCF used

Funding: not reported

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Authors' judgement

Support for judgement

Low risk

Computer-generated random numbers list

Unclear risk

Whether allocation was concealed was not reported.

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Low risk

“Assessments were completed by the same researcher at every visit who was
blinded to the participants’ group assignment”.

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

LOCF procedure was used for missing variables.

Selective reporting (re-
porting bias)

High risk

Unlike all other outcomes, no baseline data were reported for C-reactive pro-
tein; only change values with 95% CIs were provided. Cardiorespiratory fitness
and quality of life were mentioned as outcomes in parent trial; no reasons giv-
en for omission of these data here. Only P values for body composition vari-
ables were provided.

Other bias

High risk

Small sample size and imbalance between numbers allocated to the interven-
tion and control group could give rise to additional biases.

Hatchett 2013 

Methods

Study design: single-centre RCT

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

101

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Hatchett 2013  (Continued)

Number randomised: 87; 43 to intervention, 42 to control

Study start: not stated; stop date: not stated

Length of intervention: 12 weeks

Length of follow-up: to end of intervention

Country: USA

Participants

Data available only for those who completed the study

Age, years (mean SD):

• Intervention: not reported
• Control: not reported

Stage, n (%):

• Intervention: stage I, 10 (36); stage II, 17 (47); stage III, 6 (17); stage IV, 3 (8)
• Control: stage I, 14 (37); stage II, 17 (45); stage III, 5 (13); stage IV, 2 (5)

Inclusion criteria:

• Female breast cancer survivors

• Completion of cancer treatment

• 18 years of age or older

• Ability to access and navigate the Internet

• Ability to communicate through email

• Ability to complete online questionnaires

• No current physical activity reported at the outset of the intervention

• Ability to engage in physical activity safely

Interventions

43 participants assigned to exercise intervention:

• Participants assigned to the 12-week intervention group received a weekly email message for the first
5 weeks of the intervention followed by email messages every other week for the next 6 weeks of the
intervention. These messages were designed to influence social cognitive theory (SCT) variables of
interest to enhance participants’ physical activity.

• Participants were offered access to an e-counsellor, who offered advice regarding exercise and phys-

ical activity.

• General exercise recommendations for cancer rehabilitation established by the Rocky Mountain Can-
cer Rehabilitation Institute were used to craft exercise prescriptions. Components of the exercise pre-
scription for patients with cancer are the same as those recommended by the American College of
Sports Medicine.

Adherence:

For the treatment group, investigators reported 2.81 (SD 2.11) days of exercise per week at 6 weeks and
3.47 (SD 2.19) days of exercise per week at 12 weeks.

42 participants assigned to control:

• Control group did not receive email messages, nor did they have access to an e-counsellor. At the end
of 12 weeks, those assigned to the control group were offered the opportunity to participate in the
intervention.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

102

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Hatchett 2013  (Continued)

Outcomes

Outcomes:

Cochrane Database of Systematic Reviews

• 7-DPAR used as the physical activity measure
• Self-regulation measured on a 20-item, 5-point Likert-type instrument (1 = never; 5 =most frequent).
Self-regulation instrument contains 5 subscales: (1) self-monitoring, (2) cognitive goal setting, (3) so-
cial support, (4) reinforcements, and (5) relapse prevention.

• Exercise self-efficacy measured via a 14-item questionnaire. Responses to items are summed and di-
vided by 14 for a mean self-efficacy score. The higher the score on the self-efficacy instrument, the
greater is one’s confidence to overcome barriers to exercise.

• Exercise role identity measured by a 9-item, 5-point Likert-type instrument developed by Anderson
and Cychosz. Possible minimum and maximum values of scores are 0to 45. Higher score indicates
strong self-identity as an exerciser.

• Outcome  expectancy  value  assessed  with  a  19-item  self-report  questionnaire  developed  by  Stein-

hardt and Dishman

Numbers of participants assessed:

• Intervention: baseline, 43; at 6 and 8 weeks, 36
• Control: baseline, 42; at 6 and 8 weeks, 38

Adverse events: not reported

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: no

Funding: not reported

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Authors' judgement

Support for judgement

Unclear risk

“Randomly assigned”; method of randomisation not reported

Unclear risk

Whether allocation was concealed was not reported.

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Unclear risk

Blinding of outcome assessments was not described.

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

“The final sample included 74 participants (control group n = 38, intervention
group n = 36)”.

Participants who dropped out were not included in analysis.

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

103

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Heim 2007 

Methods

Study design: single-centre quasi-RCT

Number randomised: 63; 32 to intervention, 31 to control

Study start: not reported; stop date: not reported

Length of intervention: not reported

Length of follow-up: at 3 months post intervention

Country: Germany

Participants

Age, years; n (%):

• Intervention: 31 to 50 years, 14 (44); 51 to 70 years, 18 (56)
• Control: 31 to 50 years, 18 (58); 51 to 70 years, 13 (42)

Stage:

• Intervention: not reported
• Control: not reported

Inclusion criteria:

• Score ≥ 4 on a linear analogue scale evaluating fatigue, ranging in value from 0 to 10

Exclusion criteria:

• Psychiatric condition

• < 6 weeks since surgery or chemotherapy

Interventions

32 participants assigned to exercise intervention:

• Educational programme, physical therapy, group exercises (non-physical activity), and psycho-onco-

logical interventions

• Resistance exercises performed for 30 minutes 3 times per week, and aerobic exercises performed 2

times per week for 30 minutes

• Brochure with instructions for 9 muscle strength and 9 stretching exercises for all large muscle groups,

demonstrated by instructor

• Instructions for aerobic exercises (walking programme), co-ordination, and relaxation

Adherence:

• Adherence to muscle strength was 26% at end of rehabilitation and 37% at 3 months after rehabilita-

tion.

• Adherence to stretching was 30% at end of rehabilitation and 42% at 3 months after rehabilitation.
• Adherence to aerobic exercises was 163% at end of rehabilitation and 192% at 3 months after reha-

bilitation.

31 participants assigned to control:

• Educational programme, physical therapy, group exercises (non-physical activity), and psycho-onco-

logical interventions

Outcomes

Outcomes:

• Quality of life assessed via FACT-G
• Fatigue assessed via FACT-F
• Depression and anxiety assessed via HADS

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

104

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Heim 2007  (Continued)

Cochrane Database of Systematic Reviews

• MFI
• Questionnaire on physical activity and motivation to perform exercises and sport (self-developed)
• Cardiopulmonary fitness via Harvard step test
• Muscular strength with Digimax Multifunktionstest
• Maximal isometric muscle strength via dynamometer for arm flexors and leg extensors

Numbers of participants assessed:

• Intervention: baseline, not reported; end of rehabilitation, 32
• Control: baseline, not reported; end of rehabilitation, 31

Adverse events: not reported

Notes

Trial registration link: none available

Trial authors contacted: yes, contacted for means and s for outcomes. However, trial authors did not
provide these data.

Intention-to-treat analysis: no

Funding: German Fatigue Society

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

High risk

“According to their admission to hospital; depending on the alternating weeks
they were allocated to the intervention group or the control group”.

Allocation concealment
(selection bias)

High risk

Owing to use of alternating weeks in the randomisation process, allocation
was not concealed from investigators.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Blinding of outcome as-
sessment (detection bias) 
All outcomes

High risk

Study personnel and outcome assessors were not masked or blinded to study
interventions.

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

Complete data were available for 59 participants, but no information on miss-
ing participants was provided. “More patients in the control group (15) than in
the training group (12) did not continue the study”.

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

High risk

Study was poorly described, and adherence to resistance exercises was low
(42%).

Herrero 2006 

Methods

Study design: single-centre RCT

Number randomised: 20; 10 to intervention, 10 to control

Study start: recruitment started November 2003; stop date: April 2004

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

105

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Herrero 2006  (Continued)

Length of intervention: 8 weeks

Length of follow-up: to end of intervention

Country: Spain

Participants

Age, years (mean SD):

• Intervention: 50 (5)
• Control: 51 (10)

Stage, n (%):

• Intervention: stage I, 3 (37.5); stage II, 5 (62.5); not provided, 2
• Control: stage I, 4 (50); stage II, 4 (50); not provided, 2

Inclusion criteria:

• Postmenopausal women surviving breast cancer

• 2 to 5 years post treatment
• 40 to 60 years old

• Previous anticancer treatment consisting of surgery with axillary lymphadenectomy and both post-
surgery radiation therapy and chemotherapy

• Walking less than a total of 30 to 60 minutes 3 days per week

• Performing no strenuous exercise such as running, cycling, swimming, or resistance training

Exclusion criteria:

• Cardiac disease (NYHA II or greater)

• Uncontrolled hypertension (blood pressure > 160/90 mmHg)

• Uncontrolled pain, or any other condition that contraindicated exercise training

• Patients with cancer or cancer survivors, for example, increased risk of bone fracture

• Severe anaemia (< 8 g/dL)

• Platelet count lower than 50 × 109/μL, 7; lymphoedema

Interventions

10 participants assigned to exercise intervention:

• 10-Minute warm-up and cool-down periods, consisting of cycle-ergometer pedaling at very light work-

loads and stretching exercises for all major muscle groups

• 70-Minute core portion of the training session divided into resistance and aerobic training
• Resistance training with 11 exercises engaging the major muscle groups (chest press, shoulder press,
leg extension, leg curl, leg press, leg calf rise, abdominal crunch, low back extension, arm curl, arm
extension, and lateral pull-down), each for 12 to 15 repetitions at 12 to 15 repetitions maximum
• Aerobic training consisting of pedaling on a cycle-ergometer for 20 minutes at 70% maximal heart rate
(HRmax) observed during pretraining cardiorespiratory test. Duration and intensity of sessions were
gradually increased during the 8-week period, so that participants completed 30 minutes of continu-
ous pedaling at 80% HRmax by end of training programme.

• Stretching of muscles involved in an exercise performed at the end of each set of resistance exercises

Adherence:

• Mean (SD) percentage adherence was 91.1% (6.9%).

10 participants assigned to control:

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

106

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Herrero 2006  (Continued)

Cochrane Database of Systematic Reviews

• During the 8-week period, participants in the control group followed their usual sedentary lifestyle
(physical activity level < walking for a total of 30 to 60/min 3 days per week and performing no stren-
uous exercise such as running, cycling, swimming, or resistance training).

Outcomes

Primary outcomes:

• Cardiorespiratory test to measure peak oxygen uptake (VO2peak)
• Dynamic strength endurance test, maximum number of repetitions for chest and leg press exercises

at 30% to 35% and 100% to 110% of body mass

• Sit-stand test, frequency count per time
• EORTC QLQ-C30 questionnaire used to assess quality of life
• Haematocrit and haemoglobin levels
• Circulating cytokine levels by human cytokine immunoassay, including beta nerve growth factor (be-
ta-NGF), cutaneous T cell-attracting chemokine (CTACK), exotoxin, fibroblast growth factor (FGF) ba-
sic, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating fac-
tor (gmCSF), growth-related oncogene (GRO)α , hepatocyte growth factor (HGF), intercellular adhe-
sion molecule (ICAM)1, interferon (IFN)α2, IFNγ, interleukin (IL)1α, IL1β, IL1ra, IL2, IL2ra, IL3, IL4, IL6,
IL7, IL8, IL9, IL10, IL12, IL13, IL15, IL16, IL17, IL18, interferon-inducible protein (IP)10, leukaemia in-
hibitory factor (LIF), macrophage colony-stimulating factor (MCS-F), macrophage inflammatory pro-
tein (MIP)1α, MIP1β, macrophage migration inhibitory factor (MIF), monocyte chemotactic protein
(MCP)1, MCP3, monokine induced by IFNγ (MIG), platelet-derived growth factor (PDGF) bb, stem cell
factor (SCF), stem cell growth factor (SCGF)β, stromal cell-derived factor (SDF)1α, tumour necrosis fac-
tor-related apoptosis-inducing ligand (TRAIL), TNFα, TNFβ, vascular cell adhesion molecule (VCAM)1,
and vascular endothelial growth factor (VEGF). IL10/TNFα ratio was calculated.

Other outcomes:

• Peak power output (PPO) and PPO/body mass, ventilation peak (VEpeak); heart rate max, peak values
of ventilatory equivalent for oxygen (VE/VO2), carbon dioxide (VE/VCO2), and respiratory exchange ra-
tio (RER)

• Body composition assessed indirectly through changes in body mass and subcutaneous skinfolds
• Skinfold measurements made at 3 sites (triceps, abdominal, and suprailiac) to allow estimation of

percentage of body fat

• Total muscle mass (kg) estimated from anthropometrical data following the prediction equation with

use of multi-slice magnetic resonance imaging

Numbers of participants assessed:

• Intervention: baseline, 10; at 8 weeks, 8
• Control: baseline, 10; at 8 weeks, 8

Adverse events: No major adverse effects and no major health problems were noted among partici-
pants in both groups over the 8-week period.

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: no

Funding: Universidad Europea de Madrid

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

Generation of the random sequence was not described.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

107

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Herrero 2006  (Continued)

Allocation concealment
(selection bias)

Low risk

Cochrane Database of Systematic Reviews

“The treatment allocation system was set up so that the researcher who was in
charge of enrolling participants did not know in advance which treatment the
next person would get”.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Low risk

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

“Research assistants (exercise physiologists) with no knowledge of group as-
signments were designated to measure the outcome variables”.

2 participants in each group withdrew, but no information was provided on
reasons for withdrawal, and their data were not included in analysis.

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Irwin 2015 

Methods

Study design: single-centre RCT

Number randomised: 121; 61 to intervention, 60 to control

Study start: June 2009; stop date: June 2013

Length of intervention: 12 months

Length of follow-up: to end of intervention

Country: USA

Participants

Age, years (mean SD):

• Intervention: 62.0 (7.0)
• Control: 60.5 (7.0)

Stage, %:

• Intervention: stage 0, 1 (1); stage I, 36 (59); stage II, 18 (30); stage III, 6 (10)
• Control: stage 0, 0 (0); stage I, 37 (62); stage II, 19 (32); stage III, 4 (7)

Inclusion criteria:

• Physically inactive (i.e. < 90 minutes per week of physical activity in the past 6 months and no strength
training in the past year)

• Postmenopausal women given diagnosis 0.5 to 4.0 years before enrolment with hormone recep-
tor–positive stage I to III breast cancer

• Receiving an aromatase inhibitor for at least 6 months

• Experiencing arthralgia at least mild in severity for at least 2 months (i.e. score of ≥ 3 of 10 for worst
pain item of Brief Pain Inventory)

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

108

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Irwin 2015  (Continued)

Cochrane Database of Systematic Reviews

• Arthralgia started after initiation of aromatase inhibitor therapy or when pre-existing joint pain was
exacerbated by the use of aromatase inhibitors

Exclusion criteria:

• None reported

Interventions

61 participants assigned to the following intervention:

• Combination of a twice-per-week supervised resistance training programme (under supervision of
American College of Sports Medicine–certified cancer exercise trainer) at a local health club, and a
home-based aerobic exercise programme of 150 minutes per week, in accordance with current exer-
cise recommendations for cancer survivors

• Aerobic exercise intervention consisted of 150 minutes per week of primarily brisk walking (treadmill
or outside), although participants could choose other aerobic exercise, such as stationary bicycling.
Intensity of aerobic exercise started at 50% of maximal heart rate (determined from VO2max testing)
and increased over the first month to 60% to 80% of maximal heart rate for the study duration.

• Twice-weekly  strength  training  protocol  consisted  of  6  exercises  (i.e.  bench  press,  latissimus  pull-
down, seated row, leg press, leg extension, and leg curl) performed at 8 to 12 repetitions for 3 sets.
• Intensity of resistance exercise: Participants progressed up to 3 sets per exercise over the first month.
After 2 sessions during which a participant lifted the same weight 12 times during each set, weight
was increased by the smallest possible increment.

Adherence to the intervention:

• Aerobic, mean (SD) daily activity log aerobic exercise minutes/week: 119 (78)
• Resistance, twice per week attendance % (SD): 70 (28)

60 participants assigned to control:

• Women  were  instructed  to  continue  with  their  usual  activities.  Participants  were  not  discouraged
from exercising on their own but were not given any exercise instruction until the end of the study.
Women  were  telephoned  monthly  by  research  staff  to  determine  aromatase  inhibitor  adherence.
Both  exercise  and  usual-care  groups  were  provided  with  an  educational  booklet  prepared  for  the
this study, which addressed breast cancer topics such as lymphoedema and fatigue. Topics were dis-
cussed monthly over the telephone.

Outcomes

Primary outcomes:

• Arthralgia via 3 different questionnaires: (1) BPI; (2) Western Ontario and McMaster Universities Os-
teoarthritis (WOMAC) index, which measures lower extremity joint symptoms in the past 7 days in 3
domains: pain, stiffness, and physical function; and (3) DASH questionnaire, which measures physical
function and symptoms in patients with musculoskeletal disorders of the upper limbs

• Grip strength via bulb dynamometer (squeezing a rubber ball with the dominant hand with pressure

in psi averaged over 3 trials)

Secondary outcomes:

• Pain medication via medicine supplement questionnaire
• Aromatase inhibitor adherence via a log reviewed monthly by telephone
• Weight taken twice and averaged.
• Physical activity via questionnaire (Kriska et al, 1990) assessing the past 6 months of activity, including

type, frequency, and duration of 20 activities

• Cardiorespiratory fitness measured with a standard VO2max treadmill test

Numbers of participants assessed:

• Intervention: 61; completed 3 and 6 months, 58 (95%); completed 9 and 12 months, 45 (94%)
• Control: 60; completed 3 and 6 months, 49 (82%); completed 9 and 12 months, 38 (80%)

Adverse events: No adverse effects occurred as a result of the exercise programme.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

109

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Irwin 2015  (Continued)

Cochrane Database of Systematic Reviews

Notes

Trial registration link: https://clinicaltrials.gov/ct2/show/NCT02056067

Trial authors contacted: no

Intention-to-treat analysis: yes

Funding: supported by National Cancer Institute Grant No. R01 CA132931 and in part by a grant from
the Breast Cancer Research Foundation (M.L.I.), Yale Cancer Center Support Grant No. P30 CA016359,
and Clinical and Translational Science Award Grant No. UL1 TR000142, from the National Center for Ad-
vancing Translational Science

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

"Permuted block randomisation (at 1:1 ratio) with random block size was per-
formed, stratified by joint pain before AI therapy and current bisphosphonate
use".

Allocation concealment
(selection bias)

Unclear risk

Whether treatment assignment was concealed from study personnel and par-
ticipants was not described.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Unclear risk

Blinding of outcome assessments was not described.

Incomplete outcome data
(attrition bias) 
All outcomes

Low risk

Mixed-model repeated measures analysis was employed. This approach is ro-
bust because it includes all available data and accounts for correlations be-
tween repeated measures.

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

High risk

"Given funding cuts, the last 25 of the 121 women recruited were enrolled into
a 6-month rather than 12-month trial".

Therefore, participants received interventions of different durations.

Kaltsatou 2011 

Methods

Study design: single-centre RCT

Number randomised: 27; 14 to intervention, 13 to control

Study start: not reported; stop date: not reported

Length of intervention: 24 weeks

Length of follow-up: to end of intervention

Country: Greece

Participants

Age, years (mean SD):

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

110

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Kaltsatou 2011  (Continued)

• Intervention: 56.6 (4.2)
• Control: 57.1 (4.1)

Stage:

• Not reported

Inclusion criteria:

Cochrane Database of Systematic Reviews

• Participating only in the dancing exercising programme in which none of the participants had prior
physical practice or experience in traditional Greek dances

• All participants had been given a diagnosis and surgically treated for breast cancer

• Completed cancer therapies, including surgery, radiotherapy, and chemotherapy and stopped all
medical treatments at least 3 months before beginning of the study

Exclusion criteria:

• Poorly controlled hypertension

• Any health condition that would deter patient from performing the exercises

Interventions

14 participants assigned to exercise intervention:

• 60-Minute sessions were performed 3 times per week for 24 weeks, and included warm-up, aerobic

training with Greek traditional dances, upper body training, and cool-down.

• Warm-up period lasted 10 minutes and included range of motion exercises and stretching. Aerobic
training phase lasted 25 minutes and included learning and practising traditional Greek dances (in-
tensity between 65% and 80% of maximum heart rate). Dance phase consisted of basic, low-impact
steps, performed in a single group while holding hands in a semi-circle. Duration of each dance was 3
to 4 minutes, and breaks between dances lasted 15 seconds.

• Upper body exercise training and cool-down lasted 25 minutes and emphasised stretching and resis-

tance training with the use of variable resistance machines.

Adherence:

• Not reported

13 participants assigned to control:

• Participants in the control group continued their usual daily schedule.

Outcomes

Outcome measures:

• Physical function assessed via a 6-minute walking test. Participants instructed to walk as comfortably

as possible in 6 minutes

• Handgrip strength assessed on both sides with a baseline handheld dynamometer. Participants were
seated with the forearm in neutral position and the elbow at 90 degrees. They squeezed the handgrip
as hard as they could. The mean of 3 measurements was used for further analysis.

• Arm volume measured with a measuring tape to estimate arm volume
• BDI used to evaluate severity of depression
• In addition, participants completed Life Satisfaction Inventory (LSI). The LSI is a 13-item multi-dimen-

sional inventory that validates the satisfaction that the participant receives from her lifestyle.

• Resting blood pressure and heart rate measured after the individual had been sitting calmly for 5 min-
utes. HR was estimated by palpation for four 15-second periods, and blood pressure was measured
by a sphygmomanometer.

Numbers of participants assessed:

• Intervention: baseline, 14; at 24 weeks, not reported
• Control: baseline, 13; at 24 weeks, not reported

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

111

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Kaltsatou 2011  (Continued)

Adverse events: none reported

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: no missing data reported

Funding: not reported

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

Generation of the random sequence was not described.

Allocation concealment
(selection bias)

Unclear risk

Whether treatment assignment was concealed from study personnel and par-
ticipants was not described.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Unclear risk

Blinding of outcome assessments was not described.

Unclear risk

It is unclear whether any data were missing, as this was not reported.

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Kiecolt-Glaser 2014 

Methods

Study design: RCT

Number randomised: 200; 100 to the Hatha yoga intervention, 100 to wait-list control

Study start: not stated; stop date: not stated

Length of intervention: 12 weeks

Length of follow-up: at 3 months

Country: USA

Participants

Age, years (mean SD):

• Intervention: 51.8 (9.8)
• Control: 51.3 (8.7)

Stage, n (%):

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

112

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Kiecolt-Glaser 2014  (Continued)

Cochrane Database of Systematic Reviews

• Intervention: stage 0, 9 (9%); stage I, 46 (46%); stage IIA, 27 (27%); stage IIB, 10 (10%); stage IIIA, 8 (8%)
• Control: stage 0, 9 (9%); stage I, 43 (%); stage IIA, 25 (25%); stage IIB, 13 (13%); stage IIIA, 10 (10%)

Inclusion criteria:

• Completed breast cancer treatment (except for tamoxifen/aromatase inhibitors) between 2 months
and 3 years previously

Exclusion criteria:

• Engaged in over 5 hours of vigorous physical activity per week

• Prior history of any other cancer (except basal or squamous cell skin cancer)

• Major medical conditions such as anaemia, diabetes, multiple sclerosis, chronic obstructive pul-
monary disease, symptomatic ischaemic heart disease, uncontrolled hypertension, or liver or kidney
failure

• Severe cognitive impairment (e.g. dementia, Alzheimer’s disease) or abuse of alcohol or drugs

• Current yoga practice or prior yoga practice exceeding 3 months

Interventions

100 participants assigned to exercise intervention:

• Twice-weekly 90-minute Hatha Yoga classes for 12 weeks
• Home  practice  strongly  encouraged,  and  women  recorded  total  home  plus  class  practice  time  in
weekly logs. Women were also given a commercial yoga video for cancer survivors as a home practice
aid.

Adherence:

In the yoga group, participants attended a mean of 18.1 (75.4%) of 24 classes with a median of 19
(79.1%) of 24 classes and reported an average of 24.69 minutes per day of total home plus class prac-
tice across 12 weeks.

100 participants assigned to control:

• Participants assigned to wait-list control were told to continue performing their usual activities, and
to refrain from beginning any yoga practice. After final assessment, they were offered the yoga classes.

Outcomes

Outcomes:

• Fatigue via total score on the MFSI-SF
• Vitality in the past month via the MOS SF-36 Energy Scale. Higher scores indicate greater vitality and

thus lower fatigue.

• CES-D assessing depressive symptoms in the past week
• Cognitive complaints assessed on the Breast Cancer Prevention Trial (BCPT) Cognitive Problems Scale
• Sleep quality and disturbances rated by participants using the Pittsburgh Sleep Quality Index
• Perceived support assessed by the Interpersonal Support Evaluation List
• Lipopolysaccharide  (LPS)-stimulated  production  of  IL-6,  IL-1β,  and  TNF-alpha.  LPS-stimulated  cy-
tokines measured from isolated peripheral blood mononuclear cells according to Meso Scale Discov-
ery kit instructions

• Physical activity via CHAMPS questionnaire
• Mass and BMI
• Data on foods and beverages consumed in the past 90 days provided through the Women’s Health

Initiative Food Frequency Questionnaire (FFQ)

.Numbers of participants assessed:

• Intervention: baseline, 100; post intervention, 96; at 3-month follow-up, 94
• Control: baseline, 100; post intervention, 90; at 3-month follow-up, 87

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

113

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Kiecolt-Glaser 2014  (Continued)

Cochrane Database of Systematic Reviews

Adverse events: Two events appeared potentially attributable to the yoga intervention: Two women re-
ported recurrence of chronic back and/or shoulder problems.

Notes

Trial registration link: https://clinicaltrials.gov/ct2/show/NCT00486525

Trial authors contacted: no

Intention-to-treat analysis: no

Funding: grants No. R01 CA126857, R01 CA131029, K05 CA172296, UL1RR025755, and CA016058 from
the National Institutes of Health

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Authors' judgement

Support for judgement

Low risk

“online randomization program to obtain the block randomization sequence”

Low risk

“The data manager had no participant contact”.

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Low risk

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

“Participants were told not to mention their group assignment to study per-
sonnel during their post-treatment assessments; questionnaires were admin-
istered via computer. The technicians who analysed blood samples were blind
to all other data”.

No ITT analysis. Participants were excluded from analysis if they did not com-
plete either of the post-treatment assessments.

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Kim 2015 

Methods

Study design: single-centre RCT

Number randomised: 43; 23 to the home-based exercise + supplement intervention, 20 to a supple-
ment-only control

Study start: January 2012; stop date: August 2013

Length of intervention: 6 months

Length of follow-up: to end of intervention

Country: South Korea

Participants

Age, years (mean SD):

• Intervention: 55.7 (5.3)

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

114

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Kim 2015  (Continued)

• Control: 56.3 (6.7)

Stage, n (%):

Cochrane Database of Systematic Reviews

• Intervention: stage 0-I, 7 (31.8); stage II-III, 15 (68.2)
• Control: stage 0-I, 12 (60.0); stage II-III, 8 (40.0)

Inclusion criteria:

• Women aged 20 to 70 years

• Diagnosis of stage 0 to III breast cancer

• Completed primary treatment at least 3 months earlier and were postmenopausal

• Osteopenia diagnosed by a bone mineral density screening test

Exclusion criteria:

• Having other cancer(s)

• Bone metastasis

• Disease that could influence bone metabolism

• Under treatment for osteoporosis

• Condition that precluded unsupervised exercise

• Participating regularly in resistance exercise (2 or more 30-minute sessions per week)

Interventions

23 participants assigned to exercise intervention:

• For women in the exercise group, supplements (500 mg calcium and 1000 IU vitamin D) were combined

with a 6-month home-based exercise intervention.

• Participants were instructed to walk on 3 non-consecutive days for a total of at least 150 minutes per
week (RPE 11 to 13). Walking was combined with elastic band resistance exercises performed 2 to 3
days per week. Participants used resistance bands colour-coded for resistance levels to perform 2 sets
of 8 to 10 repetitions of 5 upper body and 4 lower body exercises targeting major muscle groups at
light-to-moderate intensity.

• Intervention was based on self-efficacy theory and consisted of telephone counselling, exercise logs
to review progress, exercise goal setting, and a DVD showing someone accomplishing exercise goals.
Two 30-minute education sessions with a 28-page workbook were provided before women initiated
exercise. Telephone counselling was provided through 18 15-minute sessions (weekly for 3 months
and at 2-week intervals thereafter) by 2 nurses trained in exercise prescription.

Adherence:

Mean adherence rate was 69.5% for walking and 48.5% for resistance exercise.

20 participants assigned to control:

• Women in the control group were a supplement-only group (500 mg calcium and 1000 IU vitamin D)
and were instructed to record their supplement intake in logs. They were not instructed to avoid ex-
ercise but were not included in the exercise intervention.

Outcomes

Primary outcomes:

• Bone mineral density (g/cm2) of the lumbar spine (L1-4), femur neck, and total hip with DEXA

Other outcomes:

• Serum calcium by Arsenazo III dye method
• Serum 25-hydroxyvitamin D by radioimmunoassay

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

115

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Kim 2015  (Continued)

Cochrane Database of Systematic Reviews

• Physical activity assessed via the Godin Leisure-time exercise questionnaire
• Aerobic capacity measured by the 6-minute walk test
• Forearm grip strength (kg) assessed via handgrip dynamometer
• Lower-extremity muscular strength measured by the chair-stand test (as many stands from sitting

position in 30 seconds as possible)

• Lower body muscular endurance assessed by the wall-squat test (hold squat position for as long as

possible with back against a wall)

Numbers of participants assessed:

• Intervention: baseline, 23; at 6 months, 20
• Control: baseline, 20; at 6 months, 19

Adverse events: “No injuries or adverse events and no symptoms of lymphedema were reported in ei-
ther group”.

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: yes, but LOCF

Funding: Basic Science Research Program through the National Research Foundation of Korea funded
by the Ministry of Education, Science, and Technology

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Computer-generated randomisation was used.

Allocation concealment
(selection bias)

Unclear risk

Sealed, sequentially numbered envelops were used, but trial authors did not
report whether they were opaque.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Unclear risk

Primary outcome (bone mineral density) was assessed by technicians blinded
to group allocation, but trial authors did not report whether assessors of the
remaining were also blinded to group allocation.

High risk

Missing data were imputed by the LOCF method.

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Ligibel 2008 

Methods

Study design: single-centre RCT

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

116

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Ligibel 2008  (Continued)

Number randomised: 101; 51 to intervention, 50 to control

Study start: May 2004; stop date: October 2006

Length of intervention: 16 weeks

Length of follow-up: to end of intervention

Country: USA

Participants

Age, years (mean SD):

• Intervention: 52 (9)
• Control: 53 (9)

Stage, n (%):

• Intervention: stage I, 22 (43); stage II, 22 (6); stage III, 6 (12); missing, 0 (0)
• Control: stage I, 21 (43); stage II, 22 (44); stage III, 4 (8), missing, 2 (4)

Inclusion criteria:

• Histological evidence of stage I-III invasive breast cancer

• Completion of any chemotherapy and/or radiation therapy at least 3 months before enrolment

• Absence of diabetes

• No use of corticosteroids

• BMI > 25 and/or body fat percentage > 30%

• Baseline participation in less than 40 minutes of physical activity per week

• Hormonal therapy allowed as long as participants continued therapy for duration of the study

Exclusion criteria:

• Evidence of persistent or recurrent breast cancer

• Other malignancy

• Uncontrolled heart disease

• Other contraindications to exercise

Interventions

51 participants assigned to 16-week exercise intervention:

• Resistance training programme (2 sessions of 50 minutes per week) focussed largely on lower body
and core muscle strength, given limited data regarding the impact of upper body exercise on risk of
lymphoedema. Exercises included leg press, quad extension, hamstring curl, hip adductor, hip ab-
ductor, abdominal crunches, calf press, and leg lifts. Intensity of resistance training started at 80% of
maximum weight from baseline strength testing, increased by 10% each week.

• Participants were asked to perform 90 minutes of cardiovascular exercise on their own each week.
Each participant was given a pedometer and a heart rate monitor on enrolment. Participants were
allowed to choose their own form of exercise, as long as it produced a heart rate in the target zone
(55% to 80% maximum heart rate).

• Staff worked with a personal trainer during each of these sessions, monitored by exercise physiolo-

gists

Adherence:

• Although 11 participants ultimately did not complete the intervention, at least partial exercise data
were available for 49 participants. According to intent-to-treat analyses, participants attended a mean

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

117

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Ligibel 2008  (Continued)

Cochrane Database of Systematic Reviews

of 73% of scheduled strength training sessions and performed 114 minutes of aerobic exercise per
week.

50 participants assigned to control:

• Control group received routine care for 16 weeks and then was offered consultation with an exercise
trainer at the end of the control period. All participants were asked to avoid changes in dietary habits
undertaken to lose weight for the duration of the study.

Contamination of control group: not reported

Outcomes

Outcomes:

• Anthropometric measurements; BMI, waist circumference measured at the bending line, and hip mea-

surement recorded at point of maximum girth; waist-to-hip ratio
• Body composition measured by a bioelectric impedance analyser
• Glucose measured with a hexokinase ultraviolet assay
• Insulin measured via immunochemiluminometric assay and measured in μU/mL (1 μU/mL = 6.954

pmol/L)

• Insulin resistance calculated by HOMA, with the following formula: HOMA = [insulin (μU/ mL) × glucose

(mg/dL)]/405

• Serum leptin and adiponectin determined by radioimmunoassay
• Serum high-molecular-weight adiponectin (HMWA) measured by ELISA

Time points of assessment: baseline, completion of the 16-week study period

Numbers of participants assessed:

• Intervention: baseline, 51; at 16 weeks post intervention, 40
• Control: baseline, 50; at 16 weeks post intervention, 42

Adverse events: not reported

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: unclear; ITT approach was not described

Funding: supported by the American Society of Clinical Oncology and the Lance Armstrong Foundation

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Generation of the random sequence was not described: “participants were
randomly assigned 1:1 to an exercise intervention group or control group”.

Allocation concealment
(selection bias)

Unclear risk

Whether treatment assignment was concealed from study personnel and par-
ticipants was not described.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Unclear risk

“although hormonal assays were performed by technicians blinded to group
assignment, anthropometric measures were collected by unblinded study
staff”

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

118

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Ligibel 2008  (Continued)

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

ITT approach mentioned but not described

Low risk

No selective reporting of outcomes is apparent.

Other bias

High risk

High dropout numbers in intervention group (11/51; 22%) and in control group
(8/50; 16%)

Littman 2012 

Methods

Study design: single-centre RCT

Number randomised: 63; 32 to intervention, 31 to control

Study start: May 2007; stop date: April 2008

Length of intervention: 6 months

Length of follow-up: to end of 6-month intervention

Country: USA

Participants

Age, years (mean SD):

• Intervention: 60.6 (7.1)
• Control: 58.2 (8.8)

Stage, n (%):

• Intervention: stage 0, 14 (43.8); stage I, 7 (21.9); stage II, 10 (31.3); stage III, 1 (3.1)
• Control: stage 0, 14 (45.2); stage I, 10 (32.3); stage II, 5 (16.1); stage III, 2 (6.5)

Inclusion criteria:

• Age between 21 and 75 years

• Completion of breast cancer treatment (stage 0-III) at least 3 months before (with the possible excep-
tion of ongoing hormonal therapies such as tamoxifen or aromatase inhibitors)

• BMI ≥ 24 kg/m2 (or ≥ 23 kg/m2, if of Asian descent)

Exclusion criteria:

• Myocardial infarction or stroke in the previous 6 months

• Diabetes

• Current yoga practice

• Pregnancy or plans to become pregnant

• Other factors that might lead to poor retention and yoga practice, which included plans to leave the
study area during the follow-up period or any contraindications to practising yoga

Interventions

32 participants assigned to exercise intervention:

• Yoga intervention was based on viniyoga, a Hatha therapeutic style of yoga that involves physical
stretches and poses, breath control, and meditation. Each yoga practice opened with 5 to 10 minutes
of centring exercises to promote relaxation and internal focus, followed by 50 to 60 minutes of seated

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

119

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Littman 2012  (Continued)

Cochrane Database of Systematic Reviews

and standing poses, and closed with 10 to 15 minutes of guided relaxation, breathing exercises, and
meditation.

• Participants were given the goal of practising 5 times per week, including at least one 75-minute facil-
ity-based class. Women were permitted and encouraged to attend 2 or 3 facility-based classes if they
desired; the remainder of their weekly practice sessions (i.e. 2 (if they attended 3 classes) to 4 (if they
attended 1 class)) were to be completed at home (20 to 30 minutes in duration).

Adherence:

• Women attended an average of 19.6 facility-based classes (range, 1 to 61; median, 20.5) and practised
at home an average of 55.8 times (range, 2 to 102; median, 62) during the 6-month intervention.

14 participants assigned to control:

• Participants in the wait-list control group were asked to not begin yoga and were not contacted again

until it was time to schedule their 6-month follow-up assessment.

Outcomes

Primary outcome measures:

• QoL assessed by FACT-G and the breast cancer module (FACT-B) consisting of 13 additional items
• Fatigue assessed by the 13-item Fatigue Scale (FACT-F) developed specifically for the cancer popula-

tion

• Body weight (kg) measured in a dressing gown with undergarments

Secondary outcomes:

• Waist and hip circumferences measured in a dressing gown with undergarments
• Physical activity collected through a self-administered version of the Modifiable Activity Question-
naire, which includes usual frequency, duration, and number of months of recreational activities per-
formed during previous 12 (baseline) or 6 (6-month follow-up questionnaire) months. Physical activ-
ity converted to MET-h per week

Numbers of participants assessed:

• Intervention: baseline, 32; at 6 months, 30 complete QoL and fatigue; weight and blood collection, 28
• Control: baseline, 31; at 6 months, 27 QoL and fatigue, weight and blood collection

Adverse events: not reported

Notes

Trial registration link: https://clinicaltrials.gov/ct2/show/NCT00476203

Trial authors contacted: no

Intention-to-treat analysis: no

Funding: supported in part by the Office of Research and Development Cooperative Studies Program,
Department of Veterans Affairs and the Transdisciplinary Research in Energetics in Cancer (NCI 1U54
CA116847)

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

Generation of the random sequence was not described,

Allocation concealment
(selection bias)

Unclear risk

Whether treatment assignment was concealed from study personnel and par-
ticipants was not described.

Blinding of participants
and personnel (perfor-
mance bias) 

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

120

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Littman 2012  (Continued)

All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

High risk

"we were unable to blind assessors to group assignment"

High risk

"We used an intent-to-treat approach".

However, "those who did not provide follow-up values were not included in
analyses".

Unclear risk

Blood was collected, but no outcome measures were specified or reported.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Loh 2014 

Methods

Study design: single-centre RCT

Number randomised: 197; 66 to Qigong, 65 to group line-dancing, 66 to control

Study start: not reported; stop date: not reported

Length of intervention: 8 weeks

Length of follow-up: to end of intervention (at 12 months post intervention for intervention-only
groups)

Country: Malaysia

Participants

Baseline data available for 95 participants (32, Qigong; 31, line-dancing; 32, usual care):

Age, years (mean SD):

• Qigong: not reported
• Line-dancing: not reported
• Control: not reported

Stage, n (%):

• Qigong: stage I, 11 (34.4); stage II, 21 (65.6)
• Line-dancing: stage I, 10 (32.3); stage II, 21 (67.7)
• Control: stage I, 12 (37.5); stage II, 20 (62.5)

Inclusion criteria:

• Medical contraindication to exercise

• Major medical condition such as epilepsy, uncontrolled hypertension, major orthopaedic problem or
acute cardiovascular disease (patients given diagnosis in the past 6 months and still medically unsta-
ble)

• Completed primary cancer treatment with no evidence of metastasis

• At least 1 year post diagnosis

Exclusion criteria:

• Medical contraindication to exercise

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

121

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Loh 2014  (Continued)

Cochrane Database of Systematic Reviews

• Major medical condition such as epilepsy, uncontrolled hypertension, major orthopaedic problem or
acute cardiovascular disease (patients given diagnosis in the past 6 months and still medically unsta-
ble)

• Currently practising Qigong or line-dancing

• Engaging in more than 4 hours of vigorous physical activity

Interventions

131 participants assigned to one of two 8-week exercise interventions:

• Qigong group: Low- to moderate-intensity internal Qigong (Zhi Neng Qigong) programme (group ac-
tivity) was employed. Participants were encouraged to practise a 30-minute routine at home, twice
a week (using the supplementary recording provided on a compact disc) during the 8-week interven-
tion.

• Line-dancing group: Group line-dancing programme with moderate-intensity movements. This inter-
vention consisted of 4 sets of aerobic movements that were taught face-to-face once a week. Each
session began with a 10-minute warm-up period; 60-minute dancing sequences; and a 10-minute cool
down. Two rest intervals of 5 minutes were provided during the session. Participants were encouraged
to practice a 30-minute routine at home, twice a week (aided by a compact disc recording of music
used during the face-to-face session).

Adherence:

Adherence rates were 63% for Qigong and 65% for line-dancing.

66 participants were assigned to control.

No change was made to usual management of participants assigned to this group, but they were of-
fered the Qigong or line-dancing programme at the end of the 8-week intervention period.

Outcomes

Primary outcomes:

• Quality of life measured with FACT-B

Other outcomes:

• Fatigue in the previous 7 days measured by the 13-item FACIT-F
• Experience  of  negative  emotional  states  measured  on  the  Depression  and  Anxiety  Stress  Scale-21

(DASS-21)

Numbers of participants assessed:

• Qigong: baseline, 66; at 8 weeks, 32 (at post 12 months, 14)
• Line-dancing: baseline, 65; at 8 weeks, 31 (at post 12 months, 9)
• Control: baseline, 66; at 8 weeks, 32 (at post 12 months, 0)

Adverse events: not reported

Notes

Trial registration link: none available

Trial authors contacted: yes, trial authors provided additional means and SDs for some outcomes

Intention-to-treat analysis: no, "Outliers more than 1.5SD, were removed, and missing data were re-
placed with mean-substitution"

Funding: not reported

Risk of bias

Bias

Authors' judgement

Support for judgement

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

122

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Loh 2014  (Continued)

Cochrane Database of Systematic Reviews

Random sequence genera-
tion (selection bias)

Low risk

“Block randomisation (block size=six) was performed by one of the re-
searchers”.

Allocation concealment
(selection bias)

Low risk

“Masking of treatment allocation were conducted, with ‘matching’ active,
placebo and control, using a free online Random Allocation Software”.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Unclear risk

Blinding of outcome assessments was not described.

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

Inappropriate handling of missing data: “Outliers more than 1.5SD, were re-
moved, and missing data were replaced with mean-substitution”.

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

High risk

Very high attrition. Only 48% of participants randomised at baseline complet-
ed postintervention assessments; therefore, less than half of participants re-
ceived only part of the intervention.

Loudon 2014 

Methods

Study design: multi-centre RCT

Numbers allocated, 28; 15 to exercise intervention, 13 to control

Study start: February 2011; stop date: May 2011

Length of intervention: 8 weeks

Length of follow-up: at 12 weeks

Country: Tasmania, Australia

Participants

Baseline data available for 12 in intervention and 11 in control:

Age, years (mean SD):

• Intervention: 55.1 (2.5)
• Control: 60.5 (3.6)

Stage, n (%):

• Intervention: stage 0, 0 (0); stage I, 3 (25); stage II, 6 (50); stage III, 3 (25)
• Control: stage 0, 1 (9); stage I, 4 (3); stage II, 5 (45); stage III, 1 (9)

Inclusion criteria:

• Stage I unilateral secondary lymphoedema of the arm, as defined by the International Society of Lym-
phology and confirmed by a professional lymphoedema therapist

• Completed treatment for breast cancer (surgery, radiotherapy, and chemotherapy) at least 6 months
previously

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

123

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Loudon 2014  (Continued)

• Over 18 years of age

Cochrane Database of Systematic Reviews

• Sufficient English literacy to provide informed consent

Exclusion criteria:

• Recurrent cancer

• Infection

• Receiving complex lymphoedema therapy

• Pregnancy

• Wore a pacemaker, which would affect bioimpedance spectroscopy (BIS) readings

• Severe psychological illness

Interventions

15 participants assigned to exercise intervention:

• 8-Week Yoga intervention consisted of 1 supervised sessions per week (90 minutes) and 6 home-based

sessions per week (45 minutes).

• Yoga session consisted of documented breathing practices, physical postures, meditation, and relax-

ation techniques according to the Satyananda Yoga tradition.

• Participants were given a DVD with a 45-minute yoga session and were instructed to perform it dai-
ly. The DVD followed the same sequence of practices as the class, with fewer postures and shorter
relaxation. Participants received a log book in which they recorded their daily practice along with any
relevant comments.

Adherence:

Attendance at group yoga sessions was high (97%), as was self-reported compliance with the home
practice DVD (86%).

13 participants assigned to control:

• Participants randomised to the control group maintained their usual self-care as advised by their lym-
phoedema therapist. Self-care included wearing of compression sleeves, self-massage, skin protec-
tion, and continued usual lymphatic treatment. Control group was offered yoga classes at completion
of the final measurement.

Outcomes

Primary outcome:

• Arm volume of lymphoedema measured by circumference; extracellular fluid measured by bioimped-

ance spectroscopy

Secondary outcomes:

• Tissue induration measured by tonometry
• Severity of sensations, pain, and fatigue, and degree to which sensations, pain, and fatigue limited
activity on the day of measurement on a 10-cm visual analogue scale (VAS). A score of 0 cm indicated
“no discomfort”, and a score of 10 cm indicated “the worst imaginable”.

• Quality of life based on the Lymphoedema Quality of Life Tool (LYMQOL). Total QoL was self-recorded
with scores from 0 to 10, 10 being the best and 0 the worst rating on the day of testing. Subscales, each
consisting of several questions, for function, symptoms, appearance, and emotions were also self-
recorded. Each question was scaled from 1 to 4, with 4 being the worst. The score for each subscale
was based on the mean of ratings for subscale-related questions. A higher score indicates a lower QoL
rating for that subscale.

Numbers of participants assessed:

• Intervention: baseline, 15; at 8 weeks, 12; at 12 weeks, 9
• Control: baseline, 13; at 8 weeks, 11; at 12 weeks, 10

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

124

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Loudon 2014  (Continued)

Adverse events: No adverse events were attributable to the yoga or to the control intervention.

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: no

https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000202965

Funding: Swan Research Institute (SRI) and Faculty of Health Sciences Seed Funding, UTAS. Equipment
was provided by Flinders University and University of Tasmania.

Authors' judgement

Support for judgement

Low risk

“randomisation based on a computer-generated random number system”

Low risk

“An individual not associated with the trial will perform the randomisation”.

“Group notification will be in a sealed envelope given to women after comple-
tion of the baseline measurement”.

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Low risk

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

“Measurements, based on validated instruments and protocols, were taken by
trained researchers blinded to the group allocation and previous results”.

Only those who completed post-intervention and 1-month-after-cessation as-
sessments were included in analysis.

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Malicka 2011 

Methods

Study design: single-centre RCT

Number randomised: 38; 23 to a Nordic walking intervention, 15 to control

Study start: not reported; stop date: not reported

Length of intervention: 8 weeks

Length of follow-up: to end of intervention

Country: Poland

Participants

Age, years, mean:

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

125

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Malicka 2011  (Continued)

Cochrane Database of Systematic Reviews

• Overall: 62.8

Stage, n (%):

• Intervention: not reported
• Control: not reported

Inclusion criteria:

• Women after treatment for breast cancer

Exclusion criteria:

• None reported

Interventions

23 participants assigned to exercise intervention:

• Warm-up (10-minute): exercise of upper extremities with the use of poles, not only to prepare the body

for the subsequent effort but also as part of lymphoedema prophylaxis

• Nordic walking (40-minute) aimed at learning and improving walking technique with the use of special
poles (load applied was 85% of HRmax (220–age), with pulse monitored by Polar testers throughout
the activity

• Concluding part (10-minute) involving application of muscle stretching, respiratory, and relaxation

exercises, taking into account lymphoedema prophylaxis

Adherence:

Not reported

15 participants assigned to control:

• Control group comprised 15 women not participating in any rehabilitation programme (no physical

activity for the same duration).

Outcomes

Outcomes:

• Biodex Multi-Joint 3 isokinetic dynamometer used to assess muscle strength bilaterally with the upper
limb push-pull attachment of the Biodex (pushing motion consisting of shoulder flexion and elbow
extension, and pulling motion consisting of shoulder extension and elbow flexion)

• Upper extremities circumference (volume of lymphoedema)

Time points of assessment: baseline, at 8 weeks

Numbers of participants assessed:

• Intervention: baseline, 23; at 8 weeks, 23
• Control: baseline, 15; at 8 weeks, 15

Adverse events: not reported

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: yes, no missing data were reported

Funding: none reported

Risk of bias

Bias

Authors' judgement

Support for judgement

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

126

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Malicka 2011  (Continued)

Random sequence genera-
tion (selection bias)

Unclear risk

"The participants were randomly assigned to one of two groups".

No method stated

Allocation concealment
(selection bias)

Unclear risk

Whether treatment assignment was concealed from study personnel and par-
ticipants was not described.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Unclear risk

Blinding of outcome assessments was not described.

Low risk

No missing data (no dropouts) are apparent.

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Martin 2013 

Methods

Study design: single-centre RCT

Number randomised: 26; 8 to MVe Fitness Chair, 8 to traditional resistance training, 10 to control (no ex-
ercise)

Study start: not reported but participants enrolled from January to December 2009; stop date: not re-
ported

Length of intervention: 8 weeks

Length of follow-up: to end of intervention

Country: Australia

Participants

Age, years (mean SD):

• MVe Fitness Chair: 44.6 (8.0)
• Resistance training: 47.8 (11.5)
• Control: 49.5 (14.5)

Stage, n (%):

• All 26 participants given diagnosis of stage I, II, or III breast cancer

Inclusion criteria:

• Female

• Age 29 to 69 years

• Diagnosis of stage I, II, or III breast cancer and completion of all treatments within 6 months

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

127

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Martin 2013  (Continued)

• Consent from oncologist to participate

• Underwent strict health screening

Exclusion criteria:

Cochrane Database of Systematic Reviews

• Cardiorespiratory disease; bone, joint, or muscle pain or abnormalities that would compromise the
participant’s ability to complete the exercise training protocol

• Already enrolled in a formal exercise programme

Interventions

16 participants assigned to 1 of 2 exercise interventions:

• Target of 3 days of 50-minute sessions consisted of MVe Fitness Chair (n = 8) or traditional resistance

training (n = 8).

• Both interventions are described as resistance training: MVe Fitness Chair (single leg pump, mermaid,
front  leg  pump,  calf  raises,  2-arm  pump,  and  pelvic  lift),  traditional  resistance  training  (crunches,
oblique crunches, ball squats, calf raises, chest press, bridge).

• The 2 protocols matched in volume of work and sequence of muscles exercised. For both interven-
tions, exercise sessions started with 15 minutes of aerobic exercise at 65% to 75% heart rate reserve,
using a treadmill, elliptical, or stationary cycle, followed by 5 minutes of total body stretching, then 25
minutes of resistance training. After performing resistance exercises, participants cooled down and
stretched for 5 minutes.

• Intensity of resistance exercise was quantified on the RPE scale from 6 to 20. Week 1: RPE 9 to 10;

weeks 2 to 3, RPE 10 to 11; weeks 4 to 6, RPE 12 to 13; weeks 7 to 8, RPE 13 to 14.

Adherence:

MVe Fitness Chair group had a mean adherence rate of 83.3%.

Resistance training group had an average adherence rate of 81.2%.

10 participants assigned to control:

• Control group was asked to not exercise.

Outcomes

Outcomes:

• Muscular endurance evaluated by combined repetitions on a standardised push-up test, a partial curl-
up test, and the Dynamic Muscular Endurance Test Battery for Cancer Patients of Various Ages. This
protocol provides a table, divided into age groups, which shows what percentage of body weight par-
ticipants should lift for each exercise. Exercises consisted of single-arm dumbbell biceps curls on each
arm, lateral pull-downs on a cable machine, seated machine leg extensions, and prone machine ham-
string curls via resistance training machines (Magnum Fitness Retro Series Machine, South Milwaukee,
WI). Participants performed repetitions at 60 beats per minute to a metronome until they could not
keep up with the rhythm, could not perform any more repetitions, or chose to stop. Summed total
repetitions performed on push-ups, partial curl-ups, both biceps curls, lateral pull-downs, leg exten-
sion, and hamstring curls created a composite score used in analysis of muscular endurance.

Other outcomes:

• Narrative feedback

Numbers of participants assessed:

• Intervention: baseline, 8; post intervention, 8
• Control: baseline, 10; post intervention, 10

Adverse events: not reported

Notes

Trial registration link: none available

Trial authors contacted: no

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

128

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Martin 2013  (Continued)

Intention-to-treat analysis: yes, no missing data were reported

Funding: Peak Pilates donated the MVe Fitness Chairs used in this study to the Get REAL & HEEL Breast
Cancer Rehabilitation Program. No other financial support was received for this project.

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Authors' judgement

Support for judgement

Low risk

“Simple randomization with replacement”

Unclear risk

Not described

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Unclear risk

Blinding of outcome assessments was not described.

Low risk

No data were missing.

Selective reporting (re-
porting bias)

High risk

Oxygen saturation was not reported. Composite score for all tests was report-
ed. Data for individual tests were not provided.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Matthews 2007 

Methods

Study design: single-centre RCT

Number randomised: 36; 23 to intervention, 13 to wait-list control

Study start: not reported; stop date: not reported

Length of intervention: 12 weeks

Length of follow-up: to end of intervention

Country: USA

Participants

Age, years (mean SD):

• Intervention: 51.3 (9)
• Control: 56.9 (12.3)

Stage, n (%):

• Intervention: stage I, 13 (59); stage II/III, 4 (18); not available, 5 (23)
• Control: stage I, 9 (64); stage II/III, 3 (21); not available, 2 (14)

Inclusion criteria:

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

129

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Matthews 2007  (Continued)

• Diagnosis of stage I–III cancer

• Completed adjuvant treatment in the past 12 months

• Postmenopausal

• Free of cardiovascular disease and major orthopaedic limitations

• Not currently exercising on a regular basis (≥ 5 days/week)

Exclusion criteria:

• None reported

Interventions

22 participants assigned to exercise intervention:

• Brief home-based intervention consisted of a single in-person counselling visit (30 minutes) followed
by up to 5 short telephone counselling calls during weeks 1, 2, 4, 7, and 10 calls after randomisation
(10 to 15 minutes/call).

• Home-based  intervention  primarily  sought  to  increase  walking,  consisting  of  walking  at  a  moder-
ate-intensity (RPE 11 to 13) from 3 to 5 sessions per week (weeks 1 to 4, 3/week; weeks 5 to 7, 4/week;
weeks 8 to 12, 5/week) of 20 to 40 minutes (weeks 1 to 4, 20 to 30 minutes/session; weeks 5 to 12, 30
to 40 minutes/session6) over 12 weeks.

Adherence:

• Average adherence over 12 weeks to walking goals of the intervention as reported in monthly walking
logs was 94% (SD 0.48); average walking time reported in the walking logs was 147 minutes/week.

14 participants assigned to control:

• Control participants were asked to maintain their current (baseline) activity levels over the course
of the study. They were provided no materials or advice about exercise. No efforts were made after
randomisation to stop women in this condition from initiating or increasing their activity levels on
their own.

• Women in the control condition received baseline intervention counselling and materials (e.g. pe-
dometer) upon completion of the study and were offered the opportunity to receive as much tele-
phone counselling as they wanted after this.

Outcomes

Outcomes:

• Physical activity assessed by both CHAMPS and, in a subsample (n = 23), the Manufacturing Technol-

ogy Actigraph

• Body weight and BMI
• Body composition measured for descriptive purposes by 2 methods: bioelectrical impedance analysis

in 13 participants, and DEXA in the other 23 participants

Time points of assessment: baseline, 6 weeks, and 12 weeks. For body composition-dependent vari-
ables: baseline and 12 weeks

Numbers of participants assessed:

• Intervention: baseline, 22; at 6 weeks, not reported; at 12 weeks, not reported
• Control: baseline, 14; at 6 weeks, not reported; at 12 weeks, not reported

Adverse events: not reported

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: yes, but LOCF used

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

130

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Matthews 2007  (Continued)

Risk of bias

Bias

Funding: Vanderbilt-Ingram Cancer Center, South Carolina Cancer Center, and Vanderbilt General Clini-
cal Research Center

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Generation of the random sequence was not described; “participants were
randomly assigned 2:1 to an exercise intervention group or control group”.

Allocation concealment
(selection bias)

Unclear risk

Whether treatment assignment was concealed from study personnel and par-
ticipants was not described.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Unclear risk

Blinding of outcome assessments was not described.

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

ITT analyses based on the last observation carried forward method; missing
data not reported

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

Unclear risk

Some participants were contacted via a list of participants from a breast can-
cer case-control study. Therefore, these women may have been particularly
motivated to adopt the walking programme.

McKenzie 2003 

Methods

Study design: single-centre RCT

Number randomised: 14; 7 to exercise intervention, 7 to control

Study start: not reported; stop date: not reported

Length of intervention: 8 weeks

Length of follow-up: to end of intervention

Country: Canada

Participants

Age, years (mean SD):

• Intervention: 56.4 (10.4)
• Control: 56.9 (8.2)

Stage, n (%):

• Stage I-II

Inclusion criteria:

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

131

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

McKenzie 2003  (Continued)

Cochrane Database of Systematic Reviews

• Underwent breast cancer treatment for stage I or II breast cancer that had been completed more than
6 months before enrolling in the study

• Subsequently developed unilateral lymphoedema > 2 cm and < 8 cm for at least 1 measurement point

Exclusion criteria:

• Stage III lymphoedema, bilateral disease

• Required medication that might affect upper extremity swelling

Interventions

7 participants assigned to exercise intervention:

• Three days per week of resistance training included specific exercises, beginning with a light weight
and  progressing  as  tolerated  by  each  participant.  Strength  exercises  prescribed  were  seated  row,
bench press, latissimus dorsi pull-down, 1 arm bent-over rowing, triceps extension, and biceps curl.
Two sets of 10 repetitions for each exercise were done for the first week; 3 sets of 10 were done there-
after. Training sessions consisted of a 5- to 7-minute period of aerobic warm-up such as cycling or
walking, 5 minutes of stretching, the strength training programme, and a cool-down period.

• After 2 weeks, upper body aerobic exercise with an arm cycle ergometer was added to the programme.
Participants exercised under supervision. After a programme that began with five 1-minute bouts of
cycling at resistance of 8.3 W, the programme progressed to 20 minutes of continuous cycling with
resistance up to 25 W.

Adherence:

Not reported

7 participants assigned to control:

• Control participants were given no specific exercise instruction until after they completed the study,

at which time they had the option of being taught the exercise programme.

Outcomes

Outcomes:

• Arm circumference and volume measurements
• HRQoL via the MOS SF-36

Numbers of participants assessed:

• Intervention: baseline, 7; at week 8, 7
• Control: baseline, 7, 7; at week 8, 7

Adverse events: not reported

Notes

Trial registration link: none available

Trial authors contacted: Trial authors were contacted for means and SDs for outcomes. However, they
did not provide these data.

Intention-to-treat analysis: yes, no missing data were reported

Funding: not reported

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

“randomly assigned”, but method not mentioned

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

132

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

McKenzie 2003  (Continued)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

High risk

Whether treatment assignment was concealed from study personnel and par-
ticipants was not described.

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Unclear risk

No mention of whether study personnel and outcome assessors were masked
or blinded to study interventions

Low risk

No missing data

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Mehnert 2011 

Methods

Study design: single-centre RCT

Number randomised: 63; 35 to intervention, 28 to control

Study start: not reported; stop date: not reported

Length of intervention: 10 weeks

Length of follow-up: to end of intervention

Country: Germany

Participants

Age, years (mean SD):

• Intervention: 53.03 (7.40)
• Control: 50.64 (9.44)

Stage, n (%):

• Intervention: stage I, 17 (56.7); stage IIA, 8 (26.7); stage IIB, 3 (10.0); stage IIIA, 1 (3.3); stage IIIB, 1 (3.3)
• Control: stage I, 13 (46.4); stage IIA, 7 (25.0); stage IIB, 5 (17.9); stage IIIA, 3 (10.7); stage IIIB, 0 (0)

Inclusion criteria:

• 18 to 65 years old

• Primary non-metastatic breast cancer

• Minimum 4 weeks after completion of chemotherapy, radiation therapy, or both

• Any disorder that could interfere with ability to perform the physical exercise programme

Exclusion criteria:

• Severe acute or chronic illness other than cancer (e.g. disorders of the musculoskeletal system)

Interventions

35 participants assigned to exercise intervention:

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

133

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Mehnert 2011  (Continued)

Cochrane Database of Systematic Reviews

• Gymnastics, movement games, and relaxation
• Moderate walking and jogging conducted outside
• Exercise performed twice weekly for 90-minute duration at an intensity of 60% VO2max, over 10 weeks
• Although 35 women were assigned to the exercise intervention, 5 women refused to participate before

baseline assessment.

Adherence:

Not reported

28 participants assigned to control:

• Usual care

Outcomes

Outcomes:

• Anxiety and depression measured with HADS
• Cancer-specific QoL measured by EORTC-QLQ-C30
• Generic QoL measured via MOS SF-36
• Psychological symptoms measured with SCL-90R
• Body image assessed via a German version of the Body Image Questionnaire (BIQ)

Numbers of participants assessed, anxiety and depression:

• Intervention: anxiety and depression: baseline, 30; at 10 weeks, 30. Individual body image: baseline,

27; at 10 weeks, 27. Social body image: baseline, 30; at 10 weeks, 27

• Control: anxiety and depression: baseline, 28; at 10 weeks, 28. Individual body image: baseline, 27; at

10 weeks, 27. Social body image: baseline, 27; at 10 weeks, 27

Numbers of individuals with data for cancer-specific HRQoL, generic HRQoL, and psychological symp-
toms were not reported.

Adverse events: not reported

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: unclear how missing data were handled

Funding: Friedrich and Louise Homann Foundation, Hamburg, Germany

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Authors' judgement

Support for judgement

Unclear risk

It is unclear how the allocation sequence was generated.

Low risk

Randomisation was adequately concealed through external randomisation.

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Blinding of outcome as-
sessment (detection bias) 
All outcomes

High risk

Study personnel and outcome assessors were not masked or blinded to study
interventions.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

134

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Mehnert 2011  (Continued)

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

It is unclear how missing data were handled. Five randomised participants
were reported to have “cancelled” participation in the exercise group.

Low risk

No selective reporting of outcomes is apparent.

Other bias

High risk

Participation in physical exercise by women (91%) in study groups before the
intervention was commenced could have contributed to bias.

Milne 2008 

Methods

Study design: single-centre RCT (12-week study included here)

Number randomised: 58; 29 to immediate exercise intervention, 29 to delayed exercise intervention

Study start: January 2005; stop date: recruitment ended March 2005

Length of intervention: 12 weeks

Length of follow-up: to end of intervention

Country: Australia

Participants

Age, years (mean SD):

• Intervention: 55.2 (8.4)
• Control: 55.1 (8.0)

Stage, n (%):

• Intervention: stage I, 6 (20.7); stage IIA, 14 (48.3); stage IIB, 9 (31.0); stage IIA, 0 (0.0)
• Control: stage I, 9 (31.0); stage IIA, 11 (37.9); stage IIB, 7 (24.1); stage IIIA, 2 (6.9)

Inclusion criteria:

• Women with stage I–II breast cancer

• ≥ 18 years old

• English speaking

• Within 24 months of cancer diagnosis

• Completed all treatments except hormone therapy

Exclusion criteria:

• Evidence of recurrent disease

• Previously engaged in any formal exercise programme for 6 months before participation in this study

• Failed the revised Physical Activity Readiness Questionnaire

• Evidence of recurrent disease

Interventions

29 participants assigned to exercise intervention:

• Aerobic training (cycle and rowing ergometers, mini-trampoline, and step-up blocks) and resistance
training (12 different exercises, including chest press, chest extension, biceps curls, triceps extension,

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

135

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Milne 2008  (Continued)

Cochrane Database of Systematic Reviews

leg extension, leg curls, hip abduction and adduction, back extension, abdominal crunches, standing
flies, and leg press) 3 times per week for 1 hour per session over 12 weeks

• Cardiovascular component was conducted for 20 minutes and ended with a 5-minute cool-down pe-
riod, whereas for the resistance exercise component, participants performed 2 sets of 10 to 15 repe-
titions of light weights and progressed to a heavier weight once current weight and repetitions could
be achieved and with good form. Participants performed 5 minutes of stretching at the beginning and
end of each session.

Adherence:

• Average intervention attendance was 60.4% (21.7 of 36 sessions) with a median of 23 (63.9%) and a

range of 11 to 36.

29 participants assigned to control:

• Control group was asked not to participate in exercise during weeks 1 to 12 and received telephone

calls at weeks 3, 6, 9, and 12.

Outcomes

Primary outcome:

• QoL outcomes based on FACT-B scale

Other outcomes:

• Fatigue measured on the Schwartz Cancer Fatigue Scale
• Social physique anxiety measured by the Social Physique Anxiety Scale-7 (SPAS-7)
• Physical fitness assessed by submaximal fitness tests performed before and after exercise training.

Aerobic fitness was measured by the Aerobic Power Index (API) cycle test.

• Strength was measured by recording the weight used during performance of specific exercises (i.e.

biceps curls, leg presses, and chest extensions).

• The Behavioral Regulation for Exercise Questionnaire-2 (BREQ-2) was developed to provide a measure
that assessed the self-determination continuum in exercise. BREQ-2 subscale items were as follows:
amotivation, intrinsic motivation, identified regulation, introjected regulation, and extrinsic motiva-
tion. Responses to each question were scored on a 5-point Likert scale (0 to 4) indicating how true
each item was for the individual, from not at all to very true. BREQ-2 total score was established by
calculating the sum of each subscale score.

• Basic Psychological Needs Satisfaction Scale (BPNS) was used to measure autonomy, competence,
and relatedness. The BPNS is a revised version of the 21-item Basic Need Satisfaction at Work Scale,
which  was  used  to  assess  the  extent  to  which  employees  experienced  satisfaction  of  their  3  basic
needs—autonomy (7 items), competence (6 items), and relatedness (8 items)—at their job.

Numbers of participants assessed:

• Intervention: baseline, 29; at 6 weeks, 29; at 12 weeks, 28
• Control: baseline, 29; at 6 weeks, 29; at 12 weeks, 28

Adverse events: none reported

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: yes, but LOCF was used

Funding: CCS and NCIC/CCS Sociobehavioral Cancer Research Network

Risk of bias

Bias

Authors' judgement

Support for judgement

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

136

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Milne 2008  (Continued)

Random sequence genera-
tion (selection bias)

Low risk

Randomisation by computer-generated programme

Allocation concealment
(selection bias)

Low risk

“Group assignments were concealed from the project director who recruited
participants to the trial”.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Blinding of outcome as-
sessment (detection bias) 
All outcomes

High risk

Study personnel and outcome assessors were not masked or blinded to study
interventions.

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Low risk

Minimal loss to follow-up

Low risk

No selective reporting of outcomes is apparent.

Other bias

High risk

Intervention adherence rate was low (61.3%).

Murtezani 2014 

Methods

Study design: single-centre RCT

Number randomised: 73; 37 to intervention, 36 to control

Study start: not reported; stop date: not reported

Length of intervention: 10 weeks

Length of follow-up: to end of intervention

Country: Kosovo

Participants

Characteristics data based on 62 participants (30 in exercise group, 32 in control group)

Age, years (mean SD):

• Intervention: 53 (11)
• Control: 51 (11)

Stage, n (%):

• Intervention: stage I, 10 (33); stage IIa, 11 (37); stage IIb, 6 (20); stage IIIa, 3 (10)
• Control: stage I, 15 (47); stage IIa, 8 (25); stage IIb, 7 (22); stage IIIa, 2 (6)

Inclusion criteria:

• Histologically confirmed early-stage breast cancer with no evidence of recurrent or progressive dis-
ease

• Completed surgery, radiotherapy, and/or chemotherapy with or without current hormone therapy

Exclusion criteria:

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

137

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Murtezani 2014  (Continued)

• Known cardiac disease

• Uncontrolled hypertension

Cochrane Database of Systematic Reviews

• Thyroid disease, respiratory disease, diabetes, mental illness, infection, immune or endocrine abnor-
mality

Interventions

37 participants assigned to exercise intervention:

• Women assigned to the intervention group attended a supervised group exercise programme, 3 times
per week for 10 weeks. The exercise programme was divided into a warm-up period, followed by mod-
erate-intensity aerobic exercises (50% to 75% age predicted HRmax), finishing with a cool-down pe-
riod.

• Warm-up period consisted of 5 minutes of cycling. Core portion consisted of aerobic exercise pro-
gramme performed on treadmills, stationary bicycles, and stair-climbing machines. Duration of aer-
obic exercise was initially 15 minutes, and session was divided equally among the 3 exercise modali-
ties (treadmills, stationary bicycles, and stair-climbing machines). Sessions ended with 5 minutes of
cool-down exercises consisting of slow walking. Aerobic exercise period was increased by 2 minutes
a week, such that this period lasted 35 minutes during week 10.

Adherence:

Exercise adherence was 84.9%.

36 participants assigned to control:

• Control group was told to maintain sedentary lifestyle for 10 weeks.

Outcomes

Primary outcome:

• Cardiorespiratory fitness via a 12-minute walk test

Other outcomes:

• Mass and BMI
• QoL via FACT-B

Numbers of participants assessed:

• Intervention: baseline, 37; at 10 weeks, 30
• Control: baseline, 36; at 10 weeks, 32

Adverse events: Three participants developed lymphoedema.

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: no

Funding: none

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Authors' judgement

Support for judgement

Low risk

"computer-generated random allocation sequences"

Low risk

"sequences that were prepared centrally by the trial statistician"

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

138

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Murtezani 2014  (Continued)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Low risk

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

The assessor was blinded with regard to allocation of participants to treat-
ment groups.

"The data analyses included only those participants who had completed the
10 week interventional period".

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

High risk

Inappropriate statistical analysis was performed (independent t-tests done on
change values).

Musanti 2012 

Methods

Study design: single-centre RCT

Number randomised: 55; 12 to aerobic exercise intervention, 17 to resistance exercise intervention, 13
to combined aerobic and resistance exercise intervention, 13 to flexibility control

Study start: October 2004; stop date: March 2006

Length of intervention: 12 weeks

Length of follow-up: to end of intervention

Country: USA

Participants

Age, years (mean SD):

• Aerobic intervention: 51 (5.5)
• Resistance intervention: 52 (8.9)
• Aerobic and resistance intervention: 48 (6.7)
• Flexibility control: 52 (7.9)

Stage, n (%):

• Aerobic intervention: stage I, 5 (42); stage II, 5 (42); stage III, 2 (16)
• Resistance intervention: stage I, 5 (29); stage II, 10 (59); stage III, 2 (12)
• Aerobic and resistance intervention: stage I, 7 (54); stage II, 6 (46); stage III, 0 (0)
• Flexibility control: stage I, 8 (62); stage II, 3 (23); stage III, 2 (15)

Inclusion criteria:

• English-speaking women

• Stage I–IIIB breast cancer after completion of adjuvant chemotherapy at least 3 months or radiation
therapy at least 6 weeks before entry

• No more than 24 months beyond their last treatment

• Hormonal therapy could be ongoing.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

139

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Musanti 2012  (Continued)

Exclusion criteria:

Cochrane Database of Systematic Reviews

• Medical history or physical examination revealed evidence of anaemia (haemoglobin <10 mg/dL), un-
controlled hypertension, congestive heart failure, pulmonary disease, diabetes, and thyroid or muscu-
loskeletal disease

• Current enrolment in a weight loss or exercise programme

• Positive response to any question on the Physical Activity Readiness Questionnaire, thus indicating
the need for medical clearance before starting an exercise programme

Interventions

42 participants assigned to aerobic, resistance, or aerobic plus resistance exercise interventions:

• Aerobic exercise: walking at 40% to 65% HRmax, progressing to 85% HRmax for 15 minutes, progress-

ing to 30 minutes

• Resistance exercise performed at an intensity of RPE (0 to 10) 3 to 5 progressing to 7 to 8
• Aerobic  exercise  was  performed  3  times  per  week;  resistance  exercise  was  performed  3  times  per
week; in resistance plus aerobic group, aerobic exercise was performed 4 to 5 times per week and re-
sistance was performed 2 times per week.

• All participants in intervention groups were prescribed flexibility exercise as part of the warm-up rou-

tine.

• In-person verbal instruction plus demonstration was used to teach participants how to do their as-

signed exercises.

• Each participant received a written guidebook that included general information about exercise par-
ticipation, such as clothing and safety tips, as well as an individualised exercise prescription, exercise
instructions, and an exercise log sheet.

Adherence:

• Aerobic intervention: mean compliance percentage, 107%
• Resistance intervention: mean compliance percentage, 91%
• Aerobic and resistance intervention: mean compliance percentage, 101%
• Flexibility control: mean compliance percentage, 82%

13 participants assigned to flexibility control:

• Flexibility control group consisted of a minimum of 60 sessions in total.

Outcomes

Outcomes:

• Cardiorespiratory fitness via Bruce protocol
• Muscular strength assessed by 6-repetition maximum chest press, seated row, and leg press
• Muscular endurance assessed by YMCA bench press and curl-up test
• Flexibility measures of hip flexion, hip backward extension, shoulder flexion, shoulder posterior ele-

vation, and shoulder abduction made with a goniometer

• Mass, arm and waist circumferences, and body composition via BIA
• Physical Self-Perception Profile and RSE Scale used as esteem measures
• Anxiety and depression assessed via HADS
• Physical activity via Godin Leisure Time Questionnaire at baseline only
• Resting heart rate and blood pressure

Numbers of participants assessed:

• Aerobic intervention: baseline, 12; at 12 weeks, 10
• Resistance intervention: baseline, 17; at 12 weeks, 9
• Aerobic and resistance intervention: baseline, 13; at 12 weeks, 11
• Control: baseline, 13; at 12 weeks, 12

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

140

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Musanti 2012  (Continued)

Cochrane Database of Systematic Reviews

Five women returned the survey data form but refused final fitness testing because of time constraints
related to work and family obligations; therefore, fitness test participant number was 37.

Adverse events: tendinitis (n = 2): 1 in the shoulder, the other in the foot

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: yes

Funding: award from the Greater NYC Affiliate of the Susan G. Komen Breast Cancer Foundation, Inc.,
New York, NY

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Low risk

“computer-generated randomization table generated”

Allocation concealment
(selection bias)

Low risk

“Allocation to study group was made….by the statistical department of the
cancer centre and maintained by office staff in the clinical research office".

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Low risk

Physical fitness tests: “The same research assistant, blinded to participant
group allocation, preformed these measurements at the pre-intervention and
post-intervention measurement time points”.

Incomplete outcome data
(attrition bias) 
All outcomes

Low risk

“Missing data were random and were handled using multiple imputations”.
Reasons for withdrawal were given.

Selective reporting (re-
porting bias)

High risk

Not all physical fitness test outcomes were reported.

Other bias

High risk

Small sample size was further impacted by high rate of withdrawal (24%).

Mustian 2004 

Methods

Study design: single-centre RCT

Number randomised: 31; 17 to Tai Chi Chuan intervention, 14 to control

Study start: not reported; stop date: not reported

Length of intervention: 12 weeks

Length of follow-up: to end of intervention

Country: USA

Participants

Age, years (mean SD):

• 52 (9); range 33 to 78

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

141

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Mustian 2004  (Continued)

Stage:

Cochrane Database of Systematic Reviews

• Stage 0-IIIB (stage data not reported)

Inclusion criteria:

• Female

• Histological diagnosis of primary breast cancer stage 0–IIIB

• Between 1 week and 30 months after treatment

• No drainage tubes or catheters

• Not engaging in moderate-to-vigorous physical activity more than once a week

• Physician’s clearance for fitness testing and exercise

• No physical limitations prohibiting exercise

• No clinical diagnosis of mental disorder, as defined by use of psychotropic drugs and self-report

Exclusion criteria:

• None reported

Interventions

17 participants assigned to exercise intervention, including Tai Chi Chuan (TCC):

• 10 minutes of warm-up stretching and basic Chi Kung (stationary TCC fundamentals)
• TCC 3 times per week. Each session consisted of approximately 40 minutes of TCC, and participants

learned a 15-move short form of Yang style TCC.

• During the last 10 minutes of each session, participants were instructed in regulatory breathing, im-

agery, and meditation to enhance TCC skills and provide an exercise cool-down.

• Participants were instructed not to begin any other physical exercise programmes and not to change

their normal daily physical activity during the course of the study.

Adherence:

• Intervention: 72% exercise rate with 100% compliance
• Control: 67% attendance rate with 100% compliance

14 participants assigned to psychosocial support:

• Supportive-expressive group therapy model conducted in an open-ended format that placed strong
emphasis on teaching behavioural coping strategies and providing peer support and group cohesion
• Participants instructed not to begin any physical exercise programmes and not to change their normal

daily physical activity in any way for the duration of the study

Outcomes

Primary outcomes:

• FACT-F, 28-question survey: scale from 0 to 4
• Self-esteem assessed by RSE Scale: scoring: 1 = strongly agree, 5 = strongly disagree
• Aerobic capacity, estimated by a 6-minute walk test protocol

Secondary outcomes:

• Muscular strength evaluated with a handgrip dynamometer to assess maximal voluntary grip strength
• Flexibility assessed via goniometer measurements
• Body composition calculated by bioelectrical impedance analysis
• Blood markers:

◦ Serum concentrations of insulin measured by radioimmunoassay assay
◦ IGF-I, IGFBP-1, and IGFBP-3 measured by immunoradiometric assay

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

142

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Mustian 2004  (Continued)

Cochrane Database of Systematic Reviews

◦ Serum cytokines (IL-2, IL-6, and IFN-γ) measured by OPTEIA ELISA kits
◦ Serum NTx levels determined with an enzyme-linked immunosorbent assay and a specific mono-

clonal antibody for NTx (osteomark serum NTx)

◦ Serum BSAP levels determined by a chemiluminescent immunoassay
◦ To measure the balance between bone formation and bone resorption, trial authors used the for-
mula proposed by Eastell et al to calculate a bone remodelling index (BRI). A positive number for
the BRI indicates a net bone gain; a negative number indicates a net bone loss.

Numbers of participants assessed:

• Intervention: baseline, 17; at 6 weeks, 11; at 12 weeks, 11
• Control: baseline, 14; at 6 weeks, 10; at 12 weeks, 10

16 participants had evaluable blood samples before and after the intervention for bone-biomarker
tests. 19 participants gave evaluable blood samples for IGF-1, IGFBP-1, IGFBP-3, and IL-6; 18 and 16
blood samples were evaluable for IL-2 and 16 for IFN-γ, respectively.

Adverse events: no cancer recurrence reported; cognitive deficits reported as reason for treatment ter-
mination

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: no

Funding: Susan Stout Exercise Science Research Fund, Sally Schindel Cone Women’s and Gender Stud-
ies Research Fund

Authors' judgement

Support for judgement

Low risk

“Randomization was achieved by flipping a coin”.

High risk

Allocation was not concealed from study personnel.

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

High risk

Study personnel and outcome assessors were not masked or blinded to study
interventions.

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

High risk

Withdrawals were not included in analyses (intervention, n = 6; control, n = 4).

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

143

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Naumann 2012 

Methods

Study design: quasi-RCT

Cochrane Database of Systematic Reviews

Number randomised: 46; 11 to psychological counselling only, 12 to exercise only, 12 to combined exer-
cise and psychological counselling, 11 to usual care

Study start: not stated; stop date: not stated

Length of intervention: 8 weeks

Length of follow-up: to end of intervention

Country: Australia

Participants

Age, years (mean SD):

• Counselling: 55.1 (7.5)
• Exercise: 49.0 (10.0)
• Exercise and counselling: 49.0 (8.2)
• Control: 51.8 (11.5)

Stage, n (%):

• Stage I–III invasive breast cancer

Inclusion criteria:

• Female with confirmed stage I–III invasive breast cancer within 12 months of treatment completion
(except hormone therapy)

• Aged 35 to 70 years

• Sufficiently fluent in English

• Either not participating in structured regular exercise or nutrition programmes in the past 6 months or
currently not meeting American College of Sports Medicine guidelines for adequate physical activity (>
150 minutes/week)

Exclusion criteria:

• Acute or chronic bone, joint, or muscular abnormalities that would compromise ability to participate
in exercise

• Immune deficiency that would compromise ability to participate in exercise

• Failure of Physical Activity Readiness Questionnaire

• Presence of metastatic disease

Interventions

24 participants assigned to 1 of 2 exercise interventions:

• Participants in the exercise group received 8 weeks of individualised exercise training, 3 times per
week, for 45 to 60 minutes. The target goal for each participant was 150 minutes per week of moder-
ate-intensity physical activity, which met American College of Sports Medicine guidelines. Each exer-
cise programme was individualised according to baseline health and fitness levels and personal goals.
Each session included cardiovascular training, strength training, patient-specific rehabilitation, core
training, and flexibility.

• Participants in counselling-only and combined exercise and counselling groups underwent psycho-
logical counselling by meeting with an accredited counsellor for a 1-hour session once a week for
8 weeks. Counsellors employed a client-centred therapy approach based on the individual needs of
each participant, whereby they facilitated disclosure of feelings and anxieties, clarified issues, and
provided reassurance and support for the women as required.

Adherence:

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

144

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Naumann 2012  (Continued)

Cochrane Database of Systematic Reviews

Participants completed an average of 84% of all scheduled exercise sessions and 87% of all scheduled
counselling sessions, with no significant differences among groups.

11 participants assigned to control:

• Usual care

Outcomes

Outcomes:

• Quality of life via FACT-B
• Fatigue via PFS
• Depression via BDI
• Mass and BMI
• Body  composition  via  a  7-site  skinfold  measurement  (triceps,  chest,  subscapular,  midaxilla,  ab-

domen, suprailiac, and thigh)

• Cardiorespiratory endurance assessed by the Modified Bruce Treadmill Protocol
• YMCA bench press test utilised to estimate upper body muscular strength
• 1RM leg press test utilised to assess lower body dynamic strength, with a seated leg press set at a 45-

degree angle

Numbers of participants assessed:

• Counselling: baseline, 11; at 8 weeks, 10
• Exercise: baseline, 12, at 8 weeks, 11
• Exercise and counselling: baseline, 12; at 8 weeks, 12
• Control: baseline, 11; at 8 weeks, 10

Adverse events: No adverse reactions to participation in exercise or counselling intervention were re-
ported.

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: yes

Funding: Foggarty grant and Health Benefits Funds, through the University of Notre Dame Australia

Authors' judgement

Support for judgement

High risk

“randomized to each group on a rolling enrolment basis”

High risk

Rolling enrolment was used; therefore, allocation was not concealed.

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Unclear risk

Blinding of outcome assessments was not described.

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 

Low risk

Baseline data for the 3 women who dropped out after randomisation were in-
cluded in the intention-to-treat analysis.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

145

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Naumann 2012  (Continued)

All outcomes

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Nieman 1995 

Methods

Study design: single-centre RCT

Number randomised: 16; 8 to exercise intervention, 8 to control

Study start: not reported; stop date: not reported

Length of intervention: 8 weeks

Length of follow-up: to end of intervention

Country: USA

Participants

Age, years (mean SE):

• Intervention: 60.8 (4.0)
• Control: 51.2 (4.7)

Stage:

• Not reported

Inclusion criteria:

• All patients had been diagnosed with breast cancer

• Had undergone surgery, adjuvant chemotherapy, and/or radiotherapy

• Not currently receiving chemotherapy or radiation treatment

Exclusion criteria:

• None reported

Interventions

8 participants assigned to exercise intervention:

• 3 sessions per week for 60 minutes consisting of weight training and walking, over 8 weeks
• Weight training consisting of 7 different resistance exercises for 2 sets of 12 repetitions (30 minutes)
• Walking on an indoor track for 30 minutes at a heart rate of 138 ± 13 bpm (about 75% heart rate max)

Adherence:

• Average attendance 87% (range, 72% to 100%)

8 participants assigned to control:

• Sedentary control

Outcomes

Outcomes:

• Symptom-limited exercise testing on a treadmill
• Leg extension strength testing on a Kin Com computerised testing station
• Cardiorespiratory fitness assessed by a 6-minute walking test

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

146

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Nieman 1995  (Continued)

Cochrane Database of Systematic Reviews

• Venous blood collection for assessment of natural killer cell cytotoxic activity by chromium release
assay and concentration of circulating immune cells, including per cent total natural killer and T-cell
subsets

Numbers of participants assessed:

• Intervention: baseline, 8; at 8 weeks, 6
• Control: baseline, 8; at 8 weeks, 6

Adverse events: 2 recurrences of disease

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: no

Funding: supported in part by a grant from the National Institute of Aging

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

Generation of the random sequence was not described.

Allocation concealment
(selection bias)

Unclear risk

Whether treatment assignment was concealed from study personnel and par-
ticipants was not described.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Unclear risk

Blinding of outcome assessments was not described.

High risk

Analysis was performed only on participants who completed the intervention.

Low risk

No selective reporting of outcomes is apparent.

Other bias

High risk

Potential imbalances at baseline; "larger than expected baseline differences in
these variables and others including NKCA"

Nikander 2007 

Methods

Study design: RCT

Number randomised: 29; 15 to intervention, 14 to control

Study start: not reported; stop date: not reported

Length of intervention: 12 weeks

Length of follow-up: to end of 12-week intervention

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

147

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Nikander 2007  (Continued)

Country: Finland

Participants

Age, years (mean SD):

Cochrane Database of Systematic Reviews

• Intervention: 52.5 (6.4)
• Control: 51.3 (7.3)

Stage:

• Intervention: not reported
• Control: not reported

Inclusion criteria:

• Histologically proven invasive breast cancer

• Adjuvant chemotherapy within 6 months

• Duration of endocrine therapy no longer than 6 months

• Aged from 35 to 65

Exclusion criteria:

• Haematogenous metastases

• No systemic adjuvant therapy

• Pregnancy or lactation

• Severe cardiac disease (NYHA class III or higher)

• Myocardial infarction within 12 months

• Uncontrolled hypertension

• Verified osteoporosis

• Other serious illness or medical condition that could be a contraindication for exercise

• Not capable of training (severe knee arthrosis, ligament or cartilage injury at lower extremity)

• Residence more than 1 hour from the exercise centre

• Competitive athlete

Interventions

15 participants assigned to exercise intervention:

• During alternate weeks, the effective part of guided training was based on step aerobics or circuit
training. In total, the 12-week planned 3-weekly exercise programme was intended to consist of 1
weekly  guided  training  session  and  at  least  2  home  training  sessions  (intensity  of  exercise:  first  2
weeks, intensity of training was moderate (RPE = 11); intensity was increased gradually from moder-
ate to somewhat hard or hard levels (RPE = 14 to 16) during 12-week exercise period).

• Step aerobics consisted of several typical step movements resulting in a total of 150 to 180 jumps and

leaps to diverging directions during each session.

• Circuit training consisted of 3 rounds of 8 to 10 different vigorous movements such as rope-jumping

and skate-jumping, resulting in a total of 100 to 150 jumps and leaps during each session.

• The home training session consisted of about 100 leaps and jumps similar to those employed in the
circuit training programme. In addition, endurance training (walking, cycling, swimming, etc.) per-
formed at the same RPE was recommended to complement the home training session in terms of to-
tal duration.

• Each session was performed for 50 to 60 minutes (10-minute warm-up, 30- to 40-minute main session,

10-minute cool-down).

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

148

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Nikander 2007  (Continued)

Adherence:

Cochrane Database of Systematic Reviews

• “Ignoring three participants (2 withdrawals and 1 participant who attended only three guided ses-
sions), the adherence to the weekly-supervised training sessions was 78%”. The most common rea-
sons for not attending the session included a holiday trip or flu. Home training was performed 2.1
times per week on average. The mean duration of home training sessions was 21 minutes.

14 participants assigned to control:

• Control group was advised to continue normal daily routines and activities during the 12-week fol-

low-up period.

Outcomes

Outcomes:

• Figure-8 running (a measure of dynamic agility)
• Counter movement jump (a measure of dynamic muscle performance) measured with a force-plate
• Maximal isometric muscle force of leg extension and elbow flexion tests assessed by an isometric leg

press and an arm dynamometer

• Cardiorespiratory fitness assessed via a 2-km walking test
• Weight and BMI

Numbers of participants assessed:

• Intervention: baseline, 14; at 12 weeks, 14
• Control: baseline, 14; at 12 weeks, 14

“One participant withdrew from the study before randomization due to family reasons”.

Adverse events: not reported

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: no, but minimal loss to follow-up

Funding: Support from The Finnish Cancer Foundation, Pirkanmaa Cancer Society Finland, and As-
traZeneca Finland is greatly appreciated.

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

Generation of the random sequence was not described.

Allocation concealment
(selection bias)

Unclear risk

Whether treatment assignment was concealed from study personnel and par-
ticipants was not described.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Unclear risk

Blinding of outcome assessments was not described.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

149

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Nikander 2007  (Continued)

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Low risk

Loss to follow-up was minimal. An ITT approach was stated but not described.
One participant withdrew from each group after baseline assessments were
taken, but these participants were not included in ITT analysis.

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Payne 2008 

Methods

Study design: single-centre RCT

Number randomised: 20; 10 to intervention, 10 to control

Study start and stop dates: 9-month period but dates not reported

Length of intervention: 14 weeks

Length of follow-up: to end of intervention

Country: USA

Participants

Age, years (mean SD):

• 64.7 (6.3)

Stage:

• Intervention: not reported
• Control: not reported

Inclusion criteria:

• Postmenopausal women with diagnosis of breast cancer who were receiving hormonal therapy with
tamoxifen, anastrozole, or letrozole (the 3 most frequently prescribed hormonal medications during
the period of recruitment and study enrolment)

• Aged 55 years and older and with complaints of fatigue

• Karnofsky Performance Scale score ≥ 80

• English speaking

• No documented history of neurological deficits or mental illness such as psychotic depression in the
past year

• No neuromuscular deficits that would contraindicate a walking exercise intervention

Exclusion criteria:

• None reported

Interventions

10 participants assigned to exercise intervention:

• Four weekly 20-minute home-based walking sessions with pedometers over 14 weeks

Adherence:

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

150

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Payne 2008  (Continued)

Cochrane Database of Systematic Reviews

• 9 out of 10 women completed the study; adherence data on numbers of sessions completed were
not specified: “the authors were unable to verify actual adherence to study parameters, such as the
number of times per week that subjects actually completed the 20-minute walk”.

10 participants assigned to control:

• Usual care

Outcomes

Outcomes:

• Fatigue measured using Revised PFS
• Sleep disturbance measured by PSQI
• depressive symptoms measured via CES-D
• Blood biomarkers including cortisol, serotonin, IL-6, bilirubin markers

Numbers of participants assessed:

• Intervention: baseline, 10; at 12 weeks and at 14 weeks, 9
• Control: baseline, 10; at 12 weeks, 9; at 14 weeks, 9

Adverse events: not reported

Notes

Trial registration link: none available

Trial authors contacted: Trial authors were contacted for means and SDs for outcomes. Trial authors
did provide some additional data, but not for all requested outcomes.

Intention-to-treat analysis: unclear, no description of how missing data were handled

Funding: NIH/National Institute of Nursing Research

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

Generation of allocation sequence was not described.

Allocation concealment
(selection bias)

Unclear risk

Whether treatment assignment was concealed from study personnel and par-
ticipants was not described.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Blinding of outcome as-
sessment (detection bias) 
All outcomes

High risk

Study personnel and outcome assessors were not masked or blinded to study
interventions.

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

Trial authors did not describe how missing data were handled. Participants in
each group withdrew from the study.

Low risk

No selective reporting of outcomes is apparent.

Other bias

Unclear risk

Characteristics of participants in each group were not well described; there-
fore, it was difficult to assess whether groups were similar at baseline.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

151

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Peppone 2015 

Methods

Study design: multi-centre RCT

Number randomised: 167; 75 to Yoga intervention, 92 to control

Study start: 2007; stop date: 2012

Length of intervention: 4 weeks

Length of follow-up: to end of intervention

Country: USA

Participants

Age, years (mean SE):

• Intervention: 55.1 (1.24)
• Control: 53.2 (0.86)

Stage, n (%):

• Intervention: stage 0-I, 32 (44.4); stage II, 30 (41.7); stage III, 10 (13.9)
• Control: stage I, 48 (53.9); stage II 31 (34.8); stage III, 10 (11.2)

Inclusion criteria:

• Enrolled between 2 and 24 months post surgery, chemotherapy, and/or radiation therapy.

For the original study, eligible survivors were required to:

• Have a confirmed diagnosis of cancer

• Have undergone and completed standard treatment for cancer

• Have sleep disturbance (indicated by a response ≥ 3 on a clinical symptom inventory using an 11-
point scale anchored by ‘‘0’’ = no sleep disturbance and ‘‘10’’ = worst possible sleep disturbance)

• Be able to read English

• Be 21 years of age or older

• Be able to give written informed consent

• Not have maintained a regular personal practice of yoga within the 3 months before enrolling in the
study, or be planning to start yoga on their own during the time they are enrolled in the study

• Not have a confirmed diagnosis of sleep apnoea

• Not be receiving any form of treatment for cancer, with the exception of hormonal or monoclonal an-
tibody therapy

• Not have metastatic cancer

Exclusion criteria:

• Not reported

Interventions

75 participants assigned to exercise intervention:

• YOCAS (Yoga intervention based on gentle Hatha and restorative yoga) twice a week for 4 weeks. Each

session had a duration of 75 minutes and was performed in groups.

Adherence:

Not reported

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

152

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Peppone 2015  (Continued)

92 participants assigned to control:

• Wait-list standard care control; participants were offered YOCAS training after completing study re-
quirements. During the control period, they received the same attention (as the intervention group)
from staff, apart from YOCAS training. Participants were asked not to start a new yoga or exercise reg-
imen on their own during this 4-week period to avoid exercise contamination.

Outcomes

Outcomes:

Musculoskeletal symptoms assessed via selected extracted questions from the following validated
questionnaires:

• University of Rochester Cancer Center Symptom Inventory (URCC SI)
• FACIT-F
• MFSI-Short Form

Numbers of participants assessed:

• Intervention: baseline, 72; at 4 weeks, 72
• Control: baseline, 92; at 4 weeks, 92

Adverse events: not reported

Notes

Trial registration link: https://clinicaltrials.gov/ct2/show/NCT00397930

Trial authors contacted: Trial authors were contacted for means and SDs for outcomes. However, they
did not provide these data.

Intention-to-treat analysis: yes, no missing data were reported

Funding: NCI and the Office of Cancer Complementary and Alternative Medicine

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

"Group assignment was determined by a computer-generated random num-
bers table in blocks of two and an allocation ratio of 1:1".

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Unclear risk

Whether allocation was concealed was not reported.

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Unclear risk

Incomplete outcome data
(attrition bias) 
All outcomes

Low risk

It was not mentioned whether study personnel and outcome assessors were
masked or blinded to study interventions.

No missing data were reported; "all data were analysed using the intent-to-
treat principle".

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

High risk

This study consisted of a secondary analysis from the original study; "the orig-
inal RCT was designed to test the effect of yoga on sleep quality in all cancer
survivors. There was no a priori aim in the study to examine the effect of yoga

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

153

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Peppone 2015  (Continued)

Cochrane Database of Systematic Reviews

on musculoskeletal symptoms in breast cancer survivors on endocrine thera-
py".

Pinto 2003 

Methods

Study design: single-centre RCT

Number randomised: 24; 12 to intervention, 12 to control

Study start: not reported; stop date: not reported

Length of intervention: 12 weeks

Length of follow-up: to end of intervention

Country: USA

Participants

Age, years (mean SD):

• 52.5 (6.8)

Stage, n (%):

• Stage 0, 2 (9); stage I, 18 (78); stage II, 3 (13)

Inclusion criteria:

• Sedentary women (exercised < 3 times per week for 20 minutes per session)

• Received diagnosis of breast cancer (stage 0, I, or II) over the past 3 years

• Postsurgery patients who had completed chemotherapy or radiation treatment

Exclusion criteria:

• Medical or current psychiatric illness that would make compliance with the study protocol difficult or
dangerous (e.g. coronary artery disease, hypertension, diabetes)

• Orthopaedic problems or neuropathies that would limit exercise training

• Medications that would alter training responses (e.g. beta-blockers) or affect distress outcomes (e.g.
antidepressants)

Interventions

12 participants assigned to exercise intervention:

• Following exercise tolerance test, the supervised exercise intervention group was taught basic exer-

cise principles and techniques (e.g. stretching techniques, warm-up/cool-down).

• Exercise session developed into 10 minutes of warm-up (cardiovascular and flexibility), 10 minutes
of cool-down (cardiovascular and flexibility), and 30 minutes of cardiovascular activity in one’s target
heart rate zone (60% to 70% of peak heart rate by the end of the 12-week intervention).

• Cardiovascular activities included treadmill walking, arm and leg ergometers, arm cycling, stationary
cycling, and rowing. Participants used at least 3 modes of physical activity per session that would
ensure at least 1 cardiovascular arm activity.

• During the last month, participants performed strength training with light weights (1- to 5-lb handheld
weights) for the triceps, biceps, pectoral muscles, shoulders, and upper back, and stomach crunches;
these muscle endurance exercises were offered to improve upper body endurance. The total duration
of sessions was 50 minutes. Also, participants were given instructions for exercising at home and were
encouraged to start to exercise on their own at least once a week.

Adherence:

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

154

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Pinto 2003  (Continued)

Cochrane Database of Systematic Reviews

• Three participants withdrew; the remaining 9 participants completed 88% of the 36 sessions.

12 participants assigned to control:

• Wait-list control group
• Asked not to change current level of physical activity for 12 weeks
• On completion of assessments, participants were offered the exercise programme free of charge

Outcomes

Outcomes:

• Peak workload, exercise time, blood pressure, heart rate, and rate pressure product were assessed
during a peak graded exercise stress test on a cycle ergometer (post-test included only exercise group
participants).

• POMS, a 65-item questionnaire, measures a variety of mood states including anger, tension/anxiety,
depression, vigour, fatigue, confusion, and total mood disturbance; vigour and total mood score were
used as primary outcomes in this study. Response options are presented on a scale of 0 to 4 (0 = not
at all, 4 = extremely).

• BES, a 35-item scale, assesses a participant's evaluation of sexual attractiveness, weight concerns,

and physical condition with 3 subscales, on which higher scores indicate higher esteem.

• Positive and Negative Affect Scale (PANAS) was used to assess the participant's positive and negative
affect. Each of the 20 items on the PANAS required a response to "how you are feeling at the moment?"
on a 1 to 5 Likert scale (1 = very slightly, 5 = extremely).

Numbers of participants assessed:

• Intervention: baseline, 12; after intervention, 9
• Control: baseline, 12; after intervention, 6

Nine participants in the intervention group completed exercise stress tests post intervention; 3 partici-
pants in this group withdrew but provided postintervention questionnaire data.

Adverse events: not reported

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: no

Funding: National Institute of Mental Health

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

Generation of the random sequence was not described.

Allocation concealment
(selection bias)

Unclear risk

Whether treatment assignment was concealed from study personnel and par-
ticipants was not described.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Blinding of outcome as-
sessment (detection bias) 
All outcomes

High risk

Study personnel and outcome assessors were not masked or blinded to study
interventions.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

155

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Pinto 2003  (Continued)

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

Cochrane Database of Systematic Reviews

Postintervention exercise stress test and weight data were unavailable for the
control group, and postintervention mood and self-esteem data were avail-
able for only half of the control group. Six (50%) control participants were not
included in the analyses.

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

High risk

Small sample size was further hampered by a high dropout rate, particularly in
the control group (50%).

Pinto 2005 

Methods

Study design: RCT

Number randomised: 86; 43 to intervention, 43 to control

Study start: not reported; stop date: not reported

Length of intervention: 12 weeks

Length of follow-up: at 12 weeks, and at 6 months and 9 months post baseline

Country: USA

Participants

Age, years (mean SD):

• Intervention: 53.4 (9.1)
• Control: 52.9 (10.4)

Stage, n (%):

• Intervention: stage 0, 8 (18.6); stage I, 17 (39.5); stage II, 18 (41.9)
• Control: stage 0, 6 (14.0%); stage I, 15 (34.9); stage II, 22 (51.2)

Inclusion criteria:

• Age ≥ 18 years

• Currently sedentary (exercised < 1 time per week for 20 minutes at vigorous intensity or < 2 times per
week for 30 minutes at moderate intensity for the past 6 months)

• Received diagnosis of stage 0 to II breast cancer over the last 5 years and completed surgery,
chemotherapy, and/or radiation

• Ambulatory (able to walk a mile without assistive devices)

• Willing to be randomised

Exclusion criteria:

• Prior history of cancer (exception: non-melanoma skin cancer)

• Medical or current psychiatric illness that could make compliance with the study protocol difficult or
dangerous (e.g. cardiovascular disease, diabetes, orthopaedic problems that limit exercise training)

Interventions

43 participants assigned to exercise intervention:

• Instructions were provided on how to exercise at a moderate intensity level (activities at 55% to 65%
HRmax), how to monitor heart rate, and how to warm up before exercise and cool down after exercise.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

156

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Pinto 2005  (Continued)

Cochrane Database of Systematic Reviews

• The programme promoted activities such as brisk walking, biking, swimming, and use of home exer-
cise equipment. For the first few weeks, participants exercised at least 2 days per week; this increased
over the 12 weeks to at least 5 days per week. The duration of individual sessions for the first few weeks
was at least 10 minutes; this increased over the 12 weeks to at least 30 minutes.

• Participants  received  weekly  physical  activity  counselling  via  telephone.  This  group  also  received

mailed weekly tip sheets on physical activity and cancer survivorship.

• After completing end-of-intervention assessments, participants received monthly calls for 3 months
to prompt and reinforce regular physical activity. These monthly calls stopped after 3 months; at that
time, participants were asked to try to maintain regular physical activity.

Adherence:

• Participants wore a pedometer at week 1, and participants reported an average of 43.12 (SD 44.32)
minutes of exercise per week; at week 12, they reported a mean of 128.53 (SD 76.82) minutes/week
of exercise.

• Average percentage adhering to target physical activity in intervention group over the course of 12-

week intervention was 40.7%.

43 participants assigned to control:

• No change in current level of physical activity for 12 weeks
• Phone calls from research staff
• Cancer survivor tip worksheet

Outcomes

Outcomes:

• Objective physical activity monitored by a Caltrac accelerometer
• Self-reported physical activity assessed by 7-DPAR via a standardised self-report interview
• Rockport 1-mile walk test with measurement of time taken to walk 1 mile
• Mood states including anger, tension/anxiety, depression, vigour, fatigue, confusion, and total mood
disturbance; vigour and total mood score - primary outcomes in this study - assessed by POMS, a 65-
item questionnaire

• Level of fatigue assessed by asking participants to place a vertical mark on a 10-cm linear analogue
scale. This scale was scored by measuring the distance in millimetres from the left anchor (i.e. “0”) to
the vertical mark. Higher scores represent greater fatigue.

• Participant's evaluation of sexual attractiveness, weight concerns, and physical condition assessed

by BES, a 35-item scale with 3 subscales, on which higher scores indicate higher esteem.

• Individual’s motivational readiness for physical activity assessed by Stage of Motivational Readiness

for physical activity.

• Exercise self-efficacy assessed on a 5-item measure that determines confidence in one’s ability to en-

gage in regular exercise in specific situations.

• Decisional balance for exercise assessed by a 16-item questionnaire that comprised items reflecting

positive (Pro) and negative (Con) aspects of exercise adoption.

Numbers of participants assessed:

• Intervention: baseline, 43; after intervention, 39
• Control: baseline, 43; after intervention, 43

Adverse events: not reported

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: yes, but used LOCF

Funding: National Cancer Institute grant

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

157

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Pinto 2005  (Continued)

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

Generation of the random sequence was not described.

Allocation concealment
(selection bias)

Unclear risk

Whether treatment assignment was concealed from study personnel and par-
ticipants was not described.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Blinding of outcome as-
sessment (detection bias) 
All outcomes

High risk

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

Study personnel and outcome assessors were not masked or blinded to study
interventions.

LOCF approach was used. Four participants withdrew from the exercise group
before the end of the 12-week intervention. Two participants withdrew from
the control group before the 6-month assessment, and another 2 participants
withdrew from the control group before the 9-month assessment. Reasons for
control group withdrawals were not given.

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

High risk

Adherence to physical activity was low (40.7%).

Pinto 2015 

Methods

Study design: multi-centre RCT

Number randomised: 76; 39 to intervention, 37 to control

Study start: January 2010; stop date: April 2012

Length of intervention: 12 weeks

Length of follow-up: at 24 weeks

Country: USA

Participants

Age, years (mean SD):

• Intervention: 55.64 (8.59)
• Control: 55.59 (10.59)

Stage, n (%):

• Intervention: stage 0, 3 (7.69); stage I, 16 (41.03); stage II, 16 (41.03); stage III, 4 (10.26)
• Control: stage 0, 2 (5.41); stage I, 13 (35.14); stage II, 18 (48.65); stage III, 4 (10.81)

Inclusion criteria:

• Aged ≥ 21 years with diagnosis of stage 0–III breast cancer in the past 5 years

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

158

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Pinto 2015  (Continued)

Cochrane Database of Systematic Reviews

• Completed surgery (patients receiving ongoing chemotherapy (most had completed), radiation, or
hormone treatment were eligible)

• Ability to read and speak English

• Ability to walk a half-mile without stopping

• Sedentary: < 30 minutes/week of vigorous physical activity or < 90 minutes/week of moderate-intensi-
ty physical activity for the past 6 months

• Access to a telephone and willingness to receive calls

Exclusion criteria:

• Medical or psychiatric problems (e.g. myocardial infarction, orthopaedic problems) that might inter-
fere with protocol adherence

Interventions

39 participants assigned to physical activity intervention:

• Intervention  consisted  of  telephone-delivered  counselling  tailored  to  participants’  motivational
readiness. Participants also received a pedometer (Digiwalker) and a heart rate monitor with instruc-
tions to use these during physical activity. Participants were instructed on maintaining physical activ-
ity logs (type of moderate-vigorous physical activity, duration, heart rate, rate of perceived exertion,
and pedometer steps) to facilitate self-monitoring.

• During weekly calls, coaches were asked to build a supportive relationship with participants while
assessing their motivational readiness, monitoring activity, identifying and solving problem barriers
to activity, and identifying health concerns.

• Overall goal was to encourage participants to gradually increase the amount of moderate-vigorous
physical activity (e.g. brisk walking) over 12 weeks to recommended goal of ≥ 30 minutes of moder-
ate-intensity physical activity on most days of the week.

• Participants also received the reach-to-recovery (RTR) programme, whereby coaches responded to
questions that participants asked about breast cancer and its treatment and provided informational
and emotional support.

Adherence:

At 12 weeks, weekly moderate-vigorous physical activity participation in the intervention group aver-
aged 130 minutes, and at week 24, 98 minutes.

37 participants assigned to control:

• Control group was provided Reach-to-Recovery informational booklets, and coaches provided infor-
mation  and  support  for  participants’  questions  and  concerns  about  breast  cancer.  During  weekly
calls, coaches also administered a Weekly Symptom Questionnaire that assessed problems such as
headaches. Participants were asked not to join a structured programme of MVPA during the 12-week
intervention phase. After completing assessments at 24 weeks, they were provided the same physical
activity tip sheets as were sent to the physical activity Plus RTR group.

Outcomes

Primary outcome:

• Moderate-vigorous physical activity assessed via the 7-DPAR, which was interviewer-administered

Other outcomes:

• HRQoL via the MOS SF-36, which assesses 8 health concepts (e.g. physical functioning, bodily pain)
• HRQoL also assessed via FACT-B
• Physical and functional effects of fatigue assessed via FACIT-F. In this 13-item scale, scores range from

6 (high fatigue) to 52 (low fatigue).

Numbers of participants assessed:

• Intervention: baseline, 39; at 12 weeks, 36; at 24 weeks, 36
• Control: baseline, 37; at 12 weeks, 32; at 24 weeks, 31

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

159

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Pinto 2015  (Continued)

Adverse events: not reported

Cochrane Database of Systematic Reviews

Notes

Trial registration link: https://clinicaltrials.gov/ct2/show/NCT00948701

Trial authors contacted: no

Intention-to-treat analysis: yes

Funding: grant from the National Cancer Institute (R01CA132854) to the first trial author

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

"Seventy six breast cancer survivors were randomized to PA Plus RTR or RTR
Control".

Allocation concealment
(selection bias)

Unclear risk

Whether treatment assignment was concealed from study personnel and par-
ticipants was not described.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Low risk

“A research assistant (blind to the participant’s group assignment) was respon-
sible for collecting all data by mail or by telephone”.

Incomplete outcome data
(attrition bias) 
All outcomes

Low risk

“Generalized linear models take a likelihood-based approach to estimation
and thus make use of all available data without directly imputing missing val-
ues”.

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Portela 2008 

Methods

Study design: single-centre RCT

Number randomised: 44; 16 to gym-exercise, 19 to home-exercise, 9 to no-exercise control

Study start: recruitment began 2004; stop date: recruitment ended 2007

Length of intervention: 26 weeks

Length of follow-up: to end of intervention

Country: Puerto Rico

Participants

Data available on the 34 participants who completed postintervention testing:

Age, years (mean SD):

• Gym-based exercise: 49.8 (6.9)
• Home-based exercise: 51.2 (7.3)
• Control: 59.6 (16.7)

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

160

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Portela 2008  (Continued)

Stage, n (%):

Cochrane Database of Systematic Reviews

• Gym-based exercise: stage I, 0 (0); stage II, 3 (25); stage III, 6 (50); stage IV, 0 (0); missing, 3 (25)
• Home-based exercise: stage I, 3 (23); stage II, 5 (38); stage III, 2 (15); stage IV, 0 (0); missing, 3 (23)
• Control: stage I, 2 (22); stage II, 2 (22); stage III, 1 (11); stage IV, 1 (11); missing, 3 (33)

Inclusion criteria:

• Women with new diagnosis of unilateral breast cancer who had received surgical treatment for breast
cancer in the past 5 years, with or without adjuvant therapy

Exclusion criteria:

• Unstable cardiac disease

• Coagulopathies

• Active psychiatric conditions

• Metastasis

• Haemoglobin level < 8.0 g/dL

• Absolute neutrophil count < 0.5 × 1000/mL

• Platelet count < 50 × 1000/mL

• Ataxia, dizziness, or peripheral sensory neuropathy

• Loss of more than 35% of premorbid weight

• Dyspnoea

• Bone pain

• Severe nausea, extreme fatigue, and extreme muscle weakness.

Exclusion criteria are considered contraindications to moderate-intensity exercise programme follow-
ing cancer diagnosis.

Interventions

35 participants assigned to 1 of 2 exercise interventions:

• Gym-exercise group, in which staff met with participants once a week for exercise supervision and
progression. The gym had qualified personnel who were present to assist participants during their
exercise routine.

• Home-exercise group, in which participants met with staff once a week, for the first 3 weeks. There-
after, they met once a month to monitor and progress the exercise programme, in terms of walking
and resistance intensity. A weekly telephone call was made by the program co-ordinator.

• Both groups performed 2 resistance training sessions and 3 aerobic training sessions per week. The
aerobic exercise mode was walking (30 minutes per session) for both groups. For the gym-exercise
group, resistance exercises targeted muscle groups of the chest, back, upper extremities, abdomen,
and  lower  extremities.  Weight  training  exercises  were  performed  mainly  with  weight  training  ma-
chines, and when participants experienced difficulty with the machines, free weights were used. The
resistance exercise component for the home group was provided via elastic bands (Theraband) and
consisted of exercises targeting the chest, back, upper extremities, abdomen, and lower extremities
muscle groups.

• Intensity of exercise: Gym-exercise group, aerobic: walking at 60% to 80% HRmax (220-age); resis-
tance, 2 to 3 sets of 10 to 15 reps at 13 to 15 RPE (on 6 to 20 scale). Home-exercise group, aerobic: walk-
ing at 12 to 16 RPE (6 to 20 scale); resistance, 2 to 3 sets of 10 to 15 reps at 13 to 15 RPE (on 6 to 20 scale).

Adherence:

• Gym-based exercise: Participation in aerobic sessions ranged from 19 to 54 (a mean of 37 sessions),
for a percentage of participation ranging from 24% to 69%. Participation in strengthening sessions

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

161

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Portela 2008  (Continued)

Cochrane Database of Systematic Reviews

ranged from 12 to 46 (a mean of 33 sessions), for a percentage of participation ranging from 23% to
88%.

• Home-based exercise: Endurance participation ranged from 27 to 69 sessions completed (a mean of

55 sessions); percentage of participation ranged from 35% to 88%.

• Participation in strengthening sessions ranged from 18 to 57 (a mean of 45 sessions); percentage of

participation ranged from 35% to over 100%.

9 participants assigned to control:

• The control group continued receiving usual care provided by their physicians. At the end of their par-
ticipation in the study, control group participants were offered an orientation session on the bene-
fits of participating in an exercise programme, along with exercise brochures for home exercises and
elastic bands.

Outcomes

Outcome:

• 12-Minute walk test used to assess cardiorespiratory fitness
• Handgrip strength examined with a handheld dynamometer. Participants were evaluated in a seated
position, with the arm resting at the side and the elbow flexed at 90° and the forearm in mid-position
between pronation and supination.

• BMI measured as an outcome
• Spanish version of FACT-B also administered to assess quality of life
• Function measured via the DASH questionnaire
• Shoulder flexion, abduction, and external rotation examined through goniometry
• Volumetric measurements collected to monitor the development of lymphoedema with a volumetric
oedema gauge; water displacement volumetry included to provide an estimate of volume of the up-
per extremity; volumetric measurements of the entire arm collected with the participant in a seated
position

Numbers of participants assessed:

• Gym-based exercise: baseline, 16; at 13 weeks and post intervention, 12
• Home-based exercise: baseline, 19; at 13 weeks and post intervention, 13
• Control: baseline, 9; at 13 weeks and post intervention, 9

Adverse events:

• None of the women had lymphoedema before enrolment in the study, and no participant developed
it during the course of the study. One participant developed an asthma episode during the 12-minute
walk test at baseline evaluation.

• Another participant had an episode of hypoglycaemia while at the gym during an exercise session in

the morning - the result of skipping breakfast.

• Three participants presented high blood pressure (above 140/90 mmHg) during their participation in

the exercise programmes.

• One participant from the gym-exercise group complained of severe headache at the second evalua-

tion session, after 3 months of participating in the programme without any symptoms.

• One participant from the gym-exercise group complained of severe headache at the second evalua-

tion session, after 3 months of participating in the programme without any symptoms.

• A participant in the gym-exercise group complained of foot pain before beginning participation in the
exercise programme. After the first exercise session, she commented on increased pain, underwent
foot surgery recommended by her podiatrist, and decided not to continue in the study.

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: no

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

162

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Portela 2008  (Continued)

Risk of bias

Bias

Funding: grant number 5P20RR011126 from the National Center for Research Resources, a component
of the National Institutes of Health

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Randomisation of participants was performed by a computer-generated
scheme developed with the Statistical Analysis System.

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Unclear risk

Whether allocation was concealed is unclear.

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Low risk

“One physical therapist, blinded to group assignment, evaluated the partici-
pants in this study. Participants were instructed not to discuss their exercise
programs or group assignment with the evaluator”.

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

Pre-post-test analysis was performed only on those who completed all assess-
ments. No information regarding handling of missing data was provided.

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Rahnama 2010 

Methods

Study design: single-centre RCT

Number randomised: 32; intervention, not specified; control, not specified

Study start: not reported; stop date: not reported

Length of intervention: 15 weeks

Length of follow-up: to end of intervention

Participants

Country: Iran

Age, years:

• 50 to 65

Stage: stage I-IIIB

Inclusion criteria:

• 50 to 65 years old

• Women who received surgery, chemotherapy, and radiotherapy and currently were taking hormone
therapy

• Stage I-IIIB

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

163

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Rahnama 2010  (Continued)

• No specific illness in the past 6 months

• No experience of a menstrual cycle

Cochrane Database of Systematic Reviews

• No participation in exercise training or physical activity in the past 6 months

• No change in body weight during this period (last 6 months) as great as 10% of their whole body
weight

Exclusion criteria:

• None reported

Interventions

The number of participants assigned to the exercise intervention was not specified:

• Participants took part in supervised walking programme 2 times per week at 45% maximum heart rate
during weeks 1 to 5, 55% maximum heart rate during weeks 6 to 10, and 65% maximum heart rate
during weeks 11 to 15. The duration of walking progressed from 25 minutes during weeks 1 to 5 to 35
minutes during weeks 6 to 10.

• Resistance training (60 minutes per session) was performed on different days from walking and in-
cluded 9 resistance training exercises performed on Cybex strength training equipment (Smith press
squats, leg press, leg extension, seated leg curl, lat pull-downs) and with free weights (bench press,
overhead press, biceps curls, and triceps kickbacks).

Adherence: not reported

Number of participants assigned to control not specified:

• Control group participated in measurements only and were asked not to participate in any physical
activity or exercise training. All participants were asked to avoid changes in dietary habits for weight
loss purposes for the duration of the study.

Outcomes

Outcomes:

• Weight, BMI, waist and hip circumferences
• Blood pressure measured with a Japanese sphygmomanometer model ALPK2 in seated position
• Resting heart rate measured each morning with the heart rate monitor belt
• VO2max assessed by modified Bruce protocol
• Insulin measured by electrochemiluminescent immunoassay; glucose measured with a hexokinase
ultraviolet assay; insulin resistance calculated by the HOMA; LDL-C and triglycerides measured enzy-
matically

Numbers of participants assessed:

• Intervention: baseline, not specified; at 15 weeks, 14
• Control: baseline, not specified; at 15 weeks, 15

Adverse events: not reported

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: no

Funding: none specified

Risk of bias

Bias

Authors' judgement

Support for judgement

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

164

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Rahnama 2010  (Continued)

Random sequence genera-
tion (selection bias)

Unclear risk

Generation of the random sequence was not described.

Allocation concealment
(selection bias)

Unclear risk

Whether treatment assignment was concealed from study personnel and par-
ticipants was not described.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Low risk

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

“All the measurements were obtained twice and recorded by one staff that was
blinded to subjects in pre- and post-tests”.

Three participants withdrew during the study period; reasons for withdrawals
were not reported. No intention-to-treat analysis was performed.

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Rogers 2009 

Methods

Study design: single-centre RCT

Number randomised: 41; 21 to intervention, 20 to control

Study start: April 2006; stop date: July 2007

Length of intervention: 12 weeks

Length of follow-up: immediately post intervention and at 3 months post intervention

Country: USA

Participants

Age, years (mean SD):

• Intervention: 52 (15)
• Control: 52 (8)

Stage, n (%):

• Intervention: stage I, 6 (29); stage II, 11 (52); stage III, 4 (19)
• Control: stage I, 6 (30); stage II, 10 (50); stage III, 4 (20)

Inclusion criteria:

• English-speaking female breast cancer survivors between the ages of 18 and 70 years with a diagnosis
of stage I, II, or IIIA disease

• Currently taking aromatase inhibitors or selective estrogenic receptor modulators and expected to re-
main on hormonal therapy for the duration of the study (i.e. ≥ 8 months)

Exclusion criteria:

• Diagnosis of dementia or organic brain syndrome

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

165

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Rogers 2009  (Continued)

Cochrane Database of Systematic Reviews

• Medical, psychological, or social characteristic that would interfere with ability to fully participate in
programme activities and assessments (e.g. psychosis, schizophrenia)

• Contraindication to participation in a regular physical activity programme (e.g. unstable angina, de-
bilitating arthritis pain)

• Breast cancer recurrence or metastatic disease; inability to ambulate; planning to relocate out of the
study area during the 8-month study period

• Engaged in > 60 minutes of vigorous physical activity or > 150 minutes of moderate plus vigorous ac-
tivity per week during the past month (based on self-report)

Interventions

21 participants assigned to exercise intervention:

• Behaviour change intervention with goal of gradually increasing all participants to 150 minutes of

moderate walking per week

• 6  discussion  group  sessions  with  a  clinical  psychologist  who  encouraged  social  support,  provided
breast cancer survivor exercise role models, and covered the following topics: journaling, time man-
agement, stress management, dealing with exercise barriers, and behaviour modification

• 12 individual supervised exercise sessions
• 3 individual ‘‘face-to-face’’ update counselling sessions with an exercise specialist that tapered to a

home-based programme by the end of the intervention

Adherence:

• Intervention participants completed 100% (252/252) of individual exercise sessions, 95% (60/63) of
individual update sessions, and 98% (123/126) of group sessions, for an overall 99% adherence to all
possible intervention sessions (435/441).

• Of  63  individual  update  sessions  with  exercise  specialists,  4  (6%)  were  administered  by  telephone

rather than face-to-face owing to logistical reasons and participant preference.

20 participants assigned to control:

• Control group was provided written materials related to physical activity obtained from the American
Cancer Society. These materials were considered ‘‘usual care’’ because of their availability to the gen-
eral public. No specific instructions were given to the control group concerning physical activity be-
haviour change. Participants randomised to the control group were given the opportunity to receive
the intervention at no charge once postintervention assessments were complete

Outcomes

Outcomes:

• Physical activity assessed by GT1M accelerometer for 7 consecutive days. Outcomes included total

activity counts, total steps, and minutes of light, moderate, hard, and very hard activity.

• Leisure time activity assessed via the Godin Leisure-Time Exercise Questionnaire. Outcomes included
were average weekly duration and frequency of light, moderate, and vigorous leisure time activity for
the past month. Reported duration was multiplied by frequency to determine the minutes per week
spent at each of the 3 intensity levels (light, moderate, and vigorous).

• Physical activity stage of readiness (i.e. stage of change) before learning about the study and post

intervention assessed on a previously validated scale

• Submaximal treadmill test based on the Naughton protocol with the endpoint of 85% of predicted
maximal heart rate used to determine fitness on the basis of a published regression equation estimat-
ing total oxygen cost of walking at the treadmill grade and speed achieved

• Muscle strength assessed with a back/leg extensor dynamometer and handgrip dynamometer. The

maximum reading (best of 3 efforts) provided the absolute strength measure in kilograms.

• Anthropometric  measures  including  BMI  and  waist  and  hip  circumferences  measured  on  a  non-
stretching tape measure, with the participant standing with abdomen relaxed and arms at sides. At
each testing, 3 measurements were obtained and results averaged before calculation of the waist-to-
hip ratio.

• DEXA performed using a Lunar Prodig to determine percentage body fat and bone mineral density

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

166

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Rogers 2009  (Continued)

Cochrane Database of Systematic Reviews

• Perceived health assessed by asking participants to rate their general health on a 5-point Likert scale
from 1 = poor to 5 = excellent. Participants were asked to report the number of sick days missed from
work in the past month by completing a single fill-in-the-blank question.

• Based on the sum of 5-point Likert scales, quality of life measured with the 37-item FACT-B
• 13-Item FACT-F, 19-item FACT - Endocrine Symptoms (FACT-ES), and 42-item FACT - Cognitive (FACT-

Cog) used to assess fatigue, endocrine symptoms, and cognitive function, respectively

• Sleep dysfunction assessed via the PSQI with scoring according to the published protocol so that a
higher score indicates greater sleep dysfunction (i.e. habitual sleep efficiency, sleep latency, sleep
duration, subjective sleep quality, use of sleeping medication, daytime dysfunction, and global score).
Owing to limited survey space, the sleep disturbances subscale was not included, requiring that the
global score be obtained by obtaining the sum of 6 rather than the usual 7 domains.

• Joint pain, stiffness, and physical function assessed by the 5-point Likert scale version (i.e. 1 = none

to 5 = extreme) of the 24-item WOMAC, a measure of lower extremity pain and function

Numbers of participants assessed:

• Intervention: baseline, 21; at 12 weeks, 20; at 6 months, 19
• Control: baseline, 20; at 12 weeks, 18 (19, DEXA); at 6 months, 17

Adverse events: No adverse events related to the intervention nor to other study procedures occurred.
The following non-serious, non-related events were recorded: wheezing requiring physician valuation
for asthma, cholinergic urticaria, herpes zoster, sinusitis, back pain related to falling, and elective cos-
metic reconstructive surgery.

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: no, but minimal loss to follow-up (n = 2)

Funding: Southern Illinois University School of Medicine Excellence in Academic Medicine Award,
Brooks Medical Research Fund, and Memorial Medical Center Foundation Regional Cancer Center

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Randomisation was computer generated.

Allocation concealment
(selection bias)

Low risk

“Randomization was kept in sealed envelopes until randomization to prevent
bias in group allocation by study personnel”.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Unclear risk

It was not mentioned whether study personnel and outcome assessors were
masked or blinded to study interventions.

Low risk

Loss to follow-up was minimal. Reasons for exclusions were presented.

Low risk

No selective reporting of outcomes is apparent.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

167

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Rogers 2009  (Continued)

Cochrane Database of Systematic Reviews

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Rogers 2013 

Methods

Study design: single-centre RCT

Number randomised, 28; 15 to intervention, 13 to control

Study recruitment start: June 2008; recruitment stop date: April 2009

Length of intervention: 3 months

Length of follow-up: to end of intervention

Country: USA

Participants

Age, years (mean SD):

• Intervention: 58.0 (6.1)
• Control: 53.7 (13.9)

Stage, n (%):

• Intervention: stage I, 10 (67); stage II, 4 (27); stage III, 1 (7)
• Control: stage I, 5 (39); stage II, 5 (39); stage III, 3 (23)

Inclusion criteria:

• Female

• Stage I, II, IIIA breast cancer survivors between the ages of 18 and 70 years

• Not currently receiving (and not planning to receive during the study duration) chemotherapy or radi-
ation therapy

• ≥ 8 weeks post surgery

• English speaking

• Medical clearance for participation provided by physician

Exclusion criteria:

• Dementia or organic brain syndrome

• Medical, psychological, or social characteristics that would interfere with ability to fully participate in
study activities (e.g. psychosis)

• Contraindication to participate in a regular physical activity programme

• Metastatic or recurrent disease

• Inability to ambulate

• Engaging in ≥ 60 weekly minutes of vigorous physical activity or ≥ 150 weekly minutes of moderate
plus vigorous activity during the past month (based on self-report)

• Anticipated elective surgery during the intervention that would interfere with participation (e.g.
breast reconstructive surgery)

• Did not live or work within 50 miles of study site

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

168

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Rogers 2013  (Continued)

Interventions

15 participants assigned to exercise intervention:

• Behavioural change intervention towards increasing physical activity (150 minutes weekly) and resis-
tance training (20 repetitions of 8 different exercises using major muscle groups) over 6 months. Par-
ticipants were tapered from supervised sessions with an exercise specialist to non-supervised home-
based exercise sessions within the first 6 weeks of the intervention.

• Participants attended 6 group discussion sessions with a clinical psychologist during the first 9 weeks.
They  also  met  with  exercise  specialists  for  face-to-face  updates  of  their  physical  activities  every  2
weeks during the final 6 weeks of the intervention.

Adherence:

• The  14  participants  completing  the  intervention  attended  100%  supervised  exercise  with  exercise
specialist (168/168), 100% of update sessions with exercise specialist (42/42), 73% of group sessions
(61/84), and 87.5% of resistance exercise sessions (21/24).

• Adherence to aerobic physical activity (based on accelerometer): Improvement was noted in weekly
minutes of moderate-intensity physical activity for the intervention group vs the usual care group (i.e.
45.4 vs 37.7; mean between-group difference = 83.1; effect size (d) =.76; P = .097). At M3, the mean for
moderate-intensity physical activity in the intervention group was 198.4 ± 111.7 minutes per week.
• With regard to resistance training, the 12 participants in the intervention group providing M3 data
completed 21 of 24 possible resistance exercise sessions over the 12-week period (87.5%) and report-
ed a weekly average of 1.8 sessions per week. During the final 4 weeks of the intervention, intervention
participants completed 5 of the 8 sessions (63%; weekly average = 1.3 sessions).

13 participants assigned to control:

• Control group received written materials from the American Cancer Society, which included general
information about physical activity and diet after cancer diagnosis but no specific recommendations
regarding exercise behaviour. Participants were told that they could receive the intervention free of
charge at completion of the study.

Outcomes

Outcomes:

• Adherence to intervention physical activity recommendations measured with 7-day MTI/ActiGraph

accelerometer monitoring (aerobic) and exercise log (resistance)

• Submaximal treadmill test based on the Naughton protocol for estimated fitness
• Muscle strength measured with a back/leg dynamometer
• Body composition (BMI, waist-to-hip ratio, body fat percentage via bioelectric impedance (i.e. Quan-
tum X by RJL Systems), in a standardised fashion (i.e. same time of day for each measurement after
a 4-hour fast)

• Pro-inflammatory and anti-inflammatory cytokines: 5 cytokines - IL-1 beta, IL-6, IL-8, IL-10, and TNF-
alpha - measured by the MILLIPLEX MAP human high-sensitivity cytokine assay. Total adiponectin
measured via adipokine MILLIPLEX panel A, leptin via MILLIPLEX adipokine panel B (HADK2-61K), and
high-molecular-weight adiponectin via an ELISA kit

• Fatigue via FSI
• Self-reported sleep dysfunction measured on the PSQI, which was scored according to the published

protocol (i.e. higher score indicates greater sleep dysfunction)

• Sleep latency and efficiency measured objectively with the same accelerometer used in measuring
physical activity by transferring to the wrist when in bed. Participants recorded time in and out of bed
on a record sheet.

Numbers of participants assessed:

• Intervention: baseline, 15; at 3 months, 14
• Control: baseline, 13; at 3 months, 12

Adverse events: Three adverse events were identified - 2 related and non-serious in the intervention
group, and 1 non-related and serious in the control group.

Notes

Trial registration link: https://clinicaltrials.gov/ct2/show/NCT00640666

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

169

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Rogers 2013  (Continued)

Trial authors contacted: no

Intention-to-treat analysis: no

Cochrane Database of Systematic Reviews

Funding: Simmons Cancer Institute at Southern Illinois University School of Medicine Translational Re-
search Award. Drs. Rogers, Hopkins-Price, Vicari, Rao, and Verhulst receive salary support from Nation-
al Cancer Institute Grant 1R21CA135017. Drs. Rogers, Hopkins-Price, Vicari, and Verhulst also receive
salary support from National Cancer Institute Grant 5R01CA136859. Dr. Courneya is supported by the
Canada Research Chairs Program and National Cancer Institute Grant 5R01CA136859.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

"Randomization was based on computer generated numbers, performed in
blocks of 4, and revealed in the order in which participants completed base-
line testing".

Allocation concealment
(selection bias)

Unclear risk

Whether treatment assignment was concealed from study personnel and par-
ticipants was not described.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Unclear risk

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

"All assays were performed by an investigator blinded to the experimental
treatment". Other outcome assessment blinding was not described.

Data analysis was based only on study participants completing both baseline
and 3-month follow-up. 8 participants were excluded.

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Rogers 2014 

Methods

Study design: single-centre RCT

Number randomised: 46; 22 to intervention, 24 to control group

Study start: not reported; stop date: not reported

Length of intervention: 3 months

Length of follow-up: to end of intervention

Country: USA

Participants

Baseline data available for 20 intervention and 24 control participants:

Age, years (mean SD):

• Intervention: 57.2 (5.5)
• Control: 55.2 (9.1)

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

170

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Rogers 2014  (Continued)

Stage, n (%):

Cochrane Database of Systematic Reviews

• Intervention: DCIS, 3 (15.0); stage I, 10 (50.0); stage II, 7 (35.0)
• Control: DCIS, 5 (20.8); stage I, 11 (45.8); stage II, 8 (33.3)

Inclusion criteria:

• Female

• 30 to 70 years of age, ductal carcinoma in situ (DCIS), stage I or II breast cancer

• At least 4 weeks status post final primary treatment administration (longer-term therapies such as
aromatase inhibitors, oestrogen receptor modulators allowed)

• ≥ 8 weeks post surgical procedure

• English speaking

• Medical clearance for participation provided by physician

• Postmenopausal

• Average fatigue over the past week rated as ≥ 3 on a 1 to 10 Likert scale, or sleep dysfunction ≥ 1 on a 0
to 3 Likert scale

• Willingness to abstain from “as needed” medications for 7 days before each blood draw

Exclusion criteria:

• Metastatic or recurrent breast cancer

• Inability to ambulate without assistance

• Unstable angina

• New York Heart Association Class II, III, or IV congestive heart failure

• Uncontrolled asthma

• Interstitial lung disease

• Current use of steroids

• Having been told by a physician to do only exercise prescribed by a physician

• Dementia or organic brain syndrome

• Schizophrenia or active psychosis

• Connective tissue or rheumatological disease (i.e. systemic lupus erythematosus, rheumatoid arthri-
tis, amyloidosis, Reiter's syndrome, psoriatic arthritis, mixed connective tissue disease, Sjögren's syn-
drome, progressive systemic sclerosis, CREST syndrome, polymyositis, dermatomyositis, vasculitis,
polymyalgia rheumatic, temporal arteritis)

• Participating, on average, in more than 20 minutes of physical activity on 2 or more days per week
during the past 6 months

• Elective surgery planned to occur during the time of the intervention that would interfere with inter-
vention participation (e.g. breast reconstructive surgery)

• Living or working > 50 miles from study site

• Lack of transportation to study site

• Changes in usual medications expected during the study time period

• Planning to move residence out of the local area during the 5 months of study participation

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

171

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Rogers 2014  (Continued)

Cochrane Database of Systematic Reviews

• Planning to travel out of the local area for vacation during the first 4 weeks of the intervention, or
planning to travel out of the local area for longer than a week during the last 8 weeks of the interven-
tion

• Contraindication to participation in exercise (i.e. moderate-intensity walking and strength training
with resistance bands)

Interventions

22 participants allocated to exercise intervention:

• Aerobic component: Participants were gradually advanced by week 9 to 40-minute bouts of moder-
ate-intensity (i.e. 48% to 52% of heart rate reserve) walking 4 times per week with no more than 1
day between bouts (e.g. exercise on Monday, Wednesday, Thursday, Saturday each week, exercise
on Tuesday, Wednesday, Friday, Sunday each week), resulting in a total weekly goal of 160 aerobic
minutes. Participants attended 26 individual supervised exercise sessions with an exercise specialist
(3 per week for first 2 weeks and 2 per week for last 10 weeks). Participants were also instructed to
exercise at home (2 walking sessions per week in last 10 weeks of the intervention).

• Resistance component: Resistance training occurred twice weekly during the same sessions as super-
vised aerobic walking (e.g. Monday/Thursday, Tuesday/Friday). The strength of resistance bands was
advanced as tolerated at intervals ≥ 2 weeks. Eight different resistance exercises focussed on the ma-
jor muscle groups were included, with up to 2 sets of 15 repetitions per exercise.

• Behavioural component: To improve adherence, behavioural support was provided at 6 group meet-
ings with a clinical psychologist or psychology intern under the supervision of a clinical psychologist
(every other week) based on a prior successful behaviour change intervention. Intervention partici-
pation occurred in cohorts or “waves” to enhance social support provided by group meetings.

Adherence (based on session record sheets):

• Aerobic component: 91%
• Resistance component: 93%

24 participants assigned to control:

• Control group was instructed not to change exercise behaviour beyond what they were doing at the

time of study enrolment.

Outcomes

Primary outcome:

• Physical activity assessed by MTI/Actigraph accelerometer

Other outcomes:

• Cancer-related fatigue (intensity) and interference assessed with the FSI
• General  fatigue  assessed  by  the  Patient  Reported  Outcomes  Measurement  Information  System

(PROMIS)

• Diet via 3-day diet record
• Cardiorespiratory fitness measured by submaximal treadmill testing based on a modified Naughton

protocol

• Body composition assessed by bioelectrical impedance, BMI, and waist-to-hip ratio
• Extensor leg strength measured by back and leg dynamometer
• IL-6, IL-8, IL-10 and TNF-alpha cytokines measured by high sensitivity human cytokine assay
• Depression and anxiety assessed via PROMIS
• Self-reported sleep disturbance assessed by the PSQI
• Self-reported sleep assessed with PROMIS
• Sleep latency measured via accelerometers (Actigraph)

Numbers of participants assessed:

• Intervention: baseline, 22; at 3 months, 19
• Control: baseline, 24; at 3 months, 23

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

172

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Rogers 2014  (Continued)

Adverse events:

Cochrane Database of Systematic Reviews

• No serious adverse effects occurred.
• Of the non-serious adverse effects:

◦ 2 participants in the intervention group had a modification of their resistance training programme

due to ongoing pre-existing lymphoedema.

◦ 2 participants in the intervention group broke their wrist as the result of a motor vehicle accident

and had a new breast lump with negative mammography.

◦ 2 participants in the control group experienced high blood pressure during treadmill fitness test-

ing.

Notes

Trial registration link: https://clinicaltrials.gov/ct2/show/NCT01147367

Trial authors contacted: no

Intention-to-treat analysis: no

Funding: supported by National Cancer Institute R21CA135017

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Low risk

"randomization in blocks of four based on computer generated numbers"

Allocation concealment
(selection bias)

Low risk

"Participants were randomized in the order in which they completed base-
line testing. Randomization numbers were kept in sealed, opaque envelopes
so that study staff and participants were unaware of group allocation until all
baseline testing was complete".

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Low risk

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

Physical measures were obtained by individuals who were blinded to partici-
pants' study group allocation.

"Intent-to-treat analysis was performed (i.e. differences between the study
groups were assessed with all data regardless of the participant's adherence
to the exercise in the intervention group or self-initiation of exercise in the
control group)".

However, only participants with follow-up data were included in analysis (4
participants were excluded).

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Rogers 2015 

Methods

Study design: multi-centre RCT

Number randomised: 222; 110 to intervention, 112 to control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

173

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Rogers 2015  (Continued)

Study start: January 2010; stop date: September 2013

Length of intervention: 3 months

Length of follow-up: at 3 months

Country: USA

Participants

Age, years (mean SD):

• Intervention: 54.9 (9.3)
• Control: 53.9 (7.7)

Stage, n (%):

• Intervention: stage DCIS, 13 (11.8); stage I, 47 (42.7); stage II, 37 (33.6); stage III, 13 (11.8)
• Control: stage DCIS, 12 (10.7); stage I, 46 (41.1); stage II, 41 (36.6); stage III, 13 (11.6)

Inclusion criteria:

• Women aged 18 to 70 years with history of ductal carcinoma in situ (DCIS) or stage I-IIIA breast cancer
who were not currently receiving or planning to receive chemotherapy or radiation therapy

• C8 weeks post surgical procedure

• English speaking

• Medical clearance for participation provided by physician

• Participating, on average, in 30 minutes of vigorous physical activity or 60 minutes of moderate activi-
ty per week during the past 6 months

Exclusion criteria:

• Dementia or organic brain syndrome

• Disorders that would interfere with ability to fully participate in assessments and BEAT Cancer activi-
ties (e.g. psychosis, schizophrenia)

• Contraindication to participation in regular physical activity

• Metastatic or recurrent breast cancer

• Inability to ambulate

• Elective surgery anticipated during the intervention that would interfere with participation (e.g.
breast reconstructive surgery)

• Travel plans interfering with scheduled study sessions

• Participating in another exercise study

Interventions

110 participants assigned to exercise intervention:

• 3-Month BEAT Cancer intervention included 12 supervised exercise sessions (aerobic walking on the
treadmill) with a trained exercise specialist, which were tapered over the first 6 weeks to an exclusively
home exercise programme.

• Duration of individual sessions starting at 15 to 25 minutes during week 1, to 30 to 50 minutes by week
7 (intensity: week 1, 40% to 59% of heart rate reserve, 10-point RPE = 1.5 to 3; week 7, 40% to 59% of
heart rate reserve, 10-point RPE = 3.5 to 5.5).

• Frequency starting with 3 weekly exercise sessions during week 1, to 150 minutes weekly of moder-

ate-intensity physical activity by week 7 (i.e. ≥ 3 weekly sessions)

• During  the  second  6  weeks  of  the  intervention,  participants  attended  a  face-to-face  update  coun-

selling session with the exercise specialist every 2 weeks.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

174

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Rogers 2015  (Continued)

Cochrane Database of Systematic Reviews

• Participants also attended 6 discussion group sessions led by trained facilitators during the first 9

weeks of the intervention.

Adherence:

Adherence to planned BEAT Cancer components was 98% for supervised exercise sessions, 96% for up-
date sessions, and 91% for discussion group sessions. Only 5 BEAT Cancer participants did not receive
the allocated intervention (i.e. did not complete 75% of all intervention components combined).

112 participants assigned to control:

• Usual care participants received printed American Cancer Society materials describing physical activ-
ity recommendations for cancer survivors (e.g. Living Smart: The American Cancer Society’s Guide to
Eating Healthy and Being Active). No additional instructions regarding physical activity were provided
with the materials.

Outcomes

Primary outcome:

• Weekly minutes of ≥ moderate-intensity physical activity assessed by the MTI/Acti-Graph accelerom-

eter (models GT1M and GT3X)

Other outcomes:

• Godin Leisure-Time Exercise Questionnaire, which assesses volitional, leisure time physical activity

(minutes of ≥ moderate-intensity physical activity)

• Aerobic fitness measured by a submaximal treadmill test and modified Naughton protocol
• Quality of life measured via FACT-B

Numbers of participants assessed:

• Intervention: baseline, 110; at 3 months, 106; at 6 months, 105
• Control: baseline, 112; at 3 months, 110; at 6 months, 108

Adverse events: Only 1 related serious adverse event occurred (intervention group; pelvic stress frac-
ture). Related expected adverse events in the BEAT Cancer group included back or lower extremity
musculoskeletal pain or injury (n = 14), heart rate monitor rash (n = 1), fall while walking (n = 1), breast
reconstruction (n = 3), and chest pain during treadmill fitness testing (n = 1). Related adverse events in
the UC group included arm tingling (n = 1) during the treadmill test and knee tendonitis (n = 1).

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: yes

Funding: supported by National Cancer Institute R01CA136859

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Randomisation, based on computer-generated numbers, is performed in
blocks of 4 within each site to facilitate equal distribution between the 2 study
groups at each site.

Allocation concealment
(selection bias)

Low risk

Computer generated numbers for each site; numbers were placed in sealed,
opaque envelopes and were delivered to the collaborating site with a written
protocol for use.

Blinding of participants
and personnel (perfor-
mance bias) 

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

175

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Rogers 2015  (Continued)

All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Low risk

Cochrane Database of Systematic Reviews

“Assessment tools are administered … by an exercise specialist (blinded to the
participant's study group allocation) in the exercise laboratory”.

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Low risk

“All analyses were intention-to-treat with all data available being used”.

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Saarto 2012 

Methods

Study design: single-centre RCT
Number randomised: 573; 302 to intervention, 271 to control
Study start and stop dates: enrolment between September 2005 and September 2007
Length of intervention: 12 months
Length of follow-up: at 6 and 12 months (end of intervention) after baseline

Country: Finland

Participants

Age, years, at baseline, mean (range):

• Intervention: 52 (36-68)
• Control: 52 (35-68)

Stage:

• All stage T1-4, N0-3, M0 (i.e. stage I to IIIC)

Inclusion criteria:

• Histologically confirmed newly diagnosed invasive breast cancer (T1-4 N0-3 M0)

• Pre- and postmenopausal women treated with adjuvant chemotherapy or radiation therapy within
last 4 months

• Started endocrine therapy (anti-oestrogens, aromatase inhibitors, luteinising hormone-releasing hor-
mone agonists, or a combination) no more than 4 months earlier

• 35 to 68 years old

• Signed informed consent before the start of protocol-specific procedures

Exclusion criteria:

• Male gender

• Prior malignancy except basal cell carcinoma or in situ carcinoma

• Hematogenous metastases (M1)

• Systemic adjuvant therapy

• Postmenopausal women with anti-oestrogens as the only adjuvant treatment (with or without radia-
tion therapy)

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

176

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Saarto 2012  (Continued)

• Pregnancy or recent lactation (< 1 year)

• Severe cardiac disease (NYHA Class III or greater)

• Myocardial infarction within 12 months

• Uncontrolled hypertension

Cochrane Database of Systematic Reviews

• Verified osteoporosis (proximal femur or lumbar spine T-score < -2.5 or fracture without trauma)

• Concomitant medications affecting calcium and bone metabolism such as bisphosphonates, cal-
citonin, parathyroid hormone, selective oestrogen receptor modulators, oral corticosteroids (over 6
months), anticonvulsants (phenytoin, carbamatsebin), and prolonged heparin therapy

• Other diseases affecting calcium and bone metabolism such as hyperthyroidism, newly diagnosed hy-
pothyroidism, primary hyperparathyroidism, renal failure, chronic hepatic diseases, organ transplant

• Residency more than 1 hour from the exercise centre

• Competitive athlete

• Treated only with radiation therapy

• Incapable of training (e.g. severe cardiac disease, osteoporosis, severe knee arthrosis, ligament or car-
tilage injuries at lower extremities)

• Other serious illness or medical condition, which could be a contraindication to exercise

Interventions

302 participants assigned to a 2-component supervised 12-month exercise training intervention, with
each component performed in alternate weeks. Components included:

• On alternate weeks, the effective part of guided training was based on step aerobics or circuit training.
In total, the planned 60-minute weekly exercise programme was intended to consist of supervised
training sessions and 2 to 3 home training sessions.

• Step aerobics consisted of 150 to 180 jumps and leaps in diverging directions, progressing from 10-
cm high benches to 15-cm benches after 4 months, and to 20-cm benches after 8 months. Music was
set at 118 beats per minute.

• Circuit training started with 100 steps and hops per session and progressed to 150 to 180 steps and
hops per session, with more demanding jumps in the later phase. The session started with a 20-second
training period followed by a 60-second rest, and progressed to a 40:60 second training/rest ratio, then
a 30:60 second ratio with more demanding jumps such as heel drops, star jumps, and skate jumps.
• The home training session consisted of about 100 leaps and jumps similar to those employed in the
circuit training programme. In addition, endurance training (walking, cycling, swimming, etc.) per-
formed at the same RPE was recommended to complement the home trainiIng session in terms of
total duration.

• Mostly aerobic with some anaerobic activity. Intensity of exercise for first 2 weeks was moderate (RPE
= 11), and intensity was increased gradually from moderate to somewhat hard or hard levels (RPE =
14 to 16) during the 12-week exercise period.

Adherence:

Premenopausal trainees attended a median of 30/52 (58%) supervised training sessions:

• 6/124 (5%) did not attend any training; 23/124 (18%) attended < once a month; 78/124 (63%) attended
at least every second week (i.e. > 25 times). Based on 109 returned training diaries, premenopausal
participants completed home training on average 2.8 times weekly for a total time of 2.9 hours. The
median total number of training sessions (supervised and home training sessions together) was 3.3
times per week (interquartile range 2.4 to 4.6).

Postmenopausal trainees attended a median of 33/52 (63%) training sessions:

• 2/138 (< 2%) did not attend any session; 27/138 (20%) attended sessions < once a month; 96/138 (70%)
attended at least every second week. Based on 122 returned training diaries, postmenopausal partic-

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

177

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Saarto 2012  (Continued)

Cochrane Database of Systematic Reviews

ipants completed home training on average 3.2 times (107%) weekly for a total time of 3.5 hours. The
median total number of training sessions was 4.3 times per week (interquartile range 2.3 to 5.4).

271 participants assigned to control:

• Usual care

Outcomes

No primary outcome was identified.

Physical outcomes:

• Cardiorespiratory fitness assessed via 2-km walk (minutes)
• Dynamic neuromuscular performance assessed by figure-8 running test (seconds)
• Physical activity collected via a recalled questionnaire (MET-h per week)
• Body composition assessed via DEXA (fat mass, lean mass)
• Bone density assessed via DEXA (total bone mineral content, lumbar spine and femoral neck bone

mineral density)

In subsample study of 86 participants (37 intervention and 40 control):

• Countermovement jump force assessed via force plate
• Maximal isometric muscle force of leg extension via isometric leg press
• Maximal isometric grip strength via isometric hand dynamometer
• Body composition via DEXA (fat percentage)
• Left distal tibia and tibial midshaft bone mineral content via pQCT scan

QoL outcomes:

• QoL measured by EORTC QLQ-C30
• Fatigue measured with FACIT-F scale
• Depression measured via BDI

Numbers of participants assessed:

• Intervention: at baseline, 302; at 12 months, 262
• Control: at baseline, 271; at 12 months, 236

Numbers of participants assessed in subsample study:

• Intervention: at baseline, 37; at 12 months, 30
• Control: at baseline, 40; at 12 months, 37

Adverse events: none reported

Notes

Trial registration link: https://clinicaltrials.gov/ct2/show/NCT00639210

Trial authors contacted: no

Intention-to-treat analysis: no
Funding: Finnish Cancer Institute; Finnish Cancer Foundation; Academy of Finland; Social Insurance
Institution of Finland; Finnish Ministry of Education; Finska Läkaresällskapet; Special government grant
for health science research; Helander Foundation; Gyllenberg Foundation; Paulo Foundation; Kurt and
Doris Palander Foundation; Finnish Cultural Foundation and Medical Fund of the Pirkanmaa Hospital
District; Finnish AstraZeneca-sponsored step benches for the study; Finnish Breast Cancer Group

Risk of bias

Bias

Authors' judgement

Support for judgement

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

178

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Saarto 2012  (Continued)

Cochrane Database of Systematic Reviews

Random sequence genera-
tion (selection bias)

Low risk

"A computer-generated randomisation schedule was used to allocate pa-
tients".

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Low risk

"Study nurse performed randomisation after baseline visit".

"randomisation was centralised"

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Low risk

"examiner blinded"

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

Incorrect ITT; "Analyses were performed on an intention-to-treat basis for all
participants who completed the baseline and at least one follow-up measure-
ment"

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Schmitz 2005 

Methods

Study design: single-centre RCT

Number randomised: 86; 43 to intervention, 43 to delayed exercise control

Study start: October 2001; stop date: June 2002

Length of intervention: 6 months

Length of follow-up: to end of intervention

Country: USA

Participants

Age, years (mean SD):

• Intervention: 53.3 (8.7)
• Control: 52.8 (7.6)

Stage, n (%):

• Intervention: stage 0, 7 (18); stage I, 6 (26.1); stage II, 13 (56.5); stage III, 3 (13)
• Control: stage 0, 1 (4.4); stage I, 7 (30.4); stage II, 13 (56.5); stage III, 2 (8.7)

Inclusion criteria:

• Completed all treatment except hormonal therapy for breast cancer

• Body weight stable within 10% over the past year

• Non-smoker for at least the past 2 years

• Sedentary to moderately physically active (no more than 3 sessions per week of no more than moder-
ate-intensity activity; no weight training history)

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

179

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Schmitz 2005  (Continued)

Exclusion criteria:

Cochrane Database of Systematic Reviews

• Medical condition prohibiting participation in a weight training programme

• Morbidly obese (BMI > 40 kg/m2)

• Hypertensive (systolic blood pressure > 160 mmHg, diastolic blood pressure > 99 mmHg, or both)

• Currently on a weight loss plan or planning to start a weight loss plan during the period of the study

• Planning to move away from the area or to be away from the area for > 3 weeks during study

• Not pregnant or lactating, and not planning to become pregnant during the study period

Interventions

43 participants assigned to exercise intervention:

• Resistance training was performed twice weekly for 6 months. Each 60-minute session consisted of 9
common weight training exercises with variable resistance machines and free weights (for muscles of
the chest, back, shoulders, arms, buttocks, hips, and thighs).

• Stretching exercises were performed before and after each weight training session.
• Participants were asked to make no changes in other elements of their exercise programme (e.g. walk-

ing, bicycling, swimming) while incorporating weight training.

Adherence:

• From baseline to 6 months: 1 participant attended < 80% of sessions.
• From months 7 to 12: 14 exercise group participants attended < 70% of sessions.

43 participants assigned to control:

• Wait-list

Outcomes

Primary outcomes:

• Baecke Questionnaire given to assess participant physical activity outside of the weight training pro-

tocol

• Cancer Rehabilitation Evaluation System – Short-Form (CARES-SF), which includes 59 items and 5 sub-
scales for physical, psychosocial, medical interaction, marital, sexual, and other miscellaneous sub-
scales. Items assessed on a 5-point Likert scale (0 = "not at all", 1 = "a little", 2 = "a fair amount", 3 =
"much", 4 = "very much") that queries the applicability of the problem/statement to the participant
within the last month. Items of CARES-SF are combined into a global summary score. Both global sum-
mary score and individual subscale scores range from 0 to 100; lower scores indicate fewer problems.

• Anthropometric measurements including waist circumference, body weight, and height
• DEXA (used to measure body composition), in addition to a skin pinch meter/scale
• Upper (bench press) and lower body strength (leg press) assessed by 1-repetition maximum (1RM)
• Depressive symptoms measured with the CES-D, a 20-item questionnaire scored on a standard 4-point

scale (0 to 3) for each item, with a potential range of 0 to 60

• Fasting blood glucose and plasma insulin levels assessed by colourimetric reflectance spectropho-

tometry and chemiluminescent immunoassay, respectively
• Insulin resistance measure used in this study: the HOMA index
• ELISAs to assess IGF-I, IGF-II, IGFBP-1, IGFBP-2, and IGFBP-3
• Lymphoedema measured 3 ways: arm circumference measurements, self-report of diagnosis, self-

report of symptoms

Numbers of participants assessed:

• Intervention: baseline, 43; at 6 months, 38
• Control: baseline, 43; at 6 months, 40

Adverse events: cancer recurrence: 4 in total - 2 each in intervention and control groups; some limited
musculoskeletal issues that were self-resolving

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

180

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Schmitz 2005  (Continued)

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: no

Funding: Susan G. Komen Foundation, grants to the UMN GCRC from the NIH

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

“Random number table”

Allocation concealment
(selection bias)

Low risk

“The randomization procedure used prevented investigators from influencing
treatment allocation”.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Low risk

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

Physiological measures were taken by trained staff blinded to participant sta-
tus, with the exception of strength measures.

4 participants were lost to follow-up in the intervention group - 2 for recur-
rences and 2 as the result of withdrawals; 3 participants were lost to follow-up
in the control group - 2 for recurrences and 1 as the result of withdrawal; none
of these were included in analyses.

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Schmitz 2009 

Methods

Study design: single-centre RCT

Number randomised: 295; 148 (71 with lymphoedema and 77 without lymphoedema) to the interven-
tion, 147 (70 with lymphoedema and 77 without lymphoedema) to control

Study start: October 2005; stop date: August 2008

Length of intervention: 12 months

Length of follow-up: to end of intervention

Country: USA

Participants

Age, for women with lymphoedema, years (mean SD):

• Intervention: 56 (9)
• Control: 58 (10)

Age, for women without lymphoedema, years (mean SD):

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

181

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Schmitz 2009  (Continued)

Cochrane Database of Systematic Reviews

• Intervention: 54 (8)
• Control: 56 (8)

Stage, for women with lymphoedema, n (%):

• Intervention: DCIS, 0 (0); stage I, 33 (46); stage II, 1 (1); stage III, 22 (31); unknown, 15 (31)
• Control: DCIS 0 (0); stage I, 24 (14); stage II, 0 (0); stage III, 22 (31); unknown, 24 (34)

Stage, for women without lymphoedema, n (%):

• Intervention: DCIS 1 (1); stage I, 43 (56); stage II, 8 (10); stage III, 25 (33)
• Control: DCIS 0 (0); stage I, 43 (56); stage II, 6 (8); stage III, 28 (3)

Inclusion criteria:

• Female

• History of unilateral non-metastatic breast cancer

• Body mass index (calculated as weight in kilograms divided by height in meters squared) ≤ 50

• Currently cancer free

• No medical condition that would limit participation in exercise

• No weight lifting during the year before study entry

• No plans for surgery or to be away for at least 1 month during the study

• Currently weight stable and not actively trying to lose weight

Additional inclusion criteria, for women with lymphoedema:

• 1 to 15 years post diagnosis

• At least 1 lymph node removed

• Presence of lymphoedema

Additional inclusion criteria, for women without lymphoedema:

• 1 to 5 years post diagnosis

• At least 2 lymph nodes removed

• No prior lymphoedema diagnosis

• No evidence of current lymphoedema

Exclusion criteria for women with lymphoedema:

• Intensive therapy in the past 3 months

• Recorded 10% change in volume or circumference of affected arm in the past 3 months for ≥ 7 days

• More than 1 lymphoedema-related infection requiring antibiotics (cellulitis) in the past 3 months

Interventions

148 participants (71 with lymphoedema and 77 without lymphoedema) assigned to the exercise inter-
vention, consisting of progressive strength (weight) training:

• Weight lifting intervention group received a 1-year membership to a community fitness centre (YMCA).
Resistance training was performed twice weekly (13 weeks supervised and 13 weeks unsupervised).
• Each 90-minute session consisted of upper body exercises (seated row, supine dumbbell press, lateral
or front raise, biceps curl, and triceps push-down), which were performed with dumbbells or variable
resistance machines, and lower body exercises (leg press, back extension, leg extension, and leg curl),
which were performed with variable resistance machines.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

182

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Schmitz 2009  (Continued)

Cochrane Database of Systematic Reviews

• Weight was increased for each exercise by the smallest possible increment after 2 sessions of 3 sets of

10 repetitions with no change in arm symptoms.

Adherence:

• For women with lymphoedema: Median attendance at weight lifting sessions was 88%.
• For women without lymphoedema: Median attendance at weight lifting sessions was 79%.

147 participants (70 with lymphoedema and 77 without lymphoedema) assigned to control:

• Wait-list control
• Requested not to change current level of exercise

Outcomes

Outcomes:

• Physical activity outside intervention assessed with the IPAQ
• Muscular strength assessed by bench press and leg press
• Anthropometric measures, weight, BMI, and body fat %; fat mass and lean mass via DEXA scan
• Body image measured on the Body Image and Relationship Scale
• QoL assessed with the MOS SF-36 version 2
• Diet assessed via the Diet History Questionnaire
• Lymphoedema-related outcomes (not included in this review): Primary outcome was lymphoedema
onset defined as a 5% or greater increase in arm swelling, which was defined by interlimb water vol-
ume difference [(affected arm volume − unaffected arm volume)/unaffected arm volume]. Water vol-
ume displacement was used to measure arm volumes at baseline and at 12 months.

For women with lymphoedema, outcomes were measured as follows:

• Intervention: baseline, 71; at 1 year, 65
• Control: baseline, 70; at 1 year, 65

For women without lymphoedema, outcomes were measured as follows:

• Intervention: baseline, 77; at 1 year, 66
• Control: baseline, 77; at 1 year, 68

Adverse events among participants with lymphoedema:

• Eight musculoskeletal injuries reported. Cumulative incidence of musculoskeletal injury in the weight

lifting group was 10.2 (95% CI 9.4 to 11.1) per 100 breast cancer survivors.

Adverse events among participants without lymphoedema:

• Two musculoskeletal injuries reported. Cumulative incidence of musculoskeletal injury in the weight

lifting group was 3.4 (95% CI 2.9 to 3.9) per 100 breast cancer survivors.

Notes

Trial registration link: https://clinicaltrials.gov/ct2/show/NCT00194363

Trial authors contacted: no

Intention-to-treat analysis: no

Funding: NIH/National Cancer Institute and the Public Health Services Research Grant

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Low risk

Allocation sequence was a computer-generated minimisation scheme.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

183

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Schmitz 2009  (Continued)

Allocation concealment
(selection bias)

Low risk

Cochrane Database of Systematic Reviews

“...de-identified data for ... variables were entered after completion of all base-
line measures, the study coordinator then called participants to reveal the out-
come of randomization and to schedule groups for the supervised groups"

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Low risk

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

Measurements obtained by “trained staff who were unaware of the study-
group assignments”

“Measurement staff (including CLTs) were blinded to treatment allocation”.

No evidence suggests that missing data were adequately and appropriate ad-
dressed.

Large numbers of study participants withdrew; 11 women without lymphoede-
ma withdrew from the intervention group and 9 women without lymphoede-
ma withdrew from the control group.

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Segar 1998 

Methods

Study design: single-centre quasi-randomised partial cross-over controlled trial. Only first treatment
period included here

Number randomised: 30; 10 to exercise intervention, 10 to exercise and behavioural intervention, 10 to
control

Study start: not reported; stop date: not reported

Length of intervention: 10 weeks

Length of follow-up: at 12 weeks

Country: USA

Participants

Age, years (mean SD):

• Intervention groups: 47.5 (7.1)
• Control group: 51.8 (8.1)

Stage, n (%):

• Intervention groups: not reported
• Control group: not reported

Inclusion criteria:

• Any type of breast cancer surgery

• 30 to 65 years old

• Not currently participating in exercise

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

184

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Segar 1998  (Continued)

• No contraindications to exercise

• Written release from the physician

Exclusion criteria:

• Cardiovascular or pulmonary disease

• Known physical disabilities

Interventions

10 participants assigned to exercise intervention:

• Request to exercise a minimum of 30 minutes at an intensity ≥ 60% of age-predicted maximum heart
rate on 4 days per week over 10 weeks, with type of exercise (stationary bike, stair climbers, and hy-
draulic resistance exercise equipment) as chosen by participant

10 participants assigned to exercise and behavioural modification intervention:

• Exercise as described for the exercise behavioural modification group by self-awarded rewards (ac-

tivity, food, treats, or movies) to serve as reinforcements

Adherence:

• Overall compliance assessed from self-reported exercise logs averaged 1363 (SD 577) minutes over 10

weeks, where 100% compliance was equivalent to 1200 minutes.

• Compliance for participants reaching at least 89% averaged 1532 (SD 103) minutes (mean compliance

of 130%) with a range from 89% to 250%.

10 participants assigned to control:

• Instructions to maintain sedentary lifestyle

Outcomes

Primary outcomes:

• Change in depressive symptoms measured by the 21-item BDI questionnaire, with scale score ranging

between 0 and 63. Higher score indicates greater depressive symptoms.

• Change in anxiety symptoms measured with the STAI (20 items; 1 = not at all, 4 = very much so)
• Change in self-esteem measured by the RSE Inventory - a unidimensional 64-item questionnaire with

10 scales that reflect self-evaluation of self-esteem

Time points of assessments: baseline, at 10 weeks

Numbers of participants assessed:

• Intervention: baseline, 16; at 10 weeks, 16
• Control: baseline, 8; at 10 weeks, 8

Reasons for missing data:

• Intervention: no missing data reported
• Control: no missing data reported

Adverse events: none reported

Subgroup analysis: none reported

Notes

Trial registration link: none available

Trial authors contacted: no

Intention-to-treat analysis: no

Funding: Michigan Initiative for Women’s Health Grant

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

185

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Segar 1998  (Continued)

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

High risk

“Subjects were rotated sequentially into two treatment conditions and one
control group”.

Allocation concealment
(selection bias)

Unclear risk

Whether treatment assignment was concealed from study personnel and par-
ticipants was not described.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Blinding of outcome as-
sessment (detection bias) 
All outcomes

High risk

Study personnel and outcome assessors were not masked or blinded to study
interventions.

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

4 participants were excluded from the exercise group and 2 from the control
group. Exclusion from analyses occurred because of attrition or non-compli-
ance with the study protocol.

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Short 2014 

Methods

Study design: single-centre RCT

Number randomised: 330; 109 to intervention tailored-print, 110 to intervention targeted-print, 111 to
control

Study start: October 2010; stop date: October 2013

Length of intervention: 3 months

Length of follow-up: at 4 and 10 months post intervention

Country: Australia

Participants

Age, years, mean (range):

• Intervention tailored-print: 56 (34-74)
• Intervention targeted-print: 55 (36-82)
• Control: 55 (33-75)

Stage, n (%):

• Intervention tailored-print: stage 0, 3 (2,9); stage I, 27 (26.5); stage II, 32 (31.4); stage III, 23 (22.6); stage

IV, 2 (1.9); stage unknown, 15 (14.7)

• Intervention targeted-print: stage 0, 3 (2,8); stage I, 22 (20.8); stage II, 45 (42.5); stage III, 20 (18.8); stage

IV, 1 (0.9); stage unknown, 15 (14.5)

• Control: stage 0, 1 (0.9); stage I, 25 (23.4); stage II, 36 (33.6); stage III, 26 (24.3); stage IV, 3 (2.8); stage

unknown, 16 (14.9)

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

186

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Short 2014  (Continued)

Inclusion criteria:

Cochrane Database of Systematic Reviews

• Female breast cancer survivors over the age of 18

• Finished “active” cancer treatment (defined as surgery, chemotherapy, and/or radiotherapy)

• Could read and write in English

Exclusion criteria:

• Not reported

Interventions

330 participants assigned to 2 different physical activity behavioural change interventions:

• Intervention tailored-print: Participants received 3 social cognitive theory-based computer-tailored
A4 4-page newsletters over a 12-week period (6 weeks apart). Newsletters were iteratively tailored
via personal physical activity and demographic, psychosocial, and health-related information derived
from individual assessments at baseline; and physical activity and goal-setting information derived
from "update cards", which were sent to participants via mail at 4 weeks and 8 weeks post baseline. If
participants’ update cards were not returned within 2 weeks, newsletters were printed without itera-
tive physical activity and goal-setting feedback. A recommendation was provided to engage in aero-
bic PA of at least moderate intensity for 30 minutes or longer most days of the week. Participants were
also encouraged to perform resistance training exercises 1 to 3 times per week. However, no specific
instructions for resistance training exercises were provided.

• IBntervention targeted-print: Participants received a copy of the 54-page (A5) theory of planned be-
havior-based booklet Exercise for Health: An Exercise Guide for Breast Cancer Survivors, which has been
evaluated in a previous study. We made minor changes to the guidebook to adapt it for an Australian
audience (e.g. substituting photos and text related to snow). A recommendation was provided to en-
gage in aerobic PA of at least moderate intensity for 30 minutes or longer most days of the week. Par-
ticipants were also encouraged to perform resistance training exercises (at least 6 exercises) 1 to 3
times per week. However, no specific instructions for resistance training exercises were provided.

Adherence:

• Intervention tailored-print: change in % meeting aerobic guidelines (150 minutes/week) at 4 months
vs baseline, +23.9%; mean (SD) resistance exercise score (sessions*exercise) at 4 months: 13.5 (27.0)
• Intervention targeted-print: change in % meeting aerobic guidelines (150 minutes/week) at 4 months

vs baseline, +12.5%; mean (SD) resistance exercise score at 4 months: 10.9 (27.4)

111 participants assigned to control:

• Received the brochure An Active Way to Better Health, describing national PA guidelines for Australian

adults

Outcomes

Primary outcome:

• Self-reported minutes of physical activity (aerobic and resistance exercise) measured by the adapted

version of the LSI of the Godin Leisure-Time Exercise Questionnaire

Other outcomes:

• Adherence to meeting PA guidelines for aerobic (150 minutes of aerobic activity over at least 5 days
of the week) and resistance-based (1 session per week containing at least 6 exercises, based on the
lower suggested threshold) activity, calculated on the basis of participants’ self-reported PA

• Mean daily steps assessed via at least 3 days of pedometry and a step count diary
• Self-reported sitting time measured with a validated 5-item scale assessing sitting time across 5 dif-

ferent domains on a weekday and on a weekend day

• Health-related quality of life measured by FACT-B version 4
• Fatigue measured via the FACIT-Fatigue scale

Numbers of participants assessed:

• Intervention tailored-print: baseline, 109; at 4 months, 98

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

187

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Short 2014  (Continued)

• Intervention targeted-print: baseline, 110; at 4 months, 97
• Control: baseline, 111; at 4 months, 104

Adverse events: not reported

Cochrane Database of Systematic Reviews

Notes

Trial registration link: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?AC-
TRN=12611001061921

Trial authors contacted: no

Intention-to-treat analysis: yes, but LOCF

Funding: funded by the Cancer Institute New South Wales Research Scholar Award (10/RSA/1-27 - Trial
ID in Australian New Zealand)

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Low risk

"computer-generated block randomisation sequence"

Allocation concealment
(selection bias)

Low risk

Sequence "implemented in a blinded fashion by an administrative assistant
not involved in the project"

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Low risk

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

"All project team members were blinded to this process until allocation was
complete".

Inappropriate handling of missing data in the analyses; "primary analysis was
conducted using all observed data, and sensitivity analyses using the baseline
observations carried forward approach were conducted to explore the impact
of missing data"

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Taleghani 2012 

Methods

Study design: single-centre RCT

Number randomised: 80; 40 to intervention, 40 to control

Study start: September 2009; stop date: February 2010

Length of intervention: 8 weeks

Length of follow-up: to end of intervention

Country: Iran

Participants

Age, years:

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

188

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Taleghani 2012  (Continued)

• Overall: Women aged 15 to 55 were eligible.

Stage, n (%):

• Overall: stage I-III

Inclusion criteria:

• Women with breast cancer stages I-III

• Aged 15 to 55 years

• Two years since completion of breast cancer-related treatment (except for hormone therapy)

• Performance status 0 to 4 (as determined by ECOG scale of WHO)

Exclusion criteria:

• Evidence of disease recurrence

• Treatment with anticoagulants, signs of cardiac disease

• Underwent arrhythmia or MI

• Dementia or other psychotic condition

• Regular exercise 2 to 3 sessions per week in the past 6 months

Interventions

40 participants assigned to exercise intervention:

• Protocol included 3 phases of warm-up (containing warm-up and ballistic exercises), heavy resistance
training, and cooling down (containing cooling down and ballistic exercises). Exercise sessions were
conducted under the supervision and guidance of a coach for each individual participant in this study.
• In the first 5 minutes, ballistic and stretching exercises were done to warm up. In the next phase, par-
ticipants slowly jogged on an electronic treadmill, which showed their heart rate and calories con-
sumed, for 7 minutes. They then pedaled a magnetic stationary bike, equipped with an LCD to show
heart rate and consumed calories, for another 7 minutes. The intensity of participants' exercise was
controlled by the maximum heart rate index. Therefore, participants exercised at 55% of intensity rate
for the first 2 weeks, 65% of intensity from weeks 3 to 6, and 75% of intensity from weeks 7 to 8.

• After doing aerobic exercises and taking a rest, participants performed heavy resistance training with

a chest press machine, in 2 sets of 8 to 12 repetitions.

Adherence:

Not reported

40 participants assigned to control:

• No information provided

Outcomes

Primary outcome:

• Standard instrument of quality of life for breast cancer survivors (National Medical Center and Beck-

man Research Institute)

Numbers of participants assessed:

• Intervention: baseline, 40; at 8 weeks, not reported
• Control: baseline, 40; at 8 weeks, not reported

Adverse events: not reported

Notes

Trial registration link: none available

Trial authors contacted: no

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

189

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Taleghani 2012  (Continued)

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Intention-to-treat analysis: unclear

Funding: Isfahan University of Medical Sciences

Authors' judgement

Support for judgement

Unclear risk

"randomly divided into two groups of study and control"; method not stated

Allocation concealment
(selection bias)

Unclear risk

Whether treatment assignment was concealed from study personnel and par-
ticipants was not described.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Unclear risk

Blinding of outcome assessments was not described.

Unclear risk

Numbers of participants included in postintervention analyses were not pro-
vided.

Low risk

No selective reporting of outcomes is apparent.

Other bias

Unclear risk

Trial appears to be free of other problems that could put it at high risk of bias.

Vallance 2007 

Methods

Study design: single-centre RCT

Number randomised: 337; 94 to print material intervention (PM), 94 to pedometer intervention (PED),
93 to combination of print material and pedometers intervention (COM), 96 to control

Study start: July 2005; stop date: April 2006

Length of intervention: 12 weeks

Length of follow-up: to end of intervention, at 6 months post intervention

Country: Canada

Participants

Age, years, mean (range):

• PM: 57 (31-88)
• PED: 58 (34-75)
• COM: 58 (38-86)
• Control: 57 (37-90)

Stage, n (%):

• PM group: stage I, 53 (56.4); stage IIA, 26 (27.7); stage IIB, 11 (11.8); stage IIIA, 4 (4.3)
• PED group: stage I, 38 (40.4); stage IIA, 35 (37.2); stage IIB, 15 (16.0); stage IIIA, 6 (6.4)

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

190

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Vallance 2007  (Continued)

Cochrane Database of Systematic Reviews

• COM group: stage I, 55 (59.1); stage IIA, 23 (24.7); stage IIB, 11 (11.8); stage IIIA, 4 (4.3)
• Control: stage I, 48 (50); stage IIA, 27 (28.1); stage IIB, 13 (13.5); stage IIIA, 8 (12.0)

Inclusion criteria:

• Histologically confirmed stage I-IIIA breast cancer

• Physician approval

• Freedom from chronic medical and orthopaedic conditions that would preclude physical activity (e.g.
congestive heart failure, recent knee or hip replacement)

• English as spoken language

• Completion of adjuvant therapy except hormone therapy

• Current absence of breast cancer

Exclusion criteria:

• None reported

Interventions

281 (PM, 94; PED, 94; COM, 94) participants assigned to three 12-week interventions:

• PM group received a copy of Exercise for Health: An Exercise Guide for Breast Cancer Survivors.
• PED group received a Digi-Walker SW-200 pedometer and a 12-week step calendar.
• COM group received both interventions (i.e. PM and PED).
• All groups received a standard recommendation to perform 30 minutes of moderate-vigorous PA 5

days a week.

• Survivors meeting PA guidelines at baseline were encouraged to increase their PA minutes per day

and/or days per week.

Adherence to intervention materials immediately post intervention:

• Survivors in 2 groups that received PED as an intervention (i.e. COM and PED; n = 187) recorded their
pedometer steps on 83.3% (70 of 84) of study days. Survivors in 2 groups that received PM (i.e. COM
and PM; n = 163) reported reading the entire PM an average of 2.1 times for an average of 113 minutes.

• Retention for this study was 89.7% (338 of 377) and did not differ among groups.

Adherence to intervention materials at 6-month follow-up:

• Among survivors in the 2 groups that received a PED (COM and PED; N = 136), 38.5% (N = 52) reported
that they continued to wear their PED during the 6-month follow-up period. Survivors in the 2 groups
that received PM (COM and PM; N = 127) reported reading the entire PM an average of 1.3 times for
an average of 42 minutes during the 6-month follow-up period. 60% of survivors reported reading the
PM at least once, and 34% reported reading the PM for at least 30 minutes.

• Overall retention was 71% (266/377) at the 6-month follow-up time point and did not statistically differ

among groups.

96 participants assigned to control:

• Control group was given the standard recommendation to perform 30 minutes of moderate-vigorous
physical activity 5 days a week. Participants in this group wore a pedometer only for baseline and
postintervention assessments.

Outcomes

Primary outcome:

• Self-reported  moderate-vigorous  physical  activity  between  baseline  and  post  intervention  (i.e.  12

weeks), assessed by the LSI of the Godin Leisure-Time Exercise Questionnaire

Other outcomes:

• Self-reported QoL assessed by FACT-B

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

191

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Vallance 2007  (Continued)

Cochrane Database of Systematic Reviews

• Fatigue assessed on the Fatigue Scale from the FACT measurement system. On QoL and fatigue scales,

higher scores represent better QoL/fatigue or less severe symptoms.

• Brisk walking assessed by the LSI of the Godin Leisure-Time Exercise Questionnaire
• Objective step counts assessed via a 7-day step test with the Digi-Walker pedometer

Numbers of participants assessed:

PM: baseline, 94; post intervention, 81; 6 months post intervention, 62

PED: baseline, 94; post intervention, 88; 6 months post intervention, 69

COM: baseline, 93; post intervention, 84; 6 months post intervention, 67

Control: baseline, 96; post intervention, 85; 6 months post intervention, 68

Adverse events: none reported

Notes

Trial registration link: https://clinicaltrials.gov/ct2/show/NCT00221221

Trial authors contacted: yes, additional data were received from trial authors

Intention-to-treat analysis: no

Funding: National Cancer Institute of Canada (NCIC) with funds from the Canadian Cancer Society
(CCS) and the CCS/NCIC Sociobehavioral Cancer Research Network

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Computer-generated random numbers list

Allocation concealment
(selection bias)

Low risk

“A research assistant generated the group assignments in sequentially num-
bered and sealed opaque envelopes”.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Unclear risk

It was not mentioned whether study personnel and outcome assessors were
masked or blinded to study interventions.

High risk

For all analyses, an intention-to-treat approach was employed with LOCF.

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Waltman 2010 

Methods

Study design: multi-centre RCT

Number randomised: 249; 124 to intervention, 125 to control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

192

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Waltman 2010  (Continued)

Study start: not reported; stop date: not reported

Length of intervention: 24 months.

Length of follow-up: at 36 months

Country: USA

Participants

Only baseline characteristics of sample completing the 24-month study period were reported:

Age, years (mean SD):

• Overall: 58.7 (7.5)
• Intervention: age ≤ 60 y - n (%), 60 (55); age > 60 y - 50 (45)
• Control: age ≤ 60 y - n (%), 69 (61); age > 60 y - 44 (39)

Stage, n (%):

• Intervention: stage 0, 17 (14.2); stage I, 57 (47.5); stage II, 46 (38.3)
• Control: stage 0-III (proportions not reported)

Inclusion criteria:

• 35 to 75 years of age

• History of stage 0 (in situ), I, or II breast cancer

• BMD T-score of -1.0 or less at any of 3 sites (hip, spine, forearm)

• At least 6 months post breast cancer treatment and 12 months postmenopausal

• Residing within 100 miles of 1 of 4 research sites (Omaha, Lincoln, Kearney, and Scottsbluff, NE)

• Physician's permission to participate

Exclusion criteria:

• Recurrence of breast cancer

• Currently taking hormone therapy, bisphosphonates, glucocorticosteroids, or other drugs affecting
bone

• Currently engaging in strength training exercises

• Body mass index ≥ 35

• Serum calcium, creatinine, or thyroid-stimulating hormone (if on thyroid therapy) outside normal lim-
its

• Active gastrointestinal problems or other conditions that prohibited strength training exercises; rise-
dronate, calcium, or vitamin D intake

Interventions

124 participants allocated to strength and weight training exercise interventions:

• Resistance component: Strength and weight training exercises for hip, spine, and forearm were mod-
ified with permission from exercises in Nelson and Wernick’s (1997) book entitled Strong Women Stay
Young. For the first 32 weeks, participants exercised twice weekly for 30 to 45 minutes in their homes;
they were not to lift beyond 20-pound hand or ankle weights because of safety concerns. After 32
weeks, participants exercised using weight machines at a nearby fitness centre. Facilitative strate-
gies, such as education, feedback, and coaching—based on Bandura’s (1997) self-efficacy theory—
were used by both exercise trainers and research nurses during phone contacts and home or fitness
centre visits to promote adherence to exercises.

• Certified exercise trainers demonstrated exercises to participants and safety precautions in perform-
ing exercises, monitored performance during exercises, instructed participants how to progressively

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

193

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Waltman 2010  (Continued)

Cochrane Database of Systematic Reviews

increase weights lifted, and assisted participants in the transition from home-based to fitness centre
exercise. Exercise trainers made 45-minute home or fitness centre visits to participants every 2 weeks
at the beginning of home-based and fitness-centre exercises and every 2 months for the remainder
of the 24-month study. At orientation and 6-month booster sessions, an exercise physiologist demon-
strated the correct performance of each exercise in the study, safety precautions in performing exer-
cises, and use of weight machines.

Adherence % (self-reported but also validated by research nurses during monthly interviews):

• Average (SD) 24-month adherence to resistance exercise for the 110 women was 69.4% (24.0).

125 participants assigned to control:

• Participants  in  the  comparison  group  received  calcium  and  vitamin  D  supplementation  and  rise-

dronate but performed no resistance exercises.

Outcomes

Outcomes:

• BMD at total hip, femoral neck, L1-L4 spine, total radius, and 33% radius measured by DEXA
• Bone resorption (nmol/L BCE) assessed via serum NTx assay
• Bone formation (U/L) assessed via bone-specific alkaline phosphatase (Alkphase B) serum assay
• Muscle strength (peak torque body weight at 60 degrees) assessed via Biodex System 3 Pro Velocity
Spectrum Evaluation. Knee, hip, and wrist flexion and extension were measured on the non-dominant,
non-operative arm and on 1 leg by physical therapists using this system.

• Dynamic balance assessed by the timed backward tandem walk
• Adherence was operationally defined as the ratio of reported to desired exercise sessions attended
and was further validated by research nurses during a monthly interview via the Adherence and Risk
Factor Documentation Interview technique.

• Incidence of falls
• Physical activity via 7-day physical activity record-adapted

Numbers of participants assessed:

• Intervention: baseline, 124; at 12 months, not reported; at 24 months, 110
• Control: baseline, 125; at 12 months, not reported; at 24 months, 113

Adverse events: No long-term adverse effects from exercises were noted for any of the 110 women exer-
cising, including women with a history of lymphoedema.

Notes

Trial registration link: https://clinicaltrials.gov/ct2/show/NCT00567606

Trial authors contacted: no

Intention-to-treat analysis: yes

Funding: National Institute of Nursing Research (1 R01NR07743–01A1)

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Participants "were randomised to exercise plus medication (n = 110) or med-
ication only (n = 113) treatment groups, and randomisation was stratified by
years of post menopause". Randomisation method was not stated.

Allocation concealment
(selection bias)

Unclear risk

Whether treatment assignment was concealed from study personnel and par-
ticipants was not described.

Blinding of participants
and personnel (perfor-
mance bias) 

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

194

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Waltman 2010  (Continued)

All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Unclear risk

Blinding of outcome assessments was not described.

Incomplete outcome data
(attrition bias) 
All outcomes

Low risk

"intent to treat paradigm was used where data from all participants were
analysed according to randomised assignment regardless of protocol adher-
ence"

"The generalized estimating equation (GEE) method with an exchangeable
structure for repeated measures data was used to fit a generalized linear mod-
el to examine factors associated with muscle strength, balance, BMD, and
bone turnover including time of testing (baseline, 12 and 24 months) and
group assignment (exercise or medication only)".

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent..

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

Winters-Stone 2011 

Methods

Study design: single-centre RCT

Number randomised: 106; 52 to intervention, 54 to control

Study start: October 2006; stop date: January 2009

Length of intervention: 12 months

Length of follow-up: to end of intervention

Country: USA

Participants

Age, years (mean SD):

• Intervention: 63.3 (6.7)
• Control: 62.2 (6.7)

Stage, n (%):

• Intervention: stage 0, 4 (7.7); stage I, 20 (38.5); stage II, 25 (48.1); stage IIIA, 1 (1.9); not reported, 2 (3.8)
• Control: stage 0, 2 (3.7); stage I, 22 (40.7); stage II, 19 (35.2); stage IIIA, 5 (9.3); not reported, 6 (11.1)

Inclusion criteria:

• Diagnosis of stage 0–IIIA breast cancer at or after age 50

• Postmenopausal

• ≥ 1 year post chemotherapy or radiotherapy

• Non-osteoporotic

• No bone-altering medication other than adjuvant hormone therapy

• Physician clearance to exercise

• No regular participation in resistance and/or impact exercise (fewer than two 30-minute sessions per
week) in the past month

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

195

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Winters-Stone 2011  (Continued)

• Physical and cognitive ability to complete study testing

Exclusion criteria:

• None reported

Interventions

52 participants assigned to 1-year exercise intervention:

• Resistance plus impact intervention (POWIR: Prevent Osteoporosis With Impact + Resistance) used
in this study complied with American College of Sports Medicine (ACSM) recommendations for pre-
serving bone health in postmenopausal women by using resistance and/or impact exercise at mod-
erate-to-high bone-loading forces.

• Resistance training at loads corresponding to 60% to 70% of 1RM for 1 to 3 sets of 8 to 12 repetitions to
build lean mass and strength in novice weight lifters and older adults. Free weights were used to apply
resistance—dumbbells for upper body, weighted vests for lower body, and a barbell for 1 combined
upper + lower body exercise.

• Impact exercise consisted of 2-footed jumps from the ground to a target height 1″ from the floor with
a bent-knee landing, performed with weighted vests on and in sets of 10. During a single exercise ses-
sion, participants warmed up, performed 1 to 6 jump sets, 1 to 2 sets of 3 to 4 upper body exercises,
and 3 to 4 lower body exercises, then cooled down.

• Home exercises were similar to those performed in the supervised class, except that resistance bands
replaced free weights for upper body exercises, and lower body exercises were performed without
weighted vests.

Adherence:

• Total average attendance: intervention, 57%; control, 62%
• Supervised-only average attendance: intervention, 76%; control, 72%
• Home-only average attendance: intervention, 23%; control, 44%

54 participants assigned to control:

• Progressive low-intensity stretching, 3 times per week for 1 year
• Participants performed a series of whole body stretching and relaxation exercises in a seated or lying

position.

• Selected exercises were chosen to minimise weight-bearing forces, so that little stimulus to the mus-

culoskeletal system was applied and energy expenditure was minimal.

Outcomes

Primary outcomes:

• Bone mineral density of hip and spine via DEXA
• Biomarkers of blood turnover; serum osteocalcin (ng/mL) and urinary deoxypyridinoline cross-links

(nmol/mmolCr) by ELISA

Other outcomes:

• Body weight and body composition assessed via DEXA
• Habitual physical activity measured with the CHAMPS physical activity questionnaire for older adults

(kcal/day in all activities)

• Habitual calcium (dietary + supplemental)
• Total energy intake assessed with the 2005 Block Food Frequency Questionnaire

Numbers of participants assessed:

• Intervention: baseline, 52; at 6 months, 33; at 12 months, 36
• Control: baseline, 54; at 6 months, 32; at 12 months, 31

Adverse events: No adverse effects were associated with participation in either group.

Notes

Trial registration link: https://clinicaltrials.gov/ct2/show/NCT00591747

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

196

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Winters-Stone 2011  (Continued)

Trial authors contacted: no

Cochrane Database of Systematic Reviews

Intention-to-treat analysis: yes, but data were available only for per-protocol analyses

Funding: Susan G. Komen Race for the Cure and the National Cancer Institute; partial support from the
Oregon Clinical and Translational Research Institute (OCTRI), National Center for Research Resources
(NCRR) - a component of the National Institutes of Health (NIH) - and NIH Roadmap for Medical Re-
search

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

Generation of the random sequence was not described

Allocation concealment
(selection bias)

High risk

“Group assignments were placed in sealed, sequentially numbered envelopes
and opened by the participant following the completion of baseline testing”.
Envelopes were not opaque.

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

High risk

Owing to the nature of the intervention, it was not possible to conceal alloca-
tion to the intervention from participants.

Low risk

“Trained technicians blinded to group assignment” carried out testing.

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

The intent-to-treat (ITT) analysis was performed via hierarchical linear mod-
elling. However, although inferences were based on ITT analyses, data were
available only for per-protocol analyses (in table format). High attrition rate
was reported in the intervention group.

Selective reporting (re-
porting bias)

Low risk

No selective reporting of outcomes is apparent.

Other bias

Low risk

Trial appears to be free of other problems that could put it at high risk of bias.

1RM: 1-repetition maximum.
7-DPAR: 7-day physical activity recall questionnaire.
ACSM: American College of Sports Medicine.
AIDS: acquired immunodeficiency syndrome.
AIT: aerobic interval training.
API: Aerobic Power Index.
BCE: Bone Collagen Equivalents.
BCPT: Breast Cancer Prevention Trial.
BDI: Beck Depression Inventory.
BES: Body Esteem Scale.
BFLUTS: Bristol Female Lower Urinary Tract Symptoms Questionnaire.
BIQ: Body Image Questionnaire.
BIS: bioimpedance spectroscopy.
BMI: body mass index.
BPI: Brief Pain Inventory.
BPNS: Basic Psychological Needs Satisfaction Scale.
BREQ-2: Behavioral Regulation for Exercise Questionnaire-2.
BRI: bone remodelling index.
BSAP: bone-specific alkaline phosphatase.
CARES-SF: Cancer Rehabilitation Evaluation System Short Form.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

197

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

CBT: cognitive-behavioural therapy.
CCS: Canadian Cancer Society.
CE: exercise begun after treatment.
CES-D: Centers for Epidemiological Studies—Depression Scale.
CHAMPS: Community Health Activities Model Program for Seniors.
CI: confidence interval.
CMT: continuous moderate training.
COM: combination of print material and pedometers intervention.
CP: chemotactic protein.
CRP: C-reactive protein.
CTACK: cutaneous T cell-attracting chemokine.
DASH: Disability of the Arm, Shoulder, and Hand questionnaire.
DASS-21: Depression and Anxiety Stress Scale-21.
DCIS: ductal carcinoma in situ.
DEG: delayed exercise group.
DEXA: dual-energy X-ray absorptiometry.
DWR: deep water running.
ECOG: Eastern Cooperative Oncology Group.
EE: exercise begun during treatment.
EEG: early exercise group.
ELISA: enzyme-linked immunosorbent assay.
EORTC QLQ-BR23: European Organization for Research and Treatment of Cancer core quality of life questionnaire.
EORTC QLQ-C30: European Organization for Research and Treatment of Cancer core quality of life questionnaire: breast cancer-specific
module.
EuroQoL-5D: European Quality of Life 5 dimensions.
EuroQoL-VAS: European Quality of Life visual analogue scale.
FACIT-F: Functional Assessment of Chronic Illness Therapy - Fatigue.
FACT: Functional Assessment of Cancer Therapy.
FACT-B: Functional Assessment of Cancer Therapy - Breast.
FACT-Cog: Functional Assessment of Cancer Therapy - Cognitive.
FACT-ES: Functional Assessment of Cancer Therapy - Endocrine Subscale.
FACT-F: Functional Assessment of Cancer Therapy - Fatigue.
FACT-G: Functional Assessment of Cancer Therapy - General.
FFQ: Food Frequency Questionnaire.
FGF: fibroblast growth factor.
FSI: Fatigue Symptom Inventory.
FSS: Fatigue Severity Scale.
G-CSF: granulocyte colony-stimulating factor.
gmCSF: granulocyte-macrophage colony-stimulating factor.
GRO: growth-related oncogene.
HADS: Hospital Anxiety and Depression Scale.
HbA1c: glycosylated haemoglobin.
HDL-C: high-density lipoprotein cholesterol.
HF/NS: hot flashes and night sweats.
HGF: hepatocyte growth factor.
HLRE: high-load resistance exercise.
HMWA: high-molecular-weight adiponectin.
HOMA: homeostatic model assessment.
HR: heart rate.
HRmax: maximum heart rate.
HRR: heart rate reserve.
IBCSG: International Breast Cancer Study Group.
ICAM: intercellular adhesion molecule.
IFN: interferon.
IGF: insulin-like growth factor.
IGFBP: insulin-like growth factor binding protein.
IL: interleukin.
IP: inducible protein.
IPAQ: International Physical Activity Questionnaire.
ITT: intention-to-treat.
KPS: Karnofsky Performance Status.
LDL-C: low-density lipoprotein cholesterol.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

198

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

LIF: leukaemia inhibitory factor.
LLRE: low-load resistance exercise.
LOCF: last observation carried forward.
LPS: lipopolysaccharide.
LSI: Leisure Score Index; Life Satisfaction Inventory.
LVEF: left ventricular ejection fraction.
MCS-F: macrophage colony-stimulating factor.
MET-h: metabolic equivalent hours.
METs: metabolic equivalents.
MFI: Multi-dimensional Fatigue Inventory.
MFSI: Multi-dimensional Fatigue Symptom Inventory.
MFSI-SF: Multi-dimensional Fatigue Symptom Inventory Short Form.
MI: myocardial infarction.
MIG: monokine induced by IFNγ.
MIP: macrophage inflammatory protein.
MOS SF-36: Medical Outcomes Study Short Form-36.
MVPA: moderate-vigorous physical activity.
NCI: National Cancer Institute.
NCIC: National Cancer Institute of Canada.
NGF: nerve growth factor.
NK: natural killer.
NKCA: natural killer cell activity.
NTx: N-terminal telopeptide.
NYHA: New York Heart Association.
PA: physical activity.
PAL: physical activity log.
PANAS: Positive and Negative Affect Scale.
PDGF: platelet-derived growth factor.
PE: physical education.
PED: pedometer intervention.
PFS: Piper Fatigue Scale.
PFS-R: Revised Piper Fatigue Scale.
PHA: phytohemagglutinin.
PM: print material.
POMS: Profile of Mood States.
PPO: peak power output.
pQCT: peripheral quantitative computed tomography.
PROMIS: Patient Reported Outcomes Measurement Information System.
PSQI: Pittsburgh Sleep Quality Index.
QLQ-BR23: quality of life questionnaire: breast cancer-specific module.
QoL: quality of life.
RCT: randomised controlled trial.
RER: respiratory exchange ratio.
RM: repetition maximum.
RPE: rate of perceived exertion.
RSE: Rosenberg Self-Esteem Scale.
RTR: reach-to-recovery.
SAQ: Sexual Activity Questionnaire.
SCF: stem cell factor.
SCGF: stem cell growth factor.
SCL-90R: Symptom Checklist-90 Revised.
SCT: social cognitive theory.
SD: standard deviation.
SDF: stromal cell-derived factor.
SOC: stage of change.
SPAS-7: Social Physique Anxiety Scale-7.
STAI: State-Trait Anxiety Index.
TC: total cholesterol.
TCC: Tai Chi Chuan.
TG: triglyceride.
TNF: tumour necrosis factor.
TOI: Trial Outcome Index.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

199

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

TRAIL: tumour necrosis factor-related apoptosis-inducing ligand.
TTM: Transtheoretical model.
URCC SI: University of Rochester Cancer Center Symptom Inventory.
VCAM: vascular cell adhesion molecule.
VE/VCO2: minute ventilation carbon dioxide production relationship.
VE/VO2: minute ventilation oxygen production relationship.
VEGF: vascular endothelial growth factor.
VEpeak: peak ventilation.
VO2max: maximal oxygen uptake.
VO2peak: peak oxygen uptake.
WCC: white cell count.
WHO: World Health Organization.
WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index.
YMCA: Young Men's Christian Association.
YOCAS: yoga intervention based on gentle Hatha and restorative yoga.

Characteristics of excluded studies [ordered by study ID]

Study

Reason for exclusion

Anderson 2012

This study was excluded because it included patients undergoing adjuvant cancer therapy.

Benton 2014

Bloom 2008

Buffart 2012

This study was excluded as it did not compare physical activity vs no physical activity or usual care.

This study was excluded because the effects of physical activity could not be isolated.

This study was excluded because the breast cancer population was not analysed separately.

Burnham 2002

This study was excluded because the breast cancer population was not analysed separately.

Cadmus-Bertram 2011

This study was excluded as it did not compare physical activity vs no physical activity, another in-
tervention, or usual care.

Cantarero-Villanueva 2012

This study was excluded because the effects of physical activity could not be isolated (physical ac-
tivity + manual therapy).

Cantarero-Villanueva 2012a

This study was excluded because the effects of physical activity could not be isolated (physical ac-
tivity + manual therapy).

Cantarero-Villanueva 2013a

This study was excluded because the effects of physical activity could not be isolated (physical ac-
tivity + manual therapy).

Carter 2012

Casla 2015

This study was excluded as it did not compare physical activity vs no physical activity or usual care.

This study was excluded because the effects of physical activity could not be isolated (physical ac-
tivity + diet modification).

Cheema 2006

This study was excluded as it did not compare physical activity vs no physical activity or usual care.

Cho 2006

This study was excluded because the effects of physical activity could not be isolated (physical ac-
tivity + education intervention).

Cohen 2010

This study was excluded because all patients were at pretreatment stage.

Culos-Reed 2006

This study was excluded because the breast cancer population was not analysed separately.

Cunningham 1998

This study was excluded because groups included all participants with metastatic disease.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

200

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Reason for exclusion

D'Atillio 2007

This study was excluded because it lacked a non-physical activity comparison group.

Damush 2006

This study was excluded as it did not compare physical activity vs no physical activity or usual care.

Danhauer 2009

This study was excluded because some participants were receiving treatment during the study.

De Backer 2007

This study was excluded as it did not compare physical activity vs no physical activity or usual care.

Demark 2006

Dimeo 2008

Djuric 2002

This study was excluded because it did not include a separate analysis of participants with breast
cancer.

This study was excluded as it did not compare physical activity vs no physical activity or usual care.

This study was excluded because the effects of physical activity could not be isolated (physical ac-
tivity + diet modification).

Eyigor 2010

This study was excluded because it lacked a non-physical activity comparison group.

Fernandez-Lao 2012

This study was excluded because the effects of physical activity could not be isolated (physical ac-
tivity + manual therapy).

Fernandez-Lao 2013

This study was excluded because it was a non-randomised controlled trial.

Fong 2014

This study was excluded because it was a non-randomised controlled trial.

Galantino 2013

This study was excluded because it did not include a comparison group.

Gordon 2005

Hanna 2008

Hayes 2013

Headley 2004

This study was excluded because it included exercises restricted to stretching and local muscular
endurance (i.e. training of shoulders).

This study was excluded as it did not compare physical activity vs no physical activity or usual care.

This study was excluded because it included participants undergoing adjuvant cancer therapy.

This study was excluded because all included participants had metastatic disease initiating
chemotherapy.

Hojan 2013

This study was excluded because it did not include a comparison group.

Hsiao-Fang 2013

This study was excluded because it included participants undergoing chemotherapy.

Hsieh 2008

This study was excluded because it included participants undergoing chemotherapy and radiother-
apy.

Hunt-Shanks 2006

This study was excluded because it did not include a comparison group.

Husebo 2014

Hutnick 2005

Ibfelt 2011

Isabell 2010

This study was excluded because it included participants undergoing chemotherapy.

This study was excluded because it was a non-randomised controlled trial.

This study was excluded because the breast cancer population was not analysed separately.

This study was excluded because it included participants undergoing chemotherapy and radiother-
apy.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

201

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Jeff 2012

Reason for exclusion

This study was excluded because it included exercises restricted to stretching and local muscular
endurance (i.e. training of shoulders).

Johansson 2005

This study was excluded as it did not compare physical activity vs no physical activity, another in-
tervention, or usual care.

Johnsson 2013

This study was excluded because it did not include a comparison group.

Kilbreath 2006

Kilbreath 2012

Kilgour 2008

Kim Soo 2011

Kovacic 2011

This study was excluded because it included exercises restricted to stretching and local muscular
endurance (i.e. training of shoulders).

This study was excluded because it included participants undergoing chemotherapy and radiother-
apy.

This study was excluded because it included exercises restricted to stretching and local muscular
endurance (i.e. training of shoulders).

This study was excluded because the effects of physical activity could not be isolated (physical ac-
tivity + diet modification).

This study did not include a physical activity intervention but used a relaxation intervention in-
stead.

LaStayo 2011

This study was excluded because the breast cancer population was not analysed separately.

Lee 2010

Ligibel 2012

May 2008

McClure 2010

Mefferd 2007

Moadel 2007

This study was excluded because it compared exercise vs historical control (non-randomised con-
trolled trial).

This study was excluded because the breast cancer population was not analysed separately.

This study was excluded because the breast cancer population was not analysed separately.

This study was excluded because it included exercises restricted to stretching and local muscular
endurance (i.e. training of shoulders).

This study was excluded because the effects of physical activity could not be isolated (physical ac-
tivity + diet modification).

This study was excluded because it included participants undergoing chemotherapy and radiother-
apy, as well as participants with metastatic disease.

Naraphong 2015

This study was excluded because it included participants undergoing chemotherapy.

Naumann 2012a

This study was excluded because it was a non-randomised controlled trial.

Noble 2012

Oh 2010

This study was excluded as it did not compare physical activity vs no physical activity or usual care.

This study was excluded because the breast cancer population was not analysed separately.

Oldervoll 2011

This study was excluded as it did not compare physical activity vs no physical activity or usual care.

Pinto 2008

Pinto 2013

This study was excluded as it did not compare physical activity vs no physical activity or usual care.

This study was excluded as it did not compare physical activity vs no physical activity or usual care
(healthcare professional gave PA advice to both intervention groups).

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

202

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Rabin 2006

Rabin 2009

Reason for exclusion

This study was excluded because it lacked a non-physical activity comparison group.

This study was excluded as it did not compare physical activity vs no physical activity or usual care.

Sandel 2005

This study was excluded because it included participants undergoing adjuvant cancer therapy.

Schmidt 2012

This study was excluded because it lacked a non-physical activity comparison group.

Schneider 2007

This study was excluded as it did not compare physical activity vs no physical activity or usual care.

Schwartz 1999

This study was excluded as it did not compare physical activity vs no physical activity or usual care.

Segal 2001

This study was excluded because it included participants undergoing adjuvant cancer therapy.

Sherman 2010

This study was excluded because it was a controlled clinical trial (participants allocated according
to patient preference and intervention availability).

Speed-Andrews 2010

This study was excluded because it did not include a comparison group.

Sprod 2005

Sprod 2010

Stan 2012

Stan 2013

This study was excluded because it lacked a non-physical activity comparison group.

This study was excluded because it was a non-randomised controlled trial.

This study was excluded as it did not compare physical activity vs no physical activity or usual care.

This study was excluded as it did not compare physical activity vs no physical activity or usual care.

Stevinson 2007

This study was excluded because the breast cancer population was not analysed separately.

Szczwpanska-Gieracha 2010

This study was excluded as it did not compare physical activity vs no physical activity or usual care.

Tang 2010

Taso 2014

This study was excluded because the breast cancer population was not analysed separately.

This study was excluded because it included participants undergoing adjuvant cancer therapy.

Thorsen 2005

This study was excluded because the breast cancer population was not analysed separately.

Tidhar 2010

Turner 2004

Ulger 2010

This study was excluded because it involved therapeutic exercise regimens addressing only specific
impairments related to shoulder, arm, or both.

This study was excluded as it did not compare physical activity vs no physical activity or usual care.

This study was excluded because it did not include a comparison group.

Van Puymbroeck 2011

This study was excluded because it lacked a non-physical activity comparison group.

Van Weert 2005

This study was excluded because the breast cancer population was not analysed separately.

Wong 2012

Wu 2008

Yuen 2007

This study was excluded as it did not compare physical activity vs no physical activity or usual care.

This study was excluded as it did not compare physical activity vs no physical activity or usual care.

This study was excluded because it included participants undergoing adjuvant cancer therapy.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

203

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Characteristics of studies awaiting assessment [ordered by study ID]

Lahart 2016 

Methods

Study design: RCT

Number expected to be randomised: 80; 40 to exercise intervention, 40 to control

Study start: January 2010; stop date: March 2013

Length of intervention: 6 months

Participants

Age, years (mean SD):

• Intervention: 52.4 (10.3)
• Control: 54.7 (8.3)

Stage: stage I–III

Inclusion criteria:

• Females aged 18 to 72 years

• Diagnosis of invasive breast cancer (stage I-III) within 2 years of enrolment

• Post surgery and no surgery planned for at least the next 6 months

• Fully completed adjuvant therapy (radiotherapy and/or chemotherapy) not including hormonal
therapy

• No previous malignancy

• Willing to be randomised

• Willing to maintain contact with investigators over 6 months

Exclusion criteria:

• Inability to participate in PA because of severe disability (e.g. severe arthritic conditions)

• Psychiatric illness

• Vulnerable individuals, such as pregnant women or any other patients for whom PA was not ap-
proved by their oncologist owing to the presence of 1 or more contraindications to exercise for pa-
tients with cancer

Interventions

• Intervention:

• Participants received a face-to-face consultation, followed by a support telephone call at the
end of months 1, 2, and 3 (i.e. a total of 3 telephone calls). During each of the last 2 months
(4 and 5), participants received mailed PA reminder leaflets encouraging their participation in
home-based physical activity. Face-to-face consultations were conducted by the primary re-
searcher immediately after initial baseline measurements and were based on 4 core motiva-
tional interviewing principles: expressing empathy, developing discrepancy, rolling with resis-
tance, and supporting self-efficacy. The goal of follow-up phone calls (end of months 1 to 3)
was to prevent relapse back to inactivity and/or improve maintenance of physical activity (ac-
cumulating 30 minutes of moderate-intensity PA 3 to 5 days/week); researchers covered topics
similar to those discussed in the face-to-face consultation.

• Usual care:

• Participants randomised to the usual care arm received standard information regarding PA (i.e.
current recommended PA guidelines), as provided to all participants with breast cancer treated
at the site. Usual care group participants were instructed to maintain their current lifestyle.

Outcomes

Primary outcome:

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

204

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Lahart 2016  (Continued)

Cochrane Database of Systematic Reviews

• Total physical activity levels via IPAQ

Secondary outcomes:

• Weight maintenance and BMI
• Body composition (body fat %) via bioelectrical impedence analysis
• HRQoL assessed via FACT-B
• Blood biomarkers: The Vitros 5 IFS Chemistry System (Ortho Clinical Diagnostics Inc., Rochester,
NY, USA) was used to measure all lipid components; however, total cholesterol, HDL-C, and triglyc-
erides were measured on multi-layered slides, whereas measurement of LDL-C required a dual-
chamber package. Plasma glucose was measured with the VITROS 5.1 FS Chemistry System (John-
son and Johnson Inc., Langhorne, PA, USA); insulin was estimated via solid-phase 2-site chemi-
luminescence  immunometric  assay  (Immulite  2000  Analyser,  Siemens  Healthcare  Diagnostics,
Deerfield, IL, USA); HOMA-insulin resistance was evaluated from fasting glucose and insulin.

Notes

Country of trial: UK

https://clinicaltrials.gov/ct2/show/NCT02408107

Dr. Ian Lahart; I.Lahart@wlv.ac.uk

Lohrisch 2011 

Methods

Study design: RCT

Number randomised: 22; 11 to exercise intervention, 11 to control

Study start: not reported; study completion: not reported

Length of intervention: 48 weeks

Participants

Eligible women with postmenopausal early breast cancer had arthralgias/myalgias (A/M) related to
adjuvant anastrozole.

Among 20 evaluated participants:

• Baseline median age was 62.

• BMI was 26 kg/m2 in Exercise and Control arms.

• Median number of arthralgia/myalgia sites was 5, with a median worst score of 2 (CTC version 2
criteria).

Interventions

Exercise participants exercised 3 times weekly for 48 weeks: for the first 12 weeks in a supervised
setting; for the second 12 weeks, supervised once weekly and independently twice weekly; for the
last 24 weeks, independently via aerobic and resistance programmes tailored to their fitness.

Outcomes

Primary outcome:

• Change in SF-36 bodily pain domain scores at week 12 (W12)

Secondary outcomes:

• Change in bone mineral density (BMD)
• Change in body mass index (BMI)
• Strength (bench press and leg strength)
• Hot flash index

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

205

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Lohrisch 2011  (Continued)

Notes

Study closed owing to poor accrual after 3 years, with 22 (11 exercise and 11 exercise) of the
planned 72 participants enrolled at 2 sites among 98 screened.

Only conference abstract is available.

Luu 2014 

Methods

Study design: RCT

Number randomised: 38; 24 to a yoga intervention, 14 to control

Study start: not reported; study completion: not reported

Length of intervention: 12 weeks

Participants

"Urban underserved breast cancer survivors"

Interventions

Participants were randomised to the treatment group (1-hour Hatha yoga classes) or the wait-list
control group.

Frequency of yoga classes per week is unclear.

Outcomes

Outcomes:

• Quality of life via FACT-B
• Spiritual well-being via functional assessment of chronic illness therapy - spiritual well-being

Notes

Only conference abstract is available.

A/M: arthralgia/myalgia.
BMD: bone mineral density.
BMI: body mass index.
CTC: common toxicity criteria.
FACT-B: Functional Assessment of Cancer Therapy - Breast.
HDL-C: high-density lipoprotein cholesterol.
HOMA: homeostatic model assessment.
HRQoL: health-related quality of life.
IPAQ: International Physical Activity Questionnaire.
LDL-C: low-density lipoprotein cholesterol.
PA: physical activity.
RCT: randomised controlled trial.
SD: standard deviation.
SF-36: Short Form-36.

Characteristics of ongoing studies [ordered by study ID]

Deli-Conwright 2014 

Trial name or title

Exercise Program for Early Breast Cancer Survivors

Methods

Accrual: not reported
Accrual target: 100 breast cancer survivors

Multi-centre/single-centre: single centre, but participants will be encouraged in a home-based ex-
ercise session over 30 to 45 minutes once weekly

Phase of trial: not reported

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

206

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Deli-Conwright 2014  (Continued)

Country where trial is being conducted: USA (Los Angeles, CA)
Any intended follow-up details: 12 weeks

Stated study design: RCT, efficacy study

Participants

Inclusion criteria:

Cochrane Database of Systematic Reviews

• Newly diagnosed (I-III) first primary invasive breast cancer

• Underwent lumpectomy or mastectomy

• Completed neoadjuvant/adjuvant chemotherapy and able to initiate Exercise programme (if ran-
domised to that arm) within 12 weeks of therapy completion

• Body mass index (BMI) > 25 kg/m2 or body fat > 30% (as determined by Dr. Dieli-Conwright at
baseline visit)

• Currently participate in less than 60 minutes of physical activity per week

• May use adjuvant endocrine therapy if use will be continued for duration of study period

• Non-smoker (i.e. not smoking during previous 12 months)

• Willing to travel to the exercise facility and USC

• Able to provide physician clearance to participate in exercise programme

• Women of all racial and ethnic backgrounds to be included in the study enrolment process

Exclusion criteria:

• History of chronic disease including diabetes, uncontrolled hypertension, or thyroid disease

• Weight reduction ≥ 10% in the past 6 months

• Diagnosis of human epidermal growth factor receptor 2 (HER2)-positive tumour (exclusion due to
patient use of Herceptin medication for 1 year following chemotherapy)

• Metastatic disease

• Planned reconstructive surgery with flap repair during trial and follow-up period

• Cardiovascular, respiratory, or musculoskeletal disease or joint problems that preclude moderate
physical activity

Interventions

ARM 1:

• Intervention details: Participants complete supervised exercise sessions over 60 minutes thrice
weekly and are encouraged to participate in a home-based exercise session over 30 to 45 minutes
once weekly for 16 weeks.

ARM 2:

• Comparator details: Participants refrain from increasing physical activity levels for 16 weeks.

Outcomes

Primary outcome:

• Change in components of metabolic syndrome (i.e. hypertension, high waist circumference, hy-

perglycaemia, low/high-density lipoproteins, elevated triglycerides)

Secondary outcomes:

• Cardiorespiratory fitness (4-minute walk test)
• Muscle strength (10-RM leg extension, leg flexion, chest press, seated row)
• Body composition (DEXA, weight, height, lean mass, % body fat, hip circumference)

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

207

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Deli-Conwright 2014  (Continued)

Cochrane Database of Systematic Reviews

• Quality of life (SF-36, FACT-B, CES-D)
• Shoulder strength (muscle force for scapular plane elevation and external rotation)
• Shoulder function (measured with goniometer at 90° external rotation, forward flexion)
• Upper limb musculoskeletal disorder assessment (Disabilities of the Arm, Shoulder, and Hand -

DASH - and Penn Shoulder Scale - PSS)

• Biomarkers - inflammation and endocrine function (analysed in peripheral blood)

Starting date

Start date: May 2012

Estimated completion date: May 2017

Contact information

Christina Dieli-Conwright, PhD; 323-442-2905

Email: cdieli@usc.edu

Notes

Trial registration link: https://clinicaltrials.gov/show/NCT01140282
Sponsor of the trial: University of Southern California, National Cancer Institute

This study is still recruiting participants.
Intention-to-treat analysis: not reported
Funding considerations: not funded by Pharma or otherwise

Galiano-Castillo 2013 

Trial name or title

Telehealth System to Improve Quality of Life in Breast Cancer Survivors

Methods

Accrual: 72
Accrual target: 80 breast cancer survivors

Multi-centre/single-centre: not reported but most likely home-based (paper or registry does not ex-
plicitly say this)

Phase of trial: not reported

Country where trial is being conducted: Spain
Any intended follow-up details: 8 weeks

Stated study design: RCT, efficacy study

Participants

Inclusion criteria:

• 18 to 65 years of age

• Female

• Diagnosis of stage I, II, or IIIA breast cancer

• Medical clearance for participation

• Without chronic disease or orthopaedic disease that would interfere with ability to participate in a
physical activity programme

• Access to Internet

• Basic ability to use the computer or living with a relative who has this ability

• Completion of adjuvant therapy except for hormone therapy

• No history of cancer recurrence

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

208

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Galiano-Castillo 2013  (Continued)

• Interest in improving lifestyle: fitness/stress level

• Signed informed consent

Exclusion criteria:

• Not reported

Interventions

ARM 1:

• Intervention details:

• Behavioral telerehabilitation group: Interventions will be based on providing cardiovascular,

mobility, strength, and stretching exercises through telerehabilitation system.

ARM 2:

• Comparator details: information about usual care

Outcomes

Primary outcome:

• Quality of life (European Organization for Research and Treatment of Cancer Core Quality of Life

Questionnaire 30)

Secondary outcomes:

• Algometry (pressure pain thresholds measured through an electronic algometer)
• Pain (visual analogue scale and brief pain inventory)
• Body composition (weight, body mass index, skeletal muscle mass, and percentage of body fat

obtained through bioelectrical impedance analysis)

• Physical measurements (abdominal McQuade test, handgrip strength and back muscle strength
via digital dynamometers, and multiple sit-to-stand test used to assess general lower extremity
endurance)

• Cardiorespiratory fitness (International Fitness Scale and 6-minute walk test)
• Fatigue via PFS-Revised
• Anxiety and depression via HADS
• Cognitive function (Trail Making Test and Auditory Consonant Trigram)
• Accelerometry (Actigraph tri-axial accelerometer)

Starting date

Start date: March 2012

Estimated completion date: July 2014

Contact information

Manuel Arroyo-Morales

Email: marroyo@ugr.es

Notes

Trial registration link: https://clinicaltrials.gov/ct2/show/NCT01801527

Sponsor of the trial: Universidad de Granada and Carlos III Health Institute
Intention-to-treat analysis: not reported
Funding considerations: not funded by Pharma or otherwise

IRCT2014042117379N1 

Trial name or title

Comparing Self-Efficacy, Outcome Expectations for Promoting the Physical Activity of Women With
Breast Cancer in Two Groups With and Without Educational Program

Methods

Study design: RCT

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

209

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

IRCT2014042117379N1  (Continued)

Number expected to be randomised: 70

Study start: September 2014; estimated stop date: November 2015

Length of intervention: 8 weeks

Participants

50 malignant neoplasms of breast cancer

Inclusion criteria:

• Final diagnosis of breast cancer by a physician

• Individual consent and spousal consent if married

• Physician’s written consent to participation in the educational programme

• Ability to read and write

Exclusion criteria:

• Therapist’s prescription for a ban on attending sessions

• Lack of desire to participate in the study

• Absence for more than 1 session during educational sessions

• Cognitive disorder diagnosed during the educational intervention

Age: not reported

Interventions

Intervention 1:

• The first session is devoted to identifying need for patient education in the experimental group.
Participants then receive education during at least 4 90-minute sessions with respect to the bar-
riers to self-efficacy in physical activity, energy management, stress management, lymphoedema
prevention, and other topics mentioned in the group. Training sessions are presented in Power-
Point by relevant experts on each topic.

• Educational activities are intended for promotion of self-efficacy, brainstorming strategies, verbal
persuasion, successor experience, and framing questions in the group.

Usual care:

• No special arrangement is made for the control group, except for normal medical care.

Outcomes

Primary outcomes:

• Self-efficacy for physical activity (measured before and 1 month after the intervention via the stan-

dard self-efficacy questionnaire for physical activity by Bandura)

• Outcome expectation for physical activity (measured before and 1 month after the intervention

via the "questionnaire")

Seconday outcome:

• Physical activity (measured before and 3 months after the intervention by "standard physical ac-

tivity measurement questionnaire")

Starting date

20 March 2014

Contact information

Rahele Solymani
Rahelesolymani@hlth.mui.ac.ir; raheel_s59@yahoo.com

Notes

Country of trial: Iran, Islamic Republic of

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

210

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

IRCT2014042117379N1  (Continued)

http://apps.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2014042117379N1

KIlbreath 2011 

Trial name or title

Methods

Exercise to Prevent Osteoporosis as a Consequence of Hormone Treatment in Post Menopausal
Women Treated for Breast Cancer

Accrual: not reported
Accrual target: 60

Multi-centre/single-centre: multi-centre

Phase of trial: not reported
Country where trial is being conducted: Australia
Any intended follow-up details: no follow-up

Stated study design: RCT, blinded

Participants

Inclusion criteria

• Postmenopausal

• Above 18 years of age

• Mmenses history and/or surgery

• Stage I-III breast cancer

• Oestrogen receptor and/or progesterone receptor positive breast cancer

• Commenced taking aromatase inhibitor within 10 weeks

• Eastern Collaborative Oncology Group performance status ≤ 2 (Oken et al, 1982)

• Sedentary.

Exclusion criteria

• Any clinical or radiological evidence of distant spread of disease

• Any HRT in the past 12 months

• Taken bisphosphonates in the past 6 months

• Prior treatment with continuous systemic glucocorticoids in the past 6 months

• Current treatment with any drugs known to affect the skeleton (e.g. calcitonin, calcitriol,
mithramycin, gallium nitrate)

• History of diseases that influence bone metabolism, such as Paget's disease or ongoing thyroid
toxicosis

• Previous or concomitant malignancy (apart from breast cancer) in the past 5 years except ade-
quately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix

Interventions

ARM 1:

• Intervention details: exercise programme - exercise training will run for 12 months, 3 times per
week for approximately 1 hour each session. A trainer will meet women at their local communi-
ty gym 3 times per week for the first 4 weeks, then once a month for the rest of the year. The
programme will consist of a 5-minute warm-up, 25 minutes of high-impact exercise using steps
(jumping, running, hopping), 25 minutes of resistance exercise in the limbs and trunk with free

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

211

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

KIlbreath 2011  (Continued)

Cochrane Database of Systematic Reviews

weights and resistance equipment, and a 5-minute cool-down. Daily calcium carbonate (1200 mg)
and vitamin D (1000 IU) supplements

ARM 2:

• Comparator details: daily calcium carbonate (1200 mg) and vitamin D (1000 IU) supplements. No

exercise prescription

Outcomes

Primary outcome:

• Bone mineral density (DEXA scans of spine and hip)

Secondary outcomes:

• Biochemical markers of bone remodelling (bone formation and resorption)
• Self-report outcomes (quality of life questionnaire and medical outcomes survey short forms)
• Lymphoedema status
• Bone mineral density (DEXA scans of trochanteric, femoral neck, and spinal bone mineral density)

Starting date

Start date: May 2008

Estimated completion date: not reported

Contact information

Prof Sharon Kilbreath

Email: sharon.kilbreath@sydney.edu.au

Notes

Trial registration link: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82762

Sponsor of the trial: Cancer Australia

Trial authors were contacted and we were informed by the authors that the study had been com-
pleted and they were preparing for publication.
Intention-to-treat analysis: not reported
Funding considerations: not funded by Pharma or otherwise

NCT02057536 

Trial name or title

The Effect of an Exercise Program in Breast Cancer Patients With Joint Pain While Taking Aro-
matase Inhibitors

Methods

Study design: RCT

Number expected to be randomised: 30

Study start: January 2014; estimated stop date: January 2015

Length of intervention: 8 weeks

Participants

Stage: I-III

Time since cancer diagnosis: not specified

Inclusion criteria:

• Women over age 40 with histological evidence of hormone receptor positive breast cancer

• Postmenopausal

• Adjuvant AI therapy

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

212

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT02057536  (Continued)

Cochrane Database of Systematic Reviews

• Significant joint discomfort/stiffness when attempting activities of daily living, which began or
significantly increased after initiation of AI therapy

• Currently not in an active directed exercise programme (> 60 minutes 2×/week)

• Age: 40 years or older

Ethnicity: not reported

Interventions

8-Week directed exercise programme

Outcomes

Primary objective:

• Change in Pain Disability Index from baseline to 8 weeks

Starting date

January 2014

Contact information

Christiana Care/Helen F. Graham Cancer Center, Newark, DE, USA 19713

Notes

Country of trial: USA

https://ClinicalTrials.gov/show/NCT02057536

NCT02235051 

Trial name or title

Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer
Survivors

Methods

Study design: RCT

Number expected to be randomised: 50

Study start: May 2015; estimated stop date: November 2016

Length of intervention: 16 weeks

Participants

Stage: I-IIIA

Time since cancer diagnosis: within first 3 years post treatment

Inclusion criteria:

• Women with diagnosis of first primary invasive oestrogen receptor (ER) positive (+) breast cancer
(stage I-IIIA) within first 3 years post treatment

• Postmenopausal women
• Women of childbearing potential and men must agree to use adequate contraception (hormon-
al or barrier method of birth control or abstinence) before study entry and for 6 months following
duration of study participation; should a woman become pregnant or suspect that she is pregnant
while participating in the trial, she should inform her treating physician immediately

• Any body mass index (BMI)

• Sedentary (has not participated in a regular exercise programme in the past 12 months)

• Non-smoker (not smoking during previous 12 months)

• Willing and able to travel to the exercise facility

• Diagnosis of first primary invasive ER+ breast cancer (stage I-IIIA)

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

213

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT02235051  (Continued)

• Has undergone a lumpectomy or mastectomy

• Completed adjuvant chemotherapy and/or radiation within 3 years before study enrolment (when
cytokine levels are predicted to be high) and able to initiate an exercise programme

• May use adjuvant endocrine therapy if use will be continued for duration of study period

• Must have the ability to understand and the willingness to sign a written informed consent

Age: 56 years and older

Ethnicity: not reported

Interventions

Patients participate in a supervised Curves exercise programme 3 days a week for 16 weeks. The
circuit-style workout consists of 14 exercises constructed with pneumatic or hydraulic resistance
that target opposing muscle groups in a concentric-only fashion. Each session at a Curves facility
will include 2 complete circuits, which corresponds to exercising for approximately 30 minutes, fol-
lowed by a standardised stretching routine.

Outcomes

Primary objectives:

• To test the hypothesis that regular exercise increases DNA repair capacity
• To test the hypothesis that regular exercise reduces inflammatory response
• To test the hypothesis that regular exercise modulates telomerase activity

Secondary objectives:

• To assess adherence to the study protocol
• To examine differences in body composition before and after the exercise intervention
• To examine differences in fitness before and after the exercise intervention
• To test the hypothesis that regular exercise improves quality of life in breast cancer survivors
• To examine the safety of the exercise intervention

Starting date

May 2015

Contact information

Principal Investigator: Jessica Clague DeHart

Contact: Jessica Clague DeHart; 800-826-4673; jclague@coh.org

Notes

Country of trial: USA

https://ClinicalTrials.gov/show/NCT02235051

NCT02332876 

Trial name or title

Physical Activity and Neuropsychological Outcomes in a Cancer Population

Methods

Study design: RCT

Number expected to be randomised: 87

Study start: August 2014; estimated stop date: August 2017

Length of intervention: 12 weeks

Participants

Stage: I-III

Time since cancer diagnosis: less than 5 years

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

214

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT02332876  (Continued)

Inclusion criteria:

Cochrane Database of Systematic Reviews

• Breast cancer survivors; diagnosis at stage I, II, or III less than 5 years ago

• Not scheduled for or currently undergoing chemotherapy; sedentary, defined as engaging in less
than 60 minutes of moderate-to-vigorous physical activity each week

• Accessible geographically and by telephone

• Access to the Internet

• Endorse experience difficulties with thinking abilities

• Participants on adjuvant therapy (e.g. tamoxifen, aromatase inhibitors) must be able and willing
to remain on that treatment for the 3-month intervention period to prevent confounding of bio-
marker concentrations by treatment.

Age: 21 to 85 years

Ethnicity: not reported

Interventions

12-Week individually tailored phone and email-based exercise programme

Outcomes

Primary objective:

• Change in score on the NIH Toolbox Cognition measure from baseline to 12 weeks

Starting date

August 2014

Contact information

Sheri Hartman, Assistant Professor, University of California, San Diego

Notes

Country of trial: USA

https://ClinicalTrials.gov/show/NCT02332876

NCT02420249 

Trial name or title

Qigong for Breast Cancer Survivors

Methods

Study design: RCT

Number expected to be randomised: 60

Study start: March 2015; estimated stop date: May 2017

Length of intervention: 3 months

Participants

Stage: not reported

Time since cancer diagnosis: not reported

Inclusion criteria:

• History of a breast malignancy at any stage

• History of mastectomy or lumpectomy with or without adjuvant chemotherapy or radiotherapy

• Completed conventional cancer treatment and medically stable

• No known neurological deficits resulting from breast cancer treatment or other neurological dis-
orders

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

215

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT02420249  (Continued)

Cochrane Database of Systematic Reviews

• Persistent lymphoedema defined as a circumference difference > 2 cm at any point between the
surgical upper limb and the contralateral upper limb

• Female aged 18 or above

Age: 18 years or above

Ethnicity: Chinese

Interventions

Participants assigned to the Qigong group will receive Qigong training.

The Qigong training programme will be run for 3 months with 2 supervised 1-hour sessions per
week.

Participants will learn the 18 Forms of Tai Chi Internal Qigong.

Training sessions will be conducted by a qualified Qigong instructor from the Natural Health
Qigong Association.

Outcomes

Primary objectives:

• Change in upper limb circumference
• Change in arterial resistance and blood flow velocities
• Change in shoulder flexibility
• Change in shoulder muscular strength
• Change in body balance

Secondary objective:

• Change in quality of life

Starting date

March 2015

Contact information

Shirley SM Fong, PT, PhD; 852-970-90337; smfong@hku.hk

Notes

Country of trial: Hong Kong

https://ClinicalTrials.gov/show/NCT02420249

NCT02433067 

Trial name or title

Physical Activity Intervention on Myocardial Function in Patients With HER2 + Breast Cancer (CAR-
DAPAC)

Methods

Study design: RCT

Number expected to be randomised: 117

Study start: April 2015; estimated stop date: April 2017

Length of intervention: 12 weeks

Participants

Stage: not specified

Time since cancer diagnosis: receiving adjuvant trastuzumab after undergoing surgery for breast
cancer

Inclusion criteria:

• First breast cancer HER2 + histologically confirmed

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

216

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT02433067  (Continued)

Cochrane Database of Systematic Reviews

• WHO grade performance index ≤ 1
• Normal renal function (creatinine clearance ≥ 60 mL/min-1)
• Normal heart function with LVEF ≥ 50%
• Normal liver function (AST and ALT normal)
• Physical activity certificate issued by a cardiologist or an oncologist
• Active contraception or postmenopausal
• Age: 18 to 65 years

Ethnicity: not reported

Interventions

Participants will participate in a physical activity intervention 3 times per week for 3 months and an
interval training programme on a cycle-ergometer.

Outcomes

Primary objective:

• To evaluate any change in the left ventricular ejection fraction (LVEF), as evaluated by echocar-

diography, from baseline to 6 months

Secondary objectives:

To measure any changes in the following from baseline to 3 months and 6 months:

• Weight and volume of left and right ventricular by echocardiography
• Body composition evaluated by impedance and with tape measure and pliers of Harpenden
• Metabolic responses evaluated with enzyme-linked immunosorbent assay (ELISA)
• Maximal voluntary quadriceps evaluated with chair quadriceps with strain gauge
• Quality of life evaluated with questionnaire
• Pain evaluated with questionnaire
• Fatigue evaluated with questionnaire
• Level of physical activity evaluated with questionnaire
• Pulmonary function evaluated with respiratory functional test and maximal exercise test
• Hormonal responses evaluated with ELISA
• inflammatory responses evaluated with ELISA

Starting date

April 2015

Contact information

Contact: Fabienne Mougin-Guillaume, PhD; fabienne.mougin-guillaume@univ-fcomte.fr

Principal Investigator: Nathalie Meneveau

Notes

Country of trial: France

https://clinicaltrials.gov/show/NCT02433067

NCT02527889 

Trial name or title

The Effect of Resistive Exercise on Forearm Blood Flow and Tissue Oxygenation Among Breast Can-
cer Survivors With or at Risk for Breast Cancer-Related Lymphoedema (BCRL)

Methods

Study design: RCT

Number expected to be randomised: 150

Study start: July 2015; estimated stop date: December 2016

Length of intervention: 8 weeks

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

217

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT02527889  (Continued)

Participants

Stage: not reported

Cochrane Database of Systematic Reviews

Interventions

Time since cancer diagnosis: not reported

Inclusion criteria:

• Female breast cancer survivors

• Remained disease free, as defined by unremarkable clinical examination within recent 6 months,
with a clinical diagnosis of stable lymphoedema and without lymphoedema

Age: 18 to 70 years

Ethnicity: Chinese

Participants assigned to the exercise group will receive a supervised resistive exercise programme,
which includes 1-hour physiotherapist-supervised small group-based exercise sessions twice a
week for 8 weeks. Before resistive exercises, participants will perform warm-up with movements of
large joints and shoulder girdle for 15 minutes. Resistive exercises will focus on the major muscle
groups in the upper body. Loading of resistive exercises will be prescribed and progressed accord-
ing to individual capacity and will reach a level of moderate-to-high loading (6 to 12 repetition max-
imum); these will be followed by stretching exercises specific to the muscle groups trained after the
session.

Control group: no intervention; all 30 participants recruited

Outcomes

Primary objectives:

• Changes in brachial artery blood flow as measured by a Doppler ultrasonic device with a linear

probe

• Changes in tissue oxygenation as measured by near-infrared spectroscopy

Secondary objectives:

To measure changes at 20 weeks in:

• Arm  circumference  as  measured  by  a  tape  measure  at  10-cm  interval  from  the  ulnar  styloid

process

• Extent of lymphoedema as measured by bioelectrical impedance spectroscopy
• Self-reported lymphoedema symptoms
• Hand grip strength as measured by hand grip dynamometer
• Upper limb range of motion measurement
• Shoulder range of motion measured with a standard goniometer
• Quality of life measured by FACT-Breast Cancer Subscale Questionnaire

Starting date

July 2015

Contact information

Rufina Lau; (852)27666718; Rufina.Lau@polyu.edu.hk

Notes

Country of trial: Hong Kong

https://clinicaltrials.gov/ct2/show/NCT02527889

ALT: alanine aminotransferase.
AST: aspartate aminotransferase.
BMI: body mass index.
CES-D: Centers for Epidemiological Studies—Depression Scale.
DASH: Disability of the Arm, Shoulder, and Hand questionnaire.
DEXA: dual-energy X-ray absorptiometry.
ELISA: enzyme-linked immunosorbent assay.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

218

 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

FACT-B: Functional Assessment of Cancer Therapy - Breast.
HADS: Hospital Anxiety and Depression Scale.
HER2: human epidermal growth factor receptor 2.
LVEF: left ventricular ejection fraction.
PFS: Piper Fatigue Scale.
PSS: Penn Shoulder Scale.
RCT: randomised controlled trial.
RM: repetition maximum.
USC: University of Southern California.
WHO: World Health Organization.

D A T A   A N D   A N A L Y S E S

Comparison 1.   Comparison: HRQoL outcomes, all physical activity vs control

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Overall HRQoL (follow-up
values)

1.1 End of intervention

1.2 Follow-up

2 Overall HRQoL (change
values)

2.1 End of intervention

2.2 Follow-up

3 FACT-G (follow-up values)

3.1 End of intervention

3.2 Follow-up

4 FACT-G (change values)

4.1 End of intervention

4.2 Follow-up

5 FACT-B (follow-up values)

5.1 End of intervention

5.2 Follow-up

6 FACT-B (change values)

22

22

4

14

14

2

10

10

3

6

6

2

11

11

4

6

1996

418

1459

132

1094

342

663

132

1395

421

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.39 [0.21, 0.57]

Std. Mean Difference (IV, Random, 95%
CI)

0.20 [0.00, 0.39]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.78 [0.39, 1.17]

Std. Mean Difference (IV, Random, 95%
CI)

0.52 [0.15, 0.88]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

7.06 [2.82, 11.30]

Mean Difference (IV, Random, 95% CI)

2.81 [-0.46, 6.08]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

5.04 [1.32, 8.75]

Mean Difference (IV, Random, 95% CI)

6.16 [1.63, 10.69]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

6.31 [1.15, 11.47]

Mean Difference (IV, Random, 95% CI)

3.77 [0.11, 7.43]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

219

 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

6.1 End of intervention

6.2 Follow-up

7 FACT Breast Cancer Sub-
scale (follow-up values)

7.1 End of intervention

7.2 Follow-up

8 FACT Breast Cancer Sub-
scale (change values)

8.1 End of intervention

8.2 Follow-up

9 FACT Trial Outcome Index
(follow-up values)

9.1 End of intervention

9.2 Follow-up

10 EORTC QLQ-C30 Global
Health (follow-up values)

10.1 End of intervention

10.2 Follow-up

11 EORTC QLQ-C30 Global
Health (change values)

11.1 End of intervention

11.2 Follow-up

6

2

11

11

4

7

7

1

4

4

1

4

4

0

4

4

0

12 Overall emotional func-
tion/mental health (fol-
low-up values)

26

12.1 End of intervention

26

12.2 Follow-up

13 Overall emotional func-
tion/mental health (change
values)

7

15

605

132

1043

386

646

36

658

213

195

0

633

0

2102

655

Mean Difference (IV, Random, 95% CI)

8.16 [2.56, 13.76]

Mean Difference (IV, Random, 95% CI)

6.95 [1.34, 12.56]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

1.98 [0.92, 3.04]

Mean Difference (IV, Random, 95% CI)

3.20 [-0.65, 7.05]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

1.78 [-0.14, 3.70]

Mean Difference (IV, Random, 95% CI)

1.30 [-1.56, 4.16]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

7.90 [-1.24, 17.04]

Mean Difference (IV, Random, 95% CI)

3.60 [0.01, 7.19]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

7.85 [2.16, 13.55]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

9.53 [-2.43, 21.49]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.21 [0.10, 0.32]

Std. Mean Difference (IV, Random, 95%
CI)

0.20 [0.03, 0.36]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

13.1 End of intervention

15

1579

Std. Mean Difference (IV, Random, 95%
CI)

0.31 [0.09, 0.53]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

220

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

13.2 Follow-up

14 FACT Emotional well-be-
ing (follow-up values)

14.1 End of intervention

14.2 Follow-up

15 FACT Emotional well-be-
ing (change values)

15.1 End of intervention

15.2 Follow-up

16 MOS SF Mental compos-
ite (follow-up values)

16.1 End of intervention

16.2 Follow-up

17 MOS SF Mental compos-
ite (change values)

17.1 End of intervention

17.2 Follow-up

18 MOS SF Mental health
(follow-up values)

18.1 End of intervention

18.2 Follow-up

19 MOS SF Mental health
(change values)

19.1 End of intervention

19.2 Follow-up

20 MOS SF Emotional role
(follow-up values)

20.1 End of intervention

20.2 Follow-up

21 MOS SF Emotional role
(change values)

3

11

11

3

6

6

1

5

5

3

2

2

0

7

7

2

5

5

0

5

5

1

4

179

1064

311

582

36

563

281

294

0

524

196

333

0

330

120

Std. Mean Difference (IV, Random, 95%
CI)

0.06 [-0.29, 0.41]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

0.47 [0.01, 0.94]

Mean Difference (IV, Random, 95% CI)

0.14 [-0.85, 1.14]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

0.96 [0.34, 1.57]

Mean Difference (IV, Random, 95% CI)

0.79 [-0.67, 2.25]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

0.49 [-1.09, 2.06]

Mean Difference (IV, Random, 95% CI)

2.27 [0.05, 4.50]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

2.22 [-0.95, 5.40]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

1.67 [-0.65, 3.99]

Mean Difference (IV, Random, 95% CI)

3.49 [-0.97, 7.95]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

2.22 [0.70, 3.74]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

-0.00 [-1.09, 1.09]

Mean Difference (IV, Fixed, 95% CI)

3.06 [-11.55, 17.67]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

221

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

21.1 End of intervention

21.2 Follow-up

22 EORTC QLQ-C30 Emo-
tional function (follow-up
values)

22.1 End of intervention

22.2 Follow-up

23 EORTC QLQ-C30 Emo-
tional function (change val-
ues)

23.1 End of intervention

23.2 Follow-up

24 POMS total mood distur-
bance (follow-up values)

24.1 End of intervention

24.2 Follow-up

25 POMS total mood distur-
bance (change values)

25.1 End of intervention

25.2 Follow-up

26 POMS anger subscale
(follow-up values)

26.1 End of intervention

26.2 Follow-up

27 Happiness/satisfaction
with life (follow-up values)

27.1 End of intervention

27.2 Follow-up

4

0

3

3

0

3

3

0

3

3

1

2

2

2

2

2

1

4

4

0

213

0

135

0

573

0

161

61

143

143

79

61

209

0

Mean Difference (IV, Fixed, 95% CI)

0.23 [-0.79, 1.24]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

11.53 [3.96, 19.11]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

0.90 [-5.12, 6.92]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.93 [-1.55, -0.32]

Std. Mean Difference (IV, Random, 95%
CI)

-0.54 [-1.06, -0.03]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.07 [-0.65, 0.79]

Std. Mean Difference (IV, Random, 95%
CI)

0.09 [-0.23, 0.42]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.78 [-1.25, -0.31]

Std. Mean Difference (IV, Random, 95%
CI)

-0.44 [-0.94, 0.07]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.61 [-0.16, 1.37]

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

222

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

28 Happiness/satisfaction
with life (change values)

28.1 End of intervention

28.2 Follow-up

29 Overall physical function
(follow-up values)

29.1 End of intervention

29.2 Follow-up

30 Overall physical function
(change values)

30.1 End of intervention

30.2 Follow-up

31 FACT Physical well-being
(follow-up values)

31.1 End of intervention

31.2 Follow-up

32 FACT Physical well-being
(change values)

32.1 End of intervention

32.2 Follow-up

33 MOS SF Physical com-
posite (follow-up values)

33.1 End of intervention

33.2 Follow-up

34 MOS SF Physical com-
posite (change values)

34.1 End of intervention

34.2 Follow-up

3

3

0

25

25

6

13

13

1

11

11

3

6

6

1

4

4

2

2

2

0

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.28 [-0.05, 0.62]

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.33 [0.18, 0.49]

Std. Mean Difference (IV, Random, 95%
CI)

0.21 [0.06, 0.37]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.60 [0.23, 0.97]

Std. Mean Difference (IV, Random, 95%
CI)

0.17 [-0.48, 0.83]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

1.44 [0.31, 2.56]

Mean Difference (IV, Random, 95% CI)

1.17 [0.22, 2.12]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

1.60 [-0.85, 4.05]

Mean Difference (IV, Random, 95% CI)

0.9 [-2.37, 4.17]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

1.78 [0.12, 3.43]

Mean Difference (IV, Fixed, 95% CI)

1.30 [-1.23, 3.82]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

2.56 [-0.13, 5.25]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

182

0

2129

637

1433

36

1064

311

579

36

437

163

294

0

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

223

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

35 MOS SF Physical function
(follow-up values)

35.1 End of intervention

35.2 Follow-up

36 MOS SF Physical function
(change values)

36.1 End of intervention

36.2 Follow-up

37 EORTC QLQ-C30 Physical
function (follow-up values)

37.1 End of intervention

37.2 Follow-up

38 EORTC QLQ-C30 Physical
function (change values)

38.1 End of intrevention

38.2 Follow-up

39 Body Esteem Scale -
Physical condition (fol-
low-up values)

39.1 End of intervention

39.2 Follow-up

40 Overall role function (fol-
low-up values)

40.1 End of intervention

40.2 Follow-up

41 Overall role function
(change values)

41.1 End of intervention

41.2 Follow-up

7

7

2

5

5

0

3

3

0

3

3

0

2

2

0

18

18

2

12

12

1

515

239

333

0

135

0

573

0

106

0

1370

249

1315

36

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

2.09 [0.03, 4.15]

Mean Difference (IV, Random, 95% CI)

2.71 [-1.58, 6.99]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

2.08 [0.21, 3.94]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

2.99 [-1.64, 7.63]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

3.12 [-3.24, 9.49]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

4.41 [0.57, 8.25]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.29 [0.07, 0.51]

Std. Mean Difference (IV, Random, 95%
CI)

0.13 [-0.12, 0.38]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.14 [-0.05, 0.33]

Std. Mean Difference (IV, Random, 95%
CI)

0.37 [-0.29, 1.03]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

224

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

42 FACT Functional well-be-
ing (follow-up values)

42.1 End of intervention

42.2 Follow-up

43 FACT Functional well-be-
ing (change values)

43.1 End of intervention

43.2 Follow-up

44 MOS SF Physical role (fol-
low-up values)

44.1 End of intervention

44.2 Follow-up

45 MOS SF Physical role
(change values)

45.1 End of intervention

45.2 Follow-up

46 EORTC QLQ-C30 Role
function (follow-up values)

46.1 End of intervention

46.2 Follow-up

47 EORTC QLQ-C30 Role
function (change values)

47.1 End of intervention

47.2 Follow-up

11

11

2

6

6

1

3

3

0

3

3

0

3

3

0

3

3

0

48 Overall social well-be-
ing/function (follow-up val-
ues)

18

48.1 End of intervention

18

48.2 Follow-up

49 Overall social well-be-
ing/function (change val-
ues)

1

12

1064

249

582

36

143

0

155

0

135

0

573

0

1557

213

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

1.67 [0.29, 3.06]

Mean Difference (IV, Random, 95% CI)

0.68 [-0.65, 2.01]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

0.72 [0.42, 1.01]

Mean Difference (IV, Fixed, 95% CI)

1.31 [-1.02, 3.64]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

-0.16 [-1.47, 1.15]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

0.46 [-1.52, 2.43]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

0.44 [-5.78, 6.66]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

-1.08 [-4.52, 2.36]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.19 [0.08, 0.30]

Std. Mean Difference (IV, Random, 95%
CI)

0.09 [-0.18, 0.36]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

225

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

49.1 End of intervention

12

49.2 Follow-up

50 FACT Social well-being
(follow-up values)

50.1 End of intervention

50.2 Follow-up

51 FACT Social well-being
(change values)

51.1 End of intervention

51.2 Follow-up

52 MOS SF Social function-
ing (follow-up values)

52.1 End of intervention

52.2 Follow-up

53 MOS SF Social function-
ing (change values)

53.1 End of intervention

53.2 Follow-up

54 EORTC QLQ-C30 Social
function (follow-up values)

54.1 End of intervention

54.2 Follow-up

55 EORTC QLQ-C30 Social
function (change values)

55.1 End of intervention

55.2 Follow-up

56 Overall cognitive func-
tion (follow-up values)

56.1 End of intervention

1

11

11

1

6

6

1

5

5

0

4

4

0

2

2

0

3

3

0

5

5

1384

36

1064

213

582

36

234

0

213

0

73

0

573

0

189

Std. Mean Difference (IV, Random, 95%
CI)

0.52 [0.16, 0.87]

Std. Mean Difference (IV, Random, 95%
CI)

0.69 [0.01, 1.36]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

0.77 [0.11, 1.43]

Mean Difference (IV, Random, 95% CI)

0.5 [-1.02, 2.02]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

1.93 [1.58, 2.28]

Mean Difference (IV, Fixed, 95% CI)

3.86 [0.17, 7.55]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

-0.32 [-1.87, 1.23]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

1.05 [-0.08, 2.18]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

7.55 [-11.77, 26.86]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

2.14 [-8.02, 12.30]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.40 [0.11, 0.69]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

226

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

56.2 Follow-up

57 Overall cognitive func-
tion (change values)

57.1 End of intervention

57.2 Follow-up

58 EORTC QLQ-C30 Cogni-
tive function (follow-up val-
ues)

58.1 End of intervention

58.2 Follow-up

59 EORTC QLQ-C30 Cogni-
tive function (change val-
ues)

59.1 End of intervention

59.2 Follow-up

60 POMS confusion sub-
scale (follow-up values)

60.1 End of intervention

60.2 Follow-up

61 Overall general health
(follow-up values)

61.1 End of intervention

61.2 Follow-up

62 Overall general health
(change values)

62.1 End of intervention

62.2 Follow-up

63 MOS SF General health
(follow-up values)

2

5

5

2

2

2

0

3

3

0

2

2

1

9

9

1

9

9

1

5

97

672

97

73

0

573

0

79

61

456

36

906

36

Std. Mean Difference (IV, Random, 95%
CI)

0.31 [-0.09, 0.71]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.00 [-0.27, 0.26]

Std. Mean Difference (IV, Random, 95%
CI)

0.20 [-0.20, 0.60]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

2.43 [-5.75, 10.61]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

-3.25 [-6.31, -0.18]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Std. Mean Difference (IV, Fixed, 95% CI)

-0.66 [-1.12, -0.19]

Std. Mean Difference (IV, Fixed, 95% CI)

-0.45 [-0.96, 0.06]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.18 [-0.08, 0.45]

Std. Mean Difference (IV, Random, 95%
CI)

-0.22 [-0.87, 0.44]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.17 [-0.07, 0.40]

Std. Mean Difference (IV, Random, 95%
CI)

0.07 [-0.59, 0.72]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

227

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

63.1 End of intervention

63.2 Follow-up

64 MOS SF General health
(change values)

64.1 End of intervention

64.2 Follow-up

65 Overall sexual function
(follow-up values)

65.1 End of intervention

65.2 Follow-up

66 Overall sexual function
(change values)

66.1 End of intervention

66.2 Follow-up

67 Body Esteem Scale -
sexual attractiveness (fol-
low-up values)

67.1 End of intervention

67.2 Follow-up

68 Overall sleep (follow-up
values)

68.1 End of intervention

68.2 Follow-up

69 Overall sleep (change
values)

69.1 End of intervention

69.2 Follow-up

70 PSQI Global sleep score
(follow-up values)

70.1 End of intervention

5

0

4

4

0

5

5

1

3

3

0

2

2

0

5

5

1

3

3

0

5

5

233

0

213

0

411

102

693

0

100

0

188

31

136

0

Mean Difference (IV, Random, 95% CI)

2.14 [-2.61, 6.88]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

0.10 [-1.26, 1.45]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Std. Mean Difference (IV, Fixed, 95% CI)

0.16 [-0.04, 0.35]

Std. Mean Difference (IV, Fixed, 95% CI)

0.19 [-0.20, 0.58]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.22 [-0.08, 0.52]

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

1.71 [-1.41, 4.82]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Std. Mean Difference (IV, Fixed, 95% CI)

-0.09 [-0.37, 0.20]

Std. Mean Difference (IV, Fixed, 95% CI)

-0.49 [-1.20, 0.23]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.14 [-0.20, 0.48]

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

317

Mean Difference (IV, Fixed, 95% CI)

-0.47 [-1.01, 0.08]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

228

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

70.2 Follow-up

71 PSQI Global sleep score
(change values)

71.1 End of intervention

71.2 Follow-up

72 PSQI sleep quality (fol-
low-up values)

72.1 End of intervention

72.2 Follow-up

73 PSQI sleep efficiency (fol-
low-up values)

73.1 End of intervention

73.2 Follow-up

74 PSQI sleep latency (fol-
low-up values)

74.1 End of intervention

74.2 Follow-up

75 PSQI sleep duration (fol-
low-up values)

75.1 End of intervention

75.2 Follow-up

76 PSQI daytime dysfunc-
tion (follow-up values)

76.1 End of intervention

76.2 Follow-up

77 PSQI medication use (fol-
low-up values)

77.1 End of intervention

77.2 Follow-up

1

2

2

0

2

2

0

3

3

0

3

3

0

2

2

0

3

3

0

2

2

0

31

80

0

80

0

100

0

100

0

80

0

100

0

80

0

Mean Difference (IV, Fixed, 95% CI)

-1.5 [-3.63, 0.63]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

0.54 [-1.11, 2.19]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-0.24 [-0.81, 0.32]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

0.15 [-0.24, 0.53]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

0.19 [-0.16, 0.55]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

0.06 [-0.28, 0.41]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-0.08 [-0.51, 0.35]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.06 [-0.50, 0.38]

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

229

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

78 Accelerator-derived
sleep efficiency (follow-up
values)

78.1 End of intervention

78.2 Follow-up

79 Accelerator-derived
sleep latency (follow-up val-
ues)

79.1 End of intervention

79.2 Follow-up

2

2

0

2

2

0

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

-2.25 [-5.52, 1.01]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

-2.04 [-4.78, 0.69]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

62

0

62

0

Analysis 1.1.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 1 Overall HRQoL (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.1.1 End of intervention

Herrero 2006

Cerulli 2014

Mustian 2004

Loudon 2014

Portela 2008

Milne 2008

Rogers 2009

Courneya 2003

Ergun 2013

Murtezani 2014

Mehnert 2011

Do 2015

Cadmus 2009

Pinto 2015

Schmitz 2005

Taleghani 2012

Loh 2014

Daley 2007

Littman 2012

Rogers 2015

Vallance 2007

Short 2014

Subtotal ***

81.3 (10.7)

85.2 (4.2)

121.7 (22.7)

-7.4 (1.2)

107.2 (28.5)

86.4 (8.3)

92 (11.4)

91.3 (11)

71.6 (19.9)

86.5 (7.3)

74.7 (21.7)

87.3 (13.7)

91.2 (12.6)

117.8 (12.7)

-44.2 (8.7)

217.5 (36.3)

112.4 (14.1)

90.9 (13.5)

90.3 (11)

88.1 (12.4)

91.5 (11.8)

106.8 (16.7)

8

10

11

12

25

29

20

24

40

30

30

32

37

39

39

40

63

33

30

105

250

195

1102

62.5 (16.1)

65.9 (14.7)

124.3 (25.9)

-7.4 (1.4)

91.6 (28.5)

64.1 (10.8)

87.4 (13.1)

89.3 (10.9)

67.9 (16.7)

79.1 (7.5)

65.4 (16.8)

82.4 (19.9)

86.2 (17.4)

114 (18)

-47.4 (9.4)

210.1 (41.5)

109.3 (13.3)

86.4 (15.1)

87.7 (15)

83.2 (15.5)

90.6 (13)

108.2 (18.2)

8

10

10

11

9

29

18

28

20

32

27

30

37

37

40

40

32

69

110

108

85

104

894

1.96%

2.1%

2.79%

2.96%

3.16%

3.69%

3.86%

4.46%

4.52%

4.58%

4.59%

4.78%

5.08%

5.13%

5.18%

5.22%

5.31%

5.39%

5.48%

6.46%

6.63%

6.68%

100%

1.3[0.19,2.41]

1.72[0.66,2.78]

-0.1[-0.96,0.75]

0.02[-0.8,0.84]

0.53[-0.24,1.31]

2.28[1.61,2.96]

0.37[-0.27,1.01]

0.18[-0.37,0.73]

0.19[-0.35,0.73]

0.99[0.46,1.52]

0.47[-0.06,1]

0.28[-0.22,0.79]

0.33[-0.13,0.78]

0.24[-0.21,0.69]

0.35[-0.09,0.79]

0.19[-0.25,0.63]

0.22[-0.2,0.65]

0.3[-0.12,0.72]

0.18[-0.22,0.59]

0.35[0.08,0.62]

0.08[-0.16,0.33]

-0.08[-0.32,0.16]

0.39[0.21,0.57]

Heterogeneity: Tau2=0.11; Chi2=65.99, df=21(P<0.0001); I2=68.17%

Test for overall effect: Z=4.23(P<0.0001)

1.1.2 Follow-up

Favours control

-4

-2

0

2

4

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

230

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Rogers 2009

Pinto 2015

Daley 2007

Rogers 2015

Subtotal ***

86.1 (13.6)

115.7 (15)

90.3 (14.9)

86.9 (14.5)

19

39

31

105

194

85.4 (18.4)

111.4 (17.7)

87.9 (14.3)

83.6 (15.8)

17

37

65

105

224

Heterogeneity: Tau2=0; Chi2=0.33, df=3(P=0.95); I2=0%

Test for overall effect: Z=1.99(P=0.05)

8.89%

18.65%

20.74%

51.72%

100%

0.04[-0.61,0.7]

0.26[-0.19,0.71]

0.16[-0.26,0.59]

0.22[-0.05,0.49]

0.2[0,0.39]

Favours control

-4

-2

0

2

4

Favours physical activity

Analysis 1.2.   Comparison 1 Comparison: HRQoL outcomes, all
physical activity vs control, Outcome 2 Overall HRQoL (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.2.1 End of intervention

Mustian 2004

Herrero 2006

Murtezani 2014

Naumann 2012

Rogers 2009

Cuesta-Vargas 2014

Courneya 2003

Ergun 2013

Mehnert 2011

Cadmus 2009

Schmitz 2005

Daley 2007

Vallance 2007

Saarto 2012

Subtotal ***

15 (5)

17.7 (8.3)

9.2 (2.1)

14.5 (10.6)

4.5 (8.4)

0.3 (0.2)

5.7 (7.4)

5.4 (21.5)

9.7 (21)

0.6 (7.5)

2.3 (4.5)

10.2 (11.2)

2.3 (11.1)

4.2 (16.2)

11

8

30

11

20

22

24

40

30

37

39

33

250

263

818

0 (5)

-10.4 (17.7)

-0.6 (2)

3.1 (11.4)

2.9 (12)

0.3 (0.1)

0.6 (7.4)

-6.7 (25.9)

5.6 (16.5)

-2.4 (9.8)

0.6 (4)

3.2 (11.3)

-0.2 (6.4)

5.6 (15.4)

10

8

32

10

18

20

28

20

27

37

40

69

85

237

641

Heterogeneity: Tau2=0.44; Chi2=124.6, df=13(P<0.0001); I2=89.57%

Test for overall effect: Z=3.93(P<0.0001)

1.2.2 Follow-up

Rogers 2009

Daley 2007

Subtotal ***

3.4 (11)

9.7 (15.2)

19

31

50

-3.5 (10.8)

4 (9.9)

17

65

82

Heterogeneity: Tau2=0; Chi2=0.13, df=1(P=0.72); I2=0%

Test for overall effect: Z=2.78(P=0.01)

4.53%

4.69%

5.72%

5.99%

7.23%

7.37%

7.56%

7.63%

7.73%

7.97%

8.02%

8.11%

8.65%

8.8%

100%

2.88[1.59,4.17]

1.92[0.68,3.17]

4.65[3.67,5.63]

1[0.08,1.92]

0.15[-0.49,0.79]

-0.07[-0.67,0.54]

0.68[0.12,1.24]

0.52[-0.03,1.06]

0.22[-0.31,0.74]

0.34[-0.12,0.8]

0.4[-0.05,0.84]

0.62[0.2,1.04]

0.24[-0,0.49]

-0.09[-0.26,0.09]

0.78[0.39,1.17]

29.38%

70.62%

100%

0.62[-0.05,1.29]

0.47[0.04,0.91]

0.52[0.15,0.88]

Favours control

-10

-5

0

5

10

Favours physical activity

Analysis 1.3.   Comparison 1 Comparison: HRQoL outcomes, all
physical activity vs control, Outcome 3 FACT-G (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.3.1 End of intervention

Favours control

-50

-25

0

25

50

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

231

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

Cerulli 2014

Rogers 2009

Cadmus 2009

Courneya 2003

Daley 2007

Milne 2008

Littman 2012

Rogers 2015

Murtezani 2014

Vallance 2007

Subtotal ***

85.2 (4.2)

92 (11.4)

91.2 (12.6)

91.3 (11)

90.9 (13.5)

86.4 (8.3)

90.3 (11)

88.1 (12.4)

86.5 (7.3)

91.5 (11.8)

10

20

37

24

33

29

30

105

30

250

568

10

18

37

28

69

29

110

108

32

85

526

65.9 (14.7)

87.4 (13.1)

86.2 (17.4)

89.3 (10.9)

86.4 (15.1)

64.1 (10.8)

87.7 (15)

83.2 (15.5)

79.1 (7.5)

90.6 (13)

Heterogeneity: Tau2=38.26; Chi2=64.11, df=9(P<0.0001); I2=85.96%

Test for overall effect: Z=3.26(P=0)

1.3.2 Follow-up

Rogers 2009

Daley 2007

Rogers 2015

Subtotal ***

86.1 (13.6)

90.3 (14.9)

86.9 (14.5)

19

31

105

155

17

65

105

187

85.4 (18.4)

87.9 (14.3)

83.6 (15.8)

Heterogeneity: Tau2=0; Chi2=0.22, df=2(P=0.89); I2=0%

Test for overall effect: Z=1.68(P=0.09)

7.6%

8.61%

9.21%

9.83%

9.94%

10.47%

10.54%

11.14%

11.19%

11.46%

100%

9.4%

26.95%

63.64%

100%

19.34[9.89,28.79]

4.6[-3.25,12.45]

5[-1.92,11.92]

2[-3.97,7.97]

4.41[-1.4,10.22]

22.3[17.34,27.26]

2.6[-2.23,7.43]

4.9[1.14,8.66]

7.4[3.72,11.08]

0.99[-2.13,4.11]

7.06[2.82,11.3]

0.7[-9.97,11.37]

2.39[-3.91,8.69]

3.3[-0.8,7.4]

2.81[-0.46,6.08]

Favours control

-50

-25

0

25

50

Favours physical activity

Analysis 1.4.   Comparison 1 Comparison: HRQoL outcomes, all
physical activity vs control, Outcome 4 FACT-G (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.4.1 End of intervention

Rogers 2009

Daley 2007

Courneya 2003

Cadmus 2009

Vallance 2007

Murtezani 2014

Subtotal ***

4.5 (8.4)

10.2 (11.2)

5.7 (7.4)

0.6 (7.5)

2.3 (11.1)

9.2 (2.1)

20

33

24

37

250

30

394

18

69

28

37

85

32

269

2.9 (12)

3.2 (11.3)

0.6 (7.4)

-2.4 (9.8)

-0.2 (6.4)

-0.6 (2)

Heterogeneity: Tau2=17.63; Chi2=53.23, df=5(P<0.0001); I2=90.61%

Test for overall effect: Z=2.66(P=0.01)

1.4.2 Follow-up

Rogers 2009

Daley 2007

Subtotal ***

3.4 (11)

9.7 (15.2)

19

31

50

-3.5 (10.8)

4 (9.9)

17

65

82

Heterogeneity: Tau2=0; Chi2=0.07, df=1(P=0.79); I2=0%

Test for overall effect: Z=2.67(P=0.01)

12.31%

15.43%

16.41%

16.51%

19.3%

20.05%

100%

1.6[-5.05,8.25]

7.02[2.37,11.67]

5.1[1.07,9.13]

3[-0.98,6.98]

2.46[0.53,4.39]

9.72[8.69,10.75]

5.04[1.32,8.75]

40.34%

59.66%

100%

6.9[-0.23,14.03]

5.66[-0.2,11.52]

6.16[1.63,10.69]

Favours control

-20

-10

0

10

20

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

232

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.5.   Comparison 1 Comparison: HRQoL outcomes, all
physical activity vs control, Outcome 5 FACT-B (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.5.1 End of intervention

Portela 2008

Rogers 2009

Courneya 2003

Daley 2007

Pinto 2015

Milne 2008

Loh 2014

Rogers 2015

Murtezani 2014

Vallance 2007

Short 2014

Subtotal ***

25

20

24

33

39

29

63

105

30

250

219

837

107.2 (28.5)

114.4 (16.2)

119.6 (16.9)

115.1 (17.6)

117.8 (12.7)

110.5 (10.3)

112.4 (14.1)

9

18

28

69

37

29

32

91.6 (28.5)

118.7 (14.4)

115.8 (14.9)

109.2 (19.5)

114 (18)

82.6 (14.3)

109.3 (13.3)

115.9 (17.2)

108

109.4 (20.4)

113.2 (9.7)

120.2 (16.3)

106.8 (16.7)

101.2 (9.5)

119.2 (17.3)

108.2 (18.2)

32

85

111

558

Heterogeneity: Tau2=61.3; Chi2=75.46, df=10(P<0.0001); I2=86.75%

Test for overall effect: Z=2.4(P=0.02)

1.5.2 Follow-up

Rogers 2009

Daley 2007

Pinto 2015

Rogers 2015

Subtotal ***

112.6 (17.6)

115.4 (20.1)

115.7 (15)

115.1 (18.8)

19

31

39

105

194

110.7 (22.3)

113.4 (18.2)

111.4 (17.7)

110.6 (20.2)

17

65

37

108

227

Heterogeneity: Tau2=0; Chi2=0.34, df=3(P=0.95); I2=0%

Test for overall effect: Z=2.02(P=0.04)

3.77%

8.07%

8.55%

9.1%

9.34%

9.63%

9.92%

10.2%

10.31%

10.53%

10.58%

100%

7.64%

19.21%

24.43%

48.73%

100%

15.6[-6.11,37.31]

-4.3[-14.03,5.43]

3.8[-4.93,12.53]

5.91[-1.66,13.48]

3.81[-3.24,10.86]

27.9[21.49,34.31]

3.11[-2.65,8.87]

6.5[1.44,11.56]

12[7.22,16.78]

1[-3.2,5.2]

-1.4[-5.44,2.64]

6.31[1.15,11.47]

1.9[-11.33,15.13]

2[-6.34,10.34]

4.29[-3.11,11.69]

4.5[-0.74,9.74]

3.77[0.11,7.43]

Favours control

-50

-25

0

25

50

Favours physical activity

Analysis 1.6.   Comparison 1 Comparison: HRQoL outcomes, all
physical activity vs control, Outcome 6 FACT-B (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.6.1 End of intervention

Naumann 2012

Rogers 2009

Courneya 2003

Daley 2007

Vallance 2007

Murtezani 2014

Subtotal ***

14.5 (10.6)

5.4 (10.8)

9.1 (14.1)

13.5 (14.6)

3.8 (12.7)

13.4 (2.7)

11

20

24

33

250

30

368

10

18

28

69

80

32

237

3.1 (11.4)

3.1 (14.1)

0.3 (8.5)

4.4 (15)

1.2 (13.7)

-0.8 (2.5)

Heterogeneity: Tau2=39.49; Chi2=47.55, df=5(P<0.0001); I2=89.48%

Test for overall effect: Z=2.86(P=0)

1.6.2 Follow-up

Rogers 2009

Daley 2007

Subtotal ***

4.1 (12)

13.5 (19.6)

19

31

50

17

65

82

-4.1 (13.8)

7.5 (11.8)

Heterogeneity: Tau2=0; Chi2=0.15, df=1(P=0.7); I2=0%

13.02%

14.49%

16.22%

16.6%

19.23%

20.45%

100%

11.4[1.96,20.84]

2.3[-5.75,10.35]

8.8[2.34,15.26]

9.07[2.96,15.18]

2.64[-0.75,6.03]

14.21[12.9,15.52]

8.16[2.56,13.76]

43.69%

56.31%

100%

8.2[-0.29,16.69]

5.98[-1.5,13.46]

6.95[1.34,12.56]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

233

Favours control

-20

-10

0

10

20

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

Test for overall effect: Z=2.43(P=0.02)

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 1.7.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 7 FACT Breast Cancer Subscale (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.7.1 End of intervention

Rogers 2009

Banasik 2011

Courneya 2003

Murtezani 2014

Milne 2008

Daley 2007

Cadmus 2009

Littman 2012

Pinto 2015

Rogers 2015

Vallance 2007

Subtotal ***

27 (5.5)

8.8 (3.1)

28.4 (6.7)

26.6 (5.6)

24.1 (4.9)

24.4 (5.7)

26.7 (5.8)

26.8 (4.2)

27 (5.4)

27.8 (6.2)

28.7 (6.5)

20

7

24

30

29

32

37

30

39

105

250

603

Heterogeneity: Tau2=1.45; Chi2=19.14, df=10(P=0.04); I2=47.76%

Test for overall effect: Z=3.66(P=0)

1.7.2 Follow-up

Rogers 2009

Daley 2007

Pinto 2015

Rogers 2015

Subtotal ***

26 (6)

25.3 (5.9)

27.1 (6.1)

28.2 (5.7)

19

30

39

105

193

26.7 (6.4)

8.4 (3.9)

26.4 (5.1)

22.1 (5.5)

18.5 (5.8)

21.3 (5.2)

24.1 (5.9)

25.2 (5.5)

26.3 (5)

26.2 (6.3)

28.6 (6.2)

25.3 (6.7)

23.6 (5.6)

25.2 (4.8)

20.5 (5.4)

18

7

28

32

29

32

37

27

37

108

85

440

17

31

37

108

193

Heterogeneity: Tau2=13.38; Chi2=27.76, df=3(P<0.0001); I2=89.19%

Test for overall effect: Z=1.63(P=0.1)

5.58%

5.83%

6.88%

8.5%

8.51%

8.8%

8.87%

9.26%

10.23%

13.41%

14.11%

100%

21.57%

24.88%

25.86%

27.69%

100%

0.3[-3.51,4.11]

0.37[-3.33,4.07]

2[-1.28,5.28]

4.5[1.73,7.27]

5.6[2.84,8.36]

3.1[0.42,5.78]

2.6[-0.07,5.27]

1.6[-0.96,4.16]

0.69[-1.64,3.02]

1.6[-0.08,3.28]

0.06[-1.49,1.61]

1.98[0.92,3.04]

0.7[-3.47,4.87]

1.67[-1.21,4.55]

1.94[-0.51,4.39]

7.7[6.21,9.19]

3.2[-0.65,7.05]

Favours control

-10

-5

0

5

10

Favours physical activity

Analysis 1.8.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 8 FACT Breast Cancer Subscale (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.8.1 End of intervention

Naumann 2012

Rogers 2009

Daley 2007

Courneya 2003

Cadmus 2009

Vallance 2007

Murtezani 2014

11

20

32

24

37

250

30

1.6 (3.8)

1 (5.3)

24.4 (5.7)

3.3 (4)

1 (3)

1.4 (4.8)

4.2 (1.4)

10

18

32

28

37

85

32

2.3 (3.9)

0.3 (5)

21.3 (5.2)

-0.3 (3.2)

0.8 (3.4)

1 (3.9)

-0.2 (1.4)

11.48%

11.53%

12.97%

14.64%

15.8%

16.58%

17.01%

-0.7[-4,2.6]

0.7[-2.58,3.98]

3.1[0.42,5.78]

3.6[1.61,5.59]

0.2[-1.26,1.66]

0.34[-0.68,1.36]

4.48[3.79,5.17]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

234

Favours control

-10

-5

0

5

10

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Subtotal ***

Mean(SD)

N

404

N

242

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

100%

1.78[-0.14,3.7]

Heterogeneity: Tau2=5.49; Chi2=63.43, df=6(P<0.0001); I2=90.54%

Test for overall effect: Z=1.82(P=0.07)

1.8.2 Follow-up

Rogers 2009

Subtotal ***

19

19

0.7 (3.7)

17

17

-0.6 (4.9)

100%

100%

1.3[-1.56,4.16]

1.3[-1.56,4.16]

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=0.89(P=0.37)

Favours control

-10

-5

0

5

10

Favours physical activity

Analysis 1.9.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 9 FACT Trial Outcome Index (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.9.1 End of intervention

Courneya 2003

Milne 2008

Vallance 2007

Rogers 2015

Subtotal ***

77 (12)

70.3 (7.9)

91 (13.5)

74.2 (11.9)

24

29

250

105

408

74.8 (10.1)

46.5 (12.8)

90.2 (14.9)

69 (14.5)

28

29

85

108

250

Heterogeneity: Tau2=81.1; Chi2=50.37, df=3(P<0.0001); I2=94.04%

Test for overall effect: Z=1.69(P=0.09)

23.98%

24.47%

25.77%

25.78%

100%

2.2[-3.89,8.29]

23.8[18.33,29.27]

0.8[-2.79,4.39]

5.2[1.64,8.76]

7.9[-1.24,17.04]

1.9.2 Follow-up

Rogers 2015

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.96(P=0.05)

73.6 (12.4)

105

105

108

108

70 (14.3)

100%

100%

3.6[0.01,7.19]

3.6[0.01,7.19]

Favours control

-50

-25

0

25

50

Favours physical activity

Analysis 1.10.   Comparison 1 Comparison: HRQoL outcomes, all physical activity
vs control, Outcome 10 EORTC QLQ-C30 Global Health (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.10.1 End of intervention

Herrero 2006

Mehnert 2011

Ergun 2013

Do 2015

Subtotal ***

81.3 (10.7)

74.7 (21.7)

71.6 (19.9)

87.3 (13.7)

8

30

40

32

110

8

27

20

30

85

62.5 (16.1)

65.4 (16.8)

67.9 (16.7)

82.4 (19.9)

Heterogeneity: Tau2=7.29; Chi2=3.82, df=3(P=0.28); I2=21.43%

Test for overall effect: Z=2.7(P=0.01)

1.10.2 Follow-up

15.63%

25.23%

27.12%

32.02%

100%

18.8[5.4,32.2]

9.29[-0.73,19.31]

3.69[-5.88,13.26]

4.9[-3.66,13.46]

7.85[2.16,13.55]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

235

Favours control

-50

-25

0

25

50

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Subtotal ***

0

0

Weight

Mean Difference

Random, 95% CI

Not estimable

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Favours control

-50

-25

0

25

50

Favours physical activity

Analysis 1.11.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 11 EORTC QLQ-C30 Global Health (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.11.1 End of intervention

Herrero 2006

Ergun 2013

Mehnert 2011

Saarto 2012

Subtotal ***

8

40

30

263

341

17.7 (8.3)

5.4 (21.5)

9.7 (21)

4.2 (16.2)

-10.4 (17.7)

-6.7 (25.9)

5.6 (16.5)

5.6 (15.4)

8

20

27

237

292

Heterogeneity: Tau2=121.42; Chi2=21.28, df=3(P<0.0001); I2=85.9%

Test for overall effect: Z=1.56(P=0.12)

22%

22.37%

25.46%

30.17%

100%

28.1[14.55,41.65]

12.1[-1.05,25.25]

4.17[-5.6,13.94]

-1.4[-4.17,1.37]

9.53[-2.43,21.49]

1.11.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-50

-25

0

25

50

Favours physical activity

Analysis 1.12.   Comparison 1 Comparison: HRQoL outcomes, all physical activity vs
control, Outcome 12 Overall emotional function/mental health (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.12.1 End of intervention

Banasik 2011

Herrero 2006

Mustian 2004

Pinto 2003

Loudon 2014

Rogers 2009

Cuesta-Vargas 2014

Basen-Enquist 2006

Courneya 2003

Milne 2008

Do 2015

Littman 2012

Mehnert 2011

Cantarero-Villanueva 2013

Murtezani 2014

7

8

9

12

12

20

22

28

24

29

32

30

30

32

30

0.5 (0.4)

90.6 (9.3)

24.8 (2)

-10.8 (28.1)

-1.6 (0.7)

20 (3.1)

42.9 (19.2)

78.2 (10.6)

21.5 (3.4)

19.6 (2.4)

87.4 (8.8)

20.3 (4)

77 (35.8)

-17175
(4279)

19.5 (3.3)

7

8

10

12

11

18

20

23

28

29

30

27

28

29

32

0.4 (0.3)

83.3 (14.8)

24.8 (3.2)

-27.2 (19.5)

-1.6 (0.5)

21.1 (2.9)

32.3 (33.3)

77.2 (12)

20.7 (3)

16.7 (4.1)

70.4 (21.5)

20.8 (3.1)

69.1 (40.5)

-20390
(6113)

18.3 (3.5)

1.01%

1.11%

1.35%

1.59%

1.61%

2.45%

2.66%

3.15%

3.19%

3.27%

3.33%

3.45%

3.5%

3.52%

3.65%

0.25[-0.8,1.3]

0.56[-0.45,1.56]

-0.01[-0.91,0.89]

0.65[-0.17,1.48]

0.05[-0.77,0.87]

-0.36[-1,0.28]

0.39[-0.22,1]

0.09[-0.46,0.64]

0.25[-0.3,0.79]

0.85[0.31,1.39]

1.03[0.5,1.57]

-0.14[-0.66,0.38]

0.21[-0.31,0.72]

0.61[0.09,1.12]

0.35[-0.15,0.85]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

236

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Daley 2007

Cadmus 2009

Pinto 2015

Schmitz 2005

Pinto 2005

Loh 2014

Fillion 2008

Duijits 2012

Rogers 2015

Schmitz 2009

Vallance 2007

Subtotal ***

19.1 (4.2)

20.5 (3)

54.2 (9.3)

-45.6 (8.2)

-8 (20.7)

19.9 (2.8)

48.5 (7.9)

73.9 (34.7)

20.6 (2.9)

53.2 (9.6)

20.3 (3.3)

33

37

39

39

39

63

44

37

105

112

250

1123

Heterogeneity: Tau2=0.02; Chi2=34.19, df=25(P=0.1); I2=26.88%

Test for overall effect: Z=3.71(P=0)

1.12.2 Follow-up

Rogers 2009

Cantarero-Villanueva 2013

Daley 2007

Pinto 2015

Fillion 2008

Duijits 2012

Rogers 2015

Subtotal ***

19.5 (3.1)

-17306
(4501)

19.5 (4.5)

53.4 (8.6)

51.4 (7.6)

77.5 (37.5)

20.5 (3.5)

19

32

31

39

44

36

105

306

Heterogeneity: Tau2=0.01; Chi2=6.64, df=6(P=0.36); I2=9.63%

Test for overall effect: Z=2.28(P=0.02)

18.5 (3.3)

19.8 (4.2)

52.5 (9.6)

-48.2 (8.2)

-16.5 (28.8)

20 (3.2)

47.5 (9.1)

77.5 (34.3)

19.7 (3.2)

53.8 (8.7)

19.9 (3.4)

20.8 (3)

-19915
(4966)

19 (3.3)

50.5 (10.9)

48 (9.3)

74.4 (37.2)

20 (3.2)

33

37

37

40

43

32

43

89

108

120

85

979

17

29

31

37

43

84

108

349

3.87%

4.21%

4.29%

4.39%

4.49%

4.66%

4.73%

5.36%

8.02%

8.39%

8.74%

100%

6.13%

9.95%

10.47%

12.52%

14.04%

16.31%

30.58%

100%

0.16[-0.32,0.64]

0.19[-0.27,0.65]

0.18[-0.27,0.63]

0.31[-0.13,0.76]

0.33[-0.1,0.77]

-0.04[-0.46,0.39]

0.12[-0.3,0.54]

-0.1[-0.49,0.28]

0.29[0.02,0.56]

-0.07[-0.32,0.19]

0.11[-0.14,0.35]

0.21[0.1,0.32]

-0.42[-1.08,0.25]

0.54[0.03,1.06]

0.14[-0.36,0.64]

0.3[-0.16,0.75]

0.4[-0.02,0.82]

0.08[-0.31,0.47]

0.15[-0.12,0.42]

0.2[0.03,0.36]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 1.13.   Comparison 1 Comparison: HRQoL outcomes, all physical activity
vs control, Outcome 13 Overall emotional function/mental health (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.13.1 End of intervention

Herrero 2006

Mustian 2004

Naumann 2012

Rogers 2009

Murtezani 2014

Courneya 2003

Cormie 2014

Mehnert 2011

Cantarero-Villanueva 2013

Cadmus 2009

Schmitz 2005

Pinto 2005

Schmitz 2009

Vallance 2007

8

9

11

20

30

24

43

30

32

37

39

39

58

9.3 (19.6)

2.4 (2.5)

1 (2.7)

0.9 (2.5)

2.1 (0.8)

2.3 (3.1)

4.4 (9)

2.3 (35.5)

-1445
(4452)

0.3 (2.2)

2.5 (4.4)

-3.8 (27.7)

3.3 (23.2)

250

0.5 (3.5)

8

10

10

18

32

28

19

28

29

37

40

43

62

85

-2.1 (5.9)

0.1 (1.7)

-0.1 (2.7)

-0.1 (2.7)

0.5 (0.9)

0.8 (2.9)

2.7 (8.6)

3.6 (17.6)

353 (3323)

-0.5 (3.3)

0.3 (3.9)

-11.5 (25.8)

3.1 (17.2)

0.1 (2.5)

3.3%

3.53%

4.11%

5.69%

6.09%

6.47%

6.59%

6.84%

6.9%

7.4%

7.49%

7.62%

8.41%

9.49%

0.74[-0.28,1.77]

1.06[0.08,2.03]

0.39[-0.48,1.26]

0.38[-0.27,1.02]

1.8[1.21,2.4]

0.49[-0.06,1.05]

0.19[-0.35,0.73]

-0.04[-0.56,0.47]

-0.45[-0.96,0.06]

0.28[-0.18,0.74]

0.52[0.08,0.97]

0.28[-0.15,0.72]

0.01[-0.35,0.37]

0.12[-0.13,0.36]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

237

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Saarto 2012

Subtotal ***

Mean(SD)

1.2 (17.8)

N

263

893

Mean(SD)

1.9 (18.5)

N

237

686

Heterogeneity: Tau2=0.12; Chi2=50.63, df=14(P<0.0001); I2=72.35%

Test for overall effect: Z=2.71(P=0.01)

1.13.2 Follow-up

Rogers 2009

Cantarero-Villanueva 2013

Pinto 2005

Subtotal ***

0.5 (2.7)

-1324
(5711)

3.1 (27.9)

19

32

39

90

-0.3 (1.7)

-121 (1606)

-2 (26.2)

17

29

43

89

Heterogeneity: Tau2=0.03; Chi2=2.72, df=2(P=0.26); I2=26.5%

Test for overall effect: Z=0.34(P=0.73)

Random, 95% CI

Random, 95% CI

10.06%

100%

-0.04[-0.21,0.14]

0.31[0.09,0.53]

22.91%

34.56%

42.53%

100%

0.34[-0.32,1]

-0.28[-0.78,0.23]

0.19[-0.25,0.62]

0.06[-0.29,0.41]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 1.14.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 14 FACT Emotional well-being (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.14.1 End of intervention

Rogers 2009

Littman 2012

Daley 2007

Courneya 2003

Milne 2008

Murtezani 2014

Cadmus 2009

Loh 2014

Vallance 2007

Rogers 2015

Banasik 2011

Subtotal ***

20 (3.1)

20.3 (4)

19.1 (4.2)

21.5 (3.4)

19.6 (2.4)

19.5 (3.3)

20.5 (3)

19.9 (2.8)

20.3 (3.3)

20.6 (2.9)

0.5 (0.4)

20

30

33

24

29

30

37

63

250

105

7

628

Heterogeneity: Tau2=0.21; Chi2=17.02, df=10(P=0.07); I2=41.26%

Test for overall effect: Z=1.99(P=0.05)

1.14.2 Follow-up

Rogers 2009

Daley 2007

Rogers 2015

Subtotal ***

19.5 (3.1)

19.5 (4.5)

20.5 (3.5)

19

31

105

155

Heterogeneity: Tau2=0.23; Chi2=2.71, df=2(P=0.26); I2=26.13%

Test for overall effect: Z=0.28(P=0.78)

21.1 (2.9)

20.8 (3.1)

18.5 (3.3)

20.7 (3)

16.7 (4.1)

18.3 (3.5)

19.8 (4.2)

20 (3.2)

19.9 (3.4)

19.7 (3.2)

0.4 (0.3)

20.8 (3)

19 (3.3)

20 (3.2)

18

27

33

28

29

32

37

32

85

108

7

436

17

31

108

156

4.91%

5.17%

5.3%

5.61%

5.75%

5.94%

6.11%

8.61%

14.44%

14.75%

23.42%

100%

20.38%

21.18%

58.44%

100%

-1.1[-3.01,0.81]

-0.5[-2.35,1.35]

0.61[-1.21,2.43]

0.8[-0.96,2.56]

2.9[1.17,4.63]

1.2[-0.49,2.89]

0.7[-0.96,2.36]

-0.11[-1.42,1.2]

0.36[-0.48,1.2]

0.9[0.08,1.72]

0.09[-0.26,0.44]

0.47[0.01,0.94]

-1.3[-3.29,0.69]

0.55[-1.4,2.5]

0.5[-0.4,1.4]

0.14[-0.85,1.14]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

238

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.15.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 15 FACT Emotional well-being (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.15.1 End of intervention

Naumann 2012

Rogers 2009

Courneya 2003

Cadmus 2009

Vallance 2007

Murtezani 2014

Subtotal ***

1 (2.7)

0.9 (2.5)

2.3 (3.1)

-0.3 (2.2)

0.5 (3.5)

2.1 (0.8)

11

20

24

37

250

30

372

Heterogeneity: Tau2=0.25; Chi2=10.23, df=5(P=0.07); I2=51.12%

Test for overall effect: Z=3.04(P=0)

1.15.2 Follow-up

Rogers 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.06(P=0.29)

0.5 (2.7)

19

19

-0.1 (2.7)

-0.1 (2.7)

0.8 (2.9)

-0.5 (3.3)

0.1 (2.5)

0.5 (0.9)

-0.3 (1.7)

10

18

28

37

85

32

210

17

17

5.97%

10.15%

10.33%

14.52%

26.12%

32.91%

100%

1.1[-1.22,3.42]

1[-0.66,2.66]

1.5[-0.14,3.14]

0.2[-1.08,1.48]

0.39[-0.3,1.08]

1.53[1.11,1.95]

0.96[0.34,1.57]

100%

100%

0.79[-0.67,2.25]

0.79[-0.67,2.25]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 1.16.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 16 MOS SF Mental composite (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.16.1 End of intervention

Cuesta-Vargas 2014

Pinto 2015

Fillion 2008

Duijits 2012

Schmitz 2009

Subtotal ***

42.9 (19.2)

54.2 (9.3)

48.5 (7.9)

49.4 (8.9)

53.2 (9.6)

22

39

44

37

112

254

Heterogeneity: Tau2=0; Chi2=2.75, df=4(P=0.6); I2=0%

Test for overall effect: Z=0.61(P=0.54)

1.16.2 Follow-up

Pinto 2015

Duijits 2012

Fillion 2008

Subtotal ***

53.4 (8.6)

48.7 (9.5)

51.4 (7.6)

39

36

44

119

Heterogeneity: Tau2=0; Chi2=1.28, df=2(P=0.53); I2=0%

Test for overall effect: Z=2(P=0.05)

32.3 (33.3)

52.5 (9.6)

47.5 (9.1)

48.4 (8.7)

53.8 (8.7)

50.5 (10.9)

48.1 (9.3)

48 (9.3)

20

37

43

89

120

309

37

82

43

162

0.89%

13.71%

19.34%

21.63%

44.43%

100%

25.24%

35.95%

38.81%

100%

10.6[-6.06,27.26]

1.73[-2.52,5.98]

1.05[-2.53,4.63]

1.02[-2.37,4.41]

-0.6[-2.96,1.76]

0.49[-1.09,2.06]

2.92[-1.5,7.34]

0.58[-3.13,4.29]

3.42[-0.15,6.99]

2.27[0.05,4.5]

Favours control

-20

-10

0

10

20

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

239

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.17.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 17 MOS SF Mental composite (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.17.1 End of intervention

Cormie 2014

Schmitz 2009

Subtotal ***

43

112

155

4.2 (8.8)

3.3 (18.6)

19

120

139

2.7 (8.3)

0.4 (15.5)

Heterogeneity: Tau2=0; Chi2=0.19, df=1(P=0.67); I2=0%

Test for overall effect: Z=1.37(P=0.17)

48.4%

51.6%

100%

1.5[-3.07,6.07]

2.9[-1.52,7.32]

2.22[-0.95,5.4]

1.17.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 1.18.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 18 MOS SF Mental health (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.18.1 End of intervention

Mehnert 2011

Basen-Enquist 2006

Duijits 2012

Cadmus 2009

Pinto 2015

Schmitz 2009

Mustian 2004

Subtotal ***

69.3 (18.3)

78.2 (10.6)

73.7 (15)

50.6 (10.9)

81.8 (12.7)

52.2 (9.5)

24.8 (2)

30

28

37

37

39

58

9

238

Heterogeneity: Tau2=4.06; Chi2=10.99, df=6(P=0.09); I2=45.39%

Test for overall effect: Z=1.41(P=0.16)

1.18.2 Follow-up

Pinto 2015

Duijits 2012

Subtotal ***

79.7 (13.2)

71.8 (15.7)

39

36

75

Heterogeneity: Tau2=0; Chi2=0.49, df=1(P=0.48); I2=0%

Test for overall effect: Z=1.53(P=0.13)

63.2 (18.6)

77.2 (12)

70.1 (14.6)

47.4 (12)

76.1 (5.8)

54.2 (8.5)

24.8 (3.2)

74.5 (15.8)

69.8 (15.2)

28

23

89

37

37

62

10

286

37

84

121

5.08%

9.79%

11.18%

12.55%

15.42%

20.67%

25.3%

100%

6.1[-3.41,15.61]

1[-5.27,7.27]

3.6[-2.1,9.3]

3.2[-2.02,8.42]

5.7[1.3,10.1]

-2[-5.23,1.23]

-0.02[-2.4,2.36]

1.67[-0.65,3.99]

46.04%

53.96%

100%

5.22[-1.35,11.79]

2.01[-4.06,8.08]

3.49[-0.97,7.95]

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 1.19.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 19 MOS SF Mental health (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.19.1 End of intervention

Favours control

-20

-10

0

10

20

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

240

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Physical activity

Control

Mehnert 2011

Schmitz 2009

Cormie 2014

Cadmus 2009

Mustian 2004

Subtotal ***

N

Mean(SD)

N

Mean(SD)

30

58

43

37

9

177

4.8 (17.6)

3.3 (23.2)

4.7 (7.8)

0.8 (6.6)

2.4 (2.5)

28

62

19

37

10

156

2.5 (19.1)

3.1 (17.2)

1.7 (7.6)

-0.9 (8.7)

0.1 (1.7)

Heterogeneity: Tau2=0; Chi2=0.53, df=4(P=0.97); I2=0%

Test for overall effect: Z=2.86(P=0)

Mean Difference

Fixed, 95% CI

Cochrane Database of Systematic Reviews

Weight

Mean Difference

2.57%

4.28%

13.56%

18.67%

60.92%

100%

Fixed, 95% CI

2.26[-7.22,11.74]

0.2[-7.15,7.55]

3[-1.13,7.13]

1.7[-1.82,5.22]

2.34[0.39,4.29]

2.22[0.7,3.74]

1.19.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 1.20.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 20 MOS SF Emotional role (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.20.1 End of intervention

Mehnert 2011

Basen-Enquist 2006

Duijits 2012

Cadmus 2009

Mustian 2004

Subtotal ***

77 (33.8)

81.2 (27)

73.9 (34.7)

50.2 (10.4)

2.3 (1.2)

30

28

37

37

9

141

28

25

89

37

10

189

69.1 (40.5)

79.4 (28)

77.5 (34.3)

47.4 (12)

2.4 (1.3)

Heterogeneity: Tau2=0; Chi2=2.21, df=4(P=0.7); I2=0%

Test for overall effect: Z=0(P=1)

0.32%

0.54%

0.68%

4.54%

93.92%

100%

7.96[-11.3,27.22]

1.8[-13.05,16.65]

-3.54[-16.8,9.72]

2.8[-2.32,7.92]

-0.15[-1.27,0.97]

-0[-1.09,1.09]

1.20.2 Follow-up

Duijits 2012

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.41(P=0.68)

77.5 (37.5)

36

36

74.4 (37.2)

84

84

100%

100%

3.06[-11.55,17.67]

3.06[-11.55,17.67]

Favours control

-50

-25

0

25

50

Favours physical activity

Analysis 1.21.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 21 MOS SF Emotional role (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.21.1 End of intervention

Mehnert 2011

Cormie 2014

Cadmus 2009

Mustian 2004

30

43

37

9

2.3 (35.5)

4.4 (9)

0.9 (12)

0.3 (1)

28

19

37

10

3.6 (17.6)

2.7 (8.6)

-0.9 (4.4)

0.2 (1.4)

0.51%

4.64%

6.07%

88.78%

-1.27[-15.55,13.01]

1.7[-3.01,6.41]

1.8[-2.32,5.92]

0.05[-1.03,1.13]

Favours control

-20

-10

0

10

20

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

241

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Subtotal ***

Mean(SD)

N

119

Mean(SD)

N

94

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

100%

0.23[-0.79,1.24]

Heterogeneity: Tau2=0; Chi2=1.08, df=3(P=0.78); I2=0%

Test for overall effect: Z=0.44(P=0.66)

1.21.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 1.22.   Comparison 1 Comparison: HRQoL outcomes, all physical activity
vs control, Outcome 22 EORTC QLQ-C30 Emotional function (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.22.1 End of intervention

Mehnert 2011

Herrero 2006

Do 2015

Subtotal ***

67.5 (26.9)

90.6 (9.3)

87.4 (8.8)

30

8

32

70

Heterogeneity: Tau2=13.26; Chi2=2.8, df=2(P=0.25); I2=28.53%

Test for overall effect: Z=2.99(P=0)

1.22.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

62 (27.3)

83.3 (14.8)

70.4 (21.5)

27

8

30

65

0

22.97%

29.01%

48.02%

100%

5.46[-8.64,19.56]

7.3[-4.81,19.41]

17[8.72,25.28]

11.53[3.96,19.11]

Not estimable

Favours control

-50

-25

0

25

50

Favours physical activity

Analysis 1.23.   Comparison 1 Comparison: HRQoL outcomes, all physical activity
vs control, Outcome 23 EORTC QLQ-C30 Emotional function (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.23.1 End of intervention

Mehnert 2011

Herrero 2006

Saarto 2012

Subtotal ***

30

8

263

301

3.1 (27.1)

9.3 (19.6)

1.2 (17.8)

27

8

237

272

5.3 (29.2)

-2.1 (5.9)

1.9 (18.5)

Heterogeneity: Tau2=10.66; Chi2=2.73, df=2(P=0.25); I2=26.86%

Test for overall effect: Z=0.29(P=0.77)

14.13%

14.96%

70.91%

100%

-2.19[-16.87,12.49]

11.4[-2.78,25.58]

-0.7[-3.89,2.49]

0.9[-5.12,6.92]

1.23.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-50

-25

0

25

50

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

242

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.24.   Comparison 1 Comparison: HRQoL outcomes, all physical activity
vs control, Outcome 24 POMS total mood disturbance (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.24.1 End of intervention

Pinto 2003

Cantarero-Villanueva 2013

Pinto 2005

Subtotal ***

10.8 (28.1)

17175
(4279)

8 (20.7)

12

32

39

83

Heterogeneity: Tau2=0.19; Chi2=5.81, df=2(P=0.05); I2=65.56%

Test for overall effect: Z=2.97(P=0)

1.24.2 Follow-up

Cantarero-Villanueva 2013

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.08(P=0.04)

32

32

17306
(4501)

27.2 (19.5)

20390
(6113)

42.3 (26.2)

19915
(4966)

6

29

43

78

29

29

21.91%

38.51%

39.59%

100%

-0.6[-1.61,0.4]

-0.61[-1.12,-0.09]

-1.43[-1.92,-0.94]

-0.93[-1.55,-0.32]

100%

-0.54[-1.06,-0.03]

100%

-0.54[-1.06,-0.03]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 1.25.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 25 POMS total mood disturbance (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.25.1 End of intervention

Cantarero-Villanueva 2013

Pinto 2005

Subtotal ***

1445 (4452)

3.8 (27)

32

39

71

Heterogeneity: Tau2=0.21; Chi2=4.64, df=1(P=0.03); I2=78.46%

Test for overall effect: Z=0.18(P=0.85)

1.25.2 Follow-up

Cantarero-Villanueva 2013

Pinto 2005

Subtotal ***

1324 (5711)

-3.1 (27.9)

32

39

71

Heterogeneity: Tau2=0; Chi2=0.87, df=1(P=0.35); I2=0%

Test for overall effect: Z=0.56(P=0.57)

-353 (3323)

11.5 (25.8)

121 (1606)

-2 (26.2)

29

43

72

29

43

72

48.34%

51.66%

100%

0.45[-0.06,0.96]

-0.29[-0.72,0.15]

0.07[-0.65,0.79]

42.41%

57.59%

100%

0.28[-0.23,0.78]

-0.04[-0.47,0.39]

0.09[-0.23,0.42]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 1.26.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 26 POMS anger subscale (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.26.1 End of intervention

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

243

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Pinto 2003

Cantarero-Villanueva 2013

Subtotal ***

3.3 (4.1)

48.2 (9.4)

12

32

44

Heterogeneity: Tau2=0; Chi2=0.89, df=1(P=0.35); I2=0%

Test for overall effect: Z=3.28(P=0)

1.26.2 Follow-up

Cantarero-Villanueva 2013

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.68(P=0.09)

50 (10.2)

32

32

4.8 (3.6)

58.3 (12.6)

54.9 (12.1)

6

29

35

29

29

22.24%

77.76%

100%

Random, 95% CI

-0.36[-1.35,0.63]

-0.9[-1.43,-0.37]

-0.78[-1.25,-0.31]

100%

100%

-0.44[-0.94,0.07]

-0.44[-0.94,0.07]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 1.27.   Comparison 1 Comparison: HRQoL outcomes, all physical activity
vs control, Outcome 27 Happiness/satisfaction with life (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.27.1 End of intervention

Kaltsatou 2011

Courneya 2003

Daley 2007

Cadmus 2009

Subtotal ***

45.4 (5)

65.4 (24.6)

12.6 (2.7)

68.6 (22.4)

14

24

31

37

106

13

28

25

37

103

33.3 (4)

58.3 (22)

12.3 (3.1)

68.1 (22.7)

Heterogeneity: Tau2=0.5; Chi2=19.9, df=3(P=0); I2=84.92%

Test for overall effect: Z=1.55(P=0.12)

19.26%

26.44%

26.71%

27.6%

100%

2.59[1.52,3.65]

0.3[-0.25,0.85]

0.08[-0.44,0.61]

0.02[-0.43,0.48]

0.61[-0.16,1.37]

1.27.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 1.28.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 28 Happiness/satisfaction with life (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.28.1 End of intervention

Courneya 2003

Daley 2007

Cadmus 2009

Subtotal ***

17.3 (26.1)

12.6 (2.7)

3 (18)

24

31

37

92

28

25

37

90

0.8 (23)

12.3 (3.1)

-0.1 (19.1)

Heterogeneity: Tau2=0.02; Chi2=2.58, df=2(P=0.28); I2=22.52%

Test for overall effect: Z=1.65(P=0.1)

1.28.2 Follow-up

28.75%

31.76%

39.49%

100%

0.66[0.1,1.23]

0.08[-0.44,0.61]

0.17[-0.29,0.62]

0.28[-0.05,0.62]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

244

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Subtotal ***

0

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Random, 95% CI

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 1.29.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 29 Overall physical function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.29.1 End of intervention

Banasik 2011

Herrero 2006

Mustian 2004

Pinto 2003

Milne 2008

Rogers 2009

Cuesta-Vargas 2014

Basen-Enquist 2006

Courneya 2003

Mehnert 2011

Littman 2012

Murtezani 2014

Winters-Stone 2011

Do 2015

Daley 2007

Cadmus 2009

Schmitz 2005

Pinto 2015

Pinto 2005

Loh 2014

Fillion 2008

Duijits 2012

Rogers 2015

Schmitz 2009

Vallance 2007

Subtotal ***

-0.8 (0.9)

94.1 (7.5)

26.9 (4.1)

32.3 (4.3)

24 (2.6)

23.3 (4.5)

42.9 (4.1)

82.5 (12.7)

25.3 (2.5)

89 (9.1)

25.4 (1.7)

22.6 (4.4)

51.7 (6.2)

89.4 (8.4)

25.6 (2.2)

25.1 (2.7)

-44.2 (5.6)

87.1 (4.4)

30.3 (7.9)

24.9 (2.5)

45.1 (10.4)

84 (16.9)

24.1 (3.5)

50.6 (8.2)

25.1 (3)

7

8

9

12

29

20

22

28

24

30

30

30

36

32

33

37

39

39

39

63

44

87

105

112

250

1165

-0.4 (0.3)

92.5 (6.6)

26.5 (4.1)

25.3 (8.2)

15.6 (4.5)

25.4 (2.3)

32.4 (32.5)

77.4 (11.5)

25.3 (2.8)

78.1 (21.2)

24.3 (4.4)

19.4 (4.4)

52.3 (5.9)

89 (8.7)

23.6 (5.7)

24 (4.1)

-48.3 (7.7)

84.7 (15.9)

27.3 (6.8)

24.2 (2.2)

41.8 (9.8)

80.2 (17.1)

22.5 (5)

49.1 (9.3)

25 (3.3)

7

8

10

12

29

18

20

23

28

28

27

32

25

30

33

37

40

37

43

32

43

89

108

120

85

964

Heterogeneity: Tau2=0.08; Chi2=61.95, df=24(P<0.0001); I2=61.26%

Test for overall effect: Z=4.28(P<0.0001)

1.29.2 Follow-up

Rogers 2009

Daley 2007

Pinto 2015

Fillion 2008

Duijits 2012

Rogers 2015

Subtotal ***

23.2 (4.5)

25.2 (2.8)

86.7 (13.4)

46.8 (9.2)

83.7 (18.4)

23.9 (3.9)

19

31

39

44

79

105

317

17

31

37

43

84

108

320

23.5 (5.7)

23.7 (3.9)

84.3 (15.3)

44.6 (11.1)

80.7 (18.8)

22.7 (5.1)

1.59%

1.81%

2.06%

2.19%

3.05%

3.14%

3.35%

3.7%

3.78%

3.89%

3.93%

3.99%

4.02%

4.11%

4.18%

4.41%

4.47%

4.47%

4.57%

4.65%

4.69%

5.75%

5.96%

6.07%

6.16%

100%

5.68%

9.57%

11.98%

13.69%

25.68%

33.4%

100%

-0.48[-1.54,0.59]

0.21[-0.77,1.2]

0.09[-0.81,0.99]

1.03[0.17,1.89]

2.26[1.59,2.92]

-0.57[-1.22,0.08]

0.46[-0.16,1.07]

0.41[-0.15,0.97]

0[-0.55,0.55]

0.66[0.13,1.19]

0.33[-0.19,0.86]

0.72[0.2,1.23]

-0.1[-0.61,0.41]

0.05[-0.45,0.54]

0.46[-0.03,0.95]

0.31[-0.15,0.77]

0.6[0.15,1.05]

0.21[-0.25,0.66]

0.4[-0.04,0.83]

0.3[-0.12,0.73]

0.33[-0.1,0.75]

0.23[-0.07,0.52]

0.37[0.1,0.64]

0.17[-0.09,0.43]

0.05[-0.2,0.3]

0.33[0.18,0.49]

-0.06[-0.71,0.6]

0.43[-0.07,0.93]

0.16[-0.29,0.61]

0.21[-0.21,0.63]

0.16[-0.15,0.47]

0.26[-0.01,0.53]

0.21[0.06,0.37]

Heterogeneity: Tau2=0; Chi2=1.67, df=5(P=0.89); I2=0%

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

245

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for overall effect: Z=2.7(P=0.01)

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 1.30.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 30 Overall physical function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.30.1 End of intervention

Herrero 2006

Mustian 2004

Murtezani 2014

Naumann 2012

Rogers 2009

Courneya 2003

Cormie 2014

Mehnert 2011

Cadmus 2009

Schmitz 2005

Schmitz 2009

Vallance 2007

Saarto 2012

Subtotal ***

8

9

30

11

20

24

43

30

37

39

58

247

263

819

6.7 (5)

1.9 (2.6)

4.4 (1.5)

1.9 (3.3)

2.3 (5.1)

1.9 (2)

3.5 (5.2)

4 (10.8)

0.1 (6)

1.2 (4.2)

6.6 (17.1)

1 (3.3)

1.9 (13.7)

-1.7 (6.9)

-0.2 (1.6)

-1.3 (1.2)

0.8 (3.4)

2.6 (6)

-0.2 (2.2)

-0.5 (5.7)

-2.1 (16.7)

-0.5 (7.4)

1.5 (6.8)

4.1 (17.3)

0.2 (2.1)

3.4 (13.4)

8

10

32

10

18

28

19

28

37

40

62

85

237

614

Heterogeneity: Tau2=0.37; Chi2=106.29, df=12(P<0.0001); I2=88.71%

Test for overall effect: Z=3.15(P=0)

5.22%

5.91%

6.13%

6.4%

7.57%

7.87%

7.99%

8.16%

8.48%

8.55%

8.91%

9.31%

9.5%

100%

1.32[0.21,2.43]

0.93[-0.03,1.89]

4.23[3.31,5.15]

0.32[-0.55,1.18]

-0.05[-0.69,0.58]

0.98[0.4,1.56]

0.74[0.19,1.3]

0.43[-0.09,0.95]

0.09[-0.37,0.54]

-0.05[-0.49,0.39]

0.14[-0.21,0.5]

0.26[0.02,0.51]

-0.11[-0.29,0.06]

0.6[0.23,0.97]

1.30.2 Follow-up

Rogers 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.52(P=0.6)

19

19

1.8 (5.4)

17

17

0.9 (4.6)

100%

100%

0.17[-0.48,0.83]

0.17[-0.48,0.83]

Favours control

-10

-5

0

5

10

Favours physical activity

Analysis 1.31.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 31 FACT Physical well-being (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.31.1 End of intervention

Rogers 2009

Murtezani 2014

Daley 2007

Milne 2008

Littman 2012

Cadmus 2009

Courneya 2003

Rogers 2015

20

30

33

29

30

37

24

23.3 (4.5)

22.6 (4.4)

25.6 (2.2)

24 (2.6)

25.4 (1.7)

25.1 (2.7)

25.3 (2.5)

18

32

33

29

27

37

28

25.4 (2.3)

19.4 (4.4)

23.6 (5.7)

15.6 (4.5)

24.3 (4.4)

24 (4.1)

25.3 (2.8)

105

24.1 (3.5)

108

22.5 (5)

7.67%

7.77%

8.01%

8.41%

8.67%

9.06%

9.34%

9.88%

-2.1[-4.34,0.14]

3.2[1.01,5.39]

2[-0.08,4.08]

8.4[6.51,10.29]

1.1[-0.67,2.87]

1.1[-0.48,2.68]

0[-1.44,1.44]

1.6[0.44,2.76]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

246

Favours control

-20

-10

0

10

20

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Physical activity

Control

Loh 2014

Vallance 2007

Banasik 2011

Subtotal ***

N

63

250

7

628

Mean(SD)

N

Mean(SD)

24.9 (2.5)

25.1 (3)

0.8 (0.9)

32

85

7

436

24.2 (2.2)

25 (3.3)

0.4 (0.3)

Heterogeneity: Tau2=2.97; Chi2=81.45, df=10(P<0.0001); I2=87.72%

Test for overall effect: Z=2.51(P=0.01)

1.31.2 Follow-up

Rogers 2009

Daley 2007

Rogers 2015

Subtotal ***

19

31

105

155

23.2 (4.5)

25.2 (2.8)

23.9 (3.9)

17

31

108

156

23.5 (5.7)

23.7 (3.9)

22.7 (5.1)

Heterogeneity: Tau2=0; Chi2=0.86, df=2(P=0.65); I2=0%

Test for overall effect: Z=2.42(P=0.02)

Cochrane Database of Systematic Reviews

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

10.16%

10.48%

10.56%

100%

7.86%

31.45%

60.69%

100%

0.75[-0.25,1.75]

0.15[-0.63,0.93]

0.35[-0.37,1.07]

1.44[0.31,2.56]

-0.3[-3.68,3.08]

1.48[-0.21,3.17]

1.2[-0.02,2.42]

1.17[0.22,2.12]

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 1.32.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 32 FACT Physical well-being (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.32.1 End of intervention

Rogers 2009

Cadmus 2009

Naumann 2012

Courneya 2003

Murtezani 2014

Vallance 2007

Subtotal ***

20

37

11

24

30

247

369

2.3 (5.1)

0.1 (6)

1.9 (0)

1.9 (2)

4.4 (1.5)

1 (3.3)

18

37

10

28

32

85

210

2.6 (6)

-0.5 (7.4)

2.3 (3.9)

-0.2 (2.2)

-1.3 (1.2)

0.2 (2.1)

Heterogeneity: Tau2=8.22; Chi2=128.58, df=5(P<0.0001); I2=96.11%

Test for overall effect: Z=1.28(P=0.2)

13.55%

14.61%

16.08%

18.24%

18.73%

18.78%

100%

-0.3[-3.86,3.26]

0.6[-2.48,3.68]

-0.4[-2.79,1.99]

2.1[0.96,3.24]

5.77[5.09,6.45]

0.81[0.21,1.41]

1.6[-0.85,4.05]

1.32.2 Follow-up

Rogers 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.54(P=0.59)

19

19

1.8 (5.4)

17

17

0.9 (4.6)

100%

100%

0.9[-2.37,4.17]

0.9[-2.37,4.17]

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 1.33.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 33 MOS SF Physical composite (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.33.1 End of intervention

Cuesta-Vargas 2014

Fillion 2008

22

44

42.9 (4.1)

45.1 (10.4)

20

43

32.4 (32.5)

41.8 (9.8)

1.34%

15.27%

10.5[-3.84,24.84]

3.34[-0.9,7.58]

Favours control

-20

-10

0

10

20

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

247

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Pinto 2015

Schmitz 2009

Subtotal ***

Mean(SD)

52 (6.7)

50.6 (8.2)

N

39

112

217

Heterogeneity: Tau2=0; Chi2=2.21, df=3(P=0.53); I2=0%

Test for overall effect: Z=2.1(P=0.04)

1.33.2 Follow-up

Fillion 2008

Pinto 2015

Subtotal ***

46.8 (9.2)

51.5 (7.1)

44

39

83

Heterogeneity: Tau2=0; Chi2=0.22, df=1(P=0.64); I2=0%

Test for overall effect: Z=1.01(P=0.31)

Mean(SD)

50.9 (6.9)

49.1 (9.3)

44.6 (11.1)

50.6 (6.8)

N

37

120

220

43

37

80

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

29.11%

54.29%

100%

34.66%

65.34%

100%

Fixed, 95% CI

1.07[-2,4.14]

1.5[-0.75,3.75]

1.78[0.12,3.43]

2.12[-2.17,6.41]

0.86[-2.26,3.98]

1.3[-1.23,3.82]

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 1.34.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 34 MOS SF Physical composite (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.34.1 End of intervention

Schmitz 2009

Cormie 2014

Subtotal ***

112

43

155

6.1 (17.9)

3.2 (6)

120

19

139

3.4 (19.5)

0.7 (6)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.95); I2=0%

Test for overall effect: Z=1.87(P=0.06)

31.18%

68.82%

100%

2.7[-2.11,7.51]

2.5[-0.74,5.74]

2.56[-0.13,5.25]

1.34.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 1.35.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 35 MOS SF Physical function (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.35.1 End of intervention

Mehnert 2011

Basen-Enquist 2006

Pinto 2015

Duijits 2012

Mustian 2004

Cadmus 2009

Winters-Stone 2011

Subtotal ***

89 (9.1)

82.5 (12.7)

87.1 (4.4)

84 (16.9)

26.9 (4.1)

50 (6.4)

51.7 (6.2)

30

28

39

87

9

37

36

266

28

23

37

89

10

37

25

249

78.1 (21.2)

77.4 (11.5)

84.7 (15.9)

80.2 (17.1)

26.5 (4.1)

48 (7.6)

52.3 (5.9)

Heterogeneity: Tau2=2.4; Chi2=8.87, df=6(P=0.18); I2=32.32%

5.2%

7.96%

11.37%

12.36%

18.48%

21.85%

22.78%

100%

10.84[2.33,19.35]

5.1[-1.55,11.75]

2.39[-2.92,7.7]

3.85[-1.17,8.87]

0.39[-3.32,4.1]

2[-1.2,5.2]

-0.6[-3.67,2.47]

2.09[0.03,4.15]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

248

Favours control

-20

-10

0

10

20

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

Test for overall effect: Z=1.99(P=0.05)

1.35.2 Follow-up

Pinto 2015

Duijits 2012

Subtotal ***

86.7 (13.4)

83.7 (18.4)

39

79

118

37

84

121

84.3 (15.3)

80.7 (18.8)

43.68%

56.32%

100%

2.34[-4.14,8.82]

2.99[-2.72,8.7]

2.71[-1.58,6.99]

Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.88); I2=0%

Test for overall effect: Z=1.24(P=0.22)

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 1.36.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 36 MOS SF Physical function (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.36.1 End of intervention

Mehnert 2011

Schmitz 2009

Cormie 2014

Cadmus 2009

Mustian 2004

Subtotal ***

30

58

43

37

9

177

4 (10.8)

6.6 (17.1)

3.5 (5.2)

-0.2 (5.1)

1.9 (2.6)

-2.1 (16.7)

4.1 (17.3)

-0.5 (5.7)

0 (4.4)

-0.2 (1.6)

28

62

19

37

10

156

Heterogeneity: Tau2=1.71; Chi2=6.81, df=4(P=0.15); I2=41.27%

Test for overall effect: Z=2.19(P=0.03)

5.8%

7.8%

22.48%

30.77%

33.14%

100%

6.11[-1.19,13.41]

2.5[-3.66,8.66]

3.99[1.01,6.97]

-0.2[-2.37,1.97]

2.09[0.11,4.07]

2.08[0.21,3.94]

1.36.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 1.37.   Comparison 1 Comparison: HRQoL outcomes, all physical activity
vs control, Outcome 37 EORTC QLQ-C30 Physical function (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.37.1 End of intervention

Herrero 2006

Mehnert 2011

Do 2015

Subtotal ***

94.1 (7.5)

94 (9.3)

89.4 (8.4)

8

30

32

70

Heterogeneity: Tau2=8.21; Chi2=3.89, df=2(P=0.14); I2=48.54%

Test for overall effect: Z=1.27(P=0.21)

1.37.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

0

92.5 (6.6)

86 (14.5)

89 (8.7)

8

27

30

65

0

27.06%

29.67%

43.27%

100%

1.6[-5.32,8.52]

8.05[1.65,14.45]

0.4[-3.86,4.66]

2.99[-1.64,7.63]

Not estimable

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

249

Favours control

-20

-10

0

10

20

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

Test for overall effect: Not applicable

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 1.38.   Comparison 1 Comparison: HRQoL outcomes, all physical activity
vs control, Outcome 38 EORTC QLQ-C30 Physical function (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.38.1 End of intrevention

Mehnert 2011

Herrero 2006

Saarto 2012

Subtotal ***

30

8

263

301

5.3 (10.9)

6.7 (5)

1.9 (13.7)

27

8

237

272

1.5 (13)

-1.7 (6.9)

3.4 (13.4)

Heterogeneity: Tau2=25.22; Chi2=10.65, df=2(P=0); I2=81.22%

Test for overall effect: Z=0.96(P=0.34)

29.74%

30.74%

39.52%

100%

3.81[-2.46,10.08]

8.4[2.5,14.3]

-1.5[-3.87,0.87]

3.12[-3.24,9.49]

1.38.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 1.39.   Comparison 1 Comparison: HRQoL outcomes, all physical activity
vs control, Outcome 39 Body Esteem Scale - Physical condition (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.39.1 End of intervention

Pinto 2003

Pinto 2005

Subtotal ***

32.3 (4.3)

30.3 (7.9)

12

39

51

Heterogeneity: Tau2=3.38; Chi2=1.69, df=1(P=0.19); I2=40.84%

Test for overall effect: Z=2.25(P=0.02)

1.39.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

25.3 (8.2)

27.3 (6.8)

12

43

55

0

36.45%

63.55%

100%

7[1.76,12.24]

2.93[-0.26,6.12]

4.41[0.57,8.25]

Not estimable

Favours control

-20

-10

0

10

20

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

250

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.40.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 40 Overall role function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.40.1 End of intervention

Banasik 2011

Herrero 2006

Mustian 2004

Loudon 2014

Milne 2008

Rogers 2009

Basen-Enquist 2006

Courneya 2003

Mehnert 2011

Littman 2012

Murtezani 2014

Do 2015

Daley 2007

Cadmus 2009

Schmitz 2005

Loh 2014

Rogers 2015

Vallance 2007

Subtotal ***

3.5 (0.6)

97.6 (5.9)

2.4 (1.5)

-1.3 (0.3)

22.2 (3)

21.4 (4.8)

86.1 (22.2)

23.4 (4)

90 (20.3)

22.6 (3.9)

24.2 (2.8)

78.1 (19.5)

22.9 (4.5)

23.1 (4.7)

-49.2 (6.5)

23.4 (4.3)

22.3 (4.5)

23.2 (4)

7

8

9

12

29

20

28

24

30

30

30

32

33

37

39

63

105

250

786

3.2 (0.6)

100 (0)

2.8 (1.5)

-1.3 (0.4)

12.5 (4.8)

23.8 (3.2)

73 (24.5)

23.1 (4)

79.6 (25)

21.7 (4.7)

23 (2.5)

79.2 (14.6)

20.3 (5.6)

20.6 (7.2)

-50 (6.2)

22.2 (5)

20.3 (5.5)

22.7 (4.6)

7

8

9

11

29

18

23

28

27

27

32

30

33

37

40

32

108

85

584

Heterogeneity: Tau2=0.14; Chi2=55.4, df=17(P<0.0001); I2=69.31%

Test for overall effect: Z=2.61(P=0.01)

1.40.2 Follow-up

Rogers 2009

Rogers 2015

Subtotal ***

19

105

124

21.9 (4.7)

21.4 (5.1)

17

108

125

22.4 (5.4)

20.5 (5.7)

Heterogeneity: Tau2=0; Chi2=0.53, df=1(P=0.47); I2=0%

Test for overall effect: Z=1.01(P=0.31)

2.88%

3.09%

3.41%

3.96%

4.76%

4.98%

5.6%

5.74%

5.88%

5.92%

6.05%

6.1%

6.16%

6.39%

6.55%

6.66%

7.86%

8.03%

100%

0.34[-0.72,1.4]

-0.54[-1.55,0.46]

-0.23[-1.15,0.7]

0[-0.82,0.82]

2.39[1.71,3.08]

-0.57[-1.22,0.08]

0.55[-0.01,1.12]

0.07[-0.47,0.62]

0.45[-0.07,0.98]

0.21[-0.31,0.73]

0.45[-0.06,0.95]

-0.06[-0.56,0.44]

0.5[0.01,0.99]

0.41[-0.05,0.87]

0.12[-0.32,0.57]

0.25[-0.18,0.68]

0.4[0.12,0.67]

0.12[-0.13,0.37]

0.29[0.07,0.51]

14.45%

85.55%

100%

-0.1[-0.75,0.56]

0.17[-0.1,0.43]

0.13[-0.12,0.38]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 1.41.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 41 Overall role function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.41.1 End of intervention

Herrero 2006

Mustian 2004

Naumann 2012

Rogers 2009

Courneya 2003

Cormie 2014

Murtezani 2014

Mehnert 2011

Cadmus 2009

Schmitz 2005

8

9

11

20

24

43

30

30

37

39

2.1 (13.9)

0.6 (1.6)

1.5 (4.4)

0.4 (3.3)

0.9 (2.8)

4.9 (7.1)

1.7 (0.7)

6.7 (23.8)

-0.3 (3.7)

1.2 (4.2)

8

10

10

18

28

19

32

27

37

40

2.1 (5.9)

0.8 (1.6)

0.5 (4.5)

1.4 (4.3)

0.4 (2.7)

1.7 (7.1)

0.9 (0.6)

5.6 (27)

-0.5 (3.4)

1.5 (6.8)

3.21%

3.69%

3.99%

6.22%

7.65%

7.66%

7.75%

8.13%

9.44%

9.77%

0[-0.98,0.98]

-0.15[-1.05,0.76]

0.22[-0.64,1.08]

-0.26[-0.9,0.38]

0.18[-0.37,0.73]

0.45[-0.1,0.99]

1.16[0.62,1.7]

0.04[-0.48,0.56]

0.06[-0.4,0.51]

-0.05[-0.49,0.39]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

251

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Vallance 2007

Saarto 2012

Subtotal ***

Mean(SD)

0.6 (4.1)

2.4 (21.5)

N

250

263

764

Mean(SD)

-0 (2.7)

3.8 (21.6)

N

85

237

551

Heterogeneity: Tau2=0.05; Chi2=21.96, df=11(P=0.02); I2=49.91%

Test for overall effect: Z=1.46(P=0.15)

Random, 95% CI

Random, 95% CI

15.18%

17.32%

100%

0.17[-0.08,0.41]

-0.06[-0.24,0.11]

0.14[-0.05,0.33]

1.41.2 Follow-up

Rogers 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.09(P=0.28)

19

19

1.1 (3)

17

17

-0.2 (4)

100%

100%

0.37[-0.29,1.03]

0.37[-0.29,1.03]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 1.42.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 42 FACT Functional well-being (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.42.1 End of intervention

Cadmus 2009

Rogers 2009

Daley 2007

Littman 2012

Courneya 2003

Milne 2008

Loh 2014

Rogers 2015

Murtezani 2014

Vallance 2007

Banasik 2011

Subtotal ***

37

20

33

30

24

29

63

105

30

250

7

628

23.1 (4.7)

21.4 (4.8)

22.9 (4.5)

22.6 (3.9)

23.4 (4)

22.2 (3)

23.4 (4.3)

37

18

33

27

28

29

32

20.6 (7.2)

23.8 (3.2)

20.3 (5.6)

21.7 (4.7)

23.1 (4)

12.5 (4.8)

22.2 (5)

22.3 (4.5)

108

20.3 (5.5)

24.2 (2.8)

23.2 (4)

3.5 (0.6)

32

85

7

436

23 (2.5)

22.7 (4.6)

3.2 (0.6)

Heterogeneity: Tau2=4.52; Chi2=87.26, df=10(P<0.0001); I2=88.54%

Test for overall effect: Z=2.37(P=0.02)

1.42.2 Follow-up

Rogers 2009

Rogers 2015

Subtotal ***

19

105

124

21.9 (4.7)

21.4 (5.1)

17

108

125

22.4 (5.4)

20.5 (5.7)

Heterogeneity: Tau2=0; Chi2=0.57, df=1(P=0.45); I2=0%

Test for overall effect: Z=1(P=0.32)

7.66%

8%

8.21%

8.54%

8.67%

8.87%

8.92%

9.99%

10.03%

10.33%

10.79%

100%

2.5[-0.27,5.27]

-2.4[-4.97,0.17]

2.58[0.13,5.03]

0.9[-1.36,3.16]

0.3[-1.88,2.48]

9.7[7.64,11.76]

1.15[-0.88,3.18]

2[0.65,3.35]

1.2[-0.12,2.52]

0.5[-0.59,1.59]

0.22[-0.41,0.85]

1.67[0.29,3.06]

16.01%

83.99%

100%

-0.5[-3.82,2.82]

0.9[-0.55,2.35]

0.68[-0.65,2.01]

Favours control

-20

-10

0

10

20

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

252

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.43.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 43 FACT Functional well-being (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.43.1 End of intervention

Naumann 2012

Rogers 2009

Cadmus 2009

Courneya 2003

Vallance 2007

Murtezani 2014

Subtotal ***

11

20

37

24

250

30

372

1.9 (3.3)

0.4 (3.3)

-0.3 (3.7)

0.9 (2.8)

0.6 (4.1)

1.7 (0.7)

10

18

37

28

85

32

210

0.8 (3.4)

1.4 (4.3)

-0.5 (3.4)

0.4 (2.7)

-0 (2.7)

0.9 (0.6)

Heterogeneity: Tau2=0; Chi2=2.63, df=5(P=0.76); I2=0%

Test for overall effect: Z=4.77(P<0.0001)

1.05%

1.43%

3.29%

3.83%

14.55%

75.86%

100%

1.1[-1.77,3.97]

-1[-3.46,1.46]

0.2[-1.42,1.82]

0.5[-1,2]

0.64[-0.13,1.41]

0.79[0.45,1.13]

0.72[0.42,1.01]

1.43.2 Follow-up

Rogers 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.1(P=0.27)

19

19

1.1 (3)

17

17

-0.2 (4)

100%

100%

1.31[-1.02,3.64]

1.31[-1.02,3.64]

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 1.44.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 44 MOS SF Physical role (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.44.1 End of intervention

Basen-Enquist 2006

Cadmus 2009

Mustian 2004

Subtotal ***

86.1 (22.2)

49.7 (9.3)

2.4 (1.5)

28

37

9

74

Heterogeneity: Tau2=0; Chi2=4.13, df=2(P=0.13); I2=51.63%

Test for overall effect: Z=0.24(P=0.81)

1.44.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

73 (24.5)

49.5 (7.8)

2.8 (1.5)

23

37

9

69

0

1.02%

11.24%

87.74%

100%

13.1[0.14,26.06]

0.2[-3.71,4.11]

-0.36[-1.76,1.04]

-0.16[-1.47,1.15]

Not estimable

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 1.45.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 45 MOS SF Physical role (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.45.1 End of intervention

Cadmus 2009

37

1.5 (11.9)

37

1.9 (9.1)

14.32%

-0.4[-5.23,4.43]

Favours control

-10

-5

0

5

10

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

253

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

Cormie 2014

Mustian 2004

Subtotal ***

4.9 (7.1)

0.6 (1.6)

43

9

89

Heterogeneity: Tau2=1.05; Chi2=2.77, df=2(P=0.25); I2=27.87%

Test for overall effect: Z=0.45(P=0.65)

1.45.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

1.7 (7.1)

0.8 (1.6)

19

10

66

0

20.9%

64.78%

100%

3.2[-0.63,7.03]

-0.24[-1.65,1.17]

0.46[-1.52,2.43]

Not estimable

Favours control

-10

-5

0

5

10

Favours physical activity

Analysis 1.46.   Comparison 1 Comparison: HRQoL outcomes, all physical activity
vs control, Outcome 46 EORTC QLQ-C30 Role function (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.46.1 End of intervention

Mehnert 2011

Do 2015

Herrero 2006

Subtotal ***

90 (20.3)

78.1 (19.5)

97.6 (5.9)

30

32

8

70

Heterogeneity: Tau2=15.23; Chi2=3.94, df=2(P=0.14); I2=49.27%

Test for overall effect: Z=0.14(P=0.89)

1.46.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

79.6 (25)

79.2 (14.6)

100 (0)

27

30

8

65

0

19.25%

29.39%

51.36%

100%

10.37[-1.55,22.29]

-1.1[-9.64,7.44]

-2.4[-6.49,1.69]

0.44[-5.78,6.66]

Not estimable

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 1.47.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 47 EORTC QLQ-C30 Role function (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.47.1 End of intervention

Mehnert 2011

Herrero 2006

Saarto 2012

Subtotal ***

30

8

263

301

6.7 (23.8)

2.1 (13.9)

2.4 (21.5)

27

8

237

272

5.6 (27)

2.1 (5.9)

3.8 (21.6)

Heterogeneity: Tau2=0; Chi2=0.17, df=2(P=0.92); I2=0%

Test for overall effect: Z=0.62(P=0.54)

6.69%

10.79%

82.51%

100%

1.11[-12.18,14.4]

0[-10.46,10.46]

-1.4[-5.18,2.38]

-1.08[-4.52,2.36]

1.47.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

0

0

Not estimable

Favours control

-20

-10

0

10

20

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

254

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

Test for overall effect: Not applicable

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 1.48.   Comparison 1 Comparison: HRQoL outcomes, all physical activity
vs control, Outcome 48 Overall social well-being/function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.48.1 End of intervention

Banasik 2011

Herrero 2006

Mustian 2004

Rogers 2014

Rogers 2009

Basen-Enquist 2006

Courneya 2003

Littman 2012

Milne 2008

Mehnert 2011

Murtezani 2014

Daley 2007

Cadmus 2009

Loh 2014

Schmitz 2009

Kiecolt-Glaser 2014

Rogers 2015

Vallance 2007

Subtotal ***

2.8 (0.7)

87.5 (19.4)

8.6 (1.9)

7.3 (4.9)

22.6 (4.1)

84.6 (16.9)

21.1 (3.5)

22.1 (5)

20.7 (4)

85.4 (20.9)

20.2 (2.8)

23.3 (4.8)

22.3 (4.9)

21.5 (4.9)

14.9 (5.2)

95.2 (10.8)

21 (5.7)

22.9 (5)

7

8

9

20

20

28

24

30

29

30

30

33

37

63

59

96

105

250

878

3.2 (0.8)

91.7 (23.6)

9 (1.8)

3.1 (3.2)

21.8 (5.7)

84.9 (19.2)

20.7 (3.6)

20.9 (6)

19.4 (3.9)

79.9 (22.7)

18.3 (2.7)

20.4 (6.8)

20.6 (7.2)

19.6 (4.9)

14.1 (5.8)

93.8 (9.3)

20.7 (5.8)

23 (5.1)

7

8

10

22

18

23

28

27

29

28

32

33

37

32

62

90

108

85

679

Heterogeneity: Tau2=0.01; Chi2=19.03, df=17(P=0.33); I2=10.67%

Test for overall effect: Z=3.27(P=0)

1.1%

1.28%

1.51%

2.88%

2.95%

3.88%

3.95%

4.3%

4.35%

4.37%

4.42%

4.82%

5.44%

6.12%

8.41%

11.91%

13.25%

15.07%

100%

-0.45[-1.51,0.62]

-0.18[-1.17,0.8]

-0.19[-1.09,0.71]

1.01[0.36,1.65]

0.16[-0.48,0.8]

-0.02[-0.57,0.54]

0.11[-0.43,0.66]

0.22[-0.31,0.74]

0.32[-0.19,0.84]

0.25[-0.27,0.76]

0.68[0.17,1.2]

0.49[-0,0.98]

0.27[-0.18,0.73]

0.38[-0.05,0.81]

0.14[-0.21,0.5]

0.14[-0.15,0.43]

0.05[-0.22,0.32]

-0[-0.25,0.24]

0.19[0.08,0.3]

1.48.2 Follow-up

Rogers 2015

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.64(P=0.52)

105

105

21 (5.9)

108

108

20.5 (5.4)

100%

100%

0.09[-0.18,0.36]

0.09[-0.18,0.36]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 1.49.   Comparison 1 Comparison: HRQoL outcomes, all physical activity
vs control, Outcome 49 Overall social well-being/function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.49.1 End of intervention

Mustian 2004

Naumann 2012

Rogers 2009

9

11

20

1.5 (1.5)

0.9 (3.3)

0.9 (2.6)

10

10

18

0.4 (1.2)

-0.2 (3.3)

-1.2 (2.7)

6.04%

6.47%

7.67%

0.76[-0.18,1.7]

0.32[-0.54,1.18]

0.78[0.11,1.44]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

255

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Rogers 2014

Murtezani 2014

Courneya 2003

Cormie 2014

Mehnert 2011

Cadmus 2009

Schmitz 2009

Vallance 2007

Saarto 2012

Subtotal ***

20

30

24

43

30

37

59

250

263

796

2.1 (3.2)

2.1 (0.8)

0.6 (2.4)

3.5 (8.5)

7.3 (22.3)

0.6 (4.6)

4.4 (33.8)

0.2 (4.8)

5 (21.1)

22

32

28

19

28

37

62

85

237

588

-0.8 (3.5)

0.5 (0.9)

-0.5 (3.3)

2.5 (8.3)

3.1 (24.3)

-1 (3.2)

0.7 (34)

-4.1 (3.3)

8.8 (20.8)

Heterogeneity: Tau2=0.31; Chi2=86.83, df=11(P<0.0001); I2=87.33%

Test for overall effect: Z=2.86(P=0)

7.85%

8.09%

8.37%

8.43%

8.58%

8.9%

9.47%

9.93%

10.21%

100%

0.85[0.21,1.48]

1.8[1.21,2.4]

0.37[-0.18,0.92]

0.12[-0.42,0.66]

0.18[-0.34,0.69]

0.4[-0.06,0.86]

0.11[-0.25,0.47]

0.97[0.71,1.23]

-0.18[-0.36,-0.01]

0.52[0.16,0.87]

1.49.2 Follow-up

Rogers 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.99(P=0.05)

19

19

-0 (4.3)

17

17

-3.9 (6.6)

100%

100%

0.69[0.01,1.36]

0.69[0.01,1.36]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 1.50.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 50 FACT Social well-being (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.50.1 End of intervention

Rogers 2009

Littman 2012

Daley 2007

Cadmus 2009

Loh 2014

Milne 2008

Courneya 2003

Rogers 2015

Murtezani 2014

Vallance 2007

Banasik 2011

Subtotal ***

20

30

33

37

63

29

24

105

30

250

7

628

22.6 (4.1)

22.1 (5)

23.3 (4.8)

22.3 (4.9)

21.5 (4.9)

20.7 (4)

21.1 (3.5)

18

27

33

37

32

29

28

21.8 (5.7)

20.9 (6)

20.4 (6.8)

20.6 (7.2)

19.6 (4.9)

19.4 (3.9)

20.7 (3.6)

21 (5.7)

108

20.7 (5.8)

20.2 (2.8)

22.9 (5)

2.8 (0.7)

32

85

7

436

18.3 (2.7)

23 (5.1)

3.2 (0.8)

Heterogeneity: Tau2=0.38; Chi2=15.28, df=10(P=0.12); I2=34.57%

Test for overall effect: Z=2.29(P=0.02)

3.72%

4.42%

4.55%

4.63%

7.46%

7.72%

8.31%

11.22%

12.92%

14.41%

20.63%

100%

0.8[-2.39,3.99]

1.2[-1.68,4.08]

2.9[0.06,5.74]

1.7[-1.11,4.51]

1.87[-0.21,3.95]

1.3[-0.73,3.33]

0.4[-1.53,2.33]

0.3[-1.24,1.84]

1.9[0.53,3.27]

-0.02[-1.26,1.22]

-0.36[-1.15,0.43]

0.77[0.11,1.43]

1.50.2 Follow-up

Rogers 2015

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.64(P=0.52)

105

105

21 (5.9)

108

108

20.5 (5.4)

100%

100%

0.5[-1.02,2.02]

0.5[-1.02,2.02]

Favours physical activity

-10

-5

0

5

10

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

256

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.51.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 51 FACT Social well-being (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.51.1 End of intervention

Naumann 2012

Cadmus 2009

Rogers 2009

Courneya 2003

Vallance 2007

Murtezani 2014

Subtotal ***

11

37

20

24

250

30

372

0.9 (3.3)

0.6 (4.6)

0.9 (2.6)

0.6 (2.4)

0.2 (4.8)

2.1 (0.8)

10

37

18

28

85

32

210

-0.2 (3.3)

-1 (3.2)

-1.2 (2.7)

-0.5 (3.3)

-4.1 (3.3)

0.5 (0.9)

Heterogeneity: Tau2=0; Chi2=31.48, df=5(P<0.0001); I2=84.12%

Test for overall effect: Z=10.81(P<0.0001)

1.52%

3.77%

4.31%

5.09%

14.27%

71.04%

100%

1.1[-1.74,3.94]

1.6[-0.21,3.41]

2.1[0.41,3.79]

1.1[-0.45,2.65]

4.36[3.43,5.29]

1.53[1.11,1.95]

1.93[1.58,2.28]

1.51.2 Follow-up

Rogers 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.05(P=0.04)

19

19

-0 (4.3)

17

17

-3.9 (6.6)

100%

100%

3.86[0.17,7.55]

3.86[0.17,7.55]

Favours control

-10

-5

0

5

10

Favours physical activity

Analysis 1.52.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 52 MOS SF Social functioning (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.52.1 End of intervention

Baruth 2013

Mehnert 2011

Basen-Enquist 2006

Cadmus 2009

Mustian 2004

Subtotal ***

87.2 (0)

85.4 (20.9)

84.6 (16.9)

49.5 (12)

8.6 (1.9)

20

30

28

37

9

124

12

28

23

37

10

110

78.4 (0)

79.9 (22.7)

84.9 (19.2)

50.5 (9.6)

9 (1.8)

Heterogeneity: Tau2=0; Chi2=1.09, df=3(P=0.78); I2=0%

Test for overall effect: Z=0.4(P=0.69)

1.91%

2.4%

9.84%

85.85%

100%

Not estimable

5.44[-5.79,16.67]

-0.3[-10.34,9.74]

-1[-5.95,3.95]

-0.37[-2.05,1.31]

-0.32[-1.87,1.23]

1.52.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-20

-10

0

10

20

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

257

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.53.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 53 MOS SF Social functioning (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.53.1 End of intervention

Mehnert 2011

Cormie 2014

Cadmus 2009

Mustian 2004

Subtotal ***

7.3 (22.3)

3.5 (8.5)

0.7 (11)

1.5 (1.5)

30

43

37

9

119

Heterogeneity: Tau2=0; Chi2=0.31, df=3(P=0.96); I2=0%

Test for overall effect: Z=1.83(P=0.07)

1.53.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

3.1 (24.3)

2.5 (8.3)

0.1 (6.8)

0.4 (1.2)

28

19

37

10

94

0

0.88%

6.24%

7.32%

85.56%

100%

4.21[-7.83,16.25]

1[-3.51,5.51]

0.6[-3.57,4.77]

1.06[-0.16,2.28]

1.05[-0.08,2.18]

Not estimable

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 1.54.   Comparison 1 Comparison: HRQoL outcomes, all physical activity
vs control, Outcome 54 EORTC QLQ-C30 Social function (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.54.1 End of intervention

Herrero 2006

Mehnert 2011

Subtotal ***

87.5 (19.4)

85.6 (23.1)

8

30

38

Heterogeneity: Tau2=118.36; Chi2=2.45, df=1(P=0.12); I2=59.12%

Test for overall effect: Z=0.77(P=0.44)

1.54.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

91.7 (23.6)

69.8 (28.1)

8

27

35

0

41.3%

58.7%

100%

-4.2[-25.37,16.97]

15.81[2.37,29.25]

7.55[-11.77,26.86]

Not estimable

Favours control

-50

-25

0

25

50

Favours physical activity

Analysis 1.55.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 55 EORTC QLQ-C30 Social function (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.55.1 End of intervention

Herrero 2006

Mehnert 2011

Saarto 2012

Subtotal ***

0 (15.4)

12.8 (24.9)

5 (21.1)

8

30

263

301

8

27

237

272

-4.2 (18.4)

1.2 (27.8)

8.8 (20.8)

Heterogeneity: Tau2=49.46; Chi2=5.1, df=2(P=0.08); I2=60.82%

22.12%

27.19%

50.69%

100%

4.2[-12.43,20.83]

11.55[-2.22,25.32]

-3.8[-7.48,-0.12]

2.14[-8.02,12.3]

Favours control

-50

-25

0

25

50

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

258

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

Test for overall effect: Z=0.41(P=0.68)

1.55.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-50

-25

0

25

50

Favours physical activity

Analysis 1.56.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 56 Overall cognitive function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.56.1 End of intervention

Pinto 2003

Herrero 2006

Rogers 2009

Mehnert 2011

Cantarero-Villanueva 2013

Subtotal ***

-4.3 (2.5)

91.7 (12.6)

-124.5
(30.8)

81.1 (16.8)

-37.9 (8.5)

12

8

19

30

32

101

Heterogeneity: Tau2=0; Chi2=3.41, df=4(P=0.49); I2=0%

Test for overall effect: Z=2.68(P=0.01)

1.56.2 Follow-up

Rogers 2009

Cantarero-Villanueva 2013

Subtotal ***

-126.4
(31.8)

-37.7 (7.3)

19

32

51

Heterogeneity: Tau2=0; Chi2=0.73, df=1(P=0.39); I2=0%

Test for overall effect: Z=1.52(P=0.13)

-7.2 (2.1)

89.6 (12.4)

-135.5
(19.5)

78.4 (24.4)

-43 (10)

-129.2
(31.5)

-42 (11.3)

6

8

18

27

29

88

17

29

46

7.48%

8.81%

19.97%

31.37%

32.37%

100%

37.69%

62.31%

100%

1.14[0.07,2.2]

0.16[-0.82,1.14]

0.42[-0.24,1.07]

0.13[-0.39,0.65]

0.55[0.03,1.06]

0.4[0.11,0.69]

0.09[-0.57,0.74]

0.45[-0.06,0.96]

0.31[-0.09,0.71]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 1.57.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 57 Overall cognitive function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.57.1 End of intervention

Herrero 2006

Rogers 2009

Mehnert 2011

Cantarero-Villanueva 2013

Saarto 2012

Subtotal ***

8

20

30

32

263

353

6.2 (19.8)

4.2 (16.8)

1.7 (22.4)

2.2 (7.6)

-1 (18.2)

8.3 (14.8)

-4.7 (25.9)

6.2 (24.6)

-0.2 (5.5)

2.2 (18.5)

8

18

27

29

237

319

Heterogeneity: Tau2=0.03; Chi2=6.17, df=4(P=0.19); I2=35.2%

Test for overall effect: Z=0.04(P=0.97)

6.27%

12.72%

17.39%

18.09%

45.52%

100%

-0.11[-1.09,0.87]

0.4[-0.24,1.05]

-0.19[-0.71,0.33]

0.35[-0.16,0.86]

-0.17[-0.35,0]

-0[-0.27,0.26]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

259

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.57.2 Follow-up

Rogers 2009

Cantarero-Villanueva 2013

Subtotal ***

5.4 (16.3)

2.4 (10.2)

19

32

51

0.7 (23.6)

0.8 (5)

17

29

46

Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.92); I2=0%

Test for overall effect: Z=0.99(P=0.32)

37.03%

62.97%

100%

0.23[-0.43,0.89]

0.19[-0.32,0.69]

0.2[-0.2,0.6]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 1.58.   Comparison 1 Comparison: HRQoL outcomes, all physical activity
vs control, Outcome 58 EORTC QLQ-C30 Cognitive function (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.58.1 End of intervention

Herrero 2006

Mehnert 2011

Subtotal ***

91.7 (12.6)

81.1 (16.8)

8

30

38

Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.94); I2=0%

Test for overall effect: Z=0.58(P=0.56)

1.58.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

89.6 (12.4)

78.4 (24.4)

8

27

35

0

44.58%

55.42%

100%

2.1[-10.15,14.35]

2.7[-8.29,13.69]

2.43[-5.75,10.61]

Not estimable

Favours cntrol

-20

-10

0

10

20

Favours physical activity

Analysis 1.59.   Comparison 1 Comparison: HRQoL outcomes, all physical activity
vs control, Outcome 59 EORTC QLQ-C30 Cognitive function (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.59.1 End of intervention

Herrero 2006

Mehnert 2011

Saarto 2012

Subtotal ***

8

30

263

301

6.2 (19.8)

1.7 (22.4)

-1 (18.2)

8

27

237

272

8.3 (14.8)

6.2 (24.6)

2.2 (18.5)

Heterogeneity: Tau2=0; Chi2=0.06, df=2(P=0.97); I2=0%

Test for overall effect: Z=2.08(P=0.04)

3.2%

6.25%

90.55%

100%

-2.1[-19.23,15.03]

-4.51[-16.76,7.74]

-3.2[-6.42,0.02]

-3.25[-6.31,-0.18]

1.59.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-50

-25

0

25

50

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

260

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.60.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 60 POMS confusion subscale (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

1.60.1 End of intervention

Pinto 2003

Cantarero-Villanueva 2013

Subtotal ***

4.3 (2.5)

37.9 (8.5)

12

32

44

Heterogeneity: Tau2=0; Chi2=0.96, df=1(P=0.33); I2=0%

Test for overall effect: Z=2.78(P=0.01)

1.60.2 Follow-up

Cantarero-Villanueva 2013

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.72(P=0.09)

37.8 (7.3)

32

32

7.2 (2.1)

43 (10)

42 (11.3)

6

29

35

29

29

18.76%

81.24%

100%

-1.14[-2.2,-0.07]

-0.55[-1.06,-0.03]

-0.66[-1.12,-0.19]

100%

100%

-0.45[-0.96,0.06]

-0.45[-0.96,0.06]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 1.61.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 61 Overall general health (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.61.1 End of intervention

Herrero 2006

Mustian 2004

Rogers 2009

Basen-Enquist 2006

Ergun 2013

Mehnert 2011

Do 2015

Cadmus 2009

Schmitz 2005

Subtotal ***

8

9

20

28

40

30

32

37

39

81.3 (10.7)

18.6 (4.8)

3.5 (0.9)

77.4 (11.6)

71.6 (19.9)

74.4 (11.8)

87.3 (13.7)

50 (8.8)

53.8 (5.3)

8

9

18

23

20

28

30

37

40

62.5 (16.1)

19.3 (1.9)

3.8 (0.5)

67.1 (13.4)

67.9 (16.7)

70 (20.8)

82.4 (19.9)

51.7 (8.4)

53.2 (6)

243

213

Heterogeneity: Tau2=0.08; Chi2=15.19, df=8(P=0.06); I2=47.33%

Test for overall effect: Z=1.35(P=0.18)

4.71%

6.23%

10.15%

11.5%

12.33%

12.81%

13.21%

14.32%

14.73%

100%

1.3[0.19,2.41]

-0.18[-1.11,0.74]

-0.4[-1.04,0.25]

0.81[0.24,1.39]

0.19[-0.35,0.73]

0.26[-0.26,0.77]

0.28[-0.22,0.79]

-0.2[-0.65,0.26]

0.1[-0.34,0.55]

0.18[-0.08,0.45]

1.61.2 Follow-up

Rogers 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.65(P=0.52)

19

19

3.5 (0.9)

17

17

3.7 (0.9)

100%

100%

-0.22[-0.87,0.44]

-0.22[-0.87,0.44]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

261

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.62.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 62 Overall general health (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.62.1 End of intervention

Herrero 2006

Mustian 2004

Rogers 2009

Ergun 2013

Cormie 2014

Mehnert 2011

Cadmus 2009

Schmitz 2005

Saarto 2012

Subtotal ***

17.7 (8.3)

0.2 (1.9)

0.2 (0.6)

5.4 (21.5)

3.7 (7)

6.6 (13.7)

0.2 (4.4)

0.7 (4.8)

4.2 (16.2)

8

9

20

40

43

30

37

39

263

489

Heterogeneity: Tau2=0.05; Chi2=15.82, df=8(P=0.05); I2=49.43%

Test for overall effect: Z=1.4(P=0.16)

1.62.2 Follow-up

Rogers 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.2(P=0.85)

0.2 (0.6)

19

19

-10.4 (17.7)

0.7 (2.5)

0.2 (0.7)

-6.7 (25.9)

2.8 (7.1)

3.2 (19.7)

-0.1 (5.1)

-0.6 (3.9)

5.6 (15.4)

0.1 (0.6)

8

10

18

20

19

28

37

40

237

417

17

17

3.12%

5.35%

8.91%

10.81%

10.93%

11.51%

13.13%

13.48%

22.76%

100%

1.92[0.68,3.17]

-0.2[-1.1,0.71]

-0.03[-0.67,0.61]

0.52[-0.03,1.06]

0.13[-0.41,0.67]

0.2[-0.32,0.71]

0.06[-0.39,0.52]

0.29[-0.15,0.74]

-0.09[-0.26,0.09]

0.17[-0.07,0.4]

100%

100%

0.07[-0.59,0.72]

0.07[-0.59,0.72]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 1.63.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 63 MOS SF General health (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.63.1 End of intervention

Baruth 2013

Mehnert 2011

Basen-Enquist 2006

Cadmus 2009

Mustian 2004

Subtotal ***

68.1 (0)

74.4 (11.8)

77.4 (11.6)

50 (8.8)

18.6 (4.8)

20

30

28

37

9

124

12

28

23

37

9

109

61.6 (0)

70 (20.8)

67.1 (13.4)

51.7 (8.4)

19.3 (1.9)

Heterogeneity: Tau2=15.3; Chi2=10.02, df=3(P=0.02); I2=70.05%

Test for overall effect: Z=0.88(P=0.38)

16.54%

20.95%

30.37%

32.14%

100%

Not estimable

4.37[-4.43,13.17]

10.3[3.32,17.28]

-1.7[-5.62,2.22]

-0.7[-4.06,2.66]

2.14[-2.61,6.88]

1.63.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-20

-10

0

10

20

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

262

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.64.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 64 MOS SF General health (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.64.1 End of intervention

Mehnert 2011

Cormie 2014

Cadmus 2009

Mustian 2004

Subtotal ***

6.6 (13.7)

3.7 (7)

0.2 (4.4)

0.2 (1.9)

30

43

37

9

119

Heterogeneity: Tau2=0; Chi2=1.03, df=3(P=0.79); I2=0%

Test for overall effect: Z=0.14(P=0.89)

1.64.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

3.2 (19.7)

2.8 (7.1)

-0.1 (5.1)

0.7 (2.5)

28

19

37

10

94

0

2.37%

12.58%

38.92%

46.13%

100%

3.36[-5.43,12.15]

0.9[-2.92,4.72]

0.3[-1.87,2.47]

-0.46[-2.45,1.53]

0.1[-1.26,1.45]

Not estimable

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 1.65.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 65 Overall sexual function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

1.65.1 End of intervention

Pinto 2005

Schmitz 2005

Pinto 2003

Schmitz 2009

Duijits 2012

Subtotal ***

42.8 (9.2)

-51 (7.5)

42.5 (9.2)

-27.3 (5.3)

0.6 (0.8)

12

39

39

57

53

200

Heterogeneity: Tau2=0; Chi2=1.8, df=4(P=0.77); I2=0%

Test for overall effect: Z=1.59(P=0.11)

1.65.2 Follow-up

Duijits 2012

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.94(P=0.35)

0.6 (0.7)

48

48

43.7 (6.1)

-53.5 (8)

40.1 (6.3)

-28.1 (6.2)

0.6 (0.8)

0.4 (0.7)

6

40

43

57

65

211

54

54

3.94%

19.23%

19.96%

28.06%

28.81%

100%

-0.11[-1.09,0.87]

0.32[-0.12,0.76]

0.29[-0.14,0.73]

0.14[-0.23,0.51]

0.01[-0.35,0.38]

0.16[-0.04,0.35]

100%

100%

0.19[-0.2,0.58]

0.19[-0.2,0.58]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 1.66.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 66 Overall sexual function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.66.1 End of intervention

Schmitz 2005

39

1.7 (4.8)

40

0.2 (5.2)

24.77%

0.3[-0.15,0.74]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

263

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Schmitz 2009

Saarto 2012

Subtotal ***

Mean(SD)

7.2 (14.6)

4.3 (25.4)

N

57

263

359

Mean(SD)

-0.2 (16.7)

3.8 (24.4)

N

57

237

334

Heterogeneity: Tau2=0.04; Chi2=5.22, df=2(P=0.07); I2=61.69%

Test for overall effect: Z=1.45(P=0.15)

Random, 95% CI

Random, 95% CI

29.51%

45.72%

100%

0.47[0.1,0.84]

0.02[-0.16,0.2]

0.22[-0.08,0.52]

1.66.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 1.67.   Comparison 1 Comparison: HRQoL outcomes, all physical activity vs
control, Outcome 67 Body Esteem Scale - sexual attractiveness (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.67.1 End of intervention

Pinto 2005

Pinto 2003

Subtotal ***

42.8 (9.2)

42.5 (9.2)

12

39

51

Heterogeneity: Tau2=0; Chi2=0.66, df=1(P=0.42); I2=0%

Test for overall effect: Z=1.07(P=0.28)

1.67.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

43.7 (6.1)

40.1 (6.3)

6

43

49

0

19.01%

80.99%

100%

-0.95[-8.09,6.19]

2.33[-1.13,5.79]

1.71[-1.41,4.82]

Not estimable

Favours control

-10

-5

0

5

10

Favours physical activity

Analysis 1.68.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 68 Overall sleep (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

1.68.1 End of intervention

Rogers 2013

Bower 2011

Rogers 2009

Rogers 2014

Mehnert 2011

Subtotal ***

6.3 (2.7)

8.1 (2.5)

6.7 (4.2)

6.7 (3.7)

23.8 (27)

11

16

20

20

30

97

6.2 (3.2)

7.7 (2.6)

5.5 (4)

7.1 (3.2)

38.3 (31.6)

9

15

18

22

27

91

Heterogeneity: Tau2=0; Chi2=3.98, df=4(P=0.41); I2=0%

Test for overall effect: Z=0.59(P=0.56)

10.7%

16.68%

20.26%

22.6%

29.76%

100%

0.03[-0.85,0.91]

0.15[-0.55,0.86]

0.28[-0.36,0.92]

-0.11[-0.72,0.49]

-0.49[-1.02,0.04]

-0.09[-0.37,0.2]

1.68.2 Follow-up

Bower 2011

16

7.6 (2.7)

15

9.1 (3.3)

100%

-0.49[-1.2,0.23]

Favours Physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

264

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.33(P=0.18)

Mean(SD)

N

16

N

15

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

100%

-0.49[-1.2,0.23]

Favours Physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 1.69.   Comparison 1 Comparison: HRQoL outcomes, all
physical activity vs control, Outcome 69 Overall sleep (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.69.1 End of intervention

Rogers 2009

Rogers 2014

Mehnert 2011

Subtotal ***

0.5 (2.1)

-1.3 (3.2)

-5.4 (29.9)

20

20

29

69

Heterogeneity: Tau2=0; Chi2=0.16, df=2(P=0.92); I2=0%

Test for overall effect: Z=0.82(P=0.41)

1.69.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0.3 (4.7)

-2.2 (4.4)

-9.9 (33.3)

18

22

27

67

0

28.01%

30.76%

41.24%

100%

0.05[-0.59,0.68]

0.23[-0.38,0.84]

0.14[-0.38,0.67]

0.14[-0.2,0.48]

Not estimable

Favours Physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 1.70.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 70 PSQI Global sleep score (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.70.1 End of intervention

Rogers 2013

Rogers 2009

Rogers 2014

Bower 2011

Kiecolt-Glaser 2014

Subtotal ***

6.3 (2.7)

6.7 (4.2)

6.7 (3.7)

8.1 (2.5)

6.3 (2.2)

11

20

20

16

96

163

Heterogeneity: Tau2=0; Chi2=3.1, df=4(P=0.54); I2=0%

Test for overall effect: Z=1.68(P=0.09)

1.70.2 Follow-up

Bower 2011

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.38(P=0.17)

7.6 (2.7)

16

16

6.2 (3.2)

5.5 (4)

7.1 (3.2)

7.7 (2.6)

7 (2.2)

9.1 (3.3)

9

18

22

15

90

154

15

15

4.26%

4.36%

6.67%

9.11%

75.6%

100%

0.1[-2.53,2.73]

1.15[-1.45,3.75]

-0.4[-2.5,1.7]

0.4[-1.4,2.2]

-0.7[-1.32,-0.08]

-0.47[-1.01,0.08]

100%

100%

-1.5[-3.63,0.63]

-1.5[-3.63,0.63]

Favours Physical activity

-10

-5

0

5

10

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

265

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.71.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 71 PSQI Global sleep score (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.71.1 End of intervention

Rogers 2009

Rogers 2014

Subtotal ***

0.5 (2.1)

-1.3 (3.2)

20

20

40

Heterogeneity: Tau2=0; Chi2=0.19, df=1(P=0.66); I2=0%

Test for overall effect: Z=0.64(P=0.52)

1.71.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0.3 (4.7)

-2.2 (4.4)

18

22

40

0

49.02%

50.98%

100%

0.17[-2.19,2.53]

0.9[-1.41,3.21]

0.54[-1.11,2.19]

Not estimable

Favours Physical activity

-10

-5

0

5

10

Favours control

Analysis 1.72.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 72 PSQI sleep quality (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.72.1 End of intervention

Rogers 2009

Rogers 2014

Subtotal ***

1.3 (0.9)

0.7 (0.6)

20

20

40

Heterogeneity: Tau2=0.11; Chi2=3.12, df=1(P=0.08); I2=67.96%

Test for overall effect: Z=0.85(P=0.4)

1.72.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

1.2 (0.8)

1.2 (0.6)

18

22

40

0

44.19%

55.81%

100%

0.08[-0.45,0.61]

-0.5[-0.86,-0.14]

-0.24[-0.81,0.32]

Not estimable

Favours Physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 1.73.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 73 PSQI sleep efficiency (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.73.1 End of intervention

Rogers 2013

Rogers 2009

Rogers 2014

Subtotal ***

11

20

20

51

0.8 (1)

1.1 (1.4)

0.6 (0.8)

9

18

22

49

0.7 (0.9)

0.6 (0.9)

0.6 (1)

Heterogeneity: Tau2=0; Chi2=0.94, df=2(P=0.63); I2=0%

Test for overall effect: Z=0.76(P=0.45)

21.28%

29.03%

49.7%

100%

0.1[-0.73,0.93]

0.44[-0.27,1.15]

0[-0.55,0.55]

0.15[-0.24,0.53]

Favours Physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

266

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.73.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours Physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 1.74.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 74 PSQI sleep latency (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.74.1 End of intervention

Rogers 2013

Rogers 2009

Rogers 2014

Subtotal ***

1.3 (0.6)

1.1 (0.9)

1.2 (1)

11

20

20

51

Heterogeneity: Tau2=0; Chi2=0.42, df=2(P=0.81); I2=0%

Test for overall effect: Z=1.08(P=0.28)

1.74.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

1.3 (1)

0.8 (1.1)

1 (0.7)

9

18

22

49

0

22.47%

32.8%

44.73%

100%

0[-0.74,0.74]

0.32[-0.3,0.94]

0.2[-0.33,0.73]

0.19[-0.16,0.55]

Not estimable

Favours Physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 1.75.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 75 PSQI sleep duration (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.75.1 End of intervention

Rogers 2013

Rogers 2014

Subtotal ***

1.3 (0.9)

1.1 (0.8)

20

20

40

Heterogeneity: Tau2=0; Chi2=0.92, df=1(P=0.34); I2=0%

Test for overall effect: Z=0.36(P=0.72)

1.75.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

1.1 (0.6)

1.2 (0.8)

18

22

40

0

48.42%

51.58%

100%

0.24[-0.26,0.74]

-0.1[-0.58,0.38]

0.06[-0.28,0.41]

Not estimable

Favours Physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

267

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.76.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 76 PSQI daytime dysfunction (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

1.76.1 End of intervention

Rogers 2013

Rogers 2009

Rogers 2014

Subtotal ***

0.6 (0.5)

1.2 (0.9)

0.7 (0.6)

11

20

20

51

Heterogeneity: Tau2=0.08; Chi2=4.64, df=2(P=0.1); I2=56.9%

Test for overall effect: Z=0.36(P=0.72)

1.76.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0.9 (0.9)

0.8 (0.5)

1 (0.7)

9

18

22

49

0

24.75%

35.73%

39.52%

100%

-0.3[-0.96,0.36]

0.32[-0.13,0.77]

-0.3[-0.69,0.09]

-0.08[-0.51,0.35]

Not estimable

Favours Physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 1.77.   Comparison 1 Comparison: HRQoL outcomes, all physical
activity vs control, Outcome 77 PSQI medication use (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1.77.1 End of intervention

Rogers 2009

Rogers 2014

Subtotal ***

0.8 (1.2)

0.8 (1.3)

20

20

40

Heterogeneity: Tau2=0; Chi2=0.42, df=1(P=0.52); I2=0%

Test for overall effect: Z=0.26(P=0.79)

1.77.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

1 (1.1)

0.7 (1.2)

18

22

40

0

47.35%

52.65%

100%

-0.21[-0.85,0.43]

0.08[-0.53,0.68]

-0.06[-0.5,0.38]

Not estimable

Favours Physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 1.78.   Comparison 1 Comparison: HRQoL outcomes, all physical activity
vs control, Outcome 78 Accelerator-derived sleep efficiency (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.78.1 End of intervention

Rogers 2013

Rogers 2014

Subtotal ***

79.5 (8.3)

82.9 (5.7)

11

20

31

83.2 (10.5)

84.9 (6)

9

22

31

Heterogeneity: Tau2=0; Chi2=0.13, df=1(P=0.72); I2=0%

Test for overall effect: Z=1.35(P=0.18)

14.98%

85.02%

100%

-3.7[-12.13,4.73]

-2[-5.54,1.54]

-2.25[-5.52,1.01]

Favours Physical activity

-20

-10

0

10

20

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

268

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.78.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours Physical activity

-20

-10

0

10

20

Favours control

Analysis 1.79.   Comparison 1 Comparison: HRQoL outcomes, all physical activity
vs control, Outcome 79 Accelerator-derived sleep latency (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.79.1 End of intervention

Rogers 2013

Rogers 2014

Subtotal ***

7.1 (3.8)

7.4 (5.6)

11

20

31

Heterogeneity: Tau2=0; Chi2=0.18, df=1(P=0.67); I2=0%

Test for overall effect: Z=1.46(P=0.14)

1.79.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

9.8 (5.2)

8.9 (6.6)

9

22

31

0

45.11%

54.89%

100%

-2.7[-6.77,1.37]

-1.5[-5.19,2.19]

-2.04[-4.78,0.69]

Not estimable

Favours Physical activity

-20

-10

0

10

20

Favours control

Comparison 2.   Comparison: anxiety, all physical activity vs control

Outcome or subgroup ti-
tle

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Overall anxiety (fol-
low-up values)

1.1 End of intervention

1.2 Follow-up

2 Overall anxiety (change
values)

2.1 End of intervention

2.2 Follow-up

3 POMS tension - anxiety
(follow-up values)

3.1 End of intervention

7

7

1

4

4

1

2

2

326

61

235

61

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.57 [-0.95, -0.19]

Std. Mean Difference (IV, Random, 95%
CI)

-0.47 [-0.98, 0.04]

Std. Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Std. Mean Difference (IV, Fixed, 95% CI)

-0.37 [-0.63, -0.12]

Std. Mean Difference (IV, Fixed, 95% CI)

-0.30 [-0.81, 0.20]

Std. Mean Difference (IV, Fixed, 95% CI)

Subtotals only

79

Std. Mean Difference (IV, Fixed, 95% CI)

-0.66 [-1.12, -0.20]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

269

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup ti-
tle

No. of studies

No. of partici-
pants

Statistical method

Effect size

3.2 Follow-up

4 State Trait Anxiety Inven-
tory (follow-up values)

4.1 End of intervention

4.2 Follow-up

5 Cohen's Perceived Stress
Scale

5.1 End of intervention

5.2 Follow-up

1

2

2

0

2

2

0

61

89

0

105

0

Std. Mean Difference (IV, Fixed, 95% CI)

-0.47 [-0.98, 0.04]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-1.20 [-3.49, 1.09]

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

-1.25 [-3.99, 1.50]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Analysis 2.1.   Comparison 2 Comparison: anxiety, all physical
activity vs control, Outcome 1 Overall anxiety (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

2.1.1 End of intervention

Segar 1998

Pinto 2003

Rogers 2014

Milne 2008

Mehnert 2011

Cantarero-Villanueva 2013

Cadmus 2009

Subtotal ***

28.5 (3)

7.6 (7.3)

45.6 (8.9)

15.3 (6.2)

4.8 (3.5)

42.5 (8.6)

32.1 (12.3)

10

12

20

29

30

32

37

170

39.5 (6)

10.5 (3.7)

45.7 (8)

21 (5.7)

7.1 (5)

49.9 (11.7)

34.1 (15.4)

5

6

22

29

28

29

37

156

Heterogeneity: Tau2=0.14; Chi2=14.94, df=6(P=0.02); I2=59.85%

Test for overall effect: Z=2.97(P=0)

5.13%

9.27%

15.51%

16.79%

17.22%

17.33%

18.74%

100%

-2.49[-3.98,-1]

-0.43[-1.43,0.56]

-0.01[-0.62,0.59]

-0.94[-1.49,-0.4]

-0.54[-1.06,-0.01]

-0.72[-1.24,-0.2]

-0.14[-0.6,0.31]

-0.57[-0.95,-0.19]

2.1.2 Follow-up

Cantarero-Villanueva 2013

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.79(P=0.07)

32

32

44 (9.5)

48.8 (11.2)

29

29

100%

100%

-0.47[-0.98,0.04]

-0.47[-0.98,0.04]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

270

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.2.   Comparison 2 Comparison: anxiety, all physical
activity vs control, Outcome 2 Overall anxiety (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

2.2.1 End of intervention

Cadmus 2009

Cantarero-Villanueva 2013

Mehnert 2011

Rogers 2014

Subtotal ***

-0.7 (9.2)

-4.2 (9.8)

-1.7 (3.7)

-4 (6.5)

37

32

30

20

119

Heterogeneity: Tau2=0; Chi2=1.71, df=3(P=0.63); I2=0%

Test for overall effect: Z=2.84(P=0)

2.2.2 Follow-up

Cantarero-Villanueva 2013

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.18(P=0.24)

-3.4 (13.5)

32

32

0.5 (5.8)

0.8 (5.5)

0.2 (4.9)

-1.8 (5)

-0.3 (3.6)

37

29

28

22

116

29

29

32.15%

25.28%

24.65%

17.92%

100%

-0.15[-0.61,0.3]

-0.61[-1.12,-0.09]

-0.42[-0.95,0.1]

-0.37[-0.99,0.24]

-0.37[-0.63,-0.12]

100%

100%

-0.3[-0.81,0.2]

-0.3[-0.81,0.2]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 2.3.   Comparison 2 Comparison: anxiety, all physical activity
vs control, Outcome 3 POMS tension - anxiety (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

2.3.1 End of intervention

Pinto 2003

Cantarero-Villanueva 2013

Subtotal ***

7.6 (7.3)

42.5 (8.6)

12

32

44

Heterogeneity: Tau2=0; Chi2=0.25, df=1(P=0.62); I2=0%

Test for overall effect: Z=2.8(P=0.01)

2.3.2 Follow-up

Cantarero-Villanueva 2013

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.79(P=0.07)

44 (9.5)

32

32

10.5 (3.7)

49.9 (11.7)

48.8 (11.2)

6

29

35

29

29

21.49%

78.51%

100%

-0.43[-1.43,0.56]

-0.72[-1.24,-0.2]

-0.66[-1.12,-0.2]

100%

100%

-0.47[-0.98,0.04]

-0.47[-0.98,0.04]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 2.4.   Comparison 2 Comparison: anxiety, all physical activity
vs control, Outcome 4 State Trait Anxiety Inventory (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

2.4.1 End of intervention

Segar 1998

Cadmus 2009

Subtotal ***

28.5 (3)

32.1 (12.3)

10

37

47

39.5 (6)

34.1 (15.4)

5

37

42

45.23%

54.77%

100%

-2.49[-3.98,-1]

-0.14[-0.6,0.31]

-1.2[-3.49,1.09]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

271

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Heterogeneity: Tau2=2.44; Chi2=8.68, df=1(P=0); I2=88.48%

Test for overall effect: Z=1.03(P=0.3)

2.4.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 2.5.   Comparison 2 Comparison: anxiety, all physical
activity vs control, Outcome 5 Cohen's Perceived Stress Scale.

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

2.5.1 End of intervention

Bower 2011

Cadmus 2009

Subtotal ***

23.5 (7.3)

12.9 (6.2)

16

37

53

Heterogeneity: Tau2=0; Chi2=0.12, df=1(P=0.73); I2=0%

Test for overall effect: Z=0.89(P=0.37)

2.5.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

25.4 (5.9)

13.8 (8.5)

15

37

52

0

34.61%

65.39%

100%

-1.9[-6.56,2.76]

-0.9[-4.29,2.49]

-1.25[-3.99,1.5]

Not estimable

Favours physical activity

-20

-10

0

10

20

Favours control

Comparison 3.   Comparison: depression, all physical activity vs control

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Overall depression (fol-
low-up values)

1.1 End of intervention

1.2 Follow-up

2 Overall depression
(change values)

2.1 End of intervention

2.2 Follow-up

12

12

4

7

7

1

657

340

816

61

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.34 [-0.62, -0.05]

Std. Mean Difference (IV, Random,
95% CI)

-0.28 [-0.51, -0.05]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.34 [-0.63, -0.05]

Std. Mean Difference (IV, Random,
95% CI)

-0.46 [-0.97, 0.05]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

272

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

3 Beck Depression Invento-
ry-II (follow-up values)

3.1 End of intervention

3.2 Follow-up

4 Beck Depression Invento-
ry-II (change values)

4.1 End of intervention

4.2 Follow-up

5 CES-Depression scale (fol-
low-up values)

5.1 End of intervention

5.2 Follow-up

6 POMS depression sub-
scale (follow-up values)

6.1 End of intervention

6.2 Follow-up

7 POMS tension subscale
(follow-up values)

7.1 End of intervention

7.2 Follow-up

5

5

2

3

3

0

3

3

1

2

2

1

2

2

1

198

93

581

0

280

186

79

61

79

61

Mean Difference (IV, Random, 95%
CI)

Subtotals only

Mean Difference (IV, Random, 95%
CI)

-3.25 [-5.94, -0.56]

Mean Difference (IV, Random, 95%
CI)

-2.35 [-5.31, 0.60]

Mean Difference (IV, Random, 95%
CI)

Subtotals only

Mean Difference (IV, Random, 95%
CI)

-1.84 [-5.33, 1.65]

Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

-1.36 [-3.39, 0.67]

Mean Difference (IV, Fixed, 95% CI)

-1.90 [-4.32, 0.52]

Mean Difference (IV, Random, 95%
CI)

Subtotals only

Mean Difference (IV, Random, 95%
CI)

-6.39 [-10.66, -2.12]

Mean Difference (IV, Random, 95%
CI)

-6.65 [-11.97, -1.33]

Mean Difference (IV, Random, 95%
CI)

Subtotals only

Mean Difference (IV, Random, 95%
CI)

-5.14 [-9.55, -0.73]

Mean Difference (IV, Random, 95%
CI)

-4.87 [-10.09, 0.35]

Analysis 3.1.   Comparison 3 Comparison: depression, all physical
activity vs control, Outcome 1 Overall depression (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.1.1 End of intervention

Segar 1998

Pinto 2003

10

12

5.5 (2)

6.2 (7.2)

5

6

10 (2)

9.8 (6.8)

3.25%

5.23%

-2.12[-3.51,-0.73]

-0.49[-1.49,0.5]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

273

 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Payne 2008

Kaltsatou 2011

Bower 2011

Rogers 2014

Ergun 2013

Mehnert 2011

Cantarero-Villanueva 2013

Daley 2007

Cadmus 2009

Kiecolt-Glaser 2014

Subtotal ***

10

13

16

20

40

30

32

33

37

96

12.7 (8.7)

16.5 (1.7)

7.7 (5.8)

44.2 (8.6)

6.9 (6.8)

2.7 (3)

45.6 (9.7)

6 (6.5)

9.6 (9.3)

8.1 (8.6)

10

13

15

22

20

28

29

33

37

90

11.4 (7.9)

22.3 (7.7)

11.6 (7.1)

25.1 (44.2)

5.2 (5.2)

4.6 (4.4)

53.7 (11.6)

10.3 (7.2)

10.8 (10.1)

9.2 (8.2)

349

308

Heterogeneity: Tau2=0.14; Chi2=30.12, df=11(P=0); I2=63.48%

Test for overall effect: Z=2.32(P=0.02)

3.1.2 Follow-up

Bower 2011

Cantarero-Villanueva 2013

Daley 2007

Kiecolt-Glaser 2014

Subtotal ***

16

32

31

96

175

9.9 (8)

46 (9)

6.5 (7)

8.5 (8.6)

10.5 (7.9)

52.7 (11.8)

9.6 (7)

9.7 (8.3)

15

29

31

90

165

Heterogeneity: Tau2=0.01; Chi2=3.3, df=3(P=0.35); I2=9.11%

Test for overall effect: Z=2.38(P=0.02)

6.11%

6.57%

7.53%

8.64%

9.59%

9.78%

9.81%

10.14%

10.63%

12.73%

100%

10.4%

18.73%

19.54%

51.33%

100%

0.15[-0.73,1.03]

-1[-1.83,-0.18]

-0.59[-1.31,0.13]

0.58[-0.04,1.19]

0.27[-0.27,0.81]

-0.51[-1.04,0.01]

-0.75[-1.28,-0.23]

-0.63[-1.12,-0.13]

-0.12[-0.58,0.33]

-0.13[-0.42,0.16]

-0.34[-0.62,-0.05]

-0.07[-0.78,0.63]

-0.63[-1.14,-0.11]

-0.43[-0.93,0.07]

-0.14[-0.43,0.15]

-0.28[-0.51,-0.05]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 3.2.   Comparison 3 Comparison: depression, all physical
activity vs control, Outcome 2 Overall depression (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

3.2.1 End of intervention

Naumann 2012

Rogers 2014

Ergun 2013

Mehnert 2011

Cantarero-Villanueva 2013

Cadmus 2009

Saarto 2012

Subtotal ***

-3.6 (4.3)

-1.7 (6.9)

1.2 (6.2)

2.7 (3)

-2.9 (7.8)

0.3 (6.4)

-0.3 (3.3)

11

20

40

30

32

37

263

433

Heterogeneity: Tau2=0.08; Chi2=15.81, df=6(P=0.01); I2=62.05%

Test for overall effect: Z=2.28(P=0.02)

3.2.2 Follow-up

Cantarero-Villanueva 2013

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.77(P=0.08)

-2.5 (7.8)

32

32

2 (4.6)

1.1 (4.2)

2.4 (8)

4.6 (4.4)

1.5 (7.4)

1.7 (6.3)

-0.5 (3.4)

0.4 (4.1)

10

22

20

28

29

37

237

383

29

29

6.86%

11.92%

13.66%

13.99%

14.26%

15.72%

23.59%

100%

-1.21[-2.16,-0.26]

-0.49[-1.1,0.13]

-0.16[-0.7,0.37]

-0.51[-1.04,0.01]

-0.57[-1.09,-0.06]

-0.22[-0.68,0.24]

0.06[-0.12,0.24]

-0.34[-0.63,-0.05]

100%

100%

-0.46[-0.97,0.05]

-0.46[-0.97,0.05]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

274

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.3.   Comparison 3 Comparison: depression, all physical activity
vs control, Outcome 3 Beck Depression Inventory-II (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

3.3.1 End of intervention

Bower 2011

Kaltsatou 2011

Daley 2007

Ergun 2013

Segar 1998

Subtotal ***

7.7 (5.8)

16.5 (1.7)

6 (6.5)

6.9 (6.8)

5.5 (2)

16

13

33

40

10

112

Heterogeneity: Tau2=6.31; Chi2=13.11, df=4(P=0.01); I2=69.5%

Test for overall effect: Z=2.37(P=0.02)

3.3.2 Follow-up

Bower 2011

Daley 2007

Subtotal ***

9.9 (8)

6.5 (7)

16

31

47

Heterogeneity: Tau2=0; Chi2=0.52, df=1(P=0.47); I2=0%

Test for overall effect: Z=1.56(P=0.12)

11.6 (7.1)

22.3 (7.7)

10.3 (7.2)

5.2 (5.2)

10 (2)

10.5 (7.9)

9.6 (7)

15

13

33

20

5

86

15

31

46

15.99%

16.93%

20.59%

21.41%

25.07%

100%

27.78%

72.22%

100%

-3.9[-8.48,0.68]

-5.79[-10.09,-1.49]

-4.33[-7.63,-1.03]

1.73[-1.36,4.82]

-4.5[-6.65,-2.35]

-3.25[-5.94,-0.56]

-0.6[-6.2,5]

-3.03[-6.5,0.44]

-2.35[-5.31,0.6]

Favours physical activity

-20

-10

0

10

20

Favours control

Analysis 3.4.   Comparison 3 Comparison: depression, all physical activity
vs control, Outcome 4 Beck Depression Inventory-II (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

3.4.1 End of intervention

Ergun 2013

Naumann 2012

Saarto 2012

Subtotal ***

40

11

263

314

1.2 (6.2)

-3.6 (4.3)

-0.3 (3.3)

20

10

237

267

2.4 (8)

2 (4.6)

-0.5 (3.4)

Heterogeneity: Tau2=7.21; Chi2=9.02, df=2(P=0.01); I2=77.83%

Test for overall effect: Z=1.03(P=0.3)

27.8%

28.81%

43.39%

100%

-1.13[-5.14,2.88]

-5.6[-9.41,-1.79]

0.2[-0.39,0.79]

-1.84[-5.33,1.65]

3.4.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours physical activity

-20

-10

0

10

20

Favours control

Analysis 3.5.   Comparison 3 Comparison: depression, all physical
activity vs control, Outcome 5 CES-Depression scale (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

3.5.1 End of intervention

Payne 2008

10

12.7 (8.7)

10

11.4 (7.9)

7.81%

1.3[-5.98,8.58]

Favours physical activity

-20

-10

0

10

20

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

275

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Physical activity

Control

Cadmus 2009

Kiecolt-Glaser 2014

Subtotal ***

Mean(SD)

9.6 (9.3)

8.1 (8.6)

N

37

96

143

Heterogeneity: Tau2=0; Chi2=0.59, df=2(P=0.74); I2=0%

Test for overall effect: Z=1.31(P=0.19)

3.5.2 Follow-up

Kiecolt-Glaser 2014

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.54(P=0.12)

8.5 (8.6)

96

96

Mean(SD)

10.8 (10.1)

9.8 (8.2)

10.4 (8.3)

N

37

90

137

90

90

Cochrane Database of Systematic Reviews

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

21.16%

71.04%

100%

Fixed, 95% CI

-1.2[-5.62,3.22]

-1.7[-4.11,0.71]

-1.36[-3.39,0.67]

100%

100%

-1.9[-4.32,0.52]

-1.9[-4.32,0.52]

Favours physical activity

-20

-10

0

10

20

Favours control

Analysis 3.6.   Comparison 3 Comparison: depression, all physical activity
vs control, Outcome 6 POMS depression subscale (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

3.6.1 End of intervention

Pinto 2003

Cantarero-Villanueva 2013

Subtotal ***

6.2 (7.2)

45.6 (9.7)

12

32

44

Heterogeneity: Tau2=0.19; Chi2=1.02, df=1(P=0.31); I2=1.93%

Test for overall effect: Z=2.93(P=0)

3.6.2 Follow-up

Cantarero-Villanueva 2013

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.45(P=0.01)

32

32

46 (9)

9.8 (6.8)

53.7 (11.6)

52.7 (11.8)

6

29

35

29

29

38.84%

61.16%

100%

-3.66[-10.46,3.14]

-8.13[-13.52,-2.74]

-6.39[-10.66,-2.12]

100%

100%

-6.65[-11.97,-1.33]

-6.65[-11.97,-1.33]

Favours physical activity

-50

-25

0

25

50

Favours control

Analysis 3.7.   Comparison 3 Comparison: depression, all physical
activity vs control, Outcome 7 POMS tension subscale (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

3.7.1 End of intervention

Cantarero-Villanueva 2013

Pinto 2003

Subtotal ***

42.5 (8.6)

7.6 (7.3)

32

12

44

Heterogeneity: Tau2=3.26; Chi2=1.48, df=1(P=0.22); I2=32.24%

Test for overall effect: Z=2.28(P=0.02)

3.7.2 Follow-up

Cantarero-Villanueva 2013

Subtotal ***

44 (9.5)

32

32

49.9 (11.7)

10.5 (3.7)

48.8 (11.2)

29

6

35

29

29

49.32%

50.68%

100%

-7.42[-12.61,-2.23]

-2.92[-8,2.16]

-5.14[-9.55,-0.73]

100%

100%

-4.87[-10.09,0.35]

-4.87[-10.09,0.35]

Favours physical activity

-50

-25

0

25

50

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

276

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

Heterogeneity: Not applicable

Test for overall effect: Z=1.83(P=0.07)

Favours physical activity

-50

-25

0

25

50

Favours control

Comparison 4.   Comparison: fatigue and vigour, all physical activity vs control

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Overall fatigue (follow-up
values)

1.1 End of intervention

1.2 Follow-up

2 Overall fatigue (change val-
ues)

2.1 End of intervention

2.2 Follow-up

3 FACT-Fatigue (follow-up
values)

3.1 End of intervention

3.2 Follow-up

4 FACT-Fatigue (change val-
ues)

4.1 End of intervention

4.2 Follow-up

5 EORTC QLQ-C30 Fatigue
scale (follow-up values)

5.1 End of intervention

5.2 Follow-up

6 EORTC QLQ-C30 Fatigue
scale (change values)

26

26

7

13

13

4

7

7

2

4

4

1

2

2

0

2

2020

536

1289

178

952

112

925

36

119

0

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.32 [-0.47, -0.18]

Std. Mean Difference (IV, Random,
95% CI)

-0.43 [-0.60, -0.26]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.30 [-0.61, 0.00]

Std. Mean Difference (IV, Random,
95% CI)

-0.47 [-0.84, -0.11]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

1.14 [-0.06, 2.35]

Mean Difference (IV, Fixed, 95% CI)

1.49 [-1.95, 4.93]

Mean Difference (IV, Random, 95%
CI)

Subtotals only

Mean Difference (IV, Random, 95%
CI)

-0.54 [-3.23, 2.14]

Mean Difference (IV, Random, 95%
CI)

1.28 [-4.11, 6.67]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

-6.83 [-13.08, -0.58]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95%
CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

277

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

6.1 End of intervention

6.2 Follow-up

7 Multidimensional Fatigue
Symptom Inventory (fol-
low-up values)

7.1 End of intervention

7.2 Follow-up

8 Multidimensional Fatigue
Symptom Inventory - inter-
ference (follow-up values)

8.1 End of intervention

8.2 Follow-up

9 Revised Piper Fatigue Scale
total fatigue (follow-up val-
ues)

9.1 End of intervention

9.2 Follow-up

10 Revised Piper Fatigue
Scale total fatigue (change
values)

10.1 End of intervention

10.2 Follow-up

11 Revised Piper Fatigue
Scale behavioural/severity
(follow-up values)

11.1 End of intervention

11.2 Follow-up

2

0

5

5

3

2

2

0

4

4

2

4

4

2

3

3

1

73

0

366

304

62

0

187

120

166

120

121

61

Mean Difference (IV, Random, 95%
CI)

-2.81 [-14.98, 9.36]

Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95%
CI)

Subtotals only

Mean Difference (IV, Random, 95%
CI)

-0.53 [-1.35, 0.29]

Mean Difference (IV, Random, 95%
CI)

-2.04 [-4.30, 0.23]

Mean Difference (IV, Random, 95%
CI)

Subtotals only

Mean Difference (IV, Random, 95%
CI)

-0.37 [-1.34, 0.60]

Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95%
CI)

Subtotals only

Mean Difference (IV, Random, 95%
CI)

-1.18 [-2.38, 0.02]

Mean Difference (IV, Random, 95%
CI)

-1.15 [-1.86, -0.43]

Mean Difference (IV, Random, 95%
CI)

Subtotals only

Mean Difference (IV, Random, 95%
CI)

-1.96 [-2.93, 1.00]

Mean Difference (IV, Random, 95%
CI)

-1.14 [-1.78, -0.49]

Mean Difference (IV, Random, 95%
CI)

Subtotals only

Mean Difference (IV, Random, 95%
CI)

-1.24 [-2.49, 0.01]

Mean Difference (IV, Random, 95%
CI)

-1.41 [-2.57, -0.25]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

278

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

12 Revised Piper Fatigue
Scale affective/meaning (fol-
low-up values)

12.1 End of intervention

12.2 Follow-up

13 Revised Piper Fatigue
Scale sensory (follow-up val-
ues)

13.1 End of intervention

13.2 Follow-up

14 Revised Piper Fatigue
Scale cognitive/mood (fol-
low-up values)

14.1 End of intervention

14.2 Follow-up

15 Schwartz Cancer Fatigue
Scale (follow-up values)

15.1 End of intervention

15.2 Follow-up

16 POMS fatigue scale (fol-
low-up values)

16.1 End of intervention

16.2 Follow-up

17 Visual analogue scale fa-
tigue (follow-up and change
values)

17.1 End of intervention

17.2 Follow-up

3

3

1

3

3

1

3

3

1

2

2

0

2

2

1

4

4

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

-2.11 [-3.03, -1.20]

Mean Difference (IV, Fixed, 95% CI)

-2.05 [-3.21, -0.89]

Mean Difference (IV, Random, 95%
CI)

Subtotals only

Mean Difference (IV, Random, 95%
CI)

-0.44 [-3.11, 2.22]

Mean Difference (IV, Random, 95%
CI)

-1.60 [-2.65, -0.55]

Mean Difference (IV, Random, 95%
CI)

Subtotals only

Mean Difference (IV, Random, 95%
CI)

-0.72 [-2.31, 0.87]

Mean Difference (IV, Random, 95%
CI)

-1.40 [-2.50, -0.30]

Mean Difference (IV, Random, 95%
CI)

Subtotals only

Mean Difference (IV, Random, 95%
CI)

-2.01 [-9.25, 5.23]

Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Fixed, 95%
CI)

-0.54 [1.00, -0.08]

Std. Mean Difference (IV, Fixed, 95%
CI)

-0.57 [-1.08, -0.05]

Std. Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Fixed, 95%
CI)

-0.51 [-0.88, -0.14]

Std. Mean Difference (IV, Fixed, 95%
CI)

0.0 [0.0, 0.0]

121

61

121

61

121

61

125

0

79

61

148

22

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

279

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

18 Overall vigour/vitality (fol-
low-up values)

18.1 End of intervention

10

10

18.2 Follow-up

19 Overall vigour/vitality
(change values)

19.1 End of intervention

19.2 Follow-up

20 MOS SF vitality (follow-up
values)

20.1 End of intervention

20.2 Follow-up

21 MOS SF vitality (change
values)

21.1 End of intervention

21.2 Follow-up

22 POMS vigour scale (fol-
low-up values)

22.1 End of intervention

22.2 Follow-up

23 POMS vigour scale
(change values)

23.1 End of intervention

23.2 Follow-up

4

6

6

2

6

6

2

4

4

0

4

4

2

2

2

2

762

454

359

233

514

306

212

0

248

148

147

233

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.36 [0.21, 0.50]

Std. Mean Difference (IV, Random,
95% CI)

0.26 [0.04, 0.48]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.23 [0.00, 0.45]

Std. Mean Difference (IV, Random,
95% CI)

0.20 [-0.06, 0.46]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

3.08 [0.84, 5.31]

Mean Difference (IV, Fixed, 95% CI)

5.09 [0.99, 9.19]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

1.36 [-0.52, 3.25]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.46 [0.13, 0.79]

Std. Mean Difference (IV, Random,
95% CI)

0.21 [-0.34, 0.77]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.25 [-0.45, 0.95]

Std. Mean Difference (IV, Random,
95% CI)

0.20 [-0.06, 0.46]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

280

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.1.   Comparison 4 Comparison: fatigue and vigour, all physical
activity vs control, Outcome 1 Overall fatigue (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

4.1.1 End of intervention

Banasik 2011

Pinto 2003

Payne 2008

Rogers 2013

Loudon 2014

Bower 2011

Rogers 2009

Cuesta-Vargas 2014

Rogers 2014

Milne 2008

Cantarero-Villanueva 2013

Courneya 2003

Ergun 2013

Mehnert 2011

Littman 2012

Do 2015

Daley 2007

Winters-Stone 2011

Cadmus 2009

Pinto 2015

Pinto 2005

Loh 2014

Fillion 2008

Kiecolt-Glaser 2014

Vallance 2007

Short 2014

Subtotal ***

1 (0.9)

7.2 (6.4)

4.7 (2.6)

4.2 (1.8)

1.9 (2.2)

3.4 (1.8)

-12.4 (10.4)

4 (1.8)

4.1 (2.1)

11.9 (3.2)

3.8 (1.8)

-8.3 (7.9)

2.9 (2.2)

28.5 (25.6)

-45 (5.3)

16.8 (13.3)

2.1 (1.8)

45 (5.3)

-51.9 (9)

-43.8 (7.8)

27.1 (21.4)

-41.9 (6.5)

2.7 (0.7)

6.3 (19.6)

-42.7 (8.4)

-41.5 (9.3)

7

12

9

11

12

16

20

22

20

29

32

24

40

30

30

32

33

36

37

39

39

63

44

96

250

195

1178

Heterogeneity: Tau2=0.07; Chi2=53.85, df=25(P=0); I2=53.58%

Test for overall effect: Z=4.34(P<0.0001)

4.1.2 Follow-up

Bower 2011

Rogers 2009

Cantarero-Villanueva 2013

Daley 2007

Pinto 2015

Fillion 2008

Kiecolt-Glaser 2014

Subtotal ***

2.8 (2.3)

-13.8 (11.7)

4 (2.1)

2.4 (2)

-42.2 (7.8)

2.4 (0.8)

5.8 (19.6)

16

19

32

28

39

44

96

274

Heterogeneity: Tau2=0; Chi2=5.67, df=6(P=0.46); I2=0%

Test for overall effect: Z=4.88(P<0.0001)

1.6 (1)

9 (6.4)

3.5 (1.7)

4.2 (1.6)

2.1 (2.5)

4.9 (1.3)

-10.1 (6.6)

5.2 (3.2)

4 (1.8)

17.4 (4.7)

6.2 (1.7)

-8.8 (8.1)

3.3 (1.8)

39.9 (25.1)

-43.1 (10.3)

22.3 (15.1)

3.4 (1.9)

43.1 (10.3)

-50.6 (10)

-41.2 (8.5)

42.3 (26.2)

-40.4 (9.1)

2.9 (0.8)

12.7 (19)

-42.6 (8.7)

-39.8 (10.4)

4.7 (1.5)

-13.5 (11.3)

5.5 (1.8)

3.2 (2.2)

-40.4 (9.3)

2.8 (0.9)

14.7 (19)

7

6

9

9

11

15

18

20

22

29

29

28

20

27

27

30

33

31

37

37

43

32

43

90

85

104

842

15

17

29

31

37

43

90

262

1.49%

1.72%

1.84%

2.04%

2.27%

2.59%

3.16%

3.32%

3.38%

3.59%

3.67%

3.8%

3.85%

3.94%

3.98%

4.13%

4.16%

4.3%

4.52%

4.55%

4.63%

4.79%

4.83%

6.16%

6.61%

6.69%

100%

5.28%

6.91%

10.92%

11.12%

14.53%

16.41%

34.82%

100%

-0.57[-1.65,0.51]

-0.27[-1.26,0.71]

0.52[-0.42,1.46]

0[-0.88,0.88]

-0.07[-0.89,0.75]

-0.93[-1.67,-0.18]

-0.26[-0.9,0.38]

-0.46[-1.07,0.15]

0.05[-0.56,0.66]

-1.35[-1.92,-0.78]

-1.38[-1.94,-0.82]

0.06[-0.48,0.61]

-0.17[-0.71,0.37]

-0.44[-0.97,0.08]

-0.23[-0.75,0.29]

-0.38[-0.89,0.12]

-0.71[-1.21,-0.21]

0.23[-0.25,0.72]

-0.14[-0.59,0.32]

-0.32[-0.77,0.14]

-0.63[-1.07,-0.18]

-0.21[-0.63,0.22]

-0.27[-0.69,0.15]

-0.33[-0.62,-0.04]

-0.01[-0.26,0.23]

-0.17[-0.41,0.06]

-0.32[-0.47,-0.18]

-0.95[-1.69,-0.2]

-0.03[-0.68,0.63]

-0.74[-1.26,-0.21]

-0.37[-0.89,0.14]

-0.21[-0.66,0.24]

-0.39[-0.82,0.03]

-0.46[-0.75,-0.17]

-0.43[-0.6,-0.26]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

281

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.2.   Comparison 4 Comparison: fatigue and vigour, all
physical activity vs control, Outcome 2 Overall fatigue (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

4.2.1 End of intervention

Herrero 2006

Payne 2008

Naumann 2012

Rogers 2013

Loudon 2014

Rogers 2009

Courneya 2003

Cantarero-Villanueva 2013

Mehnert 2011

Daley 2007

Pinto 2005

Vallance 2007

Saarto 2012

Subtotal ***

-4.2 (19.6)

-0.9 (2)

-3.6 (4.4)

4.2 (2)

1.9 (2.2)

1.9 (9.6)

9.3 (10.2)

-2 (1.8)

-0.7 (20.7)

2.1 (1.8)

-14.9 (23.5)

2.5 (8.2)

-2.4 (9.1)

8

9

11

11

12

20

24

32

30

33

39

250

263

742

8

9

10

9

11

18

28

29

27

33

43

85

237

547

6.4 (14.5)

0.5 (1.4)

2 (4.6)

3.9 (1.5)

2.1 (2.5)

4.2 (12.3)

2 (7.5)

0.3 (1.4)

-2.9 (25.3)

3.4 (1.9)

1.8 (23.5)

1.2 (6.6)

-2.4 (8.6)

Heterogeneity: Tau2=0.21; Chi2=59.54, df=12(P<0.0001); I2=79.85%

Test for overall effect: Z=1.94(P=0.05)

4.2.2 Follow-up

Pinto 2005

Rogers 2009

Cantarero-Villanueva 2013

Daley 2007

Subtotal ***

3 (0)

-0.1 (7.8)

-1.8 (2)

2.4 (2)

8

19

32

28

87

14

17

29

31

91

4.6 (0)

1.2 (8.6)

-0.4 (1.2)

3.2 (2.2)

Heterogeneity: Tau2=0.02; Chi2=2.61, df=2(P=0.27); I2=23.32%

Test for overall effect: Z=2.52(P=0.01)

5.1%

5.3%

5.45%

5.85%

6.28%

7.62%

8.17%

8.17%

8.57%

8.75%

9.16%

10.6%

10.97%

100%

25.83%

36.66%

37.51%

100%

-0.58[-1.59,0.43]

-0.82[-1.79,0.15]

-1.21[-2.16,-0.26]

0.16[-0.72,1.04]

-0.07[-0.89,0.75]

-0.21[-0.84,0.43]

0.81[0.24,1.38]

-1.45[-2.02,-0.88]

0.09[-0.43,0.61]

-0.71[-1.21,-0.21]

-0.7[-1.15,-0.26]

0.17[-0.08,0.42]

0[-0.18,0.18]

-0.3[-0.61,0]

Not estimable

-0.15[-0.81,0.5]

-0.81[-1.33,-0.28]

-0.37[-0.89,0.14]

-0.47[-0.84,-0.11]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 4.3.   Comparison 4 Comparison: fatigue and vigour, all
physical activity vs control, Outcome 3 FACT-Fatigue (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

4.3.1 End of intervention

Rogers 2009

Courneya 2003

Littman 2012

Pinto 2015

Loh 2014

Short 2014

Vallance 2007

Subtotal ***

12.4 (10.4)

8.3 (7.9)

45 (5.3)

43.8 (7.8)

41.9 (6.5)

41.5 (9.3)

42.7 (8.4)

20

24

30

39

63

195

250

621

10.1 (6.6)

8.8 (8.1)

43.1 (10.3)

41.2 (8.5)

40.4 (9.1)

39.8 (10.4)

42.6 (8.7)

18

28

27

37

32

104

85

331

Heterogeneity: Tau2=0; Chi2=2.64, df=6(P=0.85); I2=0%

Test for overall effect: Z=1.86(P=0.06)

4.81%

7.62%

7.74%

10.73%

11.6%

25.38%

32.11%

100%

2.3[-3.18,7.78]

-0.5[-4.86,3.86]

1.9[-2.42,6.22]

2.61[-1.06,6.28]

1.56[-1.97,5.09]

1.7[-0.69,4.09]

0.1[-2.02,2.22]

1.14[-0.06,2.35]

4.3.2 Follow-up

Rogers 2009

19

13.8 (11.7)

17

13.5 (11.3)

20.93%

0.3[-7.22,7.82]

Favours control

-20

-10

0

10

20

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

282

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Physical activity

Control

Pinto 2015

Subtotal ***

N

Mean(SD)

N

Mean(SD)

42.2 (7.8)

39

58

40.4 (9.3)

37

54

Heterogeneity: Tau2=0; Chi2=0.12, df=1(P=0.73); I2=0%

Test for overall effect: Z=0.85(P=0.4)

Cochrane Database of Systematic Reviews

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

79.07%

100%

Fixed, 95% CI

1.8[-2.07,5.67]

1.49[-1.95,4.93]

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 4.4.   Comparison 4 Comparison: fatigue and vigour, all
physical activity vs control, Outcome 4 FACT-Fatigue (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

4.4.1 End of intervention

Rogers 2009

Courneya 2003

Vallance 2007

Saarto 2012

Subtotal ***

-1.9 (9.6)

-9.3 (10.2)

2.5 (8.2)

2.4 (9.1)

20

24

250

263

557

Heterogeneity: Tau2=4.51; Chi2=10.93, df=3(P=0.01); I2=72.55%

Test for overall effect: Z=0.39(P=0.69)

4.4.2 Follow-up

Rogers 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.47(P=0.64)

0.1 (7.8)

19

19

-4.2 (12.3)

-2 (7.5)

1.2 (6.6)

2.4 (8.6)

-1.2 (8.6)

18

28

85

237

368

17

17

10.71%

17.29%

35.46%

36.54%

100%

2.3[-4.77,9.37]

-7.3[-12.24,-2.36]

1.34[-0.39,3.07]

0[-1.55,1.55]

-0.54[-3.23,2.14]

100%

100%

1.28[-4.11,6.67]

1.28[-4.11,6.67]

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 4.5.   Comparison 4 Comparison: fatigue and vigour, all physical
activity vs control, Outcome 5 EORTC QLQ-C30 Fatigue scale (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

4.5.1 End of intervention

Mehnert 2011

Do 2015

Subtotal ***

28.5 (25.6)

16.8 (13.3)

30

32

62

Heterogeneity: Tau2=0; Chi2=0.6, df=1(P=0.44); I2=0%

Test for overall effect: Z=2.14(P=0.03)

4.5.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

39.9 (25.1)

22.3 (15.1)

27

30

57

0

22.54%

77.46%

100%

-11.4[-24.57,1.77]

-5.5[-12.6,1.6]

-6.83[-13.08,-0.58]

Not estimable

Favours physical activity

-50

-25

0

25

50

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

283

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.6.   Comparison 4 Comparison: fatigue and vigour, all physical
activity vs control, Outcome 6 EORTC QLQ-C30 Fatigue scale (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

4.6.1 End of intervention

Herrero 2006

Mehnert 2011

Subtotal ***

-4.2 (19.6)

-0.7 (20.7)

8

30

38

Heterogeneity: Tau2=24.99; Chi2=1.44, df=1(P=0.23); I2=30.79%

Test for overall effect: Z=0.45(P=0.65)

4.6.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

6.4 (14.5)

-2.9 (25.3)

8

27

35

0

38.83%

61.17%

100%

-10.6[-27.49,6.29]

2.14[-9.95,14.23]

-2.81[-14.98,9.36]

Not estimable

Favours physical activity

-50

-25

0

25

50

Favours control

Analysis 4.7.   Comparison 4 Comparison: fatigue and vigour, all physical activity vs
control, Outcome 7 Multidimensional Fatigue Symptom Inventory (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

4.7.1 End of intervention

Kiecolt-Glaser 2014

Rogers 2013

Rogers 2014

Bower 2011

Fillion 2008

Subtotal ***

6.3 (19.6)

4.2 (1.8)

4.1 (2.1)

3.4 (1.8)

2.7 (0.7)

96

11

20

16

44

187

Heterogeneity: Tau2=0.45; Chi2=10.1, df=4(P=0.04); I2=60.4%

Test for overall effect: Z=1.27(P=0.2)

4.7.2 Follow-up

Kiecolt-Glaser 2014

Bower 2011

Fillion 2008

Subtotal ***

5.8 (19.6)

2.8 (2.3)

2.4 (0.8)

96

16

44

156

Heterogeneity: Tau2=2.81; Chi2=13.52, df=2(P=0); I2=85.21%

Test for overall effect: Z=1.76(P=0.08)

12.7 (19)

4.2 (1.6)

4 (1.8)

4.9 (1.3)

2.9 (0.8)

14.7 (19)

4.7 (1.5)

2.8 (0.9)

90

9

22

15

43

179

90

15

43

148

2.06%

16.98%

21.39%

22.86%

36.7%

100%

12.36%

40.64%

46.99%

100%

-6.4[-11.94,-0.86]

0[-1.49,1.49]

0.1[-1.09,1.29]

-1.5[-2.6,-0.4]

-0.21[-0.54,0.12]

-0.53[-1.35,0.29]

-8.9[-14.44,-3.36]

-1.9[-3.26,-0.54]

-0.35[-0.72,0.02]

-2.04[-4.3,0.23]

Favours physical activity

-20

-10

0

10

20

Favours control

Analysis 4.8.   Comparison 4 Comparison: fatigue and vigour, all physical activity vs control,
Outcome 8 Multidimensional Fatigue Symptom Inventory - interference (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

4.8.1 End of intervention

Rogers 2013

11

2.6 (1.5)

9

2.4 (1.1)

42.86%

0.2[-0.94,1.34]

Favours physical activity

-10

-5

0

5

10

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

284

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Rogers 2014

Subtotal ***

1.8 (0.8)

20

31

Heterogeneity: Tau2=0.23; Chi2=1.87, df=1(P=0.17); I2=46.49%

Test for overall effect: Z=0.75(P=0.45)

4.8.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

2.6 (1.9)

22

31

0

Cochrane Database of Systematic Reviews

Weight

Mean Difference

57.14%

100%

Random, 95% CI

-0.8[-1.67,0.07]

-0.37[-1.34,0.6]

Not estimable

Favours physical activity

-10

-5

0

5

10

Favours control

Analysis 4.9.   Comparison 4 Comparison: fatigue and vigour, all physical activity
vs control, Outcome 9 Revised Piper Fatigue Scale total fatigue (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

4.9.1 End of intervention

Payne 2008

Cuesta-Vargas 2014

Cantarero-Villanueva 2013

Daley 2007

Subtotal ***

4.7 (2.6)

4 (1.8)

3.8 (1.8)

2.1 (1.8)

9

22

32

33

96

Heterogeneity: Tau2=1.05; Chi2=11.59, df=3(P=0.01); I2=74.11%

Test for overall effect: Z=1.93(P=0.05)

4.9.2 Follow-up

Daley 2007

Cantarero-Villanueva 2013

Subtotal ***

2.4 (2)

4 (2.1)

28

32

60

Heterogeneity: Tau2=0; Chi2=0.86, df=1(P=0.35); I2=0%

Test for overall effect: Z=3.13(P=0)

3.5 (1.7)

5.2 (3.2)

6.2 (1.7)

3.4 (1.9)

3.2 (2.2)

5.5 (1.8)

9

20

29

33

91

31

29

60

17.71%

22%

30.09%

30.2%

100%

1.2[-0.83,3.23]

-1.2[-2.79,0.39]

-2.45[-3.33,-1.57]

-1.3[-2.17,-0.43]

-1.18[-2.38,0.02]

46.32%

53.68%

100%

-0.78[-1.83,0.27]

-1.46[-2.44,-0.48]

-1.15[-1.86,-0.43]

Favours physical activity

-10

-5

0

5

10

Favours control

Analysis 4.10.   Comparison 4 Comparison: fatigue and vigour, all physical activity
vs control, Outcome 10 Revised Piper Fatigue Scale total fatigue (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

4.10.1 End of intervention

Naumann 2012

Payne 2008

Daley 2007

Cantarero-Villanueva 2013

Subtotal ***

-3.6 (4.4)

-0.9 (2)

2.1 (1.8)

-2 (1.8)

11

9

33

32

85

10

9

33

29

81

2 (4.6)

0.5 (1.4)

3.4 (1.9)

0.3 (1.4)

Heterogeneity: Tau2=0.49; Chi2=6.96, df=3(P=0.07); I2=56.87%

Test for overall effect: Z=3.98(P<0.0001)

5.7%

21.66%

35.4%

37.24%

100%

-5.6[-9.42,-1.78]

-1.45[-3.01,0.11]

-1.3[-2.17,-0.43]

-2.34[-3.13,-1.55]

-1.96[-2.93,-1]

Favours physical activity

-20

-10

0

10

20

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

285

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

4.10.2 Follow-up

Daley 2007

Cantarero-Villanueva 2013

Subtotal ***

28

32

60

2.4 (2)

-1.8 (2)

31

29

60

3.2 (2.2)

-0.4 (1.2)

Heterogeneity: Tau2=0; Chi2=0.71, df=1(P=0.4); I2=0%

Test for overall effect: Z=3.47(P=0)

37.22%

62.78%

100%

-0.78[-1.83,0.27]

-1.35[-2.16,-0.54]

-1.14[-1.78,-0.49]

Favours physical activity

-20

-10

0

10

20

Favours control

Analysis 4.11.   Comparison 4 Comparison: fatigue and vigour, all physical activity vs
control, Outcome 11 Revised Piper Fatigue Scale behavioural/severity (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

4.11.1 End of intervention

Payne 2008

Cantarero-Villanueva 2013

Cuesta-Vargas 2014

Subtotal ***

3.4 (3.2)

3.8 (2)

3.7 (0.9)

9

32

22

63

Heterogeneity: Tau2=0.79; Chi2=6.52, df=2(P=0.04); I2=69.35%

Test for overall effect: Z=1.94(P=0.05)

4.11.2 Follow-up

Cantarero-Villanueva 2013

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.39(P=0.02)

4 (2.2)

32

32

2.9 (1.8)

6.1 (1.8)

4.7 (1.7)

5.5 (2.4)

9

29

20

58

29

29

17.87%

40.03%

42.1%

100%

0.5[-1.9,2.9]

-2.27[-3.22,-1.32]

-1[-1.84,-0.16]

-1.24[-2.49,0.01]

100%

100%

-1.41[-2.57,-0.25]

-1.41[-2.57,-0.25]

Favours physical activity

-10

-5

0

5

10

Favours control

Analysis 4.12.   Comparison 4 Comparison: fatigue and vigour, all physical activity vs
control, Outcome 12 Revised Piper Fatigue Scale affective/meaning (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

4.12.1 End of intervention

Cuesta-Vargas 2014

Payne 2008

Cantarero-Villanueva 2013

Subtotal ***

4.2 (6.3)

5.8 (2.2)

3.8 (2.3)

22

9

32

63

Heterogeneity: Tau2=0; Chi2=11.13, df=2(P=0); I2=82.03%

Test for overall effect: Z=4.52(P<0.0001)

4.12.2 Follow-up

Cantarero-Villanueva 2013

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=3.47(P=0)

4.4 (2.4)

32

32

6.1 (3)

4.8 (2.3)

6.8 (2)

6.5 (2.2)

20

9

29

58

29

29

9.64%

19.39%

70.97%

100%

-1.9[-4.85,1.05]

1[-1.08,3.08]

-2.99[-4.08,-1.9]

-2.11[-3.03,-1.2]

100%

100%

-2.05[-3.21,-0.89]

-2.05[-3.21,-0.89]

Favours physical activity

-10

-5

0

5

10

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

286

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.13.   Comparison 4 Comparison: fatigue and vigour, all physical activity
vs control, Outcome 13 Revised Piper Fatigue Scale sensory (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

4.13.1 End of intervention

Cuesta-Vargas 2014

Payne 2008

Cantarero-Villanueva 2013

Subtotal ***

4.8 (5.2)

5.9 (2.3)

3.9 (1.9)

22

9

32

63

Heterogeneity: Tau2=4.66; Chi2=13.83, df=2(P=0); I2=85.54%

Test for overall effect: Z=0.32(P=0.75)

4.13.2 Follow-up

Cantarero-Villanueva 2013

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.99(P=0)

4.1 (2.3)

32

32

5.3 (2.4)

4.1 (2)

6.3 (2.1)

5.7 (1.9)

20

9

29

58

29

29

29.98%

32.45%

37.57%

100%

-0.5[-2.9,1.9]

1.8[-0.19,3.79]

-2.33[-3.32,-1.34]

-0.44[-3.11,2.22]

100%

100%

-1.6[-2.65,-0.55]

-1.6[-2.65,-0.55]

Favours physical activity

-10

-5

0

5

10

Favours control

Analysis 4.14.   Comparison 4 Comparison: fatigue and vigour, all physical activity vs
control, Outcome 14 Revised Piper Fatigue Scale cognitive/mood (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

4.14.1 End of intervention

Cuesta-Vargas 2014

Payne 2008

Cantarero-Villanueva 2013

Subtotal ***

5.1 (4.5)

2.9 (1.8)

3.8 (1.9)

22

9

32

63

Heterogeneity: Tau2=1.29; Chi2=5.94, df=2(P=0.05); I2=66.33%

Test for overall effect: Z=0.89(P=0.37)

4.14.2 Follow-up

Cantarero-Villanueva 2013

Subtotal ***

3.7 (2)

32

32

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=2.49(P=0.01)

5.3 (2.4)

2.5 (1.9)

5.7 (2.3)

5.1 (2.4)

20

9

29

58

29

29

26.34%

31.98%

41.68%

100%

-0.2[-2.35,1.95]

0.4[-1.31,2.11]

-1.91[-2.95,-0.87]

-0.72[-2.31,0.87]

100%

100%

-1.4[-2.5,-0.3]

-1.4[-2.5,-0.3]

Favours physical activity

-10

-5

0

5

10

Favours control

Analysis 4.15.   Comparison 4 Comparison: fatigue and vigour, all physical activity
vs control, Outcome 15 Schwartz Cancer Fatigue Scale (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

4.15.1 End of intervention

Winters-Stone 2011

36

45 (5.3)

31

43.1 (10.3)

47.18%

1.9[-2.12,5.92]

Favours physical activity

-20

-10

0

10

20

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

287

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Milne 2008

Subtotal ***

11.9 (3.2)

29

65

Heterogeneity: Tau2=24.72; Chi2=10.3, df=1(P=0); I2=90.29%

Test for overall effect: Z=0.54(P=0.59)

4.15.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

17.4 (4.7)

29

60

0

Cochrane Database of Systematic Reviews

Weight

Mean Difference

52.82%

100%

Random, 95% CI

-5.5[-7.57,-3.43]

-2.01[-9.25,5.23]

Not estimable

Favours physical activity

-20

-10

0

10

20

Favours control

Analysis 4.16.   Comparison 4 Comparison: fatigue and vigour, all physical
activity vs control, Outcome 16 POMS fatigue scale (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

4.16.1 End of intervention

Pinto 2003

Cantarero-Villanueva 2013

Subtotal ***

7.2 (6.4)

47.8 (8.1)

12

32

44

Heterogeneity: Tau2=0; Chi2=0.35, df=1(P=0.55); I2=0%

Test for overall effect: Z=2.31(P=0.02)

4.16.2 Follow-up

Cantarero-Villanueva 2013

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.17(P=0.03)

47.4 (10.6)

32

32

9 (6.4)

53.3 (9.8)

53.3 (9.8)

6

29

35

29

29

21.45%

78.55%

100%

-0.27[-1.26,0.71]

-0.61[-1.13,-0.1]

-0.54[-1,-0.08]

100%

100%

-0.57[-1.08,-0.05]

-0.57[-1.08,-0.05]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 4.17.   Comparison 4 Comparison: fatigue and vigour, all physical activity
vs control, Outcome 17 Visual analogue scale fatigue (follow-up and change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

4.17.1 End of intervention

Carson 2009

Banasik 2011

Loudon 2014

Pinto 2005

Subtotal ***

2.9 (0)

1 (0.9)

1.9 (2.2)

27.1 (21.4)

12

7

12

39

70

Heterogeneity: Tau2=0; Chi2=1.37, df=2(P=0.5); I2=0%

Test for overall effect: Z=2.71(P=0.01)

4.17.2 Follow-up

Pinto 2005

Subtotal ***

8

8

3 (0)

4.3 (0)

1.6 (1)

2.1 (2.5)

42.3 (26.2)

4.6 (0)

17

7

11

43

78

14

14

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

11.62%

20.12%

68.25%

100%

Not estimable

-0.57[-1.65,0.51]

-0.07[-0.89,0.75]

-0.63[-1.07,-0.18]

-0.51[-0.88,-0.14]

Not estimable

Not estimable

288

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 4.18.   Comparison 4 Comparison: fatigue and vigour, all physical
activity vs control, Outcome 18 Overall vigour/vitality (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

4.18.1 End of intervention

Pinto 2003

Mustian 2004

Basen-Enquist 2006

Mehnert 2011

Cantarero-Villanueva 2013

Cadmus 2009

Pinto 2005

Fillion 2008

Duijits 2012

Kiecolt-Glaser 2014

Subtotal ***

12

9

28

30

32

37

39

44

37

96

17.8 (6.4)

15.2 (5.4)

60.9 (11.6)

64.2 (17.1)

51.6 (7.2)

51.9 (9)

20.6 (5.7)

2.4 (0.7)

65.2 (16.8)

58.7 (18.6)

6

10

23

28

29

37

43

43

89

90

14.2 (7.3)

15.2 (4.7)

58.1 (12)

56.1 (19.6)

50.5 (7.6)

50.6 (10)

15.8 (5.4)

2.1 (0.9)

59.7 (16.4)

52.3 (16.1)

364

398

Heterogeneity: Tau2=0; Chi2=7.11, df=9(P=0.63); I2=0%

Test for overall effect: Z=4.78(P<0.0001)

4.18.2 Follow-up

Cantarero-Villanueva 2013

Fillion 2008

Duijits 2012

Kiecolt-Glaser 2014

Subtotal ***

50.3 (9.4)

2.6 (0.7)

61.2 (18.5)

58.1 (18.6)

32

44

36

96

208

29

43

84

90

246

51.1 (8.2)

2.2 (0.9)

59 (18)

51.6 (16.1)

Heterogeneity: Tau2=0.01; Chi2=3.93, df=3(P=0.27); I2=23.63%

Test for overall effect: Z=2.27(P=0.02)

2.14%

2.62%

6.95%

7.83%

8.4%

10.23%

10.35%

11.87%

14.31%

25.31%

100%

16.41%

21.48%

24.63%

37.47%

100%

0.51[-0.49,1.51]

0[-0.9,0.9]

0.23[-0.32,0.79]

0.44[-0.09,0.96]

0.16[-0.35,0.66]

0.14[-0.32,0.59]

0.85[0.4,1.31]

0.34[-0.09,0.76]

0.33[-0.06,0.72]

0.37[0.08,0.66]

0.36[0.21,0.5]

-0.09[-0.59,0.41]

0.48[0.05,0.91]

0.12[-0.27,0.51]

0.37[0.08,0.66]

0.26[0.04,0.48]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 4.19.   Comparison 4 Comparison: fatigue and vigour, all physical
activity vs control, Outcome 19 Overall vigour/vitality (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

4.19.1 End of intervention

Mustian 2004

Cormie 2014

Mehnert 2011

Cantarero-Villanueva 2013

Cadmus 2009

Pinto 2005

Subtotal ***

2 (4)

3.4 (8.4)

6.9 (16.7)

-1.9 (17.3)

1.6 (6.6)

2.5 (6.8)

9

43

30

32

37

43

194

9

19

28

29

37

43

165

0.4 (2.1)

1 (8.1)

4 (19)

-0.4 (5.7)

1.2 (7.1)

-1.3 (6)

5.48%

15.49%

16.96%

17.75%

21.14%

23.17%

100%

0.48[-0.46,1.42]

0.29[-0.26,0.83]

0.16[-0.36,0.68]

-0.12[-0.62,0.39]

0.06[-0.4,0.51]

0.6[0.16,1.03]

0.23[0,0.45]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

289

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Heterogeneity: Tau2=0.01; Chi2=5.53, df=5(P=0.35); I2=9.63%

Test for overall effect: Z=1.99(P=0.05)

4.19.2 Follow-up

Cantarero-Villanueva 2013

Pinto 2005

Subtotal ***

32

86

118

0.6 (8.2)

1.1 (6.8)

29

86

115

0.2 (3.6)

-0.6 (6.3)

Heterogeneity: Tau2=0; Chi2=0.42, df=1(P=0.52); I2=0%

Test for overall effect: Z=1.5(P=0.13)

26.28%

73.72%

100%

0.05[-0.45,0.56]

0.25[-0.05,0.55]

0.2[-0.06,0.46]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 4.20.   Comparison 4 Comparison: fatigue and vigour, all physical
activity vs control, Outcome 20 MOS SF vitality (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

4.20.1 End of intervention

Mehnert 2011

Basen-Enquist 2006

Duijits 2012

Kiecolt-Glaser 2014

Mustian 2004

Cadmus 2009

Subtotal ***

64.2 (17.1)

60.9 (11.6)

65.2 (16.8)

58.7 (18.6)

15.2 (5.4)

51.9 (9)

30

28

37

96

9

37

237

Heterogeneity: Tau2=0; Chi2=5.68, df=5(P=0.34); I2=11.96%

Test for overall effect: Z=2.7(P=0.01)

4.20.2 Follow-up

Duijits 2012

Kiecolt-Glaser 2014

Subtotal ***

61.2 (18.5)

58.1 (18.6)

36

96

132

Heterogeneity: Tau2=0; Chi2=0.94, df=1(P=0.33); I2=0%

Test for overall effect: Z=2.43(P=0.02)

56.1 (19.6)

58.1 (12)

59.7 (16.4)

52.3 (16.1)

15.2 (4.7)

50.6 (10)

59 (18)

51.6 (16.1)

28

23

89

90

10

37

277

84

90

174

5.56%

11.74%

12.19%

20.02%

23.88%

26.61%

100%

32.71%

67.29%

100%

8.09[-1.39,17.57]

2.8[-3.73,9.33]

5.48[-0.92,11.88]

6.4[1.4,11.4]

0.02[-4.56,4.6]

1.3[-3.03,5.63]

3.08[0.84,5.31]

2.18[-4.99,9.35]

6.5[1.5,11.5]

5.09[0.99,9.19]

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 4.21.   Comparison 4 Comparison: fatigue and vigour, all
physical activity vs control, Outcome 21 MOS SF vitality (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

4.21.1 End of intervention

Mehnert 2011

Cormie 2014

Cadmus 2009

Mustian 2004

Subtotal ***

6.9 (16.7)

3.4 (8.4)

1.6 (6.6)

2 (4)

30

43

37

9

119

28

19

37

9

93

4 (19)

1 (8.1)

1.2 (7.1)

0.4 (2.1)

Heterogeneity: Tau2=0; Chi2=0.71, df=3(P=0.87); I2=0%

4.18%

18.12%

36.46%

41.25%

100%

2.9[-6.33,12.13]

2.41[-2.02,6.84]

0.4[-2.72,3.52]

1.6[-1.34,4.54]

1.36[-0.52,3.25]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

290

Favours control

-20

-10

0

10

20

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

Test for overall effect: Z=1.42(P=0.16)

4.21.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 4.22.   Comparison 4 Comparison: fatigue and vigour, all physical
activity vs control, Outcome 22 POMS vigour scale (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

4.22.1 End of intervention

Pinto 2003

Cantarero-Villanueva 2013

Pinto 2005

Fillion 2008

Subtotal ***

17.8 (6.4)

51.6 (7.2)

20.6 (5.7)

2.4 (0.7)

12

32

39

44

127

Heterogeneity: Tau2=0.04; Chi2=4.63, df=3(P=0.2); I2=35.26%

Test for overall effect: Z=2.74(P=0.01)

4.22.2 Follow-up

Cantarero-Villanueva 2013

Fillion 2008

Subtotal ***

50.3 (9.4)

2.6 (0.7)

32

44

76

Heterogeneity: Tau2=0.11; Chi2=2.87, df=1(P=0.09); I2=65.11%

Test for overall effect: Z=0.75(P=0.45)

14.2 (7.3)

50.5 (7.6)

15.8 (5.4)

2.1 (0.9)

51.1 (8.2)

2.2 (0.9)

6

29

43

43

121

29

43

72

9.52%

26.96%

30.54%

32.99%

100%

0.51[-0.49,1.51]

0.16[-0.35,0.66]

0.85[0.4,1.31]

0.34[-0.09,0.76]

0.46[0.13,0.79]

47.16%

52.84%

100%

-0.09[-0.59,0.41]

0.48[0.05,0.91]

0.21[-0.34,0.77]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 4.23.   Comparison 4 Comparison: fatigue and vigour, all physical
activity vs control, Outcome 23 POMS vigour scale (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

4.23.1 End of intervention

Cantarero-Villanueva 2013

Pinto 2005

Subtotal ***

-1.9 (17.3)

2.5 (6.8)

32

43

75

Heterogeneity: Tau2=0.2; Chi2=4.46, df=1(P=0.03); I2=77.58%

Test for overall effect: Z=0.71(P=0.48)

4.23.2 Follow-up

Cantarero-Villanueva 2013

Pinto 2005

Subtotal ***

0.6 (8.2)

1.1 (6.8)

32

86

118

Heterogeneity: Tau2=0; Chi2=0.42, df=1(P=0.52); I2=0%

-0.4 (5.7)

-1.3 (6)

0.2 (3.6)

-0.6 (6.3)

29

43

72

29

86

115

48.32%

51.68%

100%

-0.12[-0.62,0.39]

0.6[0.16,1.03]

0.25[-0.45,0.95]

26.28%

73.72%

100%

0.05[-0.45,0.56]

0.25[-0.05,0.55]

0.2[-0.06,0.46]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

291

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for overall effect: Z=1.5(P=0.13)

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Comparison 5.   Comparison: pain/disability, all physical activity vs control

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Overall pain/disability
(follow-up values)

1.1 End of intervention

1.2 Follow-up

2 Overall pain/disability
(change values)

2.1 End of intervention

2.2 Follow-up

3 Brief Pain Inventory sever-
ity score (change values)

3.1 End of intervention

3.2 Follow-up

4 Brief Pain Inventory inter-
ference score (change val-
ues)

4.1 End of intervention

4.2 Follow-up

5 DASH (follow-up and
change values)

5.1 End of intervention

5.2 Follow-up

6 EORTC QLQ-C30 Pain scale
(follow-up and change val-
ues)

6.1 End of intervention

9

9

1

6

5

1

2

2

0

2

2

0

3

3

0

2

2

535

162

296

36

145

0

145

0

179

0

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.08 [-0.09, 0.25]

Std. Mean Difference (IV, Random, 95%
CI)

0.19 [-0.12, 0.50]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.08 [-0.33, 0.16]

Std. Mean Difference (IV, Random, 95%
CI)

0.22 [-0.43, 0.88]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-0.84 [-1.92, 0.23]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-1.08 [-1.91, -0.24]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

-4.00 [-9.08, -2.91]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

119

Mean Difference (IV, Fixed, 95% CI)

-1.04 [-9.83, 7.75]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

292

 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

6.2 Follow-up

7 MOS SF Pain (follow-up
values)

7.1 End of intervention

7.2 Follow-up

8 MOS SF Pain (change val-
ues)

8.1 End of intervention

8.2 Follow-up

9 WOMAC joint pain (fol-
low-up and change values)

9.1 End of intervention

9.2 Follow-up

10 WOMAC physical dys-
function (follow-up and
change values)

10.1 End of intervention

10.2 Follow-up

11 WOMAC total score (fol-
low-up and change values)

11.1 End of intervention

11.2 Follow-up

0

5

5

1

4

4

0

2

2

0

2

2

0

2

2

0

0

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

Subtotals only

378

162

213

0

121

0

121

0

121

0

Mean Difference (IV, Random, 95% CI)

1.25 [-1.40, 3.90]

Mean Difference (IV, Random, 95% CI)

4.45 [-2.80, 11.70]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

0.07 [-1.04, 1.17]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-2.36 [-7.55, 2.82]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-6.15 [-16.21, 3.92]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-6.49 [-13.57, 0.58]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Analysis 5.1.   Comparison 5 Comparison: pain/disability, all physical
activity vs control, Outcome 1 Overall pain/disability (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

5.1.1 End of intervention

Mustian 2004

Loudon 2014

Portela 2008

Rogers 2009

Basen-Enquist 2006

Mehnert 2011

9

12

25

20

28

30

9.1 (1.4)

0.8 (1.5)

-20.6 (20.2)

-3 (3)

79.7 (10.6)

79.4 (23.1)

10

11

9

18

23

28

9.1 (1.7)

1.4 (2.2)

-20.8 (15.5)

-2.3 (2.8)

72.1 (11.5)

73.5 (24.8)

3.63%

4.33%

5.07%

7.19%

9.11%

11.01%

0.01[-0.89,0.91]

-0.33[-1.15,0.5]

0.01[-0.75,0.77]

-0.26[-0.89,0.38]

0.68[0.11,1.25]

0.24[-0.27,0.76]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

293

 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Do 2015

Cadmus 2009

Duijits 2012

Subtotal ***

21.1 (24.6)

50.3 (9.1)

79.3 (23.6)

32

37

87

280

30

37

89

255

16.5 (26.7)

50.8 (9)

78.8 (23.8)

Heterogeneity: Tau2=0; Chi2=7.35, df=8(P=0.5); I2=0%

Test for overall effect: Z=0.88(P=0.38)

11.81%

14.16%

33.7%

100%

0.18[-0.32,0.68]

-0.05[-0.51,0.4]

0.02[-0.28,0.32]

0.08[-0.09,0.25]

5.1.2 Follow-up

Duijits 2012

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.19(P=0.23)

79.1 (23.4)

79

79

83

83

74.6 (23.7)

100%

100%

0.19[-0.12,0.5]

0.19[-0.12,0.5]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 5.2.   Comparison 5 Comparison: pain/disability, all physical
activity vs control, Outcome 2 Overall pain/disability (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

5.2.1 End of intervention

Mustian 2004

Cormie 2014

Mehnert 2011

Cadmus 2009

Irwin 2015

Subtotal ***

-0.2 (1.3)

3.4 (6.5)

-2.4 (25)

-2.2 (11.3)

-6 (19)

9

43

30

37

45

164

Heterogeneity: Tau2=0; Chi2=4.22, df=4(P=0.38); I2=5.19%

Test for overall effect: Z=0.69(P=0.49)

5.2.2 Follow-up

Rogers 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.67(P=0.5)

-0.8 (1.4)

19

19

0 (1.4)

2 (6.2)

-7.6 (25.2)

-0.1 (7)

0.7 (18.6)

-1.8 (6.2)

10

19

28

37

38

132

17

17

6.96%

18.71%

20.45%

25.72%

28.16%

100%

-0.15[-1.06,0.75]

0.22[-0.33,0.76]

0.21[-0.31,0.72]

-0.22[-0.68,0.24]

-0.35[-0.79,0.08]

-0.08[-0.33,0.16]

100%

100%

0.22[-0.43,0.88]

0.22[-0.43,0.88]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 5.3.   Comparison 5 Comparison: pain/disability, all physical activity
vs control, Outcome 3 Brief Pain Inventory severity score (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

5.3.1 End of intervention

Irwin 2015

Cormie 2014

Subtotal ***

-1.1 (1.7)

-0.3 (1.1)

45

43

88

38

19

57

0.3 (1.5)

0 (1.3)

Heterogeneity: Tau2=0.49; Chi2=5.21, df=1(P=0.02); I2=80.79%

Test for overall effect: Z=1.54(P=0.12)

49.52%

50.48%

100%

-1.4[-2.08,-0.72]

-0.3[-0.95,0.35]

-0.84[-1.92,0.23]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

294

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

5.3.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 5.4.   Comparison 5 Comparison: pain/disability, all physical activity
vs control, Outcome 4 Brief Pain Inventory interference score (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

5.4.1 End of intervention

Cormie 2014

Irwin 2015

Subtotal ***

-0.5 (1.3)

-1.1 (1.7)

43

45

88

Heterogeneity: Tau2=0.21; Chi2=2.4, df=1(P=0.12); I2=58.4%

Test for overall effect: Z=2.53(P=0.01)

5.4.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0.1 (1.5)

0.4 (1.8)

19

38

57

0

49.87%

50.13%

100%

-0.65[-1.41,0.11]

-1.5[-2.26,-0.74]

-1.08[-1.91,-0.24]

Not estimable

Favours physical activity

-10

-5

0

5

10

Favours control

Analysis 5.5.   Comparison 5 Comparison: pain/disability, all physical
activity vs control, Outcome 5 DASH (follow-up and change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

5.5.1 End of intervention

Portela 2008

Irwin 2015

Cormie 2014

Subtotal ***

20.6 (20.2)

-6.7 (11)

-4.4 (8)

25

45

43

113

Heterogeneity: Tau2=0; Chi2=1.68, df=2(P=0.43); I2=0%

Test for overall effect: Z=3.81(P=0)

5.5.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

20.8 (15.5)

1.3 (11)

0.6 (7.9)

9

38

19

66

0

5.75%

42.37%

51.88%

100%

-0.2[-13.05,12.65]

-8[-12.73,-3.27]

-5[-9.28,-0.72]

-6[-9.08,-2.91]

Not estimable

Favours physical activity

-20

-10

0

10

20

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

295

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 5.6.   Comparison 5 Comparison: pain/disability, all physical activity vs
control, Outcome 6 EORTC QLQ-C30 Pain scale (follow-up and change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

5.6.1 End of intervention

Do 2015

Mehnert 2011

Subtotal ***

-21.1 (24.6)

-0.7 (20.7)

32

30

62

Heterogeneity: Tau2=0; Chi2=0.56, df=1(P=0.45); I2=0%

Test for overall effect: Z=0.23(P=0.82)

5.6.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

-16.5 (26.7)

-2.9 (25.3)

30

27

57

0

47.12%

52.88%

100%

-4.6[-17.4,8.2]

2.14[-9.95,14.23]

-1.04[-9.83,7.75]

Not estimable

Favours physical activity

-50

-25

0

25

50

Favours control

Analysis 5.7.   Comparison 5 Comparison: pain/disability, all physical
activity vs control, Outcome 7 MOS SF Pain (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

5.7.1 End of intervention

Mehnert 2011

Duijits 2012

Basen-Enquist 2006

Cadmus 2009

Mustian 2004

Subtotal ***

79.4 (23.1)

79.3 (23.6)

79.7 (10.6)

50.3 (9.1)

9.1 (1.4)

30

87

28

37

9

191

28

89

23

37

10

187

73.5 (24.8)

78.8 (23.8)

72.1 (11.5)

50.8 (9)

9.1 (1.7)

Heterogeneity: Tau2=3.37; Chi2=6.55, df=4(P=0.16); I2=38.96%

Test for overall effect: Z=0.92(P=0.36)

4.23%

11.32%

13.91%

23.42%

47.12%

100%

5.9[-6.47,18.27]

0.48[-6.52,7.48]

7.6[1.48,13.72]

-0.5[-4.62,3.62]

0.01[-1.38,1.4]

1.25[-1.4,3.9]

5.7.2 Follow-up

Duijits 2012

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.2(P=0.23)

79.1 (23.4)

79

79

74.6 (23.7)

83

83

100%

100%

4.45[-2.8,11.7]

4.45[-2.8,11.7]

Favours control

-50

-25

0

25

50

Favours physical activity

Analysis 5.8.   Comparison 5 Comparison: pain/disability, all
physical activity vs control, Outcome 8 MOS SF Pain (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

5.8.1 End of intervention

Mehnert 2011

Cadmus 2009

Cormie 2014

30

37

43

2.4 (25)

2.2 (11.3)

3.4 (6.5)

28

37

19

7.6 (25.2)

0.1 (7)

2 (6.2)

0.73%

6.64%

10.55%

-5.21[-18.13,7.71]

2.1[-2.18,6.38]

1.4[-2,4.8]

Favours control

-20

-10

0

10

20

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

296

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Physical activity

Control

Mustian 2004

Subtotal ***

N

9

119

Mean(SD)

N

Mean(SD)

-0.2 (1.3)

Heterogeneity: Tau2=0; Chi2=2.31, df=3(P=0.51); I2=0%

Test for overall effect: Z=0.12(P=0.9)

5.8.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0 (1.4)

10

94

0

Cochrane Database of Systematic Reviews

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

82.07%

100%

Fixed, 95% CI

-0.22[-1.44,1]

0.07[-1.04,1.17]

Not estimable

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 5.9.   Comparison 5 Comparison: pain/disability, all physical activity
vs control, Outcome 9 WOMAC joint pain (follow-up and change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

5.9.1 End of intervention

Irwin 2015

Rogers 2009

Subtotal ***

-6 (19)

2.3 (2.8)

45

20

65

Heterogeneity: Tau2=8.73; Chi2=1.97, df=1(P=0.16); I2=49.34%

Test for overall effect: Z=0.89(P=0.37)

5.9.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0.7 (18.6)

3 (3)

38

18

56

0

27.14%

72.86%

100%

-6.7[-14.8,1.4]

-0.75[-2.58,1.08]

-2.36[-7.55,2.82]

Not estimable

Favours physical activity

-20

-10

0

10

20

Favours control

Analysis 5.10.   Comparison 5 Comparison: pain/disability, all physical activity vs
control, Outcome 10 WOMAC physical dysfunction (follow-up and change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

5.10.1 End of intervention

Irwin 2015

Rogers 2009

Subtotal ***

-10.4 (15.3)

6 (8.2)

45

20

65

Heterogeneity: Tau2=43.73; Chi2=5.8, df=1(P=0.02); I2=82.75%

Test for overall effect: Z=1.2(P=0.23)

5.10.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

1.1 (15.2)

7.3 (8.1)

38

18

56

0

47.93%

52.07%

100%

-11.5[-18.09,-4.91]

-1.22[-6.38,3.94]

-6.15[-16.21,3.92]

Not estimable

Favours physical activity

-20

-10

0

10

20

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

297

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 5.11.   Comparison 5 Comparison: pain/disability, all physical activity
vs control, Outcome 11 WOMAC total score (follow-up and change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

5.11.1 End of intervention

Rogers 2009

Irwin 2015

Subtotal ***

10.1 (12.2)

-9.4 (16)

20

45

65

Heterogeneity: Tau2=12.38; Chi2=1.9, df=1(P=0.17); I2=47.36%

Test for overall effect: Z=1.8(P=0.07)

5.11.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

12.8 (11.9)

0.5 (15.8)

18

38

56

0

47.14%

52.86%

100%

-2.67[-10.33,4.99]

-9.9[-16.76,-3.04]

-6.49[-13.57,0.58]

Not estimable

Favours physical activity

-20

-10

0

10

20

Favours control

Comparison 6.   Comparison: self-esteem, all physical activity vs control

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Overall self-esteem/body im-
age (follow-up values)

1.1 End of intervention

1.2 Follow-up

2 Overall self-esteem/body im-
age (change values)

2.1 End of intervention

2.2 Follow-up

3 Body Esteem Scale - weight
concern (follow-up values)

3.1 End of intervention

3.2 Follow-up

4 Physical self-perception pro-
file - attractiveness of body
(follow-up values)

12

12

1

9

9

1

2

2

0

2

667

61

992

62

100

0

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.27 [0.05, 0.48]

Std. Mean Difference (IV, Random,
95% CI)

0.57 [0.05, 1.08]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.23 [-0.11, 0.58]

Std. Mean Difference (IV, Random,
95% CI)

0.46 [-0.05, 0.96]

Mean Difference (IV, Random, 95%
CI)

Subtotals only

Mean Difference (IV, Random, 95%
CI)

4.22 [-1.01, 9.45]

Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

298

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

4.1 End of intervention

4.2 Follow-up

5 Physical self-perception pro-
file - attractiveness of body
(change values)

5.1 End of intervention

5.2 Follow-up

6 Rosenberg Self-Esteem Scale
(follow-up values)

6.1 End of intervention

6.2 Follow-up

7 Rosenberg Self-Esteem Scale
(change values)

7.1 End of intervention

7.2 Follow-up

8 EORTC QLQ-C30 Body image
(follow-up and change values)

8.1 End of intervention

8.2 Follow-up

2

1

2

2

1

4

4

0

4

4

0

2

2

0

107

61

108

62

183

0

189

0

562

0

Mean Difference (IV, Fixed, 95% CI)

0.46 [0.13, 0.79]

Mean Difference (IV, Fixed, 95% CI)

0.29 [0.04, 0.54]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

0.26 [-0.07, 0.59]

Mean Difference (IV, Fixed, 95% CI)

0.26 [-0.02, 0.54]

Mean Difference (IV, Random, 95%
CI)

Subtotals only

Mean Difference (IV, Random, 95%
CI)

0.24 [-1.79, 2.26]

Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

2.78 [1.98, 3.58]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

-0.85 [-4.38, 2.68]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Analysis 6.1.   Comparison 6 Comparison: self-esteem, all physical activity
vs control, Outcome 1 Overall self-esteem/body image (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

6.1.1 End of intervention

Segar 1998

Pinto 2003

Loudon 2014

Musanti 2012

Mehnert 2011

Courneya 2003

Milne 2008

Daley 2007

Do 2015

10

12

12

30

27

24

29

33

32

33 (1.8)

32.3 (4.3)

-1.4 (0.3)

23.8 (3.5)

-5.5 (1.7)

34.8 (4.7)

-17.9 (6.8)

2 (0.8)

37.9 (18.9)

5

6

11

12

27

28

29

32

30

30.5 (2.7)

25.3 (8.2)

-1.6 (0.9)

26.3 (3.9)

-6.8 (2.6)

34.6 (4.4)

-20.1 (6.3)

1.6 (0.5)

36.1 (18.3)

2.87%

3.35%

5.12%

6.63%

8.85%

8.88%

9.4%

9.78%

9.82%

1.11[-0.06,2.28]

1.15[0.08,2.22]

0.2[-0.62,1.02]

-0.68[-1.37,0.01]

0.61[0.06,1.16]

0.04[-0.5,0.59]

0.33[-0.19,0.85]

0.66[0.16,1.16]

0.1[-0.4,0.59]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

299

 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Cadmus 2009

Pinto 2005

Schmitz 2009

Subtotal ***

34.2 (5.5)

30.3 (7.8)

-70.4 (16.3)

37

39

59

344

Heterogeneity: Tau2=0.06; Chi2=18.93, df=11(P=0.06); I2=41.9%

Test for overall effect: Z=2.46(P=0.01)

6.1.2 Follow-up

Daley 2007

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.17(P=0.03)

2.2 (0.5)

30

30

33.4 (5.9)

27.2 (6.8)

-71.5 (18)

1.9 (0.5)

37

43

63

323

31

31

10.76%

11.18%

13.35%

100%

0.14[-0.32,0.6]

0.41[-0.03,0.85]

0.06[-0.29,0.42]

0.27[0.05,0.48]

100%

100%

0.57[0.05,1.08]

0.57[0.05,1.08]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 6.2.   Comparison 6 Comparison: self-esteem, all physical activity
vs control, Outcome 2 Overall self-esteem/body image (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

6.2.1 End of intervention

Mustian 2004

Musanti 2012

Courneya 2003

Mehnert 2011

Milne 2008

Daley 2007

Cadmus 2009

Schmitz 2009

Saarto 2012

Subtotal ***

3 (1)

-0.4 (4.5)

2.6 (3.7)

0.7 (2.1)

1.5 (3.7)

1.8 (0.7)

0.4 (4.4)

-12 (15.5)

10.7 (21.5)

11

30

24

30

29

33

37

59

263

516

10

12

28

27

29

33

37

63

237

476

-1.5 (1.5)

0.6 (3.9)

-0.1 (3.5)

0.4 (2.1)

0.1 (3.9)

1.6 (0.7)

0.2 (2.9)

-4.1 (16.2)

12 (22)

Heterogeneity: Tau2=0.2; Chi2=40.55, df=8(P<0.0001); I2=80.27%

Test for overall effect: Z=1.33(P=0.18)

4.17%

9.73%

10.93%

11.44%

11.46%

11.85%

12.2%

13.27%

14.95%

100%

3.42[1.99,4.86]

-0.22[-0.89,0.45]

0.74[0.18,1.3]

0.16[-0.36,0.68]

0.36[-0.16,0.88]

0.33[-0.16,0.82]

0.05[-0.4,0.51]

-0.49[-0.86,-0.13]

-0.06[-0.24,0.12]

0.23[-0.11,0.58]

6.2.2 Follow-up

Daley 2007

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.78(P=0.08)

31

31

2 (0.6)

31

31

1.8 (0.6)

100%

100%

0.46[-0.05,0.96]

0.46[-0.05,0.96]

Favours control

-5

-2.5

0

2.5

5

Favours intervention

Analysis 6.3.   Comparison 6 Comparison: self-esteem, all physical activity vs
control, Outcome 3 Body Esteem Scale - weight concern (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

6.3.1 End of intervention

Pinto 2003

12

30.9 (8.2)

6

23.5 (4.2)

41.19%

7.41[1.68,13.14]

Favours control

-20

-10

0

10

20

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

300

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Pinto 2005

Subtotal ***

39

51

27 (9)

Heterogeneity: Tau2=8.73; Chi2=2.47, df=1(P=0.12); I2=59.46%

Test for overall effect: Z=1.58(P=0.11)

6.3.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

25 (7.4)

43

49

0

Cochrane Database of Systematic Reviews

Weight

Mean Difference

58.81%

100%

Random, 95% CI

1.99[-1.61,5.59]

4.22[-1.01,9.45]

Not estimable

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 6.4.   Comparison 6 Comparison: self-esteem, all physical activity vs control,
Outcome 4 Physical self-perception profile - attractiveness of body (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

6.4.1 End of intervention

Musanti 2012

Daley 2007

Subtotal ***

14.6 (4.2)

2 (0.8)

30

33

63

Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.92); I2=0%

Test for overall effect: Z=2.73(P=0.01)

6.4.2 Follow-up

Daley 2007

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.24(P=0.03)

2.2 (0.5)

30

30

14.3 (3.3)

1.6 (0.5)

1.9 (0.5)

12

32

44

31

31

1.89%

98.11%

100%

0.33[-2.06,2.72]

0.46[0.13,0.79]

0.46[0.13,0.79]

100%

100%

0.29[0.04,0.54]

0.29[0.04,0.54]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 6.5.   Comparison 6 Comparison: self-esteem, all physical activity vs control,
Outcome 5 Physical self-perception profile - attractiveness of body (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

6.5.1 End of intervention

Musanti 2012

Daley 2007

Subtotal ***

2.1 (3.2)

1.8 (0.7)

30

33

63

Heterogeneity: Tau2=0; Chi2=1.17, df=1(P=0.28); I2=14.54%

Test for overall effect: Z=1.57(P=0.12)

6.5.2 Follow-up

Daley 2007

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.83(P=0.07)

2 (0.6)

31

31

0.8 (2.6)

1.6 (0.7)

1.8 (0.6)

12

33

45

31

31

3.06%

96.94%

100%

1.28[-0.59,3.15]

0.23[-0.1,0.56]

0.26[-0.07,0.59]

100%

100%

0.26[-0.02,0.54]

0.26[-0.02,0.54]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

301

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 6.6.   Comparison 6 Comparison: self-esteem, all physical activity
vs control, Outcome 6 Rosenberg Self-Esteem Scale (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

6.6.1 End of intervention

Segar 1998

Cadmus 2009

Musanti 2012

Courneya 2003

Subtotal ***

33 (1.8)

34.2 (5.5)

23.8 (3.5)

34.8 (4.7)

10

37

30

24

101

Heterogeneity: Tau2=2.55; Chi2=7.47, df=3(P=0.06); I2=59.83%

Test for overall effect: Z=0.23(P=0.82)

6.6.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

30.5 (2.7)

33.4 (5.9)

26.3 (3.9)

34.6 (4.4)

5

37

12

28

82

0

24.59%

24.73%

25.08%

25.6%

100%

2.5[-0.12,5.12]

0.8[-1.8,3.4]

-2.5[-5.05,0.05]

0.2[-2.29,2.69]

0.24[-1.79,2.26]

Not estimable

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 6.7.   Comparison 6 Comparison: self-esteem, all physical activity
vs control, Outcome 7 Rosenberg Self-Esteem Scale (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

6.7.1 End of intervention

Musanti 2012

Courneya 2003

Cadmus 2009

Mustian 2004

Subtotal ***

-0.4 (4.5)

2.6 (3.7)

0.4 (4.4)

3 (1)

30

24

37

11

102

Heterogeneity: Tau2=0; Chi2=25.44, df=3(P<0.0001); I2=88.21%

Test for overall effect: Z=6.81(P<0.0001)

6.7.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0.6 (3.9)

-0.1 (3.5)

0.2 (2.9)

-1.5 (1.5)

12

28

37

10

87

0

8.49%

16.54%

22.21%

52.77%

100%

-0.98[-3.73,1.77]

2.7[0.73,4.67]

0.2[-1.5,1.9]

4.5[3.4,5.6]

2.78[1.98,3.58]

Not estimable

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 6.8.   Comparison 6 Comparison: self-esteem, all physical activity vs
control, Outcome 8 EORTC QLQ-C30 Body image (follow-up and change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

6.8.1 End of intervention

Do 2015

32

37.9 (18.9)

30

36.1 (18.3)

14.54%

1.8[-7.46,11.06]

Favours control

-20

-10

0

10

20

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

302

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Physical activity

Control

Saarto 2012

Subtotal ***

Mean(SD)

10.7 (21.5)

N

263

295

N

237

267

Mean(SD)

12 (22)

Heterogeneity: Tau2=0; Chi2=0.37, df=1(P=0.54); I2=0%

Test for overall effect: Z=0.47(P=0.64)

Cochrane Database of Systematic Reviews

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

85.46%

100%

Fixed, 95% CI

-1.3[-5.12,2.52]

-0.85[-4.38,2.68]

6.8.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-20

-10

0

10

20

Favours physical activity

Comparison 7.   Comparison: cardiorespiratory fitness, all physical activity vs control

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Overall cardiorespiratory fit-
ness (follow-up values)

1.1 End of intervention

1.2 Follow-up

2 Overall cardiorespiratory fit-
ness (change values)

2.1 End of intervention

2.2 Follow-up

3 Directly assessed VO2max/
peak (follow-up values)

3.1 End of intervention

3.2 Follow-up

4 Directly assessed VO2max/
peak (change values)

4.1 End of intervention

4.2 Follow-up

23

23

3

10

9

2

4

4

0

3

3

0

1265

362

863

115

199

0

166

0

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.44 [0.30, 0.58]

Std. Mean Difference (IV, Random,
95% CI)

0.36 [0.03, 0.69]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.83 [0.40, 1.27]

Std. Mean Difference (IV, Random,
95% CI)

0.42 [0.05, 0.79]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

1.89 [0.65, 3.13]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

1.31 [0.66, 1.96]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

303

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

5 Directly assessed VO2max/
peak - treadmill (follow-up and
change values)

5.1 End of intervention

5.2 Follow-up

6 Directly assessed VO2max/
peak - cycle ergometer (fol-
low-up values)

6.1 End of intervention

6.2 Follow-up

7 Peak Power Output - cycle
ergometer test (follow-up val-
ues)

7.1 End of intervention

7.2 Follow-up

8 Peak Respiratory Exchange
Ratio - cycle ergometer test
(follow-up values)

8.1 End of intervention

8.2 Follow-up

9 Peak Heart Rate - cycle er-
gometer test (follow-up val-
ues)

9.1 End of intervention

9.2 Follow-up

10 Ebbeling single-stage tread-
mill test (follow-up and change
values)

10.1 End of intervention

10.2 Follow-up

2

2

0

3

3

0

2

2

0

2

2

0

2

2

0

2

2

2

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

1.04 [-0.49, 2.58]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95%
CI)

Subtotals only

Mean Difference (IV, Random, 95%
CI)

1.99 [0.39, 3.59]

Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

18.92 [9.64, 28.20]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

-0.01 [-0.04, 0.03]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

2.02 [-5.65, 9.68]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95%
CI)

Subtotals only

Mean Difference (IV, Random, 95%
CI)

1.30 [-0.16, 2.75]

Mean Difference (IV, Random, 95%
CI)

1.77 [-1.23, 4.77]

116

0

116

0

66

0

66

0

66

0

189

149

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

304

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

11 Modified Bruce treadmill
test (follow-up and change val-
ues)

11.1 End of intervention

11.2 Follow-up

12 Naughton submaximal
treadmill test (follow-up and
change values)

12.1 End of intervention

12.2 Follow-up

13 Cardiorespiratory fitness
walk tests (follow-up values)

13.1 End of intervention

13.2 Follow-up

14 Cardiorespiratory fitness
walk tests (change values)

14.1 End of intervention

14.2 Follow-up

15 6-Minute walk test (fol-
low-up and change values)

15.1 End of intervention

15.2 Follow-up

16 12-Minute walk test (fol-
low-up values)

16.1 End of intervention

16.2 Follow-up

3

3

0

4

4

2

7

7

0

3

3

1

5

5

0

2

2

0

Mean Difference (IV, Random, 95%
CI)

Subtotals only

Mean Difference (IV, Random, 95%
CI)

3.57 [0.95, 6.19]

Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95%
CI)

Subtotals only

Mean Difference (IV, Random, 95%
CI)

2.02 [-0.33, 4.37]

Mean Difference (IV, Random, 95%
CI)

1.91 [0.57, 3.26]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.62 [0.33, 0.91]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.72 [-0.05, 1.49]

Std. Mean Difference (IV, Random,
95% CI)

0.54 [0.09, 0.99]

Mean Difference (IV, Random, 95%
CI)

Subtotals only

Mean Difference (IV, Random, 95%
CI)

54.74 [33.25,
76.22]

Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95%
CI)

Subtotals only

Mean Difference (IV, Random, 95%
CI)

94.56 [-24.25,
213.37]

Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

92

0

315

249

314

0

592

79

159

0

96

0

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

305

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

17 2-Kilometer walk test (fol-
low-up and change values)

17.1 End of intervention

17.2 Follow-up

18 Resting Heart Rate (fol-
low-up values)

18.1 End of intervention

18.2 Follow-up

19 Resting Heart Rate (change
values)

19.1 End of intervention

19.2 Follow-up

20 Resting Systolic Blood Pres-
sure (follow-up values)

20.1 End of intervention

20.2 Follow-up

21 Resting Systolic Blood Pres-
sure (change values)

21.1 End of intervention

21.2 Follow-up

22 Resting Diastolic Blood
Pressure (follow-up values)

22.1 End of intervention

22.2 Follow-up

23 Resting Diastolic Blood
Pressure (change values)

2

2

0

2

2

0

2

2

0

4

4

1

3

3

1

3

3

1

3

526

0

82

0

86

0

134

26

143

26

106

26

170

Mean Difference (IV, Random, 95%
CI)

Subtotals only

Mean Difference (IV, Random, 95%
CI)

-0.11 [-0.46, 0.25]

Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

-4.47 [-7.94, -1.00]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-1.05 [-2.22, 0.11]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95%
CI)

Subtotals only

Mean Difference (IV, Random, 95%
CI)

-0.83 [-3.72, 2.05]

Mean Difference (IV, Random, 95%
CI)

5.20 [-5.35, 15.75]

Mean Difference (IV, Random, 95%
CI)

Subtotals only

Mean Difference (IV, Random, 95%
CI)

-1.12 [-7.74, 5.50]

Mean Difference (IV, Random, 95%
CI)

-2.70 [-5.94, 0.54]

Mean Difference (IV, Random, 95%
CI)

Subtotals only

Mean Difference (IV, Random, 95%
CI)

0.66 [-2.89, 4.21]

Mean Difference (IV, Random, 95%
CI)

2.10 [-3.78, 7.98]

Mean Difference (IV, Random, 95%
CI)

-0.04 [-1.82, 1.73]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

306

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

23.1 End of intervention

23.2 Follow-up

3

1

144

26

Mean Difference (IV, Random, 95%
CI)

0.53 [-1.61, 2.68]

Mean Difference (IV, Random, 95%
CI)

-1.30 [-3.85, 1.25]

Analysis 7.1.   Comparison 7 Comparison: cardiorespiratory fitness, all physical
activity vs control, Outcome 1 Overall cardiorespiratory fitness (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

7.1.1 End of intervention

Herrero 2006

Cerulli 2014

Mustian 2004

Rogers 2013

Portela 2008

Kaltsatou 2011

Rahnama 2010

Nikander 2007

Musanti 2012

Rogers 2014

Kim 2015

Rogers 2009

Courneya 2003

Mehnert 2011

Basen-Enquist 2006

Do 2015

Milne 2008

Murtezani 2014

Pinto 2005

Irwin 2015

Fillion 2008

Daley 2007

Rogers 2015

Subtotal ***

25.9 (4.5)

31.3 (5)

636.1 (50.6)

23.9 (6.2)

3007
(410.8)

483.3 (86)

20.7 (5.7)

-17.6 (1.3)

24.6 (4.9)

30.9 (6.3)

424.8 (55.8)

29.5 (6.6)

21.3 (3.7)

26.9 (4.4)

1643
(122.5)

31.7 (12.4)

1.5 (0.3)

875.1 (86.7)

-16.3 (2.1)

24.6 (5.5)

27 (4.4)

35 (4.4)

23.6 (4.8)

8

10

11

12

25

14

14

14

30

20

20

20

24

27

35

30

29

30

39

45

44

33

105

639

Heterogeneity: Tau2=0.03; Chi2=31.26, df=22(P=0.09); I2=29.61%

Test for overall effect: Z=6.06(P<0.0001)

7.1.2 Follow-up

Daley 2007

Fillion 2008

Rogers 2015

Subtotal ***

33.8 (4.8)

28.1 (4.7)

23.7 (5.2)

31

44

105

180

Heterogeneity: Tau2=0.04; Chi2=4.22, df=2(P=0.12); I2=52.56%

Test for overall effect: Z=2.16(P=0.03)

25.7 (3.7)

32.3 (10.1)

610.3 (75.9)

23.9 (3.8)

2416.1
(718.6)

403.1 (71.9)

13.9 (5.2)

-17.2 (1.4)

23 (4.3)

25.1 (5)

394.4 (54)

27.6 (6.1)

18.2 (3.9)

25.7 (4.7)

1546
(127.5)

24.5 (6.6)

1.5 (0.4)

823.5 (87.1)

-17.8 (2.2)

23 (4.7)

26.5 (5.8)

33.1 (5.3)

22.7 (0.3)

30.5 (4)

27.9 (5.7)

21.8 (4.9)

8

10

10

10

9

13

15

14

12

22

19

18

26

23

25

30

29

32

43

38

43

69

108

626

31

43

108

182

1.87%

2.27%

2.32%

2.44%

2.57%

2.62%

2.64%

2.98%

3.5%

3.73%

3.78%

3.78%

4.39%

4.62%

4.94%

5.06%

5.17%

5.25%

6.2%

6.41%

6.66%

6.71%

10.11%

100%

24.72%

31.07%

44.21%

100%

0.05[-0.93,1.03]

-0.12[-0.99,0.76]

0.39[-0.48,1.25]

0[-0.84,0.84]

1.14[0.33,1.96]

0.98[0.17,1.78]

1.21[0.41,2.01]

-0.29[-1.03,0.46]

0.33[-0.34,1]

1.01[0.36,1.65]

0.54[-0.1,1.18]

0.29[-0.35,0.93]

0.8[0.22,1.38]

0.26[-0.3,0.82]

0.77[0.24,1.3]

0.72[0.19,1.24]

0.03[-0.49,0.54]

0.59[0.08,1.1]

0.69[0.24,1.14]

0.31[-0.13,0.74]

0.1[-0.32,0.52]

0.38[-0.04,0.8]

0.27[-0,0.54]

0.44[0.3,0.58]

0.74[0.22,1.25]

0.05[-0.37,0.47]

0.37[0.1,0.65]

0.36[0.03,0.69]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

307

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.2.   Comparison 7 Comparison: cardiorespiratory fitness, all physical
activity vs control, Outcome 2 Overall cardiorespiratory fitness (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

7.2.1 End of intervention

Nieman 1995

Naumann 2012

Dolan 2016

Musanti 2012

Courneya 2003

Rogers 2014

Irwin 2015

Pinto 2005

Saarto 2012

Subtotal ***

60.8 (8.4)

3.1 (2.9)

12.2 (10.2)

1 (3.1)

2.7 (2.6)

2.8 (4.9)

1.5 (2.1)

1.4 (2.4)

0.9 (1.2)

6

11

23

30

24

20

45

39

262

460

6

10

10

12

26

22

38

43

236

403

12 (17.8)

-0.1 (3.1)

-6 (7.2)

0.9 (3.4)

-0.6 (1.7)

1.1 (4.2)

-0.4 (2.7)

-0.2 (2.5)

0.7 (1)

Heterogeneity: Tau2=0.31; Chi2=44.63, df=8(P<0.0001); I2=82.07%

Test for overall effect: Z=3.79(P=0)

7.2.2 Follow-up

Rogers 2009

Pinto 2005

Subtotal ***

3.6 (22.3)

1.7 (2.7)

19

39

58

17

40

57

0.9 (0)

0.3 (2.4)

Heterogeneity: Tau2=0; Chi2=0.88, df=1(P=0.35); I2=0%

Test for overall effect: Z=2.23(P=0.03)

3.75%

9.16%

9.47%

11.44%

11.78%

11.99%

13.49%

13.52%

15.39%

100%

31.98%

68.02%

100%

3.24[1.29,5.18]

1.03[0.1,1.95]

1.88[0.99,2.77]

0.03[-0.64,0.7]

1.49[0.86,2.12]

0.37[-0.24,0.98]

0.79[0.34,1.24]

0.65[0.2,1.09]

0.16[-0.02,0.33]

0.83[0.4,1.27]

0.16[-0.49,0.82]

0.54[0.09,0.99]

0.42[0.05,0.79]

Favours control

-10

-5

0

5

10

Favours physical activity

Analysis 7.3.   Comparison 7 Comparison: cardiorespiratory fitness, all physical
activity vs control, Outcome 3 Directly assessed VO2max/peak (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

7.3.1 End of intervention

Herrero 2006

Mehnert 2011

Irwin 2015

Courneya 2003

Subtotal ***

25.9 (4.5)

26.9 (4.4)

24.6 (5.5)

21.3 (3.7)

8

27

45

24

104

Heterogeneity: Tau2=0; Chi2=2.29, df=3(P=0.51); I2=0%

Test for overall effect: Z=2.99(P=0)

7.3.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

25.7 (3.7)

25.7 (4.7)

23 (4.7)

18.2 (3.9)

8

23

38

26

95

0

9.45%

23.89%

31.97%

34.69%

100%

0.2[-3.84,4.24]

1.2[-1.34,3.74]

1.6[-0.59,3.79]

3.1[0.99,5.21]

1.89[0.65,3.13]

Not estimable

Favours control

-10

-5

0

5

10

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

308

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.4.   Comparison 7 Comparison: cardiorespiratory fitness, all physical
activity vs control, Outcome 4 Directly assessed VO2max/peak (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

7.4.1 End of intervention

Dolan 2016

Courneya 2003

Irwin 2015

Subtotal ***

12.2 (10.2)

2.7 (2.6)

1.5 (2.1)

23

24

45

92

Heterogeneity: Tau2=0.22; Chi2=6.24, df=2(P=0.04); I2=67.97%

Test for overall effect: Z=3.95(P<0.0001)

7.4.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

-6 (7.2)

-0.6 (1.7)

-0.4 (2.7)

10

26

38

74

0

25.87%

33.85%

40.28%

100%

1.88[0.99,2.77]

1.49[0.86,2.12]

0.79[0.34,1.24]

1.31[0.66,1.96]

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 7.5.   Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs
control, Outcome 5 Directly assessed VO2max/peak - treadmill (follow-up and change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

7.5.1 End of intervention

Dolan 2016

Irwin 2015

Subtotal ***

12.2 (10.2)

24.6 (5.5)

23

45

68

Heterogeneity: Tau2=1.11; Chi2=9.76, df=1(P=0); I2=89.75%

Test for overall effect: Z=1.33(P=0.18)

7.5.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

-6 (7.2)

23 (4.7)

10

38

48

0

46.86%

53.14%

100%

1.88[0.99,2.77]

0.31[-0.13,0.74]

1.04[-0.49,2.58]

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 7.6.   Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs
control, Outcome 6 Directly assessed VO2max/peak - cycle ergometer (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

7.6.1 End of intervention

Herrero 2006

Mehnert 2011

Courneya 2003

Subtotal ***

25.9 (4.5)

26.9 (4.4)

21.3 (3.7)

8

27

24

59

25.7 (3.7)

25.7 (4.7)

18.2 (3.9)

8

23

26

57

Heterogeneity: Tau2=0.19; Chi2=2.19, df=2(P=0.33); I2=8.72%

Test for overall effect: Z=2.44(P=0.01)

14.99%

35.59%

49.42%

100%

0.2[-3.84,4.24]

1.2[-1.34,3.74]

3.1[0.99,5.21]

1.99[0.39,3.59]

Favours control

-10

-5

0

5

10

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

309

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

7.6.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-10

-5

0

5

10

Favours physical activity

Analysis 7.7.   Comparison 7 Comparison: cardiorespiratory fitness, all physical activity
vs control, Outcome 7 Peak Power Output - cycle ergometer test (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

7.7.1 End of intervention

Herrero 2006

Courneya 2003

Subtotal ***

110 (16)

113.6 (23.6)

8

24

32

Heterogeneity: Tau2=0; Chi2=0.31, df=1(P=0.58); I2=0%

Test for overall effect: Z=4(P<0.0001)

7.7.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

94 (12)

92.3 (21.3)

8

26

34

0

44.85%

55.15%

100%

16[2.14,29.86]

21.3[8.8,33.8]

18.92[9.64,28.2]

Not estimable

Favours control

-50

-25

0

25

50

Favours physical activity

Analysis 7.8.   Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs
control, Outcome 8 Peak Respiratory Exchange Ratio - cycle ergometer test (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

7.8.1 End of intervention

Herrero 2006

Courneya 2003

Subtotal ***

1.1 (0.1)

1.1 (0.1)

8

24

32

Heterogeneity: Tau2=0; Chi2=0.2, df=1(P=0.65); I2=0%

Test for overall effect: Z=0.34(P=0.74)

7.8.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

1.1 (0.1)

1.1 (0.1)

8

26

34

0

20.08%

79.92%

100%

0.01[-0.07,0.09]

-0.01[-0.05,0.03]

-0.01[-0.04,0.03]

Not estimable

Favours physical activity

-0.2

-0.1

0

0.1

0.2

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

310

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.9.   Comparison 7 Comparison: cardiorespiratory fitness, all physical activity
vs control, Outcome 9 Peak Heart Rate - cycle ergometer test (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

7.9.1 End of intervention

Herrero 2006

Courneya 2003

Subtotal ***

161 (16)

157 (16)

8

24

32

Heterogeneity: Tau2=0; Chi2=0.2, df=1(P=0.66); I2=0%

Test for overall effect: Z=0.52(P=0.61)

7.9.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

156 (15)

156 (16)

8

26

34

0

25.44%

74.56%

100%

5[-10.2,20.2]

1[-7.88,9.88]

2.02[-5.65,9.68]

Not estimable

Favours physical activity

-50

-25

0

25

50

Favours control

Analysis 7.10.   Comparison 7 Comparison: cardiorespiratory fitness, all physical activity
vs control, Outcome 10 Ebbeling single-stage treadmill test (follow-up and change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

7.10.1 End of intervention

Fillion 2008

Daley 2007

Subtotal ***

27 (4.4)

35 (4.4)

44

33

77

Heterogeneity: Tau2=0; Chi2=0.92, df=1(P=0.34); I2=0%

Test for overall effect: Z=1.75(P=0.08)

7.10.2 Follow-up

Daley 2007

Fillion 2008

Subtotal ***

33.8 (4.8)

28.1 (4.7)

31

44

75

Heterogeneity: Tau2=3.43; Chi2=3.73, df=1(P=0.05); I2=73.17%

Test for overall effect: Z=1.16(P=0.25)

26.5 (5.8)

33.1 (5.3)

30.5 (4)

27.9 (5.7)

43

69

112

31

43

74

44.96%

55.04%

100%

0.51[-1.66,2.68]

1.94[-0.02,3.9]

1.3[-0.16,2.75]

49.97%

50.03%

100%

3.3[1.1,5.5]

0.24[-1.95,2.43]

1.77[-1.23,4.77]

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 7.11.   Comparison 7 Comparison: cardiorespiratory fitness, all physical activity
vs control, Outcome 11 Modified Bruce treadmill test (follow-up and change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

7.11.1 End of intervention

Rahnama 2010

Musanti 2012

Naumann 2012

Subtotal ***

20.7 (5.7)

24.6 (4.9)

3.1 (2.9)

14

30

11

55

15

12

10

37

13.9 (5.2)

23 (4.3)

-0.1 (3.1)

Heterogeneity: Tau2=2.8; Chi2=4.2, df=2(P=0.12); I2=52.37%

25.77%

34.74%

39.49%

100%

6.8[2.81,10.79]

1.6[-1.4,4.6]

3.2[0.63,5.77]

3.57[0.95,6.19]

Favours control

-20

-10

0

10

20

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

311

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

Test for overall effect: Z=2.67(P=0.01)

7.11.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 7.12.   Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs
control, Outcome 12 Naughton submaximal treadmill test (follow-up and change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

7.12.1 End of intervention

Rogers 2013

Rogers 2009

Rogers 2014

Rogers 2015

Subtotal ***

23.9 (6.2)

29.5 (6.6)

30.9 (6.3)

23.6 (4.8)

12

20

20

105

157

Heterogeneity: Tau2=3.31; Chi2=7.61, df=3(P=0.05); I2=60.6%

Test for overall effect: Z=1.69(P=0.09)

7.12.2 Follow-up

Rogers 2009

Rogers 2015

Subtotal ***

3.6 (22.3)

23.7 (5.2)

19

105

124

Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.88); I2=0%

Test for overall effect: Z=2.79(P=0.01)

23.9 (3.8)

27.6 (6.1)

25.1 (5)

22.7 (0.3)

0.9 (0)

21.8 (4.9)

10

18

22

108

158

17

108

125

18.04%

19%

22.32%

40.64%

100%

1.81%

98.19%

100%

0[-4.23,4.23]

1.9[-2.14,5.94]

5.8[2.34,9.26]

0.9[-0.02,1.82]

2.02[-0.33,4.37]

2.7[-7.31,12.71]

1.9[0.54,3.26]

1.91[0.57,3.26]

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 7.13.   Comparison 7 Comparison: cardiorespiratory fitness, all physical
activity vs control, Outcome 13 Cardiorespiratory fitness walk tests (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

7.13.1 End of intervention

Mustian 2004

Portela 2008

Kaltsatou 2011

Nikander 2007

Basen-Enquist 2006

Murtezani 2014

Pinto 2005

Subtotal ***

11

25

14

14

35

30

39

636.1 (50.6)

3007
(410.8)

483.3 (86)

-17.6 (1.3)

1643
(122.5)

875.1 (86.7)

-16.3 (2.1)

10

9

13

14

25

32

43

610.3 (75.9)

2416.1
(718.6)

403.1 (71.9)

-17.2 (1.4)

1546
(127.5)

823.5 (87.1)

-17.8 (2.2)

168

146

Heterogeneity: Tau2=0.05; Chi2=8.71, df=6(P=0.19); I2=31.09%

9.02%

9.95%

10.12%

11.42%

18.15%

19.15%

22.19%

100%

0.39[-0.48,1.25]

1.14[0.33,1.96]

0.98[0.17,1.78]

-0.29[-1.03,0.46]

0.77[0.24,1.3]

0.59[0.08,1.1]

0.69[0.24,1.14]

0.62[0.33,0.91]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

312

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for overall effect: Z=4.2(P<0.0001)

7.13.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 7.14.   Comparison 7 Comparison: cardiorespiratory fitness, all physical
activity vs control, Outcome 14 Cardiorespiratory fitness walk tests (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

7.14.1 End of intervention

Nieman 1995

Pinto 2005

Saarto 2012

Subtotal ***

60.8 (8.4)

1.4 (2.4)

0.9 (1.2)

6

39

262

307

Heterogeneity: Tau2=0.32; Chi2=13.2, df=2(P=0); I2=84.84%

Test for overall effect: Z=1.84(P=0.07)

7.14.2 Follow-up

Pinto 2005

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.37(P=0.02)

1.7 (2.7)

39

39

12 (17.8)

-0.2 (2.5)

0.7 (1)

0.3 (2.4)

6

43

236

285

40

40

11.73%

41.37%

46.9%

100%

3.24[1.29,5.18]

0.65[0.2,1.09]

0.16[-0.02,0.33]

0.72[-0.05,1.49]

100%

100%

0.54[0.09,0.99]

0.54[0.09,0.99]

Favours control

-10

-5

0

5

10

Favours physical activity

Analysis 7.15.   Comparison 7 Comparison: cardiorespiratory fitness, all physical
activity vs control, Outcome 15 6-Minute walk test (follow-up and change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

7.15.1 End of intervention

Kaltsatou 2011

Mustian 2004

Kim 2015

Basen-Enquist 2006

Nieman 1995

Subtotal ***

483.3 (86)

636.1 (50.6)

424.8 (55.8)

500.8 (37.3)

60.8 (8.4)

14

11

20

35

6

86

Heterogeneity: Tau2=316.15; Chi2=10.21, df=4(P=0.04); I2=60.83%

Test for overall effect: Z=4.99(P<0.0001)

7.15.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

403.1 (71.9)

610.3 (75.9)

394.4 (54)

421.2 (38.9)

12 (17.8)

13

10

19

25

6

73

0

9.68%

10.68%

19.22%

28.86%

31.56%

100%

80.25[20.62,139.88]

25.8[-29.94,81.54]

30.4[-4.06,64.86]

79.6[59.97,99.23]

48.8[33.05,64.55]

54.74[33.25,76.22]

Not estimable

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

313

Favours control

-200

-100

0

100

200

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.16.   Comparison 7 Comparison: cardiorespiratory fitness, all
physical activity vs control, Outcome 16 12-Minute walk test (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

7.16.1 End of intervention

Portela 2008

Murtezani 2014

Subtotal ***

916.5
(125.2)

875.1 (86.7)

25

30

55

Heterogeneity: Tau2=5032.24; Chi2=2.56, df=1(P=0.11); I2=60.96%

Test for overall effect: Z=1.56(P=0.12)

7.16.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

9

736.4 (219)

33.43%

180.09[28.81,331.37]

32

41

0

823.5 (87.1)

66.57%

100%

51.6[8.32,94.88]

94.56[-24.25,213.37]

Not estimable

Favours control

-500

-250

0

250

500

Favours physical activity

Analysis 7.17.   Comparison 7 Comparison: cardiorespiratory fitness, all physical
activity vs control, Outcome 17 2-Kilometer walk test (follow-up and change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

7.17.1 End of intervention

Nikander 2007

Saarto 2012

Subtotal ***

14

262

276

17.6 (1.3)

-0.9 (1.2)

14

236

250

17.2 (1.4)

-0.7 (1)

Heterogeneity: Tau2=0.03; Chi2=1.2, df=1(P=0.27); I2=16.87%

Test for overall effect: Z=0.58(P=0.56)

11.32%

88.68%

100%

0.4[-0.6,1.4]

-0.17[-0.36,0.02]

-0.11[-0.46,0.25]

7.17.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 7.18.   Comparison 7 Comparison: cardiorespiratory fitness, all
physical activity vs control, Outcome 18 Resting Heart Rate (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

7.18.1 End of intervention

Courneya 2003

Rahnama 2010

Subtotal ***

81.1 (8.2)

83.9 (5.6)

25

14

39

83.3 (14.1)

89.5 (5.9)

28

15

43

Heterogeneity: Tau2=0; Chi2=0.77, df=1(P=0.38); I2=0%

Test for overall effect: Z=2.53(P=0.01)

32.01%

67.99%

100%

-2.2[-8.33,3.93]

-5.54[-9.75,-1.33]

-4.47[-7.94,-1]

Favours physical activity

-20

-10

0

10

20

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

314

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

7.18.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours physical activity

-20

-10

0

10

20

Favours control

Analysis 7.19.   Comparison 7 Comparison: cardiorespiratory fitness, all
physical activity vs control, Outcome 19 Resting Heart Rate (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

7.19.1 End of intervention

Dolan 2016

Courneya 2003

Subtotal ***

-9.4 (5.5)

-4.4 (11)

23

25

48

Heterogeneity: Tau2=0.57; Chi2=5.22, df=1(P=0.02); I2=80.85%

Test for overall effect: Z=1.78(P=0.08)

7.19.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

4.9 (12.6)

1.1 (10.4)

10

28

38

0

45.95%

54.05%

100%

-1.7[-2.56,-0.84]

-0.51[-1.06,0.04]

-1.05[-2.22,0.11]

Not estimable

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 7.20.   Comparison 7 Comparison: cardiorespiratory fitness, all physical
activity vs control, Outcome 20 Resting Systolic Blood Pressure (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

7.20.1 End of intervention

Guinan 2013

Courneya 2003

Kaltsatou 2011

Rahnama 2010

Subtotal ***

118.5 (16.5)

131.6 (13.1)

125 (9)

123.6 (3.8)

16

24

14

14

68

Heterogeneity: Tau2=0; Chi2=1.33, df=3(P=0.72); I2=0%

Test for overall effect: Z=0.57(P=0.57)

7.20.2 Follow-up

Guinan 2013

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.97(P=0.33)

117 (14.2)

16

16

114.4 (9.5)

134.7 (18.2)

126.9 (7.5)

124.3 (6.3)

111.8 (12.8)

10

28

13

15

66

10

10

8.32%

11.41%

21.29%

58.99%

100%

4.1[-5.9,14.1]

-3.1[-11.64,5.44]

-1.92[-8.17,4.33]

-0.7[-4.46,3.06]

-0.83[-3.72,2.05]

100%

100%

5.2[-5.35,15.75]

5.2[-5.35,15.75]

Favours physical activity

-20

-10

0

10

20

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

315

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.21.   Comparison 7 Comparison: cardiorespiratory fitness, all physical
activity vs control, Outcome 21 Resting Systolic Blood Pressure (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

7.21.1 End of intervention

Courneya 2003

Cadmus 2009

Guinan 2013

Subtotal ***

-5.4 (15.6)

0.7 (13.3)

-6.1 (4.3)

24

35

16

75

Heterogeneity: Tau2=24.52; Chi2=7.54, df=2(P=0.02); I2=73.49%

Test for overall effect: Z=0.33(P=0.74)

7.21.2 Follow-up

Guinan 2013

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.64(P=0.1)

-7.6 (3.9)

16

16

0.1 (16.6)

-5.2 (13.3)

-2.3 (3.6)

-4.9 (4.2)

28

30

10

68

10

10

25.62%

32.15%

42.23%

100%

-5.5[-14.26,3.26]

5.89[-0.6,12.38]

-3.8[-6.89,-0.71]

-1.12[-7.74,5.5]

100%

100%

-2.7[-5.94,0.54]

-2.7[-5.94,0.54]

Favours physical activity

-20

-10

0

10

20

Favours control

Analysis 7.22.   Comparison 7 Comparison: cardiorespiratory fitness, all physical
activity vs control, Outcome 22 Resting Diastolic Blood Pressure (follow-up values).

Study or subgroup

Intervention

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

7.22.1 End of intervention

Kaltsatou 2011

Guinan 2013

Courneya 2003

Subtotal ***

78.8 (11.1)

78.8 (9.7)

85 (8.9)

14

16

25

55

Heterogeneity: Tau2=2.24; Chi2=2.57, df=2(P=0.28); I2=22.1%

Test for overall effect: Z=0.36(P=0.72)

7.22.2 Follow-up

Guinan 2013

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.7(P=0.48)

76.1 (7.8)

16

16

81.2 (7.1)

74.6 (4.4)

85.4 (7.1)

74 (7.2)

13

10

28

51

10

10

21.95%

32.59%

45.46%

100%

-2.4[-9.38,4.58]

4.2[-1.28,9.68]

-0.4[-4.77,3.97]

0.66[-2.89,4.21]

100%

100%

2.1[-3.78,7.98]

2.1[-3.78,7.98]

Favours physical activity

-20

-10

0

10

20

Favours control

Analysis 7.23.   Comparison 7 Comparison: cardiorespiratory fitness, all physical
activity vs control, Outcome 23 Resting Diastolic Blood Pressure (change values).

Study or subgroup

Intervention

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

7.23.1 End of intervention

Courneya 2003

Cadmus 2009

Guinan 2013

25

35

16

-4.1 (11)

0.8 (6.9)

0.4 (2.4)

28

30

10

-0.5 (10)

-1 (6.9)

-0.4 (2.9)

8.79%

21.27%

38.34%

-3.6[-9.28,2.08]

1.77[-1.59,5.13]

0.8[-1.38,2.98]

Favours intervention

-20

-10

0

10

20

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

316

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Intervention

Control

Subtotal ***

Mean(SD)

N

76

N

68

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

68.4%

0.53[-1.61,2.68]

Heterogeneity: Tau2=0.91; Chi2=2.59, df=2(P=0.27); I2=22.81%

Test for overall effect: Z=0.49(P=0.63)

7.23.2 Follow-up

Guinan 2013

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1(P=0.32)

Total ***

16

16

92

-2.3 (3)

10

10

78

Heterogeneity: Tau2=0.9; Chi2=4.12, df=3(P=0.25); I2=27.17%

Test for overall effect: Z=0.05(P=0.96)

Test for subgroup differences: Chi2=1.16, df=1 (P=0.28), I2=14.06%

-1 (3.4)

31.6%

31.6%

-1.3[-3.85,1.25]

-1.3[-3.85,1.25]

100%

-0.04[-1.82,1.73]

Favours intervention

-20

-10

0

10

20

Favours control

Comparison 8.   Comparison: physical activity, all physical activity vs control

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Overall self-reported physi-
cal activity (follow-up values)

1.1 End of intervention

1.2 Follow-up

2 Overall self-reported physi-
cal activity (change values)

2.1 End of intervention

2.2 Follow-up

3 Self-reported total physical
activity (follow-up values)

3.1 End of intervention

3.2 Follow-up

4 Self-reported total physical
activity (change values)

17

17

4

9

8

4

9

9

1

5

2012

683

1274

521

881

26

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.52 [0.33, 0.71]

Std. Mean Difference (IV, Random,
95% CI)

0.44 [0.17, 0.72]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.57 [0.25, 0.90]

Std. Mean Difference (IV, Random,
95% CI)

0.51 [0.08, 0.93]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.57 [0.28, 0.86]

Std. Mean Difference (IV, Random,
95% CI)

0.37 [-0.43, 1.16]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

317

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

4.1 End of intervention

4.2 Follow-up

5 Self-reported moderate
physical activity (follow-up
values)

5.1 End of intervention

5.2 Follow-up

6 Self-reported moderate
physical activity (change val-
ues)

6.1 End of intervention

6.2 Follow-up

7 Self-reported moder-
ate-vigorous physical activity
(follow-up values)

7.1 End of intervention

7.2 Follow-up

8 Self-reported moder-
ate-vigorous physical activity
(change values)

8.1 End of intervention

8.2 Follow-up

9 Self-reported vigorous
physical activity (follow-up
values)

9.1 End of intervention

9.2 Follow-up

5

2

4

4

1

2

2

1

6

6

3

4

2

3

3

3

1

332

108

249

26

93

26

1025

657

875

495

182

26

Std. Mean Difference (IV, Random,
95% CI)

0.80 [0.30, 1.31]

Std. Mean Difference (IV, Random,
95% CI)

0.73 [-0.36, 1.83]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.77 [0.47, 1.07]

Std. Mean Difference (IV, Random,
95% CI)

0.10 [-0.69, 0.89]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

1.19 [0.27, 2.11]

Std. Mean Difference (IV, Random,
95% CI)

1.20 [0.33, 2.06]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.42 [0.12, 0.72]

Std. Mean Difference (IV, Random,
95% CI)

0.46 [0.13, 0.78]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.15 [-0.14, 0.44]

Std. Mean Difference (IV, Random,
95% CI)

0.30 [0.00, 0.59]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.74 [0.43, 1.04]

Std. Mean Difference (IV, Random,
95% CI)

0.19 [-0.61, 0.98]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

318

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

10 Self-reported vigorous
physical activity (change val-
ues)

10.1 End of intervention

10.2 Follow-up

11 Self-reported walking (fol-
low-up values)

11.1 End of intervention

11.2 Follow-up

12 Self-reported walking
(change values)

12.1 End of intervention

12.2 Follow-up

13 7-Day PAR self-reported
moderate physical activity
(follow-up values)

13.1 End of intervention

13.2 Follow-up

14 7-day PAR self-reported
moderate-vigorous physical
activity (follow-up values)

14.1 End of intervention

14.2 Follow-up

15 Godin LSI self-reported
moderate-vigorous physical
activity (follow-up values)

15.1 End of intervention

15.2 Follow-up

2

2

2

2

2

1

2

2

1

2

2

0

2

2

1

5

5

2

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

1.72 [0.78, 2.66]

Std. Mean Difference (IV, Random,
95% CI)

-0.13 [-0.92, 0.66]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.40 [-0.06, 0.86]

Std. Mean Difference (IV, Random,
95% CI)

0.09 [-0.15, 0.34]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.50 [0.23, 0.77]

Std. Mean Difference (IV, Random,
95% CI)

0.23 [-0.02, 0.47]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

110.44 [72.50,
148.38]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

52.86 [29.04,
76.67]

Mean Difference (IV, Random, 95% CI)

41.2 [11.81, 70.59]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

39.42 [-1.51, 80.34]

Mean Difference (IV, Random, 95% CI)

55.07 [17.16,
92.99]

108

108

374

338

374

338

149

0

128

67

936

590

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

319

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

16 Meeting recommended
physical activity guidelines
(follow-up values)

16.1 End of intervention

16.2 Follow-up

17 Overall objective physical
activity (follow-up values)

17.1 End of intervention

6

6

2

10

10

17.2 Follow-up

18 Overall objective physical
activity (change values)

18.1 End of intervention

18.2 Follow-up

19 Objective moderate-vig-
orous physical activity (fol-
low-up values)

19.1 End of intervention

19.2 Follow-up

20 Objective moderate-vigor-
ous physical activity (change
values)

20.1 End of intervention

20.2 Follow-up

21 Objective vigorous physi-
cal activity (follow-up values)

21.1 End of intervention

21.2 Follow-up

3

6

5

2

5

5

2

3

2

1

2

2

1

Odds Ratio (M-H, Random, 95% CI)

Subtotals only

Odds Ratio (M-H, Random, 95% CI)

8.44 [2.41, 29.56]

Odds Ratio (M-H, Random, 95% CI)

3.11 [1.50, 6.46]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.43 [0.19, 0.66]

Std. Mean Difference (IV, Random,
95% CI)

0.22 [-0.21, 0.66]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.71 [0.14, 1.29]

Std. Mean Difference (IV, Random,
95% CI)

0.23 [1.00, 1.46]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

1.49 [0.47, 2.51]

Std. Mean Difference (IV, Random,
95% CI)

0.36 [-0.08, 0.79]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.92 [0.45, 1.40]

Std. Mean Difference (IV, Random,
95% CI)

0.84 [0.15, 1.52]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.46 [-0.05, 0.97]

Std. Mean Difference (IV, Random,
95% CI)

-0.16 [-0.97, 0.66]

819

280

1248

305

508

61

390

280

78

36

63

25

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

320

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

22 Accelerometer counts (fol-
low-up values)

22.1 End of intervention

22.2 Follow-up

23 Pedometer/accelerometer
steps/d (follow-up values)

23.1 End of intervention

23.2 Follow-up

24 Pedometer/accelerometer
steps/d (change values)

24.1 End of intervention

24.2 Follow-up

25 Overall sedentary behav-
iour (follow-up values)

25.1 End of intervention

25.2 Follow-up

26 Objective sedentary be-
haviour (follow-up values)

26.1 End of intervention

26.2 Follow-up

27 Objective sedentary be-
haviour (change values)

27.1 End of intervention

27.2 Follow-up

2

2

0

5

5

0

3

3

0

4

4

1

3

3

1

3

3

1

74

0

809

0

441

0

402

25

103

25

103

25

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.90 [0.08, 1.72]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.22 [-0.08, 0.53]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.45 [-0.18, 1.09]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-1.01 [-2.28, 0.26]

Std. Mean Difference (IV, Random,
95% CI)

0.58 [-0.26, 1.41]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-1.45 [-3.68, 0.78]

Std. Mean Difference (IV, Random,
95% CI)

0.58 [-0.26, 1.41]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.01 [-0.63, 0.60]

Std. Mean Difference (IV, Random,
95% CI)

0.88 [0.02, 1.74]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

321

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 8.1.   Comparison 8 Comparison: physical activity, all physical activity
vs control, Outcome 1 Overall self-reported physical activity (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.1.1 End of intervention

Guinan 2013

Matthews 2007

Rogers 2009

Kim 2015

Basen-Enquist 2006

Cadmus 2009

Pinto 2015

Littman 2012

Hatchett 2013

Winters-Stone 2011

Irwin 2015

Pinto 2005

Kiecolt-Glaser 2014

Rogers 2015

Vallance 2007

Schmitz 2009

Short 2014

Subtotal ***

38.7 (26.9)

54.2 (34.1)

121.4 (73.2)

17.6 (16)

428 (254.4)

161.7
(114.7)

70.3 (65.9)

19.2 (19.1)

3.5 (2.2)

430.8
(281.4)

222.1
(118.6)

202.4
(161.7)

11.2 (7.6)

169 (119)

207.6 (169)

3348.8
(9019.4)

217.9
(222.9)

16

22

20

20

35

34

36

32

38

36

45

39

96

110

253

131

195

1158

19.9 (11.3)

27.2 (22.7)

114.3
(131.5)

11.8 (11.6)

404 (265)

55.6 (101.9)

16.5 (31.9)

12.1 (13.6)

1.4 (1.7)

461.7
(346.4)

103.6
(104.6)

78.4 (86)

9.1 (6.1)

74 (107)

163 (121)

2339.8
(6213.7)

180.3
(206.9)

10

14

18

19

25

33

32

31

36

31

38

43

90

112

85

133

104

854

Heterogeneity: Tau2=0.1; Chi2=58.12, df=16(P<0.0001); I2=72.47%

Test for overall effect: Z=5.43(P<0.0001)

8.1.2 Follow-up

Guinan 2013

Pinto 2015

Rogers 2015

Vallance 2007

Subtotal ***

31.2 (21.1)

54.6 (81.6)

137 (137)

177.3
(190.8)

16

36

105

281

438

10

31

108

96

245

24.3 (11.9)

13.4 (35.2)

63 (95)

142 (126)

Heterogeneity: Tau2=0.04; Chi2=6.33, df=3(P=0.1); I2=52.63%

Test for overall effect: Z=3.18(P=0)

3.31%

4.01%

4.46%

4.47%

5.42%

5.47%

5.48%

5.54%

5.65%

5.71%

5.88%

5.9%

7.47%

7.6%

7.84%

7.88%

7.91%

100%

0.81[-0.01,1.64]

0.87[0.17,1.58]

0.07[-0.57,0.7]

0.4[-0.23,1.04]

0.09[-0.42,0.61]

0.97[0.46,1.47]

1.01[0.5,1.52]

0.42[-0.08,0.92]

1.04[0.55,1.53]

-0.1[-0.58,0.38]

1.04[0.58,1.51]

0.96[0.5,1.42]

0.3[0.01,0.59]

0.84[0.56,1.11]

0.28[0.03,0.53]

0.13[-0.11,0.37]

0.17[-0.07,0.41]

0.52[0.33,0.71]

9.53%

19.2%

33.77%

37.5%

0.37[-0.43,1.16]

0.63[0.14,1.12]

0.63[0.35,0.9]

0.2[-0.03,0.43]

100%

0.44[0.17,0.72]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 8.2.   Comparison 8 Comparison: physical activity, all physical activity
vs control, Outcome 2 Overall self-reported physical activity (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.2.1 End of intervention

Guinan 2013

Matthews 2007

Cadmus 2009

16

22

34

15.6 (11.4)

21.5 (30.6)

129 (117.9)

10

14

33

-8.3 (4.2)

5 (13.8)

44.3 (89.4)

5.92%

9.67%

12.23%

2.46[1.39,3.53]

0.63[-0.06,1.32]

0.8[0.3,1.3]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

322

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Irwin 2015

Pinto 2005

Schmitz 2009

Vallance 2007

Saarto 2012

Subtotal ***

159 (136)

84.7 (189.2)

2.8 (16.8)

82 (168.7)

3.5 (18.3)

45

39

48

281

262

747

38

43

57

96

236

527

49 (86)

-18.3
(200.7)

-0.8 (16.6)

30 (167.8)

3.3 (21.5)

Heterogeneity: Tau2=0.16; Chi2=39.44, df=7(P<0.0001); I2=82.25%

Test for overall effect: Z=3.5(P=0)

8.2.2 Follow-up

Guinan 2013

Rogers 2009

Pinto 2005

Vallance 2007

Subtotal ***

16

19

8 (8.8)

78.7 (119.2)

39

72.4 (208.6)

54.7 (254.5)

281

355

10

17

43

96

166

-3.9 (7.8)

-21.4
(113.9)

21.9 (203.9)

9 (251.7)

Heterogeneity: Tau2=0.12; Chi2=9.01, df=3(P=0.03); I2=66.71%

Test for overall effect: Z=2.31(P=0.02)

12.85%

13.07%

13.88%

15.89%

16.48%

100%

14.86%

19.96%

28.73%

36.45%

100%

0.94[0.48,1.4]

0.52[0.08,0.96]

0.21[-0.17,0.6]

0.31[0.08,0.54]

0.01[-0.17,0.19]

0.57[0.25,0.9]

1.37[0.48,2.25]

0.84[0.15,1.52]

0.24[-0.19,0.68]

0.18[-0.05,0.41]

0.51[0.08,0.93]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 8.3.   Comparison 8 Comparison: physical activity, all physical activity
vs control, Outcome 3 Self-reported total physical activity (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.3.1 End of intervention

Guinan 2013

Matthews 2007

Littman 2012

Hatchett 2013

Winters-Stone 2011

Irwin 2015

Pinto 2005

Kiecolt-Glaser 2014

Schmitz 2009

Subtotal ***

38.7 (26.9)

54.2 (34.1)

19.2 (19.1)

3.5 (2.2)

430.8
(281.4)

222.1
(118.6)

202.4
(161.7)

11.2 (7.6)

3348.8
(9019.4)

16

22

32

38

36

45

39

96

131

455

10

14

31

36

31

38

43

90

133

426

19.9 (11.3)

27.2 (22.7)

12.1 (13.6)

1.4 (1.7)

461.7
(346.4)

103.6
(104.6)

78.4 (86)

9.1 (6.1)

2339.8
(6213.7)

Heterogeneity: Tau2=0.14; Chi2=31.6, df=8(P=0); I2=74.69%

Test for overall effect: Z=3.84(P=0)

7.03%

8.32%

10.94%

11.11%

11.21%

11.48%

11.51%

13.9%

14.5%

100%

0.81[-0.01,1.64]

0.87[0.17,1.58]

0.42[-0.08,0.92]

1.04[0.55,1.53]

-0.1[-0.58,0.38]

1.04[0.58,1.51]

0.96[0.5,1.42]

0.3[0.01,0.59]

0.13[-0.11,0.37]

0.57[0.28,0.86]

8.3.2 Follow-up

Guinan 2013

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.9(P=0.37)

31.2 (21.1)

16

16

10

10

24.3 (11.9)

100%

100%

0.37[-0.43,1.16]

0.37[-0.43,1.16]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

323

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 8.4.   Comparison 8 Comparison: physical activity, all physical activity
vs control, Outcome 4 Self-reported total physical activity (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.4.1 End of intervention

Guinan 2013

Matthews 2007

Irwin 2015

Pinto 2005

Schmitz 2009

Subtotal ***

15.6 (11.4)

21.5 (30.6)

159 (136)

84.7 (189.2)

2.8 (16.8)

16

22

45

39

48

170

Heterogeneity: Tau2=0.24; Chi2=17.65, df=4(P=0); I2=77.34%

Test for overall effect: Z=3.1(P=0)

8.4.2 Follow-up

Guinan 2013

Pinto 2005

Subtotal ***

8 (8.8)

72.4 (208.6)

16

39

55

Heterogeneity: Tau2=0.5; Chi2=4.96, df=1(P=0.03); I2=79.85%

Test for overall effect: Z=1.32(P=0.19)

-8.3 (4.2)

5 (13.8)

49 (86)

-18.3
(200.7)

-0.8 (16.6)

-3.9 (7.8)

21.9 (203.9)

10

14

38

43

57

162

10

43

53

12.38%

18.34%

22.59%

22.86%

23.83%

100%

2.46[1.39,3.53]

0.63[-0.06,1.32]

0.94[0.48,1.4]

0.52[0.08,0.96]

0.21[-0.17,0.6]

0.8[0.3,1.31]

43.83%

56.17%

100%

1.37[0.48,2.25]

0.24[-0.19,0.68]

0.73[-0.36,1.83]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 8.5.   Comparison 8 Comparison: physical activity, all physical activity vs
control, Outcome 5 Self-reported moderate physical activity (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.5.1 End of intervention

Guinan 2013

Cadmus 2009

Hatchett 2013

Pinto 2005

Subtotal ***

16.1 (19.3)

161.7
(114.7)

1.1 (1.1)

192.6
(156.8)

16

34

38

39

127

10

33

36

43

122

14.8 (10.4)

55.6 (101.9)

0.4 (0.8)

77.2 (86.4)

Heterogeneity: Tau2=0.02; Chi2=3.92, df=3(P=0.27); I2=23.42%

Test for overall effect: Z=5(P<0.0001)

12.85%

26.57%

29.56%

31.02%

0.08[-0.71,0.87]

0.97[0.46,1.47]

0.74[0.27,1.22]

0.92[0.46,1.37]

100%

0.77[0.47,1.07]

8.5.2 Follow-up

Guinan 2013

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.26(P=0.8)

16.7 (17.1)

16

16

10

10

15 (13.9)

100%

100%

0.1[-0.69,0.89]

0.1[-0.69,0.89]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

324

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 8.6.   Comparison 8 Comparison: physical activity, all physical activity
vs control, Outcome 6 Self-reported moderate physical activity (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.6.1 End of intervention

Guinan 2013

Cadmus 2009

Subtotal ***

1.4 (3.4)

129 (117.9)

16

34

50

Heterogeneity: Tau2=0.31; Chi2=3.08, df=1(P=0.08); I2=67.58%

Test for overall effect: Z=2.53(P=0.01)

8.6.2 Follow-up

Guinan 2013

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.71(P=0.01)

2 (4.1)

16

16

-6.5 (5.6)

44.3 (89.4)

-6.3 (9.6)

10

33

43

10

10

40.86%

59.14%

100%

1.76[0.81,2.7]

0.8[0.3,1.3]

1.19[0.27,2.11]

100%

100%

1.2[0.33,2.06]

1.2[0.33,2.06]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 8.7.   Comparison 8 Comparison: physical activity, all physical activity vs
control, Outcome 7 Self-reported moderate-vigorous physical activity (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.7.1 End of intervention

Rogers 2009

20

121.4 (73.2)

Basen-Enquist 2006

Pinto 2015

Rogers 2015

Vallance 2007

Short 2014

Subtotal ***

428 (254.4)

70.3 (65.9)

169 (119)

207.6 (169)

217.9
(222.9)

35

36

110

253

195

649

Heterogeneity: Tau2=0.1; Chi2=22.1, df=5(P=0); I2=77.37%

Test for overall effect: Z=2.72(P=0.01)

8.7.2 Follow-up

Pinto 2015

Rogers 2015

Vallance 2007

Subtotal ***

54.6 (81.6)

137 (137)

177.3
(190.8)

36

105

281

422

Heterogeneity: Tau2=0.05; Chi2=6.32, df=2(P=0.04); I2=68.38%

Test for overall effect: Z=2.78(P=0.01)

114.3
(131.5)

404 (265)

16.5 (31.9)

74 (107)

163 (121)

180.3
(206.9)

13.4 (35.2)

63 (95)

142 (126)

18

25

32

112

85

104

376

31

108

96

235

11.5%

14%

14.13%

19.64%

20.27%

20.45%

0.07[-0.57,0.7]

0.09[-0.42,0.61]

1.01[0.5,1.52]

0.84[0.56,1.11]

0.28[0.03,0.53]

0.17[-0.07,0.41]

100%

0.42[0.12,0.72]

23.16%

36.87%

39.97%

0.63[0.14,1.12]

0.63[0.35,0.9]

0.2[-0.03,0.43]

100%

0.46[0.13,0.78]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

325

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 8.8.   Comparison 8 Comparison: physical activity, all physical activity vs
control, Outcome 8 Self-reported moderate-vigorous physical activity (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.8.1 End of intervention

Vallance 2007

Saarto 2012

Subtotal ***

82 (168.7)

3.5 (18.3)

281

262

543

Heterogeneity: Tau2=0.03; Chi2=4.01, df=1(P=0.05); I2=75.05%

Test for overall effect: Z=1(P=0.32)

8.8.2 Follow-up

Rogers 2009

Pinto 2005

Vallance 2007

Subtotal ***

19

78.7 (119.2)

39

72.4 (208.6)

54.7 (254.5)

281

339

Heterogeneity: Tau2=0.03; Chi2=3.18, df=2(P=0.2); I2=37.12%

Test for overall effect: Z=1.98(P=0.05)

30 (167.8)

3.3 (21.5)

-21.4
(113.9)

21.9 (203.9)

9 (251.7)

96

236

332

17

43

96

156

46.59%

53.41%

100%

0.31[0.08,0.54]

0.01[-0.17,0.19]

0.15[-0.14,0.44]

15.12%

29.65%

55.24%

100%

0.84[0.15,1.52]

0.24[-0.19,0.68]

0.18[-0.05,0.41]

0.3[0,0.59]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 8.9.   Comparison 8 Comparison: physical activity, all physical activity vs
control, Outcome 9 Self-reported vigorous physical activity (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.9.1 End of intervention

Guinan 2013

Hatchett 2013

Pinto 2005

Subtotal ***

17.2 (20.9)

2.4 (1.8)

9.9 (22.6)

16

38

39

93

Heterogeneity: Tau2=0; Chi2=1.74, df=2(P=0.42); I2=0%

Test for overall effect: Z=4.76(P<0.0001)

8.9.2 Follow-up

Guinan 2013

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.46(P=0.65)

7.3 (14.8)

16

16

0 (0)

1 (1.2)

1.2 (7)

4.5 (14.2)

10

36

43

89

10

10

12.89%

39.92%

47.19%

100%

1.01[0.16,1.85]

0.9[0.42,1.38]

0.52[0.08,0.96]

0.74[0.43,1.04]

100%

100%

0.19[-0.61,0.98]

0.19[-0.61,0.98]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 8.10.   Comparison 8 Comparison: physical activity, all physical activity
vs control, Outcome 10 Self-reported vigorous physical activity (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.10.1 End of intervention

Pinto 2005

39

0 (0)

43

0 (0)

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

326

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Guinan 2013

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=3.59(P=0)

8.10.2 Follow-up

Pinto 2005

Guinan 2013

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.33(P=0.74)

13.2 (9.4)

0 (0)

3.4 (9)

16

55

39

16

55

10

53

43

10

53

0 (0)

0 (0)

4.5 (6.3)

100%

100%

1.72[0.78,2.66]

1.72[0.78,2.66]

100%

100%

Not estimable

-0.13[-0.92,0.66]

-0.13[-0.92,0.66]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 8.11.   Comparison 8 Comparison: physical activity, all physical
activity vs control, Outcome 11 Self-reported walking (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.11.1 End of intervention

Matthews 2007

Vallance 2007

Subtotal ***

16.8 (15.3)

145.5
(194.1)

22

253

275

Heterogeneity: Tau2=0.06; Chi2=1.88, df=1(P=0.17); I2=46.83%

Test for overall effect: Z=1.69(P=0.09)

8.11.2 Follow-up

Vallance 2007

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.73(P=0.46)

253

253

105.7
(128.2)

6.6 (8.3)

102 (105)

94 (124)

14

85

99

85

85

29.35%

70.65%

0.76[0.07,1.46]

0.25[0,0.49]

100%

0.4[-0.06,0.86]

100%

100%

0.09[-0.15,0.34]

0.09[-0.15,0.34]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 8.12.   Comparison 8 Comparison: physical activity, all physical
activity vs control, Outcome 12 Self-reported walking (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.12.1 End of intervention

Matthews 2007

Vallance 2007

Subtotal ***

11.9 (14.4)

74.7 (169.2)

22

253

275

14

85

99

1.7 (5.9)

0 (166.9)

Heterogeneity: Tau2=0.01; Chi2=1.09, df=1(P=0.3); I2=8.61%

Test for overall effect: Z=3.58(P=0)

8.12.2 Follow-up

14.48%

85.52%

100%

0.84[0.14,1.54]

0.44[0.19,0.69]

0.5[0.23,0.77]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

327

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Vallance 2007

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.82(P=0.07)

N

253

253

Mean(SD)

N

Mean(SD)

Random, 95% CI

35.4 (180.8)

-6 (180.8)

85

85

100%

100%

Random, 95% CI

0.23[-0.02,0.47]

0.23[-0.02,0.47]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 8.13.   Comparison 8 Comparison: physical activity, all physical activity vs control,
Outcome 13 7-Day PAR self-reported moderate physical activity (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

192.6
(156.8)

161.7
(114.7)

43

77.2 (86.4)

33

55.6 (101.9)

8.13.1 End of intervention

Pinto 2005

Cadmus 2009

Subtotal ***

39

34

73

Heterogeneity: Tau2=0; Chi2=0.06, df=1(P=0.81); I2=0%

Test for overall effect: Z=5.71(P<0.0001)

8.13.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

76

0

46.59%

115.42[59.84,171]

53.41%

106.1[54.19,158.01]

100%

110.44[72.5,148.38]

Not estimable

Favours control

-200

-100

0

100

200

Favours physical activity

Analysis 8.14.   Comparison 8 Comparison: physical activity, all physical activity vs control,
Outcome 14 7-day PAR self-reported moderate-vigorous physical activity (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

8.14.1 End of intervention

Basen-Enquist 2006

Pinto 2015

Subtotal ***

428 (254.4)

70.3 (65.9)

35

36

71

Heterogeneity: Tau2=0; Chi2=0.18, df=1(P=0.67); I2=0%

Test for overall effect: Z=4.35(P<0.0001)

8.14.2 Follow-up

Pinto 2015

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.75(P=0.01)

54.6 (81.6)

36

36

404 (265)

16.5 (31.9)

13.4 (35.2)

25

32

57

31

31

3.17%

96.83%

100%

24[-109.77,157.77]

53.8[29.6,78]

52.86[29.04,76.67]

100%

100%

41.2[11.81,70.59]

41.2[11.81,70.59]

Favours control

-200

-100

0

100

200

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

328

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 8.15.   Comparison 8 Comparison: physical activity, all physical activity vs control,
Outcome 15 Godin LSI self-reported moderate-vigorous physical activity (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

8.15.1 End of intervention

Rogers 2009

Short 2014

Vallance 2007

Rogers 2015

Kim 2015

Subtotal ***

20

121.4 (73.2)

18

217.9
(222.9)

207.6 (169)

169 (119)

17.6 (16)

195

253

110

20

598

104

85

112

19

338

114.3
(131.5)

180.3
(206.9)

163 (121)

74 (107)

11.8 (11.6)

Heterogeneity: Tau2=1765.96; Chi2=35.84, df=4(P<0.0001); I2=88.84%

Test for overall effect: Z=1.89(P=0.06)

8.15.2 Follow-up

Vallance 2007

Rogers 2015

Subtotal ***

281

105

386

177.3
(190.8)

137 (137)

96

142 (126)

108

204

63 (95)

Heterogeneity: Tau2=470.22; Chi2=2.69, df=1(P=0.1); I2=62.79%

Test for overall effect: Z=2.85(P=0)

14.56%

17.93%

21.26%

21.84%

24.42%

100%

7.1[-61.6,75.8]

37.6[-13,88.2]

44.6[11.5,77.7]

95[65.21,124.79]

5.8[-2.95,14.55]

39.42[-1.51,80.34]

48.91%

51.09%

100%

35.3[1.64,68.96]

74[42.26,105.74]

55.07[17.16,92.99]

Favours control

-200

-100

0

100

200

Favours physical activity

Analysis 8.16.   Comparison 8 Comparison: physical activity, all physical activity vs control,
Outcome 16 Meeting recommended physical activity guidelines (follow-up values).

Physical
activity

n/N

Control

n/N

Odds Ratio

Weight

Odds Ratio

M-H, Random, 95% CI

M-H, Random, 95% CI

Study or subgroup

8.16.1 End of intervention

Pinto 2005

Pinto 2015

Irwin 2015

Cadmus 2009

Rogers 2015

Short 2014

Subtotal (95% CI)

15/43

15/36

32/45

22/36

58/106

61/195

461

0/41

2/32

2/38

3/33

24/110

33/104

358

Total events: 203 (Physical activity), 64 (Control)

Heterogeneity: Tau2=1.92; Chi2=43.87, df=5(P<0.0001); I2=88.6%

Test for overall effect: Z=3.34(P=0)

8.16.2 Follow-up

Pinto 2015

Rogers 2015

Subtotal (95% CI)

9/36

48/105

141

5/31

19/108

139

Total events: 57 (Physical activity), 24 (Control)

Heterogeneity: Tau2=0.09; Chi2=1.38, df=1(P=0.24); I2=27.7%

Test for overall effect: Z=3.04(P=0)

10.12%

15.93%

16.01%

17.02%

20.34%

20.58%

100%

45.14[2.59,785.26]

10.71[2.21,51.88]

44.31[9.28,211.49]

15.71[4.02,61.4]

4.33[2.39,7.83]

0.98[0.59,1.63]

8.44[2.41,29.56]

28.97%

71.03%

100%

1.73[0.51,5.86]

3.94[2.11,7.38]

3.11[1.5,6.46]

Favours control

0.001

0.1

1

10

1000

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

329

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 8.17.   Comparison 8 Comparison: physical activity, all physical activity
vs control, Outcome 17 Overall objective physical activity (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.17.1 End of intervention

Guinan 2013

Matthews 2007

Rogers 2014

Rogers 2009

Pinto 2015

Cadmus 2009

Pinto 2005

Rogers 2015

Vallance 2007

Short 2014

Subtotal ***

30.7 (15.6)

330.8
(114.7)

294 (175)

252191
(91893)

70.3 (65.9)

6738 (2958)

37.5 (14.3)

246 (153)

8110.5
(4133.9)

9363.1
(7922.8)

16

22

20

20

36

33

39

110

253

219

768

Heterogeneity: Tau2=0.08; Chi2=27.65, df=9(P=0); I2=67.45%

Test for overall effect: Z=3.58(P=0)

8.17.2 Follow-up

Guinan 2013

Pinto 2015

Rogers 2015

Subtotal ***

38.4 (25.9)

54.6 (81.6)

216 (131)

16

36

105

157

Heterogeneity: Tau2=0.08; Chi2=4.8, df=2(P=0.09); I2=58.32%

Test for overall effect: Z=1.01(P=0.31)

31 (15.6)

198.5 (55.4)

154 (75)

210917
(64078)

16.5 (31.9)

5537 (3352)

33.6 (19.4)

197 (138)

8028 (3457)

8301.2
(3373.4)

53.4 (53.9)

13.4 (35.2)

192 (136)

9

14

22

18

32

34

43

112

85

111

480

9

31

108

148

5.55%

6.25%

7.39%

7.4%

9.5%

9.9%

10.77%

14.06%

14.43%

14.74%

-0.02[-0.84,0.8]

1.34[0.6,2.09]

1.04[0.39,1.69]

0.51[-0.14,1.15]

1.01[0.5,1.52]

0.38[-0.11,0.86]

0.22[-0.21,0.66]

0.34[0.07,0.6]

0.02[-0.23,0.27]

0.16[-0.07,0.39]

100%

0.43[0.19,0.66]

18.89%

33.42%

47.69%

100%

-0.38[-1.21,0.44]

0.63[0.14,1.12]

0.18[-0.09,0.45]

0.22[-0.21,0.66]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 8.18.   Comparison 8 Comparison: physical activity, all physical activity
vs control, Outcome 18 Overall objective physical activity (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.18.1 End of intervention

Guinan 2013

Matthews 2007

Rogers 2014

Cadmus 2009

Vallance 2007

Subtotal ***

-1.1 (6.2)

72.2 (114.6)

114 (109)

1621 (2108)

-150
(5173.3)

16

22

20

33

253

344

9

14

22

34

85

164

-7.9 (5.3)

-16.8 (51.5)

10 (70)

-60 (2341)

91 (5155.4)

Heterogeneity: Tau2=0.33; Chi2=22.94, df=4(P=0); I2=82.56%

Test for overall effect: Z=2.43(P=0.02)

8.18.2 Follow-up

Guinan 2013

Rogers 2009

16

19

6.8 (11)

46082
(95608.9)

9

17

14.5 (26.2)

-15569
(28716.9)

16.02%

18.54%

19.28%

21.59%

24.57%

1.11[0.23,2]

0.91[0.2,1.62]

1.13[0.47,1.78]

0.75[0.25,1.24]

-0.05[-0.29,0.2]

100%

0.71[0.14,1.29]

48.24%

51.76%

-0.42[-1.25,0.41]

0.83[0.15,1.52]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

330

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Subtotal ***

Mean(SD)

N

35

N

26

Heterogeneity: Tau2=0.64; Chi2=5.24, df=1(P=0.02); I2=80.92%

Test for overall effect: Z=0.37(P=0.72)

Mean(SD)

Random, 95% CI

Random, 95% CI

100%

0.23[-1,1.46]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 8.19.   Comparison 8 Comparison: physical activity, all physical activity vs
control, Outcome 19 Objective moderate-vigorous physical activity (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.19.1 End of intervention

Rogers 2013

Matthews 2007

Rogers 2014

Pinto 2015

Rogers 2015

Subtotal ***

198.4
(111.7)

12.4 (1)

294 (175)

70.3 (65.9)

246 (153)

12

22

20

36

110

200

Heterogeneity: Tau2=0.95; Chi2=41.6, df=3(P<0.0001); I2=92.79%

Test for overall effect: Z=2.85(P=0)

8.19.2 Follow-up

Pinto 2015

Rogers 2015

Subtotal ***

54.6 (81.6)

216 (131)

36

105

141

Heterogeneity: Tau2=0.06; Chi2=2.5, df=1(P=0.11); I2=59.93%

Test for overall effect: Z=1.61(P=0.11)

0 (0)

8 (1)

154 (75)

16.5 (31.9)

197 (138)

13.4 (35.2)

192 (136)

10

14

22

32

112

190

31

108

139

19.96%

25.52%

26.59%

27.93%

100%

Not estimable

4.3[3.05,5.55]

1.04[0.39,1.69]

1.01[0.5,1.52]

0.34[0.07,0.6]

1.49[0.47,2.51]

39.17%

60.83%

100%

0.63[0.14,1.12]

0.18[-0.09,0.45]

0.36[-0.08,0.79]

Favours control

-10

-5

0

5

10

Favours physical activity

Analysis 8.20.   Comparison 8 Comparison: physical activity, all physical activity vs
control, Outcome 20 Objective moderate-vigorous physical activity (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.20.1 End of intervention

Matthews 2007

Rogers 2014

Subtotal ***

1.8 (4.4)

114 (109)

22

20

42

Heterogeneity: Tau2=0; Chi2=0.78, df=1(P=0.38); I2=0%

Test for overall effect: Z=3.8(P=0)

8.20.2 Follow-up

Rogers 2009

19

78.7 (119.2)

Subtotal ***

19

Heterogeneity: Not applicable

Test for overall effect: Z=2.4(P=0.02)

-0.9 (2.5)

10 (70)

-21.4
(113.9)

14

22

36

17

17

47.39%

52.61%

100%

0.7[0.01,1.39]

1.13[0.47,1.78]

0.92[0.45,1.4]

100%

100%

0.84[0.15,1.52]

0.84[0.15,1.52]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

331

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 8.21.   Comparison 8 Comparison: physical activity, all physical activity
vs control, Outcome 21 Objective vigorous physical activity (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.21.1 End of intervention

Guinan 2013

Rogers 2009

Subtotal ***

15.7 (15.7)

1.8 (4.3)

16

20

36

Heterogeneity: Tau2=0; Chi2=0.26, df=1(P=0.61); I2=0%

Test for overall effect: Z=1.76(P=0.08)

8.21.2 Follow-up

Guinan 2013

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.37(P=0.71)

15.8 (22.2)

16

16

11.2 (13.5)

0 (0)

19.8 (29.4)

9

18

27

9

9

38.56%

61.44%

100%

0.29[-0.53,1.11]

0.56[-0.09,1.21]

0.46[-0.05,0.97]

100%

100%

-0.16[-0.97,0.66]

-0.16[-0.97,0.66]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 8.22.   Comparison 8 Comparison: physical activity, all physical
activity vs control, Outcome 22 Accelerometer counts (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.22.1 End of intervention

Matthews 2007

Rogers 2009

Subtotal ***

330.8
(114.7)

252191
(91893)

22

20

42

Heterogeneity: Tau2=0.22; Chi2=2.75, df=1(P=0.1); I2=63.64%

Test for overall effect: Z=2.16(P=0.03)

8.22.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

14

198.5 (55.4)

210917
(64078)

18

32

0

47.45%

52.55%

1.34[0.6,2.09]

0.51[-0.14,1.15]

100%

0.9[0.08,1.72]

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 8.23.   Comparison 8 Comparison: physical activity, all physical activity
vs control, Outcome 23 Pedometer/accelerometer steps/d (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.23.1 End of intervention

Matthews 2007

Rogers 2009

22

8561.8
(2887.3)

14

5379.9
(1798.1)

20

7301 (2266)

18

8388 (5361)

11.39%

13.58%

1.23[0.5,1.97]

-0.26[-0.9,0.38]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

332

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Cadmus 2009

Vallance 2007

Short 2014

Subtotal ***

N

33

253

219

547

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

6738 (2958)

8110.5
(4133.9)

9363.1
(7922.8)

5537 (3352)

8028 (3457)

8301.2
(3373.4)

34

85

111

262

18.33%

28%

28.7%

100%

0.38[-0.11,0.86]

0.02[-0.23,0.27]

0.16[-0.07,0.39]

0.22[-0.08,0.53]

Heterogeneity: Tau2=0.07; Chi2=11.83, df=4(P=0.02); I2=66.18%

Test for overall effect: Z=1.45(P=0.15)

8.23.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 8.24.   Comparison 8 Comparison: physical activity, all physical activity
vs control, Outcome 24 Pedometer/accelerometer steps/d (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.24.1 End of intervention

Matthews 2007

Cadmus 2009

Vallance 2007

Subtotal ***

1152.5
(2408.8)

1621 (2108)

-150
(5173.3)

22

33

253

308

14

34

85

133

-559.1
(1326.5)

-60 (2341)

91 (5155.4)

Heterogeneity: Tau2=0.25; Chi2=11.38, df=2(P=0); I2=82.42%

Test for overall effect: Z=1.4(P=0.16)

27.67%

33.17%

39.15%

0.81[0.11,1.51]

0.75[0.25,1.24]

-0.05[-0.29,0.2]

100%

0.45[-0.18,1.09]

8.24.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 8.25.   Comparison 8 Comparison: physical activity, all physical activity
vs control, Outcome 25 Overall sedentary behaviour (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.25.1 End of intervention

Matthews 2007

Guinan 2013

Rogers 2014

Short 2014

22

16

20

195

72.3 (1.5)

446 (127)

7141.4
(536.2)

481.7
(225.7)

14

9

22

104

79.5 (1.8)

385.8
(107.9)

7549.2
(628.4)

486.5
(211.1)

21.78%

24.78%

-4.34[-5.6,-3.09]

0.48[-0.35,1.31]

25.98%

-0.68[-1.31,-0.06]

27.46%

-0.02[-0.26,0.22]

Favours physical activity

-10

-5

0

5

10

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

333

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Subtotal ***

Mean(SD)

N

253

N

149

Heterogeneity: Tau2=1.5; Chi2=48.79, df=3(P<0.0001); I2=93.85%

Test for overall effect: Z=1.56(P=0.12)

Mean(SD)

Random, 95% CI

Random, 95% CI

100%

-1.01[-2.28,0.26]

8.25.2 Follow-up

Guinan 2013

16

438 (121.6)

Subtotal ***

16

Heterogeneity: Not applicable

Test for overall effect: Z=1.35(P=0.18)

359.5
(149.3)

9

9

100%

100%

0.58[-0.26,1.41]

0.58[-0.26,1.41]

Favours physical activity

-10

-5

0

5

10

Favours control

Analysis 8.26.   Comparison 8 Comparison: physical activity, all physical activity
vs control, Outcome 26 Objective sedentary behaviour (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.26.1 End of intervention

Matthews 2007

Guinan 2013

Rogers 2014

Subtotal ***

72.3 (1.5)

446 (127)

7141.4
(536.2)

22

16

20

58

Heterogeneity: Tau2=3.65; Chi2=39.84, df=2(P<0.0001); I2=94.98%

Test for overall effect: Z=1.28(P=0.2)

8.26.2 Follow-up

Guinan 2013

16

438 (121.6)

Subtotal ***

16

Heterogeneity: Not applicable

Test for overall effect: Z=1.35(P=0.18)

79.5 (1.8)

385.8
(107.9)

7549.2
(628.4)

359.5
(149.3)

14

9

22

45

9

9

31.82%

33.74%

-4.34[-5.6,-3.09]

0.48[-0.35,1.31]

34.44%

-0.68[-1.31,-0.06]

100%

-1.45[-3.68,0.78]

100%

100%

0.58[-0.26,1.41]

0.58[-0.26,1.41]

Favours physical activity

-10

-5

0

5

10

Favours control

Analysis 8.27.   Comparison 8 Comparison: physical activity, all physical
activity vs control, Outcome 27 Objective sedentary behaviour (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.27.1 End of intervention

Guinan 2013

Matthews 2007

Rogers 2014

Subtotal ***

18.5 (52.2)

-1.3 (7.3)

-84.4
(788.2)

16

22

20

58

-19.8 (62.8)

2.3 (5.6)

-55.2
(435.3)

9

14

22

45

Heterogeneity: Tau2=0.17; Chi2=4.6, df=2(P=0.1); I2=56.57%

Test for overall effect: Z=0.04(P=0.97)

28.13%

34.26%

37.61%

0.66[-0.18,1.5]

-0.53[-1.21,0.16]

-0.05[-0.65,0.56]

100%

-0.01[-0.63,0.6]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

334

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

8.27.2 Follow-up

Guinan 2013

Subtotal ***

10.5 (46.7)

16

16

-46.1 (84.2)

9

9

100%

100%

0.88[0.02,1.74]

0.88[0.02,1.74]

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=2(P=0.05)

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Comparison 9.   Comparison: anthropometric outcomes, all physical activity vs control

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Mass (follow-up values)

1.1 End of intervention

1.2 Follow-up

2 Mass (change values)

2.1 End of intervention

2.2 Follow-up

3 BMI (follow-up values)

3.1 End of intervention

3.2 Follow-up

4 BMI (change values)

4.1 End of intervention

4.2 Follow-up

5 Overall body fat (fol-
low-up values)

5.1 End of intervention

5.2 Follow-up

6 Overall body fat (change
values)

6.1 End of intervention

16

16

1

11

11

0

17

17

0

8

8

0

18

18

1

9

9

1210

49

1047

0

1481

0

485

0

1162

49

499

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

0.00 [-0.57, 0.58]

Mean Difference (IV, Fixed, 95% CI)

5.02 [-5.17, 15.21]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-0.50 [-0.98, -0.01]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

0.01 [-0.19, 0.22]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-0.22 [-0.45, 0.01]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.18 [-0.34, -0.03]

Std. Mean Difference (IV, Random,
95% CI)

0.08 [-0.48, 0.64]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.62 [-1.19, -0.06]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

335

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

6.2 Follow-up

7 Percentage body fat -
DEXA (follow-up values)

7.1 End of intervention

7.2 Follow-up

8 Percentage body fat -
DEXA (change values)

8.1 End of intervention

8.2 Follow-up

9 Percentage body fat - BIA
(follow-up values)

9.1 End of intervention

9.2 Follow-up

10 Percentage body fat - BIA
(change values)

10.1 End of intervention

10.2 Follow-up

11 Percentage body fat -
SKF (follow-up values)

11.1 End of intervention

11.2 Follow-up

12 Fat mass (follow-up val-
ues)

12.1 End of intervention

12.2 Follow-up

13 Fat mass (change values)

13.1 End of intervention

13.2 Follow-up

14 Fat mass - DEXA (fol-
low-up values)

0

6

6

1

3

3

0

7

7

0

4

4

0

3

3

0

5

5

0

4

4

0

3

0

580

49

228

0

331

0

185

0

165

0

460

0

768

0

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-0.66 [-1.70, 0.37]

Mean Difference (IV, Random, 95% CI)

0.52 [-3.18, 4.22]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-1.32 [-1.66, -0.99]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

-1.47 [-2.84, -0.10]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

-0.70 [-1.26, -0.13]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-0.73 [-2.41, 0.96]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

-0.70 [-1.40, -0.00]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-0.46 [-1.08, 0.15]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

336

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

14.1 End of intervention

14.2 Follow-up

15 Fat mass - DEXA (change
values)

15.1 End of intervention

15.2 Follow-up

16 Lean mass (follow-up
values)

16.1 End of intervention

16.2 Follow-up

17 Lean mass (change val-
ues)

17.1 End of intervention

17.2 Follow-up

18 Lean mass - DEXA (fol-
low-up values)

18.1 End of intervention

18.2 Follow-up

19 Lean mass - DEXA
(change values)

19.1 End of intervention

19.2 Follow-up

20 Waist-to-hip ratio (fol-
low-up values)

20.1 End of intervention

20.2 Follow-up

21 Waist-to-hip ratio
(change values)

21.1 End of intervention

3

0

2

2

0

8

8

1

5

5

0

5

5

1

2

2

0

5

5

0

3

2

408

0

207

0

612

49

760

0

541

49

207

0

213

0

Mean Difference (IV, Fixed, 95% CI)

-0.68 [-1.39, 0.03]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-0.74 [-0.93, -0.56]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Fixed, 95%
CI)

0.05 [-0.11, 0.21]

Std. Mean Difference (IV, Fixed, 95%
CI)

0.33 [-0.24, 0.89]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.80 [-0.13, 1.72]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

0.43 [-0.54, 1.40]

Mean Difference (IV, Fixed, 95% CI)

2.41 [-1.62, 6.44]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

0.73 [0.17, 1.29]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-0.03 [-0.06, 0.01]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

124

Mean Difference (IV, Fixed, 95% CI)

0.0 [-0.01, 0.01]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

337

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

21.2 Follow-up

22 Waist circumference (fol-
low-up values)

22.1 End of intervention

22.2 Follow-up

23 Waist circumference
(change values)

23.1 End of intervention

23.2 Follow-up

24 Hip circumference (fol-
low-up values)

24.1 End of intervention

24.2 Follow-up

25 Hip circumference
(change values)

25.1 End of intervention

25.2 Follow-up

1

6

6

1

5

5

1

4

4

0

2

2

0

36

Mean Difference (IV, Fixed, 95% CI)

0.04 [-0.14, 0.22]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

330

26

285

26

249

0

115

0

Mean Difference (IV, Fixed, 95% CI)

-0.50 [-3.18, 2.18]

Mean Difference (IV, Fixed, 95% CI)

1.40 [-8.29, 11.09]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-1.71 [-2.56, -0.86]

Mean Difference (IV, Random, 95% CI)

-0.90 [-2.61, 0.81]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

-0.97 [-3.96, 2.01]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-2.37 [-3.31, -1.44]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Analysis 9.1.   Comparison 9 Comparison: anthropometric outcomes,
all physical activity vs control, Outcome 1 Mass (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

9.1.1 End of intervention

Matthews 2007

Mustian 2004

Courneya 2003

Nikander 2007

Cadmus 2009

Herrero 2006

Rahnama 2010

DeNysschen 2011

Ligibel 2008

Littman 2012

Winters-Stone 2011

Daley 2007

Murtezani 2014

Schmitz 2009

22

11

24

14

36

8

14

30

40

28

36

33

30

74.9 (15.2)

67.1 (10.4)

78.2 (20.5)

73.5 (13.3)

80.7 (16.9)

65.6 (8.7)

69.4 (13.5)

69.3 (14.2)

80 (17.5)

81.1 (13.6)

76.5 (15.6)

74.3 (12.5)

71.7 (9.5)

14

10

26

14

33

8

15

34

42

27

31

69

32

78.9 (20.3)

68.6 (13.8)

80.1 (16.2)

75.5 (12)

78.5 (20.6)

67.3 (8.9)

71.6 (9.2)

72.4 (19.6)

83.3 (18.7)

81.3 (14.3)

74.2 (12.3)

75.6 (12.5)

72.6 (10.8)

131

76.2 (15.7)

133

77.2 (17)

0.22%

0.3%

0.31%

0.38%

0.42%

0.45%

0.46%

0.48%

0.54%

0.61%

0.75%

1.24%

1.31%

2.14%

Favours physical activity

-20

-10

0

10

20

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

-4[-16.39,8.39]

-1.5[-12.06,9.06]

-1.9[-12.2,8.4]

-2[-11.38,7.38]

2.22[-6.72,11.16]

-1.7[-10.32,6.92]

-2.2[-10.67,6.27]

-3.1[-11.42,5.22]

-3.3[-11.14,4.54]

-0.2[-7.58,7.18]

2.3[-4.39,8.99]

-1.34[-6.52,3.84]

-0.9[-5.94,4.14]

-1.04[-4.98,2.9]

338

 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Physical activity

Control

Schmitz 2005

Kiecolt-Glaser 2014

Subtotal ***

Mean(SD)

69.5 (2.2)

75.2 (2.8)

N

39

96

592

Mean(SD)

69.2 (2.2)

75.2 (2.6)

N

40

90

618

Heterogeneity: Tau2=0; Chi2=4.11, df=15(P=1); I2=0%

Test for overall effect: Z=0.01(P=0.99)

Cochrane Database of Systematic Reviews

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

35.06%

55.32%

100%

0.3[-0.67,1.27]

0[-0.78,0.78]

0[-0.57,0.58]

9.1.2 Follow-up

Cadmus 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.97(P=0.33)

81.6 (19)

26

26

76.6 (17.4)

23

23

100%

100%

5.02[-5.17,15.21]

5.02[-5.17,15.21]

Favours physical activity

-20

-10

0

10

20

Favours control

Analysis 9.2.   Comparison 9 Comparison: anthropometric outcomes,
all physical activity vs control, Outcome 2 Mass (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

9.2.1 End of intervention

Dolan 2016

Irwin 2015

Mustian 2004

Ligibel 2008

Matthews 2007

Schmitz 2009

Murtezani 2014

Naumann 2012

Courneya 2003

Saarto 2012

Schmitz 2005

Subtotal ***

23

45

9

22

22

65

30

11

24

262

39

552

-0.5 (5)

-2.1 (4.3)

-0.3 (1.9)

0 (2.3)

0 (2.1)

-1 (3.7)

-2.3 (2.4)

0.5 (1.3)

0.1 (2)

0.7 (3.7)

0.3 (0.4)

10

38

10

14

14

65

32

10

26

236

40

495

1.4 (1.6)

0.1 (3.6)

0.6 (1.4)

0 (2.2)

0 (2.2)

-0.4 (4.3)

-0.3 (2.6)

0.1 (1.5)

0.7 (1.8)

0.7 (3.8)

0.2 (0.4)

Heterogeneity: Tau2=0.31; Chi2=24.45, df=10(P=0.01); I2=59.1%

Test for overall effect: Z=2.01(P=0.04)

3.67%

5.8%

6.85%

6.97%

7.32%

7.66%

8.65%

8.79%

10.27%

14.59%

19.45%

100%

-1.99[-4.28,0.3]

-2.2[-3.9,-0.5]

-0.9[-2.4,0.6]

-0.04[-1.52,1.44]

-0.03[-1.46,1.4]

-0.6[-1.98,0.78]

-2[-3.24,-0.76]

0.33[-0.9,1.56]

-0.6[-1.66,0.46]

-0.01[-0.67,0.65]

0.12[-0.07,0.31]

-0.5[-0.98,-0.01]

9.2.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 9.3.   Comparison 9 Comparison: anthropometric outcomes,
all physical activity vs control, Outcome 3 BMI (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

9.3.1 End of intervention

Portela 2008

25

29.1 (5.5)

9

34.7 (15)

0.04%

-5.6[-15.63,4.43]

Favours physical activity

-20

-10

0

10

20

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

339

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

Rogers 2013

Rogers 2009

Mustian 2004

Nikander 2007

Courneya 2003

Rogers 2014

Rahnama 2010

Cadmus 2009

Ligibel 2008

Littman 2012

Pinto 2005

Murtezani 2014

Schmitz 2009

Vallance 2007

Schmitz 2005

Kiecolt-Glaser 2014

Subtotal ***

12

20

11

14

24

20

14

36

40

28

39

30

131

253

39

96

832

33.6 (7)

30.6 (7.6)

23.9 (4.2)

26.9 (5.6)

29.4 (7.4)

29.6 (5)

27.7 (4.8)

30.5 (6)

30.3 (6.3)

27.7 (5)

27.7 (5)

25.1 (2.9)

10

18

10

14

26

22

15

33

42

27

43

32

30.6 (7.3)

30.4 (8.3)

26.7 (5.6)

27.7 (4.9)

29.3 (6)

32.2 (6.7)

28 (4.6)

29.9 (7.6)

31.5 (6.8)

29 (5.6)

29 (5.6)

25.8 (3.5)

28.5 (5.6)

133

28.9 (6.3)

27 (5.2)

26 (0.7)

27.8 (1.1)

85

40

90

649

27.2 (5.2)

25.8 (0.7)

27.8 (1)

Heterogeneity: Tau2=0; Chi2=11.79, df=16(P=0.76); I2=0%

Test for overall effect: Z=0.14(P=0.89)

0.12%

0.16%

0.23%

0.28%

0.3%

0.33%

0.36%

0.4%

0.52%

0.53%

0.8%

1.67%

2.07%

2.62%

40.1%

49.47%

100%

3[-3,9]

0.2[-4.88,5.28]

-2.8[-7.05,1.45]

-0.8[-4.7,3.1]

0.1[-3.65,3.85]

-2.6[-6.16,0.96]

-0.3[-3.71,3.11]

0.55[-2.7,3.8]

-1.2[-4.04,1.64]

-1.35[-4.17,1.47]

-1.35[-3.65,0.95]

-0.7[-2.29,0.89]

-0.48[-1.91,0.95]

-0.19[-1.46,1.08]

0.2[-0.12,0.52]

0[-0.29,0.29]

0.01[-0.19,0.22]

9.3.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours physical activity

-20

-10

0

10

20

Favours control

Analysis 9.4.   Comparison 9 Comparison: anthropometric outcomes,
all physical activity vs control, Outcome 4 BMI (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

9.4.1 End of intervention

Schmitz 2009

Mustian 2004

Rogers 2014

Naumann 2012

Courneya 2003

Murtezani 2014

Ligibel 2008

Schmitz 2005

Subtotal ***

65

9

20

11

24

30

40

39

238

-1 (3.7)

-0.4 (0.8)

-0.2 (0.9)

0.1 (0.5)

0 (0.7)

-0.8 (0.7)

0 (0.9)

0.1 (0.2)

65

10

22

10

26

32

42

40

247

-0.4 (4.3)

0.3 (0.6)

-0.3 (1.1)

-0.1 (0.6)

0.3 (0.7)

-0.1 (0.8)

0.2 (0.8)

0.1 (0.2)

Heterogeneity: Tau2=0.06; Chi2=19.97, df=7(P=0.01); I2=64.95%

Test for overall effect: Z=1.83(P=0.07)

2.52%

8.83%

9.07%

12.29%

14.3%

14.74%

14.87%

23.39%

100%

-0.6[-1.98,0.78]

-0.71[-1.33,-0.09]

0.1[-0.51,0.71]

0.2[-0.26,0.66]

-0.3[-0.69,0.09]

-0.66[-1.03,-0.29]

-0.2[-0.57,0.17]

-0.01[-0.08,0.06]

-0.22[-0.45,0.01]

9.4.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

340

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 9.5.   Comparison 9 Comparison: anthropometric outcomes, all
physical activity vs control, Outcome 5 Overall body fat (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

9.5.1 End of intervention

Herrero 2006

Cerulli 2014

Mustian 2004

Rogers 2013

Matthews 2007

Musanti 2012

Rogers 2009

Rogers 2014

Courneya 2003

DeNysschen 2011

Winters-Stone 2011

Saarto 2012

Cadmus 2009

Schmitz 2005

Pinto 2005

Ligibel 2008

Daley 2007

Schmitz 2009

Subtotal ***

22 (5)

26.7 (5.3)

38.5 (4.5)

44.2 (6.7)

39.7 (6.3)

34.1 (6.6)

44.3 (7.4)

38.6 (6.4)

131.9 (46.4)

36.9 (8.4)

40.5 (6.2)

39.9 (7.5)

40.5 (6.6)

40.9 (1.3)

37.5 (4.8)

42.9 (7.4)

39.4 (4.7)

38.5 (5.9)

8

10

11

10

22

30

20

20

24

30

36

37

36

39

39

40

33

130

575

22 (4)

30.6 (4.4)

41.7 (4.9)

42.3 (7.7)

43.1 (6.9)

33.7 (5.7)

43.5 (7.5)

41.5 (7.4)

137.1 (44.4)

38 (10.2)

38.5 (5.8)

40.2 (8)

39.6 (6)

42.3 (1.3)

38.6 (4.8)

44.7 (8)

40.1 (7.4)

39.7 (5.9)

8

10

10

12

14

12

19

22

26

34

31

30

33

40

43

42

69

132

587

Heterogeneity: Tau2=0.04; Chi2=26.29, df=17(P=0.07); I2=35.33%

Test for overall effect: Z=2.29(P=0.02)

2.2%

2.48%

2.63%

2.84%

4%

4.11%

4.52%

4.69%

5.39%

6.33%

6.46%

6.5%

6.64%

6.66%

7.34%

7.35%

7.73%

12.11%

100%

0[-0.98,0.98]

-0.75[-1.66,0.16]

-0.66[-1.54,0.23]

0.25[-0.59,1.09]

-0.51[-1.19,0.17]

0.07[-0.6,0.74]

0.11[-0.52,0.73]

-0.41[-1.02,0.2]

-0.11[-0.67,0.44]

-0.12[-0.61,0.38]

0.33[-0.16,0.81]

-0.04[-0.52,0.44]

0.15[-0.33,0.62]

-1.05[-1.52,-0.58]

-0.21[-0.64,0.22]

-0.23[-0.67,0.2]

-0.1[-0.52,0.31]

-0.21[-0.46,0.03]

-0.18[-0.34,-0.03]

9.5.2 Follow-up

Cadmus 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.27(P=0.79)

26

26

40 (7.1)

23

23

39.5 (6.1)

100%

100%

0.08[-0.48,0.64]

0.08[-0.48,0.64]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 9.6.   Comparison 9 Comparison: anthropometric outcomes, all
physical activity vs control, Outcome 6 Overall body fat (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

9.6.1 End of intervention

Mustian 2004

Naumann 2012

Musanti 2012

Matthews 2007

Schmitz 2005

Rogers 2014

Courneya 2003

Ligibel 2008

Schmitz 2009

9

11

30

22

39

20

24

40

65

-0.2 (2.9)

-0.3 (2.4)

-0.2 (2.8)

-0.2 (1.6)

-1.1 (0.5)

-1.1 (2.2)

-4.9 (15.7)

-0.2 (1.7)

-0.3 (5.7)

10

10

12

14

40

22

26

42

63

0.3 (1.6)

0.8 (2.8)

1.4 (1.6)

0.4 (1.9)

0.2 (0.4)

-0.6 (2.4)

5.1 (24.4)

0.3 (1.7)

-0.1 (3.3)

9.78%

9.97%

10.93%

10.98%

11.05%

11.31%

11.52%

12.07%

12.39%

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

-0.18[-1.09,0.72]

-0.41[-1.28,0.46]

-0.63[-1.32,0.05]

-0.34[-1.02,0.33]

-3.07[-3.73,-2.41]

-0.21[-0.82,0.39]

-0.48[-1.04,0.09]

-0.29[-0.73,0.14]

-0.04[-0.39,0.3]

341

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Subtotal ***

Mean(SD)

N

260

N

239

Heterogeneity: Tau2=0.65; Chi2=67.55, df=8(P<0.0001); I2=88.16%

Test for overall effect: Z=2.15(P=0.03)

Mean(SD)

Random, 95% CI

Random, 95% CI

100%

-0.62[-1.19,-0.06]

9.6.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 9.7.   Comparison 9 Comparison: anthropometric outcomes, all physical
activity vs control, Outcome 7 Percentage body fat - DEXA (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

9.7.1 End of intervention

Rogers 2009

DeNysschen 2011

Cadmus 2009

Winters-Stone 2011

Schmitz 2009

Schmitz 2005

Subtotal ***

20

30

36

36

130

39

291

44.3 (7.4)

36.9 (8.4)

40.5 (6.6)

40.5 (6.2)

38.5 (5.9)

40.9 (1.3)

19

34

33

31

132

40

289

43.5 (7.5)

38 (10.2)

39.6 (6)

38.5 (5.8)

39.7 (5.9)

42.3 (1.3)

Heterogeneity: Tau2=0.53; Chi2=7.84, df=5(P=0.17); I2=36.21%

Test for overall effect: Z=1.26(P=0.21)

4.44%

4.66%

9.87%

10.31%

25.96%

44.77%

100%

0.8[-3.88,5.48]

-1.1[-5.66,3.46]

0.94[-2.01,3.89]

2[-0.88,4.88]

-1.27[-2.7,0.16]

-1.38[-1.96,-0.8]

-0.66[-1.7,0.37]

9.7.2 Follow-up

Cadmus 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.28(P=0.78)

26

26

40 (7.1)

23

23

39.5 (6.1)

100%

100%

0.52[-3.18,4.22]

0.52[-3.18,4.22]

Favours physical activity

-10

-5

0

5

10

Favours control

Analysis 9.8.   Comparison 9 Comparison: anthropometric outcomes, all physical
activity vs control, Outcome 8 Percentage body fat - DEXA (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

9.8.1 End of intervention

Naumann 2012

Schmitz 2009

Schmitz 2005

Subtotal ***

11

65

39

115

-0.3 (2.4)

-0.3 (5.7)

-1.1 (0.5)

10

63

40

113

0.8 (2.8)

-0.1 (3.3)

0.2 (0.4)

Heterogeneity: Tau2=0.02; Chi2=2.09, df=2(P=0.35); I2=4.42%

Test for overall effect: Z=7.79(P<0.0001)

9.8.2 Follow-up

2.21%

4.16%

93.63%

100%

-1.1[-3.32,1.12]

-0.2[-1.81,1.41]

-1.38[-1.58,-1.18]

-1.32[-1.66,-0.99]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

342

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Subtotal ***

0

0

Weight

Mean Difference

Random, 95% CI

Not estimable

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 9.9.   Comparison 9 Comparison: anthropometric outcomes, all physical
activity vs control, Outcome 9 Percentage body fat - BIA (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

9.9.1 End of intervention

Rogers 2013

Cerulli 2014

Rogers 2014

Mustian 2004

Musanti 2012

Ligibel 2008

Daley 2007

Subtotal ***

10

10

20

11

30

40

33

154

44.2 (6.7)

26.7 (5.3)

38.6 (6.4)

38.5 (4.5)

34.1 (6.6)

42.9 (7.4)

39.4 (4.7)

12

10

22

10

12

42

69

177

42.3 (7.7)

30.6 (4.4)

41.5 (7.4)

41.7 (4.9)

33.7 (5.7)

44.7 (8)

40.1 (7.4)

Heterogeneity: Tau2=0; Chi2=4.83, df=6(P=0.57); I2=0%

Test for overall effect: Z=2.1(P=0.04)

5.21%

10.26%

10.82%

11.67%

11.76%

16.98%

33.31%

100%

1.9[-4.12,7.92]

-3.83[-8.12,0.46]

-2.9[-7.07,1.27]

-3.2[-7.22,0.82]

0.43[-3.58,4.44]

-1.8[-5.13,1.53]

-0.7[-3.08,1.68]

-1.47[-2.84,-0.1]

9.9.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours physical activity

-20

-10

0

10

20

Favours control

Analysis 9.10.   Comparison 9 Comparison: anthropometric outcomes, all physical
activity vs control, Outcome 10 Percentage body fat - BIA (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

9.10.1 End of intervention

Mustian 2004

Rogers 2014

Musanti 2012

Ligibel 2008

Subtotal ***

-0.2 (2.9)

-1.1 (2.2)

-0.2 (2.8)

-0.2 (1.7)

9

20

30

40

99

Heterogeneity: Tau2=0; Chi2=2.29, df=3(P=0.51); I2=0%

Test for overall effect: Z=2.42(P=0.02)

9.10.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0.3 (1.6)

-0.6 (2.4)

1.4 (1.6)

0.3 (1.7)

10

22

12

42

86

0

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

7%

16.49%

17.59%

58.91%

100%

-0.44[-2.58,1.7]

-0.5[-1.89,0.89]

-1.64[-2.99,-0.29]

-0.5[-1.24,0.24]

-0.7[-1.26,-0.13]

Not estimable

343

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 9.11.   Comparison 9 Comparison: anthropometric outcomes, all physical
activity vs control, Outcome 11 Percentage body fat - SKF (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

9.11.1 End of intervention

Herrero 2006

Saarto 2012

Pinto 2005

Subtotal ***

22 (5)

39.9 (7.5)

37.5 (4.8)

8

37

39

84

Heterogeneity: Tau2=0; Chi2=0.23, df=2(P=0.89); I2=0%

Test for overall effect: Z=0.85(P=0.4)

9.11.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

22 (4)

40.2 (8)

38.6 (4.8)

8

30

43

81

0

14.42%

20.23%

65.35%

100%

0[-4.44,4.44]

-0.3[-4.05,3.45]

-1.02[-3.1,1.06]

-0.73[-2.41,0.96]

Not estimable

Favours physical activity

-10

-5

0

5

10

Favours control

Analysis 9.12.   Comparison 9 Comparison: anthropometric outcomes,
all physical activity vs control, Outcome 12 Fat mass (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

9.12.1 End of intervention

Matthews 2007

Herrero 2006

Winters-Stone 2011

Schmitz 2009

Schmitz 2005

Subtotal ***

22

8

36

129

39

234

30.2 (9.2)

14.7 (4.8)

30.9 (9.7)

29.6 (9.6)

28.3 (1.7)

34.9 (14.5)

15.3 (4.6)

29 (8.1)

31.1 (10.5)

29 (1.7)

14

8

31

133

40

226

Heterogeneity: Tau2=0; Chi2=2.71, df=4(P=0.61); I2=0%

Test for overall effect: Z=1.97(P=0.05)

0.68%

2.31%

2.7%

8.24%

86.08%

100%

-4.7[-13.21,3.81]

-0.6[-5.21,4.01]

1.9[-2.36,6.16]

-1.51[-3.95,0.93]

-0.68[-1.43,0.07]

-0.7[-1.4,-0]

9.12.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours physical activity

-20

-10

0

10

20

Favours control

Analysis 9.13.   Comparison 9 Comparison: anthropometric outcomes,
all physical activity vs control, Outcome 13 Fat mass (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

9.13.1 End of intervention

Schmitz 2009

65

-1.2 (8)

63

0.6 (8.1)

4.41%

-1.8[-4.59,0.99]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

344

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Physical activity

Control

Matthews 2007

Saarto 2012

Schmitz 2005

Subtotal ***

Mean(SD)

-0.1 (1.9)

0.7 (2.8)

-0.5 (0.4)

N

22

262

39

388

Mean(SD)

0.4 (2.5)

0.7 (2.9)

0.2 (0.4)

N

14

263

40

380

Heterogeneity: Tau2=0.2; Chi2=9.58, df=3(P=0.02); I2=68.67%

Test for overall effect: Z=1.47(P=0.14)

Cochrane Database of Systematic Reviews

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

12.42%

37.1%

46.08%

100%

-0.48[-1.98,1.02]

0.05[-0.43,0.53]

-0.74[-0.93,-0.55]

-0.46[-1.08,0.15]

9.13.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 9.14.   Comparison 9 Comparison: anthropometric outcomes, all
physical activity vs control, Outcome 14 Fat mass - DEXA (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

9.14.1 End of intervention

Winters-Stone 2011

Schmitz 2009

Schmitz 2005

Subtotal ***

36

129

39

204

30.9 (9.7)

29.6 (9.6)

28.3 (1.7)

29 (8.1)

31.1 (10.5)

29 (1.7)

31

133

40

204

Heterogeneity: Tau2=0; Chi2=1.85, df=2(P=0.4); I2=0%

Test for overall effect: Z=1.87(P=0.06)

2.78%

8.5%

88.73%

100%

1.9[-2.36,6.16]

-1.51[-3.95,0.93]

-0.68[-1.43,0.07]

-0.68[-1.39,0.03]

9.14.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours physical activity

-10

-5

0

5

10

Favours control

Analysis 9.15.   Comparison 9 Comparison: anthropometric outcomes, all
physical activity vs control, Outcome 15 Fat mass - DEXA (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

9.15.1 End of intervention

Schmitz 2009

Schmitz 2005

Subtotal ***

65

39

104

-1.2 (8)

-0.5 (0.4)

63

40

103

0.6 (8.1)

0.2 (0.4)

Heterogeneity: Tau2=0; Chi2=0.55, df=1(P=0.46); I2=0%

Test for overall effect: Z=7.72(P<0.0001)

0.46%

99.54%

100%

-1.8[-4.59,0.99]

-0.74[-0.93,-0.55]

-0.74[-0.93,-0.56]

9.15.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

0

0

Not estimable

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

345

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

Test for overall effect: Not applicable

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 9.16.   Comparison 9 Comparison: anthropometric outcomes, all
physical activity vs control, Outcome 16 Lean mass (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

9.16.1 End of intervention

Herrero 2006

Mustian 2004

Matthews 2007

DeNysschen 2011

Winters-Stone 2011

Cadmus 2009

Schmitz 2005

Schmitz 2009

Subtotal ***

28 (2.7)

40.2 (7.6)

44.8 (7.7)

39.5 (5.2)

44 (6.7)

44.4 (6.6)

38.8 (0.8)

47.7 (7.5)

8

9

22

30

36

36

39

130

310

Heterogeneity: Tau2=0; Chi2=4.12, df=7(P=0.77); I2=0%

Test for overall effect: Z=0.66(P=0.51)

9.16.2 Follow-up

Cadmus 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.14(P=0.26)

44.6 (7.7)

26

26

28.3 (2.9)

39.1 (5.5)

44 (7.6)

40.7 (6.1)

45.2 (6)

42.7 (7.2)

37.7 (4.9)

47.3 (7.6)

42.2 (6.7)

8

10

14

34

31

33

40

132

302

23

23

2.63%

3.11%

5.63%

10.44%

10.93%

11.26%

12.85%

43.15%

100%

-0.1[-1.08,0.88]

0.16[-0.74,1.06]

0.1[-0.57,0.77]

-0.21[-0.7,0.28]

-0.19[-0.67,0.3]

0.24[-0.23,0.71]

0.31[-0.13,0.76]

0.05[-0.19,0.29]

0.05[-0.11,0.21]

100%

100%

0.33[-0.24,0.89]

0.33[-0.24,0.89]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 9.17.   Comparison 9 Comparison: anthropometric outcomes,
all physical activity vs control, Outcome 17 Lean mass (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

9.17.1 End of intervention

Mustian 2004

Schmitz 2005

Matthews 2007

Schmitz 2009

Saarto 2012

Subtotal ***

9

39

22

65

262

397

-0 (3.1)

0.9 (0.2)

0.2 (1.4)

-1 (3.4)

0.4 (1.8)

10

40

14

63

236

363

0.4 (1.4)

0 (0.2)

-0.3 (1.1)

-1.1 (3.6)

0.1 (1.6)

Heterogeneity: Tau2=1.02; Chi2=87.93, df=4(P<0.0001); I2=95.45%

Test for overall effect: Z=1.68(P=0.09)

18.14%

19.24%

19.62%

21.26%

21.74%

100%

-0.16[-1.06,0.74]

3.7[2.96,4.44]

0.39[-0.29,1.06]

0.03[-0.32,0.37]

0.14[-0.04,0.32]

0.8[-0.13,1.72]

9.17.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

346

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 9.18.   Comparison 9 Comparison: anthropometric outcomes, all
physical activity vs control, Outcome 18 Lean mass - DEXA (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

9.18.1 End of intervention

Cadmus 2009

Winters-Stone 2011

DeNysschen 2011

Schmitz 2009

Schmitz 2005

Subtotal ***

44.4 (6.6)

44 (6.7)

39.5 (5.2)

47.7 (7.5)

38.8 (0.8)

36

36

30

130

39

271

Heterogeneity: Tau2=0; Chi2=3.77, df=4(P=0.44); I2=0%

Test for overall effect: Z=0.86(P=0.39)

9.18.2 Follow-up

Cadmus 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.17(P=0.24)

44.6 (7.7)

26

26

42.7 (7.2)

45.2 (6)

40.7 (6.1)

47.3 (7.6)

37.7 (4.9)

42.2 (6.7)

33

31

34

132

40

270

23

23

8.88%

10.24%

12.35%

28.48%

40.06%

100%

1.67[-1.6,4.94]

-1.2[-4.24,1.84]

-1.2[-3.97,1.57]

0.36[-1.46,2.18]

1.12[-0.42,2.66]

0.43[-0.54,1.4]

100%

100%

2.41[-1.62,6.44]

2.41[-1.62,6.44]

Favours control

-10

-5

0

5

10

Favours physical activity

Analysis 9.19.   Comparison 9 Comparison: anthropometric outcomes, all
physical activity vs control, Outcome 19 Lean mass - DEXA (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

9.19.1 End of intervention

Schmitz 2009

Schmitz 2005

Subtotal ***

65

39

104

-1 (3.4)

0.9 (0.2)

63

40

103

-1.1 (3.6)

0 (0.2)

Heterogeneity: Tau2=0.1; Chi2=1.5, df=1(P=0.22); I2=33.13%

Test for overall effect: Z=2.56(P=0.01)

17.03%

82.97%

100%

0.1[-1.11,1.31]

0.86[0.76,0.96]

0.73[0.17,1.29]

9.19.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 9.20.   Comparison 9 Comparison: anthropometric outcomes, all
physical activity vs control, Outcome 20 Waist-to-hip ratio (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

9.20.1 End of intervention

Rahnama 2010

14

1 (0.7)

15

0.9 (0.7)

0.49%

0.04[-0.47,0.55]

Favours physical activity

-1

-0.5

0

0.5

1

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

347

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Physical activity

Control

Rogers 2014

Ligibel 2008

Rogers 2009

Rogers 2013

Subtotal ***

N

Mean(SD)

N

Mean(SD)

20

40

20

12

106

0.8 (0.1)

0.8 (0.1)

0.8 (0.1)

0.8 (0)

22

42

18

10

107

0.9 (0.1)

0.8 (0.1)

0.8 (0.1)

0.8 (0.1)

Heterogeneity: Tau2=0; Chi2=8.65, df=4(P=0.07); I2=53.76%

Test for overall effect: Z=1.49(P=0.14)

Cochrane Database of Systematic Reviews

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

18.98%

25.84%

26.58%

28.12%

100%

-0.1[-0.16,-0.04]

0[-0.04,0.04]

0[-0.04,0.04]

-0.03[-0.07,0.01]

-0.03[-0.06,0.01]

9.20.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours physical activity

-1

-0.5

0

0.5

1

Favours control

Analysis 9.21.   Comparison 9 Comparison: anthropometric outcomes, all
physical activity vs control, Outcome 21 Waist-to-hip ratio (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

9.21.1 End of intervention

Rogers 2014

Ligibel 2008

Subtotal ***

20

40

60

0 (0)

0 (0)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=1); I2=0%

Test for overall effect: Not applicable

9.21.2 Follow-up

Rogers 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.45(P=0.65)

0 (0.4)

19

19

0 (0.1)

0 (0)

-0 (0.1)

22

42

64

17

17

11.91%

88.09%

100%

0[-0.04,0.04]

0[-0.02,0.02]

0[-0.01,0.01]

100%

100%

0.04[-0.14,0.22]

0.04[-0.14,0.22]

Favours physical activity

-0.5

-0.25

0

0.25

0.5

Favours control

Analysis 9.22.   Comparison 9 Comparison: anthropometric outcomes, all
physical activity vs control, Outcome 22 Waist circumference (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

9.22.1 End of intervention

Rahnama 2010

Guinan 2013

Cadmus 2009

Ligibel 2008

Schmitz 2005

Littman 2012

Subtotal ***

96.4 (12.9)

85.6 (12.5)

89.8 (12.6)

89.2 (14.7)

94.6 (12.6)

93.1 (8.5)

14

16

36

40

33

28

167

99.8 (13.5)

84.8 (10.8)

88.6 (15.5)

92.5 (13.5)

94.5 (12.6)

92.7 (10.5)

15

10

33

42

36

27

163

Heterogeneity: Tau2=0; Chi2=1.64, df=5(P=0.9); I2=0%

7.78%

8.72%

15.99%

19.19%

20.27%

28.05%

100%

-3.4[-13.01,6.21]

0.8[-8.27,9.87]

1.17[-5.53,7.87]

-3.3[-9.42,2.82]

0.14[-5.81,6.09]

0.4[-4.66,5.46]

-0.5[-3.18,2.18]

Favours physical activity

-20

-10

0

10

20

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

348

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

Test for overall effect: Z=0.37(P=0.71)

9.22.2 Follow-up

Guinan 2013

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.28(P=0.78)

86.2 (12.2)

16

16

10

10

84.8 (12.3)

100%

100%

1.4[-8.29,11.09]

1.4[-8.29,11.09]

Favours physical activity

-20

-10

0

10

20

Favours control

Analysis 9.23.   Comparison 9 Comparison: anthropometric outcomes, all
physical activity vs control, Outcome 23 Waist circumference (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

9.23.1 End of intervention

Cadmus 2009

Dolan 2016

Ligibel 2008

Guinan 2013

Schmitz 2005

Subtotal ***

-1.5 (4.5)

-2.3 (2.7)

-1.5 (4.6)

-1.8 (1.7)

0.1 (1.1)

35

23

40

16

39

153

Heterogeneity: Tau2=0.41; Chi2=7.67, df=4(P=0.1); I2=47.82%

Test for overall effect: Z=3.94(P<0.0001)

9.23.2 Follow-up

Guinan 2013

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.03(P=0.3)

-1.2 (2.3)

16

16

-0.7 (4.5)

2 (3)

0.3 (3.8)

-0.2 (1.5)

1.4 (1)

-0.3 (2.1)

30

10

42

10

40

132

10

10

11.27%

11.59%

14.58%

22.61%

39.95%

100%

-0.74[-2.93,1.45]

-4.25[-6.4,-2.1]

-1.8[-3.63,0.03]

-1.6[-2.86,-0.34]

-1.27[-1.73,-0.81]

-1.71[-2.56,-0.86]

100%

100%

-0.9[-2.61,0.81]

-0.9[-2.61,0.81]

Favours physical activity

-10

-5

0

5

10

Favours control

Analysis 9.24.   Comparison 9 Comparison: anthropometric outcomes, all
physical activity vs control, Outcome 24 Hip circumference (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

9.24.1 End of intervention

Rahnama 2010

Cadmus 2009

Ligibel 2008

Littman 2012

Subtotal ***

101.7 (9.4)

111.9 (12.6)

109.7 (13.2)

113 (10.1)

14

37

40

32

123

101.4 (10.4)

111.1 (15)

113.3 (14.5)

113.9 (10.3)

15

38

42

31

126

Heterogeneity: Tau2=0; Chi2=1.17, df=3(P=0.76); I2=0%

Test for overall effect: Z=0.64(P=0.52)

17.18%

22.86%

24.81%

35.14%

100%

0.3[-6.91,7.51]

0.81[-5.44,7.06]

-3.6[-9.6,2.4]

-0.9[-5.94,4.14]

-0.97[-3.96,2.01]

9.24.2 Follow-up

Subtotal ***

0

0

Not estimable

Favours physical activity

-20

-10

0

10

20

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

349

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Favours physical activity

-20

-10

0

10

20

Favours control

Analysis 9.25.   Comparison 9 Comparison: anthropometric outcomes, all
physical activity vs control, Outcome 25 Hip circumference (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

9.25.1 End of intervention

Ligibel 2008

Dolan 2016

Subtotal ***

-2.3 (3.3)

-2 (2.2)

40

23

63

Heterogeneity: Tau2=0.02; Chi2=1.05, df=1(P=0.31); I2=4.8%

Test for overall effect: Z=4.97(P<0.0001)

9.25.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

-0.5 (3.3)

0.8 (1.2)

42

10

52

0

41.11%

58.89%

100%

-1.8[-3.23,-0.37]

-2.77[-3.95,-1.59]

-2.37[-3.31,-1.44]

Not estimable

Favours physical activity

-10

-5

0

5

10

Favours control

Comparison 10.   Comparison: muscular strength, all physical activity vs control

Outcome or subgroup
title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Lower body strength
(follow-up values)

10

1.1 End of intervention

10

1.2 Follow-up

2 Lower body strength
(change values)

2.1 End of intervention

2.2 Follow-up

3 Leg press (follow-up
values)

3.1 End of intervention

3.2 Follow-up

0

9

8

1

5

5

0

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

0.44 [0.09, 0.78]

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

0.72 [0.38, 1.07]

Std. Mean Difference (IV, Random, 95% CI)

0.78 [0.10, 1.46]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

0.79 [0.35, 1.22]

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

637

0

720

36

422

0

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

350

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup
title

No. of studies

No. of partici-
pants

Statistical method

Effect size

4 Leg press (change val-
ues)

4.1 End of intervention

4.2 Follow-up

5 Back & leg strength (fol-
low-up values)

5.1 End of intervention

5.2 Follow-up

6 Leg extension (fol-
low-up values)

6.1 End of intervention

6.2 Follow-up

7 Leg extension (change
values)

7.1 End of intervention

7.2 Follow-up

8 Hip extension (fol-
low-up values)

8.1 End of intervention

8.2 Follow-up

9 Hip flexion (follow-up
values)

9.1 End of intervention

9.2 Follow-up

10 Leg flexion (follow-up
values)

10.1 End of intervention

10.2 Follow-up

5

5

0

2

2

0

4

4

0

4

4

0

2

2

0

2

2

0

2

2

0

11 Upper body strength
(follow-up values)

13

393

0

58

0

177

0

389

0

285

0

285

0

243

0

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

0.94 [0.68, 1.20]

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

7.90 [-2.31, 18.11]

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

-0.01 [-0.34, 0.32]

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

0.57 [0.03, 1.12]

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

0.14 [-0.45, 0.72]

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

0.04 [-0.76, 0.83]

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

0.86 [-0.05, 1.76]

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

11.1 End of intervention

13

768

Std. Mean Difference (IV, Random, 95% CI)

0.42 [0.08, 0.76]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

351

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup
title

No. of studies

No. of partici-
pants

Statistical method

Effect size

11.2 Follow-up

12 Upper body strength
(change values)

12.1 End of intervention

12.2 Follow-up

13 Chest press (follow-up
values)

13.1 End of intervention

13.2 Follow-up

14 Chest press (change
values)

14.1 End of intervention

14.2 Follow-up

15 Grip strength (fol-
low-up)

15.1 End of intervention

15.2 Follow-up

16 Grip strength (change
values)

16.1 End of intervention

16.2 Follow-up

17 Grip strength right
hand (follow-up)

17.1 End of intervention

17.2 Follow-up

18 Grip strength left hand
(follow-up)

18.1 End of intervention

18.2 Follow-up

19 Elbow flexion (fol-
low-up values)

0

9

8

1

5

5

0

4

4

0

7

7

0

3

2

1

5

5

0

4

4

0

3

0

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

832

36

444

0

381

0

320

0

145

36

232

0

198

0

Std. Mean Difference (IV, Random, 95% CI)

0.72 [0.30, 1.14]

Std. Mean Difference (IV, Random, 95% CI)

0.76 [0.08, 1.44]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

0.51 [-0.15, 1.17]

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

1.13 [0.46, 1.80]

Std. Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

2.37 [0.20, 4.55]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

0.24 [-0.09, 0.58]

Std. Mean Difference (IV, Random, 95% CI)

0.76 [0.08, 1.44]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

2.30 [-0.56, 5.16]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

2.12 [-1.05, 5.30]

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

352

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup
title

No. of studies

No. of partici-
pants

Statistical method

Effect size

19.1 End of intervention

19.2 Follow-up

3

0

148

0

Std. Mean Difference (IV, Fixed, 95% CI)

-0.08 [-0.41, 0.24]

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Analysis 10.1.   Comparison 10 Comparison: muscular strength, all physical
activity vs control, Outcome 1 Lower body strength (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

10.1.1 End of intervention

Cerulli 2014

Rogers 2013

Nikander 2007

Rogers 2009

Schmitz 2005

Milne 2008

Do 2015

Saarto 2012

Winters-Stone 2011

Schmitz 2009

Subtotal ***

114.9 (17.1)

68.4 (15.5)

1305 (177)

80.3 (27)

296.6 (48.9)

66.2 (10.2)

13 (1.6)

136 (23)

201.3 (57.4)

223.4 (59.6)

10

11

14

20

23

29

32

37

36

113

325

79.1 (17.8)

67.1 (16.2)

1393 (275)

64.9 (19.7)

238.9 (46.4)

61.7 (11)

13.2 (1.6)

136 (29)

191 (51.7)

175.1 (53.5)

10

9

14

18

22

29

30

30

31

119

312

Heterogeneity: Tau2=0.22; Chi2=35.25, df=9(P<0.0001); I2=74.46%

Test for overall effect: Z=2.47(P=0.01)

5.87%

7.53%

8.71%

9.62%

9.78%

11%

11.23%

11.41%

11.41%

13.43%

100%

1.96[0.85,3.07]

0.08[-0.8,0.96]

-0.37[-1.12,0.38]

0.63[-0.02,1.29]

1.19[0.55,1.83]

0.42[-0.1,0.94]

-0.09[-0.59,0.41]

0[-0.48,0.48]

0.19[-0.3,0.67]

0.85[0.58,1.12]

0.44[0.09,0.78]

10.1.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 10.2.   Comparison 10 Comparison: muscular strength, all physical
activity vs control, Outcome 2 Lower body strength (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

10.2.1 End of intervention

Nieman 1995

Naumann 2012

Dolan 2016

Schmitz 2005

Cormie 2014

Do 2015

Schmitz 2009

Waltman 2010

Subtotal ***

28.9 (13.7)

7.7 (12.6)

11.8 (8.9)

81.8 (48.9)

37.6 (25.5)

0.9 (0.7)

33.2 (33.9)

4.4 (11.5)

6

11

23

23

43

32

113

110

361

6

10

10

22

19

60

119

113

359

3.5 (22.5)

3.5 (13.9)

0.3 (11.1)

20.3 (46)

6.7 (25.7)

1 (0.6)

7.9 (26.6)

0.2 (8.4)

Heterogeneity: Tau2=0.15; Chi2=25.57, df=7(P=0); I2=72.63%

5.27%

8.9%

9.65%

11.81%

12.82%

15.41%

18.05%

18.09%

100%

1.26[-0.03,2.55]

0.3[-0.56,1.17]

1.17[0.37,1.97]

1.27[0.63,1.92]

1.19[0.61,1.78]

-0.08[-0.51,0.35]

0.83[0.56,1.1]

0.42[0.15,0.69]

0.72[0.38,1.07]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

353

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for overall effect: Z=4.13(P<0.0001)

10.2.2 Follow-up

Rogers 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.23(P=0.03)

11.9 (13.2)

19

19

17

17

0.7 (15)

100%

100%

0.78[0.1,1.46]

0.78[0.1,1.46]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 10.3.   Comparison 10 Comparison: muscular strength, all
physical activity vs control, Outcome 3 Leg press (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

10.3.1 End of intervention

Cerulli 2014

Schmitz 2005

Milne 2008

Winters-Stone 2011

Schmitz 2009

Subtotal ***

114.9 (17.1)

296.6 (48.9)

66.2 (10.2)

201.3 (57.4)

223.4 (59.6)

10

23

29

36

113

211

79.1 (17.8)

238.9 (46.4)

61.7 (11)

191 (51.7)

175.1 (53.5)

10

22

29

31

119

211

Heterogeneity: Tau2=0.16; Chi2=13.79, df=4(P=0.01); I2=70.99%

Test for overall effect: Z=3.54(P=0)

10.26%

18.5%

21.35%

22.35%

27.53%

100%

1.96[0.85,3.07]

1.19[0.55,1.83]

0.42[-0.1,0.94]

0.19[-0.3,0.67]

0.85[0.58,1.12]

0.79[0.35,1.22]

10.3.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 10.4.   Comparison 10 Comparison: muscular strength, all
physical activity vs control, Outcome 4 Leg press (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

10.4.1 End of intervention

Naumann 2012

Dolan 2016

Schmitz 2005

Cormie 2014

Schmitz 2009

Subtotal ***

7.7 (12.6)

11.8 (8.9)

81.8 (48.9)

37.6 (25.5)

33.2 (33.9)

11

23

23

43

113

213

10

10

22

19

119

180

3.5 (13.9)

0.3 (11.1)

20.3 (46)

6.7 (25.7)

7.9 (26.6)

Heterogeneity: Tau2=0.02; Chi2=4.75, df=4(P=0.31); I2=15.8%

Test for overall effect: Z=7.12(P<0.0001)

8.37%

9.59%

14.1%

16.89%

51.05%

100%

0.3[-0.56,1.17]

1.17[0.37,1.97]

1.27[0.63,1.92]

1.19[0.61,1.78]

0.83[0.56,1.1]

0.94[0.68,1.2]

10.4.2 Follow-up

Subtotal ***

0

0

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

354

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 10.5.   Comparison 10 Comparison: muscular strength, all physical
activity vs control, Outcome 5 Back & leg strength (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

10.5.1 End of intervention

Rogers 2009

Rogers 2013

Subtotal ***

80.3 (27)

68.4 (15.5)

20

11

31

Heterogeneity: Tau2=0; Chi2=1.82, df=1(P=0.18); I2=45.17%

Test for overall effect: Z=1.52(P=0.13)

10.5.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

64.9 (19.7)

67.1 (16.2)

18

9

27

0

46.78%

53.22%

100%

15.4[0.47,30.33]

1.3[-12.7,15.3]

7.9[-2.31,18.11]

Not estimable

Favours control

-50

-25

0

25

50

Favours physical activity

Analysis 10.6.   Comparison 10 Comparison: muscular strength, all
physical activity vs control, Outcome 6 Leg extension (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

10.6.1 End of intervention

Cerulli 2014

Nikander 2007

Do 2015

Saarto 2012

Subtotal ***

51.8 (9.2)

1305 (177)

13 (1.6)

136 (23)

10

14

32

37

93

Heterogeneity: Tau2=0.02; Chi2=3.47, df=3(P=0.32); I2=13.65%

Test for overall effect: Z=0.06(P=0.96)

10.6.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

44.3 (10.8)

1393 (275)

13.2 (1.6)

136 (29)

10

14

30

30

84

0

11.95%

17.17%

34.47%

36.42%

100%

0.72[-0.19,1.63]

-0.37[-1.12,0.38]

-0.09[-0.59,0.41]

0[-0.48,0.48]

-0.01[-0.34,0.32]

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

355

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 10.7.   Comparison 10 Comparison: muscular strength, all
physical activity vs control, Outcome 7 Leg extension (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

10.7.1 End of intervention

Nieman 1995

Cormie 2014

Do 2015

Waltman 2010

Subtotal ***

28.9 (13.7)

37.6 (25.5)

0.9 (0.7)

4.4 (11.5)

6

43

32

110

191

6

19

60

113

198

3.5 (22.5)

6.7 (25.7)

1 (0.6)

0.2 (8.4)

Heterogeneity: Tau2=0.21; Chi2=13.57, df=3(P=0); I2=77.9%

Test for overall effect: Z=2.06(P=0.04)

11.95%

25.5%

29.41%

33.14%

100%

1.26[-0.03,2.55]

1.19[0.61,1.78]

-0.08[-0.51,0.35]

0.42[0.15,0.69]

0.57[0.03,1.12]

10.7.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 10.8.   Comparison 10 Comparison: muscular strength, all
physical activity vs control, Outcome 8 Hip extension (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

10.8.1 End of intervention

Do 2015

Waltman 2010

Subtotal ***

32

110

142

14.2 (2.4)

7.9 (20.6)

30

113

143

14.7 (2.5)

1.3 (11.2)

Heterogeneity: Tau2=0.14; Chi2=4.33, df=1(P=0.04); I2=76.93%

Test for overall effect: Z=0.46(P=0.65)

43.54%

56.46%

100%

-0.2[-0.7,0.3]

0.4[0.13,0.66]

0.14[-0.45,0.72]

10.8.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 10.9.   Comparison 10 Comparison: muscular strength, all
physical activity vs control, Outcome 9 Hip flexion (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

10.9.1 End of intervention

Do 2015

Waltman 2010

Subtotal ***

32

110

142

13.1 (2.1)

2.9 (7.6)

30

113

143

13.9 (2.2)

-0.9 (10.4)

Heterogeneity: Tau2=0.29; Chi2=7.85, df=1(P=0.01); I2=87.25%

Test for overall effect: Z=0.1(P=0.92)

46.4%

53.6%

100%

-0.4[-0.9,0.11]

0.42[0.15,0.68]

0.04[-0.76,0.83]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

356

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

10.9.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 10.10.   Comparison 10 Comparison: muscular strength, all
physical activity vs control, Outcome 10 Leg flexion (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

10.10.1 End of intervention

Cerulli 2014

Waltman 2010

Subtotal ***

52.6 (11.4)

3.9 (10.1)

10

110

120

10

113

123

36.8 (9.1)

-0 (4.2)

Heterogeneity: Tau2=0.32; Chi2=3.24, df=1(P=0.07); I2=69.17%

Test for overall effect: Z=1.85(P=0.06)

36.58%

63.42%

100%

1.47[0.45,2.48]

0.5[0.24,0.77]

0.86[-0.05,1.76]

10.10.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 10.11.   Comparison 10 Comparison: muscular strength, all physical
activity vs control, Outcome 11 Upper body strength (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

10.11.1 End of intervention

Mustian 2004

Cerulli 2014

Portela 2008

Nikander 2007

Musanti 2012

Schmitz 2005

Rogers 2009

Kaltsatou 2011

Milne 2008

Do 2015

Saarto 2012

Winters-Stone 2011

Schmitz 2009

Subtotal ***

29.6 (3.3)

16.1 (5.4)

39.3 (12.3)

131 (20)

52.1 (21)

83 (13.4)

27.9 (5)

59.6 (8.5)

7.6 (2.9)

9.7 (1.7)

32.7 (5.3)

63.3 (15.3)

52.9 (15.3)

11

10

25

14

30

23

20

28

29

32

37

36

113

408

26.7 (5.7)

17.2 (8.1)

35.6 (13.1)

129 (28)

36.8 (20)

63 (12.7)

24.3 (6.2)

47.6 (9.8)

9.4 (2.6)

10.1 (1.7)

30.8 (5.7)

61.1 (16.8)

40.9 (11.8)

10

10

9

14

12

22

18

26

29

30

30

31

119

360

Heterogeneity: Tau2=0.29; Chi2=56.32, df=12(P<0.0001); I2=78.69%

Test for overall effect: Z=2.41(P=0.02)

6.15%

6.16%

6.83%

6.98%

7.3%

7.43%

7.52%

7.92%

8.31%

8.49%

8.58%

8.61%

9.74%

100%

0.6[-0.28,1.49]

-0.16[-1.03,0.72]

0.29[-0.48,1.05]

0.08[-0.66,0.82]

0.73[0.04,1.42]

1.5[0.84,2.17]

0.63[-0.03,1.28]

1.29[0.7,1.88]

-0.64[-1.17,-0.12]

-0.24[-0.74,0.26]

0.34[-0.14,0.83]

0.14[-0.34,0.62]

0.88[0.61,1.15]

0.42[0.08,0.76]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

357

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

10.11.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 10.12.   Comparison 10 Comparison: muscular strength, all physical
activity vs control, Outcome 12 Upper body strength (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

10.12.1 End of intervention

Schmitz 2005

Musanti 2012

Cormie 2014

Do 2015

Mustian 2004

Irwin 2015

Waltman 2010

Schmitz 2009

Subtotal ***

32.3 (11.5)

7.7 (10.6)

5.7 (3.7)

0.3 (0.5)

4.5 (4.7)

0.4 (1.9)

1.9 (4.9)

33.2 (40.8)

23

30

43

32

45

45

110

113

441

Heterogeneity: Tau2=0.3; Chi2=51.53, df=7(P<0.0001); I2=86.41%

Test for overall effect: Z=3.39(P=0)

10.12.2 Follow-up

Rogers 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.18(P=0.03)

1.5 (2.3)

19

19

6.9 (10.8)

0.8 (12.7)

1 (3.8)

0.6 (1.2)

-0.8 (3.2)

0.1 (1.9)

0.8 (2.9)

7.6 (43.7)

-0.3 (2.4)

22

12

19

30

38

38

113

119

391

17

17

10.15%

10.84%

11.75%

12.53%

12.75%

13.14%

14.42%

14.42%

100%

2.24[1.48,2.99]

0.6[-0.08,1.29]

1.25[0.67,1.84]

-0.27[-0.77,0.23]

1.3[0.82,1.78]

0.16[-0.27,0.59]

0.29[0.02,0.55]

0.6[0.34,0.87]

0.72[0.3,1.14]

100%

100%

0.76[0.08,1.44]

0.76[0.08,1.44]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 10.13.   Comparison 10 Comparison: muscular strength, all
physical activity vs control, Outcome 13 Chest press (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

10.13.1 End of intervention

Musanti 2012

Schmitz 2005

Milne 2008

Winters-Stone 2011

Schmitz 2009

Subtotal ***

52.1 (21)

83 (13.4)

7.6 (2.9)

63.3 (15.3)

52.9 (15.3)

30

23

29

36

113

231

12

22

29

31

119

213

36.8 (20)

63 (12.7)

9.4 (2.6)

61.1 (16.8)

40.9 (11.8)

Heterogeneity: Tau2=0.49; Chi2=36.09, df=4(P<0.0001); I2=88.92%

Test for overall effect: Z=1.52(P=0.13)

18.43%

18.65%

20.1%

20.57%

22.24%

100%

0.73[0.04,1.42]

1.5[0.84,2.17]

-0.64[-1.17,-0.12]

0.14[-0.34,0.62]

0.88[0.61,1.15]

0.51[-0.15,1.17]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

358

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

10.13.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 10.14.   Comparison 10 Comparison: muscular strength, all
physical activity vs control, Outcome 14 Chest press (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

10.14.1 End of intervention

Schmitz 2005

Musanti 2012

Cormie 2014

Schmitz 2009

Subtotal ***

32.3 (11.5)

7.7 (10.6)

5.7 (3.7)

33.2 (40.8)

23

30

43

113

209

22

12

19

119

172

6.9 (10.8)

0.8 (12.7)

1 (3.8)

7.6 (43.7)

Heterogeneity: Tau2=0.38; Chi2=18.46, df=3(P=0); I2=83.75%

Test for overall effect: Z=3.3(P=0)

22.13%

23.39%

24.99%

29.49%

100%

2.24[1.48,2.99]

0.6[-0.08,1.29]

1.25[0.67,1.84]

0.6[0.34,0.87]

1.13[0.46,1.8]

10.14.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 10.15.   Comparison 10 Comparison: muscular strength, all
physical activity vs control, Outcome 15 Grip strength (follow-up).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

10.15.1 End of intervention

Portela 2008

Mustian 2004

Rogers 2009

Saarto 2012

Winters-Stone 2011

Kim 2015

Kaltsatou 2011

Subtotal ***

39.3 (12.3)

29.6 (3.9)

29.2 (5.2)

32.7 (5.3)

25.3 (5.2)

21.9 (4.2)

27.5 (3.9)

25

11

20

37

36

20

28

177

35.6 (13.1)

26.7 (6.6)

25.4 (5.9)

30.8 (5.7)

24.6 (5.7)

22.9 (3.7)

21.6 (4.5)

9

10

18

30

31

19

26

143

Heterogeneity: Tau2=5.34; Chi2=19.03, df=6(P=0); I2=68.46%

Test for overall effect: Z=2.14(P=0.03)

4.04%

11.08%

14.26%

17.13%

17.26%

17.72%

18.51%

100%

3.66[-6.16,13.48]

2.9[-1.8,7.6]

3.8[0.25,7.35]

1.9[-0.76,4.56]

0.7[-1.92,3.32]

-1[-3.48,1.48]

5.9[3.66,8.14]

2.37[0.2,4.55]

10.15.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

359

Favours control

-20

-10

0

10

20

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 10.16.   Comparison 10 Comparison: muscular strength, all
physical activity vs control, Outcome 16 Grip strength (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

10.16.1 End of intervention

Cormie 2014

Irwin 2015

Subtotal ***

1.8 (3.7)

0.4 (1.9)

43

45

88

Heterogeneity: Tau2=0; Chi2=0.4, df=1(P=0.53); I2=0%

Test for overall effect: Z=1.42(P=0.16)

10.16.2 Follow-up

Rogers 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.18(P=0.03)

1.5 (2.3)

19

19

0.4 (3.5)

0.1 (1.9)

-0.3 (2.4)

19

38

57

17

17

38.7%

61.3%

100%

0.38[-0.16,0.93]

0.16[-0.27,0.59]

0.24[-0.09,0.58]

100%

100%

0.76[0.08,1.44]

0.76[0.08,1.44]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 10.17.   Comparison 10 Comparison: muscular strength, all physical
activity vs control, Outcome 17 Grip strength right hand (follow-up).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

10.17.1 End of intervention

Portela 2008

Rogers 2009

Winters-Stone 2011

Kim 2015

Kaltsatou 2011

Subtotal ***

39.3 (12.3)

29.2 (6.6)

25.7 (5.3)

22.7 (4.3)

27 (3.4)

25

20

36

20

28

129

35.6 (13.1)

25.4 (5.9)

25.3 (5.7)

23.3 (3.9)

21.7 (4.1)

9

18

31

19

26

103

Heterogeneity: Tau2=7.08; Chi2=15.95, df=4(P=0); I2=74.92%

Test for overall effect: Z=1.58(P=0.11)

6.61%

19.03%

23.92%

24.27%

26.17%

100%

3.66[-6.16,13.48]

3.8[-0.17,7.77]

0.4[-2.25,3.05]

-0.6[-3.15,1.95]

5.3[3.28,7.32]

2.3[-0.56,5.16]

10.17.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 10.18.   Comparison 10 Comparison: muscular strength, all
physical activity vs control, Outcome 18 Grip strength left hand (follow-up).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

10.18.1 End of intervention

Rogers 2009

20

26.5 (4.6)

18

23.1 (6.4)

22.19%

3.4[-0.18,6.98]

Favours control

-20

-10

0

10

20

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

360

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

Winters-Stone 2011

Kaltsatou 2011

Kim 2015

Subtotal ***

24.8 (5.2)

27.1 (4.4)

21.1 (4.2)

36

28

20

104

Heterogeneity: Tau2=8.48; Chi2=16.36, df=3(P=0); I2=81.66%

Test for overall effect: Z=1.31(P=0.19)

10.18.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

23.8 (5.6)

21.5 (4.9)

22.4 (3.5)

31

26

19

94

0

25.61%

25.97%

26.22%

100%

1[-1.6,3.6]

5.6[3.11,8.09]

-1.3[-3.71,1.11]

2.12[-1.05,5.3]

Not estimable

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 10.19.   Comparison 10 Comparison: muscular strength, all
physical activity vs control, Outcome 19 Elbow flexion (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

10.19.1 End of intervention

Nikander 2007

Milne 2008

Do 2015

Subtotal ***

131 (20)

16.8 (3.7)

9.7 (1.7)

14

29

32

75

Heterogeneity: Tau2=0; Chi2=0.64, df=2(P=0.72); I2=0%

Test for overall effect: Z=0.51(P=0.61)

10.19.2 Follow-up

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

129 (28)

16.8 (4.2)

10.1 (1.7)

14

29

30

73

0

18.97%

39.33%

41.69%

100%

0.08[-0.66,0.82]

0[-0.51,0.51]

-0.24[-0.74,0.26]

-0.08[-0.41,0.24]

Not estimable

Favours control

-2

-1

0

1

2

Favours physical activity

Comparison 11.   Comparison: bone health, all physical activity vs control

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Bone mineral content (fol-
low-up and change values)

1.1 End of intervention

1.2 Follow-up

2 Bone mineral density -
femoral neck (follow-up and
change values)

2

2

0

4

525

0

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.04 [-0.20, 0.27]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

361

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

2.1 End of intervention

2.2 Follow-up

3 Bone mineral density - lum-
bar spine (follow-up and
change values)

3.1 End of intervention

3.2 Follow-up

4 Bone mineral density - total
hip (follow-up and change val-
ues)

4.1 End of intervention

4.2 Follow-up

5 Bone formation - alkaline
phosphatase (follow-up and
change values)

5.1 End of intervention

5.2 Follow-up

6 Bone resorption - serum NTx
(follow-up and change values)

6.1 End of intervention

6.2 Follow-up

4

0

4

4

0

3

3

0

2

2

0

3

3

0

786

0

786

0

329

0

239

0

278

0

Std. Mean Difference (IV, Random,
95% CI)

0.21 [-0.13, 0.55]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.22 [-0.09, 0.53]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.58 [-0.02, 1.18]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.25 [-1.81, 1.31]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.38 [-1.58, 2.34]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Analysis 11.1.   Comparison 11 Comparison: bone health, all physical activity
vs control, Outcome 1 Bone mineral content (follow-up and change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

11.1.1 End of intervention

Favours control

-2

-1

0

1

2

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

362

 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Cadmus 2009

Saarto 2012

Subtotal ***

Mean(SD)

2216 (383)

-45.3 (74.5)

N

36

239

275

N

32

218

250

Mean(SD)

2120 (308)

-43.5 (73.3)

Heterogeneity: Tau2=0.01; Chi2=1.28, df=1(P=0.26); I2=21.7%

Test for overall effect: Z=0.31(P=0.75)

Random, 95% CI

Random, 95% CI

20.89%

79.11%

100%

0.27[-0.21,0.75]

-0.02[-0.21,0.16]

0.04[-0.2,0.27]

11.1.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-2

-1

0

1

2

Favours physical activity

Analysis 11.2.   Comparison 11 Comparison: bone health, all physical activity vs
control, Outcome 2 Bone mineral density - femoral neck (follow-up and change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

11.2.1 End of intervention

Kim 2015

Winters-Stone 2011

Waltman 2010

Saarto 2012

Subtotal ***

20

36

110

239

405

0.8 (0.1)

0.7 (0.1)

0.9 (0.5)

-0 (0)

19

31

113

218

381

0.8 (0.1)

0.7 (0.1)

0.6 (0.4)

-0 (0)

Heterogeneity: Tau2=0.08; Chi2=11.96, df=3(P=0.01); I2=74.92%

Test for overall effect: Z=1.21(P=0.22)

16.08%

21.11%

29.76%

33.05%

100%

-0.37[-1,0.27]

0.11[-0.37,0.59]

0.63[0.36,0.9]

0.18[-0,0.37]

0.21[-0.13,0.55]

11.2.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-2

-1

0

1

2

Favours physical activity

Analysis 11.3.   Comparison 11 Comparison: bone health, all physical activity vs
control, Outcome 3 Bone mineral density - lumbar spine (follow-up and change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

11.3.1 End of intervention

Kim 2015

Winters-Stone 2011

Waltman 2010

Saarto 2012

Subtotal ***

20

36

110

239

405

1 (0.1)

1 (0.2)

3.1 (0.4)

-0 (0)

19

31

113

218

381

1 (0.1)

1 (0.1)

2.9 (0.4)

-0 (0)

Heterogeneity: Tau2=0.06; Chi2=9.95, df=3(P=0.02); I2=69.85%

Test for overall effect: Z=1.38(P=0.17)

11.3.2 Follow-up

14.92%

20.08%

30.42%

34.58%

100%

-0.26[-0.89,0.37]

0.3[-0.19,0.78]

0.55[0.28,0.81]

0.09[-0.09,0.27]

0.22[-0.09,0.53]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

363

Favours control

-2

-1

0

1

2

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Subtotal ***

0

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Random, 95% CI

Not estimable

Favours control

-2

-1

0

1

2

Favours physical activity

Analysis 11.4.   Comparison 11 Comparison: bone health, all physical activity vs
control, Outcome 4 Bone mineral density - total hip (follow-up and change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

11.4.1 End of intervention

Kim 2015

Winters-Stone 2011

Waltman 2010

Subtotal ***

20

36

110

166

0.9 (0.1)

0.9 (0.1)

2.2 (0.3)

19

31

113

163

0.8 (0.1)

0.8 (0.1)

1.8 (0.4)

Heterogeneity: Tau2=0.23; Chi2=10.71, df=2(P=0); I2=81.32%

Test for overall effect: Z=1.88(P=0.06)

28.61%

33.04%

38.35%

100%

0.4[-0.23,1.04]

0.19[-0.29,0.67]

1.05[0.77,1.33]

0.58[-0.02,1.18]

11.4.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 11.5.   Comparison 11 Comparison: bone health, all physical activity vs control,
Outcome 5 Bone formation - alkaline phosphatase (follow-up and change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

11.5.1 End of intervention

Mustian 2004

Waltman 2010

Subtotal ***

10.2 (2.9)

-11.1 (2.3)

7

110

117

9

113

122

8.1 (3.3)

-8.7 (2.6)

Heterogeneity: Tau2=1.14; Chi2=8.85, df=1(P=0); I2=88.71%

Test for overall effect: Z=0.31(P=0.75)

45.13%

54.87%

100%

0.63[-0.39,1.65]

-0.97[-1.25,-0.7]

-0.25[-1.81,1.31]

11.5.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

364

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 11.6.   Comparison 11 Comparison: bone health, all physical activity vs
control, Outcome 6 Bone resorption - serum NTx (follow-up and change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

11.6.1 End of intervention

Mustian 2004

Kim 2015

Waltman 2010

Subtotal ***

11.1 (7.7)

52.3 (17.8)

-16.7 (3.3)

7

20

110

137

18.8 (7.5)

55.7 (26.9)

-23.2 (2.8)

9

19

113

141

Heterogeneity: Tau2=2.85; Chi2=60.53, df=2(P<0.0001); I2=96.7%

Test for overall effect: Z=0.38(P=0.7)

31.69%

33.72%

34.59%

100%

-0.96[-2.02,0.1]

-0.15[-0.78,0.48]

2.12[1.79,2.45]

0.38[-1.58,2.34]

11.6.2 Follow-up

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Comparison 12.   Subanalysis: outcomes by menopausal status

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Overall HRQoL (follow-up
values)

1.1 Postmenopausal only

1.2 Not postmenopausal only

2 Overall HRQoL (change val-
ues)

2.1 Postmenopausal only

2.2 Not postmenopausal only

3 Overall emotional func-
tion/mental health (fol-
low-up values)

3.1 Postmenopausal only

3.2 Not postmenopausal only

4 Overall emotional func-
tion/mental health (change
values)

9

3

6

7

3

4

11

2

9

7

186

818

186

952

126

990

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.24 [-0.05, 0.54]

Std. Mean Difference (IV, Random,
95% CI)

0.55 [0.11, 0.98]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.49 [0.19, 0.79]

Std. Mean Difference (IV, Random,
95% CI)

0.13 [-0.11, 0.38]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.21 [-0.14, 0.56]

Std. Mean Difference (IV, Random,
95% CI)

0.25 [0.06, 0.44]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

365

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Outcome or subgroup title

No. of studies

4.1 Postmenopausal only

4.2 Not postmenopausal only

5 Overall physical function
(follow-up values)

5.1 Postmenopausal only

5.2 Not postmenopausal only

6 Overall physical function
(change values)

6.1 Postmenopausal only

6.2 Not postmenopausal only

7 Overall role function (fol-
low-up values)

7.1 Postmenopausal only

7.2 Not postmenopausal only

8 Overall role function
(change values)

8.1 Postmenopausal only

8.2 Not postmenopausal only

9 Overall social well-be-
ing/function (follow-up val-
ues)

9.1 Postmenopausal only

9.2 Not postmenopausal only

10 Overall social well-be-
ing/function (change values)

2

5

11

3

8

6

2

4

8

2

6

6

2

4

8

3

5

6

No. of partici-
pants

126

1013

187

929

126

949

126

818

126

952

168

867

Cochrane Database of Systematic Reviews

Statistical method

Effect size

Std. Mean Difference (IV, Random,
95% CI)

0.37 [0.01, 0.72]

Std. Mean Difference (IV, Random,
95% CI)

0.08 [-0.17, 0.33]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.09 [-0.20, 0.38]

Std. Mean Difference (IV, Random,
95% CI)

0.50 [0.10, 0.90]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.52 [-0.36, 1.39]

Std. Mean Difference (IV, Random,
95% CI)

0.03 [-0.20, 0.25]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.27 [-0.08, 0.62]

Std. Mean Difference (IV, Random,
95% CI)

0.42 [-0.07, 0.90]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.11 [-0.24, 0.46]

Std. Mean Difference (IV, Random,
95% CI)

-0.00 [-0.14, 0.13]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.43 [-0.06, 0.91]

Std. Mean Difference (IV, Random,
95% CI)

0.09 [-0.05, 0.24]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

366

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

10.1 Postmenopausal only

10.2 Not postmenopausal on-
ly

11 Overall cognitive function
(follow-up values)

11.1 Postmenopausal only

11.2 Not postmenopausal on-
ly

12 Overall cognitive function
(change values)

12.1 Postmenopausal only

12.2 Not postmenopausal on-
ly

13 Overall general health (fol-
low-up values)

13.1 Postmenopausal only

13.2 Not postmenopausal on-
ly

14 Overall general health
(change values)

14.1 Postmenopausal only

14.2 Not postmenopausal on-
ly

15 Overall sexual function
(follow-up values)

15.1 Postmenopausal only

15.2 Not postmenopausal on-
ly

16 Overall sexual function
(change values)

3

3

3

0

3

3

0

3

4

2

2

5

2

3

2

0

2

2

168

873

0

116

0

599

134

117

134

617

0

161

Std. Mean Difference (IV, Random,
95% CI)

0.50 [0.19, 0.80]

Std. Mean Difference (IV, Random,
95% CI)

0.50 [-0.39, 1.40]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

0.58 [0.20, 0.95]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

0.12 [-0.31, 0.55]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.03 [-0.41, 0.35]

Std. Mean Difference (IV, Random,
95% CI)

-0.09 [-0.57, 0.39]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.27 [-0.18, 0.71]

Std. Mean Difference (IV, Random,
95% CI)

-0.01 [-0.22, 0.21]

Std. Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Fixed, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Fixed, 95%
CI)

0.31 [-0.00, 0.62]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

367

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

16.1 Postmenopausal only

16.2 Not postmenopausal on-
ly

17 Overall sleep (follow-up
values)

17.1 Postmenopausal only

17.2 Not postmenopausal on-
ly

18 Overall sleep (change val-
ues)

18.1 Postmenopausal only

18.2 Not postmenopausal on-
ly

19 Overall anxiety (follow-up
values)

19.1 Postmenopausal only

19.2 Not postmenopausal on-
ly

20 Overall anxiety (change
values)

20.1 Postmenopausal only

20.2 Not postmenopausal on-
ly

21 Overall self-esteem/body
image (follow-up values)

21.1 Postmenopausal only

21.2 Not postmenopausal on-
ly

22 Overall self-esteem/body
image (change values)

0

2

4

1

3

2

1

1

4

2

2

3

2

1

4

2

2

4

0

579

42

89

42

38

116

79

116

61

126

76

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

0.08 [-0.14, 0.30]

Std. Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Fixed, 95%
CI)

-0.11 [-0.72, 0.49]

Std. Mean Difference (IV, Fixed, 95%
CI)

0.18 [-0.24, 0.60]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.23 [-0.38, 0.84]

Std. Mean Difference (IV, Random,
95% CI)

0.05 [-0.59, 0.68]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.09 [-0.46, 0.27]

Std. Mean Difference (IV, Random,
95% CI)

-0.66 [-1.12, -0.20]

Std. Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Fixed, 95%
CI)

-0.23 [-0.60, 0.13]

Std. Mean Difference (IV, Fixed, 95%
CI)

-0.61 [-1.12, -0.09]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.10 [-0.25, 0.45]

Std. Mean Difference (IV, Random,
95% CI)

0.60 [-0.15, 1.35]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

368

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

22.1 Postmenopausal only

22.2 Not postmenopausal on-
ly

23 Overall depression (fol-
low-up values)

23.1 Postmenopausal only

23.2 Not postmenopausal on-
ly

24 Overall depression
(change values)

24.1 Postmenopausal only

24.2 Not postmenopausal on-
ly

2

2

8

4

4

5

3

2

25 Overall fatigue (follow-up
values)

15

25.1 Postmenopausal only

25.2 Not postmenopausal on-
ly

26 Overall fatigue (change
values)

26.1 Postmenopausal only

26.2 Not postmenopausal on-
ly

27 Overall pain/disability (fol-
low-up values)

27.1 Postmenopausal only

27.2 Not postmenopausal on-
ly

28 Overall pain/disability
(change values)

6

9

7

2

5

2

1

1

3

126

558

196

296

176

561

313

834

70

954

74

38

Std. Mean Difference (IV, Random,
95% CI)

0.38 [-0.30, 1.05]

Std. Mean Difference (IV, Random,
95% CI)

0.08 [-0.31, 0.47]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.18 [-0.13, 0.48]

Std. Mean Difference (IV, Random,
95% CI)

-0.42 [-0.77, -0.06]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.27 [-0.57, 0.04]

Std. Mean Difference (IV, Random,
95% CI)

-0.21 [-0.82, 0.40]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.04 [-0.19, 0.26]

Std. Mean Difference (IV, Random,
95% CI)

-0.53 [-0.87, -0.18]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.05 [-1.55, 1.64]

Std. Mean Difference (IV, Random,
95% CI)

-0.24 [-0.69, 0.20]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.05 [-0.51, 0.40]

Std. Mean Difference (IV, Random,
95% CI)

-0.26 [-0.89, 0.38]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

369

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

28.1 Postmenopausal only

28.2 Not postmenopausal on-
ly

29 Overall cardiorespiratory
fitness (follow-up values)

29.1 Postmenopausal only

29.2 Not postmenopausal on-
ly

30 Overall cardiorespiratory
fitness (change values)

30.1 Postmenopausal only

30.2 Not postmenopausal on-
ly

2

1

9

4

5

5

4

1

31 Overall self-reported phys-
ical activity (follow-up val-
ues)

10

31.1 Postmenopausal only

31.2 Not postmenopausal on-
ly

32 Overall self-reported phys-
ical activity (change values)

32.1 Postmenopausal only

32.2 Not postmenopausal on-
ly

33 Overall objective physical
activity (follow-up values)

33.1 Postmenopausal only

33.2 Not postmenopausal on-
ly

34 Overall objective physical
activity (change values)

5

5

6

3

3

8

3

5

5

157

36

214

418

208

498

292

810

186

901

145

645

Std. Mean Difference (IV, Random,
95% CI)

-0.29 [-0.61, 0.02]

Std. Mean Difference (IV, Random,
95% CI)

0.22 [-0.43, 0.88]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.61 [0.30, 0.92]

Std. Mean Difference (IV, Random,
95% CI)

0.19 [-0.01, 0.38]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

1.07 [0.48, 1.67]

Std. Mean Difference (IV, Random,
95% CI)

0.16 [-0.02, 0.33]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.63 [0.17, 1.10]

Std. Mean Difference (IV, Random,
95% CI)

0.45 [0.16, 0.75]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.83 [0.53, 1.13]

Std. Mean Difference (IV, Random,
95% CI)

0.57 [-0.02, 1.16]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.87 [0.27, 1.46]

Std. Mean Difference (IV, Random,
95% CI)

0.19 [-0.03, 0.42]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

370

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

34.1 Postmenopausal only

34.2 Not postmenopausal on-
ly

35 Mass (follow-up values)

35.1 Postmenopausal only

35.2 Not postmenopausal on-
ly

36 Mass (change values)

36.1 Postmenopausal only

36.2 Not postmenopausal on-
ly

37 BMI (follow-up values)

37.1 Postmenopausal only

37.2 Not postmenopausal on-
ly

38 BMI (change values)

38.1 Postmenopausal only

38.2 Not postmenopausal on-
ly

3

2

8

4

4

7

4

3

9

3

6

4

2

2

39 Overall body fat (follow-up
values)

11

39.1 Postmenopausal only

39.2 Not postmenopausal on-
ly

40 Overall body fat (change
values)

40.1 Postmenopausal only

40.2 Not postmenopausal on-
ly

41 Lower body strength (fol-
low-up values)

5

6

5

3

2

6

145

363

222

411

202

613

161

745

92

161

264

353

128

161

Std. Mean Difference (IV, Random,
95% CI)

0.89 [0.54, 1.24]

Std. Mean Difference (IV, Random,
95% CI)

0.45 [-0.67, 1.58]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

0.69 [-3.74, 5.13]

Mean Difference (IV, Fixed, 95% CI)

0.08 [-0.52, 0.68]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-0.99 [-1.96, -0.02]

Mean Difference (IV, Random, 95% CI)

0.11 [-0.07, 0.29]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

-0.60 [-2.62, 1.42]

Mean Difference (IV, Fixed, 95% CI)

0.08 [-0.13, 0.29]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-0.17 [-0.54, 0.20]

Mean Difference (IV, Random, 95% CI)

-0.02 [-0.09, 0.05]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.06 [-0.36, 0.25]

Std. Mean Difference (IV, Random,
95% CI)

-0.22 [-0.59, 0.15]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.35 [-0.70, 0.00]

Std. Mean Difference (IV, Random,
95% CI)

-1.67 [-4.39, 1.05]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

371

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

41.1 Postmenopausal only

41.2 Not postmenopausal on-
ly

42 Lower body strength
(change values)

42.1 Postmenopausal only

42.2 Not postmenopausal on-
ly

43 Upper body strength (fol-
low-up values)

43.1 Postmenopausal only

43.2 Not postmenopausal on-
ly

44 Upper body strength
(change values)

44.1 Postmenopausal only

44.2 Not postmenopausal on-
ly

45 Bone mineral density -
femoral neck (follow-up and
change values)

45.1 Postmenopausal only

45.2 Not postmenopausal on-
ly

46 Bone mineral density -
lumbar spine (follow-up and
change values)

46.1 Postmenopausal only

46.2 Not postmenopausal on-
ly

1

5

3

2

1

5

1

4

4

2

2

4

3

1

4

3

1

67

228

256

45

67

208

306

81

329

457

329

457

Std. Mean Difference (IV, Random,
95% CI)

0.19 [-0.30, 0.67]

Std. Mean Difference (IV, Random,
95% CI)

0.46 [0.04, 0.88]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.70 [-0.01, 1.41]

Std. Mean Difference (IV, Random,
95% CI)

1.27 [0.63, 1.92]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.14 [-0.34, 0.62]

Std. Mean Difference (IV, Random,
95% CI)

0.44 [-0.40, 1.28]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.25 [0.03, 0.48]

Std. Mean Difference (IV, Random,
95% CI)

1.49 [0.04, 2.93]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.18 [-0.39, 0.75]

Std. Mean Difference (IV, Random,
95% CI)

0.18 [-0.00, 0.37]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.27 [-0.16, 0.70]

Std. Mean Difference (IV, Random,
95% CI)

0.09 [-0.09, 0.27]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

372

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 12.1.   Comparison 12 Subanalysis: outcomes by
menopausal status, Outcome 1 Overall HRQoL (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.1.1 Postmenopausal only

Courneya 2003

Ergun 2013

Cadmus 2009

Subtotal ***

91.3 (11)

71.6 (19.9)

91.2 (12.6)

24

40

37

101

Heterogeneity: Tau2=0; Chi2=0.21, df=2(P=0.9); I2=0%

Test for overall effect: Z=1.62(P=0.1)

12.1.2 Not postmenopausal only

Milne 2008

Rogers 2009

Schmitz 2005

Loh 2014

Rogers 2015

Vallance 2007

Subtotal ***

86.4 (8.3)

92 (11.4)

-44.2 (8.7)

112.4 (14.1)

88.1 (12.4)

91.5 (11.8)

29

20

39

63

105

250

506

Heterogeneity: Tau2=0.24; Chi2=36.76, df=5(P<0.0001); I2=86.4%

Test for overall effect: Z=2.44(P=0.01)

89.3 (10.9)

67.9 (16.7)

86.2 (17.4)

64.1 (10.8)

87.4 (13.1)

-47.4 (9.4)

109.3 (13.3)

83.2 (15.5)

90.6 (13)

28

20

37

85

29

18

40

32

108

85

312

28.99%

29.91%

41.1%

100%

13.79%

14.17%

16.86%

17.09%

18.92%

19.16%

100%

0.18[-0.37,0.73]

0.19[-0.35,0.73]

0.33[-0.13,0.78]

0.24[-0.05,0.54]

2.28[1.61,2.96]

0.37[-0.27,1.01]

0.35[-0.09,0.79]

0.22[-0.2,0.65]

0.35[0.08,0.62]

0.08[-0.16,0.33]

0.55[0.11,0.98]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 12.2.   Comparison 12 Subanalysis: outcomes by
menopausal status, Outcome 2 Overall HRQoL (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.2.1 Postmenopausal only

Courneya 2003

Ergun 2013

Cadmus 2009

Subtotal ***

5.7 (7.4)

5.4 (21.5)

0.6 (7.5)

24

40

37

101

Heterogeneity: Tau2=0; Chi2=0.85, df=2(P=0.65); I2=0%

Test for overall effect: Z=3.22(P=0)

12.2.2 Not postmenopausal only

Rogers 2009

Schmitz 2005

Vallance 2007

Saarto 2012

Subtotal ***

4.5 (8.4)

2.3 (4.5)

2.3 (11.1)

4.2 (16.2)

20

39

250

263

572

Heterogeneity: Tau2=0.03; Chi2=7.11, df=3(P=0.07); I2=57.8%

Test for overall effect: Z=1.07(P=0.28)

0.6 (7.4)

-6.7 (25.9)

-2.4 (9.8)

2.9 (12)

0.6 (4)

-0.2 (6.4)

5.6 (15.4)

28

20

37

85

18

40

85

237

380

28.1%

29.83%

42.07%

100%

11.29%

18.5%

32.05%

38.15%

100%

0.68[0.12,1.24]

0.52[-0.03,1.06]

0.34[-0.12,0.8]

0.49[0.19,0.79]

0.15[-0.49,0.79]

0.4[-0.05,0.84]

0.24[-0,0.49]

-0.09[-0.26,0.09]

0.13[-0.11,0.38]

Favours control

-10

-5

0

5

10

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

373

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 12.3.   Comparison 12 Subanalysis: outcomes by menopausal status,
Outcome 3 Overall emotional function/mental health (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.3.1 Postmenopausal only

Courneya 2003

Cadmus 2009

Subtotal ***

21.5 (3.4)

20.5 (3)

24

37

61

Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.88); I2=0%

Test for overall effect: Z=1.19(P=0.23)

12.3.2 Not postmenopausal only

Pinto 2003

Rogers 2009

Milne 2008

Cantarero-Villanueva 2013

Schmitz 2005

Loh 2014

Fillion 2008

Rogers 2015

Vallance 2007

Subtotal ***

-10.8 (28.1)

20 (3.1)

19.6 (2.4)

-17175
(4279)

-45.6 (8.2)

19.9 (2.8)

48.5 (7.9)

20.6 (2.9)

20.3 (3.3)

12

20

29

32

39

63

44

105

250

594

Heterogeneity: Tau2=0.04; Chi2=14.46, df=8(P=0.07); I2=44.66%

Test for overall effect: Z=2.57(P=0.01)

20.7 (3)

19.8 (4.2)

-27.2 (19.5)

21.1 (2.9)

16.7 (4.1)

-20390
(6113)

-48.2 (8.2)

20 (3.2)

47.5 (9.1)

19.7 (3.2)

19.9 (3.4)

28

37

65

12

18

29

29

40

32

43

108

85

396

41.04%

58.96%

100%

0.25[-0.3,0.79]

0.19[-0.27,0.65]

0.21[-0.14,0.56]

4.52%

6.72%

8.65%

9.2%

11.08%

11.64%

11.79%

17.65%

18.76%

100%

0.65[-0.17,1.48]

-0.36[-1,0.28]

0.85[0.31,1.39]

0.61[0.09,1.12]

0.31[-0.13,0.76]

-0.04[-0.46,0.39]

0.12[-0.3,0.54]

0.29[0.02,0.56]

0.11[-0.14,0.35]

0.25[0.06,0.44]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 12.4.   Comparison 12 Subanalysis: outcomes by menopausal status,
Outcome 4 Overall emotional function/mental health (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.4.1 Postmenopausal only

Courneya 2003

Cadmus 2009

Subtotal ***

2.3 (3.1)

0.3 (2.2)

24

37

61

Heterogeneity: Tau2=0; Chi2=0.33, df=1(P=0.56); I2=0%

Test for overall effect: Z=2.04(P=0.04)

12.4.2 Not postmenopausal only

Rogers 2009

Cantarero-Villanueva 2013

Schmitz 2005

Vallance 2007

Saarto 2012

Subtotal ***

0.9 (2.5)

-1445
(4452)

2.5 (4.4)

0.5 (3.5)

1.2 (17.8)

20

32

39

250

263

604

Heterogeneity: Tau2=0.04; Chi2=10.22, df=4(P=0.04); I2=60.85%

Test for overall effect: Z=0.65(P=0.51)

0.8 (2.9)

-0.5 (3.3)

-0.1 (2.7)

353 (3323)

0.3 (3.9)

0.1 (2.5)

1.9 (18.5)

28

37

65

18

29

40

85

237

409

40.6%

59.4%

100%

0.49[-0.06,1.05]

0.28[-0.18,0.74]

0.37[0.01,0.72]

10.6%

14.44%

16.7%

27.08%

31.18%

100%

0.38[-0.27,1.02]

-0.45[-0.96,0.06]

0.52[0.08,0.97]

0.12[-0.13,0.36]

-0.04[-0.21,0.14]

0.08[-0.17,0.33]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

374

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 12.5.   Comparison 12 Subanalysis: outcomes by menopausal
status, Outcome 5 Overall physical function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.5.1 Postmenopausal only

Courneya 2003

Winters-Stone 2011

Cadmus 2009

Subtotal ***

25.3 (2.5)

51.7 (6.2)

25.1 (2.7)

24

36

37

97

Heterogeneity: Tau2=0; Chi2=1.53, df=2(P=0.46); I2=0%

Test for overall effect: Z=0.63(P=0.53)

12.5.2 Not postmenopausal only

Pinto 2003

Milne 2008

Rogers 2009

Schmitz 2005

Loh 2014

Fillion 2008

Rogers 2015

Vallance 2007

Subtotal ***

32.3 (4.3)

24 (2.6)

23.3 (4.5)

-44.2 (5.6)

24.9 (2.5)

45.1 (10.4)

24.1 (3.5)

25.1 (3)

12

29

20

39

63

44

105

250

562

Heterogeneity: Tau2=0.26; Chi2=48.26, df=7(P<0.0001); I2=85.5%

Test for overall effect: Z=2.47(P=0.01)

25.3 (2.8)

52.3 (5.9)

24 (4.1)

25.3 (8.2)

15.6 (4.5)

25.4 (2.3)

-48.3 (7.7)

24.2 (2.2)

41.8 (9.8)

22.5 (5)

25 (3.3)

28

25

37

90

12

29

18

40

32

43

108

85

367

28.14%

32.09%

39.77%

100%

9.01%

10.86%

11.03%

13.05%

13.28%

13.32%

14.64%

14.81%

100%

0[-0.55,0.55]

-0.1[-0.61,0.41]

0.31[-0.15,0.77]

0.09[-0.2,0.38]

1.03[0.17,1.89]

2.26[1.59,2.92]

-0.57[-1.22,0.08]

0.6[0.15,1.05]

0.3[-0.12,0.73]

0.33[-0.1,0.75]

0.37[0.1,0.64]

0.05[-0.2,0.3]

0.5[0.1,0.9]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 12.6.   Comparison 12 Subanalysis: outcomes by menopausal
status, Outcome 6 Overall physical function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.6.1 Postmenopausal only

Courneya 2003

Cadmus 2009

Subtotal ***

1.9 (2)

0.1 (6)

24

37

61

Heterogeneity: Tau2=0.33; Chi2=5.63, df=1(P=0.02); I2=82.23%

Test for overall effect: Z=1.16(P=0.25)

12.6.2 Not postmenopausal only

Rogers 2009

Schmitz 2005

Vallance 2007

Saarto 2012

Subtotal ***

2.3 (5.1)

1.2 (4.2)

1 (3.3)

1.9 (13.7)

20

39

247

263

569

Heterogeneity: Tau2=0.02; Chi2=6.01, df=3(P=0.11); I2=50.09%

Test for overall effect: Z=0.23(P=0.81)

-0.2 (2.2)

-0.5 (7.4)

2.6 (6)

1.5 (6.8)

0.2 (2.1)

3.4 (13.4)

28

37

65

18

40

85

237

380

47.91%

52.09%

100%

0.98[0.4,1.56]

0.09[-0.37,0.54]

0.52[-0.36,1.39]

10%

17.34%

32.37%

40.29%

100%

-0.05[-0.69,0.58]

-0.05[-0.49,0.39]

0.26[0.02,0.51]

-0.11[-0.29,0.06]

0.03[-0.2,0.25]

Favours control

-10

-5

0

5

10

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

375

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 12.7.   Comparison 12 Subanalysis: outcomes by menopausal
status, Outcome 7 Overall role function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.7.1 Postmenopausal only

Courneya 2003

Cadmus 2009

Subtotal ***

23.4 (4)

23.1 (4.7)

24

37

61

Heterogeneity: Tau2=0; Chi2=0.84, df=1(P=0.36); I2=0%

Test for overall effect: Z=1.49(P=0.14)

12.7.2 Not postmenopausal only

Milne 2008

Rogers 2009

Schmitz 2005

Loh 2014

Rogers 2015

Vallance 2007

Subtotal ***

22.2 (3)

21.4 (4.8)

-49.2 (6.5)

23.4 (4.3)

22.3 (4.5)

23.2 (4)

29

20

39

63

105

250

506

23.1 (4)

20.6 (7.2)

12.5 (4.8)

23.8 (3.2)

-50 (6.2)

22.2 (5)

20.3 (5.5)

22.7 (4.6)

28

37

65

29

18

40

32

108

85

312

Heterogeneity: Tau2=0.32; Chi2=45.91, df=5(P<0.0001); I2=89.11%

Test for overall effect: Z=1.67(P=0.1)

41.63%

58.37%

100%

0.07[-0.47,0.62]

0.41[-0.05,0.87]

0.27[-0.08,0.62]

14.19%

14.57%

16.93%

17.08%

18.52%

18.71%

100%

2.39[1.71,3.08]

-0.57[-1.22,0.08]

0.12[-0.32,0.57]

0.25[-0.18,0.68]

0.4[0.12,0.67]

0.12[-0.13,0.37]

0.42[-0.07,0.9]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 12.8.   Comparison 12 Subanalysis: outcomes by
menopausal status, Outcome 8 Overall role function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.8.1 Postmenopausal only

Courneya 2003

Cadmus 2009

Subtotal ***

0.9 (2.8)

-0.3 (3.7)

24

37

61

Heterogeneity: Tau2=0; Chi2=0.12, df=1(P=0.73); I2=0%

Test for overall effect: Z=0.6(P=0.55)

12.8.2 Not postmenopausal only

Rogers 2009

Schmitz 2005

Vallance 2007

Saarto 2012

Subtotal ***

0.4 (3.3)

1.2 (4.2)

0.6 (4.1)

2.4 (21.5)

20

39

250

263

572

Heterogeneity: Tau2=0; Chi2=2.96, df=3(P=0.4); I2=0%

Test for overall effect: Z=0.07(P=0.95)

0.4 (2.7)

-0.5 (3.4)

1.4 (4.3)

1.5 (6.8)

-0 (2.7)

3.8 (21.6)

28

37

65

18

40

85

237

380

41.03%

58.97%

100%

0.18[-0.37,0.73]

0.06[-0.4,0.51]

0.11[-0.24,0.46]

4.33%

9.1%

29.16%

57.42%

100%

-0.26[-0.9,0.38]

-0.05[-0.49,0.39]

0.17[-0.08,0.41]

-0.06[-0.24,0.11]

-0[-0.14,0.13]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

376

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 12.9.   Comparison 12 Subanalysis: outcomes by menopausal
status, Outcome 9 Overall social well-being/function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.9.1 Postmenopausal only

Rogers 2014

Courneya 2003

Cadmus 2009

Subtotal ***

7.3 (4.9)

21.1 (3.5)

22.3 (4.9)

20

24

37

81

Heterogeneity: Tau2=0.11; Chi2=4.74, df=2(P=0.09); I2=57.84%

Test for overall effect: Z=1.73(P=0.08)

12.9.2 Not postmenopausal only

Rogers 2009

Loh 2014

Kiecolt-Glaser 2014

Rogers 2015

Vallance 2007

Subtotal ***

22.6 (4.1)

21.5 (4.9)

95.2 (10.8)

21 (5.7)

22.9 (5)

20

63

96

105

250

534

Heterogeneity: Tau2=0; Chi2=2.54, df=4(P=0.64); I2=0%

Test for overall effect: Z=1.32(P=0.19)

3.1 (3.2)

20.7 (3.6)

20.6 (7.2)

21.8 (5.7)

19.6 (4.9)

93.8 (9.3)

20.7 (5.8)

23 (5.1)

22

28

37

87

18

32

90

108

85

333

28.51%

33.36%

38.13%

100%

4.88%

10.8%

23.97%

27.53%

32.82%

100%

1.01[0.36,1.65]

0.11[-0.43,0.66]

0.27[-0.18,0.73]

0.43[-0.06,0.91]

0.16[-0.48,0.8]

0.38[-0.05,0.81]

0.14[-0.15,0.43]

0.05[-0.22,0.32]

-0[-0.25,0.24]

0.09[-0.05,0.24]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 12.10.   Comparison 12 Subanalysis: outcomes by menopausal
status, Outcome 10 Overall social well-being/function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.10.1 Postmenopausal only

Rogers 2014

Courneya 2003

Cadmus 2009

Subtotal ***

2.1 (3.2)

0.6 (2.4)

0.6 (4.6)

20

24

37

81

Heterogeneity: Tau2=0; Chi2=1.54, df=2(P=0.46); I2=0%

Test for overall effect: Z=3.15(P=0)

12.10.2 Not postmenopausal only

Rogers 2009

Vallance 2007

Saarto 2012

Subtotal ***

0.9 (2.6)

0.2 (4.8)

5 (21.1)

20

250

263

533

-0.8 (3.5)

-0.5 (3.3)

-1 (3.2)

-1.2 (2.7)

-4.1 (3.3)

8.8 (20.8)

22

28

37

87

18

85

237

340

Heterogeneity: Tau2=0.58; Chi2=55.25, df=2(P<0.0001); I2=96.38%

Test for overall effect: Z=1.11(P=0.27)

23.64%

31.45%

44.91%

100%

29.89%

34.78%

35.33%

100%

0.85[0.21,1.48]

0.37[-0.18,0.92]

0.4[-0.06,0.86]

0.5[0.19,0.8]

0.78[0.11,1.44]

0.97[0.71,1.23]

-0.18[-0.36,-0.01]

0.5[-0.39,1.4]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

377

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 12.11.   Comparison 12 Subanalysis: outcomes by menopausal
status, Outcome 11 Overall cognitive function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.11.1 Postmenopausal only

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

12.11.2 Not postmenopausal only

Pinto 2003

Rogers 2009

Cantarero-Villanueva 2013

Subtotal ***

0

12

19

32

63

0

6

18

29

53

-7.2 (2.1)

-135.5
(19.5)

-43 (10)

-4.3 (2.5)

-124.5
(30.8)

-37.9 (8.5)

Heterogeneity: Tau2=0; Chi2=1.31, df=2(P=0.52); I2=0%

Test for overall effect: Z=2.99(P=0)

Not estimable

12.5%

33.38%

54.12%

100%

1.14[0.07,2.2]

0.42[-0.24,1.07]

0.55[0.03,1.06]

0.58[0.2,0.95]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 12.12.   Comparison 12 Subanalysis: outcomes by menopausal
status, Outcome 12 Overall cognitive function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.12.1 Postmenopausal only

Subtotal ***

0

0

Not estimable

Heterogeneity: Not applicable

Test for overall effect: Not applicable

12.12.2 Not postmenopausal only

Rogers 2009

Cantarero-Villanueva 2013

Saarto 2012

Subtotal ***

20

32

263

315

4.2 (16.8)

2.2 (7.6)

-1 (18.2)

18

29

237

284

-4.7 (25.9)

-0.2 (5.5)

2.2 (18.5)

23.68%

29.7%

46.62%

100%

0.4[-0.24,1.05]

0.35[-0.16,0.86]

-0.17[-0.35,0]

0.12[-0.31,0.55]

Heterogeneity: Tau2=0.1; Chi2=6.03, df=2(P=0.05); I2=66.84%

Test for overall effect: Z=0.54(P=0.59)

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 12.13.   Comparison 12 Subanalysis: outcomes by menopausal
status, Outcome 13 Overall general health (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.13.1 Postmenopausal only

Ergun 2013

Cadmus 2009

Subtotal ***

71.6 (19.9)

50 (8.8)

40

37

77

67.9 (16.7)

51.7 (8.4)

20

37

57

Heterogeneity: Tau2=0.01; Chi2=1.16, df=1(P=0.28); I2=13.97%

43.03%

56.97%

100%

0.19[-0.35,0.73]

-0.2[-0.65,0.26]

-0.03[-0.41,0.35]

Favours control

-100

-50

0

50

100

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

378

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for overall effect: Z=0.15(P=0.88)

12.13.2 Not postmenopausal only

Rogers 2009

Schmitz 2005

Subtotal ***

3.5 (0.9)

53.8 (5.3)

20

39

59

18

40

58

3.8 (0.5)

53.2 (6)

Heterogeneity: Tau2=0.05; Chi2=1.59, df=1(P=0.21); I2=37.2%

Test for overall effect: Z=0.37(P=0.71)

38.68%

61.32%

100%

-0.4[-1.04,0.25]

0.1[-0.34,0.55]

-0.09[-0.57,0.39]

Favours control

-100

-50

0

50

100

Favours physical activity

Analysis 12.14.   Comparison 12 Subanalysis: outcomes by menopausal
status, Outcome 14 Overall general health (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.14.1 Postmenopausal only

Ergun 2013

Cadmus 2009

Subtotal ***

5.4 (21.5)

0.2 (4.4)

40

37

77

Heterogeneity: Tau2=0.04; Chi2=1.59, df=1(P=0.21); I2=37%

Test for overall effect: Z=1.17(P=0.24)

12.14.2 Not postmenopausal only

Rogers 2009

Schmitz 2005

Saarto 2012

Subtotal ***

0.2 (0.6)

0.7 (4.8)

4.2 (16.2)

20

39

263

322

Heterogeneity: Tau2=0.01; Chi2=2.48, df=2(P=0.29); I2=19.25%

Test for overall effect: Z=0.05(P=0.96)

-6.7 (25.9)

-0.1 (5.1)

0.2 (0.7)

-0.6 (3.9)

5.6 (15.4)

20

37

57

18

40

237

295

44.41%

55.59%

100%

0.52[-0.03,1.06]

0.06[-0.39,0.52]

0.27[-0.18,0.71]

10.62%

20.11%

69.27%

100%

-0.03[-0.67,0.61]

0.29[-0.15,0.74]

-0.09[-0.26,0.09]

-0.01[-0.22,0.21]

Favours control

-100

-50

0

50

100

Favours physical activity

Analysis 12.15.   Comparison 12 Subanalysis: outcomes by menopausal
status, Outcome 15 Overall sexual function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

12.15.1 Postmenopausal only

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

12.15.2 Not postmenopausal only

Schmitz 2005

Pinto 2003

Subtotal ***

0

39

39

78

0

40

43

83

-53.5 (8)

40.1 (6.3)

-51 (7.5)

42.5 (9.2)

Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.94); I2=0%

Test for overall effect: Z=1.93(P=0.05)

Not estimable

49.07%

50.93%

100%

0.32[-0.12,0.76]

0.29[-0.14,0.73]

0.31[-0,0.62]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

379

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 12.16.   Comparison 12 Subanalysis: outcomes by menopausal
status, Outcome 16 Overall sexual function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.16.1 Postmenopausal only

Subtotal ***

0

0

Not estimable

Heterogeneity: Not applicable

Test for overall effect: Not applicable

12.16.2 Not postmenopausal only

Schmitz 2005

Saarto 2012

Subtotal ***

39

263

302

1.7 (4.8)

4.3 (25.4)

40

237

277

0.2 (5.2)

3.8 (24.4)

Heterogeneity: Tau2=0.01; Chi2=1.29, df=1(P=0.26); I2=22.57%

Test for overall effect: Z=0.7(P=0.48)

21.77%

78.23%

100%

0.3[-0.15,0.74]

0.02[-0.16,0.2]

0.08[-0.14,0.3]

Favours control

-100

-50

0

50

100

Favours physical activity

Analysis 12.17.   Comparison 12 Subanalysis: outcomes by
menopausal status, Outcome 17 Overall sleep (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

12.17.1 Postmenopausal only

Rogers 2014

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.37(P=0.71)

12.17.2 Not postmenopausal only

Rogers 2013

Bower 2011

Rogers 2009

Subtotal ***

20

20

11

16

20

47

6.7 (3.7)

6.3 (2.7)

8.1 (2.5)

6.7 (4.2)

22

22

9

15

18

42

7.1 (3.2)

6.2 (3.2)

7.7 (2.6)

5.5 (4)

Heterogeneity: Tau2=0; Chi2=0.2, df=2(P=0.91); I2=0%

Test for overall effect: Z=0.84(P=0.4)

100%

100%

-0.11[-0.72,0.49]

-0.11[-0.72,0.49]

22.46%

35.01%

42.54%

100%

0.03[-0.85,0.91]

0.15[-0.55,0.86]

0.28[-0.36,0.92]

0.18[-0.24,0.6]

Favours Physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 12.18.   Comparison 12 Subanalysis: outcomes by
menopausal status, Outcome 18 Overall sleep (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.18.1 Postmenopausal only

Rogers 2014

Subtotal ***

-1.3 (3.2)

20

20

22

22

-2.2 (4.4)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

100%

100%

0.23[-0.38,0.84]

0.23[-0.38,0.84]

Favours Physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

380

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for overall effect: Z=0.73(P=0.46)

12.18.2 Not postmenopausal only

Rogers 2009

Subtotal ***

20

20

0.5 (2.1)

18

18

0.3 (4.7)

100%

100%

0.05[-0.59,0.68]

0.05[-0.59,0.68]

Heterogeneity: Not applicable

Test for overall effect: Z=0.14(P=0.89)

Favours Physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 12.19.   Comparison 12 Subanalysis: outcomes by
menopausal status, Outcome 19 Overall anxiety (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.19.1 Postmenopausal only

Rogers 2014

Cadmus 2009

Subtotal ***

45.6 (8.9)

32.1 (12.3)

20

37

57

Heterogeneity: Tau2=0; Chi2=0.11, df=1(P=0.74); I2=0%

Test for overall effect: Z=0.51(P=0.61)

12.19.2 Not postmenopausal only

Pinto 2003

Cantarero-Villanueva 2013

Subtotal ***

7.6 (7.3)

42.5 (8.6)

12

32

44

Heterogeneity: Tau2=0; Chi2=0.25, df=1(P=0.62); I2=0%

Test for overall effect: Z=2.8(P=0.01)

45.7 (8)

34.1 (15.4)

10.5 (3.7)

49.9 (11.7)

22

37

59

6

29

35

36.22%

63.78%

100%

-0.01[-0.62,0.59]

-0.14[-0.6,0.31]

-0.09[-0.46,0.27]

21.49%

78.51%

100%

-0.43[-1.43,0.56]

-0.72[-1.24,-0.2]

-0.66[-1.12,-0.2]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 12.20.   Comparison 12 Subanalysis: outcomes by
menopausal status, Outcome 20 Overall anxiety (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

12.20.1 Postmenopausal only

Cadmus 2009

Rogers 2014

Subtotal ***

-0.7 (9.2)

-4 (6.5)

37

20

57

Heterogeneity: Tau2=0; Chi2=0.32, df=1(P=0.57); I2=0%

Test for overall effect: Z=1.25(P=0.21)

12.20.2 Not postmenopausal only

Cantarero-Villanueva 2013

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.31(P=0.02)

-4.2 (9.8)

32

32

0.5 (5.8)

-1.8 (5)

0.8 (5.5)

37

22

59

29

29

64.21%

35.79%

100%

-0.15[-0.61,0.3]

-0.37[-0.99,0.24]

-0.23[-0.6,0.13]

100%

100%

-0.61[-1.12,-0.09]

-0.61[-1.12,-0.09]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

381

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 12.21.   Comparison 12 Subanalysis: outcomes by menopausal
status, Outcome 21 Overall self-esteem/body image (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.21.1 Postmenopausal only

Courneya 2003

Cadmus 2009

Subtotal ***

34.8 (4.7)

34.2 (5.5)

24

37

61

Heterogeneity: Tau2=0; Chi2=0.07, df=1(P=0.79); I2=0%

Test for overall effect: Z=0.56(P=0.58)

12.21.2 Not postmenopausal only

Pinto 2003

Milne 2008

Subtotal ***

32.3 (4.3)

-17.9 (6.8)

12

29

41

Heterogeneity: Tau2=0.15; Chi2=1.82, df=1(P=0.18); I2=45.02%

Test for overall effect: Z=1.56(P=0.12)

34.6 (4.4)

33.4 (5.9)

25.3 (8.2)

-20.1 (6.3)

28

37

65

6

29

35

41.18%

58.82%

100%

0.04[-0.5,0.59]

0.14[-0.32,0.6]

0.1[-0.25,0.45]

33%

67%

100%

1.15[0.08,2.22]

0.33[-0.19,0.85]

0.6[-0.15,1.35]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 12.22.   Comparison 12 Subanalysis: outcomes by menopausal
status, Outcome 22 Overall self-esteem/body image (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.22.1 Postmenopausal only

Courneya 2003

Cadmus 2009

Subtotal ***

2.6 (3.7)

0.4 (4.4)

24

37

61

Heterogeneity: Tau2=0.17; Chi2=3.44, df=1(P=0.06); I2=70.94%

Test for overall effect: Z=1.1(P=0.27)

12.22.2 Not postmenopausal only

Milne 2008

Saarto 2012

Subtotal ***

1.5 (3.7)

10.7 (21.5)

29

263

292

Heterogeneity: Tau2=0.05; Chi2=2.29, df=1(P=0.13); I2=56.3%

Test for overall effect: Z=0.39(P=0.69)

-0.1 (3.5)

0.2 (2.9)

0.1 (3.9)

12 (22)

28

37

65

29

237

266

46.93%

53.07%

100%

0.74[0.18,1.3]

0.05[-0.4,0.51]

0.38[-0.3,1.05]

32.63%

67.37%

100%

0.36[-0.16,0.88]

-0.06[-0.24,0.12]

0.08[-0.31,0.47]

Favours control

-5

-2.5

0

2.5

5

Favours intervention

Analysis 12.23.   Comparison 12 Subanalysis: outcomes by menopausal
status, Outcome 23 Overall depression (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.23.1 Postmenopausal only

Payne 2008

10

12.7 (8.7)

10

11.4 (7.9)

11.62%

0.15[-0.73,1.03]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

382

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Rogers 2014

Ergun 2013

Cadmus 2009

Subtotal ***

44.2 (8.6)

6.9 (6.8)

9.6 (9.3)

20

40

37

107

Heterogeneity: Tau2=0.01; Chi2=3.36, df=3(P=0.34); I2=10.78%

Test for overall effect: Z=1.12(P=0.26)

12.23.2 Not postmenopausal only

Pinto 2003

Bower 2011

Cantarero-Villanueva 2013

Kiecolt-Glaser 2014

Subtotal ***

6.2 (7.2)

7.7 (5.8)

45.6 (9.7)

8.1 (8.6)

12

16

32

96

156

Heterogeneity: Tau2=0.05; Chi2=4.99, df=3(P=0.17); I2=39.82%

Test for overall effect: Z=2.3(P=0.02)

25.1 (44.2)

5.2 (5.2)

10.8 (10.1)

9.8 (6.8)

11.6 (7.1)

53.7 (11.6)

9.2 (8.2)

22

20

37

89

6

15

29

90

140

22.21%

28.4%

37.77%

100%

10.64%

17.62%

26.91%

44.83%

100%

0.58[-0.04,1.19]

0.27[-0.27,0.81]

-0.12[-0.58,0.33]

0.18[-0.13,0.48]

-0.49[-1.49,0.5]

-0.59[-1.31,0.13]

-0.75[-1.28,-0.23]

-0.13[-0.42,0.16]

-0.42[-0.77,-0.06]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 12.24.   Comparison 12 Subanalysis: outcomes by
menopausal status, Outcome 24 Overall depression (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.24.1 Postmenopausal only

Rogers 2014

Ergun 2013

Cadmus 2009

Subtotal ***

-1.7 (6.9)

1.2 (6.2)

0.3 (6.4)

20

40

37

97

Heterogeneity: Tau2=0; Chi2=0.68, df=2(P=0.71); I2=0%

Test for overall effect: Z=1.72(P=0.09)

12.24.2 Not postmenopausal only

Cantarero-Villanueva 2013

Saarto 2012

Subtotal ***

-2.9 (7.8)

-0.3 (3.3)

32

263

295

Heterogeneity: Tau2=0.16; Chi2=5.22, df=1(P=0.02); I2=80.83%

Test for overall effect: Z=0.67(P=0.5)

1.1 (4.2)

2.4 (8)

1.7 (6.3)

1.5 (7.4)

-0.5 (3.4)

22

20

37

79

29

237

266

24.26%

31.78%

43.96%

100%

-0.49[-1.1,0.13]

-0.16[-0.7,0.37]

-0.22[-0.68,0.24]

-0.27[-0.57,0.04]

42.42%

57.58%

100%

-0.57[-1.09,-0.06]

0.06[-0.12,0.24]

-0.21[-0.82,0.4]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 12.25.   Comparison 12 Subanalysis: outcomes by
menopausal status, Outcome 25 Overall fatigue (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.25.1 Postmenopausal only

Payne 2008

Rogers 2014

Courneya 2003

9

20

24

4.7 (2.6)

4.1 (2.1)

-8.3 (7.9)

9

22

28

3.5 (1.7)

4 (1.8)

-8.8 (8.1)

5.68%

13.78%

17%

0.52[-0.42,1.46]

0.05[-0.56,0.66]

0.06[-0.48,0.61]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

383

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Ergun 2013

Winters-Stone 2011

Cadmus 2009

Subtotal ***

2.9 (2.2)

45 (5.3)

-51.9 (9)

40

36

37

166

Heterogeneity: Tau2=0; Chi2=2.77, df=5(P=0.73); I2=0%

Test for overall effect: Z=0.31(P=0.76)

12.25.2 Not postmenopausal only

Pinto 2003

Rogers 2013

Bower 2011

Rogers 2009

Milne 2008

Cantarero-Villanueva 2013

Fillion 2008

Kiecolt-Glaser 2014

Vallance 2007

Subtotal ***

7.2 (6.4)

4.2 (1.8)

3.4 (1.8)

-12.4 (10.4)

11.9 (3.2)

3.8 (1.8)

2.7 (0.7)

6.3 (19.6)

-42.7 (8.4)

12

11

16

20

29

32

44

96

250

510

3.3 (1.8)

43.1 (10.3)

-50.6 (10)

9 (6.4)

4.2 (1.6)

4.9 (1.3)

-10.1 (6.6)

17.4 (4.7)

6.2 (1.7)

2.9 (0.8)

12.7 (19)

-42.6 (8.7)

20

31

37

147

6

9

15

18

29

29

43

90

85

324

Heterogeneity: Tau2=0.19; Chi2=34.94, df=8(P<0.0001); I2=77.1%

Test for overall effect: Z=2.98(P=0)

17.49%

21.76%

24.29%

100%

7.02%

7.92%

9.26%

10.46%

11.24%

11.38%

13.1%

14.6%

15.03%

100%

-0.17[-0.71,0.37]

0.23[-0.25,0.72]

-0.14[-0.59,0.32]

0.04[-0.19,0.26]

-0.27[-1.26,0.71]

0[-0.88,0.88]

-0.93[-1.67,-0.18]

-0.26[-0.9,0.38]

-1.35[-1.92,-0.78]

-1.38[-1.94,-0.82]

-0.27[-0.69,0.15]

-0.33[-0.62,-0.04]

-0.01[-0.26,0.23]

-0.53[-0.87,-0.18]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 12.26.   Comparison 12 Subanalysis: outcomes by
menopausal status, Outcome 26 Overall fatigue (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.26.1 Postmenopausal only

Payne 2008

Courneya 2003

Subtotal ***

-0.9 (2)

9.3 (10.2)

9

24

33

Heterogeneity: Tau2=1.16; Chi2=8.05, df=1(P=0); I2=87.58%

Test for overall effect: Z=0.06(P=0.95)

12.26.2 Not postmenopausal only

Rogers 2013

Rogers 2009

Cantarero-Villanueva 2013

Vallance 2007

Saarto 2012

Subtotal ***

4.2 (2)

1.9 (9.6)

-2 (1.8)

2.5 (8.2)

-2.4 (9.1)

11

20

32

250

263

576

9

28

37

9

18

29

85

237

378

Heterogeneity: Tau2=0.19; Chi2=27.19, df=4(P<0.0001); I2=85.29%

Test for overall effect: Z=1.08(P=0.28)

0.5 (1.4)

2 (7.5)

3.9 (1.5)

4.2 (12.3)

0.3 (1.4)

1.2 (6.6)

-2.4 (8.6)

46.96%

53.04%

100%

-0.82[-1.79,0.15]

0.81[0.24,1.38]

0.05[-1.55,1.64]

13.08%

17.34%

18.73%

24.94%

25.91%

100%

0.16[-0.72,1.04]

-0.21[-0.84,0.43]

-1.45[-2.02,-0.88]

0.17[-0.08,0.42]

0[-0.18,0.18]

-0.24[-0.69,0.2]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

384

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 12.27.   Comparison 12 Subanalysis: outcomes by menopausal
status, Outcome 27 Overall pain/disability (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.27.1 Postmenopausal only

Cadmus 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.24(P=0.81)

12.27.2 Not postmenopausal only

Rogers 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.78(P=0.43)

37

37

20

20

50.3 (9.1)

-3 (3)

50.8 (9)

-2.3 (2.8)

37

37

18

18

100%

100%

-0.05[-0.51,0.4]

-0.05[-0.51,0.4]

100%

100%

-0.26[-0.89,0.38]

-0.26[-0.89,0.38]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 12.28.   Comparison 12 Subanalysis: outcomes by menopausal
status, Outcome 28 Overall pain/disability (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.28.1 Postmenopausal only

Cadmus 2009

Irwin 2015

Subtotal ***

-2.2 (11.3)

-6 (19)

37

45

82

Heterogeneity: Tau2=0; Chi2=0.17, df=1(P=0.68); I2=0%

Test for overall effect: Z=1.81(P=0.07)

12.28.2 Not postmenopausal only

Rogers 2009

Subtotal ***

-0.8 (1.4)

19

19

Heterogeneity: Not applicable

Test for overall effect: Z=0.67(P=0.5)

-0.1 (7)

0.7 (18.6)

-1.8 (6.2)

37

38

75

17

17

47.55%

52.45%

100%

-0.22[-0.68,0.24]

-0.35[-0.79,0.08]

-0.29[-0.61,0.02]

100%

100%

0.22[-0.43,0.88]

0.22[-0.43,0.88]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 12.29.   Comparison 12 Subanalysis: outcomes by menopausal
status, Outcome 29 Overall cardiorespiratory fitness (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.29.1 Postmenopausal only

Rogers 2014

Kim 2015

Courneya 2003

Irwin 2015

Subtotal ***

30.9 (6.3)

424.8 (55.8)

21.3 (3.7)

24.6 (5.5)

20

20

24

45

109

22

19

26

38

105

25.1 (5)

394.4 (54)

18.2 (3.9)

23 (4.7)

Heterogeneity: Tau2=0.02; Chi2=3.75, df=3(P=0.29); I2=20.02%

19.73%

20.03%

23.69%

36.55%

100%

1.01[0.36,1.65]

0.54[-0.1,1.18]

0.8[0.22,1.38]

0.31[-0.13,0.74]

0.61[0.3,0.92]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

385

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for overall effect: Z=3.81(P=0)

12.29.2 Not postmenopausal only

Rogers 2013

Rogers 2009

Milne 2008

Fillion 2008

Rogers 2015

Subtotal ***

12

20

29

44

105

210

23.9 (6.2)

29.5 (6.6)

1.5 (0.3)

27 (4.4)

23.6 (4.8)

10

18

29

43

108

208

23.9 (3.8)

27.6 (6.1)

1.5 (0.4)

26.5 (5.8)

22.7 (0.3)

Heterogeneity: Tau2=0; Chi2=1.16, df=4(P=0.88); I2=0%

Test for overall effect: Z=1.89(P=0.06)

5.25%

9.02%

13.97%

20.92%

50.83%

100%

0[-0.84,0.84]

0.29[-0.35,0.93]

0.03[-0.49,0.54]

0.1[-0.32,0.52]

0.27[-0,0.54]

0.19[-0.01,0.38]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 12.30.   Comparison 12 Subanalysis: outcomes by menopausal
status, Outcome 30 Overall cardiorespiratory fitness (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.30.1 Postmenopausal only

Dolan 2016

Courneya 2003

Rogers 2014

Irwin 2015

Subtotal ***

12.2 (10.2)

2.7 (2.6)

2.8 (4.9)

1.5 (2.1)

23

24

20

45

112

10

26

22

38

96

-6 (7.2)

-0.6 (1.7)

1.1 (4.2)

-0.4 (2.7)

Heterogeneity: Tau2=0.26; Chi2=11.04, df=3(P=0.01); I2=72.83%

Test for overall effect: Z=3.52(P=0)

12.30.2 Not postmenopausal only

Saarto 2012

Subtotal ***

262

262

0.9 (1.2)

236

236

0.7 (1)

Heterogeneity: Not applicable

Test for overall effect: Z=1.74(P=0.08)

19.81%

25.19%

25.68%

29.32%

100%

1.88[0.99,2.77]

1.49[0.86,2.12]

0.37[-0.24,0.98]

0.79[0.34,1.24]

1.07[0.48,1.67]

100%

100%

0.16[-0.02,0.33]

0.16[-0.02,0.33]

Favours control

-10

-5

0

5

10

Favours physical activity

Analysis 12.31.   Comparison 12 Subanalysis: outcomes by menopausal
status, Outcome 31 Overall self-reported physical activity (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.31.1 Postmenopausal only

Cadmus 2009

Irwin 2015

Kim 2015

Matthews 2007

Winters-Stone 2011

34

45

20

22

36

161.7
(114.7)

222.1
(118.6)

17.6 (16)

54.2 (34.1)

430.8
(281.4)

33

55.6 (101.9)

38

19

14

31

103.6
(104.6)

11.8 (11.6)

27.2 (22.7)

461.7
(346.4)

21%

0.97[0.46,1.47]

21.96%

18.4%

17.08%

21.56%

1.04[0.58,1.51]

0.4[-0.23,1.04]

0.87[0.17,1.58]

-0.1[-0.58,0.38]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

386

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Subtotal ***

Mean(SD)

N

157

Heterogeneity: Tau2=0.2; Chi2=14.52, df=4(P=0.01); I2=72.46%

Test for overall effect: Z=2.67(P=0.01)

12.31.2 Not postmenopausal only

Guinan 2013

Kiecolt-Glaser 2014

Rogers 2009

Rogers 2015

Vallance 2007

Subtotal ***

38.7 (26.9)

11.2 (7.6)

121.4 (73.2)

169 (119)

207.6 (169)

16

96

20

110

253

495

Heterogeneity: Tau2=0.07; Chi2=12.58, df=4(P=0.01); I2=68.19%

Test for overall effect: Z=2.99(P=0)

N

135

10

90

18

112

85

315

Mean(SD)

Random, 95% CI

Random, 95% CI

100%

0.63[0.17,1.1]

19.9 (11.3)

9.1 (6.1)

114.3
(131.5)

74 (107)

163 (121)

9.23%

25.12%

13.04%

25.73%

26.88%

100%

0.81[-0.01,1.64]

0.3[0.01,0.59]

0.07[-0.57,0.7]

0.84[0.56,1.11]

0.28[0.03,0.53]

0.45[0.16,0.75]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 12.32.   Comparison 12 Subanalysis: outcomes by menopausal
status, Outcome 32 Overall self-reported physical activity (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.32.1 Postmenopausal only

Cadmus 2009

Irwin 2015

Matthews 2007

Subtotal ***

129 (117.9)

159 (136)

21.5 (30.6)

34

45

22

101

Heterogeneity: Tau2=0; Chi2=0.56, df=2(P=0.76); I2=0%

Test for overall effect: Z=5.37(P<0.0001)

12.32.2 Not postmenopausal only

Guinan 2013

Saarto 2012

Vallance 2007

Subtotal ***

15.6 (11.4)

3.5 (18.3)

82 (168.7)

16

262

281

559

Heterogeneity: Tau2=0.21; Chi2=22, df=2(P<0.0001); I2=90.91%

Test for overall effect: Z=1.88(P=0.06)

44.3 (89.4)

49 (86)

5 (13.8)

-8.3 (4.2)

3.3 (21.5)

30 (167.8)

33

38

14

85

10

236

96

342

36.73%

43.95%

19.32%

100%

17.81%

41.66%

40.53%

100%

0.8[0.3,1.3]

0.94[0.48,1.4]

0.63[-0.06,1.32]

0.83[0.53,1.13]

2.46[1.39,3.53]

0.01[-0.17,0.19]

0.31[0.08,0.54]

0.57[-0.02,1.16]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 12.33.   Comparison 12 Subanalysis: outcomes by menopausal
status, Outcome 33 Overall objective physical activity (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.33.1 Postmenopausal only

Matthews 2007

Rogers 2014

22

20

330.8
(114.7)

14

198.5 (55.4)

294 (175)

22

154 (75)

28.69%

32.28%

1.34[0.6,2.09]

1.04[0.39,1.69]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

387

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Cadmus 2009

Subtotal ***

6738 (2958)

33

75

5537 (3352)

34

70

Heterogeneity: Tau2=0.17; Chi2=5.47, df=2(P=0.06); I2=63.45%

Test for overall effect: Z=2.87(P=0)

12.33.2 Not postmenopausal only

Rogers 2013

Guinan 2013

Rogers 2009

Rogers 2015

Vallance 2007

Subtotal ***

198.4
(111.7)

30.7 (15.6)

252191
(91893)

246 (153)

8110.5
(4133.9)

12

16

20

110

253

411

10

9

18

112

85

234

0 (0)

31 (15.6)

210917
(64078)

197 (138)

8028 (3457)

Heterogeneity: Tau2=0.01; Chi2=4.13, df=3(P=0.25); I2=27.35%

Test for overall effect: Z=1.7(P=0.09)

39.03%

100%

0.38[-0.11,0.86]

0.87[0.27,1.46]

6.86%

10.43%

39.66%

43.05%

Not estimable

-0.02[-0.84,0.8]

0.51[-0.14,1.15]

0.34[0.07,0.6]

0.02[-0.23,0.27]

100%

0.19[-0.03,0.42]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 12.34.   Comparison 12 Subanalysis: outcomes by menopausal
status, Outcome 34 Overall objective physical activity (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.34.1 Postmenopausal only

Matthews 2007

Rogers 2014

Cadmus 2009

Subtotal ***

72.2 (114.6)

114 (109)

1621 (2108)

22

20

33

75

Heterogeneity: Tau2=0; Chi2=0.83, df=2(P=0.66); I2=0%

Test for overall effect: Z=5.05(P<0.0001)

12.34.2 Not postmenopausal only

Guinan 2013

Vallance 2007

Subtotal ***

-1.1 (6.2)

-150
(5173.3)

16

253

269

Heterogeneity: Tau2=0.56; Chi2=6.16, df=1(P=0.01); I2=83.76%

Test for overall effect: Z=0.79(P=0.43)

-16.8 (51.5)

10 (70)

-60 (2341)

-7.9 (5.3)

91 (5155.4)

14

22

34

70

9

85

94

23.91%

27.69%

48.41%

100%

0.91[0.2,1.62]

1.13[0.47,1.78]

0.75[0.25,1.24]

0.89[0.54,1.24]

43.05%

56.95%

1.11[0.23,2]

-0.05[-0.29,0.2]

100%

0.45[-0.67,1.58]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 12.35.   Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 35 Mass (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

12.35.1 Postmenopausal only

Matthews 2007

Courneya 2003

22

24

74.9 (15.2)

78.2 (20.5)

14

26

78.9 (20.3)

80.1 (16.2)

12.83%

18.56%

-4[-16.39,8.39]

-1.9[-12.2,8.4]

Favours physical activity

-20

-10

0

10

20

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

388

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Physical activity

Control

Cadmus 2009

Winters-Stone 2011

Subtotal ***

Mean(SD)

80.7 (16.9)

76.5 (15.6)

N

36

36

118

Heterogeneity: Tau2=0; Chi2=1.13, df=3(P=0.77); I2=0%

Test for overall effect: Z=0.31(P=0.76)

12.35.2 Not postmenopausal only

DeNysschen 2011

Ligibel 2008

Schmitz 2005

Kiecolt-Glaser 2014

Subtotal ***

69.3 (14.2)

80 (17.5)

69.5 (2.2)

75.2 (2.8)

30

40

39

96

205

Heterogeneity: Tau2=0; Chi2=1.51, df=3(P=0.68); I2=0%

Test for overall effect: Z=0.26(P=0.8)

Mean(SD)

78.5 (20.6)

74.2 (12.3)

72.4 (19.6)

83.3 (18.7)

69.2 (2.2)

75.2 (2.6)

N

33

31

104

34

42

40

90

206

Mean Difference

Fixed, 95% CI

Cochrane Database of Systematic Reviews

Weight

Mean Difference

24.6%

44.01%

100%

0.53%

0.59%

38.36%

60.52%

100%

Fixed, 95% CI

2.22[-6.72,11.16]

2.3[-4.39,8.99]

0.69[-3.74,5.13]

-3.1[-11.42,5.22]

-3.3[-11.14,4.54]

0.3[-0.67,1.27]

0[-0.78,0.78]

0.08[-0.52,0.68]

Favours physical activity

-20

-10

0

10

20

Favours control

Analysis 12.36.   Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 36 Mass (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

12.36.1 Postmenopausal only

Dolan 2016

Irwin 2015

Matthews 2007

Courneya 2003

Subtotal ***

-0.5 (5)

-2.1 (4.3)

0 (2.1)

0.1 (2)

23

45

22

24

114

Heterogeneity: Tau2=0.37; Chi2=4.85, df=3(P=0.18); I2=38.1%

Test for overall effect: Z=2(P=0.05)

12.36.2 Not postmenopausal only

Ligibel 2008

Saarto 2012

Schmitz 2005

Subtotal ***

0 (2.3)

0.7 (3.7)

0.3 (0.4)

22

262

39

323

Heterogeneity: Tau2=0; Chi2=0.18, df=2(P=0.92); I2=0%

Test for overall effect: Z=1.18(P=0.24)

10

38

14

26

88

14

236

40

290

1.4 (1.6)

0.1 (3.6)

0 (2.2)

0.7 (1.8)

0 (2.2)

0.7 (3.8)

0.2 (0.4)

14.09%

21.8%

27.12%

36.98%

100%

1.46%

7.31%

91.23%

100%

-1.99[-4.28,0.3]

-2.2[-3.9,-0.5]

-0.03[-1.46,1.4]

-0.6[-1.66,0.46]

-0.99[-1.96,-0.02]

-0.04[-1.52,1.44]

-0.01[-0.67,0.65]

0.12[-0.07,0.31]

0.11[-0.07,0.29]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 12.37.   Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 37 BMI (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

12.37.1 Postmenopausal only

Courneya 2003

Rogers 2014

Cadmus 2009

Subtotal ***

29.4 (7.4)

29.6 (5)

30.5 (6)

24

20

36

80

29.3 (6)

32.2 (6.7)

29.9 (7.6)

26

22

33

81

28.99%

32.3%

38.71%

100%

0.1[-3.65,3.85]

-2.6[-6.16,0.96]

0.55[-2.7,3.8]

-0.6[-2.62,1.42]

Favours physical activity

-20

-10

0

10

20

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

389

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

Heterogeneity: Tau2=0; Chi2=1.83, df=2(P=0.4); I2=0%

Test for overall effect: Z=0.58(P=0.56)

12.37.2 Not postmenopausal only

Rogers 2013

Rogers 2009

Ligibel 2008

Vallance 2007

Schmitz 2005

Kiecolt-Glaser 2014

Subtotal ***

12

20

40

253

39

96

460

33.6 (7)

30.6 (7.6)

30.3 (6.3)

27 (5.2)

26 (0.7)

27.8 (1.1)

10

18

42

85

40

90

285

30.6 (7.3)

30.4 (8.3)

31.5 (6.8)

27.2 (5.2)

25.8 (0.7)

27.8 (1)

Heterogeneity: Tau2=0; Chi2=2.68, df=5(P=0.75); I2=0%

Test for overall effect: Z=0.72(P=0.47)

0.13%

0.18%

0.56%

2.81%

43.12%

53.2%

100%

3[-3,9]

0.2[-4.88,5.28]

-1.2[-4.04,1.64]

-0.19[-1.46,1.08]

0.2[-0.12,0.52]

0[-0.29,0.29]

0.08[-0.13,0.29]

Favours physical activity

-20

-10

0

10

20

Favours control

Analysis 12.38.   Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 38 BMI (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

12.38.1 Postmenopausal only

Rogers 2014

Courneya 2003

Subtotal ***

-0.2 (0.9)

0 (0.7)

20

24

44

Heterogeneity: Tau2=0.01; Chi2=1.19, df=1(P=0.28); I2=15.77%

Test for overall effect: Z=0.91(P=0.36)

12.38.2 Not postmenopausal only

Ligibel 2008

Schmitz 2005

Subtotal ***

0 (0.9)

0.1 (0.2)

40

39

79

Heterogeneity: Tau2=0; Chi2=0.98, df=1(P=0.32); I2=0%

Test for overall effect: Z=0.47(P=0.64)

-0.3 (1.1)

0.3 (0.7)

0.2 (0.8)

0.1 (0.2)

22

26

48

42

40

82

32.43%

67.57%

100%

0.1[-0.51,0.71]

-0.3[-0.69,0.09]

-0.17[-0.54,0.2]

3.75%

96.25%

100%

-0.2[-0.57,0.17]

-0.01[-0.08,0.06]

-0.02[-0.09,0.05]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 12.39.   Comparison 12 Subanalysis: outcomes by
menopausal status, Outcome 39 Overall body fat (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.39.1 Postmenopausal only

Matthews 2007

Rogers 2014

Courneya 2003

Winters-Stone 2011

Cadmus 2009

Subtotal ***

39.7 (6.3)

38.6 (6.4)

131.9 (46.4)

40.5 (6.2)

40.5 (6.6)

22

20

24

36

36

138

14

22

26

31

33

126

43.1 (6.9)

41.5 (7.4)

137.1 (44.4)

38.5 (5.8)

39.6 (6)

Heterogeneity: Tau2=0.04; Chi2=6.11, df=4(P=0.19); I2=34.55%

14.9%

17.38%

19.86%

23.62%

24.24%

100%

-0.51[-1.19,0.17]

-0.41[-1.02,0.2]

-0.11[-0.67,0.44]

0.33[-0.16,0.81]

0.15[-0.33,0.62]

-0.06[-0.36,0.25]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

390

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for overall effect: Z=0.36(P=0.72)

12.39.2 Not postmenopausal only

Rogers 2013

Rogers 2009

DeNysschen 2011

Saarto 2012

Schmitz 2005

Ligibel 2008

Subtotal ***

10

20

30

37

39

40

176

44.2 (6.7)

44.3 (7.4)

36.9 (8.4)

39.9 (7.5)

40.9 (1.3)

42.9 (7.4)

12

19

34

30

40

42

177

42.3 (7.7)

43.5 (7.5)

38 (10.2)

40.2 (8)

42.3 (1.3)

44.7 (8)

Heterogeneity: Tau2=0.14; Chi2=14.56, df=5(P=0.01); I2=65.66%

Test for overall effect: Z=1.16(P=0.24)

11.17%

14.99%

17.96%

18.19%

18.41%

19.28%

100%

0.25[-0.59,1.09]

0.11[-0.52,0.73]

-0.12[-0.61,0.38]

-0.04[-0.52,0.44]

-1.05[-1.52,-0.58]

-0.23[-0.67,0.2]

-0.22[-0.59,0.15]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 12.40.   Comparison 12 Subanalysis: outcomes by
menopausal status, Outcome 40 Overall body fat (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.40.1 Postmenopausal only

Matthews 2007

Rogers 2014

Courneya 2003

Subtotal ***

-0.2 (1.6)

-1.1 (2.2)

-4.9 (15.7)

22

20

24

66

Heterogeneity: Tau2=0; Chi2=0.39, df=2(P=0.82); I2=0%

Test for overall effect: Z=1.95(P=0.05)

12.40.2 Not postmenopausal only

Schmitz 2005

Ligibel 2008

Subtotal ***

-1.1 (0.5)

-0.2 (1.7)

39

40

79

Heterogeneity: Tau2=3.78; Chi2=47.46, df=1(P<0.0001); I2=97.89%

Test for overall effect: Z=1.2(P=0.23)

0.4 (1.9)

-0.6 (2.4)

5.1 (24.4)

0.2 (0.4)

0.3 (1.7)

14

22

26

62

40

42

82

27.23%

33.64%

39.13%

100%

-0.34[-1.02,0.33]

-0.21[-0.82,0.39]

-0.48[-1.04,0.09]

-0.35[-0.7,0]

49.59%

50.41%

100%

-3.07[-3.73,-2.41]

-0.29[-0.73,0.14]

-1.67[-4.39,1.05]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 12.41.   Comparison 12 Subanalysis: outcomes by menopausal
status, Outcome 41 Lower body strength (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.41.1 Postmenopausal only

Winters-Stone 2011

Subtotal ***

201.3 (57.4)

36

36

31

31

191 (51.7)

100%

100%

0.19[-0.3,0.67]

0.19[-0.3,0.67]

Heterogeneity: Not applicable

Test for overall effect: Z=0.76(P=0.45)

12.41.2 Not postmenopausal only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

391

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Rogers 2013

Rogers 2009

Schmitz 2005

Milne 2008

Saarto 2012

Subtotal ***

68.4 (15.5)

80.3 (27)

296.6 (48.9)

66.2 (10.2)

136 (23)

11

20

23

29

37

120

67.1 (16.2)

64.9 (19.7)

238.9 (46.4)

61.7 (11)

136 (29)

9

18

22

29

30

108

Heterogeneity: Tau2=0.13; Chi2=9.46, df=4(P=0.05); I2=57.74%

Test for overall effect: Z=2.14(P=0.03)

13.94%

19.16%

19.59%

23.04%

24.27%

100%

0.08[-0.8,0.96]

0.63[-0.02,1.29]

1.19[0.55,1.83]

0.42[-0.1,0.94]

0[-0.48,0.48]

0.46[0.04,0.88]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 12.42.   Comparison 12 Subanalysis: outcomes by
menopausal status, Outcome 42 Lower body strength (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.42.1 Postmenopausal only

Dolan 2016

Waltman 2010

Subtotal ***

23

110

133

11.8 (8.9)

4.4 (11.5)

10

113

123

0.3 (11.1)

0.2 (8.4)

Heterogeneity: Tau2=0.19; Chi2=3.04, df=1(P=0.08); I2=67.07%

Test for overall effect: Z=1.92(P=0.05)

12.42.2 Not postmenopausal only

Schmitz 2005

Subtotal ***

81.8 (48.9)

23

23

22

22

20.3 (46)

Heterogeneity: Not applicable

Test for overall effect: Z=3.86(P=0)

36.79%

63.21%

100%

1.17[0.37,1.97]

0.42[0.15,0.69]

0.7[-0.01,1.41]

100%

100%

1.27[0.63,1.92]

1.27[0.63,1.92]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 12.43.   Comparison 12 Subanalysis: outcomes by menopausal
status, Outcome 43 Upper body strength (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.43.1 Postmenopausal only

Winters-Stone 2011

Subtotal ***

63.3 (15.3)

36

36

Heterogeneity: Not applicable

Test for overall effect: Z=0.55(P=0.58)

12.43.2 Not postmenopausal only

Schmitz 2005

Rogers 2009

Milne 2008

Saarto 2012

Subtotal ***

83 (13.4)

27.9 (5)

7.6 (2.9)

32.7 (5.3)

23

20

29

37

109

Heterogeneity: Tau2=0.65; Chi2=25.69, df=3(P<0.0001); I2=88.32%

61.1 (16.8)

63 (12.7)

24.3 (6.2)

9.4 (2.6)

30.8 (5.7)

31

31

22

18

29

30

99

100%

100%

0.14[-0.34,0.62]

0.14[-0.34,0.62]

24.13%

24.29%

25.58%

26%

100%

1.5[0.84,2.17]

0.63[-0.03,1.28]

-0.64[-1.17,-0.12]

0.34[-0.14,0.83]

0.44[-0.4,1.28]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

392

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for overall effect: Z=1.02(P=0.31)

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 12.44.   Comparison 12 Subanalysis: outcomes by
menopausal status, Outcome 44 Upper body strength (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.44.1 Postmenopausal only

Irwin 2015

Waltman 2010

Subtotal ***

0.4 (1.9)

1.9 (4.9)

45

110

155

Heterogeneity: Tau2=0; Chi2=0.25, df=1(P=0.62); I2=0%

Test for overall effect: Z=2.19(P=0.03)

12.44.2 Not postmenopausal only

Schmitz 2005

Rogers 2009

Subtotal ***

32.3 (11.5)

1.5 (2.3)

23

19

42

Heterogeneity: Tau2=0.96; Chi2=8.08, df=1(P=0); I2=87.62%

Test for overall effect: Z=2.01(P=0.04)

0.1 (1.9)

0.8 (2.9)

6.9 (10.8)

-0.3 (2.4)

38

113

151

22

17

39

27.13%

72.87%

100%

49.33%

50.67%

100%

0.16[-0.27,0.59]

0.29[0.02,0.55]

0.25[0.03,0.48]

2.24[1.48,2.99]

0.76[0.08,1.44]

1.49[0.04,2.93]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 12.45.   Comparison 12 Subanalysis: outcomes by menopausal status,
Outcome 45 Bone mineral density - femoral neck (follow-up and change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.45.1 Postmenopausal only

Kim 2015

Winters-Stone 2011

Waltman 2010

Subtotal ***

20

36

110

166

0.8 (0.1)

0.7 (0.1)

0.9 (0.5)

19

31

113

163

0.8 (0.1)

0.7 (0.1)

0.6 (0.4)

Heterogeneity: Tau2=0.2; Chi2=9.77, df=2(P=0.01); I2=79.54%

Test for overall effect: Z=0.61(P=0.54)

12.45.2 Not postmenopausal only

Saarto 2012

Subtotal ***

239

239

-0 (0)

218

218

-0 (0)

Heterogeneity: Not applicable

Test for overall effect: Z=1.93(P=0.05)

28.05%

32.86%

39.09%

100%

-0.37[-1,0.27]

0.11[-0.37,0.59]

0.63[0.36,0.9]

0.18[-0.39,0.75]

100%

100%

0.18[-0,0.37]

0.18[-0,0.37]

Favours control

-2

-1

0

1

2

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

393

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 12.46.   Comparison 12 Subanalysis: outcomes by menopausal status,
Outcome 46 Bone mineral density - lumbar spine (follow-up and change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

12.46.1 Postmenopausal only

Kim 2015

Winters-Stone 2011

Waltman 2010

Subtotal ***

20

36

110

166

1 (0.1)

1 (0.2)

3.1 (0.4)

19

31

113

163

1 (0.1)

1 (0.1)

2.9 (0.4)

Heterogeneity: Tau2=0.09; Chi2=5.52, df=2(P=0.06); I2=63.75%

Test for overall effect: Z=1.23(P=0.22)

12.46.2 Not postmenopausal only

Saarto 2012

Subtotal ***

239

239

-0 (0)

218

218

-0 (0)

Heterogeneity: Not applicable

Test for overall effect: Z=0.95(P=0.34)

24.58%

31.58%

43.84%

100%

-0.26[-0.89,0.37]

0.3[-0.19,0.78]

0.55[0.28,0.81]

0.27[-0.16,0.7]

100%

100%

0.09[-0.09,0.27]

0.09[-0.09,0.27]

Favours control

-2

-1

0

1

2

Favours physical activity

Comparison 13.   Subanalysis: outcomes by mode of physical activity intervention

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Overall HRQoL (follow-up
values)

1.1 Aerobic exercise interven-
tions

1.2 Resistance exercise inter-
ventions

1.3 Combined aerobic and re-
sistance exercise

1.4 Yoga, Tai Chi, and Pilates
interventions

22

12

1

7

3

2 Overall HRQoL (change val-
ues)

14

2.1 Aerobic exercise interven-
tions

2.2 Resistance exercise inter-
ventions

2.3 Combined aerobic and re-
sistance exercise

2.4 Yoga, Tai Chi, and Pilates
interventions

9

1

4

1

971

79

589

184

1280

79

139

21

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.41 [0.19, 0.63]

Std. Mean Difference (IV, Random,
95% CI)

0.35 [-0.09, 0.79]

Std. Mean Difference (IV, Random,
95% CI)

0.63 [0.08, 1.19]

Std. Mean Difference (IV, Random,
95% CI)

0.11 [-0.22, 0.45]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.68 [0.22, 1.15]

Std. Mean Difference (IV, Random,
95% CI)

0.40 [-0.05, 0.84]

Std. Mean Difference (IV, Random,
95% CI)

0.69 [0.01, 1.38]

Std. Mean Difference (IV, Random,
95% CI)

2.88 [1.59, 4.17]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

394

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

3 Overall emotional func-
tion/mental health (follow-up
values)

3.1 Aerobic exercise interven-
tions

3.2 Resistance exercise inter-
ventions

3.3 Combined aerobic and re-
sistance exercise

3.4 Yoga, Tai Chi, and Pilates
interventions

4 Overall emotional func-
tion/mental health (change
values)

4.1 Aerobic exercise

4.2 Resistance exercise

4.3 Combined aerobic and re-
sistance exercise

4.4 Yoga, Tai Chi, and Pilates

5 Overall physical function
(follow-up values)

5.1 Aerobic exercise

5.2 Resistance exercise

5.3 Combined aerobic and re-
sistance exercise

5.4 Yoga, Tai Chi, and Pilates

6 Overall physical function
(change values)

6.1 Aerobic exercise

6.2 Resistance exercise

26

14

2

6

4

15

7

3

4

1

25

14

3

5

3

13

7

3

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.15 [0.04, 0.25]

Std. Mean Difference (IV, Random,
95% CI)

0.08 [-0.28, 0.44]

Std. Mean Difference (IV, Random,
95% CI)

0.72 [0.47, 0.97]

Std. Mean Difference (IV, Random,
95% CI)

-0.03 [-0.40, 0.34]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.44 [0.06, 0.82]

Std. Mean Difference (IV, Random,
95% CI)

0.22 [-0.09, 0.54]

Std. Mean Difference (IV, Random,
95% CI)

-0.01 [-0.38, 0.36]

Std. Mean Difference (IV, Random,
95% CI)

1.06 [0.08, 2.03]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.28 [0.15, 0.41]

Std. Mean Difference (IV, Random,
95% CI)

0.23 [-0.11, 0.57]

Std. Mean Difference (IV, Random,
95% CI)

0.80 [-0.04, 1.64]

Std. Mean Difference (IV, Random,
95% CI)

0.16 [-0.26, 0.57]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.72 [0.14, 1.30]

Std. Mean Difference (IV, Random,
95% CI)

0.24 [-0.17, 0.65]

1415

311

263

113

701

261

598

19

1465

372

202

90

1116

261

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

395

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

6.3 Combined aerobic and re-
sistance exercise

6.4 Yoga, Tai Chi, and Pilates

7 Overall role function (fol-
low-up values)

7.1 Aerobic exercise

7.2 Resistance exercise

7.3 Combined aerobic and re-
sistance exercise

7.4 Yoga, Tai Chi, and Pilates

2

1

18

10

1

3

4

8 Overall role function (change
values)

12

8.1 Aerobic exercise

8.2 Resistance exercise

8.3 Combined aerobic and re-
sistance exercise

8.4 Yoga, Tai Chi, and Pilates

9 Overall social well-be-
ing/function (follow-up values)

9.1 Aerobic exercise

9.2 Resistance exercise

9.3 Combined aerobic and re-
sistance exercise

9.4 Yoga, Tai Chi, and Pilates

7

2

2

1

18

10

1

3

4

37

19

1043

79

136

112

1118

141

37

19

1044

121

116

276

Std. Mean Difference (IV, Random,
95% CI)

0.75 [-0.22, 1.73]

Std. Mean Difference (IV, Random,
95% CI)

0.93 [-0.03, 1.89]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.28 [0.12, 0.44]

Std. Mean Difference (IV, Random,
95% CI)

0.12 [-0.32, 0.57]

Std. Mean Difference (IV, Random,
95% CI)

0.61 [-1.15, 2.37]

Std. Mean Difference (IV, Random,
95% CI)

0.11 [-0.26, 0.48]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.16 [-0.10, 0.43]

Std. Mean Difference (IV, Random,
95% CI)

0.17 [-0.32, 0.65]

Std. Mean Difference (IV, Random,
95% CI)

0.12 [-0.52, 0.77]

Std. Mean Difference (IV, Random,
95% CI)

-0.15 [-1.05, 0.76]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.18 [0.04, 0.31]

Std. Mean Difference (IV, Random,
95% CI)

0.14 [-0.21, 0.50]

Std. Mean Difference (IV, Random,
95% CI)

0.45 [-0.16, 1.05]

Std. Mean Difference (IV, Random,
95% CI)

0.10 [-0.13, 0.34]

10 Overall social well-be-
ing/function (change values)

12

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

396

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Outcome or subgroup title

No. of studies

10.1 Aerobic exercise

10.2 Resistance exercise

10.3 Combined aerobic and re-
sistance exercise

10.4 Yoga, Tai Chi, and Pilates

11 Overall cognitive function
(follow-up values)

11.1 Aerobic exercise

11.2 Resistance exercise

11.3 Combined aerobic and re-
sistance exercise

11.4 Yoga, Tai Chi, and Pilates

12 Overall cognitive function
(change values)

12.1 Aerobic exercise

12.2 Resistance exercise

12.3 Combined aerobic and re-
sistance exercise

12.4 Yoga, Tai Chi, and Pilates

7

2

2

1

5

2

0

3

0

5

2

0

3

0

13 Overall general health (fol-
low-up values)

10

13.1 Aerobic exercise

13.2 Resistance exercise

13.3 Combined aerobic and re-
sistance exercise

6

1

3

Cochrane Database of Systematic Reviews

Statistical method

Effect size

Std. Mean Difference (IV, Random,
95% CI)

0.60 [0.07, 1.13]

Std. Mean Difference (IV, Random,
95% CI)

0.11 [-0.19, 0.41]

Std. Mean Difference (IV, Random,
95% CI)

0.66 [0.15, 1.17]

Std. Mean Difference (IV, Random,
95% CI)

0.76 [-0.18, 1.70]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.24 [-0.17, 0.65]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

0.57 [0.15, 0.98]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.08 [-0.50, 0.65]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

-0.01 [-0.38, 0.35]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.11 [-0.29, 0.51]

Std. Mean Difference (IV, Random,
95% CI)

0.10 [-0.34, 0.55]

Std. Mean Difference (IV, Random,
95% CI)

0.46 [0.00, 0.91]

No. of partici-
pants

1119

183

63

19

94

0

95

0

95

0

577

0

293

79

118

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

397

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

13.4 Yoga, Tai Chi, and Pilates

14 Overall general health
(change values)

14.1 Aerobic exercise

14.2 Resistance exercise

14.3 Combined aerobic and re-
sistance exercise

14.4 Yoga, Tai Chi, and Pilates

15 Overall sexual function (fol-
low-up values)

15.1 Aerobic exercise

15.2 Resistance exercise

15.3 Combined aerobic and re-
sistance exercise

15.4 Yoga, Tai Chi, and Pilates

16 Overall sexual function
(change values)

16.1 Aerobic exercise

16.2 Resistance exercise

16.3 Combined aerobic and re-
sistance exercise

16.4 Yoga, Tai Chi, and Pilates

17 Overall sleep (follow-up val-
ues)

17.1 Aerobic exercise

1

9

5

2

2

1

5

2

2

1

0

3

1

2

0

0

5

2

18

710

141

76

19

136

193

82

0

500

193

0

0

95

Std. Mean Difference (IV, Random,
95% CI)

-0.18 [-1.11, 0.74]

Std. Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Fixed, 95%
CI)

-0.02 [-0.17, 0.13]

Std. Mean Difference (IV, Fixed, 95%
CI)

0.23 [-0.12, 0.57]

Std. Mean Difference (IV, Fixed, 95%
CI)

0.66 [0.17, 1.16]

Std. Mean Difference (IV, Fixed, 95%
CI)

-0.20 [-1.10, 0.71]

Std. Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Fixed, 95%
CI)

-0.00 [-0.34, 0.34]

Std. Mean Difference (IV, Fixed, 95%
CI)

0.21 [-0.07, 0.49]

Std. Mean Difference (IV, Fixed, 95%
CI)

0.29 [-0.14, 0.73]

Std. Mean Difference (IV, Fixed, 95%
CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95%
CI)

Subtotals only

Mean Difference (IV, Random, 95%
CI)

0.5 [-3.86, 4.86]

Mean Difference (IV, Random, 95%
CI)

3.83 [-1.83, 9.48]

Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Fixed, 95%
CI)

-0.18 [-0.59, 0.23]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

398

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

17.2 Resistance exercise

17.3 Combined aerobic and re-
sistance exercise

17.4 Yoga, Tai Chi, and Pilates

18 Overall sleep (change val-
ues)

18.1 Aerobic exercise

18.2 Resistance exercise

18.3 Combined aerobic and re-
sistance exercise

18.4 Yoga, Tai Chi, and Pilates

19 Overall anxiety (follow-up
values)

19.1 Aerobic exercise

19.2 Resistance exercise

19.3 Combined aerobic and re-
sistance exercise

19.4 Yoga, Tai Chi, and Pilates

20 Overall anxiety (change val-
ues)

20.1 Aerobic exercise

20.2 Resistance exercise

20.3 Combined aerobic and re-
sistance exercise

20.4 Yoga, Tai Chi, and Pilates

0

2

1

3

2

0

1

0

7

4

0

3

0

4

2

0

2

0

0

62

31

94

0

42

0

205

0

121

0

132

0

103

0

Std. Mean Difference (IV, Fixed, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Fixed, 95%
CI)

-0.07 [-0.57, 0.43]

Std. Mean Difference (IV, Fixed, 95%
CI)

0.15 [-0.55, 0.86]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.10 [-0.30, 0.51]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

0.23 [-0.38, 0.84]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.76 [-1.37, -0.14]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

-0.40 [-0.87, 0.07]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Fixed, 95%
CI)

-0.27 [-0.61, 0.07]

Std. Mean Difference (IV, Fixed, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Fixed, 95%
CI)

-0.51 [-0.90, -0.12]

Std. Mean Difference (IV, Fixed, 95%
CI)

0.0 [0.0, 0.0]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

399

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

21 Overall depression (fol-
low-up values)

12

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

21.1 Aerobic exercise

21.2 Resistance exercise

21.3 Combined aerobic and re-
sistance exercise

21.4 Yoga, Tai Chi, and Pilates

22 Overall depression (change
values)

22.1 Aerobic exercise

22.2 Resistance exercise

22.3 Combined aerobic and re-
sistance exercise

22.4 Yoga, Tai Chi, and Pilates

23 Overall fatigue (follow-up
values)

23.1 Aerobic exercise

23.2 Resistance exercise

23.3 Combined aerobic and re-
sistance exercise

23.4 Yoga, Tai Chi, and Pilates

6

0

5

2

7

4

0

4

0

25

11

1

9

5

24 Overall fatigue (change val-
ues)

12

24.1 Aerobic exercise

24.2 Resistance exercise

7

0

273

0

187

217

672

0

164

0

925

67

642

311

1130

0

Std. Mean Difference (IV, Random,
95% CI)

-0.32 [-0.78, 0.14]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

-0.33 [-0.90, 0.24]

Std. Mean Difference (IV, Random,
95% CI)

-0.23 [-0.61, 0.14]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.18 [-0.48, 0.11]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

-0.47 [-0.92, -0.02]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.24 [-0.41, -0.07]

Std. Mean Difference (IV, Random,
95% CI)

0.23 [-0.25, 0.72]

Std. Mean Difference (IV, Random,
95% CI)

-0.48 [-0.83, -0.13]

Std. Mean Difference (IV, Random,
95% CI)

-0.36 [-0.58, -0.13]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.08 [-0.38, 0.23]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

400

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

24.3 Combined aerobic and re-
sistance exercise

24.4 Yoga, Tai Chi, and Pilates

25 Overall pain/disability (fol-
low-up values)

25.1 Aerobic exercise

25.2 Resistance exercise

25.3 Combined aerobic and re-
sistance exercise

25.4 Yoga, Tai Chi, and Pilates

26 Overall pain/disability
(change values)

26.1 Aerobic exercise

26.2 Resistance exercise

26.3 Combined aerobic and re-
sistance exercise

26.4 Yoga, Tai Chi, and Pilates

4

1

9

5

0

2

2

5

2

1

1

1

27 Overall self-esteem/body
image (follow-up values)

12

27.1 Aerobic exercise

27.2 Resistance exercise

27.3 Combined aerobic and re-
sistance exercise

27.4 Yoga, Tai Chi, and Pilates

28 Overall self-esteem/body
image (change values)

7

2

4

1

9

118

23

397

0

96

42

132

62

83

19

364

143

161

23

Std. Mean Difference (IV, Random,
95% CI)

-0.81 [-1.57, -0.05]

Std. Mean Difference (IV, Random,
95% CI)

-0.07 [-0.89, 0.75]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.11 [-0.15, 0.37]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

0.13 [-0.29, 0.54]

Std. Mean Difference (IV, Random,
95% CI)

-0.18 [-0.78, 0.43]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.03 [-0.44, 0.39]

Std. Mean Difference (IV, Random,
95% CI)

0.22 [-0.33, 0.76]

Std. Mean Difference (IV, Random,
95% CI)

-0.35 [-0.79, 0.08]

Std. Mean Difference (IV, Random,
95% CI)

-0.15 [-1.06, 0.75]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.29 [-0.07, 0.64]

Std. Mean Difference (IV, Random,
95% CI)

0.06 [-0.27, 0.39]

Std. Mean Difference (IV, Random,
95% CI)

0.14 [-0.46, 0.74]

Std. Mean Difference (IV, Random,
95% CI)

0.20 [-0.62, 1.02]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

401

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

28.1 Aerobic exercise

28.2 Resistance exercise

28.3 Combined aerobic and re-
sistance exercise

28.4 Yoga, Tai Chi, and Pilates

29 Overall cardiorespiratory
fitness (follow-up values)

29.1 Aerobic exercise

29.2 Resistance exercise

29.3 Combined aerobic and re-
sistance exercise

29.4 Yoga, Tai Chi, and Pilates

30 Overall cardiorespiratory
fitness (change values)

30.1 Aerobic exercise

30.2 Resistance exercise

30.3 Combined aerobic and re-
sistance exercise

30.4 Yoga, Tai Chi, and Pilates

31 Overall self-reported physi-
cal activity (follow-up values)

31.1 Aerobic exercise

31.2 Resistance exercise

31.3 Combined aerobic and re-
sistance exercise

6

2

2

1

23

12

1

11

1

9

5

1

5

0

17

10

2

3

771

143

81

21

814

21

433

21

685

21

181

0

1011

331

421

Std. Mean Difference (IV, Random,
95% CI)

0.14 [-0.12, 0.39]

Std. Mean Difference (IV, Random,
95% CI)

-0.29 [-0.88, 0.30]

Std. Mean Difference (IV, Random,
95% CI)

0.10 [-0.54, 0.75]

Std. Mean Difference (IV, Random,
95% CI)

3.42 [1.99, 4.86]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.37 [0.21, 0.54]

Std. Mean Difference (IV, Random,
95% CI)

0.27 [-0.60, 1.14]

Std. Mean Difference (IV, Random,
95% CI)

0.56 [0.30, 0.81]

Std. Mean Difference (IV, Random,
95% CI)

0.39 [-0.48, 1.25]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.79 [0.17, 1.42]

Std. Mean Difference (IV, Random,
95% CI)

-0.04 [-0.91, 0.82]

Std. Mean Difference (IV, Random,
95% CI)

0.75 [0.18, 1.31]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.69 [0.44, 0.94]

Std. Mean Difference (IV, Random,
95% CI)

0.08 [-0.13, 0.30]

Std. Mean Difference (IV, Random,
95% CI)

0.53 [-0.05, 1.10]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

402

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

31.4 Yoga, Tai Chi, and Pilates

32 Overall self-reported physi-
cal activity (change values)

32.1 Aerobic exercise

32.2 Resistance exercise

32.3 Combined aerobic and re-
sistance exercise

32.4 Yoga, Tai Chi, and Pilates

2

8

6

1

1

0

33 Overall objective physical
activity (follow-up values)

11

33.1 Aerobic exercise

33.2 Resistance exercise

33.3 Combined aerobic and re-
sistance exercise

33.4 Yoga, Tai Chi, and Pilates

34 Overall objective physical
activity (change values)

34.1 Aerobic exercise

34.2 Resistance exercise

34.3 Combined aerobic and re-
sistance exercise

34.4 Yoga, Tai Chi, and Pilates

8

0

3

0

5

4

0

1

0

35 Mass (follow-up values)

16

35.1 Aerobic exercise

35.2 Resistance exercise

7

3

249

1086

105

83

0

876

0

394

0

466

0

42

0

411

410

Std. Mean Difference (IV, Random,
95% CI)

0.33 [0.08, 0.58]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.59 [0.20, 0.97]

Std. Mean Difference (IV, Random,
95% CI)

0.21 [-0.17, 0.60]

Std. Mean Difference (IV, Random,
95% CI)

0.94 [0.48, 1.40]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.43 [0.15, 0.70]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

0.54 [-0.31, 1.40]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.61 [-0.01, 1.23]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

1.13 [0.47, 1.78]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

-1.29 [-4.06, 1.47]

Mean Difference (IV, Fixed, 95% CI)

0.26 [-0.67, 1.20]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

403

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

35.3 Combined aerobic and re-
sistance exercise

35.4 Yoga, Tai Chi, and Pilates

36 Mass (change values)

36.1 Aerobic exercise

36.2 Resistance exercise

36.3 Combined aerobic and re-
sistance exercise

36.4 Yoga, Tai Chi, and Pilates

3

3

11

5

2

3

1

37 BMI (follow-up values)

17

37.1 Aerobic exercise

37.2 Resistance exercise

37.3 Combined aerobic and re-
sistance exercise

37.4 Yoga, Tai Chi, and Pilates

38 BMI (change values)

38.1 Aerobic exercise

38.2 Resistance exercise

38.3 Combined aerobic and re-
sistance exercise

38.4 Yoga, Tai Chi, and Pilates

39 Overall body fat (follow-up
values)

39.1 Aerobic exercise

39.2 Resistance exercise

6

2

6

3

8

2

2

3

1

18

10

4

127

262

679

209

140

19

639

343

237

262

112

209

145

19

551

429

Mean Difference (IV, Fixed, 95% CI)

-2.46 [-7.24, 2.33]

Mean Difference (IV, Fixed, 95% CI)

-0.01 [-0.78, 0.76]

Mean Difference (IV, Random, 95%
CI)

Subtotals only

Mean Difference (IV, Random, 95%
CI)

-0.74 [-1.58, 0.09]

Mean Difference (IV, Random, 95%
CI)

0.10 [-0.15, 0.34]

Mean Difference (IV, Random, 95%
CI)

-0.55 [-1.99, 0.90]

Mean Difference (IV, Random, 95%
CI)

-0.90 [-2.40, 0.60]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

-0.41 [-1.26, 0.43]

Mean Difference (IV, Fixed, 95% CI)

0.17 [-0.15, 0.48]

Mean Difference (IV, Fixed, 95% CI)

-1.03 [-2.63, 0.56]

Mean Difference (IV, Fixed, 95% CI)

-0.03 [-0.32, 0.26]

Mean Difference (IV, Random, 95%
CI)

Subtotals only

Mean Difference (IV, Random, 95%
CI)

-0.48 [-0.84, -0.13]

Mean Difference (IV, Random, 95%
CI)

-0.01 [-0.08, 0.06]

Mean Difference (IV, Random, 95%
CI)

-0.02 [-0.28, 0.24]

Mean Difference (IV, Random, 95%
CI)

-0.71 [-1.33, -0.09]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.11 [-0.28, 0.06]

Std. Mean Difference (IV, Random,
95% CI)

-0.26 [-0.81, 0.28]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

404

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

39.3 Combined aerobic and re-
sistance exercise

39.4 Yoga, Tai Chi, and Pilates

40 Overall body fat (change
values)

40.1 Aerobic exercise

40.2 Resistance exercise

40.3 Combined aerobic and re-
sistance exercise

40.4 Yoga, Tai Chi, and Pilates

5

1

9

3

3

4

1

41 Lower body strength (fol-
low-up values)

10

41.1 Aerobic exercise

41.2 Resistance exercise

41.3 Combined aerobic and re-
sistance exercise

41.4 Yoga, Tai Chi, and Pilates

42 Lower body strength
(change values)

42.1 Aerobic exercise

42.2 Resistance exercise

42.3 Combined aerobic and re-
sistance exercise

42.4 Yoga, Tai Chi, and Pilates

3

3

4

0

8

1

4

3

0

185

21

108

228

168

19

125

344

168

0

33

562

125

0

Std. Mean Difference (IV, Random,
95% CI)

-0.13 [-0.42, 0.16]

Std. Mean Difference (IV, Random,
95% CI)

-0.66 [-1.54, 0.23]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.43 [-0.82, -0.05]

Std. Mean Difference (IV, Random,
95% CI)

-1.38 [-3.39, 0.63]

Std. Mean Difference (IV, Random,
95% CI)

-0.30 [-0.61, 0.00]

Std. Mean Difference (IV, Random,
95% CI)

-0.18 [-1.09, 0.72]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.75 [-0.20, 1.69]

Std. Mean Difference (IV, Random,
95% CI)

0.72 [0.22, 1.23]

Std. Mean Difference (IV, Random,
95% CI)

0.05 [-0.28, 0.38]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

1.17 [0.37, 1.97]

Std. Mean Difference (IV, Random,
95% CI)

0.85 [0.48, 1.22]

Std. Mean Difference (IV, Random,
95% CI)

0.28 [-0.37, 0.93]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

43 Upper body strength (fol-
low-up values)

13

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

405

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

43.1 Aerobic exercise

43.2 Resistance exercise

43.3 Combined aerobic and re-
sistance exercise

43.4 Yoga, Tai Chi, and Pilates

44 Upper body strength
(change values)

44.1 Aerobic exercise

44.2 Resistance exercise

44.3 Combined aerobic and re-
sistance exercise

44.4 Yoga, Tai Chi, and Pilates

45 Bone mineral density -
femoral neck (follow-up and
change values)

45.1 Aerobic exercise

45.2 Resistance exercise

45.3 Combined aerobic and re-
sistance exercise

45.4 Yoga, Tai Chi, and Pilates

46 Bone mineral density -
lumbar spine (follow-up and
change values)

46.1 Aerobic exercise

46.2 Resistance exercise

46.3 Combined aerobic and re-
sistance exercise

5

4

5

1

8

1

5

3

1

4

1

2

1

0

4

1

2

1

175

365

231

21

22

583

168

83

457

290

39

0

457

290

39

Std. Mean Difference (IV, Random,
95% CI)

0.35 [0.05, 0.65]

Std. Mean Difference (IV, Random,
95% CI)

0.80 [0.28, 1.33]

Std. Mean Difference (IV, Random,
95% CI)

0.25 [-0.47, 0.97]

Std. Mean Difference (IV, Random,
95% CI)

0.60 [-0.28, 1.49]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.36 [-0.48, 1.21]

Std. Mean Difference (IV, Random,
95% CI)

0.96 [0.43, 1.49]

Std. Mean Difference (IV, Random,
95% CI)

0.07 [-0.34, 0.48]

Std. Mean Difference (IV, Random,
95% CI)

1.30 [0.82, 1.78]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.18 [-0.00, 0.37]

Std. Mean Difference (IV, Random,
95% CI)

0.41 [-0.09, 0.91]

Std. Mean Difference (IV, Random,
95% CI)

-0.37 [-1.00, 0.27]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.09 [-0.09, 0.27]

Std. Mean Difference (IV, Random,
95% CI)

0.49 [0.25, 0.72]

Std. Mean Difference (IV, Random,
95% CI)

-0.26 [-0.89, 0.37]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

406

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

46.4 Yoga, Tai Chi, and Pilates

47 Bone mineral density - total
hip (follow-up and change val-
ues)

47.1 Aerobic exercise

47.2 Resistance exercise

47.3 Combined aerobic and re-
sistance exercise

47.4 Yoga, Tai Chi, and Pilates

0

3

0

2

1

0

0

0

290

39

0

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random,
95% CI)

0.64 [-0.20, 1.48]

Std. Mean Difference (IV, Random,
95% CI)

10.34 [7.84, 12.84]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Analysis 13.1.   Comparison 13 Subanalysis: outcomes by mode of physical
activity intervention, Outcome 1 Overall HRQoL (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.1.1 Aerobic exercise interventions

Rogers 2015

Cerulli 2014

Rogers 2009

Ergun 2013

Courneya 2003

Murtezani 2014

Mehnert 2011

Cadmus 2009

Pinto 2015

Loh 2014

Daley 2007

Vallance 2007

Subtotal ***

85.2 (4.2)

85.2 (4.2)

92 (11.4)

69 (21.2)

91.3 (11)

86.5 (7.3)

74.7 (21.7)

91.2 (12.6)

117.8 (12.7)

112.4 (14.1)

90.9 (13.5)

91.5 (11.8)

10

10

20

20

24

30

30

37

39

63

33

250

566

Heterogeneity: Tau2=0.08; Chi2=24.66, df=11(P=0.01); I2=55.39%

Test for overall effect: Z=3.61(P=0)

13.1.2 Resistance exercise interventions

Schmitz 2005

Subtotal ***

-44.2 (8.7)

39

39

Heterogeneity: Not applicable

Test for overall effect: Z=1.54(P=0.12)

13.1.3 Combined aerobic and resistance exercise

65.9 (14.7)

65.9 (14.7)

87.4 (13.1)

67.9 (16.7)

89.3 (10.9)

79.1 (7.5)

65.4 (16.8)

86.2 (17.4)

114 (18)

109.3 (13.3)

86.4 (15.1)

90.6 (13)

-47.4 (9.4)

10

10

18

20

28

32

27

37

37

32

69

85

405

40

40

3.43%

3.43%

6.88%

7.18%

8.22%

8.48%

8.51%

9.66%

9.79%

10.24%

10.42%

13.77%

100%

1.72[0.66,2.78]

1.72[0.66,2.78]

0.37[-0.27,1.01]

0.05[-0.57,0.67]

0.18[-0.37,0.73]

0.99[0.46,1.52]

0.47[-0.06,1]

0.33[-0.13,0.78]

0.24[-0.21,0.69]

0.22[-0.2,0.65]

0.3[-0.12,0.72]

0.08[-0.16,0.33]

0.41[0.19,0.63]

100%

100%

0.35[-0.09,0.79]

0.35[-0.09,0.79]

Herrero 2006

8

81.3 (10.7)

8

62.5 (16.1)

10.33%

1.3[0.19,2.41]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

407

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Portela 2008

Milne 2008

Ergun 2013

Do 2015

Taleghani 2012

Short 2014

Subtotal ***

107.2 (28.5)

86.4 (8.3)

74.2 (18.7)

87.3 (13.7)

217.5 (36.3)

106.8 (16.7)

25

29

20

32

40

195

349

Heterogeneity: Tau2=0.46; Chi2=46.88, df=6(P<0.0001); I2=87.2%

Test for overall effect: Z=2.23(P=0.03)

13.1.4 Yoga, Tai Chi, and Pilates interventions

Mustian 2004

Loudon 2014

Littman 2012

Subtotal ***

121.7 (22.7)

-7.4 (1.2)

90.3 (11)

11

12

30

53

Heterogeneity: Tau2=0; Chi2=0.4, df=2(P=0.82); I2=0%

Test for overall effect: Z=0.66(P=0.51)

91.6 (28.5)

64.1 (10.8)

67.9 (16.7)

82.4 (19.9)

210.1 (41.5)

108.2 (18.2)

124.3 (25.9)

-7.4 (1.4)

87.7 (15)

9

29

20

30

40

104

240

10

11

110

131

13.1%

13.98%

14.37%

15.37%

15.83%

17.01%

100%

15.17%

16.65%

68.18%

100%

0.53[-0.24,1.31]

2.28[1.61,2.96]

0.35[-0.28,0.97]

0.28[-0.22,0.79]

0.19[-0.25,0.63]

-0.08[-0.32,0.16]

0.63[0.08,1.19]

-0.1[-0.96,0.75]

0.02[-0.8,0.84]

0.18[-0.22,0.59]

0.11[-0.22,0.45]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 13.2.   Comparison 13 Subanalysis: outcomes by mode of
physical activity intervention, Outcome 2 Overall HRQoL (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.2.1 Aerobic exercise interventions

Murtezani 2014

Rogers 2009

Courneya 2003

Ergun 2013

Mehnert 2011

Cadmus 2009

Daley 2007

Vallance 2007

Saarto 2012

Subtotal ***

9.2 (2.1)

4.5 (8.4)

5.7 (7.4)

5.4 (21.5)

9.7 (21)

0.6 (7.5)

10.2 (11.2)

2.3 (11.1)

4.2 (16.2)

30

20

24

40

30

37

33

250

263

727

Heterogeneity: Tau2=0.44; Chi2=97.57, df=8(P<0.0001); I2=91.8%

Test for overall effect: Z=2.88(P=0)

13.2.2 Resistance exercise interventions

Schmitz 2005

Subtotal ***

2.3 (4.5)

39

39

Heterogeneity: Not applicable

Test for overall effect: Z=1.74(P=0.08)

13.2.3 Combined aerobic and resistance exercise

Herrero 2006

Naumann 2012

Cuesta-Vargas 2014

Ergun 2013

8

11

22

40

17.7 (8.3)

14.5 (10.6)

0.3 (0.2)

5.4 (21.5)

32

18

28

20

27

37

69

85

237

553

40

40

8

10

20

20

-0.6 (2)

2.9 (12)

0.6 (7.4)

-6.7 (25.9)

5.6 (16.5)

-2.4 (9.8)

3.2 (11.3)

-0.2 (6.4)

5.6 (15.4)

0.6 (4)

-10.4 (17.7)

3.1 (11.4)

0.3 (0.1)

-6.7 (25.9)

8.22%

10.41%

10.89%

10.99%

11.13%

11.49%

11.69%

12.48%

12.7%

100%

4.65[3.67,5.63]

0.15[-0.49,0.79]

0.68[0.12,1.24]

0.52[-0.03,1.06]

0.22[-0.31,0.74]

0.34[-0.12,0.8]

0.62[0.2,1.04]

0.24[-0,0.49]

-0.09[-0.26,0.09]

0.68[0.22,1.15]

100%

100%

0.4[-0.05,0.84]

0.4[-0.05,0.84]

16.94%

22.69%

29.51%

30.86%

1.92[0.68,3.17]

1[0.08,1.92]

-0.07[-0.67,0.54]

0.52[-0.03,1.06]

Favours control

-10

-5

0

5

10

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

408

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Subtotal ***

Mean(SD)

N

81

N

58

Heterogeneity: Tau2=0.32; Chi2=9.52, df=3(P=0.02); I2=68.47%

Test for overall effect: Z=1.98(P=0.05)

Mean(SD)

Random, 95% CI

Random, 95% CI

100%

0.69[0.01,1.38]

13.2.4 Yoga, Tai Chi, and Pilates interventions

Mustian 2004

Subtotal ***

11

11

15 (5)

10

10

0 (5)

Heterogeneity: Not applicable

Test for overall effect: Z=4.37(P<0.0001)

100%

100%

2.88[1.59,4.17]

2.88[1.59,4.17]

Favours control

-10

-5

0

5

10

Favours physical activity

Analysis 13.3.   Comparison 13 Subanalysis: outcomes by mode of physical activity
intervention, Outcome 3 Overall emotional function/mental health (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.3.1 Aerobic exercise interventions

Rogers 2009

Basen-Enquist 2006

Courneya 2003

Mehnert 2011

Murtezani 2014

Daley 2007

Cadmus 2009

Pinto 2015

Pinto 2005

Loh 2014

Fillion 2008

Duijits 2012

Rogers 2015

Vallance 2007

Subtotal ***

20 (3.1)

78.2 (10.6)

21.5 (3.4)

77 (35.8)

19.5 (3.3)

19.1 (4.2)

20.5 (3)

54.2 (9.3)

-8 (20.7)

19.9 (2.8)

48.5 (7.9)

73.9 (34.7)

20.6 (2.9)

20.3 (3.3)

20

28

24

30

30

33

37

39

39

63

44

37

105

250

779

Heterogeneity: Tau2=0; Chi2=7.55, df=13(P=0.87); I2=0%

Test for overall effect: Z=2.61(P=0.01)

13.3.2 Resistance exercise interventions

Schmitz 2005

Schmitz 2009

Subtotal ***

-45.6 (8.2)

53.2 (9.6)

39

112

151

Heterogeneity: Tau2=0.04; Chi2=2.1, df=1(P=0.15); I2=52.36%

Test for overall effect: Z=0.43(P=0.67)

13.3.3 Combined aerobic and resistance exercise

21.1 (2.9)

77.2 (12)

20.7 (3)

69.1 (40.5)

18.3 (3.5)

18.5 (3.3)

19.8 (4.2)

52.5 (9.6)

-16.5 (28.8)

20 (3.2)

47.5 (9.1)

77.5 (34.3)

19.7 (3.2)

19.9 (3.4)

-48.2 (8.2)

53.8 (8.7)

18

23

28

28

32

33

37

37

43

32

43

89

108

85

636

40

120

160

Herrero 2006

Pinto 2003

Cuesta-Vargas 2014

Milne 2008

Do 2015

8

12

22

29

32

90.6 (9.3)

-10.8 (28.1)

42.9 (19.2)

19.6 (2.4)

87.4 (8.8)

8

12

20

29

30

83.3 (14.8)

-27.2 (19.5)

32.3 (33.3)

16.7 (4.1)

70.4 (21.5)

2.88%

3.9%

3.96%

4.45%

4.71%

5.09%

5.69%

5.85%

6.23%

6.56%

6.71%

8.07%

16.29%

19.6%

100%

-0.36[-1,0.28]

0.09[-0.46,0.64]

0.25[-0.3,0.79]

0.21[-0.31,0.72]

0.35[-0.15,0.85]

0.16[-0.32,0.64]

0.19[-0.27,0.65]

0.18[-0.27,0.63]

0.33[-0.1,0.77]

-0.04[-0.46,0.39]

0.12[-0.3,0.54]

-0.1[-0.49,0.28]

0.29[0.02,0.56]

0.11[-0.14,0.35]

0.15[0.04,0.25]

38.18%

61.82%

100%

0.31[-0.13,0.76]

-0.07[-0.32,0.19]

0.08[-0.28,0.44]

6.24%

9.25%

16.83%

21.67%

22.22%

0.56[-0.45,1.56]

0.65[-0.17,1.48]

0.39[-0.22,1]

0.85[0.31,1.39]

1.03[0.5,1.57]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

409

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Cantarero-Villanueva 2013

Subtotal ***

Mean(SD)

-17175
(4279)

N

32

135

Heterogeneity: Tau2=0; Chi2=3.01, df=5(P=0.7); I2=0%

Test for overall effect: Z=5.62(P<0.0001)

13.3.4 Yoga, Tai Chi, and Pilates interventions

Banasik 2011

Mustian 2004

Loudon 2014

Littman 2012

Subtotal ***

0.5 (0.4)

24.8 (2)

-1.6 (0.7)

20.3 (4)

7

9

12

30

58

Heterogeneity: Tau2=0; Chi2=0.47, df=3(P=0.93); I2=0%

Test for overall effect: Z=0.16(P=0.88)

N

29

128

7

10

11

27

55

Mean(SD)

Random, 95% CI

Random, 95% CI

-20390
(6113)

0.4 (0.3)

24.8 (3.2)

-1.6 (0.5)

20.8 (3.1)

23.78%

0.61[0.09,1.12]

100%

0.72[0.47,0.97]

12.32%

16.85%

20.41%

50.42%

100%

0.25[-0.8,1.3]

-0.01[-0.91,0.89]

0.05[-0.77,0.87]

-0.14[-0.66,0.38]

-0.03[-0.4,0.34]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 13.4.   Comparison 13 Subanalysis: outcomes by mode of physical activity
intervention, Outcome 4 Overall emotional function/mental health (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.4.1 Aerobic exercise

Rogers 2009

Murtezani 2014

Courneya 2003

Mehnert 2011

Cadmus 2009

Pinto 2005

Vallance 2007

Subtotal ***

0.9 (2.5)

2.1 (0.8)

2.3 (3.1)

2.3 (35.5)

0.3 (2.2)

-3.8 (27.7)

0.5 (3.5)

20

30

24

30

37

39

250

430

Heterogeneity: Tau2=0.2; Chi2=28.69, df=6(P<0.0001); I2=79.09%

Test for overall effect: Z=2.28(P=0.02)

13.4.2 Resistance exercise

Cormie 2014

Schmitz 2005

Schmitz 2009

Subtotal ***

4.4 (9)

2.5 (4.4)

3.3 (23.2)

43

39

58

140

Heterogeneity: Tau2=0.03; Chi2=3.09, df=2(P=0.21); I2=35.27%

Test for overall effect: Z=1.37(P=0.17)

13.4.3 Combined aerobic and resistance exercise

Herrero 2006

Naumann 2012

Cantarero-Villanueva 2013

Saarto 2012

Subtotal ***

9.3 (19.6)

1 (2.7)

-1445
(4452)

1.2 (17.8)

8

11

32

263

314

Heterogeneity: Tau2=0.06; Chi2=5.67, df=3(P=0.13); I2=47.13%

Test for overall effect: Z=0.04(P=0.97)

-0.1 (2.7)

0.5 (0.9)

0.8 (2.9)

3.6 (17.6)

-0.5 (3.3)

-11.5 (25.8)

0.1 (2.5)

2.7 (8.6)

0.3 (3.9)

3.1 (17.2)

-2.1 (5.9)

-0.1 (2.7)

353 (3323)

1.9 (18.5)

18

32

28

28

37

43

85

271

19

40

62

121

8

10

29

237

284

12.26%

12.89%

13.47%

14.01%

14.8%

15.11%

17.46%

100%

25.03%

32.43%

42.54%

100%

10.49%

13.63%

26.87%

49.01%

100%

0.38[-0.27,1.02]

1.8[1.21,2.4]

0.49[-0.06,1.05]

-0.04[-0.56,0.47]

0.28[-0.18,0.74]

0.28[-0.15,0.72]

0.12[-0.13,0.36]

0.44[0.06,0.82]

0.19[-0.35,0.73]

0.52[0.08,0.97]

0.01[-0.35,0.37]

0.22[-0.09,0.54]

0.74[-0.28,1.77]

0.39[-0.48,1.26]

-0.45[-0.96,0.06]

-0.04[-0.21,0.14]

-0.01[-0.38,0.36]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

410

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.4.4 Yoga, Tai Chi, and Pilates

Mustian 2004

Subtotal ***

9

9

2.4 (2.5)

10

10

0.1 (1.7)

Heterogeneity: Not applicable

Test for overall effect: Z=2.12(P=0.03)

100%

100%

1.06[0.08,2.03]

1.06[0.08,2.03]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 13.5.   Comparison 13 Subanalysis: outcomes by mode of physical
activity intervention, Outcome 5 Overall physical function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.5.1 Aerobic exercise

Rogers 2009

Basen-Enquist 2006

Courneya 2003

Mehnert 2011

Murtezani 2014

Daley 2007

Cadmus 2009

Pinto 2015

Pinto 2005

Loh 2014

Fillion 2008

Duijits 2012

Rogers 2015

Vallance 2007

Subtotal ***

23.3 (4.5)

82.5 (12.7)

25.3 (2.5)

89 (9.1)

22.6 (4.4)

25.6 (2.2)

25.1 (2.7)

87.1 (4.4)

30.3 (7.9)

24.9 (2.5)

45.1 (10.4)

84 (16.9)

24.1 (3.5)

25.1 (3)

20

28

24

30

30

33

37

39

39

63

44

87

105

250

829

Heterogeneity: Tau2=0.01; Chi2=17.34, df=13(P=0.18); I2=25.03%

Test for overall effect: Z=4.24(P<0.0001)

13.5.2 Resistance exercise

Winters-Stone 2011

Schmitz 2005

Schmitz 2009

Subtotal ***

51.7 (6.2)

-44.2 (5.6)

50.6 (8.2)

36

39

112

187

Heterogeneity: Tau2=0.05; Chi2=4.37, df=2(P=0.11); I2=54.27%

Test for overall effect: Z=1.32(P=0.19)

13.5.3 Combined aerobic and resistance exercise

Herrero 2006

Pinto 2003

Milne 2008

Cuesta-Vargas 2014

Do 2015

Subtotal ***

94.1 (7.5)

32.3 (4.3)

24 (2.6)

42.9 (4.1)

89.4 (8.4)

8

12

29

22

32

103

25.4 (2.3)

77.4 (11.5)

25.3 (2.8)

78.1 (21.2)

19.4 (4.4)

23.6 (5.7)

24 (4.1)

84.7 (15.9)

27.3 (6.8)

24.2 (2.2)

41.8 (9.8)

80.2 (17.1)

22.5 (5)

25 (3.3)

52.3 (5.9)

-48.3 (7.7)

49.1 (9.3)

92.5 (6.6)

25.3 (8.2)

15.6 (4.5)

32.4 (32.5)

89 (8.7)

18

23

28

28

32

33

37

37

43

32

43

89

108

85

636

25

40

120

185

8

12

29

20

30

99

Heterogeneity: Tau2=0.78; Chi2=29.57, df=4(P<0.0001); I2=86.47%

Test for overall effect: Z=1.87(P=0.06)

3.44%

4.5%

4.67%

4.9%

5.14%

5.59%

6.2%

6.37%

6.67%

6.92%

7.03%

11.52%

12.82%

14.24%

100%

25.59%

29.3%

45.11%

100%

17.83%

18.9%

20.53%

20.95%

21.79%

100%

-0.57[-1.22,0.08]

0.41[-0.15,0.97]

0[-0.55,0.55]

0.66[0.13,1.19]

0.72[0.2,1.23]

0.46[-0.03,0.95]

0.31[-0.15,0.77]

0.21[-0.25,0.66]

0.4[-0.04,0.83]

0.3[-0.12,0.73]

0.33[-0.1,0.75]

0.23[-0.07,0.52]

0.37[0.1,0.64]

0.05[-0.2,0.3]

0.28[0.15,0.41]

-0.1[-0.61,0.41]

0.6[0.15,1.05]

0.17[-0.09,0.43]

0.23[-0.11,0.57]

0.21[-0.77,1.2]

1.03[0.17,1.89]

2.26[1.59,2.92]

0.46[-0.16,1.07]

0.05[-0.45,0.54]

0.8[-0.04,1.64]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

411

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.5.4 Yoga, Tai Chi, and Pilates

Banasik 2011

Mustian 2004

Littman 2012

Subtotal ***

-0.8 (0.9)

26.9 (4.1)

25.4 (1.7)

7

9

30

46

-0.4 (0.3)

26.5 (4.1)

24.3 (4.4)

7

10

27

44

Heterogeneity: Tau2=0; Chi2=1.8, df=2(P=0.41); I2=0%

Test for overall effect: Z=0.74(P=0.46)

15.23%

21.4%

63.36%

100%

-0.48[-1.54,0.59]

0.09[-0.81,0.99]

0.33[-0.19,0.86]

0.16[-0.26,0.57]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 13.6.   Comparison 13 Subanalysis: outcomes by mode of physical
activity intervention, Outcome 6 Overall physical function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.6.1 Aerobic exercise

Murtezani 2014

Rogers 2009

Courneya 2003

Mehnert 2011

Cadmus 2009

Vallance 2007

Saarto 2012

Subtotal ***

30

20

24

30

37

247

263

651

4.4 (1.5)

2.3 (5.1)

1.9 (2)

4 (10.8)

0.1 (6)

1 (3.3)

1.9 (13.7)

-1.3 (1.2)

2.6 (6)

-0.2 (2.2)

-2.1 (16.7)

-0.5 (7.4)

0.2 (2.1)

3.4 (13.4)

32

18

28

28

37

85

237

465

Heterogeneity: Tau2=0.55; Chi2=94.83, df=6(P<0.0001); I2=93.67%

Test for overall effect: Z=2.42(P=0.02)

13.6.2 Resistance exercise

Cormie 2014

Schmitz 2005

Schmitz 2009

Subtotal ***

3.5 (5.2)

1.2 (4.2)

6.6 (17.1)

43

39

58

140

Heterogeneity: Tau2=0.08; Chi2=4.99, df=2(P=0.08); I2=59.93%

Test for overall effect: Z=1.16(P=0.24)

13.6.3 Combined aerobic and resistance exercise

Herrero 2006

Naumann 2012

Subtotal ***

6.7 (5)

1.9 (3.3)

8

11

19

Heterogeneity: Tau2=0.24; Chi2=1.95, df=1(P=0.16); I2=48.68%

Test for overall effect: Z=1.51(P=0.13)

13.6.4 Yoga, Tai Chi, and Pilates

Mustian 2004

Subtotal ***

1.9 (2.6)

9

9

Heterogeneity: Not applicable

Test for overall effect: Z=1.9(P=0.06)

19

40

62

121

8

10

18

10

10

-0.5 (5.7)

1.5 (6.8)

4.1 (17.3)

-1.7 (6.9)

0.8 (3.4)

-0.2 (1.6)

11.58%

13.59%

13.98%

14.36%

14.76%

15.76%

15.98%

100%

27.31%

33.72%

38.97%

100%

4.23[3.31,5.15]

-0.05[-0.69,0.58]

0.98[0.4,1.56]

0.43[-0.09,0.95]

0.09[-0.37,0.54]

0.26[0.02,0.51]

-0.11[-0.29,0.06]

0.72[0.14,1.3]

0.74[0.19,1.3]

-0.05[-0.49,0.39]

0.14[-0.21,0.5]

0.24[-0.17,0.65]

43.62%

56.38%

100%

1.32[0.21,2.43]

0.32[-0.55,1.18]

0.75[-0.22,1.73]

100%

100%

0.93[-0.03,1.89]

0.93[-0.03,1.89]

Favours control

-10

-5

0

5

10

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

412

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 13.7.   Comparison 13 Subanalysis: outcomes by mode of physical
activity intervention, Outcome 7 Overall role function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.7.1 Aerobic exercise

Rogers 2009

Basen-Enquist 2006

Courneya 2003

Mehnert 2011

Murtezani 2014

Daley 2007

Cadmus 2009

Loh 2014

Rogers 2015

Vallance 2007

Subtotal ***

21.4 (4.8)

86.1 (22.2)

23.4 (4)

90 (20.3)

24.2 (2.8)

22.9 (4.5)

23.1 (4.7)

23.4 (4.3)

22.3 (4.5)

23.2 (4)

20

28

24

30

30

33

37

63

105

250

620

18

23

28

27

32

33

37

32

108

85

423

Heterogeneity: Tau2=0.02; Chi2=12.25, df=9(P=0.2); I2=26.56%

Test for overall effect: Z=3.49(P=0)

13.7.2 Resistance exercise

Schmitz 2005

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.55(P=0.58)

-49.2 (6.5)

39

39

13.7.3 Combined aerobic and resistance exercise

Herrero 2006

Milne 2008

Do 2015

Subtotal ***

97.6 (5.9)

22.2 (3)

78.1 (19.5)

8

29

32

69

Heterogeneity: Tau2=2.28; Chi2=38.11, df=2(P<0.0001); I2=94.75%

Test for overall effect: Z=0.68(P=0.5)

13.7.4 Yoga, Tai Chi, and Pilates

Banasik 2011

Mustian 2004

Loudon 2014

Littman 2012

Subtotal ***

3.5 (0.6)

2.4 (1.5)

-1.3 (0.3)

22.6 (3.9)

7

9

12

30

58

Heterogeneity: Tau2=0; Chi2=0.89, df=3(P=0.83); I2=0%

Test for overall effect: Z=0.59(P=0.56)

40

40

8

29

30

67

7

9

11

27

54

23.8 (3.2)

73 (24.5)

23.1 (4)

79.6 (25)

23 (2.5)

20.3 (5.6)

20.6 (7.2)

22.2 (5)

20.3 (5.5)

22.7 (4.6)

-50 (6.2)

100 (0)

12.5 (4.8)

79.2 (14.6)

3.2 (0.6)

2.8 (1.5)

-1.3 (0.4)

21.7 (4.7)

5.15%

6.6%

6.95%

7.35%

7.88%

8.25%

9.1%

10.21%

18.3%

20.21%

100%

-0.57[-1.22,0.08]

0.55[-0.01,1.12]

0.07[-0.47,0.62]

0.45[-0.07,0.98]

0.45[-0.06,0.95]

0.5[0.01,0.99]

0.41[-0.05,0.87]

0.25[-0.18,0.68]

0.4[0.12,0.67]

0.12[-0.13,0.37]

0.28[0.12,0.44]

100%

100%

0.12[-0.32,0.57]

0.12[-0.32,0.57]

31.82%

33.68%

34.5%

100%

12.35%

16.08%

20.67%

50.9%

100%

-0.54[-1.55,0.46]

2.39[1.71,3.08]

-0.06[-0.56,0.44]

0.61[-1.15,2.37]

0.34[-0.72,1.4]

-0.23[-1.15,0.7]

0[-0.82,0.82]

0.21[-0.31,0.73]

0.11[-0.26,0.48]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 13.8.   Comparison 13 Subanalysis: outcomes by mode of physical
activity intervention, Outcome 8 Overall role function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.8.1 Aerobic exercise

Rogers 2009

20

0.4 (3.3)

18

1.4 (4.3)

9.83%

-0.26[-0.9,0.38]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

413

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Courneya 2003

Murtezani 2014

Mehnert 2011

Cadmus 2009

Vallance 2007

Saarto 2012

Subtotal ***

0.9 (2.8)

1.7 (0.7)

6.7 (23.8)

-0.3 (3.7)

0.6 (4.1)

2.4 (21.5)

24

30

30

37

250

263

654

Heterogeneity: Tau2=0.08; Chi2=19.53, df=6(P=0); I2=69.28%

Test for overall effect: Z=1.22(P=0.22)

13.8.2 Resistance exercise

Cormie 2014

Schmitz 2005

Subtotal ***

4.9 (7.1)

1.2 (4.2)

43

39

82

Heterogeneity: Tau2=0.06; Chi2=1.93, df=1(P=0.16); I2=48.17%

Test for overall effect: Z=0.68(P=0.49)

13.8.3 Combined aerobic and resistance exercise

Herrero 2006

Naumann 2012

Subtotal ***

2.1 (13.9)

1.5 (4.4)

8

11

19

Heterogeneity: Tau2=0; Chi2=0.11, df=1(P=0.75); I2=0%

Test for overall effect: Z=0.37(P=0.71)

13.8.4 Yoga, Tai Chi, and Pilates

Mustian 2004

Subtotal ***

0.6 (1.6)

9

9

Heterogeneity: Not applicable

Test for overall effect: Z=0.32(P=0.75)

28

32

27

37

85

237

464

19

40

59

8

10

18

10

10

0.4 (2.7)

0.9 (0.6)

5.6 (27)

-0.5 (3.4)

-0 (2.7)

3.8 (21.6)

1.7 (7.1)

1.5 (6.8)

2.1 (5.9)

0.5 (4.5)

0.8 (1.6)

11.67%

11.79%

12.25%

13.77%

19.46%

21.24%

100%

0.18[-0.37,0.73]

1.16[0.62,1.7]

0.04[-0.48,0.56]

0.06[-0.4,0.51]

0.17[-0.08,0.41]

-0.06[-0.24,0.11]

0.16[-0.1,0.43]

44.56%

55.44%

100%

0.45[-0.1,0.99]

-0.05[-0.49,0.39]

0.17[-0.32,0.65]

43.47%

56.53%

100%

0[-0.98,0.98]

0.22[-0.64,1.08]

0.12[-0.52,0.77]

100%

100%

-0.15[-1.05,0.76]

-0.15[-1.05,0.76]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 13.9.   Comparison 13 Subanalysis: outcomes by mode of physical activity
intervention, Outcome 9 Overall social well-being/function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.9.1 Aerobic exercise

Rogers 2009

Basen-Enquist 2006

Courneya 2003

Mehnert 2011

Murtezani 2014

Daley 2007

Cadmus 2009

Loh 2014

Rogers 2015

Vallance 2007

Subtotal ***

22.6 (4.1)

84.6 (16.9)

21.1 (3.5)

85.4 (20.9)

20.2 (2.8)

23.3 (4.8)

22.3 (4.9)

21.5 (4.9)

21 (5.7)

22.9 (5)

20

28

24

30

30

33

37

63

105

250

620

18

23

28

28

32

33

37

32

108

85

424

21.8 (5.7)

84.9 (19.2)

20.7 (3.6)

79.9 (22.7)

18.3 (2.7)

20.4 (6.8)

20.6 (7.2)

19.6 (4.9)

20.7 (5.8)

23 (5.1)

4.4%

5.81%

5.93%

6.57%

6.66%

7.27%

8.26%

9.32%

21.26%

24.52%

100%

0.16[-0.48,0.8]

-0.02[-0.57,0.54]

0.11[-0.43,0.66]

0.25[-0.27,0.76]

0.68[0.17,1.2]

0.49[-0,0.98]

0.27[-0.18,0.73]

0.38[-0.05,0.81]

0.05[-0.22,0.32]

-0[-0.25,0.24]

0.18[0.04,0.31]

Heterogeneity: Tau2=0; Chi2=9.78, df=9(P=0.37); I2=8.02%

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

414

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for overall effect: Z=2.56(P=0.01)

13.9.2 Resistance exercise

Schmitz 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.79(P=0.43)

14.9 (5.2)

59

59

13.9.3 Combined aerobic and resistance exercise

Herrero 2006

Rogers 2014

Milne 2008

Subtotal ***

87.5 (19.4)

7.3 (4.9)

20.7 (4)

8

20

29

57

Heterogeneity: Tau2=0.16; Chi2=4.64, df=2(P=0.1); I2=56.91%

Test for overall effect: Z=1.45(P=0.15)

13.9.4 Yoga, Tai Chi, and Pilates

Banasik 2011

Mustian 2004

Littman 2012

Kiecolt-Glaser 2014

Subtotal ***

2.8 (0.7)

8.6 (1.9)

22.1 (5)

95.2 (10.8)

7

9

30

96

142

Heterogeneity: Tau2=0; Chi2=1.66, df=3(P=0.65); I2=0%

Test for overall effect: Z=0.85(P=0.4)

14.1 (5.8)

91.7 (23.6)

3.1 (3.2)

19.4 (3.9)

3.2 (0.8)

9 (1.8)

20.9 (6)

93.8 (9.3)

62

62

8

22

29

59

7

10

27

90

134

100%

100%

0.14[-0.21,0.5]

0.14[-0.21,0.5]

23.19%

35.43%

41.38%

100%

4.93%

6.87%

20.6%

67.59%

100%

-0.18[-1.17,0.8]

1.01[0.36,1.65]

0.32[-0.19,0.84]

0.45[-0.16,1.05]

-0.45[-1.51,0.62]

-0.19[-1.09,0.71]

0.22[-0.31,0.74]

0.14[-0.15,0.43]

0.1[-0.13,0.34]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 13.10.   Comparison 13 Subanalysis: outcomes by mode of physical activity
intervention, Outcome 10 Overall social well-being/function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.10.1 Aerobic exercise

Rogers 2009

Murtezani 2014

Courneya 2003

Mehnert 2011

Cadmus 2009

Vallance 2007

Saarto 2012

Subtotal ***

20

30

24

30

37

250

263

654

0.9 (2.6)

2.1 (0.8)

0.6 (2.4)

7.3 (22.3)

0.6 (4.6)

0.2 (4.8)

5 (21.1)

18

32

28

28

37

85

237

465

-1.2 (2.7)

0.5 (0.9)

-0.5 (3.3)

3.1 (24.3)

-1 (3.2)

-4.1 (3.3)

8.8 (20.8)

Heterogeneity: Tau2=0.45; Chi2=81.52, df=6(P<0.0001); I2=92.64%

Test for overall effect: Z=2.21(P=0.03)

13.10.2 Resistance exercise

Cormie 2014

Schmitz 2009

Subtotal ***

3.5 (8.5)

4.4 (33.8)

43

59

102

19

62

81

2.5 (8.3)

0.7 (34)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.98); I2=0%

Test for overall effect: Z=0.73(P=0.46)

12.9%

13.42%

13.77%

14.02%

14.41%

15.58%

15.89%

100%

0.78[0.11,1.44]

1.8[1.21,2.4]

0.37[-0.18,0.92]

0.18[-0.34,0.69]

0.4[-0.06,0.86]

0.97[0.71,1.23]

-0.18[-0.36,-0.01]

0.6[0.07,1.13]

30.36%

69.64%

100%

0.12[-0.42,0.66]

0.11[-0.25,0.47]

0.11[-0.19,0.41]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

415

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.10.3 Combined aerobic and resistance exercise

Naumann 2012

Rogers 2014

Subtotal ***

0.9 (3.3)

2.1 (3.2)

11

20

31

Heterogeneity: Tau2=0; Chi2=0.94, df=1(P=0.33); I2=0%

Test for overall effect: Z=2.53(P=0.01)

13.10.4 Yoga, Tai Chi, and Pilates

Mustian 2004

Subtotal ***

1.5 (1.5)

9

9

Heterogeneity: Not applicable

Test for overall effect: Z=1.58(P=0.11)

-0.2 (3.3)

-0.8 (3.5)

0.4 (1.2)

10

22

32

10

10

35.1%

64.9%

100%

0.32[-0.54,1.18]

0.85[0.21,1.48]

0.66[0.15,1.17]

100%

100%

0.76[-0.18,1.7]

0.76[-0.18,1.7]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 13.11.   Comparison 13 Subanalysis: outcomes by mode of physical
activity intervention, Outcome 11 Overall cognitive function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.11.1 Aerobic exercise

Rogers 2009

Mehnert 2011

Subtotal ***

-124.5
(30.8)

81.1 (16.8)

19

30

49

Heterogeneity: Tau2=0; Chi2=0.45, df=1(P=0.5); I2=0%

Test for overall effect: Z=1.16(P=0.25)

13.11.2 Resistance exercise

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

13.11.3 Combined aerobic and resistance exercise

Pinto 2003

Herrero 2006

Cantarero-Villanueva 2013

Subtotal ***

-4.3 (2.5)

91.7 (12.6)

-37.9 (8.5)

12

8

32

52

Heterogeneity: Tau2=0; Chi2=1.76, df=2(P=0.41); I2=0%

Test for overall effect: Z=2.65(P=0.01)

13.11.4 Yoga, Tai Chi, and Pilates

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

-135.5
(19.5)

78.4 (24.4)

-7.2 (2.1)

89.6 (12.4)

-43 (10)

18

27

45

0

6

8

29

43

0

38.9%

61.1%

100%

0.42[-0.24,1.07]

0.13[-0.39,0.65]

0.24[-0.17,0.65]

Not estimable

15.37%

18.11%

66.53%

100%

1.14[0.07,2.2]

0.16[-0.82,1.14]

0.55[0.03,1.06]

0.57[0.15,0.98]

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

416

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 13.12.   Comparison 13 Subanalysis: outcomes by mode of physical
activity intervention, Outcome 12 Overall cognitive function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.12.1 Aerobic exercise

Rogers 2009

Mehnert 2011

Subtotal ***

4.2 (16.8)

1.7 (22.4)

20

30

50

Heterogeneity: Tau2=0.09; Chi2=1.97, df=1(P=0.16); I2=49.28%

Test for overall effect: Z=0.26(P=0.8)

13.12.2 Resistance exercise

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

13.12.3 Combined aerobic and resistance exercise

Herrero 2006

Cantarero-Villanueva 2013

Saarto 2012

Subtotal ***

6.2 (19.8)

2.2 (7.6)

-1 (18.2)

8

32

263

303

Heterogeneity: Tau2=0.05; Chi2=3.67, df=2(P=0.16); I2=45.45%

Test for overall effect: Z=0.07(P=0.94)

-4.7 (25.9)

6.2 (24.6)

8.3 (14.8)

-0.2 (5.5)

2.2 (18.5)

18

27

45

0

8

29

237

274

13.12.4 Yoga, Tai Chi, and Pilates

Subtotal ***

0

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

44.71%

55.29%

100%

0.4[-0.24,1.05]

-0.19[-0.71,0.33]

0.08[-0.5,0.65]

Not estimable

11.36%

29.33%

59.31%

100%

-0.11[-1.09,0.87]

0.35[-0.16,0.86]

-0.17[-0.35,0]

-0.01[-0.38,0.35]

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 13.13.   Comparison 13 Subanalysis: outcomes by mode of physical
activity intervention, Outcome 13 Overall general health (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.13.1 Aerobic exercise

Baruth 2013

Rogers 2009

Ergun 2013

Basen-Enquist 2006

Mehnert 2011

Cadmus 2009

Subtotal ***

68.1 (0)

3.5 (0.9)

69 (21.2)

77.4 (11.6)

74.4 (11.8)

50 (8.8)

20

20

20

28

30

37

155

Heterogeneity: Tau2=0.12; Chi2=10.17, df=4(P=0.04); I2=60.68%

Test for overall effect: Z=0.53(P=0.59)

13.13.2 Resistance exercise

Schmitz 2005

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.47(P=0.64)

53.8 (5.3)

39

39

61.6 (0)

3.8 (0.5)

67.9 (16.7)

67.1 (13.4)

70 (20.8)

51.7 (8.4)

53.2 (6)

12

18

20

23

28

37

138

40

40

17.74%

18.36%

19.57%

21.25%

23.08%

100%

Not estimable

-0.4[-1.04,0.25]

0.05[-0.57,0.67]

0.81[0.24,1.39]

0.26[-0.26,0.77]

-0.2[-0.65,0.26]

0.11[-0.29,0.51]

100%

100%

0.1[-0.34,0.55]

0.1[-0.34,0.55]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

417

Favours control

-100

-50

0

50

100

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.13.3 Combined aerobic and resistance exercise

Herrero 2006

Ergun 2013

Do 2015

Subtotal ***

81.3 (10.7)

74.2 (18.7)

87.3 (13.7)

8

20

32

60

Heterogeneity: Tau2=0.05; Chi2=2.76, df=2(P=0.25); I2=27.41%

Test for overall effect: Z=1.96(P=0.05)

13.13.4 Yoga, Tai Chi, and Pilates

Mustian 2004

Subtotal ***

18.6 (4.8)

9

9

Heterogeneity: Not applicable

Test for overall effect: Z=0.39(P=0.7)

62.5 (16.1)

67.9 (16.7)

82.4 (19.9)

19.3 (1.9)

8

20

30

58

9

9

14.81%

36.64%

48.55%

100%

1.3[0.19,2.41]

0.35[-0.28,0.97]

0.28[-0.22,0.79]

0.46[0,0.91]

100%

100%

-0.18[-1.11,0.74]

-0.18[-1.11,0.74]

Favours control

-100

-50

0

50

100

Favours physical activity

Analysis 13.14.   Comparison 13 Subanalysis: outcomes by mode of physical
activity intervention, Outcome 14 Overall general health (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

13.14.1 Aerobic exercise

Rogers 2009

Ergun 2013

Mehnert 2011

Cadmus 2009

Saarto 2012

Subtotal ***

0.2 (0.6)

4.6 (26.5)

6.6 (13.7)

0.2 (4.4)

4.2 (16.2)

20

20

30

37

263

370

Heterogeneity: Tau2=0; Chi2=3.29, df=4(P=0.51); I2=0%

Test for overall effect: Z=0.24(P=0.81)

13.14.2 Resistance exercise

Cormie 2014

Schmitz 2005

Subtotal ***

3.7 (7)

0.7 (4.8)

43

39

82

Heterogeneity: Tau2=0; Chi2=0.22, df=1(P=0.64); I2=0%

Test for overall effect: Z=1.3(P=0.19)

13.14.3 Combined aerobic and resistance exercise

Herrero 2006

Ergun 2013

Subtotal ***

17.7 (8.3)

4.6 (26.5)

8

40

48

Heterogeneity: Tau2=0; Chi2=4.68, df=1(P=0.03); I2=78.65%

Test for overall effect: Z=2.61(P=0.01)

13.14.4 Yoga, Tai Chi, and Pilates

Mustian 2004

Subtotal ***

Heterogeneity: Not applicable

0.2 (1.9)

9

9

0.2 (0.7)

-6.7 (25.9)

3.2 (19.7)

-0.1 (5.1)

5.6 (15.4)

2.8 (7.1)

-0.6 (3.9)

-10.4 (17.7)

-6.7 (25.9)

0.7 (2.5)

18

20

28

37

237

340

19

40

59

8

20

28

10

10

5.36%

5.52%

8.16%

10.47%

70.49%

100%

-0.03[-0.67,0.61]

0.42[-0.21,1.05]

0.2[-0.32,0.71]

0.06[-0.39,0.52]

-0.09[-0.26,0.09]

-0.02[-0.17,0.13]

40.25%

59.75%

100%

0.13[-0.41,0.67]

0.29[-0.15,0.74]

0.23[-0.12,0.57]

15.97%

84.03%

100%

1.92[0.68,3.17]

0.42[-0.12,0.97]

0.66[0.17,1.16]

100%

100%

-0.2[-1.1,0.71]

-0.2[-1.1,0.71]

Favours control

-100

-50

0

50

100

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

418

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

Test for overall effect: Z=0.42(P=0.67)

Favours control

-100

-50

0

50

100

Favours physical activity

Analysis 13.15.   Comparison 13 Subanalysis: outcomes by mode of physical
activity intervention, Outcome 15 Overall sexual function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

13.15.1 Aerobic exercise

Pinto 2005

Duijits 2012

Subtotal ***

42.8 (9.2)

0.6 (0.8)

12

53

65

Heterogeneity: Tau2=0; Chi2=0.05, df=1(P=0.82); I2=0%

Test for overall effect: Z=0.01(P=0.99)

13.15.2 Resistance exercise

Schmitz 2005

Schmitz 2009

Subtotal ***

-51 (7.5)

-27.3 (5.3)

39

57

96

Heterogeneity: Tau2=0; Chi2=0.38, df=1(P=0.54); I2=0%

Test for overall effect: Z=1.46(P=0.14)

13.15.3 Combined aerobic and resistance exercise

42.5 (9.2)

Pinto 2003

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.32(P=0.19)

13.15.4 Yoga, Tai Chi, and Pilates

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

39

39

0

43.7 (6.1)

0.6 (0.8)

-53.5 (8)

-28.1 (6.2)

40.1 (6.3)

6

65

71

40

57

97

43

43

0

12.03%

87.97%

100%

-0.11[-1.09,0.87]

0.01[-0.35,0.38]

-0[-0.34,0.34]

40.67%

59.33%

100%

0.32[-0.12,0.76]

0.14[-0.23,0.51]

0.21[-0.07,0.49]

100%

100%

0.29[-0.14,0.73]

0.29[-0.14,0.73]

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 13.16.   Comparison 13 Subanalysis: outcomes by mode of physical
activity intervention, Outcome 16 Overall sexual function (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

13.16.1 Aerobic exercise

Saarto 2012

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.22(P=0.82)

13.16.2 Resistance exercise

263

263

4.3 (25.4)

237

237

3.8 (24.4)

100%

100%

0.5[-3.86,4.86]

0.5[-3.86,4.86]

Schmitz 2009

57

7.2 (14.6)

57

-0.2 (16.7)

39.42%

7.4[1.64,13.16]

Favours control

-20

-10

0

10

20

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

419

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

0.2 (5.2)

Schmitz 2005

Subtotal ***

1.7 (4.8)

39

96

Heterogeneity: Tau2=12.46; Chi2=3.52, df=1(P=0.06); I2=71.56%

Test for overall effect: Z=1.33(P=0.18)

13.16.3 Combined aerobic and resistance exercise

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

13.16.4 Yoga, Tai Chi, and Pilates

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

40

97

0

0

Cochrane Database of Systematic Reviews

Weight

Mean Difference

60.58%

100%

Random, 95% CI

1.5[-0.71,3.71]

3.83[-1.83,9.48]

Not estimable

Not estimable

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 13.17.   Comparison 13 Subanalysis: outcomes by mode of physical
activity intervention, Outcome 17 Overall sleep (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

13.17.1 Aerobic exercise

Rogers 2009

Mehnert 2011

Subtotal ***

6.7 (4.2)

23.8 (27)

20

30

50

Heterogeneity: Tau2=0; Chi2=3.26, df=1(P=0.07); I2=69.31%

Test for overall effect: Z=0.86(P=0.39)

13.17.2 Resistance exercise

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

13.17.3 Combined aerobic and resistance exercise

Rogers 2013

Rogers 2014

Subtotal ***

6.3 (2.7)

6.7 (3.7)

11

20

31

Heterogeneity: Tau2=0; Chi2=0.07, df=1(P=0.79); I2=0%

Test for overall effect: Z=0.26(P=0.79)

13.17.4 Yoga, Tai Chi, and Pilates

Bower 2011

Subtotal ***

8.1 (2.5)

16

16

Heterogeneity: Not applicable

Test for overall effect: Z=0.42(P=0.67)

5.5 (4)

38.3 (31.6)

6.2 (3.2)

7.1 (3.2)

7.7 (2.6)

18

27

45

0

9

22

31

15

15

40.51%

59.49%

100%

0.28[-0.36,0.92]

-0.49[-1.02,0.04]

-0.18[-0.59,0.23]

Not estimable

32.12%

67.88%

100%

0.03[-0.85,0.91]

-0.11[-0.72,0.49]

-0.07[-0.57,0.43]

100%

100%

0.15[-0.55,0.86]

0.15[-0.55,0.86]

Favours Physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

420

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 13.18.   Comparison 13 Subanalysis: outcomes by mode of
physical activity intervention, Outcome 18 Overall sleep (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.18.1 Aerobic exercise

Rogers 2009

Mehnert 2011

Subtotal ***

0.5 (2.1)

-5.4 (29.9)

20

29

49

Heterogeneity: Tau2=0; Chi2=0.05, df=1(P=0.82); I2=0%

Test for overall effect: Z=0.5(P=0.62)

13.18.2 Resistance exercise

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

13.18.3 Combined aerobic and resistance exercise

Rogers 2014

Subtotal ***

-1.3 (3.2)

20

20

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=0.73(P=0.46)

13.18.4 Yoga, Tai Chi, and Pilates

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

18

27

45

0

22

22

0

0.3 (4.7)

-9.9 (33.3)

40.45%

59.55%

100%

0.05[-0.59,0.68]

0.14[-0.38,0.67]

0.1[-0.3,0.51]

Not estimable

-2.2 (4.4)

100%

100%

0.23[-0.38,0.84]

0.23[-0.38,0.84]

Not estimable

Favours Physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 13.19.   Comparison 13 Subanalysis: outcomes by mode of physical
activity intervention, Outcome 19 Overall anxiety (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.19.1 Aerobic exercise

Segar 1998

Milne 2008

Mehnert 2011

Cadmus 2009

Subtotal ***

28.5 (3)

15.3 (6.2)

4.8 (3.5)

32.1 (12.3)

10

29

30

37

106

Heterogeneity: Tau2=0.27; Chi2=11.56, df=3(P=0.01); I2=74.04%

Test for overall effect: Z=2.42(P=0.02)

13.19.2 Resistance exercise

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

13.19.3 Combined aerobic and resistance exercise

Pinto 2003

Rogers 2014

Cantarero-Villanueva 2013

12

20

32

7.6 (7.3)

45.6 (8.9)

42.5 (8.6)

5

29

28

37

99

0

6

22

29

39.5 (6)

21 (5.7)

7.1 (5)

34.1 (15.4)

10.5 (3.7)

45.7 (8)

49.9 (11.7)

11.62%

28.62%

29.09%

30.67%

100%

-2.49[-3.98,-1]

-0.94[-1.49,-0.4]

-0.54[-1.06,-0.01]

-0.14[-0.6,0.31]

-0.76[-1.37,-0.14]

Not estimable

18.25%

37.26%

44.49%

-0.43[-1.43,0.56]

-0.01[-0.62,0.59]

-0.72[-1.24,-0.2]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

421

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Subtotal ***

Mean(SD)

N

64

N

57

Heterogeneity: Tau2=0.06; Chi2=3.02, df=2(P=0.22); I2=33.76%

Test for overall effect: Z=1.68(P=0.09)

13.19.4 Yoga, Tai Chi, and Pilates

Subtotal ***

0

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Mean(SD)

Random, 95% CI

Random, 95% CI

100%

-0.4[-0.87,0.07]

Not estimable

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 13.20.   Comparison 13 Subanalysis: outcomes by mode of physical
activity intervention, Outcome 20 Overall anxiety (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

0.2 (4.9)

0.5 (5.8)

-1.8 (5)

0.8 (5.5)

13.20.1 Aerobic exercise

Mehnert 2011

Cadmus 2009

Subtotal ***

-1.7 (3.7)

-0.7 (9.2)

30

37

67

Heterogeneity: Tau2=0; Chi2=0.58, df=1(P=0.45); I2=0%

Test for overall effect: Z=1.55(P=0.12)

13.20.2 Resistance exercise

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

13.20.3 Combined aerobic and resistance exercise

Rogers 2014

Cantarero-Villanueva 2013

Subtotal ***

-4 (6.5)

-4.2 (9.8)

20

32

52

Heterogeneity: Tau2=0; Chi2=0.32, df=1(P=0.57); I2=0%

Test for overall effect: Z=2.54(P=0.01)

13.20.4 Yoga, Tai Chi, and Pilates

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

28

37

65

0

22

29

51

0

43.4%

56.6%

100%

-0.42[-0.95,0.1]

-0.15[-0.61,0.3]

-0.27[-0.61,0.07]

Not estimable

41.48%

58.52%

100%

-0.37[-0.99,0.24]

-0.61[-1.12,-0.09]

-0.51[-0.9,-0.12]

Not estimable

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 13.21.   Comparison 13 Subanalysis: outcomes by mode of physical
activity intervention, Outcome 21 Overall depression (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.21.1 Aerobic exercise

Segar 1998

10

5.5 (2)

5

10 (2)

7.82%

-2.12[-3.51,-0.73]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

422

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Payne 2008

Ergun 2013

Mehnert 2011

Daley 2007

Cadmus 2009

Subtotal ***

12.7 (8.7)

8.9 (10.5)

2.7 (3)

6 (6.5)

9.6 (9.3)

10

20

30

33

37

140

Heterogeneity: Tau2=0.21; Chi2=15.8, df=5(P=0.01); I2=68.36%

Test for overall effect: Z=1.35(P=0.18)

13.21.2 Resistance exercise

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

13.21.3 Combined aerobic and resistance exercise

Pinto 2003

Kaltsatou 2011

Ergun 2013

Rogers 2014

Cantarero-Villanueva 2013

Subtotal ***

6.2 (7.2)

16.5 (1.7)

4.7 (4.1)

44.2 (8.6)

45.6 (9.7)

12

13

20

20

32

97

Heterogeneity: Tau2=0.3; Chi2=13.96, df=4(P=0.01); I2=71.35%

Test for overall effect: Z=1.12(P=0.26)

11.4 (7.9)

5.2 (5.2)

4.6 (4.4)

10.3 (7.2)

10.8 (10.1)

9.8 (6.8)

22.3 (7.7)

5.2 (5.2)

25.1 (44.2)

53.7 (11.6)

10

20

28

33

37

133

0

6

13

20

22

29

90

13.21.4 Yoga, Tai Chi, and Pilates

Bower 2011

Kiecolt-Glaser 2014

Subtotal ***

16

96

112

7.7 (5.8)

8.1 (8.6)

15

90

105

11.6 (7.1)

9.2 (8.2)

Heterogeneity: Tau2=0.03; Chi2=1.33, df=1(P=0.25); I2=24.98%

Test for overall effect: Z=1.22(P=0.22)

13.53%

17.74%

19.69%

20.24%

20.97%

100%

0.15[-0.73,1.03]

0.44[-0.19,1.07]

-0.51[-1.04,0.01]

-0.63[-1.12,-0.13]

-0.12[-0.58,0.33]

-0.32[-0.78,0.14]

Not estimable

15.43%

18.1%

21.58%

21.59%

23.3%

100%

-0.49[-1.49,0.5]

-1[-1.83,-0.18]

-0.09[-0.71,0.53]

0.58[-0.04,1.19]

-0.75[-1.28,-0.23]

-0.33[-0.9,0.24]

22.79%

77.21%

100%

-0.59[-1.31,0.13]

-0.13[-0.42,0.16]

-0.23[-0.61,0.14]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 13.22.   Comparison 13 Subanalysis: outcomes by mode of physical
activity intervention, Outcome 22 Overall depression (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.22.1 Aerobic exercise

Ergun 2013

Mehnert 2011

Cadmus 2009

Saarto 2012

Subtotal ***

20

30

37

263

350

-0.6 (6.7)

2.7 (3)

0.3 (6.4)

-0.3 (3.3)

20

28

37

237

322

2.4 (8)

4.6 (4.4)

1.7 (6.3)

-0.5 (3.4)

Heterogeneity: Tau2=0.05; Chi2=6.16, df=3(P=0.1); I2=51.28%

Test for overall effect: Z=1.22(P=0.22)

13.22.2 Resistance exercise

Subtotal ***

0

0

Heterogeneity: Not applicable

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

15.36%

19.4%

22.72%

42.52%

100%

-0.39[-1.02,0.23]

-0.51[-1.04,0.01]

-0.22[-0.68,0.24]

0.06[-0.12,0.24]

-0.18[-0.48,0.11]

Not estimable

423

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for overall effect: Not applicable

13.22.3 Combined aerobic and resistance exercise

Naumann 2012

Ergun 2013

Rogers 2014

Cantarero-Villanueva 2013

Subtotal ***

-3.6 (4.3)

3.1 (5.2)

-1.7 (6.9)

-2.9 (7.8)

11

20

20

32

83

Heterogeneity: Tau2=0.1; Chi2=5.74, df=3(P=0.12); I2=47.74%

Test for overall effect: Z=2.07(P=0.04)

13.22.4 Yoga, Tai Chi, and Pilates

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

2 (4.6)

2.4 (8)

1.1 (4.2)

1.5 (7.4)

10

20

22

29

81

0

15.75%

26.35%

26.57%

31.33%

100%

-1.21[-2.16,-0.26]

0.1[-0.52,0.72]

-0.49[-1.1,0.13]

-0.57[-1.09,-0.06]

-0.47[-0.92,-0.02]

Not estimable

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 13.23.   Comparison 13 Subanalysis: outcomes by mode of physical
activity intervention, Outcome 23 Overall fatigue (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.23.1 Aerobic exercise

Payne 2008

Rogers 2009

Ergun 2013

Courneya 2003

Mehnert 2011

Daley 2007

Cadmus 2009

Pinto 2015

Pinto 2005

Fillion 2008

Vallance 2007

Subtotal ***

4.7 (2.6)

-12.4 (10.4)

3 (2.5)

-8.3 (7.9)

28.5 (25.6)

2.1 (1.8)

-51.9 (9)

-43.8 (7.8)

27.1 (21.4)

2.7 (0.7)

-42.7 (8.4)

9

20

20

24

30

33

37

39

39

44

250

545

Heterogeneity: Tau2=0.02; Chi2=14.26, df=10(P=0.16); I2=29.87%

Test for overall effect: Z=2.74(P=0.01)

13.23.2 Resistance exercise

Winters-Stone 2011

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.95(P=0.34)

45 (5.3)

36

36

13.23.3 Combined aerobic and resistance exercise

Pinto 2003

Rogers 2013

Ergun 2013

Cuesta-Vargas 2014

12

11

20

22

7.2 (6.4)

4.2 (1.8)

2.9 (2)

4 (1.8)

9

18

20

28

27

33

37

37

43

43

85

380

31

31

6

9

20

20

3.5 (1.7)

-10.1 (6.6)

3.3 (1.8)

-8.8 (8.1)

39.9 (25.1)

3.4 (1.9)

-50.6 (10)

-41.2 (8.5)

42.3 (26.2)

2.9 (0.8)

-42.6 (8.7)

43.1 (10.3)

9 (6.4)

4.2 (1.6)

3.3 (1.8)

5.2 (3.2)

3.02%

5.92%

6.22%

7.62%

8.03%

8.71%

9.88%

9.98%

10.24%

10.97%

19.41%

100%

0.52[-0.42,1.46]

-0.26[-0.9,0.38]

-0.13[-0.75,0.49]

0.06[-0.48,0.61]

-0.44[-0.97,0.08]

-0.71[-1.21,-0.21]

-0.14[-0.59,0.32]

-0.32[-0.77,0.14]

-0.63[-1.07,-0.18]

-0.27[-0.69,0.15]

-0.01[-0.26,0.23]

-0.24[-0.41,-0.07]

100%

100%

0.23[-0.25,0.72]

0.23[-0.25,0.72]

7.24%

8.17%

10.99%

11.08%

-0.27[-1.26,0.71]

0[-0.88,0.88]

-0.23[-0.85,0.4]

-0.46[-1.07,0.15]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

424

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Rogers 2014

Milne 2008

Cantarero-Villanueva 2013

Do 2015

Short 2014

Subtotal ***

4.1 (2.1)

11.9 (3.2)

3.8 (1.8)

16.8 (13.3)

-41.5 (9.3)

20

29

32

32

195

373

Heterogeneity: Tau2=0.19; Chi2=28.92, df=8(P=0); I2=72.33%

Test for overall effect: Z=2.69(P=0.01)

13.23.4 Yoga, Tai Chi, and Pilates

Banasik 2011

Loudon 2014

Bower 2011

Littman 2012

Kiecolt-Glaser 2014

Subtotal ***

1 (0.9)

1.9 (2.2)

3.4 (1.8)

-45 (5.3)

6.3 (19.6)

7

12

16

30

96

161

Heterogeneity: Tau2=0; Chi2=3.09, df=4(P=0.54); I2=0%

Test for overall effect: Z=3.11(P=0)

4 (1.8)

17.4 (4.7)

6.2 (1.7)

22.3 (15.1)

-39.8 (10.4)

1.6 (1)

2.1 (2.5)

4.9 (1.3)

-43.1 (10.3)

12.7 (19)

22

29

29

30

104

269

7

11

15

27

90

150

11.19%

11.58%

11.72%

12.48%

15.55%

100%

4.37%

7.56%

9.09%

18.6%

60.39%

100%

0.05[-0.56,0.66]

-1.35[-1.92,-0.78]

-1.38[-1.94,-0.82]

-0.38[-0.89,0.12]

-0.17[-0.41,0.06]

-0.48[-0.83,-0.13]

-0.57[-1.65,0.51]

-0.07[-0.89,0.75]

-0.93[-1.67,-0.18]

-0.23[-0.75,0.29]

-0.33[-0.62,-0.04]

-0.36[-0.58,-0.13]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 13.24.   Comparison 13 Subanalysis: outcomes by mode of
physical activity intervention, Outcome 24 Overall fatigue (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.24.1 Aerobic exercise

Rogers 2009

Courneya 2003

Mehnert 2011

Daley 2007

Pinto 2005

Vallance 2007

Saarto 2012

Subtotal ***

1.9 (9.6)

9.3 (10.2)

-0.7 (20.7)

2.1 (1.8)

-14.9 (23.5)

2.5 (8.2)

-2.4 (9.1)

20

24

30

33

39

250

263

659

Heterogeneity: Tau2=0.12; Chi2=27.53, df=6(P=0); I2=78.2%

Test for overall effect: Z=0.49(P=0.62)

13.24.2 Resistance exercise

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

13.24.3 Combined aerobic and resistance exercise

Herrero 2006

Naumann 2012

Rogers 2013

Cantarero-Villanueva 2013

Subtotal ***

-4.2 (19.6)

-3.6 (4.4)

4.2 (2)

-2 (1.8)

8

11

11

32

62

Heterogeneity: Tau2=0.41; Chi2=9.89, df=3(P=0.02); I2=69.65%

4.2 (12.3)

2 (7.5)

-2.9 (25.3)

3.4 (1.9)

1.8 (23.5)

1.2 (6.6)

-2.4 (8.6)

6.4 (14.5)

2 (4.6)

3.9 (1.5)

0.3 (1.4)

18

28

27

33

43

85

237

471

0

8

10

9

29

56

10.81%

11.96%

12.82%

13.22%

14.19%

17.96%

19.04%

100%

-0.21[-0.84,0.43]

0.81[0.24,1.38]

0.09[-0.43,0.61]

-0.71[-1.21,-0.21]

-0.7[-1.15,-0.26]

0.17[-0.08,0.42]

0[-0.18,0.18]

-0.08[-0.38,0.23]

Not estimable

22.16%

23.2%

24.38%

30.26%

100%

-0.58[-1.59,0.43]

-1.21[-2.16,-0.26]

0.16[-0.72,1.04]

-1.45[-2.02,-0.88]

-0.81[-1.57,-0.05]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

425

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for overall effect: Z=2.1(P=0.04)

13.24.4 Yoga, Tai Chi, and Pilates

Loudon 2014

Subtotal ***

12

12

1.9 (2.2)

11

11

2.1 (2.5)

100%

100%

-0.07[-0.89,0.75]

-0.07[-0.89,0.75]

Heterogeneity: Not applicable

Test for overall effect: Z=0.18(P=0.86)

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 13.25.   Comparison 13 Subanalysis: outcomes by mode of physical
activity intervention, Outcome 25 Overall pain/disability (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.25.1 Aerobic exercise

Rogers 2009

Basen-Enquist 2006

Mehnert 2011

Cadmus 2009

Duijits 2012

Subtotal ***

-3 (3)

79.7 (10.6)

79.4 (23.1)

50.3 (9.1)

79.3 (23.6)

20

28

30

37

87

202

Heterogeneity: Tau2=0.03; Chi2=6.19, df=4(P=0.19); I2=35.4%

Test for overall effect: Z=0.83(P=0.41)

13.25.2 Resistance exercise

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

13.25.3 Combined aerobic and resistance exercise

Portela 2008

Do 2015

Subtotal ***

-20.6 (20.2)

21.1 (24.6)

25

32

57

Heterogeneity: Tau2=0; Chi2=0.13, df=1(P=0.72); I2=0%

Test for overall effect: Z=0.6(P=0.55)

13.25.4 Yoga, Tai Chi, and Pilates

Mustian 2004

Loudon 2014

Subtotal ***

9.1 (1.4)

0.8 (1.5)

9

12

21

Heterogeneity: Tau2=0; Chi2=0.29, df=1(P=0.59); I2=0%

Test for overall effect: Z=0.57(P=0.57)

-2.3 (2.8)

72.1 (11.5)

73.5 (24.8)

50.8 (9)

78.8 (23.8)

-20.8 (15.5)

16.5 (26.7)

9.1 (1.7)

1.4 (2.2)

18

23

28

37

89

195

0

9

30

39

10

11

21

12.93%

15.45%

17.67%

20.89%

33.06%

100%

-0.26[-0.89,0.38]

0.68[0.11,1.25]

0.24[-0.27,0.76]

-0.05[-0.51,0.4]

0.02[-0.28,0.32]

0.11[-0.15,0.37]

Not estimable

30.03%

69.97%

100%

0.01[-0.75,0.77]

0.18[-0.32,0.68]

0.13[-0.29,0.54]

45.61%

54.39%

100%

0.01[-0.89,0.91]

-0.33[-1.15,0.5]

-0.18[-0.78,0.43]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

426

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 13.26.   Comparison 13 Subanalysis: outcomes by mode of physical
activity intervention, Outcome 26 Overall pain/disability (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.26.1 Aerobic exercise

Mehnert 2011

Cadmus 2009

Subtotal ***

-2.4 (25)

-2.2 (11.3)

30

37

67

Heterogeneity: Tau2=0.03; Chi2=1.47, df=1(P=0.23); I2=31.79%

Test for overall effect: Z=0.12(P=0.9)

13.26.2 Resistance exercise

Cormie 2014

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.78(P=0.44)

3.4 (6.5)

43

43

13.26.3 Combined aerobic and resistance exercise

Irwin 2015

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.59(P=0.11)

13.26.4 Yoga, Tai Chi, and Pilates

Mustian 2004

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.34(P=0.74)

45

45

9

9

-6 (19)

-0.2 (1.3)

28

37

65

19

19

38

38

10

10

-7.6 (25.2)

-0.1 (7)

2 (6.2)

0.7 (18.6)

0 (1.4)

45.86%

54.14%

100%

0.21[-0.31,0.72]

-0.22[-0.68,0.24]

-0.03[-0.44,0.39]

100%

100%

0.22[-0.33,0.76]

0.22[-0.33,0.76]

100%

100%

-0.35[-0.79,0.08]

-0.35[-0.79,0.08]

100%

100%

-0.15[-1.06,0.75]

-0.15[-1.06,0.75]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 13.27.   Comparison 13 Subanalysis: outcomes by mode of physical activity
intervention, Outcome 27 Overall self-esteem/body image (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.27.1 Aerobic exercise

Segar 1998

Musanti 2012

Mehnert 2011

Courneya 2003

Daley 2007

Cadmus 2009

Pinto 2005

Subtotal ***

33 (1.8)

21.7 (4.4)

-5.5 (1.7)

34.8 (4.7)

2 (0.8)

34.2 (5.5)

30.3 (7.8)

10

10

27

24

33

37

39

180

Heterogeneity: Tau2=0.13; Chi2=15.4, df=6(P=0.02); I2=61.03%

Test for overall effect: Z=1.58(P=0.12)

13.27.2 Resistance exercise

Musanti 2012

Schmitz 2009

Subtotal ***

26.4 (2.6)

-70.4 (16.3)

9

59

68

30.5 (2.7)

26.3 (3.9)

-6.8 (2.6)

34.6 (4.4)

1.6 (0.5)

33.4 (5.9)

27.2 (6.8)

26.3 (3.9)

-71.5 (18)

5

12

27

28

32

37

43

184

12

63

75

6.73%

9.46%

15.68%

15.7%

16.69%

17.67%

18.08%

100%

1.11[-0.06,2.28]

-1.07[-1.98,-0.16]

0.61[0.06,1.16]

0.04[-0.5,0.59]

0.66[0.16,1.16]

0.14[-0.32,0.6]

0.41[-0.03,0.85]

0.29[-0.07,0.64]

14.45%

85.55%

100%

0.03[-0.83,0.9]

0.06[-0.29,0.42]

0.06[-0.27,0.39]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

427

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.95); I2=0%

Test for overall effect: Z=0.35(P=0.73)

13.27.3 Combined aerobic and resistance exercise

Pinto 2003

Musanti 2012

Milne 2008

Do 2015

Subtotal ***

32.3 (4.3)

23.6 (1.2)

-17.9 (6.8)

37.9 (18.9)

12

11

29

32

84

Heterogeneity: Tau2=0.24; Chi2=9.25, df=3(P=0.03); I2=67.56%

Test for overall effect: Z=0.46(P=0.64)

13.27.4 Yoga, Tai Chi, and Pilates

Loudon 2014

Subtotal ***

-1.4 (0.3)

12

12

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=0.47(P=0.64)

25.3 (8.2)

26.3 (3.9)

-20.1 (6.3)

36.1 (18.3)

-1.6 (0.9)

6

12

29

30

77

11

11

17.5%

21.61%

30.18%

30.7%

100%

1.15[0.08,2.22]

-0.87[-1.74,-0.01]

0.33[-0.19,0.85]

0.1[-0.4,0.59]

0.14[-0.46,0.74]

100%

100%

0.2[-0.62,1.02]

0.2[-0.62,1.02]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 13.28.   Comparison 13 Subanalysis: outcomes by mode of physical
activity intervention, Outcome 28 Overall self-esteem/body image (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.28.1 Aerobic exercise

Musanti 2012

Courneya 2003

Mehnert 2011

Daley 2007

Cadmus 2009

Saarto 2012

Subtotal ***

-1.3 (6)

2.6 (3.7)

0.7 (2.1)

1.8 (0.7)

0.4 (4.4)

10.7 (21.5)

10

24

30

33

37

263

397

Heterogeneity: Tau2=0.04; Chi2=9.58, df=5(P=0.09); I2=47.79%

Test for overall effect: Z=1.05(P=0.29)

13.28.2 Resistance exercise

Musanti 2012

Schmitz 2009

Subtotal ***

1.1 (1.8)

-12 (15.5)

9

59

68

Heterogeneity: Tau2=0.1; Chi2=1.87, df=1(P=0.17); I2=46.47%

Test for overall effect: Z=0.96(P=0.34)

13.28.3 Combined aerobic and resistance exercise

Musanti 2012

Milne 2008

Subtotal ***

-0.8 (4.7)

1.5 (3.7)

11

29

40

Heterogeneity: Tau2=0.11; Chi2=1.86, df=1(P=0.17); I2=46.2%

Test for overall effect: Z=0.31(P=0.75)

12

28

27

33

37

237

374

12

63

75

12

29

41

0.6 (3.9)

-0.1 (3.5)

0.4 (2.1)

1.6 (0.7)

0.2 (2.9)

12 (22)

0.6 (3.9)

-4.1 (16.2)

0.6 (3.9)

0.1 (3.9)

7.23%

13.14%

14.58%

15.84%

17.04%

32.17%

100%

-0.37[-1.21,0.48]

0.74[0.18,1.3]

0.16[-0.36,0.68]

0.33[-0.16,0.82]

0.05[-0.4,0.51]

-0.06[-0.24,0.12]

0.14[-0.12,0.39]

31.15%

68.85%

100%

0.16[-0.71,1.03]

-0.49[-0.86,-0.13]

-0.29[-0.88,0.3]

38.39%

61.61%

100%

-0.31[-1.14,0.51]

0.36[-0.16,0.88]

0.1[-0.54,0.75]

Favours control

-5

-2.5

0

2.5

5

Favours intervention

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

428

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.28.4 Yoga, Tai Chi, and Pilates

Mustian 2004

Subtotal ***

11

11

3 (1)

10

10

-1.5 (1.5)

Heterogeneity: Not applicable

Test for overall effect: Z=4.68(P<0.0001)

100%

100%

3.42[1.99,4.86]

3.42[1.99,4.86]

Favours control

-5

-2.5

0

2.5

5

Favours intervention

Analysis 13.29.   Comparison 13 Subanalysis: outcomes by mode of physical activity
intervention, Outcome 29 Overall cardiorespiratory fitness (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.29.1 Aerobic exercise

Cerulli 2014

Musanti 2012

Nikander 2007

Rogers 2009

Courneya 2003

Mehnert 2011

Basen-Enquist 2006

Murtezani 2014

Pinto 2005

Fillion 2008

Daley 2007

Rogers 2015

Subtotal ***

31.3 (5)

24.8 (6.5)

-17.6 (1.3)

29.5 (6.6)

21.3 (3.7)

26.9 (4.4)

1643
(122.5)

875.1 (86.7)

-16.3 (2.1)

27 (4.4)

35 (4.4)

23.6 (4.8)

10

10

14

20

24

27

35

30

39

44

33

105

391

Heterogeneity: Tau2=0.01; Chi2=13.52, df=11(P=0.26); I2=18.63%

Test for overall effect: Z=4.49(P<0.0001)

13.29.2 Resistance exercise

Musanti 2012

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.61(P=0.54)

24.2 (4.4)

9

9

13.29.3 Combined aerobic and resistance exercise

Herrero 2006

Rogers 2013

Musanti 2012

Portela 2008

Kaltsatou 2011

Rahnama 2010

Rogers 2014

Kim 2015

Do 2015

Milne 2008

Irwin 2015

Subtotal ***

8

12

11

25

14

14

20

20

30

29

45

25.9 (4.5)

23.9 (6.2)

24.7 (4.1)

3007
(410.8)

483.3 (86)

20.7 (5.7)

30.9 (6.3)

424.8 (55.8)

31.7 (12.4)

1.5 (0.3)

24.6 (5.5)

228

205

10

12

14

18

26

23

25

32

43

43

69

108

423

12

12

8

10

12

9

13

15

22

19

30

29

38

32.3 (10.1)

23 (4.3)

-17.2 (1.4)

27.6 (6.1)

18.2 (3.9)

25.7 (4.7)

1546
(127.5)

823.5 (87.1)

-17.8 (2.2)

26.5 (5.8)

33.1 (5.3)

22.7 (0.3)

23 (4.3)

25.7 (3.7)

23.9 (3.8)

23 (4.3)

2416.1
(718.6)

403.1 (71.9)

13.9 (5.2)

25.1 (5)

394.4 (54)

24.5 (6.6)

1.5 (0.4)

23 (4.7)

3.2%

3.43%

4.32%

5.66%

6.75%

7.17%

7.76%

8.36%

10.31%

11.3%

11.4%

20.34%

100%

-0.12[-0.99,0.76]

0.31[-0.53,1.16]

-0.29[-1.03,0.46]

0.29[-0.35,0.93]

0.8[0.22,1.38]

0.26[-0.3,0.82]

0.77[0.24,1.3]

0.59[0.08,1.1]

0.69[0.24,1.14]

0.1[-0.32,0.52]

0.38[-0.04,0.8]

0.27[-0,0.54]

0.37[0.21,0.54]

100%

100%

0.27[-0.6,1.14]

0.27[-0.6,1.14]

5.39%

6.83%

6.97%

7.13%

7.24%

7.29%

9.72%

9.83%

12.35%

12.56%

14.69%

100%

0.05[-0.93,1.03]

0[-0.84,0.84]

0.39[-0.44,1.22]

1.14[0.33,1.96]

0.98[0.17,1.78]

1.21[0.41,2.01]

1.01[0.36,1.65]

0.54[-0.1,1.18]

0.72[0.19,1.24]

0.03[-0.49,0.54]

0.31[-0.13,0.74]

0.56[0.3,0.81]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

429

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Heterogeneity: Tau2=0.07; Chi2=15.96, df=10(P=0.1); I2=37.35%

Test for overall effect: Z=4.27(P<0.0001)

13.29.4 Yoga, Tai Chi, and Pilates

Mustian 2004

Subtotal ***

636.1 (50.6)

11

11

610.3 (75.9)

10

10

Heterogeneity: Not applicable

Test for overall effect: Z=0.88(P=0.38)

100%

100%

0.39[-0.48,1.25]

0.39[-0.48,1.25]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 13.30.   Comparison 13 Subanalysis: outcomes by mode of physical activity
intervention, Outcome 30 Overall cardiorespiratory fitness (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.30.1 Aerobic exercise

Dolan 2016

Musanti 2012

Courneya 2003

Pinto 2005

Saarto 2012

Subtotal ***

12.2 (10.2)

1 (2.4)

2.7 (2.6)

1.4 (2.4)

0.9 (1.2)

23

10

24

39

262

358

10

12

26

43

236

327

-6 (7.2)

0.9 (3.4)

-0.6 (1.7)

-0.2 (2.5)

0.7 (1)

Heterogeneity: Tau2=0.41; Chi2=30.86, df=4(P<0.0001); I2=87.04%

Test for overall effect: Z=2.49(P=0.01)

13.30.2 Resistance exercise

Musanti 2012

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.09(P=0.93)

0.8 (3.7)

9

9

13.30.3 Combined aerobic and resistance exercise

Nieman 1995

Naumann 2012

Musanti 2012

Rogers 2014

Irwin 2015

Subtotal ***

60.8 (8.4)

3.1 (2.9)

1.2 (2.8)

2.8 (4.9)

1.5 (2.1)

6

11

11

20

45

93

Heterogeneity: Tau2=0.23; Chi2=10.47, df=4(P=0.03); I2=61.79%

Test for overall effect: Z=2.59(P=0.01)

13.30.4 Yoga, Tai Chi, and Pilates

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0.9 (3.4)

12 (17.8)

-0.1 (3.1)

0.9 (3.4)

1.1 (4.2)

-0.4 (2.7)

12

12

6

10

12

22

38

88

0

16.56%

17.15%

19.81%

22.08%

24.4%

100%

1.88[0.99,2.77]

0.03[-0.81,0.87]

1.49[0.86,2.12]

0.65[0.2,1.09]

0.16[-0.02,0.33]

0.79[0.17,1.42]

100%

100%

-0.04[-0.91,0.82]

-0.04[-0.91,0.82]

6.85%

18.32%

20.44%

25.22%

29.17%

100%

3.24[1.29,5.18]

1.03[0.1,1.95]

0.08[-0.74,0.9]

0.37[-0.24,0.98]

0.79[0.34,1.24]

0.75[0.18,1.31]

Not estimable

Favours control

-10

-5

0

5

10

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

430

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 13.31.   Comparison 13 Subanalysis: outcomes by mode of physical activity
intervention, Outcome 31 Overall self-reported physical activity (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.31.1 Aerobic exercise

Guinan 2013

Matthews 2007

Rogers 2009

Basen-Enquist 2006

Cadmus 2009

Pinto 2015

Hatchett 2013

Pinto 2005

Rogers 2015

Vallance 2007

Subtotal ***

38.7 (26.9)

54.2 (34.1)

121.4 (73.2)

428 (254.4)

161.7
(114.7)

70.3 (65.9)

3.5 (2.2)

202.4
(161.7)

169 (119)

207.6 (169)

16

22

20

35

34

36

38

39

110

253

603

Heterogeneity: Tau2=0.1; Chi2=26.28, df=9(P=0); I2=65.75%

Test for overall effect: Z=5.4(P<0.0001)

13.31.2 Resistance exercise

Winters-Stone 2011

Schmitz 2009

Subtotal ***

430.8
(281.4)

3348.8
(9019.4)

36

131

167

Heterogeneity: Tau2=0; Chi2=0.69, df=1(P=0.41); I2=0%

Test for overall effect: Z=0.76(P=0.44)

13.31.3 Combined aerobic and resistance exercise

Kim 2015

Irwin 2015

Short 2014

Subtotal ***

17.6 (16)

222.1
(118.6)

217.9
(222.9)

20

45

195

260

Heterogeneity: Tau2=0.21; Chi2=10.84, df=2(P=0); I2=81.55%

Test for overall effect: Z=1.78(P=0.07)

13.31.4 Yoga, Tai Chi, and Pilates

Littman 2012

Kiecolt-Glaser 2014

Subtotal ***

19.2 (19.1)

11.2 (7.6)

32

96

128

Heterogeneity: Tau2=0; Chi2=0.16, df=1(P=0.69); I2=0%

Test for overall effect: Z=2.6(P=0.01)

19.9 (11.3)

27.2 (22.7)

114.3
(131.5)

404 (265)

55.6 (101.9)

16.5 (31.9)

1.4 (1.7)

78.4 (86)

74 (107)

163 (121)

461.7
(346.4)

2339.8
(6213.7)

11.8 (11.6)

103.6
(104.6)

180.3
(206.9)

12.1 (13.6)

9.1 (6.1)

10

14

18

25

33

32

36

43

112

85

408

31

133

164

19

38

104

161

31

90

121

5.91%

7.19%

8.01%

9.81%

9.9%

9.91%

10.23%

10.7%

13.94%

14.41%

100%

0.81[-0.01,1.64]

0.87[0.17,1.58]

0.07[-0.57,0.7]

0.09[-0.42,0.61]

0.97[0.46,1.47]

1.01[0.5,1.52]

1.04[0.55,1.53]

0.96[0.5,1.42]

0.84[0.56,1.11]

0.28[0.03,0.53]

0.69[0.44,0.94]

20.17%

79.83%

-0.1[-0.58,0.38]

0.13[-0.11,0.37]

100%

0.08[-0.13,0.3]

27.81%

33.06%

39.13%

0.4[-0.23,1.04]

1.04[0.58,1.51]

0.17[-0.07,0.41]

100%

0.53[-0.05,1.1]

25.09%

74.91%

100%

0.42[-0.08,0.92]

0.3[0.01,0.59]

0.33[0.08,0.58]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

431

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 13.32.   Comparison 13 Subanalysis: outcomes by mode of physical activity
intervention, Outcome 32 Overall self-reported physical activity (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.32.1 Aerobic exercise

Guinan 2013

Matthews 2007

Cadmus 2009

Pinto 2005

Vallance 2007

Saarto 2012

Subtotal ***

15.6 (11.4)

21.5 (30.6)

129 (117.9)

84.7 (189.2)

82 (168.7)

3.5 (18.3)

16

22

34

39

281

262

654

10

14

33

43

96

236

432

-8.3 (4.2)

5 (13.8)

44.3 (89.4)

-18.3
(200.7)

30 (167.8)

3.3 (21.5)

Heterogeneity: Tau2=0.17; Chi2=30.98, df=5(P<0.0001); I2=83.86%

Test for overall effect: Z=2.96(P=0)

13.32.2 Resistance exercise

Schmitz 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.09(P=0.28)

2.8 (16.8)

48

48

13.32.3 Combined aerobic and resistance exercise

159 (136)

Irwin 2015

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=4.04(P<0.0001)

13.32.4 Yoga, Tai Chi, and Pilates

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

45

45

0

57

57

38

38

0

-0.8 (16.6)

49 (86)

8.36%

13.42%

16.77%

17.86%

21.43%

22.16%

100%

2.46[1.39,3.53]

0.63[-0.06,1.32]

0.8[0.3,1.3]

0.52[0.08,0.96]

0.31[0.08,0.54]

0.01[-0.17,0.19]

0.59[0.2,0.97]

100%

100%

0.21[-0.17,0.6]

0.21[-0.17,0.6]

100%

100%

0.94[0.48,1.4]

0.94[0.48,1.4]

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 13.33.   Comparison 13 Subanalysis: outcomes by mode of physical activity
intervention, Outcome 33 Overall objective physical activity (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.33.1 Aerobic exercise

Guinan 2013

Matthews 2007

Rogers 2009

Pinto 2015

Cadmus 2009

Pinto 2005

Rogers 2015

Vallance 2007

Subtotal ***

30.7 (15.6)

330.8
(114.7)

252191
(91893)

70.3 (65.9)

6738 (2958)

37.5 (14.3)

246 (153)

8110.5
(4133.9)

16

22

20

36

33

39

110

253

529

31 (15.6)

198.5 (55.4)

210917
(64078)

16.5 (31.9)

5537 (3352)

33.6 (19.4)

197 (138)

8028 (3457)

9

14

18

32

34

43

112

85

347

7.42%

8.3%

9.75%

12.3%

12.79%

13.82%

17.6%

18.01%

-0.02[-0.84,0.8]

1.34[0.6,2.09]

0.51[-0.14,1.15]

1.01[0.5,1.52]

0.38[-0.11,0.86]

0.22[-0.21,0.66]

0.34[0.07,0.6]

0.02[-0.23,0.27]

100%

0.43[0.15,0.7]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

432

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Heterogeneity: Tau2=0.09; Chi2=21.18, df=7(P=0); I2=66.95%

Test for overall effect: Z=3.01(P=0)

13.33.2 Resistance exercise

Subtotal ***

0

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

13.33.3 Combined aerobic and resistance exercise

Rogers 2013

Rogers 2014

Short 2014

Subtotal ***

12

20

219

251

198.4
(111.7)

294 (175)

9363.1
(7922.8)

10

22

111

143

0 (0)

154 (75)

8301.2
(3373.4)

Heterogeneity: Tau2=0.33; Chi2=6.3, df=1(P=0.01); I2=84.13%

Test for overall effect: Z=1.24(P=0.21)

13.33.4 Yoga, Tai Chi, and Pilates

Subtotal ***

0

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Not estimable

43.82%

56.18%

Not estimable

1.04[0.39,1.69]

0.16[-0.07,0.39]

100%

0.54[-0.31,1.4]

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 13.34.   Comparison 13 Subanalysis: outcomes by mode of physical activity
intervention, Outcome 34 Overall objective physical activity (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.34.1 Aerobic exercise

Guinan 2013

Matthews 2007

Cadmus 2009

Vallance 2007

Subtotal ***

-1.1 (6.2)

72.2 (114.6)

1621 (2108)

-150
(5173.3)

16

22

33

253

324

Heterogeneity: Tau2=0.3; Chi2=16.43, df=3(P=0); I2=81.74%

Test for overall effect: Z=1.94(P=0.05)

13.34.2 Resistance exercise

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

13.34.3 Combined aerobic and resistance exercise

Rogers 2014

Subtotal ***

114 (109)

20

20

Heterogeneity: Not applicable

Test for overall effect: Z=3.36(P=0)

9

14

34

85

142

0

22

22

-7.9 (5.3)

-16.8 (51.5)

-60 (2341)

91 (5155.4)

19.48%

22.77%

26.84%

30.91%

1.11[0.23,2]

0.91[0.2,1.62]

0.75[0.25,1.24]

-0.05[-0.29,0.2]

100%

0.61[-0.01,1.23]

Not estimable

10 (70)

100%

100%

1.13[0.47,1.78]

1.13[0.47,1.78]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

433

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.34.4 Yoga, Tai Chi, and Pilates

Subtotal ***

0

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 13.35.   Comparison 13 Subanalysis: outcomes by mode of
physical activity intervention, Outcome 35 Mass (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

13.35.1 Aerobic exercise

Matthews 2007

Courneya 2003

Nikander 2007

Cadmus 2009

DeNysschen 2011

Daley 2007

Murtezani 2014

Subtotal ***

74.9 (15.2)

78.2 (20.5)

73.5 (13.3)

80.7 (16.9)

69.3 (14.2)

74.3 (12.5)

71.7 (9.5)

22

24

14

36

30

33

30

189

Heterogeneity: Tau2=0; Chi2=1.02, df=6(P=0.98); I2=0%

Test for overall effect: Z=0.92(P=0.36)

13.35.2 Resistance exercise

Winters-Stone 2011

Schmitz 2009

Schmitz 2005

Subtotal ***

76.5 (15.6)

76.2 (15.7)

69.5 (2.2)

36

131

39

206

Heterogeneity: Tau2=0; Chi2=0.78, df=2(P=0.68); I2=0%

Test for overall effect: Z=0.55(P=0.58)

13.35.3 Combined aerobic and resistance exercise

Herrero 2006

Rahnama 2010

Ligibel 2008

Subtotal ***

65.6 (8.7)

69.4 (13.5)

80 (17.5)

8

14

40

62

Heterogeneity: Tau2=0; Chi2=0.08, df=2(P=0.96); I2=0%

Test for overall effect: Z=1.01(P=0.31)

13.35.4 Yoga, Tai Chi, and Pilates

Mustian 2004

Littman 2012

Kiecolt-Glaser 2014

Subtotal ***

67.1 (10.4)

81.1 (13.6)

75.2 (2.8)

11

28

96

135

Heterogeneity: Tau2=0; Chi2=0.08, df=2(P=0.96); I2=0%

Test for overall effect: Z=0.03(P=0.98)

78.9 (20.3)

80.1 (16.2)

75.5 (12)

78.5 (20.6)

72.4 (19.6)

75.6 (12.5)

72.6 (10.8)

74.2 (12.3)

77.2 (17)

69.2 (2.2)

67.3 (8.9)

71.6 (9.2)

83.3 (18.7)

68.6 (13.8)

81.3 (14.3)

75.2 (2.6)

14

26

14

33

34

69

32

222

31

133

40

204

8

15

42

65

10

27

90

127

4.98%

7.21%

8.68%

9.56%

11.04%

28.46%

30.06%

100%

1.96%

5.64%

92.39%

100%

30.78%

31.94%

37.29%

100%

0.53%

1.09%

98.38%

100%

-4[-16.39,8.39]

-1.9[-12.2,8.4]

-2[-11.38,7.38]

2.22[-6.72,11.16]

-3.1[-11.42,5.22]

-1.34[-6.52,3.84]

-0.9[-5.94,4.14]

-1.29[-4.06,1.47]

2.3[-4.39,8.99]

-1.04[-4.98,2.9]

0.3[-0.67,1.27]

0.26[-0.67,1.2]

-1.7[-10.32,6.92]

-2.2[-10.67,6.27]

-3.3[-11.14,4.54]

-2.46[-7.24,2.33]

-1.5[-12.06,9.06]

-0.2[-7.58,7.18]

0[-0.78,0.78]

-0.01[-0.78,0.76]

Favours physical activity

-20

-10

0

10

20

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

434

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 13.36.   Comparison 13 Subanalysis: outcomes by mode of
physical activity intervention, Outcome 36 Mass (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

13.36.1 Aerobic exercise

Dolan 2016

Matthews 2007

Murtezani 2014

Courneya 2003

Saarto 2012

Subtotal ***

-0.5 (5)

0 (2.1)

-2.3 (2.4)

0.1 (2)

0.7 (3.7)

23

22

30

24

262

361

Heterogeneity: Tau2=0.5; Chi2=9.76, df=4(P=0.04); I2=59%

Test for overall effect: Z=1.74(P=0.08)

13.36.2 Resistance exercise

Schmitz 2009

Schmitz 2005

Subtotal ***

-1 (3.7)

0.3 (0.4)

65

39

104

Heterogeneity: Tau2=0.01; Chi2=1.03, df=1(P=0.31); I2=2.73%

Test for overall effect: Z=0.78(P=0.44)

13.36.3 Combined aerobic and resistance exercise

Irwin 2015

Ligibel 2008

Naumann 2012

Subtotal ***

-2.1 (4.3)

0 (2.3)

0.5 (1.3)

45

22

11

78

Heterogeneity: Tau2=1.08; Chi2=5.89, df=2(P=0.05); I2=66.06%

Test for overall effect: Z=0.74(P=0.46)

13.36.4 Yoga, Tai Chi, and Pilates

Mustian 2004

Subtotal ***

-0.3 (1.9)

9

9

Heterogeneity: Not applicable

Test for overall effect: Z=1.17(P=0.24)

10

14

32

26

236

318

65

40

105

38

14

10

62

10

10

1.4 (1.6)

0 (2.2)

-0.3 (2.6)

0.7 (1.8)

0.7 (3.8)

-0.4 (4.3)

0.2 (0.4)

0.1 (3.6)

0 (2.2)

0.1 (1.5)

0.6 (1.4)

9.72%

17.6%

20.11%

22.96%

29.61%

100%

3.13%

96.87%

100%

29.82%

33.04%

37.13%

100%

-1.99[-4.28,0.3]

-0.03[-1.46,1.4]

-2[-3.24,-0.76]

-0.6[-1.66,0.46]

-0.01[-0.67,0.65]

-0.74[-1.58,0.09]

-0.6[-1.98,0.78]

0.12[-0.07,0.31]

0.1[-0.15,0.34]

-2.2[-3.9,-0.5]

-0.04[-1.52,1.44]

0.33[-0.9,1.56]

-0.55[-1.99,0.9]

100%

100%

-0.9[-2.4,0.6]

-0.9[-2.4,0.6]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 13.37.   Comparison 13 Subanalysis: outcomes by mode of
physical activity intervention, Outcome 37 BMI (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

13.37.1 Aerobic exercise

Rogers 2009

Courneya 2003

Cadmus 2009

Pinto 2005

Murtezani 2014

Vallance 2007

Subtotal ***

20

24

36

39

30

253

402

30.6 (7.6)

29.4 (7.4)

30.5 (6)

27.7 (5)

25.1 (2.9)

27 (5.2)

18

26

33

43

32

85

237

30.4 (8.3)

29.3 (6)

29.9 (7.6)

29 (5.6)

25.8 (3.5)

27.2 (5.2)

Heterogeneity: Tau2=0; Chi2=1.35, df=5(P=0.93); I2=0%

Test for overall effect: Z=0.96(P=0.34)

2.75%

5.03%

6.72%

13.39%

28.1%

44.01%

100%

0.2[-4.88,5.28]

0.1[-3.65,3.85]

0.55[-2.7,3.8]

-1.35[-3.65,0.95]

-0.7[-2.29,0.89]

-0.19[-1.46,1.08]

-0.41[-1.26,0.43]

Favours physical activity

-20

-10

0

10

20

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

435

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

13.37.2 Resistance exercise

Schmitz 2009

Schmitz 2005

Subtotal ***

28.5 (5.6)

26 (0.7)

131

39

170

Heterogeneity: Tau2=0; Chi2=0.83, df=1(P=0.36); I2=0%

Test for overall effect: Z=1.03(P=0.3)

13.37.3 Combined aerobic and resistance exercise

Portela 2008

Rogers 2013

Nikander 2007

Rogers 2014

Rahnama 2010

Ligibel 2008

Subtotal ***

29.1 (5.5)

33.6 (7)

26.9 (5.6)

29.6 (5)

27.7 (4.8)

30.3 (6.3)

25

12

14

20

14

40

125

Heterogeneity: Tau2=0; Chi2=3.48, df=5(P=0.63); I2=0%

Test for overall effect: Z=1.27(P=0.2)

13.37.4 Yoga, Tai Chi, and Pilates

Mustian 2004

Littman 2012

Kiecolt-Glaser 2014

Subtotal ***

23.9 (4.2)

27.7 (5)

27.8 (1.1)

11

28

96

135

Heterogeneity: Tau2=0; Chi2=2.51, df=2(P=0.28); I2=20.45%

Test for overall effect: Z=0.18(P=0.85)

28.9 (6.3)

25.8 (0.7)

34.7 (15)

30.6 (7.3)

27.7 (4.9)

32.2 (6.7)

28 (4.6)

31.5 (6.8)

26.7 (5.6)

29 (5.6)

27.8 (1)

133

40

173

9

10

14

22

15

42

112

10

27

90

127

4.9%

95.1%

100%

-0.48[-1.91,0.95]

0.2[-0.12,0.52]

0.17[-0.15,0.48]

2.53%

7.06%

16.76%

20.14%

21.83%

31.67%

100%

0.46%

1.06%

98.48%

100%

-5.6[-15.63,4.43]

3[-3,9]

-0.8[-4.7,3.1]

-2.6[-6.16,0.96]

-0.3[-3.71,3.11]

-1.2[-4.04,1.64]

-1.03[-2.63,0.56]

-2.8[-7.05,1.45]

-1.35[-4.17,1.47]

0[-0.29,0.29]

-0.03[-0.32,0.26]

Favours physical activity

-20

-10

0

10

20

Favours control

Analysis 13.38.   Comparison 13 Subanalysis: outcomes by mode
of physical activity intervention, Outcome 38 BMI (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

13.38.1 Aerobic exercise

Courneya 2003

Murtezani 2014

Subtotal ***

0 (0.7)

-0.8 (0.7)

24

30

54

Heterogeneity: Tau2=0.03; Chi2=1.71, df=1(P=0.19); I2=41.67%

Test for overall effect: Z=2.69(P=0.01)

13.38.2 Resistance exercise

Schmitz 2009

Schmitz 2005

Subtotal ***

-1 (3.7)

0.1 (0.2)

65

39

104

Heterogeneity: Tau2=0; Chi2=0.7, df=1(P=0.4); I2=0%

Test for overall effect: Z=0.31(P=0.75)

13.38.3 Combined aerobic and resistance exercise

0.3 (0.7)

-0.1 (0.8)

-0.4 (4.3)

0.1 (0.2)

26

32

58

65

40

105

48.87%

51.13%

100%

-0.3[-0.69,0.09]

-0.66[-1.03,-0.29]

-0.48[-0.84,-0.13]

0.28%

99.72%

100%

-0.6[-1.98,0.78]

-0.01[-0.08,0.06]

-0.01[-0.08,0.06]

Rogers 2014

20

-0.2 (0.9)

22

-0.3 (1.1)

18.45%

0.1[-0.51,0.71]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

436

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Naumann 2012

Ligibel 2008

Subtotal ***

0.1 (0.5)

0 (0.9)

11

40

71

Heterogeneity: Tau2=0; Chi2=1.94, df=2(P=0.38); I2=0%

Test for overall effect: Z=0.13(P=0.9)

13.38.4 Yoga, Tai Chi, and Pilates

Mustian 2004

Subtotal ***

-0.4 (0.8)

9

9

Heterogeneity: Not applicable

Test for overall effect: Z=2.25(P=0.02)

-0.1 (0.6)

0.2 (0.8)

0.3 (0.6)

10

42

74

10

10

Cochrane Database of Systematic Reviews

Weight

Mean Difference

31.91%

49.64%

100%

Random, 95% CI

0.2[-0.26,0.66]

-0.2[-0.57,0.17]

-0.02[-0.28,0.24]

100%

100%

-0.71[-1.33,-0.09]

-0.71[-1.33,-0.09]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 13.39.   Comparison 13 Subanalysis: outcomes by mode of physical
activity intervention, Outcome 39 Overall body fat (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.39.1 Aerobic exercise

Cerulli 2014

Musanti 2012

Matthews 2007

Rogers 2009

Courneya 2003

DeNysschen 2011

Saarto 2012

Cadmus 2009

Pinto 2005

Daley 2007

Subtotal ***

10

10

22

20

24

30

37

36

39

33

26.7 (5.3)

33.8 (7.6)

39.7 (6.3)

44.3 (7.4)

131.9 (46.4)

36.9 (8.4)

39.9 (7.5)

40.5 (6.6)

37.5 (4.8)

39.4 (4.7)

10

12

14

19

26

34

30

33

43

69

30.6 (4.4)

33.7 (5.7)

43.1 (6.9)

43.5 (7.5)

137.1 (44.4)

38 (10.2)

40.2 (8)

39.6 (6)

38.6 (4.8)

40.1 (7.4)

261

290

Heterogeneity: Tau2=0; Chi2=5.16, df=9(P=0.82); I2=0%

Test for overall effect: Z=1.26(P=0.21)

13.39.2 Resistance exercise

Musanti 2012

Winters-Stone 2011

Schmitz 2005

Schmitz 2009

Subtotal ***

33.3 (7.1)

40.5 (6.2)

40.9 (1.3)

38.5 (5.9)

9

36

39

130

214

Heterogeneity: Tau2=0.24; Chi2=16.72, df=3(P=0); I2=82.06%

Test for overall effect: Z=0.95(P=0.34)

13.39.3 Combined aerobic and resistance exercise

Herrero 2006

Rogers 2013

Musanti 2012

Rogers 2014

Ligibel 2008

Subtotal ***

22 (5)

44.2 (6.7)

35.2 (4.8)

38.6 (6.4)

42.9 (7.4)

8

10

11

20

40

89

33.7 (5.7)

38.5 (5.8)

42.3 (1.3)

39.7 (5.9)

22 (4)

42.3 (7.7)

33.7 (5.7)

41.5 (7.4)

44.7 (8)

12

31

40

132

215

8

12

12

22

42

96

3.46%

4.11%

6.23%

7.33%

9.38%

11.98%

12.47%

12.93%

15.31%

16.79%

100%

17.82%

25.77%

26.02%

30.38%

100%

8.76%

11.83%

12.43%

22.42%

44.56%

100%

-0.75[-1.66,0.16]

0.01[-0.82,0.85]

-0.51[-1.19,0.17]

0.11[-0.52,0.73]

-0.11[-0.67,0.44]

-0.12[-0.61,0.38]

-0.04[-0.52,0.44]

0.15[-0.33,0.62]

-0.21[-0.64,0.22]

-0.1[-0.52,0.31]

-0.11[-0.28,0.06]

-0.06[-0.93,0.8]

0.33[-0.16,0.81]

-1.05[-1.52,-0.58]

-0.21[-0.46,0.03]

-0.26[-0.81,0.28]

0[-0.98,0.98]

0.25[-0.59,1.09]

0.27[-0.55,1.1]

-0.41[-1.02,0.2]

-0.23[-0.67,0.2]

-0.13[-0.42,0.16]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

437

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Heterogeneity: Tau2=0; Chi2=2.79, df=4(P=0.59); I2=0%

Test for overall effect: Z=0.89(P=0.38)

13.39.4 Yoga, Tai Chi, and Pilates

Mustian 2004

Subtotal ***

38.5 (4.5)

11

11

41.7 (4.9)

10

10

Heterogeneity: Not applicable

Test for overall effect: Z=1.46(P=0.15)

100%

100%

-0.66[-1.54,0.23]

-0.66[-1.54,0.23]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 13.40.   Comparison 13 Subanalysis: outcomes by mode of physical
activity intervention, Outcome 40 Overall body fat (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.40.1 Aerobic exercise

Musanti 2012

Matthews 2007

Courneya 2003

Subtotal ***

-0.3 (4.8)

-0.2 (1.6)

-4.9 (15.7)

10

22

24

56

Heterogeneity: Tau2=0; Chi2=0.1, df=2(P=0.95); I2=0%

Test for overall effect: Z=2.19(P=0.03)

13.40.2 Resistance exercise

Musanti 2012

Schmitz 2005

Schmitz 2009

Subtotal ***

-0.7 (2.3)

-1.1 (0.5)

-0.3 (5.7)

9

39

65

113

12

14

26

52

12

40

63

115

Heterogeneity: Tau2=3.03; Chi2=63.85, df=2(P<0.0001); I2=96.87%

Test for overall effect: Z=1.34(P=0.18)

13.40.3 Combined aerobic and resistance exercise

Naumann 2012

Musanti 2012

Rogers 2014

Ligibel 2008

Subtotal ***

-0.3 (2.4)

0.2 (3.6)

-1.1 (2.2)

-0.2 (1.7)

11

11

20

40

82

Heterogeneity: Tau2=0; Chi2=0.23, df=3(P=0.97); I2=0%

Test for overall effect: Z=1.96(P=0.05)

13.40.4 Yoga, Tai Chi, and Pilates

Mustian 2004

Subtotal ***

-0.2 (2.9)

9

9

Heterogeneity: Not applicable

Test for overall effect: Z=0.4(P=0.69)

10

12

22

42

86

10

10

1.4 (1.6)

0.4 (1.9)

5.1 (24.4)

1.4 (1.6)

0.2 (0.4)

-0.1 (3.3)

0.8 (2.8)

1.4 (1.6)

-0.6 (2.4)

0.3 (1.7)

0.3 (1.6)

20.44%

32.64%

46.92%

100%

32.26%

33.42%

34.32%

100%

12.35%

13.5%

25.17%

48.98%

100%

-0.48[-1.33,0.38]

-0.34[-1.02,0.33]

-0.48[-1.04,0.09]

-0.43[-0.82,-0.05]

-1.04[-1.98,-0.11]

-3.07[-3.73,-2.41]

-0.04[-0.39,0.3]

-1.38[-3.39,0.63]

-0.41[-1.28,0.46]

-0.43[-1.26,0.4]

-0.21[-0.82,0.39]

-0.29[-0.73,0.14]

-0.3[-0.61,0]

100%

100%

-0.18[-1.09,0.72]

-0.18[-1.09,0.72]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

438

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 13.41.   Comparison 13 Subanalysis: outcomes by mode of physical
activity intervention, Outcome 41 Lower body strength (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

79.1 (17.8)

64.9 (19.7)

136 (29)

238.9 (46.4)

191 (51.7)

175.1 (53.5)

67.1 (16.2)

1393 (275)

61.7 (11)

13.2 (1.6)

13.41.1 Aerobic exercise

Cerulli 2014

Rogers 2009

Saarto 2012

Subtotal ***

114.9 (17.1)

80.3 (27)

136 (23)

10

20

37

67

Heterogeneity: Tau2=0.55; Chi2=10.77, df=2(P=0); I2=81.43%

Test for overall effect: Z=1.55(P=0.12)

13.41.2 Resistance exercise

Schmitz 2005

Winters-Stone 2011

Schmitz 2009

Subtotal ***

296.6 (48.9)

201.3 (57.4)

223.4 (59.6)

23

36

113

172

Heterogeneity: Tau2=0.15; Chi2=7.64, df=2(P=0.02); I2=73.81%

Test for overall effect: Z=2.8(P=0.01)

13.41.3 Combined aerobic and resistance exercise

Rogers 2013

Nikander 2007

Milne 2008

Do 2015

Subtotal ***

68.4 (15.5)

1305 (177)

66.2 (10.2)

13 (1.6)

11

14

29

32

86

Heterogeneity: Tau2=0.02; Chi2=3.45, df=3(P=0.33); I2=13.09%

Test for overall effect: Z=0.3(P=0.76)

13.41.4 Yoga, Tai Chi, and Pilates

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

10

18

30

58

22

31

119

172

9

14

29

30

82

0

26.73%

35.16%

38.1%

100%

26.63%

32.57%

40.81%

100%

13.17%

17.78%

33.29%

35.76%

100%

1.96[0.85,3.07]

0.63[-0.02,1.29]

0[-0.48,0.48]

0.75[-0.2,1.69]

1.19[0.55,1.83]

0.19[-0.3,0.67]

0.85[0.58,1.12]

0.72[0.22,1.23]

0.08[-0.8,0.96]

-0.37[-1.12,0.38]

0.42[-0.1,0.94]

-0.09[-0.59,0.41]

0.05[-0.28,0.38]

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 13.42.   Comparison 13 Subanalysis: outcomes by mode of physical
activity intervention, Outcome 42 Lower body strength (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.42.1 Aerobic exercise

Dolan 2016

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.86(P=0)

13.42.2 Resistance exercise

Schmitz 2005

Cormie 2014

Schmitz 2009

Waltman 2010

23

23

23

43

113

110

11.8 (8.9)

81.8 (48.9)

37.6 (25.5)

33.2 (33.9)

4.4 (11.5)

10

10

22

19

119

113

0.3 (11.1)

20.3 (46)

6.7 (25.7)

7.9 (26.6)

0.2 (8.4)

100%

100%

1.17[0.37,1.97]

1.17[0.37,1.97]

17.64%

19.59%

31.33%

31.45%

1.27[0.63,1.92]

1.19[0.61,1.78]

0.83[0.56,1.1]

0.42[0.15,0.69]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

439

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Subtotal ***

Mean(SD)

N

289

N

273

Heterogeneity: Tau2=0.1; Chi2=10.89, df=3(P=0.01); I2=72.46%

Test for overall effect: Z=4.47(P<0.0001)

Mean(SD)

Random, 95% CI

Random, 95% CI

100%

0.85[0.48,1.22]

13.42.3 Combined aerobic and resistance exercise

Nieman 1995

Naumann 2012

Do 2015

Subtotal ***

28.9 (13.7)

7.7 (12.6)

0.9 (0.7)

6

11

32

49

Heterogeneity: Tau2=0.17; Chi2=3.98, df=2(P=0.14); I2=49.77%

Test for overall effect: Z=0.86(P=0.39)

13.42.4 Yoga, Tai Chi, and Pilates

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

3.5 (22.5)

3.5 (13.9)

1 (0.6)

6

10

60

76

0

18.37%

30.49%

51.14%

100%

1.26[-0.03,2.55]

0.3[-0.56,1.17]

-0.08[-0.51,0.35]

0.28[-0.37,0.93]

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 13.43.   Comparison 13 Subanalysis: outcomes by mode of physical
activity intervention, Outcome 43 Upper body strength (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.43.1 Aerobic exercise

Cerulli 2014

Musanti 2012

Nikander 2007

Rogers 2009

Saarto 2012

Subtotal ***

16.1 (5.4)

52.5 (21)

131 (20)

27.9 (5)

32.7 (5.3)

10

10

14

20

37

91

Heterogeneity: Tau2=0; Chi2=3.25, df=4(P=0.52); I2=0%

Test for overall effect: Z=2.27(P=0.02)

13.43.2 Resistance exercise

Musanti 2012

Schmitz 2005

Winters-Stone 2011

Schmitz 2009

Subtotal ***

56.4 (28)

83 (13.4)

63.3 (15.3)

52.9 (15.3)

9

23

36

113

181

Heterogeneity: Tau2=0.2; Chi2=11.9, df=3(P=0.01); I2=74.79%

Test for overall effect: Z=3(P=0)

13.43.3 Combined aerobic and resistance exercise

Musanti 2012

Portela 2008

Kaltsatou 2011

Milne 2008

Do 2015

Subtotal ***

48.3 (14.8)

39.3 (12.3)

59.6 (8.5)

7.6 (2.9)

9.7 (1.7)

11

25

28

29

32

125

10

12

14

18

30

84

12

22

31

119

184

12

9

26

29

30

106

17.2 (8.1)

36.8 (20)

129 (28)

24.3 (6.2)

30.8 (5.7)

36.8 (20)

63 (12.7)

61.1 (16.8)

40.9 (11.8)

36.8 (20)

35.6 (13.1)

47.6 (9.8)

9.4 (2.6)

10.1 (1.7)

11.77%

11.91%

16.53%

21.23%

38.56%

100%

17.3%

22.58%

27.47%

32.64%

100%

18.01%

18.81%

20.58%

21.17%

21.43%

100%

-0.16[-1.03,0.72]

0.74[-0.13,1.61]

0.08[-0.66,0.82]

0.63[-0.03,1.28]

0.34[-0.14,0.83]

0.35[0.05,0.65]

0.8[-0.11,1.7]

1.5[0.84,2.17]

0.14[-0.34,0.62]

0.88[0.61,1.15]

0.8[0.28,1.33]

0.63[-0.22,1.47]

0.29[-0.48,1.05]

1.29[0.7,1.88]

-0.64[-1.17,-0.12]

-0.24[-0.74,0.26]

0.25[-0.47,0.97]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

440

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Heterogeneity: Tau2=0.56; Chi2=26.67, df=4(P<0.0001); I2=85%

Test for overall effect: Z=0.67(P=0.5)

13.43.4 Yoga, Tai Chi, and Pilates

Mustian 2004

Subtotal ***

29.6 (3.3)

11

11

26.7 (5.7)

10

10

Heterogeneity: Not applicable

Test for overall effect: Z=1.35(P=0.18)

100%

100%

0.6[-0.28,1.49]

0.6[-0.28,1.49]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 13.44.   Comparison 13 Subanalysis: outcomes by mode of physical
activity intervention, Outcome 44 Upper body strength (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.44.1 Aerobic exercise

Musanti 2012

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.84(P=0.4)

13.44.2 Resistance exercise

Musanti 2012

Schmitz 2005

Cormie 2014

Waltman 2010

Schmitz 2009

Subtotal ***

5.5 (11.9)

11.8 (13.7)

32.3 (11.5)

5.7 (3.7)

1.9 (4.9)

33.2 (40.8)

10

10

9

23

43

110

113

298

Heterogeneity: Tau2=0.28; Chi2=28.18, df=4(P<0.0001); I2=85.8%

Test for overall effect: Z=3.55(P=0)

13.44.3 Combined aerobic and resistance exercise

Musanti 2012

Do 2015

Irwin 2015

Subtotal ***

6.5 (5.1)

0.3 (0.5)

0.4 (1.9)

11

32

45

88

Heterogeneity: Tau2=0.05; Chi2=3.21, df=2(P=0.2); I2=37.73%

Test for overall effect: Z=0.34(P=0.74)

13.44.4 Yoga, Tai Chi, and Pilates

Mustian 2004

Subtotal ***

4.5 (4.7)

45

45

Heterogeneity: Not applicable

Test for overall effect: Z=5.35(P<0.0001)

12

12

12

22

19

113

119

285

12

30

38

80

38

38

0.8 (12.7)

0.8 (12.7)

6.9 (10.8)

1 (3.8)

0.8 (2.9)

7.6 (43.7)

0.8 (12.7)

0.6 (1.2)

0.1 (1.9)

-0.8 (3.2)

100%

100%

0.36[-0.48,1.21]

0.36[-0.48,1.21]

14.74%

16.91%

19.66%

24.34%

24.34%

100%

18.55%

37.55%

43.9%

100%

0.8[-0.1,1.71]

2.24[1.48,2.99]

1.25[0.67,1.84]

0.29[0.02,0.55]

0.6[0.34,0.87]

0.96[0.43,1.49]

0.55[-0.28,1.39]

-0.27[-0.77,0.23]

0.16[-0.27,0.59]

0.07[-0.34,0.48]

100%

100%

1.3[0.82,1.78]

1.3[0.82,1.78]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

441

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 13.45.   Comparison 13 Subanalysis: outcomes by mode of physical activity
intervention, Outcome 45 Bone mineral density - femoral neck (follow-up and change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.45.1 Aerobic exercise

Saarto 2012

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.93(P=0.05)

13.45.2 Resistance exercise

Winters-Stone 2011

Waltman 2010

Subtotal ***

239

239

-0 (0)

218

218

-0 (0)

100%

100%

0.18[-0,0.37]

0.18[-0,0.37]

36

110

146

0.7 (0.1)

0.9 (0.5)

31

113

144

0.7 (0.1)

0.6 (0.4)

42.32%

57.68%

100%

0.11[-0.37,0.59]

0.63[0.36,0.9]

0.41[-0.09,0.91]

Heterogeneity: Tau2=0.09; Chi2=3.4, df=1(P=0.07); I2=70.62%

Test for overall effect: Z=1.59(P=0.11)

13.45.3 Combined aerobic and resistance exercise

Kim 2015

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.14(P=0.26)

13.45.4 Yoga, Tai Chi, and Pilates

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

20

20

0

0.8 (0.1)

19

19

0

0.8 (0.1)

100%

100%

-0.37[-1,0.27]

-0.37[-1,0.27]

Not estimable

Favours control

-2

-1

0

1

2

Favours physical activity

Analysis 13.46.   Comparison 13 Subanalysis: outcomes by mode of physical activity
intervention, Outcome 46 Bone mineral density - lumbar spine (follow-up and change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.46.1 Aerobic exercise

Saarto 2012

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.95(P=0.34)

13.46.2 Resistance exercise

Winters-Stone 2011

Waltman 2010

Subtotal ***

239

239

-0 (0)

218

218

-0 (0)

100%

100%

0.09[-0.09,0.27]

0.09[-0.09,0.27]

36

110

146

1 (0.2)

3.1 (0.4)

31

113

144

1 (0.1)

2.9 (0.4)

23.46%

76.54%

100%

0.3[-0.19,0.78]

0.55[0.28,0.81]

0.49[0.25,0.72]

Heterogeneity: Tau2=0; Chi2=0.78, df=1(P=0.38); I2=0%

Test for overall effect: Z=4.08(P<0.0001)

13.46.3 Combined aerobic and resistance exercise

Kim 2015

Subtotal ***

Heterogeneity: Not applicable

20

20

1 (0.1)

19

19

1 (0.1)

100%

100%

-0.26[-0.89,0.37]

-0.26[-0.89,0.37]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

442

Favours control

-2

-1

0

1

2

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for overall effect: Z=0.81(P=0.42)

13.46.4 Yoga, Tai Chi, and Pilates

Subtotal ***

0

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Not estimable

Favours control

-2

-1

0

1

2

Favours physical activity

Analysis 13.47.   Comparison 13 Subanalysis: outcomes by mode of physical activity
intervention, Outcome 47 Bone mineral density - total hip (follow-up and change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

13.47.1 Aerobic exercise

Subtotal ***

0

0

Not estimable

Heterogeneity: Not applicable

Test for overall effect: Not applicable

13.47.2 Resistance exercise

Winters-Stone 2011

Waltman 2010

Subtotal ***

36

110

146

0.9 (0.1)

2.2 (0.3)

31

113

144

0.8 (0.1)

1.8 (0.4)

47.32%

52.68%

100%

0.19[-0.29,0.67]

1.05[0.77,1.33]

0.64[-0.2,1.48]

Heterogeneity: Tau2=0.33; Chi2=9.19, df=1(P=0); I2=89.12%

Test for overall effect: Z=1.49(P=0.14)

13.47.3 Combined aerobic and resistance exercise

Kim 2015

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=8.11(P<0.0001)

13.47.4 Yoga, Tai Chi, and Pilates

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

20

20

0

0.9 (0.1)

19

19

0

0.1 (0.1)

100%

100%

10.34[7.84,12.84]

10.34[7.84,12.84]

Not estimable

Favours control

-2

-1

0

1

2

Favours physical activity

Comparison 14.   Subanalysis: outcomes by intensity of physical activity intervention

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Overall HRQoL (follow-up
values)

1.1 Light-to-moderate intensi-
ty

22

16

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

983

Std. Mean Difference (IV, Random,
95% CI)

0.51 [0.25, 0.77]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

443

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.2 Moderate-to-high intensity

6

820

2 Overall HRQoL (change val-
ues)

2.1 Light-to-moderate intensi-
ty

14

10

2.2 Moderate-to-high intensity

4

3 Overall emotional func-
tion/mental health (follow-up
values)

3.1 Light-to-moderate intensi-
ty

26

21

3.2 Moderate-to-high intensity

5

4 Overall emotional func-
tion/mental health (change
values)

4.1 Light-to-moderate intensi-
ty

15

10

4.2 Moderate-to-high intensity

5

5 Overall physical function
(follow-up values)

5.1 Light-to-moderate intensi-
ty

25

20

5.2 Moderate-to-high intensity

5

6 Overall physical function
(change values)

6.1 Light-to-moderate intensi-
ty

6.2 Moderate-to-high intensity

7 Overall role function (fol-
low-up values)

7.1 Light-to-moderate intensi-
ty

13

8

5

18

14

534

925

1489

613

592

987

1466

663

449

984

883

Std. Mean Difference (IV, Random,
95% CI)

0.19 [-0.05, 0.43]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.99 [0.39, 1.60]

Std. Mean Difference (IV, Random,
95% CI)

0.28 [-0.11, 0.67]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.19 [0.08, 0.30]

Std. Mean Difference (IV, Random,
95% CI)

0.29 [-0.07, 0.65]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.41 [0.04, 0.77]

Std. Mean Difference (IV, Random,
95% CI)

0.07 [-0.07, 0.21]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.38 [0.19, 0.58]

Std. Mean Difference (IV, Random,
95% CI)

0.14 [-0.02, 0.30]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.81 [0.11, 1.51]

Std. Mean Difference (IV, Random,
95% CI)

0.28 [-0.06, 0.62]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.36 [0.08, 0.64]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

444

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

7.2 Moderate-to-high intensity

4

487

Std. Mean Difference (IV, Random,
95% CI)

0.11 [-0.13, 0.35]

8 Overall role function (change
values)

12

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

8.1 Light-to-moderate intensi-
ty

8.2 Moderate-to-high intensity

9 Overall social well-be-
ing/function (follow-up values)

9.1 Light-to-moderate intensi-
ty

7

5

18

15

9.2 Moderate-to-high intensity

3

10 Overall social well-be-
ing/function (change values)

12

10.1 Light-to-moderate inten-
sity

10.2 Moderate-to-high intensi-
ty

11 Overall cognitive function
(follow-up values)

11.1 Light-to-moderate inten-
sity

11.2 Moderate-to-high intensi-
ty

12 Overall cognitive function
(change values)

12.1 Light-to-moderate inten-
sity

12.2 Moderate-to-high intensi-
ty

13 Overall general health (fol-
low-up values)

13.1 Light-to-moderate inten-
sity

8

4

5

4

1

5

3

2

10

6

328

987

1132

425

413

971

173

16

156

516

304

Std. Mean Difference (IV, Random,
95% CI)

0.18 [-0.19, 0.56]

Std. Mean Difference (IV, Random,
95% CI)

0.06 [-0.09, 0.21]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.23 [0.10, 0.36]

Std. Mean Difference (IV, Random,
95% CI)

0.05 [-0.16, 0.26]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.63 [0.21, 1.04]

Std. Mean Difference (IV, Random,
95% CI)

0.33 [-0.33, 0.98]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.43 [0.11, 0.74]

Std. Mean Difference (IV, Random,
95% CI)

0.16 [-0.82, 1.14]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.17 [-0.21, 0.55]

Std. Mean Difference (IV, Random,
95% CI)

-0.17 [-0.35, 0.00]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.17 [-0.14, 0.48]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

445

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

13.2 Moderate-to-high intensi-
ty

14 Overall general health
(change values)

14.1 Light-to-moderate inten-
sity

14.2 Moderate-to-high intensi-
ty

15 Overall sexual function (fol-
low-up values)

15.1 Light-to-moderate inten-
sity

15.2 Moderate-to-high intensi-
ty

16 Overall sexual function
(change values)

16.1 Light-to-moderate inten-
sity

16.2 Moderate-to-high intensi-
ty

17 Overall anxiety (follow-up
values)

17.1 Light-to-moderate inten-
sity

17.2 Moderate-to-high intensi-
ty

18 Overall anxiety (change val-
ues)

18.1 Light-to-moderate inten-
sity

18.2 Moderate-to-high intensi-
ty

4

9

5

4

5

4

1

3

2

1

7

5

2

4

3

1

19 Overall depression (fol-
low-up values)

19.1 Light-to-moderate inten-
sity

12

9

184

254

652

293

118

193

500

237

89

161

74

542

Std. Mean Difference (IV, Random,
95% CI)

0.30 [-0.35, 0.95]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.23 [-0.02, 0.48]

Std. Mean Difference (IV, Random,
95% CI)

0.20 [-0.24, 0.64]

Std. Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Fixed, 95%
CI)

0.22 [-0.01, 0.45]

Std. Mean Difference (IV, Fixed, 95%
CI)

0.01 [-0.35, 0.38]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

3.83 [-1.83, 9.48]

Mean Difference (IV, Random, 95% CI)

0.5 [-3.86, 4.86]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.56 [-0.88,
-0.25]

Std. Mean Difference (IV, Random,
95% CI)

-1.20 [-3.49, 1.09]

Std. Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Fixed, 95%
CI)

-0.48 [-0.79,
-0.16]

Std. Mean Difference (IV, Fixed, 95%
CI)

-0.15 [-0.61, 0.30]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.24 [-0.53, 0.06]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

446

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

19.2 Moderate-to-high intensi-
ty

20 Overall depression (change
values)

20.1 Light-to-moderate inten-
sity

20.2 Moderate-to-high intensi-
ty

21 Overall fatigue (follow-up
values)

21.1 Light-to-moderate inten-
sity

21.2 Moderate-to-high intensi-
ty

22 Overall fatigue (change val-
ues)

22.1 Light-to-moderate inten-
sity

22.2 Moderate-to-high intensi-
ty

23 Overall pain/disability (fol-
low-up values)

23.1 Light-to-moderate inten-
sity

23.2 Moderate-to-high intensi-
ty

24 Overall pain/disability
(change values)

24.1 Light-to-moderate inten-
sity

24.2 Moderate-to-high intensi-
ty

25 Overall self-esteem/body
image (follow-up values)

25.1 Light-to-moderate inten-
sity

3

6

4

2

25

21

4

12

9

3

9

5

4

5

2

3

12

8

115

182

574

1155

770

420

851

189

346

77

219

474

Std. Mean Difference (IV, Random,
95% CI)

-0.92 [-1.95, 0.11]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.60 [-0.89,
-0.30]

Std. Mean Difference (IV, Random,
95% CI)

0.00 [-0.21, 0.22]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.38 [-0.56,
-0.19]

Std. Mean Difference (IV, Random,
95% CI)

-0.13 [-0.28, 0.03]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.36 [-0.84, 0.11]

Std. Mean Difference (IV, Random,
95% CI)

0.05 [-0.14, 0.24]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.13 [-0.25, 0.50]

Std. Mean Difference (IV, Random,
95% CI)

0.03 [-0.18, 0.24]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.12 [-0.33, 0.56]

Std. Mean Difference (IV, Random,
95% CI)

-0.15 [-0.47, 0.16]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.35 [0.14, 0.55]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

447

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

25.2 Moderate-to-high intensi-
ty

26 Overall self-esteem/body
image (change values)

26.1 Light-to-moderate inten-
sity

26.2 Moderate-to-high intensi-
ty

27 Overall cardiorespiratory
fitness (follow-up values)

27.1 Light-to-moderate inten-
sity

27.2 Moderate-to-high intensi-
ty

28 Overall cardiorespiratory
fitness (change values)

28.1 Light-to-moderate inten-
sity

28.2 Moderate-to-high intensi-
ty

29 Overall self-reported physi-
cal activity (follow-up values)

29.1 Light-to-moderate inten-
sity

29.2 Moderate-to-high intensi-
ty

30 Overall self-reported physi-
cal activity (change values)

30.1 Light-to-moderate inten-
sity

30.2 Moderate-to-high intensi-
ty

31 Overall objective physical
activity (follow-up values)

31.1 Light-to-moderate inten-
sity

4

9

6

3

23

16

7

9

6

4

17

11

6

8

4

4

12

9

193

376

616

975

290

228

645

1112

893

249

1025

574

Std. Mean Difference (IV, Random,
95% CI)

0.06 [-0.45, 0.56]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.52 [-0.09, 1.13]

Std. Mean Difference (IV, Random,
95% CI)

-0.05 [-0.21, 0.10]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.43 [0.27, 0.59]

Std. Mean Difference (IV, Random,
95% CI)

0.46 [0.13, 0.80]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

1.18 [0.60, 1.77]

Std. Mean Difference (IV, Random,
95% CI)

0.57 [0.01, 1.14]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.47 [0.23, 0.72]

Std. Mean Difference (IV, Random,
95% CI)

0.65 [0.27, 1.03]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.79 [0.15, 1.44]

Std. Mean Difference (IV, Random,
95% CI)

0.46 [0.07, 0.85]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.58 [0.29, 0.87]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

448

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

31.2 Moderate-to-high intensi-
ty

32 Overall objective physical
activity (change values)

32.1 Light-to-moderate inten-
sity

32.2 Moderate-to-high intensi-
ty

33 Mass (follow-up values)

33.1 Light-to-moderate inten-
sity

33.2 Moderate-to-high intensi-
ty

34 Mass (change values)

34.1 Light-to-moderate inten-
sity

34.2 Moderate-to-high intensi-
ty

35 BMI (follow-up values)

35.1 Light-to-moderate inten-
sity

35.2 Moderate-to-high intensi-
ty

36 BMI (change values)

36.1 Light-to-moderate inten-
sity

36.2 Moderate-to-high intensi-
ty

37 Overall body fat (follow-up
values)

37.1 Light-to-moderate inten-
sity

37.2 Moderate-to-high intensi-
ty

38 Overall body fat (change
values)

3

5

3

2

16

12

4

11

8

4

17

12

5

8

7

1

18

13

5

9

735

103

405

1015

195

418

639

930

551

403

82

886

276

Std. Mean Difference (IV, Random,
95% CI)

0.12 [-0.03, 0.28]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

1.05 [0.62, 1.47]

Std. Mean Difference (IV, Random,
95% CI)

0.32 [-0.45, 1.09]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

0.03 [-0.56, 0.61]

Mean Difference (IV, Fixed, 95% CI)

-1.34 [-5.66, 2.98]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-0.58 [-1.21, 0.05]

Mean Difference (IV, Random, 95% CI)

-0.97 [-2.18, 0.24]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

0.03 [-0.18, 0.24]

Mean Difference (IV, Fixed, 95% CI)

-0.35 [-1.40, 0.69]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-0.23 [-0.50, 0.05]

Mean Difference (IV, Random, 95% CI)

-0.2 [-0.57, 0.17]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.24 [-0.44,
-0.04]

Std. Mean Difference (IV, Random,
95% CI)

-0.03 [-0.27, 0.21]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

449

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

38.1 Light-to-moderate inten-
sity

38.2 Moderate-to-high intensi-
ty

39 Lower body strength (fol-
low-up values)

39.1 Light-to-moderate inten-
sity

39.2 Moderate-to-high intensi-
ty

40 Lower body strength
(change values)

40.1 Light-to-moderate inten-
sity

40.2 Moderate-to-high intensi-
ty

7

2

10

7

3

8

5

4

41 Upper body strength (fol-
low-up values)

13

41.1 Light-to-moderate inten-
sity

41.2 Moderate-to-high intensi-
ty

42 Upper body strength
(change values)

42.1 Light-to-moderate inten-
sity

42.2 Moderate-to-high intensi-
ty

43 Bone mineral density -
femoral neck (follow-up and
change values)

43.1 Light-to-moderate inten-
sity

43.2 Moderate-to-high intensi-
ty

44 Bone mineral density -
lumbar spine (follow-up and
change values)

7

6

8

3

5

4

2

2

4

375

124

480

157

331

399

481

287

360

472

106

680

Std. Mean Difference (IV, Random,
95% CI)

-0.68 [-1.44, 0.09]

Std. Mean Difference (IV, Random,
95% CI)

-0.39 [-0.76,
-0.02]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.69 [0.34, 1.04]

Std. Mean Difference (IV, Random,
95% CI)

-0.10 [-0.42, 0.21]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.87 [0.64, 1.09]

Std. Mean Difference (IV, Random,
95% CI)

0.62 [0.07, 1.17]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.43 [-0.11, 0.96]

Std. Mean Difference (IV, Random,
95% CI)

0.41 [-0.05, 0.87]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

1.32 [0.47, 2.16]

Std. Mean Difference (IV, Random,
95% CI)

0.37 [-0.05, 0.79]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.08 [-0.54, 0.37]

Std. Mean Difference (IV, Random,
95% CI)

0.39 [-0.04, 0.83]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

450

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

44.1 Light-to-moderate inten-
sity

44.2 Moderate-to-high intensi-
ty

45 Bone mineral density - total
hip (follow-up and change val-
ues)

45.1 Light-to-moderate inten-
sity

45.2 Moderate-to-high intensi-
ty

2

2

3

2

1

106

680

106

223

Std. Mean Difference (IV, Random,
95% CI)

0.06 [-0.48, 0.60]

Std. Mean Difference (IV, Random,
95% CI)

0.31 [-0.14, 0.75]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

5.19 [-4.76,
15.14]

Std. Mean Difference (IV, Random,
95% CI)

1.05 [0.77, 1.33]

Analysis 14.1.   Comparison 14 Subanalysis: outcomes by intensity of
physical activity intervention, Outcome 1 Overall HRQoL (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.1.1 Light-to-moderate intensity

Cerulli 2014

Rogers 2015

Mustian 2004

Loudon 2014

Milne 2008

Rogers 2009

Courneya 2003

Ergun 2013

Murtezani 2014

Mehnert 2011

Pinto 2015

Schmitz 2005

Taleghani 2012

Loh 2014

Daley 2007

Littman 2012

Subtotal ***

85.2 (4.2)

85.2 (4.2)

121.7 (22.7)

-7.4 (1.2)

86.4 (8.3)

92 (11.4)

91.3 (11)

71.6 (19.9)

86.5 (7.3)

74.7 (21.7)

117.8 (12.7)

-44.2 (8.7)

217.5 (36.3)

112.4 (14.1)

90.9 (13.5)

90.3 (11)

10

10

11

12

29

20

24

40

30

30

39

39

40

63

33

30

460

65.9 (14.7)

65.9 (14.7)

124.3 (25.9)

-7.4 (1.4)

64.1 (10.8)

87.4 (13.1)

89.3 (10.9)

67.9 (16.7)

79.1 (7.5)

65.4 (16.8)

114 (18)

-47.4 (9.4)

210.1 (41.5)

109.3 (13.3)

86.4 (15.1)

87.7 (15)

10

10

10

11

29

18

28

20

32

27

37

40

40

32

69

110

523

Heterogeneity: Tau2=0.2; Chi2=53.65, df=15(P<0.0001); I2=72.04%

Test for overall effect: Z=3.8(P=0)

14.1.2 Moderate-to-high intensity

Herrero 2006

Portela 2008

Do 2015

Cadmus 2009

Vallance 2007

Short 2014

8

25

32

37

250

195

81.3 (10.7)

107.2 (28.5)

87.3 (13.7)

91.2 (12.6)

91.5 (11.8)

8

9

30

37

85

62.5 (16.1)

91.6 (28.5)

82.4 (19.9)

86.2 (17.4)

90.6 (13)

106.8 (16.7)

104

108.2 (18.2)

3.71%

3.71%

4.68%

4.89%

5.78%

5.97%

6.62%

6.68%

6.73%

6.75%

7.27%

7.32%

7.36%

7.44%

7.51%

7.59%

100%

4.15%

7.7%

14.56%

16.23%

28.39%

28.96%

1.72[0.66,2.78]

1.72[0.66,2.78]

-0.1[-0.96,0.75]

0.02[-0.8,0.84]

2.28[1.61,2.96]

0.37[-0.27,1.01]

0.18[-0.37,0.73]

0.19[-0.35,0.73]

0.99[0.46,1.52]

0.47[-0.06,1]

0.24[-0.21,0.69]

0.35[-0.09,0.79]

0.19[-0.25,0.63]

0.22[-0.2,0.65]

0.3[-0.12,0.72]

0.18[-0.22,0.59]

0.51[0.25,0.77]

1.3[0.19,2.41]

0.53[-0.24,1.31]

0.28[-0.22,0.79]

0.33[-0.13,0.78]

0.08[-0.16,0.33]

-0.08[-0.32,0.16]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

451

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Subtotal ***

Mean(SD)

N

547

N

273

Heterogeneity: Tau2=0.04; Chi2=9.41, df=5(P=0.09); I2=46.85%

Test for overall effect: Z=1.56(P=0.12)

Mean(SD)

Random, 95% CI

Random, 95% CI

100%

0.19[-0.05,0.43]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 14.2.   Comparison 14 Subanalysis: outcomes by intensity of
physical activity intervention, Outcome 2 Overall HRQoL (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.2.1 Light-to-moderate intensity

Mustian 2004

Murtezani 2014

Naumann 2012

Rogers 2009

Cuesta-Vargas 2014

Courneya 2003

Ergun 2013

Mehnert 2011

Schmitz 2005

Daley 2007

Subtotal ***

11

30

11

20

22

24

40

30

39

33

15 (5)

9.2 (2.1)

14.5 (10.6)

4.5 (8.4)

0.3 (0.2)

5.7 (7.4)

5.4 (21.5)

9.7 (21)

2.3 (4.5)

10.2 (11.2)

10

32

10

18

20

28

20

27

40

69

0 (5)

-0.6 (2)

3.1 (11.4)

2.9 (12)

0.3 (0.1)

0.6 (7.4)

-6.7 (25.9)

5.6 (16.5)

0.6 (4)

3.2 (11.3)

260

274

Heterogeneity: Tau2=0.82; Chi2=87.64, df=9(P<0.0001); I2=89.73%

Test for overall effect: Z=3.22(P=0)

14.2.2 Moderate-to-high intensity

Herrero 2006

Cadmus 2009

Vallance 2007

Saarto 2012

Subtotal ***

8

37

250

263

558

17.7 (8.3)

0.6 (7.5)

2.3 (11.1)

4.2 (16.2)

-10.4 (17.7)

-2.4 (9.8)

-0.2 (6.4)

5.6 (15.4)

8

37

85

237

367

Heterogeneity: Tau2=0.1; Chi2=14.84, df=3(P=0); I2=79.79%

Test for overall effect: Z=1.42(P=0.16)

7.58%

8.88%

9.14%

10.28%

10.39%

10.55%

10.6%

10.68%

10.92%

10.98%

100%

7.75%

24.67%

32.66%

34.92%

100%

2.88[1.59,4.17]

4.65[3.67,5.63]

1[0.08,1.92]

0.15[-0.49,0.79]

-0.07[-0.67,0.54]

0.68[0.12,1.24]

0.52[-0.03,1.06]

0.22[-0.31,0.74]

0.4[-0.05,0.84]

0.62[0.2,1.04]

0.99[0.39,1.6]

1.92[0.68,3.17]

0.34[-0.12,0.8]

0.24[-0,0.49]

-0.09[-0.26,0.09]

0.28[-0.11,0.67]

Favours control

-10

-5

0

5

10

Favours physical activity

Analysis 14.3.   Comparison 14 Subanalysis: outcomes by intensity of physical activity
intervention, Outcome 3 Overall emotional function/mental health (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.3.1 Light-to-moderate intensity

Banasik 2011

Mustian 2004

Pinto 2003

Loudon 2014

Rogers 2009

Cuesta-Vargas 2014

7

9

12

12

20

22

0.5 (0.4)

24.8 (2)

-10.8 (28.1)

-1.6 (0.7)

20 (3.1)

42.9 (19.2)

7

10

12

11

18

20

0.4 (0.3)

24.8 (3.2)

-27.2 (19.5)

-1.6 (0.5)

21.1 (2.9)

32.3 (33.3)

1.04%

1.41%

1.67%

1.7%

2.72%

2.99%

0.25[-0.8,1.3]

-0.01[-0.91,0.89]

0.65[-0.17,1.48]

0.05[-0.77,0.87]

-0.36[-1,0.28]

0.39[-0.22,1]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

452

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Basen-Enquist 2006

Courneya 2003

Milne 2008

Littman 2012

Mehnert 2011

Cantarero-Villanueva 2013

Murtezani 2014

Daley 2007

Pinto 2015

Schmitz 2005

Pinto 2005

Loh 2014

Fillion 2008

Rogers 2015

Schmitz 2009

Subtotal ***

78.2 (10.6)

21.5 (3.4)

19.6 (2.4)

20.3 (4)

77 (35.8)

-17175
(4279)

19.5 (3.3)

19.1 (4.2)

54.2 (9.3)

-45.6 (8.2)

-8 (20.7)

19.9 (2.8)

48.5 (7.9)

20.6 (2.9)

53.2 (9.6)

28

24

29

30

30

32

30

33

39

39

39

63

44

105

112

759

Heterogeneity: Tau2=0; Chi2=21.35, df=20(P=0.38); I2=6.34%

Test for overall effect: Z=3.49(P=0)

14.3.2 Moderate-to-high intensity

Herrero 2006

Do 2015

Cadmus 2009

Duijits 2012

Vallance 2007

Subtotal ***

90.6 (9.3)

87.4 (8.8)

20.5 (3)

73.9 (34.7)

20.3 (3.3)

8

32

37

37

250

364

Heterogeneity: Tau2=0.11; Chi2=12.84, df=4(P=0.01); I2=68.84%

Test for overall effect: Z=1.58(P=0.11)

77.2 (12)

20.7 (3)

16.7 (4.1)

20.8 (3.1)

69.1 (40.5)

-20390
(6113)

18.3 (3.5)

18.5 (3.3)

52.5 (9.6)

-48.2 (8.2)

-16.5 (28.8)

20 (3.2)

47.5 (9.1)

19.7 (3.2)

53.8 (8.7)

83.3 (14.8)

70.4 (21.5)

19.8 (4.2)

77.5 (34.3)

19.9 (3.4)

23

28

29

27

28

29

32

33

37

40

43

32

43

108

120

730

8

30

37

89

85

249

3.64%

3.7%

3.81%

4.07%

4.13%

4.16%

4.36%

4.68%

5.33%

5.49%

5.66%

5.93%

6.06%

13.19%

14.26%

100%

9.14%

18.76%

21.04%

23.37%

27.7%

100%

0.09[-0.46,0.64]

0.25[-0.3,0.79]

0.85[0.31,1.39]

-0.14[-0.66,0.38]

0.21[-0.31,0.72]

0.61[0.09,1.12]

0.35[-0.15,0.85]

0.16[-0.32,0.64]

0.18[-0.27,0.63]

0.31[-0.13,0.76]

0.33[-0.1,0.77]

-0.04[-0.46,0.39]

0.12[-0.3,0.54]

0.29[0.02,0.56]

-0.07[-0.32,0.19]

0.19[0.08,0.3]

0.56[-0.45,1.56]

1.03[0.5,1.57]

0.19[-0.27,0.65]

-0.1[-0.49,0.28]

0.11[-0.14,0.35]

0.29[-0.07,0.65]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 14.4.   Comparison 14 Subanalysis: outcomes by intensity of physical activity
intervention, Outcome 4 Overall emotional function/mental health (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.4.1 Light-to-moderate intensity

Mustian 2004

Naumann 2012

Rogers 2009

Murtezani 2014

Courneya 2003

Mehnert 2011

Cantarero-Villanueva 2013

Schmitz 2005

Pinto 2005

Schmitz 2009

Subtotal ***

9

11

20

30

24

30

32

39

39

58

2.4 (2.5)

1 (2.7)

0.9 (2.5)

2.1 (0.8)

2.3 (3.1)

2.3 (35.5)

-1445
(4452)

2.5 (4.4)

-3.8 (27.7)

3.3 (23.2)

10

10

18

32

28

28

29

40

43

62

0.1 (1.7)

-0.1 (2.7)

-0.1 (2.7)

0.5 (0.9)

0.8 (2.9)

3.6 (17.6)

353 (3323)

0.3 (3.9)

-11.5 (25.8)

3.1 (17.2)

292

300

Heterogeneity: Tau2=0.26; Chi2=40.71, df=9(P<0.0001); I2=77.89%

6.87%

7.67%

9.51%

9.92%

10.29%

10.63%

10.68%

11.19%

11.31%

11.93%

100%

1.06[0.08,2.03]

0.39[-0.48,1.26]

0.38[-0.27,1.02]

1.8[1.21,2.4]

0.49[-0.06,1.05]

-0.04[-0.56,0.47]

-0.45[-0.96,0.06]

0.52[0.08,0.97]

0.28[-0.15,0.72]

0.01[-0.35,0.37]

0.41[0.04,0.77]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

453

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for overall effect: Z=2.18(P=0.03)

14.4.2 Moderate-to-high intensity

Herrero 2006

Cormie 2014

Cadmus 2009

Vallance 2007

Saarto 2012

Subtotal ***

8

43

37

250

263

601

9.3 (19.6)

4.4 (9)

0.3 (2.2)

0.5 (3.5)

1.2 (17.8)

8

19

37

85

237

386

-2.1 (5.9)

2.7 (8.6)

-0.5 (3.3)

0.1 (2.5)

1.9 (18.5)

Heterogeneity: Tau2=0; Chi2=4.26, df=4(P=0.37); I2=6.14%

Test for overall effect: Z=0.93(P=0.35)

1.91%

6.71%

9.27%

29.56%

52.54%

100%

0.74[-0.28,1.77]

0.19[-0.35,0.73]

0.28[-0.18,0.74]

0.12[-0.13,0.36]

-0.04[-0.21,0.14]

0.07[-0.07,0.21]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 14.5.   Comparison 14 Subanalysis: outcomes by intensity of physical
activity intervention, Outcome 5 Overall physical function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.5.1 Light-to-moderate intensity

Banasik 2011

Mustian 2004

Pinto 2003

Milne 2008

Rogers 2009

Cuesta-Vargas 2014

Basen-Enquist 2006

Courneya 2003

Mehnert 2011

Littman 2012

Murtezani 2014

Winters-Stone 2011

Daley 2007

Schmitz 2005

Pinto 2015

Pinto 2005

Loh 2014

Fillion 2008

Rogers 2015

Schmitz 2009

Subtotal ***

-0.8 (0.9)

26.9 (4.1)

32.3 (4.3)

24 (2.6)

23.3 (4.5)

42.9 (4.1)

82.5 (12.7)

25.3 (2.5)

89 (9.1)

25.4 (1.7)

22.6 (4.4)

51.7 (6.2)

25.6 (2.2)

-44.2 (5.6)

87.1 (4.4)

30.3 (7.9)

24.9 (2.5)

45.1 (10.4)

24.1 (3.5)

50.6 (8.2)

7

9

12

29

20

22

28

24

30

30

30

36

33

39

39

39

63

44

105

112

751

-0.4 (0.3)

26.5 (4.1)

25.3 (8.2)

15.6 (4.5)

25.4 (2.3)

32.4 (32.5)

77.4 (11.5)

25.3 (2.8)

78.1 (21.2)

24.3 (4.4)

19.4 (4.4)

52.3 (5.9)

23.6 (5.7)

-48.3 (7.7)

84.7 (15.9)

27.3 (6.8)

24.2 (2.2)

41.8 (9.8)

22.5 (5)

49.1 (9.3)

7

10

12

29

18

20

23

28

28

27

32

25

33

40

37

43

32

43

108

120

715

Heterogeneity: Tau2=0.11; Chi2=55.68, df=19(P<0.0001); I2=65.88%

Test for overall effect: Z=3.95(P<0.0001)

14.5.2 Moderate-to-high intensity

Herrero 2006

Do 2015

Cadmus 2009

Duijits 2012

Vallance 2007

8

32

37

87

94.1 (7.5)

89.4 (8.4)

25.1 (2.7)

84 (16.9)

250

25.1 (3)

8

30

37

89

85

92.5 (6.6)

89 (8.7)

24 (4.1)

80.2 (17.1)

25 (3.3)

2.3%

2.91%

3.08%

4.12%

4.22%

4.46%

4.86%

4.95%

5.06%

5.11%

5.17%

5.21%

5.37%

5.67%

5.67%

5.78%

5.86%

5.89%

7.11%

7.21%

100%

2.74%

10.69%

12.61%

30.18%

43.78%

-0.48[-1.54,0.59]

0.09[-0.81,0.99]

1.03[0.17,1.89]

2.26[1.59,2.92]

-0.57[-1.22,0.08]

0.46[-0.16,1.07]

0.41[-0.15,0.97]

0[-0.55,0.55]

0.66[0.13,1.19]

0.33[-0.19,0.86]

0.72[0.2,1.23]

-0.1[-0.61,0.41]

0.46[-0.03,0.95]

0.6[0.15,1.05]

0.21[-0.25,0.66]

0.4[-0.04,0.83]

0.3[-0.12,0.73]

0.33[-0.1,0.75]

0.37[0.1,0.64]

0.17[-0.09,0.43]

0.38[0.19,0.58]

0.21[-0.77,1.2]

0.05[-0.45,0.54]

0.31[-0.15,0.77]

0.23[-0.07,0.52]

0.05[-0.2,0.3]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

454

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Subtotal ***

Mean(SD)

N

414

N

249

Heterogeneity: Tau2=0; Chi2=1.55, df=4(P=0.82); I2=0%

Test for overall effect: Z=1.69(P=0.09)

Mean(SD)

Random, 95% CI

Random, 95% CI

100%

0.14[-0.02,0.3]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 14.6.   Comparison 14 Subanalysis: outcomes by intensity of physical
activity intervention, Outcome 6 Overall physical function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.6.1 Light-to-moderate intensity

Mustian 2004

Murtezani 2014

Naumann 2012

Rogers 2009

Courneya 2003

Mehnert 2011

Schmitz 2005

Schmitz 2009

Subtotal ***

1.9 (2.6)

4.4 (1.5)

1.9 (3.3)

2.3 (5.1)

1.9 (2)

4 (10.8)

1.2 (4.2)

6.6 (17.1)

9

30

11

20

24

30

39

58

221

Heterogeneity: Tau2=0.9; Chi2=79.79, df=7(P<0.0001); I2=91.23%

Test for overall effect: Z=2.27(P=0.02)

14.6.2 Moderate-to-high intensity

Herrero 2006

Cormie 2014

Cadmus 2009

Vallance 2007

Saarto 2012

Subtotal ***

6.7 (5)

3.5 (5.2)

0.1 (6)

1 (3.3)

1.9 (13.7)

8

43

37

247

263

598

Heterogeneity: Tau2=0.1; Chi2=16.88, df=4(P=0); I2=76.3%

Test for overall effect: Z=1.6(P=0.11)

-0.2 (1.6)

-1.3 (1.2)

0.8 (3.4)

2.6 (6)

-0.2 (2.2)

-2.1 (16.7)

1.5 (6.8)

4.1 (17.3)

-1.7 (6.9)

-0.5 (5.7)

-0.5 (7.4)

0.2 (2.1)

3.4 (13.4)

10

32

10

18

28

28

40

62

228

8

19

37

85

237

386

11.18%

11.4%

11.65%

12.67%

12.91%

13.13%

13.4%

13.65%

100%

7.27%

17.09%

20.07%

26.79%

28.78%

100%

0.93[-0.03,1.89]

4.23[3.31,5.15]

0.32[-0.55,1.18]

-0.05[-0.69,0.58]

0.98[0.4,1.56]

0.43[-0.09,0.95]

-0.05[-0.49,0.39]

0.14[-0.21,0.5]

0.81[0.11,1.51]

1.32[0.21,2.43]

0.74[0.19,1.3]

0.09[-0.37,0.54]

0.26[0.02,0.51]

-0.11[-0.29,0.06]

0.28[-0.06,0.62]

Favours control

-10

-5

0

5

10

Favours physical activity

Analysis 14.7.   Comparison 14 Subanalysis: outcomes by intensity of physical
activity intervention, Outcome 7 Overall role function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.7.1 Light-to-moderate intensity

Banasik 2011

Mustian 2004

Loudon 2014

Milne 2008

Rogers 2009

Basen-Enquist 2006

Courneya 2003

7

9

12

29

20

28

24

3.5 (0.6)

2.4 (1.5)

-1.3 (0.3)

22.2 (3)

21.4 (4.8)

86.1 (22.2)

23.4 (4)

7

9

11

29

18

23

28

3.2 (0.6)

2.8 (1.5)

-1.3 (0.4)

12.5 (4.8)

23.8 (3.2)

73 (24.5)

23.1 (4)

4.16%

4.84%

5.5%

6.43%

6.68%

7.36%

7.5%

0.34[-0.72,1.4]

-0.23[-1.15,0.7]

0[-0.82,0.82]

2.39[1.71,3.08]

-0.57[-1.22,0.08]

0.55[-0.01,1.12]

0.07[-0.47,0.62]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

455

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Mehnert 2011

Littman 2012

Murtezani 2014

Daley 2007

Schmitz 2005

Loh 2014

Rogers 2015

Subtotal ***

90 (20.3)

22.6 (3.9)

24.2 (2.8)

22.9 (4.5)

-49.2 (6.5)

23.4 (4.3)

22.3 (4.5)

30

30

30

33

39

63

105

459

27

27

32

33

40

32

108

424

79.6 (25)

21.7 (4.7)

23 (2.5)

20.3 (5.6)

-50 (6.2)

22.2 (5)

20.3 (5.5)

Heterogeneity: Tau2=0.19; Chi2=47.79, df=13(P<0.0001); I2=72.8%

Test for overall effect: Z=2.55(P=0.01)

14.7.2 Moderate-to-high intensity

Herrero 2006

Do 2015

Cadmus 2009

Vallance 2007

Subtotal ***

97.6 (5.9)

78.1 (19.5)

23.1 (4.7)

23.2 (4)

8

32

37

250

327

8

30

37

85

160

100 (0)

79.2 (14.6)

20.6 (7.2)

22.7 (4.6)

Heterogeneity: Tau2=0.01; Chi2=3.69, df=3(P=0.3); I2=18.64%

Test for overall effect: Z=0.92(P=0.36)

7.65%

7.7%

7.83%

7.94%

8.34%

8.45%

9.6%

100%

5.45%

19.43%

22.12%

53%

100%

0.45[-0.07,0.98]

0.21[-0.31,0.73]

0.45[-0.06,0.95]

0.5[0.01,0.99]

0.12[-0.32,0.57]

0.25[-0.18,0.68]

0.4[0.12,0.67]

0.36[0.08,0.64]

-0.54[-1.55,0.46]

-0.06[-0.56,0.44]

0.41[-0.05,0.87]

0.12[-0.13,0.37]

0.11[-0.13,0.35]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 14.8.   Comparison 14 Subanalysis: outcomes by intensity of physical
activity intervention, Outcome 8 Overall role function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.8.1 Light-to-moderate intensity

Mustian 2004

Naumann 2012

Rogers 2009

Courneya 2003

Murtezani 2014

Mehnert 2011

Schmitz 2005

Subtotal ***

0.6 (1.6)

1.5 (4.4)

0.4 (3.3)

0.9 (2.8)

1.7 (0.7)

6.7 (23.8)

1.2 (4.2)

9

11

20

24

30

30

39

163

Heterogeneity: Tau2=0.15; Chi2=16.15, df=6(P=0.01); I2=62.85%

Test for overall effect: Z=0.95(P=0.34)

14.8.2 Moderate-to-high intensity

Herrero 2006

Cormie 2014

Cadmus 2009

Vallance 2007

Saarto 2012

Subtotal ***

2.1 (13.9)

4.9 (7.1)

-0.3 (3.7)

0.6 (4.1)

2.4 (21.5)

8

43

37

250

263

601

Heterogeneity: Tau2=0; Chi2=4.51, df=4(P=0.34); I2=11.35%

Test for overall effect: Z=0.73(P=0.47)

0.8 (1.6)

0.5 (4.5)

1.4 (4.3)

0.4 (2.7)

0.9 (0.6)

5.6 (27)

1.5 (6.8)

2.1 (5.9)

1.7 (7.1)

-0.5 (3.4)

-0 (2.7)

3.8 (21.6)

10

10

18

28

32

27

40

165

8

19

37

85

237

386

9.96%

10.52%

13.98%

15.71%

15.82%

16.23%

17.79%

100%

2.34%

7.28%

10.24%

30.18%

49.97%

100%

-0.15[-1.05,0.76]

0.22[-0.64,1.08]

-0.26[-0.9,0.38]

0.18[-0.37,0.73]

1.16[0.62,1.7]

0.04[-0.48,0.56]

-0.05[-0.49,0.39]

0.18[-0.19,0.56]

0[-0.98,0.98]

0.45[-0.1,0.99]

0.06[-0.4,0.51]

0.17[-0.08,0.41]

-0.06[-0.24,0.11]

0.06[-0.09,0.21]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

456

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 14.9.   Comparison 14 Subanalysis: outcomes by intensity of physical activity
intervention, Outcome 9 Overall social well-being/function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.9.1 Light-to-moderate intensity

Banasik 2011

Mustian 2004

Rogers 2014

Rogers 2009

Basen-Enquist 2006

Courneya 2003

Littman 2012

Milne 2008

Mehnert 2011

Murtezani 2014

Daley 2007

Loh 2014

Schmitz 2009

Kiecolt-Glaser 2014

Rogers 2015

Subtotal ***

2.8 (0.7)

8.6 (1.9)

7.3 (4.9)

22.6 (4.1)

84.6 (16.9)

21.1 (3.5)

22.1 (5)

20.7 (4)

85.4 (20.9)

20.2 (2.8)

23.3 (4.8)

21.5 (4.9)

14.9 (5.2)

95.2 (10.8)

21 (5.7)

7

9

20

20

28

24

30

29

30

30

33

63

59

96

105

583

Heterogeneity: Tau2=0.01; Chi2=15.82, df=14(P=0.32); I2=11.5%

Test for overall effect: Z=3.44(P=0)

14.9.2 Moderate-to-high intensity

Herrero 2006

Cadmus 2009

Vallance 2007

Subtotal ***

87.5 (19.4)

22.3 (4.9)

22.9 (5)

8

37

250

295

Heterogeneity: Tau2=0; Chi2=1.31, df=2(P=0.52); I2=0%

Test for overall effect: Z=0.43(P=0.66)

3.2 (0.8)

9 (1.8)

3.1 (3.2)

21.8 (5.7)

84.9 (19.2)

20.7 (3.6)

20.9 (6)

19.4 (3.9)

79.9 (22.7)

18.3 (2.7)

20.4 (6.8)

19.6 (4.9)

14.1 (5.8)

93.8 (9.3)

20.7 (5.8)

91.7 (23.6)

20.6 (7.2)

23 (5.1)

7

10

22

18

23

28

27

29

28

32

33

32

62

90

108

549

8

37

85

130

1.43%

1.98%

3.74%

3.83%

5.01%

5.11%

5.55%

5.61%

5.64%

5.71%

6.21%

7.85%

10.71%

15%

16.6%

100%

4.64%

21.37%

73.99%

100%

-0.45[-1.51,0.62]

-0.19[-1.09,0.71]

1.01[0.36,1.65]

0.16[-0.48,0.8]

-0.02[-0.57,0.54]

0.11[-0.43,0.66]

0.22[-0.31,0.74]

0.32[-0.19,0.84]

0.25[-0.27,0.76]

0.68[0.17,1.2]

0.49[-0,0.98]

0.38[-0.05,0.81]

0.14[-0.21,0.5]

0.14[-0.15,0.43]

0.05[-0.22,0.32]

0.23[0.1,0.36]

-0.18[-1.17,0.8]

0.27[-0.18,0.73]

-0[-0.25,0.24]

0.05[-0.16,0.26]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 14.10.   Comparison 14 Subanalysis: outcomes by intensity of physical
activity intervention, Outcome 10 Overall social well-being/function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.10.1 Light-to-moderate intensity

Mustian 2004

Naumann 2012

Rogers 2009

Rogers 2014

Murtezani 2014

Courneya 2003

Mehnert 2011

Schmitz 2009

Subtotal ***

9

11

20

20

30

24

30

59

203

1.5 (1.5)

0.9 (3.3)

0.9 (2.6)

2.1 (3.2)

2.1 (0.8)

0.6 (2.4)

7.3 (22.3)

4.4 (33.8)

10

10

18

22

32

28

28

62

210

0.4 (1.2)

-0.2 (3.3)

-1.2 (2.7)

-0.8 (3.5)

0.5 (0.9)

-0.5 (3.3)

3.1 (24.3)

0.7 (34)

Heterogeneity: Tau2=0.25; Chi2=26.88, df=7(P=0); I2=73.95%

Test for overall effect: Z=2.97(P=0)

9.26%

10.01%

12.19%

12.51%

12.96%

13.5%

13.9%

15.67%

100%

0.76[-0.18,1.7]

0.32[-0.54,1.18]

0.78[0.11,1.44]

0.85[0.21,1.48]

1.8[1.21,2.4]

0.37[-0.18,0.92]

0.18[-0.34,0.69]

0.11[-0.25,0.47]

0.63[0.21,1.04]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

457

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.10.2 Moderate-to-high intensity

Cormie 2014

Cadmus 2009

Vallance 2007

Saarto 2012

Subtotal ***

43

37

250

263

593

3.5 (8.5)

0.6 (4.6)

0.2 (4.8)

5 (21.1)

19

37

85

237

378

2.5 (8.3)

-1 (3.2)

-4.1 (3.3)

8.8 (20.8)

Heterogeneity: Tau2=0.41; Chi2=53.19, df=3(P<0.0001); I2=94.36%

Test for overall effect: Z=0.98(P=0.32)

23%

24.04%

26.19%

26.77%

100%

0.12[-0.42,0.66]

0.4[-0.06,0.86]

0.97[0.71,1.23]

-0.18[-0.36,-0.01]

0.33[-0.33,0.98]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 14.11.   Comparison 14 Subanalysis: outcomes by intensity of physical
activity intervention, Outcome 11 Overall cognitive function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.11.1 Light-to-moderate intensity

Pinto 2003

Rogers 2009

Mehnert 2011

Cantarero-Villanueva 2013

Subtotal ***

-4.3 (2.5)

-124.5
(30.8)

81.1 (16.8)

-37.9 (8.5)

12

19

30

32

93

Heterogeneity: Tau2=0.01; Chi2=3.16, df=3(P=0.37); I2=5.18%

Test for overall effect: Z=2.64(P=0.01)

14.11.2 Moderate-to-high intensity

Herrero 2006

Subtotal ***

91.7 (12.6)

8

8

Heterogeneity: Not applicable

Test for overall effect: Z=0.32(P=0.75)

-7.2 (2.1)

-135.5
(19.5)

78.4 (24.4)

-43 (10)

89.6 (12.4)

6

18

27

29

80

8

8

8.61%

22.28%

34.05%

35.06%

100%

1.14[0.07,2.2]

0.42[-0.24,1.07]

0.13[-0.39,0.65]

0.55[0.03,1.06]

0.43[0.11,0.74]

100%

100%

0.16[-0.82,1.14]

0.16[-0.82,1.14]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 14.12.   Comparison 14 Subanalysis: outcomes by intensity of physical
activity intervention, Outcome 12 Overall cognitive function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.12.1 Light-to-moderate intensity

Rogers 2009

Mehnert 2011

Cantarero-Villanueva 2013

Subtotal ***

4.2 (16.8)

1.7 (22.4)

2.2 (7.6)

20

30

32

82

-4.7 (25.9)

6.2 (24.6)

-0.2 (5.5)

18

27

29

74

Heterogeneity: Tau2=0.03; Chi2=2.82, df=2(P=0.24); I2=29.01%

Test for overall effect: Z=0.88(P=0.38)

14.12.2 Moderate-to-high intensity

26.49%

36.05%

37.46%

100%

0.4[-0.24,1.05]

-0.19[-0.71,0.33]

0.35[-0.16,0.86]

0.17[-0.21,0.55]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

458

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Herrero 2006

Saarto 2012

Subtotal ***

Mean(SD)

6.2 (19.8)

-1 (18.2)

N

8

263

271

Mean(SD)

8.3 (14.8)

2.2 (18.5)

N

8

237

245

Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.9); I2=0%

Test for overall effect: Z=1.95(P=0.05)

Random, 95% CI

Random, 95% CI

3.11%

96.89%

100%

-0.11[-1.09,0.87]

-0.17[-0.35,0]

-0.17[-0.35,0]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 14.13.   Comparison 14 Subanalysis: outcomes by intensity of physical
activity intervention, Outcome 13 Overall general health (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.13.1 Light-to-moderate intensity

Mustian 2004

Rogers 2009

Basen-Enquist 2006

Ergun 2013

Mehnert 2011

Schmitz 2005

Subtotal ***

18.6 (4.8)

3.5 (0.9)

77.4 (11.6)

71.6 (19.9)

74.4 (11.8)

53.8 (5.3)

9

20

28

40

30

39

166

Heterogeneity: Tau2=0.06; Chi2=8.53, df=5(P=0.13); I2=41.37%

Test for overall effect: Z=1.08(P=0.28)

14.13.2 Moderate-to-high intensity

Baruth 2013

Herrero 2006

Do 2015

Cadmus 2009

Subtotal ***

68.1 (0)

81.3 (10.7)

87.3 (13.7)

50 (8.8)

20

8

32

37

97

Heterogeneity: Tau2=0.22; Chi2=6.6, df=2(P=0.04); I2=69.68%

Test for overall effect: Z=0.9(P=0.37)

19.3 (1.9)

3.8 (0.5)

67.1 (13.4)

67.9 (16.7)

70 (20.8)

53.2 (6)

61.6 (0)

62.5 (16.1)

82.4 (19.9)

51.7 (8.4)

9

18

23

20

28

40

138

12

8

30

37

87

8.72%

14.72%

16.9%

18.26%

19.06%

22.32%

100%

20.53%

38.95%

40.52%

100%

-0.18[-1.11,0.74]

-0.4[-1.04,0.25]

0.81[0.24,1.39]

0.19[-0.35,0.73]

0.26[-0.26,0.77]

0.1[-0.34,0.55]

0.17[-0.14,0.48]

Not estimable

1.3[0.19,2.41]

0.28[-0.22,0.79]

-0.2[-0.65,0.26]

0.3[-0.35,0.95]

Favours control

-100

-50

0

50

100

Favours physical activity

Analysis 14.14.   Comparison 14 Subanalysis: outcomes by intensity of physical
activity intervention, Outcome 14 Overall general health (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.14.1 Light-to-moderate intensity

Mustian 2004

Rogers 2009

Ergun 2013

Mehnert 2011

Schmitz 2005

Subtotal ***

9

20

40

30

39

138

0.2 (1.9)

0.2 (0.6)

5.4 (21.5)

6.6 (13.7)

0.7 (4.8)

0.7 (2.5)

0.2 (0.7)

-6.7 (25.9)

3.2 (19.7)

-0.6 (3.9)

10

18

20

28

40

116

Heterogeneity: Tau2=0; Chi2=2.67, df=4(P=0.61); I2=0%

Test for overall effect: Z=1.8(P=0.07)

7.71%

15.52%

21.17%

23.61%

31.99%

100%

-0.2[-1.1,0.71]

-0.03[-0.67,0.61]

0.52[-0.03,1.06]

0.2[-0.32,0.71]

0.29[-0.15,0.74]

0.23[-0.02,0.48]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

459

Favours control

-100

-50

0

50

100

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.14.2 Moderate-to-high intensity

Herrero 2006

Cormie 2014

Cadmus 2009

Saarto 2012

Subtotal ***

8

43

37

263

351

17.7 (8.3)

3.7 (7)

0.2 (4.4)

4.2 (16.2)

-10.4 (17.7)

2.8 (7.1)

-0.1 (5.1)

5.6 (15.4)

8

19

37

237

301

Heterogeneity: Tau2=0.13; Chi2=10.34, df=3(P=0.02); I2=70.99%

Test for overall effect: Z=0.89(P=0.38)

9.57%

24.96%

27.98%

37.49%

100%

1.92[0.68,3.17]

0.13[-0.41,0.67]

0.06[-0.39,0.52]

-0.09[-0.26,0.09]

0.2[-0.24,0.64]

Favours control

-100

-50

0

50

100

Favours physical activity

Analysis 14.15.   Comparison 14 Subanalysis: outcomes by intensity of physical
activity intervention, Outcome 15 Overall sexual function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

14.15.1 Light-to-moderate intensity

Pinto 2005

Schmitz 2005

Pinto 2003

Schmitz 2009

Subtotal ***

42.8 (9.2)

-51 (7.5)

42.5 (9.2)

-27.3 (5.3)

12

39

39

57

147

Heterogeneity: Tau2=0; Chi2=0.93, df=3(P=0.82); I2=0%

Test for overall effect: Z=1.84(P=0.07)

14.15.2 Moderate-to-high intensity

Duijits 2012

Subtotal ***

0.6 (0.8)

53

53

Heterogeneity: Not applicable

Test for overall effect: Z=0.07(P=0.95)

43.7 (6.1)

-53.5 (8)

40.1 (6.3)

-28.1 (6.2)

0.6 (0.8)

6

40

43

57

146

65

65

5.54%

27.01%

28.03%

39.41%

100%

-0.11[-1.09,0.87]

0.32[-0.12,0.76]

0.29[-0.14,0.73]

0.14[-0.23,0.51]

0.22[-0.01,0.45]

100%

100%

0.01[-0.35,0.38]

0.01[-0.35,0.38]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 14.16.   Comparison 14 Subanalysis: outcomes by intensity of physical
activity intervention, Outcome 16 Overall sexual function (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

14.16.1 Light-to-moderate intensity

Schmitz 2009

Schmitz 2005

Subtotal ***

7.2 (14.6)

1.7 (4.8)

57

39

96

-0.2 (16.7)

0.2 (5.2)

57

40

97

Heterogeneity: Tau2=12.46; Chi2=3.52, df=1(P=0.06); I2=71.56%

Test for overall effect: Z=1.33(P=0.18)

14.16.2 Moderate-to-high intensity

Saarto 2012

Subtotal ***

263

263

4.3 (25.4)

237

237

3.8 (24.4)

39.42%

60.58%

100%

7.4[1.64,13.16]

1.5[-0.71,3.71]

3.83[-1.83,9.48]

100%

100%

0.5[-3.86,4.86]

0.5[-3.86,4.86]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

460

Favours control

-20

-10

0

10

20

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

Heterogeneity: Not applicable

Test for overall effect: Z=0.22(P=0.82)

Favours control

-20

-10

0

10

20

Favours physical activity

Analysis 14.17.   Comparison 14 Subanalysis: outcomes by intensity of
physical activity intervention, Outcome 17 Overall anxiety (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.17.1 Light-to-moderate intensity

Pinto 2003

Rogers 2014

Milne 2008

Mehnert 2011

Cantarero-Villanueva 2013

Subtotal ***

7.6 (7.3)

45.6 (8.9)

15.3 (6.2)

4.8 (3.5)

42.5 (8.6)

12

20

29

30

32

123

Heterogeneity: Tau2=0.03; Chi2=5.48, df=4(P=0.24); I2=27.05%

Test for overall effect: Z=3.51(P=0)

14.17.2 Moderate-to-high intensity

Segar 1998

Cadmus 2009

Subtotal ***

28.5 (3)

32.1 (12.3)

10

37

47

Heterogeneity: Tau2=2.44; Chi2=8.68, df=1(P=0); I2=88.48%

Test for overall effect: Z=1.03(P=0.3)

10.5 (3.7)

45.7 (8)

21 (5.7)

7.1 (5)

49.9 (11.7)

39.5 (6)

34.1 (15.4)

6

22

29

28

29

114

5

37

42

8.79%

19.71%

22.93%

24.12%

24.45%

100%

45.23%

54.77%

100%

-0.43[-1.43,0.56]

-0.01[-0.62,0.59]

-0.94[-1.49,-0.4]

-0.54[-1.06,-0.01]

-0.72[-1.24,-0.2]

-0.56[-0.88,-0.25]

-2.49[-3.98,-1]

-0.14[-0.6,0.31]

-1.2[-3.49,1.09]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 14.18.   Comparison 14 Subanalysis: outcomes by intensity of
physical activity intervention, Outcome 18 Overall anxiety (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

14.18.1 Light-to-moderate intensity

Rogers 2014

Mehnert 2011

Cantarero-Villanueva 2013

Subtotal ***

-4 (6.5)

-1.7 (3.7)

-4.2 (9.8)

20

30

32

82

Heterogeneity: Tau2=0; Chi2=0.39, df=2(P=0.82); I2=0%

Test for overall effect: Z=2.99(P=0)

14.18.2 Moderate-to-high intensity

Cadmus 2009

Subtotal ***

-0.7 (9.2)

37

37

Heterogeneity: Not applicable

Test for overall effect: Z=0.66(P=0.51)

-1.8 (5)

0.2 (4.9)

0.8 (5.5)

0.5 (5.8)

22

28

29

79

37

37

26.41%

36.34%

37.26%

100%

-0.37[-0.99,0.24]

-0.42[-0.95,0.1]

-0.61[-1.12,-0.09]

-0.48[-0.79,-0.16]

100%

100%

-0.15[-0.61,0.3]

-0.15[-0.61,0.3]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

461

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 14.19.   Comparison 14 Subanalysis: outcomes by intensity of physical
activity intervention, Outcome 19 Overall depression (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.19.1 Light-to-moderate intensity

Pinto 2003

Payne 2008

Bower 2011

Rogers 2014

Ergun 2013

Mehnert 2011

Cantarero-Villanueva 2013

Daley 2007

Kiecolt-Glaser 2014

Subtotal ***

12

10

16

20

40

30

32

33

96

6.2 (7.2)

12.7 (8.7)

7.7 (5.8)

44.2 (8.6)

6.9 (6.8)

2.7 (3)

45.6 (9.7)

6 (6.5)

8.1 (8.6)

6

10

15

22

20

28

29

33

90

9.8 (6.8)

11.4 (7.9)

11.6 (7.1)

25.1 (44.2)

5.2 (5.2)

4.6 (4.4)

53.7 (11.6)

10.3 (7.2)

9.2 (8.2)

289

253

Heterogeneity: Tau2=0.11; Chi2=19.68, df=8(P=0.01); I2=59.35%

Test for overall effect: Z=1.59(P=0.11)

14.19.2 Moderate-to-high intensity

Segar 1998

Kaltsatou 2011

Cadmus 2009

Subtotal ***

5.5 (2)

16.5 (1.7)

9.6 (9.3)

10

13

37

60

10 (2)

22.3 (7.7)

10.8 (10.1)

5

13

37

55

Heterogeneity: Tau2=0.62; Chi2=9.24, df=2(P=0.01); I2=78.35%

Test for overall effect: Z=1.75(P=0.08)

6.1%

7.24%

9.15%

10.7%

12.09%

12.37%

12.42%

12.91%

17.02%

100%

24.54%

34.59%

40.87%

100%

-0.49[-1.49,0.5]

0.15[-0.73,1.03]

-0.59[-1.31,0.13]

0.58[-0.04,1.19]

0.27[-0.27,0.81]

-0.51[-1.04,0.01]

-0.75[-1.28,-0.23]

-0.63[-1.12,-0.13]

-0.13[-0.42,0.16]

-0.24[-0.53,0.06]

-2.12[-3.51,-0.73]

-1[-1.83,-0.18]

-0.12[-0.58,0.33]

-0.92[-1.95,0.11]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 14.20.   Comparison 14 Subanalysis: outcomes by intensity of physical
activity intervention, Outcome 20 Overall depression (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.20.1 Light-to-moderate intensity

Naumann 2012

Rogers 2014

Mehnert 2011

Cantarero-Villanueva 2013

Subtotal ***

-3.6 (4.3)

-1.7 (6.9)

2.7 (3)

-2.9 (7.8)

11

20

30

32

93

Heterogeneity: Tau2=0; Chi2=1.84, df=3(P=0.61); I2=0%

Test for overall effect: Z=3.91(P<0.0001)

14.20.2 Moderate-to-high intensity

Cadmus 2009

Saarto 2012

Subtotal ***

0.3 (6.4)

-0.3 (3.3)

37

263

300

Heterogeneity: Tau2=0.01; Chi2=1.24, df=1(P=0.27); I2=19.17%

Test for overall effect: Z=0.04(P=0.97)

2 (4.6)

1.1 (4.2)

4.6 (4.4)

1.5 (7.4)

1.7 (6.3)

-0.5 (3.4)

10

22

28

29

89

37

237

274

9.95%

23.6%

32.55%

33.91%

100%

19.98%

80.02%

100%

-1.21[-2.16,-0.26]

-0.49[-1.1,0.13]

-0.51[-1.04,0.01]

-0.57[-1.09,-0.06]

-0.6[-0.89,-0.3]

-0.22[-0.68,0.24]

0.06[-0.12,0.24]

0[-0.21,0.22]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

462

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 14.21.   Comparison 14 Subanalysis: outcomes by intensity of
physical activity intervention, Outcome 21 Overall fatigue (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.21.1 Light-to-moderate intensity

Banasik 2011

Pinto 2003

Payne 2008

Rogers 2013

Loudon 2014

Bower 2011

Rogers 2009

Cuesta-Vargas 2014

Rogers 2014

Milne 2008

Cantarero-Villanueva 2013

Courneya 2003

Ergun 2013

Mehnert 2011

Littman 2012

Daley 2007

Winters-Stone 2011

Pinto 2015

Pinto 2005

Fillion 2008

Kiecolt-Glaser 2014

Subtotal ***

7

12

9

11

12

16

20

22

20

29

32

24

40

30

30

33

36

39

39

44

96

1 (0.9)

7.2 (6.4)

4.7 (2.6)

4.2 (1.8)

1.9 (2.2)

3.4 (1.8)

-12.4 (10.4)

4 (1.8)

4.1 (2.1)

11.9 (3.2)

3.8 (1.8)

-8.3 (7.9)

2.9 (2.2)

28.5 (25.6)

-45 (5.3)

2.1 (1.8)

45 (5.3)

-43.8 (7.8)

27.1 (21.4)

2.7 (0.7)

6.3 (19.6)

7

6

9

9

11

15

18

20

22

29

29

28

20

27

27

33

31

37

43

43

90

1.6 (1)

9 (6.4)

3.5 (1.7)

4.2 (1.6)

2.1 (2.5)

4.9 (1.3)

-10.1 (6.6)

5.2 (3.2)

4 (1.8)

17.4 (4.7)

6.2 (1.7)

-8.8 (8.1)

3.3 (1.8)

39.9 (25.1)

-43.1 (10.3)

3.4 (1.9)

43.1 (10.3)

-41.2 (8.5)

42.3 (26.2)

2.9 (0.8)

12.7 (19)

601

554

Heterogeneity: Tau2=0.1; Chi2=45.29, df=20(P=0); I2=55.84%

Test for overall effect: Z=3.94(P<0.0001)

14.21.2 Moderate-to-high intensity

Do 2015

Cadmus 2009

Vallance 2007

Short 2014

Subtotal ***

16.8 (13.3)

-51.9 (9)

-42.7 (8.4)

-41.5 (9.3)

32

37

250

195

514

22.3 (15.1)

-50.6 (10)

-42.6 (8.7)

-39.8 (10.4)

30

37

85

104

256

Heterogeneity: Tau2=0; Chi2=1.99, df=3(P=0.57); I2=0%

Test for overall effect: Z=1.63(P=0.1)

2.28%

2.6%

2.76%

3.04%

3.35%

3.75%

4.45%

4.64%

4.7%

4.95%

5.04%

5.19%

5.25%

5.34%

5.38%

5.59%

5.74%

6%

6.08%

6.29%

7.57%

100%

-0.57[-1.65,0.51]

-0.27[-1.26,0.71]

0.52[-0.42,1.46]

0[-0.88,0.88]

-0.07[-0.89,0.75]

-0.93[-1.67,-0.18]

-0.26[-0.9,0.38]

-0.46[-1.07,0.15]

0.05[-0.56,0.66]

-1.35[-1.92,-0.78]

-1.38[-1.94,-0.82]

0.06[-0.48,0.61]

-0.17[-0.71,0.37]

-0.44[-0.97,0.08]

-0.23[-0.75,0.29]

-0.71[-1.21,-0.21]

0.23[-0.25,0.72]

-0.32[-0.77,0.14]

-0.63[-1.07,-0.18]

-0.27[-0.69,0.15]

-0.33[-0.62,-0.04]

-0.38[-0.56,-0.19]

9.22%

11.21%

38.52%

41.05%

100%

-0.38[-0.89,0.12]

-0.14[-0.59,0.32]

-0.01[-0.26,0.23]

-0.17[-0.41,0.06]

-0.13[-0.28,0.03]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 14.22.   Comparison 14 Subanalysis: outcomes by intensity of
physical activity intervention, Outcome 22 Overall fatigue (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.22.1 Light-to-moderate intensity

Naumann 2012

Rogers 2013

Loudon 2014

Rogers 2009

Courneya 2003

11

11

12

20

24

-3.6 (4.4)

4.2 (2)

1.9 (2.2)

1.9 (9.6)

9.3 (10.2)

10

9

11

18

28

2 (4.6)

3.9 (1.5)

2.1 (2.5)

4.2 (12.3)

2 (7.5)

9.02%

9.48%

9.94%

11.24%

11.74%

-1.21[-2.16,-0.26]

0.16[-0.72,1.04]

-0.07[-0.89,0.75]

-0.21[-0.84,0.43]

0.81[0.24,1.38]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

463

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Cantarero-Villanueva 2013

Mehnert 2011

Daley 2007

Pinto 2005

Subtotal ***

-2 (1.8)

-0.7 (20.7)

2.1 (1.8)

-14.9 (23.5)

32

30

33

39

212

29

27

33

43

208

0.3 (1.4)

-2.9 (25.3)

3.4 (1.9)

1.8 (23.5)

Heterogeneity: Tau2=0.41; Chi2=42.67, df=8(P<0.0001); I2=81.25%

Test for overall effect: Z=1.51(P=0.13)

14.22.2 Moderate-to-high intensity

Herrero 2006

Vallance 2007

Saarto 2012

Subtotal ***

-4.2 (19.6)

2.5 (8.2)

-2.4 (9.1)

8

250

263

521

8

85

237

330

6.4 (14.5)

1.2 (6.6)

-2.4 (8.6)

Heterogeneity: Tau2=0.01; Chi2=2.75, df=2(P=0.25); I2=27.19%

Test for overall effect: Z=0.48(P=0.63)

11.74%

12.07%

12.22%

12.55%

100%

3.46%

38.99%

57.56%

100%

-1.45[-2.02,-0.88]

0.09[-0.43,0.61]

-0.71[-1.21,-0.21]

-0.7[-1.15,-0.26]

-0.36[-0.84,0.11]

-0.58[-1.59,0.43]

0.17[-0.08,0.42]

0[-0.18,0.18]

0.05[-0.14,0.24]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 14.23.   Comparison 14 Subanalysis: outcomes by intensity of physical
activity intervention, Outcome 23 Overall pain/disability (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.23.1 Light-to-moderate intensity

Mustian 2004

Loudon 2014

Rogers 2009

Basen-Enquist 2006

Mehnert 2011

Subtotal ***

9.1 (1.4)

0.8 (1.5)

-3 (3)

79.7 (10.6)

79.4 (23.1)

9

12

20

28

30

99

Heterogeneity: Tau2=0.07; Chi2=6.39, df=4(P=0.17); I2=37.37%

Test for overall effect: Z=0.66(P=0.51)

14.23.2 Moderate-to-high intensity

Portela 2008

Do 2015

Cadmus 2009

Duijits 2012

Subtotal ***

-20.6 (20.2)

21.1 (24.6)

50.3 (9.1)

79.3 (23.6)

25

32

37

87

181

Heterogeneity: Tau2=0; Chi2=0.47, df=3(P=0.92); I2=0%

Test for overall effect: Z=0.29(P=0.77)

9.1 (1.7)

1.4 (2.2)

-2.3 (2.8)

72.1 (11.5)

73.5 (24.8)

-20.8 (15.5)

16.5 (26.7)

50.8 (9)

78.8 (23.8)

10

11

18

23

28

90

9

30

37

89

165

13.14%

14.97%

21.04%

24.15%

26.71%

100%

7.83%

18.24%

21.88%

52.05%

100%

0.01[-0.89,0.91]

-0.33[-1.15,0.5]

-0.26[-0.89,0.38]

0.68[0.11,1.25]

0.24[-0.27,0.76]

0.13[-0.25,0.5]

0.01[-0.75,0.77]

0.18[-0.32,0.68]

-0.05[-0.51,0.4]

0.02[-0.28,0.32]

0.03[-0.18,0.24]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

464

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 14.24.   Comparison 14 Subanalysis: outcomes by intensity of physical
activity intervention, Outcome 24 Overall pain/disability (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.24.1 Light-to-moderate intensity

Mustian 2004

Mehnert 2011

Subtotal ***

-0.2 (1.3)

-2.4 (25)

9

30

39

Heterogeneity: Tau2=0; Chi2=0.46, df=1(P=0.5); I2=0%

Test for overall effect: Z=0.51(P=0.61)

14.24.2 Moderate-to-high intensity

Cormie 2014

Cadmus 2009

Irwin 2015

Subtotal ***

3.4 (6.5)

-2.2 (11.3)

-6 (19)

43

37

45

125

Heterogeneity: Tau2=0.02; Chi2=2.68, df=2(P=0.26); I2=25.26%

Test for overall effect: Z=0.94(P=0.35)

0 (1.4)

-7.6 (25.2)

2 (6.2)

-0.1 (7)

0.7 (18.6)

10

28

38

19

37

38

94

24.68%

75.32%

100%

-0.15[-1.06,0.75]

0.21[-0.31,0.72]

0.12[-0.33,0.56]

27.14%

35.14%

37.72%

100%

0.22[-0.33,0.76]

-0.22[-0.68,0.24]

-0.35[-0.79,0.08]

-0.15[-0.47,0.16]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 14.25.   Comparison 14 Subanalysis: outcomes by intensity of physical
activity intervention, Outcome 25 Overall self-esteem/body image (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.25.1 Light-to-moderate intensity

Pinto 2003

Loudon 2014

Mehnert 2011

Courneya 2003

Milne 2008

Daley 2007

Pinto 2005

Schmitz 2009

Subtotal ***

32.3 (4.3)

-1.4 (0.3)

-5.5 (1.7)

34.8 (4.7)

-17.9 (6.8)

2 (0.8)

30.3 (7.8)

-70.4 (16.3)

12

12

27

24

29

33

39

59

235

Heterogeneity: Tau2=0.01; Chi2=8.4, df=7(P=0.3); I2=16.68%

Test for overall effect: Z=3.32(P=0)

14.25.2 Moderate-to-high intensity

Segar 1998

Musanti 2012

Do 2015

Cadmus 2009

Subtotal ***

33 (1.8)

23.8 (3.5)

37.9 (18.9)

34.2 (5.5)

10

30

32

37

109

Heterogeneity: Tau2=0.15; Chi2=7.66, df=3(P=0.05); I2=60.85%

Test for overall effect: Z=0.21(P=0.83)

25.3 (8.2)

-1.6 (0.9)

-6.8 (2.6)

34.6 (4.4)

-20.1 (6.3)

1.6 (0.5)

27.2 (6.8)

-71.5 (18)

30.5 (2.7)

26.3 (3.9)

36.1 (18.3)

33.4 (5.9)

6

11

27

28

29

32

43

63

239

5

12

30

37

84

3.52%

5.78%

11.88%

11.93%

12.98%

13.77%

17%

23.15%

100%

13.12%

24.17%

30.59%

32.13%

100%

1.15[0.08,2.22]

0.2[-0.62,1.02]

0.61[0.06,1.16]

0.04[-0.5,0.59]

0.33[-0.19,0.85]

0.66[0.16,1.16]

0.41[-0.03,0.85]

0.06[-0.29,0.42]

0.35[0.14,0.55]

1.11[-0.06,2.28]

-0.68[-1.37,0.01]

0.1[-0.4,0.59]

0.14[-0.32,0.6]

0.06[-0.45,0.56]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

465

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 14.26.   Comparison 14 Subanalysis: outcomes by intensity of physical
activity intervention, Outcome 26 Overall self-esteem/body image (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.26.1 Light-to-moderate intensity

Mustian 2004

Courneya 2003

Mehnert 2011

Milne 2008

Daley 2007

Schmitz 2009

Subtotal ***

11

24

30

29

33

59

186

3 (1)

2.6 (3.7)

0.7 (2.1)

1.5 (3.7)

1.8 (0.7)

-12 (15.5)

-1.5 (1.5)

-0.1 (3.5)

0.4 (2.1)

0.1 (3.9)

1.6 (0.7)

-4.1 (16.2)

10

28

27

29

33

63

190

Heterogeneity: Tau2=0.47; Chi2=37.69, df=5(P<0.0001); I2=86.74%

Test for overall effect: Z=1.66(P=0.1)

14.26.2 Moderate-to-high intensity

Musanti 2012

Cadmus 2009

Saarto 2012

Subtotal ***

-0.4 (4.5)

0.4 (4.4)

10.7 (21.5)

30

37

263

330

12

37

237

286

0.6 (3.9)

0.2 (2.9)

12 (22)

Heterogeneity: Tau2=0; Chi2=0.45, df=2(P=0.8); I2=0%

Test for overall effect: Z=0.68(P=0.5)

9.63%

17.43%

17.83%

17.85%

18.14%

19.12%

100%

5.62%

12.2%

82.18%

100%

3.42[1.99,4.86]

0.74[0.18,1.3]

0.16[-0.36,0.68]

0.36[-0.16,0.88]

0.33[-0.16,0.82]

-0.49[-0.86,-0.13]

0.52[-0.09,1.13]

-0.22[-0.89,0.45]

0.05[-0.4,0.51]

-0.06[-0.24,0.12]

-0.05[-0.21,0.1]

Favours control

-5

-2.5

0

2.5

5

Favours intervention

Analysis 14.27.   Comparison 14 Subanalysis: outcomes by intensity of physical
activity intervention, Outcome 27 Overall cardiorespiratory fitness (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.27.1 Light-to-moderate intensity

Cerulli 2014

Mustian 2004

Rogers 2013

Rahnama 2010

Rogers 2014

Kim 2015

Rogers 2009

Courneya 2003

Mehnert 2011

Basen-Enquist 2006

Milne 2008

Murtezani 2014

Pinto 2005

Fillion 2008

Daley 2007

Rogers 2015

Subtotal ***

31.3 (5)

636.1 (50.6)

23.9 (6.2)

20.7 (5.7)

30.9 (6.3)

424.8 (55.8)

29.5 (6.6)

21.3 (3.7)

26.9 (4.4)

1643
(122.5)

1.5 (0.3)

875.1 (86.7)

-16.3 (2.1)

27 (4.4)

35 (4.4)

23.6 (4.8)

10

11

12

14

20

20

20

24

27

35

29

30

39

44

33

105

473

32.3 (10.1)

610.3 (75.9)

23.9 (3.8)

13.9 (5.2)

25.1 (5)

394.4 (54)

27.6 (6.1)

18.2 (3.9)

25.7 (4.7)

1546
(127.5)

1.5 (0.4)

823.5 (87.1)

-17.8 (2.2)

26.5 (5.8)

33.1 (5.3)

22.7 (0.3)

10

10

10

15

22

19

18

26

23

25

29

32

43

43

69

108

502

Heterogeneity: Tau2=0.03; Chi2=20.81, df=15(P=0.14); I2=27.93%

Test for overall effect: Z=5.31(P<0.0001)

2.91%

2.98%

3.15%

3.4%

4.87%

4.94%

4.94%

5.78%

6.09%

6.54%

6.86%

6.97%

8.33%

8.99%

9.06%

14.2%

100%

-0.12[-0.99,0.76]

0.39[-0.48,1.25]

0[-0.84,0.84]

1.21[0.41,2.01]

1.01[0.36,1.65]

0.54[-0.1,1.18]

0.29[-0.35,0.93]

0.8[0.22,1.38]

0.26[-0.3,0.82]

0.77[0.24,1.3]

0.03[-0.49,0.54]

0.59[0.08,1.1]

0.69[0.24,1.14]

0.1[-0.32,0.52]

0.38[-0.04,0.8]

0.27[-0,0.54]

0.43[0.27,0.59]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

466

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.27.2 Moderate-to-high intensity

Herrero 2006

Portela 2008

Kaltsatou 2011

Nikander 2007

Musanti 2012

Do 2015

Irwin 2015

Subtotal ***

25.9 (4.5)

3007
(410.8)

483.3 (86)

-17.6 (1.3)

24.6 (4.9)

31.7 (12.4)

24.6 (5.5)

8

25

14

14

30

30

45

166

25.7 (3.7)

2416.1
(718.6)

403.1 (71.9)

-17.2 (1.4)

23 (4.3)

24.5 (6.6)

23 (4.7)

8

9

13

14

12

30

38

124

Heterogeneity: Tau2=0.08; Chi2=10.35, df=6(P=0.11); I2=42.04%

Test for overall effect: Z=2.71(P=0.01)

8.73%

11.39%

11.55%

12.8%

14.49%

18.92%

22.11%

100%

0.05[-0.93,1.03]

1.14[0.33,1.96]

0.98[0.17,1.78]

-0.29[-1.03,0.46]

0.33[-0.34,1]

0.72[0.19,1.24]

0.31[-0.13,0.74]

0.46[0.13,0.8]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 14.28.   Comparison 14 Subanalysis: outcomes by intensity of physical
activity intervention, Outcome 28 Overall cardiorespiratory fitness (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.28.1 Light-to-moderate intensity

Nieman 1995

Dolan 2016

Naumann 2012

Courneya 2003

Rogers 2014

Pinto 2005

Subtotal ***

60.8 (8.4)

13 (10.4)

3.1 (2.9)

2.7 (2.6)

2.8 (4.9)

1.4 (2.4)

6

11

11

24

20

39

111

Heterogeneity: Tau2=0.34; Chi2=17.08, df=5(P=0); I2=70.72%

Test for overall effect: Z=3.95(P<0.0001)

14.28.2 Moderate-to-high intensity

Dolan 2016

Musanti 2012

Irwin 2015

Saarto 2012

Subtotal ***

11.5 (10.5)

1 (3.1)

1.5 (2.1)

0.9 (1.2)

12

30

45

262

349

Heterogeneity: Tau2=0.24; Chi2=16.01, df=3(P=0); I2=81.26%

Test for overall effect: Z=1.98(P=0.05)

12 (17.8)

-6 (7.2)

-0.1 (3.1)

-0.6 (1.7)

1.1 (4.2)

-0.2 (2.5)

-6 (7.2)

0.9 (3.4)

-0.4 (2.7)

0.7 (1)

6

10

10

26

22

43

117

10

12

38

236

296

6.78%

13.79%

15.95%

20.15%

20.48%

22.86%

100%

15.97%

23.04%

28.03%

32.96%

100%

3.24[1.29,5.18]

2.01[0.92,3.1]

1.03[0.1,1.95]

1.49[0.86,2.12]

0.37[-0.24,0.98]

0.65[0.2,1.09]

1.18[0.6,1.77]

1.83[0.8,2.86]

0.03[-0.64,0.7]

0.79[0.34,1.24]

0.16[-0.02,0.33]

0.57[0.01,1.14]

Favours control

-10

-5

0

5

10

Favours physical activity

Analysis 14.29.   Comparison 14 Subanalysis: outcomes by intensity of physical activity
intervention, Outcome 29 Overall self-reported physical activity (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.29.1 Light-to-moderate intensity

Guinan 2013

16

38.7 (26.9)

10

19.9 (11.3)

5.41%

0.81[-0.01,1.64]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

467

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Matthews 2007

Rogers 2009

Basen-Enquist 2006

Pinto 2015

Littman 2012

Winters-Stone 2011

Pinto 2005

Kiecolt-Glaser 2014

Rogers 2015

Schmitz 2009

Subtotal ***

54.2 (34.1)

121.4 (73.2)

428 (254.4)

70.3 (65.9)

19.2 (19.1)

430.8
(281.4)

202.4
(161.7)

11.2 (7.6)

169 (119)

3348.8
(9019.4)

22

20

35

36

32

36

39

96

110

131

573

Heterogeneity: Tau2=0.11; Chi2=35.18, df=10(P=0); I2=71.58%

Test for overall effect: Z=3.78(P=0)

14.29.2 Moderate-to-high intensity

Baruth 2013

Cadmus 2009

Hatchett 2013

Irwin 2015

Vallance 2007

Short 2014

Subtotal ***

0 (0)

161.7
(114.7)

3.5 (2.2)

222.1
(118.6)

207.6 (169)

217.9
(222.9)

20

34

38

45

253

195

585

Heterogeneity: Tau2=0.15; Chi2=22.93, df=4(P=0); I2=82.55%

Test for overall effect: Z=3.36(P=0)

27.2 (22.7)

114.3
(131.5)

404 (265)

16.5 (31.9)

12.1 (13.6)

461.7
(346.4)

78.4 (86)

9.1 (6.1)

74 (107)

2339.8
(6213.7)

0 (0)

55.6 (101.9)

1.4 (1.7)

103.6
(104.6)

163 (121)

180.3
(206.9)

14

18

25

32

31

31

43

90

112

133

539

12

33

36

38

85

104

308

6.51%

7.21%

8.69%

8.77%

8.86%

9.12%

9.41%

11.74%

11.93%

12.35%

0.87[0.17,1.58]

0.07[-0.57,0.7]

0.09[-0.42,0.61]

1.01[0.5,1.52]

0.42[-0.08,0.92]

-0.1[-0.58,0.38]

0.96[0.5,1.42]

0.3[0.01,0.59]

0.84[0.56,1.11]

0.13[-0.11,0.37]

100%

0.47[0.23,0.72]

17.49%

17.94%

18.5%

22.96%

23.11%

Not estimable

0.97[0.46,1.47]

1.04[0.55,1.53]

1.04[0.58,1.51]

0.28[0.03,0.53]

0.17[-0.07,0.41]

100%

0.65[0.27,1.03]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 14.30.   Comparison 14 Subanalysis: outcomes by intensity of physical activity
intervention, Outcome 30 Overall self-reported physical activity (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.30.1 Light-to-moderate intensity

Guinan 2013

Matthews 2007

Pinto 2005

Schmitz 2009

Subtotal ***

15.6 (11.4)

21.5 (30.6)

84.7 (189.2)

2.8 (16.8)

16

22

39

48

125

10

14

43

57

124

-8.3 (4.2)

5 (13.8)

-18.3
(200.7)

-0.8 (16.6)

Heterogeneity: Tau2=0.33; Chi2=15.08, df=3(P=0); I2=80.11%

Test for overall effect: Z=2.41(P=0.02)

14.30.2 Moderate-to-high intensity

Cadmus 2009

Irwin 2015

Vallance 2007

34

45

281

129 (117.9)

159 (136)

82 (168.7)

33

38

96

44.3 (89.4)

49 (86)

30 (167.8)

17.32%

24.14%

28.8%

29.75%

100%

20.73%

21.93%

28.05%

2.46[1.39,3.53]

0.63[-0.06,1.32]

0.52[0.08,0.96]

0.21[-0.17,0.6]

0.79[0.15,1.44]

0.8[0.3,1.3]

0.94[0.48,1.4]

0.31[0.08,0.54]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

468

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Saarto 2012

Subtotal ***

Mean(SD)

3.5 (18.3)

N

262

622

Mean(SD)

3.3 (21.5)

N

236

403

Heterogeneity: Tau2=0.13; Chi2=20.76, df=3(P=0); I2=85.55%

Test for overall effect: Z=2.3(P=0.02)

Random, 95% CI

Random, 95% CI

29.28%

100%

0.01[-0.17,0.19]

0.46[0.07,0.85]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 14.31.   Comparison 14 Subanalysis: outcomes by intensity of physical activity
intervention, Outcome 31 Overall objective physical activity (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.31.1 Light-to-moderate intensity

Rogers 2013

Guinan 2013

Matthews 2007

Rogers 2014

Rogers 2009

Kim 2015

Pinto 2015

Pinto 2005

Rogers 2015

Subtotal ***

198.4
(111.7)

30.7 (15.6)

330.8
(114.7)

294 (175)

252191
(91893)

17.6 (16)

70.3 (65.9)

37.5 (14.3)

246 (153)

12

16

22

20

20

20

36

39

110

295

Heterogeneity: Tau2=0.09; Chi2=16.06, df=7(P=0.02); I2=56.41%

Test for overall effect: Z=3.91(P<0.0001)

14.31.2 Moderate-to-high intensity

Cadmus 2009

Vallance 2007

Short 2014

Subtotal ***

6738 (2958)

8110.5
(4133.9)

9363.1
(7922.8)

33

253

219

505

Heterogeneity: Tau2=0; Chi2=1.8, df=2(P=0.41); I2=0%

Test for overall effect: Z=1.53(P=0.12)

0 (0)

31 (15.6)

198.5 (55.4)

154 (75)

210917
(64078)

11.8 (11.6)

16.5 (31.9)

33.6 (19.4)

197 (138)

5537 (3352)

8028 (3457)

8301.2
(3373.4)

10

9

14

22

18

19

32

43

112

279

34

85

111

230

8.26%

9.26%

10.9%

10.92%

11.16%

13.85%

15.61%

20.04%

100%

10.71%

41.44%

47.85%

Not estimable

-0.02[-0.84,0.8]

1.34[0.6,2.09]

1.04[0.39,1.69]

0.51[-0.14,1.15]

0.4[-0.23,1.04]

1.01[0.5,1.52]

0.22[-0.21,0.66]

0.34[0.07,0.6]

0.58[0.29,0.87]

0.38[-0.11,0.86]

0.02[-0.23,0.27]

0.16[-0.07,0.39]

100%

0.12[-0.03,0.28]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 14.32.   Comparison 14 Subanalysis: outcomes by intensity of physical
activity intervention, Outcome 32 Overall objective physical activity (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.32.1 Light-to-moderate intensity

Guinan 2013

Matthews 2007

Rogers 2014

16

22

20

-1.1 (6.2)

72.2 (114.6)

114 (109)

9

14

22

-7.9 (5.3)

-16.8 (51.5)

10 (70)

22.85%

35.75%

41.4%

1.11[0.23,2]

0.91[0.2,1.62]

1.13[0.47,1.78]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

469

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Subtotal ***

Mean(SD)

N

58

Heterogeneity: Tau2=0; Chi2=0.22, df=2(P=0.9); I2=0%

Test for overall effect: Z=4.86(P<0.0001)

14.32.2 Moderate-to-high intensity

Cadmus 2009

Vallance 2007

Subtotal ***

1621 (2108)

-150
(5173.3)

33

253

286

Heterogeneity: Tau2=0.27; Chi2=7.85, df=1(P=0.01); I2=87.27%

Test for overall effect: Z=0.81(P=0.42)

N

45

34

85

119

Mean(SD)

Random, 95% CI

Random, 95% CI

100%

1.05[0.62,1.47]

-60 (2341)

91 (5155.4)

46.14%

53.86%

0.75[0.25,1.24]

-0.05[-0.29,0.2]

100%

0.32[-0.45,1.09]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 14.33.   Comparison 14 Subanalysis: outcomes by intensity of
physical activity intervention, Outcome 33 Mass (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

14.33.1 Light-to-moderate intensity

Matthews 2007

Mustian 2004

Courneya 2003

Rahnama 2010

DeNysschen 2011

Littman 2012

Winters-Stone 2011

Daley 2007

Murtezani 2014

Schmitz 2009

Schmitz 2005

Kiecolt-Glaser 2014

Subtotal ***

22

11

24

14

30

28

36

33

30

74.9 (15.2)

67.1 (10.4)

78.2 (20.5)

69.4 (13.5)

69.3 (14.2)

81.1 (13.6)

76.5 (15.6)

74.3 (12.5)

71.7 (9.5)

131

76.2 (15.7)

69.5 (2.2)

75.2 (2.8)

39

96

494

Heterogeneity: Tau2=0; Chi2=2.86, df=11(P=0.99); I2=0%

Test for overall effect: Z=0.09(P=0.93)

14.33.2 Moderate-to-high intensity

Nikander 2007

Cadmus 2009

Herrero 2006

Ligibel 2008

Subtotal ***

73.5 (13.3)

80.7 (16.9)

65.6 (8.7)

80 (17.5)

14

36

8

40

98

Heterogeneity: Tau2=0; Chi2=0.87, df=3(P=0.83); I2=0%

Test for overall effect: Z=0.61(P=0.54)

78.9 (20.3)

68.6 (13.8)

80.1 (16.2)

71.6 (9.2)

72.4 (19.6)

81.3 (14.3)

74.2 (12.3)

75.6 (12.5)

72.6 (10.8)

77.2 (17)

69.2 (2.2)

75.2 (2.6)

75.5 (12)

78.5 (20.6)

67.3 (8.9)

83.3 (18.7)

14

10

26

15

34

27

31

69

32

133

40

90

521

14

33

8

42

97

0.22%

0.3%

0.32%

0.47%

0.49%

0.62%

0.76%

1.26%

1.33%

2.18%

35.7%

56.33%

100%

21.19%

23.33%

25.09%

30.39%

100%

-4[-16.39,8.39]

-1.5[-12.06,9.06]

-1.9[-12.2,8.4]

-2.2[-10.67,6.27]

-3.1[-11.42,5.22]

-0.2[-7.58,7.18]

2.3[-4.39,8.99]

-1.34[-6.52,3.84]

-0.9[-5.94,4.14]

-1.04[-4.98,2.9]

0.3[-0.67,1.27]

0[-0.78,0.78]

0.03[-0.56,0.61]

-2[-11.38,7.38]

2.22[-6.72,11.16]

-1.7[-10.32,6.92]

-3.3[-11.14,4.54]

-1.34[-5.66,2.98]

Favours physical activity

-20

-10

0

10

20

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

470

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 14.34.   Comparison 14 Subanalysis: outcomes by intensity
of physical activity intervention, Outcome 34 Mass (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

14.34.1 Light-to-moderate intensity

Dolan 2016

Mustian 2004

Matthews 2007

Schmitz 2009

Murtezani 2014

Naumann 2012

Courneya 2003

Schmitz 2005

Subtotal ***

-0.4 (2.1)

-0.3 (1.9)

0 (2.1)

-1 (3.7)

-2.3 (2.4)

0.5 (1.3)

0.1 (2)

0.3 (0.4)

11

9

22

65

30

11

24

39

211

Heterogeneity: Tau2=0.46; Chi2=20.32, df=7(P=0); I2=65.55%

Test for overall effect: Z=1.81(P=0.07)

14.34.2 Moderate-to-high intensity

Irwin 2015

Ligibel 2008

Dolan 2016

Saarto 2012

Subtotal ***

-2.1 (4.3)

0 (2.3)

-0.7 (1.9)

0.7 (3.7)

45

22

12

262

341

Heterogeneity: Tau2=1.07; Chi2=10.92, df=3(P=0.01); I2=72.52%

Test for overall effect: Z=1.57(P=0.12)

1.4 (1.6)

0.6 (1.4)

0 (2.2)

-0.4 (4.3)

-0.3 (2.6)

0.1 (1.5)

0.7 (1.8)

0.2 (0.4)

0.1 (3.6)

0 (2.2)

1.4 (1.6)

0.7 (3.8)

10

10

14

65

32

10

26

40

207

38

14

10

236

298

9.24%

9.83%

10.4%

10.8%

11.94%

12.1%

13.72%

21.97%

100%

21%

23.28%

23.43%

32.29%

100%

-1.85[-3.44,-0.26]

-0.9[-2.4,0.6]

-0.03[-1.46,1.4]

-0.6[-1.98,0.78]

-2[-3.24,-0.76]

0.33[-0.9,1.56]

-0.6[-1.66,0.46]

0.12[-0.07,0.31]

-0.58[-1.21,0.05]

-2.2[-3.9,-0.5]

-0.04[-1.52,1.44]

-2.11[-3.58,-0.64]

-0.01[-0.67,0.65]

-0.97[-2.18,0.24]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 14.35.   Comparison 14 Subanalysis: outcomes by intensity
of physical activity intervention, Outcome 35 BMI (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

14.35.1 Light-to-moderate intensity

Rogers 2013

Rogers 2009

Mustian 2004

Courneya 2003

Rogers 2014

Rahnama 2010

Littman 2012

Pinto 2005

Murtezani 2014

Schmitz 2009

Schmitz 2005

Kiecolt-Glaser 2014

Subtotal ***

12

20

11

24

20

14

28

39

30

131

39

96

464

33.6 (7)

30.6 (7.6)

23.9 (4.2)

29.4 (7.4)

29.6 (5)

27.7 (4.8)

27.7 (5)

27.7 (5)

25.1 (2.9)

28.5 (5.6)

26 (0.7)

27.8 (1.1)

10

18

10

26

22

15

27

43

32

133

40

90

466

30.6 (7.3)

30.4 (8.3)

26.7 (5.6)

29.3 (6)

32.2 (6.7)

28 (4.6)

29 (5.6)

29 (5.6)

25.8 (3.5)

28.9 (6.3)

25.8 (0.7)

27.8 (1)

Heterogeneity: Tau2=0; Chi2=9.49, df=11(P=0.58); I2=0%

Test for overall effect: Z=0.28(P=0.78)

14.35.2 Moderate-to-high intensity

0.12%

0.17%

0.24%

0.31%

0.35%

0.38%

0.55%

0.83%

1.74%

2.15%

41.71%

51.46%

100%

3[-3,9]

0.2[-4.88,5.28]

-2.8[-7.05,1.45]

0.1[-3.65,3.85]

-2.6[-6.16,0.96]

-0.3[-3.71,3.11]

-1.35[-4.17,1.47]

-1.35[-3.65,0.95]

-0.7[-2.29,0.89]

-0.48[-1.91,0.95]

0.2[-0.12,0.52]

0[-0.29,0.29]

0.03[-0.18,0.24]

Portela 2008

25

29.1 (5.5)

9

34.7 (15)

1.08%

-5.6[-15.63,4.43]

Favours physical activity

-20

-10

0

10

20

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

471

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Physical activity

Control

Nikander 2007

Cadmus 2009

Ligibel 2008

Vallance 2007

Subtotal ***

N

Mean(SD)

N

Mean(SD)

14

36

40

253

368

26.9 (5.6)

30.5 (6)

30.3 (6.3)

27 (5.2)

14

33

42

85

183

27.7 (4.9)

29.9 (7.6)

31.5 (6.8)

27.2 (5.2)

Heterogeneity: Tau2=0; Chi2=1.8, df=4(P=0.77); I2=0%

Test for overall effect: Z=0.66(P=0.51)

Cochrane Database of Systematic Reviews

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

7.19%

10.35%

13.58%

67.79%

100%

-0.8[-4.7,3.1]

0.55[-2.7,3.8]

-1.2[-4.04,1.64]

-0.19[-1.46,1.08]

-0.35[-1.4,0.69]

Favours physical activity

-20

-10

0

10

20

Favours control

Analysis 14.36.   Comparison 14 Subanalysis: outcomes by intensity
of physical activity intervention, Outcome 36 BMI (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

14.36.1 Light-to-moderate intensity

Schmitz 2009

Mustian 2004

Rogers 2014

Naumann 2012

Courneya 2003

Murtezani 2014

Schmitz 2005

Subtotal ***

65

9

20

11

24

30

39

198

-1 (3.7)

-0.4 (0.8)

-0.2 (0.9)

0.1 (0.5)

0 (0.7)

-0.8 (0.7)

0.1 (0.2)

65

10

22

10

26

32

40

205

-0.4 (4.3)

0.3 (0.6)

-0.3 (1.1)

-0.1 (0.6)

0.3 (0.7)

-0.1 (0.8)

0.1 (0.2)

Heterogeneity: Tau2=0.08; Chi2=19.32, df=6(P=0); I2=68.94%

Test for overall effect: Z=1.61(P=0.11)

14.36.2 Moderate-to-high intensity

Ligibel 2008

Subtotal ***

40

40

0 (0.9)

42

42

0.2 (0.8)

Heterogeneity: Not applicable

Test for overall effect: Z=1.06(P=0.29)

3.42%

11.09%

11.36%

14.84%

16.88%

17.32%

25.09%

100%

-0.6[-1.98,0.78]

-0.71[-1.33,-0.09]

0.1[-0.51,0.71]

0.2[-0.26,0.66]

-0.3[-0.69,0.09]

-0.66[-1.03,-0.29]

-0.01[-0.08,0.06]

-0.23[-0.5,0.05]

100%

100%

-0.2[-0.57,0.17]

-0.2[-0.57,0.17]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 14.37.   Comparison 14 Subanalysis: outcomes by intensity of physical
activity intervention, Outcome 37 Overall body fat (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.37.1 Light-to-moderate intensity

Cerulli 2014

Mustian 2004

Rogers 2013

Matthews 2007

Rogers 2009

Rogers 2014

Courneya 2003

DeNysschen 2011

10

11

10

22

20

20

24

30

26.7 (5.3)

38.5 (4.5)

44.2 (6.7)

39.7 (6.3)

44.3 (7.4)

38.6 (6.4)

131.9 (46.4)

36.9 (8.4)

10

10

12

14

19

22

26

34

30.6 (4.4)

41.7 (4.9)

42.3 (7.7)

43.1 (6.9)

43.5 (7.5)

41.5 (7.4)

137.1 (44.4)

38 (10.2)

3.85%

4.05%

4.36%

5.91%

6.56%

6.78%

7.62%

8.71%

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

-0.75[-1.66,0.16]

-0.66[-1.54,0.23]

0.25[-0.59,1.09]

-0.51[-1.19,0.17]

0.11[-0.52,0.73]

-0.41[-1.02,0.2]

-0.11[-0.67,0.44]

-0.12[-0.61,0.38]

472

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Winters-Stone 2011

Schmitz 2005

Pinto 2005

Daley 2007

Schmitz 2009

Subtotal ***

40.5 (6.2)

40.9 (1.3)

37.5 (4.8)

39.4 (4.7)

38.5 (5.9)

36

39

39

33

130

424

Heterogeneity: Tau2=0.06; Chi2=22.86, df=12(P=0.03); I2=47.51%

Test for overall effect: Z=2.34(P=0.02)

14.37.2 Moderate-to-high intensity

Herrero 2006

Musanti 2012

Saarto 2012

Cadmus 2009

Ligibel 2008

Subtotal ***

22 (5)

34.1 (6.6)

39.9 (7.5)

40.5 (6.6)

42.9 (7.4)

8

30

37

36

40

151

Heterogeneity: Tau2=0; Chi2=1.45, df=4(P=0.84); I2=0%

Test for overall effect: Z=0.27(P=0.78)

38.5 (5.8)

42.3 (1.3)

38.6 (4.8)

40.1 (7.4)

39.7 (5.9)

22 (4)

33.7 (5.7)

40.2 (8)

39.6 (6)

44.7 (8)

31

40

43

69

132

462

8

12

30

33

42

125

8.85%

9.07%

9.8%

10.21%

14.23%

100%

6%

12.86%

24.85%

25.76%

30.53%

100%

0.33[-0.16,0.81]

-1.05[-1.52,-0.58]

-0.21[-0.64,0.22]

-0.1[-0.52,0.31]

-0.21[-0.46,0.03]

-0.24[-0.44,-0.04]

0[-0.98,0.98]

0.07[-0.6,0.74]

-0.04[-0.52,0.44]

0.15[-0.33,0.62]

-0.23[-0.67,0.2]

-0.03[-0.27,0.21]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 14.38.   Comparison 14 Subanalysis: outcomes by intensity of
physical activity intervention, Outcome 38 Overall body fat (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.38.1 Light-to-moderate intensity

Mustian 2004

Naumann 2012

Matthews 2007

Schmitz 2005

Rogers 2014

Courneya 2003

Schmitz 2009

Subtotal ***

-0.2 (2.9)

-0.3 (2.4)

-0.2 (1.6)

-1.1 (0.5)

-1.1 (2.2)

-4.9 (15.7)

-0.3 (5.7)

9

11

22

39

20

24

65

190

10

10

14

40

22

26

63

185

0.3 (1.6)

0.8 (2.8)

0.4 (1.9)

0.2 (0.4)

-0.6 (2.4)

5.1 (24.4)

-0.1 (3.3)

Heterogeneity: Tau2=0.95; Chi2=66.52, df=6(P<0.0001); I2=90.98%

Test for overall effect: Z=1.73(P=0.08)

14.38.2 Moderate-to-high intensity

Musanti 2012

Ligibel 2008

Subtotal ***

-0.2 (2.8)

-0.2 (1.7)

30

40

70

12

42

54

1.4 (1.6)

0.3 (1.7)

Heterogeneity: Tau2=0; Chi2=0.68, df=1(P=0.41); I2=0%

Test for overall effect: Z=2.08(P=0.04)

13.13%

13.32%

14.28%

14.35%

14.59%

14.78%

15.55%

100%

-0.18[-1.09,0.72]

-0.41[-1.28,0.46]

-0.34[-1.02,0.33]

-3.07[-3.73,-2.41]

-0.21[-0.82,0.39]

-0.48[-1.04,0.09]

-0.04[-0.39,0.3]

-0.68[-1.44,0.09]

28.82%

71.18%

100%

-0.63[-1.32,0.05]

-0.29[-0.73,0.14]

-0.39[-0.76,-0.02]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

473

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 14.39.   Comparison 14 Subanalysis: outcomes by intensity of physical
activity intervention, Outcome 39 Lower body strength (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.39.1 Light-to-moderate intensity

Cerulli 2014

Rogers 2013

Rogers 2009

Schmitz 2005

Milne 2008

Winters-Stone 2011

Schmitz 2009

Subtotal ***

114.9 (17.1)

68.4 (15.5)

80.3 (27)

296.6 (48.9)

66.2 (10.2)

201.3 (57.4)

223.4 (59.6)

10

11

20

23

29

36

113

242

Heterogeneity: Tau2=0.13; Chi2=15.91, df=6(P=0.01); I2=62.29%

Test for overall effect: Z=3.84(P=0)

14.39.2 Moderate-to-high intensity

Nikander 2007

Do 2015

Saarto 2012

Subtotal ***

1305 (177)

13 (1.6)

136 (23)

14

32

37

83

Heterogeneity: Tau2=0; Chi2=0.66, df=2(P=0.72); I2=0%

Test for overall effect: Z=0.64(P=0.52)

79.1 (17.8)

67.1 (16.2)

64.9 (19.7)

238.9 (46.4)

61.7 (11)

191 (51.7)

175.1 (53.5)

1393 (275)

13.2 (1.6)

136 (29)

10

9

18

22

29

31

119

238

14

30

30

74

7.2%

9.78%

13.51%

13.82%

16.32%

17.22%

22.15%

100%

17.65%

39.76%

42.59%

100%

1.96[0.85,3.07]

0.08[-0.8,0.96]

0.63[-0.02,1.29]

1.19[0.55,1.83]

0.42[-0.1,0.94]

0.19[-0.3,0.67]

0.85[0.58,1.12]

0.69[0.34,1.04]

-0.37[-1.12,0.38]

-0.09[-0.59,0.41]

0[-0.48,0.48]

-0.1[-0.42,0.21]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 14.40.   Comparison 14 Subanalysis: outcomes by intensity of physical
activity intervention, Outcome 40 Lower body strength (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.40.1 Light-to-moderate intensity

Nieman 1995

Dolan 2016

Naumann 2012

Schmitz 2005

Schmitz 2009

Subtotal ***

28.9 (13.7)

10.3 (10)

7.7 (12.6)

81.8 (48.9)

33.2 (33.9)

6

11

11

23

113

164

Heterogeneity: Tau2=0; Chi2=3.58, df=4(P=0.47); I2=0%

Test for overall effect: Z=7.48(P<0.0001)

14.40.2 Moderate-to-high intensity

Dolan 2016

Cormie 2014

Do 2015

Waltman 2010

Subtotal ***

13.3 (7.9)

37.6 (25.5)

0.9 (0.7)

4.4 (11.5)

12

43

32

110

197

Heterogeneity: Tau2=0.24; Chi2=15.35, df=3(P=0); I2=80.45%

Test for overall effect: Z=2.21(P=0.03)

3.5 (22.5)

0.3 (11.1)

3.5 (13.9)

20.3 (46)

7.9 (26.6)

0.3 (11.1)

6.7 (25.7)

1 (0.6)

0.2 (8.4)

6

10

10

22

119

167

10

19

60

113

202

3.1%

6.24%

6.92%

12.33%

71.41%

100%

16.91%

24.34%

27.77%

30.98%

100%

1.26[-0.03,2.55]

0.9[-0,1.81]

0.3[-0.56,1.17]

1.27[0.63,1.92]

0.83[0.56,1.1]

0.87[0.64,1.09]

1.31[0.37,2.26]

1.19[0.61,1.78]

-0.08[-0.51,0.35]

0.42[0.15,0.69]

0.62[0.07,1.17]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

474

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 14.41.   Comparison 14 Subanalysis: outcomes by intensity of physical
activity intervention, Outcome 41 Upper body strength (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.41.1 Light-to-moderate intensity

Mustian 2004

Cerulli 2014

Schmitz 2005

Rogers 2009

Milne 2008

Winters-Stone 2011

Schmitz 2009

Subtotal ***

29.6 (3.3)

16.1 (5.4)

83 (13.4)

27.9 (5)

7.6 (2.9)

63.3 (15.3)

52.9 (15.3)

11

10

23

20

29

36

113

242

26.7 (5.7)

17.2 (8.1)

63 (12.7)

24.3 (6.2)

9.4 (2.6)

61.1 (16.8)

40.9 (11.8)

10

10

22

18

29

31

119

239

Heterogeneity: Tau2=0.41; Chi2=38.52, df=6(P<0.0001); I2=84.42%

Test for overall effect: Z=1.57(P=0.12)

14.41.2 Moderate-to-high intensity

Portela 2008

Nikander 2007

Musanti 2012

Kaltsatou 2011

Do 2015

Saarto 2012

Subtotal ***

39.3 (12.3)

131 (20)

52.1 (21)

59.6 (8.5)

9.7 (1.7)

32.7 (5.3)

25

14

30

28

32

37

166

35.6 (13.1)

129 (28)

36.8 (20)

47.6 (9.8)

10.1 (1.7)

30.8 (5.7)

9

14

12

26

30

30

121

Heterogeneity: Tau2=0.22; Chi2=16.68, df=5(P=0.01); I2=70.02%

Test for overall effect: Z=1.77(P=0.08)

12%

12.02%

13.95%

14.08%

15.21%

15.62%

17.12%

100%

14.43%

14.81%

15.63%

17.26%

18.8%

19.05%

100%

0.6[-0.28,1.49]

-0.16[-1.03,0.72]

1.5[0.84,2.17]

0.63[-0.03,1.28]

-0.64[-1.17,-0.12]

0.14[-0.34,0.62]

0.88[0.61,1.15]

0.43[-0.11,0.96]

0.29[-0.48,1.05]

0.08[-0.66,0.82]

0.73[0.04,1.42]

1.29[0.7,1.88]

-0.24[-0.74,0.26]

0.34[-0.14,0.83]

0.41[-0.05,0.87]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 14.42.   Comparison 14 Subanalysis: outcomes by intensity of physical
activity intervention, Outcome 42 Upper body strength (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.42.1 Light-to-moderate intensity

Schmitz 2005

Mustian 2004

Schmitz 2009

Subtotal ***

32.3 (11.5)

4.5 (4.7)

33.2 (40.8)

23

45

113

181

Heterogeneity: Tau2=0.49; Chi2=19.5, df=2(P<0.0001); I2=89.75%

Test for overall effect: Z=3.05(P=0)

14.42.2 Moderate-to-high intensity

Musanti 2012

Cormie 2014

Do 2015

Irwin 2015

Waltman 2010

Subtotal ***

7.7 (10.6)

5.7 (3.7)

0.3 (0.5)

0.4 (1.9)

1.9 (4.9)

30

43

32

45

110

260

Heterogeneity: Tau2=0.16; Chi2=16.36, df=4(P=0); I2=75.55%

Test for overall effect: Z=1.75(P=0.08)

6.9 (10.8)

-0.8 (3.2)

7.6 (43.7)

0.8 (12.7)

1 (3.8)

0.6 (1.2)

0.1 (1.9)

0.8 (2.9)

22

38

119

179

12

19

30

38

113

212

29.19%

34.02%

36.79%

100%

15.92%

17.94%

19.83%

21.37%

24.95%

100%

2.24[1.48,2.99]

1.3[0.82,1.78]

0.6[0.34,0.87]

1.32[0.47,2.16]

0.6[-0.08,1.29]

1.25[0.67,1.84]

-0.27[-0.77,0.23]

0.16[-0.27,0.59]

0.29[0.02,0.55]

0.37[-0.05,0.79]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

475

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 14.43.   Comparison 14 Subanalysis: outcomes by intensity of physical activity
intervention, Outcome 43 Bone mineral density - femoral neck (follow-up and change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.43.1 Light-to-moderate intensity

Kim 2015

Winters-Stone 2011

Subtotal ***

0.8 (0.1)

0.7 (0.1)

20

36

56

Heterogeneity: Tau2=0.03; Chi2=1.37, df=1(P=0.24); I2=27.19%

Test for overall effect: Z=0.36(P=0.72)

14.43.2 Moderate-to-high intensity

Waltman 2010

Saarto 2012

Subtotal ***

0.9 (0.5)

-0 (0)

110

239

349

Heterogeneity: Tau2=0.09; Chi2=7.17, df=1(P=0.01); I2=86.05%

Test for overall effect: Z=1.77(P=0.08)

0.8 (0.1)

0.7 (0.1)

0.6 (0.4)

-0 (0)

19

31

50

113

218

331

40.18%

59.82%

100%

-0.37[-1,0.27]

0.11[-0.37,0.59]

-0.08[-0.54,0.37]

47.47%

52.53%

100%

0.63[0.36,0.9]

0.18[-0,0.37]

0.39[-0.04,0.83]

Favours control

-2

-1

0

1

2

Favours physical activity

Analysis 14.44.   Comparison 14 Subanalysis: outcomes by intensity of physical activity
intervention, Outcome 44 Bone mineral density - lumbar spine (follow-up and change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.44.1 Light-to-moderate intensity

Kim 2015

Winters-Stone 2011

Subtotal ***

1 (0.1)

1 (0.2)

20

36

56

Heterogeneity: Tau2=0.07; Chi2=1.89, df=1(P=0.17); I2=47.1%

Test for overall effect: Z=0.21(P=0.84)

14.44.2 Moderate-to-high intensity

Waltman 2010

Saarto 2012

Subtotal ***

3.1 (0.4)

-0 (0)

110

239

349

Heterogeneity: Tau2=0.09; Chi2=7.59, df=1(P=0.01); I2=86.83%

Test for overall effect: Z=1.35(P=0.18)

1 (0.1)

1 (0.1)

2.9 (0.4)

-0 (0)

19

31

50

113

218

331

43.1%

56.9%

100%

-0.26[-0.89,0.37]

0.3[-0.19,0.78]

0.06[-0.48,0.6]

47.63%

52.37%

100%

0.55[0.28,0.81]

0.09[-0.09,0.27]

0.31[-0.14,0.75]

Favours control

-2

-1

0

1

2

Favours physical activity

Analysis 14.45.   Comparison 14 Subanalysis: outcomes by intensity of physical activity
intervention, Outcome 45 Bone mineral density - total hip (follow-up and change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

14.45.1 Light-to-moderate intensity

Kim 2015

20

0.9 (0.1)

19

0.1 (0.1)

49.24%

10.34[7.84,12.84]

Favours control

-20

-10

0

10

20

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

476

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Winters-Stone 2011

Subtotal ***

36

56

0.9 (0.1)

31

50

0.8 (0.1)

Heterogeneity: Tau2=50.72; Chi2=61.08, df=1(P<0.0001); I2=98.36%

Test for overall effect: Z=1.02(P=0.31)

14.45.2 Moderate-to-high intensity

Waltman 2010

Subtotal ***

110

110

2.2 (0.3)

113

113

1.8 (0.4)

Heterogeneity: Not applicable

Test for overall effect: Z=7.33(P<0.0001)

50.76%

100%

Random, 95% CI

0.19[-0.29,0.67]

5.19[-4.76,15.14]

100%

100%

1.05[0.77,1.33]

1.05[0.77,1.33]

Favours control

-20

-10

0

10

20

Favours physical activity

Comparison 15.   Subanalysis: outcomes by duration of physical activity intervention

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Overall HRQoL (follow-up
values)

1.1 12 weeks or less

1.2 More than 12 weeks

2 Overall HRQoL (change
values)

2.1 12 weeks or less

2.2 More than 12 weeks

3 Overall emotional func-
tion/mental health (fol-
low-up values)

3.1 12 weeks or less

3.2 More than 12 weeks

4 Overall emotional func-
tion/mental health (change
values)

4.1 12 weeks or less

22

16

6

14

11

3

26

20

6

15

10

1404

399

828

631

1557

545

754

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.45 [0.19, 0.70]

Std. Mean Difference (IV, Random, 95%
CI)

0.38 [0.10, 0.65]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.99 [0.45, 1.52]

Std. Mean Difference (IV, Random, 95%
CI)

0.27 [-0.21, 0.76]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.26 [0.12, 0.39]

Std. Mean Difference (IV, Random, 95%
CI)

0.06 [-0.11, 0.23]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.39 [0.03, 0.76]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

477

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

4.2 More than 12 weeks

5 Overall physical function
(follow-up values)

5.1 12 weeks or less

5.2 More than 12 weeks

6 Overall physical function
(change values)

6.1 12 weeks or less

6.2 More than 12 weeks

7 Overall role function (fol-
low-up values)

7.1 12 weeks or less

7.2 More than 12 weeks

8 Overall role function
(change values)

8.1 12 weeks or less

8.2 More than 12 weeks

9 Overall social well-be-
ing/function (follow-up val-
ues)

9.1 12 weeks or less

9.2 More than 12 weeks

10 Overall social well-be-
ing/function (change val-
ues)

5

25

18

7

13

8

5

18

13

5

12

8

4

18

13

5

12

825

1523

606

608

825

1057

313

610

705

1202

355

Std. Mean Difference (IV, Random, 95%
CI)

0.19 [-0.05, 0.43]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.37 [0.17, 0.58]

Std. Mean Difference (IV, Random, 95%
CI)

0.24 [0.08, 0.40]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.97 [0.27, 1.66]

Std. Mean Difference (IV, Random, 95%
CI)

0.15 [-0.16, 0.45]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.30 [-0.01, 0.60]

Std. Mean Difference (IV, Random, 95%
CI)

0.27 [0.04, 0.49]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.24 [-0.06, 0.55]

Std. Mean Difference (IV, Random, 95%
CI)

-0.03 [-0.18, 0.11]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.23 [0.06, 0.39]

Std. Mean Difference (IV, Random, 95%
CI)

0.15 [-0.05, 0.36]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

10.1 12 weeks or less

8

637

Std. Mean Difference (IV, Random, 95%
CI)

0.73 [0.35, 1.11]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

478

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

10.2 More than 12 weeks

11 Overall cognitive func-
tion (follow-up values)

11.1 12 weeks or less

11.2 More than 12 weeks

12 Overall cognitive func-
tion (change values)

12.1 12 weeks or less

12.2 More than 12 weeks

13 Overall general health
(follow-up values)

13.1 12 weeks or less

13.2 More than 12 weeks

14 Overall general health
(change values)

14.1 12 weeks or less

14.2 More than 12 weeks

15 Overall sexual function
(follow-up values)

15.1 12 weeks or less

15.2 More than 12 weeks

16 Overall sexual function
(change values)

16.1 12 weeks or less

16.2 More than 12 weeks

17 Overall sleep (follow-up
values)

4

5

5

0

5

4

1

9

6

3

9

6

3

5

3

2

3

0

3

5

747

189

0

172

500

252

204

253

653

218

193

0

693

Std. Mean Difference (IV, Random, 95%
CI)

0.11 [-0.19, 0.42]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.40 [0.11, 0.69]

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.14 [-0.17, 0.44]

Std. Mean Difference (IV, Random, 95%
CI)

-0.17 [-0.35, 0.00]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.17 [-0.16, 0.50]

Std. Mean Difference (IV, Random, 95%
CI)

0.21 [-0.32, 0.75]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.29 [-0.09, 0.67]

Std. Mean Difference (IV, Random, 95%
CI)

0.01 [-0.20, 0.22]

Std. Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Std. Mean Difference (IV, Fixed, 95% CI)

0.11 [-0.16, 0.38]

Std. Mean Difference (IV, Fixed, 95% CI)

0.21 [-0.07, 0.49]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

2.44 [-0.76, 5.64]

Std. Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

479

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

17.1 12 weeks or less

17.2 More than 12 weeks

18 Overall sleep (change
values)

18.1 12 weeks or less

18.2 More than 12 weeks

19 Overall anxiety (fol-
low-up values)

19.1 12 weeks or less

19.2 More than 12 weeks

20 Overall anxiety (change
values)

20.1 12 weeks or less

20.2 More than 12 weeks

5

0

3

3

0

7

6

1

4

3

1

21 Overall depression (fol-
low-up values)

12

21.1 12 weeks or less

21.2 More than 12 weeks

22 Overall depression
(change values)

22.1 12 weeks or less

22.2 More than 12 weeks

23 Overall fatigue (fol-
low-up values)

23.1 12 weeks or less

9

3

6

4

2

25

20

23.2 More than 12 weeks

5

188

0

136

0

252

74

161

74

537

120

182

574

1657

268

Std. Mean Difference (IV, Fixed, 95% CI)

-0.09 [-0.37, 0.20]

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.14 [-0.20, 0.48]

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.67 [-1.09, -0.25]

Std. Mean Difference (IV, Random, 95%
CI)

-0.14 [-0.60, 0.31]

Std. Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Std. Mean Difference (IV, Fixed, 95% CI)

-0.48 [-0.79, -0.16]

Std. Mean Difference (IV, Fixed, 95% CI)

-0.15 [-0.61, 0.30]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.36 [-0.70, -0.01]

Std. Mean Difference (IV, Random, 95%
CI)

-0.30 [-0.90, 0.30]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.60 [-0.89, -0.30]

Std. Mean Difference (IV, Random, 95%
CI)

0.00 [-0.21, 0.22]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.42 [-0.59, -0.25]

Std. Mean Difference (IV, Random, 95%
CI)

0.02 [-0.22, 0.26]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

480

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

24 Overall fatigue (change
values)

24.1 12 weeks or less

24.2 More than 12 weeks

25 Overall pain/disability
(follow-up values)

25.1 12 weeks or less

25.2 More than 12 weeks

26 Overall pain/disability
(change values)

26.1 12 weeks or less

26.2 More than 12 weeks

12

10

2

9

6

3

5

3

2

27 Overall self-esteem/body
image (follow-up values)

12

27.1 12 weeks or less

27.2 More than 12 weeks

28 Overall self-esteem/body
image (change values)

28.1 12 weeks or less

28.2 More than 12 weeks

29 Overall cardiorespiratory
fitness (follow-up values)

29.1 12 weeks or less

9

3

9

5

4

23

15

29.2 More than 12 weeks

8

719

552

376

159

139

157

419

248

244

748

923

342

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.44 [-0.83, -0.05]

Std. Mean Difference (IV, Random, 95%
CI)

0.36 [-0.43, 1.15]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.03 [-0.17, 0.23]

Std. Mean Difference (IV, Random, 95%
CI)

0.21 [-0.27, 0.70]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.16 [-0.19, 0.50]

Std. Mean Difference (IV, Random, 95%
CI)

-0.29 [-0.61, 0.02]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.36 [0.07, 0.66]

Std. Mean Difference (IV, Random, 95%
CI)

0.08 [-0.17, 0.33]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.54 [-0.10, 1.18]

Std. Mean Difference (IV, Random, 95%
CI)

0.01 [-0.37, 0.39]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.35 [0.20, 0.49]

Std. Mean Difference (IV, Random, 95%
CI)

0.67 [0.40, 0.94]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

481

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

30 Overall cardiorespiratory
fitness (change values)

30.1 12 weeks or less

30.2 More than 12 weeks

31 Overall self-reported
physical activity (follow-up
values)

31.1 12 weeks or less

31.2 More than 12 weeks

32 Overall self-reported
physical activity (change
values)

32.1 12 weeks or less

32.2 More than 12 weeks

33 Overall objective physi-
cal activity (follow-up val-
ues)

33.1 12 weeks or less

33.2 More than 12 weeks

34 Overall objective physi-
cal activity (change values)

34.1 12 weeks or less

34.2 More than 12 weeks

9

6

3

18

11

7

8

4

4

11

10

1

5

4

1

35 Mass (follow-up values)

16

35.1 12 weeks or less

35.2 More than 12 weeks

7

9

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.91 [0.31, 1.52]

Std. Mean Difference (IV, Random, 95%
CI)

0.76 [0.02, 1.51]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.60 [0.36, 0.84]

Std. Mean Difference (IV, Random, 95%
CI)

0.41 [0.09, 0.74]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.78 [0.20, 1.36]

Std. Mean Difference (IV, Random, 95%
CI)

0.46 [-0.01, 0.92]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.44 [0.18, 0.70]

Std. Mean Difference (IV, Random, 95%
CI)

0.38 [-0.11, 0.86]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.72 [-0.02, 1.46]

Std. Mean Difference (IV, Random, 95%
CI)

0.75 [0.25, 1.24]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

-0.10 [-0.85, 0.65]

Mean Difference (IV, Fixed, 95% CI)

0.14 [-0.76, 1.05]

232

631

1401

643

521

753

1203

67

441

67

451

759

36 Mass (change values)

11

Mean Difference (IV, Random, 95% CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

482

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

36.1 12 weeks or less

36.2 More than 12 weeks

5

6

37 BMI (follow-up values)

17

37.1 12 weeks or less

37.2 More than 12 weeks

38 BMI (change values)

38.1 12 weeks or less

38.2 More than 12 weeks

39 Overall body fat (fol-
low-up values)

39.1 12 weeks or less

39.2 More than 12 weeks

40 Overall body fat (change
values)

40.1 12 weeks or less

40.2 More than 12 weeks

9

8

8

4

4

18

9

9

9

5

4

41 Lower body strength (fol-
low-up values)

10

41.1 12 weeks or less

41.2 More than 12 weeks

42 Lower body strength
(change values)

42.1 12 weeks or less

42.2 More than 12 weeks

5

5

8

5

3

171

876

819

662

144

341

402

760

160

339

206

431

220

500

Mean Difference (IV, Random, 95% CI)

-0.82 [-1.81, 0.17]

Mean Difference (IV, Random, 95% CI)

-0.25 [-0.73, 0.24]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

-0.07 [-0.35, 0.20]

Mean Difference (IV, Fixed, 95% CI)

0.13 [-0.18, 0.43]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-0.27 [-0.76, 0.22]

Mean Difference (IV, Random, 95% CI)

-0.08 [-0.22, 0.07]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.16 [-0.37, 0.04]

Std. Mean Difference (IV, Random, 95%
CI)

-0.20 [-0.45, 0.05]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.36 [-0.68, -0.04]

Std. Mean Difference (IV, Random, 95%
CI)

-0.94 [-2.07, 0.18]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.15 [-0.19, 0.50]

Std. Mean Difference (IV, Random, 95%
CI)

0.72 [0.20, 1.24]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.71 [0.06, 1.37]

Std. Mean Difference (IV, Random, 95%
CI)

0.76 [0.36, 1.17]

43 Upper body strength (fol-
low-up values)

13

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

483

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

43.1 12 weeks or less

43.2 More than 12 weeks

44 Upper body strength
(change values)

44.1 12 weeks or less

44.2 More than 12 weeks

6

7

8

4

4

249

519

249

583

Std. Mean Difference (IV, Random, 95%
CI)

0.15 [-0.32, 0.62]

Std. Mean Difference (IV, Random, 95%
CI)

0.64 [0.24, 1.04]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.72 [-0.06, 1.50]

Std. Mean Difference (IV, Random, 95%
CI)

0.71 [0.17, 1.25]

Analysis 15.1.   Comparison 15 Subanalysis: outcomes by duration of
physical activity intervention, Outcome 1 Overall HRQoL (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.1.1 12 weeks or less

Herrero 2006

Rogers 2015

Mustian 2004

Loudon 2014

Milne 2008

Rogers 2009

Ergun 2013

Murtezani 2014

Mehnert 2011

Do 2015

Pinto 2015

Taleghani 2012

Loh 2014

Daley 2007

Vallance 2007

Short 2014

Subtotal ***

81.3 (10.7)

85.2 (4.2)

121.7 (22.7)

-7.4 (1.2)

86.4 (8.3)

92 (11.4)

71.6 (19.9)

86.5 (7.3)

74.7 (21.7)

87.3 (13.7)

117.8 (12.7)

217.5 (36.3)

112.4 (14.1)

90.9 (13.5)

91.5 (11.8)

106.8 (16.7)

8

10

11

12

29

20

40

30

30

32

39

40

63

33

250

195

842

62.5 (16.1)

65.9 (14.7)

124.3 (25.9)

-7.4 (1.4)

64.1 (10.8)

87.4 (13.1)

67.9 (16.7)

79.1 (7.5)

65.4 (16.8)

82.4 (19.9)

114 (18)

210.1 (41.5)

109.3 (13.3)

86.4 (15.1)

90.6 (13)

108.2 (18.2)

8

10

10

11

29

18

20

32

27

30

37

40

32

69

85

104

562

Heterogeneity: Tau2=0.19; Chi2=64.72, df=15(P<0.0001); I2=76.82%

Test for overall effect: Z=3.43(P=0)

15.1.2 More than 12 weeks

Cerulli 2014

Portela 2008

Courneya 2003

Cadmus 2009

Schmitz 2005

Littman 2012

Subtotal ***

85.2 (4.2)

107.2 (28.5)

91.3 (11)

91.2 (12.6)

-44.2 (8.7)

90.3 (11)

10

25

24

37

39

30

165

10

9

28

37

40

110

234

65.9 (14.7)

91.6 (28.5)

89.3 (10.9)

86.2 (17.4)

-47.4 (9.4)

87.7 (15)

3.37%

3.56%

4.52%

4.73%

5.62%

5.8%

6.52%

6.58%

6.59%

6.78%

7.13%

7.21%

7.3%

7.37%

8.44%

8.49%

100%

6.02%

10.18%

16.93%

21%

21.77%

24.11%

100%

1.3[0.19,2.41]

1.72[0.66,2.78]

-0.1[-0.96,0.75]

0.02[-0.8,0.84]

2.28[1.61,2.96]

0.37[-0.27,1.01]

0.19[-0.35,0.73]

0.99[0.46,1.52]

0.47[-0.06,1]

0.28[-0.22,0.79]

0.24[-0.21,0.69]

0.19[-0.25,0.63]

0.22[-0.2,0.65]

0.3[-0.12,0.72]

0.08[-0.16,0.33]

-0.08[-0.32,0.16]

0.45[0.19,0.7]

1.72[0.66,2.78]

0.53[-0.24,1.31]

0.18[-0.37,0.73]

0.33[-0.13,0.78]

0.35[-0.09,0.79]

0.18[-0.22,0.59]

0.38[0.1,0.65]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

484

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Heterogeneity: Tau2=0.04; Chi2=7.67, df=5(P=0.18); I2=34.83%

Test for overall effect: Z=2.66(P=0.01)

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 15.2.   Comparison 15 Subanalysis: outcomes by duration of
physical activity intervention, Outcome 2 Overall HRQoL (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.2.1 12 weeks or less

Mustian 2004

Herrero 2006

Murtezani 2014

Naumann 2012

Rogers 2009

Cuesta-Vargas 2014

Ergun 2013

Mehnert 2011

Cadmus 2009

Daley 2007

Vallance 2007

Subtotal ***

15 (5)

17.7 (8.3)

9.2 (2.1)

14.5 (10.6)

4.5 (8.4)

0.3 (0.2)

5.4 (21.5)

9.7 (21)

0.6 (7.5)

10.2 (11.2)

2.3 (11.1)

11

8

30

11

20

22

40

30

37

33

250

492

0 (5)

-10.4 (17.7)

-0.6 (2)

3.1 (11.4)

2.9 (12)

0.3 (0.1)

-6.7 (25.9)

5.6 (16.5)

-2.4 (9.8)

3.2 (11.3)

-0.2 (6.4)

10

8

32

10

18

20

20

27

37

69

85

336

Heterogeneity: Tau2=0.68; Chi2=98.44, df=10(P<0.0001); I2=89.84%

Test for overall effect: Z=3.61(P=0)

15.2.2 More than 12 weeks

Courneya 2003

Schmitz 2005

Saarto 2012

Subtotal ***

24

39

263

326

5.7 (7.4)

2.3 (4.5)

4.2 (16.2)

28

40

237

305

0.6 (7.4)

0.6 (4)

5.6 (15.4)

Heterogeneity: Tau2=0.14; Chi2=9.45, df=2(P=0.01); I2=78.84%

Test for overall effect: Z=1.11(P=0.26)

6.7%

6.89%

8.02%

8.3%

9.5%

9.63%

9.86%

9.94%

10.16%

10.27%

10.73%

100%

27.32%

31.67%

41.02%

100%

2.88[1.59,4.17]

1.92[0.68,3.17]

4.65[3.67,5.63]

1[0.08,1.92]

0.15[-0.49,0.79]

-0.07[-0.67,0.54]

0.52[-0.03,1.06]

0.22[-0.31,0.74]

0.34[-0.12,0.8]

0.62[0.2,1.04]

0.24[-0,0.49]

0.99[0.45,1.52]

0.68[0.12,1.24]

0.4[-0.05,0.84]

-0.09[-0.26,0.09]

0.27[-0.21,0.76]

Favours control

-10

-5

0

5

10

Favours physical activity

Analysis 15.3.   Comparison 15 Subanalysis: outcomes by duration of physical activity
intervention, Outcome 3 Overall emotional function/mental health (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.3.1 12 weeks or less

Banasik 2011

Herrero 2006

Mustian 2004

Pinto 2003

Loudon 2014

Rogers 2009

Cuesta-Vargas 2014

7

8

9

12

12

20

22

0.5 (0.4)

90.6 (9.3)

24.8 (2)

-10.8 (28.1)

-1.6 (0.7)

20 (3.1)

42.9 (19.2)

7

8

10

12

11

18

20

0.4 (0.3)

83.3 (14.8)

24.8 (3.2)

-27.2 (19.5)

-1.6 (0.5)

21.1 (2.9)

32.3 (33.3)

1.49%

1.62%

1.97%

2.3%

2.34%

3.5%

3.78%

0.25[-0.8,1.3]

0.56[-0.45,1.56]

-0.01[-0.91,0.89]

0.65[-0.17,1.48]

0.05[-0.77,0.87]

-0.36[-1,0.28]

0.39[-0.22,1]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

485

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Milne 2008

Do 2015

Mehnert 2011

Cantarero-Villanueva 2013

Murtezani 2014

Daley 2007

Pinto 2015

Pinto 2005

Loh 2014

Fillion 2008

Duijits 2012

Rogers 2015

Vallance 2007

Subtotal ***

19.6 (2.4)

87.4 (8.8)

77 (35.8)

-17175
(4279)

19.5 (3.3)

19.1 (4.2)

54.2 (9.3)

-8 (20.7)

19.9 (2.8)

48.5 (7.9)

73.9 (34.7)

20.6 (2.9)

20.3 (3.3)

29

32

30

32

30

33

39

39

63

44

37

105

250

853

Heterogeneity: Tau2=0.03; Chi2=27.63, df=19(P=0.09); I2=31.23%

Test for overall effect: Z=3.74(P=0)

15.3.2 More than 12 weeks

Basen-Enquist 2006

Courneya 2003

Littman 2012

Cadmus 2009

Schmitz 2005

Schmitz 2009

Subtotal ***

78.2 (10.6)

21.5 (3.4)

20.3 (4)

20.5 (3)

-45.6 (8.2)

53.2 (9.6)

28

24

30

37

39

112

270

Heterogeneity: Tau2=0; Chi2=3.49, df=5(P=0.63); I2=0%

Test for overall effect: Z=0.7(P=0.48)

16.7 (4.1)

70.4 (21.5)

69.1 (40.5)

-20390
(6113)

18.3 (3.5)

18.5 (3.3)

52.5 (9.6)

-16.5 (28.8)

20 (3.2)

47.5 (9.1)

77.5 (34.3)

19.7 (3.2)

19.9 (3.4)

77.2 (12)

20.7 (3)

20.8 (3.1)

19.8 (4.2)

-48.2 (8.2)

53.8 (8.7)

29

30

28

29

32

33

37

43

32

43

89

108

85

704

23

28

27

37

40

120

275

4.59%

4.67%

4.89%

4.91%

5.09%

5.37%

5.9%

6.16%

6.36%

6.46%

7.23%

10.29%

11.07%

100%

9.32%

9.47%

10.47%

13.6%

14.4%

42.76%

100%

0.85[0.31,1.39]

1.03[0.5,1.57]

0.21[-0.31,0.72]

0.61[0.09,1.12]

0.35[-0.15,0.85]

0.16[-0.32,0.64]

0.18[-0.27,0.63]

0.33[-0.1,0.77]

-0.04[-0.46,0.39]

0.12[-0.3,0.54]

-0.1[-0.49,0.28]

0.29[0.02,0.56]

0.11[-0.14,0.35]

0.26[0.12,0.39]

0.09[-0.46,0.64]

0.25[-0.3,0.79]

-0.14[-0.66,0.38]

0.19[-0.27,0.65]

0.31[-0.13,0.76]

-0.07[-0.32,0.19]

0.06[-0.11,0.23]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 15.4.   Comparison 15 Subanalysis: outcomes by duration of physical activity
intervention, Outcome 4 Overall emotional function/mental health (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.4.1 12 weeks or less

Herrero 2006

Mustian 2004

Naumann 2012

Rogers 2009

Murtezani 2014

Cormie 2014

Mehnert 2011

Cantarero-Villanueva 2013

Pinto 2005

Vallance 2007

Subtotal ***

9.3 (19.6)

2.4 (2.5)

1 (2.7)

0.9 (2.5)

2.1 (0.8)

4.4 (9)

2.3 (35.5)

-1445
(4452)

-3.8 (27.7)

0.5 (3.5)

8

9

11

20

30

43

30

32

39

250

472

-2.1 (5.9)

0.1 (1.7)

-0.1 (2.7)

-0.1 (2.7)

0.5 (0.9)

2.7 (8.6)

3.6 (17.6)

353 (3323)

-11.5 (25.8)

0.1 (2.5)

8

10

10

18

32

19

28

29

43

85

282

Heterogeneity: Tau2=0.24; Chi2=39.44, df=9(P<0.0001); I2=77.18%

Test for overall effect: Z=2.11(P=0.03)

6.69%

7.03%

7.88%

9.86%

10.3%

10.83%

11.08%

11.13%

11.82%

13.37%

100%

0.74[-0.28,1.77]

1.06[0.08,2.03]

0.39[-0.48,1.26]

0.38[-0.27,1.02]

1.8[1.21,2.4]

0.19[-0.35,0.73]

-0.04[-0.56,0.47]

-0.45[-0.96,0.06]

0.28[-0.15,0.72]

0.12[-0.13,0.36]

0.39[0.03,0.76]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

486

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.4.2 More than 12 weeks

Courneya 2003

Cadmus 2009

Schmitz 2005

Schmitz 2009

Saarto 2012

Subtotal ***

24

37

39

58

263

421

2.3 (3.1)

0.3 (2.2)

2.5 (4.4)

3.3 (23.2)

1.2 (17.8)

28

37

40

62

237

404

0.8 (2.9)

-0.5 (3.3)

0.3 (3.9)

3.1 (17.2)

1.9 (18.5)

Heterogeneity: Tau2=0.04; Chi2=8.55, df=4(P=0.07); I2=53.23%

Test for overall effect: Z=1.52(P=0.13)

12.83%

16.34%

16.73%

21.21%

32.9%

100%

0.49[-0.06,1.05]

0.28[-0.18,0.74]

0.52[0.08,0.97]

0.01[-0.35,0.37]

-0.04[-0.21,0.14]

0.19[-0.05,0.43]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 15.5.   Comparison 15 Subanalysis: outcomes by duration of physical
activity intervention, Outcome 5 Overall physical function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.5.1 12 weeks or less

Banasik 2011

Herrero 2006

Mustian 2004

Pinto 2003

Milne 2008

Rogers 2009

Cuesta-Vargas 2014

Mehnert 2011

Murtezani 2014

Do 2015

Daley 2007

Pinto 2015

Pinto 2005

Loh 2014

Fillion 2008

Duijits 2012

Rogers 2015

Vallance 2007

Subtotal ***

-0.8 (0.9)

94.1 (7.5)

26.9 (4.1)

32.3 (4.3)

24 (2.6)

23.3 (4.5)

42.9 (4.1)

89 (9.1)

22.6 (4.4)

89.4 (8.4)

25.6 (2.2)

87.1 (4.4)

30.3 (7.9)

24.9 (2.5)

45.1 (10.4)

84 (16.9)

24.1 (3.5)

25.1 (3)

7

8

9

12

29

20

22

30

30

32

33

39

39

63

44

87

105

250

859

-0.4 (0.3)

92.5 (6.6)

26.5 (4.1)

25.3 (8.2)

15.6 (4.5)

25.4 (2.3)

32.4 (32.5)

78.1 (21.2)

19.4 (4.4)

89 (8.7)

23.6 (5.7)

84.7 (15.9)

27.3 (6.8)

24.2 (2.2)

41.8 (9.8)

80.2 (17.1)

22.5 (5)

25 (3.3)

7

8

10

12

29

18

20

28

32

30

33

37

43

32

43

89

108

85

664

Heterogeneity: Tau2=0.12; Chi2=55.55, df=17(P<0.0001); I2=69.4%

Test for overall effect: Z=3.54(P=0)

15.5.2 More than 12 weeks

Basen-Enquist 2006

Courneya 2003

Littman 2012

Winters-Stone 2011

Cadmus 2009

Schmitz 2005

Schmitz 2009

Subtotal ***

82.5 (12.7)

25.3 (2.5)

25.4 (1.7)

51.7 (6.2)

25.1 (2.7)

-44.2 (5.6)

50.6 (8.2)

28

24

30

36

37

39

112

306

23

28

27

25

37

40

120

300

77.4 (11.5)

25.3 (2.8)

24.3 (4.4)

52.3 (5.9)

24 (4.1)

-48.3 (7.7)

49.1 (9.3)

2.66%

2.98%

3.34%

3.54%

4.68%

4.79%

5.05%

5.7%

5.82%

5.95%

6.03%

6.35%

6.46%

6.54%

6.58%

7.65%

7.85%

8.04%

100%

8.29%

8.68%

9.41%

9.9%

12.27%

12.66%

38.78%

100%

-0.48[-1.54,0.59]

0.21[-0.77,1.2]

0.09[-0.81,0.99]

1.03[0.17,1.89]

2.26[1.59,2.92]

-0.57[-1.22,0.08]

0.46[-0.16,1.07]

0.66[0.13,1.19]

0.72[0.2,1.23]

0.05[-0.45,0.54]

0.46[-0.03,0.95]

0.21[-0.25,0.66]

0.4[-0.04,0.83]

0.3[-0.12,0.73]

0.33[-0.1,0.75]

0.23[-0.07,0.52]

0.37[0.1,0.64]

0.05[-0.2,0.3]

0.37[0.17,0.58]

0.41[-0.15,0.97]

0[-0.55,0.55]

0.33[-0.19,0.86]

-0.1[-0.61,0.41]

0.31[-0.15,0.77]

0.6[0.15,1.05]

0.17[-0.09,0.43]

0.24[0.08,0.4]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

487

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Heterogeneity: Tau2=0; Chi2=5.75, df=6(P=0.45); I2=0%

Test for overall effect: Z=2.89(P=0)

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 15.6.   Comparison 15 Subanalysis: outcomes by duration of physical
activity intervention, Outcome 6 Overall physical function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.6.1 12 weeks or less

Herrero 2006

Mustian 2004

Murtezani 2014

Naumann 2012

Rogers 2009

Cormie 2014

Mehnert 2011

Vallance 2007

Subtotal ***

8

9

30

11

20

43

30

247

398

6.7 (5)

1.9 (2.6)

4.4 (1.5)

1.9 (3.3)

2.3 (5.1)

3.5 (5.2)

4 (10.8)

1 (3.3)

8

10

32

10

18

19

28

85

210

-1.7 (6.9)

-0.2 (1.6)

-1.3 (1.2)

0.8 (3.4)

2.6 (6)

-0.5 (5.7)

-2.1 (16.7)

0.2 (2.1)

Heterogeneity: Tau2=0.86; Chi2=73.76, df=7(P<0.0001); I2=90.51%

Test for overall effect: Z=2.72(P=0.01)

15.6.2 More than 12 weeks

Courneya 2003

Cadmus 2009

Schmitz 2005

Schmitz 2009

Saarto 2012

Subtotal ***

24

37

39

58

263

421

1.9 (2)

0.1 (6)

1.2 (4.2)

6.6 (17.1)

1.9 (13.7)

28

37

40

62

237

404

-0.2 (2.2)

-0.5 (7.4)

1.5 (6.8)

4.1 (17.3)

3.4 (13.4)

Heterogeneity: Tau2=0.08; Chi2=13.32, df=4(P=0.01); I2=69.96%

Test for overall effect: Z=0.96(P=0.34)

10.65%

11.44%

11.67%

11.94%

13.03%

13.38%

13.52%

14.36%

100%

14.4%

18.03%

18.51%

21.37%

27.69%

100%

1.32[0.21,2.43]

0.93[-0.03,1.89]

4.23[3.31,5.15]

0.32[-0.55,1.18]

-0.05[-0.69,0.58]

0.74[0.19,1.3]

0.43[-0.09,0.95]

0.26[0.02,0.51]

0.97[0.27,1.66]

0.98[0.4,1.56]

0.09[-0.37,0.54]

-0.05[-0.49,0.39]

0.14[-0.21,0.5]

-0.11[-0.29,0.06]

0.15[-0.16,0.45]

Favours control

-10

-5

0

5

10

Favours physical activity

Analysis 15.7.   Comparison 15 Subanalysis: outcomes by duration of physical
activity intervention, Outcome 7 Overall role function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.7.1 12 weeks or less

Banasik 2011

Herrero 2006

Mustian 2004

Loudon 2014

Milne 2008

Rogers 2009

Mehnert 2011

Murtezani 2014

7

8

9

12

29

20

30

30

3.5 (0.6)

97.6 (5.9)

2.4 (1.5)

-1.3 (0.3)

22.2 (3)

21.4 (4.8)

90 (20.3)

24.2 (2.8)

7

8

9

11

29

18

27

32

3.2 (0.6)

100 (0)

2.8 (1.5)

-1.3 (0.4)

12.5 (4.8)

23.8 (3.2)

79.6 (25)

23 (2.5)

4.71%

5%

5.45%

6.15%

7.12%

7.38%

8.37%

8.56%

0.34[-0.72,1.4]

-0.54[-1.55,0.46]

-0.23[-1.15,0.7]

0[-0.82,0.82]

2.39[1.71,3.08]

-0.57[-1.22,0.08]

0.45[-0.07,0.98]

0.45[-0.06,0.95]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

488

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Do 2015

Daley 2007

Loh 2014

Rogers 2015

Vallance 2007

Subtotal ***

78.1 (19.5)

22.9 (4.5)

23.4 (4.3)

22.3 (4.5)

23.2 (4)

32

33

63

105

250

628

30

33

32

108

85

429

79.2 (14.6)

20.3 (5.6)

22.2 (5)

20.3 (5.5)

22.7 (4.6)

Heterogeneity: Tau2=0.21; Chi2=53.08, df=12(P<0.0001); I2=77.39%

Test for overall effect: Z=1.92(P=0.05)

15.7.2 More than 12 weeks

Basen-Enquist 2006

Courneya 2003

Littman 2012

Cadmus 2009

Schmitz 2005

Subtotal ***

86.1 (22.2)

23.4 (4)

22.6 (3.9)

23.1 (4.7)

-49.2 (6.5)

28

24

30

37

39

158

23

28

27

37

40

155

73 (24.5)

23.1 (4)

21.7 (4.7)

20.6 (7.2)

-50 (6.2)

Heterogeneity: Tau2=0; Chi2=2.29, df=4(P=0.68); I2=0%

Test for overall effect: Z=2.33(P=0.02)

8.61%

8.67%

9.18%

10.32%

10.47%

100%

15.75%

16.77%

18.35%

23.52%

25.6%

100%

-0.06[-0.56,0.44]

0.5[0.01,0.99]

0.25[-0.18,0.68]

0.4[0.12,0.67]

0.12[-0.13,0.37]

0.3[-0.01,0.6]

0.55[-0.01,1.12]

0.07[-0.47,0.62]

0.21[-0.31,0.73]

0.41[-0.05,0.87]

0.12[-0.32,0.57]

0.27[0.04,0.49]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 15.8.   Comparison 15 Subanalysis: outcomes by duration of physical
activity intervention, Outcome 8 Overall role function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.8.1 12 weeks or less

Herrero 2006

Mustian 2004

Naumann 2012

Rogers 2009

Cormie 2014

Murtezani 2014

Mehnert 2011

Vallance 2007

Subtotal ***

2.1 (13.9)

0.6 (1.6)

1.5 (4.4)

0.4 (3.3)

4.9 (7.1)

1.7 (0.7)

6.7 (23.8)

0.6 (4.1)

8

9

11

20

43

30

30

250

401

Heterogeneity: Tau2=0.1; Chi2=15.72, df=7(P=0.03); I2=55.47%

Test for overall effect: Z=1.56(P=0.12)

15.8.2 More than 12 weeks

Courneya 2003

Cadmus 2009

Schmitz 2005

Saarto 2012

Subtotal ***

0.9 (2.8)

-0.3 (3.7)

1.2 (4.2)

2.4 (21.5)

24

37

39

263

363

Heterogeneity: Tau2=0; Chi2=0.86, df=3(P=0.84); I2=0%

Test for overall effect: Z=0.44(P=0.66)

2.1 (5.9)

0.8 (1.6)

0.5 (4.5)

1.4 (4.3)

1.7 (7.1)

0.9 (0.6)

5.6 (27)

-0 (2.7)

0.4 (2.7)

-0.5 (3.4)

1.5 (6.8)

3.8 (21.6)

8

10

10

18

19

32

27

85

209

28

37

40

237

342

7.06%

7.93%

8.47%

12.03%

14.03%

14.15%

14.63%

21.7%

100%

7.32%

10.53%

11.24%

70.92%

100%

0[-0.98,0.98]

-0.15[-1.05,0.76]

0.22[-0.64,1.08]

-0.26[-0.9,0.38]

0.45[-0.1,0.99]

1.16[0.62,1.7]

0.04[-0.48,0.56]

0.17[-0.08,0.41]

0.24[-0.06,0.55]

0.18[-0.37,0.73]

0.06[-0.4,0.51]

-0.05[-0.49,0.39]

-0.06[-0.24,0.11]

-0.03[-0.18,0.11]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

489

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 15.9.   Comparison 15 Subanalysis: outcomes by duration of physical activity
intervention, Outcome 9 Overall social well-being/function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.9.1 12 weeks or less

Banasik 2011

Herrero 2006

Mustian 2004

Rogers 2014

Rogers 2009

Milne 2008

Mehnert 2011

Murtezani 2014

Daley 2007

Loh 2014

Kiecolt-Glaser 2014

Rogers 2015

Vallance 2007

Subtotal ***

2.8 (0.7)

87.5 (19.4)

8.6 (1.9)

7.3 (4.9)

22.6 (4.1)

20.7 (4)

85.4 (20.9)

20.2 (2.8)

23.3 (4.8)

21.5 (4.9)

95.2 (10.8)

21 (5.7)

22.9 (5)

7

8

9

20

20

29

30

30

33

63

96

105

250

700

Heterogeneity: Tau2=0.03; Chi2=18.26, df=12(P=0.11); I2=34.3%

Test for overall effect: Z=2.74(P=0.01)

15.9.2 More than 12 weeks

Basen-Enquist 2006

Courneya 2003

Littman 2012

Cadmus 2009

Schmitz 2009

Subtotal ***

84.6 (16.9)

21.1 (3.5)

22.1 (5)

22.3 (4.9)

14.9 (5.2)

28

24

30

37

59

178

Heterogeneity: Tau2=0; Chi2=0.71, df=4(P=0.95); I2=0%

Test for overall effect: Z=1.45(P=0.15)

3.2 (0.8)

91.7 (23.6)

9 (1.8)

3.1 (3.2)

21.8 (5.7)

19.4 (3.9)

79.9 (22.7)

18.3 (2.7)

20.4 (6.8)

19.6 (4.9)

93.8 (9.3)

20.7 (5.8)

23 (5.1)

84.9 (19.2)

20.7 (3.6)

20.9 (6)

20.6 (7.2)

14.1 (5.8)

7

8

10

22

18

29

28

32

33

32

90

108

85

502

23

28

27

37

62

177

2.1%

2.43%

2.83%

4.99%

5.1%

6.99%

7.02%

7.09%

7.58%

9.06%

14.01%

14.87%

15.93%

100%

14.33%

14.64%

16.03%

20.79%

34.21%

100%

-0.45[-1.51,0.62]

-0.18[-1.17,0.8]

-0.19[-1.09,0.71]

1.01[0.36,1.65]

0.16[-0.48,0.8]

0.32[-0.19,0.84]

0.25[-0.27,0.76]

0.68[0.17,1.2]

0.49[-0,0.98]

0.38[-0.05,0.81]

0.14[-0.15,0.43]

0.05[-0.22,0.32]

-0[-0.25,0.24]

0.23[0.06,0.39]

-0.02[-0.57,0.54]

0.11[-0.43,0.66]

0.22[-0.31,0.74]

0.27[-0.18,0.73]

0.14[-0.21,0.5]

0.15[-0.05,0.36]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 15.10.   Comparison 15 Subanalysis: outcomes by duration of physical
activity intervention, Outcome 10 Overall social well-being/function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.10.1 12 weeks or less

Mustian 2004

Naumann 2012

Rogers 2009

Rogers 2014

Murtezani 2014

Cormie 2014

Mehnert 2011

Vallance 2007

Subtotal ***

9

11

20

20

30

43

30

250

413

1.5 (1.5)

0.9 (3.3)

0.9 (2.6)

2.1 (3.2)

2.1 (0.8)

3.5 (8.5)

7.3 (22.3)

0.2 (4.8)

10

10

18

22

32

19

28

85

224

0.4 (1.2)

-0.2 (3.3)

-1.2 (2.7)

-0.8 (3.5)

0.5 (0.9)

2.5 (8.3)

3.1 (24.3)

-4.1 (3.3)

Heterogeneity: Tau2=0.2; Chi2=25.43, df=7(P=0); I2=72.47%

Test for overall effect: Z=3.77(P=0)

8.73%

9.53%

11.93%

12.3%

12.81%

13.58%

13.91%

17.22%

100%

0.76[-0.18,1.7]

0.32[-0.54,1.18]

0.78[0.11,1.44]

0.85[0.21,1.48]

1.8[1.21,2.4]

0.12[-0.42,0.66]

0.18[-0.34,0.69]

0.97[0.71,1.23]

0.73[0.35,1.11]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

490

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.10.2 More than 12 weeks

Courneya 2003

Cadmus 2009

Schmitz 2009

Saarto 2012

Subtotal ***

24

37

59

263

383

0.6 (2.4)

0.6 (4.6)

4.4 (33.8)

5 (21.1)

28

37

62

237

364

-0.5 (3.3)

-1 (3.2)

0.7 (34)

8.8 (20.8)

Heterogeneity: Tau2=0.06; Chi2=8.78, df=3(P=0.03); I2=65.82%

Test for overall effect: Z=0.72(P=0.47)

17.52%

21.07%

26%

35.41%

100%

0.37[-0.18,0.92]

0.4[-0.06,0.86]

0.11[-0.25,0.47]

-0.18[-0.36,-0.01]

0.11[-0.19,0.42]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 15.11.   Comparison 15 Subanalysis: outcomes by duration of physical
activity intervention, Outcome 11 Overall cognitive function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.11.1 12 weeks or less

Pinto 2003

Herrero 2006

Rogers 2009

Mehnert 2011

Cantarero-Villanueva 2013

Subtotal ***

-4.3 (2.5)

91.7 (12.6)

-124.5
(30.8)

81.1 (16.8)

-37.9 (8.5)

12

8

19

30

32

101

Heterogeneity: Tau2=0; Chi2=3.41, df=4(P=0.49); I2=0%

Test for overall effect: Z=2.68(P=0.01)

15.11.2 More than 12 weeks

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

-7.2 (2.1)

89.6 (12.4)

-135.5
(19.5)

78.4 (24.4)

-43 (10)

6

8

18

27

29

88

0

7.48%

8.81%

19.97%

31.37%

32.37%

100%

1.14[0.07,2.2]

0.16[-0.82,1.14]

0.42[-0.24,1.07]

0.13[-0.39,0.65]

0.55[0.03,1.06]

0.4[0.11,0.69]

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 15.12.   Comparison 15 Subanalysis: outcomes by duration of physical
activity intervention, Outcome 12 Overall cognitive function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.12.1 12 weeks or less

Herrero 2006

Rogers 2009

Mehnert 2011

Cantarero-Villanueva 2013

Subtotal ***

6.2 (19.8)

4.2 (16.8)

1.7 (22.4)

2.2 (7.6)

8

20

30

32

90

8.3 (14.8)

-4.7 (25.9)

6.2 (24.6)

-0.2 (5.5)

8

18

27

29

82

Heterogeneity: Tau2=0; Chi2=3.1, df=3(P=0.38); I2=3.09%

Test for overall effect: Z=0.88(P=0.38)

15.12.2 More than 12 weeks

9.67%

22.08%

33.2%

35.05%

100%

-0.11[-1.09,0.87]

0.4[-0.24,1.05]

-0.19[-0.71,0.33]

0.35[-0.16,0.86]

0.14[-0.17,0.44]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

491

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Saarto 2012

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.94(P=0.05)

Mean(SD)

-1 (18.2)

N

263

263

Mean(SD)

2.2 (18.5)

N

237

237

Random, 95% CI

Random, 95% CI

100%

100%

-0.17[-0.35,0]

-0.17[-0.35,0]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 15.13.   Comparison 15 Subanalysis: outcomes by duration of physical
activity intervention, Outcome 13 Overall general health (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.13.1 12 weeks or less

Herrero 2006

Mustian 2004

Rogers 2009

Ergun 2013

Mehnert 2011

Do 2015

Subtotal ***

81.3 (10.7)

18.6 (4.8)

3.5 (0.9)

71.6 (19.9)

74.4 (11.8)

87.3 (13.7)

8

9

20

40

30

32

139

Heterogeneity: Tau2=0.06; Chi2=7.85, df=5(P=0.16); I2=36.35%

Test for overall effect: Z=1.03(P=0.31)

15.13.2 More than 12 weeks

Basen-Enquist 2006

Cadmus 2009

Schmitz 2005

Subtotal ***

77.4 (11.6)

50 (8.8)

53.8 (5.3)

28

37

39

104

Heterogeneity: Tau2=0.16; Chi2=7.33, df=2(P=0.03); I2=72.72%

Test for overall effect: Z=0.78(P=0.44)

62.5 (16.1)

19.3 (1.9)

3.8 (0.5)

67.9 (16.7)

70 (20.8)

82.4 (19.9)

67.1 (13.4)

51.7 (8.4)

53.2 (6)

8

9

18

20

28

30

113

23

37

40

100

7.47%

10.02%

16.92%

20.99%

21.91%

22.68%

100%

30.21%

34.61%

35.19%

100%

1.3[0.19,2.41]

-0.18[-1.11,0.74]

-0.4[-1.04,0.25]

0.19[-0.35,0.73]

0.26[-0.26,0.77]

0.28[-0.22,0.79]

0.17[-0.16,0.5]

0.81[0.24,1.39]

-0.2[-0.65,0.26]

0.1[-0.34,0.55]

0.21[-0.32,0.75]

Favours control

-100

-50

0

50

100

Favours physical activity

Analysis 15.14.   Comparison 15 Subanalysis: outcomes by duration of physical
activity intervention, Outcome 14 Overall general health (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.14.1 12 weeks or less

Herrero 2006

Mustian 2004

Rogers 2009

Ergun 2013

Cormie 2014

Mehnert 2011

Subtotal ***

8

9

20

40

43

30

150

17.7 (8.3)

0.2 (1.9)

0.2 (0.6)

5.4 (21.5)

3.7 (7)

6.6 (13.7)

-10.4 (17.7)

0.7 (2.5)

0.2 (0.7)

-6.7 (25.9)

2.8 (7.1)

3.2 (19.7)

8

10

18

20

19

28

103

Heterogeneity: Tau2=0.11; Chi2=9.79, df=5(P=0.08); I2=48.91%

Test for overall effect: Z=1.49(P=0.14)

7.4%

11.85%

17.85%

20.6%

20.76%

21.55%

100%

1.92[0.68,3.17]

-0.2[-1.1,0.71]

-0.03[-0.67,0.61]

0.52[-0.03,1.06]

0.13[-0.41,0.67]

0.2[-0.32,0.71]

0.29[-0.09,0.67]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

492

Favours control

-100

-50

0

50

100

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.14.2 More than 12 weeks

Cadmus 2009

Schmitz 2005

Saarto 2012

Subtotal ***

37

39

263

339

0.2 (4.4)

0.7 (4.8)

4.2 (16.2)

37

40

237

314

-0.1 (5.1)

-0.6 (3.9)

5.6 (15.4)

Heterogeneity: Tau2=0.01; Chi2=2.64, df=2(P=0.27); I2=24.13%

Test for overall effect: Z=0.1(P=0.92)

17.92%

18.76%

63.32%

100%

0.06[-0.39,0.52]

0.29[-0.15,0.74]

-0.09[-0.26,0.09]

0.01[-0.2,0.22]

Favours control

-100

-50

0

50

100

Favours physical activity

Analysis 15.15.   Comparison 15 Subanalysis: outcomes by duration of physical
activity intervention, Outcome 15 Overall sexual function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

15.15.1 12 weeks or less

Pinto 2005

Pinto 2003

Duijits 2012

Subtotal ***

42.8 (9.2)

42.5 (9.2)

0.6 (0.8)

12

39

53

104

Heterogeneity: Tau2=0; Chi2=1.16, df=2(P=0.56); I2=0%

Test for overall effect: Z=0.81(P=0.42)

15.15.2 More than 12 weeks

Schmitz 2005

Schmitz 2009

Subtotal ***

-51 (7.5)

-27.3 (5.3)

39

57

96

Heterogeneity: Tau2=0; Chi2=0.38, df=1(P=0.54); I2=0%

Test for overall effect: Z=1.46(P=0.14)

43.7 (6.1)

40.1 (6.3)

0.6 (0.8)

-53.5 (8)

-28.1 (6.2)

6

43

65

114

40

57

97

7.48%

37.86%

54.66%

100%

-0.11[-1.09,0.87]

0.29[-0.14,0.73]

0.01[-0.35,0.38]

0.11[-0.16,0.38]

40.67%

59.33%

100%

0.32[-0.12,0.76]

0.14[-0.23,0.51]

0.21[-0.07,0.49]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 15.16.   Comparison 15 Subanalysis: outcomes by duration of physical
activity intervention, Outcome 16 Overall sexual function (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

15.16.1 12 weeks or less

Subtotal ***

0

0

Not estimable

Heterogeneity: Not applicable

Test for overall effect: Not applicable

15.16.2 More than 12 weeks

Schmitz 2009

Saarto 2012

Schmitz 2005

Subtotal ***

57

263

39

359

7.2 (14.6)

4.3 (25.4)

1.7 (4.8)

57

237

40

334

-0.2 (16.7)

3.8 (24.4)

0.2 (5.2)

Heterogeneity: Tau2=4.09; Chi2=4.03, df=2(P=0.13); I2=50.31%

Test for overall effect: Z=1.5(P=0.13)

20.91%

29.42%

49.67%

100%

7.4[1.64,13.16]

0.5[-3.86,4.86]

1.5[-0.71,3.71]

2.44[-0.76,5.64]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

493

Favours control

-20

-10

0

10

20

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 15.17.   Comparison 15 Subanalysis: outcomes by duration of
physical activity intervention, Outcome 17 Overall sleep (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

15.17.1 12 weeks or less

Rogers 2013

Bower 2011

Rogers 2009

Rogers 2014

Mehnert 2011

Subtotal ***

6.3 (2.7)

8.1 (2.5)

6.7 (4.2)

6.7 (3.7)

23.8 (27)

11

16

20

20

30

97

Heterogeneity: Tau2=0; Chi2=3.98, df=4(P=0.41); I2=0%

Test for overall effect: Z=0.59(P=0.56)

15.17.2 More than 12 weeks

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

6.2 (3.2)

7.7 (2.6)

5.5 (4)

7.1 (3.2)

38.3 (31.6)

9

15

18

22

27

91

0

10.7%

16.68%

20.26%

22.6%

29.76%

100%

0.03[-0.85,0.91]

0.15[-0.55,0.86]

0.28[-0.36,0.92]

-0.11[-0.72,0.49]

-0.49[-1.02,0.04]

-0.09[-0.37,0.2]

Not estimable

Favours Physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 15.18.   Comparison 15 Subanalysis: outcomes by duration of
physical activity intervention, Outcome 18 Overall sleep (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.18.1 12 weeks or less

Rogers 2009

Rogers 2014

Mehnert 2011

Subtotal ***

0.5 (2.1)

-1.3 (3.2)

-5.4 (29.9)

20

20

29

69

Heterogeneity: Tau2=0; Chi2=0.16, df=2(P=0.92); I2=0%

Test for overall effect: Z=0.82(P=0.41)

15.18.2 More than 12 weeks

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0.3 (4.7)

-2.2 (4.4)

-9.9 (33.3)

18

22

27

67

0

28.01%

30.76%

41.24%

100%

0.05[-0.59,0.68]

0.23[-0.38,0.84]

0.14[-0.38,0.67]

0.14[-0.2,0.48]

Not estimable

Favours Physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 15.19.   Comparison 15 Subanalysis: outcomes by duration of
physical activity intervention, Outcome 19 Overall anxiety (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.19.1 12 weeks or less

Segar 1998

10

28.5 (3)

5

39.5 (6)

6.36%

-2.49[-3.98,-1]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

494

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Pinto 2003

Rogers 2014

Milne 2008

Mehnert 2011

Cantarero-Villanueva 2013

Subtotal ***

12

20

29

30

32

133

7.6 (7.3)

45.6 (8.9)

15.3 (6.2)

4.8 (3.5)

42.5 (8.6)

10.5 (3.7)

45.7 (8)

21 (5.7)

7.1 (5)

49.9 (11.7)

6

22

29

28

29

119

Heterogeneity: Tau2=0.15; Chi2=11.63, df=5(P=0.04); I2=56.99%

Test for overall effect: Z=3.12(P=0)

11.46%

19.08%

20.64%

21.16%

21.3%

100%

-0.43[-1.43,0.56]

-0.01[-0.62,0.59]

-0.94[-1.49,-0.4]

-0.54[-1.06,-0.01]

-0.72[-1.24,-0.2]

-0.67[-1.09,-0.25]

15.19.2 More than 12 weeks

Cadmus 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.61(P=0.54)

32.1 (12.3)

37

37

37

37

34.1 (15.4)

100%

100%

-0.14[-0.6,0.31]

-0.14[-0.6,0.31]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 15.20.   Comparison 15 Subanalysis: outcomes by duration of
physical activity intervention, Outcome 20 Overall anxiety (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

15.20.1 12 weeks or less

Rogers 2014

Mehnert 2011

Cantarero-Villanueva 2013

Subtotal ***

-4 (6.5)

-1.7 (3.7)

-4.2 (9.8)

20

30

32

82

Heterogeneity: Tau2=0; Chi2=0.39, df=2(P=0.82); I2=0%

Test for overall effect: Z=2.99(P=0)

15.20.2 More than 12 weeks

Cadmus 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.66(P=0.51)

-0.7 (9.2)

37

37

-1.8 (5)

0.2 (4.9)

0.8 (5.5)

0.5 (5.8)

22

28

29

79

37

37

26.41%

36.34%

37.26%

100%

-0.37[-0.99,0.24]

-0.42[-0.95,0.1]

-0.61[-1.12,-0.09]

-0.48[-0.79,-0.16]

100%

100%

-0.15[-0.61,0.3]

-0.15[-0.61,0.3]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 15.21.   Comparison 15 Subanalysis: outcomes by duration of physical
activity intervention, Outcome 21 Overall depression (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.21.1 12 weeks or less

Segar 1998

Pinto 2003

Bower 2011

Rogers 2014

Ergun 2013

10

12

16

20

40

5.5 (2)

6.2 (7.2)

7.7 (5.8)

44.2 (8.6)

6.9 (6.8)

5

6

15

22

20

10 (2)

9.8 (6.8)

11.6 (7.1)

25.1 (44.2)

5.2 (5.2)

4.6%

7.2%

10.05%

11.36%

12.46%

-2.12[-3.51,-0.73]

-0.49[-1.49,0.5]

-0.59[-1.31,0.13]

0.58[-0.04,1.19]

0.27[-0.27,0.81]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

495

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Mehnert 2011

Cantarero-Villanueva 2013

Daley 2007

Kiecolt-Glaser 2014

Subtotal ***

2.7 (3)

45.6 (9.7)

6 (6.5)

8.1 (8.6)

30

32

33

96

289

Heterogeneity: Tau2=0.17; Chi2=25.79, df=8(P=0); I2=68.98%

Test for overall effect: Z=2.02(P=0.04)

15.21.2 More than 12 weeks

Payne 2008

Kaltsatou 2011

Cadmus 2009

Subtotal ***

12.7 (8.7)

16.5 (1.7)

9.6 (9.3)

10

13

37

60

Heterogeneity: Tau2=0.15; Chi2=4.31, df=2(P=0.12); I2=53.56%

Test for overall effect: Z=0.99(P=0.32)

4.6 (4.4)

53.7 (11.6)

10.3 (7.2)

9.2 (8.2)

11.4 (7.9)

22.3 (7.7)

10.8 (10.1)

28

29

33

90

248

10

13

37

60

12.67%

12.71%

13.08%

15.89%

100%

26.36%

28.3%

45.34%

100%

-0.51[-1.04,0.01]

-0.75[-1.28,-0.23]

-0.63[-1.12,-0.13]

-0.13[-0.42,0.16]

-0.36[-0.7,-0.01]

0.15[-0.73,1.03]

-1[-1.83,-0.18]

-0.12[-0.58,0.33]

-0.3[-0.9,0.3]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 15.22.   Comparison 15 Subanalysis: outcomes by duration of physical
activity intervention, Outcome 22 Overall depression (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.22.1 12 weeks or less

Naumann 2012

Rogers 2014

Mehnert 2011

Cantarero-Villanueva 2013

Subtotal ***

-3.6 (4.3)

-1.7 (6.9)

2.7 (3)

-2.9 (7.8)

11

20

30

32

93

Heterogeneity: Tau2=0; Chi2=1.84, df=3(P=0.61); I2=0%

Test for overall effect: Z=3.91(P<0.0001)

15.22.2 More than 12 weeks

Cadmus 2009

Saarto 2012

Subtotal ***

0.3 (6.4)

-0.3 (3.3)

37

263

300

Heterogeneity: Tau2=0.01; Chi2=1.24, df=1(P=0.27); I2=19.17%

Test for overall effect: Z=0.04(P=0.97)

2 (4.6)

1.1 (4.2)

4.6 (4.4)

1.5 (7.4)

1.7 (6.3)

-0.5 (3.4)

10

22

28

29

89

37

237

274

9.95%

23.6%

32.55%

33.91%

100%

19.98%

80.02%

100%

-1.21[-2.16,-0.26]

-0.49[-1.1,0.13]

-0.51[-1.04,0.01]

-0.57[-1.09,-0.06]

-0.6[-0.89,-0.3]

-0.22[-0.68,0.24]

0.06[-0.12,0.24]

0[-0.21,0.22]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 15.23.   Comparison 15 Subanalysis: outcomes by duration of
physical activity intervention, Outcome 23 Overall fatigue (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.23.1 12 weeks or less

Banasik 2011

Pinto 2003

7

12

1 (0.9)

7.2 (6.4)

7

6

1.6 (1)

9 (6.4)

1.99%

2.29%

-0.57[-1.65,0.51]

-0.27[-1.26,0.71]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

496

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Rogers 2013

Loudon 2014

Bower 2011

Rogers 2009

Cuesta-Vargas 2014

Rogers 2014

Milne 2008

Cantarero-Villanueva 2013

Ergun 2013

Mehnert 2011

Do 2015

Daley 2007

Pinto 2015

Pinto 2005

Fillion 2008

Kiecolt-Glaser 2014

Vallance 2007

Short 2014

Subtotal ***

4.2 (1.8)

1.9 (2.2)

3.4 (1.8)

-12.4 (10.4)

4 (1.8)

4.1 (2.1)

11.9 (3.2)

3.8 (1.8)

2.9 (2.2)

28.5 (25.6)

16.8 (13.3)

2.1 (1.8)

-43.8 (7.8)

27.1 (21.4)

2.7 (0.7)

6.3 (19.6)

-42.7 (8.4)

-41.5 (9.3)

11

12

16

20

22

20

29

32

40

30

32

33

39

39

44

96

250

195

979

Heterogeneity: Tau2=0.07; Chi2=43.47, df=19(P=0); I2=56.29%

Test for overall effect: Z=4.82(P<0.0001)

15.23.2 More than 12 weeks

Payne 2008

Courneya 2003

Littman 2012

Winters-Stone 2011

Cadmus 2009

Subtotal ***

4.7 (2.6)

-8.3 (7.9)

-45 (5.3)

45 (5.3)

-51.9 (9)

9

24

30

36

37

136

Heterogeneity: Tau2=0; Chi2=3.21, df=4(P=0.52); I2=0%

Test for overall effect: Z=0.14(P=0.89)

4.2 (1.6)

2.1 (2.5)

4.9 (1.3)

-10.1 (6.6)

5.2 (3.2)

4 (1.8)

17.4 (4.7)

6.2 (1.7)

3.3 (1.8)

39.9 (25.1)

22.3 (15.1)

3.4 (1.9)

-41.2 (8.5)

42.3 (26.2)

2.9 (0.8)

12.7 (19)

-42.6 (8.7)

-39.8 (10.4)

3.5 (1.7)

-8.8 (8.1)

-43.1 (10.3)

43.1 (10.3)

-50.6 (10)

9

11

15

18

20

22

29

29

20

27

30

33

37

43

43

90

85

104

678

9

28

27

31

37

132

2.72%

3.02%

3.43%

4.16%

4.37%

4.44%

4.71%

4.81%

5.04%

5.15%

5.39%

5.43%

5.92%

6.01%

6.27%

7.9%

8.44%

8.53%

100%

6.5%

19.47%

21.27%

24.93%

27.82%

100%

0[-0.88,0.88]

-0.07[-0.89,0.75]

-0.93[-1.67,-0.18]

-0.26[-0.9,0.38]

-0.46[-1.07,0.15]

0.05[-0.56,0.66]

-1.35[-1.92,-0.78]

-1.38[-1.94,-0.82]

-0.17[-0.71,0.37]

-0.44[-0.97,0.08]

-0.38[-0.89,0.12]

-0.71[-1.21,-0.21]

-0.32[-0.77,0.14]

-0.63[-1.07,-0.18]

-0.27[-0.69,0.15]

-0.33[-0.62,-0.04]

-0.01[-0.26,0.23]

-0.17[-0.41,0.06]

-0.42[-0.59,-0.25]

0.52[-0.42,1.46]

0.06[-0.48,0.61]

-0.23[-0.75,0.29]

0.23[-0.25,0.72]

-0.14[-0.59,0.32]

0.02[-0.22,0.26]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 15.24.   Comparison 15 Subanalysis: outcomes by duration of
physical activity intervention, Outcome 24 Overall fatigue (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.24.1 12 weeks or less

Herrero 2006

Naumann 2012

Rogers 2013

Loudon 2014

Rogers 2009

Cantarero-Villanueva 2013

Mehnert 2011

Daley 2007

Pinto 2005

Vallance 2007

8

11

11

12

20

32

30

33

39

-4.2 (19.6)

-3.6 (4.4)

4.2 (2)

1.9 (2.2)

1.9 (9.6)

-2 (1.8)

-0.7 (20.7)

2.1 (1.8)

-14.9 (23.5)

250

2.5 (8.2)

8

10

9

11

18

29

27

33

43

85

6.4 (14.5)

2 (4.6)

3.9 (1.5)

2.1 (2.5)

4.2 (12.3)

0.3 (1.4)

-2.9 (25.3)

3.4 (1.9)

1.8 (23.5)

1.2 (6.6)

7.23%

7.65%

8.13%

8.64%

10.14%

10.75%

11.16%

11.35%

11.77%

13.19%

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

-0.58[-1.59,0.43]

-1.21[-2.16,-0.26]

0.16[-0.72,1.04]

-0.07[-0.89,0.75]

-0.21[-0.84,0.43]

-1.45[-2.02,-0.88]

0.09[-0.43,0.61]

-0.71[-1.21,-0.21]

-0.7[-1.15,-0.26]

0.17[-0.08,0.42]

497

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Subtotal ***

Mean(SD)

N

446

N

273

Heterogeneity: Tau2=0.28; Chi2=42.74, df=9(P<0.0001); I2=78.94%

Test for overall effect: Z=2.19(P=0.03)

Mean(SD)

Random, 95% CI

Random, 95% CI

100%

-0.44[-0.83,-0.05]

15.24.2 More than 12 weeks

Courneya 2003

Saarto 2012

Subtotal ***

24

263

287

9.3 (10.2)

-2.4 (9.1)

28

237

265

2 (7.5)

-2.4 (8.6)

Heterogeneity: Tau2=0.28; Chi2=7.16, df=1(P=0.01); I2=86.04%

Test for overall effect: Z=0.89(P=0.37)

44.23%

55.77%

100%

0.81[0.24,1.38]

0[-0.18,0.18]

0.36[-0.43,1.15]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 15.25.   Comparison 15 Subanalysis: outcomes by duration of physical
activity intervention, Outcome 25 Overall pain/disability (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.25.1 12 weeks or less

Mustian 2004

Loudon 2014

Rogers 2009

Mehnert 2011

Do 2015

Duijits 2012

Subtotal ***

9.1 (1.4)

0.8 (1.5)

-3 (3)

79.4 (23.1)

21.1 (24.6)

79.3 (23.6)

9

12

20

30

32

87

190

Heterogeneity: Tau2=0; Chi2=2.48, df=5(P=0.78); I2=0%

Test for overall effect: Z=0.3(P=0.76)

15.25.2 More than 12 weeks

Portela 2008

Basen-Enquist 2006

Cadmus 2009

Subtotal ***

-20.6 (20.2)

79.7 (10.6)

50.3 (9.1)

25

28

37

90

Heterogeneity: Tau2=0.1; Chi2=4.17, df=2(P=0.12); I2=52.08%

Test for overall effect: Z=0.86(P=0.39)

9.1 (1.7)

1.4 (2.2)

-2.3 (2.8)

73.5 (24.8)

16.5 (26.7)

78.8 (23.8)

-20.8 (15.5)

72.1 (11.5)

50.8 (9)

10

11

18

28

30

89

186

9

23

37

69

5.06%

6.04%

10.04%

15.36%

16.48%

47.02%

100%

24.87%

34.14%

40.99%

100%

0.01[-0.89,0.91]

-0.33[-1.15,0.5]

-0.26[-0.89,0.38]

0.24[-0.27,0.76]

0.18[-0.32,0.68]

0.02[-0.28,0.32]

0.03[-0.17,0.23]

0.01[-0.75,0.77]

0.68[0.11,1.25]

-0.05[-0.51,0.4]

0.21[-0.27,0.7]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 15.26.   Comparison 15 Subanalysis: outcomes by duration of physical
activity intervention, Outcome 26 Overall pain/disability (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.26.1 12 weeks or less

Mustian 2004

Cormie 2014

Mehnert 2011

Subtotal ***

-0.2 (1.3)

3.4 (6.5)

-2.4 (25)

9

43

30

82

0 (1.4)

2 (6.2)

-7.6 (25.2)

10

19

28

57

14.64%

40.67%

44.69%

100%

-0.15[-1.06,0.75]

0.22[-0.33,0.76]

0.21[-0.31,0.72]

0.16[-0.19,0.5]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

498

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Heterogeneity: Tau2=0; Chi2=0.54, df=2(P=0.76); I2=0%

Test for overall effect: Z=0.89(P=0.37)

15.26.2 More than 12 weeks

Cadmus 2009

Irwin 2015

Subtotal ***

-2.2 (11.3)

-6 (19)

37

45

82

37

38

75

-0.1 (7)

0.7 (18.6)

Heterogeneity: Tau2=0; Chi2=0.17, df=1(P=0.68); I2=0%

Test for overall effect: Z=1.81(P=0.07)

47.55%

52.45%

100%

-0.22[-0.68,0.24]

-0.35[-0.79,0.08]

-0.29[-0.61,0.02]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 15.27.   Comparison 15 Subanalysis: outcomes by duration of physical
activity intervention, Outcome 27 Overall self-esteem/body image (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.27.1 12 weeks or less

Segar 1998

Pinto 2003

Loudon 2014

Musanti 2012

Mehnert 2011

Milne 2008

Daley 2007

Do 2015

Pinto 2005

Subtotal ***

10

12

12

30

27

29

33

32

39

33 (1.8)

32.3 (4.3)

-1.4 (0.3)

23.8 (3.5)

-5.5 (1.7)

-17.9 (6.8)

2 (0.8)

37.9 (18.9)

30.3 (7.8)

5

6

11

12

27

29

32

30

43

30.5 (2.7)

25.3 (8.2)

-1.6 (0.9)

26.3 (3.9)

-6.8 (2.6)

-20.1 (6.3)

1.6 (0.5)

36.1 (18.3)

27.2 (6.8)

224

195

Heterogeneity: Tau2=0.09; Chi2=15.97, df=8(P=0.04); I2=49.9%

Test for overall effect: Z=2.42(P=0.02)

15.27.2 More than 12 weeks

Courneya 2003

Cadmus 2009

Schmitz 2009

Subtotal ***

34.8 (4.7)

34.2 (5.5)

-70.4 (16.3)

24

37

59

120

28

37

63

128

34.6 (4.4)

33.4 (5.9)

-71.5 (18)

Heterogeneity: Tau2=0; Chi2=0.09, df=2(P=0.96); I2=0%

Test for overall effect: Z=0.64(P=0.52)

5%

5.75%

8.35%

10.36%

13.06%

13.68%

14.09%

14.14%

15.57%

100%

20.9%

29.85%

49.25%

100%

1.11[-0.06,2.28]

1.15[0.08,2.22]

0.2[-0.62,1.02]

-0.68[-1.37,0.01]

0.61[0.06,1.16]

0.33[-0.19,0.85]

0.66[0.16,1.16]

0.1[-0.4,0.59]

0.41[-0.03,0.85]

0.36[0.07,0.66]

0.04[-0.5,0.59]

0.14[-0.32,0.6]

0.06[-0.29,0.42]

0.08[-0.17,0.33]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 15.28.   Comparison 15 Subanalysis: outcomes by duration of physical
activity intervention, Outcome 28 Overall self-esteem/body image (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.28.1 12 weeks or less

Mustian 2004

Musanti 2012

11

30

3 (1)

-0.4 (4.5)

10

12

-1.5 (1.5)

0.6 (3.9)

11.43%

20.52%

3.42[1.99,4.86]

-0.22[-0.89,0.45]

Favours control

-5

-2.5

0

2.5

5

Favours intervention

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

499

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Mehnert 2011

Milne 2008

Daley 2007

Subtotal ***

0.7 (2.1)

1.5 (3.7)

1.8 (0.7)

30

29

33

133

Heterogeneity: Tau2=0.41; Chi2=20.91, df=4(P=0); I2=80.87%

Test for overall effect: Z=1.64(P=0.1)

15.28.2 More than 12 weeks

Courneya 2003

Cadmus 2009

Schmitz 2009

Saarto 2012

Subtotal ***

2.6 (3.7)

0.4 (4.4)

-12 (15.5)

10.7 (21.5)

24

37

59

263

383

Heterogeneity: Tau2=0.11; Chi2=13.52, df=3(P=0); I2=77.81%

Test for overall effect: Z=0.04(P=0.96)

0.4 (2.1)

0.1 (3.9)

1.6 (0.7)

-0.1 (3.5)

0.2 (2.9)

-4.1 (16.2)

12 (22)

27

29

33

111

28

37

63

237

365

22.53%

22.55%

22.97%

100%

19.49%

22.88%

26.03%

31.6%

100%

0.16[-0.36,0.68]

0.36[-0.16,0.88]

0.33[-0.16,0.82]

0.54[-0.1,1.18]

0.74[0.18,1.3]

0.05[-0.4,0.51]

-0.49[-0.86,-0.13]

-0.06[-0.24,0.12]

0.01[-0.37,0.39]

Favours control

-5

-2.5

0

2.5

5

Favours intervention

Analysis 15.29.   Comparison 15 Subanalysis: outcomes by duration of physical
activity intervention, Outcome 29 Overall cardiorespiratory fitness (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.29.1 12 weeks or less

Herrero 2006

Mustian 2004

Rogers 2013

Nikander 2007

Musanti 2012

Rogers 2014

Rogers 2009

Mehnert 2011

Do 2015

Milne 2008

Murtezani 2014

Pinto 2005

Fillion 2008

Daley 2007

Rogers 2015

Subtotal ***

25.9 (4.5)

636.1 (50.6)

23.9 (6.2)

-17.6 (1.3)

24.6 (4.9)

30.9 (6.3)

29.5 (6.6)

26.9 (4.4)

31.7 (12.4)

1.5 (0.3)

875.1 (86.7)

-16.3 (2.1)

27 (4.4)

35 (4.4)

23.6 (4.8)

8

11

12

14

30

20

20

27

30

29

30

39

44

33

105

452

25.7 (3.7)

610.3 (75.9)

23.9 (3.8)

-17.2 (1.4)

23 (4.3)

25.1 (5)

27.6 (6.1)

25.7 (4.7)

24.5 (6.6)

1.5 (0.4)

823.5 (87.1)

-17.8 (2.2)

26.5 (5.8)

33.1 (5.3)

22.7 (0.3)

8

10

10

14

12

22

18

23

30

29

32

43

43

69

108

471

Heterogeneity: Tau2=0.01; Chi2=16.15, df=14(P=0.3); I2=13.3%

Test for overall effect: Z=4.6(P<0.0001)

15.29.2 More than 12 weeks

Cerulli 2014

Portela 2008

Kaltsatou 2011

Rahnama 2010

Kim 2015

10

25

14

14

20

31.3 (5)

3007
(410.8)

483.3 (86)

20.7 (5.7)

424.8 (55.8)

10

9

13

15

19

32.3 (10.1)

2416.1
(718.6)

403.1 (71.9)

13.9 (5.2)

394.4 (54)

2.16%

2.73%

2.9%

3.62%

4.36%

4.7%

4.78%

6.1%

6.85%

7.04%

7.17%

8.95%

9.87%

9.96%

18.82%

100%

7.9%

8.92%

9.07%

9.14%

12.84%

0.05[-0.93,1.03]

0.39[-0.48,1.25]

0[-0.84,0.84]

-0.29[-1.03,0.46]

0.33[-0.34,1]

1.01[0.36,1.65]

0.29[-0.35,0.93]

0.26[-0.3,0.82]

0.72[0.19,1.24]

0.03[-0.49,0.54]

0.59[0.08,1.1]

0.69[0.24,1.14]

0.1[-0.32,0.52]

0.38[-0.04,0.8]

0.27[-0,0.54]

0.35[0.2,0.49]

-0.12[-0.99,0.76]

1.14[0.33,1.96]

0.98[0.17,1.78]

1.21[0.41,2.01]

0.54[-0.1,1.18]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

500

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Courneya 2003

Basen-Enquist 2006

Irwin 2015

Subtotal ***

24

35

45

187

21.3 (3.7)

1643
(122.5)

24.6 (5.5)

26

25

38

155

18.2 (3.9)

1546
(127.5)

23 (4.7)

Heterogeneity: Tau2=0.04; Chi2=9.8, df=7(P=0.2); I2=28.58%

Test for overall effect: Z=4.84(P<0.0001)

14.79%

16.47%

20.88%

100%

0.8[0.22,1.38]

0.77[0.24,1.3]

0.31[-0.13,0.74]

0.67[0.4,0.94]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 15.30.   Comparison 15 Subanalysis: outcomes by duration of physical
activity intervention, Outcome 30 Overall cardiorespiratory fitness (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.30.1 12 weeks or less

Nieman 1995

Naumann 2012

Dolan 2016

Musanti 2012

Rogers 2014

Pinto 2005

Subtotal ***

60.8 (8.4)

3.1 (2.9)

12.2 (10.2)

1 (3.1)

2.8 (4.9)

1.4 (2.4)

6

11

23

30

20

39

129

Heterogeneity: Tau2=0.38; Chi2=18.87, df=5(P=0); I2=73.51%

Test for overall effect: Z=2.96(P=0)

15.30.2 More than 12 weeks

Courneya 2003

Irwin 2015

Saarto 2012

Subtotal ***

2.7 (2.6)

1.5 (2.1)

0.9 (1.2)

24

45

262

331

Heterogeneity: Tau2=0.38; Chi2=20.62, df=2(P<0.0001); I2=90.3%

Test for overall effect: Z=2.01(P=0.04)

12 (17.8)

-0.1 (3.1)

-6 (7.2)

0.9 (3.4)

1.1 (4.2)

-0.2 (2.5)

-0.6 (1.7)

-0.4 (2.7)

0.7 (1)

6

10

10

12

22

43

103

26

38

236

300

6.98%

15.79%

16.25%

19.11%

19.89%

21.98%

100%

29.7%

33.25%

37.05%

100%

3.24[1.29,5.18]

1.03[0.1,1.95]

1.88[0.99,2.77]

0.03[-0.64,0.7]

0.37[-0.24,0.98]

0.65[0.2,1.09]

0.91[0.31,1.52]

1.49[0.86,2.12]

0.79[0.34,1.24]

0.16[-0.02,0.33]

0.76[0.02,1.51]

Favours control

-10

-5

0

5

10

Favours physical activity

Analysis 15.31.   Comparison 15 Subanalysis: outcomes by duration of physical activity
intervention, Outcome 31 Overall self-reported physical activity (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.31.1 12 weeks or less

Baruth 2013

Guinan 2013

Matthews 2007

Rogers 2009

Pinto 2015

Hatchett 2013

20

16

22

20

36

38

0 (0)

38.7 (26.9)

54.2 (34.1)

121.4 (73.2)

70.3 (65.9)

3.5 (2.2)

12

10

14

18

32

36

0 (0)

19.9 (11.3)

27.2 (22.7)

114.3
(131.5)

16.5 (31.9)

1.4 (1.7)

5.47%

6.65%

7.4%

9.14%

9.44%

Not estimable

0.81[-0.01,1.64]

0.87[0.17,1.58]

0.07[-0.57,0.7]

1.01[0.5,1.52]

1.04[0.55,1.53]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

501

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Pinto 2005

Kiecolt-Glaser 2014

Rogers 2015

Vallance 2007

Short 2014

Subtotal ***

Mean(SD)

202.4
(161.7)

11.2 (7.6)

169 (119)

207.6 (169)

217.9
(222.9)

N

39

96

110

253

195

845

Heterogeneity: Tau2=0.1; Chi2=33.71, df=9(P=0); I2=73.3%

Test for overall effect: Z=4.87(P<0.0001)

15.31.2 More than 12 weeks

Kim 2015

Basen-Enquist 2006

Cadmus 2009

Littman 2012

Winters-Stone 2011

Irwin 2015

Schmitz 2009

Subtotal ***

17.6 (16)

428 (254.4)

161.7
(114.7)

19.2 (19.1)

430.8
(281.4)

222.1
(118.6)

3348.8
(9019.4)

20

35

34

32

36

45

131

333

Heterogeneity: Tau2=0.13; Chi2=21.91, df=6(P=0); I2=72.61%

Test for overall effect: Z=2.48(P=0.01)

Mean(SD)

78.4 (86)

9.1 (6.1)

74 (107)

163 (121)

180.3
(206.9)

11.8 (11.6)

404 (265)

55.6 (101.9)

12.1 (13.6)

461.7
(346.4)

103.6
(104.6)

2339.8
(6213.7)

N

43

90

112

85

104

556

19

25

33

31

31

38

133

310

Random, 95% CI

9.87%

12.59%

12.82%

13.25%

13.37%

Random, 95% CI

0.96[0.5,1.42]

0.3[0.01,0.59]

0.84[0.56,1.11]

0.28[0.03,0.53]

0.17[-0.07,0.41]

100%

0.6[0.36,0.84]

11.55%

13.62%

13.72%

13.86%

14.21%

14.56%

18.47%

0.4[-0.23,1.04]

0.09[-0.42,0.61]

0.97[0.46,1.47]

0.42[-0.08,0.92]

-0.1[-0.58,0.38]

1.04[0.58,1.51]

0.13[-0.11,0.37]

100%

0.41[0.09,0.74]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 15.32.   Comparison 15 Subanalysis: outcomes by duration of physical activity
intervention, Outcome 32 Overall self-reported physical activity (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.32.1 12 weeks or less

Guinan 2013

Matthews 2007

Pinto 2005

Vallance 2007

Subtotal ***

15.6 (11.4)

21.5 (30.6)

84.7 (189.2)

82 (168.7)

16

22

39

281

358

Heterogeneity: Tau2=0.25; Chi2=15.29, df=3(P=0); I2=80.37%

Test for overall effect: Z=2.65(P=0.01)

15.32.2 More than 12 weeks

Cadmus 2009

Irwin 2015

Schmitz 2009

Saarto 2012

Subtotal ***

129 (117.9)

159 (136)

2.8 (16.8)

3.5 (18.3)

34

45

48

262

389

Heterogeneity: Tau2=0.18; Chi2=20.15, df=3(P=0); I2=85.11%

Test for overall effect: Z=1.93(P=0.05)

-8.3 (4.2)

5 (13.8)

-18.3
(200.7)

30 (167.8)

44.3 (89.4)

49 (86)

-0.8 (16.6)

3.3 (21.5)

10

14

43

96

163

33

38

57

236

364

15.75%

23.12%

28.62%

32.51%

100%

22.43%

23.43%

25.07%

29.07%

100%

2.46[1.39,3.53]

0.63[-0.06,1.32]

0.52[0.08,0.96]

0.31[0.08,0.54]

0.78[0.2,1.36]

0.8[0.3,1.3]

0.94[0.48,1.4]

0.21[-0.17,0.6]

0.01[-0.17,0.19]

0.46[-0.01,0.92]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

502

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 15.33.   Comparison 15 Subanalysis: outcomes by duration of physical activity
intervention, Outcome 33 Overall objective physical activity (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.33.1 12 weeks or less

Rogers 2013

Guinan 2013

Matthews 2007

Rogers 2014

Rogers 2009

Pinto 2015

Pinto 2005

Rogers 2015

Vallance 2007

Short 2014

Subtotal ***

198.4
(111.7)

30.7 (15.6)

330.8
(114.7)

294 (175)

252191
(91893)

70.3 (65.9)

37.5 (14.3)

246 (153)

8110.5
(4133.9)

9363.1
(7922.8)

12

16

22

20

20

36

39

110

253

219

747

0 (0)

31 (15.6)

198.5 (55.4)

154 (75)

210917
(64078)

16.5 (31.9)

33.6 (19.4)

197 (138)

8028 (3457)

8301.2
(3373.4)

10

9

14

22

18

32

43

112

85

111

456

Heterogeneity: Tau2=0.09; Chi2=27.53, df=8(P=0); I2=70.94%

Test for overall effect: Z=3.35(P=0)

6.43%

7.2%

8.44%

8.46%

10.67%

11.99%

15.27%

15.62%

15.93%

Not estimable

-0.02[-0.84,0.8]

1.34[0.6,2.09]

1.04[0.39,1.69]

0.51[-0.14,1.15]

1.01[0.5,1.52]

0.22[-0.21,0.66]

0.34[0.07,0.6]

0.02[-0.23,0.27]

0.16[-0.07,0.39]

100%

0.44[0.18,0.7]

15.33.2 More than 12 weeks

Cadmus 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.52(P=0.13)

6738 (2958)

33

33

5537 (3352)

34

34

100%

100%

0.38[-0.11,0.86]

0.38[-0.11,0.86]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 15.34.   Comparison 15 Subanalysis: outcomes by duration of physical
activity intervention, Outcome 34 Overall objective physical activity (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.34.1 12 weeks or less

Guinan 2013

Matthews 2007

Rogers 2014

Vallance 2007

Subtotal ***

-1.1 (6.2)

72.2 (114.6)

114 (109)

-150
(5173.3)

16

22

20

253

311

9

14

22

85

130

-7.9 (5.3)

-16.8 (51.5)

10 (70)

91 (5155.4)

Heterogeneity: Tau2=0.46; Chi2=19.44, df=3(P=0); I2=84.57%

Test for overall effect: Z=1.92(P=0.06)

21.38%

24.04%

24.78%

29.8%

1.11[0.23,2]

0.91[0.2,1.62]

1.13[0.47,1.78]

-0.05[-0.29,0.2]

100%

0.72[-0.02,1.46]

15.34.2 More than 12 weeks

Cadmus 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.94(P=0)

1621 (2108)

33

33

34

34

-60 (2341)

100%

100%

0.75[0.25,1.24]

0.75[0.25,1.24]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

503

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 15.35.   Comparison 15 Subanalysis: outcomes by duration of
physical activity intervention, Outcome 35 Mass (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

15.35.1 12 weeks or less

Matthews 2007

Mustian 2004

Nikander 2007

Herrero 2006

Daley 2007

Murtezani 2014

Kiecolt-Glaser 2014

Subtotal ***

74.9 (15.2)

67.1 (10.4)

73.5 (13.3)

65.6 (8.7)

74.3 (12.5)

71.7 (9.5)

75.2 (2.8)

22

11

14

8

33

30

96

214

Heterogeneity: Tau2=0; Chi2=1.12, df=6(P=0.98); I2=0%

Test for overall effect: Z=0.25(P=0.8)

15.35.2 More than 12 weeks

Courneya 2003

Cadmus 2009

Rahnama 2010

DeNysschen 2011

Ligibel 2008

Littman 2012

Winters-Stone 2011

Schmitz 2009

Schmitz 2005

Subtotal ***

78.2 (20.5)

80.7 (16.9)

69.4 (13.5)

69.3 (14.2)

80 (17.5)

81.1 (13.6)

76.5 (15.6)

76.2 (15.7)

69.5 (2.2)

24

36

14

30

40

28

36

131

39

378

Heterogeneity: Tau2=0; Chi2=2.83, df=8(P=0.94); I2=0%

Test for overall effect: Z=0.31(P=0.75)

78.9 (20.3)

68.6 (13.8)

75.5 (12)

67.3 (8.9)

75.6 (12.5)

72.6 (10.8)

75.2 (2.6)

80.1 (16.2)

78.5 (20.6)

71.6 (9.2)

72.4 (19.6)

83.3 (18.7)

81.3 (14.3)

74.2 (12.3)

77.2 (17)

69.2 (2.2)

14

10

14

8

69

32

90

237

26

33

15

34

42

27

31

133

40

381

0.37%

0.5%

0.64%

0.76%

2.09%

2.21%

93.43%

100%

0.77%

1.02%

1.14%

1.18%

1.33%

1.5%

1.83%

5.25%

85.98%

100%

-4[-16.39,8.39]

-1.5[-12.06,9.06]

-2[-11.38,7.38]

-1.7[-10.32,6.92]

-1.34[-6.52,3.84]

-0.9[-5.94,4.14]

0[-0.78,0.78]

-0.1[-0.85,0.65]

-1.9[-12.2,8.4]

2.22[-6.72,11.16]

-2.2[-10.67,6.27]

-3.1[-11.42,5.22]

-3.3[-11.14,4.54]

-0.2[-7.58,7.18]

2.3[-4.39,8.99]

-1.04[-4.98,2.9]

0.3[-0.67,1.27]

0.14[-0.76,1.05]

Favours physical activity

-20

-10

0

10

20

Favours control

Analysis 15.36.   Comparison 15 Subanalysis: outcomes by duration
of physical activity intervention, Outcome 36 Mass (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

15.36.1 12 weeks or less

Dolan 2016

Mustian 2004

Matthews 2007

Murtezani 2014

Naumann 2012

Subtotal ***

-0.5 (5)

-0.3 (1.9)

0 (2.1)

-2.3 (2.4)

0.5 (1.3)

23

9

22

30

11

95

Heterogeneity: Tau2=0.69; Chi2=8.99, df=4(P=0.06); I2=55.49%

Test for overall effect: Z=1.63(P=0.1)

15.36.2 More than 12 weeks

Irwin 2015

Ligibel 2008

45

22

-2.1 (4.3)

0 (2.3)

10

10

14

32

10

76

38

14

1.4 (1.6)

0.6 (1.4)

0 (2.2)

-0.3 (2.6)

0.1 (1.5)

0.1 (3.6)

0 (2.2)

12.38%

19.92%

20.85%

23.3%

23.55%

100%

-1.99[-4.28,0.3]

-0.9[-2.4,0.6]

-0.03[-1.46,1.4]

-2[-3.24,-0.76]

0.33[-0.9,1.56]

-0.82[-1.81,0.17]

6.71%

8.37%

-2.2[-3.9,-0.5]

-0.04[-1.52,1.44]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

504

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Physical activity

Control

Schmitz 2009

Courneya 2003

Saarto 2012

Schmitz 2005

Subtotal ***

Mean(SD)

-1 (3.7)

0.1 (2)

0.7 (3.7)

0.3 (0.4)

N

65

24

262

39

457

Mean(SD)

-0.4 (4.3)

0.7 (1.8)

0.7 (3.8)

0.2 (0.4)

N

65

26

236

40

419

Heterogeneity: Tau2=0.15; Chi2=9.62, df=5(P=0.09); I2=48%

Test for overall effect: Z=1(P=0.32)

Cochrane Database of Systematic Reviews

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

9.39%

13.76%

23.1%

38.66%

100%

-0.6[-1.98,0.78]

-0.6[-1.66,0.46]

-0.01[-0.67,0.65]

0.12[-0.07,0.31]

-0.25[-0.73,0.24]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 15.37.   Comparison 15 Subanalysis: outcomes by duration
of physical activity intervention, Outcome 37 BMI (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

15.37.1 12 weeks or less

Rogers 2013

Rogers 2009

Mustian 2004

Nikander 2007

Rogers 2014

Pinto 2005

Murtezani 2014

Vallance 2007

Kiecolt-Glaser 2014

Subtotal ***

33.6 (7)

30.6 (7.6)

23.9 (4.2)

26.9 (5.6)

29.6 (5)

27.7 (5)

25.1 (2.9)

27 (5.2)

27.8 (1.1)

12

20

11

14

20

39

30

253

96

495

Heterogeneity: Tau2=0; Chi2=6.73, df=8(P=0.57); I2=0%

Test for overall effect: Z=0.52(P=0.6)

15.37.2 More than 12 weeks

Portela 2008

Courneya 2003

Rahnama 2010

Cadmus 2009

Ligibel 2008

Littman 2012

Schmitz 2009

Schmitz 2005

Subtotal ***

29.1 (5.5)

29.4 (7.4)

27.7 (4.8)

30.5 (6)

30.3 (6.3)

27.7 (5)

28.5 (5.6)

26 (0.7)

25

24

14

36

40

28

131

39

337

Heterogeneity: Tau2=0; Chi2=4.16, df=7(P=0.76); I2=0%

Test for overall effect: Z=0.8(P=0.42)

30.6 (7.3)

30.4 (8.3)

26.7 (5.6)

27.7 (4.9)

32.2 (6.7)

29 (5.6)

25.8 (3.5)

27.2 (5.2)

27.8 (1)

34.7 (15)

29.3 (6)

28 (4.6)

29.9 (7.6)

31.5 (6.8)

29 (5.6)

28.9 (6.3)

25.8 (0.7)

10

18

10

14

22

43

32

85

90

324

9

26

15

33

42

27

133

40

325

0.21%

0.29%

0.42%

0.5%

0.6%

1.43%

3%

4.7%

88.85%

100%

0.09%

0.68%

0.82%

0.9%

1.18%

1.2%

4.66%

90.47%

100%

3[-3,9]

0.2[-4.88,5.28]

-2.8[-7.05,1.45]

-0.8[-4.7,3.1]

-2.6[-6.16,0.96]

-1.35[-3.65,0.95]

-0.7[-2.29,0.89]

-0.19[-1.46,1.08]

0[-0.29,0.29]

-0.07[-0.35,0.2]

-5.6[-15.63,4.43]

0.1[-3.65,3.85]

-0.3[-3.71,3.11]

0.55[-2.7,3.8]

-1.2[-4.04,1.64]

-1.35[-4.17,1.47]

-0.48[-1.91,0.95]

0.2[-0.12,0.52]

0.13[-0.18,0.43]

Favours physical activity

-20

-10

0

10

20

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

505

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 15.38.   Comparison 15 Subanalysis: outcomes by duration
of physical activity intervention, Outcome 38 BMI (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

15.38.1 12 weeks or less

Mustian 2004

Rogers 2014

Naumann 2012

Murtezani 2014

Subtotal ***

-0.4 (0.8)

-0.2 (0.9)

0.1 (0.5)

-0.8 (0.7)

9

20

11

30

70

Heterogeneity: Tau2=0.18; Chi2=11.45, df=3(P=0.01); I2=73.79%

Test for overall effect: Z=1.09(P=0.28)

15.38.2 More than 12 weeks

Schmitz 2009

Courneya 2003

Ligibel 2008

Schmitz 2005

Subtotal ***

-1 (3.7)

0 (0.7)

0 (0.9)

0.1 (0.2)

65

24

40

39

168

Heterogeneity: Tau2=0.01; Chi2=3.61, df=3(P=0.31); I2=16.98%

Test for overall effect: Z=1.03(P=0.3)

0.3 (0.6)

-0.3 (1.1)

-0.1 (0.6)

-0.1 (0.8)

-0.4 (4.3)

0.3 (0.7)

0.2 (0.8)

0.1 (0.2)

10

22

10

32

74

65

26

42

40

173

22.25%

22.59%

26.43%

28.73%

100%

1.07%

11.84%

12.92%

74.17%

100%

-0.71[-1.33,-0.09]

0.1[-0.51,0.71]

0.2[-0.26,0.66]

-0.66[-1.03,-0.29]

-0.27[-0.76,0.22]

-0.6[-1.98,0.78]

-0.3[-0.69,0.09]

-0.2[-0.57,0.17]

-0.01[-0.08,0.06]

-0.08[-0.22,0.07]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 15.39.   Comparison 15 Subanalysis: outcomes by duration of physical
activity intervention, Outcome 39 Overall body fat (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.39.1 12 weeks or less

Herrero 2006

Mustian 2004

Rogers 2013

Matthews 2007

Musanti 2012

Rogers 2009

Rogers 2014

Pinto 2005

Daley 2007

Subtotal ***

8

11

10

22

30

20

20

39

33

22 (5)

38.5 (4.5)

44.2 (6.7)

39.7 (6.3)

34.1 (6.6)

44.3 (7.4)

38.6 (6.4)

37.5 (4.8)

39.4 (4.7)

8

10

12

14

12

19

22

43

69

22 (4)

41.7 (4.9)

42.3 (7.7)

43.1 (6.9)

33.7 (5.7)

43.5 (7.5)

41.5 (7.4)

38.6 (4.8)

40.1 (7.4)

193

209

Heterogeneity: Tau2=0; Chi2=5.12, df=8(P=0.74); I2=0%

Test for overall effect: Z=1.58(P=0.11)

15.39.2 More than 12 weeks

Cerulli 2014

Courneya 2003

DeNysschen 2011

Winters-Stone 2011

Saarto 2012

Cadmus 2009

Schmitz 2005

Ligibel 2008

10

24

30

36

37

36

39

40

26.7 (5.3)

131.9 (46.4)

36.9 (8.4)

40.5 (6.2)

39.9 (7.5)

40.5 (6.6)

40.9 (1.3)

42.9 (7.4)

10

26

34

31

30

33

40

42

30.6 (4.4)

137.1 (44.4)

38 (10.2)

38.5 (5.8)

40.2 (8)

39.6 (6)

42.3 (1.3)

44.7 (8)

4.27%

5.24%

5.76%

8.82%

9.14%

10.38%

10.92%

21.69%

23.78%

100%

5.42%

9.89%

11.05%

11.19%

11.23%

11.4%

11.42%

12.17%

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

0[-0.98,0.98]

-0.66[-1.54,0.23]

0.25[-0.59,1.09]

-0.51[-1.19,0.17]

0.07[-0.6,0.74]

0.11[-0.52,0.73]

-0.41[-1.02,0.2]

-0.21[-0.64,0.22]

-0.1[-0.52,0.31]

-0.16[-0.37,0.04]

-0.75[-1.66,0.16]

-0.11[-0.67,0.44]

-0.12[-0.61,0.38]

0.33[-0.16,0.81]

-0.04[-0.52,0.44]

0.15[-0.33,0.62]

-1.05[-1.52,-0.58]

-0.23[-0.67,0.2]

506

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Schmitz 2009

Subtotal ***

Mean(SD)

38.5 (5.9)

N

130

382

Mean(SD)

39.7 (5.9)

N

132

378

Random, 95% CI

16.22%

100%

Random, 95% CI

-0.21[-0.46,0.03]

-0.2[-0.45,0.05]

Heterogeneity: Tau2=0.09; Chi2=21.11, df=8(P=0.01); I2=62.1%

Test for overall effect: Z=1.54(P=0.12)

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 15.40.   Comparison 15 Subanalysis: outcomes by duration of
physical activity intervention, Outcome 40 Overall body fat (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.40.1 12 weeks or less

Mustian 2004

Naumann 2012

Musanti 2012

Matthews 2007

Rogers 2014

Subtotal ***

-0.2 (2.9)

-0.3 (2.4)

-0.2 (2.8)

-0.2 (1.6)

-1.1 (2.2)

9

11

30

22

20

92

Heterogeneity: Tau2=0; Chi2=1, df=4(P=0.91); I2=0%

Test for overall effect: Z=2.18(P=0.03)

15.40.2 More than 12 weeks

Schmitz 2005

Courneya 2003

Ligibel 2008

Schmitz 2009

Subtotal ***

-1.1 (0.5)

-4.9 (15.7)

-0.2 (1.7)

-0.3 (5.7)

39

24

40

65

168

0.3 (1.6)

0.8 (2.8)

1.4 (1.6)

0.4 (1.9)

-0.6 (2.4)

0.2 (0.4)

5.1 (24.4)

0.3 (1.7)

-0.1 (3.3)

10

10

12

14

22

68

40

26

42

63

171

Heterogeneity: Tau2=1.24; Chi2=65.67, df=3(P<0.0001); I2=95.43%

Test for overall effect: Z=1.65(P=0.1)

12.78%

13.86%

22.25%

22.86%

28.25%

100%

24.17%

24.73%

25.37%

25.73%

100%

-0.18[-1.09,0.72]

-0.41[-1.28,0.46]

-0.63[-1.32,0.05]

-0.34[-1.02,0.33]

-0.21[-0.82,0.39]

-0.36[-0.68,-0.04]

-3.07[-3.73,-2.41]

-0.48[-1.04,0.09]

-0.29[-0.73,0.14]

-0.04[-0.39,0.3]

-0.94[-2.07,0.18]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 15.41.   Comparison 15 Subanalysis: outcomes by duration of physical
activity intervention, Outcome 41 Lower body strength (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.41.1 12 weeks or less

Rogers 2013

Nikander 2007

Rogers 2009

Milne 2008

Do 2015

Subtotal ***

68.4 (15.5)

1305 (177)

80.3 (27)

66.2 (10.2)

13 (1.6)

11

14

20

29

32

106

67.1 (16.2)

1393 (275)

64.9 (19.7)

61.7 (11)

13.2 (1.6)

9

14

18

29

30

100

Heterogeneity: Tau2=0.05; Chi2=5.9, df=4(P=0.21); I2=32.21%

Test for overall effect: Z=0.88(P=0.38)

15.41.2 More than 12 weeks

12.25%

15.8%

19.18%

25.72%

27.06%

100%

0.08[-0.8,0.96]

-0.37[-1.12,0.38]

0.63[-0.02,1.29]

0.42[-0.1,0.94]

-0.09[-0.59,0.41]

0.15[-0.19,0.5]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

507

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Cerulli 2014

Schmitz 2005

Saarto 2012

Winters-Stone 2011

Schmitz 2009

Subtotal ***

114.9 (17.1)

296.6 (48.9)

136 (23)

201.3 (57.4)

223.4 (59.6)

10

23

37

36

113

219

79.1 (17.8)

238.9 (46.4)

136 (29)

191 (51.7)

175.1 (53.5)

10

22

30

31

119

212

Heterogeneity: Tau2=0.26; Chi2=20.83, df=4(P=0); I2=80.8%

Test for overall effect: Z=2.7(P=0.01)

12.13%

19.14%

21.84%

21.84%

25.04%

100%

1.96[0.85,3.07]

1.19[0.55,1.83]

0[-0.48,0.48]

0.19[-0.3,0.67]

0.85[0.58,1.12]

0.72[0.2,1.24]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 15.42.   Comparison 15 Subanalysis: outcomes by duration of physical
activity intervention, Outcome 42 Lower body strength (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.42.1 12 weeks or less

Nieman 1995

Naumann 2012

Dolan 2016

Cormie 2014

Do 2015

Subtotal ***

28.9 (13.7)

7.7 (12.6)

11.8 (8.9)

37.6 (25.5)

0.9 (0.7)

6

11

23

43

32

115

Heterogeneity: Tau2=0.4; Chi2=16.62, df=4(P=0); I2=75.93%

Test for overall effect: Z=2.14(P=0.03)

15.42.2 More than 12 weeks

Schmitz 2005

Schmitz 2009

Waltman 2010

Subtotal ***

81.8 (48.9)

33.2 (33.9)

4.4 (11.5)

23

113

110

246

Heterogeneity: Tau2=0.09; Chi2=8.1, df=2(P=0.02); I2=75.31%

Test for overall effect: Z=3.68(P=0)

3.5 (22.5)

3.5 (13.9)

0.3 (11.1)

6.7 (25.7)

1 (0.6)

20.3 (46)

7.9 (26.6)

0.2 (8.4)

6

10

10

19

60

105

22

119

113

254

13.43%

18.85%

19.74%

22.95%

25.03%

100%

21.57%

39.14%

39.29%

100%

1.26[-0.03,2.55]

0.3[-0.56,1.17]

1.17[0.37,1.97]

1.19[0.61,1.78]

-0.08[-0.51,0.35]

0.71[0.06,1.37]

1.27[0.63,1.92]

0.83[0.56,1.1]

0.42[0.15,0.69]

0.76[0.36,1.17]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 15.43.   Comparison 15 Subanalysis: outcomes by duration of physical
activity intervention, Outcome 43 Upper body strength (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.43.1 12 weeks or less

Mustian 2004

Nikander 2007

Musanti 2012

Rogers 2009

Milne 2008

Do 2015

Subtotal ***

11

14

30

20

29

32

136

29.6 (3.3)

131 (20)

52.1 (21)

27.9 (5)

7.6 (2.9)

9.7 (1.7)

10

14

12

18

29

30

113

26.7 (5.7)

129 (28)

36.8 (20)

24.3 (6.2)

9.4 (2.6)

10.1 (1.7)

13.34%

15.4%

16.22%

16.79%

18.88%

19.37%

100%

0.6[-0.28,1.49]

0.08[-0.66,0.82]

0.73[0.04,1.42]

0.63[-0.03,1.28]

-0.64[-1.17,-0.12]

-0.24[-0.74,0.26]

0.15[-0.32,0.62]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

508

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Heterogeneity: Tau2=0.24; Chi2=16.15, df=5(P=0.01); I2=69.03%

Test for overall effect: Z=0.62(P=0.54)

15.43.2 More than 12 weeks

Cerulli 2014

Portela 2008

Schmitz 2005

Kaltsatou 2011

Saarto 2012

Winters-Stone 2011

Schmitz 2009

Subtotal ***

16.1 (5.4)

39.3 (12.3)

83 (13.4)

59.6 (8.5)

32.7 (5.3)

63.3 (15.3)

52.9 (15.3)

10

25

23

28

37

36

113

272

17.2 (8.1)

35.6 (13.1)

63 (12.7)

47.6 (9.8)

30.8 (5.7)

61.1 (16.8)

40.9 (11.8)

10

9

22

26

30

31

119

247

Heterogeneity: Tau2=0.2; Chi2=23.22, df=6(P=0); I2=74.16%

Test for overall effect: Z=3.15(P=0)

10.32%

11.74%

13.07%

14.23%

15.84%

15.9%

18.9%

100%

-0.16[-1.03,0.72]

0.29[-0.48,1.05]

1.5[0.84,2.17]

1.29[0.7,1.88]

0.34[-0.14,0.83]

0.14[-0.34,0.62]

0.88[0.61,1.15]

0.64[0.24,1.04]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 15.44.   Comparison 15 Subanalysis: outcomes by duration of physical
activity intervention, Outcome 44 Upper body strength (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

15.44.1 12 weeks or less

Musanti 2012

Cormie 2014

Do 2015

Mustian 2004

Subtotal ***

7.7 (10.6)

5.7 (3.7)

0.3 (0.5)

4.5 (4.7)

30

43

32

45

150

0.8 (12.7)

1 (3.8)

0.6 (1.2)

-0.8 (3.2)

12

19

30

38

99

Heterogeneity: Tau2=0.56; Chi2=24.08, df=3(P<0.0001); I2=87.54%

Test for overall effect: Z=1.8(P=0.07)

15.44.2 More than 12 weeks

Schmitz 2005

Irwin 2015

Waltman 2010

Schmitz 2009

Subtotal ***

32.3 (11.5)

0.4 (1.9)

1.9 (4.9)

33.2 (40.8)

23

45

110

113

291

22

38

113

119

292

6.9 (10.8)

0.1 (1.9)

0.8 (2.9)

7.6 (43.7)

Heterogeneity: Tau2=0.25; Chi2=25.58, df=3(P<0.0001); I2=88.27%

Test for overall effect: Z=2.59(P=0.01)

23.58%

24.75%

25.71%

25.96%

100%

18.81%

25.16%

28.01%

28.02%

100%

0.6[-0.08,1.29]

1.25[0.67,1.84]

-0.27[-0.77,0.23]

1.3[0.82,1.78]

0.72[-0.06,1.5]

2.24[1.48,2.99]

0.16[-0.27,0.59]

0.29[0.02,0.55]

0.6[0.34,0.87]

0.71[0.17,1.25]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Comparison 16.   Subanalysis: outcomes by format of intervention

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Overall HRQoL (follow-up
values)

21

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

509

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.1 Group format

1.2 Individual format

1.3 Both group and individ-
ual formats

2 Overall HRQoL (change
values)

2.1 Group format

2.2 Individual format

2.3 Both group and individ-
ual formats

3 Overall emotional func-
tion/mental health (fol-
low-up values)

3.1 Group format

3.2 Individual format

3.3 Both group and individ-
ual formats

4 Overall emotional func-
tion/mental health (change
values)

4.1 Group format

4.2 Individual format

4.3 Both group and individ-
ual formats

5 Overall physical function
(follow-up values)

5.1 Group format

5.2 Individual format

5

10

6

14

5

6

3

26

10

10

6

15

7

5

3

24

9

9

214

1137

390

198

649

612

649

923

500

398

569

612

588

941

Std. Mean Difference (IV, Random, 95%
CI)

0.99 [0.22, 1.75]

Std. Mean Difference (IV, Random, 95%
CI)

0.21 [0.03, 0.38]

Std. Mean Difference (IV, Random, 95%
CI)

0.33 [0.04, 0.62]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

1.88 [0.19, 3.56]

Std. Mean Difference (IV, Random, 95%
CI)

0.43 [0.25, 0.61]

Std. Mean Difference (IV, Random, 95%
CI)

0.06 [-0.22, 0.33]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.28 [0.07, 0.49]

Std. Mean Difference (IV, Random, 95%
CI)

0.16 [0.02, 0.30]

Std. Mean Difference (IV, Random, 95%
CI)

0.10 [-0.09, 0.29]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.42 [-0.14, 0.99]

Std. Mean Difference (IV, Random, 95%
CI)

0.26 [0.08, 0.44]

Std. Mean Difference (IV, Random, 95%
CI)

0.09 [-0.16, 0.34]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.53 [0.12, 0.94]

Std. Mean Difference (IV, Random, 95%
CI)

0.28 [0.12, 0.45]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

510

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

5.3 Both group and individ-
ual formats

6 Overall physical function
(change values)

6.1 Group format

6.2 Individual format

6.3 Both group and individ-
ual formats

6

13

6

3

4

7 Overall role function (fol-
low-up values)

18

7.1 Group format

7.2 Individual format

7.3 Both group and individ-
ual formats

8 Overall role function
(change values)

8.1 Group format

8.2 Individual format

8.3 Both group and individ-
ual formats

9 Overall social well-be-
ing/function (follow-up val-
ues)

9.1 Group format

9.2 Individual format

9.3 Both group and individ-
ual formats

10 Overall social well-be-
ing/function (change val-
ues)

6

7

5

12

5

4

3

18

7

5

6

12

538

337

432

664

225

689

426

216

487

612

348

546

663

Std. Mean Difference (IV, Random, 95%
CI)

0.18 [-0.06, 0.42]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

1.25 [0.29, 2.21]

Std. Mean Difference (IV, Random, 95%
CI)

0.20 [-0.01, 0.41]

Std. Mean Difference (IV, Random, 95%
CI)

0.19 [-0.25, 0.63]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.52 [-0.27, 1.30]

Std. Mean Difference (IV, Random, 95%
CI)

0.23 [0.07, 0.40]

Std. Mean Difference (IV, Random, 95%
CI)

0.15 [-0.15, 0.45]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.36 [-0.14, 0.85]

Std. Mean Difference (IV, Random, 95%
CI)

0.13 [-0.07, 0.32]

Std. Mean Difference (IV, Random, 95%
CI)

-0.06 [-0.22, 0.10]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.22 [0.00, 0.45]

Std. Mean Difference (IV, Random, 95%
CI)

0.27 [-0.07, 0.61]

Std. Mean Difference (IV, Random, 95%
CI)

0.16 [0.01, 0.32]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

511

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

10.1 Group format

10.2 Individual format

10.3 Both group and indi-
vidual formats

11 Overall cognitive func-
tion (follow-up values)

11.1 Group format

11.2 Individual format

11.3 Both group and indi-
vidual formats

12 Overall cognitive func-
tion (change values)

12.1 Group format

12.2 Individual format

12.3 Both group and indi-
vidual formats

13 Overall general health
(follow-up values)

13.1 Group format

13.2 Individual format

13.3 Both group and indi-
vidual formats

14 Overall general health
(change values)

14.1 Group format

14.2 Individual format

5

4

3

5

3

1

1

5

3

0

2

9

3

4

2

9

4

2

322

450

612

134

18

37

134

0

538

92

222

112

155

139

Std. Mean Difference (IV, Random, 95%
CI)

0.57 [-0.06, 1.19]

Std. Mean Difference (IV, Random, 95%
CI)

0.72 [0.38, 1.06]

Std. Mean Difference (IV, Random, 95%
CI)

0.27 [-0.31, 0.85]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.32 [-0.02, 0.66]

Std. Mean Difference (IV, Random, 95%
CI)

1.14 [0.07, 2.20]

Std. Mean Difference (IV, Random, 95%
CI)

0.42 [-0.24, 1.07]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.06 [-0.31, 0.43]

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

0.03 [-0.51, 0.57]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.38 [-0.31, 1.07]

Std. Mean Difference (IV, Random, 95%
CI)

0.34 [-0.08, 0.76]

Std. Mean Difference (IV, Random, 95%
CI)

-0.26 [-0.64, 0.11]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.35 [-0.25, 0.95]

Std. Mean Difference (IV, Random, 95%
CI)

0.38 [0.04, 0.73]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

512

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

14.3 Both group and indi-
vidual formats

15 Overall sexual function
(follow-up values)

15.1 Group format

15.2 Individual format

15.3 Both group and indi-
vidual formats

16 Overall sleep (follow-up
values)

16.1 Group format

16.2 Individual format

16.3 Both group and indi-
vidual formats

17 Overall anxiety (fol-
low-up values)

17.1 Group format

17.2 Individual format

17.3 Both group and indi-
vidual formats

18 Overall anxiety (change
values)

18.1 Group format

18.2 Individual format

18.3 Both group and indi-
vidual formats

19 Overall depression
(change values)

19.1 Group format

19.2 Individual format

3

5

1

4

0

5

2

2

1

6

3

2

1

4

2

1

1

7

2

3

612

114

297

0

88

62

38

177

60

74

119

42

74

119

123

Std. Mean Difference (IV, Random, 95%
CI)

-0.07 [-0.23, 0.09]

Std. Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Std. Mean Difference (IV, Fixed, 95% CI)

0.14 [-0.23, 0.51]

Std. Mean Difference (IV, Fixed, 95% CI)

0.17 [-0.06, 0.40]

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Std. Mean Difference (IV, Fixed, 95% CI)

-0.26 [-0.68, 0.16]

Std. Mean Difference (IV, Fixed, 95% CI)

-0.07 [-0.57, 0.43]

Std. Mean Difference (IV, Fixed, 95% CI)

0.28 [-0.36, 0.92]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.73 [-1.03, -0.42]

Std. Mean Difference (IV, Random, 95%
CI)

-0.13 [-0.64, 0.39]

Std. Mean Difference (IV, Random, 95%
CI)

-0.14 [-0.60, 0.31]

Std. Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Std. Mean Difference (IV, Fixed, 95% CI)

-0.52 [-0.88, -0.15]

Std. Mean Difference (IV, Fixed, 95% CI)

-0.37 [-0.99, 0.24]

Std. Mean Difference (IV, Fixed, 95% CI)

-0.15 [-0.61, 0.30]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.54 [-0.91, -0.18]

Std. Mean Difference (IV, Random, 95%
CI)

-0.51 [-1.03, 0.01]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

513

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

19.3 Both group and indi-
vidual formats

20 Overall depression (fol-
low-up values)

20.1 Group format

20.2 Individual format

20.3 Both group and indi-
vidual formats

21 Overall fatigue (fol-
low-up values)

21.1 Group format

21.2 Individual format

21.3 Both group and indi-
vidual formats

22 Overall fatigue (change
values)

22.1 Group format

22.2 Individual format

22.3 Both group and indi-
vidual formats

23 Overall pain/disability
(follow-up values)

23.1 Group format

23.2 Individual format

23.3 Both group and indi-
vidual formats

24 Overall pain/disability
(change values)

2

11

4

5

2

24

7

11

6

12

2

7

3

8

2

3

3

3

574

176

206

260

350

1068

445

73

637

561

77

261

135

Std. Mean Difference (IV, Random, 95%
CI)

0.00 [-0.21, 0.22]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.68 [-0.98, -0.37]

Std. Mean Difference (IV, Random, 95%
CI)

-0.01 [-0.51, 0.49]

Std. Mean Difference (IV, Random, 95%
CI)

-0.13 [-0.37, 0.12]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.77 [-1.15, -0.39]

Std. Mean Difference (IV, Random, 95%
CI)

-0.19 [-0.36, -0.02]

Std. Mean Difference (IV, Random, 95%
CI)

-0.18 [-0.37, 0.01]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.10 [-0.70, 0.50]

Std. Mean Difference (IV, Random, 95%
CI)

-0.40 [-0.98, 0.17]

Std. Mean Difference (IV, Random, 95%
CI)

-0.02 [-0.18, 0.15]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.18 [-0.26, 0.63]

Std. Mean Difference (IV, Random, 95%
CI)

0.22 [-0.22, 0.65]

Std. Mean Difference (IV, Random, 95%
CI)

-0.16 [-0.50, 0.18]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

514

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

24.1 Group format

24.2 Individual format

24.3 Both group and indi-
vidual formats

3

0

0

25 Overall self-esteem/body
image (follow-up values)

10

25.1 Group format

25.2 Individual format

25.3 Both group and indi-
vidual formats

26 Overall self-esteem/body
image (change values)

26.1 Group format

26.2 Individual format

26.3 Both group and indi-
vidual formats

27 Overall cardiorespiratory
fitness (follow-up values)

27.1 Group format

27.2 Individual format

27.3 Both group and indi-
vidual formats

28 Overall cardiorespiratory
fitness (change values)

28.1 Group format

28.2 Individual format

3

5

2

9

4

3

2

21

7

10

4

6

0

4

139

0

0

234

259

97

258

160

574

321

493

362

0

216

Std. Mean Difference (IV, Random, 95%
CI)

0.16 [-0.19, 0.50]

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.28 [-0.04, 0.60]

Std. Mean Difference (IV, Random, 95%
CI)

0.27 [-0.21, 0.76]

Std. Mean Difference (IV, Random, 95%
CI)

0.15 [-0.25, 0.55]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.59 [-0.33, 1.51]

Std. Mean Difference (IV, Random, 95%
CI)

0.31 [-0.19, 0.81]

Std. Mean Difference (IV, Random, 95%
CI)

-0.05 [-0.21, 0.12]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.29 [0.06, 0.51]

Std. Mean Difference (IV, Random, 95%
CI)

0.59 [0.38, 0.79]

Std. Mean Difference (IV, Random, 95%
CI)

0.24 [0.03, 0.44]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

0.64 [0.08, 1.19]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

515

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

28.3 Both group and indi-
vidual formats

29 Overall self-reported
physical activity (follow-up
values)

29.1 Group format

29.2 Individual format

29.3 Both group and indi-
vidual formats

30 Overall self-reported
physical activity (change
values)

30.1 Group format

30.2 Individual format

30.3 Both group and indi-
vidual formats

2

17

1

8

8

8

1

3

4

31 Overall objective physi-
cal activity (follow-up val-
ues)

12

31.1 Group format

31.2 Individual format

31.3 Both group and indi-
vidual formats

32 Overall objective physi-
cal activity (change values)

32.1 Group format

32.2 Individual format

32.3 Both group and indi-
vidual formats

0

8

4

5

0

3

2

581

264

989

752

105

495

674

0

957

352

0

416

92

Std. Mean Difference (IV, Random, 95%
CI)

0.44 [-0.18, 1.05]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.13 [-0.11, 0.37]

Std. Mean Difference (IV, Random, 95%
CI)

0.59 [0.28, 0.90]

Std. Mean Difference (IV, Random, 95%
CI)

0.55 [0.25, 0.84]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.21 [-0.17, 0.60]

Std. Mean Difference (IV, Random, 95%
CI)

0.38 [0.18, 0.57]

Std. Mean Difference (IV, Random, 95%
CI)

0.92 [0.14, 1.70]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

0.51 [0.18, 0.85]

Std. Mean Difference (IV, Random, 95%
CI)

0.34 [0.13, 0.55]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

0.62 [-0.23, 1.46]

Std. Mean Difference (IV, Random, 95%
CI)

0.83 [0.40, 1.27]

33 Mass (follow-up values)

15

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

516

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

33.1 Group format

33.2 Individual format

33.3 Both group and indi-
vidual formats

4

5

6

34 Mass (change values)

10

34.1 Group format

34.2 Individual format

34.3 Both group and indi-
vidual formats

3

4

3

35 BMI (follow-up values)

16

35.1 Group format

35.2 Individual format

35.3 Both group and indi-
vidual formats

36 BMI (change values)

36.1 Group format

36.2 Individual format

36.3 Both group and indi-
vidual formats

37 Overall body fat (fol-
low-up values)

37.1 Group format

37.2 Individual format

37.3 Both group and indi-
vidual formats

38 Overall body fat (change
values)

38.1 Group format

38.2 Individual format

3

7

6

8

3

3

2

18

3

10

5

9

2

6

363

331

487

211

186

617

347

647

458

211

150

124

299

539

324

147

270

Mean Difference (IV, Fixed, 95% CI)

-1.10 [-3.92, 1.72]

Mean Difference (IV, Fixed, 95% CI)

0.16 [-0.79, 1.10]

Mean Difference (IV, Fixed, 95% CI)

-0.00 [-0.76, 0.76]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-1.23 [-2.10, -0.35]

Mean Difference (IV, Random, 95% CI)

0.10 [-0.08, 0.28]

Mean Difference (IV, Random, 95% CI)

-0.58 [-1.80, 0.63]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

-0.71 [-1.74, 0.32]

Mean Difference (IV, Fixed, 95% CI)

0.13 [-0.18, 0.44]

Mean Difference (IV, Fixed, 95% CI)

-0.03 [-0.31, 0.26]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-0.67 [-0.98, -0.36]

Mean Difference (IV, Random, 95% CI)

-0.03 [-0.22, 0.15]

Mean Difference (IV, Random, 95% CI)

-0.12 [-0.43, 0.20]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.23 [-0.46, -0.00]

Std. Mean Difference (IV, Random, 95%
CI)

-0.30 [-0.54, -0.06]

Std. Mean Difference (IV, Random, 95%
CI)

0.05 [-0.17, 0.26]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.06 [-0.38, 0.26]

Std. Mean Difference (IV, Random, 95%
CI)

-0.86 [-1.74, 0.02]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

517

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

38.3 Both group and indi-
vidual formats

39 Lower body strength (fol-
low-up values)

39.1 Group format

39.2 Individual format

39.3 Both group and indi-
vidual formats

40 Lower body strength
(change values)

40.1 Group format

40.2 Individual format

40.3 Both group and indi-
vidual formats

1

9

2

3

4

5

2

3

0

41 Upper body strength (fol-
low-up values)

12

41.1 Group format

41.2 Individual format

41.3 Both group and indi-
vidual formats

42 Upper body strength
(change values)

42.1 Group format

42.2 Individual format

42.3 Both group and indi-
vidual formats

43 Bone mineral density -
femoral neck (follow-up and
change values)

4

4

4

7

3

3

1

4

82

290

85

200

294

289

0

365

141

200

377

310

83

Std. Mean Difference (IV, Random, 95%
CI)

-0.29 [-0.73, 0.14]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.69 [0.29, 1.10]

Std. Mean Difference (IV, Random, 95%
CI)

1.04 [0.08, 2.00]

Std. Mean Difference (IV, Random, 95%
CI)

0.13 [-0.22, 0.47]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.92 [0.61, 1.22]

Std. Mean Difference (IV, Random, 95%
CI)

0.65 [0.09, 1.22]

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.53 [-0.29, 1.35]

Std. Mean Difference (IV, Random, 95%
CI)

0.63 [-0.06, 1.32]

Std. Mean Difference (IV, Random, 95%
CI)

0.29 [0.01, 0.57]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

1.01 [0.49, 1.53]

Std. Mean Difference (IV, Random, 95%
CI)

1.00 [-0.08, 2.09]

Std. Mean Difference (IV, Random, 95%
CI)

0.16 [-0.27, 0.59]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

518

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

43.1 Group format

43.2 Individual format

43.3 Both group and indi-
vidual formats

44 Bone mineral density
- lumbar spine (follow-up
and change values)

44.1 Group format

44.2 Individual format

44.3 Both group and indi-
vidual formats

45 Bone mineral density
- total hip (follow-up and
change values)

45.1 Group format

45.2 Individual format

45.3 Both group and indi-
vidual formats

0

2

2

4

0

2

2

3

0

1

2

0

262

524

0

262

524

0

39

290

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

0.17 [-0.80, 1.14]

Std. Mean Difference (IV, Random, 95%
CI)

0.17 [0.00, 0.34]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

0.20 [-0.59, 0.98]

Std. Mean Difference (IV, Random, 95%
CI)

0.12 [-0.06, 0.29]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

10.34 [7.84, 12.84]

Std. Mean Difference (IV, Random, 95%
CI)

0.64 [-0.20, 1.48]

Analysis 16.1.   Comparison 16 Subanalysis: outcomes by format
of intervention, Outcome 1 Overall HRQoL (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.1.1 Group format

Herrero 2006

Mustian 2004

Milne 2008

Murtezani 2014

Mehnert 2011

Subtotal ***

81.3 (10.7)

121.7 (22.7)

86.4 (8.3)

86.5 (7.3)

74.7 (21.7)

8

11

29

30

30

108

62.5 (16.1)

124.3 (25.9)

64.1 (10.8)

79.1 (7.5)

65.4 (16.8)

8

10

29

32

27

106

Heterogeneity: Tau2=0.62; Chi2=24.56, df=4(P<0.0001); I2=83.72%

Test for overall effect: Z=2.53(P=0.01)

16.25%

18.84%

20.74%

22.08%

22.09%

100%

1.3[0.19,2.41]

-0.1[-0.96,0.75]

2.28[1.61,2.96]

0.99[0.46,1.52]

0.47[-0.06,1]

0.99[0.22,1.75]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

519

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.1.2 Individual format

Cerulli 2014

Portela 2008

Courneya 2003

Ergun 2013

Pinto 2015

Schmitz 2005

Taleghani 2012

Daley 2007

Vallance 2007

Short 2014

Subtotal ***

85.2 (4.2)

107.2 (28.5)

91.3 (11)

71.6 (19.9)

117.8 (12.7)

-44.2 (8.7)

217.5 (36.3)

90.9 (13.5)

91.5 (11.8)

106.8 (16.7)

10

25

24

40

39

39

40

33

250

195

695

Heterogeneity: Tau2=0.03; Chi2=14.77, df=9(P=0.1); I2=39.08%

Test for overall effect: Z=2.3(P=0.02)

16.1.3 Both group and individual formats

Rogers 2015

Loudon 2014

Rogers 2009

Cadmus 2009

Loh 2014

Littman 2012

Subtotal ***

85.2 (4.2)

-7.4 (1.2)

92 (11.4)

91.2 (12.6)

112.4 (14.1)

90.3 (11)

10

12

20

37

63

30

172

Heterogeneity: Tau2=0.04; Chi2=7.84, df=5(P=0.17); I2=36.24%

Test for overall effect: Z=2.26(P=0.02)

65.9 (14.7)

91.6 (28.5)

89.3 (10.9)

67.9 (16.7)

114 (18)

-47.4 (9.4)

210.1 (41.5)

86.4 (15.1)

90.6 (13)

108.2 (18.2)

65.9 (14.7)

-7.4 (1.4)

87.4 (13.1)

86.2 (17.4)

109.3 (13.3)

87.7 (15)

10

9

28

20

37

40

40

69

85

104

442

10

11

18

37

32

110

218

2.5%

4.35%

7.56%

7.73%

9.85%

10.05%

10.21%

10.9%

18.2%

18.63%

100%

6.4%

9.83%

14.14%

21.62%

23.36%

24.65%

100%

1.72[0.66,2.78]

0.53[-0.24,1.31]

0.18[-0.37,0.73]

0.19[-0.35,0.73]

0.24[-0.21,0.69]

0.35[-0.09,0.79]

0.19[-0.25,0.63]

0.3[-0.12,0.72]

0.08[-0.16,0.33]

-0.08[-0.32,0.16]

0.21[0.03,0.38]

1.72[0.66,2.78]

0.02[-0.8,0.84]

0.37[-0.27,1.01]

0.33[-0.13,0.78]

0.22[-0.2,0.65]

0.18[-0.22,0.59]

0.33[0.04,0.62]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 16.2.   Comparison 16 Subanalysis: outcomes by format
of intervention, Outcome 2 Overall HRQoL (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.2.1 Group format

Mustian 2004

Herrero 2006

Murtezani 2014

Cuesta-Vargas 2014

Mehnert 2011

Subtotal ***

15 (5)

17.7 (8.3)

9.2 (2.1)

0.3 (0.2)

9.7 (21)

11

8

30

22

30

101

Heterogeneity: Tau2=3.43; Chi2=83.96, df=4(P<0.0001); I2=95.24%

Test for overall effect: Z=2.19(P=0.03)

16.2.2 Individual format

Naumann 2012

Courneya 2003

Ergun 2013

Schmitz 2005

Daley 2007

Vallance 2007

11

24

40

39

33

14.5 (10.6)

5.7 (7.4)

5.4 (21.5)

2.3 (4.5)

10.2 (11.2)

250

2.3 (11.1)

10

8

32

20

27

97

10

28

20

40

69

85

0 (5)

-10.4 (17.7)

-0.6 (2)

0.3 (0.1)

5.6 (16.5)

3.1 (11.4)

0.6 (7.4)

-6.7 (25.9)

0.6 (4)

3.2 (11.3)

-0.2 (6.4)

19.02%

19.17%

19.97%

20.85%

20.99%

100%

3.75%

9.8%

10.38%

15.25%

16.76%

44.07%

2.88[1.59,4.17]

1.92[0.68,3.17]

4.65[3.67,5.63]

-0.07[-0.67,0.54]

0.22[-0.31,0.74]

1.88[0.19,3.56]

1[0.08,1.92]

0.68[0.12,1.24]

0.52[-0.03,1.06]

0.4[-0.05,0.84]

0.62[0.2,1.04]

0.24[-0,0.49]

Favours control

-10

-5

0

5

10

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

520

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Subtotal ***

Mean(SD)

N

397

Heterogeneity: Tau2=0; Chi2=5.29, df=5(P=0.38); I2=5.56%

Test for overall effect: Z=4.69(P<0.0001)

16.2.3 Both group and individual formats

Rogers 2009

Cadmus 2009

Saarto 2012

Subtotal ***

4.5 (8.4)

0.6 (7.5)

4.2 (16.2)

20

37

263

320

Heterogeneity: Tau2=0.03; Chi2=3.23, df=2(P=0.2); I2=38%

Test for overall effect: Z=0.39(P=0.69)

N

252

18

37

237

292

Mean(SD)

Random, 95% CI

Random, 95% CI

100%

0.43[0.25,0.61]

2.9 (12)

-2.4 (9.8)

5.6 (15.4)

15.32%

25.01%

59.66%

100%

0.15[-0.49,0.79]

0.34[-0.12,0.8]

-0.09[-0.26,0.09]

0.06[-0.22,0.33]

Favours control

-10

-5

0

5

10

Favours physical activity

Analysis 16.3.   Comparison 16 Subanalysis: outcomes by format of intervention,
Outcome 3 Overall emotional function/mental health (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.3.1 Group format

Banasik 2011

Herrero 2006

Mustian 2004

Cuesta-Vargas 2014

Milne 2008

Mehnert 2011

Cantarero-Villanueva 2013

Murtezani 2014

Fillion 2008

Schmitz 2009

Subtotal ***

0.5 (0.4)

90.6 (9.3)

24.8 (2)

42.9 (19.2)

19.6 (2.4)

77 (35.8)

-17175
(4279)

19.5 (3.3)

48.5 (7.9)

53.2 (9.6)

7

8

9

22

29

30

32

30

44

112

323

Heterogeneity: Tau2=0.04; Chi2=13.58, df=9(P=0.14); I2=33.74%

Test for overall effect: Z=2.64(P=0.01)

16.3.2 Individual format

Baruth 2013

Pinto 2003

Basen-Enquist 2006

Courneya 2003

Daley 2007

Pinto 2015

Schmitz 2005

Pinto 2005

Duijits 2012

Vallance 2007

Subtotal ***

83.5 (0)

-10.8 (28.1)

78.2 (10.6)

21.5 (3.4)

19.1 (4.2)

54.2 (9.3)

-45.6 (8.2)

-8 (20.7)

73.9 (34.7)

20.3 (3.3)

20

12

28

24

33

39

39

39

37

250

521

Heterogeneity: Tau2=0; Chi2=4.57, df=8(P=0.8); I2=0%

Test for overall effect: Z=2.22(P=0.03)

0.4 (0.3)

83.3 (14.8)

24.8 (3.2)

32.3 (33.3)

16.7 (4.1)

69.1 (40.5)

-20390
(6113)

18.3 (3.5)

47.5 (9.1)

53.8 (8.7)

68.5 (0)

-27.2 (19.5)

77.2 (12)

20.7 (3)

18.5 (3.3)

52.5 (9.6)

-48.2 (8.2)

-16.5 (28.8)

77.5 (34.3)

19.9 (3.4)

7

8

10

20

29

28

29

32

43

120

326

12

12

23

28

33

37

40

43

89

85

402

3.54%

3.84%

4.65%

8.63%

10.31%

10.93%

10.98%

11.34%

14.06%

21.73%

100%

2.88%

6.45%

6.56%

8.41%

9.67%

9.97%

10.31%

13.35%

32.4%

100%

0.25[-0.8,1.3]

0.56[-0.45,1.56]

-0.01[-0.91,0.89]

0.39[-0.22,1]

0.85[0.31,1.39]

0.21[-0.31,0.72]

0.61[0.09,1.12]

0.35[-0.15,0.85]

0.12[-0.3,0.54]

-0.07[-0.32,0.19]

0.28[0.07,0.49]

Not estimable

0.65[-0.17,1.48]

0.09[-0.46,0.64]

0.25[-0.3,0.79]

0.16[-0.32,0.64]

0.18[-0.27,0.63]

0.31[-0.13,0.76]

0.33[-0.1,0.77]

-0.1[-0.49,0.28]

0.11[-0.14,0.35]

0.16[0.02,0.3]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

521

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.3.3 Both group and individual formats

Loudon 2014

Rogers 2009

Littman 2012

Cadmus 2009

Loh 2014

Rogers 2015

Subtotal ***

12

20

30

37

63

105

267

-1.6 (0.7)

20 (3.1)

20.3 (4)

20.5 (3)

19.9 (2.8)

20.6 (2.9)

11

18

27

37

32

108

233

-1.6 (0.5)

21.1 (2.9)

20.8 (3.1)

19.8 (4.2)

20 (3.2)

19.7 (3.2)

Heterogeneity: Tau2=0; Chi2=5.27, df=5(P=0.38); I2=5.19%

Test for overall effect: Z=1.05(P=0.29)

5.08%

8.15%

12.24%

15.71%

17.95%

40.87%

100%

0.05[-0.77,0.87]

-0.36[-1,0.28]

-0.14[-0.66,0.38]

0.19[-0.27,0.65]

-0.04[-0.46,0.39]

0.29[0.02,0.56]

0.1[-0.09,0.29]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 16.4.   Comparison 16 Subanalysis: outcomes by format of intervention,
Outcome 4 Overall emotional function/mental health (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.4.1 Group format

Herrero 2006

Mustian 2004

Murtezani 2014

Cormie 2014

Mehnert 2011

Cantarero-Villanueva 2013

Schmitz 2009

Subtotal ***

8

9

30

43

30

32

58

210

9.3 (19.6)

2.4 (2.5)

2.1 (0.8)

4.4 (9)

2.3 (35.5)

-1445
(4452)

3.3 (23.2)

-2.1 (5.9)

0.1 (1.7)

0.5 (0.9)

2.7 (8.6)

3.6 (17.6)

353 (3323)

3.1 (17.2)

8

10

32

19

28

29

62

188

Heterogeneity: Tau2=0.46; Chi2=39.78, df=6(P<0.0001); I2=84.92%

Test for overall effect: Z=1.48(P=0.14)

16.4.2 Individual format

Naumann 2012

Courneya 2003

Schmitz 2005

Pinto 2005

Vallance 2007

Subtotal ***

1 (2.7)

2.3 (3.1)

2.5 (4.4)

-3.8 (27.7)

0.5 (3.5)

11

24

39

39

250

363

Heterogeneity: Tau2=0; Chi2=3.4, df=4(P=0.49); I2=0%

Test for overall effect: Z=2.86(P=0)

16.4.3 Both group and individual formats

Rogers 2009

Cadmus 2009

Saarto 2012

Subtotal ***

0.9 (2.5)

0.3 (2.2)

1.2 (17.8)

20

37

263

320

Heterogeneity: Tau2=0.02; Chi2=2.87, df=2(P=0.24); I2=30.25%

Test for overall effect: Z=0.7(P=0.48)

-0.1 (2.7)

0.8 (2.9)

0.3 (3.9)

-11.5 (25.8)

0.1 (2.5)

-0.1 (2.7)

-0.5 (3.3)

1.9 (18.5)

10

28

40

43

85

206

18

37

237

292

11.14%

11.53%

14.76%

15.2%

15.41%

15.45%

16.51%

100%

4.26%

10.4%

15.84%

16.83%

52.67%

100%

13.31%

22.99%

63.7%

100%

0.74[-0.28,1.77]

1.06[0.08,2.03]

1.8[1.21,2.4]

0.19[-0.35,0.73]

-0.04[-0.56,0.47]

-0.45[-0.96,0.06]

0.01[-0.35,0.37]

0.42[-0.14,0.99]

0.39[-0.48,1.26]

0.49[-0.06,1.05]

0.52[0.08,0.97]

0.28[-0.15,0.72]

0.12[-0.13,0.36]

0.26[0.08,0.44]

0.38[-0.27,1.02]

0.28[-0.18,0.74]

-0.04[-0.21,0.14]

0.09[-0.16,0.34]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

522

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 16.5.   Comparison 16 Subanalysis: outcomes by format of
intervention, Outcome 5 Overall physical function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.5.1 Group format

Banasik 2011

Herrero 2006

Mustian 2004

Milne 2008

Cuesta-Vargas 2014

Mehnert 2011

Murtezani 2014

Fillion 2008

Schmitz 2009

Subtotal ***

-0.8 (0.9)

94.1 (7.5)

26.9 (4.1)

24 (2.6)

42.9 (4.1)

89 (9.1)

22.6 (4.4)

45.1 (10.4)

50.6 (8.2)

7

8

9

29

22

30

30

44

112

291

Heterogeneity: Tau2=0.28; Chi2=38.27, df=8(P<0.0001); I2=79.1%

Test for overall effect: Z=2.52(P=0.01)

16.5.2 Individual format

Pinto 2003

Basen-Enquist 2006

Courneya 2003

Daley 2007

Schmitz 2005

Pinto 2015

Pinto 2005

Duijits 2012

Vallance 2007

Subtotal ***

32.3 (4.3)

82.5 (12.7)

25.3 (2.5)

25.6 (2.2)

-44.2 (5.6)

87.1 (4.4)

30.3 (7.9)

84 (16.9)

25.1 (3)

12

28

24

33

39

39

39

87

250

551

Heterogeneity: Tau2=0.01; Chi2=10.38, df=8(P=0.24); I2=22.93%

Test for overall effect: Z=3.44(P=0)

16.5.3 Both group and individual formats

Rogers 2009

Littman 2012

Winters-Stone 2011

Cadmus 2009

Loh 2014

Rogers 2015

Subtotal ***

23.3 (4.5)

25.4 (1.7)

51.7 (6.2)

25.1 (2.7)

24.9 (2.5)

24.1 (3.5)

20

30

36

37

63

105

291

Heterogeneity: Tau2=0.04; Chi2=8.72, df=5(P=0.12); I2=42.68%

Test for overall effect: Z=1.45(P=0.15)

-0.4 (0.3)

92.5 (6.6)

26.5 (4.1)

15.6 (4.5)

32.4 (32.5)

78.1 (21.2)

19.4 (4.4)

41.8 (9.8)

49.1 (9.3)

25.3 (8.2)

77.4 (11.5)

25.3 (2.8)

23.6 (5.7)

-48.3 (7.7)

84.7 (15.9)

27.3 (6.8)

80.2 (17.1)

25 (3.3)

25.4 (2.3)

24.3 (4.4)

52.3 (5.9)

24 (4.1)

24.2 (2.2)

22.5 (5)

7

8

10

29

20

28

32

43

120

297

12

23

28

33

40

37

43

89

85

390

18

27

25

37

32

108

247

7.59%

8.23%

8.9%

11.02%

11.53%

12.33%

12.48%

13.32%

14.61%

100%

3.29%

7.2%

7.49%

8.97%

10.22%

10.23%

10.72%

18.68%

23.2%

100%

10.32%

13.99%

14.46%

16.51%

17.88%

26.84%

100%

-0.48[-1.54,0.59]

0.21[-0.77,1.2]

0.09[-0.81,0.99]

2.26[1.59,2.92]

0.46[-0.16,1.07]

0.66[0.13,1.19]

0.72[0.2,1.23]

0.33[-0.1,0.75]

0.17[-0.09,0.43]

0.53[0.12,0.94]

1.03[0.17,1.89]

0.41[-0.15,0.97]

0[-0.55,0.55]

0.46[-0.03,0.95]

0.6[0.15,1.05]

0.21[-0.25,0.66]

0.4[-0.04,0.83]

0.23[-0.07,0.52]

0.05[-0.2,0.3]

0.28[0.12,0.45]

-0.57[-1.22,0.08]

0.33[-0.19,0.86]

-0.1[-0.61,0.41]

0.31[-0.15,0.77]

0.3[-0.12,0.73]

0.37[0.1,0.64]

0.18[-0.06,0.42]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 16.6.   Comparison 16 Subanalysis: outcomes by format of
intervention, Outcome 6 Overall physical function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.6.1 Group format

Favours control

-10

-5

0

5

10

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

523

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Herrero 2006

Mustian 2004

Murtezani 2014

Cormie 2014

Mehnert 2011

Schmitz 2009

Subtotal ***

8

9

30

43

30

58

178

6.7 (5)

1.9 (2.6)

4.4 (1.5)

3.5 (5.2)

4 (10.8)

6.6 (17.1)

-1.7 (6.9)

-0.2 (1.6)

-1.3 (1.2)

-0.5 (5.7)

-2.1 (16.7)

4.1 (17.3)

8

10

32

19

28

62

159

Heterogeneity: Tau2=1.29; Chi2=68.65, df=5(P<0.0001); I2=92.72%

Test for overall effect: Z=2.55(P=0.01)

16.6.2 Individual format

Naumann 2012

Schmitz 2005

Vallance 2007

Subtotal ***

1.9 (3.3)

1.2 (4.2)

1 (3.3)

11

39

247

297

Heterogeneity: Tau2=0; Chi2=1.59, df=2(P=0.45); I2=0%

Test for overall effect: Z=1.84(P=0.07)

16.6.3 Both group and individual formats

Rogers 2009

Courneya 2003

Cadmus 2009

Saarto 2012

Subtotal ***

2.3 (5.1)

1.9 (2)

0.1 (6)

1.9 (13.7)

20

24

37

263

344

Heterogeneity: Tau2=0.15; Chi2=12.68, df=3(P=0.01); I2=76.34%

Test for overall effect: Z=0.83(P=0.4)

0.8 (3.4)

1.5 (6.8)

0.2 (2.1)

2.6 (6)

-0.2 (2.2)

-0.5 (7.4)

3.4 (13.4)

10

40

85

135

18

28

37

237

320

14.92%

15.72%

15.95%

17.55%

17.68%

18.18%

100%

5.88%

22.51%

71.61%

100%

20.15%

21.71%

25.31%

32.83%

100%

1.32[0.21,2.43]

0.93[-0.03,1.89]

4.23[3.31,5.15]

0.74[0.19,1.3]

0.43[-0.09,0.95]

0.14[-0.21,0.5]

1.25[0.29,2.21]

0.32[-0.55,1.18]

-0.05[-0.49,0.39]

0.26[0.02,0.51]

0.2[-0.01,0.41]

-0.05[-0.69,0.58]

0.98[0.4,1.56]

0.09[-0.37,0.54]

-0.11[-0.29,0.06]

0.19[-0.25,0.63]

Favours control

-10

-5

0

5

10

Favours physical activity

Analysis 16.7.   Comparison 16 Subanalysis: outcomes by format of
intervention, Outcome 7 Overall role function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.7.1 Group format

Banasik 2011

Herrero 2006

Mustian 2004

Milne 2008

Mehnert 2011

Murtezani 2014

Subtotal ***

3.5 (0.6)

97.6 (5.9)

2.4 (1.5)

22.2 (3)

90 (20.3)

24.2 (2.8)

7

8

9

29

30

30

113

Heterogeneity: Tau2=0.8; Chi2=35.2, df=5(P<0.0001); I2=85.8%

Test for overall effect: Z=1.29(P=0.2)

16.7.2 Individual format

Baruth 2013

Basen-Enquist 2006

Courneya 2003

Daley 2007

20

28

24

33

72.9 (0)

86.1 (22.2)

23.4 (4)

22.9 (4.5)

7

8

9

29

27

32

112

12

23

28

33

3.2 (0.6)

100 (0)

2.8 (1.5)

12.5 (4.8)

79.6 (25)

23 (2.5)

65.6 (0)

73 (24.5)

23.1 (4)

20.3 (5.6)

14.72%

15.13%

15.7%

17.44%

18.44%

18.57%

100%

8.53%

9.08%

11.23%

0.34[-0.72,1.4]

-0.54[-1.55,0.46]

-0.23[-1.15,0.7]

2.39[1.71,3.08]

0.45[-0.07,0.98]

0.45[-0.06,0.95]

0.52[-0.27,1.3]

Not estimable

0.55[-0.01,1.12]

0.07[-0.47,0.62]

0.5[0.01,0.99]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

524

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Cadmus 2009

Schmitz 2005

Vallance 2007

Subtotal ***

N

37

39

250

431

23.1 (4.7)

-49.2 (6.5)

23.2 (4)

Heterogeneity: Tau2=0; Chi2=4.32, df=5(P=0.5); I2=0%

Test for overall effect: Z=2.78(P=0.01)

16.7.3 Both group and individual formats

Loudon 2014

Rogers 2009

Littman 2012

Loh 2014

Rogers 2015

Subtotal ***

-1.3 (0.3)

21.4 (4.8)

22.6 (3.9)

23.4 (4.3)

22.3 (4.5)

12

20

30

63

105

230

Heterogeneity: Tau2=0.05; Chi2=7.56, df=4(P=0.11); I2=47.08%

Test for overall effect: Z=0.95(P=0.34)

20.6 (7.2)

-50 (6.2)

22.7 (4.6)

-1.3 (0.4)

23.8 (3.2)

21.7 (4.7)

22.2 (5)

20.3 (5.5)

37

40

85

258

11

18

27

32

108

196

12.74%

13.86%

44.56%

100%

10.33%

14.4%

19.02%

23.47%

32.78%

100%

0.41[-0.05,0.87]

0.12[-0.32,0.57]

0.12[-0.13,0.37]

0.23[0.07,0.4]

0[-0.82,0.82]

-0.57[-1.22,0.08]

0.21[-0.31,0.73]

0.25[-0.18,0.68]

0.4[0.12,0.67]

0.15[-0.15,0.45]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 16.8.   Comparison 16 Subanalysis: outcomes by format
of intervention, Outcome 8 Overall role function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.8.1 Group format

Herrero 2006

Mustian 2004

Cormie 2014

Murtezani 2014

Mehnert 2011

Subtotal ***

2.1 (13.9)

0.6 (1.6)

4.9 (7.1)

1.7 (0.7)

6.7 (23.8)

8

9

43

30

30

120

Heterogeneity: Tau2=0.2; Chi2=11.36, df=4(P=0.02); I2=64.8%

Test for overall effect: Z=1.42(P=0.15)

16.8.2 Individual format

Naumann 2012

Courneya 2003

Schmitz 2005

Vallance 2007

Subtotal ***

1.5 (4.4)

0.9 (2.8)

1.2 (4.2)

0.6 (4.1)

11

24

39

250

324

Heterogeneity: Tau2=0; Chi2=0.81, df=3(P=0.85); I2=0%

Test for overall effect: Z=1.29(P=0.2)

16.8.3 Both group and individual formats

Rogers 2009

Cadmus 2009

Saarto 2012

Subtotal ***

0.4 (3.3)

-0.3 (3.7)

2.4 (21.5)

20

37

263

320

Heterogeneity: Tau2=0; Chi2=0.62, df=2(P=0.74); I2=0%

Test for overall effect: Z=0.77(P=0.44)

8

10

19

32

27

96

10

28

40

85

163

18

37

237

292

2.1 (5.9)

0.8 (1.6)

1.7 (7.1)

0.9 (0.6)

5.6 (27)

0.5 (4.5)

0.4 (2.7)

1.5 (6.8)

-0 (2.7)

1.4 (4.3)

-0.5 (3.4)

3.8 (21.6)

14.24%

15.57%

23.15%

23.27%

23.77%

100%

5.15%

12.73%

19.53%

62.59%

100%

6.16%

12.13%

81.72%

100%

0[-0.98,0.98]

-0.15[-1.05,0.76]

0.45[-0.1,0.99]

1.16[0.62,1.7]

0.04[-0.48,0.56]

0.36[-0.14,0.85]

0.22[-0.64,1.08]

0.18[-0.37,0.73]

-0.05[-0.49,0.39]

0.17[-0.08,0.41]

0.13[-0.07,0.32]

-0.26[-0.9,0.38]

0.06[-0.4,0.51]

-0.06[-0.24,0.11]

-0.06[-0.22,0.1]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

525

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 16.9.   Comparison 16 Subanalysis: outcomes by format of
intervention, Outcome 9 Overall social well-being/function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.9.1 Group format

Banasik 2011

Herrero 2006

Mustian 2004

Milne 2008

Mehnert 2011

Murtezani 2014

Schmitz 2009

Subtotal ***

2.8 (0.7)

87.5 (19.4)

8.6 (1.9)

20.7 (4)

85.4 (20.9)

20.2 (2.8)

14.9 (5.2)

7

8

9

29

30

30

59

172

Heterogeneity: Tau2=0.01; Chi2=6.4, df=6(P=0.38); I2=6.27%

Test for overall effect: Z=1.97(P=0.05)

16.9.2 Individual format

Rogers 2014

Basen-Enquist 2006

Courneya 2003

Daley 2007

Vallance 2007

Subtotal ***

7.3 (4.9)

84.6 (16.9)

21.1 (3.5)

23.3 (4.8)

22.9 (5)

20

28

24

33

250

355

Heterogeneity: Tau2=0.09; Chi2=10.43, df=4(P=0.03); I2=61.64%

Test for overall effect: Z=1.54(P=0.12)

16.9.3 Both group and individual formats

Rogers 2009

Littman 2012

Cadmus 2009

Loh 2014

Kiecolt-Glaser 2014

Rogers 2015

Subtotal ***

22.6 (4.1)

22.1 (5)

22.3 (4.9)

21.5 (4.9)

95.2 (10.8)

21 (5.7)

20

30

37

63

96

105

351

Heterogeneity: Tau2=0; Chi2=1.92, df=5(P=0.86); I2=0%

Test for overall effect: Z=2.09(P=0.04)

3.2 (0.8)

91.7 (23.6)

9 (1.8)

19.4 (3.9)

79.9 (22.7)

18.3 (2.7)

14.1 (5.8)

3.1 (3.2)

84.9 (19.2)

20.7 (3.6)

20.4 (6.8)

23 (5.1)

21.8 (5.7)

20.9 (6)

20.6 (7.2)

19.6 (4.9)

93.8 (9.3)

20.7 (5.8)

7

8

10

29

28

32

62

176

22

23

28

33

85

191

18

27

37

32

90

108

312

4.3%

5.04%

5.94%

17.08%

17.15%

17.38%

33.11%

100%

15.22%

17.91%

18.1%

19.9%

28.87%

100%

5.82%

8.7%

11.29%

12.86%

28.55%

32.79%

100%

-0.45[-1.51,0.62]

-0.18[-1.17,0.8]

-0.19[-1.09,0.71]

0.32[-0.19,0.84]

0.25[-0.27,0.76]

0.68[0.17,1.2]

0.14[-0.21,0.5]

0.22[0,0.45]

1.01[0.36,1.65]

-0.02[-0.57,0.54]

0.11[-0.43,0.66]

0.49[-0,0.98]

-0[-0.25,0.24]

0.27[-0.07,0.61]

0.16[-0.48,0.8]

0.22[-0.31,0.74]

0.27[-0.18,0.73]

0.38[-0.05,0.81]

0.14[-0.15,0.43]

0.05[-0.22,0.32]

0.16[0.01,0.32]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 16.10.   Comparison 16 Subanalysis: outcomes by format of
intervention, Outcome 10 Overall social well-being/function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.10.1 Group format

Mustian 2004

Murtezani 2014

Cormie 2014

Mehnert 2011

Schmitz 2009

9

30

43

30

59

1.5 (1.5)

2.1 (0.8)

3.5 (8.5)

7.3 (22.3)

4.4 (33.8)

10

32

19

28

62

0.4 (1.2)

0.5 (0.9)

2.5 (8.3)

3.1 (24.3)

0.7 (34)

15.73%

20%

20.67%

20.96%

22.65%

0.76[-0.18,1.7]

1.8[1.21,2.4]

0.12[-0.42,0.66]

0.18[-0.34,0.69]

0.11[-0.25,0.47]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

526

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Subtotal ***

Mean(SD)

N

171

Heterogeneity: Tau2=0.41; Chi2=26.1, df=4(P<0.0001); I2=84.67%

Test for overall effect: Z=1.78(P=0.08)

16.10.2 Individual format

Naumann 2012

Rogers 2014

Courneya 2003

Vallance 2007

Subtotal ***

0.9 (3.3)

2.1 (3.2)

0.6 (2.4)

0.2 (4.8)

11

20

24

250

305

Heterogeneity: Tau2=0.05; Chi2=5.14, df=3(P=0.16); I2=41.63%

Test for overall effect: Z=4.17(P<0.0001)

16.10.3 Both group and individual formats

Rogers 2009

Cadmus 2009

Saarto 2012

Subtotal ***

0.9 (2.6)

0.6 (4.6)

5 (21.1)

20

37

263

320

Heterogeneity: Tau2=0.21; Chi2=11.76, df=2(P=0); I2=82.99%

Test for overall effect: Z=0.91(P=0.36)

N

151

10

22

28

85

145

18

37

237

292

Mean(SD)

Random, 95% CI

Random, 95% CI

100%

0.57[-0.06,1.19]

-0.2 (3.3)

-0.8 (3.5)

-0.5 (3.3)

-4.1 (3.3)

-1.2 (2.7)

-1 (3.2)

8.8 (20.8)

12.35%

19.45%

23.38%

44.82%

100%

26.97%

32.97%

40.06%

100%

0.32[-0.54,1.18]

0.85[0.21,1.48]

0.37[-0.18,0.92]

0.97[0.71,1.23]

0.72[0.38,1.06]

0.78[0.11,1.44]

0.4[-0.06,0.86]

-0.18[-0.36,-0.01]

0.27[-0.31,0.85]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 16.11.   Comparison 16 Subanalysis: outcomes by format of
intervention, Outcome 11 Overall cognitive function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.11.1 Group format

Herrero 2006

Mehnert 2011

Cantarero-Villanueva 2013

Subtotal ***

91.7 (12.6)

81.1 (16.8)

-37.9 (8.5)

8

30

32

70

Heterogeneity: Tau2=0; Chi2=1.36, df=2(P=0.51); I2=0%

Test for overall effect: Z=1.82(P=0.07)

16.11.2 Individual format

Pinto 2003

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.09(P=0.04)

-4.3 (2.5)

12

12

16.11.3 Both group and individual formats

Rogers 2009

Subtotal ***

19

19

-124.5
(30.8)

Heterogeneity: Not applicable

Test for overall effect: Z=1.25(P=0.21)

89.6 (12.4)

78.4 (24.4)

-43 (10)

-7.2 (2.1)

-135.5
(19.5)

8

27

29

64

6

6

18

18

12.15%

43.23%

44.62%

100%

0.16[-0.82,1.14]

0.13[-0.39,0.65]

0.55[0.03,1.06]

0.32[-0.02,0.66]

100%

100%

1.14[0.07,2.2]

1.14[0.07,2.2]

100%

100%

0.42[-0.24,1.07]

0.42[-0.24,1.07]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

527

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 16.12.   Comparison 16 Subanalysis: outcomes by format of
intervention, Outcome 12 Overall cognitive function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.12.1 Group format

Herrero 2006

Mehnert 2011

Cantarero-Villanueva 2013

Subtotal ***

6.2 (19.8)

1.7 (22.4)

2.2 (7.6)

8

30

32

70

Heterogeneity: Tau2=0.01; Chi2=2.26, df=2(P=0.32); I2=11.37%

Test for overall effect: Z=0.32(P=0.75)

16.12.2 Individual format

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

8.3 (14.8)

6.2 (24.6)

-0.2 (5.5)

8

27

29

64

0

16.12.3 Both group and individual formats

Rogers 2009

Saarto 2012

Subtotal ***

20

263

283

4.2 (16.8)

-1 (18.2)

18

237

255

-4.7 (25.9)

2.2 (18.5)

Heterogeneity: Tau2=0.11; Chi2=2.88, df=1(P=0.09); I2=65.29%

Test for overall effect: Z=0.1(P=0.92)

13.42%

42.26%

44.33%

100%

-0.11[-1.09,0.87]

-0.19[-0.71,0.33]

0.35[-0.16,0.86]

0.06[-0.31,0.43]

Not estimable

35.06%

64.94%

100%

0.4[-0.24,1.05]

-0.17[-0.35,0]

0.03[-0.51,0.57]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 16.13.   Comparison 16 Subanalysis: outcomes by format of
intervention, Outcome 13 Overall general health (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.13.1 Group format

Herrero 2006

Mustian 2004

Mehnert 2011

Subtotal ***

81.3 (10.7)

18.6 (4.8)

74.4 (11.8)

8

9

30

47

Heterogeneity: Tau2=0.2; Chi2=4.19, df=2(P=0.12); I2=52.3%

Test for overall effect: Z=1.07(P=0.28)

16.13.2 Individual format

Baruth 2013

Basen-Enquist 2006

Ergun 2013

Schmitz 2005

Subtotal ***

68.1 (0)

77.4 (11.6)

71.6 (19.9)

53.8 (5.3)

20

28

40

39

127

Heterogeneity: Tau2=0.07; Chi2=3.94, df=2(P=0.14); I2=49.3%

Test for overall effect: Z=1.61(P=0.11)

62.5 (16.1)

19.3 (1.9)

70 (20.8)

61.6 (0)

67.1 (13.4)

67.9 (16.7)

53.2 (6)

8

9

28

45

12

23

20

40

95

16.13.3 Both group and individual formats

Rogers 2009

Cadmus 2009

20

37

3.5 (0.9)

50 (8.8)

18

37

3.8 (0.5)

51.7 (8.4)

23.95%

29.48%

46.57%

100%

29.61%

31.87%

38.52%

100%

1.3[0.19,2.41]

-0.18[-1.11,0.74]

0.26[-0.26,0.77]

0.38[-0.31,1.07]

Not estimable

0.81[0.24,1.39]

0.19[-0.35,0.73]

0.1[-0.34,0.55]

0.34[-0.08,0.76]

33.49%

66.51%

-0.4[-1.04,0.25]

-0.2[-0.65,0.26]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

528

Favours control

-100

-50

0

50

100

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Subtotal ***

Mean(SD)

N

57

N

55

Heterogeneity: Tau2=0; Chi2=0.25, df=1(P=0.62); I2=0%

Test for overall effect: Z=1.38(P=0.17)

Mean(SD)

Random, 95% CI

Random, 95% CI

100%

-0.26[-0.64,0.11]

Favours control

-100

-50

0

50

100

Favours physical activity

Analysis 16.14.   Comparison 16 Subanalysis: outcomes by format of
intervention, Outcome 14 Overall general health (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.14.1 Group format

Herrero 2006

Mustian 2004

Cormie 2014

Mehnert 2011

Subtotal ***

17.7 (8.3)

0.2 (1.9)

3.7 (7)

6.6 (13.7)

8

9

43

30

90

Heterogeneity: Tau2=0.22; Chi2=8.11, df=3(P=0.04); I2=63%

Test for overall effect: Z=1.14(P=0.25)

16.14.2 Individual format

Ergun 2013

Schmitz 2005

Subtotal ***

5.4 (21.5)

0.7 (4.8)

40

39

79

Heterogeneity: Tau2=0; Chi2=0.39, df=1(P=0.53); I2=0%

Test for overall effect: Z=2.19(P=0.03)

16.14.3 Both group and individual formats

-10.4 (17.7)

0.7 (2.5)

2.8 (7.1)

3.2 (19.7)

-6.7 (25.9)

-0.6 (3.9)

8

10

19

28

65

20

40

60

Rogers 2009

Cadmus 2009

Saarto 2012

Subtotal ***

20

37

263

320

0.2 (0.6)

0.2 (4.4)

4.2 (16.2)

18

37

237

292

0.2 (0.7)

-0.1 (5.1)

5.6 (15.4)

Heterogeneity: Tau2=0; Chi2=0.38, df=2(P=0.83); I2=0%

Test for overall effect: Z=0.82(P=0.41)

14.97%

21.54%

31.39%

32.1%

100%

39.82%

60.18%

100%

6.21%

12.12%

81.66%

100%

1.92[0.68,3.17]

-0.2[-1.1,0.71]

0.13[-0.41,0.67]

0.2[-0.32,0.71]

0.35[-0.25,0.95]

0.52[-0.03,1.06]

0.29[-0.15,0.74]

0.38[0.04,0.73]

-0.03[-0.67,0.61]

0.06[-0.39,0.52]

-0.09[-0.26,0.09]

-0.07[-0.23,0.09]

Favours control

-100

-50

0

50

100

Favours physical activity

Analysis 16.15.   Comparison 16 Subanalysis: outcomes by format of
intervention, Outcome 15 Overall sexual function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

16.15.1 Group format

Schmitz 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.73(P=0.46)

16.15.2 Individual format

-27.3 (5.3)

57

57

57

57

-28.1 (6.2)

100%

100%

0.14[-0.23,0.51]

0.14[-0.23,0.51]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

529

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

Pinto 2005

Schmitz 2005

Pinto 2003

Duijits 2012

Subtotal ***

12

39

39

53

143

42.8 (9.2)

-51 (7.5)

42.5 (9.2)

0.6 (0.8)

6

40

43

65

154

43.7 (6.1)

-53.5 (8)

40.1 (6.3)

0.6 (0.8)

Heterogeneity: Tau2=0; Chi2=1.78, df=3(P=0.62); I2=0%

Test for overall effect: Z=1.42(P=0.16)

16.15.3 Both group and individual formats

Subtotal ***

0

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

5.48%

26.73%

27.74%

40.05%

100%

-0.11[-1.09,0.87]

0.32[-0.12,0.76]

0.29[-0.14,0.73]

0.01[-0.35,0.38]

0.17[-0.06,0.4]

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 16.16.   Comparison 16 Subanalysis: outcomes by format
of intervention, Outcome 16 Overall sleep (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

16.16.1 Group format

Bower 2011

Mehnert 2011

Subtotal ***

8.1 (2.5)

23.8 (27)

16

30

46

Heterogeneity: Tau2=0; Chi2=2.04, df=1(P=0.15); I2=50.93%

Test for overall effect: Z=1.2(P=0.23)

16.16.2 Individual format

Rogers 2013

Rogers 2014

Subtotal ***

6.3 (2.7)

6.7 (3.7)

11

20

31

Heterogeneity: Tau2=0; Chi2=0.07, df=1(P=0.79); I2=0%

Test for overall effect: Z=0.26(P=0.79)

16.16.3 Both group and individual formats

Rogers 2009

Subtotal ***

6.7 (4.2)

20

20

Heterogeneity: Not applicable

Test for overall effect: Z=0.84(P=0.4)

7.7 (2.6)

38.3 (31.6)

6.2 (3.2)

7.1 (3.2)

5.5 (4)

15

27

42

9

22

31

18

18

35.91%

64.09%

100%

0.15[-0.55,0.86]

-0.49[-1.02,0.04]

-0.26[-0.68,0.16]

32.12%

67.88%

100%

0.03[-0.85,0.91]

-0.11[-0.72,0.49]

-0.07[-0.57,0.43]

100%

100%

0.28[-0.36,0.92]

0.28[-0.36,0.92]

Favours Physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 16.17.   Comparison 16 Subanalysis: outcomes by format
of intervention, Outcome 17 Overall anxiety (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.17.1 Group format

Milne 2008

29

15.3 (6.2)

29

21 (5.7)

31.49%

-0.94[-1.49,-0.4]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

530

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Mehnert 2011

Cantarero-Villanueva 2013

Subtotal ***

4.8 (3.5)

42.5 (8.6)

30

32

91

Heterogeneity: Tau2=0; Chi2=1.12, df=2(P=0.57); I2=0%

Test for overall effect: Z=4.67(P<0.0001)

16.17.2 Individual format

Pinto 2003

Rogers 2014

Subtotal ***

7.6 (7.3)

45.6 (8.9)

12

20

32

Heterogeneity: Tau2=0; Chi2=0.51, df=1(P=0.48); I2=0%

Test for overall effect: Z=0.48(P=0.63)

16.17.3 Both group and individual formats

Cadmus 2009

Subtotal ***

32.1 (12.3)

37

37

Heterogeneity: Not applicable

Test for overall effect: Z=0.61(P=0.54)

7.1 (5)

49.9 (11.7)

10.5 (3.7)

45.7 (8)

34.1 (15.4)

28

29

86

6

22

28

37

37

33.91%

34.6%

100%

Random, 95% CI

-0.54[-1.06,-0.01]

-0.72[-1.24,-0.2]

-0.73[-1.03,-0.42]

27.1%

72.9%

100%

-0.43[-1.43,0.56]

-0.01[-0.62,0.59]

-0.13[-0.64,0.39]

100%

100%

-0.14[-0.6,0.31]

-0.14[-0.6,0.31]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 16.18.   Comparison 16 Subanalysis: outcomes by format
of intervention, Outcome 18 Overall anxiety (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

16.18.1 Group format

Mehnert 2011

Cantarero-Villanueva 2013

Subtotal ***

-1.7 (3.7)

-4.2 (9.8)

30

32

62

Heterogeneity: Tau2=0; Chi2=0.24, df=1(P=0.62); I2=0%

Test for overall effect: Z=2.76(P=0.01)

16.18.2 Individual format

Rogers 2014

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.2(P=0.23)

-4 (6.5)

20

20

16.18.3 Both group and individual formats

Cadmus 2009

Subtotal ***

-0.7 (9.2)

37

37

Heterogeneity: Not applicable

Test for overall effect: Z=0.66(P=0.51)

0.2 (4.9)

0.8 (5.5)

-1.8 (5)

0.5 (5.8)

28

29

57

22

22

37

37

49.37%

50.63%

100%

-0.42[-0.95,0.1]

-0.61[-1.12,-0.09]

-0.52[-0.88,-0.15]

100%

100%

-0.37[-0.99,0.24]

-0.37[-0.99,0.24]

100%

100%

-0.15[-0.61,0.3]

-0.15[-0.61,0.3]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

531

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 16.19.   Comparison 16 Subanalysis: outcomes by format
of intervention, Outcome 19 Overall depression (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.19.1 Group format

Mehnert 2011

Cantarero-Villanueva 2013

Subtotal ***

2.7 (3)

-2.9 (7.8)

30

32

62

Heterogeneity: Tau2=0; Chi2=0.03, df=1(P=0.87); I2=0%

Test for overall effect: Z=2.9(P=0)

16.19.2 Individual format

Naumann 2012

Rogers 2014

Ergun 2013

Subtotal ***

-3.6 (4.3)

-1.7 (6.9)

1.2 (6.2)

11

20

40

71

Heterogeneity: Tau2=0.09; Chi2=3.58, df=2(P=0.17); I2=44.16%

Test for overall effect: Z=1.91(P=0.06)

4.6 (4.4)

1.5 (7.4)

2 (4.6)

1.1 (4.2)

2.4 (8)

28

29

57

10

22

20

52

16.19.3 Both group and individual formats

Cadmus 2009

Saarto 2012

Subtotal ***

37

263

300

0.3 (6.4)

-0.3 (3.3)

37

237

274

1.7 (6.3)

-0.5 (3.4)

Heterogeneity: Tau2=0.01; Chi2=1.24, df=1(P=0.27); I2=19.17%

Test for overall effect: Z=0.04(P=0.97)

48.98%

51.02%

100%

-0.51[-1.04,0.01]

-0.57[-1.09,-0.06]

-0.54[-0.91,-0.18]

21.52%

36.7%

41.78%

100%

19.98%

80.02%

100%

-1.21[-2.16,-0.26]

-0.49[-1.1,0.13]

-0.16[-0.7,0.37]

-0.51[-1.03,0.01]

-0.22[-0.68,0.24]

0.06[-0.12,0.24]

0[-0.21,0.22]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 16.20.   Comparison 16 Subanalysis: outcomes by format
of intervention, Outcome 20 Overall depression (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.20.1 Group format

Kaltsatou 2011

Bower 2011

Mehnert 2011

Cantarero-Villanueva 2013

Subtotal ***

16.5 (1.7)

7.7 (5.8)

2.7 (3)

45.6 (9.7)

13

16

30

32

91

Heterogeneity: Tau2=0; Chi2=1.13, df=3(P=0.77); I2=0%

Test for overall effect: Z=4.34(P<0.0001)

16.20.2 Individual format

Pinto 2003

Payne 2008

Rogers 2014

Ergun 2013

Daley 2007

Subtotal ***

6.2 (7.2)

12.7 (8.7)

44.2 (8.6)

6.9 (6.8)

6 (6.5)

12

10

20

40

33

115

Heterogeneity: Tau2=0.21; Chi2=11.43, df=4(P=0.02); I2=64.99%

Test for overall effect: Z=0.04(P=0.97)

22.3 (7.7)

11.6 (7.1)

4.6 (4.4)

53.7 (11.6)

9.8 (6.8)

11.4 (7.9)

25.1 (44.2)

5.2 (5.2)

10.3 (7.2)

13

15

28

29

85

6

10

22

20

33

91

13.75%

17.92%

33.99%

34.34%

100%

14.22%

16.24%

21.6%

23.45%

24.49%

100%

-1[-1.83,-0.18]

-0.59[-1.31,0.13]

-0.51[-1.04,0.01]

-0.75[-1.28,-0.23]

-0.68[-0.98,-0.37]

-0.49[-1.49,0.5]

0.15[-0.73,1.03]

0.58[-0.04,1.19]

0.27[-0.27,0.81]

-0.63[-1.12,-0.13]

-0.01[-0.51,0.49]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

532

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.20.3 Both group and individual formats

Cadmus 2009

Kiecolt-Glaser 2014

Subtotal ***

37

96

133

9.6 (9.3)

8.1 (8.6)

37

90

127

10.8 (10.1)

9.2 (8.2)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.98); I2=0%

Test for overall effect: Z=1.03(P=0.3)

28.49%

71.51%

100%

-0.12[-0.58,0.33]

-0.13[-0.42,0.16]

-0.13[-0.37,0.12]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 16.21.   Comparison 16 Subanalysis: outcomes by format
of intervention, Outcome 21 Overall fatigue (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.21.1 Group format

Banasik 2011

Bower 2011

Cuesta-Vargas 2014

Milne 2008

Cantarero-Villanueva 2013

Mehnert 2011

Fillion 2008

Subtotal ***

1 (0.9)

3.4 (1.8)

4 (1.8)

11.9 (3.2)

3.8 (1.8)

28.5 (25.6)

2.7 (0.7)

7

16

22

29

32

30

44

180

Heterogeneity: Tau2=0.16; Chi2=16.43, df=6(P=0.01); I2=63.48%

Test for overall effect: Z=3.97(P<0.0001)

16.21.2 Individual format

Pinto 2003

Payne 2008

Rogers 2013

Rogers 2014

Courneya 2003

Ergun 2013

Daley 2007

Pinto 2015

Pinto 2005

Vallance 2007

Short 2014

Subtotal ***

7.2 (6.4)

4.7 (2.6)

4.2 (1.8)

4.1 (2.1)

-8.3 (7.9)

2.9 (2.2)

2.1 (1.8)

-43.8 (7.8)

27.1 (21.4)

-42.7 (8.4)

-41.5 (9.3)

12

9

11

20

24

40

33

39

39

250

195

672

Heterogeneity: Tau2=0.02; Chi2=14.04, df=10(P=0.17); I2=28.77%

Test for overall effect: Z=2.24(P=0.03)

16.21.3 Both group and individual formats

Loudon 2014

Rogers 2009

Littman 2012

Winters-Stone 2011

Cadmus 2009

Kiecolt-Glaser 2014

Subtotal ***

1.9 (2.2)

-12.4 (10.4)

-45 (5.3)

45 (5.3)

-51.9 (9)

6.3 (19.6)

12

20

30

36

37

96

231

1.6 (1)

4.9 (1.3)

5.2 (3.2)

17.4 (4.7)

6.2 (1.7)

39.9 (25.1)

2.9 (0.8)

9 (6.4)

3.5 (1.7)

4.2 (1.6)

4 (1.8)

-8.8 (8.1)

3.3 (1.8)

3.4 (1.9)

-41.2 (8.5)

42.3 (26.2)

-42.6 (8.7)

-39.8 (10.4)

2.1 (2.5)

-10.1 (6.6)

-43.1 (10.3)

43.1 (10.3)

-50.6 (10)

12.7 (19)

7

15

20

29

29

27

43

170

6

9

9

22

28

20

33

37

43

85

104

396

11

18

27

31

37

90

214

8.1%

12.29%

14.52%

15.26%

15.47%

16.16%

18.19%

100%

2.7%

2.93%

3.32%

6.35%

7.51%

7.68%

8.63%

9.94%

10.21%

20.09%

20.63%

100%

5.21%

8.53%

12.82%

15.03%

16.77%

41.63%

100%

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

-0.57[-1.65,0.51]

-0.93[-1.67,-0.18]

-0.46[-1.07,0.15]

-1.35[-1.92,-0.78]

-1.38[-1.94,-0.82]

-0.44[-0.97,0.08]

-0.27[-0.69,0.15]

-0.77[-1.15,-0.39]

-0.27[-1.26,0.71]

0.52[-0.42,1.46]

0[-0.88,0.88]

0.05[-0.56,0.66]

0.06[-0.48,0.61]

-0.17[-0.71,0.37]

-0.71[-1.21,-0.21]

-0.32[-0.77,0.14]

-0.63[-1.07,-0.18]

-0.01[-0.26,0.23]

-0.17[-0.41,0.06]

-0.19[-0.36,-0.02]

-0.07[-0.89,0.75]

-0.26[-0.9,0.38]

-0.23[-0.75,0.29]

0.23[-0.25,0.72]

-0.14[-0.59,0.32]

-0.33[-0.62,-0.04]

-0.18[-0.37,0.01]

533

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Heterogeneity: Tau2=0; Chi2=4.07, df=5(P=0.54); I2=0%

Test for overall effect: Z=1.89(P=0.06)

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 16.22.   Comparison 16 Subanalysis: outcomes by format
of intervention, Outcome 22 Overall fatigue (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.22.1 Group format

Herrero 2006

Mehnert 2011

Subtotal ***

-4.2 (19.6)

-0.7 (20.7)

8

30

38

Heterogeneity: Tau2=0.06; Chi2=1.35, df=1(P=0.24); I2=26.17%

Test for overall effect: Z=0.33(P=0.74)

16.22.2 Individual format

Naumann 2012

Rogers 2013

Courneya 2003

Cantarero-Villanueva 2013

Daley 2007

Pinto 2005

Vallance 2007

Subtotal ***

-3.6 (4.4)

4.2 (2)

9.3 (10.2)

-2 (1.8)

2.1 (1.8)

-14.9 (23.5)

2.5 (8.2)

11

11

24

32

33

39

250

400

Heterogeneity: Tau2=0.51; Chi2=53.5, df=6(P<0.0001); I2=88.79%

Test for overall effect: Z=1.37(P=0.17)

16.22.3 Both group and individual formats

Loudon 2014

Rogers 2009

Saarto 2012

Subtotal ***

1.9 (2.2)

1.9 (9.6)

-2.4 (9.1)

12

20

263

295

Heterogeneity: Tau2=0; Chi2=0.39, df=2(P=0.82); I2=0%

Test for overall effect: Z=0.2(P=0.84)

8

27

35

10

9

28

29

33

43

85

237

11

18

237

266

6.4 (14.5)

-2.9 (25.3)

2 (4.6)

3.9 (1.5)

2 (7.5)

0.3 (1.4)

3.4 (1.9)

1.8 (23.5)

1.2 (6.6)

2.1 (2.5)

4.2 (12.3)

-2.4 (8.6)

28.64%

71.36%

100%

11.66%

12.16%

14.59%

14.59%

15.09%

15.43%

16.49%

100%

4.1%

6.74%

89.16%

100%

-0.58[-1.59,0.43]

0.09[-0.43,0.61]

-0.1[-0.7,0.5]

-1.21[-2.16,-0.26]

0.16[-0.72,1.04]

0.81[0.24,1.38]

-1.45[-2.02,-0.88]

-0.71[-1.21,-0.21]

-0.7[-1.15,-0.26]

0.17[-0.08,0.42]

-0.4[-0.98,0.17]

-0.07[-0.89,0.75]

-0.21[-0.84,0.43]

0[-0.18,0.18]

-0.02[-0.18,0.15]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 16.23.   Comparison 16 Subanalysis: outcomes by format of
intervention, Outcome 23 Overall pain/disability (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.23.1 Group format

Mustian 2004

Mehnert 2011

Subtotal ***

9.1 (1.4)

79.4 (23.1)

9

30

39

10

28

38

9.1 (1.7)

73.5 (24.8)

Heterogeneity: Tau2=0; Chi2=0.2, df=1(P=0.65); I2=0%

24.79%

75.21%

100%

0.01[-0.89,0.91]

0.24[-0.27,0.76]

0.18[-0.26,0.63]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

534

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for overall effect: Z=0.81(P=0.42)

16.23.2 Individual format

Portela 2008

Basen-Enquist 2006

Duijits 2012

Subtotal ***

-20.6 (20.2)

79.7 (10.6)

79.3 (23.6)

25

28

87

140

Heterogeneity: Tau2=0.08; Chi2=4.21, df=2(P=0.12); I2=52.46%

Test for overall effect: Z=0.98(P=0.33)

16.23.3 Both group and individual formats

Loudon 2014

Rogers 2009

Cadmus 2009

Subtotal ***

0.8 (1.5)

-3 (3)

50.3 (9.1)

12

20

37

69

Heterogeneity: Tau2=0; Chi2=0.45, df=2(P=0.8); I2=0%

Test for overall effect: Z=0.91(P=0.36)

-20.8 (15.5)

72.1 (11.5)

78.8 (23.8)

1.4 (2.2)

-2.3 (2.8)

50.8 (9)

9

23

89

121

11

18

37

66

21.28%

30.12%

48.61%

100%

16.84%

28%

55.15%

100%

0.01[-0.75,0.77]

0.68[0.11,1.25]

0.02[-0.28,0.32]

0.22[-0.22,0.65]

-0.33[-1.15,0.5]

-0.26[-0.89,0.38]

-0.05[-0.51,0.4]

-0.16[-0.5,0.18]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 16.24.   Comparison 16 Subanalysis: outcomes by format of
intervention, Outcome 24 Overall pain/disability (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.24.1 Group format

Mustian 2004

Cormie 2014

Mehnert 2011

Subtotal ***

-0.2 (1.3)

3.4 (6.5)

-2.4 (25)

9

43

30

82

Heterogeneity: Tau2=0; Chi2=0.54, df=2(P=0.76); I2=0%

Test for overall effect: Z=0.89(P=0.37)

16.24.2 Individual format

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

16.24.3 Both group and individual formats

Subtotal ***

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0 (1.4)

2 (6.2)

-7.6 (25.2)

10

19

28

57

0

0

14.64%

40.67%

44.69%

100%

-0.15[-1.06,0.75]

0.22[-0.33,0.76]

0.21[-0.31,0.72]

0.16[-0.19,0.5]

Not estimable

Not estimable

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

535

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 16.25.   Comparison 16 Subanalysis: outcomes by format of
intervention, Outcome 25 Overall self-esteem/body image (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.25.1 Group format

Mehnert 2011

Milne 2008

Schmitz 2009

Subtotal ***

-5.5 (1.7)

-17.9 (6.8)

-70.4 (16.3)

27

29

59

115

Heterogeneity: Tau2=0.02; Chi2=2.82, df=2(P=0.24); I2=29.02%

Test for overall effect: Z=1.73(P=0.08)

16.25.2 Individual format

Pinto 2003

Musanti 2012

Courneya 2003

Daley 2007

Pinto 2005

Subtotal ***

32.3 (4.3)

23.8 (3.5)

34.8 (4.7)

2 (0.8)

30.3 (7.8)

12

30

24

33

39

138

Heterogeneity: Tau2=0.21; Chi2=13.33, df=4(P=0.01); I2=69.99%

Test for overall effect: Z=1.1(P=0.27)

16.25.3 Both group and individual formats

Loudon 2014

Cadmus 2009

Subtotal ***

-1.4 (0.3)

34.2 (5.5)

12

37

49

Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.91); I2=0%

Test for overall effect: Z=0.75(P=0.45)

27

29

63

119

6

12

28

32

43

121

11

37

48

-6.8 (2.6)

-20.1 (6.3)

-71.5 (18)

25.3 (8.2)

26.3 (3.9)

34.6 (4.4)

1.6 (0.5)

27.2 (6.8)

-1.6 (0.9)

33.4 (5.9)

25.75%

27.9%

46.35%

100%

12.33%

18.84%

21.84%

22.83%

24.17%

100%

0.61[0.06,1.16]

0.33[-0.19,0.85]

0.06[-0.29,0.42]

0.28[-0.04,0.6]

1.15[0.08,2.22]

-0.68[-1.37,0.01]

0.04[-0.5,0.59]

0.66[0.16,1.16]

0.41[-0.03,0.85]

0.27[-0.21,0.76]

23.62%

76.38%

100%

0.2[-0.62,1.02]

0.14[-0.32,0.6]

0.15[-0.25,0.55]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 16.26.   Comparison 16 Subanalysis: outcomes by format of
intervention, Outcome 26 Overall self-esteem/body image (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.26.1 Group format

Mustian 2004

Mehnert 2011

Milne 2008

Schmitz 2009

Subtotal ***

11

30

29

59

129

3 (1)

0.7 (2.1)

1.5 (3.7)

-12 (15.5)

-1.5 (1.5)

0.4 (2.1)

0.1 (3.9)

-4.1 (16.2)

10

27

29

63

129

Heterogeneity: Tau2=0.74; Chi2=31.39, df=3(P<0.0001); I2=90.44%

Test for overall effect: Z=1.26(P=0.21)

16.26.2 Individual format

Musanti 2012

Courneya 2003

Daley 2007

Subtotal ***

-0.4 (4.5)

2.6 (3.7)

1.8 (0.7)

30

24

33

87

12

28

33

73

0.6 (3.9)

-0.1 (3.5)

1.6 (0.7)

Heterogeneity: Tau2=0.11; Chi2=4.6, df=2(P=0.1); I2=56.53%

Test for overall effect: Z=1.22(P=0.22)

17.26%

27.15%

27.16%

28.44%

100%

28.54%

33.61%

37.85%

100%

3.42[1.99,4.86]

0.16[-0.36,0.68]

0.36[-0.16,0.88]

-0.49[-0.86,-0.13]

0.59[-0.33,1.51]

-0.22[-0.89,0.45]

0.74[0.18,1.3]

0.33[-0.16,0.82]

0.31[-0.19,0.81]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

536

Favours control

-5

-2.5

0

2.5

5

Favours intervention

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.26.3 Both group and individual formats

Cadmus 2009

Saarto 2012

Subtotal ***

0.4 (4.4)

10.7 (21.5)

37

263

300

37

237

274

0.2 (2.9)

12 (22)

Heterogeneity: Tau2=0; Chi2=0.2, df=1(P=0.65); I2=0%

Test for overall effect: Z=0.54(P=0.59)

12.92%

87.08%

100%

0.05[-0.4,0.51]

-0.06[-0.24,0.12]

-0.05[-0.21,0.12]

Favours control

-5

-2.5

0

2.5

5

Favours intervention

Analysis 16.27.   Comparison 16 Subanalysis: outcomes by format of
intervention, Outcome 27 Overall cardiorespiratory fitness (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.27.1 Group format

Herrero 2006

Mustian 2004

Kaltsatou 2011

Mehnert 2011

Milne 2008

Murtezani 2014

Fillion 2008

Subtotal ***

25.9 (4.5)

636.1 (50.6)

483.3 (86)

26.9 (4.4)

1.5 (0.3)

875.1 (86.7)

27 (4.4)

8

11

14

27

29

30

44

163

Heterogeneity: Tau2=0; Chi2=6.21, df=6(P=0.4); I2=3.31%

Test for overall effect: Z=2.49(P=0.01)

16.27.2 Individual format

Cerulli 2014

Rogers 2013

Portela 2008

Musanti 2012

Rogers 2014

Kim 2015

Courneya 2003

Basen-Enquist 2006

Pinto 2005

Daley 2007

Subtotal ***

10

12

25

30

20

20

24

35

39

33

31.3 (5)

23.9 (6.2)

3007
(410.8)

24.6 (4.9)

30.9 (6.3)

424.8 (55.8)

21.3 (3.7)

1643
(122.5)

-16.3 (2.1)

35 (4.4)

8

10

13

23

29

32

43

158

10

10

9

12

22

19

26

25

43

69

25.7 (3.7)

610.3 (75.9)

403.1 (71.9)

25.7 (4.7)

1.5 (0.4)

823.5 (87.1)

26.5 (5.8)

32.3 (10.1)

23.9 (3.8)

2416.1
(718.6)

23 (4.3)

25.1 (5)

394.4 (54)

18.2 (3.9)

1546
(127.5)

-17.8 (2.2)

33.1 (5.3)

248

245

Heterogeneity: Tau2=0.01; Chi2=10.42, df=9(P=0.32); I2=13.62%

Test for overall effect: Z=5.63(P<0.0001)

16.27.3 Both group and individual formats

Nikander 2007

Rogers 2009

Irwin 2015

Rogers 2015

Subtotal ***

-17.6 (1.3)

29.5 (6.6)

24.6 (5.5)

23.6 (4.8)

14

20

45

105

184

14

18

38

108

178

-17.2 (1.4)

27.6 (6.1)

23 (4.7)

22.7 (0.3)

Heterogeneity: Tau2=0; Chi2=2.08, df=3(P=0.56); I2=0%

5.27%

6.72%

7.75%

15.8%

18.49%

18.86%

27.1%

100%

5.08%

5.52%

5.83%

8.22%

8.84%

8.98%

10.72%

12.33%

16.37%

18.11%

100%

7.74%

10.47%

22.77%

59.02%

100%

0.05[-0.93,1.03]

0.39[-0.48,1.25]

0.98[0.17,1.78]

0.26[-0.3,0.82]

0.03[-0.49,0.54]

0.59[0.08,1.1]

0.1[-0.32,0.52]

0.29[0.06,0.51]

-0.12[-0.99,0.76]

0[-0.84,0.84]

1.14[0.33,1.96]

0.33[-0.34,1]

1.01[0.36,1.65]

0.54[-0.1,1.18]

0.8[0.22,1.38]

0.77[0.24,1.3]

0.69[0.24,1.14]

0.38[-0.04,0.8]

0.59[0.38,0.79]

-0.29[-1.03,0.46]

0.29[-0.35,0.93]

0.31[-0.13,0.74]

0.27[-0,0.54]

0.24[0.03,0.44]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

537

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for overall effect: Z=2.22(P=0.03)

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 16.28.   Comparison 16 Subanalysis: outcomes by format of
intervention, Outcome 28 Overall cardiorespiratory fitness (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.28.1 Group format

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

16.28.2 Individual format

0

0

Not estimable

Musanti 2012

Courneya 2003

Rogers 2014

Pinto 2005

Subtotal ***

1 (3.1)

2.7 (2.6)

2.8 (4.9)

1.4 (2.4)

30

24

20

39

113

Heterogeneity: Tau2=0.23; Chi2=10.9, df=3(P=0.01); I2=72.47%

Test for overall effect: Z=2.25(P=0.02)

16.28.3 Both group and individual formats

Irwin 2015

Saarto 2012

Subtotal ***

1.5 (2.1)

0.9 (1.2)

45

262

307

Heterogeneity: Tau2=0.17; Chi2=6.56, df=1(P=0.01); I2=84.77%

Test for overall effect: Z=1.39(P=0.16)

0.9 (3.4)

-0.6 (1.7)

1.1 (4.2)

-0.2 (2.5)

-0.4 (2.7)

0.7 (1)

12

26

22

43

103

38

236

274

23.11%

23.96%

24.48%

28.45%

100%

0.03[-0.64,0.7]

1.49[0.86,2.12]

0.37[-0.24,0.98]

0.65[0.2,1.09]

0.64[0.08,1.19]

44.42%

55.58%

100%

0.79[0.34,1.24]

0.16[-0.02,0.33]

0.44[-0.18,1.05]

Favours control

-10

-5

0

5

10

Favours physical activity

Analysis 16.29.   Comparison 16 Subanalysis: outcomes by format of intervention,
Outcome 29 Overall self-reported physical activity (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.29.1 Group format

Schmitz 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.06(P=0.29)

16.29.2 Individual format

Baruth 2013

Matthews 2007

Basen-Enquist 2006

Pinto 2015

131

131

3348.8
(9019.4)

133

133

2339.8
(6213.7)

100%

100%

0.13[-0.11,0.37]

0.13[-0.11,0.37]

20

22

35

36

0 (0)

54.2 (34.1)

428 (254.4)

70.3 (65.9)

12

14

25

32

0 (0)

27.2 (22.7)

404 (265)

16.5 (31.9)

9.97%

13.07%

13.19%

Not estimable

0.87[0.17,1.58]

0.09[-0.42,0.61]

1.01[0.5,1.52]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

538

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Hatchett 2013

Pinto 2005

Vallance 2007

Short 2014

Subtotal ***

3.5 (2.2)

202.4
(161.7)

207.6 (169)

217.9
(222.9)

38

39

253

195

638

36

43

85

104

351

1.4 (1.7)

78.4 (86)

163 (121)

180.3
(206.9)

Heterogeneity: Tau2=0.12; Chi2=25.23, df=6(P=0); I2=76.22%

Test for overall effect: Z=3.72(P=0)

16.29.3 Both group and individual formats

Guinan 2013

Rogers 2009

Cadmus 2009

Littman 2012

Winters-Stone 2011

Irwin 2015

Kiecolt-Glaser 2014

Rogers 2015

Subtotal ***

16

20

34

32

36

45

96

110

389

38.7 (26.9)

121.4 (73.2)

10

18

19.9 (11.3)

114.3
(131.5)

161.7
(114.7)

19.2 (19.1)

430.8
(281.4)

222.1
(118.6)

11.2 (7.6)

169 (119)

33

55.6 (101.9)

12.1 (13.6)

461.7
(346.4)

103.6
(104.6)

9.1 (6.1)

74 (107)

31

31

38

90

112

363

Heterogeneity: Tau2=0.12; Chi2=23.8, df=7(P=0); I2=70.58%

Test for overall effect: Z=3.65(P=0)

13.56%

14.08%

18%

18.14%

1.04[0.55,1.53]

0.96[0.5,1.42]

0.28[0.03,0.53]

0.17[-0.07,0.41]

100%

0.59[0.28,0.9]

7.58%

10.03%

12.13%

12.27%

12.61%

12.95%

16.09%

16.35%

100%

0.81[-0.01,1.64]

0.07[-0.57,0.7]

0.97[0.46,1.47]

0.42[-0.08,0.92]

-0.1[-0.58,0.38]

1.04[0.58,1.51]

0.3[0.01,0.59]

0.84[0.56,1.11]

0.55[0.25,0.84]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 16.30.   Comparison 16 Subanalysis: outcomes by format of
intervention, Outcome 30 Overall self-reported physical activity (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.30.1 Group format

Schmitz 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.09(P=0.28)

16.30.2 Individual format

Matthews 2007

Pinto 2005

Vallance 2007

Subtotal ***

2.8 (16.8)

21.5 (30.6)

84.7 (189.2)

82 (168.7)

48

48

22

39

281

342

57

57

14

43

96

153

-0.8 (16.6)

5 (13.8)

-18.3
(200.7)

30 (167.8)

Heterogeneity: Tau2=0; Chi2=1.28, df=2(P=0.53); I2=0%

Test for overall effect: Z=3.75(P=0)

16.30.3 Both group and individual formats

Guinan 2013

Cadmus 2009

Irwin 2015

16

34

45

15.6 (11.4)

129 (117.9)

159 (136)

10

33

38

-8.3 (4.2)

44.3 (89.4)

49 (86)

100%

100%

0.21[-0.17,0.6]

0.21[-0.17,0.6]

8.22%

19.99%

71.79%

100%

18.78%

26.03%

26.49%

0.63[-0.06,1.32]

0.52[0.08,0.96]

0.31[0.08,0.54]

0.38[0.18,0.57]

2.46[1.39,3.53]

0.8[0.3,1.3]

0.94[0.48,1.4]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

539

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Saarto 2012

Subtotal ***

Mean(SD)

3.5 (18.3)

N

262

357

Mean(SD)

3.3 (21.5)

N

236

317

Heterogeneity: Tau2=0.54; Chi2=36.9, df=3(P<0.0001); I2=91.87%

Test for overall effect: Z=2.32(P=0.02)

Random, 95% CI

Random, 95% CI

28.7%

100%

0.01[-0.17,0.19]

0.92[0.14,1.7]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 16.31.   Comparison 16 Subanalysis: outcomes by format of
intervention, Outcome 31 Overall objective physical activity (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

0

Not estimable

16.31.1 Group format

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

16.31.2 Individual format

Rogers 2013

Matthews 2007

Rogers 2014

Kim 2015

Pinto 2015

Pinto 2005

Vallance 2007

Short 2014

Subtotal ***

0

12

22

20

20

36

39

253

219

621

198.4
(111.7)

330.8
(114.7)

294 (175)

17.6 (16)

70.3 (65.9)

37.5 (14.3)

8110.5
(4133.9)

9363.1
(7922.8)

10

0 (0)

14

198.5 (55.4)

154 (75)

11.8 (11.6)

16.5 (31.9)

33.6 (19.4)

8028 (3457)

8301.2
(3373.4)

22

19

32

43

85

111

336

Heterogeneity: Tau2=0.14; Chi2=26.54, df=6(P=0); I2=77.4%

Test for overall effect: Z=3.01(P=0)

16.31.3 Both group and individual formats

Guinan 2013

Rogers 2009

Cadmus 2009

Rogers 2015

Subtotal ***

16

20

30.7 (15.6)

252191
(91893)

9

18

31 (15.6)

210917
(64078)

33

6738 (2958)

34

5537 (3352)

110

179

246 (153)

112

173

197 (138)

Heterogeneity: Tau2=0; Chi2=1.01, df=3(P=0.8); I2=0%

Test for overall effect: Z=3.13(P=0)

10.14%

11.58%

11.79%

13.95%

15.25%

18.52%

18.77%

Not estimable

1.34[0.6,2.09]

1.04[0.39,1.69]

0.4[-0.23,1.04]

1.01[0.5,1.52]

0.22[-0.21,0.66]

0.02[-0.23,0.27]

0.16[-0.07,0.39]

100%

0.51[0.18,0.85]

6.69%

10.63%

19.1%

63.57%

100%

-0.02[-0.84,0.8]

0.51[-0.14,1.15]

0.38[-0.11,0.86]

0.34[0.07,0.6]

0.34[0.13,0.55]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

540

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 16.32.   Comparison 16 Subanalysis: outcomes by format of
intervention, Outcome 32 Overall objective physical activity (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.32.1 Group format

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

16.32.2 Individual format

0

0

Not estimable

Matthews 2007

Rogers 2014

Vallance 2007

Subtotal ***

72.2 (114.6)

114 (109)

-150
(5173.3)

22

20

253

295

Heterogeneity: Tau2=0.48; Chi2=15.36, df=2(P=0); I2=86.98%

Test for overall effect: Z=1.43(P=0.15)

16.32.3 Both group and individual formats

Guinan 2013

Cadmus 2009

Subtotal ***

-1.1 (6.2)

1621 (2108)

16

33

49

Heterogeneity: Tau2=0; Chi2=0.51, df=1(P=0.48); I2=0%

Test for overall effect: Z=3.78(P=0)

-16.8 (51.5)

10 (70)

91 (5155.4)

-7.9 (5.3)

-60 (2341)

14

22

85

121

9

34

43

30.65%

31.58%

37.77%

0.91[0.2,1.62]

1.13[0.47,1.78]

-0.05[-0.29,0.2]

100%

0.62[-0.23,1.46]

24%

76%

100%

1.11[0.23,2]

0.75[0.25,1.24]

0.83[0.4,1.27]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 16.33.   Comparison 16 Subanalysis: outcomes by
format of intervention, Outcome 33 Mass (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

16.33.1 Group format

Mustian 2004

Herrero 2006

Murtezani 2014

Schmitz 2009

Subtotal ***

67.1 (10.4)

65.6 (8.7)

71.7 (9.5)

76.2 (15.7)

11

8

30

131

180

Heterogeneity: Tau2=0; Chi2=0.03, df=3(P=1); I2=0%

Test for overall effect: Z=0.76(P=0.44)

16.33.2 Individual format

Matthews 2007

Courneya 2003

DeNysschen 2011

Daley 2007

Schmitz 2005

Subtotal ***

74.9 (15.2)

78.2 (20.5)

69.3 (14.2)

74.3 (12.5)

69.5 (2.2)

22

24

30

33

39

148

Heterogeneity: Tau2=0; Chi2=1.58, df=4(P=0.81); I2=0%

Test for overall effect: Z=0.33(P=0.74)

16.33.3 Both group and individual formats

68.6 (13.8)

67.3 (8.9)

72.6 (10.8)

77.2 (17)

78.9 (20.3)

80.1 (16.2)

72.4 (19.6)

75.6 (12.5)

69.2 (2.2)

10

8

32

133

183

14

26

34

69

40

183

7.12%

10.67%

31.21%

51.01%

100%

0.58%

0.84%

1.29%

3.32%

93.96%

100%

-1.5[-12.06,9.06]

-1.7[-10.32,6.92]

-0.9[-5.94,4.14]

-1.04[-4.98,2.9]

-1.1[-3.92,1.72]

-4[-16.39,8.39]

-1.9[-12.2,8.4]

-3.1[-11.42,5.22]

-1.34[-6.52,3.84]

0.3[-0.67,1.27]

0.16[-0.79,1.1]

Favours physical activity

-20

-10

0

10

20

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

541

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Physical activity

Control

Nikander 2007

Cadmus 2009

Ligibel 2008

Littman 2012

Winters-Stone 2011

Kiecolt-Glaser 2014

Subtotal ***

N

Mean(SD)

N

Mean(SD)

73.5 (13.3)

80.7 (16.9)

80 (17.5)

81.1 (13.6)

76.5 (15.6)

75.2 (2.8)

14

36

40

28

36

96

250

14

33

42

27

31

90

237

75.5 (12)

78.5 (20.6)

83.3 (18.7)

81.3 (14.3)

74.2 (12.3)

75.2 (2.6)

Heterogeneity: Tau2=0; Chi2=1.55, df=5(P=0.91); I2=0%

Test for overall effect: Z=0(P=1)

Cochrane Database of Systematic Reviews

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

0.65%

0.72%

0.94%

1.05%

1.28%

95.36%

100%

-2[-11.38,7.38]

2.22[-6.72,11.16]

-3.3[-11.14,4.54]

-0.2[-7.58,7.18]

2.3[-4.39,8.99]

0[-0.78,0.78]

-0[-0.76,0.76]

Favours physical activity

-20

-10

0

10

20

Favours control

Analysis 16.34.   Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 34 Mass (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

16.34.1 Group format

Mustian 2004

Schmitz 2009

Murtezani 2014

Subtotal ***

-0.3 (1.9)

-1 (3.7)

-2.3 (2.4)

9

65

30

104

Heterogeneity: Tau2=0.11; Chi2=2.46, df=2(P=0.29); I2=18.57%

Test for overall effect: Z=2.75(P=0.01)

16.34.2 Individual format

Matthews 2007

Naumann 2012

Courneya 2003

Schmitz 2005

Subtotal ***

0 (2.1)

0.5 (1.3)

0.1 (2)

0.3 (0.4)

22

11

24

39

96

Heterogeneity: Tau2=0; Chi2=1.89, df=3(P=0.59); I2=0%

Test for overall effect: Z=1.09(P=0.27)

16.34.3 Both group and individual formats

Irwin 2015

Ligibel 2008

Saarto 2012

Subtotal ***

-2.1 (4.3)

0 (2.3)

0.7 (3.7)

45

22

262

329

Heterogeneity: Tau2=0.74; Chi2=5.64, df=2(P=0.06); I2=64.52%

Test for overall effect: Z=0.94(P=0.35)

10

65

32

107

14

10

26

40

90

38

14

236

288

0.6 (1.4)

-0.4 (4.3)

-0.3 (2.6)

0 (2.2)

0.1 (1.5)

0.7 (1.8)

0.2 (0.4)

0.1 (3.6)

0 (2.2)

0.7 (3.8)

28.45%

32.85%

38.7%

100%

1.61%

2.18%

2.93%

93.29%

100%

25.73%

29.23%

45.03%

100%

-0.9[-2.4,0.6]

-0.6[-1.98,0.78]

-2[-3.24,-0.76]

-1.23[-2.1,-0.35]

-0.03[-1.46,1.4]

0.33[-0.9,1.56]

-0.6[-1.66,0.46]

0.12[-0.07,0.31]

0.1[-0.08,0.28]

-2.2[-3.9,-0.5]

-0.04[-1.52,1.44]

-0.01[-0.67,0.65]

-0.58[-1.8,0.63]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 16.35.   Comparison 16 Subanalysis: outcomes by
format of intervention, Outcome 35 BMI (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

16.35.1 Group format

Favours physical activity

-20

-10

0

10

20

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

542

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Physical activity

Control

Mustian 2004

Murtezani 2014

Schmitz 2009

Subtotal ***

Mean(SD)

23.9 (4.2)

25.1 (2.9)

28.5 (5.6)

N

11

30

131

172

Heterogeneity: Tau2=0; Chi2=1.03, df=2(P=0.6); I2=0%

Test for overall effect: Z=1.35(P=0.18)

16.35.2 Individual format

Portela 2008

Rogers 2013

Courneya 2003

Rogers 2014

Pinto 2005

Vallance 2007

Schmitz 2005

Subtotal ***

29.1 (5.5)

33.6 (7)

29.4 (7.4)

29.6 (5)

27.7 (5)

27 (5.2)

26 (0.7)

25

12

24

20

39

253

39

412

Heterogeneity: Tau2=0; Chi2=6.41, df=6(P=0.38); I2=6.37%

Test for overall effect: Z=0.82(P=0.41)

16.35.3 Both group and individual formats

Rogers 2009

Nikander 2007

Cadmus 2009

Ligibel 2008

Littman 2012

Kiecolt-Glaser 2014

Subtotal ***

30.6 (7.6)

26.9 (5.6)

30.5 (6)

30.3 (6.3)

27.7 (5)

27.8 (1.1)

20

14

36

40

28

96

234

Heterogeneity: Tau2=0; Chi2=1.82, df=5(P=0.87); I2=0%

Test for overall effect: Z=0.18(P=0.86)

Mean(SD)

26.7 (5.6)

25.8 (3.5)

28.9 (6.3)

34.7 (15)

30.6 (7.3)

29.3 (6)

32.2 (6.7)

29 (5.6)

27.2 (5.2)

25.8 (0.7)

30.4 (8.3)

27.7 (4.9)

29.9 (7.6)

31.5 (6.8)

29 (5.6)

27.8 (1)

N

10

32

133

175

9

10

26

22

43

85

40

235

18

14

33

42

27

90

224

Mean Difference

Fixed, 95% CI

Cochrane Database of Systematic Reviews

Weight

Mean Difference

5.87%

42.07%

52.05%

100%

0.09%

0.26%

0.68%

0.75%

1.8%

5.91%

90.51%

100%

0.32%

0.54%

0.78%

1.02%

1.03%

96.31%

100%

Fixed, 95% CI

-2.8[-7.05,1.45]

-0.7[-2.29,0.89]

-0.48[-1.91,0.95]

-0.71[-1.74,0.32]

-5.6[-15.63,4.43]

3[-3,9]

0.1[-3.65,3.85]

-2.6[-6.16,0.96]

-1.35[-3.65,0.95]

-0.19[-1.46,1.08]

0.2[-0.12,0.52]

0.13[-0.18,0.44]

0.2[-4.88,5.28]

-0.8[-4.7,3.1]

0.55[-2.7,3.8]

-1.2[-4.04,1.64]

-1.35[-4.17,1.47]

0[-0.29,0.29]

-0.03[-0.31,0.26]

Favours physical activity

-20

-10

0

10

20

Favours control

Analysis 16.36.   Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 36 BMI (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

16.36.1 Group format

Schmitz 2009

Mustian 2004

Murtezani 2014

Subtotal ***

-1 (3.7)

-0.4 (0.8)

-0.8 (0.7)

65

9

30

104

Heterogeneity: Tau2=0; Chi2=0.03, df=2(P=0.99); I2=0%

Test for overall effect: Z=4.21(P<0.0001)

16.36.2 Individual format

Naumann 2012

Courneya 2003

Schmitz 2005

Subtotal ***

0.1 (0.5)

0 (0.7)

0.1 (0.2)

11

24

39

74

Heterogeneity: Tau2=0.01; Chi2=2.92, df=2(P=0.23); I2=31.6%

-0.4 (4.3)

0.3 (0.6)

-0.1 (0.8)

-0.1 (0.6)

0.3 (0.7)

0.1 (0.2)

65

10

32

107

10

26

40

76

5.1%

25.34%

69.55%

100%

13.09%

17.24%

69.67%

100%

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

-0.6[-1.98,0.78]

-0.71[-1.33,-0.09]

-0.66[-1.03,-0.29]

-0.67[-0.98,-0.36]

0.2[-0.26,0.66]

-0.3[-0.69,0.09]

-0.01[-0.08,0.06]

-0.03[-0.22,0.15]

543

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

Test for overall effect: Z=0.35(P=0.73)

16.36.3 Both group and individual formats

Rogers 2014

Ligibel 2008

Subtotal ***

-0.2 (0.9)

0 (0.9)

20

40

60

22

42

64

-0.3 (1.1)

0.2 (0.8)

Heterogeneity: Tau2=0; Chi2=0.69, df=1(P=0.41); I2=0%

Test for overall effect: Z=0.74(P=0.46)

27.09%

72.91%

100%

0.1[-0.51,0.71]

-0.2[-0.57,0.17]

-0.12[-0.43,0.2]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 16.37.   Comparison 16 Subanalysis: outcomes by format
of intervention, Outcome 37 Overall body fat (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.37.1 Group format

Herrero 2006

Mustian 2004

Schmitz 2009

Subtotal ***

8

11

130

149

22 (5)

38.5 (4.5)

38.5 (5.9)

8

10

132

150

22 (4)

41.7 (4.9)

39.7 (5.9)

Heterogeneity: Tau2=0; Chi2=1.12, df=2(P=0.57); I2=0%

Test for overall effect: Z=2(P=0.05)

16.37.2 Individual format

Cerulli 2014

Rogers 2013

Matthews 2007

Musanti 2012

Rogers 2014

Courneya 2003

DeNysschen 2011

Schmitz 2005

Pinto 2005

Daley 2007

Subtotal ***

10

10

22

30

20

24

30

39

39

33

26.7 (5.3)

44.2 (6.7)

39.7 (6.3)

34.1 (6.6)

38.6 (6.4)

131.9 (46.4)

36.9 (8.4)

40.9 (1.3)

37.5 (4.8)

39.4 (4.7)

10

12

14

12

22

26

34

40

43

69

30.6 (4.4)

42.3 (7.7)

43.1 (6.9)

33.7 (5.7)

41.5 (7.4)

137.1 (44.4)

38 (10.2)

42.3 (1.3)

38.6 (4.8)

40.1 (7.4)

257

282

Heterogeneity: Tau2=0.06; Chi2=15.84, df=9(P=0.07); I2=43.16%

Test for overall effect: Z=2.44(P=0.01)

16.37.3 Both group and individual formats

Rogers 2009

Winters-Stone 2011

Saarto 2012

Cadmus 2009

Ligibel 2008

Subtotal ***

20

36

37

36

40

169

44.3 (7.4)

40.5 (6.2)

39.9 (7.5)

40.5 (6.6)

42.9 (7.4)

19

31

30

33

42

155

43.5 (7.5)

38.5 (5.8)

40.2 (8)

39.6 (6)

44.7 (8)

Heterogeneity: Tau2=0; Chi2=3.2, df=4(P=0.52); I2=0%

Test for overall effect: Z=0.4(P=0.69)

5.4%

6.64%

87.96%

100%

5.37%

6.07%

8.2%

8.39%

9.39%

10.54%

12.01%

12.5%

13.49%

14.03%

100%

12.13%

20.47%

20.65%

21.4%

25.36%

100%

0[-0.98,0.98]

-0.66[-1.54,0.23]

-0.21[-0.46,0.03]

-0.23[-0.46,-0]

-0.75[-1.66,0.16]

0.25[-0.59,1.09]

-0.51[-1.19,0.17]

0.07[-0.6,0.74]

-0.41[-1.02,0.2]

-0.11[-0.67,0.44]

-0.12[-0.61,0.38]

-1.05[-1.52,-0.58]

-0.21[-0.64,0.22]

-0.1[-0.52,0.31]

-0.3[-0.54,-0.06]

0.11[-0.52,0.73]

0.33[-0.16,0.81]

-0.04[-0.52,0.44]

0.15[-0.33,0.62]

-0.23[-0.67,0.2]

0.05[-0.17,0.26]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

544

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 16.38.   Comparison 16 Subanalysis: outcomes by format
of intervention, Outcome 38 Overall body fat (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.38.1 Group format

Mustian 2004

Schmitz 2009

Subtotal ***

-0.2 (2.9)

-0.3 (5.7)

9

65

74

Heterogeneity: Tau2=0; Chi2=0.08, df=1(P=0.78); I2=0%

Test for overall effect: Z=0.37(P=0.71)

16.38.2 Individual format

Naumann 2012

Musanti 2012

Matthews 2007

Schmitz 2005

Rogers 2014

Courneya 2003

Subtotal ***

-0.3 (2.4)

-0.2 (2.8)

-0.2 (1.6)

-1.1 (0.5)

-1.1 (2.2)

-4.9 (15.7)

11

30

22

39

20

24

146

Heterogeneity: Tau2=1.1; Chi2=52.97, df=5(P<0.0001); I2=90.56%

Test for overall effect: Z=1.91(P=0.06)

16.38.3 Both group and individual formats

Ligibel 2008

Subtotal ***

-0.2 (1.7)

40

40

Heterogeneity: Not applicable

Test for overall effect: Z=1.31(P=0.19)

10

63

73

10

12

14

40

22

26

124

42

42

0.3 (1.6)

-0.1 (3.3)

0.8 (2.8)

1.4 (1.6)

0.4 (1.9)

0.2 (0.4)

-0.6 (2.4)

5.1 (24.4)

0.3 (1.7)

12.84%

87.16%

100%

-0.18[-1.09,0.72]

-0.04[-0.39,0.3]

-0.06[-0.38,0.26]

15.69%

16.65%

16.69%

16.76%

17.01%

17.2%

100%

-0.41[-1.28,0.46]

-0.63[-1.32,0.05]

-0.34[-1.02,0.33]

-3.07[-3.73,-2.41]

-0.21[-0.82,0.39]

-0.48[-1.04,0.09]

-0.86[-1.74,0.02]

100%

100%

-0.29[-0.73,0.14]

-0.29[-0.73,0.14]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 16.39.   Comparison 16 Subanalysis: outcomes by format of
intervention, Outcome 39 Lower body strength (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.39.1 Group format

Milne 2008

Schmitz 2009

Subtotal ***

66.2 (10.2)

223.4 (59.6)

29

113

142

Heterogeneity: Tau2=0.05; Chi2=2.09, df=1(P=0.15); I2=52.25%

Test for overall effect: Z=3.34(P=0)

16.39.2 Individual format

Cerulli 2014

Rogers 2013

Schmitz 2005

Subtotal ***

114.9 (17.1)

68.4 (15.5)

296.6 (48.9)

10

11

23

44

Heterogeneity: Tau2=0.52; Chi2=7.43, df=2(P=0.02); I2=73.08%

Test for overall effect: Z=2.13(P=0.03)

16.39.3 Both group and individual formats

61.7 (11)

175.1 (53.5)

79.1 (17.8)

67.1 (16.2)

238.9 (46.4)

29

119

148

10

9

22

41

36.19%

63.81%

100%

28.53%

33.19%

38.29%

100%

0.42[-0.1,0.94]

0.85[0.58,1.12]

0.69[0.29,1.1]

1.96[0.85,3.07]

0.08[-0.8,0.96]

1.19[0.55,1.83]

1.04[0.08,2]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

545

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Nikander 2007

Rogers 2009

Saarto 2012

Winters-Stone 2011

Subtotal ***

1305 (177)

80.3 (27)

136 (23)

201.3 (57.4)

14

20

37

36

107

14

18

30

31

93

1393 (275)

64.9 (19.7)

136 (29)

191 (51.7)

Heterogeneity: Tau2=0.04; Chi2=4.31, df=3(P=0.23); I2=30.4%

Test for overall effect: Z=0.72(P=0.47)

16.72%

20.58%

31.34%

31.36%

100%

-0.37[-1.12,0.38]

0.63[-0.02,1.29]

0[-0.48,0.48]

0.19[-0.3,0.67]

0.13[-0.22,0.47]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 16.40.   Comparison 16 Subanalysis: outcomes by format
of intervention, Outcome 40 Lower body strength (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.40.1 Group format

Cormie 2014

Schmitz 2009

Subtotal ***

37.6 (25.5)

33.2 (33.9)

43

113

156

Heterogeneity: Tau2=0.01; Chi2=1.24, df=1(P=0.27); I2=19.09%

Test for overall effect: Z=5.93(P<0.0001)

16.40.2 Individual format

Naumann 2012

Schmitz 2005

Waltman 2010

Subtotal ***

7.7 (12.6)

81.8 (48.9)

4.4 (11.5)

11

23

110

144

Heterogeneity: Tau2=0.17; Chi2=5.98, df=2(P=0.05); I2=66.58%

Test for overall effect: Z=2.26(P=0.02)

6.7 (25.7)

7.9 (26.6)

3.5 (13.9)

20.3 (46)

0.2 (8.4)

19

119

138

10

22

113

145

16.40.3 Both group and individual formats

Subtotal ***

0

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

23.74%

76.26%

100%

23.44%

30.72%

45.84%

100%

1.19[0.61,1.78]

0.83[0.56,1.1]

0.92[0.61,1.22]

0.3[-0.56,1.17]

1.27[0.63,1.92]

0.42[0.15,0.69]

0.65[0.09,1.22]

Not estimable

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 16.41.   Comparison 16 Subanalysis: outcomes by format of
intervention, Outcome 41 Upper body strength (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.41.1 Group format

Mustian 2004

Kaltsatou 2011

Milne 2008

Schmitz 2009

Subtotal ***

29.6 (3.3)

59.6 (8.5)

7.6 (2.9)

52.9 (15.3)

11

28

29

113

181

10

26

29

119

184

26.7 (5.7)

47.6 (9.8)

9.4 (2.6)

40.9 (11.8)

Heterogeneity: Tau2=0.61; Chi2=30.31, df=3(P<0.0001); I2=90.1%

21.57%

24.97%

25.63%

27.82%

100%

0.6[-0.28,1.49]

1.29[0.7,1.88]

-0.64[-1.17,-0.12]

0.88[0.61,1.15]

0.53[-0.29,1.35]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

546

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for overall effect: Z=1.27(P=0.2)

16.41.2 Individual format

Cerulli 2014

Portela 2008

Musanti 2012

Schmitz 2005

Subtotal ***

16.1 (5.4)

39.3 (12.3)

52.1 (21)

83 (13.4)

10

25

30

23

88

Heterogeneity: Tau2=0.35; Chi2=10.32, df=3(P=0.02); I2=70.92%

Test for overall effect: Z=1.78(P=0.08)

16.41.3 Both group and individual formats

Nikander 2007

Rogers 2009

Saarto 2012

Winters-Stone 2011

Subtotal ***

131 (20)

27.9 (5)

32.7 (5.3)

63.3 (15.3)

14

20

37

36

107

Heterogeneity: Tau2=0; Chi2=1.78, df=3(P=0.62); I2=0%

Test for overall effect: Z=2.01(P=0.04)

17.2 (8.1)

35.6 (13.1)

36.8 (20)

63 (12.7)

129 (28)

24.3 (6.2)

30.8 (5.7)

61.1 (16.8)

10

9

12

22

53

14

18

30

31

93

22.53%

24.69%

26.19%

26.59%

100%

14.3%

18.36%

33.36%

33.98%

100%

-0.16[-1.03,0.72]

0.29[-0.48,1.05]

0.73[0.04,1.42]

1.5[0.84,2.17]

0.63[-0.06,1.32]

0.08[-0.66,0.82]

0.63[-0.03,1.28]

0.34[-0.14,0.83]

0.14[-0.34,0.62]

0.29[0.01,0.57]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 16.42.   Comparison 16 Subanalysis: outcomes by format
of intervention, Outcome 42 Upper body strength (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.42.1 Group format

Cormie 2014

Mustian 2004

Schmitz 2009

Subtotal ***

5.7 (3.7)

4.5 (4.7)

33.2 (40.8)

43

45

113

201

Heterogeneity: Tau2=0.16; Chi2=8.61, df=2(P=0.01); I2=76.77%

Test for overall effect: Z=3.82(P=0)

16.42.2 Individual format

Schmitz 2005

Musanti 2012

Waltman 2010

Subtotal ***

32.3 (11.5)

7.7 (10.6)

1.9 (4.9)

23

30

110

163

1 (3.8)

-0.8 (3.2)

7.6 (43.7)

6.9 (10.8)

0.8 (12.7)

0.8 (2.9)

19

38

119

176

22

12

113

147

Heterogeneity: Tau2=0.83; Chi2=22.68, df=2(P<0.0001); I2=91.18%

Test for overall effect: Z=1.81(P=0.07)

16.42.3 Both group and individual formats

Irwin 2015

Subtotal ***

45

45

0.4 (1.9)

38

38

0.1 (1.9)

Heterogeneity: Not applicable

Test for overall effect: Z=0.71(P=0.47)

28.22%

32.13%

39.65%

100%

31.39%

32.33%

36.28%

100%

1.25[0.67,1.84]

1.3[0.82,1.78]

0.6[0.34,0.87]

1.01[0.49,1.53]

2.24[1.48,2.99]

0.6[-0.08,1.29]

0.29[0.02,0.55]

1[-0.08,2.09]

100%

100%

0.16[-0.27,0.59]

0.16[-0.27,0.59]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

547

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 16.43.   Comparison 16 Subanalysis: outcomes by format of intervention,
Outcome 43 Bone mineral density - femoral neck (follow-up and change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.43.1 Group format

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

16.43.2 Individual format

Kim 2015

Waltman 2010

Subtotal ***

0.8 (0.1)

0.9 (0.5)

20

110

130

Heterogeneity: Tau2=0.43; Chi2=8.01, df=1(P=0); I2=87.51%

Test for overall effect: Z=0.35(P=0.73)

16.43.3 Both group and individual formats

Winters-Stone 2011

Saarto 2012

Subtotal ***

0.7 (0.1)

-0 (0)

36

239

275

Heterogeneity: Tau2=0; Chi2=0.08, df=1(P=0.78); I2=0%

Test for overall effect: Z=1.96(P=0.05)

0.8 (0.1)

0.6 (0.4)

0.7 (0.1)

-0 (0)

19

113

132

31

218

249

45.66%

54.34%

100%

12.78%

87.22%

100%

-0.37[-1,0.27]

0.63[0.36,0.9]

0.17[-0.8,1.14]

0.11[-0.37,0.59]

0.18[-0,0.37]

0.17[0,0.34]

Favours control

-2

-1

0

1

2

Favours physical activity

Analysis 16.44.   Comparison 16 Subanalysis: outcomes by format of intervention,
Outcome 44 Bone mineral density - lumbar spine (follow-up and change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.44.1 Group format

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

0

0

Not estimable

16.44.2 Individual format

Kim 2015

Waltman 2010

Subtotal ***

1 (0.1)

3.1 (0.4)

20

110

130

Heterogeneity: Tau2=0.26; Chi2=5.31, df=1(P=0.02); I2=81.17%

Test for overall effect: Z=0.49(P=0.62)

16.44.3 Both group and individual formats

Winters-Stone 2011

Saarto 2012

Subtotal ***

36

239

275

1 (0.2)

-0 (0)

Heterogeneity: Tau2=0; Chi2=0.62, df=1(P=0.43); I2=0%

Test for overall effect: Z=1.32(P=0.19)

1 (0.1)

2.9 (0.4)

1 (0.1)

-0 (0)

19

113

132

31

218

249

43.45%

56.55%

100%

-0.26[-0.89,0.37]

0.55[0.28,0.81]

0.2[-0.59,0.98]

12.63%

87.37%

100%

0.3[-0.19,0.78]

0.09[-0.09,0.27]

0.12[-0.06,0.29]

Favours control

-2

-1

0

1

2

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

548

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 16.45.   Comparison 16 Subanalysis: outcomes by format of intervention,
Outcome 45 Bone mineral density - total hip (follow-up and change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

16.45.1 Group format

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

16.45.2 Individual format

Kim 2015

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=8.11(P<0.0001)

0

20

20

0

19

19

0.9 (0.1)

Not estimable

0.1 (0.1)

100%

100%

10.34[7.84,12.84]

10.34[7.84,12.84]

16.45.3 Both group and individual formats

Winters-Stone 2011

Waltman 2010

Subtotal ***

36

110

146

0.9 (0.1)

2.2 (0.3)

31

113

144

0.8 (0.1)

1.8 (0.4)

Heterogeneity: Tau2=0.33; Chi2=9.19, df=1(P=0); I2=89.12%

Test for overall effect: Z=1.49(P=0.14)

47.32%

52.68%

100%

0.19[-0.29,0.67]

1.05[0.77,1.33]

0.64[-0.2,1.48]

Favours control

-2

-1

0

1

2

Favours physical activity

Comparison 17.   Subanalysis: outcomes by setting of intervention

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Overall HRQoL (follow-up
values)

1.1 Home-based

1.2 Facility-based

1.3 Both home- and facili-
ty-based

2 Overall HRQoL (change
values)

2.1 Home-based

2.2 Facility-based

2.3 Both home- and facili-
ty-based

22

5

15

4

14

2

10

3

792

833

227

375

492

612

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.04 [-0.11, 0.19]

Std. Mean Difference (IV, Random, 95%
CI)

0.55 [0.27, 0.83]

Std. Mean Difference (IV, Random, 95%
CI)

0.48 [0.04, 0.92]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.27 [0.04, 0.50]

Std. Mean Difference (IV, Random, 95%
CI)

1.18 [0.53, 1.82]

Std. Mean Difference (IV, Random, 95%
CI)

0.06 [-0.22, 0.33]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

549

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

3 Overall emotional func-
tion/mental health (fol-
low-up values)

3.1 Home-based

3.2 Facility-based

3.3 Both home- and facili-
ty-based

4 Overall emotional func-
tion/mental health (change
values)

4.1 Home-based

4.2 Facility-based

4.3 Both home- and facili-
ty-based

5 Overall physical function
(follow-up values)

5.1 Home-based

5.2 Facility-based

5.3 Both home- and facili-
ty-based

6 Overall physical function
(change values)

6.1 Home-based

6.2 Facility-based

6.3 Both home- and facili-
ty-based

7 Overall role function (fol-
low-up values)

7.1 Home-based

26

5

15

6

15

2

10

3

25

5

13

7

13

1

9

3

18

2

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.11 [-0.06, 0.27]

Std. Mean Difference (IV, Random, 95%
CI)

0.31 [0.12, 0.50]

Std. Mean Difference (IV, Random, 95%
CI)

0.15 [-0.04, 0.34]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.16 [-0.06, 0.37]

Std. Mean Difference (IV, Random, 95%
CI)

0.43 [0.04, 0.82]

Std. Mean Difference (IV, Random, 95%
CI)

0.09 [-0.16, 0.34]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.19 [0.03, 0.34]

Std. Mean Difference (IV, Random, 95%
CI)

0.43 [0.14, 0.73]

Std. Mean Difference (IV, Random, 95%
CI)

0.23 [-0.02, 0.48]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.26 [0.02, 0.51]

Std. Mean Difference (IV, Random, 95%
CI)

0.95 [0.31, 1.59]

Std. Mean Difference (IV, Random, 95%
CI)

-0.08 [-0.24, 0.08]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.26 [-0.14, 0.66]

670

901

531

417

550

612

720

816

592

332

489

612

386

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

550

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

7.2 Facility-based

7.3 Both home- and facili-
ty-based

8 Overall role function
(change values)

8.1 Home-based

8.2 Facility-based

8.3 Both home- and facili-
ty-based

9 Overall social well-be-
ing/function (follow-up val-
ues)

9.1 Home-based

9.2 Facility-based

9.3 Both home- and facili-
ty-based

10 Overall social well-be-
ing/function (change val-
ues)

10.1 Home-based

10.2 Facility-based

10.3 Both home- and facili-
ty-based

11 Overall cognitive func-
tion (follow-up values)

11.1 Home-based

11.2 Facility-based

11.3 Both home- and facili-
ty-based

12

4

12

1

8

3

18

2

11

5

12

1

7

4

5

0

3

2

564

420

335

368

612

386

709

462

335

395

654

0

134

55

Std. Mean Difference (IV, Random, 95%
CI)

0.33 [-0.03, 0.69]

Std. Mean Difference (IV, Random, 95%
CI)

0.20 [-0.14, 0.54]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.17 [-0.08, 0.41]

Std. Mean Difference (IV, Random, 95%
CI)

0.26 [-0.06, 0.58]

Std. Mean Difference (IV, Random, 95%
CI)

-0.06 [-0.22, 0.10]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.01 [-0.23, 0.22]

Std. Mean Difference (IV, Random, 95%
CI)

0.22 [0.07, 0.37]

Std. Mean Difference (IV, Random, 95%
CI)

0.31 [0.03, 0.59]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.97 [0.71, 1.23]

Std. Mean Difference (IV, Random, 95%
CI)

0.50 [0.05, 0.95]

Std. Mean Difference (IV, Random, 95%
CI)

0.41 [-0.15, 0.96]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

0.32 [-0.02, 0.66]

Std. Mean Difference (IV, Random, 95%
CI)

0.65 [-0.01, 1.31]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

551

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

12 Overall cognitive func-
tion (change values)

12.1 Home-based

12.2 Facility-based

12.3 Both home- and facili-
ty-based

13 Overall general health
(follow-up values)

13.1 Home-based

13.2 Facility-based

13.3 Both home- and facili-
ty-based

14 Overall general health
(change values)

14.1 Home-based

14.2 Facility-based

14.3 Both home- and facili-
ty-based

15 Overall sexual function
(follow-up values)

15.1 Home-based

15.2 Facility-based

15.3 Both home- and facili-
ty-based

16 Overall sexual function
(change values)

16.1 Home-based

16.2 Facility-based

16.3 Both home- and facili-
ty-based

5

0

3

2

9

2

6

2

5

1

2

3

5

2

2

1

3

0

2

1

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

0.06 [-0.31, 0.43]

Std. Mean Difference (IV, Random, 95%
CI)

0.03 [-0.51, 0.57]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.43 [-0.32, 1.17]

Std. Mean Difference (IV, Random, 95%
CI)

0.25 [0.01, 0.49]

Std. Mean Difference (IV, Random, 95%
CI)

-0.26 [-0.64, 0.11]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.42 [-0.21, 1.05]

Std. Mean Difference (IV, Random, 95%
CI)

0.27 [-0.49, 1.03]

Std. Mean Difference (IV, Random, 95%
CI)

-0.07 [-0.23, 0.09]

Std. Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Std. Mean Difference (IV, Fixed, 95% CI)

-0.00 [-0.34, 0.34]

Std. Mean Difference (IV, Fixed, 95% CI)

0.21 [-0.07, 0.49]

Std. Mean Difference (IV, Fixed, 95% CI)

0.29 [-0.14, 0.73]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

3.83 [-1.83, 9.48]

Mean Difference (IV, Random, 95% CI)

0.5 [-3.86, 4.86]

0

134

538

111

273

112

40

59

612

136

193

82

0

193

500

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

552

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

17 Overall sleep (follow-up
values)

17.1 Home-based

17.2 Facility-based

17.3 Both home- and facili-
ty-based

18 Overall sleep (change
values)

18.1 Home-based

18.2 Facility-based

18.3 Both home- and facili-
ty-based

19 Overall anxiety (fol-
low-up values)

19.1 Home-based

19.2 Facility-based

19.3 Both home- and facili-
ty-based

20 Overall anxiety (change
values)

20.1 Home-based

20.2 Facility-based

20.3 Both home- and facili-
ty-based

5

0

2

3

3

0

1

2

7

0

4

3

4

0

2

2

21 Overall depression (fol-
low-up values)

12

21.1 Home-based

21.2 Facility-based

21.3 Both home- and facili-
ty-based

2

8

3

0

88

100

0

56

80

0

192

134

0

119

116

60

483

134

Std. Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Fixed, 95% CI)

-0.26 [-0.68, 0.16]

Std. Mean Difference (IV, Fixed, 95% CI)

0.06 [-0.33, 0.46]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

0.14 [-0.38, 0.67]

Std. Mean Difference (IV, Random, 95%
CI)

0.14 [-0.30, 0.58]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

-0.87 [-1.34, -0.41]

Std. Mean Difference (IV, Random, 95%
CI)

-0.14 [-0.48, 0.21]

Std. Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Fixed, 95% CI)

-0.52 [-0.88, -0.15]

Std. Mean Difference (IV, Fixed, 95% CI)

-0.23 [-0.60, 0.13]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.34 [-0.17, 0.85]

Std. Mean Difference (IV, Random, 95%
CI)

-0.55 [-0.85, -0.25]

Std. Mean Difference (IV, Random, 95%
CI)

0.05 [-0.52, 0.61]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

553

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

22 Overall depression
(change values)

22.1 Home-based

22.2 Facility-based

22.3 Both home- and facili-
ty-based

23 Overall fatigue (fol-
low-up values)

23.1 Home-based

23.2 Facility-based

23.3 Both home- and facili-
ty-based

24 Overall fatigue (change
values)

24.1 Home-based

24.2 Facility-based

24.3 Both home- and facili-
ty-based

25 Overall pain/disability
(follow-up values)

25.1 Home-based

25.2 Facility-based

25.3 Both home- and facili-
ty-based

26 Overall pain/disability
(change values)

26.1 Home-based

7

1

3

3

25

6

13

7

12

2

7

3

9

3

5

2

5

0

40

140

616

850

749

346

417

296

558

249

183

112

0

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.39 [-1.02, 0.23]

Std. Mean Difference (IV, Random, 95%
CI)

-0.63 [-0.97, -0.29]

Std. Mean Difference (IV, Random, 95%
CI)

-0.11 [-0.41, 0.19]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.18 [-0.39, 0.03]

Std. Mean Difference (IV, Random, 95%
CI)

-0.53 [-0.77, -0.29]

Std. Mean Difference (IV, Random, 95%
CI)

-0.09 [-0.30, 0.13]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.25 [-1.10, 0.61]

Std. Mean Difference (IV, Random, 95%
CI)

-0.43 [-1.06, 0.20]

Std. Mean Difference (IV, Random, 95%
CI)

-0.01 [-0.17, 0.16]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.24 [-0.20, 0.68]

Std. Mean Difference (IV, Random, 95%
CI)

0.09 [-0.20, 0.38]

Std. Mean Difference (IV, Random, 95%
CI)

-0.12 [-0.49, 0.25]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

554

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

26.2 Facility-based

26.3 Both home- and facili-
ty-based

3

2

27 Overall self-esteem/body
image (follow-up values)

12

27.1 Home-based

27.2 Facility-based

27.3 Both home- and facili-
ty-based

28 Overall self-esteem/body
image (change values)

28.1 Home-based

28.2 Facility-based

28.3 Both home- and facili-
ty-based

29 Overall cardiorespiratory
fitness (follow-up values)

29.1 Home-based

29.2 Facility-based

29.3 Both home- and facili-
ty-based

30 Overall cardiorespiratory
fitness (change values)

30.1 Home-based

30.2 Facility-based

30.3 Both home- and facili-
ty-based

2

8

2

9

1

6

2

23

5

13

6

9

2

4

3

139

157

124

451

92

42

376

574

245

603

426

124

116

623

Std. Mean Difference (IV, Random, 95%
CI)

0.16 [-0.19, 0.50]

Std. Mean Difference (IV, Random, 95%
CI)

-0.29 [-0.61, 0.02]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.10 [-1.17, 0.97]

Std. Mean Difference (IV, Random, 95%
CI)

0.29 [0.09, 0.50]

Std. Mean Difference (IV, Random, 95%
CI)

0.52 [-0.44, 1.48]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.22 [-0.89, 0.45]

Std. Mean Difference (IV, Random, 95%
CI)

0.52 [-0.09, 1.13]

Std. Mean Difference (IV, Random, 95%
CI)

-0.05 [-0.21, 0.12]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.66 [0.40, 0.92]

Std. Mean Difference (IV, Random, 95%
CI)

0.45 [0.25, 0.66]

Std. Mean Difference (IV, Random, 95%
CI)

0.29 [0.03, 0.56]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.39 [-0.20, 0.99]

Std. Mean Difference (IV, Random, 95%
CI)

1.62 [1.03, 2.21]

Std. Mean Difference (IV, Random, 95%
CI)

0.40 [-0.02, 0.82]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

555

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

31 Overall self-reported
physical activity (follow-up
values)

18

31.1 Home-based

31.2 Facility-based

31.3 Both home- and facili-
ty-based

32 Overall self-reported
physical activity (change
values)

32.1 Home-based

32.2 Facility-based

32.3 Both home- and facili-
ty-based

9

3

6

8

3

1

4

33 Overall objective physi-
cal activity (follow-up val-
ues)

11

33.1 Home-based

33.2 Facility-based

33.3 Both home- and facili-
ty-based

34 Overall objective physi-
cal activity (change values)

34.1 Home-based

34.2 Facility-based

34.3 Both home- and facili-
ty-based

35 Mass (follow-up values)

35.1 Home-based

5

0

6

5

2

0

3

16

2

1028

513

503

495

105

674

854

0

416

374

0

134

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.57 [0.29, 0.85]

Std. Mean Difference (IV, Random, 95%
CI)

0.23 [0.05, 0.40]

Std. Mean Difference (IV, Random, 95%
CI)

0.62 [0.23, 1.00]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.38 [0.18, 0.57]

Std. Mean Difference (IV, Random, 95%
CI)

0.21 [-0.17, 0.60]

Std. Mean Difference (IV, Random, 95%
CI)

0.92 [0.14, 1.70]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.45 [0.07, 0.82]

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

0.43 [0.17, 0.68]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.37 [-0.56, 1.30]

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

0.92 [0.56, 1.28]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

100

Mean Difference (IV, Fixed, 95% CI)

-3.38 [-10.29, 3.53]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

556

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

35.2 Facility-based

35.3 Both home- and facili-
ty-based

36 Mass (change values)

36.1 Home-based

36.2 Facility-based

36.3 Both home- and facili-
ty-based

10

4

11

1

7

3

37 BMI (follow-up values)

17

37.1 Home-based

37.2 Facility-based

37.3 Both home- and facili-
ty-based

38 BMI (change values)

38.1 Home-based

38.2 Facility-based

38.3 Both home- and facili-
ty-based

3

9

6

8

0

6

2

39 Overall body fat (fol-
low-up values)

18

39.1 Home-based

39.2 Facility-based

39.3 Both home- and facili-
ty-based

40 Overall body fat (change
values)

40.1 Home-based

40.2 Facility-based

40.3 Both home- and facili-
ty-based

4

7

7

9

2

5

2

864

246

36

394

617

442

767

281

0

361

124

224

550

388

78

297

124

Mean Difference (IV, Fixed, 95% CI)

0.03 [-0.56, 0.61]

Mean Difference (IV, Fixed, 95% CI)

0.04 [-3.96, 4.04]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-0.03 [-1.46, 1.40]

Mean Difference (IV, Random, 95% CI)

-0.61 [-1.31, 0.08]

Mean Difference (IV, Random, 95% CI)

-0.58 [-1.80, 0.63]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

-0.53 [-1.64, 0.57]

Mean Difference (IV, Fixed, 95% CI)

0.04 [-0.17, 0.26]

Mean Difference (IV, Fixed, 95% CI)

-0.61 [-2.14, 0.91]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Mean Difference (IV, Random, 95% CI)

-0.27 [-0.58, 0.04]

Mean Difference (IV, Random, 95% CI)

-0.12 [-0.43, 0.20]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.18 [-0.45, 0.09]

Std. Mean Difference (IV, Random, 95%
CI)

-0.39 [-0.69, -0.08]

Std. Mean Difference (IV, Random, 95%
CI)

0.01 [-0.19, 0.21]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.48 [-0.97, -0.00]

Std. Mean Difference (IV, Random, 95%
CI)

-0.84 [-1.94, 0.26]

Std. Mean Difference (IV, Random, 95%
CI)

-0.26 [-0.62, 0.09]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

557

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

41 Lower body strength (fol-
low-up values)

10

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

41.1 Home-based

41.2 Facility-based

41.3 Both home- and facili-
ty-based

42 Lower body strength
(change values)

42.1 Home-based

42.2 Facility-based

42.3 Both home- and facili-
ty-based

0

5

5

8

0

7

1

43 Upper body strength (fol-
low-up values)

13

43.1 Home-based

43.2 Facility-based

43.3 Both home- and facili-
ty-based

44 Upper body strength
(change values)

44.1 Home-based

44.2 Facility-based

44.3 Both home- and facili-
ty-based

45 Bone mineral density -
femoral neck (follow-up and
change values)

45.1 Home-based

2

8

4

8

0

6

2

4

1

0

417

220

0

497

223

64

513

200

0

526

306

39

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

0.75 [0.24, 1.27]

Std. Mean Difference (IV, Random, 95%
CI)

0.12 [-0.16, 0.40]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

0.80 [0.38, 1.23]

Std. Mean Difference (IV, Random, 95%
CI)

0.42 [0.15, 0.69]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.58 [0.05, 1.12]

Std. Mean Difference (IV, Random, 95%
CI)

0.43 [-0.12, 0.98]

Std. Mean Difference (IV, Random, 95%
CI)

0.29 [0.01, 0.57]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

0.92 [0.34, 1.50]

Std. Mean Difference (IV, Random, 95%
CI)

0.25 [0.03, 0.48]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.37 [-1.00, 0.27]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

558

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

45.2 Facility-based

45.3 Both home- and facili-
ty-based

46 Bone mineral density
- lumbar spine (follow-up
and change values)

46.1 Home-based

46.2 Facility-based

46.3 Both home- and facili-
ty-based

47 Bone mineral density
- total hip (follow-up and
change values)

47.1 Home-based

47.2 Facility-based

47.3 Both home- and facili-
ty-based

0

3

4

1

0

3

3

1

0

2

0

747

39

0

747

39

0

290

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

0.32 [-0.01, 0.65]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.26 [-0.89, 0.37]

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

0.30 [-0.02, 0.63]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

10.34 [7.84, 12.84]

Std. Mean Difference (IV, Random, 95%
CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Random, 95%
CI)

0.64 [-0.20, 1.48]

Analysis 17.1.   Comparison 17 Subanalysis: outcomes by setting
of intervention, Outcome 1 Overall HRQoL (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.1.1 Home-based

Portela 2008

Ergun 2013

Pinto 2015

Vallance 2007

Short 2014

Subtotal ***

104.8 (32.1)

69 (19.9)

117.8 (12.7)

91.5 (11.8)

106.8 (16.7)

13

40

39

250

195

537

91.6 (28.5)

67.9 (16.7)

114 (18)

90.6 (13)

108.2 (18.2)

9

20

37

85

104

255

Heterogeneity: Tau2=0; Chi2=2.6, df=4(P=0.63); I2=0%

Test for overall effect: Z=0.55(P=0.58)

3.08%

7.91%

11.18%

37.62%

40.22%

100%

0.41[-0.45,1.27]

0.06[-0.48,0.59]

0.24[-0.21,0.69]

0.08[-0.16,0.33]

-0.08[-0.32,0.16]

0.04[-0.11,0.19]

17.1.2 Facility-based

Herrero 2006

Cerulli 2014

8

10

81.3 (10.7)

85.2 (4.2)

8

10

62.5 (16.1)

65.9 (14.7)

3.97%

4.2%

1.3[0.19,2.41]

1.72[0.66,2.78]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

559

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Portela 2008

Mustian 2004

Loudon 2014

Milne 2008

Ergun 2013

Courneya 2003

Murtezani 2014

Mehnert 2011

Do 2015

Schmitz 2005

Taleghani 2012

Daley 2007

Littman 2012

Subtotal ***

109.8 (25.2)

121.7 (22.7)

-7.4 (1.2)

86.4 (8.3)

74.2 (18.7)

91.3 (11)

86.5 (7.3)

74.7 (21.7)

87.3 (13.7)

-44.2 (8.7)

217.5 (36.3)

90.9 (13.5)

90.3 (11)

12

11

12

29

20

24

30

30

32

39

40

33

30

360

91.6 (28.5)

124.3 (25.9)

-7.4 (1.4)

64.1 (10.8)

67.9 (16.7)

89.3 (10.9)

79.1 (7.5)

65.4 (16.8)

82.4 (19.9)

-47.4 (9.4)

210.1 (41.5)

86.4 (15.1)

87.7 (15)

9

10

11

29

20

28

32

27

30

40

40

69

110

473

Heterogeneity: Tau2=0.21; Chi2=48.47, df=14(P<0.0001); I2=71.12%

Test for overall effect: Z=3.8(P=0)

17.1.3 Both home- and facility-based

Rogers 2015

Rogers 2009

Cadmus 2009

Loh 2014

Subtotal ***

85.2 (4.2)

92 (11.4)

91.2 (12.6)

112.4 (14.1)

10

20

37

63

130

65.9 (14.7)

87.4 (13.1)

86.2 (17.4)

109.3 (13.3)

10

18

37

32

97

Heterogeneity: Tau2=0.11; Chi2=6.7, df=3(P=0.08); I2=55.25%

Test for overall effect: Z=2.14(P=0.03)

5.05%

5.25%

5.49%

6.45%

6.77%

7.34%

7.46%

7.48%

7.67%

8.08%

8.12%

8.28%

8.37%

100%

12.58%

23.48%

31.22%

32.73%

100%

0.66[-0.24,1.55]

-0.1[-0.96,0.75]

0.02[-0.8,0.84]

2.28[1.61,2.96]

0.35[-0.28,0.97]

0.18[-0.37,0.73]

0.99[0.46,1.52]

0.47[-0.06,1]

0.28[-0.22,0.79]

0.35[-0.09,0.79]

0.19[-0.25,0.63]

0.3[-0.12,0.72]

0.18[-0.22,0.59]

0.55[0.27,0.83]

1.72[0.66,2.78]

0.37[-0.27,1.01]

0.33[-0.13,0.78]

0.22[-0.2,0.65]

0.48[0.04,0.92]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 17.2.   Comparison 17 Subanalysis: outcomes by setting
of intervention, Outcome 2 Overall HRQoL (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.2.1 Home-based

Ergun 2013

Vallance 2007

Subtotal ***

20

250

270

4.6 (26.5)

2.3 (11.1)

20

85

105

-6.7 (25.9)

-0.2 (6.4)

Heterogeneity: Tau2=0; Chi2=0.27, df=1(P=0.6); I2=0%

Test for overall effect: Z=2.28(P=0.02)

17.2.2 Facility-based

Mustian 2004

Herrero 2006

Murtezani 2014

Naumann 2012

Ergun 2013

Cuesta-Vargas 2014

Courneya 2003

Mehnert 2011

Schmitz 2005

11

8

30

11

20

22

24

30

39

15 (5)

17.7 (8.3)

9.2 (2.1)

14.5 (10.6)

6.3 (15.5)

0.3 (0.2)

5.7 (7.4)

9.7 (21)

2.3 (4.5)

10

8

32

10

20

20

28

27

40

0 (5)

-10.4 (17.7)

-0.6 (2)

3.1 (11.4)

-6.7 (25.9)

0.3 (0.1)

0.6 (7.4)

5.6 (16.5)

0.6 (4)

13.4%

86.6%

100%

7.99%

8.17%

9.23%

9.48%

10.54%

10.63%

10.78%

10.9%

11.11%

0.42[-0.21,1.05]

0.24[-0,0.49]

0.27[0.04,0.5]

2.88[1.59,4.17]

1.92[0.68,3.17]

4.65[3.67,5.63]

1[0.08,1.92]

0.59[-0.04,1.23]

-0.07[-0.67,0.54]

0.68[0.12,1.24]

0.22[-0.31,0.74]

0.4[-0.05,0.84]

Favours control

-10

-5

0

5

10

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

560

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Daley 2007

Subtotal ***

Mean(SD)

10.2 (11.2)

N

33

228

N

69

264

Mean(SD)

3.2 (11.3)

Heterogeneity: Tau2=0.93; Chi2=88.77, df=9(P<0.0001); I2=89.86%

Test for overall effect: Z=3.57(P=0)

17.2.3 Both home- and facility-based

Rogers 2009

Cadmus 2009

Saarto 2012

Subtotal ***

20

37

263

320

4.5 (8.4)

0.6 (7.5)

4.2 (16.2)

18

37

237

292

2.9 (12)

-2.4 (9.8)

5.6 (15.4)

Heterogeneity: Tau2=0.03; Chi2=3.23, df=2(P=0.2); I2=38%

Test for overall effect: Z=0.39(P=0.69)

Random, 95% CI

Random, 95% CI

11.17%

100%

0.62[0.2,1.04]

1.18[0.53,1.82]

15.32%

25.01%

59.66%

100%

0.15[-0.49,0.79]

0.34[-0.12,0.8]

-0.09[-0.26,0.09]

0.06[-0.22,0.33]

Favours control

-10

-5

0

5

10

Favours physical activity

Analysis 17.3.   Comparison 17 Subanalysis: outcomes by setting of intervention,
Outcome 3 Overall emotional function/mental health (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.3.1 Home-based

Basen-Enquist 2006

Pinto 2015

Pinto 2005

Duijits 2012

Vallance 2007

Subtotal ***

78.2 (10.6)

54.2 (9.3)

-8 (20.7)

73.9 (34.7)

20.3 (3.3)

28

39

39

37

250

393

Heterogeneity: Tau2=0; Chi2=2.28, df=4(P=0.68); I2=0%

Test for overall effect: Z=1.3(P=0.2)

17.3.2 Facility-based

Banasik 2011

Herrero 2006

Mustian 2004

Loudon 2014

Cuesta-Vargas 2014

Courneya 2003

Milne 2008

Do 2015

Littman 2012

Mehnert 2011

Cantarero-Villanueva 2013

Murtezani 2014

Daley 2007

Schmitz 2005

Schmitz 2009

Subtotal ***

0.5 (0.4)

90.6 (9.3)

24.8 (2)

-1.6 (0.7)

42.9 (19.2)

21.5 (3.4)

19.6 (2.4)

87.4 (8.8)

20.3 (4)

77 (35.8)

-17175
(4279)

19.5 (3.3)

19.1 (4.2)

-45.6 (8.2)

53.2 (9.6)

7

8

9

12

22

24

29

32

30

30

32

30

33

39

112

449

Heterogeneity: Tau2=0.05; Chi2=24.33, df=14(P=0.04); I2=42.47%

Test for overall effect: Z=3.23(P=0)

77.2 (12)

52.5 (9.6)

-16.5 (28.8)

77.5 (34.3)

19.9 (3.4)

0.4 (0.3)

83.3 (14.8)

24.8 (3.2)

-1.6 (0.5)

32.3 (33.3)

20.7 (3)

16.7 (4.1)

70.4 (21.5)

20.8 (3.1)

69.1 (40.5)

-20390
(6113)

18.3 (3.5)

18.5 (3.3)

-48.2 (8.2)

53.8 (8.7)

23

37

43

89

85

277

7

8

10

11

20

28

29

30

27

28

29

32

33

40

120

452

8.94%

13.39%

14.28%

18.5%

44.89%

100%

2.67%

2.89%

3.45%

4.01%

6.06%

6.96%

7.08%

7.19%

7.38%

7.44%

7.47%

7.68%

8.01%

8.74%

12.96%

100%

0.09[-0.46,0.64]

0.18[-0.27,0.63]

0.33[-0.1,0.77]

-0.1[-0.49,0.28]

0.11[-0.14,0.35]

0.11[-0.06,0.27]

0.25[-0.8,1.3]

0.56[-0.45,1.56]

-0.01[-0.91,0.89]

0.05[-0.77,0.87]

0.39[-0.22,1]

0.25[-0.3,0.79]

0.85[0.31,1.39]

1.03[0.5,1.57]

-0.14[-0.66,0.38]

0.21[-0.31,0.72]

0.61[0.09,1.12]

0.35[-0.15,0.85]

0.16[-0.32,0.64]

0.31[-0.13,0.76]

-0.07[-0.32,0.19]

0.31[0.12,0.5]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

561

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.3.3 Both home- and facility-based

Pinto 2003

Rogers 2009

Cadmus 2009

Loh 2014

Fillion 2008

Rogers 2015

Subtotal ***

-10.8 (28.1)

20 (3.1)

20.5 (3)

19.9 (2.8)

48.5 (7.9)

20.6 (2.9)

12

20

37

63

44

105

281

-27.2 (19.5)

21.1 (2.9)

19.8 (4.2)

20 (3.2)

47.5 (9.1)

19.7 (3.2)

12

18

37

32

43

108

250

Heterogeneity: Tau2=0.01; Chi2=5.67, df=5(P=0.34); I2=11.85%

Test for overall effect: Z=1.59(P=0.11)

5.1%

8.22%

15.34%

17.38%

17.73%

36.24%

100%

0.65[-0.17,1.48]

-0.36[-1,0.28]

0.19[-0.27,0.65]

-0.04[-0.46,0.39]

0.12[-0.3,0.54]

0.29[0.02,0.56]

0.15[-0.04,0.34]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 17.4.   Comparison 17 Subanalysis: outcomes by setting of intervention,
Outcome 4 Overall emotional function/mental health (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.4.1 Home-based

Pinto 2005

Vallance 2007

Subtotal ***

-3.8 (27.7)

0.5 (3.5)

39

250

289

-11.5 (25.8)

0.1 (2.5)

43

85

128

Heterogeneity: Tau2=0; Chi2=0.43, df=1(P=0.51); I2=0%

Test for overall effect: Z=1.44(P=0.15)

17.4.2 Facility-based

Herrero 2006

Mustian 2004

Naumann 2012

Murtezani 2014

Courneya 2003

Cormie 2014

Mehnert 2011

Cantarero-Villanueva 2013

Schmitz 2005

Schmitz 2009

Subtotal ***

8

9

11

30

24

43

30

32

39

58

9.3 (19.6)

2.4 (2.5)

1 (2.7)

2.1 (0.8)

2.3 (3.1)

4.4 (9)

2.3 (35.5)

-1445
(4452)

2.5 (4.4)

3.3 (23.2)

8

10

10

32

28

19

28

29

40

62

-2.1 (5.9)

0.1 (1.7)

-0.1 (2.7)

0.5 (0.9)

0.8 (2.9)

2.7 (8.6)

3.6 (17.6)

353 (3323)

0.3 (3.9)

3.1 (17.2)

284

266

Heterogeneity: Tau2=0.29; Chi2=41.54, df=9(P<0.0001); I2=78.33%

Test for overall effect: Z=2.14(P=0.03)

17.4.3 Both home- and facility-based

Rogers 2009

Cadmus 2009

Saarto 2012

Subtotal ***

20

37

263

320

0.9 (2.5)

0.3 (2.2)

1.2 (17.8)

18

37

237

292

-0.1 (2.7)

-0.5 (3.3)

1.9 (18.5)

Heterogeneity: Tau2=0.02; Chi2=2.87, df=2(P=0.24); I2=30.25%

Test for overall effect: Z=0.7(P=0.48)

24.21%

75.79%

100%

0.28[-0.15,0.72]

0.12[-0.13,0.36]

0.16[-0.06,0.37]

7.04%

7.36%

8.15%

10.32%

10.66%

10.77%

10.98%

11.03%

11.51%

12.18%

100%

13.31%

22.99%

63.7%

100%

0.74[-0.28,1.77]

1.06[0.08,2.03]

0.39[-0.48,1.26]

1.8[1.21,2.4]

0.49[-0.06,1.05]

0.19[-0.35,0.73]

-0.04[-0.56,0.47]

-0.45[-0.96,0.06]

0.52[0.08,0.97]

0.01[-0.35,0.37]

0.43[0.04,0.82]

0.38[-0.27,1.02]

0.28[-0.18,0.74]

-0.04[-0.21,0.14]

0.09[-0.16,0.34]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

562

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 17.5.   Comparison 17 Subanalysis: outcomes by setting of
intervention, Outcome 5 Overall physical function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.5.1 Home-based

Basen-Enquist 2006

Pinto 2015

Pinto 2005

Duijits 2012

Vallance 2007

Subtotal ***

82.5 (12.7)

87.1 (4.4)

30.3 (7.9)

84 (16.9)

25.1 (3)

28

39

39

87

250

443

Heterogeneity: Tau2=0; Chi2=2.78, df=4(P=0.59); I2=0%

Test for overall effect: Z=2.38(P=0.02)

17.5.2 Facility-based

Banasik 2011

Herrero 2006

Mustian 2004

Milne 2008

Cuesta-Vargas 2014

Courneya 2003

Mehnert 2011

Littman 2012

Murtezani 2014

Do 2015

Daley 2007

Schmitz 2005

Schmitz 2009

Subtotal ***

-0.8 (0.9)

94.1 (7.5)

2.4 (1.5)

24 (2.6)

42.9 (4.1)

25.3 (2.5)

89 (9.1)

25.4 (1.7)

22.6 (4.4)

89.4 (8.4)

25.6 (2.2)

-44.2 (5.6)

50.6 (8.2)

7

8

9

29

22

24

30

30

30

32

33

39

112

405

77.4 (11.5)

84.7 (15.9)

27.3 (6.8)

80.2 (17.1)

25 (3.3)

-0.4 (0.3)

92.5 (6.6)

2.8 (1.5)

15.6 (4.5)

32.4 (32.5)

25.3 (2.8)

78.1 (21.2)

24.3 (4.4)

19.4 (4.4)

89 (8.7)

23.6 (5.7)

-48.3 (7.7)

49.1 (9.3)

23

37

43

89

85

277

7

8

9

29

20

28

28

27

32

30

33

40

120

411

Heterogeneity: Tau2=0.19; Chi2=44.5, df=12(P<0.0001); I2=73.04%

Test for overall effect: Z=2.91(P=0)

17.5.3 Both home- and facility-based

Pinto 2003

Rogers 2009

Winters-Stone 2011

Cadmus 2009

Loh 2014

Fillion 2008

Rogers 2015

Subtotal ***

32.3 (4.3)

23.3 (4.5)

51.7 (6.2)

25.1 (2.7)

24.9 (2.5)

45.1 (10.4)

24.1 (3.5)

12

20

36

37

63

44

105

317

12

18

25

37

32

43

108

275

25.3 (8.2)

25.4 (2.3)

52.3 (5.9)

24 (4.1)

24.2 (2.2)

41.8 (9.8)

22.5 (5)

Heterogeneity: Tau2=0.05; Chi2=11.97, df=6(P=0.06); I2=49.87%

Test for overall effect: Z=1.81(P=0.07)

7.79%

11.92%

12.65%

27.6%

40.04%

100%

4.54%

5%

5.33%

7.19%

7.63%

8.21%

8.34%

8.4%

8.47%

8.62%

8.69%

9.02%

10.54%

100%

6.61%

9.96%

13.44%

15.07%

16.13%

16.3%

22.48%

100%

0.41[-0.15,0.97]

0.21[-0.25,0.66]

0.4[-0.04,0.83]

0.23[-0.07,0.52]

0.05[-0.2,0.3]

0.19[0.03,0.34]

-0.48[-1.54,0.59]

0.21[-0.77,1.2]

-0.23[-1.15,0.7]

2.26[1.59,2.92]

0.46[-0.16,1.07]

0[-0.55,0.55]

0.66[0.13,1.19]

0.33[-0.19,0.86]

0.72[0.2,1.23]

0.05[-0.45,0.54]

0.46[-0.03,0.95]

0.6[0.15,1.05]

0.17[-0.09,0.43]

0.43[0.14,0.73]

1.03[0.17,1.89]

-0.57[-1.22,0.08]

-0.1[-0.61,0.41]

0.31[-0.15,0.77]

0.3[-0.12,0.73]

0.33[-0.1,0.75]

0.37[0.1,0.64]

0.23[-0.02,0.48]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

563

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 17.6.   Comparison 17 Subanalysis: outcomes by setting of
intervention, Outcome 6 Overall physical function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.6.1 Home-based

Vallance 2007

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=2.1(P=0.04)

17.6.2 Facility-based

Herrero 2006

Mustian 2004

Murtezani 2014

Naumann 2012

Courneya 2003

Cormie 2014

Mehnert 2011

Schmitz 2005

Schmitz 2009

Subtotal ***

247

247

1 (3.3)

8

9

30

11

24

43

30

39

58

6.7 (5)

1.9 (2.6)

4.4 (1.5)

1.9 (3.3)

1.9 (2)

3.5 (5.2)

4 (10.8)

1.2 (4.2)

6.6 (17.1)

85

85

8

10

32

10

28

19

28

40

62

0.2 (2.1)

-1.7 (6.9)

-0.2 (1.6)

-1.3 (1.2)

0.8 (3.4)

-0.2 (2.2)

-0.5 (5.7)

-2.1 (16.7)

1.5 (6.8)

4.1 (17.3)

252

237

Heterogeneity: Tau2=0.82; Chi2=79.49, df=8(P<0.0001); I2=89.94%

Test for overall effect: Z=2.9(P=0)

17.6.3 Both home- and facility-based

Rogers 2009

Cadmus 2009

Saarto 2012

Subtotal ***

20

37

263

320

2.3 (5.1)

0.1 (6)

1.9 (13.7)

18

37

237

292

2.6 (6)

-0.5 (7.4)

3.4 (13.4)

Heterogeneity: Tau2=0; Chi2=0.64, df=2(P=0.72); I2=0%

Test for overall effect: Z=1.03(P=0.3)

100%

100%

0.26[0.02,0.51]

0.26[0.02,0.51]

9.29%

10.01%

10.22%

10.47%

11.69%

11.78%

11.91%

12.19%

12.43%

100%

6.21%

12.13%

81.66%

100%

1.32[0.21,2.43]

0.93[-0.03,1.89]

4.23[3.31,5.15]

0.32[-0.55,1.18]

0.98[0.4,1.56]

0.74[0.19,1.3]

0.43[-0.09,0.95]

-0.05[-0.49,0.39]

0.14[-0.21,0.5]

0.95[0.31,1.59]

-0.05[-0.69,0.58]

0.09[-0.37,0.54]

-0.11[-0.29,0.06]

-0.08[-0.24,0.08]

Favours control

-10

-5

0

5

10

Favours physical activity

Analysis 17.7.   Comparison 17 Subanalysis: outcomes by setting of
intervention, Outcome 7 Overall role function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.7.1 Home-based

Basen-Enquist 2006

Vallance 2007

Subtotal ***

86.1 (22.2)

23.2 (4)

28

250

278

Heterogeneity: Tau2=0.05; Chi2=1.92, df=1(P=0.17); I2=47.84%

Test for overall effect: Z=1.28(P=0.2)

17.7.2 Facility-based

Banasik 2011

Herrero 2006

Mustian 2004

Loudon 2014

Milne 2008

7

8

9

12

29

3.5 (0.6)

97.6 (5.9)

2.4 (1.5)

-1.3 (0.3)

22.2 (3)

23

85

108

7

8

9

11

29

73 (24.5)

22.7 (4.6)

3.2 (0.6)

100 (0)

2.8 (1.5)

-1.3 (0.4)

12.5 (4.8)

32.3%

67.7%

100%

5.76%

6.07%

6.53%

7.24%

8.17%

0.55[-0.01,1.12]

0.12[-0.13,0.37]

0.26[-0.14,0.66]

0.34[-0.72,1.4]

-0.54[-1.55,0.46]

-0.23[-1.15,0.7]

0[-0.82,0.82]

2.39[1.71,3.08]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

564

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Courneya 2003

Mehnert 2011

Littman 2012

Murtezani 2014

Do 2015

Daley 2007

Schmitz 2005

Subtotal ***

23.4 (4)

90 (20.3)

22.6 (3.9)

24.2 (2.8)

78.1 (19.5)

22.9 (4.5)

-49.2 (6.5)

24

30

30

30

32

33

39

283

28

27

27

32

30

33

40

281

23.1 (4)

79.6 (25)

21.7 (4.7)

23 (2.5)

79.2 (14.6)

20.3 (5.6)

-50 (6.2)

Heterogeneity: Tau2=0.29; Chi2=44.95, df=11(P<0.0001); I2=75.53%

Test for overall effect: Z=1.82(P=0.07)

17.7.3 Both home- and facility-based

Rogers 2009

Cadmus 2009

Loh 2014

Rogers 2015

Subtotal ***

20

37

63

105

225

21.4 (4.8)

23.1 (4.7)

23.4 (4.3)

22.3 (4.5)

18

37

32

108

195

23.8 (3.2)

20.6 (7.2)

22.2 (5)

20.3 (5.5)

Heterogeneity: Tau2=0.07; Chi2=7.56, df=3(P=0.06); I2=60.32%

Test for overall effect: Z=1.15(P=0.25)

9.17%

9.3%

9.34%

9.46%

9.5%

9.56%

9.9%

100%

16.69%

24.02%

25.6%

33.69%

100%

0.07[-0.47,0.62]

0.45[-0.07,0.98]

0.21[-0.31,0.73]

0.45[-0.06,0.95]

-0.06[-0.56,0.44]

0.5[0.01,0.99]

0.12[-0.32,0.57]

0.33[-0.03,0.69]

-0.57[-1.22,0.08]

0.41[-0.05,0.87]

0.25[-0.18,0.68]

0.4[0.12,0.67]

0.2[-0.14,0.54]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 17.8.   Comparison 17 Subanalysis: outcomes by setting
of intervention, Outcome 8 Overall role function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.8.1 Home-based

Vallance 2007

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.33(P=0.18)

17.8.2 Facility-based

Herrero 2006

Mustian 2004

Naumann 2012

Courneya 2003

Cormie 2014

Murtezani 2014

Mehnert 2011

Schmitz 2005

Subtotal ***

250

250

8

9

11

24

43

30

30

39

194

0.6 (4.1)

2.1 (13.9)

0.6 (1.6)

1.5 (4.4)

0.9 (2.8)

4.9 (7.1)

1.7 (0.7)

6.7 (23.8)

1.2 (4.2)

85

85

8

10

10

28

19

32

27

40

174

-0 (2.7)

2.1 (5.9)

0.8 (1.6)

0.5 (4.5)

0.4 (2.7)

1.7 (7.1)

0.9 (0.6)

5.6 (27)

1.5 (6.8)

Heterogeneity: Tau2=0.11; Chi2=14.73, df=7(P=0.04); I2=52.47%

Test for overall effect: Z=1.62(P=0.11)

17.8.3 Both home- and facility-based

Rogers 2009

Cadmus 2009

Saarto 2012

20

37

263

0.4 (3.3)

-0.3 (3.7)

2.4 (21.5)

18

37

237

1.4 (4.3)

-0.5 (3.4)

3.8 (21.6)

100%

100%

0.17[-0.08,0.41]

0.17[-0.08,0.41]

7.43%

8.33%

8.87%

14.43%

14.44%

14.55%

15.03%

16.93%

100%

6.16%

12.13%

81.72%

0[-0.98,0.98]

-0.15[-1.05,0.76]

0.22[-0.64,1.08]

0.18[-0.37,0.73]

0.45[-0.1,0.99]

1.16[0.62,1.7]

0.04[-0.48,0.56]

-0.05[-0.49,0.39]

0.26[-0.06,0.58]

-0.26[-0.9,0.38]

0.06[-0.4,0.51]

-0.06[-0.24,0.11]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

565

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Subtotal ***

Mean(SD)

N

320

N

292

Heterogeneity: Tau2=0; Chi2=0.62, df=2(P=0.74); I2=0%

Test for overall effect: Z=0.77(P=0.44)

Mean(SD)

Random, 95% CI

Random, 95% CI

100%

-0.06[-0.22,0.1]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 17.9.   Comparison 17 Subanalysis: outcomes by setting of
intervention, Outcome 9 Overall social well-being/function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.9.1 Home-based

Basen-Enquist 2006

Vallance 2007

Subtotal ***

84.6 (16.9)

22.9 (5)

28

250

278

23

85

108

84.9 (19.2)

23 (5.1)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.97); I2=0%

Test for overall effect: Z=0.05(P=0.96)

17.9.2 Facility-based

Banasik 2011

Herrero 2006

Mustian 2004

Courneya 2003

Littman 2012

Milne 2008

Mehnert 2011

Murtezani 2014

Daley 2007

Schmitz 2009

Kiecolt-Glaser 2014

Subtotal ***

7

8

9

24

30

29

30

30

33

59

96

2.8 (0.7)

87.5 (19.4)

8.6 (1.9)

21.1 (3.5)

22.1 (5)

20.7 (4)

85.4 (20.9)

20.2 (2.8)

23.3 (4.8)

14.9 (5.2)

95.2 (10.8)

7

8

10

28

27

29

28

32

33

62

90

3.2 (0.8)

91.7 (23.6)

9 (1.8)

20.7 (3.6)

20.9 (6)

19.4 (3.9)

79.9 (22.7)

18.3 (2.7)

20.4 (6.8)

14.1 (5.8)

93.8 (9.3)

355

354

Heterogeneity: Tau2=0; Chi2=8.01, df=10(P=0.63); I2=0%

Test for overall effect: Z=2.87(P=0)

17.9.3 Both home- and facility-based

Rogers 2014

Rogers 2009

Cadmus 2009

Loh 2014

Rogers 2015

Subtotal ***

20

20

37

63

105

245

7.3 (4.9)

22.6 (4.1)

22.3 (4.9)

21.5 (4.9)

21 (5.7)

22

18

37

32

108

217

3.1 (3.2)

21.8 (5.7)

20.6 (7.2)

19.6 (4.9)

20.7 (5.8)

Heterogeneity: Tau2=0.05; Chi2=7.76, df=4(P=0.1); I2=48.48%

Test for overall effect: Z=2.14(P=0.03)

16.6%

83.4%

100%

-0.02[-0.57,0.54]

-0[-0.25,0.24]

-0.01[-0.23,0.22]

1.93%

2.28%

2.69%

7.38%

8.08%

8.18%

8.22%

8.34%

9.15%

17.25%

26.51%

100%

13.33%

13.58%

20.31%

21.71%

31.06%

100%

-0.45[-1.51,0.62]

-0.18[-1.17,0.8]

-0.19[-1.09,0.71]

0.11[-0.43,0.66]

0.22[-0.31,0.74]

0.32[-0.19,0.84]

0.25[-0.27,0.76]

0.68[0.17,1.2]

0.49[-0,0.98]

0.14[-0.21,0.5]

0.14[-0.15,0.43]

0.22[0.07,0.37]

1.01[0.36,1.65]

0.16[-0.48,0.8]

0.27[-0.18,0.73]

0.38[-0.05,0.81]

0.05[-0.22,0.32]

0.31[0.03,0.59]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

566

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 17.10.   Comparison 17 Subanalysis: outcomes by setting of
intervention, Outcome 10 Overall social well-being/function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.10.1 Home-based

Vallance 2007

Subtotal ***

0.2 (4.8)

250

250

Heterogeneity: Not applicable

Test for overall effect: Z=7.39(P<0.0001)

17.10.2 Facility-based

Mustian 2004

Naumann 2012

Murtezani 2014

Courneya 2003

Cormie 2014

Mehnert 2011

Schmitz 2009

Subtotal ***

1.5 (1.5)

0.9 (3.3)

2.1 (0.8)

0.6 (2.4)

3.5 (8.5)

7.3 (22.3)

4.4 (33.8)

9

11

30

24

43

30

59

206

Heterogeneity: Tau2=0.28; Chi2=26.16, df=6(P=0); I2=77.06%

Test for overall effect: Z=2.16(P=0.03)

17.10.3 Both home- and facility-based

Rogers 2009

Rogers 2014

Cadmus 2009

Saarto 2012

Subtotal ***

0.9 (2.6)

2.1 (3.2)

0.6 (4.6)

5 (21.1)

20

20

37

263

340

Heterogeneity: Tau2=0.26; Chi2=19.06, df=3(P=0); I2=84.26%

Test for overall effect: Z=1.42(P=0.16)

-4.1 (3.3)

0.4 (1.2)

-0.2 (3.3)

0.5 (0.9)

-0.5 (3.3)

2.5 (8.3)

3.1 (24.3)

0.7 (34)

-1.2 (2.7)

-0.8 (3.5)

-1 (3.2)

8.8 (20.8)

85

85

10

10

32

28

19

28

62

189

18

22

37

237

314

100%

100%

0.97[0.71,1.23]

0.97[0.71,1.23]

10.62%

11.44%

14.58%

15.15%

15.27%

15.56%

17.38%

100%

21.7%

22.27%

25.76%

30.27%

100%

0.76[-0.18,1.7]

0.32[-0.54,1.18]

1.8[1.21,2.4]

0.37[-0.18,0.92]

0.12[-0.42,0.66]

0.18[-0.34,0.69]

0.11[-0.25,0.47]

0.5[0.05,0.95]

0.78[0.11,1.44]

0.85[0.21,1.48]

0.4[-0.06,0.86]

-0.18[-0.36,-0.01]

0.41[-0.15,0.96]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 17.11.   Comparison 17 Subanalysis: outcomes by setting of
intervention, Outcome 11 Overall cognitive function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.11.1 Home-based

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

17.11.2 Facility-based

Herrero 2006

Mehnert 2011

Cantarero-Villanueva 2013

Subtotal ***

0

8

30

32

70

91.7 (12.6)

81.1 (16.8)

-37.9 (8.5)

Heterogeneity: Tau2=0; Chi2=1.36, df=2(P=0.51); I2=0%

Test for overall effect: Z=1.82(P=0.07)

17.11.3 Both home- and facility-based

0

8

27

29

64

89.6 (12.4)

78.4 (24.4)

-43 (10)

Not estimable

12.15%

43.23%

44.62%

100%

0.16[-0.82,1.14]

0.13[-0.39,0.65]

0.55[0.03,1.06]

0.32[-0.02,0.66]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

567

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Pinto 2003

Rogers 2009

Subtotal ***

-4.3 (2.5)

-124.5
(30.8)

12

19

31

-7.2 (2.1)

-135.5
(19.5)

6

18

24

Heterogeneity: Tau2=0.06; Chi2=1.28, df=1(P=0.26); I2=21.64%

Test for overall effect: Z=1.92(P=0.05)

32.17%

67.83%

1.14[0.07,2.2]

0.42[-0.24,1.07]

100%

0.65[-0.01,1.31]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 17.12.   Comparison 17 Subanalysis: outcomes by setting of
intervention, Outcome 12 Overall cognitive function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.12.1 Home-based

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

17.12.2 Facility-based

Herrero 2006

Mehnert 2011

Cantarero-Villanueva 2013

Subtotal ***

0

8

30

32

70

0

8

27

29

64

8.3 (14.8)

6.2 (24.6)

-0.2 (5.5)

6.2 (19.8)

1.7 (22.4)

2.2 (7.6)

Heterogeneity: Tau2=0.01; Chi2=2.26, df=2(P=0.32); I2=11.37%

Test for overall effect: Z=0.32(P=0.75)

17.12.3 Both home- and facility-based

Rogers 2009

Saarto 2012

Subtotal ***

20

263

283

4.2 (16.8)

-1 (18.2)

18

237

255

-4.7 (25.9)

2.2 (18.5)

Heterogeneity: Tau2=0.11; Chi2=2.88, df=1(P=0.09); I2=65.29%

Test for overall effect: Z=0.1(P=0.92)

Not estimable

13.42%

42.26%

44.33%

100%

-0.11[-1.09,0.87]

-0.19[-0.71,0.33]

0.35[-0.16,0.86]

0.06[-0.31,0.43]

35.06%

64.94%

100%

0.4[-0.24,1.05]

-0.17[-0.35,0]

0.03[-0.51,0.57]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 17.13.   Comparison 17 Subanalysis: outcomes by setting of
intervention, Outcome 13 Overall general health (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.13.1 Home-based

Basen-Enquist 2006

Ergun 2013

Subtotal ***

77.4 (11.6)

69 (19.9)

28

40

68

67.1 (13.4)

67.9 (16.7)

23

20

43

Heterogeneity: Tau2=0.21; Chi2=3.56, df=1(P=0.06); I2=71.91%

Test for overall effect: Z=1.13(P=0.26)

17.13.2 Facility-based

49.03%

50.97%

100%

0.81[0.24,1.39]

0.06[-0.48,0.59]

0.43[-0.32,1.17]

Favours control

-100

-50

0

50

100

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

568

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Herrero 2006

Mustian 2004

Ergun 2013

Mehnert 2011

Do 2015

Schmitz 2005

Subtotal ***

81.3 (10.7)

18.6 (4.8)

74.2 (18.7)

74.4 (11.8)

87.3 (13.7)

53.8 (5.3)

8

9

20

30

32

39

138

Heterogeneity: Tau2=0; Chi2=4.81, df=5(P=0.44); I2=0%

Test for overall effect: Z=2.05(P=0.04)

17.13.3 Both home- and facility-based

Rogers 2009

Cadmus 2009

Subtotal ***

3.5 (0.9)

50 (8.8)

20

37

57

Heterogeneity: Tau2=0; Chi2=0.25, df=1(P=0.62); I2=0%

Test for overall effect: Z=1.38(P=0.17)

62.5 (16.1)

19.3 (1.9)

67.9 (16.7)

70 (20.8)

82.4 (19.9)

53.2 (6)

3.8 (0.5)

51.7 (8.4)

8

9

20

28

30

40

135

18

37

55

4.67%

6.7%

14.72%

21.48%

22.92%

29.51%

100%

1.3[0.19,2.41]

-0.18[-1.11,0.74]

0.35[-0.28,0.97]

0.26[-0.26,0.77]

0.28[-0.22,0.79]

0.1[-0.34,0.55]

0.25[0.01,0.49]

33.49%

66.51%

100%

-0.4[-1.04,0.25]

-0.2[-0.65,0.26]

-0.26[-0.64,0.11]

Favours control

-100

-50

0

50

100

Favours physical activity

Analysis 17.14.   Comparison 17 Subanalysis: outcomes by setting of
intervention, Outcome 14 Overall general health (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.14.1 Home-based

Ergun 2013

Subtotal ***

4.6 (26.5)

20

20

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=1.32(P=0.19)

17.14.2 Facility-based

Mustian 2004

Ergun 2013

Subtotal ***

0.2 (1.9)

6.3 (15.5)

9

20

29

Heterogeneity: Tau2=0.15; Chi2=1.96, df=1(P=0.16); I2=49.04%

Test for overall effect: Z=0.69(P=0.49)

17.14.3 Both home- and facility-based

Rogers 2009

Cadmus 2009

Saarto 2012

Subtotal ***

0.2 (0.6)

0.2 (4.4)

4.2 (16.2)

20

37

263

320

Heterogeneity: Tau2=0; Chi2=0.38, df=2(P=0.83); I2=0%

Test for overall effect: Z=0.82(P=0.41)

20

20

10

20

30

18

37

237

292

-6.7 (25.9)

0.7 (2.5)

-6.7 (25.9)

0.2 (0.7)

-0.1 (5.1)

5.6 (15.4)

100%

100%

0.42[-0.21,1.05]

0.42[-0.21,1.05]

41.37%

58.63%

100%

-0.2[-1.1,0.71]

0.59[-0.04,1.23]

0.27[-0.49,1.03]

6.21%

12.12%

81.66%

100%

-0.03[-0.67,0.61]

0.06[-0.39,0.52]

-0.09[-0.26,0.09]

-0.07[-0.23,0.09]

Favours control

-100

-50

0

50

100

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

569

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 17.15.   Comparison 17 Subanalysis: outcomes by setting of
intervention, Outcome 15 Overall sexual function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

17.15.1 Home-based

Pinto 2005

Duijits 2012

Subtotal ***

42.8 (9.2)

0.6 (0.8)

12

53

65

Heterogeneity: Tau2=0; Chi2=0.05, df=1(P=0.82); I2=0%

Test for overall effect: Z=0.01(P=0.99)

17.15.2 Facility-based

Schmitz 2005

Schmitz 2009

Subtotal ***

-51 (7.5)

-27.3 (5.3)

39

57

96

Heterogeneity: Tau2=0; Chi2=0.38, df=1(P=0.54); I2=0%

Test for overall effect: Z=1.46(P=0.14)

17.15.3 Both home- and facility-based

Pinto 2003

Subtotal ***

42.5 (9.2)

39

39

Heterogeneity: Not applicable

Test for overall effect: Z=1.32(P=0.19)

43.7 (6.1)

0.6 (0.8)

-53.5 (8)

-28.1 (6.2)

40.1 (6.3)

6

65

71

40

57

97

43

43

12.03%

87.97%

100%

-0.11[-1.09,0.87]

0.01[-0.35,0.38]

-0[-0.34,0.34]

40.67%

59.33%

100%

0.32[-0.12,0.76]

0.14[-0.23,0.51]

0.21[-0.07,0.49]

100%

100%

0.29[-0.14,0.73]

0.29[-0.14,0.73]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 17.16.   Comparison 17 Subanalysis: outcomes by setting of
intervention, Outcome 16 Overall sexual function (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

17.16.1 Home-based

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

17.16.2 Facility-based

Schmitz 2009

Schmitz 2005

Subtotal ***

0

57

39

96

0

57

40

97

-0.2 (16.7)

0.2 (5.2)

7.2 (14.6)

1.7 (4.8)

Heterogeneity: Tau2=12.46; Chi2=3.52, df=1(P=0.06); I2=71.56%

Test for overall effect: Z=1.33(P=0.18)

17.16.3 Both home- and facility-based

Saarto 2012

Subtotal ***

263

263

4.3 (25.4)

237

237

3.8 (24.4)

Heterogeneity: Not applicable

Test for overall effect: Z=0.22(P=0.82)

Not estimable

39.42%

60.58%

100%

7.4[1.64,13.16]

1.5[-0.71,3.71]

3.83[-1.83,9.48]

100%

100%

0.5[-3.86,4.86]

0.5[-3.86,4.86]

Favours control

-20

-10

0

10

20

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

570

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 17.17.   Comparison 17 Subanalysis: outcomes by setting
of intervention, Outcome 17 Overall sleep (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

17.17.1 Home-based

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

17.17.2 Facility-based

Bower 2011

Mehnert 2011

Subtotal ***

0

16

30

46

8.1 (2.5)

23.8 (27)

Heterogeneity: Tau2=0; Chi2=2.04, df=1(P=0.15); I2=50.93%

Test for overall effect: Z=1.2(P=0.23)

17.17.3 Both home- and facility-based

Rogers 2013

Rogers 2009

Rogers 2014

Subtotal ***

6.3 (2.7)

6.7 (4.2)

6.7 (3.7)

11

20

20

51

Heterogeneity: Tau2=0; Chi2=0.75, df=2(P=0.69); I2=0%

Test for overall effect: Z=0.31(P=0.76)

0

15

27

42

9

18

22

49

7.7 (2.6)

38.3 (31.6)

6.2 (3.2)

5.5 (4)

7.1 (3.2)

Not estimable

35.91%

64.09%

100%

0.15[-0.55,0.86]

-0.49[-1.02,0.04]

-0.26[-0.68,0.16]

19.97%

37.83%

42.2%

100%

0.03[-0.85,0.91]

0.28[-0.36,0.92]

-0.11[-0.72,0.49]

0.06[-0.33,0.46]

Favours Physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 17.18.   Comparison 17 Subanalysis: outcomes by setting
of intervention, Outcome 18 Overall sleep (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.18.1 Home-based

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

17.18.2 Facility-based

Mehnert 2011

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.53(P=0.6)

17.18.3 Both home- and facility-based

Rogers 2009

Rogers 2014

Subtotal ***

0

29

29

20

20

40

-5.4 (29.9)

0.5 (2.1)

-1.3 (3.2)

Heterogeneity: Tau2=0; Chi2=0.16, df=1(P=0.69); I2=0%

Test for overall effect: Z=0.63(P=0.53)

0

27

27

18

22

40

-9.9 (33.3)

0.3 (4.7)

-2.2 (4.4)

Not estimable

100%

100%

0.14[-0.38,0.67]

0.14[-0.38,0.67]

47.66%

52.34%

100%

0.05[-0.59,0.68]

0.23[-0.38,0.84]

0.14[-0.3,0.58]

Favours Physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

571

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 17.19.   Comparison 17 Subanalysis: outcomes by setting
of intervention, Outcome 19 Overall anxiety (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.19.1 Home-based

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

17.19.2 Facility-based

Segar 1998

Milne 2008

Mehnert 2011

Cantarero-Villanueva 2013

Subtotal ***

0

10

29

30

32

101

28.5 (3)

15.3 (6.2)

4.8 (3.5)

42.5 (8.6)

Heterogeneity: Tau2=0.11; Chi2=6.25, df=3(P=0.1); I2=52.04%

Test for overall effect: Z=3.69(P=0)

17.19.3 Both home- and facility-based

Pinto 2003

Rogers 2014

Cadmus 2009

Subtotal ***

7.6 (7.3)

45.6 (8.9)

32.1 (12.3)

12

20

37

69

Heterogeneity: Tau2=0; Chi2=0.51, df=2(P=0.77); I2=0%

Test for overall effect: Z=0.77(P=0.44)

0

5

29

28

29

91

6

22

37

65

39.5 (6)

21 (5.7)

7.1 (5)

49.9 (11.7)

10.5 (3.7)

45.7 (8)

34.1 (15.4)

Not estimable

-2.49[-3.98,-1]

-0.94[-1.49,-0.4]

-0.54[-1.06,-0.01]

-0.72[-1.24,-0.2]

-0.87[-1.34,-0.41]

-0.43[-1.43,0.56]

-0.01[-0.62,0.59]

-0.14[-0.6,0.31]

-0.14[-0.48,0.21]

8.12%

29.94%

30.85%

31.09%

100%

11.87%

31.92%

56.21%

100%

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 17.20.   Comparison 17 Subanalysis: outcomes by setting
of intervention, Outcome 20 Overall anxiety (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

17.20.1 Home-based

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

17.20.2 Facility-based

Mehnert 2011

Cantarero-Villanueva 2013

Subtotal ***

0

30

32

62

-1.7 (3.7)

-4.2 (9.8)

Heterogeneity: Tau2=0; Chi2=0.24, df=1(P=0.62); I2=0%

Test for overall effect: Z=2.76(P=0.01)

17.20.3 Both home- and facility-based

Rogers 2014

Cadmus 2009

Subtotal ***

-4 (6.5)

-0.7 (9.2)

20

37

57

Heterogeneity: Tau2=0; Chi2=0.32, df=1(P=0.57); I2=0%

Test for overall effect: Z=1.25(P=0.21)

0

28

29

57

22

37

59

0.2 (4.9)

0.8 (5.5)

-1.8 (5)

0.5 (5.8)

Not estimable

49.37%

50.63%

100%

-0.42[-0.95,0.1]

-0.61[-1.12,-0.09]

-0.52[-0.88,-0.15]

35.79%

64.21%

100%

-0.37[-0.99,0.24]

-0.15[-0.61,0.3]

-0.23[-0.6,0.13]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

572

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 17.21.   Comparison 17 Subanalysis: outcomes by setting
of intervention, Outcome 21 Overall depression (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.21.1 Home-based

Payne 2008

Ergun 2013

Subtotal ***

12.7 (8.7)

8.9 (10.5)

10

20

30

Heterogeneity: Tau2=0; Chi2=0.28, df=1(P=0.6); I2=0%

Test for overall effect: Z=1.32(P=0.19)

17.21.2 Facility-based

Segar 1998

Kaltsatou 2011

Bower 2011

Ergun 2013

Mehnert 2011

Cantarero-Villanueva 2013

Daley 2007

Kiecolt-Glaser 2014

Subtotal ***

5.5 (2)

16.5 (1.7)

7.7 (5.8)

4.7 (4.1)

2.7 (3)

45.6 (9.7)

6 (6.5)

8.1 (8.6)

10

13

16

20

30

32

33

96

250

Heterogeneity: Tau2=0.09; Chi2=15.18, df=7(P=0.03); I2=53.88%

Test for overall effect: Z=3.58(P=0)

17.21.3 Both home- and facility-based

Pinto 2003

Rogers 2014

Cadmus 2009

Subtotal ***

6.2 (7.2)

44.2 (8.6)

9.6 (9.3)

12

20

37

69

Heterogeneity: Tau2=0.13; Chi2=4.45, df=2(P=0.11); I2=55.07%

Test for overall effect: Z=0.16(P=0.87)

11.4 (7.9)

5.2 (5.2)

10 (2)

22.3 (7.7)

11.6 (7.1)

5.2 (5.2)

4.6 (4.4)

53.7 (11.6)

10.3 (7.2)

9.2 (8.2)

9.8 (6.8)

25.1 (44.2)

10.8 (10.1)

10

20

30

5

13

15

20

28

29

33

90

233

6

22

37

65

33.85%

66.15%

100%

0.15[-0.73,1.03]

0.44[-0.19,1.07]

0.34[-0.17,0.85]

3.95%

8.75%

10.34%

12.25%

14.4%

14.46%

15.11%

20.75%

100%

21%

35.24%

43.77%

100%

-2.12[-3.51,-0.73]

-1[-1.83,-0.18]

-0.59[-1.31,0.13]

-0.09[-0.71,0.53]

-0.51[-1.04,0.01]

-0.75[-1.28,-0.23]

-0.63[-1.12,-0.13]

-0.13[-0.42,0.16]

-0.55[-0.85,-0.25]

-0.49[-1.49,0.5]

0.58[-0.04,1.19]

-0.12[-0.58,0.33]

0.05[-0.52,0.61]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 17.22.   Comparison 17 Subanalysis: outcomes by setting
of intervention, Outcome 22 Overall depression (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.22.1 Home-based

Ergun 2013

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.23(P=0.22)

17.22.2 Facility-based

Naumann 2012

Mehnert 2011

Cantarero-Villanueva 2013

Subtotal ***

-0.6 (6.7)

-3.6 (4.3)

2.7 (3)

-2.9 (7.8)

20

20

11

30

32

73

20

20

10

28

29

67

2.4 (8)

2 (4.6)

4.6 (4.4)

1.5 (7.4)

100%

100%

-0.39[-1.02,0.23]

-0.39[-1.02,0.23]

13.02%

42.6%

44.38%

100%

-1.21[-2.16,-0.26]

-0.51[-1.04,0.01]

-0.57[-1.09,-0.06]

-0.63[-0.97,-0.29]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

573

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Heterogeneity: Tau2=0; Chi2=1.68, df=2(P=0.43); I2=0%

Test for overall effect: Z=3.61(P=0)

17.22.3 Both home- and facility-based

Rogers 2014

Cadmus 2009

Saarto 2012

Subtotal ***

20

37

263

320

-1.7 (6.9)

0.3 (6.4)

-0.3 (3.3)

22

37

237

296

1.1 (4.2)

1.7 (6.3)

-0.5 (3.4)

Heterogeneity: Tau2=0.03; Chi2=3.71, df=2(P=0.16); I2=46.05%

Test for overall effect: Z=0.73(P=0.47)

17.85%

26.68%

55.47%

100%

-0.49[-1.1,0.13]

-0.22[-0.68,0.24]

0.06[-0.12,0.24]

-0.11[-0.41,0.19]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 17.23.   Comparison 17 Subanalysis: outcomes by setting
of intervention, Outcome 23 Overall fatigue (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.23.1 Home-based

Payne 2008

Ergun 2013

Pinto 2015

Pinto 2005

Vallance 2007

Short 2014

Subtotal ***

4.7 (2.6)

3 (2.5)

-43.8 (7.8)

27.1 (21.4)

-42.7 (8.4)

-41.5 (9.3)

9

20

39

39

250

195

552

Heterogeneity: Tau2=0.02; Chi2=8.11, df=5(P=0.15); I2=38.33%

Test for overall effect: Z=1.72(P=0.09)

17.23.2 Facility-based

Banasik 2011

Loudon 2014

Bower 2011

Ergun 2013

Cuesta-Vargas 2014

Milne 2008

Cantarero-Villanueva 2013

Courneya 2003

Mehnert 2011

Littman 2012

Do 2015

Daley 2007

Kiecolt-Glaser 2014

Subtotal ***

7

12

16

20

22

29

32

24

30

30

32

33

96

1 (0.9)

1.9 (2.2)

3.4 (1.8)

2.9 (2)

4 (1.8)

11.9 (3.2)

3.8 (1.8)

-8.3 (7.9)

28.5 (25.6)

-45 (5.3)

16.8 (13.3)

2.1 (1.8)

6.3 (19.6)

9

20

37

43

85

104

298

7

11

15

20

20

29

29

28

27

27

30

33

90

3.5 (1.7)

3.3 (1.8)

-41.2 (8.5)

42.3 (26.2)

-42.6 (8.7)

-39.8 (10.4)

1.6 (1)

2.1 (2.5)

4.9 (1.3)

3.3 (1.8)

5.2 (3.2)

17.4 (4.7)

6.2 (1.7)

-8.8 (8.1)

39.9 (25.1)

-43.1 (10.3)

22.3 (15.1)

3.4 (1.9)

12.7 (19)

383

366

Heterogeneity: Tau2=0.1; Chi2=28.25, df=12(P=0.01); I2=57.52%

Test for overall effect: Z=4.38(P<0.0001)

17.23.3 Both home- and facility-based

Pinto 2003

Rogers 2013

12

11

7.2 (6.4)

4.2 (1.8)

6

9

9 (6.4)

4.2 (1.6)

4.36%

8.99%

14.47%

14.85%

28.31%

29.03%

100%

3.67%

5.35%

5.98%

7.27%

7.36%

7.84%

7.98%

8.2%

8.44%

8.51%

8.76%

8.82%

11.83%

100%

0.52[-0.42,1.46]

-0.13[-0.75,0.49]

-0.32[-0.77,0.14]

-0.63[-1.07,-0.18]

-0.01[-0.26,0.23]

-0.17[-0.41,0.06]

-0.18[-0.39,0.03]

-0.57[-1.65,0.51]

-0.07[-0.89,0.75]

-0.93[-1.67,-0.18]

-0.23[-0.85,0.4]

-0.46[-1.07,0.15]

-1.35[-1.92,-0.78]

-1.38[-1.94,-0.82]

0.06[-0.48,0.61]

-0.44[-0.97,0.08]

-0.23[-0.75,0.29]

-0.38[-0.89,0.12]

-0.71[-1.21,-0.21]

-0.33[-0.62,-0.04]

-0.53[-0.77,-0.29]

4.64%

5.8%

-0.27[-1.26,0.71]

0[-0.88,0.88]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

574

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Rogers 2009

Rogers 2014

Winters-Stone 2011

Cadmus 2009

Fillion 2008

Subtotal ***

-12.4 (10.4)

4.1 (2.1)

45 (5.3)

-51.9 (9)

2.7 (0.7)

20

20

36

37

44

180

18

22

31

37

43

166

-10.1 (6.6)

4 (1.8)

43.1 (10.3)

-50.6 (10)

2.9 (0.8)

Heterogeneity: Tau2=0; Chi2=3.1, df=6(P=0.8); I2=0%

Test for overall effect: Z=0.8(P=0.43)

11.01%

12.28%

19.39%

21.63%

25.26%

100%

-0.26[-0.9,0.38]

0.05[-0.56,0.66]

0.23[-0.25,0.72]

-0.14[-0.59,0.32]

-0.27[-0.69,0.15]

-0.09[-0.3,0.13]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 17.24.   Comparison 17 Subanalysis: outcomes by setting
of intervention, Outcome 24 Overall fatigue (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.24.1 Home-based

Pinto 2005

Vallance 2007

Subtotal ***

-14.9 (23.5)

2.5 (8.2)

39

250

289

Heterogeneity: Tau2=0.35; Chi2=11.3, df=1(P=0); I2=91.15%

Test for overall effect: Z=0.56(P=0.57)

17.24.2 Facility-based

Herrero 2006

Naumann 2012

Loudon 2014

Courneya 2003

Cantarero-Villanueva 2013

Mehnert 2011

Daley 2007

Subtotal ***

-4.2 (19.6)

-3.6 (4.4)

1.9 (2.2)

9.3 (10.2)

-2 (1.8)

-0.7 (20.7)

2.1 (1.8)

8

11

12

24

32

30

33

150

Heterogeneity: Tau2=0.6; Chi2=39.08, df=6(P<0.0001); I2=84.65%

Test for overall effect: Z=1.33(P=0.19)

17.24.3 Both home- and facility-based

Rogers 2013

Rogers 2009

Saarto 2012

Subtotal ***

4.2 (2)

1.9 (9.6)

-2.4 (9.1)

11

20

263

294

Heterogeneity: Tau2=0; Chi2=0.51, df=2(P=0.77); I2=0%

Test for overall effect: Z=0.1(P=0.92)

43

85

128

8

10

11

28

29

27

33

146

9

18

237

264

1.8 (23.5)

1.2 (6.6)

6.4 (14.5)

2 (4.6)

2.1 (2.5)

2 (7.5)

0.3 (1.4)

-2.9 (25.3)

3.4 (1.9)

3.9 (1.5)

4.2 (12.3)

-2.4 (8.6)

47.64%

52.36%

100%

12.09%

12.53%

13.49%

15.28%

15.28%

15.6%

15.73%

100%

3.55%

6.78%

89.68%

100%

-0.7[-1.15,-0.26]

0.17[-0.08,0.42]

-0.25[-1.1,0.61]

-0.58[-1.59,0.43]

-1.21[-2.16,-0.26]

-0.07[-0.89,0.75]

0.81[0.24,1.38]

-1.45[-2.02,-0.88]

0.09[-0.43,0.61]

-0.71[-1.21,-0.21]

-0.43[-1.06,0.2]

0.16[-0.72,1.04]

-0.21[-0.84,0.43]

0[-0.18,0.18]

-0.01[-0.17,0.16]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

575

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 17.25.   Comparison 17 Subanalysis: outcomes by setting of
intervention, Outcome 25 Overall pain/disability (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.25.1 Home-based

Portela 2008

Basen-Enquist 2006

Duijits 2012

Subtotal ***

-19.4 (18.2)

79.7 (10.6)

79.3 (23.6)

13

28

87

128

-20.8 (15.5)

72.1 (11.5)

78.8 (23.8)

9

23

89

121

Heterogeneity: Tau2=0.08; Chi2=4.11, df=2(P=0.13); I2=51.29%

Test for overall effect: Z=1.05(P=0.29)

17.25.2 Facility-based

Mustian 2004

Portela 2008

Loudon 2014

Mehnert 2011

Do 2015

Subtotal ***

9.1 (1.4)

-21.8 (23)

0.8 (1.5)

79.4 (23.1)

21.1 (24.6)

9

12

12

30

32

95

Heterogeneity: Tau2=0; Chi2=1.57, df=4(P=0.81); I2=0%

Test for overall effect: Z=0.62(P=0.54)

17.25.3 Both home- and facility-based

Rogers 2009

Cadmus 2009

Subtotal ***

-3 (3)

50.3 (9.1)

20

37

57

Heterogeneity: Tau2=0; Chi2=0.25, df=1(P=0.62); I2=0%

Test for overall effect: Z=0.65(P=0.52)

9.1 (1.7)

-20.8 (15.5)

1.4 (2.2)

73.5 (24.8)

16.5 (26.7)

-2.3 (2.8)

50.8 (9)

10

9

11

28

30

88

18

37

55

18.96%

31.1%

49.94%

100%

10.45%

11.35%

12.46%

31.71%

34.03%

100%

0.08[-0.77,0.93]

0.68[0.11,1.25]

0.02[-0.28,0.32]

0.24[-0.2,0.68]

0.01[-0.89,0.91]

-0.05[-0.91,0.82]

-0.33[-1.15,0.5]

0.24[-0.27,0.76]

0.18[-0.32,0.68]

0.09[-0.2,0.38]

33.67%

66.33%

100%

-0.26[-0.89,0.38]

-0.05[-0.51,0.4]

-0.12[-0.49,0.25]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 17.26.   Comparison 17 Subanalysis: outcomes by setting of
intervention, Outcome 26 Overall pain/disability (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.26.1 Home-based

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

17.26.2 Facility-based

Mustian 2004

Cormie 2014

Mehnert 2011

Subtotal ***

0

9

43

30

82

-0.2 (1.3)

3.4 (6.5)

-2.4 (25)

0

10

19

28

57

0 (1.4)

2 (6.2)

-7.6 (25.2)

Heterogeneity: Tau2=0; Chi2=0.54, df=2(P=0.76); I2=0%

Test for overall effect: Z=0.89(P=0.37)

17.26.3 Both home- and facility-based

Cadmus 2009

Irwin 2015

37

45

-2.2 (11.3)

-6 (19)

37

38

-0.1 (7)

0.7 (18.6)

Not estimable

14.64%

40.67%

44.69%

100%

-0.15[-1.06,0.75]

0.22[-0.33,0.76]

0.21[-0.31,0.72]

0.16[-0.19,0.5]

47.55%

52.45%

-0.22[-0.68,0.24]

-0.35[-0.79,0.08]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

576

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Subtotal ***

Mean(SD)

N

82

N

75

Heterogeneity: Tau2=0; Chi2=0.17, df=1(P=0.68); I2=0%

Test for overall effect: Z=1.81(P=0.07)

Mean(SD)

Random, 95% CI

Random, 95% CI

100%

-0.29[-0.61,0.02]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 17.27.   Comparison 17 Subanalysis: outcomes by setting of
intervention, Outcome 27 Overall self-esteem/body image (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.27.1 Home-based

Musanti 2012

Pinto 2005

Subtotal ***

23.8 (3.5)

30.3 (7.8)

30

39

69

Heterogeneity: Tau2=0.51; Chi2=6.89, df=1(P=0.01); I2=85.49%

Test for overall effect: Z=0.18(P=0.85)

17.27.2 Facility-based

Segar 1998

Loudon 2014

Mehnert 2011

Courneya 2003

Milne 2008

Daley 2007

Do 2015

Schmitz 2009

Subtotal ***

33 (1.8)

-1.4 (0.3)

-5.5 (1.7)

34.8 (4.7)

-17.9 (6.8)

2 (0.8)

37.9 (18.9)

-70.4 (16.3)

10

12

27

24

29

33

32

59

226

Heterogeneity: Tau2=0.01; Chi2=8.32, df=7(P=0.31); I2=15.88%

Test for overall effect: Z=2.76(P=0.01)

17.27.3 Both home- and facility-based

Pinto 2003

Cadmus 2009

Subtotal ***

32.3 (4.3)

34.2 (5.5)

12

37

49

Heterogeneity: Tau2=0.33; Chi2=2.9, df=1(P=0.09); I2=65.53%

Test for overall effect: Z=1.07(P=0.29)

26.3 (3.9)

27.2 (6.8)

30.5 (2.7)

-1.6 (0.9)

-6.8 (2.6)

34.6 (4.4)

-20.1 (6.3)

1.6 (0.5)

36.1 (18.3)

-71.5 (18)

25.3 (8.2)

33.4 (5.9)

12

43

55

5

11

27

28

29

32

30

63

225

6

37

43

46.95%

53.05%

100%

3.07%

5.99%

12.33%

12.38%

13.47%

14.3%

14.38%

24.07%

100%

-0.68[-1.37,0.01]

0.41[-0.03,0.85]

-0.1[-1.17,0.97]

1.11[-0.06,2.28]

0.2[-0.62,1.02]

0.61[0.06,1.16]

0.04[-0.5,0.59]

0.33[-0.19,0.85]

0.66[0.16,1.16]

0.1[-0.4,0.59]

0.06[-0.29,0.42]

0.29[0.09,0.5]

38.09%

61.91%

100%

1.15[0.08,2.22]

0.14[-0.32,0.6]

0.52[-0.44,1.48]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 17.28.   Comparison 17 Subanalysis: outcomes by setting of
intervention, Outcome 28 Overall self-esteem/body image (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.28.1 Home-based

Musanti 2012

Subtotal ***

Heterogeneity: Not applicable

-0.4 (4.5)

30

30

12

12

0.6 (3.9)

100%

100%

-0.22[-0.89,0.45]

-0.22[-0.89,0.45]

Favours control

-5

-2.5

0

2.5

5

Favours intervention

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

577

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for overall effect: Z=0.64(P=0.52)

17.28.2 Facility-based

Mustian 2004

Courneya 2003

Mehnert 2011

Milne 2008

Daley 2007

Schmitz 2009

Subtotal ***

11

24

30

29

33

59

186

3 (1)

2.6 (3.7)

0.7 (2.1)

1.5 (3.7)

1.8 (0.7)

-12 (15.5)

-1.5 (1.5)

-0.1 (3.5)

0.4 (2.1)

0.1 (3.9)

1.6 (0.7)

-4.1 (16.2)

10

28

27

29

33

63

190

Heterogeneity: Tau2=0.47; Chi2=37.69, df=5(P<0.0001); I2=86.74%

Test for overall effect: Z=1.66(P=0.1)

17.28.3 Both home- and facility-based

Cadmus 2009

Saarto 2012

Subtotal ***

0.4 (4.4)

10.7 (21.5)

37

263

300

37

237

274

0.2 (2.9)

12 (22)

Heterogeneity: Tau2=0; Chi2=0.2, df=1(P=0.65); I2=0%

Test for overall effect: Z=0.54(P=0.59)

9.63%

17.43%

17.83%

17.85%

18.14%

19.12%

100%

3.42[1.99,4.86]

0.74[0.18,1.3]

0.16[-0.36,0.68]

0.36[-0.16,0.88]

0.33[-0.16,0.82]

-0.49[-0.86,-0.13]

0.52[-0.09,1.13]

12.92%

87.08%

100%

0.05[-0.4,0.51]

-0.06[-0.24,0.12]

-0.05[-0.21,0.12]

Favours control

-5

-2.5

0

2.5

5

Favours intervention

Analysis 17.29.   Comparison 17 Subanalysis: outcomes by setting of
intervention, Outcome 29 Overall cardiorespiratory fitness (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.29.1 Home-based

Portela 2008

Musanti 2012

Kim 2015

Basen-Enquist 2006

Pinto 2005

Subtotal ***

3044.3
(440.9)

24.6 (4.9)

424.8 (55.8)

1643
(122.5)

-16.3 (2.1)

13

30

20

35

39

137

Heterogeneity: Tau2=0; Chi2=1.97, df=4(P=0.74); I2=0%

Test for overall effect: Z=4.9(P<0.0001)

17.29.2 Facility-based

Herrero 2006

Portela 2008

Cerulli 2014

Mustian 2004

Kaltsatou 2011

Rahnama 2010

Courneya 2003

Mehnert 2011

Do 2015

Milne 2008

8

12

10

11

14

14

24

27

30

29

25.9 (4.5)

2966.5
(390.7)

31.3 (5)

636.1 (50.6)

483.3 (86)

20.7 (5.7)

21.3 (3.7)

26.9 (4.4)

31.7 (12.4)

1.5 (0.3)

9

12

19

25

43

108

8

9

10

10

13

15

26

23

30

29

2416.1
(718.6)

23 (4.3)

394.4 (54)

1546
(127.5)

-17.8 (2.2)

25.7 (3.7)

2416.1
(718.6)

32.3 (10.1)

610.3 (75.9)

403.1 (71.9)

13.9 (5.2)

18.2 (3.9)

25.7 (4.7)

24.5 (6.6)

1.5 (0.4)

8.26%

15.34%

16.96%

24.54%

34.89%

100%

3.73%

4.14%

4.5%

4.6%

5.18%

5.22%

8.53%

8.95%

9.76%

9.96%

1.06[0.15,1.98]

0.33[-0.34,1]

0.54[-0.1,1.18]

0.77[0.24,1.3]

0.69[0.24,1.14]

0.66[0.4,0.92]

0.05[-0.93,1.03]

0.96[0.03,1.88]

-0.12[-0.99,0.76]

0.39[-0.48,1.25]

0.98[0.17,1.78]

1.21[0.41,2.01]

0.8[0.22,1.38]

0.26[-0.3,0.82]

0.72[0.19,1.24]

0.03[-0.49,0.54]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

578

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Murtezani 2014

Fillion 2008

Daley 2007

Subtotal ***

875.1 (86.7)

27 (4.4)

35 (4.4)

30

44

33

286

Heterogeneity: Tau2=0.04; Chi2=17.02, df=12(P=0.15); I2=29.51%

Test for overall effect: Z=4.35(P<0.0001)

17.29.3 Both home- and facility-based

Rogers 2013

Nikander 2007

Rogers 2014

Rogers 2009

Irwin 2015

Rogers 2015

Subtotal ***

23.9 (6.2)

-17.6 (1.3)

30.9 (6.3)

29.5 (6.6)

24.6 (5.5)

23.6 (4.8)

12

14

20

20

45

105

216

Heterogeneity: Tau2=0.04; Chi2=7.52, df=5(P=0.18); I2=33.52%

Test for overall effect: Z=2.16(P=0.03)

823.5 (87.1)

26.5 (5.8)

33.1 (5.3)

23.9 (3.8)

-17.2 (1.4)

25.1 (5)

27.6 (6.1)

23 (4.7)

22.7 (0.3)

32

43

69

317

10

14

22

18

38

108

210

10.09%

12.63%

12.7%

100%

8.42%

10.24%

12.78%

12.95%

21.77%

33.83%

100%

0.59[0.08,1.1]

0.1[-0.32,0.52]

0.38[-0.04,0.8]

0.45[0.25,0.66]

0[-0.84,0.84]

-0.29[-1.03,0.46]

1.01[0.36,1.65]

0.29[-0.35,0.93]

0.31[-0.13,0.74]

0.27[-0,0.54]

0.29[0.03,0.56]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 17.30.   Comparison 17 Subanalysis: outcomes by setting of
intervention, Outcome 30 Overall cardiorespiratory fitness (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.30.1 Home-based

Musanti 2012

Pinto 2005

Subtotal ***

1 (3.1)

1.4 (2.4)

30

39

69

Heterogeneity: Tau2=0.11; Chi2=2.25, df=1(P=0.13); I2=55.56%

Test for overall effect: Z=1.29(P=0.2)

17.30.2 Facility-based

Nieman 1995

Naumann 2012

Dolan 2016

Courneya 2003

Subtotal ***

60.8 (8.4)

3.1 (2.9)

12.2 (10.2)

2.7 (2.6)

6

11

23

24

64

Heterogeneity: Tau2=0.13; Chi2=4.69, df=3(P=0.2); I2=36.09%

Test for overall effect: Z=5.38(P<0.0001)

0.9 (3.4)

-0.2 (2.5)

12 (17.8)

-0.1 (3.1)

-6 (7.2)

-0.6 (1.7)

12

43

55

6

10

10

26

52

17.30.3 Both home- and facility-based

Rogers 2014

Irwin 2015

Saarto 2012

Subtotal ***

20

45

262

327

2.8 (4.9)

1.5 (2.1)

0.9 (1.2)

22

38

236

296

1.1 (4.2)

-0.4 (2.7)

0.7 (1)

Heterogeneity: Tau2=0.09; Chi2=6.72, df=2(P=0.03); I2=70.23%

Test for overall effect: Z=1.89(P=0.06)

41.4%

58.6%

100%

0.03[-0.64,0.7]

0.65[0.2,1.09]

0.39[-0.2,0.99]

8.14%

25.83%

27.18%

38.85%

100%

23.95%

31.25%

44.8%

100%

3.24[1.29,5.18]

1.03[0.1,1.95]

1.88[0.99,2.77]

1.49[0.86,2.12]

1.62[1.03,2.21]

0.37[-0.24,0.98]

0.79[0.34,1.24]

0.16[-0.02,0.33]

0.4[-0.02,0.82]

Favours control

-10

-5

0

5

10

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

579

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 17.31.   Comparison 17 Subanalysis: outcomes by setting of intervention,
Outcome 31 Overall self-reported physical activity (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.31.1 Home-based

Baruth 2013

Matthews 2007

Kim 2015

Basen-Enquist 2006

Pinto 2015

Hatchett 2013

Pinto 2005

Vallance 2007

Short 2014

Subtotal ***

0 (0)

54.2 (34.1)

17.6 (16)

428 (254.4)

70.3 (65.9)

3.5 (2.2)

202.4
(161.7)

207.6 (169)

217.9
(222.9)

20

22

20

35

36

38

39

253

195

658

Heterogeneity: Tau2=0.11; Chi2=25.24, df=7(P=0); I2=72.26%

Test for overall effect: Z=3.94(P<0.0001)

17.31.2 Facility-based

Littman 2012

Kiecolt-Glaser 2014

Schmitz 2009

Subtotal ***

19.2 (19.1)

11.2 (7.6)

3348.8
(9019.4)

32

96

131

259

Heterogeneity: Tau2=0; Chi2=1.46, df=2(P=0.48); I2=0%

Test for overall effect: Z=2.57(P=0.01)

17.31.3 Both home- and facility-based

0 (0)

27.2 (22.7)

11.8 (11.6)

404 (265)

16.5 (31.9)

1.4 (1.7)

78.4 (86)

163 (121)

180.3
(206.9)

12.1 (13.6)

9.1 (6.1)

2339.8
(6213.7)

12

14

19

25

32

36

43

85

104

370

31

90

133

254

Guinan 2013

Rogers 2009

Cadmus 2009

Winters-Stone 2011

Irwin 2015

Rogers 2015

Subtotal ***

16

20

34

36

45

110

261

38.7 (26.9)

121.4 (73.2)

10

18

19.9 (11.3)

114.3
(131.5)

161.7
(114.7)

430.8
(281.4)

222.1
(118.6)

169 (119)

33

55.6 (101.9)

461.7
(346.4)

103.6
(104.6)

74 (107)

31

38

112

242

Heterogeneity: Tau2=0.16; Chi2=18.59, df=5(P=0); I2=73.1%

Test for overall effect: Z=3.14(P=0)

8.73%

9.7%

11.68%

11.79%

12.14%

12.66%

16.58%

16.72%

Not estimable

0.87[0.17,1.58]

0.4[-0.23,1.04]

0.09[-0.42,0.61]

1.01[0.5,1.52]

1.04[0.55,1.53]

0.96[0.5,1.42]

0.28[0.03,0.53]

0.17[-0.07,0.41]

100%

0.57[0.29,0.85]

12.1%

36.11%

51.79%

0.42[-0.08,0.92]

0.3[0.01,0.59]

0.13[-0.11,0.37]

100%

0.23[0.05,0.4]

11.44%

14.54%

17.01%

17.55%

17.93%

21.51%

100%

0.81[-0.01,1.64]

0.07[-0.57,0.7]

0.97[0.46,1.47]

-0.1[-0.58,0.38]

1.04[0.58,1.51]

0.84[0.56,1.11]

0.62[0.23,1]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 17.32.   Comparison 17 Subanalysis: outcomes by setting of
intervention, Outcome 32 Overall self-reported physical activity (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.32.1 Home-based

Matthews 2007

22

21.5 (30.6)

14

5 (13.8)

8.22%

0.63[-0.06,1.32]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

580

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Pinto 2005

Vallance 2007

Subtotal ***

N

Mean(SD)

39

84.7 (189.2)

82 (168.7)

281

342

Heterogeneity: Tau2=0; Chi2=1.28, df=2(P=0.53); I2=0%

Test for overall effect: Z=3.75(P=0)

17.32.2 Facility-based

Schmitz 2009

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.09(P=0.28)

2.8 (16.8)

48

48

17.32.3 Both home- and facility-based

Guinan 2013

Cadmus 2009

Irwin 2015

Saarto 2012

Subtotal ***

15.6 (11.4)

129 (117.9)

159 (136)

3.5 (18.3)

16

34

45

262

357

Heterogeneity: Tau2=0.54; Chi2=36.9, df=3(P<0.0001); I2=91.87%

Test for overall effect: Z=2.32(P=0.02)

Mean(SD)

-18.3
(200.7)

30 (167.8)

-0.8 (16.6)

-8.3 (4.2)

44.3 (89.4)

49 (86)

3.3 (21.5)

N

43

96

153

57

57

10

33

38

236

317

Random, 95% CI

19.99%

71.79%

100%

Random, 95% CI

0.52[0.08,0.96]

0.31[0.08,0.54]

0.38[0.18,0.57]

100%

100%

0.21[-0.17,0.6]

0.21[-0.17,0.6]

18.78%

26.03%

26.49%

28.7%

100%

2.46[1.39,3.53]

0.8[0.3,1.3]

0.94[0.48,1.4]

0.01[-0.17,0.19]

0.92[0.14,1.7]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 17.33.   Comparison 17 Subanalysis: outcomes by setting of
intervention, Outcome 33 Overall objective physical activity (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.33.1 Home-based

Matthews 2007

Pinto 2015

Pinto 2005

Vallance 2007

Short 2014

Subtotal ***

330.8
(114.7)

70.3 (65.9)

37.5 (14.3)

8110.5
(4133.9)

9363.1
(7922.8)

22

36

39

253

219

569

Heterogeneity: Tau2=0.14; Chi2=20.75, df=4(P=0); I2=80.72%

Test for overall effect: Z=2.33(P=0.02)

17.33.2 Facility-based

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

17.33.3 Both home- and facility-based

Rogers 2013

Guinan 2013

Rogers 2014

0

12

16

20

198.4
(111.7)

30.7 (15.6)

294 (175)

14

198.5 (55.4)

32

43

85

111

285

0

10

9

22

16.5 (31.9)

33.6 (19.4)

8028 (3457)

8301.2
(3373.4)

0 (0)

31 (15.6)

154 (75)

13.12%

18.15%

19.88%

24.26%

24.6%

100%

1.34[0.6,2.09]

1.01[0.5,1.52]

0.22[-0.21,0.66]

0.02[-0.23,0.27]

0.16[-0.07,0.39]

0.45[0.07,0.82]

Not estimable

8.54%

12.83%

Not estimable

-0.02[-0.84,0.8]

1.04[0.39,1.69]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

581

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Rogers 2009

Cadmus 2009

Rogers 2015

Subtotal ***

N

20

Mean(SD)

252191
(91893)

N

18

Mean(SD)

210917
(64078)

33

6738 (2958)

34

5537 (3352)

110

211

246 (153)

112

205

197 (138)

Heterogeneity: Tau2=0.02; Chi2=5.06, df=4(P=0.28); I2=21.02%

Test for overall effect: Z=3.32(P=0)

Random, 95% CI

12.86%

20.75%

45.02%

100%

Random, 95% CI

0.51[-0.14,1.15]

0.38[-0.11,0.86]

0.34[0.07,0.6]

0.43[0.17,0.68]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 17.34.   Comparison 17 Subanalysis: outcomes by setting of
intervention, Outcome 34 Overall objective physical activity (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.34.1 Home-based

Matthews 2007

Vallance 2007

Subtotal ***

72.2 (114.6)

-150
(5173.3)

22

253

275

Heterogeneity: Tau2=0.39; Chi2=6.3, df=1(P=0.01); I2=84.12%

Test for overall effect: Z=0.78(P=0.43)

17.34.2 Facility-based

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

17.34.3 Both home- and facility-based

Guinan 2013

Rogers 2014

Cadmus 2009

Subtotal ***

0

16

20

33

69

-1.1 (6.2)

114 (109)

1621 (2108)

Heterogeneity: Tau2=0; Chi2=1.04, df=2(P=0.59); I2=0%

Test for overall effect: Z=5(P<0.0001)

14

85

99

0

9

22

34

65

-16.8 (51.5)

91 (5155.4)

-7.9 (5.3)

10 (70)

-60 (2341)

43.78%

56.22%

0.91[0.2,1.62]

-0.05[-0.29,0.2]

100%

0.37[-0.56,1.3]

Not estimable

16.73%

30.3%

52.97%

100%

1.11[0.23,2]

1.13[0.47,1.78]

0.75[0.25,1.24]

0.92[0.56,1.28]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 17.35.   Comparison 17 Subanalysis: outcomes by
setting of intervention, Outcome 35 Mass (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

17.35.1 Home-based

Matthews 2007

DeNysschen 2011

Subtotal ***

74.9 (15.2)

69.3 (14.2)

22

30

52

14

34

48

78.9 (20.3)

72.4 (19.6)

Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.91); I2=0%

Test for overall effect: Z=0.96(P=0.34)

31.09%

68.91%

100%

-4[-16.39,8.39]

-3.1[-11.42,5.22]

-3.38[-10.29,3.53]

Favours physical activity

-20

-10

0

10

20

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

582

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

17.35.2 Facility-based

Mustian 2004

Courneya 2003

Herrero 2006

Rahnama 2010

Littman 2012

Daley 2007

Murtezani 2014

Schmitz 2009

Schmitz 2005

Kiecolt-Glaser 2014

Subtotal ***

11

24

8

14

28

33

30

67.1 (10.4)

78.2 (20.5)

65.6 (8.7)

69.4 (13.5)

81.1 (13.6)

74.3 (12.5)

71.7 (9.5)

131

76.2 (15.7)

69.5 (2.2)

75.2 (2.8)

39

96

414

Heterogeneity: Tau2=0; Chi2=1.62, df=9(P=1); I2=0%

Test for overall effect: Z=0.09(P=0.93)

17.35.3 Both home- and facility-based

Nikander 2007

Cadmus 2009

Ligibel 2008

Winters-Stone 2011

Subtotal ***

73.5 (13.3)

80.7 (16.9)

80 (17.5)

76.5 (15.6)

14

36

40

36

126

Heterogeneity: Tau2=0; Chi2=1.55, df=3(P=0.67); I2=0%

Test for overall effect: Z=0.02(P=0.98)

68.6 (13.8)

80.1 (16.2)

67.3 (8.9)

71.6 (9.2)

81.3 (14.3)

75.6 (12.5)

72.6 (10.8)

77.2 (17)

69.2 (2.2)

75.2 (2.6)

75.5 (12)

78.5 (20.6)

83.3 (18.7)

74.2 (12.3)

10

26

8

15

27

69

32

133

40

90

450

14

33

42

31

120

0.31%

0.32%

0.46%

0.48%

0.63%

1.28%

1.35%

2.2%

36.07%

56.91%

100%

18.17%

20%

26.06%

35.78%

100%

-1.5[-12.06,9.06]

-1.9[-12.2,8.4]

-1.7[-10.32,6.92]

-2.2[-10.67,6.27]

-0.2[-7.58,7.18]

-1.34[-6.52,3.84]

-0.9[-5.94,4.14]

-1.04[-4.98,2.9]

0.3[-0.67,1.27]

0[-0.78,0.78]

0.03[-0.56,0.61]

-2[-11.38,7.38]

2.22[-6.72,11.16]

-3.3[-11.14,4.54]

2.3[-4.39,8.99]

0.04[-3.96,4.04]

Favours physical activity

-20

-10

0

10

20

Favours control

Analysis 17.36.   Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 36 Mass (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

17.36.1 Home-based

Matthews 2007

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.04(P=0.97)

17.36.2 Facility-based

Dolan 2016

Mustian 2004

Schmitz 2009

Murtezani 2014

Naumann 2012

Courneya 2003

Schmitz 2005

Subtotal ***

22

22

0 (2.1)

14

14

0 (2.2)

100%

100%

-0.03[-1.46,1.4]

-0.03[-1.46,1.4]

23

9

65

30

11

24

39

201

-0.5 (5)

-0.3 (1.9)

-1 (3.7)

-2.3 (2.4)

0.5 (1.3)

0.1 (2)

0.3 (0.4)

10

10

65

32

10

26

40

193

1.4 (1.6)

0.6 (1.4)

-0.4 (4.3)

-0.3 (2.6)

0.1 (1.5)

0.7 (1.8)

0.2 (0.4)

6.74%

11.58%

12.67%

13.97%

14.15%

15.97%

24.93%

100%

-1.99[-4.28,0.3]

-0.9[-2.4,0.6]

-0.6[-1.98,0.78]

-2[-3.24,-0.76]

0.33[-0.9,1.56]

-0.6[-1.66,0.46]

0.12[-0.07,0.31]

-0.61[-1.31,0.08]

Heterogeneity: Tau2=0.49; Chi2=17.95, df=6(P=0.01); I2=66.56%

Test for overall effect: Z=1.73(P=0.08)

17.36.3 Both home- and facility-based

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

583

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Physical activity

Control

Irwin 2015

Ligibel 2008

Saarto 2012

Subtotal ***

Mean(SD)

-2.1 (4.3)

0 (2.3)

0.7 (3.7)

N

45

22

262

329

Mean(SD)

0.1 (3.6)

0 (2.2)

0.7 (3.8)

N

38

14

236

288

Heterogeneity: Tau2=0.74; Chi2=5.64, df=2(P=0.06); I2=64.52%

Test for overall effect: Z=0.94(P=0.35)

Cochrane Database of Systematic Reviews

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

25.73%

29.23%

45.03%

100%

-2.2[-3.9,-0.5]

-0.04[-1.52,1.44]

-0.01[-0.67,0.65]

-0.58[-1.8,0.63]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 17.37.   Comparison 17 Subanalysis: outcomes by
setting of intervention, Outcome 37 BMI (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

17.37.1 Home-based

Portela 2008

Pinto 2005

Vallance 2007

Subtotal ***

27.8 (6.3)

27.7 (5)

27 (5.2)

13

39

253

305

Heterogeneity: Tau2=0; Chi2=2.21, df=2(P=0.33); I2=9.5%

Test for overall effect: Z=0.95(P=0.34)

17.37.2 Facility-based

Portela 2008

Mustian 2004

Courneya 2003

Rahnama 2010

Littman 2012

Murtezani 2014

Schmitz 2009

Schmitz 2005

Kiecolt-Glaser 2014

Subtotal ***

30.5 (4.4)

23.9 (4.2)

29.4 (7.4)

27.7 (4.8)

27.7 (5)

25.1 (2.9)

28.5 (5.6)

26 (0.7)

27.8 (1.1)

12

11

24

14

28

30

131

39

96

385

Heterogeneity: Tau2=0; Chi2=5.71, df=8(P=0.68); I2=0%

Test for overall effect: Z=0.42(P=0.68)

17.37.3 Both home- and facility-based

Rogers 2013

Rogers 2009

Nikander 2007

Rogers 2014

Cadmus 2009

Ligibel 2008

Subtotal ***

33.6 (7)

30.6 (7.6)

26.9 (5.6)

29.6 (5)

30.5 (6)

30.3 (6.3)

12

20

14

20

36

40

142

Heterogeneity: Tau2=0; Chi2=3.36, df=5(P=0.65); I2=0%

Test for overall effect: Z=0.79(P=0.43)

34.7 (15)

29 (5.6)

27.2 (5.2)

34.7 (15)

26.7 (5.6)

29.3 (6)

28 (4.6)

29 (5.6)

25.8 (3.5)

28.9 (6.3)

25.8 (0.7)

27.8 (1)

30.6 (7.3)

30.4 (8.3)

27.7 (4.9)

32.2 (6.7)

29.9 (7.6)

31.5 (6.8)

9

43

85

137

9

10

26

15

27

32

133

40

90

382

10

18

14

22

33

42

139

1.13%

23.06%

75.8%

100%

0.04%

0.25%

0.32%

0.38%

0.56%

1.76%

2.18%

42.31%

52.2%

100%

6.44%

9%

15.29%

18.37%

22.02%

28.88%

100%

-6.9[-17.28,3.48]

-1.35[-3.65,0.95]

-0.19[-1.46,1.08]

-0.53[-1.64,0.57]

-4.2[-14.31,5.91]

-2.8[-7.05,1.45]

0.1[-3.65,3.85]

-0.3[-3.71,3.11]

-1.35[-4.17,1.47]

-0.7[-2.29,0.89]

-0.48[-1.91,0.95]

0.2[-0.12,0.52]

0[-0.29,0.29]

0.04[-0.17,0.26]

3[-3,9]

0.2[-4.88,5.28]

-0.8[-4.7,3.1]

-2.6[-6.16,0.96]

0.55[-2.7,3.8]

-1.2[-4.04,1.64]

-0.61[-2.14,0.91]

Favours physical activity

-20

-10

0

10

20

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

584

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 17.38.   Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 38 BMI (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

0

0

Not estimable

17.38.1 Home-based

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

17.38.2 Facility-based

Schmitz 2009

Mustian 2004

Naumann 2012

Courneya 2003

Murtezani 2014

Schmitz 2005

Subtotal ***

-1 (3.7)

-0.4 (0.8)

0.1 (0.5)

0 (0.7)

-0.8 (0.7)

0.1 (0.2)

65

9

11

24

30

39

178

Heterogeneity: Tau2=0.09; Chi2=19.09, df=5(P=0); I2=73.81%

Test for overall effect: Z=1.73(P=0.08)

17.38.3 Both home- and facility-based

Rogers 2014

Ligibel 2008

Subtotal ***

-0.2 (0.9)

0 (0.9)

20

40

60

Heterogeneity: Tau2=0; Chi2=0.69, df=1(P=0.41); I2=0%

Test for overall effect: Z=0.74(P=0.46)

-0.4 (4.3)

0.3 (0.6)

-0.1 (0.6)

0.3 (0.7)

-0.1 (0.8)

0.1 (0.2)

-0.3 (1.1)

0.2 (0.8)

65

10

10

26

32

40

183

22

42

64

4.24%

13.05%

17.03%

19.12%

19.56%

26.99%

100%

27.09%

72.91%

100%

-0.6[-1.98,0.78]

-0.71[-1.33,-0.09]

0.2[-0.26,0.66]

-0.3[-0.69,0.09]

-0.66[-1.03,-0.29]

-0.01[-0.08,0.06]

-0.27[-0.58,0.04]

0.1[-0.51,0.71]

-0.2[-0.57,0.17]

-0.12[-0.43,0.2]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 17.39.   Comparison 17 Subanalysis: outcomes by setting
of intervention, Outcome 39 Overall body fat (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.39.1 Home-based

Matthews 2007

Musanti 2012

DeNysschen 2011

Pinto 2005

Subtotal ***

39.7 (6.3)

34.1 (6.6)

36.9 (8.4)

37.5 (4.8)

22

30

30

39

121

Heterogeneity: Tau2=0; Chi2=1.5, df=3(P=0.68); I2=0%

Test for overall effect: Z=1.34(P=0.18)

17.39.2 Facility-based

Herrero 2006

Cerulli 2014

Mustian 2004

Courneya 2003

Schmitz 2005

Daley 2007

Schmitz 2009

Subtotal ***

22 (5)

26.7 (5.3)

38.5 (4.5)

131.9 (46.4)

40.9 (1.3)

39.4 (4.7)

38.5 (5.9)

8

10

11

24

39

33

130

255

Heterogeneity: Tau2=0.08; Chi2=13.24, df=6(P=0.04); I2=54.69%

43.1 (6.9)

33.7 (5.7)

38 (10.2)

38.6 (4.8)

22 (4)

30.6 (4.4)

41.7 (4.9)

137.1 (44.4)

42.3 (1.3)

40.1 (7.4)

39.7 (5.9)

14

12

34

43

103

8

10

10

26

40

69

132

295

15.58%

16.14%

29.97%

38.31%

100%

7.23%

8.02%

8.42%

14.89%

17.3%

19.11%

25.02%

100%

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

-0.51[-1.19,0.17]

0.07[-0.6,0.74]

-0.12[-0.61,0.38]

-0.21[-0.64,0.22]

-0.18[-0.45,0.09]

0[-0.98,0.98]

-0.75[-1.66,0.16]

-0.66[-1.54,0.23]

-0.11[-0.67,0.44]

-1.05[-1.52,-0.58]

-0.1[-0.52,0.31]

-0.21[-0.46,0.03]

-0.39[-0.69,-0.08]

585

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for overall effect: Z=2.5(P=0.01)

17.39.3 Both home- and facility-based

Rogers 2013

Rogers 2009

Rogers 2014

Winters-Stone 2011

Saarto 2012

Cadmus 2009

Ligibel 2008

Subtotal ***

10

20

20

36

37

36

40

199

44.2 (6.7)

44.3 (7.4)

38.6 (6.4)

40.5 (6.2)

39.9 (7.5)

40.5 (6.6)

42.9 (7.4)

12

19

22

31

30

33

42

189

42.3 (7.7)

43.5 (7.5)

41.5 (7.4)

38.5 (5.8)

40.2 (8)

39.6 (6)

44.7 (8)

Heterogeneity: Tau2=0; Chi2=5.42, df=6(P=0.49); I2=0%

Test for overall effect: Z=0.08(P=0.94)

5.64%

10.15%

10.68%

17.13%

17.28%

17.91%

21.22%

100%

0.25[-0.59,1.09]

0.11[-0.52,0.73]

-0.41[-1.02,0.2]

0.33[-0.16,0.81]

-0.04[-0.52,0.44]

0.15[-0.33,0.62]

-0.23[-0.67,0.2]

0.01[-0.19,0.21]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 17.40.   Comparison 17 Subanalysis: outcomes by setting
of intervention, Outcome 40 Overall body fat (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.40.1 Home-based

Musanti 2012

Matthews 2007

Subtotal ***

-0.2 (2.8)

-0.2 (1.6)

30

22

52

Heterogeneity: Tau2=0; Chi2=0.35, df=1(P=0.55); I2=0%

Test for overall effect: Z=1.98(P=0.05)

17.40.2 Facility-based

Mustian 2004

Naumann 2012

Schmitz 2005

Courneya 2003

Schmitz 2009

Subtotal ***

-0.2 (2.9)

-0.3 (2.4)

-1.1 (0.5)

-4.9 (15.7)

-0.3 (5.7)

9

11

39

24

65

148

1.4 (1.6)

0.4 (1.9)

0.3 (1.6)

0.8 (2.8)

0.2 (0.4)

5.1 (24.4)

-0.1 (3.3)

12

14

26

10

10

40

26

63

149

Heterogeneity: Tau2=1.45; Chi2=64.94, df=4(P<0.0001); I2=93.84%

Test for overall effect: Z=1.49(P=0.14)

17.40.3 Both home- and facility-based

Rogers 2014

Ligibel 2008

Subtotal ***

-1.1 (2.2)

-0.2 (1.7)

20

40

60

22

42

64

-0.6 (2.4)

0.3 (1.7)

Heterogeneity: Tau2=0; Chi2=0.04, df=1(P=0.84); I2=0%

Test for overall effect: Z=1.47(P=0.14)

49.33%

50.67%

100%

18.94%

19.13%

20.14%

20.54%

21.25%

100%

-0.63[-1.32,0.05]

-0.34[-1.02,0.33]

-0.48[-0.97,-0]

-0.18[-1.09,0.72]

-0.41[-1.28,0.46]

-3.07[-3.73,-2.41]

-0.48[-1.04,0.09]

-0.04[-0.39,0.3]

-0.84[-1.94,0.26]

33.94%

66.06%

100%

-0.21[-0.82,0.39]

-0.29[-0.73,0.14]

-0.26[-0.62,0.09]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

586

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 17.41.   Comparison 17 Subanalysis: outcomes by setting of
intervention, Outcome 41 Lower body strength (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.41.1 Home-based

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

17.41.2 Facility-based

0

0

Not estimable

Cerulli 2014

Schmitz 2005

Milne 2008

Do 2015

Schmitz 2009

Subtotal ***

114.9 (17.1)

296.6 (48.9)

66.2 (10.2)

13 (1.6)

223.4 (59.6)

10

23

29

32

113

207

Heterogeneity: Tau2=0.25; Chi2=19.31, df=4(P=0); I2=79.28%

Test for overall effect: Z=2.85(P=0)

17.41.3 Both home- and facility-based

Rogers 2013

Nikander 2007

Rogers 2009

Saarto 2012

Winters-Stone 2011

Subtotal ***

68.4 (15.5)

1305 (177)

80.3 (27)

136 (23)

201.3 (57.4)

11

14

20

37

36

118

Heterogeneity: Tau2=0.01; Chi2=4.32, df=4(P=0.36); I2=7.42%

Test for overall effect: Z=0.86(P=0.39)

79.1 (17.8)

238.9 (46.4)

61.7 (11)

13.2 (1.6)

175.1 (53.5)

67.1 (16.2)

1393 (275)

64.9 (19.7)

136 (29)

191 (51.7)

10

22

29

30

119

210

9

14

18

30

31

102

12.11%

19.28%

21.39%

21.79%

25.43%

100%

9.72%

13.29%

17.11%

29.93%

29.95%

100%

1.96[0.85,3.07]

1.19[0.55,1.83]

0.42[-0.1,0.94]

-0.09[-0.59,0.41]

0.85[0.58,1.12]

0.75[0.24,1.27]

0.08[-0.8,0.96]

-0.37[-1.12,0.38]

0.63[-0.02,1.29]

0[-0.48,0.48]

0.19[-0.3,0.67]

0.12[-0.16,0.4]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 17.42.   Comparison 17 Subanalysis: outcomes by setting
of intervention, Outcome 42 Lower body strength (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.42.1 Home-based

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

17.42.2 Facility-based

Nieman 1995

Naumann 2012

Dolan 2016

Schmitz 2005

Cormie 2014

Do 2015

Schmitz 2009

Subtotal ***

0

0

Not estimable

28.9 (13.7)

7.7 (12.6)

11.8 (8.9)

81.8 (48.9)

37.6 (25.5)

0.9 (0.7)

33.2 (33.9)

6

11

23

23

43

32

113

251

6

10

10

22

19

60

119

246

3.5 (22.5)

3.5 (13.9)

0.3 (11.1)

20.3 (46)

6.7 (25.7)

1 (0.6)

7.9 (26.6)

7.31%

11.59%

12.4%

14.65%

15.65%

18.06%

20.34%

100%

1.26[-0.03,2.55]

0.3[-0.56,1.17]

1.17[0.37,1.97]

1.27[0.63,1.92]

1.19[0.61,1.78]

-0.08[-0.51,0.35]

0.83[0.56,1.1]

0.8[0.38,1.23]

Heterogeneity: Tau2=0.21; Chi2=22.01, df=6(P=0); I2=72.74%

Test for overall effect: Z=3.69(P=0)

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

587

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.42.3 Both home- and facility-based

Waltman 2010

Subtotal ***

110

110

4.4 (11.5)

113

113

0.2 (8.4)

Heterogeneity: Not applicable

Test for overall effect: Z=3.1(P=0)

100%

100%

0.42[0.15,0.69]

0.42[0.15,0.69]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 17.43.   Comparison 17 Subanalysis: outcomes by setting of
intervention, Outcome 43 Upper body strength (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

17.43.1 Home-based

Portela 2008

Musanti 2012

Subtotal ***

40.6 (13.5)

52.1 (21)

13

30

43

Heterogeneity: Tau2=0; Chi2=0.43, df=1(P=0.51); I2=0%

Test for overall effect: Z=2.13(P=0.03)

17.43.2 Facility-based

Mustian 2004

Cerulli 2014

Portela 2008

Schmitz 2005

Kaltsatou 2011

Milne 2008

Do 2015

Schmitz 2009

Subtotal ***

29.6 (3.3)

16.1 (5.4)

37.8 (14.4)

83 (13.4)

59.6 (8.5)

7.6 (2.9)

9.7 (1.7)

52.9 (15.3)

11

10

12

23

28

29

32

113

258

35.6 (13.1)

36.8 (20)

26.7 (5.7)

17.2 (8.1)

35.6 (13.1)

63 (12.7)

47.6 (9.8)

9.4 (2.6)

10.1 (1.7)

40.9 (11.8)

9

12

21

10

10

9

22

26

29

30

119

255

Heterogeneity: Tau2=0.52; Chi2=51.98, df=7(P<0.0001); I2=86.53%

Test for overall effect: Z=1.54(P=0.12)

17.43.3 Both home- and facility-based

Nikander 2007

Rogers 2009

Saarto 2012

Winters-Stone 2011

Subtotal ***

131 (20)

27.9 (5)

32.7 (5.3)

63.3 (15.3)

14

20

37

36

107

129 (28)

24.3 (6.2)

30.8 (5.7)

61.1 (16.8)

14

18

30

31

93

Heterogeneity: Tau2=0; Chi2=1.78, df=3(P=0.62); I2=0%

Test for overall effect: Z=2.01(P=0.04)

39.22%

60.78%

100%

10.97%

10.98%

11.07%

12.44%

12.96%

13.36%

13.53%

14.69%

100%

14.3%

18.36%

33.36%

33.98%

100%

0.36[-0.5,1.22]

0.73[0.04,1.42]

0.58[0.05,1.12]

0.6[-0.28,1.49]

-0.16[-1.03,0.72]

0.15[-0.71,1.02]

1.5[0.84,2.17]

1.29[0.7,1.88]

-0.64[-1.17,-0.12]

-0.24[-0.74,0.26]

0.88[0.61,1.15]

0.43[-0.12,0.98]

0.08[-0.66,0.82]

0.63[-0.03,1.28]

0.34[-0.14,0.83]

0.14[-0.34,0.62]

0.29[0.01,0.57]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

588

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 17.44.   Comparison 17 Subanalysis: outcomes by setting
of intervention, Outcome 44 Upper body strength (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

0

0

Not estimable

17.44.1 Home-based

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

17.44.2 Facility-based

Schmitz 2005

Musanti 2012

Cormie 2014

Do 2015

Mustian 2004

Schmitz 2009

Subtotal ***

32.3 (11.5)

7.7 (10.6)

5.7 (3.7)

0.3 (0.5)

4.5 (4.7)

33.2 (40.8)

23

30

43

32

45

113

286

22

12

19

30

38

119

240

6.9 (10.8)

0.8 (12.7)

1 (3.8)

0.6 (1.2)

-0.8 (3.2)

7.6 (43.7)

Heterogeneity: Tau2=0.44; Chi2=40.07, df=5(P<0.0001); I2=87.52%

Test for overall effect: Z=3.13(P=0)

17.44.3 Both home- and facility-based

Irwin 2015

Waltman 2010

Subtotal ***

45

110

155

0.4 (1.9)

1.9 (4.9)

38

113

151

0.1 (1.9)

0.8 (2.9)

Heterogeneity: Tau2=0; Chi2=0.25, df=1(P=0.62); I2=0%

Test for overall effect: Z=2.19(P=0.03)

14.7%

15.44%

16.38%

17.17%

17.37%

18.94%

100%

27.13%

72.87%

100%

2.24[1.48,2.99]

0.6[-0.08,1.29]

1.25[0.67,1.84]

-0.27[-0.77,0.23]

1.3[0.82,1.78]

0.6[0.34,0.87]

0.92[0.34,1.5]

0.16[-0.27,0.59]

0.29[0.02,0.55]

0.25[0.03,0.48]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 17.45.   Comparison 17 Subanalysis: outcomes by setting of intervention,
Outcome 45 Bone mineral density - femoral neck (follow-up and change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

0.8 (0.1)

17.45.1 Home-based

Kim 2015

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.14(P=0.26)

17.45.2 Facility-based

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

20

20

0

17.45.3 Both home- and facility-based

Winters-Stone 2011

Waltman 2010

Saarto 2012

Subtotal ***

0.7 (0.1)

0.9 (0.5)

-0 (0)

36

110

239

385

Heterogeneity: Tau2=0.06; Chi2=7.87, df=2(P=0.02); I2=74.58%

Test for overall effect: Z=1.91(P=0.06)

0.8 (0.1)

0.7 (0.1)

0.6 (0.4)

-0 (0)

19

19

0

31

113

218

362

100%

100%

-0.37[-1,0.27]

-0.37[-1,0.27]

Not estimable

23.53%

35.68%

40.8%

100%

0.11[-0.37,0.59]

0.63[0.36,0.9]

0.18[-0,0.37]

0.32[-0.01,0.65]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

589

Favours control

-2

-1

0

1

2

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 17.46.   Comparison 17 Subanalysis: outcomes by setting of intervention,
Outcome 46 Bone mineral density - lumbar spine (follow-up and change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

1 (0.1)

17.46.1 Home-based

Kim 2015

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.81(P=0.42)

17.46.2 Facility-based

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

20

20

0

17.46.3 Both home- and facility-based

Winters-Stone 2011

Waltman 2010

Saarto 2012

Subtotal ***

1 (0.2)

3.1 (0.4)

-0 (0)

36

110

239

385

Heterogeneity: Tau2=0.06; Chi2=7.65, df=2(P=0.02); I2=73.85%

Test for overall effect: Z=1.81(P=0.07)

1 (0.1)

1 (0.1)

2.9 (0.4)

-0 (0)

19

19

0

31

113

218

362

100%

100%

-0.26[-0.89,0.37]

-0.26[-0.89,0.37]

Not estimable

23.16%

35.8%

41.04%

100%

0.3[-0.19,0.78]

0.55[0.28,0.81]

0.09[-0.09,0.27]

0.3[-0.02,0.63]

Favours control

-2

-1

0

1

2

Favours physical activity

Analysis 17.47.   Comparison 17 Subanalysis: outcomes by setting of intervention,
Outcome 47 Bone mineral density - total hip (follow-up and change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

0.1 (0.1)

100%

100%

10.34[7.84,12.84]

10.34[7.84,12.84]

17.47.1 Home-based

Kim 2015

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=8.11(P<0.0001)

17.47.2 Facility-based

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Not applicable

20

20

0

0.9 (0.1)

19

19

0

17.47.3 Both home- and facility-based

Winters-Stone 2011

Waltman 2010

Subtotal ***

36

110

146

0.9 (0.1)

2.2 (0.3)

31

113

144

0.8 (0.1)

1.8 (0.4)

Heterogeneity: Tau2=0.33; Chi2=9.19, df=1(P=0); I2=89.12%

Test for overall effect: Z=1.49(P=0.14)

Not estimable

47.32%

52.68%

100%

0.19[-0.29,0.67]

1.05[0.77,1.33]

0.64[-0.2,1.48]

Favours control

-2

-1

0

1

2

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

590

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Comparison 18.   Sensitivity analysis: outcomes by risk of bias

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Overall HRQoL (follow-up
values)

1.1 Low risk of bias

22

15

1.2 Unclear/high risk of bias

7

2 Overall HRQoL (change val-
ues)

2.1 Low risk of bias

14

11

2.2 Unclear/high risk of bias

3

3 Overall emotional func-
tion/mental health (fol-
low-up values)

3.1 Low risk of bias

26

15

3.2 Unclear/high risk of bias

11

4 Overall emotional func-
tion/mental health (change
values)

4.1 Low risk of bias

15

11

4.2 Unclear/high risk of bias

4

5 Overall physical function
(follow-up values)

5.1 Low risk of bias

25

13

5.2 Unclear/high risk of bias

12

6 Overall physical function
(change values)

6.1 Low risk of bias

13

10

1521

475

1360

99

1427

675

1399

180

1343

786

1335

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.43 [0.19, 0.66]

Std. Mean Difference (IV, Random,
95% CI)

0.30 [0.06, 0.55]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.70 [0.28, 1.12]

Std. Mean Difference (IV, Random,
95% CI)

1.26 [-0.11, 2.62]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.22 [0.09, 0.34]

Std. Mean Difference (IV, Random,
95% CI)

0.19 [-0.02, 0.40]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.31 [0.04, 0.58]

Std. Mean Difference (IV, Random,
95% CI)

0.28 [-0.08, 0.65]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.38 [0.13, 0.63]

Std. Mean Difference (IV, Random,
95% CI)

0.28 [0.14, 0.42]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.63 [0.19, 1.07]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

591

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

6.2 Unclear/high risk of bias

3

98

7 Overall role function (fol-
low-up values)

7.1 Low risk of bias

18

12

7.2 Unclear/high risk of bias

6

8 Overall role function
(change values)

8.1 Low risk of bias

8.2 Unclear/high risk of bias

9 Overall social well-be-
ing/function (follow-up val-
ues)

9.1 Low risk of bias

12

9

3

18

12

9.2 Unclear/high risk of bias

6

10 Overall social well-be-
ing/function (change values)

12

10.1 Low risk of bias

10.2 Unclear/high risk of bias

11 Overall cognitive function
(follow-up values)

11.1 Low risk of bias

11.2 Unclear/high risk of bias

12 Overall cognitive function
(change values)

12.1 Low risk of bias

9

3

5

3

2

5

4

1111

259

1218

97

1263

294

1286

98

114

75

615

Std. Mean Difference (IV, Random,
95% CI)

0.50 [0.09, 0.90]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.32 [0.02, 0.61]

Std. Mean Difference (IV, Random,
95% CI)

0.24 [-0.01, 0.48]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.17 [-0.06, 0.40]

Std. Mean Difference (IV, Random,
95% CI)

0.04 [-0.36, 0.44]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.21 [0.07, 0.36]

Std. Mean Difference (IV, Random,
95% CI)

0.17 [-0.06, 0.40]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.56 [0.13, 0.98]

Std. Mean Difference (IV, Random,
95% CI)

0.31 [-0.09, 0.71]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.45 [0.07, 0.82]

Std. Mean Difference (IV, Random,
95% CI)

0.52 [-0.44, 1.48]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.07 [-0.28, 0.42]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

592

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

12.2 Unclear/high risk of bias

13 Overall general health (fol-
low-up values)

13.1 Low risk of bias

13.2 Unclear/high risk of bias

14 Overall general health
(change values)

14.1 Low risk of bias

14.2 Unclear/high risk of bias

15 Overall sexual function
(follow-up values)

15.1 Low risk of bias

15.2 Unclear/high risk of bias

16 Overall sexual function
(change values)

16.1 Low risk of bias

16.2 Unclear/high risk of bias

17 Overall sleep (follow-up
values)

17.1 Low risk of bias

17.2 Unclear/high risk of bias

18 Overall sleep (change val-
ues)

18.1 Low risk of bias

1

9

5

4

9

7

2

5

2

3

3

3

0

5

3

2

3

2

57

267

189

829

77

193

218

693

0

111

77

80

Std. Mean Difference (IV, Random,
95% CI)

-0.19 [-0.71, 0.33]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.06 [-0.31, 0.43]

Std. Mean Difference (IV, Random,
95% CI)

0.36 [0.02, 0.70]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.21 [-0.08, 0.49]

Std. Mean Difference (IV, Random,
95% CI)

0.10 [-0.35, 0.55]

Std. Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Fixed, 95%
CI)

0.21 [-0.07, 0.49]

Std. Mean Difference (IV, Fixed, 95%
CI)

0.11 [-0.16, 0.38]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.22 [-0.08, 0.52]

Std. Mean Difference (IV, Random,
95% CI)

0.0 [0.0, 0.0]

Std. Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Fixed, 95%
CI)

0.09 [-0.28, 0.47]

Std. Mean Difference (IV, Fixed, 95%
CI)

-0.35 [-0.80, 0.10]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.14 [-0.30, 0.58]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

593

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

18.2 Unclear/high risk of bias

19 Overall anxiety (follow-up
values)

19.1 Low risk of bias

19.2 Unclear/high risk of bias

20 Overall anxiety (change
values)

20.1 Low risk of bias

20.2 Unclear/high risk of bias

1

7

4

3

4

3

1

21 Overall self-esteem/body
image (follow-up values)

12

21.1 Low risk of bias

21.2 Unclear/high risk of bias

22 Overall self-esteem/body
image (change values)

22.1 Low risk of bias

22.2 Unclear/high risk of bias

7

5

9

7

2

23 Overall depression (fol-
low-up values)

12

23.1 Low risk of bias

23.2 Unclear/high risk of bias

24 Overall depression
(change values)

24.1 Low risk of bias

7

5

7

5

56

235

91

177

58

436

231

914

78

520

137

737

Std. Mean Difference (IV, Random,
95% CI)

0.14 [-0.38, 0.67]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.46 [-0.89, -0.03]

Std. Mean Difference (IV, Random,
95% CI)

-0.95 [-1.92, 0.02]

Std. Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Fixed, 95%
CI)

-0.36 [-0.66, -0.06]

Std. Mean Difference (IV, Fixed, 95%
CI)

-0.42 [-0.95, 0.10]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.14 [-0.12, 0.40]

Std. Mean Difference (IV, Random,
95% CI)

0.48 [0.16, 0.80]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.07 [-0.21, 0.34]

Std. Mean Difference (IV, Random,
95% CI)

1.72 [-1.48, 4.92]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.20 [-0.52, 0.12]

Std. Mean Difference (IV, Random,
95% CI)

-0.67 [-1.23, -0.11]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.20 [-0.47, 0.06]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

594

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

24.2 Unclear/high risk of bias

2

79

25 Overall fatigue (follow-up
values)

25.1 Low risk of bias

25

15

25.2 Unclear/high risk of bias

10

26 Overall fatigue (change
values)

13

26.1 Low risk of bias

26.2 Unclear/high risk of bias

27 Overall pain/disability (fol-
low-up values)

27.1 Low risk of bias

27.2 Unclear/high risk of bias

28 Overall pain/disability
(change values)

28.1 Low risk of bias

28.2 Unclear/high risk of bias

29 Overall cardiorespiratory
fitness (follow-up values)

29.1 Low risk of bias

8

5

9

4

5

6

2

4

23

10

29.2 Unclear/high risk of bias

13

30 Overall cardiorespiratory
fitness (change values)

30.1 Low risk of bias

9

4

1443

482

1091

198

169

352

136

196

657

608

632

Std. Mean Difference (IV, Random,
95% CI)

-0.75 [-1.39, -0.10]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.38 [-0.59, -0.18]

Std. Mean Difference (IV, Random,
95% CI)

-0.25 [-0.45, -0.05]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.22 [-0.61, 0.16]

Std. Mean Difference (IV, Random,
95% CI)

-0.45 [-0.95, 0.05]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.13 [-0.44, 0.18]

Std. Mean Difference (IV, Random,
95% CI)

0.25 [0.04, 0.46]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.03 [-0.45, 0.40]

Std. Mean Difference (IV, Random,
95% CI)

-0.05 [-0.36, 0.26]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.44 [0.24, 0.65]

Std. Mean Difference (IV, Random,
95% CI)

0.44 [0.23, 0.65]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.49 [-0.09, 1.06]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

595

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

30.2 Unclear/high risk of bias

5

231

31 Overall self-reported phys-
ical activity (follow-up val-
ues)

17

31.1 Low risk of bias

31.2 Unclear/high risk of bias

32 Overall self-reported phys-
ical activity (change values)

32.1 Low risk of bias

32.2 Unclear/high risk of bias

8

9

8

4

4

33 Overall objective physical
activity (follow-up values)

11

33.1 Low risk of bias

33.2 Unclear/high risk of bias

34 Overall objective physical
activity (change values)

34.1 Low risk of bias

34.2 Unclear/high risk of bias

7

4

5

3

2

35 Mass (follow-up values)

16

35.1 Low risk of bias

35.2 Unclear/high risk of bias

36 Mass (change values)

36.1 Low risk of bias

36.2 Unclear/high risk of bias

37 BMI (follow-up values)

37.1 Low risk of bias

8

8

11

5

6

17

10

Std. Mean Difference (IV, Random,
95% CI)

1.16 [0.60, 1.72]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.45 [0.21, 0.68]

Std. Mean Difference (IV, Random,
95% CI)

0.61 [0.31, 0.91]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.27 [-0.00, 0.55]

Std. Mean Difference (IV, Random,
95% CI)

0.99 [0.40, 1.58]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.41 [0.15, 0.66]

Std. Mean Difference (IV, Random,
95% CI)

0.50 [-0.24, 1.25]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.56 [-0.18, 1.30]

Std. Mean Difference (IV, Random,
95% CI)

0.99 [0.44, 1.54]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

0.05 [-0.54, 0.64]

Mean Difference (IV, Fixed, 95% CI)

-1.28 [-4.26, 1.70]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-0.43 [-1.05, 0.20]

Mean Difference (IV, Random, 95% CI)

-0.62 [-1.44, 0.19]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

1482

530

1047

227

1105

165

447

61

828

382

819

228

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

596

1162

Mean Difference (IV, Fixed, 95% CI)

0.05 [-0.16, 0.26]

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

37.2 Unclear/high risk of bias

38 BMI (change values)

38.1 Low risk of bias

38.2 Unclear/high risk of bias

39 Overall body fat (follow-up
values)

39.1 Low risk of bias

39.2 Unclear/high risk of bias

40 Overall body fat (change
values)

40.1 Low risk of bias

40.2 Unclear/high risk of bias

7

8

5

3

18

10

8

9

5

4

41 Lower body strength (fol-
low-up values)

10

41.1 Low risk of bias

41.2 Unclear/high risk of bias

42 Lower body strength
(change values)

42.1 Low risk of bias

42.2 Unclear/high risk of bias

5

5

8

3

5

43 Upper body strength (fol-
low-up values)

13

43.1 Low risk of bias

43.2 Unclear/high risk of bias

44 Upper body strength
(change values)

7

6

9

319

363

122

768

394

341

158

440

197

339

381

516

252

Mean Difference (IV, Fixed, 95% CI)

-1.07 [-2.29, 0.14]

Mean Difference (IV, Random, 95% CI)

Subtotals only

Mean Difference (IV, Random, 95% CI)

-0.24 [-0.56, 0.08]

Mean Difference (IV, Random, 95% CI)

-0.20 [-0.65, 0.25]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.19 [-0.41, 0.03]

Std. Mean Difference (IV, Random,
95% CI)

-0.17 [-0.40, 0.07]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.87 [-1.86, 0.12]

Std. Mean Difference (IV, Random,
95% CI)

-0.30 [-0.62, 0.01]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.61 [0.22, 1.00]

Std. Mean Difference (IV, Random,
95% CI)

0.23 [-0.32, 0.79]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.97 [0.70, 1.25]

Std. Mean Difference (IV, Random,
95% CI)

0.46 [0.04, 0.88]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.53 [0.04, 1.01]

Std. Mean Difference (IV, Random,
95% CI)

0.29 [-0.21, 0.78]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

597

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

44.1 Low risk of bias

44.2 Unclear/high risk of bias

45 Bone mineral density -
femoral neck (follow-up and
change values)

45.1 Low risk of bias

45.2 Unclear/high risk of bias

46 Bone mineral density -
lumbar spine (follow-up and
change values)

46.1 Low risk of bias

46.2 Unclear/high risk of bias

4

5

4

1

3

4

1

3

381

487

457

329

457

329

Std. Mean Difference (IV, Random,
95% CI)

1.13 [0.46, 1.80]

Std. Mean Difference (IV, Random,
95% CI)

0.43 [-0.05, 0.91]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.18 [-0.00, 0.37]

Std. Mean Difference (IV, Random,
95% CI)

0.18 [-0.39, 0.75]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.09 [-0.09, 0.27]

Std. Mean Difference (IV, Random,
95% CI)

0.27 [-0.16, 0.70]

Analysis 18.1.   Comparison 18 Sensitivity analysis: outcomes
by risk of bias, Outcome 1 Overall HRQoL (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.1.1 Low risk of bias

Herrero 2006

Loudon 2014

Portela 2008

Milne 2008

Rogers 2009

Courneya 2003

Ergun 2013

Murtezani 2014

Cadmus 2009

Pinto 2015

Schmitz 2005

Daley 2007

Rogers 2015

Vallance 2007

Short 2014

Subtotal ***

81.3 (10.7)

-7.4 (1.2)

107.2 (28.5)

86.4 (8.3)

92 (11.4)

91.3 (11)

71.6 (19.9)

86.5 (7.3)

91.2 (12.6)

117.8 (12.7)

-44.2 (8.7)

90.9 (13.5)

88.1 (12.4)

91.5 (11.8)

106.8 (16.7)

8

12

25

29

20

24

40

30

37

39

39

33

105

250

195

886

62.5 (16.1)

-7.4 (1.4)

91.6 (28.5)

64.1 (10.8)

87.4 (13.1)

89.3 (10.9)

67.9 (16.7)

79.1 (7.5)

86.2 (17.4)

114 (18)

-47.4 (9.4)

86.4 (15.1)

83.2 (15.5)

90.6 (13)

108.2 (18.2)

8

11

9

29

18

28

20

32

37

37

40

69

108

85

104

635

3.13%

4.55%

4.83%

5.54%

5.75%

6.51%

6.58%

6.66%

7.25%

7.32%

7.38%

7.62%

8.82%

9%

9.06%

100%

1.3[0.19,2.41]

0.02[-0.8,0.84]

0.53[-0.24,1.31]

2.28[1.61,2.96]

0.37[-0.27,1.01]

0.18[-0.37,0.73]

0.19[-0.35,0.73]

0.99[0.46,1.52]

0.33[-0.13,0.78]

0.24[-0.21,0.69]

0.35[-0.09,0.79]

0.3[-0.12,0.72]

0.35[0.08,0.62]

0.08[-0.16,0.33]

-0.08[-0.32,0.16]

0.43[0.19,0.66]

Heterogeneity: Tau2=0.15; Chi2=57.17, df=14(P<0.0001); I2=75.51%

Test for overall effect: Z=3.52(P=0)

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

598

 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.1.2 Unclear/high risk of bias

Cerulli 2014

Mustian 2004

Mehnert 2011

Do 2015

Taleghani 2012

Loh 2014

Littman 2012

Subtotal ***

85.2 (4.2)

121.7 (22.7)

74.7 (21.7)

87.3 (13.7)

217.5 (36.3)

112.4 (14.1)

90.3 (11)

10

11

30

32

40

63

30

216

65.9 (14.7)

124.3 (25.9)

65.4 (16.8)

82.4 (19.9)

210.1 (41.5)

109.3 (13.3)

87.7 (15)

10

10

27

30

40

32

110

259

Heterogeneity: Tau2=0.03; Chi2=8.81, df=6(P=0.18); I2=31.87%

Test for overall effect: Z=2.43(P=0.02)

4.76%

6.89%

14.62%

15.68%

18.51%

19.16%

20.38%

100%

1.72[0.66,2.78]

-0.1[-0.96,0.75]

0.47[-0.06,1]

0.28[-0.22,0.79]

0.19[-0.25,0.63]

0.22[-0.2,0.65]

0.18[-0.22,0.59]

0.3[0.06,0.55]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 18.2.   Comparison 18 Sensitivity analysis: outcomes
by risk of bias, Outcome 2 Overall HRQoL (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.2.1 Low risk of bias

Herrero 2006

Murtezani 2014

Rogers 2009

Cuesta-Vargas 2014

Courneya 2003

Ergun 2013

Cadmus 2009

Schmitz 2005

Daley 2007

Vallance 2007

Saarto 2012

Subtotal ***

17.7 (8.3)

9.2 (2.1)

4.5 (8.4)

0.3 (0.2)

5.7 (7.4)

5.4 (21.5)

0.6 (7.5)

2.3 (4.5)

10.2 (11.2)

2.3 (11.1)

4.2 (16.2)

8

30

20

22

24

40

37

39

33

250

263

766

-10.4 (17.7)

-0.6 (2)

2.9 (12)

0.3 (0.1)

0.6 (7.4)

-6.7 (25.9)

-2.4 (9.8)

0.6 (4)

3.2 (11.3)

-0.2 (6.4)

5.6 (15.4)

8

32

18

20

28

20

37

40

69

85

237

594

Heterogeneity: Tau2=0.42; Chi2=106.14, df=10(P<0.0001); I2=90.58%

Test for overall effect: Z=3.24(P=0)

18.2.2 Unclear/high risk of bias

Mustian 2004

Naumann 2012

Mehnert 2011

Subtotal ***

15 (5)

14.5 (10.6)

9.7 (21)

11

11

30

52

10

10

27

47

0 (5)

3.1 (11.4)

5.6 (16.5)

Heterogeneity: Tau2=1.24; Chi2=14.64, df=2(P=0); I2=86.34%

Test for overall effect: Z=1.8(P=0.07)

5.65%

6.93%

8.83%

9%

9.24%

9.33%

9.77%

9.84%

9.94%

10.64%

10.83%

100%

29.2%

33.49%

37.31%

100%

1.92[0.68,3.17]

4.65[3.67,5.63]

0.15[-0.49,0.79]

-0.07[-0.67,0.54]

0.68[0.12,1.24]

0.52[-0.03,1.06]

0.34[-0.12,0.8]

0.4[-0.05,0.84]

0.62[0.2,1.04]

0.24[-0,0.49]

-0.09[-0.26,0.09]

0.7[0.28,1.12]

2.88[1.59,4.17]

1[0.08,1.92]

0.22[-0.31,0.74]

1.26[-0.11,2.62]

Favours control

-10

-5

0

5

10

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

599

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 18.3.   Comparison 18 Sensitivity analysis: outcomes by risk of bias,
Outcome 3 Overall emotional function/mental health (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.3.1 Low risk of bias

Herrero 2006

Loudon 2014

Rogers 2009

Cuesta-Vargas 2014

Courneya 2003

Milne 2008

Cantarero-Villanueva 2013

Murtezani 2014

Daley 2007

Cadmus 2009

Pinto 2015

Schmitz 2005

Rogers 2015

Schmitz 2009

Vallance 2007

Subtotal ***

90.6 (9.3)

-1.6 (0.7)

20 (3.1)

42.9 (19.2)

21.5 (3.4)

19.6 (2.4)

-17175
(4279)

19.5 (3.3)

19.1 (4.2)

20.5 (3)

54.2 (9.3)

-45.6 (8.2)

20.6 (2.9)

53.2 (9.6)

20.3 (3.3)

8

12

20

22

24

29

32

30

33

37

39

39

105

112

250

792

Heterogeneity: Tau2=0.01; Chi2=17.62, df=14(P=0.22); I2=20.56%

Test for overall effect: Z=3.32(P=0)

18.3.2 Unclear/high risk of bias

Banasik 2011

Mustian 2004

Pinto 2003

Basen-Enquist 2006

Do 2015

Littman 2012

Mehnert 2011

Pinto 2005

Loh 2014

Fillion 2008

Duijits 2012

Subtotal ***

7

9

12

28

32

30

30

39

63

44

37

0.5 (0.4)

24.8 (2)

-10.8 (28.1)

78.2 (10.6)

87.4 (8.8)

20.3 (4)

77 (35.8)

-8 (20.7)

19.9 (2.8)

48.5 (7.9)

73.9 (34.7)

331

344

8

11

18

20

28

29

29

32

33

37

37

40

108

120

85

635

7

10

12

23

30

27

28

43

32

43

89

83.3 (14.8)

-1.6 (0.5)

21.1 (2.9)

32.3 (33.3)

20.7 (3)

16.7 (4.1)

-20390
(6113)

18.3 (3.5)

18.5 (3.3)

19.8 (4.2)

52.5 (9.6)

-48.2 (8.2)

19.7 (3.2)

53.8 (8.7)

19.9 (3.4)

0.4 (0.3)

24.8 (3.2)

-27.2 (19.5)

77.2 (12)

70.4 (21.5)

20.8 (3.1)

69.1 (40.5)

-16.5 (28.8)

20 (3.2)

47.5 (9.1)

77.5 (34.3)

1.55%

2.28%

3.55%

3.88%

4.71%

4.83%

5.23%

5.46%

5.82%

6.38%

6.52%

6.69%

13.59%

14.38%

15.14%

100%

3.37%

4.38%

5.05%

8.99%

9.4%

9.66%

9.75%

11.77%

12.08%

12.22%

13.34%

100%

0.56[-0.45,1.56]

0.05[-0.77,0.87]

-0.36[-1,0.28]

0.39[-0.22,1]

0.25[-0.3,0.79]

0.85[0.31,1.39]

0.61[0.09,1.12]

0.35[-0.15,0.85]

0.16[-0.32,0.64]

0.19[-0.27,0.65]

0.18[-0.27,0.63]

0.31[-0.13,0.76]

0.29[0.02,0.56]

-0.07[-0.32,0.19]

0.11[-0.14,0.35]

0.22[0.09,0.34]

0.25[-0.8,1.3]

-0.01[-0.91,0.89]

0.65[-0.17,1.48]

0.09[-0.46,0.64]

1.03[0.5,1.57]

-0.14[-0.66,0.38]

0.21[-0.31,0.72]

0.33[-0.1,0.77]

-0.04[-0.46,0.39]

0.12[-0.3,0.54]

-0.1[-0.49,0.28]

0.19[-0.02,0.4]

Heterogeneity: Tau2=0.05; Chi2=16.47, df=10(P=0.09); I2=39.29%

Test for overall effect: Z=1.78(P=0.08)

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 18.4.   Comparison 18 Sensitivity analysis: outcomes by risk of
bias, Outcome 4 Overall emotional function/mental health (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.4.1 Low risk of bias

Herrero 2006

Rogers 2009

Murtezani 2014

8

20

30

9.3 (19.6)

0.9 (2.5)

2.1 (0.8)

8

18

32

-2.1 (5.9)

-0.1 (2.7)

0.5 (0.9)

4.53%

7.51%

7.99%

0.74[-0.28,1.77]

0.38[-0.27,1.02]

1.8[1.21,2.4]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

600

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Courneya 2003

Cormie 2014

Cantarero-Villanueva 2013

Cadmus 2009

Schmitz 2005

Schmitz 2009

Vallance 2007

Saarto 2012

Subtotal ***

24

43

32

37

39

58

250

263

804

2.3 (3.1)

4.4 (9)

-1445
(4452)

0.3 (2.2)

2.5 (4.4)

3.3 (23.2)

0.5 (3.5)

1.2 (17.8)

0.8 (2.9)

2.7 (8.6)

353 (3323)

-0.5 (3.3)

0.3 (3.9)

3.1 (17.2)

0.1 (2.5)

1.9 (18.5)

28

19

29

37

40

62

85

237

595

Heterogeneity: Tau2=0.14; Chi2=46.12, df=10(P<0.0001); I2=78.32%

Test for overall effect: Z=2.26(P=0.02)

18.4.2 Unclear/high risk of bias

Mustian 2004

Naumann 2012

Mehnert 2011

Pinto 2005

Subtotal ***

2.4 (2.5)

1 (2.7)

2.3 (35.5)

-3.8 (27.7)

9

11

30

39

89

0.1 (1.7)

-0.1 (2.7)

3.6 (17.6)

-11.5 (25.8)

10

10

28

43

91

Heterogeneity: Tau2=0.03; Chi2=3.99, df=3(P=0.26); I2=24.84%

Test for overall effect: Z=1.55(P=0.12)

8.44%

8.58%

8.93%

9.51%

9.62%

10.65%

11.82%

12.43%

100%

12.01%

14.76%

32.78%

40.46%

100%

0.49[-0.06,1.05]

0.19[-0.35,0.73]

-0.45[-0.96,0.06]

0.28[-0.18,0.74]

0.52[0.08,0.97]

0.01[-0.35,0.37]

0.12[-0.13,0.36]

-0.04[-0.21,0.14]

0.31[0.04,0.58]

1.06[0.08,2.03]

0.39[-0.48,1.26]

-0.04[-0.56,0.47]

0.28[-0.15,0.72]

0.28[-0.08,0.65]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 18.5.   Comparison 18 Sensitivity analysis: outcomes by
risk of bias, Outcome 5 Overall physical function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.5.1 Low risk of bias

Herrero 2006

Milne 2008

Rogers 2009

Cuesta-Vargas 2014

Courneya 2003

Murtezani 2014

Daley 2007

Cadmus 2009

Schmitz 2005

Pinto 2015

Rogers 2015

Schmitz 2009

Vallance 2007

Subtotal ***

94.1 (7.5)

24 (2.6)

23.3 (4.5)

42.9 (4.1)

25.3 (2.5)

22.6 (4.4)

25.6 (2.2)

25.1 (2.7)

-44.2 (5.6)

87.1 (4.4)

24.1 (3.5)

50.6 (8.2)

25.1 (3)

8

29

20

22

24

30

33

37

39

39

105

112

250

748

92.5 (6.6)

15.6 (4.5)

25.4 (2.3)

32.4 (32.5)

25.3 (2.8)

19.4 (4.4)

23.6 (5.7)

24 (4.1)

-48.3 (7.7)

84.7 (15.9)

22.5 (5)

49.1 (9.3)

25 (3.3)

8

29

18

20

28

32

33

37

40

37

108

120

85

595

Heterogeneity: Tau2=0.15; Chi2=51.23, df=12(P<0.0001); I2=76.57%

Test for overall effect: Z=2.99(P=0)

18.5.2 Unclear/high risk of bias

Banasik 2011

Mustian 2004

7

9

-0.8 (0.9)

26.9 (4.1)

7

10

-0.4 (0.3)

26.5 (4.1)

4.1%

6.2%

6.34%

6.65%

7.27%

7.55%

7.79%

8.08%

8.15%

8.15%

9.8%

9.91%

10%

100%

0.21[-0.77,1.2]

2.26[1.59,2.92]

-0.57[-1.22,0.08]

0.46[-0.16,1.07]

0[-0.55,0.55]

0.72[0.2,1.23]

0.46[-0.03,0.95]

0.31[-0.15,0.77]

0.6[0.15,1.05]

0.21[-0.25,0.66]

0.37[0.1,0.64]

0.17[-0.09,0.43]

0.05[-0.2,0.3]

0.38[0.13,0.63]

1.77%

2.49%

-0.48[-1.54,0.59]

0.09[-0.81,0.99]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

601

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Pinto 2003

Basen-Enquist 2006

Mehnert 2011

Littman 2012

Winters-Stone 2011

Do 2015

Pinto 2005

Loh 2014

Fillion 2008

Duijits 2012

Subtotal ***

12

28

30

30

36

32

39

63

44

87

32.3 (4.3)

82.5 (12.7)

89 (9.1)

25.4 (1.7)

51.7 (6.2)

89.4 (8.4)

30.3 (7.9)

24.9 (2.5)

45.1 (10.4)

84 (16.9)

12

23

28

27

25

30

43

32

43

89

25.3 (8.2)

77.4 (11.5)

78.1 (21.2)

24.3 (4.4)

52.3 (5.9)

89 (8.7)

27.3 (6.8)

24.2 (2.2)

41.8 (9.8)

80.2 (17.1)

417

369

Heterogeneity: Tau2=0; Chi2=10.69, df=11(P=0.47); I2=0%

Test for overall effect: Z=3.88(P=0)

2.73%

6.51%

7.21%

7.38%

7.77%

8.16%

10.56%

11.07%

11.3%

23.04%

100%

1.03[0.17,1.89]

0.41[-0.15,0.97]

0.66[0.13,1.19]

0.33[-0.19,0.86]

-0.1[-0.61,0.41]

0.05[-0.45,0.54]

0.4[-0.04,0.83]

0.3[-0.12,0.73]

0.33[-0.1,0.75]

0.23[-0.07,0.52]

0.28[0.14,0.42]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 18.6.   Comparison 18 Sensitivity analysis: outcomes by
risk of bias, Outcome 6 Overall physical function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.6.1 Low risk of bias

Herrero 2006

Murtezani 2014

Rogers 2009

Courneya 2003

Cormie 2014

Cadmus 2009

Schmitz 2005

Schmitz 2009

Vallance 2007

Saarto 2012

Subtotal ***

8

30

20

24

43

37

39

58

247

263

769

6.7 (5)

4.4 (1.5)

2.3 (5.1)

1.9 (2)

3.5 (5.2)

0.1 (6)

1.2 (4.2)

6.6 (17.1)

1 (3.3)

1.9 (13.7)

8

32

18

28

19

37

40

62

85

237

566

-1.7 (6.9)

-1.3 (1.2)

2.6 (6)

-0.2 (2.2)

-0.5 (5.7)

-0.5 (7.4)

1.5 (6.8)

4.1 (17.3)

0.2 (2.1)

3.4 (13.4)

Heterogeneity: Tau2=0.42; Chi2=103.01, df=9(P<0.0001); I2=91.26%

Test for overall effect: Z=2.8(P=0.01)

18.6.2 Unclear/high risk of bias

Mustian 2004

Naumann 2012

Mehnert 2011

Subtotal ***

9

11

30

50

1.9 (2.6)

1.9 (3.3)

4 (10.8)

-0.2 (1.6)

0.8 (3.4)

-2.1 (16.7)

10

10

28

48

Heterogeneity: Tau2=0; Chi2=1.02, df=2(P=0.6); I2=0%

Test for overall effect: Z=2.4(P=0.02)

6.79%

7.89%

9.58%

9.93%

10.06%

10.62%

10.7%

11.11%

11.56%

11.77%

100%

17.76%

22%

60.24%

100%

1.32[0.21,2.43]

4.23[3.31,5.15]

-0.05[-0.69,0.58]

0.98[0.4,1.56]

0.74[0.19,1.3]

0.09[-0.37,0.54]

-0.05[-0.49,0.39]

0.14[-0.21,0.5]

0.26[0.02,0.51]

-0.11[-0.29,0.06]

0.63[0.19,1.07]

0.93[-0.03,1.89]

0.32[-0.55,1.18]

0.43[-0.09,0.95]

0.5[0.09,0.9]

Favours control

-10

-5

0

5

10

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

602

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 18.7.   Comparison 18 Sensitivity analysis: outcomes by
risk of bias, Outcome 7 Overall role function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.7.1 Low risk of bias

Herrero 2006

Loudon 2014

Milne 2008

Rogers 2009

Courneya 2003

Murtezani 2014

Daley 2007

Cadmus 2009

Schmitz 2005

Loh 2014

Rogers 2015

Vallance 2007

Subtotal ***

97.6 (5.9)

-1.3 (0.3)

22.2 (3)

21.4 (4.8)

23.4 (4)

24.2 (2.8)

22.9 (4.5)

23.1 (4.7)

-49.2 (6.5)

23.4 (4.3)

22.3 (4.5)

23.2 (4)

8

12

29

20

24

30

33

37

39

63

105

250

650

8

11

29

18

28

32

33

37

40

32

108

85

461

100 (0)

-1.3 (0.4)

12.5 (4.8)

23.8 (3.2)

23.1 (4)

23 (2.5)

20.3 (5.6)

20.6 (7.2)

-50 (6.2)

22.2 (5)

20.3 (5.5)

22.7 (4.6)

Heterogeneity: Tau2=0.19; Chi2=50.99, df=11(P<0.0001); I2=78.43%

Test for overall effect: Z=2.12(P=0.03)

18.7.2 Unclear/high risk of bias

Banasik 2011

Mustian 2004

Basen-Enquist 2006

Mehnert 2011

Littman 2012

Do 2015

Subtotal ***

3.5 (0.6)

2.4 (1.5)

86.1 (22.2)

90 (20.3)

22.6 (3.9)

78.1 (19.5)

7

9

28

30

30

32

136

7

9

23

27

27

30

123

3.2 (0.6)

2.8 (1.5)

73 (24.5)

79.6 (25)

21.7 (4.7)

79.2 (14.6)

Heterogeneity: Tau2=0; Chi2=4.26, df=5(P=0.51); I2=0%

Test for overall effect: Z=1.89(P=0.06)

4.9%

6.08%

7.1%

7.37%

8.28%

8.64%

8.76%

9.03%

9.19%

9.32%

10.58%

10.75%

100%

5.41%

7.03%

19.11%

21.8%

22.27%

24.39%

100%

-0.54[-1.55,0.46]

0[-0.82,0.82]

2.39[1.71,3.08]

-0.57[-1.22,0.08]

0.07[-0.47,0.62]

0.45[-0.06,0.95]

0.5[0.01,0.99]

0.41[-0.05,0.87]

0.12[-0.32,0.57]

0.25[-0.18,0.68]

0.4[0.12,0.67]

0.12[-0.13,0.37]

0.32[0.02,0.61]

0.34[-0.72,1.4]

-0.23[-1.15,0.7]

0.55[-0.01,1.12]

0.45[-0.07,0.98]

0.21[-0.31,0.73]

-0.06[-0.56,0.44]

0.24[-0.01,0.48]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 18.8.   Comparison 18 Sensitivity analysis: outcomes
by risk of bias, Outcome 8 Overall role function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.8.1 Low risk of bias

Herrero 2006

Rogers 2009

Courneya 2003

Cormie 2014

Murtezani 2014

Cadmus 2009

Schmitz 2005

Vallance 2007

Saarto 2012

Subtotal ***

8

20

24

43

30

37

39

250

263

714

2.1 (13.9)

0.4 (3.3)

0.9 (2.8)

4.9 (7.1)

1.7 (0.7)

-0.3 (3.7)

1.2 (4.2)

0.6 (4.1)

2.4 (21.5)

8

18

28

19

32

37

40

85

237

504

2.1 (5.9)

1.4 (4.3)

0.4 (2.7)

1.7 (7.1)

0.9 (0.6)

-0.5 (3.4)

1.5 (6.8)

-0 (2.7)

3.8 (21.6)

Heterogeneity: Tau2=0.07; Chi2=21.6, df=8(P=0.01); I2=62.96%

Test for overall effect: Z=1.43(P=0.15)

4.38%

8.01%

9.61%

9.62%

9.72%

11.49%

11.82%

16.8%

18.55%

100%

0[-0.98,0.98]

-0.26[-0.9,0.38]

0.18[-0.37,0.73]

0.45[-0.1,0.99]

1.16[0.62,1.7]

0.06[-0.4,0.51]

-0.05[-0.49,0.39]

0.17[-0.08,0.41]

-0.06[-0.24,0.11]

0.17[-0.06,0.4]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

603

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.8.2 Unclear/high risk of bias

Mustian 2004

Naumann 2012

Mehnert 2011

Subtotal ***

0.6 (1.6)

1.5 (4.4)

6.7 (23.8)

9

11

30

50

10

10

27

47

0.8 (1.6)

0.5 (4.5)

5.6 (27)

Heterogeneity: Tau2=0; Chi2=0.32, df=2(P=0.85); I2=0%

Test for overall effect: Z=0.21(P=0.83)

19.57%

21.55%

58.88%

100%

-0.15[-1.05,0.76]

0.22[-0.64,1.08]

0.04[-0.48,0.56]

0.04[-0.36,0.44]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 18.9.   Comparison 18 Sensitivity analysis: outcomes by risk of
bias, Outcome 9 Overall social well-being/function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.9.1 Low risk of bias

Herrero 2006

Rogers 2014

Rogers 2009

Courneya 2003

Milne 2008

Murtezani 2014

Daley 2007

Cadmus 2009

Schmitz 2009

Kiecolt-Glaser 2014

Rogers 2015

Vallance 2007

Subtotal ***

87.5 (19.4)

7.3 (4.9)

22.6 (4.1)

21.1 (3.5)

20.7 (4)

20.2 (2.8)

23.3 (4.8)

22.3 (4.9)

14.9 (5.2)

95.2 (10.8)

21 (5.7)

22.9 (5)

8

20

20

24

29

30

33

37

59

96

105

250

711

Heterogeneity: Tau2=0.02; Chi2=15.66, df=11(P=0.15); I2=29.75%

Test for overall effect: Z=2.87(P=0)

18.9.2 Unclear/high risk of bias

Banasik 2011

Mustian 2004

Basen-Enquist 2006

Littman 2012

Mehnert 2011

Loh 2014

Subtotal ***

2.8 (0.7)

8.6 (1.9)

84.6 (16.9)

22.1 (5)

85.4 (20.9)

21.5 (4.9)

7

9

28

30

30

63

167

Heterogeneity: Tau2=0; Chi2=3.37, df=5(P=0.64); I2=0%

Test for overall effect: Z=1.42(P=0.16)

91.7 (23.6)

3.1 (3.2)

21.8 (5.7)

20.7 (3.6)

19.4 (3.9)

18.3 (2.7)

20.4 (6.8)

20.6 (7.2)

14.1 (5.8)

93.8 (9.3)

20.7 (5.8)

23 (5.1)

3.2 (0.8)

9 (1.8)

84.9 (19.2)

20.9 (6)

79.9 (22.7)

19.6 (4.9)

8

22

18

28

29

32

33

37

62

90

108

85

552

7

10

23

27

28

32

127

2.07%

4.38%

4.48%

5.81%

6.31%

6.4%

6.89%

7.63%

10.8%

13.94%

14.98%

16.31%

100%

4.83%

6.72%

18.02%

20.15%

20.5%

29.78%

100%

-0.18[-1.17,0.8]

1.01[0.36,1.65]

0.16[-0.48,0.8]

0.11[-0.43,0.66]

0.32[-0.19,0.84]

0.68[0.17,1.2]

0.49[-0,0.98]

0.27[-0.18,0.73]

0.14[-0.21,0.5]

0.14[-0.15,0.43]

0.05[-0.22,0.32]

-0[-0.25,0.24]

0.21[0.07,0.36]

-0.45[-1.51,0.62]

-0.19[-1.09,0.71]

-0.02[-0.57,0.54]

0.22[-0.31,0.74]

0.25[-0.27,0.76]

0.38[-0.05,0.81]

0.17[-0.06,0.4]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

604

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 18.10.   Comparison 18 Sensitivity analysis: outcomes by risk
of bias, Outcome 10 Overall social well-being/function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.10.1 Low risk of bias

Rogers 2009

Rogers 2014

Murtezani 2014

Courneya 2003

Cormie 2014

Cadmus 2009

Schmitz 2009

Vallance 2007

Saarto 2012

Subtotal ***

0.9 (2.6)

2.1 (3.2)

2.1 (0.8)

0.6 (2.4)

3.5 (8.5)

0.6 (4.6)

4.4 (33.8)

0.2 (4.8)

5 (21.1)

20

20

30

24

43

37

59

250

263

746

Heterogeneity: Tau2=0.36; Chi2=85.7, df=8(P<0.0001); I2=90.67%

Test for overall effect: Z=2.56(P=0.01)

18.10.2 Unclear/high risk of bias

Mustian 2004

Naumann 2012

Mehnert 2011

Subtotal ***

1.5 (1.5)

0.9 (3.3)

7.3 (22.3)

9

11

30

50

Heterogeneity: Tau2=0; Chi2=1.12, df=2(P=0.57); I2=0%

Test for overall effect: Z=1.53(P=0.12)

-1.2 (2.7)

-0.8 (3.5)

0.5 (0.9)

-0.5 (3.3)

2.5 (8.3)

-1 (3.2)

0.7 (34)

-4.1 (3.3)

8.8 (20.8)

0.4 (1.2)

-0.2 (3.3)

3.1 (24.3)

18

22

32

28

19

37

62

85

237

540

10

10

28

48

9.88%

10.08%

10.35%

10.67%

10.74%

11.27%

11.9%

12.4%

12.7%

100%

18.16%

21.56%

60.28%

100%

0.78[0.11,1.44]

0.85[0.21,1.48]

1.8[1.21,2.4]

0.37[-0.18,0.92]

0.12[-0.42,0.66]

0.4[-0.06,0.86]

0.11[-0.25,0.47]

0.97[0.71,1.23]

-0.18[-0.36,-0.01]

0.56[0.13,0.98]

0.76[-0.18,1.7]

0.32[-0.54,1.18]

0.18[-0.34,0.69]

0.31[-0.09,0.71]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 18.11.   Comparison 18 Sensitivity analysis: outcomes by risk
of bias, Outcome 11 Overall cognitive function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.11.1 Low risk of bias

Herrero 2006

Rogers 2009

Cantarero-Villanueva 2013

Subtotal ***

91.7 (12.6)

-124.5
(30.8)

-37.9 (8.5)

8

19

32

59

Heterogeneity: Tau2=0; Chi2=0.48, df=2(P=0.79); I2=0%

Test for overall effect: Z=2.35(P=0.02)

18.11.2 Unclear/high risk of bias

Pinto 2003

Mehnert 2011

Subtotal ***

-4.3 (2.5)

81.1 (16.8)

12

30

42

Heterogeneity: Tau2=0.32; Chi2=2.77, df=1(P=0.1); I2=63.87%

Test for overall effect: Z=1.06(P=0.29)

89.6 (12.4)

-135.5
(19.5)

-43 (10)

-7.2 (2.1)

78.4 (24.4)

8

18

29

55

6

27

33

14.41%

32.65%

52.94%

100%

0.16[-0.82,1.14]

0.42[-0.24,1.07]

0.55[0.03,1.06]

0.45[0.07,0.82]

38.89%

61.11%

100%

1.14[0.07,2.2]

0.13[-0.39,0.65]

0.52[-0.44,1.48]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

605

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 18.12.   Comparison 18 Sensitivity analysis: outcomes by
risk of bias, Outcome 12 Overall cognitive function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.12.1 Low risk of bias

Herrero 2006

Rogers 2009

Cantarero-Villanueva 2013

Saarto 2012

Subtotal ***

6.2 (19.8)

4.2 (16.8)

2.2 (7.6)

-1 (18.2)

8

20

32

263

323

Heterogeneity: Tau2=0.06; Chi2=6.03, df=3(P=0.11); I2=50.28%

Test for overall effect: Z=0.4(P=0.69)

18.12.2 Unclear/high risk of bias

Mehnert 2011

Subtotal ***

1.7 (22.4)

30

30

Heterogeneity: Not applicable

Test for overall effect: Z=0.71(P=0.48)

8.3 (14.8)

-4.7 (25.9)

-0.2 (5.5)

2.2 (18.5)

6.2 (24.6)

8

18

29

237

292

27

27

10.27%

18.89%

24.94%

45.9%

100%

-0.11[-1.09,0.87]

0.4[-0.24,1.05]

0.35[-0.16,0.86]

-0.17[-0.35,0]

0.07[-0.28,0.42]

100%

100%

-0.19[-0.71,0.33]

-0.19[-0.71,0.33]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 18.13.   Comparison 18 Sensitivity analysis: outcomes by
risk of bias, Outcome 13 Overall general health (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.13.1 Low risk of bias

Herrero 2006

Rogers 2009

Ergun 2013

Cadmus 2009

Schmitz 2005

Subtotal ***

81.3 (10.7)

3.5 (0.9)

71.6 (19.9)

50 (8.8)

53.8 (5.3)

8

20

40

37

39

144

Heterogeneity: Tau2=0.09; Chi2=8.13, df=4(P=0.09); I2=50.8%

Test for overall effect: Z=0.32(P=0.75)

18.13.2 Unclear/high risk of bias

Mustian 2004

Basen-Enquist 2006

Mehnert 2011

Do 2015

Subtotal ***

18.6 (4.8)

77.4 (11.6)

74.4 (11.8)

87.3 (13.7)

9

28

30

32

99

Heterogeneity: Tau2=0.03; Chi2=3.94, df=3(P=0.27); I2=23.83%

Test for overall effect: Z=2.07(P=0.04)

62.5 (16.1)

3.8 (0.5)

67.9 (16.7)

51.7 (8.4)

53.2 (6)

19.3 (1.9)

67.1 (13.4)

70 (20.8)

82.4 (19.9)

8

18

20

37

40

123

9

23

28

30

90

8.71%

18.25%

21.93%

25.22%

25.89%

100%

11.85%

26%

30.37%

31.79%

100%

1.3[0.19,2.41]

-0.4[-1.04,0.25]

0.19[-0.35,0.73]

-0.2[-0.65,0.26]

0.1[-0.34,0.55]

0.06[-0.31,0.43]

-0.18[-1.11,0.74]

0.81[0.24,1.39]

0.26[-0.26,0.77]

0.28[-0.22,0.79]

0.36[0.02,0.7]

Favours control

-100

-50

0

50

100

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

606

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 18.14.   Comparison 18 Sensitivity analysis: outcomes by
risk of bias, Outcome 14 Overall general health (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.14.1 Low risk of bias

Herrero 2006

Rogers 2009

Ergun 2013

Cormie 2014

Cadmus 2009

Schmitz 2005

Saarto 2012

Subtotal ***

17.7 (8.3)

0.2 (0.6)

5.4 (21.5)

3.7 (7)

0.2 (4.4)

0.7 (4.8)

4.2 (16.2)

8

20

40

43

37

39

263

450

Heterogeneity: Tau2=0.08; Chi2=15.22, df=6(P=0.02); I2=60.58%

Test for overall effect: Z=1.41(P=0.16)

18.14.2 Unclear/high risk of bias

Mustian 2004

Mehnert 2011

Subtotal ***

0.2 (1.9)

6.6 (13.7)

9

30

39

Heterogeneity: Tau2=0; Chi2=0.55, df=1(P=0.46); I2=0%

Test for overall effect: Z=0.44(P=0.66)

-10.4 (17.7)

0.2 (0.7)

-6.7 (25.9)

2.8 (7.1)

-0.1 (5.1)

-0.6 (3.9)

5.6 (15.4)

0.7 (2.5)

3.2 (19.7)

8

18

20

19

37

40

237

379

10

28

38

4.4%

11.51%

13.59%

13.71%

15.98%

16.33%

24.49%

100%

24.63%

75.37%

100%

1.92[0.68,3.17]

-0.03[-0.67,0.61]

0.52[-0.03,1.06]

0.13[-0.41,0.67]

0.06[-0.39,0.52]

0.29[-0.15,0.74]

-0.09[-0.26,0.09]

0.21[-0.08,0.49]

-0.2[-1.1,0.71]

0.2[-0.32,0.71]

0.1[-0.35,0.55]

Favours control

-100

-50

0

50

100

Favours physical activity

Analysis 18.15.   Comparison 18 Sensitivity analysis: outcomes by
risk of bias, Outcome 15 Overall sexual function (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

18.15.1 Low risk of bias

Schmitz 2005

Schmitz 2009

Subtotal ***

-51 (7.5)

-27.3 (5.3)

39

57

96

Heterogeneity: Tau2=0; Chi2=0.38, df=1(P=0.54); I2=0%

Test for overall effect: Z=1.46(P=0.14)

18.15.2 Unclear/high risk of bias

Pinto 2005

Pinto 2003

Duijits 2012

Subtotal ***

42.8 (9.2)

42.5 (9.2)

0.6 (0.8)

12

39

53

104

Heterogeneity: Tau2=0; Chi2=1.16, df=2(P=0.56); I2=0%

Test for overall effect: Z=0.81(P=0.42)

-53.5 (8)

-28.1 (6.2)

43.7 (6.1)

40.1 (6.3)

0.6 (0.8)

40

57

97

6

43

65

114

40.67%

59.33%

100%

0.32[-0.12,0.76]

0.14[-0.23,0.51]

0.21[-0.07,0.49]

7.48%

37.86%

54.66%

100%

-0.11[-1.09,0.87]

0.29[-0.14,0.73]

0.01[-0.35,0.38]

0.11[-0.16,0.38]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

607

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 18.16.   Comparison 18 Sensitivity analysis: outcomes by
risk of bias, Outcome 16 Overall sexual function (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.16.1 Low risk of bias

Schmitz 2005

Schmitz 2009

Saarto 2012

Subtotal ***

39

57

263

359

1.7 (4.8)

7.2 (14.6)

4.3 (25.4)

40

57

237

334

0.2 (5.2)

-0.2 (16.7)

3.8 (24.4)

Heterogeneity: Tau2=0.04; Chi2=5.22, df=2(P=0.07); I2=61.69%

Test for overall effect: Z=1.45(P=0.15)

18.16.2 Unclear/high risk of bias

Subtotal ***

0

0

Heterogeneity: Not applicable

Test for overall effect: Not applicable

24.77%

29.51%

45.72%

100%

0.3[-0.15,0.74]

0.47[0.1,0.84]

0.02[-0.16,0.2]

0.22[-0.08,0.52]

Not estimable

Favours control

-100

-50

0

50

100

Favours physical activity

Analysis 18.17.   Comparison 18 Sensitivity analysis: outcomes
by risk of bias, Outcome 17 Overall sleep (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

18.17.1 Low risk of bias

Bower 2011

Rogers 2009

Rogers 2014

Subtotal ***

8.1 (2.5)

6.7 (4.2)

6.7 (3.7)

16

20

20

56

Heterogeneity: Tau2=0; Chi2=0.79, df=2(P=0.67); I2=0%

Test for overall effect: Z=0.49(P=0.62)

18.17.2 Unclear/high risk of bias

Rogers 2013

Mehnert 2011

Subtotal ***

6.3 (2.7)

23.8 (27)

11

30

41

Heterogeneity: Tau2=0; Chi2=0.99, df=1(P=0.32); I2=0%

Test for overall effect: Z=1.52(P=0.13)

7.7 (2.6)

5.5 (4)

7.1 (3.2)

6.2 (3.2)

38.3 (31.6)

15

18

22

55

9

27

36

28.01%

34.03%

37.96%

100%

26.44%

73.56%

100%

0.15[-0.55,0.86]

0.28[-0.36,0.92]

-0.11[-0.72,0.49]

0.09[-0.28,0.47]

0.03[-0.85,0.91]

-0.49[-1.02,0.04]

-0.35[-0.8,0.1]

Favours Physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 18.18.   Comparison 18 Sensitivity analysis: outcomes
by risk of bias, Outcome 18 Overall sleep (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.18.1 Low risk of bias

Rogers 2009

Rogers 2014

Subtotal ***

0.5 (2.1)

-1.3 (3.2)

20

20

40

0.3 (4.7)

-2.2 (4.4)

18

22

40

47.66%

52.34%

100%

0.05[-0.59,0.68]

0.23[-0.38,0.84]

0.14[-0.3,0.58]

Favours Physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

608

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Heterogeneity: Tau2=0; Chi2=0.16, df=1(P=0.69); I2=0%

Test for overall effect: Z=0.63(P=0.53)

18.18.2 Unclear/high risk of bias

Mehnert 2011

Subtotal ***

-5.4 (29.9)

29

29

27

27

-9.9 (33.3)

Heterogeneity: Not applicable

Test for overall effect: Z=0.53(P=0.6)

100%

100%

0.14[-0.38,0.67]

0.14[-0.38,0.67]

Favours Physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 18.19.   Comparison 18 Sensitivity analysis: outcomes
by risk of bias, Outcome 19 Overall anxiety (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.19.1 Low risk of bias

Rogers 2014

Milne 2008

Cantarero-Villanueva 2013

Cadmus 2009

Subtotal ***

45.6 (8.9)

15.3 (6.2)

42.5 (8.6)

32.1 (12.3)

20

29

32

37

118

Heterogeneity: Tau2=0.12; Chi2=7.96, df=3(P=0.05); I2=62.29%

Test for overall effect: Z=2.08(P=0.04)

18.19.2 Unclear/high risk of bias

Segar 1998

Pinto 2003

Mehnert 2011

Subtotal ***

28.5 (3)

7.6 (7.3)

4.8 (3.5)

10

12

30

52

Heterogeneity: Tau2=0.48; Chi2=6.16, df=2(P=0.05); I2=67.55%

Test for overall effect: Z=1.93(P=0.05)

45.7 (8)

21 (5.7)

49.9 (11.7)

34.1 (15.4)

39.5 (6)

10.5 (3.7)

7.1 (5)

22

29

29

37

117

5

6

28

39

22.41%

24.48%

25.38%

27.73%

100%

22.92%

32.99%

44.09%

100%

-0.01[-0.62,0.59]

-0.94[-1.49,-0.4]

-0.72[-1.24,-0.2]

-0.14[-0.6,0.31]

-0.46[-0.89,-0.03]

-2.49[-3.98,-1]

-0.43[-1.43,0.56]

-0.54[-1.06,-0.01]

-0.95[-1.92,0.02]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 18.20.   Comparison 18 Sensitivity analysis: outcomes
by risk of bias, Outcome 20 Overall anxiety (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Fixed, 95% CI

18.20.1 Low risk of bias

Cadmus 2009

Cantarero-Villanueva 2013

Rogers 2014

Subtotal ***

-0.7 (9.2)

-4.2 (9.8)

-4 (6.5)

37

32

20

89

37

29

22

88

0.5 (5.8)

0.8 (5.5)

-1.8 (5)

Heterogeneity: Tau2=0; Chi2=1.67, df=2(P=0.43); I2=0%

Test for overall effect: Z=2.36(P=0.02)

18.20.2 Unclear/high risk of bias

42.67%

33.55%

23.78%

100%

-0.15[-0.61,0.3]

-0.61[-1.12,-0.09]

-0.37[-0.99,0.24]

-0.36[-0.66,-0.06]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

609

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Fixed, 95% CI

Mehnert 2011

Subtotal ***

-1.7 (3.7)

30

30

28

28

0.2 (4.9)

Heterogeneity: Not applicable

Test for overall effect: Z=1.59(P=0.11)

100%

100%

Fixed, 95% CI

-0.42[-0.95,0.1]

-0.42[-0.95,0.1]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 18.21.   Comparison 18 Sensitivity analysis: outcomes by risk
of bias, Outcome 21 Overall self-esteem/body image (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.21.1 Low risk of bias

Loudon 2014

Musanti 2012

Courneya 2003

Milne 2008

Daley 2007

Cadmus 2009

Schmitz 2009

Subtotal ***

-1.4 (0.3)

23.8 (3.5)

34.8 (4.7)

-17.9 (6.8)

2 (0.8)

34.2 (5.5)

-70.4 (16.3)

12

30

24

29

33

37

59

224

Heterogeneity: Tau2=0.05; Chi2=10.46, df=6(P=0.11); I2=42.66%

Test for overall effect: Z=1.04(P=0.3)

18.21.2 Unclear/high risk of bias

Segar 1998

Pinto 2003

Mehnert 2011

Do 2015

Pinto 2005

Subtotal ***

33 (1.8)

32.3 (4.3)

-5.5 (1.7)

37.9 (18.9)

30.3 (7.8)

10

12

27

32

39

120

Heterogeneity: Tau2=0.03; Chi2=5.17, df=4(P=0.27); I2=22.63%

Test for overall effect: Z=2.96(P=0)

-1.6 (0.9)

26.3 (3.9)

34.6 (4.4)

-20.1 (6.3)

1.6 (0.5)

33.4 (5.9)

-71.5 (18)

30.5 (2.7)

25.3 (8.2)

-6.8 (2.6)

36.1 (18.3)

27.2 (6.8)

11

12

28

29

32

37

63

212

5

6

27

30

43

111

7.87%

10.25%

13.85%

14.69%

15.3%

16.88%

21.16%

100%

6.81%

8.04%

24.41%

27.81%

32.93%

100%

0.2[-0.62,1.02]

-0.68[-1.37,0.01]

0.04[-0.5,0.59]

0.33[-0.19,0.85]

0.66[0.16,1.16]

0.14[-0.32,0.6]

0.06[-0.29,0.42]

0.14[-0.12,0.4]

1.11[-0.06,2.28]

1.15[0.08,2.22]

0.61[0.06,1.16]

0.1[-0.4,0.59]

0.41[-0.03,0.85]

0.48[0.16,0.8]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 18.22.   Comparison 18 Sensitivity analysis: outcomes by risk
of bias, Outcome 22 Overall self-esteem/body image (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.22.1 Low risk of bias

Musanti 2012

Courneya 2003

Milne 2008

Daley 2007

Cadmus 2009

Schmitz 2009

Saarto 2012

30

24

29

33

37

59

-0.4 (4.5)

2.6 (3.7)

1.5 (3.7)

1.8 (0.7)

0.4 (4.4)

-12 (15.5)

12

28

29

33

37

63

0.6 (3.9)

-0.1 (3.5)

0.1 (3.9)

1.6 (0.7)

0.2 (2.9)

-4.1 (16.2)

263

10.7 (21.5)

237

12 (22)

9.77%

11.77%

12.75%

13.51%

14.23%

16.66%

21.31%

-0.22[-0.89,0.45]

0.74[0.18,1.3]

0.36[-0.16,0.88]

0.33[-0.16,0.82]

0.05[-0.4,0.51]

-0.49[-0.86,-0.13]

-0.06[-0.24,0.12]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

610

Favours control

-5

-2.5

0

2.5

5

Favours intervention

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Subtotal ***

Mean(SD)

N

475

N

439

Heterogeneity: Tau2=0.08; Chi2=18.32, df=6(P=0.01); I2=67.25%

Test for overall effect: Z=0.49(P=0.62)

Mean(SD)

Random, 95% CI

Random, 95% CI

100%

0.07[-0.21,0.34]

18.22.2 Unclear/high risk of bias

Mustian 2004

Mehnert 2011

Subtotal ***

11

30

41

3 (1)

0.7 (2.1)

10

27

37

-1.5 (1.5)

0.4 (2.1)

Heterogeneity: Tau2=5.03; Chi2=17.62, df=1(P<0.0001); I2=94.33%

Test for overall effect: Z=1.05(P=0.29)

47.83%

52.17%

100%

3.42[1.99,4.86]

0.16[-0.36,0.68]

1.72[-1.48,4.92]

Favours control

-5

-2.5

0

2.5

5

Favours intervention

Analysis 18.23.   Comparison 18 Sensitivity analysis: outcomes by
risk of bias, Outcome 23 Overall depression (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.23.1 Low risk of bias

Bower 2011

Rogers 2014

Ergun 2013

Cantarero-Villanueva 2013

Daley 2007

Cadmus 2009

Kiecolt-Glaser 2014

Subtotal ***

7.7 (5.8)

44.2 (8.6)

6.9 (6.8)

45.6 (9.7)

6 (6.5)

9.6 (9.3)

8.1 (8.6)

16

20

40

32

33

37

96

274

Heterogeneity: Tau2=0.12; Chi2=17.59, df=6(P=0.01); I2=65.89%

Test for overall effect: Z=1.21(P=0.23)

18.23.2 Unclear/high risk of bias

Segar 1998

Pinto 2003

Payne 2008

Kaltsatou 2011

Mehnert 2011

Subtotal ***

5.5 (2)

6.2 (7.2)

12.7 (8.7)

16.5 (1.7)

2.7 (3)

10

12

10

13

30

75

Heterogeneity: Tau2=0.21; Chi2=8.45, df=4(P=0.08); I2=52.69%

Test for overall effect: Z=2.33(P=0.02)

11.6 (7.1)

25.1 (44.2)

5.2 (5.2)

53.7 (11.6)

10.3 (7.2)

10.8 (10.1)

9.2 (8.2)

10 (2)

9.8 (6.8)

11.4 (7.9)

22.3 (7.7)

4.6 (4.4)

15

22

20

29

33

37

90

246

5

6

10

13

28

62

10.51%

12.24%

13.77%

14.14%

14.68%

15.51%

19.16%

100%

11.53%

17.59%

20.09%

21.35%

29.43%

100%

-0.59[-1.31,0.13]

0.58[-0.04,1.19]

0.27[-0.27,0.81]

-0.75[-1.28,-0.23]

-0.63[-1.12,-0.13]

-0.12[-0.58,0.33]

-0.13[-0.42,0.16]

-0.2[-0.52,0.12]

-2.12[-3.51,-0.73]

-0.49[-1.49,0.5]

0.15[-0.73,1.03]

-1[-1.83,-0.18]

-0.51[-1.04,0.01]

-0.67[-1.23,-0.11]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 18.24.   Comparison 18 Sensitivity analysis: outcomes
by risk of bias, Outcome 24 Overall depression (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.24.1 Low risk of bias

Rogers 2014

20

-1.7 (6.9)

22

1.1 (4.2)

13.12%

-0.49[-1.1,0.13]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

611

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Ergun 2013

Cantarero-Villanueva 2013

Cadmus 2009

Saarto 2012

Subtotal ***

1.2 (6.2)

-2.9 (7.8)

0.3 (6.4)

-0.3 (3.3)

40

32

37

263

392

Heterogeneity: Tau2=0.04; Chi2=8.05, df=4(P=0.09); I2=50.33%

Test for overall effect: Z=1.49(P=0.14)

18.24.2 Unclear/high risk of bias

Naumann 2012

Mehnert 2011

Subtotal ***

-3.6 (4.3)

2.7 (3)

11

30

41

Heterogeneity: Tau2=0.09; Chi2=1.6, df=1(P=0.21); I2=37.42%

Test for overall effect: Z=2.26(P=0.02)

2.4 (8)

1.5 (7.4)

1.7 (6.3)

-0.5 (3.4)

2 (4.6)

4.6 (4.4)

20

29

37

237

345

10

28

38

15.67%

16.59%

18.97%

35.64%

100%

-0.16[-0.7,0.37]

-0.57[-1.09,-0.06]

-0.22[-0.68,0.24]

0.06[-0.12,0.24]

-0.2[-0.47,0.06]

33.36%

66.64%

100%

-1.21[-2.16,-0.26]

-0.51[-1.04,0.01]

-0.75[-1.39,-0.1]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 18.25.   Comparison 18 Sensitivity analysis: outcomes
by risk of bias, Outcome 25 Overall fatigue (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.25.1 Low risk of bias

Loudon 2014

Bower 2011

Rogers 2009

Cuesta-Vargas 2014

Rogers 2014

Milne 2008

Cantarero-Villanueva 2013

Courneya 2003

Ergun 2013

Daley 2007

Cadmus 2009

Pinto 2015

Kiecolt-Glaser 2014

Vallance 2007

Short 2014

Subtotal ***

1.9 (2.2)

3.4 (1.8)

-12.4 (10.4)

4 (1.8)

4.1 (2.1)

11.9 (3.2)

3.8 (1.8)

-8.3 (7.9)

2.9 (2.2)

2.1 (1.8)

-51.9 (9)

-43.8 (7.8)

6.3 (19.6)

-42.7 (8.4)

-41.5 (9.3)

12

16

20

22

20

29

32

24

40

33

37

39

96

250

195

865

2.1 (2.5)

4.9 (1.3)

-10.1 (6.6)

5.2 (3.2)

4 (1.8)

17.4 (4.7)

6.2 (1.7)

-8.8 (8.1)

3.3 (1.8)

3.4 (1.9)

-50.6 (10)

-41.2 (8.5)

12.7 (19)

-42.6 (8.7)

-39.8 (10.4)

11

15

18

20

22

29

29

28

20

33

37

37

90

85

104

578

Heterogeneity: Tau2=0.1; Chi2=42.98, df=14(P<0.0001); I2=67.43%

Test for overall effect: Z=3.61(P=0)

18.25.2 Unclear/high risk of bias

Banasik 2011

Pinto 2003

Payne 2008

Rogers 2013

Mehnert 2011

Littman 2012

Do 2015

7

12

9

11

30

30

32

1 (0.9)

7.2 (6.4)

4.7 (2.6)

4.2 (1.8)

28.5 (25.6)

-45 (5.3)

16.8 (13.3)

7

6

9

9

27

27

30

1.6 (1)

9 (6.4)

3.5 (1.7)

4.2 (1.6)

39.9 (25.1)

-43.1 (10.3)

22.3 (15.1)

4.1%

4.58%

5.43%

5.65%

5.73%

6.02%

6.13%

6.3%

6.38%

6.78%

7.24%

7.28%

9.12%

9.59%

9.67%

100%

3.33%

3.94%

4.27%

4.86%

12%

12.18%

12.93%

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

-0.07[-0.89,0.75]

-0.93[-1.67,-0.18]

-0.26[-0.9,0.38]

-0.46[-1.07,0.15]

0.05[-0.56,0.66]

-1.35[-1.92,-0.78]

-1.38[-1.94,-0.82]

0.06[-0.48,0.61]

-0.17[-0.71,0.37]

-0.71[-1.21,-0.21]

-0.14[-0.59,0.32]

-0.32[-0.77,0.14]

-0.33[-0.62,-0.04]

-0.01[-0.26,0.23]

-0.17[-0.41,0.06]

-0.38[-0.59,-0.18]

-0.57[-1.65,0.51]

-0.27[-1.26,0.71]

0.52[-0.42,1.46]

0[-0.88,0.88]

-0.44[-0.97,0.08]

-0.23[-0.75,0.29]

-0.38[-0.89,0.12]

612

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Winters-Stone 2011

Pinto 2005

Fillion 2008

Subtotal ***

45 (5.3)

27.1 (21.4)

2.7 (0.7)

36

39

44

250

43.1 (10.3)

42.3 (26.2)

2.9 (0.8)

31

43

43

232

Heterogeneity: Tau2=0.02; Chi2=10.64, df=9(P=0.3); I2=15.4%

Test for overall effect: Z=2.43(P=0.02)

13.84%

15.7%

16.95%

100%

0.23[-0.25,0.72]

-0.63[-1.07,-0.18]

-0.27[-0.69,0.15]

-0.25[-0.45,-0.05]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 18.26.   Comparison 18 Sensitivity analysis: outcomes
by risk of bias, Outcome 26 Overall fatigue (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.26.1 Low risk of bias

Herrero 2006

Loudon 2014

Rogers 2009

Courneya 2003

Cantarero-Villanueva 2013

Daley 2007

Vallance 2007

Saarto 2012

Subtotal ***

-4.2 (19.6)

1.9 (2.2)

1.9 (9.6)

9.3 (10.2)

-2 (1.8)

2.1 (1.8)

2.5 (8.2)

-2.4 (9.1)

8

12

20

24

32

33

250

263

642

8

11

18

28

29

33

85

237

449

6.4 (14.5)

2.1 (2.5)

4.2 (12.3)

2 (7.5)

0.3 (1.4)

3.4 (1.9)

1.2 (6.6)

-2.4 (8.6)

Heterogeneity: Tau2=0.22; Chi2=43.73, df=7(P<0.0001); I2=83.99%

Test for overall effect: Z=1.14(P=0.25)

18.26.2 Unclear/high risk of bias

Payne 2008

Naumann 2012

Rogers 2013

Mehnert 2011

Pinto 2005

Subtotal ***

-0.9 (2)

-3.6 (4.4)

4.2 (2)

-0.7 (20.7)

-14.9 (23.5)

9

11

11

30

39

100

9

10

9

27

43

98

0.5 (1.4)

2 (4.6)

3.9 (1.5)

-2.9 (25.3)

1.8 (23.5)

Heterogeneity: Tau2=0.19; Chi2=10.24, df=4(P=0.04); I2=60.92%

Test for overall effect: Z=1.77(P=0.08)

7.88%

9.65%

11.64%

12.47%

12.47%

13.31%

16.03%

16.56%

100%

15.09%

15.53%

16.76%

25.34%

27.28%

100%

-0.58[-1.59,0.43]

-0.07[-0.89,0.75]

-0.21[-0.84,0.43]

0.81[0.24,1.38]

-1.45[-2.02,-0.88]

-0.71[-1.21,-0.21]

0.17[-0.08,0.42]

0[-0.18,0.18]

-0.22[-0.61,0.16]

-0.82[-1.79,0.15]

-1.21[-2.16,-0.26]

0.16[-0.72,1.04]

0.09[-0.43,0.61]

-0.7[-1.15,-0.26]

-0.45[-0.95,0.05]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 18.27.   Comparison 18 Sensitivity analysis: outcomes by
risk of bias, Outcome 27 Overall pain/disability (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.27.1 Low risk of bias

Loudon 2014

Portela 2008

Rogers 2009

Cadmus 2009

12

25

20

37

0.8 (1.5)

-20.6 (20.2)

-3 (3)

50.3 (9.1)

11

9

18

37

1.4 (2.2)

-20.8 (15.5)

-2.3 (2.8)

50.8 (9)

14.07%

16.48%

23.39%

46.06%

-0.33[-1.15,0.5]

0.01[-0.75,0.77]

-0.26[-0.89,0.38]

-0.05[-0.51,0.4]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

613

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Subtotal ***

Mean(SD)

N

94

Heterogeneity: Tau2=0; Chi2=0.6, df=3(P=0.9); I2=0%

Test for overall effect: Z=0.82(P=0.41)

18.27.2 Unclear/high risk of bias

Mustian 2004

Basen-Enquist 2006

Mehnert 2011

Do 2015

Duijits 2012

Subtotal ***

9.1 (1.4)

79.7 (10.6)

79.4 (23.1)

21.1 (24.6)

79.1 (23.4)

9

28

30

32

79

178

Heterogeneity: Tau2=0; Chi2=2.71, df=4(P=0.61); I2=0%

Test for overall effect: Z=2.35(P=0.02)

N

75

10

23

28

30

83

174

Mean(SD)

Random, 95% CI

Random, 95% CI

100%

-0.13[-0.44,0.18]

9.1 (1.7)

72.1 (11.5)

73.5 (24.8)

16.5 (26.7)

74.6 (23.7)

5.46%

13.71%

16.57%

17.78%

46.47%

100%

0.01[-0.89,0.91]

0.68[0.11,1.25]

0.24[-0.27,0.76]

0.18[-0.32,0.68]

0.19[-0.12,0.5]

0.25[0.04,0.46]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 18.28.   Comparison 18 Sensitivity analysis: outcomes by
risk of bias, Outcome 28 Overall pain/disability (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.28.1 Low risk of bias

Cormie 2014

Cadmus 2009

Subtotal ***

3.4 (6.5)

-2.2 (11.3)

43

37

80

Heterogeneity: Tau2=0.03; Chi2=1.46, df=1(P=0.23); I2=31.47%

Test for overall effect: Z=0.13(P=0.9)

18.28.2 Unclear/high risk of bias

Mustian 2004

Rogers 2009

Mehnert 2011

Irwin 2015

Subtotal ***

-0.2 (1.3)

-0.8 (1.4)

-2.4 (25)

-6 (19)

9

19

30

45

103

Heterogeneity: Tau2=0.02; Chi2=3.51, df=3(P=0.32); I2=14.64%

Test for overall effect: Z=0.31(P=0.75)

2 (6.2)

-0.1 (7)

0 (1.4)

-1.8 (6.2)

-7.6 (25.2)

0.7 (18.6)

19

37

56

10

17

28

38

93

44.26%

55.74%

100%

11.15%

19.85%

29.86%

39.14%

100%

0.22[-0.33,0.76]

-0.22[-0.68,0.24]

-0.03[-0.45,0.4]

-0.15[-1.06,0.75]

0.22[-0.43,0.88]

0.21[-0.31,0.72]

-0.35[-0.79,0.08]

-0.05[-0.36,0.26]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 18.29.   Comparison 18 Sensitivity analysis: outcomes by risk of
bias, Outcome 29 Overall cardiorespiratory fitness (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.29.1 Low risk of bias

Herrero 2006

Portela 2008

Musanti 2012

8

25

30

25.9 (4.5)

3007
(410.8)

8

9

24.6 (4.9)

12

25.7 (3.7)

2416.1
(718.6)

23 (4.3)

3.82%

5.28%

7.25%

0.05[-0.93,1.03]

1.14[0.33,1.96]

0.33[-0.34,1]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

614

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Rogers 2014

Rogers 2009

Courneya 2003

Milne 2008

Murtezani 2014

Daley 2007

Rogers 2015

Subtotal ***

30.9 (6.3)

29.5 (6.6)

21.3 (3.7)

1.5 (0.3)

875.1 (86.7)

35 (4.4)

23.6 (4.8)

20

20

24

29

30

33

105

324

Heterogeneity: Tau2=0.03; Chi2=12.55, df=9(P=0.18); I2=28.29%

Test for overall effect: Z=4.3(P<0.0001)

18.29.2 Unclear/high risk of bias

Cerulli 2014

Mustian 2004

Rogers 2013

Kaltsatou 2011

Rahnama 2010

Nikander 2007

Kim 2015

Mehnert 2011

Basen-Enquist 2006

Do 2015

Pinto 2005

Irwin 2015

Fillion 2008

Subtotal ***

10

11

12

14

14

14

20

27

35

30

39

45

44

31.3 (5)

636.1 (50.6)

23.9 (6.2)

483.3 (86)

20.7 (5.7)

-17.6 (1.3)

424.8 (55.8)

26.9 (4.4)

1643
(122.5)

31.7 (12.4)

-16.3 (2.1)

24.6 (5.5)

27 (4.4)

22

18

26

29

32

69

108

333

10

10

10

13

15

14

19

23

25

30

43

38

43

25.1 (5)

27.6 (6.1)

18.2 (3.9)

1.5 (0.4)

823.5 (87.1)

33.1 (5.3)

22.7 (0.3)

32.3 (10.1)

610.3 (75.9)

23.9 (3.8)

403.1 (71.9)

13.9 (5.2)

-17.2 (1.4)

394.4 (54)

25.7 (4.7)

1546
(127.5)

24.5 (6.6)

-17.8 (2.2)

23 (4.7)

26.5 (5.8)

7.75%

7.86%

9.2%

10.92%

11.08%

14.38%

22.46%

100%

4.59%

4.69%

4.93%

5.24%

5.28%

5.9%

7.31%

8.73%

9.25%

9.44%

11.21%

11.53%

11.9%

100%

1.01[0.36,1.65]

0.29[-0.35,0.93]

0.8[0.22,1.38]

0.03[-0.49,0.54]

0.59[0.08,1.1]

0.38[-0.04,0.8]

0.27[-0,0.54]

0.44[0.24,0.65]

-0.12[-0.99,0.76]

0.39[-0.48,1.25]

0[-0.84,0.84]

0.98[0.17,1.78]

1.21[0.41,2.01]

-0.29[-1.03,0.46]

0.54[-0.1,1.18]

0.26[-0.3,0.82]

0.77[0.24,1.3]

0.72[0.19,1.24]

0.69[0.24,1.14]

0.31[-0.13,0.74]

0.1[-0.32,0.52]

0.44[0.23,0.65]

315

293

Heterogeneity: Tau2=0.05; Chi2=18.66, df=12(P=0.1); I2=35.69%

Test for overall effect: Z=4.06(P<0.0001)

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 18.30.   Comparison 18 Sensitivity analysis: outcomes by risk
of bias, Outcome 30 Overall cardiorespiratory fitness (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.30.1 Low risk of bias

Musanti 2012

Courneya 2003

Rogers 2014

Saarto 2012

Subtotal ***

30

24

20

262

336

1 (3.1)

2.7 (2.6)

2.8 (4.9)

0.9 (1.2)

12

26

22

236

296

0.9 (3.4)

-0.6 (1.7)

1.1 (4.2)

0.7 (1)

Heterogeneity: Tau2=0.27; Chi2=16.41, df=3(P=0); I2=81.72%

Test for overall effect: Z=1.65(P=0.1)

18.30.2 Unclear/high risk of bias

Nieman 1995

Naumann 2012

Dolan 2016

6

11

23

60.8 (8.4)

3.1 (2.9)

12.2 (10.2)

6

10

10

12 (17.8)

-0.1 (3.1)

-6 (7.2)

22.33%

23.07%

23.52%

31.07%

100%

6.74%

17.9%

18.61%

0.03[-0.64,0.7]

1.49[0.86,2.12]

0.37[-0.24,0.98]

0.16[-0.02,0.33]

0.49[-0.09,1.06]

3.24[1.29,5.18]

1.03[0.1,1.95]

1.88[0.99,2.77]

Favours control

-10

-5

0

5

10

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

615

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Irwin 2015

Pinto 2005

Subtotal ***

Mean(SD)

1.5 (2.1)

1.4 (2.4)

N

45

39

124

Mean(SD)

-0.4 (2.7)

-0.2 (2.5)

N

38

43

107

Heterogeneity: Tau2=0.24; Chi2=11.81, df=4(P=0.02); I2=66.14%

Test for overall effect: Z=4.04(P<0.0001)

Random, 95% CI

Random, 95% CI

28.33%

28.42%

100%

0.79[0.34,1.24]

0.65[0.2,1.09]

1.16[0.6,1.72]

Favours control

-10

-5

0

5

10

Favours physical activity

Analysis 18.31.   Comparison 18 Sensitivity analysis: outcomes by risk of
bias, Outcome 31 Overall self-reported physical activity (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.31.1 Low risk of bias

Cadmus 2009

Kiecolt-Glaser 2014

Pinto 2015

Rogers 2009

Rogers 2015

Schmitz 2009

Short 2014

Vallance 2007

Subtotal ***

161.7
(114.7)

11.2 (7.6)

70.3 (65.9)

121.4 (73.2)

169 (119)

3348.8
(9019.4)

217.9
(222.9)

207.6 (169)

34

96

36

20

110

131

195

253

875

Heterogeneity: Tau2=0.08; Chi2=30.5, df=7(P<0.0001); I2=77.05%

Test for overall effect: Z=3.66(P=0)

18.31.2 Unclear/high risk of bias

Basen-Enquist 2006

Guinan 2013

Hatchett 2013

Irwin 2015

Kim 2015

Littman 2012

Matthews 2007

Pinto 2005

Winters-Stone 2011

35

16

38

45

20

32

22

39

36

428 (254.4)

38.7 (26.9)

3.5 (2.2)

222.1
(118.6)

17.6 (16)

19.2 (19.1)

54.2 (34.1)

202.4
(161.7)

430.8
(281.4)

33

55.6 (101.9)

90

32

18

112

133

104

85

607

25

10

36

38

19

31

14

43

31

9.1 (6.1)

16.5 (31.9)

114.3
(131.5)

74 (107)

2339.8
(6213.7)

180.3
(206.9)

163 (121)

404 (265)

19.9 (11.3)

1.4 (1.7)

103.6
(104.6)

11.8 (11.6)

12.1 (13.6)

27.2 (22.7)

78.4 (86)

461.7
(346.4)

9.76%

13.93%

9.77%

7.79%

14.22%

14.85%

14.91%

14.76%

100%

11.75%

7.67%

12.15%

12.56%

9.98%

11.96%

9.08%

12.59%

12.26%

0.97[0.46,1.47]

0.3[0.01,0.59]

1.01[0.5,1.52]

0.07[-0.57,0.7]

0.84[0.56,1.11]

0.13[-0.11,0.37]

0.17[-0.07,0.41]

0.28[0.03,0.53]

0.45[0.21,0.68]

0.09[-0.42,0.61]

0.81[-0.01,1.64]

1.04[0.55,1.53]

1.04[0.58,1.51]

0.4[-0.23,1.04]

0.42[-0.08,0.92]

0.87[0.17,1.58]

0.96[0.5,1.42]

-0.1[-0.58,0.38]

Subtotal ***

283

247

100%

0.61[0.31,0.91]

Heterogeneity: Tau2=0.14; Chi2=22.6, df=8(P=0); I2=64.6%

Test for overall effect: Z=3.93(P<0.0001)

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

616

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 18.32.   Comparison 18 Sensitivity analysis: outcomes by risk of
bias, Outcome 32 Overall self-reported physical activity (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.32.1 Low risk of bias

Cadmus 2009

Saarto 2012

Schmitz 2009

Vallance 2007

Subtotal ***

129 (117.9)

3.5 (18.3)

2.8 (16.8)

82 (168.7)

34

262

48

281

625

Heterogeneity: Tau2=0.05; Chi2=10.67, df=3(P=0.01); I2=71.9%

Test for overall effect: Z=1.95(P=0.05)

18.32.2 Unclear/high risk of bias

Guinan 2013

Irwin 2015

Matthews 2007

Pinto 2005

Subtotal ***

15.6 (11.4)

159 (136)

21.5 (30.6)

84.7 (189.2)

16

45

22

39

122

Heterogeneity: Tau2=0.25; Chi2=11.28, df=3(P=0.01); I2=73.4%

Test for overall effect: Z=3.31(P=0)

44.3 (89.4)

3.3 (21.5)

-0.8 (16.6)

30 (167.8)

-8.3 (4.2)

49 (86)

5 (13.8)

-18.3
(200.7)

33

236

57

96

422

10

38

14

43

105

16.71%

32.36%

21.51%

29.42%

100%

16.33%

29.61%

24.1%

29.96%

0.8[0.3,1.3]

0.01[-0.17,0.19]

0.21[-0.17,0.6]

0.31[0.08,0.54]

0.27[-0,0.55]

2.46[1.39,3.53]

0.94[0.48,1.4]

0.63[-0.06,1.32]

0.52[0.08,0.96]

100%

0.99[0.4,1.58]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 18.33.   Comparison 18 Sensitivity analysis: outcomes by risk of
bias, Outcome 33 Overall objective physical activity (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.33.1 Low risk of bias

Rogers 2014

Rogers 2009

Pinto 2015

Cadmus 2009

Rogers 2015

Vallance 2007

Short 2014

Subtotal ***

294 (175)

252191
(91893)

70.3 (65.9)

6738 (2958)

246 (153)

8110.5
(4133.9)

9363.1
(7922.8)

20

20

36

33

110

253

219

691

Heterogeneity: Tau2=0.07; Chi2=19.34, df=6(P=0); I2=68.97%

Test for overall effect: Z=3.16(P=0)

18.33.2 Unclear/high risk of bias

Rogers 2013

Guinan 2013

Matthews 2007

Pinto 2005

Subtotal ***

198.4
(111.7)

30.7 (15.6)

330.8
(114.7)

37.5 (14.3)

12

16

22

39

89

Heterogeneity: Tau2=0.32; Chi2=7.75, df=2(P=0.02); I2=74.18%

154 (75)

210917
(64078)

16.5 (31.9)

5537 (3352)

197 (138)

8028 (3457)

8301.2
(3373.4)

0 (0)

31 (15.6)

198.5 (55.4)

33.6 (19.4)

22

18

32

34

112

85

111

414

10

9

14

43

76

9.17%

9.18%

11.99%

12.55%

18.52%

19.06%

19.53%

1.04[0.39,1.69]

0.51[-0.14,1.15]

1.01[0.5,1.52]

0.38[-0.11,0.86]

0.34[0.07,0.6]

0.02[-0.23,0.27]

0.16[-0.07,0.39]

100%

0.41[0.15,0.66]

29.42%

31.23%

39.35%

100%

Not estimable

-0.02[-0.84,0.8]

1.34[0.6,2.09]

0.22[-0.21,0.66]

0.5[-0.24,1.25]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

617

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Test for overall effect: Z=1.32(P=0.19)

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 18.34.   Comparison 18 Sensitivity analysis: outcomes by risk
of bias, Outcome 34 Overall objective physical activity (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.34.1 Low risk of bias

Rogers 2014

Cadmus 2009

Vallance 2007

Subtotal ***

114 (109)

1621 (2108)

-150
(5173.3)

20

33

253

306

Heterogeneity: Tau2=0.37; Chi2=16.13, df=2(P=0); I2=87.6%

Test for overall effect: Z=1.49(P=0.14)

18.34.2 Unclear/high risk of bias

Guinan 2013

Matthews 2007

Subtotal ***

-1.1 (6.2)

72.2 (114.6)

16

22

38

Heterogeneity: Tau2=0; Chi2=0.12, df=1(P=0.72); I2=0%

Test for overall effect: Z=3.52(P=0)

10 (70)

-60 (2341)

91 (5155.4)

-7.9 (5.3)

-16.8 (51.5)

22

34

85

141

9

14

23

29.73%

33.04%

37.23%

1.13[0.47,1.78]

0.75[0.25,1.24]

-0.05[-0.29,0.2]

100%

0.56[-0.18,1.3]

39%

61%

100%

1.11[0.23,2]

0.91[0.2,1.62]

0.99[0.44,1.54]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 18.35.   Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 35 Mass (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

18.35.1 Low risk of bias

Courneya 2003

Cadmus 2009

Herrero 2006

Daley 2007

Murtezani 2014

Schmitz 2009

Schmitz 2005

Kiecolt-Glaser 2014

Subtotal ***

24

36

8

33

30

78.2 (20.5)

80.7 (16.9)

65.6 (8.7)

74.3 (12.5)

71.7 (9.5)

131

76.2 (15.7)

69.5 (2.2)

75.2 (2.8)

39

96

397

26

33

8

69

32

133

40

90

431

80.1 (16.2)

78.5 (20.6)

67.3 (8.9)

75.6 (12.5)

72.6 (10.8)

77.2 (17)

69.2 (2.2)

75.2 (2.6)

Heterogeneity: Tau2=0; Chi2=1.5, df=7(P=0.98); I2=0%

Test for overall effect: Z=0.17(P=0.86)

18.35.2 Unclear/high risk of bias

Matthews 2007

Mustian 2004

Nikander 2007

Rahnama 2010

22

11

14

14

74.9 (15.2)

67.1 (10.4)

73.5 (13.3)

69.4 (13.5)

14

10

14

15

78.9 (20.3)

68.6 (13.8)

75.5 (12)

71.6 (9.2)

0.33%

0.43%

0.47%

1.29%

1.36%

2.22%

36.43%

57.47%

100%

5.81%

7.99%

10.12%

12.43%

Favours physical activity

-20

-10

0

10

20

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

-1.9[-12.2,8.4]

2.22[-6.72,11.16]

-1.7[-10.32,6.92]

-1.34[-6.52,3.84]

-0.9[-5.94,4.14]

-1.04[-4.98,2.9]

0.3[-0.67,1.27]

0[-0.78,0.78]

0.05[-0.54,0.64]

-4[-16.39,8.39]

-1.5[-12.06,9.06]

-2[-11.38,7.38]

-2.2[-10.67,6.27]

618

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Physical activity

Control

DeNysschen 2011

Ligibel 2008

Littman 2012

Winters-Stone 2011

Subtotal ***

N

Mean(SD)

N

Mean(SD)

69.3 (14.2)

80 (17.5)

81.1 (13.6)

76.5 (15.6)

30

40

28

36

195

72.4 (19.6)

83.3 (18.7)

81.3 (14.3)

74.2 (12.3)

34

42

27

31

187

Heterogeneity: Tau2=0; Chi2=1.88, df=7(P=0.97); I2=0%

Test for overall effect: Z=0.84(P=0.4)

Cochrane Database of Systematic Reviews

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

12.87%

14.51%

16.36%

19.92%

100%

-3.1[-11.42,5.22]

-3.3[-11.14,4.54]

-0.2[-7.58,7.18]

2.3[-4.39,8.99]

-1.28[-4.26,1.7]

Favours physical activity

-20

-10

0

10

20

Favours control

Analysis 18.36.   Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 36 Mass (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

18.36.1 Low risk of bias

Schmitz 2009

Murtezani 2014

Courneya 2003

Saarto 2012

Schmitz 2005

Subtotal ***

-1 (3.7)

-2.3 (2.4)

0.1 (2)

0.7 (3.7)

0.3 (0.4)

65

30

24

262

39

420

Heterogeneity: Tau2=0.31; Chi2=13.27, df=4(P=0.01); I2=69.87%

Test for overall effect: Z=1.34(P=0.18)

18.36.2 Unclear/high risk of bias

Dolan 2016

Irwin 2015

Mustian 2004

Ligibel 2008

Matthews 2007

Naumann 2012

Subtotal ***

-0.5 (5)

-2.1 (4.3)

-0.3 (1.9)

0 (2.3)

0 (2.1)

0.5 (1.3)

23

45

9

22

22

11

132

Heterogeneity: Tau2=0.4; Chi2=8.28, df=5(P=0.14); I2=39.59%

Test for overall effect: Z=1.49(P=0.14)

-0.4 (4.3)

-0.3 (2.6)

0.7 (1.8)

0.7 (3.8)

0.2 (0.4)

1.4 (1.6)

0.1 (3.6)

0.6 (1.4)

0 (2.2)

0 (2.2)

0.1 (1.5)

65

32

26

236

40

399

10

38

10

14

14

10

96

12.62%

14.25%

16.93%

24.08%

32.12%

100%

9.76%

14.96%

17.41%

17.68%

18.47%

21.72%

100%

-0.6[-1.98,0.78]

-2[-3.24,-0.76]

-0.6[-1.66,0.46]

-0.01[-0.67,0.65]

0.12[-0.07,0.31]

-0.43[-1.05,0.2]

-1.99[-4.28,0.3]

-2.2[-3.9,-0.5]

-0.9[-2.4,0.6]

-0.04[-1.52,1.44]

-0.03[-1.46,1.4]

0.33[-0.9,1.56]

-0.62[-1.44,0.19]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 18.37.   Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 37 BMI (follow-up values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

18.37.1 Low risk of bias

Portela 2008

Rogers 2009

Courneya 2003

Rogers 2014

Cadmus 2009

Murtezani 2014

Schmitz 2009

25

20

24

20

36

30

29.1 (5.5)

30.6 (7.6)

29.4 (7.4)

29.6 (5)

30.5 (6)

25.1 (2.9)

9

18

26

22

33

32

34.7 (15)

30.4 (8.3)

29.3 (6)

32.2 (6.7)

29.9 (7.6)

25.8 (3.5)

131

28.5 (5.6)

133

28.9 (6.3)

0.04%

0.17%

0.31%

0.34%

0.41%

1.72%

2.13%

Favours physical activity

-20

-10

0

10

20

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

-5.6[-15.63,4.43]

0.2[-4.88,5.28]

0.1[-3.65,3.85]

-2.6[-6.16,0.96]

0.55[-2.7,3.8]

-0.7[-2.29,0.89]

-0.48[-1.91,0.95]

619

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Physical activity

Control

Mean(SD)

N

Mean(SD)

Vallance 2007

Schmitz 2005

Kiecolt-Glaser 2014

Subtotal ***

N

253

39

96

674

27 (5.2)

26 (0.7)

27.8 (1.1)

Heterogeneity: Tau2=0; Chi2=5.9, df=9(P=0.75); I2=0%

Test for overall effect: Z=0.44(P=0.66)

18.37.2 Unclear/high risk of bias

Rogers 2013

Mustian 2004

Nikander 2007

Rahnama 2010

Ligibel 2008

Littman 2012

Pinto 2005

Subtotal ***

33.6 (7)

23.9 (4.2)

26.9 (5.6)

27.7 (4.8)

30.3 (6.3)

27.7 (5)

27.7 (5)

12

11

14

14

40

28

39

158

Heterogeneity: Tau2=0; Chi2=2.72, df=6(P=0.84); I2=0%

Test for overall effect: Z=1.73(P=0.08)

27.2 (5.2)

25.8 (0.7)

27.8 (1)

30.6 (7.3)

26.7 (5.6)

27.7 (4.9)

28 (4.6)

31.5 (6.8)

29 (5.6)

29 (5.6)

85

40

90

488

10

10

14

15

42

27

43

161

Mean Difference

Fixed, 95% CI

Cochrane Database of Systematic Reviews

Weight

Mean Difference

2.69%

41.27%

50.92%

100%

4.12%

8.21%

9.77%

12.72%

18.45%

18.7%

28.03%

100%

Fixed, 95% CI

-0.19[-1.46,1.08]

0.2[-0.12,0.52]

0[-0.29,0.29]

0.05[-0.16,0.26]

3[-3,9]

-2.8[-7.05,1.45]

-0.8[-4.7,3.1]

-0.3[-3.71,3.11]

-1.2[-4.04,1.64]

-1.35[-4.17,1.47]

-1.35[-3.65,0.95]

-1.07[-2.29,0.14]

Favours physical activity

-20

-10

0

10

20

Favours control

Analysis 18.38.   Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 38 BMI (change values).

Study or subgroup

Physical activity

Control

N

Mean(SD)

N

Mean(SD)

Mean Difference

Random, 95% CI

Weight

Mean Difference

Random, 95% CI

18.38.1 Low risk of bias

Schmitz 2009

Rogers 2014

Courneya 2003

Murtezani 2014

Schmitz 2005

Subtotal ***

-1 (3.7)

-0.2 (0.9)

0 (0.7)

-0.8 (0.7)

0.1 (0.2)

65

20

24

30

39

178

Heterogeneity: Tau2=0.08; Chi2=13.79, df=4(P=0.01); I2=70.99%

Test for overall effect: Z=1.45(P=0.15)

18.38.2 Unclear/high risk of bias

Mustian 2004

Naumann 2012

Ligibel 2008

Subtotal ***

-0.4 (0.8)

0.1 (0.5)

0 (0.9)

9

11

40

60

Heterogeneity: Tau2=0.1; Chi2=5.43, df=2(P=0.07); I2=63.14%

Test for overall effect: Z=0.86(P=0.39)

-0.4 (4.3)

-0.3 (1.1)

0.3 (0.7)

-0.1 (0.8)

0.1 (0.2)

0.3 (0.6)

-0.1 (0.6)

0.2 (0.8)

65

22

26

32

40

185

10

10

42

62

4.71%

15.48%

22.83%

23.41%

33.57%

100%

26.55%

34.21%

39.23%

100%

-0.6[-1.98,0.78]

0.1[-0.51,0.71]

-0.3[-0.69,0.09]

-0.66[-1.03,-0.29]

-0.01[-0.08,0.06]

-0.24[-0.56,0.08]

-0.71[-1.33,-0.09]

0.2[-0.26,0.66]

-0.2[-0.57,0.17]

-0.2[-0.65,0.25]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

620

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 18.39.   Comparison 18 Sensitivity analysis: outcomes
by risk of bias, Outcome 39 Overall body fat (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.39.1 Low risk of bias

Herrero 2006

Musanti 2012

Rogers 2009

Rogers 2014

Courneya 2003

Saarto 2012

Cadmus 2009

Schmitz 2005

Daley 2007

Schmitz 2009

Subtotal ***

22 (5)

34.1 (6.6)

44.3 (7.4)

38.6 (6.4)

131.9 (46.4)

39.9 (7.5)

40.5 (6.6)

40.9 (1.3)

39.4 (4.7)

38.5 (5.9)

8

30

20

20

24

37

36

39

33

130

377

Heterogeneity: Tau2=0.06; Chi2=17.33, df=9(P=0.04); I2=48.08%

Test for overall effect: Z=1.66(P=0.1)

18.39.2 Unclear/high risk of bias

Cerulli 2014

Mustian 2004

Rogers 2013

Matthews 2007

DeNysschen 2011

Winters-Stone 2011

Pinto 2005

Ligibel 2008

Subtotal ***

26.7 (5.3)

38.5 (4.5)

44.2 (6.7)

39.7 (6.3)

36.9 (8.4)

40.5 (6.2)

37.5 (4.8)

42.9 (7.4)

10

11

10

22

30

36

39

40

198

Heterogeneity: Tau2=0.02; Chi2=8.84, df=7(P=0.26); I2=20.77%

Test for overall effect: Z=1.41(P=0.16)

22 (4)

33.7 (5.7)

43.5 (7.5)

41.5 (7.4)

137.1 (44.4)

40.2 (8)

39.6 (6)

42.3 (1.3)

40.1 (7.4)

39.7 (5.9)

30.6 (4.4)

41.7 (4.9)

42.3 (7.7)

43.1 (6.9)

38 (10.2)

38.5 (5.8)

38.6 (4.8)

44.7 (8)

8

12

19

22

26

30

33

40

69

132

391

10

10

12

14

34

31

43

42

196

4.11%

7.29%

7.93%

8.2%

9.25%

10.84%

11.04%

11.07%

12.52%

17.74%

100%

5.8%

6.15%

6.7%

9.69%

16.27%

16.65%

19.36%

19.37%

100%

0[-0.98,0.98]

0.07[-0.6,0.74]

0.11[-0.52,0.73]

-0.41[-1.02,0.2]

-0.11[-0.67,0.44]

-0.04[-0.52,0.44]

0.15[-0.33,0.62]

-1.05[-1.52,-0.58]

-0.1[-0.52,0.31]

-0.21[-0.46,0.03]

-0.19[-0.41,0.03]

-0.75[-1.66,0.16]

-0.66[-1.54,0.23]

0.25[-0.59,1.09]

-0.51[-1.19,0.17]

-0.12[-0.61,0.38]

0.33[-0.16,0.81]

-0.21[-0.64,0.22]

-0.23[-0.67,0.2]

-0.17[-0.4,0.07]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 18.40.   Comparison 18 Sensitivity analysis: outcomes
by risk of bias, Outcome 40 Overall body fat (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.40.1 Low risk of bias

Musanti 2012

Schmitz 2005

Rogers 2014

Courneya 2003

Schmitz 2009

Subtotal ***

-0.2 (2.8)

-1.1 (0.5)

-1.1 (2.2)

-4.9 (15.7)

-0.3 (5.7)

30

39

20

24

65

178

12

40

22

26

63

163

1.4 (1.6)

0.2 (0.4)

-0.6 (2.4)

5.1 (24.4)

-0.1 (3.3)

Heterogeneity: Tau2=1.19; Chi2=65.49, df=4(P<0.0001); I2=93.89%

Test for overall effect: Z=1.72(P=0.08)

18.40.2 Unclear/high risk of bias

Mustian 2004

Naumann 2012

9

11

-0.2 (2.9)

-0.3 (2.4)

10

10

0.3 (1.6)

0.8 (2.8)

19.49%

19.61%

19.88%

20.09%

20.93%

100%

-0.63[-1.32,0.05]

-3.07[-3.73,-2.41]

-0.21[-0.82,0.39]

-0.48[-1.04,0.09]

-0.04[-0.39,0.3]

-0.87[-1.86,0.12]

12.24%

13.26%

-0.18[-1.09,0.72]

-0.41[-1.28,0.46]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

621

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Matthews 2007

Ligibel 2008

Subtotal ***

-0.2 (1.6)

-0.2 (1.7)

22

40

82

14

42

76

0.4 (1.9)

0.3 (1.7)

Heterogeneity: Tau2=0; Chi2=0.14, df=3(P=0.99); I2=0%

Test for overall effect: Z=1.89(P=0.06)

21.88%

52.62%

100%

-0.34[-1.02,0.33]

-0.29[-0.73,0.14]

-0.3[-0.62,0.01]

Favours physical activity

-5

-2.5

0

2.5

5

Favours control

Analysis 18.41.   Comparison 18 Sensitivity analysis: outcomes by
risk of bias, Outcome 41 Lower body strength (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.41.1 Low risk of bias

Rogers 2009

Schmitz 2005

Milne 2008

Saarto 2012

Schmitz 2009

Subtotal ***

80.3 (27)

296.6 (48.9)

66.2 (10.2)

136 (23)

223.4 (59.6)

20

23

29

37

113

222

Heterogeneity: Tau2=0.13; Chi2=12.62, df=4(P=0.01); I2=68.31%

Test for overall effect: Z=3.1(P=0)

18.41.2 Unclear/high risk of bias

Cerulli 2014

Rogers 2013

Nikander 2007

Do 2015

Winters-Stone 2011

Subtotal ***

114.9 (17.1)

68.4 (15.5)

1305 (177)

13 (1.6)

201.3 (57.4)

10

11

14

32

36

103

Heterogeneity: Tau2=0.26; Chi2=13.05, df=4(P=0.01); I2=69.34%

Test for overall effect: Z=0.83(P=0.41)

64.9 (19.7)

238.9 (46.4)

61.7 (11)

136 (29)

175.1 (53.5)

79.1 (17.8)

67.1 (16.2)

1393 (275)

13.2 (1.6)

191 (51.7)

18

22

29

30

119

218

10

9

14

30

31

94

16.28%

16.65%

19.66%

20.74%

26.67%

100%

13.78%

17.26%

19.65%

24.49%

24.82%

100%

0.63[-0.02,1.29]

1.19[0.55,1.83]

0.42[-0.1,0.94]

0[-0.48,0.48]

0.85[0.58,1.12]

0.61[0.22,1]

1.96[0.85,3.07]

0.08[-0.8,0.96]

-0.37[-1.12,0.38]

-0.09[-0.59,0.41]

0.19[-0.3,0.67]

0.23[-0.32,0.79]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 18.42.   Comparison 18 Sensitivity analysis: outcomes
by risk of bias, Outcome 42 Lower body strength (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.42.1 Low risk of bias

Schmitz 2005

Cormie 2014

Schmitz 2009

Subtotal ***

81.8 (48.9)

37.6 (25.5)

33.2 (33.9)

23

43

113

179

22

19

119

160

20.3 (46)

6.7 (25.7)

7.9 (26.6)

Heterogeneity: Tau2=0.01; Chi2=2.39, df=2(P=0.3); I2=16.21%

Test for overall effect: Z=6.95(P<0.0001)

18.42.2 Unclear/high risk of bias

16.3%

19.64%

64.06%

100%

1.27[0.63,1.92]

1.19[0.61,1.78]

0.83[0.56,1.1]

0.97[0.7,1.25]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

622

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

Nieman 1995

Naumann 2012

Dolan 2016

Do 2015

Waltman 2010

Subtotal ***

28.9 (13.7)

7.7 (12.6)

11.8 (8.9)

0.9 (0.7)

4.4 (11.5)

6

11

23

32

110

182

6

10

10

60

113

199

3.5 (22.5)

3.5 (13.9)

0.3 (11.1)

1 (0.6)

0.2 (8.4)

Heterogeneity: Tau2=0.12; Chi2=10, df=4(P=0.04); I2=59.99%

Test for overall effect: Z=2.13(P=0.03)

8.38%

14.73%

16.09%

27.47%

33.32%

100%

1.26[-0.03,2.55]

0.3[-0.56,1.17]

1.17[0.37,1.97]

-0.08[-0.51,0.35]

0.42[0.15,0.69]

0.46[0.04,0.88]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 18.43.   Comparison 18 Sensitivity analysis: outcomes by
risk of bias, Outcome 43 Upper body strength (follow-up values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.43.1 Low risk of bias

Portela 2008

Musanti 2012

Schmitz 2005

Rogers 2009

Milne 2008

Saarto 2012

Schmitz 2009

Subtotal ***

39.3 (12.3)

52.1 (21)

83 (13.4)

27.9 (5)

7.6 (2.9)

32.7 (5.3)

52.9 (15.3)

25

30

23

20

29

37

113

277

35.6 (13.1)

36.8 (20)

63 (12.7)

24.3 (6.2)

9.4 (2.6)

30.8 (5.7)

40.9 (11.8)

9

12

22

18

29

30

119

239

Heterogeneity: Tau2=0.33; Chi2=34.25, df=6(P<0.0001); I2=82.48%

Test for overall effect: Z=2.14(P=0.03)

18.43.2 Unclear/high risk of bias

Mustian 2004

Cerulli 2014

Nikander 2007

Kaltsatou 2011

Do 2015

Winters-Stone 2011

Subtotal ***

29.6 (3.3)

16.1 (5.4)

131 (20)

59.6 (8.5)

9.7 (1.7)

63.3 (15.3)

11

10

14

28

32

36

131

26.7 (5.7)

17.2 (8.1)

129 (28)

47.6 (9.8)

10.1 (1.7)

61.1 (16.8)

10

10

14

26

30

31

121

Heterogeneity: Tau2=0.26; Chi2=17.44, df=5(P=0); I2=71.34%

Test for overall effect: Z=1.14(P=0.25)

12.44%

13.22%

13.43%

13.59%

14.87%

15.31%

17.14%

100%

13.66%

13.68%

15.64%

17.96%

19.38%

19.68%

100%

0.29[-0.48,1.05]

0.73[0.04,1.42]

1.5[0.84,2.17]

0.63[-0.03,1.28]

-0.64[-1.17,-0.12]

0.34[-0.14,0.83]

0.88[0.61,1.15]

0.53[0.04,1.01]

0.6[-0.28,1.49]

-0.16[-1.03,0.72]

0.08[-0.66,0.82]

1.29[0.7,1.88]

-0.24[-0.74,0.26]

0.14[-0.34,0.62]

0.29[-0.21,0.78]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 18.44.   Comparison 18 Sensitivity analysis: outcomes
by risk of bias, Outcome 44 Upper body strength (change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.44.1 Low risk of bias

Schmitz 2005

Musanti 2012

23

30

32.3 (11.5)

7.7 (10.6)

22

12

6.9 (10.8)

0.8 (12.7)

22.13%

23.39%

2.24[1.48,2.99]

0.6[-0.08,1.29]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

623

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

Cormie 2014

Schmitz 2009

Subtotal ***

Mean(SD)

5.7 (3.7)

33.2 (40.8)

N

43

113

209

Heterogeneity: Tau2=0.38; Chi2=18.46, df=3(P=0); I2=83.75%

Test for overall effect: Z=3.3(P=0)

18.44.2 Unclear/high risk of bias

Rogers 2009

Do 2015

Mustian 2004

Irwin 2015

Waltman 2010

Subtotal ***

1.5 (2.3)

0.3 (0.5)

4.5 (4.7)

0.4 (1.9)

1.9 (4.9)

19

32

45

45

110

251

Heterogeneity: Tau2=0.24; Chi2=23.51, df=4(P=0); I2=82.99%

Test for overall effect: Z=1.77(P=0.08)

Mean(SD)

1 (3.8)

7.6 (43.7)

-0.3 (2.4)

0.6 (1.2)

-0.8 (3.2)

0.1 (1.9)

0.8 (2.9)

N

19

119

172

17

30

38

38

113

236

Random, 95% CI

Random, 95% CI

24.99%

29.49%

100%

16.58%

19.58%

19.97%

20.7%

23.16%

100%

1.25[0.67,1.84]

0.6[0.34,0.87]

1.13[0.46,1.8]

0.76[0.08,1.44]

-0.27[-0.77,0.23]

1.3[0.82,1.78]

0.16[-0.27,0.59]

0.29[0.02,0.55]

0.43[-0.05,0.91]

Favours control

-5

-2.5

0

2.5

5

Favours physical activity

Analysis 18.45.   Comparison 18 Sensitivity analysis: outcomes by risk of bias,
Outcome 45 Bone mineral density - femoral neck (follow-up and change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.45.1 Low risk of bias

Saarto 2012

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.93(P=0.05)

18.45.2 Unclear/high risk of bias

239

239

-0 (0)

218

218

-0 (0)

100%

100%

0.18[-0,0.37]

0.18[-0,0.37]

Kim 2015

Winters-Stone 2011

Waltman 2010

Subtotal ***

20

36

110

166

0.8 (0.1)

0.7 (0.1)

0.9 (0.5)

19

31

113

163

0.8 (0.1)

0.7 (0.1)

0.6 (0.4)

Heterogeneity: Tau2=0.2; Chi2=9.77, df=2(P=0.01); I2=79.54%

Test for overall effect: Z=0.61(P=0.54)

28.05%

32.86%

39.09%

100%

-0.37[-1,0.27]

0.11[-0.37,0.59]

0.63[0.36,0.9]

0.18[-0.39,0.75]

Favours control

-2

-1

0

1

2

Favours physical activity

Analysis 18.46.   Comparison 18 Sensitivity analysis: outcomes by risk of bias,
Outcome 46 Bone mineral density - lumbar spine (follow-up and change values).

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.46.1 Low risk of bias

Saarto 2012

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.95(P=0.34)

239

239

-0 (0)

218

218

-0 (0)

100%

100%

0.09[-0.09,0.27]

0.09[-0.09,0.27]

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

624

Favours control

-2

-1

0

1

2

Favours physical activity

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Physical activity

Control

Std. Mean Difference

Weight

Std. Mean Difference

N

Mean(SD)

N

Mean(SD)

Random, 95% CI

Random, 95% CI

18.46.2 Unclear/high risk of bias

Kim 2015

Winters-Stone 2011

Waltman 2010

Subtotal ***

20

36

110

166

1 (0.1)

1 (0.2)

3.1 (0.4)

19

31

113

163

1 (0.1)

1 (0.1)

2.9 (0.4)

Heterogeneity: Tau2=0.09; Chi2=5.52, df=2(P=0.06); I2=63.75%

Test for overall effect: Z=1.23(P=0.22)

24.58%

31.58%

43.84%

100%

-0.26[-0.89,0.37]

0.3[-0.19,0.78]

0.55[0.28,0.81]

0.27[-0.16,0.7]

Favours control

-2

-1

0

1

2

Favours physical activity

A D D I T I O N A L   T A B L E S

Table 1.   HRQoL subscales and HRQoL-related instruments used by investigators 

QoL domain and instrument name

Direction of response

Trials using this scale

Cognitive function

Cognitive problems - Breast Cancer Pre-
vention Trial (BCPT) Symptom Checklist

Cognitive function - European Organiza-
tion for Research and Treatment of Cancer
Quality of Life Questionnaire-C30 (EORTC
QLQ-C30)

Cognitive function - Functional Assessment
of Cancer Therapy-Cognitive (FACT-C)

Higher score indicates worse status.

Kiecolt-Glaser 2014

Higher score indicates

Herrero 2006; Mehnert 2011; Saarto 2012

better status.

Higher score indicates

Rogers 2009

worse status.

Confusion - Profile of Mood States (POMS)

Higher score indicates worse status.

Cantarero-Villanueva 2013; Pinto 2003

Emotional function/mental health

Psychosocial global score - Cancer Reha-
bilitation Evaluation System Short Form
(CARES-SF)

Higher score indicates

Schmitz 2005

worse status.

Emotional function - EORTC QLQ-C30

Higher score indicates better status.

Emotional well-being - FACT-General
(FACT-G)

Higher score indicates better status.

Do 2015; Herrero 2006; Mehnert 2011; Saar-
to 2012

Banasik 2011; Cadmus 2009; Courneya
2003; Daley 2007; Littman 2012; Loh 2014;
Milne 2008; Murtezani 2014; Naumann
2012; Rogers 2009; Rogers 2015; Vallance
2007

Emotions - Lymphedema Quality of Life
Tool (LYMQOL)

Higher score indicates

Loudon 2014

worse status.

Mental composite - Medical Outcomes
Study Short Form-12 (MOS SF-12) and MOS
SF-36

Higher score indicates better status.

SF-12: Cuesta-Vargas 2014; Fillion 2008

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

625

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 1.   HRQoL subscales and HRQoL-related instruments used by investigators  (Continued)

Mental health - MOS SF-12

Higher score indicates better status.

Role emotion - MOS SF-36

Higher score indicates better status.

SF-36: (Cormie 2014; Kiecolt-Glaser 2014;
Pinto 2015; Schmitz 2009

Baruth 2013; Basen-Enquist 2006; Cadmus
2009; Cormie 2014; Duijits 2012; Kiecolt-
Glaser 2014; McKenzie 2003; Mehnert 2011;
Pinto 2015

Baruth 2013; Basen-Enquist 2006; Cadmus
2009; Cormie 2014; Duijits 2012; Kiecolt-
Glaser 2014; McKenzie 2003; Mehnert 2011

Positive and Negative Affect Scale (PANAS)

Higher score indicates better status.

Pinto 2003

Total mood disturbance score - POMS

Higher score indicates worse status.

Cantarero-Villanueva 2013; Pinto 2003; Pin-
to 2005

Anxiety and depression - POMS

Higher score indicates worse status.

Fillion 2008

Anger - POMS

Higher score indicates worse status.

Cantarero-Villanueva 2013; Pinto 2003

General health perspective

Global health - EORTC QLQ-C30

Higher score indicates better status.

Do 2015; Ergun 2013; Herrero 2006; Mehn-
ert 2011; Saarto 2012

Current health - International Breast Can-
cer Study Group (IBCSG)

Higher score indicates better status.

Baruth 2013

General health - MOS SF-36

Higher score indicates better status.

Baruth 2013; Basen-Enquist 2006; Cadmus
2009; Cormie 2014; Duijits 2012; Kiecolt-
Glaser 2014; McKenzie 2003; Mehnert 2011;
Mustian 2004

Single question on perceived general
health

Perceived physical function

Physical condition - Body Esteem Scale
(BES)

Physical strength - Body Image and Rela-
tionships Scale (BIRS)

Higher score indicates better status.

Rogers 2009

Higher score indicates better status.

Pinto 2003; Pinto 2005

Higher score indicates worse status.

Schmitz 2009

Physical global - CARES-SF

Higher score indicates worse status.

Schmitz 2005

Physical function - EORTC QLQ-C30

Higher score indicates better status.

Physical well-being - FACT-G

Higher score indicates better status.

Do 2015; Herrero 2006; Mehnert 2011; Saar-
to 2012

Banasik 2011; Cadmus 2009; Courneya
2003; Daley 2007; Littman 2012; Loh 2014;
Milne 2008; Murtezani 2014; Naumann
2012; Rogers 2009; Rogers 2015; Vallance
2007

Physical well-being - IBCSG

Higher score indicates better status.

Baruth 2013

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

626

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 1.   HRQoL subscales and HRQoL-related instruments used by investigators  (Continued)

Physical function - MOS SF-12

Higher score indicates better status.

Cuesta-Vargas 2014; Fillion 2008

Physical function composite score - MOS
SF-36

Higher score indicates better status.

Baruth 2013; Cormie 2014; Duijits 2012;
McKenzie 2003; Mehnert 2011; Mustian
2004; Schmitz 2009; Winters-Stone 2011

Role function

Marital global score - CARES-SF

Higher score indicates

Schmitz 2005

Role function - EORTC QLQ-C30

Higher score indicates better status.

worse status.

Functional well-being - FACT-G

Higher score indicates better status.

Do 2015; Herrero 2006; Mehnert 2011; Saar-
to 2012

Banasik 2011; Cadmus 2009; Courneya
2003; Daley 2007; Littman 2012; Loh 2014;
Milne 2008; Murtezani 2014; Naumann
2012; Rogers 2009; Rogers 2015; Vallance
2007

Function - LYMQOL

Higher score indicates

Loudon 2014

Physical role function - MOS SF-36

Higher score indicates better status.

worse status.

Baruth 2013; Basen-Enquist 2006; Cadmus
2009; Cormie 2014; Duijits 2012; Kiecolt-
Glaser 2014; McKenzie 2003; Mehnert 2011;
Mustian 2004

Sexuality

Sexual attractiveness - BES

Higher score indicates

Pinto 2003; Pinto 2005

better status.

Appearance and sexuality - BIRS

Higher score indicates

Schmitz 2009

worse status.

Sexual function and sexual enjoyment -
EORTC QLQ-C30

Higher score indicates

Saarto 2012

better status.

Sexual global - CARES-SF

Higher score indicates

Schmitz 2005

worse status.

Sexual functioning - Sexual Activity Ques-
tionnaire

Higher score indicates

Duijits 2012

better status.

Sleep

Pittsburgh Sleep Quality Index (PSI)

Higher score indicates

worse status.

Bower 2011; Carson 2009; Kiecolt-Glaser
2014; Payne 2008; Rogers 2009; Rogers
2013; Rogers 2014

Sleep disturbance (0 to 9 scale)

Higher score indicates

Carson 2009

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

627

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 1.   HRQoL subscales and HRQoL-related instruments used by investigators  (Continued)

higher disturbance.

Sleep objectively via accelerometers

Higher sleep time and efficiency indi-
cate better status.

Rogers 2013; Rogers 2014

Social function

Social functioning - BIRS

Higher score indicates

Schmitz 2009

worse status.

Body Image Questionnaire (BIQ)

Higher score indicates

Mehnert 2011

worse status.

Social function - EORTC QLQ-C30

Higher score indicates better status.

Herrero 2006; Mehnert 2011; Saarto 2012

Social well-being - FACT-G

Higher score indicates better status.

Banasik 2011; Cadmus 2009; Courneya
2003; Daley 2007; Littman 2012; Loh 2014;
Milne 2008; Murtezani 2014; Naumann
2012; Rogers 2009; Rogers 2015; Vallance
2007

Social support - IBCSG

Higher score indicates better status.

Baruth 2013

Social functioning - MOS SF-36

Higher score indicates better status.

Baruth 2013; Basen-Enquist 2006; Cadmus
2009; Cormie 2014; Duijits 2012; Kiecolt-
Glaser 2014; McKenzie 2003; Mehnert 2011;
Mustian 2004

Social Barriers Scale

Higher score indicates

Mehnert 2011

better status.

Other psychological outcomes

Anxiety

Depression and Anxiety Stress Scale-21
(DASS-21)

Hospital Anxiety and Depression scale
(HADS)

Higher score indicates

Loh 2014

worse status.

Higher score indicates

worse status.

Duijits 2012; Heim 2007; Mehnert 2011; Mu-
santi 2012

Cantarero-Villanueva 2013; Fillion 2008;
Pinto 2003

Tension-anxiety - POMS

Higher score indicates

worse status.

Anxiety - Patient Reported Outcomes Mea-
surement Information System (PROMIS)

Higher score indicates

Rogers 2014

worse status.

Social Physique Anxiety Scale-7 (SPAS-7)

Higher score indicates

Milne 2008

worse status.

State-Trait Anxiety Index (STAI)

Higher score indicates

Cadmus 2009; Segar 1998

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

628

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 1.   HRQoL subscales and HRQoL-related instruments used by investigators  (Continued)

worse status.

Cohen’s 10-item perceived stress scale

Higher score indicates

Bower 2011; Cadmus 2009

worse status.

Symptoms of Stress Inventory (SOSI)

Higher score indicates

Mehnert 2011

worse status.

Depression

Beck Depression Inventory (BDI)

Higher score indicates

Centres for Epidemiological Studies De-
pression scale (CES-D)

worse status.

Higher score indicates

worse status.

Bower 2011; Daley 2007; Ergun 2013; Kalt-
satou 2011; Naumann 2012; Saarto 2012;
Segar 1998

Cadmus 2009; Kiecolt-Glaser 2014; Payne
2008; Schmitz 2005

DASS-21

HADS

Higher score indicates

Loh 2014

worse status.

Higher score indicates

worse status.

Duijits 2012; Heim 2007; Mehnert 2011; Mu-
santi 2012

Cantarero-Villanueva 2013; Fillion 2008;
Pinto 2003

Depression subscale - POMS

Higher score indicates

worse status.

Depression - PROMIS

Higher score indicates

Rogers 2014

Fatigue

worse status.

Brief Fatigue Inventory

Higher score indicates

Ergun 2013

worse status.

Fatigue subscale - FACT-F

Higher score indicates

better status.

Baruth 2013; Courneya 2003; Littman 2012;
Loh 2014; Peppone 2015; Rogers 2009;
Saarto 2012; Short 2014; Vallance 2007

Likert scale responses to fatigue-related
items (0 to 4)

Linear visual analogue scale (VAS) for fa-
tigue (0 to 10)

Multidimensional Fatigue Symptom Inven-
tory (MFSI)

Higher score indicates

Banasik 2011

worse status.

Higher score indicates

Loudon 2014; Pinto 2005

worse status.

Higher score indicates

worse status.

Bower 2011; Fillion 2008; Heim 2007; Pep-
pone 2015; Rogers 2013; Rogers 2014

Fatigue subscale - POMS

Higher score indicates

Cantarero-Villanueva 2013; Pinto 2003

worse status.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

629

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 1.   HRQoL subscales and HRQoL-related instruments used by investigators  (Continued)

Fatigue - PROMIS

Higher score indicates

Rogers 2014

worse status.

Revised Piper Fatigue Scale (PFS)

Higher score indicates

worse status.

Cantarero-Villanueva 2013; Cuesta-Vargas
2014; Daley 2007; Musanti 2012; Naumann
2012; Payne 2008

Schwartz Cancer Fatigue Scale (SCFS)

Higher score indicates

Milne 2008; Winters-Stone 2011

Fatigue 0 to 9 scale

Higher score indicates

Carson 2009

worse status.

Happiness/satisfaction with life

worse status.

2-Item Fordyce Happiness Measure

Higher score indicates

Cadmus 2009

better status.

Happiness measure

Higher score indicates

Courneya 2003

better status.

Life Satisfaction Inventory (LSI)

Higher score indicates

Kaltsatou 2011

better status.

Satisfaction With Life Scale (SWLS)

Higher score indicates

Daley 2007

Pain/disability

better status.

Brief Pain Inventory (BPI)

Higher score indicates

Cormie 2014; Fillion 2008; Irwin 2015

worse status.

Disabilities of the Arm, Shoulder, and Hand
(DASH)

Higher score indicates

Cormie 2014; Irwin 2015; Portela 2008

worse status.

Pain subscale - EORTC QLQ-C30

Higher score indicates

Do 2015; Mehnert 2011

worse status.

Pain scale - MOS SF-36

Higher score indicates

better status.

Baruth 2013; Basen-Enquist 2006; Cadmus
2009; Cormie 2014; Duijits 2012; Mehnert
2011; Mustian 2004

University of Rochester Cancer Center
Symptom Inventory (URCC SI)

Higher score indicates

Peppone 2015

worse status.

Pain VAS 0 to 10

Higher score indicates

Loudon 2014

worse status.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

630

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 1.   HRQoL subscales and HRQoL-related instruments used by investigators  (Continued)

5-Point Likert scale version of 24-item
Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC)

Higher score indicates

Irwin 2015; Rogers 2009

worse status.

Pain 0 to 9 scale

Higher score indicates

Carson 2009

worse status.

Self-esteem

BES

Higher score indicates

Pinto 2003; Pinto 2005

better status.

Body Image Questionnaire (BIQ)

Higher score indicates

Mehnert 2011

worse status.

Body Image and Relationships Scale (BIRS)

Higher score indicates

Schmitz 2009

worse status.

Body image - EORTC QLQ-Breast-Related
23

Higher score indicates

Do 2015; Duijits 2012; Saarto 2012

better status.

Physical Self-Perception Profile

Higher score indicates

Daley 2007; Musanti 2012

better status.

Rosenberg Self-Esteem Scale (RSE)

Higher score indicates

better status.

Cadmus 2009; Courneya 2003; Musanti
2012; Mustian 2004; Segar 1998

Social Physique Anxiety Scale 7 (SPAS-7)

Higher score indicates

Milne 2008

worse status.

Vitality/vigour

Vitality scale - MOS SF-36

Higher score indicates

better status.

Vigour subscale - POMS

Higher score indicates

better status.

Baruth 2013; Basen-Enquist 2006; Cadmus
2009; Cormie 2014; Duijits 2012; Kiecolt-
Glaser 2014; Mehnert 2011; Mustian 2004

Cantarero-Villanueva 2013; Fillion 2008;
Pinto 2003; Pinto 2005

Other psychological measures

Basic Psychological Needs Satisfaction
Scale (BNS)

Higher score indicates

Milne 2008

better status.

Behavioral Regulation for Exercise Ques-
tionnaire 2 (BREQ-2)

Higher score indicates higher status of
each subscale.

Milne 2008

Endocrine symptoms - FACT-Endocrine
symptoms

Higher score indicates

Duijits 2012; Rogers 2009

worse status.

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

631

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 1.   HRQoL subscales and HRQoL-related instruments used by investigators  (Continued)

Exercise role identity - 9-item, 5-point Lik-
ert-type instrument (Anderson and Cy-
chosz)

Exercise self-efficacy - 14-item Steinhardt
and Dishman Questionnaire

Higher score indicates

Hatchett 2013

greater exercise role identity.

Higher score indicates

Hatchett 2013

better status.

Hot flashes and night sweats - Hot Flush
Rating Scale

Higher score indicates

Duijits 2012;

worse status.

Outcome expectancy value - 19-item Stein-
hardt and
Dishman Self-Report Questionnaire

Higher score indicates

Hatchett 2013

higher outcome expectancy.

Menopausal symptoms 0 to 9 scale

Higher score indicates

Carson 2009

worse status.

Menopausal symptoms - Women’s Health
Questionnaire (WHQ)

Higher score indicates

Saarto 2012

worse status.

Self-regulation - 20-item, 5-point Lik-
ert-type instrument

Higher score indicates

Hatchett 2013

better status.

Symptom Checklist-90 Revised (SCL-90R)

Higher score indicates

DeNysschen 2011; Mehnert 2011

worse status.

Urinary symptoms - Bristol Female Low-
er Urinary Tract Symptoms Questionnaire
(BFLUTS)

Higher score indicates

Duijits 2012

worse status.

Table 2.   Physical fitness, physical activity, and body composition measurement instruments used by investigators 

Instrument or test name

Outcome

Measurement
units

Trials using this instrument or test

12-Minute walk test

Cardiorespiratory
fitness

Distance covered in
metres

Murtezani 2014; Portela 2008

2-Kilometre walking test

Cardiorespiratory
fitness

Time to complete in
minutes

Nikander 2007; Saarto 2012

6-Minute walk test

Cardiorespiratory
fitness

Distance covered in
metres

Basen-Enquist 2006; Kaltsatou 2011; Kim 2015; Mustian
2004; Nieman 1995

Aerobic Power Index cycle
test

Cardiorespiratory
fitness

Relative power out-
put in W/kg

Milne 2008

Astrand-Rhyming cycle test

Cardiorespiratory
fitness

Estimated maxi-
mal oxygen uptake

Cerulli 2014

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

632

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 2.   Physical fitness, physical activity, and body composition measurement instruments used by
investigators  (Continued)

(VO2max) in mL/kg/
min

Ebbeling 8-minute sin-
gle-stage walking treadmill
test

Cardiorespiratory
fitness

Distance covered in
metres

Daley 2007; Fillion 2008

Graded exercise treadmill
test

Cardiorespiratory
fitness

Direct VO2max in
mL/kg/min

DeNysschen 2011; Dolan 2016; Irwin 2015

Graded exercise cycle er-
gometer test

Cardiorespiratory
fitness

Direct VO2max in
mL/kg/min

Courneya 2003; Herrero 2006; Mehnert 2011

Harvard step test

Cardiorespiratory
fitness

Heart rate in beats
per minute (bpm)
post test

Heim 2007

Modified Bruce protocol

Cardiorespiratory
fitness

Estimated VO2max
in mL/kg/min

Musanti 2012; Naumann 2012; Rahnama 2010

Naughton submaximal
treadmill test

Cardiorespiratory
fitness

Estimated VO2max
in mL/kg/min

Do 2015; Rogers 2009; Rogers 2013; Rogers 2014; Rogers
2015

Rockport 1-mile walk test

Cardiorespiratory
fitness

Time to complete in
minutes

Pinto 2005

7-Day Physical Activity Re-
call (PAR)

Self-reported physi-
cal activity

Minutes/week

Basen-Enquist 2006; Cadmus 2009; Hatchett 2013; Pin-
to 2005; Pinto 2015

Community Health Activi-
ties Model Programme for
Seniors (CHAMPS)

Self-reported physi-
cal activity

Metabolic equiva-
lent (MET)-h/week

Baruth 2013; Kiecolt-Glaser 2014; Matthews 2007; Win-
ters-Stone 2011

International Physical Activ-
ity Questionnaire (IPAQ)

Self-reported physi-
cal activity

MET-h/week

Schmitz 2009

Physical activity question-
naire

Self-reported physi-
cal activity

Minutes/week

Irwin 2015; Kriska 1990

Leisure Score Index (LSI) of
Godin Leisure-Time Exer-
cise Questionnaire

Self-reported physi-
cal activity

Minutes/week

Courneya 2003; Guinan 2013; Kim 2015; Rogers 2009;
Rogers 2015; Short 2014; Vallance 2007

Modifiable Activity Ques-
tionnaire

Self-reported physi-
cal activity

MET-h/week

Littman 2012

Physical Activity Recall
Questionnaire

Self-reported physi-
cal activity

MET-h/week

Saarto 2012

Accelerometer

Pedometer

Objective physical
activity

Counts per minute/
d

Guinan 2013; Matthews 2007; Pinto 2005; Pinto 2015;
Rogers 2009; Rogers 2013; Rogers 2014; Rogers 2015

Objective physical
activity

Steps/d

Cadmus 2009; Nikander 2007; Short 2014; Vallance
2007

Body fat via bioelectrical
impedance analysis (BIA)

Body composition

% and/or kg

Cerulli 2014; Daley 2007; Guinan 2013; Ligibel 2008;
Matthews 2007; Musanti 2012; Mustian 2004; Rogers
2013; Rogers 2014

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

633

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 2.   Physical fitness, physical activity, and body composition measurement instruments used by
investigators  (Continued)

Body composition

% and/or kg

Body fat and lean mass via
dual-energy X-ray absorp-
tiometry (DEXA)

Cadmus 2009; DeNysschen 2011; Matthews 2007;
Rogers 2009; Saarto 2012; Schmitz 2005; Schmitz 2009;
Winters-Stone 2011

Body fat and muscle mass
via multi-slice magnetic res-
onance imaging (MRI)

Body composition

% and kg

Herrero 2006

Body mass index (BMI)

Anthropometric

kg/m2

Body mass

Anthropometric

kg

Basen-Enquist 2006; Cadmus 2009; Courneya 2003;
Daley 2007; Kiecolt-Glaser 2014; Ligibel 2008; Littman
2012; Murtezani 2014; Mustian 2004; Naumann 2012;
Nikander 2007; Pinto 2003; Portela 2008; Rahnama
2010; Rogers 2009; Rogers 2013; Rogers 2014; Schmitz
2005; Schmitz 2009

Cadmus 2009; Courneya 2003; Daley 2007; DeNyss-
chen 2011; Dolan 2016; Guinan 2013; Herrero 2006; Ir-
win 2015; Kiecolt-Glaser 2014; Ligibel 2008; Littman
2012; Matthews 2007; Murtezani 2014; Musanti 2012;
Naumann 2012; Nikander 2007; Pinto 2003; Rahnama
2010; Saarto 2012; Schmitz 2005; Schmitz 2009; Win-
ters-Stone 2011

Skinfold thickness

Body composition

mm and/or %

Courneya 2003; Herrero 2006; Naumann 2012

Hip circumference

Anthropometric

cm

Waist circumference

Anthropometric

cm

Waist-to-hip ratio

Anthropometric

NA

Handgrip strength

Muscular strength

kg

Basen-Enquist 2006; Cadmus 2009; Dolan 2016; Ligibel
2008; Littman 2012; Rahnama 2010; Rogers 2009

Basen-Enquist 2006; Cadmus 2009; Dolan 2016; Guinan
2013; Ligibel 2008; Littman 2012; Rahnama 2010;
Rogers 2009; Schmitz 2005

Ligibel 2008; Rahnama 2010; Rogers 2009; Rogers 2013;
Rogers 2014

Irwin 2015; Kaltsatou 2011; Kim 2015; Mustian 2004;
Portela 2008; Rogers 2009; Saarto 2012; Winters-Stone
2011

Repetition maximum (RM)
bench/chest press

Muscular strength

kg

Cormie 2014; Milne 2008; Musanti 2012; Naumann 2012;
Schmitz 2005; Schmitz 2009; Winters-Stone 2011)

RM leg press

Muscular strength

kg

Cerulli 2014; Cormie 2014; Dolan 2016; Milne 2008; Mu-
santi 2012; Naumann 2012; Schmitz 2005; Schmitz
2009; Winters-Stone 2011

Total bone mineral content
(BMC)

Bone-related out-
comes

BMC of distal tibia, tibial
midshaft, and femoral neck

Bone-related out-
comes

Bone mineral density (BMD)
via DEXA

Bone-related out-
comes

BMD of femoral neck and
lumbar spine

Bone-related out-
comes

g/cm

g/cm

g/cm2

g/cm2

Cadmus 2009; Saarto 2012

Saarto 2012

Cadmus 2009; Kim 2015; Rogers 2009; Saarto 2012;
Waltman 2010; Winters-Stone 2011

Kim 2015; Rogers 2009; Saarto 2012; Waltman 2010;
Winters-Stone 2011

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

634

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 2.   Physical fitness, physical activity, and body composition measurement instruments used by
investigators  (Continued)

g/cm2

Winters-Stone 2011

BMD greater trochanter via
DEXA

Bone-related out-
comes

BMD total hip via DEXA

Bone-related out-
comes

BMD total radius and 33%
radius via DEXA

Bone-related out-
comes

Bone Remodeling Index
(BRI)

Bone-related out-
comes

Serum bone-specific alka-
line phosphatase (BSAP)

Bone-related out-
comes

g/cm2

g/cm2

NA

μg/L

Kim 2015; Waltman 2010; Winters-Stone 2011

Waltman 2010

Mustian 2004

Mustian 2004; Waltman 2010

SerumN-telopeptides of
type I collagen (NTx)

Bone-related out-
comes

nm bone collagen
equivalent (BCE)

Kim 2015; Mustian 2004; Waltman 2010

Serum osteocalcin

Bone-related out-
comes

nmol

Winters-Stone 2011

Table 3.   Meta-analysis findings for each HRQoL subscale and secondary outcome 

Outcome

Immediate postintervention

estimate (95% CI)

QoL subscale domain

Cognitive func-
tion

SMD: 0.40 (0.11 to 0.69)

N women (trials): 189 (5)

I2 = 0%

Emotional func-
tion/mental
health

SMD: 0.21 (0.10 to 0.32)

N women (trials): 2102 (26)

I2 = 27%

≥ 3-Month
postinterven-
tion

estimate (95%
CI)

Change from baseline to
end of intervention

estimate (95% CI)

SMD: 0.31 (-0.09
to 0.71)

SMD: -0.00 (-0.27 to 0.26)

N women (trials): 672 (5)

N women (trials):
97 (2)

I2 = 35%

I2 = 0%

SMD: 0.20 (0.03
to 0.36)

SMD: 0.31 (0.09 to 0.53)

N women (trials): 1579 (15)

N women (trials):
655 (7)

I2 = 72%

I2 = 10%

Change from
baseline to ≥ 3-
month postin-
tervention

estimate (95%
CI)

SMD: 0.20 (-0.20
to 0.60)

N women (trials):
97 (2)

I2 = 0%

SMD: 0.06 (-0.29
to 0.41)

N women (trials):
179 (3)

I2 = 27%

General health
perspective

SMD: 0.18 (-0.08 to 0.45)

NA

SMD: 0.17 (-0.07 to 0.40)

NA

N women (trials): 456 (1)

N women (trials): 906 (9)

I2 = 47%

I2 = 49%

Perceived physi-
cal function

SMD: 0.33 (0.18 to 0.49)

N women (trials): 2129 (25)

SMD: 0.21 (0.06
to 0.37)

SMD: 0.60 (0.23 to 0.97)

NA

N women (trials): 1433 (13)

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

635

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 3.   Meta-analysis findings for each HRQoL subscale and secondary outcome  (Continued)

I2 = 61%

N women (trials):
637 (6)

I2 = 89%

Role function

SMD: 0.29 (0.07 to 0.51)

N women (trials): 1370 (18)

I2 = 69%

Sexual function

SMD: 0.16 (-0.04 to 0.35)

I2 = 0%

SMD: 0.13 (-0.12
to 0.38)

SMD: 0.14 (-0.05 to 0.33)

NA

N women (trials): 1315 (12)

N women (trials):
249 (2)

I2 = 50%

I2 = 0%

NA

SMD: 0.22 (-0.08 to 0.52)

NA

N women (trials): 411 (5)

N women (trials): 693 (3)

I2 = 0%

I2 = 62%

Sleep

SMD: -0.09 (-0.37 to 0.20)

N women (trials): 188 (5)

I2 = 0%

Social function

SMD: 0.19 (0.08 to 0.30)

NA

NA

SMD: 0.14 (-0.20 to 0.48)

NA

N women (trials): 136 (3)

I2 = 0%

SMD: 0.52 (0.16 to 0.87)

NA

N women (trials): 1557 (18)

N women (trials): 1384 (12)

I2 = 11%

I2 = 87%

Other psychological outcomes

Anxiety

SMD: -0.57 (-0.95 to -0.19)

NA

SMD: -0.37 (-0.63 to -0.12)

NA

N women (trials): 326 (7)

N women (trials): 235 (4)

I2 = 60%

I2 = 0%

Depression

SMD: -0.34 (-0.62 to -0.05)

N women (trials): 657 (12)

I2 = 63%

SMD: -0.28 (-0.51
to -0.05)

SMD: -0.34 (-0.63 to -0.05)

NA

N women (trials): 816 (7)

N women (trials):
340 (4)

I2 = 62%

I2 = 9%

Fatigue

SMD: -0.32 (-0.47 to -0.18)

N women (trials): 2020 (26)

I2 = 54%

SMD: -0.43 (-0.60
to -0.26)

SMD:-0.30 (-0.61 to 0.00)

N women (trials): 1289 (13)

N women (trials):
536 (7)

I2 = 80%

Happiness/satis-
faction with life

SMD: 0.61 (-0.16 to 1.37)

N women (studies): 209 (4)

I2 = 85%

I2 = 0%

NA

SMD: 0.28 (-0.05 to 0.62)

NA

N women (studies): 182 (3)

I2 = 23%

SMD: -0.47 (-0.84
to -0.11)

N women (trials):
178 (4)

I2 = 23%

Pain/disability

SMD: 0.08 (-0.09 to 0.25)

NA

SMD: -0.08 (-0.33 to 0.16)

NA

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

636

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 3.   Meta-analysis findings for each HRQoL subscale and secondary outcome  (Continued)

N women (trials): 535 (9)

N women (trials): 296 (5)

I2 = 0%

I2 = 5%

Self-esteem

SMD: 0.27 (0.05 to 0.48)

NA

SMD: 0.23 (-0.11 to 0.58)

NA

N women (trials): 667 (12)

N women (trials): 992 (9)

I2 = 42%

I2 = 80%

Vigour/vitality

SMD: 0.36 (0.21 to 0.50)

N women (trials): 762 (10)

I2 = 0%

Cardiorespiratory fitness outcomes

Overall car-
diorespiratory
fitness

SMD: 0.44 (0.30 to 0.58)

N women (trials): 1265 (23)

I2 = 30%

Directly assessed
VO2peak (mL/kg/
min)

MD: 1.89 (0.65 to 3.13)

N women (trials): 199 (4)

I2 = 0%

Peak power out-
put (W)

MD: 18.92 (9.64 to 28.20)

N women (trials): 66 (2)

I2 = 0%

Resting heart
rate (bpm)

MD: -4.47 (-7.94 to -1.00)

N women (trials): 82 (2)

I2 = 0%

Resting systolic
blood pressure
(mmHg)

MD: -0.83 (-3.72 to 2.05)

N women (trials): 134 (4)

I2 = 0%

Resting diastolic
blood pressure
(mmHg)

MD: 0.66 (-2.89 to 4.21)

N women (trials): 106 (3)

I2 = 22%

Physical activity outcomes

SMD: 0.26 (0.04
to 0.48)

SMD: 0.23 (0.00 to 0.45)

N women (trials): 359 (6)

N women (trials):
454 (4)

I2 = 10%

I2 = 24%

SMD: 0.36 (0.03
to 0.69)

SMD: 0.83 (0.40 to 1.27)

N women (trials): 863 (9)

N women (trials):
362 (3)

I2 = 82%

I2 = 53%

SMD: 0.20 (-0.06
to 0.46)

N women (trials):
233 (2)

I2 = 0%

SMD: 0.42 (0.05
to 0.79)

N women (trials):
115 (2)

I2 = 0%

NA

NA

NA

NA

NA

MD: 1.31 (0.66 to 1.96)

NA

N women (trials): 166 (3)

I2 = 68%

NA

NA

MD: -1.05 (-2.22 to 0.11)

NA

N women (trials): 86 (2)

I2 = 81%

MD: -1.12 (-7.74 to 5.50)

NA

N women (trials): 143 (3)

I2 = 73%

MD: 0.53 (-1.61 to 2.68)

NA

N women (trials): 144 (3)

I2 = 23%

Self-reported
physical activity

SMD: 0.52 (0.33 to 0.71)

N women (trials): 2012 (17)

SMD: 0.44 (0.17
to 0.72)

SMD: 0.57 (0.25 to 0.90)

N women (trials): 1274 (8)

SMD: 0.51 (0.08
to 0.93)

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

637

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 3.   Meta-analysis findings for each HRQoL subscale and secondary outcome  (Continued)

I2 = 72%

Meeting recom-
mended physical
activity guide-
lines

OR: 8.44 (2.41 to 29.56)

N women (trials): 819 (6)

I2 = 89%

Objective physi-
cal activity

SMD: 0.43 (0.19 to 0.66)

N women (trials): 1248 (10)

I2 = 67%

N women (trials):
683 (4)

I2 = 82%

I2 = 53%

OR: 3.11 (1.50 to
6.46)

NA

N women (trials):
280 (2)

I2 = 28%

N women (trials):
521 (4)

I2 = 67%

NA

SMD: 0.22 (-0.21
to 0.66)

SMD: 0.71 (0.14 to 1.29)

N women (trials): 508 (5)

N women (trials):
305 (3)

I2 = 83%

I2 = 58%

SMD: 0.23 (-1.00
to 1.46)

N women (trials):
61 (2)

I2 = 81%

Objective seden-
tary behaviour

SMD: -1.45 (-3.68 to 0.78)

NA

SMD: -0.01 (-0.63 to 0.60)

NA

N women (trials): 103 (3)

N women (trials): 103 (3)

I2 = 95%

I2 = 57%

Anthropometric outcomes

Mass (kg)

MD: 0.00 (-0.57 to 0.58)

N women (trials): 1210 (16)

I2 = 0%

BMI (kg/m2)

MD: 0.01 (-0.19 to 0.22)

N women (trials): 1481 (17)

I2 = 0%

Body fat

SMD: -0.18 (-0.34 to -0.03)

N women (trials): 1162 (18)

I2 = 35%

Lean mass

MD: 0.05 (-0.11 to 0.21)

N women (trials): 612 (8)

I2 = 0%

Waist-to-hip ra-
tio

MD: -0.03 (-0.06 to 0.01)

N women (trials): 213 (5)

I2 = 54%

Waist circumfer-
ence (cm)

MD: -0.50 (-3.18 to 2.18)

N women (trials): 330 (6)

NA

NA

NA

NA

NA

NA

MD: -0.50 (-0.98 to -0.01)

NA

N women (trials): 1047 (11)

I2 = 59%

MD: -0.22 (-0.45 to 0.01)

NA

N women (trials): 485 (8)

I2 = 65%

SMD: -0.62 (-1.19 to -0.06)

NA

N women (trials): 499 (9)

I2 = 88%

MD: 0.80 (-0.13 to 1.72)

NA

N women (trials): 760 (5)

I2 = 95%

MD: 0.00 (-0.01 to 0.01)

NA

N women (trials): 124 (2)

I2 = 0%

MD: -1.71 (-2.56 to -0.86)

NA

N women (trials): 285 (5)

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

638

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 3.   Meta-analysis findings for each HRQoL subscale and secondary outcome  (Continued)

I2 = 0%

I2 = 48%

Hip circumfer-
ence (cm)

MD: -0.97 (-3.96 to 2.01)

NA

MD: -2.37 (-3.31 to -1.44)

NA

N women (trials): 249 (4)

N women (trials): 115 (2)

I2 = 0%

I2 = 5%

NA

NA

NA

NA

NA

SMD: 0.72 (0.38 to 1.07)

NA

N women (trials): 720 (8)

I2 = 73%

SMD: 0.72 (0.30 to 1.14)

NA

N women (trials): 832 (8)

I2 = 86%

SMD: 0.24 (-0.09 to 0.58)

NA

N women (trials): 145 (2)

I2 = 0%

NA

NA

Muscular strength outcomes

Lower body
strength

SMD: 0.44 (0.09 to 0.78)

N women (trials): 637 (10)

I2 = 74%

Upper body
strength

SMD: 0.42 (0.08 to 0.76)

N women (trials): 13 (768)

I2 = 79%

Grip strength

MD: 2.37 kg (0.20 to 4.55)

N women (trials): 320 (7)

I2 = 68%

Bone health outcomes

SMD: 0.04 (-0.20 to 0.27)

N women (trials): 525 (2)

I2 = 22%

SMD: 0.21 (-0.13 to 0.55)

N women (trials): 786 (4)

I2 = 75%

Bone mineral
content (change
and postinter-
vention values)

Bone mineral
density – femoral
neck (change
and postinter-
vention values)

Bone mineral
density – lumbar
spine (change
and postinter-
vention values)

Bone mineral
density – total
hip (change and
postintervention
values)

Bone formation
- Alkaline phos-
phatase (change
and postinter-
vention values)

SMD: 0.22 (-0.09 to 0.53)

NA

NA

N women (trials): 786 (4)

I2 = 70%

SMD: 0.58 (-0.02 to 1.18)

NA

NA

N women (trials): 329 (3)

I2 = 97%

SMD: -0.25 (-1.81 to 1.31)

NA

NA

N women (trials): 239 (2)

I2 = 89%

NA

NA

NA

NA

NA

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

639

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 3.   Meta-analysis findings for each HRQoL subscale and secondary outcome  (Continued)

Bone resorp-
tion - serum NTx
(change and
postintervention
values)

SMD: 0.38 (-1.58 to 2.34)

NA

NA

NA

N women (trials): 278 (3)

I2 = 97%

CI: confidence interval.
MD: mean difference.
NA: not applicable.
OR: odds ratio.
SMD: standardised mean difference.

A P P E N D I C E S

Appendix 1. MEDLINE

PubMed search:

1.  (randomized  controlled  trial[pt]  OR  controlled  clinical  trial[pt]  OR  randomized[tiab]  OR  placebo[tw]  OR  drug  therapy[sh]  OR
randomly[tiab] OR trial[tiab] OR groups[tiab])

2. (((Breast neoplasms[mh] OR ((breast[mh] OR breast diseases[mh]) AND neoplasms[mh])) AND humans[mh]) OR DCIS[tiab] OR LCIS[tiab]
OR ductal carcinoma in situ[tiab] OR lobular carcinoma in situ[tiab] OR (breast[tiab] AND (ductal carcinoma*[ti] OR lobular carcinoma*[ti]))
OR ((Breast[ti] OR mammary[ti]) AND (cancer*[ti] OR neoplas*[ti] OR tumor*[ti] OR tumour*[ti] OR carcinoma*[ti] OR malignan*[ti] OR
sarcoma[ti] OR lymphoma[ti])))

3. (((Breast neoplasms[mh] OR ((breast[mh] OR breast diseases[mh]) AND neoplasms[mh])) AND humans[mh]) OR DCIS[tiab] OR LCIS[tiab]
OR ductal carcinoma in situ[tiab] OR lobular carcinoma in situ[tiab] OR (breast[tiab] AND (ductal carcinoma*[ti] OR lobular carcinoma*[ti]))
OR ((Breast[ti] OR mammary[ti]) AND (cancer*[ti] OR neoplas*[ti] OR tumor*[ti] OR tumour*[ti] OR carcinoma*[ti] OR malignan*[ti] OR
sarcoma[ti] OR lymphoma[ti]))) AND (Neoplasm Metastasis[Mh] OR secondary[sh] OR Neoplasm Recurrence, Local[mh] OR metast*[tiab]
OR advanced[tiab] OR recurren*[tiab] OR HER-2*[tiab] OR HER2*[tiab] OR N1[tiab] OR N2[tiab] OR N2a[tiab] OR N2b[tiab] OR N3[tiab] OR
N3a[tiab] OR N3b[tiab] OR N3c[tiab] OR M1[tiab] OR pN1*[tiab] OR pN2*[tiab] OR pN3*[tiab] OR stage IV[tiab] OR stage four[tiab] OR stage
4[tiab] OR local*[tiab] OR loco*[tiab] OR region*[tiab] OR LABC[tiab] OR T3[tiab] OR T4[tiab] OR Stage III*[tiab] OR Stage three*[tiab] OR
stage 3*[tiab])

4. #2 NOT #3

5. (Exercise [mh] OR exercis*[tiab] OR Motor activity[mh] OR Sports[mh] OR sport*[tiab] OR Resistance training[mh] OR training[tiab] OR
fitness[tiab] OR physical activity[tiab] OR physical activities[tiab] OR physical activity intervention*[tiab] OR exercise intervention* OR
active[tiab])

6. #1 AND #4 AND #5

7. Animals [MH] NOT Humans [mh]

8. #6 not #7

Appendix 2. Embase

Embase.com search:

1. random* OR factorial* OR crossover* OR cross NEXT/1 over* OR placebo* OR (doubl* AND blind*) OR (singl* AND blind*) OR assign*OR
allocat* OR volunteer* OR 'crossover procedure'/exp OR 'double blind procedure'/exp OR 'randomized controlled trial'/exp OR'single blind
procedure'/exp

2. 'breast cancer'/exp OR 'breast cancer'

3. 'breast neoplasm'

4. 'breast carcinoma'/exp OR 'breast carcinoma'

5. 'breast tumour'

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

640

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

6. 'breast tumor'/exp OR 'breast tumor'

7. 'mamma carcinoma'/exp OR 'mamma carcinoma'

8. 'mammary neoplasm'

9. 'mammary carcinoma'/exp OR 'mammary carcinoma'

10. 'mammary gland carcinoma'

11. #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10

Cochrane Database of Systematic Reviews

12.  (metastatic  OR  advance)  AND  ('breast  cancer'/exp  OR  'breast  neoplasm'  OR  'breast  carcinoma'/exp  OR  'breast  tumour'  OR  'breast
tumor'/exp)

13. #11 NOT #12

14. 'exercise'/exp OR 'exercise'

15. exercis*

16. 'sport'/exp OR 'sport'

17. sport*

18. 'resistance training'/exp OR 'resistance training'

19. 'training'/exp OR training

20. 'fitness'/exp OR fitness

21. 'physical activity'/exp OR 'physical activity'

22. 'physical activities'

23. physical NEAR/6 activit*

24. 'physical activity intervention'

25. 'physical activity interventions'

26. 'exercise interventions'

27. 'exercise intervention'

28. #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27

29. #1 AND #13 AND #28

30. #29 NOT ([animals]/lim NOT [humans]/lim)

31. #30 AND [embase]/lim

Appendix 3. CENTRAL

The Cochrane Library search:

1. MeSH descriptor: [Breast Neoplasms] explode all trees

2. breast near cancer* or breast near neoplasm* or breast near carcinoma* or breast near tumour* or breast near tumor*

3. #1 or #2

4. (metastatic or advance) and (breast cancer or breast neoplasm or breast carcinoma or breast tumour or breast tumor)

5. #3 not #4

6. MeSH descriptor: [Exercise] explode all trees

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

641

 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

7. exercis*

8. MeSH descriptor: [Motor Activity] explode all trees

9. MeSH descriptor: [Sports] explode all trees

10. sport*

11. MeSH descriptor: [Resistance Training] explode all trees

12. training

13. fitness

14. physical activit*

15. physical activity intervention*

16. exercise intervention*

17. active

18. #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17

19. #5 and #18

Appendix 4. WHO ICTRP

Basic searches:

1. Physical activity for women with breast cancer after adjuvant therapy

2. Breast cancer AND physical activit*

3. Breast cancer AND physical activity intervention*

4. Breast cancer AND exercise intervention*

Advanced searches:

1. Title: Physical activity for women with breast cancer after adjuvant therapy

Recruitment: ALL

2. Condition: breast cancer

Intervention: physical activit*

Recruitment: ALL

3. Condition: breast cancer

Intervention: physical activity intervention*

Recruitment: ALL

4. Condition: breast cancer

Intervention: exercise intervention*

Recruitment: ALL

Appendix 5. Clinicaltrials.gov

Basic searches:

1. Physical activity for women with breast cancer after adjuvant therapy

2. Breast cancer AND physical activity

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

642

 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

3. Breast cancer AND physical activities

4. Breast cancer AND physical activity intervention

5. Breast cancer AND physical activity interventions

6. Breast cancer AND exercise intervention

7. Breast cancer AND exercise interventions

Advanced searches:

1. Title: breast surgery for metastatic breast cancer

Recruitment: All studies

Study Results: All studies

Study Type: All studies

Gender: All studies

2. Condition: breast cancer NOT (advanced breast cancer OR metastatic breast cancer)

Intervention: physical activity intervention OR exercise intervention physical activity interventions OR exercise interventions

Recruitment: All studies

Study Results: All studies

Study Type: All studies

Gender: All studies

3. Condition: breast cancer NOT (advanced breast cancer OR metastatic breast cancer)

Intervention: physical activity OR physical activities

Recruitment: All studies

Study Results: All studies

Study Type: All studies

Gender: All studies

Appendix 6. CINAHL

EBSCOhost search:

S1. (MH "Clinical Trials+")

S2. PT Clinical trial

S3. TX clinic* n1 trial*

S4. TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*) or (tripl* n1 mask*) )
or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) )

S5. TX randomi* control* trial*

S6. (MH "Random Assignment")

S7. TX random* allocat*

S8. TX placebo*

S9. (MH "Placebos")

S10. (MH "Quantitative Studies")

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

643

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

S11. TX allocat* random*

S12. S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11

S13. (MH "Breast Neoplasms+")

S14. "breast cancer"

S15. "breast neoplasm"

S16. "breast carcinoma"

S17. "breast tumour"

S18. "breast tumor"

S19. S13 OR S14 OR S15 OR S16 OR S17 OR S18

S20. "metastatic breast cancer"

S21. "metastatic breast neoplasm"

S22. "metastatic breast carcinoma"

S23. "metastatic breast tumour"

S24. "metastatic breast tumor"

S25. "advanced breast cancer"

S26. "advanced breast neoplasm"

S27. "advanced breast carcinoma"

S28. "advanced breast tumour"

S29. "advanced breast tumor"

S30. S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29

S31. S19 NOT S30

S32. (MH "Exercise+")

S33. "exercis*"

S34. (MH "Motor Activity+")

S35. (MH "Sports+")

S36. "sport*"

S37. (MH "Resistance Training")

S38. "training"

S39. "fitness"

S40. (MH "Physical Activity")

S41. "physical activit*"

S42. "physical activity intervention*"

S43. "exercise intervention*"

S44. "active"

S45. S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR S43 OR S44

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

644

 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

S46. S12 AND S31 AND S45

Appendix 7. PEDro

1. Abstract & Title: breast cancer AND physical activity

Method: clinical trial

2. Abstract & Title: breast cancer AND exercise

Method: clinical trial

3. Abstract & Title: breast cancer AND physical activity intervention

Method: clinical trial

4. Abstract & Title: breast cancer AND exercise intervention

Method: clinical trial

5. Abstract & Title: breast cancer AND resistance training

Method: clinical trial

6. Abstract & Title: breast cancer AND strength training

Method: clinical trial

7. Abstract & Title: breast cancer AND weight lifting

Method: clinical trial

Appendix 8. SPORT Discus

EBSCOhost search:

S1. randomized

S2. placebo

S3. randomly

S4. randomized controlled trial

S5. controlled clinical trial

S6. random*

S7. S1 OR S2 OR S3 OR S4 OR S5 OR S6

S8. breast cancer OR breast neoplasm OR breast carcinoma OR breast tumour OR breast tumor

S9. (metastatic or advance) AND (breast cancer OR breast neoplasm OR breast carcinoma OR breast tumour OR breast tumor)

S10. S8 NOT S9

S11. exercis* OR sport* OR training OR fitness OR physical activit* OR physical activity intervention* OR exercise intervention* OR active
OR resistance training OR strength training OR weight lifting

S12. S7 AND S10 AND S11

Appendix 9. PsycINFO

Searches

1

exp Treatment Effectiveness Evaluation/

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

645

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

  (Continued)

Cochrane Database of Systematic Reviews

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

exp Treatment Outcomes/

exp Placebo/

exp Followup Studies/

placebo*.mp.

random*.mp.

comparative stud*.mp.

(clinical adj3 trial*).mp.

(research adj3 design).mp.

(evaluat* adj3 stud*).mp.

(clinical adj3 trial*).mp.

(research adj3 design).mp.

(evaluat* adj3 stud*).mp.

(prospectiv* adj3 stud*).mp.

((singl* or doubl* or trebl* or tripl*) adj3 (blind* or mask*)).mp.

1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15

exp Breast Neoplasms/

(breast adj6 cancer$).mp.

(breast adj6 neoplasm$).mp.

(breast adj6 carcinoma$).mp.

(breast adj6 tumour$).mp.

(breast adj6 tumor$).mp.

17 or 18 or 19 or 20 or 21 or 22

((metastatic or advance*) and (breast cancer* or breast neoplasm* or breast carcinoma* or breast
tumour* or breast tumor*)).af.

23 not 24

(exercis* or resistance training or training or fitness or physical activit* or physical activity interven-
tion* or exercise intervention* or active).mp.

exp Exercise/ or exp Aerobic Exercise/ or exp Physical Activity/ or exp Training/ or exp Physical Fit-
ness/

26 or 27

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

646

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

  (Continued)

29

30

31

16 and 25 and 28

Animals/ not Humans/

29 not 30

C O N T R I B U T I O N S   O F   A U T H O R S

• Drafting the protocol: IML, GSM, ANM, ARC.
• Selecting studies: IML, GSM.
• Extracting data from studies: IML, GSM.
• Entering data into RevMan: IML.
• Carrying out the analysis: IML, GSM, ANM.
• Interpreting the analysis: IML, GSM, ANM.
• Drafting the final review: IML, GSM, ANM, ARC.
• Resolving disagreements: ANM, ARC.
• Updating the review: IML, GSM.

D E C L A R A T I O N S   O F   I N T E R E S T

None known.

S O U R C E S   O F   S U P P O R T

Internal sources

• No support provided, UK.

External sources

• No support provided, UK.

D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W

Review authors did not perform planned analysis of effects of physical activity on blood biomarkers because we considered these outcomes
to  be  beyond  the  scope  of  the  current  review,  and  because  the  prognostic  value  of  blood  biomarkers  for  breast  cancer  populations
remains uncertain (Ballard-Barbash 2012). We originally planned to conduct a subgroup analysis by treatment regimen (chemotherapy vs
no chemotherapy). However, the numbers of trials conducted with patients who had not undergone chemotherapy were insufficient for
performance of this analysis.

I N D E X   T E R M S

Medical Subject Headings (MeSH)

*Exercise;  *Resistance Training;  Anxiety  [therapy];  Breast Neoplasms  [psychology]  [*therapy];  Chemotherapy, Adjuvant;  Depression
 [therapy];  Fatigue  [etiology];  Physical Fitness;  Prognosis;  Quality of Life;  Radiotherapy, Adjuvant

MeSH check words

Female; Humans

Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

647
